<SEC-DOCUMENT>0001193125-17-063925.txt : 20170301
<SEC-HEADER>0001193125-17-063925.hdr.sgml : 20170301
<ACCEPTANCE-DATETIME>20170301080033
ACCESSION NUMBER:		0001193125-17-063925
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		109
CONFORMED PERIOD OF REPORT:	20161231
FILED AS OF DATE:		20170301
DATE AS OF CHANGE:		20170301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMEDISYS INC
		CENTRAL INDEX KEY:			0000896262
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOME HEALTH CARE SERVICES [8082]
		IRS NUMBER:				113131700
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24260
		FILM NUMBER:		17651458

	BUSINESS ADDRESS:	
		STREET 1:		3854 AMERICAN WAY
		STREET 2:		SUITE A
		CITY:			BATON ROUGE
		STATE:			LA
		ZIP:			70816
		BUSINESS PHONE:		2252922031

	MAIL ADDRESS:	
		STREET 1:		3854 AMERICAN WAY
		STREET 2:		SUITE A
		CITY:			BATON ROUGE
		STATE:			LA
		ZIP:			70816

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANALYTICAL NURSING MANAGEMENT CORP
		DATE OF NAME CHANGE:	19940819

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	M&N CAPITAL CORP
		DATE OF NAME CHANGE:	19930125
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>d332070d10k.htm
<DESCRIPTION>10-K
<TEXT>
<HTML><HEAD>
<TITLE>10-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM <FONT
STYLE="white-space:nowrap">10-K</FONT> </B></FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Mark One) </B></FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B></B>&#9746;<B></B><B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:3px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For the fiscal year ended: December&nbsp;31, 2016 </B></FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>OR </B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B></B>&#9744;<B></B><B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:3px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For the transition period from
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commission File Number: <FONT STYLE="white-space:nowrap">0-24260</FONT> </B></FONT></P>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g332070g58p88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>AMEDISYS, INC. </B></FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Exact Name of Registrant as Specified in its Charter) </B></FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">11-3131700</FONT></B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3854 American Way, Suite A, Baton Rouge, LA 70816 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices, including zip code) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(225) <FONT STYLE="white-space:nowrap">292-2031</FONT> or <FONT STYLE="white-space:nowrap">(800)&nbsp;467-2662</FONT> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Securities
registered pursuant to Section&nbsp;12(b) of the Act: </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:64pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title of Each Class</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:156pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name of Each Exchange on Which Registered</B></FONT></P></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common Stock, par value $0.001 per share</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>The NASDAQ Global Select Market</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Securities registered pursuant to Section&nbsp;12(g) of the Act: None </B></FONT></P>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the
registrant is not required to file reports pursuant to Section&nbsp;13 or 15(d) of the Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9745; </FONT></P>
<P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90
days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark
whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation <FONT STYLE="white-space:nowrap">S-T</FONT>
(&#167;&nbsp;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such
files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if
disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> (&#167; 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant&#146;s knowledge, in
definitive proxy or information statements incorporated by reference in Part III of this Form <FONT STYLE="white-space:nowrap">10-K</FONT> or any amendment to this
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K.&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</FONT> </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the
registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148;
and &#147;smaller reporting company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Large accelerated filer&nbsp;&nbsp;&#9745;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accelerated filer&nbsp;&nbsp;&#9744;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer&nbsp;&nbsp;&#9744;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Smaller&nbsp;reporting&nbsp;company&nbsp;&nbsp;&#9744;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Do not check if a smaller reporting company)</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant is a shell company (as defined in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> of the Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9745; </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The aggregate market value of the voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of the registrant, based on the
last sale price as quoted by the NASDAQ Global Select Market on June&nbsp;30, 2016 (the last business day of the registrant&#146;s most recently completed second fiscal quarter) was $1.0&nbsp;billion. For purposes of this determination shares
beneficially owned by executive officers, directors and ten percent stockholders have been excluded, which does not constitute a determination that such persons are affiliates. </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of February&nbsp;24, 2017, the registrant had 33,607,420&nbsp;shares of Common Stock outstanding. </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>DOCUMENTS INCORPORATED BY REFERENCE </B></FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Portions of the registrant&#146;s
definitive Proxy Statement for its 2017 Annual Meeting of Stockholders (the &#147;2017 Proxy Statement&#148;) to be filed pursuant to the Securities Exchange Act of 1934 with the Securities and Exchange Commission within 120 days of
December&nbsp;31, 2016 are incorporated herein by reference into Part III of this Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K.</FONT> </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_1">SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_2">PART I. </A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ITEM&nbsp;1.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_3">BUSINESS</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ITEM&nbsp;1A.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_4">RISK FACTORS</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ITEM&nbsp;1B.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_5">UNRESOLVED STAFF COMMENTS</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ITEM&nbsp;2.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_6">PROPERTIES</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ITEM&nbsp;3.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_7">LEGAL PROCEEDINGS</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ITEM&nbsp;4.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_8">MINE SAFETY DISCLOSURES</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_9">PART II. </A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ITEM&nbsp;5.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_10">MARKET FOR REGISTRANT&#146;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ITEM&nbsp;6.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_11">SELECTED FINANCIAL DATA</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ITEM&nbsp;7.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_12">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ITEM&nbsp;7A.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_13">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ITEM&nbsp;8.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_14">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ITEM&nbsp;9.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_15">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">104</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ITEM&nbsp;9A.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_16">CONTROLS AND PROCEDURES</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">104</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ITEM&nbsp;9B.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_17">OTHER INFORMATION</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">107</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_18">PART III. </A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ITEM&nbsp;10.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_20">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">107</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ITEM&nbsp;11.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_21">EXECUTIVE COMPENSATION</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">107</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ITEM&nbsp;12.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_22">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT&nbsp;AND RELATED STOCKHOLDER MATTERS</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">107</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ITEM&nbsp;13.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_23">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">107</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ITEM&nbsp;14.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_24">PRINCIPAL ACCOUNTING FEES AND SERVICES</A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">107</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_25">PART IV. </A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ITEM&nbsp;15.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_26">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES </A></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ITEM&nbsp;16.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_37">FORM 10-K SUMMARY</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_27">SIGNATURES</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc332070_28">EXHIBIT INDEX</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">110</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="6"><FONT STYLE="font-family:Times New Roman" SIZE="2">EX-10.3 COMPOSITE AMEDISYS, INC. 2008 OMNIBUS INCENTIVE COMPENSATION PLAN, AS AMENDED</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="6"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">EX-10.15 AMEDISYS HOLDING, L.L.C. SEVERANCE PLAN FOR KEY EXECUTIVES, AS AMENDED</FONT></P></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">EX-21.1 LIST OF SUBSIDIARIES</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">EX-23.1 CONSENT OF KPMG LLP</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">EX-31.1 SECTION 302 CERTIFICATION OF PEO</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">EX-31.2 SECTION 302 CERTIFICATION OF PFO</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">EX-32.1 SECTION 906 CERTIFICATION OF PEO</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">EX-32.2 SECTION 906 CERTIFICATION OF PFO</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">EX-101 INTERACTIVE DATA FILE</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_1"></A>SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>When included in this Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,</FONT> or in other documents
that we file with the Securities and Exchange Commission (&#147;SEC&#148;) or in statements made by or on behalf of the Company, words like &#147;believes,&#148; &#147;belief,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148;
&#147;intends,&#148; &#147;projects,&#148; &#147;estimates,&#148; &#147;may,&#148; &#147;might,&#148; &#147;would,&#148; &#147;should&#148; and similar expressions are intended to identify forward-looking statements as defined by the Private
Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are
not limited to the following: changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, changes in or our failure to comply with
existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, competition in the healthcare industry, our ability to integrate our personal care segment into our business efficiently,
changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract and retain
qualified personnel, changes in payments and covered services due to the economic downturn and deficit spending by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our
ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, our ability to integrate, manage and keep our information systems secure, our ability to
comply with requirements stipulated in our corporate integrity agreement and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.
</I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be
predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events.&nbsp;We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our
expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.&nbsp;For a discussion of some of the factors discussed
above as well as additional factors, see Part&nbsp;I, Item&nbsp;1A, &#147;Risk Factors&#148; and Part&nbsp;II, Item&nbsp;7, &#147;Critical Accounting Estimates&#148; within &#147;Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations.&#148; </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Unless otherwise provided, &#147;Amedisys,&#148; &#147;we,&#148; &#147;us,&#148;
&#147;our,&#148; and the &#147;Company&#148; refer to Amedisys, Inc. and our consolidated subsidiaries and when we refer to 2016, 2015 and 2014, we mean the twelve month period then ended December&nbsp;31, unless otherwise provided. </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>A copy of this Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2016 as
filed with the SEC, including all exhibits, is available on our internet website at http://www.amedisys.com on the &#147;Investors&#148; page under the &#147;SEC Filings&#148; link. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_2"></A>PART I </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_3"></A>ITEM&nbsp;1.&nbsp;BUSINESS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amedisys, Inc. is a leading healthcare services company focused
on bringing care to the home. Our operations involve servicing patients across the United States through our three operating divisions: home health, hospice and personal care. We deliver the care that is best for our patients, whether that is
home-based recovery and rehabilitation after an operation or injury, care that empowers patients to manage a chronic disease, hospice care at the end of life, or providing assistance with daily activities through our personal care division.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are among the largest, best established and most advanced providers of home health and hospice care in the United States,
with 420 care centers in 34&nbsp;states. Our 16,000&nbsp;employees deliver the highest quality of care to the doorsteps of&nbsp;patients in need, making more than 7.5&nbsp;million patient visits to 385,000&nbsp;patients annually. Over
2,200&nbsp;hospitals and 61,900&nbsp;physicians nationwide have chosen us as a partner in post-acute care. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our services are
primarily paid for by Medicare due to the age demographics of our patient base (average age&nbsp;81). Medicare represented approximately 78% to 82% of our net service revenue over the last three years. We remain focused on maintaining a profitable
and strategically important managed care contract portfolio. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amedisys is headquartered in Baton Rouge, Louisiana, with an
executive office in Nashville, Tennessee. Our common stock is currently traded on NASDAQ Global Select Market under the trading symbol &#147;AMED&#148;. Founded and incorporated in Louisiana in 1982, Amedisys was reincorporated as a Delaware
corporation prior to becoming a publicly traded company in August, 1994. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our strategy is to become the best choice for care
wherever our patients call home by excelling in clinical distinction, operational excellence and efficiency and growth. Our mission is to provide compassionate home health, hospice and personal care services that apply the most advanced clinical
practices toward allowing our patients to maintain a sense of independence, quality of life and dignity. We believe that focusing on providing excellent care and becoming an employer of choice across the United States will differentiate us from our
competitors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Our Home Health Segment: </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Amedisys Home Health provides experienced, compassionate healthcare to help our patients recover from surgery or illness, live with chronic diseases, and prevent avoidable hospital readmissions with 327
care centers located in 32&nbsp;states. Our care team includes skilled nurses who are trained and certified to administer medications, care for wounds, monitor vital signs and provide a wide range of other nursing services; therapists specialized in
physical, speech and occupational therapy; and aides who assist our patients with completing important personal tasks. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
take an empowering approach to helping our patients and their families understand their condition, how to manage it and how to live life to the fullest with a chronic disease or other health condition. Our professional and compassionate clinicians
are trained to understand the whole patient &#150; not just their medical diagnosis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">This commitment to clinical distinction
is evident in our clinical performance measures such as Star Ratings. In the Center for Medicare and Medicaid Services (&#147;CMS&#148;) preview reports for the April 2017 release, the Quality of Patient Care star average across all Amedisys
providers is 4.03. This number is subject to change for the final release, and CMS has indicated proposed changes that may impact star scores starting with the July 2017 release. Our goal is to have all of our care centers achieve a 4.0 Quality Star
Rating, and we are implementing targeted action plans to continue to improve the quality of care we deliver for our patients across the country. Our Patient Satisfaction average as of the last known release was 3.76, outperforming the industry
average of 3.67. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Our Hospice Segment: </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Hospice is a special form of care that is designed to provide comfort and support for those who are dealing with a terminal illness. It is a compassionate form of care that promotes dignity and affirms
quality of life for the patient, family members and other loved ones. We operate 79 hospice care centers in 21 states. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Individuals with a terminal illness such as heart disease, pulmonary disease, Alzheimer&#146;s, HIV/AIDS or cancer may be eligible for
hospice care, if they have a life expectancy of six months or less. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">At Amedisys Hospice, our focus is on building and
retaining an exceptional team, delivering the highest quality care and service to our patients and their families, and establishing Amedisys as the preferred and preeminent hospice provider in each community we serve. In order to realize these
goals, we invest in tailored training, development, and recognition programs for our employees, with specific focus in 2016 on the implementation of a new electronic medical record, employee skills training and leadership development. This has led
to our team&#146;s consistent achievement at or above the national average in family satisfaction results and quality scores, as well as the trust of the healthcare community driving a 17% increase in new patient admissions and a 16% increase in
census. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Another element of our approach is our outreach strategy to more fully reach the entire community of eligible
patients.&nbsp;These outreach efforts have built our hospice patient population to more accurately represent the causes of death in the communities we serve, with a specific focus on heart disease, lung disease, and dementia in order to address the
historical underrepresentation of <FONT STYLE="white-space:nowrap">non-cancer</FONT> diagnoses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">By working to accept every
patient with a life expectancy of six months or less who wants our compassionate care, we fulfill our hospice mission and strengthen our standing in the community. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>Our Personal Care Segment: </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;1, 2016, Amedisys acquired its
first personal care company&nbsp;&#150; an important step in executing our strategy of improving the continuity of care our patients receive as their clinical needs change. Our new segment was further expanded when we purchased the assets of
Professional Profiles, Inc. on September&nbsp;1, 2016. We now operate 14 personal-care care centers in Massachusetts. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Personal care provides assistance with the essential activities of daily living. We believe that personal care services are highly
synergistic with our core skilled home health and hospice businesses, and that by acquiring these capabilities in one of our most successful regions we will realize these benefits quickly. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>Responding to Changing Regulatory and Reimbursement Environment: </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As the
government continues to seek opportunities to refine payment models, we believe that our strategy of becoming a leader in providing a range of service across the <FONT STYLE="white-space:nowrap">at-home</FONT> care center continuum positions us well
for the future. Our ability to provide quality home health, hospice and personal care allows us to partner with health systems and managed care organizations to improve care coordination, reduce hospitalizations and lower costs. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Homecare Homebase Implementation: </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During 2015, we made the strategic decision to discontinue AMS3, our third generation, proprietary operating system, and transition to Homecare Homebase (&#147;HCHB&#148;), a leading home health and
hospice platform. We completed our rollout of HCHB during 2016 with all our care centers fully transitioned to our new platform as of November&nbsp;1, 2016. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>Acquisitions: </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;1, 2016, we acquired Associated Home Care for
a total purchase price of $27.7&nbsp;million. Associated Home Care owned and operated nine personal-care care centers servicing the state of Massachusetts. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;1, 2016, we acquired the assets of four personal-care care centers in
Massachusetts for a total purchase price of $4.4&nbsp;million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;20, 2016, we acquired the assets of a home
health care center in New York for a total purchase price of $4.6&nbsp;million. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Financial Information: </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial information for our home health, hospice and personal care segments can be found in our consolidated financial statements
included in this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Employees </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of February&nbsp;24, 2017, we employed approximately 16,000&nbsp;employees, consisting of approximately 10,800 home health care
employees, 2,800 hospice care employees, 1,800 personal care employees and 600 corporate and divisional support employees. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Payment for Our
Services </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Home Health Medicare </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; " ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Medicare home health benefit is available both for patients who need care following discharge from a hospital and patients who suffer from chronic conditions that require ongoing but intermittent
care. As a condition of participation under Medicare, beneficiaries must be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or
speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. Medicare rates are based on the severity of the patient&#146;s condition, his or her service needs and other factors relating
to the cost of providing services and supplies, bundled into <FONT STYLE="white-space:nowrap">60-day</FONT> episodes of care. An episode starts with the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier. If
a patient is still in treatment on the 60</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> day, a
recertification assessment is undertaken to determine whether the patient needs additional care. If the patient&#146;s physician determines that further care is necessary, another episode begins on the 61</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> day (regardless of whether a billable visit is rendered on that day)
and ends 60 days later. The first day of a consecutive episode, therefore, is not necessarily the new episode&#146;s first billable visit. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Annually, the Medicare program base episodic rates are set through federal legislation, as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:22pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Period</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Base&nbsp;episode<BR>payment</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;1, 2014 through December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,869</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;1, 2015 through December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,961</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;1, 2016 through December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,965</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;1, 2017 through December&nbsp;31, 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,990</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payments can be adjusted for: (a)&nbsp;an outlier payment if our patient&#146;s care was unusually costly
(capped at 10% of total reimbursement per provider number); (b)&nbsp;a low utilization payment adjustment (&#147;LUPA&#148;) if the number of visits during the episode was fewer than five; (c)&nbsp;a partial payment if our patient transferred to
another provider or we received a patient from another provider before an episode was complete; (d)&nbsp;a payment adjustment based upon the level of therapy services required (with various incremental adjustments made for additional visits, with
larger payment increases associated with the sixth, fourteenth and twentieth visit thresholds); (e) a payment adjustment if we are unable to perform periodic therapy assessments; (f)&nbsp;the number of episodes of care provided to a patient,
regardless of whether the same home health provider provided care for the entire series of episodes; (g)&nbsp;changes in the base episode payments established by the Medicare program; (h)&nbsp;adjustments to the base
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
episode payments for case mix and geographic wages; and (i)&nbsp;recoveries of overpayments. Medicare can also make various adjustments to payments received if we are unable to produce
appropriate billing documentation or acceptable authorizations. In addition, we make adjustments to Medicare revenue if we find that we are unable to obtain appropriate billing documentation, authorizations or face to face documentation. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Home Health <FONT STYLE="white-space:nowrap">Non-Medicare</FONT> </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Payments from Medicaid and private insurance carriers are episodic-based rates <FONT STYLE="white-space:nowrap">(60-day</FONT> episode of care) or <FONT STYLE="white-space:nowrap">per-visit</FONT> rates
depending upon the terms and conditions established with such payors. Episodic-based rates paid by our <FONT STYLE="white-space:nowrap">non-Medicare</FONT> payors are paid in a similar manner and subject to the same adjustments as discussed above
for Medicare; however, these rates can vary based upon negotiated terms. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Hospice Medicare </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Medicare hospice benefit is also available to Medicare-eligible patients with terminal illnesses, certified by a physician, where life
expectancy is six months or less. Medicare rates are based on standard prospective rates for delivering care over a base <FONT STYLE="white-space:nowrap">90-day</FONT> or <FONT STYLE="white-space:nowrap">60-day</FONT> period <FONT
STYLE="white-space:nowrap">(90-day</FONT> episodes of care for the first two episodes and <FONT STYLE="white-space:nowrap">60-day</FONT> episodes of care for any subsequent episodes). Payments are based on daily rates for each day a beneficiary is
enrolled in the hospice benefit. Rates are set based on specific levels of care, are adjusted by a wage index to reflect health care labor costs across the country and are established annually through federal legislation. We make adjustments to
Medicare revenue when we find we are unable to obtain appropriate billing documentation, authorizations or face to face documentation and other reasons unrelated to credit risk. The levels of care are routine care, general inpatient care, continuous
home care and respite care. Beginning January&nbsp;1, 2016, CMS has provided for two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, on January&nbsp;1,
2016, Medicare also began reimbursing for a service intensity <FONT STYLE="white-space:nowrap">add-on</FONT> (&#147;SIA&#148;). The SIA is based on visits made in the last seven days of life by a registered nurse (&#147;RN&#148;) or medical social
worker (&#147;MSW&#148;) for patients in a routine level of care. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We bill Medicare for hospice services on a monthly basis
and our payments are subject to two fixed annual caps, which are assessed on a provider number basis. Generally, each hospice care center has its own provider number. However, where we have created branch care centers to help our parent care centers
serve a geographic location, the parent and branch may have the same provider number. The annual caps per patient, known as hospice caps, are calculated and published by the Medicare fiscal intermediary on an annual basis and cover the twelve month
period from November&nbsp;1 through October 31. The caps can be subject to annual and retroactive adjustments, which can cause providers to be required to reimburse the Medicare program if such caps are exceeded. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The two caps are detailed below: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Inpatient Cap.</I></B> When we provide hospice care on an inpatient basis, the payments that we are entitled to receive at the higher
inpatient reimbursement rate are subject to a cap. This cap limits the number of days that are paid at the inpatient care rate (both respite and general) under a provider number to 20% of the total number of days of hospice care (both inpatient and <FONT
STYLE="white-space:nowrap">in-home)</FONT> that is furnished to all Medicare patients served by the provider. The daily Medicare payment rate for any inpatient days of service that exceed the cap is at the routine home care rate, and the provider is
required to reimburse Medicare for any amounts it receives in excess of the cap; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overall Payment Cap. </I></B>This cap is calculated by the Medicare fiscal intermediary at the end of each hospice cap period to determine the
maximum allowable payments per provider number. We estimate our potential cap exposure using information available for both inpatient day limits as well as per beneficiary cap amounts. The total cap amount for each provider is calculated by
multiplying the number of beneficiaries electing hospice care during the period by a statutory amount that is indexed for inflation. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ability to stay within these limitations depends on a number of factors, each determined
on a provider number basis, including the average length of stay and mix in level of care. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Hospice
<FONT STYLE="white-space:nowrap">Non-Medicare</FONT> </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-Medicare</FONT> payors pay at
rates different from established Medicare rates for hospice services, which are based on separate, negotiated agreements. We bill and are paid by these <FONT STYLE="white-space:nowrap">non-Medicare</FONT> payors based on such negotiated agreements.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Personal Care <FONT STYLE="white-space:nowrap">Non-Medicare</FONT> </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Personal care payments are received from payor clients including state and local governmental agencies, managed care organizations,
commercial insurers and private consumers, based on rates that are either contractual or fixed by legislation. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Controls over Our Business
System Infrastructure </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We establish and maintain processes and controls over coding, clinical operations, billing, patient
recertifications and compliance to help monitor and promote compliance with Medicare requirements. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Coding &#150;</I></B> Specified diagnosis codes are assigned to each of our patients based on their particular health condition and ailment
(such as diabetes, coronary artery disease or congestive heart failure). Because coding regulations are complex and are subject to frequent change, we maintain controls surrounding our coding process. In order to reduce associated risk of coding
failures, we provide coding training and annual update training to clinical assessment managers; provide coding training during orientation for new employees; provide monthly specialized coding education; obtain outside expert coding instruction;
have certified coders code all patient outcome and assessment information sets (&#147;OASIS&#148;) and have automated coding edits based on <FONT STYLE="white-space:nowrap">pre-defined</FONT> compliance metrics in our point of care (&#147;POC&#148;)
system. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Clinical Operations &#150; </I></B>Regulatory requirements allow patients to be admitted to home health care if they are considered homebound
and require skilled nursing, physical therapy or speech therapy services. These clinical services include: educating the patient about their disease; assessment and observation of disease status; delivery of clinical skills such as wound care;
administration of injections or intravenous fluids; management and evaluation of a patient&#146;s plan of care; physical therapy services to assist patients with functional limitations and speech therapy services for speech or swallowing disorders.
In order to help monitor and promote compliance with regulatory requirements, we provide education on Medicare Guidelines and Conditions of participation; hold recurrent homecare regulatory education; utilize outside expert regulatory services; and
have a toll-free hotline to offer additional assistance. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Billing &#150; </I></B>We maintain controls over our billing processes to help promote accurate and complete billing. In order to promote the
accuracy and completeness of our billing, we have annual billing compliance testing; use formalized billing attestations; limit access to billing systems; hold weekly operational meetings; use automated daily billing operational indicators; and take
prompt corrective action with employees who knowingly fail to follow our billing policies and procedures in accordance with a well-publicized &#147;Zero Tolerance Policy&#148;. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Patient Recertification &#150; </I></B>In order to be recertified for an additional episode of care, a patient must continue to meet
qualifying criteria and have a continuing medical need. This could be caused by changes in the patient&#146;s condition requiring changes to the patient&#146;s medical regimen or modified care protocols within the episode of care. The patient&#146;s
progress towards goals is evaluated prior to recertification. As with the initial episode of care, a recertification requires orders from the patient&#146;s physician. Before any employee recommends recertification to a physician, we conduct a care
center level, multidisciplinary care team conference. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Compliance &#150; </I></B>The quality and reputation of our personnel and operations are critical to our success. We develop, implement and
maintain ethics, compliance and quality improvement programs as a component of the centralized corporate services provided to our home health and hospice care centers. Our ethics and compliance program includes a Code of Ethical Business Conduct for
our employees, officers, directors and affiliates and a process for reporting regulatory or ethical concerns to our Chief Compliance Officer through a confidential hotline, which is augmented by exit interviews of departing employees and monthly
interviews with randomly-selected, current employees. We promote a culture of compliance within our company through persistent messages from our senior leadership to our employees stressing the importance of strict compliance with legal requirements
and company policies and procedures.&nbsp;We also employ a comprehensive compliance training program that includes mandatory compliance training and testing for all new employees upon hire and annually for all staff thereafter. In addition to our
compliance training, we also conduct numerous proactive, compliance audits focusing on key risk areas, which are conducted by clinical auditors who work for our Compliance Department.</FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Regulatory Environment </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are highly regulated by federal, state and local authorities. Regulations and policies frequently change, and we monitor changes through trade and governmental publications and associations. Our home
health and hospice subsidiaries are certified by CMS and therefore are eligible to receive payment for services through the Medicare system. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are also subject to federal, state and local laws and regulations dealing with issues such as occupational safety, employment, medical leave, insurance, civil rights, discrimination, building codes,
environmental issues and adverse event reporting and recordkeeping. Federal, state and local governments are expanding the number of regulatory requirements on businesses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have set forth below a discussion of the regulations that we believe most significantly affect our home health and hospice businesses. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Licensure, Certificates of Need (CON) and Permits of Approval (POA) </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Home health and hospice care centers operate under licenses granted by the health authorities of their respective states. Additionally,
certain states, including a number in which we operate, carefully restrict new entrants into the market based on demographic and/or demonstrative usage of additional providers. In such states, expansion by existing providers or entry into the market
by new providers is permitted only where a given amount of unmet need exists, resulting either from population increases or a reduction in competing providers. These states ration the entry of new providers or services and the expansion of existing
providers or services in their markets through a CON process, which is periodically evaluated and updated as required by applicable state law. Currently, state health authorities in 17 states and the District of Columbia require a CON or, in the
State of Arkansas, a POA, in order to establish and operate a home health care center, and state health authorities in 12 states and the District of Columbia require a CON to operate a hospice care center. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We operate home health care centers in the following CON states: Alabama, Arkansas (POA), Georgia, Kentucky, Maryland, Mississippi, New
Jersey, New York, North Carolina, South Carolina, Tennessee and West Virginia, as well as the District of Columbia. We provide hospice related services in the following CON states: Alabama, Maryland, North Carolina, Tennessee and West Virginia.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In every state where required, our care centers possess a license and/or CON or POA issued by the state health authority that
determines the local service areas for the home health or hospice care center. In general, the process for opening a home health or hospice care center begins by a provider submitting an application for licensure and certification to the state and
federal regulatory bodies, which is followed by a testing period of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
transmitting data from the applicant to CMS. Once this process is complete, the care center receives a provider agreement and corresponding number and can begin billing for services that it
provides unless a CON or POA is required. For those states that require a CON or POA, the provider must also complete a separate application process before billing can commence and receive required approvals for capital expenditures exceeding
amounts above prescribed thresholds. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">State CON and POA laws generally provide that, prior to the addition of new capacity,
the construction of new facilities or the introduction of new services, a designated state health planning agency must determine that a need exists for those beds, facilities or services. The process is intended to promote comprehensive health care
planning, assist in providing high-quality health care at the lowest possible cost and avoid unnecessary duplication by ensuring that only those health care facilities and operations that are needed will be built and opened. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Medicare Participation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our care centers must comply with regulations promulgated by the United States Department of Health and Human Services and CMS in order to participate in the Medicare program and receive Medicare
payments. Among other things, these regulations, known as &#147;conditions of participation (&#147;COPs&#148;),&#148; relate to the type of facility, its personnel and its standards of medical care, as well as its compliance with state and local
laws and regulations. CMS has adopted alternative sanction enforcement options which allow CMS (i)&nbsp;effective as of July&nbsp;1, 2013, to impose temporary management, direct plans of correction, or direct training, and (ii)&nbsp;effective as of
July&nbsp;1, 2014, to impose payment suspensions and civil monetary penalties in each case on providers out of compliance with the conditions of participation. CMS issued a proposed rule on October&nbsp;9, 2014, revising the current home health
conditions of participation. We provided public comments on the proposed changes. On January&nbsp;12, 2017, CMS finalized the new COPs and published them in the Federal Register. The new COPs are currently scheduled to go into effect on
July&nbsp;13, 2017, though that could be further delayed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">CMS has engaged a number of third party firms, including Recovery
Audit Contractors (&#147;RACs&#148;), Program Safeguard Contractors (&#147;PSCs&#148;), Zone Program Integrity Contractors (&#147;ZPICs&#148;) and Medicaid Integrity Contributors (&#147;MICs&#148;), to conduct extensive reviews of claims data and
state and Federal Government health care program laws and regulations applicable to healthcare providers. These audits evaluate the appropriateness of billings submitted for payment. In addition to identifying overpayments, audit contractors can
refer suspected violations of law to government enforcement authorities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Federal and State Anti-Fraud and Anti-Kickback
Laws </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a provider under the Medicare and Medicaid systems, we are subject to various anti-fraud and abuse laws,
including the Federal health care programs&#146; anti-kickback statute and, where applicable, its state law counterparts. Subject to certain exceptions, these laws prohibit any offer, payment, solicitation or receipt of any form of remuneration to
induce or reward the referral of business payable under a government health care program or in return for the purchase, lease, order, arranging for, or recommendation of items or services covered under a government health care program. Affected
government health care programs include any health care plans or programs that are funded by the United States government (other than certain federal employee health insurance benefits/programs), including certain state health care programs that
receive federal funds, such as Medicaid. A related law forbids the offer or transfer of anything of value, including certain waivers of <FONT STYLE="white-space:nowrap">co-payment</FONT> obligations and deductible amounts, to a beneficiary of
Medicare or Medicaid that is likely to influence the beneficiary&#146;s selection of health care providers, again subject to certain exceptions. Violations of the anti-fraud and abuse laws can result in the imposition of substantial civil and
criminal penalties and, potentially, exclusion from furnishing services under any government health care program. In addition, the states in which we operate generally have laws that prohibit certain direct or indirect payments or <FONT
STYLE="white-space:nowrap">fee-splitting</FONT> arrangements between health care providers where they are designed to obtain the referral of patients from a particular provider. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stark Laws </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Congress adopted legislation in 1989, known as the &#147;Stark Law,&#148; that generally prohibited a physician from ordering clinical
laboratory services for a Medicare beneficiary where the entity providing that service has a financial relationship (including direct or indirect ownership or compensation relationships) with the physician (or a member of his/her immediate family),
and further prohibits such entity from billing for or receiving payment for such services, unless a specified exception is available. The Stark Law was amended through additional legislation, known as &#147;Stark II,&#148; which became effective
January&nbsp;1, 1993. That legislation extended the Stark Law prohibitions beyond clinical laboratory services to a more extensive list of statutorily defined &#147;designated health services,&#148; which includes, among other things, home health
services, durable medical equipment and outpatient prescription drugs. Violations of the Stark Law result in payment denials and may also trigger civil monetary penalties and program exclusion. Several of the states in which we conduct business have
also enacted statutes similar in scope and purpose to the federal fraud and abuse laws and the Stark Laws. These state laws may mirror the Federal Stark Laws or may be different in scope. The available guidance and enforcement activity associated
with such state laws varies considerably. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Federal and State Privacy and Security Laws </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Administrative Simplification provisions of the Health Insurance Portability and Accountability Act of 1996, as amended
(&#147;HIPAA&#148;), directed that the Secretary of the U.S. Department of Health and Human Services (&#147;HHS&#148;) promulgate regulations prescribing standard requirements for electronic health care transactions and establishing protections for
the privacy and security of individually identifiable health information, known as &#147;protected health information.&#148; The HIPAA transactions regulations establish form, format and data content requirements for most electronic health care
transactions, such as health care claims that are submitted electronically. The HIPAA privacy regulations establish comprehensive requirements relating to the use and disclosure of protected health information. The HIPAA security regulations
establish minimum standards for the protection of protected health information that is stored or transmitted electronically. Violations of the privacy and security regulations are punishable by civil and criminal penalties. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The American Recovery and Economic Reinvestment Act of 2009 (&#147;ARRA&#148;), signed into law by President Obama on February&nbsp;17,
2009, contained significant changes to the privacy and security provisions of HIPAA, including major changes to the enforcement provisions. Among other things, ARRA significantly increased the amount of civil monetary penalties that can be imposed
for violations of HIPAA. ARRA also authorized state attorneys general to bring civil enforcement actions under HIPAA. These enhanced penalties and enforcement provisions went into effect immediately upon enactment of ARRA. ARRA also required that
HHS promulgate regulations requiring that certain notifications be made to individuals, to HHS and potentially to the media in the event of breaches of the privacy of protected health information. These breach notification regulations went into
effect on September&nbsp;23, 2009, and HHS began to enforce violations on February&nbsp;22, 2010. Violations of the breach notification provisions of HIPAA can trigger the increased civil monetary penalties described above. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARRA&#146;s numerous other changes to HIPAA have delayed effective dates and require the issuance of implementing regulations by HHS. The
Health Information Technology for Economic and Clinical Health (&#147;HITECH&#148;) Act was enacted in conjunction with ARRA. On January&nbsp;25, 2013, HHS issued final modifications to the HIPAA Privacy, Security, and Enforcement Rules mandated by
the HITECH Act, which had been previously issued as a proposed rule on July&nbsp;14, 2010. Among other things, these modifications make business associates of covered entities directly liable for compliance with certain HIPAA requirements,
strengthen the limitations on the use and disclosure of protected health information without individual authorizations, and adopt the additional HITECH Act enhancements, including enforcement of noncompliance with HIPAA due to willful neglect. The
changes to HIPAA enacted as part of ARRA reflect a Congressional intent that HIPAA&#146;s privacy and security provisions be more strictly enforced. It is likely that these changes will stimulate increased enforcement activity and enhance the
potential that health care providers will be subject to financial penalties for violations of HIPAA. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to the federal HIPAA regulations, most states also have laws that protect the
confidentiality of health information. Also, in response to concerns about identity theft, many states have adopted <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;security breach&#148; notification laws that may impose requirements
regarding the safeguarding of personal information, such as social security numbers and bank and credit card account numbers, and that impose an obligation to notify persons when their personal information has or may have been accessed by an
unauthorized person. Some state security breach notification laws may also impose physical and electronic security requirements. Violation of state security breach notification laws can trigger significant monetary penalties. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The False Claims Act </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Federal False Claims Act gives the Federal Government an additional way to police false bills or requests for payment for health care services. Under the False Claims Act, the government may fine any
person who knowingly submits, or participates in submitting, claims for payment to the Federal Government which are false or fraudulent, or which contain false or misleading information. Any person who knowingly makes or uses a false record or
statement to avoid paying the Federal Government, or knowingly conceals or avoids an obligation to pay money to the Federal Government, may also be subject to fines under the False Claims Act. Under the False Claims Act, the term &#147;person&#148;
means an individual, company, or corporation. The Federal Government has widely used the False Claims Act to prosecute Medicare and other governmental program fraud in areas such as violations of the Federal anti-kickback statute or the Stark Laws,
coding errors, billing for services not provided, and submitting false cost reports. The False Claims Act has also been used to prosecute people or entities that bill services at a higher reimbursement rate than is allowed and that bill for care
that is not medically necessary. In addition to government enforcement, the False Claims Act authorizes private citizens to bring qui tam or &#147;whistleblower&#148; lawsuits, greatly extending the practical reach of the False Claims Act. The
penalty for violation of the False Claims Act is a minimum of $5,500 for each fraudulent claim plus three times the amount of damages caused to the government as a result of each fraudulent claim. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Fraud Enforcement and Recovery Act of 2009 (&#147;FERA&#148;) amended the False Claims Act with the intent of enhancing the powers of
government enforcement authorities and whistleblowers to bring False Claims Act cases. In particular, FERA attempts to clarify that liability may be established not only for false claims submitted directly to the government, but also for claims
submitted to government contractors and grantees. FERA also seeks to clarify that liability exists for attempts to avoid repayment of overpayments, including improper retention of federal funds. FERA also included amendments to False Claims Act
procedures, expanding the government&#146;s ability to use the Civil Investigative Demand process to investigate defendants, and permitting government complaints in intervention to relate back to the filing of the whistleblower&#146;s original
complaint. FERA is likely to increase both the volume and liability exposure of False Claims Act cases brought against health care providers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;12, 2016, CMS finalized the <FONT STYLE="white-space:nowrap">so-called</FONT> <FONT STYLE="white-space:nowrap">&#147;60-day</FONT> rule,&#148; which is the obligation of providers to
report and return Medicare overpayments within 60 days of identifying the same. A provider who retains overpayments beyond 60 days may be liable under the False Claims Act. &#147;Identification&#148; is identified as when a person &#147;has, or
should have through the exercise of reasonable diligence,&#148; identified and quantified the amount of an overpayment. The final rule also established a six year lookback period, meaning overpayments must be reported and returned if a person
identifies the overpayment within six years of the date the overpayment was received. Providers must report and return overpayments even if they did not cause the overpayment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In June 2016, the Department of Justice issued a rule that more than doubles civil monetary penalties under the False Claims Act. These increases took effect on August&nbsp;1, 2016 and apply to False
Claims Act violations after November&nbsp;2, 2015. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to the False Claims Act, the Federal Government may use
several criminal statutes to prosecute the submission of false or fraudulent claims for payment to the Federal Government. Many states have similar false claims statutes that impose liability for the types of acts prohibited by the False Claims Act.
As part of the Deficit </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Reduction Act of 2005 (the &#147;DRA&#148;), Congress provided states an incentive to adopt state false claims acts consistent with the Federal False Claims Act. Additionally, the DRA required
providers who receive $5&nbsp;million or more annually from Medicaid to include information on Federal and state false claims acts, whistleblower protections and the providers&#146; own policies on detecting and preventing fraud in their written
employee policies. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Civil Monetary Penalties </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The United States Department of Health and Human Services may impose civil monetary penalties upon any person or entity who presents, or
causes to be presented, certain ineligible claims for medical items or services. The amount of penalties varies, depending on the offense, from $2,000 to $50,000 per violation. In addition, persons who have been excluded from the Medicare or
Medicaid program and still retain ownership in a participating entity, or who contract with excluded persons, may be penalized. Penalties also are applicable in certain other cases, including violations of the Federal anti-kickback statute, Stark
Law or False Claims Act, and payments to limit certain patient services and improper execution of statements of medical necessity. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>FDA Regulation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The U.S. Food and Drug Administration
(&#147;FDA&#148;) regulates medical device user facilities, which include home health care providers. FDA regulations require user facilities to report patient deaths and serious injuries to FDA and/or the manufacturer of a device used by the
facility if the device may have caused or contributed to the death or serious injury of any patient. FDA regulations also require user facilities to maintain files related to adverse events and to establish and implement appropriate procedures to
ensure compliance with the above reporting and recordkeeping requirements. User facilities are subject to FDA inspection, and noncompliance with applicable requirements may result in warning letters or sanctions including civil monetary penalties,
injunction, product seizure, criminal fines and/or imprisonment. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Patient Protection and Affordable Care Act
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In March&nbsp;2010, comprehensive health care reform legislation was signed into law in the United States through the
passage of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (collectively, &#147;PPACA&#148;). Since the 2016 election, it has been widely discussed that the PPACA will be &#147;repealed and
replaced.&#148; The effect of any major modification or repeal of the PPACA on our business, operations, or financial condition cannot be predicted at this time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Even as of December&nbsp;31, 2016, it is difficult to predict the full impact of PPACA due to the law&#146;s complexity and phased in effective dates, as well as our inability to foresee how CMS and other
participants in the health care industry will respond to the choices available to them under the law. PPACA calls for a number of changes to be made over time that will likely have a significant impact upon the health care delivery system. For
example, PPACA mandates decreases in home health reimbursement rates, including a four-year phased rebasing of the home health payment system that began in 2014 and will continue through 2017. These reimbursement changes are described in detail in
Part II, Item 7, &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations: Overview &#150; Economic and Industry Factors.&#148; PPACA has established a number of new requirements impacting our business
operations, and promises to give rise to other changes that could significantly impact our businesses in the future. For example, PPACA also mandates the creation of a home health value-based purchasing program, the development of quality measures,
and the testing of alternative payment and delivery models, including ACOs and the Bundled Payments for Care Improvement initiative. See Part I, Item 1A, &#147;Risk Factors: Risks Related to Laws and Government Regulations&#148; for a more complete
discussion of PPACA and the risks it presents to our businesses. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The Improving Medicare Post-Acute Care Transformation Act </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2014, the Improving Medicare Post-Acute Care Transformation Act (&#147;IMPACT Act&#148;)&nbsp;was signed into law requiring the
reporting of standardized patient assessment data for quality improvement, payment and discharge planning purposes across the spectrum of post-acute care providers (&#147;PACs&#148;), including skilled nursing facilities and home health agencies.
The IMPACT Act requires PACs to begin reporting: (1)&nbsp;standardized patient assessment data at admission and discharge by October&nbsp;1, 2018 for post-acute care providers, including skilled nursing facilities and by January&nbsp;1, 2019 for
home health agencies; (2)&nbsp;new quality measures, including functional status, skin integrity, medication reconciliation, incidence of major falls, and patient preference regarding treatment and discharge at various intervals between
October&nbsp;1, 2016 and January&nbsp;1, 2019; and (3)&nbsp;resource use measures, including Medicare spending per beneficiary, discharge to community, and hospitalization rates of potentially preventable readmissions by October&nbsp;1, 2016 for
post-acute care providers, including skilled nursing facilities and by October&nbsp;1, 2017 for home health agencies. Failure to report such data when required would subject a facility to a two percent reduction in market basket prices then in
effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The IMPACT Act further requires HHS and the Medicare Payment Advisory Commission (&#147;MedPAC&#148;), a commission
chartered by Congress to advise it on Medicare payment issues, to study alternative PAC payment models, including payment based upon individual patient characteristics and not care setting, with corresponding Congressional reports required based on
such analysis. The IMPACT Act also included provisions impacting Medicare-certified hospices, including: (1)&nbsp;increasing survey frequency for Medicare-certified hospices to once every 36 months; (2)&nbsp;imposing a medical review process for
facilities with a high percentage of stays in excess of 180 days; and (3)&nbsp;updating the annual aggregate Medicare payment cap. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>The Comprehensive Care for Joint Replacement Bundled Payment Program </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In November 2015, CMS announced the final Comprehensive Care for Joint Replacement bundled payment program (&#147;CJR Program&#148;). The
CJR Program implements a mandatory payment model in which acute care hospitals in 67 metropolitan statistical areas will receive a bundled payment for all inpatient care provided in connection with a lower extremity joint replacement or reattachment
procedure, as well as for all related care provided within a <FONT STYLE="white-space:nowrap">90-day</FONT> episode of care following discharge from such hospital. The bundled payment will be in lieu of separate payments provided to post-acute
healthcare providers for services provided within such <FONT STYLE="white-space:nowrap">90-day</FONT> episode of care. The CJR Program will test this payment model over five performance periods between April&nbsp;1, 2016 and December&nbsp;31, 2020
to see if Medicare expenditures can be reduced while at the same time improving care coordination and preserving or enhancing the quality of care provided to Medicare beneficiaries. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Pre-Claim</FONT> Review Demonstration for Home Health Services </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;8, 2016, CMS announced the implementation of a three year Medicare <FONT STYLE="white-space:nowrap">pre-claim</FONT> review
demonstration for home health services provided to beneficiaries in the states of Illinois, Florida, Texas, Michigan and Massachusetts. The demonstration began in Illinois in August 2016 and will expand to Florida for home health services that begin
on or after April&nbsp;1, 2017. CMS is expected to announce staggered start dates for the other states in the coming months. The <FONT STYLE="white-space:nowrap">pre-claim</FONT> review is a process through which a request for provisional
affirmation of coverage is submitted for review before a final claim is submitted for payment. The <FONT STYLE="white-space:nowrap">pre-claim</FONT> review demonstration may result in an increase in administrative costs or reimbursement delays
related to home health services in such states, which could have an adverse effect on our results of operations and cash flow. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Home Health Groupings Model </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the Calendar Year 2017 Home Health Proposed Rule, released in July 2016, CMS provided information regarding potential changes to the Home Health Prospective Payment System (&#147;HHPPS&#148;), known as
the Home Health Groupings Model (&#147;HHGM&#148;). Among a number of major differences from the current payment system, the HHGM would distinguish between referrals from institutions and those from the community, with
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
community referrals receiving lower payments.&nbsp;In addition, a 60-day episode would consist of two 30-day periods, each paid separately, with the initial 30-day period paid higher than any
other period.&nbsp;CMS did not solicit comments at that time but noted that a more detailed Technical Report would be released with additional research and analysis conducted on the HHGM. The HHGM Technical Report was issued in December
2016.&nbsp;We are closely monitoring this potential change to the HHPPS and have joined industry stakeholders in directly engaging CMS on this concept and its impact on home health agencies.&nbsp;CMS has not indicated if HHGM will be included in the
Calendar Year 2018 Home Health Proposed Rule which will be released in mid-summer 2017.&nbsp;At this time we are unable to determine the impact this potential change in reimbursement methodology might have on Amedisys. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Competitors </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">There
are few barriers to entry in the home health and hospice jurisdictions that do not require certificates of need or permits of approval.&nbsp;Our primary competition in these jurisdictions comes from local privately and publicly-owned and
hospital-owned health care providers.&nbsp;We compete based on the availability of personnel, the quality of services, expertise of visiting staff, and, in certain instances, on the price of our services.&nbsp;In addition, we compete with a number
of <FONT STYLE="white-space:nowrap">non-profit</FONT> organizations that finance acquisitions and capital expenditures on a <FONT STYLE="white-space:nowrap">tax-exempt</FONT> basis or receive charitable contributions that are unavailable to us.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Available Information </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our company website address is <U>www.amedisys.com</U>. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst
presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled &#147;Investors&#148; on our website home page.
Visitors to our website can also register to receive automatic <FONT STYLE="white-space:nowrap">e-mail</FONT> and other notifications alerting them when new information is made available on the &#147;Investors&#148; subpage of our website. In
addition, we make available on the Investors subpage of our website (under the link &#147;SEC Filings&#148;), free of charge, our annual reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,</FONT> quarterly reports on Form <FONT
STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as reasonably practicable after we electronically file or
furnish such reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct, our Corporate Governance Guidelines and the charters for the Audit, Compensation, Compliance and Ethics,
Nominating and Corporate Governance and Quality of Care Committees of our Board are also available on the Investors subpage of our website (under the link &#147;Corporate Governance&#148;). Reference to our website does not constitute incorporation
by reference of the information contained on the website and should not be considered part of this document. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally,
the public may read and copy any of the materials we file with the SEC at the SEC&#146;s Public Reference Room at 100 F Street, NE, Room 1580, Washington, D.C. 20549. Information on the operation of the Public Reference Room may be obtained by
calling the SEC at <FONT STYLE="white-space:nowrap">(800)&nbsp;SEC-0330.</FONT> Our electronically filed reports can also be obtained on the SEC&#146;s internet site at <U>http://www.sec.gov</U>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_4"></A>ITEM&nbsp;1A.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RISK FACTORS </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The
risks described below, and risks described elsewhere in this Form <FONT STYLE="white-space:nowrap">10-K,</FONT> could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows and the
actual outcome of matters as to which forward-looking statements are made in this <FONT STYLE="white-space:nowrap">Form&nbsp;10-K.</FONT> The risk factors described below and elsewhere in this Form <FONT STYLE="white-space:nowrap">10-K</FONT> are
not the only risks faced by Amedisys. Our business and consolidated financial condition, results of operations and cash flows may also be materially adversely affected by factors that are not currently known to us, by factors that we currently
consider immaterial or by factors that are not specific to us, such as general economic conditions. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>If any of the
following risks are actually realized, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected. In that case, the trading price of our common stock could decline. </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>You should refer to the explanation of the qualifications and limitations on forward-looking statements under &#147;Special Caution
Concerning Forward-Looking Statements.&#148; All forward-looking statements made by us are qualified by the risk factors described below. </I></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Reimbursement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Federal and state changes to reimbursement and other aspects of Medicare and Medicaid could have a material adverse effect on our business and consolidated financial condition, results of operations
and cash flows. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our net service revenue is primarily derived from Medicare, which accounted for 78%, 80% and 82% of
our revenue during 2016, 2015 and 2014, respectively. Payments received from Medicare are subject to changes made through federal legislation. When such changes are implemented, we must also modify our internal billing processes and procedures
accordingly, which can require significant time and expense. These changes, as further detailed in Part I, Item 1, &#147;Business: Payment for Our Services,&#148; can include changes to base episode payments and adjustments for home health services,
changes to cap limits and per diem rates for hospice services and changes to Medicare eligibility and documentation requirements or changes designed to restrict utilization. Any such changes, including retroactive adjustments, adopted in the future
by the Center for Medicare and Medicaid Services (&#147;CMS&#148;) could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April of 2015, Congress passed and President Obama signed the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;doc fix&#148; in
the form of the Medicare Access and CHIP Reauthorization Act of 2015 (&#147;MACRA&#148;). This law replaces a long-standing physician reimbursement formula with statutorily prescribed physician payment updates and provisions. MACRA provides for an
increase of 3% of the payment amount otherwise made for home health services furnished in rural areas, and sets Medicare reimbursements for post-acute care providers to increase by 1.0% in fiscal year 2018. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;1, 2016, CMS published annual changes in Medicaid hospice payment rates. As finalized, CMS estimates hospices will see
a 2.1% ($350 million) increase in Medicare payments for fiscal year 2017, which reflects a market basket update of 2.7%, reduced by 0.6% as required by PPACA. CMS will reimburse hospice providers with two routine home care rates, to provide separate
payment rates for the first 60 days of care and care beyond 60 days, a change that was instituted in 2016. In addition, the rule finalizes changes to the hospice quality reporting program, including new quality measures. The final rule also
describes a potential future enhanced data collection instrument as well as plans to publicly display quality measures and other hospice data beginning in the middle of 2017. As of December&nbsp;31, 2016, we estimate our impact of the 2017 final
rule to be an increase of approximately 2%. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2016, CMS issued a final rule to update and revise Medicare home
health reimbursement rates for calendar year 2017. The final rule implements the final year of the four-year <FONT STYLE="white-space:nowrap">phase-in</FONT> of the rebasing adjustments </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to the home health prospective payment system rates as required by the PPACA. CMS also provides an update to the Home Health Quality Reporting Program. CMS estimates that the net impact of the
payment provisions of the final rule will result in a decrease of 0.7% in reimbursement to home health providers. The decrease is the result of a 2.8% market basket increase minus 0.3% for productivity, a 2.3% decrease for the last year in the
four-year rebasing cycle and a 0.97% decrease for the second year in a three-year series of cuts for nominal case mix growth. Our impact could differ depending on differences in the wage index and the impact of coding and outlier changes. As of
December&nbsp;31, 2016, we estimate our impact of the 2017 final rule to be a decrease of approximately 2%. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
February&nbsp;2, 2016 CMS published a final rule adding new requirements for Medicaid home health services. Among other things, the final rule requires that for the initial ordering of home health services, the physician must document that a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">face-to-face</FONT></FONT> encounter that is related to the primary reason the beneficiary requires home health services occurred no more than 90 days before or 30 days after the start of
services. The final rule requires that for the initial ordering of certain medical equipment, the physician or authorized <FONT STYLE="white-space:nowrap">non-physician</FONT> practitioner must document that a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">face-to-face</FONT></FONT> encounter that is related to the primary reason the beneficiary requires medical equipment occurred no more than 6 months prior to the start of services. Although the final rule&#146;s stated
effective date is July&nbsp;1, 2016, CMS created an exception for state legislation by giving state agencies that require state legislation to until July&nbsp;1, 2017 or July&nbsp;1, 2018 to publish requirements imposed by the rule. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are continuing efforts to reform governmental health care programs that could result in major changes in the health care delivery
and reimbursement system on a national and state level, including changes directly impacting the reimbursement systems for our home health and hospice care centers. Though we cannot predict what, if any, reform proposals will be adopted, health care
reform and legislation may have a material adverse effect on our business and our financial condition, results of operations and cash flows through decreasing payments made for our services. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We could be affected adversely by the continuing efforts of governmental payors to contain health care costs. We cannot assure you that
reimbursement payments under governmental payor programs, including Medicare supplemental insurance policies, will remain at levels comparable to present levels or will be sufficient to cover the costs allocable to patients eligible for
reimbursement pursuant to these programs. Any such changes could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our hospice operations are subject to two annual Medicare caps. If such caps were to be exceeded by any of our hospice providers,
our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">With respect to our hospice operations, overall payments made by Medicare to each provider number (generally corresponding to a hospice care center) are subject to an inpatient cap amount and an overall
payment cap, which are calculated and published by the Medicare fiscal intermediary on an annual basis covering the period from November&nbsp;1 through October 31.&nbsp;If payments received by any one of our hospice provider numbers exceeds either
of these caps, we may be required to reimburse the Medicare program for payments received in excess of the caps, which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Quality reporting requirements may negatively impact Medicare reimbursement. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hospice quality reporting was mandated by PPACA, which directs the Secretary to establish quality reporting requirements for hospice
programs. For fiscal year 2014, and each subsequent year, failure to submit required quality data will result in a 2 percentage point reduction to the market basket percentage increase for that fiscal year. This quality reporting program is
currently <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;pay-for-reporting,&#148;</FONT></FONT> meaning it is the act of submitting data that determines compliance with program requirements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Similarly, in the Calendar Year 2015 Home Health Final Rule, CMS proposed to establish a new
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;Pay-for-Reporting</FONT></FONT> Performance Requirement&#148; with which provider compliance with quality reporting program requirements can be measured. Home health agencies
that do not submit quality measure data to CMS are subject to a 2.0% reduction in their annual home health payment update percentage. Home health agencies are required to report prescribed quality assessment data for a minimum of 70.0% of all
patients with episodes of care that occur on or after July&nbsp;1, 2015. This compliance threshold increases by 10.0% in each of two subsequent <FONT STYLE="white-space:nowrap">periods--i.e.,</FONT> for episodes beginning on or after July&nbsp;1,
2016 and before June&nbsp;30, 2017, home health agencies must score at least 80%, and for episodes beginning on or after July&nbsp;1, 2017 and thereafter, the required performance level is at least 90%. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Improving Medicare Post-Acute Care Transformation Act of 2014 (the &#147;IMPACT Act&#148;) requires the submission of standardized
data by home health agencies and other providers. Specifically, the IMPACT Act requires, among other significant activities, the reporting of standardized patient assessment data with regard to quality measures, resource use, and other measures.
Failure to report data as required will subject providers to a 2% reduction in market basket prices then in effect. Additionally, reporting activities associated with the IMPACT Act are anticipated to be quite burdensome. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">There can be no assurance that all of our agencies will continue to meet quality reporting requirements in the future which may result in
one or more of our agencies seeing a reduction in its Medicare reimbursements. Regardless, we, like other healthcare providers, are likely to incur additional expenses in an effort to comply with additional and changing quality reporting
requirements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Any economic downturn, deepening of an economic downturn, continued deficit spending by the Federal
Government or state budget pressures may result in a reduction in payments and covered services. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adverse developments
in the United States could lead to a reduction in Federal Government expenditures, including governmentally funded programs in which we participate, such as Medicare and Medicaid. In addition, if at any time the Federal Government is not able to
meet its debt payments unless the federal debt ceiling is raised, and legislation increasing the debt ceiling is not enacted, the Federal Government may stop or delay making payments on its obligations, including funding for government programs in
which we participate, such as Medicare and Medicaid. Failure of the government to make payments under these programs could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.
Further, any failure by the United States Congress to complete the federal budget process and fund government operations may result in a Federal Government shutdown, potentially causing us to incur substantial costs without reimbursement under the
Medicare program, which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. As an example, the failure of the 2011 Joint Select Committee to meet its Deficit Reduction goal
resulted in an automatic reduction in Medicare home and hospice payments of 2% beginning April&nbsp;1, 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Historically,
state budget pressures have resulted in reductions in state spending. Given that Medicaid outlays are a significant component of state budgets, we can expect continuing cost containment pressures on Medicaid outlays for our services. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, sustained unfavorable economic conditions may affect the number of patients enrolled in managed care programs and the
profitability of managed care companies, which could result in reduced payment rates and could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Future cost containment initiatives undertaken by private third party payors may limit our future revenue and profitability.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our <FONT STYLE="white-space:nowrap">non-Medicare</FONT> revenue and profitability are affected by continuing efforts
of third party payors to maintain or reduce costs of health care by lowering payment rates, narrowing the scope of covered services, increasing case </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
management review of services and negotiating pricing. There can be no assurance that third party payors will make timely payments for our services, and there is no assurance that we will
continue to maintain our current payor or revenue mix. We are continuing our efforts to develop our <FONT STYLE="white-space:nowrap">non-Medicare</FONT> sources of revenue and any changes in payment levels from current or future third party payors
could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks
Related to Laws and Government Regulations </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are operating under a Corporate Integrity Agreement. Violations of
this agreement could result in substantial penalties or exclusion from participation in the Medicare program. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
April&nbsp;23, 2014, with no admissions of liability on our part, we entered into a settlement agreement with the U.S. Department of Justice relating to certain of our clinical and business operations. Concurrently with our entry into this
agreement, we entered into a Corporate Integrity Agreement (&#147;CIA&#148;) with the Office of Inspector <FONT STYLE="white-space:nowrap">General-HHS</FONT> (&#147;OIG&#148;). The CIA, which has a term of five years, formalizes various aspects of
our already existing ethics and compliance programs and contains other requirements designed to help ensure our ongoing compliance with federal health care program requirements. Among other things, the CIA requires us to maintain our existing
compliance program, executive compliance committee and compliance committee of the Board of Directors; provide certain compliance training; continue screening new and current employees to ensure they are eligible to participate in federal health
care programs; engage an independent review organization (&#147;IRO&#148;) to perform certain auditing and reviews and prepare certain reports regarding our compliance with federal health care programs, our billing submissions to federal health care
programs and our compliance and risk mitigation programs; and provide certain reports and management certifications to the OIG. Additionally, the CIA specifically requires that we report substantial overpayments that we discover we have received
from the federal health care programs, as well as probable violations of federal health care laws. Upon breach of the CIA, we could become liable for payment of certain stipulated penalties, or could be excluded from participation in federal health
care programs. Although we believe that we are currently in compliance with the CIA, any violations of the agreement could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pending civil litigation could have a material adverse effect on the Company. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and certain of our current and former directors, senior executives and other employees are defendants in a federal securities class
action. We are also a defendant in several class action lawsuits. See Part II, Item&nbsp;8, Note&nbsp;10 &#150; Commitments and Contingencies for a more detailed description of these proceedings. These actions remain in preliminary stages and it is
not yet possible to assess their probable outcome or our potential liability, if any. We cannot provide any assurances that the legal and other costs associated with the defense of these actions, the amount of time required to be spent by management
on these matters and the ultimate outcome of these actions will not have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our insurance may not cover all of the costs associated with defending the pending federal securities class action, and any
potential liability costs associated with this matter, and we maintain no insurance that covers any portion of the pending class action lawsuits. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">With respect to the pending securities class action, we may be obligated to indemnify (and advance legal expenses to) both current and former officers, employees and directors in connection with this
matter. We maintain directors&#146; and officers&#146; liability insurance that we believe should cover a portion of the legal costs and potential liability costs associated with this matter. However, such insurance coverage does not extend to all
of these expenditures, and the insurance limits may be insufficient even with respect to expenditures that would otherwise be covered. Furthermore, our insurance carriers may seek to deny coverage in this matter, in which case we may have to fund
the indemnification amounts owed to such directors and officers ourselves. We do not </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
maintain any insurance that will cover any part of the class action lawsuits in which we are defendants. If our insurance coverage is denied or is not adequate, it may have a material adverse
effect on our business and consolidated financial condition, results of operations and cash flows. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are subject to
extensive government regulation. Any changes to the laws and regulations governing our business, or to the interpretation and enforcement of those laws or regulations, could have a material adverse effect on our business and consolidated financial
condition, results of operations and cash flows. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our industry is subject to extensive federal and state laws and
regulations. See Part I, Item 1, &#147;Our Regulatory Environment&#148; for additional information on such laws and regulations. Federal and state laws and regulations impact how we conduct our business, the services we offer and our interactions
with patients, our employees and the public and impose certain requirements on us such as: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">licensure and certification; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">adequacy and quality of health care services; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">qualifications of health care and support personnel; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">quality and safety of medical equipment; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">confidentiality, maintenance and security issues associated with medical records and claims processing; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">relationships with physicians and other referral sources; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">operating policies and procedures; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">policies and procedures regarding employee relations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">addition of facilities and services; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">billing for services; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">requirements for utilization of services; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">documentation required for billing and patient care; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">reporting and maintaining records regarding adverse events. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">These laws and regulations, and their interpretations, are subject to change. Changes in existing laws and regulations, or their
interpretations, or the enactment of new laws or regulations could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows by: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">increasing our administrative and other costs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">increasing or decreasing mandated services; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">causing us to abandon business opportunities we might have otherwise pursued; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">decreasing utilization of services; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">forcing us to restructure our relationships with referral sources and providers; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">requiring us to implement additional or different programs and systems. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, we are subject to various routine and <FONT STYLE="white-space:nowrap">non-routine</FONT> reviews, audits and
investigations by the Medicare and Medicaid programs and other federal and state governmental agencies, which have various rights and remedies against us if they establish that we have overcharged the programs or failed to comply with program
requirements. Violation of the laws governing our operations, or changes in interpretations of those laws, could result in the imposition of fines, civil or criminal penalties, and the termination of our rights to participate in federal and
state-sponsored programs and/or the suspension or revocation of our licenses. If we become subject to material fines, or if other sanctions or other corrective actions are imposed on us, our business and consolidated financial condition, results of
operations and cash flows could be materially adversely affected. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We face periodic and routine reviews, audits and investigations under our contracts
with federal and state government agencies and private payors, and these audits could have adverse findings that may negatively impact our business. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As a result of our participation in the Medicare and Medicaid programs, we are subject to various governmental reviews, audits and investigations to verify our compliance with these programs and
applicable laws and regulations. We also are subject to audits under various government programs, including the RAC, ZPIC, PSC and MIC programs as well as in accordance with the requirements of our CIA, in which third party firms engaged by CMS or
by the Company conduct extensive reviews of claims data and medical and other records to identify potential improper payments under the Medicare program. Private pay sources also reserve the right to conduct audits. If billing errors are identified
in the sample of reviewed claims, the billing error can be extrapolated to all claims filed which could result in a larger overpayment than originally identified in the sample of reviewed claims. Our costs to respond to and defend reviews, audits
and investigations may be significant and could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. Moreover, an adverse review, audit or investigation could result in:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">required refunding or retroactive adjustment of amounts we have been paid pursuant to the federal or state programs or from private payors;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">state or federal agencies imposing fines, penalties and other sanctions on us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">loss of our right to participate in the Medicare program, state programs, or one or more private payor networks;&nbsp;or
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">damage to our business and reputation in various markets. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">These results could have a material adverse effect on our business and consolidated financial condition, results of operations and cash
flows. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If a care center fails to comply with the conditions of participation in the Medicare program, that care center
could be subjected to sanctions or terminated from the Medicare program. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each of our care centers must comply with
required conditions of participation in the Medicare program. If we fail to meet the conditions of participation at a care center, we may receive a notice of deficiency from the applicable state surveyor. If that care center then fails to institute
an acceptable plan of correction to remediate the deficiency within the correction period provided by the state surveyor, that care center could be terminated from the Medicare program or subjected to alternative sanctions. CMS outlined its
alternative sanction enforcement options for home health care centers through a regulation published in 2012; under the regulation, CMS may impose temporary management, direct a plan of correction, direct training or impose payment suspensions and
civil monetary penalties, in each case, upon providers who fail to comply with the conditions of participation. Termination of one or more of our care centers from the Medicare program for failure to satisfy the program&#146;s conditions of
participation, or the imposition of alternative sanctions, could disrupt operations, require significant attention by management, or have a material adverse effect on our business and reputation and consolidated financial condition, results of
operations and cash flows. CMS issued a proposed rule on October&nbsp;9, 2014, revising the Medicare conditions of participation for home health care centers across the industry, with an unknown effective date. We provided public comments on the
proposed changes, but do not know at this time what effect the finalized revisions will have on our operations, and there can be no assurances that the revisions will not have a material adverse effect on our business and consolidated financial
condition, results of operations and cash flows. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are subject to federal and state laws that govern our financial
relationships with physicians and other health care providers, including potential or current referral sources. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are
required to comply with federal and state laws, generally referred to as &#147;anti-kickback laws,&#148; that prohibit certain direct and indirect payments or other financial arrangements between health care providers that are
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
designed to encourage the referral of patients to a particular provider for medical services. In addition to these anti-kickback laws, the Federal Government has enacted specific legislation,
commonly known as the &#147;Stark Law,&#148; that prohibits certain financial relationships, specifically including ownership interests and compensation arrangements, between physicians (and the immediate family members of physicians) and providers
of designated health services, such as home health care centers, to whom the physicians refer patients. Some of these same financial relationships are also subject to additional regulation by states. Although we believe we have structured our
relationships with physicians and other potential referral sources to comply with these laws where applicable, we cannot assure you that courts or regulatory agencies will not interpret state and federal anti-kickback laws and/or the Stark Law and
similar state laws regulating relationships between health care providers and physicians in ways that will adversely implicate our practices or that isolated instances of noncompliance will not occur. Violations of federal or state Stark or
anti-kickback laws could lead to criminal or civil fines or other sanctions, including denials of government program reimbursement or even exclusion from participation in governmental health care programs, which could have a material adverse effect
on our business and consolidated financial condition, results of operations and cash flows. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may face significant
uncertainty in the industry due to government health care reform. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The health care industry in the United States is
subject to fundamental changes due to ongoing health care reform efforts and related political, economic and regulatory influences. In March&nbsp;2010, comprehensive health care reform legislation was signed into law in the United States through the
passage of the Patient Protection and Affordable Health Care Act and the Health Care and Education Reconciliation Act (collectively, &#147;PPACA&#148;). However, it is difficult to predict the full impact of PPACA due to the law&#146;s complexity
and <FONT STYLE="white-space:nowrap">phased-in</FONT> effective dates, as well as our inability to foresee how CMS and other participants in the health care industry will respond to the choices available to them under the law. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">PPACA makes a number of changes to Medicare payment rates and also calls for a rebasing of the home health payment system that began in
2014 and will continue through 2017. These reimbursement changes are described in detail in Part II, Item 7, &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations: Overview &#150; Economic and Industry
Factors.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Regulations implementing the provisions of the PPACA and related initiatives may similarly increase our costs,
decrease our revenues, expose us to expanded liability or require us to revise the ways in which we conduct our business. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">PPACA also calls for a number of other changes to be made over time that will likely have a significant impact upon the health care
delivery system. For example, PPACA mandates creation of a home health value-based purchasing program, the development of quality measures, and decreases in home health reimbursement rates, including rebasing, as further described in Part II, Item
7, &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations: Overview &#150; Economic and Industry Factors.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, various health care reform proposals similar to the federal reforms described above have also emerged at the state level, including in several states which we operate. We cannot predict with
certainty what health care initiatives, if any, will be implemented at the state level, or what the ultimate effect of federal health care reform or any future legislation or regulation may have on us or on our business and consolidated financial
condition, results of operations and cash flows. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to impacting our Medicare businesses, PPACA may also
significantly affect our <FONT STYLE="white-space:nowrap">non-Medicare</FONT> businesses. PPACA makes many changes to the underwriting and marketing practices of private payors. The resulting economic pressures could prompt these payors to seek to
lower their rates of reimbursement for the services we provide. At this time, it is not possible to estimate what impact PPACA may have on our <FONT STYLE="white-space:nowrap">non-Medicare</FONT> businesses. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finally, efforts to repeal or substantially modify provisions of the PPACA continue in
Congress. The ultimate outcomes of legislative efforts to repeal, substantially amend, eliminate or reduce funding for the PPACA is unknown. While these attempts have not been successful to date, the results of the Presidential and Congressional
elections in 2016 could have a significant impact on future efforts to amend or repeal PPACA. In addition to the prospect for legislative repeal or revision, the President and members of his administration hostile to the PPACA could seek to impose
substantial changes upon the PPACA through administrative action, including revised regulation and other Executive Branch action. The effect of any major modification or repeal of the PPACA on our business, operations, or financial condition cannot
be predicted, but could be materially adverse. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to our Growth Strategies </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our growth strategy depends on our ability to acquire additional care centers and integrate and operate these care centers
effectively. If our growth strategy is unsuccessful or we are not able to successfully integrate newly acquired care centers into our existing operations, our business and consolidated financial condition, results of operations and cash flows could
be materially adversely affected. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may not be able to fully integrate the operations of our acquired businesses
with our current business structure in an efficient and cost-effective manner. Acquisitions involve significant risks and uncertainties, including difficulties in recouping partial episode payments and other types of misdirected payments for
services from the previous owners; difficulties integrating acquired personnel and business practices into our business; the potential loss of key employees, referral sources or patients of acquired care centers; the delay in payments associated
with change in ownership, control and the internal process of the Medicare fiscal intermediary; and the assumption of liabilities and exposure to unforeseen liabilities of acquired care centers. Further, the financial benefits we expect to realize
from many of our acquisitions are largely dependent upon our ability to improve clinical performance, overcome regulatory deficiencies, improve the reputation of the acquired business in the community and control costs. The failure to accomplish any
of these objectives or to effectively integrate any of these businesses could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>State efforts to regulate the establishment or expansion of health care providers could impair our ability to expand our
operations. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Some states require health care providers (including skilled nursing facilities, hospice care centers,
home health care centers and assisted living facilities) to obtain prior approval, known as a CON or POA, in order to commence operations. See Part I, Item 1, &#147;Our Regulatory Environment&#148; for additional information on CONs and POAs. If we
are not able to obtain such approvals, our ability to expand our operations could be impaired, which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Federal regulation may impair our ability to consummate acquisitions or open new care centers. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in federal laws or regulations may materially adversely impact our ability to acquire care centers or open new <FONT
STYLE="white-space:nowrap">start-up</FONT> care centers. For example, PPACA authorized CMS to impose temporary moratoria on the enrollment of new Medicare providers, if deemed necessary to combat fraud, waste or abuse under government programs. The
moratoria on new enrollments may be applied to categories of providers or to specific geographic regions. In 2012, the OIG released a report that concluded Medicare had overpaid home health agencies due to inappropriate and questionable billing
practices. Citing this report, in 2014, CMS adopted a temporary moratorium on new home health agencies and home health agency subunits in certain regions of Texas, Michigan, Florida and Illinois. On July&nbsp;29, 2016, CMS announced it was extending
such moratorium for an additional six months, and that the moratorium would be expanded statewide in each targeted state. If a moratorium is imposed on the enrollment of new home health or hospice providers in a geographic area we desire to service,
it could have a material impact on our ability to open new care centers. Additionally, in 2010, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
CMS implemented and amended a regulation known as the &#147;36 Month Rule&#148; that is applicable to home health care center acquisitions.&nbsp;Subject to certain exceptions, the 36 Month Rule
prohibits buyers of certain home health care centers &#150; those that either enrolled in Medicare or underwent a change in majority ownership fewer than 36 months prior to the acquisition &#150; from assuming the Medicare billing privileges of the
acquired care center. These changes in federal laws and regulations, and similar future changes, may further increase competition for acquisition targets and could have a material detrimental impact on our acquisition strategy. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We could face a variety of risks by expanding into our personal care line of business. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We established a personal care segment of our business with the acquisition of Associated Home Care, which closed on March&nbsp;1, 2016.
Risks of our entry into the new personal care segment include, without limitation: (i)&nbsp;potential diversion of management&#146;s time and other resources from our existing home health and hospice businesses; (ii)&nbsp;unanticipated liabilities
or contingencies; (iii)&nbsp;the need for additional capital and other resources to expand into this new line of business; and (iv)&nbsp;inefficient integration of operational and management systems and controls. Entry into a new line of business
may also subject us to new laws and regulations with which we are not familiar, and may lead to increased litigation and regulatory risk. If we are unable to successfully implement our growth strategies, our revenue and profitability may not grow as
we expect, our competitiveness may be materially and adversely affected, and our reputation and business may be harmed. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to
our Operations </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Because we are limited in our ability to control rates received for our services, our business and
consolidated financial condition, results of operations and cash flows could be materially adversely affected if we are not able to maintain or reduce our costs to provide such services. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As Medicare is our primary payor and rates are established through federal legislation, we have to manage our costs of providing care to
achieve a desired level of profitability. Additionally, <FONT STYLE="white-space:nowrap">non-Medicare</FONT> rates are difficult for us to negotiate as such payors are under pressure to reduce their own costs. As a result, we manage our costs in
order to achieve a desired level of profitability including, but not limited to, centralization of various processes, the use of technology and management of the number of employees utilized. If we are not able to continue to streamline our
processes and reduce our costs, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our industry is highly competitive, with few barriers to entry in certain states. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There are few barriers to entry in home health markets that do not require a CON or POA. Our primary competition comes from local privately-owned and hospital-owned health care providers. We compete based
on the availability of personnel; the quality of services, expertise of visiting staff; and in certain instances, on the price of our services. Increased competition in the future may limit our ability to maintain or increase our market share.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Further, the introduction of new and enhanced service offerings by others, in combination with industry consolidation and the
development of strategic relationships by our competitors, could cause a decline in revenue or loss of market acceptance of our services or make our services less attractive. Additionally, we compete with a number of
<FONT STYLE="white-space:nowrap">non-profit</FONT> organizations that can finance acquisitions and capital expenditures on a <FONT STYLE="white-space:nowrap">tax-exempt</FONT> basis or receive charitable contributions that are unavailable to us.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Managed care organizations and other third party payors continue to consolidate, which enhances their ability to influence
the delivery of health care services. Consequently, the health care needs of patients in the United States are increasingly served by a smaller number of managed care organizations. These organizations generally enter into service agreements with a
limited number of providers. Our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected if these organizations terminate us as
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
a provider and/or engage our competitors as a preferred or exclusive provider. In addition, should private payors, including managed care payors, seek to negotiate additional discounted fee
structures or the assumption by health care providers of all or a portion of the financial risk through prepaid capitation arrangements, our business and consolidated financial condition, results of operations and cash flows could be materially
adversely affected. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are unable to react competitively to new developments, our operating results may suffer. Further,
if states remove existing CONs or POAs, we would face increased competition in these states. For example, in 2013, the Governor of South Carolina vetoed funding for that state&#146;s CON program, effectively shutting down the program. Following a
judicial challenge, the South Carolina Supreme Court ruled in April 2014 that the South Carolina Department of Health and Environmental Control was statutorily obligated to administer the CON program, regardless of the Governor&#146;s veto.
Following this ruling, legislation has been introduced in the South Carolina House of Representatives for the purpose of limiting the application of that state&#146;s CON program. We do not know at this time what the outcome of this matter will be
in South Carolina, and whether this will have any impact upon our operations. Similarly, there can be no assurances that other states will not seek to eliminate or limit their existing CON or POA programs in a similar manner, leading to increased
competition in these states. Further, we cannot assure you that we will be able to compete successfully against current or future competitors, which could have a material adverse effect on our business and consolidated financial condition, results
of operations and cash flows. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are unable to maintain relationships with existing patient referral sources, our
business and consolidated financial condition, results of operations and cash flows could be materially adversely affected. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our success depends on referrals from physicians, hospitals and other sources in the communities we serve and on our ability to maintain good relationships with existing referral sources. Our referral
sources are not contractually obligated to refer patients to us and may refer their patients to other providers. Our growth and profitability depends, in part, on our ability to establish and maintain close working relationships with these patient
referral sources and to increase awareness and acceptance of the benefits of home health and hospice care by our referral sources and their patients. Our loss of, or failure to maintain, existing relationships or our failure to develop new referral
relationships could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are unable to provide consistently high quality of care, our business will be adversely impacted. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Providing quality patient care is the cornerstone of our business. We believe that hospitals, physicians and other referral sources refer patients to us in large part because of our reputation for
delivering quality care. Clinical quality is becoming increasingly important within our industry. Effective October 2012, Medicare began to impose a financial penalty upon hospitals that have excessive rates of patient readmissions within 30 days
from hospital discharge. We believe this new regulation provides a competitive advantage to home health providers who can differentiate themselves based upon quality, particularly by achieving low patient acute care hospitalization readmission rates
and by implementing disease management programs designed to be responsive to the needs of patients served by referring hospitals. We are focused intently upon improving our patient outcomes, particularly our patient acute care hospitalization
readmission rates. If we should fail to attain our goals regarding acute care hospitalization readmission rates and other quality metrics, we expect our ability to generate referrals would be adversely impacted, which could have a material adverse
effect upon our business and consolidated financial condition, results of operations and cash flows. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our business
depends on our information systems. Our inability to effectively integrate, manage and keep our information systems secure and operational could disrupt our operations. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our business depends on effective, secure and operational information systems which include systems provided by external contractors and other service providers. Problems with, or the failure of, our
technology and systems or any system upgrades or programming changes associated with such technology and systems, including any </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
problems we may experience with the implementation of the new clinical software system, could have a material adverse effect on data capture, medical documentation, billing, collections,
assessment of internal controls and management and reporting capabilities. Any such problems or failures and the costs incurred in correcting any such problems or failures, could have a material adverse effect on our business and consolidated
financial condition, results of operations and cash flows. Further, to the extent our external information technology contractors or other service providers become insolvent or fail to support the software or systems we have licensed from them, our
operations could be materially adversely affected. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our care centers also depend upon our information systems for accounting,
billing, collections, risk management, quality assurance, human resources, payroll and other information. If we experience a reduction in the performance, reliability, or availability of our information systems, our operations and ability to produce
timely and accurate reports could be materially adversely affected. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our information systems and applications require
continual maintenance, upgrading and enhancement to meet our operational needs. Our acquisition activity requires transitions and integration of various information systems. We regularly upgrade and expand our information systems&#146; capabilities.
If we experience difficulties with the transition and integration of information systems or are unable to implement, maintain, or expand our systems properly, we could suffer from, among other things, operational disruptions, regulatory problems and
increases in administrative expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may be required to expend significant capital and other resources to protect against
the threat of security breaches or to alleviate problems caused by breaches, including unauthorized access to patient data and personally identifiable information stored in our information systems, and the introduction of computer viruses or other
malicious software programs to our systems. Our security measures may be inadequate to prevent security breaches and our business operations could be materially adversely affected by federal and state fines and penalties, legal claims or
proceedings, cancellation of contracts and loss of patients if security breaches are not prevented. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have installed privacy
protection systems and devices on our network and POC laptops in an attempt to prevent unauthorized access to information in our database. However, our technology may fail to adequately secure the confidential health information and personally
identifiable information we maintain in our databases. In such circumstances, we may be held liable to our patients and regulators, which could result in fines, litigation or adverse publicity that could have a material adverse effect on our
business and consolidated financial condition, results of operations and cash flows. Even if we are not held liable, any resulting negative publicity could harm our business and distract the attention of management. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Further, our information systems are vulnerable to damage or interruption from fire, flood, power loss, telecommunications failure, <FONT
STYLE="white-space:nowrap">break-ins</FONT> and similar events. A failure to restore our information systems after the occurrence of any of these events could have a material adverse effect on our business and consolidated financial condition,
results of operations and cash flows. Because of the confidential health information we store and transmit, loss of electronically stored information for any reason could expose us to a risk of regulatory action and litigation and possible liability
and loss. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe we have all the necessary licenses from third parties to use technology and software that we do not own.
A third party could, however, allege that we are infringing its rights, which may deter our ability to obtain licenses on commercially reasonable terms from the third party, if at all, or cause the third party to commence litigation against us. In
addition, we may find it necessary to initiate litigation to protect our trade secrets, to enforce our intellectual property rights and to determine the scope and validity of any proprietary rights of others. Any such litigation, or the failure to
obtain any necessary licenses or other rights, could materially and adversely affect our business. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Possible changes in the case mix of patients, as well as payor mix and payment
methodologies, could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our revenue is determined by a number of factors, including our mix of patients and the rates of payment among payors. Changes in the case mix of our patients, payment methodologies or the payor mix among
Medicare, Medicaid and private payors could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our failure to negotiate favorable managed care contracts, or our loss of existing favorable managed care contracts, could have a material adverse effect on our business and consolidated financial
condition, results of operations and cash flows. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">One of our strategies is to diversify our payor sources by increasing
the business we do with managed care companies, and we strive to put in place favorable contracts with managed care payors. However, we may not be successful in these efforts. Additionally, there is a risk that the favorable managed care contracts
that we put in place may be terminated, and managed care contracts typically permit the payor to terminate the contract without cause, on very short notice, typically 60 days, which can provide payors leverage to reduce volume or obtain favorable
pricing. Our failure to negotiate and put in place favorable managed care contracts, or our failure to maintain in place favorable managed care contracts, could have a material adverse effect on our business and consolidated financial condition,
results of operations and cash flows. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>A write off of a significant amount of intangible assets or long-lived assets
could have a material adverse effect on our consolidated financial condition and results of operations. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">A significant
and sustained decline in our stock price and market capitalization, a significant decline in our expected future cash flows, a significant adverse change in the business climate, or slower growth rates could result in the need to perform an
impairment analysis under Accounting Standard Codification (&#147;ASC&#148;) Topic 350 &#147;Intangibles &#150; Goodwill and Other&#148; in future periods in addition to our annual impairment test. If we were to conclude that a write down of
goodwill is necessary, then we would record the appropriate charge, which could result in material charges that are adverse to our consolidated financial condition and results of operations. See Part II, Item&nbsp;8, Note&nbsp;5 &#150; Goodwill and
Other Intangible Assets, Net to our consolidated financial statements for additional information. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because we have grown in
part through acquisitions, goodwill and other acquired intangible assets represent a substantial portion of our assets. Goodwill was approximately $289.0&nbsp;million as of December&nbsp;31, 2016 and if we make additional acquisitions, it is likely
that we will record additional intangible assets in our consolidated financial statements. We also have long-lived assets consisting of property and equipment and other identifiable intangible assets of $83.8&nbsp;million as of December&nbsp;31,
2016, which we review both on a periodic basis for indefinite lived intangible assets as well as when events or circumstances indicate that the carrying amount of an asset may not be recoverable. If a determination that a significant impairment in
value of our unamortized intangible assets or long-lived assets occurs, such determination could require us to write off a substantial portion of our assets. A write off of these assets could have a material adverse effect on our consolidated
financial condition and results of operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>A shortage of qualified registered nursing staff and other clinicians,
such as therapists and nurse practitioners, could materially impact our ability to attract, train and retain qualified personnel and could increase operating costs. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We compete for qualified personnel with other healthcare providers. Our ability to attract and retain clinicians depends on several factors, including our ability to provide these personnel with
attractive assignments and competitive salaries and benefits. We cannot be assured we will succeed in any of these areas. In addition, there </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
are shortages of qualified health care personnel in some of our markets. As a result, we may face higher costs of attracting clinicians and providing them with attractive benefit packages than we
originally anticipated which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. In addition, if we expand our operations into geographic areas where health care providers
historically have been unionized, or if any of our care center employees become unionized, being subject to a collective bargaining agreement may have a negative impact on our ability to timely and successfully recruit qualified personnel and may
increase our operating costs. Generally, if we are unable to attract and retain clinicians, the quality of our services may decline and we could lose patients and referral sources, which could have a material adverse effect on our business and
consolidated financial condition, results of operations and cash flows. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our insurance liability coverage may not be
sufficient for our business needs. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result of operating in the home health industry, our business entails an
inherent risk of claims, losses and potential lawsuits alleging incidents involving our employees that are likely to occur in a patient&#146;s home. We maintain professional liability insurance to provide coverage to us and our subsidiaries against
these risks. However, we cannot assure you claims will not be made in the future in excess of the limits of our insurance, nor can we assure you that any such claims, if successful and in excess of such limits, will not have a material adverse
effect on our business and consolidated financial condition, results of operations and cash flows. Our insurance coverage also includes fire, property damage and general liability with varying limits. We cannot assure you that the insurance we
maintain will satisfy claims made against us or that insurance coverage will continue to be available to us at commercially reasonable rates, in adequate amounts or on satisfactory terms. Any claims made against us, regardless of their merit or
eventual outcome, could damage our reputation and business. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be subject to substantial malpractice or other
similar claims. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The services we offer involve an inherent risk of professional liability and related substantial
damage awards. As of February&nbsp;24, 2017, we had approximately 16,000&nbsp;employees (10,800 home health, 2,800 hospice, 1,800 personal care and 600 corporate employees). In addition, we employ direct care workers on a contractual basis to
support our existing workforce. Due to the nature of our business, we, through our employees and caregivers who provide services on our behalf, may be the subject of medical malpractice claims. A court could find these individuals should be
considered our agents, and, as a result, we could be held liable for their acts or omissions. We cannot predict the effect that any claims of this nature, regardless of&nbsp;their ultimate outcome, could have on our business or reputation or on our
ability to attract and retain patients and employees. While we maintain malpractice liability coverage that we believe is appropriate given the nature and breadth of our operations, any claims against us in excess of insurance limits, or multiple
claims requiring us to pay deductibles, could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are unable to maintain our corporate reputation, our business may suffer. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our success depends on our ability to maintain our corporate reputation, including our reputation for providing quality patient care and for compliance with Medicare requirements and the other laws to
which we are subject. Adverse publicity surrounding any aspect of our business, including the death or disability of any of our patients due to our failure to provide proper care, or due to any failure on our part to comply with Medicare
requirements or other laws to which we are subject, could negatively affect our Company&#146;s overall reputation and the willingness of referral sources to refer patients to us. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We depend on the services of our executive officers and other key employees. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We depend greatly on the efforts of our executive officers and other key employees to manage our operations. The loss or departure of any
one of these executives or other key employees could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our operations could be impacted by natural disasters. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The occurrence of natural disasters in the markets in which we operate could not only impact the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations of our care centers, but could also disrupt our relationships with patients, employees and referral sources located in the affected areas and, in the case of our corporate office, our
ability to provide administrative support services, including billing and collection services. In addition, any episode of care that is not completed due to the impact of a natural disaster will generally result in lower revenue for the episode. For
example, our corporate office and a number of our care centers are located in the southeastern United States and the Gulf Coast Region, increasing our exposure to hurricanes and flooding. Future hurricanes or other natural disasters may have a
material adverse effect on our business and consolidated financial condition, results of operations and cash flows. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to
Liquidity </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Delays in payment may cause liquidity problems. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business is characterized by delays from the time we provide services to the time we receive payment for these services. If we have
difficulty in obtaining documentation, such as physician orders, experience information system problems or experience other issues that arise with Medicare or other payors, we may encounter additional delays in our payment cycle. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, timing delays in billings and collections may cause working capital shortages. Working capital management, including prompt
and diligent billing and collection, is an important factor in achieving our financial results and maintaining liquidity. It is possible that documentation support, system problems, Medicare or other provider issues or industry trends may extend our
collection period, which may materially adversely affect our working capital, and our working capital management procedures may not successfully mitigate this risk. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">CMS is implementing a three-year <FONT STYLE="white-space:nowrap">pre-claim</FONT> review demonstration for home health services in the states of Illinois, Florida, Michigan, Massachusetts, and Texas,
which will be phased in during 2016 and 2017, depending on the state. CMS is testing whether <FONT STYLE="white-space:nowrap">pre-claim</FONT> review improves methods for the identification, investigation, and prosecution of Medicare fraud occurring
among home health agencies providing services to Medicare beneficiaries. Additionally, CMS is testing whether the demonstration helps reduce expenditures while maintaining or improving quality of care. The
<FONT STYLE="white-space:nowrap">pre-claim</FONT> review demonstration for home health services does not create new clinical documentation requirements. CMS has indicated that home health agencies will submit the same information they currently
submit for payment, but will do so earlier in the process. CMS has further indicated that this demonstration should not delay care to Medicare beneficiaries and does not alter the Medicare home health benefit. However, this process could result in
increased administrative costs or delays in reimbursement for home health services in states subject to the demonstration. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, our hospice operations may experience payment delays. We have experienced payment delays when attempting to collect funds
from state Medicaid programs in certain instances. Delays in receiving payments from these programs may also materially adversely affect our working capital. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>The volatility and disruption of the capital and credit markets and adverse changes in the United States and global economies could impact our ability to access both available and affordable
financing, and without such financing, we may be unable to achieve our objectives for strategic acquisitions and internal growth. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">While we intend to finance strategic acquisitions and internal growth with cash flows from operations and borrowings under our revolving credit facility, we may require sources of capital in addition to
those presently available to us. Uncertainty in the capital and credit markets may impact our ability to access capital on terms acceptable to us (i.e. at attractive/affordable rates) or at all, and this may result in our inability to achieve
present objectives for strategic acquisitions and internal growth. Further, in the event we need additional funds, and we </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
are unable to raise the necessary funds on acceptable terms, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our indebtedness could impact our financial condition and impair our ability to fulfill other obligations.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2016, we had total outstanding indebtedness of approximately $95.7&nbsp;million, comprised
mainly of indebtedness incurred in connection with our April&nbsp;23, 2014 settlement agreement with the U.S. Department of Justice relating to certain of our clinical and business operations.&nbsp;Our level of indebtedness could have a material
adverse effect on our business and consolidated financial position, results of operations and cash flows and impair our ability to fulfill other obligations in several ways, including: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">it could require us to dedicate a portion of our cash flow from operations to payments on our indebtedness, which could reduce the availability of
cash flow to fund acquisitions, <FONT STYLE="white-space:nowrap">start-ups,</FONT> working capital, capital expenditures and other general corporate purposes; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">it could limit our ability to borrow money or sell stock for working capital, capital expenditures, debt service requirements and other purposes;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">it could limit our flexibility in planning for, and reacting to, changes in our industry or business; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">it could make us more vulnerable to unfavorable economic or business conditions;&nbsp;and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">it could limit our ability to make acquisitions or take advantage of other business opportunities. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event we incur additional indebtedness, the risks described above could increase. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The agreements governing our indebtedness contain various covenants that limit our discretion in the operation of our business and
our failure to satisfy requirements in these agreements could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The agreements governing our indebtedness (the &#147;Debt Agreements&#148;) contain certain obligations, including restrictive covenants
that require us to comply with or maintain certain financial covenants and ratios and restrict our ability to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">incur additional debt; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">redeem or repurchase stock, pay dividends or make other distributions; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">make certain investments; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">create liens; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">enter into transactions with affiliates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">make acquisitions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">enter into joint ventures; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">merge or consolidate; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">invest in foreign subsidiaries; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">amend acquisition documents; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">enter into certain swap agreements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">make certain restricted payments; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">transfer, sell or leaseback assets; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">make fundamental changes in our corporate existence and principal business. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, events beyond our control could affect our ability to comply with the Debt
Agreements. Any failure by us to comply with or maintain all applicable financial covenants and ratios and to comply with all other applicable covenants could result in an event of default with respect to the Debt Agreements.&nbsp;If we are unable
to obtain a waiver from our lenders in the event of any <FONT STYLE="white-space:nowrap">non-compliance,</FONT> our lenders could accelerate the maturity of any outstanding indebtedness and terminate the commitments to make further extensions of
credit (including our ability to borrow under our revolving credit facility).&nbsp;Any failure to comply with these covenants could have a material adverse effect on our business and consolidated financial condition, results of operations and cash
flows. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Ownership of Our Common Stock </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>The price of our common stock may be volatile. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The price at which
our common stock trades may be volatile. The stock market from time to time experiences significant price and volume fluctuations that impact the market prices of securities, particularly those of health care companies. The market price of our
common stock may be influenced by many factors, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">our operating and financial performance; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">variances in our quarterly financial results compared to research analyst expectations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">the depth and liquidity of the market for our common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">future sales of common stock by the Company or large stockholders or the perception that such sales could occur; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">investor, analyst and media perception of our business and our prospects; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">developments relating to litigation or governmental investigations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes or proposed changes in health care laws or regulations or enforcement of these laws and regulations, or announcements relating to these
matters; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">departure of key personnel; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in the Medicare, Medicaid and private insurance payment rates for home health and hospice; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments; or
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">general economic and stock market conditions. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, the stock market in general, and the NASDAQ Global Select Market (&#147;NASDAQ&#148;) in particular, has experienced price and volume fluctuations that we believe have often been unrelated or
disproportionate to the operating performance of health care provider companies. These broad market and industry factors may materially reduce the market price of our common stock, regardless of our operating performance. Securities class-action
cases have often been brought against companies following periods of volatility in the market price of their securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
activities of short sellers could reduce the price or prevent increases in the price of our common stock. &#147;Short sale&#148; is defined as the sale of stock by an investor that the investor does not own. Typically, investors who sell short
believe the price of the stock will fall, and anticipate selling shares at a higher price than the purchase price at which they will buy the stock. As of December&nbsp;31, 2016, investors held a short position of approximately 3.2&nbsp;million
shares of our common stock which represented 9.5% of our outstanding common stock. The anticipated downward pressure on our stock price due to actual or anticipated sales of our stock by some institutions or individuals who engage in short sales of
our common stock could cause our stock price to decline. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Sales of substantial amounts of our common stock or the availability of those shares
for future sale, could materially impact our stock price and limit our ability to raise capital. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table
presents information about our outstanding common and preferred stock and our outstanding securities exercisable for or convertible into shares of common stock: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;of&nbsp;December&nbsp;31,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,597,215</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred stock outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock available under 2008 Omnibus Incentive Compensation Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,204,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock options outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,008,157</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock options exercisable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">281,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-vested</FONT> stock outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">209,378</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-vested</FONT> stock units outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">474,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we were to sell substantial amounts of our common stock in the public market or if there was a public
perception that substantial sales could occur, the market price of our common stock could decline. These sales or the perception of substantial future sales may also make it difficult for us to sell common stock in the future to raise capital.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our Board of Directors may use anti-takeover provisions or issue stock to discourage a change of control.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our certificate of incorporation currently authorizes us to issue up to 60,000,000&nbsp;shares of common stock and
5,000,000 shares of undesignated preferred stock. Our Board of Directors may cause us to issue additional stock to discourage an attempt to obtain control of our company. For example, shares of stock could be sold to purchasers who might support our
Board of Directors in a control contest or to dilute the voting or other rights of a person seeking to obtain control. In addition, our Board of Directors could cause us to issue preferred stock entitling holders to vote separately on any proposed
transaction, convert preferred stock into common stock, demand redemption at a specified price in connection with a change in control, or exercise other rights designed to impede a takeover. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The issuance of additional shares may, among other things, dilute the earnings and equity per share of our common stock and the voting
rights of common stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have implemented other anti-takeover provisions or provisions that could have an
anti-takeover effect, including advance notice requirements for director nominations and stockholder proposals. These provisions, and others that our Board of Directors may adopt hereafter, may discourage offers to acquire us and may permit our
Board of Directors to choose not to entertain offers to purchase us, even if such offers include a substantial premium to the market price of our stock. Therefore, our stockholders may be deprived of opportunities to profit from a sale of control.
</FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_5"></A>ITEM&nbsp;1B.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>UNRESOLVED STAFF COMMENTS </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">None. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_6"></A>ITEM&nbsp;2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROPERTIES </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our executive
office is located in Nashville, Tennessee in a leased property consisting of 15,825 square feet; our corporate headquarters is located in Baton Rouge, Louisiana in a leased property consisting of 75,243 square feet. We believe we have adequate space
to accommodate our corporate staff located in these locations for the foreseeable future.</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to our executive office and corporate headquarters, we also lease facilities for
our home health, hospice and personal-care care centers.&nbsp;Generally, these leases have an initial term of five years with a three year early termination option, but range from one to seven years.&nbsp;Most of these leases also contain an option
to extend the lease period. The following table shows the location of our 327 Medicare-certified home health care centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers at December&nbsp;31, 2016: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:17pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>State</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Home&nbsp;Health</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Hospice</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Personal&nbsp;Care</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>State</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Home&nbsp;Health</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Hospice</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Personal&nbsp;Care</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alabama</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">New Jersey</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arkansas</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">New York</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arizona</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">New Hampshire</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">California</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">North Carolina</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Connecticut</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ohio</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Delaware</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oklahoma</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Florida</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oregon</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Georgia</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pennsylvania</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Illinois</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rhode Island</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indiana</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">South Carolina</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kansas</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tennessee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kentucky</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Texas</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Louisiana</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Virginia</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Massachusetts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">West Virginia</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maine</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wisconsin</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Washington, D.C.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mississippi</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">327</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">79</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Missouri</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_7"></A>ITEM&nbsp;3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LEGAL PROCEEDINGS </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">See
Part II, Item&nbsp;8, Note 10 &#150; Commitments and Contingencies for information concerning our legal proceedings. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_8"></A>ITEM&nbsp;4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MINE SAFETY DISCLOSURES </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not applicable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_9"></A>PART II </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:-8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_10"></A>ITEM&nbsp;5. MARKET FOR REGISTRANT&#146;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND
ISSUER PURCHASES OF EQUITY SECURITIES </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Market Information and Holders </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our common stock trades on the NASDAQ Global Select Market under the trading symbol &#147;AMED&#148;. The following table presents the
range of high and low sales prices for our common stock for the periods indicated as reported on NASDAQ: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Price Range of</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common
Stock</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>High</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Low</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Year Ended December&nbsp;31, 2016:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54.42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46.12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45.48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fourth Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48.13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34.58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Year Ended December&nbsp;31, 2015:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25.83</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43.61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24.81</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48.34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36.11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fourth Quarter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34.72</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of February&nbsp;24, 2017, there were approximately 513&nbsp;holders of record of our common stock.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dividend Policy </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have not declared or paid any cash dividends on our common stock or any other of our securities and do not expect to pay cash dividends for the foreseeable future. We currently intend to retain our
future earnings, if any, to fund the development and growth of our business. Future decisions concerning the payment of dividends will depend upon our results of operations, financial condition, capital expenditure plans and debt service
requirements, as well as such other factors as our Board of Directors, in its sole discretion, may consider relevant. In addition, our outstanding indebtedness restricts, and we anticipate any additional future indebtedness may restrict, our ability
to pay cash dividends; provided, however, that we may pay (i) dividends payable solely in our equity securities and (ii) dividends if (1) no default or event of default under the Credit Agreement shall have occurred and be continuing at the time of
such dividend or would result therefrom, (2) we demonstrate that, upon giving pro forma effect to such dividend, our consolidated leverage ratio (as defined in the Credit Agreement) is less than 2.00 to 1.0 and (3) we demonstrate a minimum liquidity
of $50 million upon giving effect to such dividend. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Purchases of Equity Securities </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table provides the information with respect to purchases made by us of shares of our common stock during each of the months
during the three-month period ended December&nbsp;31, 2016: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:22pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Period</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(a)</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total&nbsp;Number<BR>of&nbsp;
Shares&nbsp;(or&nbsp;Units)<BR>Purchased</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(b)</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Average&nbsp;Price<BR>Paid&nbsp;
per&nbsp;Share&nbsp;(or&nbsp;Unit)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(c)</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total&nbsp;Number&nbsp;
of<BR>Shares&nbsp;(or&nbsp;Units)<BR>Purchased&nbsp;as&nbsp;Part&nbsp;of<BR>Publicly Announced<BR>Plans or Programs</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(d)</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Maximum&nbsp;Number&nbsp;
(or<BR>Approximate Dollar<BR>Value) of Shares (or<BR>Units)&nbsp;That&nbsp;May&nbsp;Yet&nbsp;Be<BR>Purchased Under the<BR>Plans or Programs</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">October&nbsp;1, 2016 to October&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">676</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43.86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">November&nbsp;1, 2016 to November&nbsp;30, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">December&nbsp;1, 2016 to December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,472</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42.85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42.91</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Includes shares of common stock surrendered to us by certain employees to satisfy tax withholding obligations in connection with the vesting of stock previously awarded
to such employees under our 2008 Omnibus Incentive Compensation Plan. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stock Performance Graph </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Performance Graph below compares the cumulative total stockholder return on our common stock, $0.001 par value per share, for the five-year period ended December&nbsp;31, 2016, with the cumulative
total return on the NASDAQ composite index and an industry peer group over the same period (assuming the investment of $100 in our common stock, the NASDAQ composite index and the industry peer group) on December&nbsp;31, 2011 and the reinvestment
of dividends. The peer group we selected is comprised of: LHC Group, Inc. (&#147;LHCG&#148;) and Almost Family, Inc. (&#147;AFAM&#148;). The cumulative total stockholder return on the following graph is historical and is not necessarily indicative
of future stock price performance. No cash dividends have been paid on our common stock. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g332070g66x66.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>12/31/2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>12/31/2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>12/31/2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>12/31/2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>12/31/2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>12/31/2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amedisys, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">103.64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">134.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">269.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">360.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">390.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NASDAQ Composite</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">116.41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">165.47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">188.69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200.32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">216.54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peer Group</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">153.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">198.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">223.44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">314.73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">331.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This stock performance information is &#147;furnished&#148; and shall not be deemed to be
&#147;soliciting material&#148; or subject to Regulation 14A under the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;), shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Exchange Act or otherwise subject to
the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this report and irrespective of any general
incorporation by reference language in any such filing, except to the extent we specifically incorporate the information by reference. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_11"></A>ITEM&nbsp;6. SELECTED FINANCIAL DATA </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The selected consolidated financial data presented below is derived from our audited consolidated financial statements for the five-year
period ended December&nbsp;31, 2016, based on our continuing operations. The financial data for the years ended December&nbsp;31, 2016, 2015 and 2014 should be read together with our consolidated financial statements and related notes included in
Item&nbsp;8, &#147;Financial Statements and Supplementary Data&#148; and the information included in Item&nbsp;7, &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; herein. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016 (1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015 (2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014 (3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013 (4)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012 (5)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Amounts in thousands, except per share data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Income Statement Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net service revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,437,454</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,280,541</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,204,554</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,249,344</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,440,836</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating income (loss) from continuing operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,047</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(154,971</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(108,855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss) from continuing operations attributable to Amedisys, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,261</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,992</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(93,105</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(80,262</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss) from continuing operations attributable to Amedisys, Inc. per basic share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.98</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.68</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss) from continuing operations attributable to Amedisys, Inc. per diluted share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.98</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.68</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2016, we recorded charges related to Homecare Homebase (&#147;HCHB&#148;) implementation costs in the amount of $8.4&nbsp;million
($5.1&nbsp;million, net of tax) and recognized a <FONT STYLE="white-space:nowrap">non-cash</FONT> charge to write off assets as a result of our conversion to the HCHB platform in the amount of $4.4&nbsp;million ($2.7&nbsp;million, net of tax).
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2015, we recorded <FONT STYLE="white-space:nowrap">non-cash</FONT> charges to write off the software costs incurred related to the
development of AMS3 Home Health and Hospice in the amount of $75.2&nbsp;million ($45.5&nbsp;million, net of tax) and to reduce the carrying value of our corporate headquarters in the amount of $2.1&nbsp;million ($1.2&nbsp;million, net of tax).
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2014, we recorded charges for relators&#146; fees and exit and restructuring activity in the amount of $13.9&nbsp;million ($8.5&nbsp;million,
net of tax) and recognized <FONT STYLE="white-space:nowrap">non-cash</FONT> other intangibles impairment charges of $3.1&nbsp;million ($2.0&nbsp;million, net of tax). </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2013, we recorded a charge for the accrual for the U.S. Department of Justice settlement, which amounted to $150.0&nbsp;million
($93.9&nbsp;million, net of tax) and recognized <FONT STYLE="white-space:nowrap">non-cash</FONT> goodwill and other intangibles impairment charges of $9.5&nbsp;million ($5.8&nbsp;million, net of tax). </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2012, we recorded a $162.1&nbsp;million ($110.2&nbsp;million, net of tax and <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interests) charge for the impairment of goodwill and other intangibles and incurred certain costs associated with our exit activities in the amount of $2.7&nbsp;million ($1.6&nbsp;million, net of tax). </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Amounts in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance Sheet Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets (1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">734,029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">681,715</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">666,956</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">724,237</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">728,132</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total debt, including current portion (1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">93,029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">96,630</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">113,586</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,735</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100,248</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Amedisys, Inc. stockholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">460,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">409,568</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">397,167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">372,201</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">452,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash dividends declared per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets and Total debt, including current portion have been recast to present our retrospective adoption of Accounting Standards Update <FONT
STYLE="white-space:nowrap">2015-03,</FONT> <I>Interest &#150; Imputation of Interest (Subtopic <FONT STYLE="white-space:nowrap">835-30):</FONT> Simplifying the Presentation of Debt Issuance Costs</I>. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_12"></A>ITEM&nbsp;7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of
operations and financial condition for 2016, 2015 and 2014. This discussion should be read in conjunction with our audited financial statements included in Item 8, &#147;Financial Statements and Supplementary Data&#148; and Part I, Item 1,
&#147;Business&#148; of this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> The following analysis contains forward-looking statements about our future revenues, operating results and expectations. See &#147;Special Caution
Concerning Forward-Looking Statements&#148; for a discussion of the risks, assumptions and uncertainties affecting these statements as well as Part I, Item 1A, &#147;Risk Factors.&#148; </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a provider of high-quality
<FONT STYLE="white-space:nowrap">in-home</FONT> healthcare and related services to the chronic, <FONT STYLE="white-space:nowrap">co-morbid,</FONT> aging American population, with approximately 78%, 80% and 82% of our revenue derived from Medicare
for 2016, 2015 and 2014, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our operations involve servicing patients through our three reportable business
segments: home health, hospice and personal care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from an illness, injury or surgery. Our hospice segment provides care that is designed to
provide comfort and support for those who are facing a terminal illness. Our personal care segment provides patients assistance with the essential activities of daily living. As of December&nbsp;31, 2016, we owned and operated 327 Medicare-certified
home health care centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>2016 Developments </I></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Completed the rollout of Homecare Homebase (&#147;HCHB&#148;), a leading platform for home health and hospice companies, to all of our care centers.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Integrated Infinity HomeCare which we acquired on December&nbsp;31, 2015. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Closed the acquisition of Associated Home Care on March&nbsp;1, 2016, which resulted in the establishment of our personal care segment which was
further expanded with the purchase of the assets of Professional Profiles, Inc. on September&nbsp;1, 2016. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>2017 Strategy
</I></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Continue to focus on growth through acquisitions in all three segments and increased volumes in existing care centers. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Continue to focus on commitment to clinical distinction with a goal of all care centers achieving a 4.0 Quality Star Rating.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gain operating efficiencies from investments in infrastructure, including HCHB. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Focus on recruitment and retention of world class employees while fostering a culture of engagement to become the employer of choice in the
industry. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Financial Performance </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The year ended December&nbsp;31, 2016 continued our focus on operational improvements that began during 2014 despite the disruption related to the conversion from our proprietary operating system to HCHB.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our home health care centers experienced same store revenue and admissions growth in 2016.
The home health segment saw an increase in <FONT STYLE="white-space:nowrap">non-Medicare</FONT> revenue and Medicare revenue per episode offset by increases in cost per visit and other operating expenses which resulted in a $2&nbsp;million reduction
in our operating income over the year ended December&nbsp;31, 2015 (see &#147;Results of Operations&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our hospice
segment achieved significant growth in admissions and average daily census combined with strong cost controls in 2016, all of which helped deliver an $8&nbsp;million improvement in our operating income over the year ended December&nbsp;31, 2015 (see
&#147;Results of Operations&#148;). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Care Centers Summary </I></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Home&nbsp;Health</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Hospice</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Personal&nbsp;Care</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">367</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Closed/Consolidated/Sold</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">316</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acquisitions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Closed/Consolidated/Sold</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">329</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">79</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Acquisitions/Start-Ups</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Closed/Consolidated</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">327</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">79</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">When we refer to &#147;same store business,&#148; we mean home health, hospice and personal-care care
centers that we have operated for at least the last twelve months; when we refer to &#147;acquisitions,&#148; we mean home health, hospice and personal-care care centers that we acquired within the last twelve months; and when we refer to <FONT
STYLE="white-space:nowrap">&#147;start-ups,&#148;</FONT> we mean home health, hospice and personal-care care centers opened by us in the last twelve months. Once a care center has been in operation for a twelve month period, the results for that
particular care center are included as part of our same store business from that date forward. <FONT STYLE="white-space:nowrap">Non-Medicare</FONT> revenue, admissions, recertifications or completed episodes includes home health revenue, admissions,
recertifications or completed episodes of care for those payors that pay on an episodic or per visit basis, which includes Medicare Advantage programs and private payors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Economic and Industry Factors </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Home health, hospice and personal care
services are a highly fragmented and highly competitive industry. The degree of competiveness varies based upon whether our care centers operate in states that require a certificate of need (CON) or permit of approval (POA). In such states,
expansion by existing providers or entry into the market by new providers is permitted only where determination is made by state health authorities that a given amount of unmet healthcare need exists. Currently, 68% and 40% of our home health and
hospice care centers, respectively operate in CON/POA states. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As the Federal government continues to debate a reduction in
expenditures and a reform of the Medicare system, our industry continues to face reimbursement pressures. The Centers for Medicare and Medicaid Services (&#147;CMS&#148;) instituted a rebasing cut of approximately $81 per episode (2.7%) per year for
2014 &#150; 2017; however, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
we do expect some offset from a market basket update in each of these years. The following payment adjustments are effective for the years indicated based on CMS&#146;s final rules relative to
Medicare reimbursement: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Home Health</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Hospice</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;2017&nbsp;(1)&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;2016&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;2015&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;2017&nbsp;(2)&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;2016&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;2015&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Market Basket Update</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.8&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.7&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.9&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rebasing</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">50/50 Blend of Wage Index</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nominal Case Mix Adjustment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">PPACA Adjustment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Budget Neutrality Adjustment Factor</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Productivity Adjustment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.4&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective for episodes scheduled to be completed on or after January&nbsp;1, 2017. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective for services provided from October&nbsp;1, 2016 to September&nbsp;30, 2017. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our company-specific impact of the final rules could differ depending on differences in the wage index and the impact of coding and
outlier changes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As part of the 2016 final rule issued in October 2015, CMS finalized their proposal to implement a Home
Health Value-Based Purchasing model in nine states that seeks to test whether incentives for better care can improve outcomes in the delivery of home health services. Financial impacts from this change, either positive or negative, would begin
January&nbsp;1, 2018, applied to that calendar year based on 2015 performance data. Care centers operating in the states included in the proposed model account for approximately 31% of our 2016 home health Medicare revenue. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Governmental Inquiries and Investigations and Other Litigation </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>September 2010 Civil Investigative Demand Issued by the U.S. Department of Justice </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;23, 2014, with no admission of liability on our part, we entered into a settlement agreement to resolve the U.S. Department of Justice investigation which began with a Civil Investigative
Demand (&#147;CID&#148;) issued by the U.S. Department of Justice on September&nbsp;27, 2010 and the Stark Law Self-Referral Matter disclosed to CMS in May 2012. Pursuant to the settlement agreement, on May&nbsp;2, 2014, we paid the United States an
initial payment in the amount of $116.5&nbsp;million representing the first installment of $115&nbsp;million plus interest thereon due under the settlement agreement, and on October&nbsp;23, 2014, we paid the United States an additional payment in
the amount of $35.8&nbsp;million, representing the second and final installment of $35&nbsp;million plus interest thereon due under the settlement agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The settlement agreement also resolved allegations made against us by various qui tam relators, who were required to dismiss their claims with prejudice. We accrued and paid various relators&#146;
attorneys&#146; fees and expenses in the aggregate sum of approximately $3.9&nbsp;million during 2014. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the
settlement agreement, on April&nbsp;23, 2014, we entered into a corporate integrity agreement (&#147;CIA&#148;) with the Office of Inspector <FONT STYLE="white-space:nowrap">General-HHS</FONT> (&#147;OIG&#148;). The CIA formalizes various aspects of
our already existing ethics and compliance programs and contains other requirements designed to help ensure our ongoing compliance with federal health care program requirements. Among other things, the CIA requires us to maintain our existing
compliance program, executive compliance committee and compliance committee of the Board of Directors; provide certain compliance training; continue screening new and current employees to ensure they are eligible to participate in federal health
care programs; engage an independent review organization to perform certain auditing and reviews and prepare certain reports regarding our compliance with federal health care </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
programs, our billing submissions to federal health care programs and our compliance and risk mitigation programs; and provide certain reports and management certifications to the OIG.
Additionally, the CIA specifically requires that we report substantial overpayments that we discover we have received from federal health care programs, as well as probable violations of federal health care laws. Upon breach of the CIA, we could
become liable for payment of certain stipulated penalties, or could be excluded from participation in federal health care programs. The CIA has a term of five years. We expect the CIA to impact operating expenses by approximately $1 to
$2&nbsp;million annually. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>May 2015 Subpoena Duces Tecum Issued by the U.S. Department of Justice </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;21, 2015, we received a Subpoena Duces Tecum (&#147;Subpoena&#148;) issued by the U.S. Department of Justice. The Subpoena
requests the delivery of information regarding 53 identified hospice patients to the United States Attorney&#146;s Office for the District of Massachusetts. It also requests the delivery of documents relating to our hospice clinical and business
operations and related compliance activities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>November 2015 Civil Investigative Demand Issued by the U.S. Department of Justice
</U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On November&nbsp;3, 2015, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims
Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>June 2016 Civil Investigative Demand Issued by the U.S. Department of Justice </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services
provided through designated facilities in the Parkersburg, West Virginia area. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">See Item 8, Note 10 &#150; Commitments and
Contingencies to our consolidated financial statements for additional information regarding our April 2014 CIA, the May 2015 Subpoena issued by the U.S. Department of Justice, the November 2015 CID issued by the U.S. Department of Justice, the June
2016 CID issued by the U.S. Department of Justice and for a discussion of and updates regarding class action litigation we are involved in. No assurances can be given as to the timing or outcome of these items. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>Consolidated </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes our results from continuing
operations (amounts in millions): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Years Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net service revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,437.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,280.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,204.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross margin, excluding depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">604.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">554.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">513.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>% of revenue</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">542.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">486.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">486.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>% of revenue</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Asset impairment charge</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total other income (expense), net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(23.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Effective income tax rate</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">650.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income (loss) from continuing operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss from discontinued operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income attributable to noncontrolling interests</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss) attributable to Amedisys, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Year Ended December&nbsp;31, 2016 Compared to the Year Ended December&nbsp;31, 2015
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our 2016 operating results include the results of Infinity HomeCare (&#147;Infinity&#148;), Associated Home Care and
Professional Profiles beginning on the date of their acquisition. These three acquisitions accounted for $85&nbsp;million of our $157&nbsp;million increase in revenue and $35&nbsp;million of our $56&nbsp;million increase in other operating expenses.
Our operating results were also impacted by an increase of approximately $21&nbsp;million in costs associated with our move to HCHB. Approximately $8&nbsp;million relates to implementation services provided by a third party while $4&nbsp;million is
the result of a <FONT STYLE="white-space:nowrap">non-cash</FONT> charge to write off assets (primarily laptops) not compatible with our new platform. The remaining $9&nbsp;million is related to disruption in care center operations as well as
additional corporate resources to support multiple systems. In addition to the $21&nbsp;million related to HCHB, we experienced an increase of $5&nbsp;million in bad debt and contractual reserves due to increased write-offs and accounts receivable
aging due to the HCHB disruption. While we anticipated these costs to continue as we completed the <FONT STYLE="white-space:nowrap">roll-out,</FONT> our care centers generally return to normal operating results approximately 60 to 90 days after
implementation; we completed the HCHB <FONT STYLE="white-space:nowrap">roll-out</FONT> during the three-month period ended December&nbsp;31, 2016. Additionally, our results were impacted by approximately $12&nbsp;million as a result of the 2016 CMS
rate cut. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total other income (expense), net decreased $1&nbsp;million in 2016 from 2015 after
considering the impact of the following items (amounts in millions): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Legal settlements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity in earnings from equity method investment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense related to tax audit reserve</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Life insurance proceeds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Debt refinance costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense related to long-term obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gain (loss) on disposal of property and equipment or sale of care centers</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Year Ended December&nbsp;31, 2015 Compared to the Year Ended December&nbsp;31, 2014
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our 2015 results were impacted by a $75&nbsp;million <FONT STYLE="white-space:nowrap">non-cash</FONT> charge to write
off the software costs incurred related to the development of AMS3 Home Health and Hospice and a $2&nbsp;million <FONT STYLE="white-space:nowrap">non-cash</FONT> charge to reduce the carrying value of our corporate headquarters. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the first quarter of 2014, we committed to a plan to consolidate 21 operating home health care centers and four operating hospice
care centers with care centers servicing the same markets and close 23 home health care centers and six hospice care centers. As a result of this exit activity, we reduced our regional leadership structure and corporate support functions. Separate
from the restructuring costs, we also recorded severance costs associated with the departure of our former Chief Executive Officer and a charge for relator fees associated with our U.S. Department of Justice settlement during the first quarter of
2014. Additionally, we recorded a <FONT STYLE="white-space:nowrap">non-cash</FONT> other intangibles impairment charge during the fourth quarter of 2014. The following details the costs associated with these activities (amounts in millions):
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Year Ended December&nbsp;31, 2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Home&nbsp;Health</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Hospice</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Severance&nbsp;(a)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restructuring severance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease terminations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other intangibles impairment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exit and restructuring activities cost</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Department of Justice Settlement/Relator Fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes $0.8&nbsp;million and $0.1&nbsp;million for severance included in cost of service for home health and hospice, respectively.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our operating results were impacted by the sale, closure and consolidation of numerous care centers as
mentioned above. Accordingly, our results for the year ended December&nbsp;31, 2015 were not fully comparable to the year ended December&nbsp;31, 2014. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our operating income, excluding the $77&nbsp;million asset impairment charges in 2015 and the $17&nbsp;million in costs incurred in 2014 noted above, increased $27&nbsp;million as our home health
operating income increased $29&nbsp;million, our hospice operating income increased $13&nbsp;million and our corporate operating expense increased $15&nbsp;million. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
The primary drivers of our improvement in performance were the closure/consolidation of care centers that had a negative operating contribution, an increase in our revenue per episode, an
increase in <FONT STYLE="white-space:nowrap">non-Medicare</FONT> revenue, growth in hospice census and a reduction in operating expenses. The increase in corporate operating expenses was primarily due to the $6&nbsp;million Wage and Hour Litigation
settlement accrual and HCHB maintenance and hosting and implementation costs of $8&nbsp;million. The increase in HCHB maintenance and hosting was offset by a $4&nbsp;million decrease in depreciation and amortization as we moved from our proprietary
software to HCHB. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total other income (expense), net decreased $1&nbsp;million in 2015 from 2014 after considering the impact
of the following items (amounts in millions): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Legal settlements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity in earnings from equity method investment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Life insurance proceeds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Debt refinance costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gain (loss) on disposal of property and equipment or sale of care centers</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The difference in income tax expense in 2015 and 2014 was driven primarily by the decrease in income
before income taxes. Additionally, the effective tax rate for the year ended December&nbsp;31, 2015 does not provide a meaningful comparison to other periods. The effective tax rate for the year was influenced by the relationship of the amount of
&#147;effective tax rate drivers&#148; (i.e. <FONT STYLE="white-space:nowrap">non-deductible</FONT> expenses, <FONT STYLE="white-space:nowrap">non-taxable</FONT> income, tax credits, valuation allowance, uncertain tax positions, etc.) to (loss)
income before income taxes. A significant asset impairment was recorded during the three-month period ended March&nbsp;31, 2015, resulting in a scenario where the company&#146;s (loss) income before income taxes for 2015 was near zero. Consequently,
for 2015, the relationship between the &#147;effective tax rate drivers&#148; and (loss) income before income taxes was distorted. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Home Health Division </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes our home health segment results from continuing operations: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Years Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Information </B><B><I>(in millions)</I></B><B>:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Medicare</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">822.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">761.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">751.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-Medicare</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">263.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">243.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">205.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net service revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,085.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,005.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">956.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost of service</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">643.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">584.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">559.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross margin</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">441.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">420.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">397.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">303.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">280.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">294.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">138.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">140.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">103.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Key Statistical Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Medicare:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Same Store (1):</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Admissions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recertifications</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Total (2):</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Admissions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">194,662</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">178,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">177,243</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recertifications</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">103,193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">99,762</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">102,263</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Completed episodes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">289,862</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">269,227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">272,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Visits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,124,002</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,797,734</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,794,609</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Average revenue per completed episode (3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,839</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,825</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,768</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Visits per completed episode (4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">Non-Medicare:</FONT></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Same Store (1):</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Admissions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recertifications</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Total (2):</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Admissions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98,448</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">96,934</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">83,940</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recertifications</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38,618</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,870</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,074</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Visits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,050,975</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,954,543</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,651,745</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total (2):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Visiting Clinician Cost per Visit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81.18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">78.23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">78.47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical Manager Cost per Visit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Cost per Visit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">89.71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">86.52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">86.77</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Visits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,174,977</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,752,277</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,446,354</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Same store information represents the percent increase (decrease) in our Medicare and <FONT STYLE="white-space:nowrap">Non-Medicare</FONT> revenue,
admissions or recertifications for the period as a percent of the Medicare and <FONT STYLE="white-space:nowrap">Non-Medicare</FONT> revenue, admissions or recertifications of the prior period. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total includes acquisitions; based on continuing operations for all periods presented. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care.
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes
completed during the period. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Year Ended December&nbsp;31, 2016 Compared to the Year Ended December&nbsp;31, 2015
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Overall, our operating income decreased $2&nbsp;million on a $21&nbsp;million increase in gross margin offset by a
$23&nbsp;million increase in other operating expenses. These results are inclusive of Infinity which accounted for $49&nbsp;million of our total revenue increase and $18&nbsp;million of other operating expenses. Our results have been negatively
impacted by approximately $12&nbsp;million related to the CMS rate cut which became effective January&nbsp;1, 2016 and approximately $6&nbsp;million as the result of disruptions associated with the <FONT STYLE="white-space:nowrap">roll-out</FONT> of
HCHB. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Net Service Revenue </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our Medicare revenue increased $61&nbsp;million which is inclusive of $48&nbsp;million from acquired care centers. The increase in same store revenue is due to higher admission volumes. Our revenue per
episode was relatively flat despite the impact of the CMS rate cut in 2016; the increase was due to an increase in patient acuity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our <FONT STYLE="white-space:nowrap">non-Medicare</FONT> revenue increased approximately $19&nbsp;million, with revenues from episodic payors increasing 16% while our revenue from per visit payors grew
5%. We continue to focus on contract payors with significant concentrations in our markets and those that add incremental margin to our operations as we continue to evaluate our portfolio of managed care contracts. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Cost of Service, Excluding Depreciation and Amortization </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our cost of service increased $59&nbsp;million primarily as a result of a 6% increase in visits and a 4% increase in cost per visit. The increase in cost per visit is primarily due to higher health
insurance expense, planned wage increases and additional costs related to our HCHB <FONT STYLE="white-space:nowrap">roll-out.</FONT> We believe that the impact of the HCHB <FONT STYLE="white-space:nowrap">roll-out</FONT> is temporary and will
normalize now that the <FONT STYLE="white-space:nowrap">roll-out</FONT> is complete. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Other Operating Expenses </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other operating expenses increased $23&nbsp;million due to increases in other care center related expenses, primarily salaries and
benefits, travel and training expense and HCHB maintenance and hosting fees. Other operating expense related to care centers acquired from Infinity were approximately $18&nbsp;million. We have completed the consolidation of our legacy Florida
operations with Infinity and the conversion of Infinity to our back office platform. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Year Ended December&nbsp;31, 2015
Compared to the Year Ended December&nbsp;31, 2014 </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Overall, our operating income excluding the $8&nbsp;million in exit
activity costs in 2014, increased $29&nbsp;million on a $22&nbsp;million increase in gross margin and a $7&nbsp;million decline in other operating expenses. 2014 results included revenue of $16&nbsp;million and operating losses of $5&nbsp;million
for those care centers that were closed, consolidated or sold. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Net Service Revenue </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Medicare revenue increase of approximately $10&nbsp;million consisted of a $16&nbsp;million increase due to higher revenue per episode
offset by $6&nbsp;million due to lower volumes. The decrease in volumes is primarily due to the sale, closure and consolidation of 51 care centers since December&nbsp;31, 2013, as we experienced a 3% increase in same store admissions in 2015. Net
service revenue included a reduction of $1&nbsp;million for the estimated impact of the 2016 rate change. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our <FONT
STYLE="white-space:nowrap">non-Medicare</FONT> revenue increased $38&nbsp;million as we have focused on contracted payors with significant concentrations in our markets and those that add incremental margin to our operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As mentioned above, we have closed numerous care centers since December&nbsp;31, 2013.
Accordingly, our 2015 results were not fully comparable to the prior year. The following table summarizes our net service revenue for our operating care centers and those care centers that were closed, consolidated or sold. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Years
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Revenue </B><B><I>(in millions)</I></B><B>:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating care centers</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,005.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">941.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Closed/Consolidated/Sold care centers</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net service revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,005.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">956.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Cost of Service, Excluding Depreciation and Amortization </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our cost of service, excluding the $1&nbsp;million in exit activity costs in 2014, increased $26&nbsp;million primarily as a result of a
5% increase in visits. Our cost per visit remained relatively flat. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Other Operating Expenses </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other operating expenses, excluding the $7&nbsp;million in exit activity costs in 2014, decreased $7&nbsp;million due to decreases in
other care center related expenses as a result of our closure and consolidation strategy and the reduction in divisional leadership; the majority of the reductions were in salaries and benefits and rent expense, offset by a $5&nbsp;million increase
in legal expense related to the self-disclosure matter. In addition, our provision for doubtful accounts decreased $3&nbsp;million and our depreciation and amortization expense decreased $4&nbsp;million compared to 2014. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Hospice Division </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes our hospice segment results from continuing operations: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Years
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Information</B><B><I> (in millions):</I></B><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Medicare</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">297.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">258.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">232.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-Medicare</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net service revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">316.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">247.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost of service</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">163.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">141.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">131.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross margin</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">152.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">133.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">115.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Key Statistical Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Same Store (1):</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Medicare revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-Medicare</FONT> revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hospice admissions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Average daily census</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Total (2):</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hospice admissions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,526</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,081</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Average daily census</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,105</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,632</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue per day, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">146.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">147.78</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">146.51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost of service per day</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75.36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77.93</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Average discharge length of stay</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">96</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Same store information presented is the percent increase (decrease) in our Medicare and <FONT STYLE="white-space:nowrap">Non-Medicare</FONT>
revenue, Hospice admissions or average daily census for the period as a percent of the Medicare and <FONT STYLE="white-space:nowrap">Non-Medicare</FONT> revenue, Hospice admissions or average daily census of the prior period.
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total includes acquisitions; based on continuing operations for all periods presented. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Year Ended December&nbsp;31, 2016 Compared to the Year Ended December&nbsp;31, 2015 </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Overall, our operating income increased $8&nbsp;million on a $19&nbsp;million increase in gross margin offset by an $11&nbsp;million
increase in other operating expenses. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Net Service Revenue </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our hospice revenue increased approximately $41&nbsp;million due to an increase in our average daily census as a result of a 17% increase in hospice admissions. We benefited from a 1.1% hospice rate
increase effective October&nbsp;1, 2015. Beginning January&nbsp;1, 2016, CMS provided for two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two rates, beginning
January&nbsp;1, 2016, Medicare is also reimbursing for a service intensity <FONT STYLE="white-space:nowrap">add-on</FONT> (&#147;SIA&#148;). The SIA is based on visits made in the last seven days of life by a registered nurse (&#147;RN&#148;) or
medical social worker (&#147;MSW&#148;) for patients in a routine level of care. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our revenue per day was impacted by an
increase in contractual reserves and write-offs which occurred during the HCHB <FONT STYLE="white-space:nowrap">roll-out.</FONT> We expect to return to normal levels during 2017. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Cost of Service, Excluding Depreciation and Amortization </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our hospice cost of service increased $21&nbsp;million as the result of a 16% increase in average daily census. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Other Operating Expenses </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other operating expenses increased $11&nbsp;million due to increases in other care center related expenses, primarily salaries and
benefits and HCHB maintenance and hosting fees. We have experienced an increase in days revenue outstanding, net as we transitioned to the HCHB platform. As such, our provision for doubtful accounts increased approximately $4&nbsp;million, which is
reflective of an increase in our accounts receivable aging. We do expect to return to normal days revenue outstanding, net now that we are on one operating platform. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Year Ended December&nbsp;31, 2015 Compared to the Year Ended December&nbsp;31, 2014 </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Overall, our operating income, excluding the $2&nbsp;million in exit activity costs in 2014, increased $13&nbsp;million on an $18&nbsp;million increase in gross margin offset by a $5&nbsp;million increase
in other operating expenses. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Net Service Revenue </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our hospice revenue increased $28&nbsp;million, primarily as the result of an increase in our average daily census as a result of a 16% increase in hospice admissions. We benefitted from a 1.4% hospice
rate increase effective October&nbsp;1, 2014. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As mentioned above, we have closed numerous care centers since
December&nbsp;31, 2013. Accordingly, our 2015 results were not fully comparable to the prior year. The following table summarizes our net service revenue for our operating care centers and those care centers that were closed, consolidated or sold.
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For&nbsp;the&nbsp;Years&nbsp;
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Revenue </B><B><I>(in millions)</I></B><B>:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating care centers</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">243.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Closed/Consolidated/Sold care centers</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net service revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">247.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Cost of Service, Excluding Depreciation and Amortization </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our hospice cost of service increased $10&nbsp;million as the result of a 10% increase in average daily census offset by a decrease in
cost of service per day. We experienced significant improvement in pharmacy and DME cost per day during 2015. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Other Operating Expenses
</U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other operating expenses, excluding the $2&nbsp;million in exit activity costs in 2014, increased $5&nbsp;million due to
increases in other care center related expenses, primarily salaries and benefits expense and travel costs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Personal Care Division </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes our personal care segment results from continuing operations: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Years
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Information</B><B><I> (in millions):</I></B><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Medicare</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-Medicare</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net service revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost of service</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross margin</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Key Statistical Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Billable hours</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,539,093</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clients served</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,520</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Year Ended December&nbsp;31, 2016 </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;1, 2016, we acquired Associated Home Care, a personal care home health care company with 9 care centers. On
September&nbsp;1, 2016, we acquired the assets of Professional Profiles, Inc. which owned and operated 4 personal-care care centers. In addition, during the three-month period ended September&nbsp;30, 2016 we opened a
<FONT STYLE="white-space:nowrap">start-up</FONT> personal-care care center. Operating income related to our new personal care division for 2016 was approximately $2&nbsp;million on net service revenue of $36&nbsp;million and cost of service of
$26&nbsp;million; other operating expenses were approximately $8&nbsp;million. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Corporate </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes our corporate results from continuing operations: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Years
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Information</B><B><I> (in millions):</I></B><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">141.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">126.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">114.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total operating expenses before asset impairment charge</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">154.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">139.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">131.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Asset impairment charge</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">158.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">217.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">131.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate expenses consist of costs relating to our executive management and administrative support
functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Year Ended December&nbsp;31, 2016 Compared to the Year Ended December&nbsp;31, 2015 </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate other operating expenses have increased approximately $14&nbsp;million which is inclusive of approximately $12&nbsp;million in
corporate support expenses related to acquisitions, a $3&nbsp;million increase in <FONT STYLE="white-space:nowrap">non-cash</FONT> compensation and a $4&nbsp;million increase related to HCHB implementation costs offset by decreases of approximately
$5&nbsp;million in various other costs (including a $2&nbsp;million decrease in legal settlement expenses). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Year Ended December&nbsp;31, 2015 Compared to the Year Ended December&nbsp;31, 2014
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Excluding the $77&nbsp;million asset impairment charge in 2015 and the $7&nbsp;million in exit and restructuring
activities costs and relator fees associated with our U.S. Department of Justice settlement agreement during 2014, corporate other operating expenses increased $15&nbsp;million which is inclusive of the $6&nbsp;million Wage and Hour Litigation
settlement accrual, $4&nbsp;million in HCHB maintenance and hosting costs, $4&nbsp;million related to HCHB implementation and $2&nbsp;million in severance costs. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Liquidity and Capital Resources </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cash Flows </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes our cash flows for the periods indicated (amounts in millions): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Years
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash provided by (used in) operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">107.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(65.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash used in investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(52.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(67.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash (used in) provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net increase (decrease) in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents at beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents at end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash provided by operating activities decreased $45.6&nbsp;million during 2016 compared to 2015 primarily
due to a decrease in our cash collections relative to growth in accounts receivable as our days revenue outstanding, net increased eight days (approximately $41 million) from December&nbsp;31, 2015. For additional information regarding our operating
performance, see &#147;Results of Operations&#148;. Cash provided by operating activities increased $173.3&nbsp;million during 2015 compared to 2014 primarily due to an increase in our operating performance as compared to 2014 and the payment of the
$150.0&nbsp;million in 2014 under our settlement agreement with the U.S. Department of Justice. The recognition of the asset impairment charge of $77.3&nbsp;million, which resulted in the net loss for 2015 was a
<FONT STYLE="white-space:nowrap">non-cash</FONT> item and therefore had no impact on our cash flow from operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash used
in investing activities decreased $15.4&nbsp;million during 2016 compared to 2015 primarily due to decreases in cash paid for acquisitions ($33.6 million), capital expenditures ($5.7 million) and investments ($2.4&nbsp;million), offset by decreases
in proceeds from the sale of property and equipment related to the sale of our former corporate headquarters and in proceeds from the sale of investments. Cash used in investing activities increased $53.1&nbsp;million during 2015 compared to 2014
primarily due to our acquisition activity ($69.1 million) and an increase in capital expenditures ($9.4 million), offset by proceeds from the sale of property and equipment ($20.0 million) and investments ($5.0 million). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash used in financing activities decreased $13.4&nbsp;million during 2016 compared to 2015 primarily due to tax benefits from stock
compensation plans and a decrease in repayments of outstanding borrowings, offset by repurchases of company stock pursuant to our stock repurchase program. Cash used in financing activities increased $91.4&nbsp;million during 2015 compared to 2014
primarily due to an increase in our borrowings under our long-term obligations partially offset by principal payments. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Liquidity </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Typically, our principal source of liquidity is the collection of our patient accounts receivable, primarily through the Medicare program. In addition to our collection of patient accounts receivable,
from time to time, we can and do obtain additional sources of liquidity by the incurrence of additional indebtedness. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2016, we spent $6.8&nbsp;million in routine capital expenditures compared to
$9.3&nbsp;million and $7.0&nbsp;million during 2015 and 2014, respectively. Routine capital expenditures primarily include equipment and computer software and hardware. In addition, we spent $8.9&nbsp;million in
<FONT STYLE="white-space:nowrap">non-routine</FONT> capital expenditures related to leasehold improvements and IT infrastructure upgrades compared to $12.1&nbsp;million and $5.0&nbsp;million during 2015 and 2014, respectively, related to
enhancements to our point of care software. Our capital expenditures for 2017 are expected to be approximately $10.0 million &#150; $12.0&nbsp;million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During 2014, we paid the U.S. government $152.3&nbsp;million representing the $150&nbsp;million settlement plus interest thereon due under the settlement agreement to resolve both the U.S. Department of
Justice investigation and the Stark Law Self-Referral Matter. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;28, 2015, we entered into a Credit Agreement
that provides for senior secured facilities in an initial aggregate principal amount of up to $300&nbsp;million comprised of (a)&nbsp;a term loan facility in an initial aggregate principal amount of $100&nbsp;million and (b)&nbsp;a revolving credit
facility in an initial aggregate principal amount of up to $200&nbsp;million. The net proceeds of the term loan and existing cash on hand were used to pay off (i)&nbsp;our existing term loan under our prior Credit Agreement dated as of
October&nbsp;22, 2012, as amended with a principal balance of $27&nbsp;million and (ii)&nbsp;our existing term loan under our prior Second Lien Credit Agreement dated July&nbsp;28, 2014, with a principal balance of $70&nbsp;million. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2016, we had $30.2&nbsp;million in cash and cash equivalents and $173.3&nbsp;million in availability under our
$200.0&nbsp;million Revolving Credit Facility. Based on our operating forecasts and our new debt service requirements, we believe we will have sufficient liquidity to fund our operations, capital requirements and debt service requirements.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Outstanding Patient Accounts Receivable </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our patient accounts receivable, net increased $41.0&nbsp;million from December&nbsp;31, 2015 to December&nbsp;31, 2016. Our cash
collection as a percentage of revenue was 99% and 100% for December&nbsp;31, 2016 and 2015, respectively. Our days revenue outstanding, net at December&nbsp;31, 2016 was 40.2 days which is an increase of 8.3 days from December&nbsp;31, 2015. We have
experienced a slowdown in collections primarily as the result of our shift from our legacy platforms (AMS2 and AMS3) to HCHB. We anticipate further reductions in days revenue outstanding now that we have completed our HCHB implementation and are
completely off our legacy system. Our days revenue outstanding, net at December&nbsp;31, 2015 does not include Infinity HomeCare, which was acquired on December&nbsp;31, 2015. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our patient accounts receivable includes unbilled receivables and are aged based upon our initial service date. We monitor unbilled receivables on a care center by care center basis to ensure that all
efforts are made to bill claims within timely filing deadlines. Our unbilled patient accounts receivable can be impacted by acquisition activity, probe edits or regulatory changes which result in additional information or procedures needed prior to
billing. The timely filing deadline for Medicare is one year from the date the episode was completed and varies by state for Medicaid-reimbursable services and among insurance companies and other private payors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our provision for estimated revenue adjustments (which is deducted from our service revenue to determine net service revenue) and
provision for doubtful accounts were as follows for the periods indicated (amounts in millions). We fully reserve for both our Medicare and other patient accounts receivable that are aged over 365&nbsp;days. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For&nbsp;the&nbsp;Years&nbsp;
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provision for estimated revenue adjustments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provision for doubtful accounts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a percent of revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following schedules detail our patient accounts receivable, net of estimated revenue adjustments, by
payor class, aged based upon initial date of service (amounts in millions, except days revenue outstanding, net): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">0-90</FONT></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">91-180</FONT></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">181-365</FONT></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Over&nbsp;365</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>At December&nbsp;31, 2016:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Medicare patient accounts receivable, net (1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">82.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">101.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other patient accounts receivable:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Medicaid</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Private</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">82.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Allowance for doubtful accounts (2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-Medicare</FONT> patient accounts receivable, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total patient accounts receivable, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">166.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Days revenue outstanding, net (3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">0-90</FONT></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">91-180</FONT></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">181-365</FONT></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Over&nbsp;365</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>At December&nbsp;31, 2015:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Medicare patient accounts receivable, net (1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">73.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other patient accounts receivable:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Medicaid</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Private</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Allowance for doubtful accounts (2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-Medicare</FONT> patient accounts receivable, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total patient accounts receivable, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Days revenue outstanding, net (3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the activity and ending balances in our estimated revenue adjustments (amounts in millions), which is recorded to
reduce our Medicare outstanding patient accounts receivable to their estimated net realizable value, as we do not estimate an allowance for doubtful accounts for our Medicare claims. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Years
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provision for estimated revenue adjustments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Write offs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our estimated revenue adjustments were 3.9% and 4.8% of our outstanding Medicare patient
accounts receivable at December&nbsp;31, 2016 and December&nbsp;31, 2015, respectively. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the activity and ending balances in our allowance for doubtful accounts (amounts in millions), which is recorded to
reduce only our Medicaid and private payer outstanding patient accounts receivable to their estimated net realizable value. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Years
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provision for doubtful accounts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Write offs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our allowance for doubtful accounts was 21.5% and 26.9% of our outstanding Medicaid and
private patient accounts receivable at December&nbsp;31, 2016 and 2015, respectively. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our calculation of days revenue outstanding, net is derived by dividing our ending net patient accounts receivable (i.e., net of estimated revenue
adjustments and allowance for doubtful accounts ) at December&nbsp;31, 2016 and 2015 by our average daily net patient revenue for the three-month periods ended December&nbsp;31, 2016 and 2015, respectively. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Indebtedness </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Credit Agreement </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
August&nbsp;28, 2015, we entered into a Credit Agreement that provides for senior secured facilities in an initial aggregate principal amount of up to $300&nbsp;million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Credit Facilities are comprised of (a)&nbsp;a term loan facility in an initial aggregate principal amount of $100&nbsp;million (the &#147;Term Loan&#148;); and (b)&nbsp;a revolving credit facility in
an initial aggregate principal amount of up to $200&nbsp;million (the &#147;Revolving Credit Facility&#148;). The Revolving Credit Facility provides for and includes within its $200&nbsp;million limit a $25&nbsp;million swingline facility and
commitments for up to $50&nbsp;million in letters of credit. Upon lender approval, we may increase the aggregate loan amount under the Credit Facilities by a maximum amount of $150&nbsp;million. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The net proceeds of the Term Loan and existing cash on hand were used to pay off (i)&nbsp;our existing term loan under our Prior Credit
Agreement, dated as of October&nbsp;22, 2012, as amended (the &#147;Prior Credit Agreement&#148;) with a principal balance of $27&nbsp;million and (ii)&nbsp;our existing term loan under our prior Second Lien Credit Agreement dated July&nbsp;28, 2014
(the &#147;Second Lien Credit Agreement&#148;), with a principal balance of $70&nbsp;million. The final maturity of the Term Loan is August&nbsp;28, 2020. The Term Loan began amortizing on March&nbsp;31, 2016 and will continue amortizing over 14
quarterly installments (four remaining quarterly installments of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
$1.25&nbsp;million followed by eight quarterly installments of $2.5&nbsp;million beginning March&nbsp;31, 2018, followed by two quarterly installments of $3.1&nbsp;million beginning
March&nbsp;31, 2020, subject to adjustment for prepayments), with the remaining balance due upon maturity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Revolving
Credit Facility may be used to provide ongoing working capital and for general corporate purposes of the Company and its subsidiaries, including permitted acquisitions, as defined in the Credit Agreement. The final maturity of the Revolving Credit
Facility is August&nbsp;28, 2020 and will be payable in full at that time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The interest rate in connection with the Credit
Facilities shall be selected from the following by us: (i)&nbsp;the Base Rate plus the Applicable Rate or (ii)&nbsp;the Eurodollar Rate plus the Applicable Rate. The &#147;Base Rate&#148; means a fluctuating rate per annum equal to the highest of
(a)&nbsp;the federal funds rate plus 0.50% per annum, (b)&nbsp;the prime rate of interest established by the Administrative Agent, and (c)&nbsp;the Eurodollar Rate for an interest period of one month plus 1% per annum. The &#147;Eurodollar
Rate&#148; means the rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months (as selected by us) are quoted. The &#147;Applicable Rate&#148; is based on the consolidated leverage ratio
and is presented in the table below. As of December&nbsp;31, 2016, the Applicable Rate is 1.00% per annum for Base Rate Loans and 2.00% per annum for Eurodollar Rate Loans. We are also subject to a commitment fee and letter of credit fee under the
terms of the Credit Facilities, as presented in the table below. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:99pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Consolidated Leverage Ratio</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Margin&nbsp;for<BR>ABR&nbsp;Loans</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Margin&nbsp;for<BR>Eurodollar&nbsp;Loans</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Commitment<BR>Fee</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Letter&nbsp;of<BR>Credit&nbsp;Fee</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 2.75 to 1.0</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&lt; 2.75 to 1.0 but <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 1.75 to 1.0</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&lt; 1.75 to 1.0 but <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 0.75 to 1.0</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&lt; 0.75 to 1.0</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our weighted average interest rate for our $100.0&nbsp;million Term Loan, under our Credit Agreement, was
2.5% for 2016 and 2.7% for the period August&nbsp;28, 2015 to December&nbsp;31, 2015. Our weighted average interest rate for our $200.0&nbsp;million Revolving Credit Facility was 3.5% for 2016. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2016, our availability under our $200.0&nbsp;million Revolving Credit Facility was $173.3&nbsp;million as we had
$26.7&nbsp;million outstanding in letters of credit. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Credit Agreement requires maintenance of two financial covenants:
(i)&nbsp;a consolidated leverage ratio of funded indebtedness to EBITDA, as defined in the Credit Agreement, and (ii)&nbsp;a consolidated fixed charge coverage ratio of EBITDA plus rent expense (less cash taxes less capital expenditures) to
scheduled debt repayments plus interest expense plus rent expense, all as defined in the Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. As of
December&nbsp;31, 2016, our consolidated leverage ratio was 1.0 and our consolidated fixed charge coverage ratio was 3.8 and we are in compliance with the Credit Agreement. The Credit Agreement also contains customary covenants, including, but not
limited to, restrictions on: incurrence of liens; incurrence of additional debt; sales of assets and other fundamental corporate changes; investments; and declarations of dividends. These covenants contain customary exclusions and baskets.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Credit Facilities are guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Credit
Agreement requires at all times that we (i)&nbsp;provide guaranties from wholly-owned subsidiaries that in the aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and
(ii)&nbsp;provide guarantees from subsidiaries that in the aggregate represent not less than 70% of consolidated adjusted EBITDA, subject to certain exceptions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with entering into the Credit Agreement, we entered into (i)&nbsp;a Security Agreement with the Administrative Agent dated August&nbsp;28, 2015 and (ii)&nbsp;a Pledge Agreement with the
Administrative Agent dated as </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of August&nbsp;28, 2015 for the purpose of securing the payment of our obligations under the Credit Agreement. Pursuant to the Security Agreement and the Pledge Agreement, as of the effective
date of the Credit Agreement, our obligations under the Credit Agreement are secured by (i)&nbsp;the grant of a first lien security interest in the <FONT STYLE="white-space:nowrap">non-real</FONT> estate assets of substantially all of our direct and
indirect, wholly-owned subsidiaries (subject to exceptions) and (ii)&nbsp;the pledge of the equity interests in (a)&nbsp;substantially all of our direct and indirect, wholly-owned corporate, limited liability company and limited partnership
subsidiaries and (b)&nbsp;those joint ventures which constitute subsidiaries under the Credit Agreement (subject, in the case of the Pledge Agreement, to exceptions). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with the entry into the Credit Agreement, on August&nbsp;28, 2015, each of the Prior Credit Agreement and the Second Lien Credit Agreement were terminated. The Company paid a call premium of
$700,000 associated with the termination of the Second Lien Credit Agreement and the voluntary prepayment of the amounts owed thereunder as of August&nbsp;28, 2015, and expensed $2.5&nbsp;million in deferred debt issuance costs during the
three-month period ended September&nbsp;30, 2015. Also in connection with our entry into the Credit Agreement, we recorded $2.4&nbsp;million in deferred debt issuance costs as other assets in our consolidated balance sheet during 2015 which was
reclassified to long-term obligations, less current portion during 2016 in accordance with Accounting Standards Update <FONT STYLE="white-space:nowrap">2015-03,</FONT> <I>Interest &#150; Imputation of Interest (Subtopic <FONT
STYLE="white-space:nowrap">835-30):</FONT> Simplifying the Presentation of Debt Issuance Costs</I>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Repurchase Program
</I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;9, 2015, we announced that our Board of Directors authorized a stock repurchase program, under which we
may repurchase up to $75&nbsp;million of our outstanding common stock on or before September&nbsp;6, 2016. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the terms of
the program, we may repurchase shares from time to time in open market transactions, block purchases or in private transactions in accordance with applicable federal securities laws and other legal requirements. We may enter into Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> plans to effect some or all of the repurchases. The timing and the amount of the repurchases, if any, was determined by management based on a number of factors, including but not limited to share price,
trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to this program, we repurchased 324,141 shares of our common stock at a weighted average price of $37.96 per share and a total cost of approximately $12.3&nbsp;million during 2016 and 116,859
shares of our common stock at a weighted average price of $39.20 per share and a total cost of approximately $4.6&nbsp;million during 2015. The repurchased shares are classified as treasury shares. The stock repurchase program expired on
September&nbsp;6, 2016. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Contractual Obligations and Medicare Liabilities </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our future contractual obligations and Medicare liabilities at December&nbsp;31, 2016 were as follows (amounts in millions): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Payments Due by Period</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Less&nbsp;than<BR>1&nbsp;Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">1-3</FONT><BR>Years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">4-5</FONT><BR>Years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>After<BR>5&nbsp;Years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">95.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest on long-term obligations (1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating leases</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Capital commitments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchase obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Uncertain tax positions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">228.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">84.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">93.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest on debt with variable rates was calculated using the current rate of that particular debt instrument at December&nbsp;31, 2016.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Critical Accounting Estimates </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted
accounting principles (&#147;U.S. GAAP&#148;). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses and related disclosures of
contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, collectability of accounts receivable, reserves related to insurance and litigation, goodwill, intangible assets,
income taxes and contingencies. We base these estimates on our historical experience and various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
values of assets and liabilities that are not readily apparent from other sources. Actual results experienced may vary materially and adversely from our estimates. To the extent there are material differences between our estimates and the actual
results, our future results of operations may be affected. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe the following critical accounting policies represent
our most significant judgments and estimates used in the preparation of our consolidated financial statements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue
Recognition </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We earn net service revenue through our home health, hospice and personal-care care centers by providing a
variety of services almost exclusively in the homes of our patients. This net service revenue is earned and billed either on an episode of care basis, on a per visit basis or on a daily basis depending upon the payment terms and conditions
established with each payor for services provided. We refer to home health revenue earned and billed on a <FONT STYLE="white-space:nowrap">60-day</FONT> episode of care as episodic-based revenue. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">When we record our service revenue, we record it net of estimated revenue adjustments and contractual adjustments to reflect amounts we
estimate to be realizable for services provided, as discussed below. We believe, based on information currently available to us and based on our judgment, that changes to one or more factors that impact the accounting estimates (such as our
estimates related to revenue adjustments, contractual adjustments and episodes in progress) we make in determining net service revenue, which changes are likely to occur from period to period, will not materially impact our reported consolidated
financial condition, results of operations, cash flows or our future financial results. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Home Health Revenue Recognition </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Medicare Revenue </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net
service revenue is recorded under the Medicare prospective payment system (&#147;PPS&#148;) based on a <FONT STYLE="white-space:nowrap">60-day</FONT> episode payment rate that is subject to adjustment based on certain variables. We make adjustments
to Medicare revenue on completed episodes to reflect differences between estimated and actual payment amounts, and our discovered inability to obtain appropriate billing documentation or authorizations and other reasons unrelated to credit risk. We
estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered as an
estimated revenue adjustment and a corresponding reduction to patient accounts receivable. In addition, management evaluates the potential for revenue adjustments and, when appropriate, provides allowances based upon the best available information.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to revenue recognized on completed episodes, we also recognize a portion of revenue associated with episodes in
progress. Episodes in progress are <FONT STYLE="white-space:nowrap">60-day</FONT> episodes of care that begin during the reporting period, but </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
were not completed as of the end of the period. We estimate this revenue on a monthly basis based upon historical trends. The primary factors underlying this estimate are the number of episodes
in progress at the end of the reporting period, expected Medicare revenue per episode and our estimate of the average percentage complete based on the number of days elapsed during an episode of care. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U><FONT STYLE="white-space:nowrap">Non-Medicare</FONT> Revenue </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Episodic-based Revenue. </I>We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage
programs; however, these rates can vary based upon the negotiated terms. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><FONT STYLE="white-space:nowrap">Non-episodic</FONT> Based Revenue. </I>Gross revenue is recorded on an accrual basis based upon the
date of service at amounts equal to our established or estimated <FONT STYLE="white-space:nowrap">per-visit</FONT> rates, as applicable. Contractual adjustments are recorded for the difference between our standard rates and the contracted rates to
be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue and are also recorded as a reduction to our outstanding patient accounts receivable. In addition, we
receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance <FONT STYLE="white-space:nowrap">co-payment.</FONT> </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Hospice Revenue Recognition </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Hospice Medicare Revenue </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The
estimated payment rates are daily or hourly rates for each of the four levels of care we deliver. We make adjustments to Medicare revenue for our discovered inability to obtain appropriate billing documentation or authorizations and other reasons
unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes our historical collection rate on Medicare claims, and record it during the period services are rendered as an
estimated revenue adjustment and as a reduction to our outstanding patient accounts receivable. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; " ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap for each
provider number, we monitor these caps and estimate amounts due back to Medicare if a cap has been exceeded.&nbsp;We record these adjustments as a reduction to revenue and an increase in other accrued liabilities. Beginning for the cap year ending
October&nbsp;31, 2014, providers are required to self-report and pay their estimated cap liability by March
31</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> of the following year. As of December&nbsp;31, 2016,
we have settled our Medicare hospice reimbursements for all fiscal years through October&nbsp;31, 2012 and we have recorded $0.8&nbsp;million for estimated amounts due back to Medicare in other accrued liabilities for the Federal cap years ended
October&nbsp;31, 2013 through October&nbsp;31, 2016. As of December&nbsp;31, 2015, we had recorded $1.4&nbsp;million for estimated amounts due back to Medicare in other accrued liabilities for the Federal cap years ended October&nbsp;31, 2013
through October&nbsp;31, 2016. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Hospice <FONT STYLE="white-space:nowrap">Non-Medicare</FONT> Revenue </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per
visit rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients, third parties and others for services provided and are deducted from gross
revenue to determine our net service revenue and patient accounts receivable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Personal Care Revenue Recognition </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>Personal Care <FONT STYLE="white-space:nowrap">Non-Medicare</FONT> Revenue </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We generate net service revenues by providing our services directly to patients primarily on a per hour, visit or unit basis. We receive
payment for providing such services from our payor clients, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Net service revenues are principally provided based on authorized
hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation which are recognized as net service revenue at the time services are rendered. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Patient Accounts Receivable &#150; Allowance for Doubtful Accounts </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and
patients. We fully reserve for accounts which are aged at 365 days or greater. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We do not record an allowance for doubtful
accounts for our Medicare patient accounts receivable, which are recorded at their net realizable value after recording estimated revenue adjustments as discussed above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We believe there is a certain level of credit risk associated with <FONT STYLE="white-space:nowrap">non-Medicare</FONT> payors. To provide for our <FONT STYLE="white-space:nowrap">non-Medicare</FONT>
patient accounts receivable that could become uncollectible in the future, we establish an allowance for doubtful accounts to reduce the carrying amount to its estimated net realizable value. We estimate an allowance for doubtful accounts based upon
our assessment of historical and expected net collections, business and economic conditions, trends in payment and an evaluation of collectability based upon the date that the service was provided. Based upon our best judgment, we believe the
allowance for doubtful accounts adequately provides for accounts that will not be collected due to credit risk. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Insurance </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are obligated for certain costs associated with our insurance programs, including employee health, workers&#146; compensation and professional liability. While we maintain various insurance programs to
cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs in the period in which a claim is incurred, including with respect to both reported claims and claims
incurred but not reported, up to specified deductible limits. These costs have generally been estimated based upon independent third-party actuarial calculations which consider historical claims data. Such estimates, and the resulting reserves, are
reviewed and updated by us on a quarterly basis. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Goodwill and Other Intangible Assets </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Goodwill represents the amount of the purchase price in excess of the fair values assigned to the underlying identifiable net assets of
acquired businesses. Goodwill is not amortized, but is subject to an annual impairment test. Tests are performed more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit
below its carrying amount. These events or circumstances include but are not limited to, a significant adverse change in the business environment; regulatory environment or legal factors; or a substantial decline in market capitalization of our
stock. To determine whether goodwill is impaired, we perform a <FONT STYLE="white-space:nowrap">two-step</FONT> impairment test. In the first step of the test, the fair values of the reporting units are compared to their aggregate carrying values,
including goodwill. If the fair value of the reporting unit is greater than its carrying amount, goodwill is not considered impaired and no further testing is required. If the fair value of the reporting unit is less than its carrying amount, we
would proceed to step two of the test. In step two of the test, the implied fair value of the goodwill of the reporting unit is determined by a hypothetical allocation of the fair value calculated in step one to all of the assets and liabilities of
that reporting unit (including any recognized and unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value was reflective of the price paid to acquire the reporting unit. The implied
fair value of goodwill is the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
excess, if any, of the calculated fair value after hypothetical allocation to the reporting unit&#146;s assets and liabilities. If the implied fair value of the goodwill is greater than the
carrying amount of the goodwill at the analysis date, goodwill is not impaired and the analysis is complete. If the implied fair value of the goodwill is less than the carrying value of goodwill at the analysis date, goodwill is deemed impaired by
the amount of that variance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We calculate the estimated fair value of our reporting units using discounted cash flows as well
as a market approach that compares our reporting units&#146; earnings and revenue multiples to those of comparable public companies. To determine fair value we must make assumptions about a wide variety of internal and external factors. Significant
assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations, in particular expected organic growth rates, future Medicare reimbursement rates, capital requirements
and income taxes), long-term growth rates for determining terminal value, and discount rates. Our estimates of discounted cash flows may differ from actual cash flows due to, among other things, economic conditions, changes to our business model or
changes in operating performance. These factors increase the risk of differences between projected and actual performance that could impact future estimates of fair value of all reporting units. Significant differences between these estimates and
actual cash flows could result in additional impairment in future periods. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each of our operating segments described in the
notes to our financial statements is considered to represent an individual reporting unit for goodwill impairment testing purposes. We consider each of our home health care centers to constitute an individual business for which discrete financial
information is available. However, since these care centers have substantially similar operating and economic characteristics and resource allocation and significant investment decisions concerning these businesses are centralized and the benefits
broadly distributed, we have aggregated these care centers and deemed them to constitute a single reporting unit. We have applied this same aggregation principle to our hospice and personal-care care centers and have also deemed them to be a single
reporting unit. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2016, we did not record any goodwill impairment charges and none of the goodwill associated with our
various reporting units were considered at risk of impairment as of October&nbsp;31, 2016. Since the date of our last annual goodwill impairment test, there have been no material developments, events, changes in operating performance or other
circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than its carrying amount. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Intangible assets consist of Certificates of Need, licenses, acquired names and <FONT STYLE="white-space:nowrap">non-compete</FONT> agreements. We amortize
<FONT STYLE="white-space:nowrap">non-compete</FONT> agreements and acquired names that we do not intend to use in the future on a straight-line basis over their estimated useful lives, which is generally three years for <FONT
STYLE="white-space:nowrap">non-compete</FONT> agreements and up to five years for acquired names. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income Taxes
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We use the asset and liability approach for measuring deferred tax assets and liabilities based on temporary
differences existing at each balance sheet date using currently enacted tax rates. Our deferred tax calculation requires us to make certain estimates about future operations. Deferred tax assets are reduced by a valuation allowance when we believe
it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect of a change in tax rate is recognized as income or expense in the period that includes the enactment date. As of December&nbsp;31, 2016
and 2015 our net deferred tax assets were $107.9&nbsp;million and $125.2&nbsp;million, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management regularly
assesses the ability to realize deferred tax assets recorded in the Company&#146;s entities based upon the weight of available evidence, including such factors as the recent earnings history and expected future taxable income. In the event future
taxable income is below management&#146;s estimates or is generated in tax </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
jurisdictions different than projected, we could be required to increase the valuation allowance for deferred tax assets. This would result in an increase in our effective tax rate. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_13"></A>ITEM&nbsp;7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are exposed to market risk from fluctuations in interest rates. Our Revolving Credit Facility and Term Loan carry a floating interest
rate which is tied to the Eurodollar rate (<I>i.e.</I> LIBOR) or the Prime Rate and therefore, our consolidated statements of operations and our consolidated statements of cash flows are exposed to changes in interest rates. As of December&nbsp;31,
2016, the total amount of outstanding debt subject to interest rate fluctuations was $95.0&nbsp;million. A 1.0% interest rate change would cause interest expense to change by approximately $0.9&nbsp;million annually. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_14"></A>ITEM&nbsp;8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Report of Independent Registered Public Accounting Firm </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board of Directors and Stockholders </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amedisys, Inc.: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have audited
the accompanying consolidated balance sheets of Amedisys, Inc. and subsidiaries (the Company) as of December&nbsp;31, 2016 and 2015, and the related consolidated statements of operations, comprehensive income (loss), stockholders&#146; equity, and
cash flows for each of the years in the three-year period ended December&nbsp;31, 2016. These consolidated financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these
consolidated financial statements based on our audits. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We conducted our audits in accordance with the standards of the Public
Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating
the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our
opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Amedisys, Inc. and subsidiaries as of December&nbsp;31, 2016 and 2015, and the results of their operations and their
cash flows for each of the years in the three-year period ended December&nbsp;31, 2016, in conformity with U.S. generally accepted accounting principles. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Amedisys, Inc.&#146;s internal control over financial reporting as of
December&nbsp;31, 2016, based on criteria established in <I>Internal Control &#150; Integrated Framework</I> <I>(2013)</I>&nbsp;issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated March&nbsp;1, 2017,
expressed an unqualified opinion on the effectiveness of Amedisys, Inc.&#146;s internal control over financial reporting. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ KPMG
LLP&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Baton Rouge, Louisiana </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;1, 2017 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED BALANCE SHEETS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Amounts in thousands, except share data) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ASSETS</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,502</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patient accounts receivable, net of allowance for doubtful accounts of $17,716, and $16,526</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">166,056</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125,010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,397</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,110</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,641</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">214,910</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">175,263</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property and equipment, net of accumulated depreciation of $138,650 and $141,793</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,999</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,695</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Goodwill</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">288,957</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">261,663</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intangible assets, net of accumulated amortization of $27,864 and $25,386</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46,755</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,047</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">107,940</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125,245</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other assets, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38,468</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,802</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">734,029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">681,715</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LIABILITIES AND EQUITY</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,358</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,682</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payroll and employee benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">82,480</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72,546</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,290</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71,965</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current portion of long-term obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">181,348</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">175,193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term obligations, less current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87,809</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">91,630</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other long-term obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,730</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,456</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">272,887</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">271,279</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commitments and Contingencies &#150; Note 10</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock, $0.001 par value, 60,000,000 shares authorized; 35,253,577, and 34,786,966 shares issued; and 33,597,215 and
33,607,282 shares outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">537,472</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">504,290</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Treasury stock at cost 1,656,362, and 1,179,684 shares of common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(46,774</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(26,966</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated other comprehensive income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Retained earnings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(30,545</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(67,806</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Amedisys, Inc. stockholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">460,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">409,568</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Noncontrolling interests</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">939</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">868</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">461,142</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">410,436</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities and equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">734,029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">681,715</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:40px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED STATEMENTS OF OPERATIONS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Amounts in thousands, except per share data) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Years Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net service revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,437,454</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,280,541</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,204,554</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost of service, excluding depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">833,055</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">725,915</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">691,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Salaries and benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">306,981</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">279,425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">292,497</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-cash</FONT> compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">180,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">161,186</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">143,644</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provision for doubtful accounts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,519</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,053</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,294</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,678</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,036</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,307</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Asset impairment charge</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,432</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77,268</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,107</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,380,114</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,289,707</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,180,507</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,047</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income (expense):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,164</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,783</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,217</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity in earnings from equity method investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,991</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Miscellaneous, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,727</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,747</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total other income (expense), net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,858</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,071</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income (loss) before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61,566</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(308</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,976</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(23,935</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,671</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income (loss) from continuing operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,631</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,312</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,305</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Discontinued operations, net of tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(216</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,631</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,312</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income attributable to noncontrolling interests</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(709</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(313</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss) attributable to Amedisys, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,261</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,776</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="8"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic earnings per common share:</FONT></P></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income (loss) from continuing operations attributable to Amedisys, Inc. common stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Discontinued operations, net of tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income (loss) attributable to Amedisys, Inc. common stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average shares outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="8"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted earnings per common share:</FONT></P></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income (loss) from continuing operations attributable to Amedisys, Inc. common stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Discontinued operations, net of tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income (loss) attributable to Amedisys, Inc. common stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average shares outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,741</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="8"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts attributable to Amedisys, Inc. common stockholders:</FONT></P></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income (loss) from continuing operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,261</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,992</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Discontinued operations, net of tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(216</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,261</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,776</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">61 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Amounts in thousands) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,631</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,312</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Comprehensive income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,631</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,312</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Comprehensive income attributable to <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(709</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(313</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Comprehensive income (loss) attributable to Amedisys, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,261</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,776</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:454px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an
integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; EQUITY </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Amounts in thousands, except common stock shares) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD ROWSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common Stock</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Treasury<BR>Stock</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Loss&nbsp;(Income)</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Retained<BR>Earnings</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Noncontrolling<BR>Interests</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Balance, December&nbsp;31, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">372,479</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">33,413,970</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">467,890</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(18,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(77,561</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">278</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of stock &#150; employee stock purchase plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">176,796</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of stock &#150; 401(k) plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">7,062</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">430,919</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">7,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">564</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">28,229</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">564</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance/(cancellation) of <FONT STYLE="white-space:nowrap">non-vested</FONT> stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">519,612</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="white-space:nowrap">Non-cash</FONT> compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">5,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">5,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Tax deficit from stock options exercised and restricted stock vesting</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(579</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(579</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Surrendered shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(1,684</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(1,684</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Sale of noncontrolling interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(1,549</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(1,056</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Decrease in noncontrolling interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">350</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(710</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,060</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Net income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">13,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">12,776</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">313</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Balance, December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">397,762</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">34,569,526</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">481,762</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(19,860</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(64,785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">595</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of stock &#150; employee stock purchase plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,204</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">79,323</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,204</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of stock &#150; 401(k) plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">6,032</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">184,412</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">6,032</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exercise of stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">399</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">15,380</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">399</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance/(cancellation) of <FONT STYLE="white-space:nowrap">non-vested</FONT> stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(61,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="white-space:nowrap">Non-cash</FONT> compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">11,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">11,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Tax benefit from stock options exercised and restricted stock vesting</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,073</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,073</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Tax deficit from stock options exercised and restricted stock vesting</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Surrendered shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(2,525</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(2,525</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Shares repurchased</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(4,581</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(4,581</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Noncontrolling interest distribution</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(436</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(436</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(2,312</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(3,021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">709</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Balance, December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">410,436</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">34,786,966</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">504,290</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(26,966</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(67,806</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">868</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of stock &#150; employee stock purchase plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,483</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">63,688</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,483</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of stock &#150; 401(k) plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">6,682</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">145,660</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">6,682</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance/(cancellation) of <FONT STYLE="white-space:nowrap">non-vested</FONT> stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">257,263</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="white-space:nowrap">Non-cash</FONT> compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16,401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16,401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Tax benefit from stock options exercised and restricted stock vesting</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">7,241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">7,241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Surrendered shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(7,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(7,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Shares repurchased</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(12,315</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(12,315</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Noncontrolling interest distribution</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(329</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(329</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Assets contributed to equity investment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Net income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">37,631</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">37,261</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Balance, December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">461,142</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">35,253,577</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">537,472</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(46,774</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(30,545</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">939</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:54px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Amounts in thousands) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Years Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Cash Flows from Operating Activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Net income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">37,631</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(2,312</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">13,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">19,678</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">20,036</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">28,347</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Provision for doubtful accounts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">19,519</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">14,053</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16,369</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="white-space:nowrap">Non-cash</FONT> compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16,401</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">11,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">5,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">401(k) employer match</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">6,875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">6,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">6,216</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="white-space:nowrap">Write-off</FONT> of investment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">196</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Loss on disposal of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">582</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">775</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4,592</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Gain on sale of care centers</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(2,967</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Deferred income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">24,547</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(677</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">22,561</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Write off of deferred debt issuance costs/debt discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">488</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Equity in earnings from equity method investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(5,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(9,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(2,991</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Amortization of deferred debt issuance costs/debt discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">740</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">959</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">797</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Return on equity investment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4,323</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">5,610</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Asset impairment charge</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4,432</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">77,268</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,107</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Changes in operating assets and liabilities, net of impact of acquisitions:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Patient accounts receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(55,519</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(36,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(5,290</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4,231</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">6,455</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(6,269</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(11,415</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(3,523</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,694</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,970</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">7,639</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(3,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">U.S. Department of Justice settlement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(7,618</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">8,406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,495</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Other long-term obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(726</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(829</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(3,226</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Net cash provided by (used in) operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">62,259</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">107,785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(65,534</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Cash Flows from Investing Activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Proceeds from sale of deferred compensation plan assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,229</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Proceeds from the sale of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Purchases of deferred compensation plan assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(132</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Purchases of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(15,717</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(21,429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(12,008</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Purchase of investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(1,040</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(3,485</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(6,407</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Proceeds from sale of investment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">5,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Acquisitions of businesses, net of cash acquired</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(35,522</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(69,130</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Proceeds from disposition of care centers</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">413</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4,233</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Net cash used in investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(52,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(67,421</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(14,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Cash Flows from Financing Activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Proceeds from issuance of stock upon exercise of stock options and warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">399</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">564</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Proceeds from issuance of stock to employee stock purchase plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,483</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,204</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Tax benefit from stock options exercised and restricted stock vesting</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">7,241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,073</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interest distribution</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(329</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(436</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Proceeds from revolving line of credit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">134,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">63,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">241,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Repayments of revolving line of credit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(134,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(78,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(226,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Proceeds from issuance of long-term obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">100,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">68,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Principal payments of long-term obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(5,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(103,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(13,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Debt issuance costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(2,553</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(1,780</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Purchase of company stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(12,315</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(4,581</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Assets contributed to equity investment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Net cash (used in) provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(7,515</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(20,894</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">70,563</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Net increase (decrease) in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,695</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">19,470</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(9,271</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Cash and cash equivalents at beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">27,502</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">8,032</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17,303</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Cash and cash equivalents at end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">30,197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">27,502</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">8,032</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Supplemental Disclosures of Cash Flow Information:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Cash paid for interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,897</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">6,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">7,602</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Cash paid for income taxes, net of refunds received</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">755</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(12,185</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(1,766</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Supplemental Disclosures of <FONT STYLE="white-space:nowrap">Non-Cash</FONT> Financing and Investing
Activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">(Sale) acquisition of <FONT STYLE="white-space:nowrap">non-controlling</FONT> interests</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(1,549</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF
FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amedisys, Inc., a Delaware corporation, and its consolidated subsidiaries (&#147;Amedisys,&#148;
&#147;we,&#148; &#147;us,&#148; or &#147;our&#148;) are a multi-state provider of home health, hospice and personal care services with approximately 78%, 80% and 82% of our revenue derived from Medicare for 2016, 2015 and 2014, respectively. As of
December&nbsp;31, 2016, we owned and operated 327 Medicare-certified home health care centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Use of Estimates </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our accounting and reporting policies conform with U.S. Generally Accepted Accounting Principles (&#147;U.S. GAAP&#148;). In preparing the consolidated financial statements, we are required to make
estimates and assumptions that impact the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Reclassifications and Comparability </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Certain reclassifications have been made to prior periods&#146; financial statements in order to conform to the current period&#146;s presentation. In compliance with Accounting Standards Update
(&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">2015-03,</FONT> <I>Interest &#150; Imputation of Interest (Subtopic <FONT STYLE="white-space:nowrap">835-30):</FONT> Simplifying the Presentation of Debt Issuance Costs, </I>we have reclassified
2015 amounts related to unamortized debt issuance costs from other assets, net to long-term obligations, less current portion. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Principles of Consolidation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">These consolidated financial statements include the accounts of Amedisys, Inc., and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our
accompanying consolidated financial statements, and business combinations accounted for as purchases have been included in our consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned
subsidiaries, we also have certain equity investments that are accounted for as set forth below. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Equity Investments
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we
have controlling interests in the entity, which is generally ownership in excess of 50%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our consolidated financial statements. During the
three-month period ended September&nbsp;30, 2016, we sold a 30% interest in one of our care centers while maintaining controlling interest in the newly formed joint venture. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a variable
interest entity in which we are the primary beneficiary. The book value of investments that we accounted for under the equity method of accounting was $27.8&nbsp;million as of December&nbsp;31, 2016 and $25.7&nbsp;million as of December&nbsp;31,
2015. We account for investments in entities in which we have less than a 20% ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">65 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue Recognition </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We earn net service revenue through our home health, hospice and personal-care care centers by providing a variety of services almost exclusively in the homes of our patients. This net service revenue is
earned and billed either on an episode of care basis, on a per visit basis or on a daily basis depending upon the payment terms and conditions established with each payor for services provided. We refer to home health revenue earned and billed on a <FONT
STYLE="white-space:nowrap">60-day</FONT> episode of care as episodic-based revenue. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">When we record our service revenue, we
record it net of estimated revenue adjustments and contractual adjustments to reflect amounts we estimate to be realizable for services provided, as discussed below. We believe, based on information currently available to us and based on our
judgment, that changes to one or more factors that impact the accounting estimates (such as our estimates related to revenue adjustments, contractual adjustments and episodes in progress) we make in determining net service revenue, which changes are
likely to occur from period to period, will not materially impact our reported consolidated financial condition, results of operations, cash flows or our future financial results. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Home Health Revenue Recognition </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Medicare Revenue </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net service revenue is recorded under the Medicare prospective payment system (&#147;PPS&#148;) based on a
<FONT STYLE="white-space:nowrap">60-day</FONT> episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a)&nbsp;an outlier payment if our patient&#146;s care was unusually costly (capped at 10% of
total reimbursement per provider number); (b)&nbsp;a low utilization payment adjustment (&#147;LUPA&#148;) if the number of visits was fewer than five; (c)&nbsp;a partial payment if our patient transferred to another provider or we received a
patient from another provider before completing the episode; (d)&nbsp;a payment adjustment based upon the level of therapy services required (with various incremental adjustments made for additional visits, with larger payment increases associated
with the sixth, fourteenth and twentieth visit thresholds); (e) adjustments to payments if we are unable to perform periodic therapy assessments; (f)&nbsp;the number of episodes of care provided to a patient, regardless of whether the same home
health provider provided care for the entire series of episodes; (g)&nbsp;changes in the base episode payments established by the Medicare Program; (h)&nbsp;adjustments to the base episode payments for case mix and geographic wages; and
(i)&nbsp;recoveries of overpayments. In addition, we make adjustments to Medicare revenue if we find that we are unable to produce appropriate documentation of a face to face encounter between the patient and physician. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We make adjustments to Medicare revenue to reflect differences between estimated and actual payment amounts, our discovered inability to
obtain appropriate billing documentation or authorizations and other reasons unrelated to credit risk. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99%
on Medicare claims, and record this estimate during the period in which services are rendered as an estimated revenue adjustment and a corresponding reduction to patient accounts receivable. Therefore, we believe that our reported net service
revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
addition to revenue recognized on completed episodes, we also recognize a portion of revenue associated with episodes in progress. Episodes in progress are <FONT STYLE="white-space:nowrap">60-day</FONT> episodes of care that begin during the
reporting period, but were not completed as of the end of the period. We estimate this revenue on a monthly basis based upon historical trends. The primary factors underlying this estimate are the number of episodes in progress at the end
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">66 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of the reporting period, expected Medicare revenue per episode and our estimate of the average percentage complete based on the number of days elapsed during an episodes of care. As of
December&nbsp;31, 2016 and 2015, the difference between the cash received from Medicare for a request for anticipated payment (&#147;RAP&#148;) on episodes in progress and the associated estimated revenue was immaterial and, therefore, the resulting
credits were recorded as a reduction to our outstanding patient accounts receivable in our consolidated balance sheets for such periods. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U><FONT
STYLE="white-space:nowrap">Non-Medicare</FONT> Revenue </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Episodic-based Revenue. </I>We recognize revenue in a similar
manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><FONT STYLE="white-space:nowrap">Non-episodic</FONT> based Revenue. </I>Gross revenue is recorded on an accrual basis based upon the
date of service at amounts equal to our established or estimated <FONT STYLE="white-space:nowrap">per-visit</FONT> rates, as applicable. Contractual adjustments are recorded for the difference between our standard rates and the contracted rates to
be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue and are also recorded as a reduction to our outstanding patient accounts receivable. In addition, we
receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance <FONT STYLE="white-space:nowrap">co-payment.</FONT> </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Hospice Revenue Recognition </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Hospice Medicare Revenue </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The
estimated payment rates are daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounts for 99%, 99%, and 98% of
our total net Medicare hospice service revenue for 2016, 2015 and 2014, respectively. Beginning January&nbsp;1, 2016, CMS has provided for two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days.
In addition to the two routine rates, beginning January&nbsp;1, 2016, Medicare is also reimbursing for a service intensity <FONT STYLE="white-space:nowrap">add-on</FONT> (&#147;SIA&#148;). The SIA is based on visits made in the last seven days of
life by a registered nurse (&#147;RN&#148;) or medical social worker (&#147;MSW&#148;) for patients in a routine level of care. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We make adjustments to Medicare revenue for an inability to obtain appropriate billing documentation or acceptable authorizations and
other reasons unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes our historical collection rate on Medicare claims, and record it during the period services are rendered
as an estimated revenue adjustment and as a reduction to our outstanding patient accounts receivable. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; " ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap for each
provider number, we monitor these caps and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&nbsp;We record these adjustments as a reduction to revenue and an increase in other accrued liabilities. Beginning for the cap
year ending October&nbsp;31, 2014, providers are required to self-report and pay their estimated cap liability by March
31</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> of the following year. As of December&nbsp;31, 2016,
we have settled our Medicare hospice reimbursements for all fiscal years through October&nbsp;31, 2012 and we have recorded $0.8&nbsp;million for estimated amounts due back to Medicare in other accrued liabilities for the Federal cap years
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">67 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
ended October&nbsp;31, 2013 through October&nbsp;31, 2016. As of December&nbsp;31, 2015, we had recorded $1.4&nbsp;million for estimated amounts due back to Medicare in other accrued liabilities
for the Federal cap years ended October&nbsp;31, 2013 through October&nbsp;31, 2016. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Hospice
<FONT STYLE="white-space:nowrap">Non-Medicare</FONT> Revenue </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We record gross revenue on an accrual basis based upon the
date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients,
third parties and others for services provided and are deducted from gross revenue to determine our net service revenue and patient accounts receivable. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Personal Care Revenue Recognition </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Personal Care
<FONT STYLE="white-space:nowrap">Non-Medicare</FONT> Revenue </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We generate net service revenues by providing our services
directly to patients primarily on a per hour, visit or unit basis. We receive payment for providing such services from our payor clients, including state and local governmental agencies, managed care organizations, commercial insurers and private
consumers. Net service revenues are principally provided based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation, which are recognized as net service revenue at the
time services are rendered. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cash and Cash Equivalents </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less
when purchased. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Patient Accounts Receivable </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and
patients. As of December&nbsp;31, 2016, there is one single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables (approximately 10.1%). Thus, we believe there are no other significant
concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We fully reserve for accounts which are aged at 365 days or greater. We write off accounts on a monthly basis
once we have exhausted our collection efforts and deem an account to be uncollectible. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe the credit risk associated
with our Medicare accounts, which represent 61% and 64% of our net patient accounts receivable at December&nbsp;31, 2016 and December&nbsp;31, 2015, respectively, is limited due to our historical collection rate of over 99% from Medicare and the
fact that Medicare is a U.S. government payor. Accordingly, we do not record an allowance for doubtful accounts for our Medicare patient accounts receivable, which are recorded at their net realizable value after recording estimated revenue
adjustments as discussed above. During 2016, 2015 and 2014, we recorded $7.9&nbsp;million, $6.1&nbsp;million and $5.1&nbsp;million, respectively, in estimated revenue adjustments to Medicare revenue. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe there is a certain level of credit risk associated with <FONT STYLE="white-space:nowrap">non-Medicare</FONT> payors. To
provide for our <FONT STYLE="white-space:nowrap">non-Medicare</FONT> patient accounts receivable that could become uncollectible in the future, we establish an allowance for doubtful accounts to reduce the carrying amount to its estimated net
realizable value. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">68 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Medicare Home Health </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For our home health patients, our <FONT STYLE="white-space:nowrap">pre-billing</FONT> process includes verifying that we are eligible for payment from Medicare for the services that we provide to our
patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for 60% of our estimated payment for the initial episode at the start of
care or 50% of the estimated payment for any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed (&#147;final billed&#148;). The RAP
received for that particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of 120 days from the start of the episode, or 60 days from the date the RAP was paid, any RAPs received for that
episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be resubmitted. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Medicare Hospice </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">For our hospice patients, our <FONT
STYLE="white-space:nowrap">pre-billing</FONT> process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are
accurate through the utilization of an electronic Medicare claim review. Once each patient has been confirmed for eligibility, we will bill Medicare on a monthly basis for the services provided to the patient. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><FONT STYLE="white-space:nowrap">Non-Medicare</FONT> Home Health, Hospice, and Personal Care </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">For our <FONT STYLE="white-space:nowrap">non-Medicare</FONT> patients, our <FONT STYLE="white-space:nowrap">pre-billing</FONT> process
primarily begins with verifying a patient&#146;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and
evaluation of <FONT STYLE="white-space:nowrap">non-Medicare</FONT> accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with
similar characteristics that would subject us to any significant credit risk. We estimate an allowance for doubtful accounts based upon our assessment of historical and expected net collections, business and economic conditions, trends in payment
and an evaluation of collectability based upon the date that the service was provided. Based upon our best judgment, we believe the allowance for doubtful accounts adequately provides for accounts that will not be collected due to credit risk.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Property and Equipment </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Property and equipment is stated at cost and we depreciate it on a straight-line basis over the estimated useful lives of the assets. Additionally, we have internally developed computer software for our
own use. Additions and improvements (including interest costs for construction of qualifying long-lived assets) are capitalized. Maintenance and repair expenses are charged to expense as incurred. The cost of property and equipment sold or disposed
of and the related accumulated depreciation are eliminated from the property and related accumulated depreciation accounts, and any gain or loss is credited or charged to other general and administrative expenses. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We consider our reporting units to represent asset groups for purposes of testing long-lived assets for impairment. We assess the
impairment of a long-lived asset group whenever events or changes in circumstances indicate that the asset&#146;s carrying value may not be recoverable. Factors we consider important that could trigger an impairment review include but are not
limited to the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">A significant change in the extent or manner in which the long-lived asset group is being used. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">69 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">A significant change in the business climate that could affect the value of the long-lived asset group. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">A significant change in the market value of the assets included in the asset group. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we determine that the carrying value of long-lived assets may not be recoverable, we compare the carrying value of the asset group to
the undiscounted cash flows expected to be generated by the asset group. If the carrying value exceeds the undiscounted cash flows, an impairment charge is indicated. An impairment charge is recognized to the extent that the carrying value of the
asset group exceeds its fair value. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We generally provide for depreciation over the following estimated useful service lives.
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Years</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lesser&nbsp;of&nbsp;life&nbsp;or&nbsp;lease&nbsp;or&nbsp;expected&nbsp;useful&nbsp;life</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equipment and furniture</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 to 7</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vehicles</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Computer software</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 to 5</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2014, we had $75.8&nbsp;million of internally developed software costs related to
the development of AMS3 Home Health and Hospice (&#147;AMS3&#148;). Expanded beta testing to additional sites in February of 2015 demonstrated that AMS3 was disruptive to operations. Additional analysis of the system determined that the system was
not ready to be fully implemented and would require significant time and investment to redesign. Therefore, during the three-month period ended March&nbsp;31, 2015, we made the decision to discontinue AMS3 and recorded a <FONT
STYLE="white-space:nowrap">non-cash</FONT> asset impairment charge of $75.2&nbsp;million to <FONT STYLE="white-space:nowrap">write-off</FONT> the software costs incurred related to the development of AMS3. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2015, we began the transition of all our care centers from our proprietary operating system to Homecare Homebase
(&#147;HCHB&#148;), a leading home health and hospice platform, with all of our care centers operating on HCHB as of December&nbsp;31, 2016. As part of our conversion process, we determined that a number of assets (primarily laptops) were not
compatible with HCHB and had no other alternative or secondary use. As a result, we recorded a <FONT STYLE="white-space:nowrap">non-cash</FONT> asset impairment charge of $4.4&nbsp;million to <FONT STYLE="white-space:nowrap">write-off</FONT> these
assets during the three-month period ended December&nbsp;31, 2016. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the three-month period ended September&nbsp;30,
2015, we commenced an active program to sell our corporate headquarters located in Baton Rouge, Louisiana. In accordance with U.S. GAAP, we classified this asset as held for sale and reduced the carrying value of the asset to its estimated fair
value less estimated costs to sell the asset; no further depreciation expense for the asset was recorded. As a result, we recorded a <FONT STYLE="white-space:nowrap">non-cash</FONT> asset impairment charge of $2.1&nbsp;million during the three-month
period ended September&nbsp;30, 2015. The asset was sold during the three-month period ended December&nbsp;31, 2015 and the Company now leases equivalent office space. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">70 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the balances related to our property and equipment for
2016 and 2015 (amounts in millions): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building and leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equipment and furniture</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">89.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Computer software</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">96.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">92.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">175.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">184.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less: accumulated depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(138.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(141.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation expense for 2016, 2015 and 2014 was $17.2&nbsp;million, $20.0&nbsp;million and
$28.0&nbsp;million, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Goodwill and Other Intangible Assets </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Goodwill represents the amount of the purchase price in excess of the fair values assigned to the underlying identifiable net assets of
acquired businesses. Goodwill is not amortized, but is subject to an annual impairment test. Tests are performed more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit
below its carrying amount. These events or circumstances include but are not limited to, a significant adverse change in the business environment; regulatory environment or legal factors; or a substantial decline in market capitalization of our
stock. To determine whether goodwill is impaired, we perform a <FONT STYLE="white-space:nowrap">two-step</FONT> impairment test. In the first step of the test, the fair values of the reporting units are compared to their aggregate carrying values,
including goodwill. If the fair value of the reporting unit is greater than its carrying amount, goodwill is not considered impaired and no further testing is required. If the fair value of the reporting unit is less than its carrying amount, we
would proceed to step two of the test. In step two of the test, the implied fair value of the goodwill of the reporting unit is determined by a hypothetical allocation of the fair value calculated in step one to all of the assets and liabilities of
that reporting unit (including any recognized and unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value was reflective of the price paid to acquire the reporting unit. The implied
fair value of goodwill is the excess, if any, of the calculated fair value after hypothetical allocation to the reporting unit&#146;s assets and liabilities. If the implied fair value of the goodwill is greater than the carrying amount of the
goodwill at the analysis date, goodwill is not impaired and the analysis is complete. If the implied fair value of the goodwill is less than the carrying value of goodwill at the analysis date, goodwill is deemed impaired by the amount of that
variance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We calculate the estimated fair value of our reporting units using discounted cash flows as well as a market
approach that compares our reporting units&#146; earnings and revenue multiples to those of comparable public companies. To determine fair value we must make assumptions about a wide variety of internal and external factors. Significant assumptions
used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations, in particular expected organic growth rates, future Medicare reimbursement rates, capital requirements and income
taxes), long-term growth rates for determining terminal value, and discount rates. Our estimates of discounted cash flows may differ from actual cash flows due to, among other things, economic conditions, changes to our business model or changes in
operating performance. These factors increase the risk of differences between projected and actual performance that could impact future estimates of fair value of all reporting units. Significant differences between these estimates and actual cash
flows could result in additional impairment in future periods. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">71 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each of our operating segments described in Note 15 &#150; Segment Information is
considered to represent an individual reporting unit for goodwill impairment testing purposes. We consider each of our home health care centers to constitute an individual business for which discrete financial information is available. However,
since these care centers have substantially similar operating and economic characteristics and resource allocation and significant investment decisions concerning these businesses are centralized and the benefits broadly distributed, we have
aggregated these care centers and deemed them to constitute a single reporting unit. We have applied this same aggregation principle to our hospice care centers and personal-care care centers and have also deemed them to be a single reporting unit.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2016, we did not record any goodwill impairment charges as a result of our annual impairment test and none of the
goodwill associated with our various reporting units was considered at risk of impairment as of October&nbsp;31, 2016. Since the date of our last annual goodwill impairment test, there have been no material developments, events, changes in operating
performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than its carrying amount. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intangible assets consist of Certificates of Need, licenses, acquired names and <FONT STYLE="white-space:nowrap">non-compete</FONT>
agreements. We amortize <FONT STYLE="white-space:nowrap">non-compete</FONT> agreements and acquired names that we do not intend to use in the future on a straight-line basis over their estimated useful lives, which is generally three years for <FONT
STYLE="white-space:nowrap">non-compete</FONT> agreements and up to five years for acquired names. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Debt Issuance Costs
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We amortize deferred debt issuance costs related to our long-term obligations over its term through interest expense,
unless the debt is extinguished, in which case unamortized balances are immediately expensed. We amortized $0.7&nbsp;million, $0.8&nbsp;million and $0.7&nbsp;million in deferred debt issuance costs in 2016, 2015 and 2014, respectively. As of
December&nbsp;31, 2016 and 2015, we had unamortized debt issuance costs of $2.7&nbsp;million and $3.4&nbsp;million, respectively, recorded as long-term obligations, less current portion in our accompanying consolidated balance sheets. The
unamortized debt issuance costs of $2.7&nbsp;million at December&nbsp;31, 2016, will be amortized over a weighted-average amortization period of 3.7 years. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Fair Value of Financial Instruments </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following details our
financial instruments where the carrying value and the fair value differ (amounts in millions): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair Value at Reporting Date Using</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:72pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Financial Instrument</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of<BR>December&nbsp;31,&nbsp;2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Quoted&nbsp;Prices&nbsp;in&nbsp;Active<BR>Markets&nbsp;for&nbsp;Identical<BR>Items<BR>(Level&nbsp;
1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Significant&nbsp;Other<BR>Observable&nbsp;Inputs<BR>(Level&nbsp;2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Significant<BR>Unobservable&nbsp;Inputs<BR>(Level&nbsp;3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long-term obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">95.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">97.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fair value hierarchy is based on three levels of inputs, of which the first two are considered
observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level&nbsp;1 &#150; Quoted prices in active markets for identical assets and liabilities. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">72 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level&nbsp;2 &#150; Inputs other than Level&nbsp;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or
liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level&nbsp;3 &#150; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or
liabilities. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our deferred compensation plan assets are recorded at fair value and are considered a level 2
measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts&#146; approximate fair
value. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income Taxes </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We use the asset and liability approach for measuring deferred tax assets and liabilities based on temporary differences existing at each balance sheet date using currently enacted tax rates. Our deferred
tax calculation requires us to make certain estimates about future operations. Deferred tax assets are reduced by a valuation allowance when we believe it is more likely than not that some portion or all of the deferred tax assets will not be
realized. The effect of a change in tax rate is recognized as income or expense in the period that includes the enactment date. As of December&nbsp;31, 2016 and 2015 our net deferred tax assets were $107.9&nbsp;million and $125.2&nbsp;million,
respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management regularly assesses the ability to realize deferred tax assets recorded in the Company&#146;s
entities based upon the weight of available evidence, including such factors as the recent earnings history and expected future taxable income. In the event future taxable income is below management&#146;s estimates or is generated in tax
jurisdictions different than projected, we could be required to increase the valuation allowance for deferred tax assets. This would result in an increase in our effective tax rate. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Share-Based Compensation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We record all share-based compensation as expense in the financial statements measured at the fair value of the award. We recognize compensation cost on a straight-line basis over the requisite service
period for each separately vesting portion of the award. We reflect the excess tax benefits related to stock option exercises as financing cash flows. Share-based compensation expense for 2016, 2015 and 2014 was $16.4&nbsp;million,
$11.8&nbsp;million and $5.6&nbsp;million, respectively, and the total income tax benefit recognized for these expenses was $6.4&nbsp;million, $4.7&nbsp;million and $2.0&nbsp;million, respectively. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">73 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Weighted-Average Shares Outstanding </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income (loss) per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the
weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted
net income (loss) attributable to Amedisys, Inc. common stockholders (amounts in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average number of shares outstanding &#150; basic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effect of dilutive securities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">162</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-vested</FONT> stock and stock units</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">381</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">521</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average number of shares outstanding &#150; diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,741</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anti-dilutive securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">221</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">106</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Advertising Costs </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We expense advertising costs as incurred. Advertising expense for 2016, 2015 and 2014 was $7.8&nbsp;million, $6.9&nbsp;million and $4.7&nbsp;million, respectively. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Recently Issued Accounting Pronouncements </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In May 2014, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">2014-09,</FONT> <I>Revenue from Contracts
with Customers (Topic 606)</I>, which requires an entity to recognize the amount of revenue for which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition
guidance in U.S. GAAP. In August 2015, the FASB issued ASU <FONT STYLE="white-space:nowrap">2015-14,</FONT> <I>Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</I>, to defer the effective date of the standard from
January&nbsp;1, 2017, to January&nbsp;1, 2018, with an option that permits companies to adopt the standard as early as the original effective date. The new ASU reflects the decisions reached by the FASB at its meeting in July 2015. Early application
prior to the original effective date is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company does not expect an impact on its consolidated financial statements upon
implementation of ASU <FONT STYLE="white-space:nowrap">2014-09</FONT> and ASU <FONT STYLE="white-space:nowrap">2015-14</FONT> on January&nbsp;1, 2018, but is still evaluating the effect the standard will have on its related disclosures. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2015, the FASB issued ASU <FONT STYLE="white-space:nowrap">2015-03,</FONT> <I>Interest&#151;Imputation of Interest</I>
<I>(Subtopic <FONT STYLE="white-space:nowrap">835-30):</FONT> Simplifying the Presentation of Debt Issuance Costs</I>.&nbsp;The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the
balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. ASU <FONT
STYLE="white-space:nowrap">2015-03</FONT> is effective for annual and interim periods beginning on or after December&nbsp;15, 2015. We adopted this ASU during the three-month period ended March&nbsp;31, 2016, and applied the change retrospectively
for prior period balances of unamortized debt issuance costs, resulting in a $3.4&nbsp;million reduction in other assets, net and long-term obligations, less current portion, on our consolidated balance sheet as of December&nbsp;31, 2015.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">74 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT>
<I>Leases (Topic 842), </I>which will require lessees to recognize a lease liability and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset for all leases (with the exception of short-term leases) at
the commencement date. The ASU is effective for annual and interim periods beginning on or after December&nbsp;15, 2018. Early adoption is permitted. The standard requires a modified retrospective transition method which requires application of the
new guidance for all periods presented. While the Company expects adoption of this standard to lead to a material increase in the assets and liabilities recorded on our balance sheet, we are still evaluating the overall impact on our consolidated
financial statements and related disclosures and the effect of the standard on our ongoing financial reporting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In March
2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-09,</FONT> <I>Compensation &#150; Stock Compensation (Topic 718): Improvement to Employee Share-Based Payment Accounting</I>, which will simplify the accounting for share-based payment
award transactions, including income tax consequences, classification of awards as either equity or liability, and classification on the statement of cash flows. The ASU is effective for annual and interim periods beginning after December&nbsp;15,
2016. Early adoption is permitted. The element of the new standard that will have the most impact on our consolidated financial statements will be income tax consequences. Excess tax benefits and tax deficiencies on share-based compensation awards
will now be included in our tax provision within our consolidated statement of operations as discrete items in the reporting period in which they occur, rather than our current accounting of recording in additional
<FONT STYLE="white-space:nowrap">paid-in</FONT> capital on our consolidated balance sheets. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In August 2016, the FASB issued
ASU <FONT STYLE="white-space:nowrap">2016-15,</FONT> <I>Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</I>, which provides specific guidance on eight cash flow classification issues not specifically
addressed by U.S. GAAP. The ASU is effective for annual and interim periods beginning after December&nbsp;15, 2017. Early adoption is permitted. The standard should be applied using a retrospective transition method unless it is impractical to do so
for some of the issues. In such case, the amendments for those issues would be applied prospectively as of the earliest date practicable. The Company is evaluating the effect that ASU <FONT STYLE="white-space:nowrap">2016-15</FONT> will have on its
consolidated financial statements and related disclosures and the effect of the standard on its ongoing financial reporting. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.
ACQUISITIONS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence
by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice and personal care services. The purchase price paid for acquisitions is negotiated through arm&#146;s length
transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their
respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate
strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets. Preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if
management obtains more information regarding asset valuation and liabilities assumed. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2016 Acquisitions
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Personal Care Division </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;1, 2016, we acquired Associated Home Care which owns and operates 9 personal-care care centers servicing the state of Massachusetts for a total purchase price of $27.7&nbsp;million, net of
cash acquired (subject to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">75 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
certain adjustments), of which $0.5&nbsp;million was placed in escrow for indemnification purposes and working capital price adjustments. The purchase price was paid with cash on hand on the date
of the transaction. Based on our preliminary purchase price allocation, in connection with the acquisition, we recorded goodwill ($23.5 million) and other assets and liabilities, net ($4.2 million) during the three-month period ended March&nbsp;31,
2016. During the three-month period ended June&nbsp;30, 2016, we received the final report from our outside appraisal firm. As a result, we reduced our preliminary goodwill by $5.0&nbsp;million and recorded corresponding increases in the fair value
of assets acquired ($0.2 million), other intangibles &#150; acquired names of business ($3.5 million) and other intangibles &#150; <FONT STYLE="white-space:nowrap">non-compete</FONT> agreements ($1.3 million). We expect the entire amount of goodwill
recorded for this acquisition to be deductible for income tax purposes over approximately 15 years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;1,
2016, we acquired the assets of Professional Profiles, Inc. which owns and operates 4 personal-care care centers servicing the state of Massachusetts for a total purchase price of $4.4&nbsp;million, (subject to certain adjustments), of which
$0.7&nbsp;million was placed in a promissory note to be paid over 24 months, subject to any offsets or withholds for indemnification purposes. The purchase price was paid with cash on hand on the date of the transaction. During the three-month
period ended September&nbsp;30, 2016, we recorded goodwill ($4.2 million) and other intangibles &#150; <FONT STYLE="white-space:nowrap">non-compete</FONT> agreements ($0.2&nbsp;million) in connection with the acquisition. We expect the entire amount
of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Home Health Division
</I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;20, 2016, we acquired the assets of a former nonprofit organization in New York for a purchase price of
$4.6&nbsp;million. During the three-month period ended December&nbsp;31, 2016, we recorded goodwill ($4.4 million) and other intangibles &#150; certificate of need ($0.2&nbsp;million) in connection with the acquisition. We expect the entire amount
of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following
table contains unaudited pro forma condensed consolidated statement of operations information assuming that our 2016 acquisitions closed on January&nbsp;1, 2015, for the years ended December&nbsp;31, 2016 and 2015 (amounts in millions, except per
share data): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net service revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,449.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,322.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic earnings (loss) per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted earnings (loss) per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.03</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The pro forma information presented above includes adjustments for (i)&nbsp;amortization of identifiable
intangible assets and (ii)&nbsp;income tax provision using the Company&#146;s statutory tax rate. This pro forma information is presented for illustrative purposes only and may not be indicative of the results of operations that would have actually
occurred. In addition, future results may vary significantly from the results reflected in the pro forma information. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">76 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2015 Acquisitions </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Hospice Division </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;24, 2015, we acquired one hospice care
center in Tennessee for a total purchase price of $5.8&nbsp;million. The purchase price was paid with cash on hand on the date of the transaction. In connection with the acquisition, we recorded goodwill ($5.5 million) and other intangibles ($0.3
million). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Home Health Division </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;2, 2015, we acquired the assets of a home health care center in Georgia for a total purchase price of $0.3&nbsp;million. The purchase price was paid with cash on hand on the date of the
transaction. In connection with the acquisition, we recorded goodwill ($0.3 million). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On December&nbsp;31, 2015, we acquired
Infinity HomeCare (&#147;Infinity&#148;) for a total purchase price of $63&nbsp;million, net of cash acquired (subject to certain adjustments), of which $3.2&nbsp;million was placed in escrow for indemnification purposes and working capital price
adjustments. The purchase price was paid with cash on hand on the date of the transaction. Infinity owned and operated 15 home health care centers servicing the state of Florida. In connection with the acquisition, we recorded goodwill ($50.2
million), other intangibles ($10.9 million) and other assets and liabilities, net ($1.9 million). Approximately $47.6&nbsp;million of the $50.2 recorded as goodwill is expected to be deductible for income tax purposes over approximately 15 years.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. DISCONTINUED OPERATIONS AND ASSETS HELD FOR SALE </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2013, we had three care centers classified as held for sale. During 2014, we sold assets associated with two of these care centers and consolidated one of these care centers with a
care center servicing the same market. There were no care centers classified as held for sale as of December&nbsp;31, 2014. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As we exited certain geographical areas and in accordance with applicable accounting guidance, the care centers which were classified as
held for sale as of December&nbsp;31, 2013 and subsequently sold in 2014 are presented as discontinued operations in our consolidated financial statements. The care center consolidated with a care center servicing the same markets is presented in
continuing operations as we expect continuing cash flows from these markets. For additional information on the care centers consolidated with care centers servicing the same markets and the care centers sold, see Note 13 &#150; Exit Activities and
Restructuring Activities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating results for the twelve-month period ended December&nbsp;31, 2014 for those care centers
classified as discontinued operations are as follows: loss before income taxes of $0.3&nbsp;million, income tax benefit of $0.1&nbsp;million and net loss from discontinued operations of $0.2&nbsp;million. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. GOODWILL AND OTHER INTANGIBLE ASSETS, NET </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During 2016, we did not record any goodwill impairment charges as a result of our annual impairment test and none of the goodwill associated with our various reporting units were considered at risk of
impairment as of October&nbsp;31, 2016. Since the date of our last annual goodwill impairment test, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it
is more likely than not that the fair value of any of our reporting units would be less than its carrying amount. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the
fiscal year 2015, we did not record any goodwill impairment charges as a result of our annual impairment test and none of the goodwill associated with our various reporting units were considered at risk of impairment. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">77 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the fiscal year 2014, we recognized a
<FONT STYLE="white-space:nowrap">non-cash</FONT> other intangible impairment charge of $0.9&nbsp;million during step one of our 2014 annual goodwill impairment test. In addition, we recorded <FONT STYLE="white-space:nowrap">non-cash</FONT>
impairment charges of $2.2&nbsp;million related to those care centers that were closed or consolidated during 2014 as discussed in Note 13 &#150; Exit and Restructuring Activities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the activity related to our goodwill for 2016, 2015 and 2014 (amounts in millions): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Goodwill</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Home&nbsp;Health</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Hospice</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Personal&nbsp;Care</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balances at December&nbsp;31, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">192.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">208.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Write-off</FONT> (1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balances at December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">189.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">205.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balances at December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">194.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">261.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments related to acquisitions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balances at December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">194.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">288.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Write-off</FONT> of goodwill related to the sale of care centers as discussed in Note 13 &#150; Exit and
Restructuring Activities. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2016, we adjusted goodwill by $0.1&nbsp;million as a result of our
completion of the purchase price accounting for our 2015 acquisition of Infinity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the activity
related to our other intangible assets, net for 2016, 2015 and 2014 (amounts in millions): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Other Intangible Assets, Net</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Certificates&nbsp;of<BR>Need and<BR>Licenses</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Acquired<BR>Names of<BR>Business</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">Non-Compete</FONT><BR>Agreements&nbsp;(2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balances at December&nbsp;31, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Write-off</FONT> (1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Impairment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balances at December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Write-off</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balances at December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balances at December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Write-off</FONT> of intangible assets related to the sale of care centers as discussed in Note 13 &#150; Exit and
Restructuring Activities. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The weighted average amortization period of our <FONT STYLE="white-space:nowrap">non-compete</FONT> agreements is 1.9 years.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">See Note 3 &#150; Acquisitions for further details on additions to goodwill and other intangible assets,
net. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">78 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The estimated aggregate amortization expense related to intangible assets for each of
the five succeeding years is as follows (amounts in millions): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2020</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2021</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional information regarding certain balance sheet accounts is presented below (amounts in millions): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other current assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payroll tax escrow</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Due from joint ventures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Workers&#146; compensation deposits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Health insurance deposits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other miscellaneous deposits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Health insurance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Workers&#146; compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Legal and other settlements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Charity care</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Estimated Medicare cap liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hospice cost of revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">OIG self-disclosure accrual</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patient liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other long-term obligations:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reserve for uncertain tax positions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred compensation plan liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">79 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. LONG-TERM OBLIGATIONS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Long-term debt consisted of the following for the periods indicated (amounts in millions): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">$100.0&nbsp;million Term Loan; principal payments plus accrued interest payable quarterly; interest rate at ABR Rate plus
applicable percentage or Eurodollar Rate plus the applicable percentage (2.77% at December&nbsp;31, 2016); due August&nbsp;28, 2020</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">95.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">$200.0&nbsp;million Revolving Credit Facility; interest only quarterly payments; interest rate at ABR Rate plus applicable
percentage or Eurodollar Rate plus the applicable percentage; due August&nbsp;28, 2020</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Promissory notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred debt issuance costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">93.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">96.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current portion of long-term obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">91.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maturities of debt as of December&nbsp;31, 2016 are as follows (amounts in millions): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Long-term<BR>obligations</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2020</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2021</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">95.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Credit Agreement </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;28, 2015, we entered into a Credit Agreement that provides for senior secured facilities in an initial aggregate principal amount of up to $300&nbsp;million (the &#147;Credit
Facilities&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Credit Facilities are comprised of (a)&nbsp;a term loan facility in an initial aggregate principal
amount of $100&nbsp;million (the &#147;Term Loan&#148;); and (b)&nbsp;a revolving credit facility in an initial aggregate principal amount of up to $200&nbsp;million (the &#147;Revolving Credit Facility&#148;). The Revolving Credit Facility provides
for and includes within its $200&nbsp;million limit a $25&nbsp;million swingline facility and commitments for up to $50&nbsp;million in letters of credit. Upon lender approval, we may increase the aggregate loan amount under the Credit Facilities by
a maximum amount of $150&nbsp;million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The net proceeds of the Term Loan and existing cash on hand were used to pay off
(i)&nbsp;our existing term loan under our prior Credit Agreement, dated as of October&nbsp;22, 2012, as amended (the &#147;Prior Credit Agreement&#148;) with a principal balance of $27&nbsp;million and (ii)&nbsp;our existing term loan under our
prior Second Lien Credit Agreement dated July&nbsp;28, 2014 (the &#147;Second Lien Credit Agreement&#148;), with a principal balance of $70&nbsp;million. The final maturity of the Term Loan is August&nbsp;28, 2020. The Term Loan began amortizing on
March&nbsp;31, 2016 and will </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">80 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
continue amortizing over 14 quarterly installments (four remaining quarterly installments of $1.25&nbsp;million followed by eight quarterly installments of $2.5&nbsp;million, followed by two
quarterly installments of $3.1&nbsp;million, subject to adjustment for prepayments), with the remaining balance due upon maturity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Revolving Credit Facility may be used to provide ongoing working capital and for general corporate purposes of the Company and our subsidiaries, including permitted acquisitions, as defined in the
Credit Agreement. The final maturity of the Revolving Credit Facility is August&nbsp;28, 2020 and will be payable in full at that time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The interest rate in connection with the Credit Facilities shall be selected from the following by us: (i)&nbsp;the Base Rate plus the Applicable Rate or (ii)&nbsp;the Eurodollar Rate plus the Applicable
Rate. The &#147;Base Rate&#148; means a fluctuating rate per annum equal to the highest of (a)&nbsp;the federal funds rate plus 0.50% per annum, (b)&nbsp;the prime rate of interest established by the Administrative Agent, and (c)&nbsp;the Eurodollar
Rate for an interest period of one month plus 1% per annum. The &#147;Eurodollar Rate&#148; means the rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months (as selected by us) are
quoted. The &#147;Applicable Rate&#148; is based on the consolidated leverage ratio and is presented in the table below. As of December&nbsp;31, 2016, the Applicable Rate is 1.00% per annum for Base Rate Loans and 2.00% per annum for Eurodollar Rate
Loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Credit Facilities, as presented in the table below. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:99pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Consolidated Leverage Ratio</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Margin&nbsp;for&nbsp;ABR<BR>Loans</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Margin&nbsp;for&nbsp;Eurodollar<BR>Loans</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Commitment<BR>Fee</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Letter&nbsp;of<BR>Credit&nbsp;Fee</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>&nbsp;2.75 to 1.0</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&lt; 2.75 to 1.0 but <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>&nbsp;1.75 to
1.0</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&lt; 1.75 to 1.0 but <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>&nbsp;0.75 to
1.0</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&lt; 0.75 to 1.0</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our weighted average interest rate for our $100.0&nbsp;million Term Loan, under our Credit Agreement, was
2.5% for 2016 and 2.7% for the period August&nbsp;28, 2015 to December&nbsp;31, 2015. Our weighted average interest rate for our $200.0&nbsp;million Revolving Credit Facility was 3.5% for 2016. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2016, our availability under our $200.0&nbsp;million Revolving Credit Facility was $173.3&nbsp;million as we had
$26.7&nbsp;million outstanding in letters of credit. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Credit Agreement requires maintenance of two financial covenants:
(i)&nbsp;a consolidated leverage ratio of funded indebtedness to EBITDA, as defined in the Credit Agreement, and (ii)&nbsp;a consolidated fixed charge coverage ratio of EBITDA plus rent expense (less cash taxes less capital expenditures) to
scheduled debt repayments plus interest expense plus rent expense, all as defined in the Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. As of
December&nbsp;31, 2016, our consolidated leverage ratio was 1.0 and our consolidated fixed charge coverage ratio was 3.8 and we are in compliance with the Credit Agreement. The Credit Agreement also contains customary covenants, including, but not
limited to, restrictions on: incurrence of liens; incurrence of additional debt; sales of assets and other fundamental corporate changes; investments; and declarations of dividends. These covenants contain customary exclusions and baskets.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Credit Facilities are guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Credit
Agreement requires at all times that we (i)&nbsp;provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">81 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
<FONT STYLE="white-space:nowrap">wholly-owned</FONT> subsidiaries and (ii)&nbsp;provide guarantees from subsidiaries that in the aggregate represent not less than 70% of consolidated adjusted
EBITDA, subject to certain exceptions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with entering into the Credit Agreement, we entered into (i)&nbsp;a
Security Agreement with the Administrative Agent dated August&nbsp;28, 2015 and (ii)&nbsp;a Pledge Agreement with the Administrative Agent dated as of August&nbsp;28, 2015 for the purpose of securing the payment of our obligations under the Credit
Agreement. Pursuant to the Security Agreement and the Pledge Agreement, as of the effective date of the Credit Agreement, our obligations under the Credit Agreement are secured by (i)&nbsp;the grant of a first lien security interest in the <FONT
STYLE="white-space:nowrap">non-real</FONT> estate assets of substantially all of our direct and indirect, wholly-owned subsidiaries (subject to exceptions) and (ii)&nbsp;the pledge of the equity interests in (a)&nbsp;substantially all of our direct
and indirect, wholly-owned corporate, limited liability company and limited partnership subsidiaries and (b)&nbsp;those joint ventures which constitute subsidiaries under the Credit Agreement (subject, in the case of the Pledge Agreement, to
exceptions). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with our entry into the Credit Agreement, on August&nbsp;28, 2015, each of the Prior Credit
Agreement and the Second Lien Credit Agreement were terminated. The Company paid a call premium of $700,000 associated with the termination of the Second Lien Credit Agreement and the voluntary prepayment of the amounts owed thereunder as of
August&nbsp;28, 2015, and expensed $2.5&nbsp;million in deferred debt issuance costs during the three-month period ended September&nbsp;30, 2015. Also in connection with our entry into the Credit Agreement, we recorded $2.4&nbsp;million in deferred
debt issuance costs as other assets in our consolidated balance sheet during 2015 which was reclassified to long-term obligations, less current portion during 2016 in accordance with ASU <FONT STYLE="white-space:nowrap">2015-03.</FONT> </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Promissory Notes </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our promissory note outstanding of $0.7&nbsp;million, issued in conjunction with an acquisition, bears an interest rate of 2.6%. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>8. INCOME TAXES </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income taxes attributable to continuing operations consist
of the following (amounts in millions): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Years Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current income tax expense/(benefit):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Federal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">State and local</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred income tax expense/(benefit):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Federal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">State and local</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Foreign</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax expense/(benefit) from continuing operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">82 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total income tax expense for the years ended December&nbsp;31, 2016, 2015 and 2014 was
allocated as follows (amounts in millions): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Years Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income from continuing operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income from discontinued operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Goodwill</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">A reconciliation of significant differences between the reported amount of income tax expense and the
expected amount of income tax expense that would result from applying the U.S. federal statutory income tax rate of 35&nbsp;percent to income before taxes from continuing operations is as follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Years Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;(1)&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax expense at U.S. federal statutory rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35.0&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35.0&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35.0&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">State and local income taxes, net of federal income tax benefit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Valuation allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">79.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax credits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">136.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Uncertain tax positions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(230.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other items, net (2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(663.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax expense/(benefit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38.9&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(650.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36.6&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information provided for the year ended December&nbsp;31, 2015 does not provide a meaningful reconciliation of the effective tax rate or
comparable to other periods. The effective tax rate for the year is influenced by the relationship of the amount of &#147;effective tax rate drivers&#148; (i.e. <FONT STYLE="white-space:nowrap">non-deductible</FONT> expenses, <FONT
STYLE="white-space:nowrap">non-taxable</FONT> income, tax credits, valuation allowance, uncertain tax positions, etc.) to income or loss before taxes. A significant asset impairment was recorded in the first quarter, resulting in a scenario where
the company&#146;s loss before tax for the year was near zero. Consequently, for 2015, the relationship between the &#147;effective tax rate drivers&#148; and loss before taxes is distorted. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes various items such as, <FONT STYLE="white-space:nowrap">non-deductible</FONT> expenses, <FONT STYLE="white-space:nowrap">non-taxable</FONT>
income, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">return-to-accrual</FONT></FONT> adjustments, and foreign tax rate differential. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2016 and 2015, the Company had income taxes receivable of $1.3&nbsp;million and $0.5&nbsp;million, respectively, included in other current assets. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">83 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax assets (liabilities) consist of the following components (amounts in
millions): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Allowance for doubtful accounts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued payroll&nbsp;&amp; employee benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Workers&#146; compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization of intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net operating loss carryforwards (1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax credit carryforwards (2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross deferred tax assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">143.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">155.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less: valuation allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net deferred tax assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">143.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">155.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax (liabilities):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(23.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investment in partnerships</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross deferred tax (liabilities)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(35.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(30.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net deferred tax assets (liabilities)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">107.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The net operating loss (&#147;NOL&#148;) carry forwards in the income tax returns include unrecognized tax benefits resulting from uncertain tax
positions. Accordingly, the deferred tax assets recognized for the NOL carry forwards, as of December&nbsp;31, 2016 and 2015, are presented net of unrecognized tax benefits of $3.1&nbsp;million. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The tax credit carry forwards in the income tax returns include unrecognized tax benefits resulting from uncertain tax positions. Accordingly, the
deferred tax assets recognized for the tax credit carry forwards are presented net of unrecognized tax benefits of $0.7&nbsp;million for each of the years ended December&nbsp;31, 2016 and 2015. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2016, we have U.S. net operating loss (&#147;NOL&#148;) carry forwards of $102.1&nbsp;million that are available
to reduce future taxable income and begin to expire in 2034. In addition, we have research and development tax credits, employment tax credits, and alternative minimum tax credits of $1.9&nbsp;million, $0.2&nbsp;million and $1.4&nbsp;million,
respectively, available to reduce future U.S. federal income taxes. The research and development tax credits and employment tax credits begin to expire in 2032, and the alternative minimum tax credits are available indefinitely. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2016, we have state NOL carry forwards of $268.4&nbsp;million that are available to reduce future taxable income.
In addition, we have $3.1&nbsp;million of various state tax credits available to reduce future taxable income. The state NOL and tax credit carry forwards begin to expire at various times. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The valuation allowance for deferred tax assets as of December&nbsp;31, 2016 and 2015 was $0.4&nbsp;million and $0.3&nbsp;million,
respectively. The net change in the total valuation allowance for the year ended December&nbsp;31, 2016 and December&nbsp;31, 2015 was an increase of $0.1&nbsp;million and a decrease of $0.3&nbsp;million, respectively. The valuation allowance during
2016 and 2015 was primarily related to certain state NOL and state tax credit carry forwards. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">84 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In assessing the realizability of deferred tax assets, management considers whether it
is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those jurisdictions during the periods in
which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities (including the impact of available carry back and carry forward periods), projected future taxable income, and <FONT
STYLE="white-space:nowrap">tax-planning</FONT> strategies in making this assessment. In order to fully realize the deferred tax assets, the Company will need to generate future taxable income before the expiration of the carry forwards governed by
the tax code. Based on the current level of pretax earnings, the Company will generate the minimum amount of future taxable income to support the realization of the deferred tax assets. As a result, management believes that it is more likely than
not that we will realize the benefits of these deferred tax assets, net of the existing valuation allowances at December&nbsp;31, 2016. The amount of the deferred tax asset considered realizable, however, could be reduced in the near term if
estimates of future taxable income during the carry forward period are reduced. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Uncertain Tax Positions
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We account for uncertain tax positions in accordance with the authoritative guidance for uncertain tax positions. A
reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (amounts in millions): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Years Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additions for tax positions related to current year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additions for tax positions related to prior year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reductions for tax positions related to prior years</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lapse of statute of limitations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Settlements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2016, there are $0.3&nbsp;million and $3.8&nbsp;million of unrecognized tax
benefits recorded in accrued other long-term obligations and deferred income taxes, respectively, within the consolidated balance sheet. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Included in the balance of unrecognized tax benefits at December&nbsp;31, 2016 is $4.1&nbsp;million of tax benefits that, if recognized in future periods, would impact our effective tax rate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the years ended December&nbsp;31, 2016 and 2015, we recognized interest and penalties of $(0.1) million and $0.2&nbsp;million,
respectively, as components of penalties or interest expense in connection with our reserve for uncertain tax positions. Interest and penalties, related to uncertain tax positions, included in the consolidated balance sheet at December&nbsp;31, 2016
and 2015 were less than $0.1 and $0.2&nbsp;million, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are subject to income taxes in the U.S. and in many of
the 50 individual states, with significant operations in Louisiana, Alabama, Georgia, and Tennessee. We are open to examination in the U.S. and in various individual states for tax years ended December&nbsp;31, 2013 through December&nbsp;31, 2016.
We are also open to examination in various states for the years ended 2001 &#150; 2016 resulting from net operating losses generated and available for carry forward from those years. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">85 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that it is reasonably possible that decreases of up to $0.3&nbsp;million in
unrecognized tax benefits, each of which are individually insignificant, may be recognized by the end of December&nbsp;31, 2017 as a result of an anticipated settlement and lapse of the statute of limitations. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9. CAPITAL STOCK AND SHARE-BASED COMPENSATION </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are authorized by our Certificate of Incorporation to issue 60,000,000 shares of common stock, $0.001 par value and 5,000,000 shares of preferred stock, $0.001 par value. As of December&nbsp;31, 2016,
there were 35,253,577 and 33,597,215 shares of common stock issued and outstanding, respectively, and no shares of preferred stock issued or outstanding. Our Board of Directors is authorized to fix the dividend rights and terms, conversion and
voting rights, redemption rights and other privileges and restrictions applicable to our preferred stock. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Share-Based
Awards </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our 2008 Omnibus Incentive Compensation Plan (the &#147;Plan&#148;) authorizes the grant of various types of
equity-based awards, such as stock awards, restricted stock units, stock appreciation rights and stock options to eligible participants, which include all of our employees and all employees of our 50% or more owned subsidiaries, our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors and certain consultants. The vesting terms of the awards may be tied to continued employment (or, for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, continued service on
the Board of Directors) and/or achievement of certain <FONT STYLE="white-space:nowrap">pre-determined</FONT> performance goals. We refer to stock awards subject to service-based vesting conditions as
<FONT STYLE="white-space:nowrap">&#147;non-vested</FONT> stock&#148; and restricted stock units subject to service-based and performance-based or market-based vesting conditions as <FONT STYLE="white-space:nowrap">&#147;non-vested</FONT> stock
units.&#148; The Plan is administered by the Compensation Committee of our Board of Directors, which determines, within the provisions of the Plan, those eligible employees to whom, and the times at which, awards shall be granted. The Compensation
Committee, in its discretion, may delegate its authority and duties under the Plan to specified officers; however, only the Compensation Committee may approve the terms of awards to our executive officers. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity-based awards may be granted for a number of shares not to exceed, in the aggregate, approximately 5.5&nbsp;million shares of
common stock, and we had approximately 1.2&nbsp;million shares available at December&nbsp;31, 2016. The price per share for stock options shall be of no less than the greater of (a) 100% of the fair value of a share of common stock on the date the
option is granted or (b)&nbsp;the aggregate par value of the shares of our common stock on the date the option is granted. If a stock option is granted to any owner of 10% or more of our total combined voting power of us and our subsidiaries, the
price is to be at least 110% of the fair value of a share of our common stock on the date the award is granted. Each equity-based award vests ratably over a 12 month to six year period, with the exception of those issued under contractual
arrangements that specify otherwise, that may be exercised during a period as determined by our Compensation Committee or as otherwise approved by our Compensation Committee. The contractual terms of stock options exercised shall not exceed ten
years from the date such option is granted. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Employee Stock Purchase Plan (&#147;ESPP&#148;) </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have a plan whereby our eligible employees may purchase our common stock at 85% of the market price at the time of purchase. On
June&nbsp;7, 2012, our stockholders ratified an amendment adopted by our Board of Directors to increase the total number of shares of our common stock authorized for the issuance under our ESPP
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">86 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
from 2,500,000 shares to 4,500,000 shares, and as of December&nbsp;31, 2016, there were 1,460,800 shares available for future issuance. The following is a detail of the purchases that were made
or pending Board of Director approval under the plan: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:130pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Employee Stock Purchase Plan Period</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares&nbsp;Issued</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Price</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2014 and Prior</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,899,528</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.78</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;1, 2015 to March&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22.76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;1, 2015 to June&nbsp;30, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33.77</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">July&nbsp;1, 2015 to September&nbsp;30, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,984</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">October&nbsp;1, 2015 to December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,082</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33.42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;1, 2016 to March&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;1, 2016 to June&nbsp;30, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42.91</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">July&nbsp;1, 2016 to September&nbsp;30, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,520</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40.32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">October&nbsp;1, 2016 to December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,882</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,039,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">ESPP expense included in general and administrative expense in our accompanying consolidated statements
of operations was $0.4&nbsp;million for each of 2016, 2015 and 2014, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stock Options </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We use the Black-Scholes option pricing model to estimate the fair value of our stock options. There were 268,538, 590,647 and 250,000
options granted during 2016, 2015 and 2014, respectively. Stock option compensation expense included in general and administrative expense in our accompanying consolidated statements of operations was $6.3&nbsp;million, $3.8&nbsp;million and
$0.1&nbsp;million for 2016, 2015 and 2014, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fair value of the 2016 awards were estimated using the following
assumptions: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk Free Rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.19%&nbsp;&#150;&nbsp;1.58%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected Volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53.44%&nbsp;&#150;&nbsp;54.89%</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected Term</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.86&nbsp;&#150;&nbsp;6.25&nbsp;years</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted Average Fair Value</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">$25.99</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We used the simplified method to estimate the expected term for the stock options granted during 2016.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table presents our stock option activity for 2016: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of<BR>Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted<BR>Average&nbsp;Exercise<BR>Price</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted<BR>Average&nbsp;Contractual<BR>Life&nbsp;(Years)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding options at January&nbsp;1, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">838,494</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30.18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">268,538</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37.21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercised</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Canceled, forfeited or expired</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(98,875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding options at December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,008,157</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31.54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercisable options at December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">281,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28.86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">87 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The aggregate intrinsic value of our outstanding options and exercisable options at
December&nbsp;31, 2016 was $11.9&nbsp;million and $3.9&nbsp;million, respectively. There were no options exercised during 2016. Total intrinsic value of options exercised was $0.2&nbsp;million and $0.1&nbsp;million for 2015 and 2014, respectively.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table presents our <FONT STYLE="white-space:nowrap">non-vested</FONT> stock option award activity for 2016:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of<BR>Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted&nbsp;Average<BR>Grant Date Fair<BR>Value</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-vested</FONT> stock options at January&nbsp;1, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">775,994</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30.47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">268,538</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37.21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vested</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(219,872</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29.55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(97,961</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-vested</FONT> stock options at December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">726,699</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32.58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2016, there was $7.2&nbsp;million of unrecognized compensation cost related to stock
options that we expect to be recognized over a weighted-average period of 2.1 years. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Non-Vested</FONT> Stock </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We issue shares of <FONT STYLE="white-space:nowrap">non-vested</FONT> stock with vesting terms ranging from one to six years. The
compensation expense is determined based on the market price of our common stock at the date of grant applied to the total number of shares that are anticipated to fully vest. <FONT STYLE="white-space:nowrap">Non-vested</FONT> stock compensation
expense included in general and administrative expenses in our accompanying consolidated statements of operations was $2.3&nbsp;million, $5.0&nbsp;million and $4.6&nbsp;million for 2016, 2015 and 2014, respectively. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table presents our <FONT STYLE="white-space:nowrap">non-vested</FONT> stock award activity for 2016: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of<BR>Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted&nbsp;Average<BR>Grant Date Fair<BR>Value</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-vested</FONT> stock at January&nbsp;1, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50.55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vested</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(222,783</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Canceled, forfeited or expired</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(89,929</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-vested</FONT> stock at December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">209,378</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The weighted average grant date fair value of <FONT STYLE="white-space:nowrap">non-vested</FONT> stock
granted was $50.55, $28.48 and $16.38 in 2016, 2015, and 2014, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2016, there was
$1.4&nbsp;million of unrecognized compensation cost related to <FONT STYLE="white-space:nowrap">non-vested</FONT> stock award payments that we expect to be recognized over a weighted average period of 0.9 years. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Non-Vested</FONT> Stock Units </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We issue <FONT STYLE="white-space:nowrap">non-vested</FONT> stock unit awards that are service-based, performance-based or a combination
of both with vesting terms ranging from one to six years. Based on the terms and conditions of these awards, we determine if </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">88 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the awards should be recorded as either equity or liability instruments. The compensation expense is determined based on the market price of our common stock at the date of grant, applied to the
total number of units that are anticipated to vest, unless the award specifies differently. We account for such awards similar to our <FONT STYLE="white-space:nowrap">non-vested</FONT> stock awards; however, no shares of stock are issued to the
recipient until the stock unit awards have vested and after the <FONT STYLE="white-space:nowrap">pre-determined</FONT> delivery date has occurred. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Non-Vested Stock Units &#150; Service-Based </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Service-based <FONT
STYLE="white-space:nowrap">non-vested</FONT> stock unit compensation expense included in general and administrative expenses in our accompanying consolidated statements of operations was $3.6&nbsp;million and $1.0&nbsp;million for 2016 and 2015,
respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table presents our service-based <FONT STYLE="white-space:nowrap">non-vested</FONT> stock units
activity for 2016: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted&nbsp;Average<BR>Grant Date Fair<BR>Value</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-vested</FONT> stock units at January&nbsp;1, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">183,332</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37.89</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">147,896</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vested</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(32,607</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38.81</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Canceled, forfeited or expired</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(49,192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-vested</FONT> stock units at December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">249,429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The weighted average grant date fair value of service-based
<FONT STYLE="white-space:nowrap">non-vested</FONT> stock units granted was $45.60 and $37.98 in 2016 and 2015, respectively. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2016, there was $6.7&nbsp;million of unrecognized compensation cost related to our service-based <FONT
STYLE="white-space:nowrap">non-vested</FONT> stock units that we expect to be recognized over a weighted average period of 2.2 years. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Non-Vested</FONT> Stock Units &#150; Service-Based and Performance-Based Awards </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During 2016, we awarded performance-based awards to certain employees. The target level established by the award, which is based on the Company&#146;s 2016 adjusted earnings before interest, taxes and
depreciation (&#147;EBITDA&#148;), provided for the recipients to receive 182,796 <FONT STYLE="white-space:nowrap">non-vested</FONT> stock units if the target was achieved. The target number of shares to be potentially awarded has been reduced by
forfeitures as indicated in the table below. Performance-based <FONT STYLE="white-space:nowrap">non-vested</FONT> stock units compensation expense included in general and administrative expenses in our consolidated statements of operations was
$3.7&nbsp;million and $1.3&nbsp;million for 2016 and 2015, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table presents our performance-based <FONT
STYLE="white-space:nowrap">non-vested</FONT> stock units activity for 2016: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted&nbsp;Average<BR>Grant Date Fair<BR>Value</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-vested</FONT> stock units at January&nbsp;1, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">151,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39.44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">182,796</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46.29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vested</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(44,729</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34.83</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Canceled, forfeited or expired</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(64,273</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42.41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-vested</FONT> stock units at December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">224,857</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">89 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016&#151;(Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The weighted average grant date fair value of performance-based <FONT
STYLE="white-space:nowrap">non-vested</FONT> stock units granted was $46.29 and $39.54 in 2016 and 2015, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">At
December&nbsp;31, 2016, there were $6.4&nbsp;million in unrecognized compensation costs related to our performance-based <FONT STYLE="white-space:nowrap">non-vested</FONT> stock units that we expect to be recognized over a weighted average period of
2.0 years. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Non-Vested</FONT> Stock Units &#150; Service-Based and Market-Based Awards
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2013, we awarded market-based awards to certain employees. The target level established by the award, which was
based on our average December 2015 stock price, provided for the recipients to receive 417,330 <FONT STYLE="white-space:nowrap">non-vested</FONT> stock units if the target is achieved. If the target objective was surpassed to the point of achieving
the projected maximum payout, the recipients would receive 667,728 <FONT STYLE="white-space:nowrap">non-vested</FONT> stock units. The target number of shares to be potentially awarded was reduced by forfeitures as indicated in the table below. As
of March&nbsp;3, 2016, it was determined that the market-based objective established by the award was satisfied at maximum payout and as a result, 248,654 stock units were awarded to the recipients on April 1, 2016. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">For market-based awards, the effect of the market condition is reflected in the fair value of the awards at the date of grant using a
Monte-Carlo simulation model. A Monte-Carlo simulation model estimates the fair value of the market-based award based upon the expected term, risk-free interest rate and expected volatility. Compensation expense for market-based awards is recognized
over the vesting period regardless of whether the market conditions are expected to be achieved. Market-based <FONT STYLE="white-space:nowrap">non-vested</FONT> stock units compensation expense included in general and administrative expenses in our
accompanying consolidated statements of operations was $0.1&nbsp;million, $0.3&nbsp;million and $0.5&nbsp;million for 2016, 2015 and 2014, respectively. The fair value of the 2013 award was estimated using the following assumptions: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forward Interest Rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.327&nbsp;%&nbsp;&#150;&nbsp;1.460%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected Volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54.38%</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Requisite Service Period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3&nbsp;years</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair Value</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">$10.51</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table presents our market-based <FONT STYLE="white-space:nowrap">non-vested</FONT> stock
units activity for 2016: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted&nbsp;Average<BR>Grant&nbsp;Date&nbsp;Fair<BR>Value</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-vested</FONT> stock units at January&nbsp;1, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">164,534</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted (1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">93,257</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vested</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(248,654</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Canceled, forfeited or expired</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-vested</FONT> stock units at December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Represents shares awarded upon achievement of maximum payout. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The weighted average grant date fair value of market-based <FONT STYLE="white-space:nowrap">non-vested</FONT> stock units granted was
$10.51 in 2013. All of our outstanding market-based <FONT STYLE="white-space:nowrap">non-vested</FONT> stock units were fully vested as of April&nbsp;1, 2016. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">90 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. COMMITMENTS AND CONTINGENCIES </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Legal Proceedings &#150; Ongoing </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are involved in the following legal actions: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Securities Class&nbsp;Action Lawsuits
</I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;10, 2010, a putative securities class action complaint was filed in the United States District Court for the
Middle District of Louisiana (the &#147;District Court&#148;) against the Company and certain of our current and former senior executives. Additional putative securities class actions were filed in the District Court on
July&nbsp;14,&nbsp;July&nbsp;16, and July&nbsp;28, 2010. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;18, 2011, the
<FONT STYLE="white-space:nowrap">Co-Lead</FONT> Plaintiffs filed an amended, consolidated&nbsp;class action complaint (the &#147;Securities Complaint&#148;) which supersedes the earlier-filed securities class action complaints.&nbsp;The Securities
Complaint alleges that the defendants made false and/or misleading statements and failed to disclose material facts about our business, financial condition, operations and prospects, particularly relating to our policies and practices regarding home
therapy visits under the Medicare home health prospective payment system and the related alleged impact on our business, financial condition, operations and prospects. The Securities Complaint seeks a determination that the action may be maintained
as a class action on behalf of all persons who purchased the Company&#146;s securities between August&nbsp;2, 2005 and September&nbsp;28, 2010 and an unspecified amount of damages. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">All defendants moved to dismiss the Securities Complaint. On June&nbsp;28, 2012, the District Court granted the defendants&#146; motion
to dismiss the Securities Complaint. On July&nbsp;26, 2012, the <FONT STYLE="white-space:nowrap">Co-Lead</FONT> Plaintiffs filed a motion for reconsideration, which the District Court denied on April&nbsp;9, 2013. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;3, 2013, the <FONT STYLE="white-space:nowrap">Co-Lead</FONT> Plaintiffs appealed the dismissal of the Securities Complaint to
the United States Court of Appeals for the Fifth Circuit (the &#147;Fifth Circuit&#148;). On October&nbsp;2, 2014, a three-judge panel of the Fifth Circuit issued a decision reversing the District Court&#146;s dismissal of the Securities Complaint.
On October&nbsp;16, 2014, all defendants filed a petition with the Fifth Circuit to review the three-judge panel&#146;s decision <I>en banc</I>, or as a whole court. On December&nbsp;29, 2014, the Fifth Circuit denied the defendants&#146; motion for
<I>en banc</I> review of the Fifth Circuit panel&#146;s decision reversing the District Court&#146;s dismissal of the Securities Complaint.&nbsp;The case then returned to the District Court for further proceedings. On March&nbsp;30, 2015, the
defendants filed a Petition for Writ of Certiorari (the &#147;Petition&#148;) with the United States Supreme Court asking the Supreme Court to consider whether the Fifth Circuit erred in reversing the District Court&#146;s dismissal of the
Securities Complaint. The Supreme Court denied the Petition on June&nbsp;29, 2015, which did not affect the ongoing proceedings before the District Court, including the District Court&#146;s consideration of a motion filed on April&nbsp;3, 2015, by
the <FONT STYLE="white-space:nowrap">Co-Lead</FONT> Plaintiffs for leave to amend the Securities Complaint, which motion was granted by the District Court. On December&nbsp;15, 2015, the defendants filed a motion to dismiss the <FONT
STYLE="white-space:nowrap">Co-Lead</FONT> Plaintiffs&#146; First Amended Consolidated Complaint. All discovery in the case is currently stayed pursuant to federal law. The parties agreed to explore the possibility of a mediated settlement of this
matter, and a mediation was held on June&nbsp;21, 2016. The parties were unable to resolve this matter during the mediation. On August&nbsp;19, 2016, the District Court denied the defendants motion to dismiss the
<FONT STYLE="white-space:nowrap">Co-Lead</FONT> Plantiffs&#146; First Amended Consolidated Complaint. The Defendants filed an Answer to the Complaint on October&nbsp;20, 2016. The case is currently in discovery. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are unable to assess the probable outcome or reasonably estimate the potential liability, if any, arising from the securities
litigation described above.&nbsp;The Company intends to continue to vigorously defend itself in the securities litigation matter but, if decided adverse to the Company, its impact could be material.&nbsp;No assurances
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">91 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
can be given as to the timing or outcome of the securities matter described above or the impact of any of the inquiry or litigation matters on the Company, its consolidated financial condition,
results of operations or cash flows, which could be material, individually or in the aggregate. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Subpoena Duces Tecum Issued by the U.S.
Department of Justice </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;21, 2015, we received a Subpoena Duces Tecum (&#147;Subpoena&#148;) issued by the U.S.
Department of Justice. The Subpoena requests the delivery of information regarding 53 identified hospice patients to the United States Attorney&#146;s Office for the District of Massachusetts. It also requests the delivery of documents relating to
our hospice clinical and business operations and related compliance activities. The Subpoena generally covers the period from January&nbsp;1, 2011, through the present. We are fully cooperating with the U.S. Department of Justice with respect to
this investigation. Based on the information currently available to us, we cannot predict the timing or outcome of this investigation or reasonably estimate the amount or range of potential losses, if any, which may arise from this matter.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Civil Investigative Demand Issued by the U.S. Department of Justice </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On November&nbsp;3, 2015, we received a civil investigative demand (&#147;CID&#148;) issued by the U.S. Department of Justice pursuant to
the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requests the delivery of information to the United
States Attorney&#146;s Office for the Northern District of West Virginia regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covers the
period from January&nbsp;1, 2009 through August&nbsp;31, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. Based on the information currently available to us, we cannot predict the timing or
outcome of this investigation or reasonably estimate the amount or range of potential losses, if any, which may arise from this matter. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services
provided through designated facilities in the Parkersburg, West Virginia area. The CID requests the delivery of information to the United States Attorney&#146;s Office for the Southern District of West Virginia regarding 68 identified hospice
patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covers the period from January&nbsp;1, 2011 through June&nbsp;20, 2016. We are fully cooperating with the U.S.
Department of Justice with respect to this investigation. Based on the information currently available to us, we cannot predict the timing or outcome of this investigation or reasonably estimate the amount or range of potential losses, if any, which
may arise from this matter. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to the matters referenced in this note, we are involved in legal actions in the
normal course of business, some of which seek monetary damages, including claims for punitive damages. We do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated
financial condition, results of operations or cash flows. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Legal Proceedings &#150; Settled </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Wage and Hour Litigation </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;25, 2012, a putative collective and class action complaint was filed in the United States District Court for the District of
Connecticut against us in which three former employees allege wage and hour law violations.&nbsp;The </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">92 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
former employees claim that they were not paid overtime for all hours worked over 40 hours in violation of the Federal Fair Labor Standards Act (&#147;FLSA&#148;), as well as the Pennsylvania
Minimum Wage Act. More specifically, they allege they were paid on both a <FONT STYLE="white-space:nowrap">per-visit</FONT> and an hourly basis, and that such a pay scheme resulted in their misclassification as exempt employees, thereby denying them
overtime pay. Moreover, in response to a Company motion arguing that plaintiffs&#146; complaint was deficient in that it was ambiguous and failed to provide fair notice of the claims asserted and plaintiffs&#146; opposition thereto, the Court, on
April&nbsp;8, 2013, held that the complaint adequately raises general allegations that the plaintiffs were not paid overtime for all hours worked in a week over 40, which may include claims for unpaid overtime under other theories of liability, such
as alleged <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-clock</FONT></FONT> work, in addition to plaintiffs&#146; more clearly stated allegations based on misclassification. On behalf of themselves and a class of current
and former employees they allege are similarly situated, plaintiffs seek attorneys&#146; fees, back wages and liquidated damages going back three years under the FLSA and three years under the Pennsylvania statute. On October&nbsp;8, 2013, the Court
granted plaintiffs&#146; motion for equitable tolling requesting that the statute of limitations for claims under the FLSA for plaintiffs who <FONT STYLE="white-space:nowrap">opt-in</FONT> to the lawsuit be tolled from September&nbsp;24, 2012, the
date upon which plaintiffs filed their original motion for conditional certification, until 90 days after any notice of this lawsuit is issued following conditional certification. Following a motion for reconsideration filed by the Company, on
December&nbsp;3, 2013, the Court modified this order, holding that putative class members&#146; FLSA claims are tolled from October&nbsp;29, 2012 through the date of the Court&#146;s order on plaintiffs&#146; motion for conditional certification. On
January&nbsp;13, 2014, the Court granted plaintiffs&#146; July&nbsp;10, 2013 motion for conditional certification of their FLSA claims and authorized issuance of notice to putative class members to provide them an opportunity to opt in to the
action. On April&nbsp;17, 2014, that notice was mailed to putative class members. The period within which putative class members were permitted to opt into the action expired on July&nbsp;16, 2014. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;10, 2014, the plaintiffs in the Connecticut case filed a motion for leave to amend their complaint to add a new claim
under the Kentucky Wage and Hour Act (&#147;KWHA&#148;) alleging that the Company did not pay certain home health clinicians working in the Commonwealth of Kentucky all of the overtime wages they were owed, either because the Company misclassified
them as exempt from overtime or, while treating them as overtime eligible, did not properly pay them overtime for all hours worked over 40 in a week. On behalf of themselves and a class of current and former employees they allege are similarly
situated, plaintiffs seek attorneys&#146; fees, back wages and liquidated damages going back five years before the filing of their original complaint under the KWHA. On October&nbsp;1, 2014, the Company filed an opposition to the plaintiffs&#146;
motion to amend. On October&nbsp;15, 2014, plaintiffs filed a reply brief in support of their motion. On December&nbsp;12, 2014, the Court granted the plaintiffs&#146; motion to amend the complaint to add the claims under the KWHA. The Company and
the plaintiffs agreed to explore the possibility of a mediated settlement of the Connecticut case, and on February&nbsp;23, 2015 filed a joint motion to stay proceedings for six months to pursue that process, which was granted by the Court on
February&nbsp;24, 2015. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;10, 2015, the Company and plaintiffs participated in a mediation whereby they agreed to
fully resolve all of plaintiffs&#146; claims in the lawsuit for $8.0&nbsp;million, subject to approval by the Court.&nbsp;The settlement agreement was submitted to the Court for preliminary approval and plaintiffs requested certification of
Pennsylvania and Kentucky classes for the sole purpose of this proposed settlement.&nbsp;The Court granted preliminary approval, notice was issued to members of the settlement classes to provide them with an opportunity to object to the settlement
and, in the case of members of the Pennsylvania and Kentucky classes, opt out of the settlement.&nbsp;Following this notice period, the Court held a final fairness hearing for the&nbsp;purpose of considering objections and deciding whether to grant
final approval of the settlement. As of September&nbsp;30, 2015, we had an accrual of $8.0&nbsp;million for this matter. On January&nbsp;29, 2016, the Court approved the final settlement of this case. The settlement became effective on
February&nbsp;26, 2016. As a result of the final amount calculated by the settlement administrator based on claims timely submitted, we reduced our accrual to $5.3&nbsp;million as of December&nbsp;31, 2015; this amount was paid during the
three-month period ended March&nbsp;31, 2016. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">93 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016&#151;(Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;13, 2012, a putative collective and class action complaint was filed
in the United States District Court for the Northern District of Illinois against us in which a former employee alleges wage and hour law violations.&nbsp;The former employee claims she was paid on both a
<FONT STYLE="white-space:nowrap">per-visit</FONT> and an hourly basis, and that such a pay scheme resulted in her misclassification as an exempt employee, thereby denying her overtime. The plaintiff alleges violations of federal and state law and
seeks damages under the FLSA and the Illinois Minimum Wage Law. Plaintiff seeks class certification of similar employees who were or are employed in Illinois and seeks attorneys&#146; fees, back wages and liquidated damages going back three years
under the FLSA and three years under the Illinois statute. On May&nbsp;28, 2013, the Court granted the Company&#146;s motion to stay the case pending resolution of class certification issues and dispositive motions in the earlier-filed Connecticut
case. On December&nbsp;23, 2015, the parties agreed to explore the possibility of a mediated settlement of the Illinois case, and a mediation occurred on April&nbsp;18, 2016. The parties agreed to settle the case for $0.8&nbsp;million, subject to
court approval, which the Company had accrued as of September&nbsp;30, 2016. On August&nbsp;4, 2016, the Court approved the final settlement of this case. The final payment of $0.6&nbsp;million was paid on November&nbsp;21, 2016. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Frontier Litigation </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
April&nbsp;2, 2015, Frontier Home Health and Hospice, L.L.C. (&#147;Frontier&#148;) filed a complaint against the Company in the United States District Court for the District of Connecticut alleging breach of contract, negligent misrepresentation
and unfair and deceptive trade practices under Conn. Gen. Stat. <FONT STYLE="white-space:nowrap">&#167;42-110b.&nbsp;Frontier</FONT> acquired our interest in five home health and four hospice care centers in Wyoming and Idaho in April 2014.&nbsp;The
complaint alleges that certain of the hospice patients on service at the time of the acquisition did not meet Medicare eligibility requirements and that we breached certain of the representations and warranties under the purchase agreement and
therefore, the businesses were worth less than the purchase price. Under the complaint, Frontier seeks declaratory judgment from the District Court that, under the terms of the purchase agreement with Frontier, we are obligated to determine the
amount of the alleged Medicare overpayments and reimburse the government for the same in a timely manner, as well as unspecified compensatory and punitive damages, attorneys&#146; fees and <FONT STYLE="white-space:nowrap">pre-</FONT> and
post-judgment interest. The Company resolved the Frontier litigation for $2.9&nbsp;million during the three-month period ended December&nbsp;31, 2016. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Investigative Matters &#150; Ongoing </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Corporate Integrity Agreement
</I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;23, 2014, with no admissions of liability on our part, we entered into a settlement agreement with the U.S.
Department of Justice relating to certain of our clinical and business operations. Concurrently with our entry into this agreement, we entered into a corporate integrity agreement (&#147;CIA&#148;) with the Office of Inspector <FONT
STYLE="white-space:nowrap">General-HHS</FONT> (&#147;OIG&#148;). The CIA formalizes various aspects of our already existing ethics and compliance programs and contains other requirements designed to help ensure our ongoing compliance with federal
health care program requirements. Among other things, the CIA requires us to maintain our existing compliance program, executive compliance committee and compliance committee of the Board of Directors; provide certain compliance training; continue
screening new and current employees to ensure they are eligible to participate in federal health care programs; engage an independent review organization to perform certain auditing and reviews and prepare certain reports regarding our compliance
with federal health care programs, our billing submissions to federal health care programs and our compliance and risk mitigation programs; and provide certain reports and management certifications to the OIG. Additionally, the CIA specifically
requires that we report substantial overpayments that we discover we have received from federal health care programs, as well as probable violations of federal health care laws. Upon breach of the CIA, we could become liable for payment of certain
stipulated penalties, or could be excluded from participation in federal health care programs. The corporate integrity agreement has a term of five years. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">94 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016&#151;(Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Computer Inventory and Data Security Reporting </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;1 and March&nbsp;2, 2015, we provided official notice under federal and state data privacy laws concerning the outcome of an
extensive risk management process to locate and verify our large computer inventory. The process identified approximately 142 encrypted computers and laptops for which reports were required under federal and state data privacy laws. The devices at
issue were originally assigned to Company clinicians and other team members who left the Company between 2011 and 2014. We reported these devices to the U.S. Department of Health and Human Services, state agencies, and individuals whose information
may be involved, as required under applicable law because we could not rule out unauthorized access to patient data on the devices. The Office of Civil Rights, U.S. Department of Health and Human Services (&#147;OCR&#148;) is reviewing our
compliance with applicable laws, as is typical for any data breach involving more than 500 individuals. We are cooperating with OCR in its review and if any other regulatory reviews are formally commenced, will cooperate with applicable regulatory
authorities. In accordance with our CIA, we have notified the OIG of this matter. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Frontier Litigation </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Separate from the Frontier litigation described above under &#147;Legal Proceedings &#150; Settled&#148;, the Company engaged an
independent auditing firm to perform a clinical audit of the hospice care centers acquired by Frontier. No assurances can be given as to the timing or outcome of the audit on the Company, its consolidated financial condition, results of operations
or cash flows, which could be material, individually or in the aggregate. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Investigative Matters &#150; Settled
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Corporate Integrity Agreement </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During the course of our compliance with the CIA, the Company identified several reportable events and notified the OIG as required. As of December&nbsp;31, 2015, the Company had an accrual of
$4.7&nbsp;million for these matters. On May&nbsp;5, 2016, the company entered into a settlement agreement with the OIG and the matters were fully resolved for $4.7&nbsp;million; this amount was paid during the three-month period ended June&nbsp;30,
2016. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Third Party Audits &#150; Ongoing </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party
firms engaged by the Centers for Medicare and Medicaid Services (&#147;CMS&#148;) conduct extensive review of claims data to identify potential improper payments under the Medicare program. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a Zone Program Integrity Contractor
(&#147;ZPIC&#148;) a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January&nbsp;1, 2008 through March&nbsp;31, 2010 (the &#147;Review Period&#148;) to determine whether the
underlying services met pertinent Medicare payment requirements.&nbsp;We acquired the hospice operations subject to this review on August&nbsp;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice
operations.&nbsp;Based on the ZPIC&#146;s findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&nbsp;6, 2011, the MAC for the subsidiary
issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking
to have those findings overturned. An ALJ hearing was held in early January 2015. On January&nbsp;18, 2016 we received a letter dated January&nbsp;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&nbsp;6, 2011. The
decision was partially favorable with a new overpayment amount of $3.7&nbsp;million with a balance owed of $5.6&nbsp;million </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">95 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016&#151;(Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
including interest based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method
used to select the sample was not valid.&nbsp;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of June&nbsp;30, 2016, Medicare has withheld payments of $5.7&nbsp;million (including additional
interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are indemnified by the prior owners of the hospice operations for amounts
relating to the period prior to August&nbsp;1, 2009. As of December&nbsp;31, 2016, we have an indemnity receivable for the amount withheld related to the period prior to August&nbsp;1, 2009. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C. (&#147;SafeGuard&#148;), a ZPIC, related
to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December 31, 2015.
Subsequent to the initial ZPIC letter, on September 16, 2016, the Company received a letter from SafeGuard notifying the Company&nbsp;that the Winterhaven, Bradenton, and Tampa care centers were on a prepayment review.&nbsp;On October 28, 2016, the
company received a &#147;Notice of Suspension of Medicare Payments&#148; for up to 180 days for these three care centers.&nbsp;On January 10, 2017, the Company received a letter from SafeGuard notifying the Company&nbsp;that the Clearwater care
center was on a prepayment review.&nbsp;Subsequently, on February 2, 2017, the Company received a &#147;Notice of Suspension of Medicare Payments&#148; for up to 180 days for the Clearwater care center.&nbsp;Based on the information currently
available to the Company, the Company cannot predict the timing or outcome of this audit or reasonably estimate the amount or range of potential losses, which may arise from this matter. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Third Party Audits &#150; Settled </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In January 2010, our subsidiary that provides home health services in Dayton, Ohio received from a Medicare Program Safeguard Contractor (&#147;PSC&#148;) a request for records regarding 137 claims
submitted by the subsidiary paid from January&nbsp;2, 2008 through November&nbsp;10, 2009 (the &#147;Claim Period&#148;) to determine whether the underlying services met pertinent Medicare payment requirements. Based on the PSC&#146;s findings for
114 of the claims, which were extrapolated to all claims for home health services provided by the Dayton subsidiary paid during the Claim Period, on March&nbsp;9, 2011, the Medicare Administrative Contractor (&#147;MAC&#148;) for the subsidiary
issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment of approximately $5.6&nbsp;million. We disputed these findings, and our Dayton subsidiary filed appeals through the Original Medicare Standard Appeals
Process, in which we were seeking to have those findings overturned. A consolidated administrative law judge (&#147;ALJ&#148;) hearing was held in late March 2013. In January 2014, the ALJ found fully in favor of our Dayton subsidiary on 74 appeals
and partially in favor of our Dayton subsidiary on eight appeals. Taking into account the ALJ&#146;s decision, certain determinations that our Dayton subsidiary decided not to appeal as well as certain determinations made by the MAC, of the 114
claims that were originally extrapolated by the MAC, 76 claims were decided in favor of our Dayton subsidiary in full, 10 claims were decided in favor of our Dayton subsidiary in part, and 28 claims were decided against or not appealed by our Dayton
subsidiary. The ALJ ordered the MAC to recalculate the extrapolation amount based on the ALJ&#146;s decision. The Medicare Appeals Council could decide on its own motion to review the ALJ&#146;s decisions. As of July&nbsp;13, 2016, we were notified
that the PSC elected not to <FONT STYLE="white-space:nowrap">re-extrapolate</FONT> the overpayment and instead issued a new calculated overpayment in the amount of $0.2&nbsp;million. The overpayment has been paid in full and the matter is fully
resolved. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Operating Leases </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have leased office space at various locations under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> agreements that expire between 2017 and 2026, and require various minimum annual rentals. Our
typical operating leases are for lease terms of one to seven </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">96 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016&#151;(Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">
years and may include, in addition to base rental amounts, certain landlord pass-through costs for our <FONT STYLE="white-space:nowrap">pro-rata</FONT> share of the lessor&#146;s real estate
taxes, utilities and common area maintenance costs. Some of our operating leases contain escalation clauses, in which annual minimum base rentals increase over the term of the lease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total minimum rental commitments as of December&nbsp;31, 2016 are as follows (amounts in millions): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2020</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2021</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Future years</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rent expense for <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating leases was
$27.5&nbsp;million, $23.7&nbsp;million and $26.5&nbsp;million for 2016, 2015 and 2014. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Insurance </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are obligated for certain costs associated with our insurance programs, including employee health, workers&#146; compensation and
professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible
limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and
the resulting reserves, are reviewed and updated by us on a quarterly basis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table presents details of our
insurance programs, including amounts accrued for the periods indicated (amounts in millions) in accrued expenses in our accompanying balance sheets. The amounts accrued below represent our total estimated liability for individual claims that are
less than our noted insurance coverage amounts, which can include outstanding claims and claims incurred but not reported. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:62pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Type of Insurance</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Health insurance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Workers&#146; compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Professional liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Less: long-term portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The retention limit per claim for our health insurance, worker&#146;s compensation and professional
liability is $0.9&nbsp;million, $0.5&nbsp;million and $0.3&nbsp;million, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Employment Contracts
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have commitments related to employment contracts with a number of our senior executives. These contracts generally
commit us to pay severance benefits under certain circumstances. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">97 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016&#151;(Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are subject to various other types of claims and disputes arising in the ordinary course of our business. While the resolution of such
issues is not presently determinable, we believe that the ultimate resolution of such matters will not have a significant effect on our consolidated financial condition, results of operations and cash flows. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11. EMPLOYEE BENEFIT PLANS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>401(K) Benefit Plan </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We maintain a plan qualified under Section
401(k) of the Internal Revenue Code for all employees who have reached 21 years of age, effective the first month after hire date. Under the plan, eligible employees may elect to defer a portion of their compensation, subject to Internal Revenue
Service limits. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2016, 2015 and 2014, our match of contributions to be made to each eligible employee contribution was
$0.375 for every $1.00 of contribution made up to the first 6% of their salary. Effective January&nbsp;1, 2017, our match of contributions to be made to each eligible employee contribution is $0.44 for every $1.00 of contribution made up to the
first 6% of their salary. The match is discretionary and thus is subject to change at the discretion of management. These contributions are made in the form of our common stock, valued based upon the fair value of the stock as of the end of each
calendar quarter end. We expensed approximately $6.9&nbsp;million, $6.1&nbsp;million and $6.2&nbsp;million for 2016, 2015 and 2014, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Deferred Compensation Plan </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We had a Deferred Compensation Plan for
additional <FONT STYLE="white-space:nowrap">tax-deferred</FONT> savings to a select group of management or highly compensated employees. Amounts credited under the Deferred Compensation Plan were funded into a rabbi trust, which is managed by a
trustee. The trustee has the discretion to manage the assets of the Deferred Compensation Plan as deemed fit, thus the assets are not necessarily reflective of the same investment choices made by the participants. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective January&nbsp;1, 2015, all prospective salary deferrals ceased. Participants will be allowed to make transactions with any
remaining account balances as they wish per plan guidelines. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12. STOCK REPURCHASE PROGRAM </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;9, 2015, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase
up to $75&nbsp;million of our outstanding common stock on or before September&nbsp;6, 2016. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the terms of the program,
we could repurchase shares from time to time in open market transactions, block purchases or in private transactions in accordance with applicable federal securities laws and other legal requirements. We could enter into Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> plans to effect some or all of the repurchases. The timing and the amount of the repurchases, if any, was determined by management based on a number of factors, including but not limited to share price,
trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to this program, we repurchased 324,141 shares of our common stock at a weighted average price of $37.96 per share and a total cost of approximately $12.3&nbsp;million during 2016 and 116,859
shares of our common stock at a weighted average price of $39.20 per share and a total cost of approximately $4.6&nbsp;million. The repurchased shares are classified as treasury shares. The stock repurchase program expired on September&nbsp;6, 2016.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">98 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016&#151;(Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13. EXIT AND RESTRUCTURING ACTIVITIES </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2013, we reported three home health care centers as held for sale. During 2014, we sold assets associated with two
of these care centers for cash consideration of approximately $0.8&nbsp;million and recognized a gain of approximately $0.8&nbsp;million which is included in discontinued operations. The remaining care center classified as held for sale was
consolidated with a care center servicing the same market during 2014. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2014, the Company sold its interest in five
home health and four hospice care centers in Wyoming and Idaho for approximately $5.0&nbsp;million and recognized a gain of $2.1&nbsp;million. We also exited our hospice inpatient unit in New Hampshire and recognized a loss of $0.5&nbsp;million.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to the exit activity related to the care centers mentioned above, we consolidated 21 operating home health care
centers and four operating hospice care centers with care centers servicing the same markets and closed 22 home health care centers and four hospice care centers during 2014. In connection with these care centers, we recorded <FONT
STYLE="white-space:nowrap">non-cash</FONT> charges of $2.2&nbsp;million in other intangibles impairment expense related to the <FONT STYLE="white-space:nowrap">write-off</FONT> of intangible assets, $2.1&nbsp;million in other general and
administrative expenses related to lease termination costs and $2.1&nbsp;million in salaries and benefits related to severance costs. These care centers were not concentrated in certain selected geographical areas and did not meet the criteria to be
classified as discontinued operations in accordance with applicable accounting guidance. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Restructuring Activity
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2014, we restructured our regional leadership and corporate support functions. As such, we recorded charges of
$3.4&nbsp;million in salaries and benefits related to severance costs. In addition, during 2014, William F. Borne stepped down from his positions as Chief Executive Officer, Chairman and a member of our Board of Directors and we recorded charges of
$2.3&nbsp;million in salaries and benefits related to severance costs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our reserve activity for our 2014 exit and
restructuring activity is as follows (amounts in millions): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014 Exit Activity</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Lease<BR>Termination</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Severance</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balances at December&nbsp;31, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Charge in 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash expenditures in 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balances at December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0.5</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.3</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Charge in 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash expenditures in 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balances at December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0.1</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0.4</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Charge in 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash expenditures in 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balances at December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016&#151;(Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14. VALUATION AND QUALIFYING ACCOUNTS </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the activity and ending balances in our allowance for doubtful accounts and estimated revenue adjustments
(amounts in millions): </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Allowance for Doubtful Accounts </I></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:33pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year End</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Balance&nbsp;at<BR>Beginning&nbsp;of&nbsp;Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Provision&nbsp;for<BR>Doubtful<BR>Accounts&nbsp;(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">Write-Offs</FONT></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Balance&nbsp;at&nbsp;End<BR>of Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes $0.1&nbsp;million from discontinued operations for the year ended December&nbsp;31, 2014. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Estimated Revenue Adjustments </I></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:33pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year End</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Balance&nbsp;at<BR>Beginning&nbsp;of&nbsp;Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Provision&nbsp;for<BR>Estimated<BR>Revenue<BR>Adjustments&nbsp;(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">Write-Offs</FONT></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Balance&nbsp;at&nbsp;End<BR>of Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes $0.1&nbsp;million from discontinued operations for the year ended December&nbsp;31, 2014. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15. SEGMENT INFORMATION </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our operations involve servicing patients through our three reportable business segments: home health, hospice and personal care. Our home
health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with the essential activities of daily living. Our hospice segment
provides palliative care and comfort to terminally ill patients and their families. Our personal care segment, which was established with the acquisition of Associated Home Care during the three-month period ended March&nbsp;31, 2016, provides
patients with assistance with the essential activities of daily living. The &#147;other&#148; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services,
accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016&#151;(Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management evaluates performance and allocates resources based on the operating income
of the reportable segments, which includes an allocation of corporate expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by
the company&#146;s chief operating decision maker and therefore are not disclosed below (amounts in millions). </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Year Ended December&nbsp;31, 2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Home&nbsp;Health</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Hospice</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Personal&nbsp;Care</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Other</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net service revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,085.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">316.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,437.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost of service, excluding depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">643.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">163.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">833.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">283.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">141.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">503.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provision for doubtful accounts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Asset impairment charge</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">946.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">240.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">158.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,380.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">138.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">75.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(158.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Year Ended December&nbsp;31, 2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Home&nbsp;Health</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Hospice</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Personal&nbsp;Care</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Other</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net service revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,005.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,280.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost of service, excluding depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">584.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">141.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">725.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">263.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">126.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">452.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provision for doubtful accounts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Asset impairment charge</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">864.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">207.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">217.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,289.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">140.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(217.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For the Year Ended December&nbsp;31, 2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Home&nbsp;Health</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Hospice</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Personal&nbsp;Care</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Other</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net service revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">956.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">247.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,204.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost of service, excluding depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">559.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">131.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">691.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">269.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">114.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">441.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provision for doubtful accounts</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Asset impairment charge</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">853.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">195.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">131.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,180.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">103.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(131.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">101
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016&#151;(Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>16. UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Net&nbsp;Income&nbsp;(Loss)<BR>Attributable to<BR>Amedisys,
Inc.<BR>Common<BR>Stockholders&nbsp;(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Revenue</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Net&nbsp;Income&nbsp;(Loss)<BR>Attributable to<BR>Amedisys, Inc.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Basic</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Diluted</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2016:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1st Quarter (2)(3)(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">348.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2nd Quarter (2)(3)(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">360.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3rd Quarter (2)(3)(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">361.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4th Quarter (2)(3)(4)(5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">366.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,437.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2015:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1st Quarter (6)(7)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">301.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(35.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2nd Quarter (7)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">314.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3rd Quarter (6)(7)(9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">326.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4th Quarter (7)(8)(9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">338.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,280.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.09</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because of the method used in calculating per share data, the quarterly per share data may not necessarily total to the per share data as computed
for the entire year. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During each of the four quarters of 2016, we incurred certain costs associated with the implementation of Homecare Homebase. Net of income taxes,
these costs amounted to $1.5&nbsp;million, $1.6&nbsp;million, $1.2&nbsp;million and $0.8&nbsp;million for the three-month periods ended March&nbsp;31, 2016, June&nbsp;30, 2016, September&nbsp;30, 2016 and December&nbsp;31, 2016, respectively.
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During each of the four quarters of 2016, we incurred certain costs associated with various legal matters. Net of income taxes, these costs amounted
to $0.9&nbsp;million, $0.3&nbsp;million, $0.2&nbsp;million and $1.8&nbsp;million for the three-month periods ended March&nbsp;31, 2016, June&nbsp;30, 2016, September&nbsp;30, 2016 and December&nbsp;31, 2016, respectively.
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During each of the four quarters of 2016, we incurred certain costs associated with various acquisition costs. Net of income taxes, these costs
amounted to $1.0&nbsp;million, $0.2&nbsp;million, $0.3&nbsp;million and $0.5&nbsp;million for the three-month periods ended March&nbsp;31, 2016, June&nbsp;30, 2016, September&nbsp;30, 2016 and December&nbsp;31, 2016, respectively.
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the fourth quarter of 2016, we recorded a <FONT STYLE="white-space:nowrap">non-cash</FONT> asset impairment charge to <FONT
STYLE="white-space:nowrap">write-off</FONT> assets as a result of our conversion from our proprietary operating system to Homecare Homebase in the amount of $2.7&nbsp;million, net of income taxes. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the first quarter of 2015, we recorded a <FONT STYLE="white-space:nowrap">non-cash</FONT> asset impairment charge to <FONT
STYLE="white-space:nowrap">write-off</FONT> the software costs incurred related to the development of AMS3 Home Health and Hospice in the amount of $45.5&nbsp;million, net of income taxes. During the third quarter of 2015, we recorded a <FONT
STYLE="white-space:nowrap">non-cash</FONT> asset impairment charge related to our corporate headquarters in the amount of $1.2&nbsp;million, net of income taxes. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During each of the four quarters of 2015, we incurred certain costs associated with various legal matters. Net of income taxes, these costs amounted
to $1.3&nbsp;million, $4.8&nbsp;million, $0.2&nbsp;million and $(1.1) million for the three-month periods ended March&nbsp;31, 2015, June&nbsp;30, 2015, September&nbsp;30, 2015 and December&nbsp;31, 2015, respectively. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">102
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMEDISYS, INC. AND SUBSIDIARIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>December&nbsp;31, 2016&#151;(Continued) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the fourth quarter of 2015, we recorded an accrual related to an OIG Self-Disclosure matter. Net of income taxes, this charge amounted to
$3.4&nbsp;million. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the third and fourth quarters of 2015, we incurred certain costs associated with the implementation of Homecare Homebase. Net of income
taxes, these costs amounted to $1.2&nbsp;million and $1.4&nbsp;million for the three-month periods ended September&nbsp;30, 2015 and December&nbsp;31, 2015, respectively. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>17.&nbsp;RELATED PARTY TRANSACTIONS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On November&nbsp;20, 2015, we engaged
KKR Consulting, LLC (&#147;KKR Capstone&#148;), a consulting company of operational professionals that works exclusively with portfolio companies of Kohlberg Kravis Roberts&nbsp;&amp; Co. Nathaniel M. Zilkha, a member of our Board of Directors, is a
member of KKR Management, LLC, which is an affiliate of KKR Asset Management LLC (&#147;KAM&#148;), a substantial stockholder of our Company, and an affiliate of Kohlberg Kravis Roberts&nbsp;&amp; Co. KKR Capstone will receive a fee in connection
with providing consulting services to the Company in the ordinary course of business. Mr.&nbsp;Zilkha will not receive any direct compensation or direct financial benefit from the engagement of KKR Capstone. During 2016, we incurred costs of
approximately $1.6&nbsp;million related to this related party engagement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective October&nbsp;22, 2015, we entered into a
contract for telemonitoring services with Care Innovations, LLC (&#147;Care Innovations&#148;). Paul Kusserow, our President and Chief Executive Officer, is a member of the Advisory Board to Care Innovations. Care Innovations will receive an annual
fee of approximately $1.8&nbsp;million in connection with our contract for telemonitoring services for the Company. Care Innovations has confirmed to us that Mr.&nbsp;Kusserow will not receive any direct compensation or direct financial benefit from
the engagement of Care Innovations as our telemonitoring partner. During 2016 we incurred costs of approximately $1.5&nbsp;million related to this related party engagement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>18.&nbsp;SUBSEQUENT EVENTS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;1, 2017, we acquired Home
Staff, LLC, a personal care provider with three care centers for a purchase price of $4.0&nbsp;million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unaudited &#150; On
February 28, 2017, we signed a definitive agreement to acquire Tenet Healthcare&#146;s home health and hospice operations in Arizona, Illinois, Massachusetts and Texas. We do not believe that the closing of this acquisition will have a material
impact on our 2017 results of operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">103
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:-8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_15"></A>ITEM&nbsp;9.&nbsp;CHANGES IN AND
DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">None. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:8%; text-indent:-8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_16"></A>ITEM&nbsp;9A.&nbsp;CONTROLS AND PROCEDURES </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Evaluation of Disclosure Controls and Procedures </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have established disclosure controls and procedures which are designed to provide reasonable assurance of achieving their objectives and to ensure that information required to be disclosed in our
reports filed under the Exchange Act is recorded, processed, summarized, disclosed and reported within the time periods specified in the SEC&#146;s rules and forms. This information is also accumulated and communicated to our management and Board of
Directors to allow timely decisions regarding required disclosure. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the preparation of this Annual Report
on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as of December&nbsp;31, 2016, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an
evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e)</FONT> promulgated under the Exchange
Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure
controls and procedures were effective at a reasonable assurance level as of December&nbsp;31, 2016, the end of the period covered by this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Management&#146;s Annual Report on Internal Control over Financial Reporting </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is
defined in Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f)</FONT> promulgated under the Exchange Act. Under the supervision and with the participation of our management, including our principal
executive officer and our principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in <I>Internal Control &#150; Integrated Framework</I> issued by the
Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework in <I>Internal Control &#150; Integrated Framework</I>, our management concluded our internal control over financial reporting was
effective as of December&nbsp;31, 2016. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our internal control system is designed to provide reasonable assurance to our
management and Board of Directors regarding the preparation and fair presentation of published financial statements. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be
effective can provide only reasonable assurance with respect to financial statement preparation and presentation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
conducting this evaluation, management did not include an assessment of internal control over financial reporting of Associated Home Care acquired on March&nbsp;1, 2016 and Professional Profiles, Inc. acquired on September&nbsp;1, 2016, which are
included in the consolidated financial statements of the Company for the year ended December&nbsp;31, 2016. Associated Home Care and Professional Profiles accounted for approximately 1% of total assets and 2% of revenue as of and for the year ended
December&nbsp;31, 2016. As a result of its evaluation, management has concluded that the Company&#146;s internal control over financial reporting was effective as of December&nbsp;31, 2016 based on those criteria. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">KPMG LLP, the independent registered public accounting firm that audited our consolidated financial statements included in this Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> has issued a report on our internal control over financial reporting, which is included herein. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">104
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Changes in Internal Controls </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During 2015, we began the implementation of Homecare Homebase (&#147;HCHB&#148;) with all care centers operating on HCHB as of December&nbsp;31, 2016. The Company has included the changes to processes,
information technology systems and other components of internal controls over financial reporting as part of its ongoing implementation activities as part of its review of internal controls over financial reporting. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">There have been no other changes in our internal control over financial reporting (as defined in Exchange Act Rule <FONT
STYLE="white-space:nowrap">13a-15(f))</FONT> that have occurred during the quarter ended December&nbsp;31, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Inherent Limitations on Effectiveness of Controls </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls or our internal controls over financial reporting will prevent or
detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#146;s objectives will be met. The design of a control system must reflect the
fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that
misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns
can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in
part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls&#146;
effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures. Our disclosure controls and procedures are
designed to provide reasonable assurance of achieving their objectives and, based on an evaluation of our controls and procedures, our principal executive officer and our principal financial officer concluded our disclosure controls and procedures
were effective at a reasonable assurance level as of December 2016, the end of the period covered by this Annual Report. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">105
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Report of Independent Registered Public Accounting Firm </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board of Directors and Stockholders </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Amedisys, Inc.: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have audited Amedisys, Inc.&#146;s internal control over
financial reporting as of December&nbsp;31, 2016, based on criteria established in <I>Internal Control &#150; Integrated Framework (2013), </I>issued by the Committee of Sponsoring Organizations of the Treadway Commission<I>. </I>Amedisys,
Inc.&#146;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying <I>Management&#146;s
Annual Report on Internal Control over Financial Reporting </I>under Item&nbsp;9A. Our responsibility is to express an opinion on Amedisys, Inc.&#146;s internal control over financial reporting based on our audit. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control
over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures
as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">A
company&#146;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in
accordance with generally accepted accounting principles. A company&#146;s internal control over financial reporting includes those policies and procedures that (1)&nbsp;pertain to the maintenance of records that, in reasonable detail, accurately
and fairly reflect the transactions and dispositions of the assets of the company; (2)&nbsp;provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with
generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&nbsp;provide reasonable assurance regarding
prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#146;s assets that could have a material effect on the consolidated financial statements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections
of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our opinion, Amedisys, Inc. maintained, in all material respects, effective internal control over financial reporting as of
December&nbsp;31, 2016, based on criteria established in <I>Internal Control &#150; Integrated Framework (2013),</I> issued by the Committee of Sponsoring Organizations of the Treadway Commission. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amedisys, Inc. acquired Associated Home Care on March&nbsp;1, 2016 and the assets of Professional Profiles, Inc. on September&nbsp;1,
2016, and management excluded from its assessment of the effectiveness of Amedisys, Inc.&#146;s internal control over financial reporting as of December&nbsp;31, 2016, Associated Home Care and Professional Profiles, Inc.&#146;s internal control over
financial reporting associated with approximately 1% of total assets and 2% of revenue included in the consolidated financial statements of Amedisys, Inc. as of and for the year ended December&nbsp;31, 2016. Our audit of internal control over
financial reporting of Amedisys, Inc. also excluded an evaluation of the internal control over financial reporting of Associated Home Care and Professional Profiles, Inc. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Amedisys, Inc. and subsidiaries as of
December&nbsp;31, 2016 and 2015, and the related consolidated statements of operations, comprehensive income (loss), stockholders&#146; equity, and cash flows for each of the years in the three-year period ended December&nbsp;31, 2016, and our
report dated March&nbsp;1, 2017, expressed an unqualified opinion on those consolidated financial statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ KPMG LLP </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Baton Rouge, Louisiana </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;1, 2017
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">106
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_17"></A>ITEM&nbsp;9B.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OTHER INFORMATION </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">None.
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_18"></A>PART III </B></FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_20"></A>ITEM&nbsp;10.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The information required by this item is incorporated by reference to the 2017 Proxy Statement to be filed with the SEC within 120 days after the end of the year ended December&nbsp;31, 2016. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Code of Conduct and Ethics </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have adopted a code of ethics that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer. This
code of ethics, which is entitled Code of Ethical Business Conduct, is posted at our internet website, http://www.amedisys.com. Any amendments to, or waivers of, the code of ethics will be disclosed on our website promptly following the date of such
amendment or waiver. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_21"></A>ITEM&nbsp;11.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXECUTIVE COMPENSATION </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information required by this item is incorporated by reference to the 2017 Proxy Statement to be filed with the SEC within 120 days
after the end of the year ended December&nbsp;31, 2016. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_22"></A>ITEM&nbsp;12.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information required by this item is incorporated by reference to the 2017 Proxy Statement to be filed with the SEC within 120 days
after the end of the year ended December&nbsp;31, 2016. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_23"></A>ITEM&nbsp;13.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The information required by this item is incorporated by reference to the 2017 Proxy Statement to be filed with the SEC within 120 days after the end of the year ended December&nbsp;31, 2016. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_24"></A>ITEM&nbsp;14.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRINCIPAL ACCOUNTING FEES AND SERVICES </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The information required by this item is incorporated by reference to the 2017 Proxy Statement to be filed with the SEC within 120 days after the end of the year ended December&nbsp;31, 2016. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">107
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_25"></A>PART IV </B></FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_26"></A>ITEM&nbsp;15.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBITS AND FINANCIAL STATEMENT SCHEDULES </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial Statements</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">All financial statements are set forth under Part II, Item 8 of this report.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial Statement Schedules</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are no financial statement schedules included in this report as they are either not applicable or included in the financial statements.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibits</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Exhibits are listed in the Exhibit Index required by Item&nbsp;601 of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K</FONT> immediate following the signature pages of
this report, which is incorporated by reference.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_37"></A>ITEM&nbsp;16.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FORM 10-K SUMMARY </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">None.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">108
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_27"></A>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">A<SMALL>MEDISYS</SMALL>, I<SMALL>NC</SMALL>.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;P<SMALL>AUL</SMALL> B.
K<SMALL>USSEROW&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</SMALL></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Paul B. Kusserow,</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>President, Chief Executive Officer and</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Member of the Board</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: March&nbsp;1, 2017 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the
date indicated: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:33pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Signature</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:15pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Date</B></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;P<SMALL>AUL</SMALL> B.
K<SMALL>USSEROW</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Paul B. Kusserow</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">President, Chief Executive Officer<BR>and Member of the Board (Principal<BR>Executive Officer)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;1, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;G<SMALL>ARY</SMALL> D.
W<SMALL>ILLIS</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Gary D. Willis</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer (Principal<BR>Financial Officer)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;1, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;S<SMALL>COTT</SMALL> G.
G<SMALL>INN</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Scott G. Ginn</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Accounting Officer (Principal<BR>Accounting Officer)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;1, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;L<SMALL>INDA</SMALL> J.
H<SMALL>ALL</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Linda J. Hall</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;1, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;J<SMALL>ULIE</SMALL> D.
K<SMALL>LAPSTEIN</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Julie D. Klapstein</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;1, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;R<SMALL>ICHARD</SMALL> A.
L<SMALL>ECHLEITER</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Richard A. Lechleiter</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;1, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;J<SMALL>AKE</SMALL> L.
N<SMALL>ETTERVILLE</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Jake L. Netterville</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;1, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;B<SMALL>RUCE</SMALL> D.
P<SMALL>ERKINS</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Bruce D. Perkins</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;1, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;J<SMALL>EFFREY</SMALL> A.
R<SMALL>IDEOUT</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Jeffrey A. Rideout</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;1, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;D<SMALL>ONALD</SMALL> A.
W<SMALL>ASHBURN</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Donald A. Washburn</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-Executive Chairman of the<BR>Board</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;1, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/<SMALL>S</SMALL>/&nbsp;&nbsp;&nbsp;&nbsp;N<SMALL>ATHANIEL</SMALL> M.
Z<SMALL>ILKHA</SMALL></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nathaniel M. Zilkha</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;1, 2017</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">109
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc332070_28"></A>EXHIBIT INDEX </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The exhibits marked with the cross symbol (&#134;) are filed and the exhibits marked with a double cross (&#134;&#134;) are furnished
with this Form <FONT STYLE="white-space:nowrap">10-K.</FONT> Any exhibits marked with the asterisk symbol (*) are management contracts or compensatory plans or arrangements filed pursuant to Item&nbsp;601(b)(10)(iii) of Regulation <FONT
STYLE="white-space:nowrap">S-K.</FONT> The registrant agrees to furnish to the Commission supplementally upon request a copy of any schedules or exhibits omitted pursuant to Item&nbsp;601(b)(2) of Regulation
<FONT STYLE="white-space:nowrap">S-K</FONT> of any material plan of acquisition, disposition or reorganization set forth below. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Document Description</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Report&nbsp;or&nbsp;Registration&nbsp;Statement</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>SEC&nbsp;File&nbsp;or<BR>Registration<BR>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>or&nbsp;Other<BR>Reference</B></FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity Purchase Agreement dated February 5, 2016, by and between the Company, as Purchaser, and Michael Trigilro, as Seller</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0-24260</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Composite of Certificate of Incorporation of the Company inclusive of all amendments through June&nbsp;14, 2007</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2007</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Composite of <FONT STYLE="white-space:nowrap">By-Laws</FONT> of the Company inclusive of all amendments through April&nbsp;20, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock Specimen</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> filed August&nbsp;20, 2007</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">333-145582</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.8</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Director Indemnification Agreement dated February&nbsp;12, 2009</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2008</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Amedisys, Inc. Employee Stock Purchase Plan dated June&nbsp;7, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed June&nbsp;8, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;10.3*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Composite Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan (inclusive of Plan amendments dated June&nbsp;7, 2012 and October&nbsp;25, 2012, April&nbsp;23,
2015 and June&nbsp;4, 2015, January&nbsp;20, 2017 and February&nbsp;22, 2017 and the full text of the Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Nonvested Stock Award Agreement Issued under the Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2008</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">110
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Document Description</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Report&nbsp;or&nbsp;Registration&nbsp;Statement</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>SEC&nbsp;File&nbsp;or<BR>Registration<BR>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>or&nbsp;Other<BR>Reference</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Restricted Stock Unit Agreement Issued under the Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2008</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Stock Option Award Agreement Issued under the Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Performance Stock Option Award Agreement Issued under the Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Restricted Stock Award Agreement Issued under the Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.8</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.9*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Restricted Performance Stock Award Agreement Issued under the Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.9</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.10*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Composite Amedisys, Inc. 1998 Stock Option Plan (inclusive of amendments dated June&nbsp;10, 2004, June&nbsp;8, 2006 and June&nbsp;22, 2006 and the full text of
the Amedisys, Inc. 1998 Stock Option Plan)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> filed June&nbsp;22, 2007</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">333-143967</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.11*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Composite Director&#146;s Stock Option Plan (inclusive of Plan amendments dated June&nbsp;10, 2004, and the full text of the Directors Stock Option
Plan)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2005</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.12*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employment Agreement dated December&nbsp;11, 2014 by and among Amedisys, Inc., Amedisys Holding, L.L.C. and Paul B. Kusserow</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.12</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.13.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employment Agreement dated November&nbsp;1, 2011 by and among Amedisys, Inc., Amedisys Holding, L.L.C. and Ronald A. LaBorde</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed November&nbsp;2, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.13.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No.&nbsp;1 dated December&nbsp;29, 2011 to Employment Agreement dated November&nbsp;1, 2011 by and among Amedisys, Inc., Amedisys Holding, L.L.C. and
Ronald A. LaBorde</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed December&nbsp;30, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">111
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Document Description</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Report&nbsp;or&nbsp;Registration&nbsp;Statement</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>SEC&nbsp;File&nbsp;or<BR>Registration<BR>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>or&nbsp;Other<BR>Reference</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.13.3*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No.&nbsp;2 dated December&nbsp;19, 2012 to Employment Agreement dated November&nbsp;1, 2011 by and among Amedisys, Inc., Amedisys Holding, L.L.C. and
Ronald A. LaBorde</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.10.3</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.13.4*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No.&nbsp;3 dated May&nbsp;1, 2014 to Employment Agreement dated November&nbsp;1, 2011 by and among Amedisys, Inc., Amedisys Holding, L.L.C. and Ronald
A. LaBorde</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.14*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employment Agreement dated as of May&nbsp;2, 2016 between Amedisys, Inc. and Jeffrey&nbsp;D. Jeter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0-24260</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;10.15*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amedisys Holding, L.L.C. Severance Plan for Key Executives dated as of April&nbsp;30, 2015 (inclusive of all amendments thereto adopted on or before
December&nbsp;13, 2016)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.16.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Credit Agreement dated October&nbsp;26, 2012 among Amedisys, Inc. and Amedisys Holding, L.L.C., as <FONT STYLE="white-space:nowrap">co-borrowers,</FONT> the
several banks and other financial institutions party thereto from time to time, BOKF, NA DBA Bank of Texas, Compass Bank, Fifth Third Bank and RBS Citizens, N.A., as Documentation Agents, Bank of America, N.A., as Syndication Agent, JPMorgan Chase
Bank, N.A., as Administrative Agent, and J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated, as <FONT STYLE="white-space:nowrap">Co-Lead</FONT> Arrangers and Joint Bookrunners</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on October&nbsp;30, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">112
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Document Description</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Report&nbsp;or&nbsp;Registration&nbsp;Statement</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>SEC&nbsp;File&nbsp;or<BR>Registration<BR>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>or&nbsp;Other<BR>Reference</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.16.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Amendment and Limited Waiver dated as of September&nbsp;4, 2013 to the Credit Agreement dated October&nbsp;26, 2012 among Amedisys, Inc. and Amedisys
Holding, L.L.C., as <FONT STYLE="white-space:nowrap">co-borrowers,</FONT> the several banks and other financial institutions party thereto from time to time, BOKF, NA DBA Bank of Texas, Compass Bank, Fifth Third Bank and RBS Citizens, N.A., as
Documentation Agents, Bank of America, N.A., as Syndication Agent, JPMorgan Chase Bank, N.A., as Administrative Agent, and J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated, as
<FONT STYLE="white-space:nowrap">Co-Lead</FONT> Arrangers and Joint Bookrunners</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1.1</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.16.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Amendment dated as of November&nbsp;11, 2013 to the Credit Agreement dated October&nbsp;26, 2012 among Amedisys, Inc. and Amedisys Holding, L.L.C., as <FONT
STYLE="white-space:nowrap">co-borrowers,</FONT> the several banks and other financial institutions party thereto from time to time, BOKF, NA DBA Bank of Texas, Compass Bank, Fifth Third Bank and RBS Citizens, N.A., as Documentation Agents, Bank of
America, N.A., as Syndication Agent, JPMorgan Chase Bank, N.A., as Administrative Agent, and J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated, as <FONT STYLE="white-space:nowrap">Co-Lead</FONT> Arrangers and
Joint Bookrunners</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1.2</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.16.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third Amendment dated as of April&nbsp;17, 2014 to the Credit Agreement dated October&nbsp;26, 2012 among Amedisys, Inc. and Amedisys Holding, L.L.C., as <FONT
STYLE="white-space:nowrap">co-borrowers,</FONT> the several banks and other financial institutions party thereto from time to time, BOKF, NA DBA Bank of Texas, Compass Bank, Fifth Third Bank and RBS Citizens, N.A., as Documentation Agents, Bank of
America, N.A., as Syndication Agent, JPMorgan Chase Bank, N.A., as Administrative Agent, and J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated, as <FONT STYLE="white-space:nowrap">Co-Lead</FONT> Arrangers and
Joint Bookrunners</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">113
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Document Description</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Report&nbsp;or&nbsp;Registration&nbsp;Statement</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>SEC&nbsp;File&nbsp;or<BR>Registration<BR>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>or&nbsp;Other<BR>Reference</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.16.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fourth Amendment dated as of July&nbsp;28, 2014 to the Credit Agreement dated October&nbsp;26, 2012 among Amedisys, Inc. and Amedisys Holding, L.L.C., as <FONT
STYLE="white-space:nowrap">co-borrowers,</FONT> the several banks and other financial institutions party thereto from time to time, BOKF, NA DBA Bank of Texas, Compass Bank, Fifth Third Bank and RBS Citizens, N.A., as Documentation Agents, Bank of
America, N.A., as Syndication Agent, JPMorgan Chase Bank, N.A., as Administrative Agent, and J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated, as <FONT STYLE="white-space:nowrap">Co-Lead</FONT> Arrangers and
Joint Bookrunners</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1.2</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.17</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Security and Pledge Agreement dated as of November&nbsp;11, 2013, among Amedisys, Inc., Amedisys Holding, L.L.C., the Guarantors party thereto and JPMorgan Chase
Bank, N.A., not in its individual capacity but solely as Administrative Agent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.18</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Lien Credit Agreement dated as of July&nbsp;28, 2014 by and among Amedisys, Inc. and Amedisys Holding, L.L.C., as
<FONT STYLE="white-space:nowrap">co-borrowers,</FONT> the banks and other financial institutions or entities from time to time parties thereto as lenders, and Cortland Capital Market Services LLC, as Administrative Agent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.8</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.19</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Lien Security and Pledge Agreement dated as of July&nbsp;28, 2014 by and among Amedisys, Inc., Amedisys Holding, L.L.C, the guarantors party thereto and
Cortland Capital Market Services LLC, not in its individual capacity, but solely as collateral agent for the secured parties</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.9</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.20</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intercreditor Agreement dated as of July&nbsp;28, 2014 by and among JPMorgan Chase Bank, N.A., as Administrative Agent for the first priority secured parties,
Cortland Capital Market Services LLC, as Administrative Agent for the second priority secured parties, and the direct and indirect subsidiaries of Amedisys, Inc. and Amedisys Holding, L.L.C. from time to time party thereto</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.10</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">114
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Document Description</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Report&nbsp;or&nbsp;Registration&nbsp;Statement</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>SEC&nbsp;File&nbsp;or<BR>Registration<BR>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>or&nbsp;Other<BR>Reference</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.21.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Credit Agreement dated as of August&nbsp;28, 2015, among Amedisys, Inc. and Amedisys Holding, L.L.C., as borrowers, certain subsidiaries of Amedisys, Inc. party
thereto as guarantors, Bank of America, N.A., as Administrative Agent, Swingline Lender and L/C Issuer, JPMorgan Chase Bank, N.A., as Syndication Agent, Citizens Bank, N.A., Compass Bank, Fifth Third Bank, and Regions Bank, as <FONT
STYLE="white-space:nowrap">Co-Documentation</FONT> Agents, the lenders party thereto, Merrill Lynch, Pierce Fenner&nbsp;&amp; Smith Incorporated, Citizens Bank N.A., Fifth Third Bank and J.P. Morgan Securities LLC, as Joint Lead Arrangers, and
Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated and J.P. Morgan Securities LLC, as Joint Bookrunners</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed September&nbsp;2, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.212</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Security Agreement dated as of August&nbsp;28, 2015, among Amedisys, Inc. and Amedisys Holding, L.L.C., as borrowers, certain other parties identified as
&#147;grantors&#148; on the signature pages thereto and Bank of America, N.A., in its capacity as Administrative Agent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed September&nbsp;2, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.21.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pledge Agreement dated as of August&nbsp;28, 2015, among Amedisys, Inc. and Amedisys Holding, L.L.C., as borrowers, certain other parties identified as
&#147;pledgers&#148; on the signature pages thereto, and Bank of America, N.A., in its capacity as Administrative Agent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed September&nbsp;2, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.22</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Settlement Agreement effective April&nbsp;23, 2014 by and among (a)&nbsp;the United States of America, acting through the United States Department of Justice and
on Behalf of the Office of Inspector General of the Department of Health and Human Services, (b)&nbsp;Amedisys, Inc. and Amedisys Holding, L.L.C. and (c)&nbsp;the various Relators named therein</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on April&nbsp;24, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.23</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate Integrity Agreement effective April&nbsp;22, 2014 between the Office of Inspector General of the Department of Health and Human Services and Amedisys,
Inc. and Amedisys Holding, L.L.C.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on April&nbsp;24, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">0-24260</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">115
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Document Description</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Report&nbsp;or&nbsp;Registration&nbsp;Statement</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>SEC&nbsp;File&nbsp;or<BR>Registration<BR>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>or&nbsp;Other<BR>Reference</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.24</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Agreement and Plan of Merger dated October&nbsp;31, 2015 by and among Amedisys Health Care West, L.L.C., IHC Acquisitions, L.L.C., Infinity Home Care, L.L.C.,
Axiom HealthEquity Holdings Management, LLC, Infinity Healthcare Holdings, LLC, and Amedisys, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0-24260</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.27</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.25</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Agreement of Purchase and Sale dated as of November&nbsp;25, 2015, between Amedisys, Inc., through its wholly-owned subsidiary, Amedisys Property, L.L.C., as
seller and Franciscan Missionaries of Our Lady of the Lake Heath System, Inc., as purchaser.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">0-24260</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.28</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;21.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsidiaries of the Registrant</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;23.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of KPMG LLP</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;31.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of Paul B. Kusserow, President and Chief Executive Officer (principal executive officer), pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of
2002</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;31.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of Gary&nbsp;D. Willis, Chief Financial Officer (principal financial officer), pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of
2002</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;&#134;32.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of Paul B. Kusserow, President and Chief Executive Officer (principal executive officer), pursuant to 18&nbsp;U.S.C. Section&nbsp;1350, as adopted
pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;&#134;32.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of Gary&nbsp;D. Willis, Chief Financial Officer (principal financial officer), pursuant to 18&nbsp;U.S.C. Section&nbsp;1350, as adopted pursuant to
Section&nbsp;906 of the Sarbanes-Oxley Act of 2002</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;101.INS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Instance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;101.SCH</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Schema Document</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;101.CAL</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Calculation Linkbase Document</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">116
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Document Description</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Report&nbsp;or&nbsp;Registration&nbsp;Statement</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>SEC&nbsp;File&nbsp;or<BR>Registration<BR>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>or&nbsp;Other<BR>Reference</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;101.DEF</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Definition Linkbase</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;101.LAB</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Labels Linkbase Document</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;101.PRE</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P ALIGN="justify"><FONT STYLE="font-family:Times New Roman" SIZE="2">XBRL Taxonomy Extension Presentation Linkbase Document</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">117
</FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>d332070dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc332070_36"></A>COMPOSITE AMEDISYS, INC. 2008 OMNIBUS INCENTIVE COMPENSATION PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Inclusive of Plan amendments dated June&nbsp;7, 2012, October&nbsp;25, 2012, April&nbsp;23, 2015, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>January&nbsp;20, 2017, February&nbsp;22, 2017, the full text of the Plan and the proposed Plan </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>amendment to increase the number of shares authorized for issuance under the Plan) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.</B><B><I> PURPOSE</I></B><B>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the
Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan (the &#147;Plan&#148;) is to promote the interests of Amedisys, Inc., a Delaware corporation (the &#147;Company&#148;) and its stockholders by (i)&nbsp;attracting and retaining key officers,
employees, and directors of, and consultants to, the Company and its Subsidiaries and Affiliates; (ii)&nbsp;motivating such individuals by means of performance-related incentives to achieve long-range performance goals; (iii)&nbsp;enabling such
individuals to participate in the long-term growth and financial success of the Company; (iv)&nbsp;encouraging ownership of stock in the Company by such individuals; and (v)&nbsp;linking their compensation to the long-term interests of the Company
and its stockholders. Toward this objective, the Committee may grant stock options, SAR, Stock Awards, cash bonuses and other incentive awards to Employees of the Company and its Subsidiaries and Affiliates on the terms and subject to the conditions
set forth in the Plan. In addition, this Plan is intended to enable the Company to effectively attract, retain and reward Outside Directors by providing for grants of Outside Director Awards to Outside Directors. No Award under this Plan (or
modification thereof) shall provide for deferral of compensation that does not comply with Section&nbsp;409A of the Code unless the Committee, at the time of grant, specifically provides that the Award is not intended to comply with
Section&nbsp;409A of the Code. Notwithstanding any provision of this Plan to the contrary, if one or more of the payments or benefits received or to be received by a Participant pursuant to an Award would cause the Participant to incur any
additional tax or interest under Section&nbsp;409A of the Code, the Committee may reform such provision to maintain to the maximum extent practicable the original intent of the applicable provision without violating the provisions of
Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.</B><B><I> DEFINITIONS</I></B><B>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1 &#147;Affiliate&#148;</B> means any entity (other than the Company and any Subsidiary) that is designated by the Board as a
participating employer under the Plan, provided that the Company directly or indirectly owns at least 20% of the combined voting power of all classes of stock of that entity or at least 20% of the ownership interests in that entity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2 &#147;Alternative Award&#148;</B> has the meaning assigned to such term in Section&nbsp;22, herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3 &#147;Award&#148;</B> means any form of Option, SAR, Stock Award, Restricted Share Unit, cash bonus or other incentive award granted
under the Plan, whether singly, in combination, or in tandem, to a Participant by the Committee pursuant to terms, conditions, restrictions and limitations, if any, as the Committee may establish by the Award Notice or otherwise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4 &#147;Award Notice&#148;</B> means a written notice from the Company to a Participant that establishes the terms, conditions,
restrictions, and limitations applicable to an Award in addition to those established by the Plan and by the Committee&#146;s exercise of its administrative powers. In the event of a conflict between the terms of the Plan and any Award Notice, the
terms of the Plan shall prevail. The Committee shall, subject to applicable law, determine the date an Award is deemed to be granted. The Committee or, except to the extent prohibited under applicable law, its delegate(s) may establish the terms of
agreements or other documents evidencing Awards under this Plan and may, but need not, require as a condition to any such agreement&#146;s or document&#146;s effectiveness that such agreement or document be executed by the Participant, including by
electronic signature or other electronic indication of acceptance, and that such Participant agree to such further terms and conditions as specified in such agreement or document. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.5 &#147;Board&#148;</B> means the Board of Directors of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.6 &#147;Cause&#148;</B> means, when used in connection with the termination of a
Participant&#146;s Employment, (i)&nbsp;if the Participant has an effective employment agreement with the Company or any Subsidiary or Affiliate as of the date an Award is granted, the definition used in such employment agreement as of such date, or
(ii)&nbsp;if the Participant does not have an effective employment agreement with the Company or any Subsidiary or Affiliate as of the date an Award is granted, unless otherwise provided in the Participant&#146;s Award Notice, matters which, in the
judgment of the Committee, constitute any one or more of the following: (i)&nbsp;default or breach of any of the provisions of any agreement that the Participant may have with the Company or any Affiliate or Subsidiary; (ii)&nbsp;actions
constituting fraud, abuse, dishonesty, embezzlement, destruction or theft of Company property, or breach of the duty of loyalty owned by the Participant to the Company; (iii)&nbsp;violation of any applicable laws, rules or regulations (including,
without limitation, all Medicare and other health care laws, rules and regulations pertaining to the provision of home health care, hospice or any other services provided by the Company); (iv)&nbsp;furnishing materially false, inaccurate, misleading
or incomplete information to the Company; (v)&nbsp;actions constituting a material breach of the Company&#146;s Code of Ethical Business Conduct, the Company&#146;s employee handbook or any other Company policy; (vi)&nbsp;willful failure to follow
reasonable and lawful directives of the Participant&#146;s supervisor, or any of the Company&#146;s senior executive officers, which are consistent with the Participant&#146;s job responsibilities and performance; or (vii)&nbsp;failure to satisfy
the requirements of the Participant&#146;s job, regardless whether or not such failure is willful, including the failure to satisfy the objectives of any action plan or performance improvement plan that the Participant may be under. Any
determination of Cause for purposes of the Plan or any Award shall be made by the Committee in its sole discretion. Any such determination shall be final and binding on a Participant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.7 &#147;Change In Control&#148;</B> means the happening of any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">any person or entity, including a &#147;group&#148; as defined in Section&nbsp;13(d)(3) of the Exchange Act, other than the Company or a wholly-owned Subsidiary, or any employee benefit plan of the Company or any
Subsidiary, becomes the beneficial owner of the Company&#146;s securities having 50% or more of the combined voting power of the then outstanding securities of the Company that may be cast for the election of directors of the Company (other than as
a result of an issuance of securities initiated by the Company in the ordinary course of business); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">as the result of, or in connection with, any cash tender or exchange offer, merger or other business combination, sales of assets or contested election, or any combination of the foregoing transactions, after the
transaction less than a majority of the combined voting power of the then outstanding securities of the Company, or any successor corporation or cooperative or entity, entitled to vote generally in the election of the directors of the Company, or
other successor corporation or other entity, are held in the aggregate by the holders of the Company&#146;s securities who immediately prior to the transaction had been entitled to vote generally in the election of directors of the Company; or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">during any period of 2 consecutive years, individuals who at the beginning of the period constitute the Board cease for any reason to constitute at least a majority of the Board, unless the election, or the nomination
for election by the Company&#146;s stockholders, of each director of the Company first elected during the relevant 2-year period was approved by a vote of at least 2/3 of the directors of the Company then still in office who were directors of the
Company at the beginning of that period. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.8 &#147;Change In Control Price&#148;</B> means the closing price (or, if the
shares are not traded on an exchange, the last sale price or closing &#147;asked&#148; price) per share paid for the purchase of Common Stock in a national securities market on the date the Change In Control occurs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.9 &#147;Code&#148;</B> means the Internal Revenue Code of 1986, as amended from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.10 &#147;Committee&#148;</B> means the Compensation Committee of the Board, or any other
committee designated by the Board, authorized to administer the Plan under Section&nbsp;3 of this Plan. The Committee shall consist of not less than 2&nbsp;members who shall be appointed by, and shall serve at the pleasure of, the Board. The
directors appointed to serve on the Committee shall be: (i)&nbsp;&#147;independent&#148; within the meaning of the listing standards of any securities exchange or automated quotation system upon which the Common Stock is listed or quoted;
(ii)&nbsp;&#147;non-employee directors&#148; (within the meaning of <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3</FONT> under the Exchange Act); and (iii)&nbsp;&#147;outside directors&#148; (within the meaning of Code Section&nbsp;162(m) and its
related regulations). However, the mere fact that a Committee member fails to qualify under any of the foregoing requirements shall not invalidate any Award made by the Committee if the Award is otherwise validly made under the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.11 &#147;Common Stock&#148;</B> means the $0.001 par value common stock of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.12 &#147;Company&#148;</B> means Amedisys, Inc. or any successor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.13 &#147;Consultant&#148;</B> shall mean any consultant to the Company or its Subsidiaries or Affiliates. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.14 &#147;Covered Employee&#148;</B> means an individual who is, with respect to the Company, an individual defined in Code
Section&nbsp;162(m)(3). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.15 &#147;Director&#148;</B> means an individual who is a member of the Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.16 &#147;Disability&#148;</B> has the same meaning as provided in the long-term disability plan or policy maintained by the Company or if
applicable, most recently maintained, by the Company or if applicable, a Subsidiary or Affiliate, for the Participant, whether or not that Participant actually receives disability benefits under the plan or policy. If no long-term disability plan or
policy was ever maintained on behalf of Participant or if the determination of Disability relates to an Incentive Stock Option, Disability means Permanent and Total Disability as defined in Section&nbsp;22(e)(3) of the Code. In a dispute, the
determination whether a Participant has suffered a Disability will be made by the Committee and may be supported by the advice of a physician competent in the area to which that Disability relates. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.17 &#147;Effective Date&#148;</B> is defined in Section&nbsp;6. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.18 &#147;Employee&#148;</B> means an employee or prospective employee of the Company, a Subsidiary or an Affiliate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.19 &#147;Employment&#148;</B> means, except as otherwise required by Section&nbsp;409A of the Code, employment with the Company or any
Affiliate or Subsidiary, and shall include the provision of services as an Outside Director or Consultant for the Company or any Affiliate or Subsidiary. A Participant&#146;s Employment shall terminate on the date the Participant is no longer
employed by an entity that is at least one of (i)&nbsp;the Company, (ii)&nbsp;an Affiliate or (iii)&nbsp;a Subsidiary as of such date. <B>&#147;Employed&#148;</B> shall have a correlative meaning. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.20 &#147;Exchange Act&#148;</B> means the Securities and Exchange Act of 1934, as amended from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.21 &#147;Exercise Price&#148;</B> means the purchase price payable to purchase one Share upon the exercise of an Option or the price by
which the value of a SAR shall be determined upon exercise, pursuant to Section&nbsp;2.34. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.22 &#147;Fair Market Value&#148;</B> with
respect to the Common Stock, as of any given date, unless otherwise determined by the Committee in good faith, means the reported closing sale price of a share of Common Stock on the automated quotation system or other market or exchange that is the
principal trading market for the Common Stock, or if no sale of a share of Common Stock is so reported on that date, the fair market value of a share of Common Stock as determined by the Committee in good faith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.23 &#147;Immediate Family&#148;</B> means any child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling,
mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, and includes adoptive relationships. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.24 &#147;Incentive Stock Option&#148;</B> means an option to purchase Common Stock from the
Company that is granted under Section&nbsp;8 of the Plan and that is intended to meet the requirements of Section&nbsp;422 of the Code or any successor provision thereto. To the extent the aggregate Fair Market Value (determined at the time the
Incentive Stock Option is granted) of the Common Stock with respect to which all Incentive Stock Options are exercisable for the first time by an Employee during any calendar year (under all plans described in subsection (d)&nbsp;of Section&nbsp;422
of the Code of the Employee&#146;s employer corporation and its parent and Subsidiaries) exceeds $100,000, such Options shall be treated as Non-Qualified Stock Options. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.25 &#147;Non-Qualified Stock Option&#148;</B> shall mean an option to purchase Common Stock from the Company that is granted under
Section&nbsp;8 or 23 of the Plan and is not intended to be an Incentive Stock Option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.26 &#147;Option&#148;</B> means an Incentive
Stock Option or a Non-Qualified Stock Option. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.27 &#147;Outside Director&#148;</B> means a member of the Board who is not an officer
or employee of the Company or any Subsidiary or Affiliate of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.28 &#147;Outside Director Award&#148;</B> means either a
Director Option or a Director Stock Award or combination thereof awarded to an Outside Director under Section&nbsp;23. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.29
&#147;Participant&#148;</B> means any individual to whom an Award has been granted by the Committee under this Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.30
&#147;Qualified Performance-Based Award&#148;</B> means (i)&nbsp;any Option or SAR granted under the Plan, or (ii)&nbsp;any other Award that is intended to qualify for the Section&nbsp;162(m) Exemption and is made subject to performance goals based
on Qualified Performance Measures as set forth in Section&nbsp;12. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.31 &#147;Qualified Performance Measures&#148;</B> means one or
more of the performance measures listed in Section&nbsp;12.2 upon which performance goals for certain Qualified Performance-Based Awards may be established by the Committee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.32 &#147;Qualifying Termination&#148;</B> means, with respect to a Participant, a termination of such Participant&#146;s Employment by the
Company (and all then-Affiliates or Subsidiaries) without Cause following a Change in Control of the Company. It is understood that a Participant shall not have a Qualifying Termination by virtue of ceasing to be Employed by an entity or its
subsidiaries undergoing a Change in Control where, following such Change in Control, the Participant remains employed by an entity that is at least one of (i)&nbsp;the Company or (ii)&nbsp;any entity that was an Affiliate or Subsidiary undergoing a
Change in Control immediately prior to such Change in Control. Notwithstanding the foregoing, payments on account of a Participant&#146;s Qualifying Termination that constitute &#147;deferred compensation&#148; within the meaning of
Section&nbsp;409A of the Code shall not commence unless and until the Participant has also incurred a &#147;separation from service&#148; within the meaning of Code Section&nbsp;409A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.33 &#147;Restricted Share Unit&#148;</B> means a bookkeeping entry used by the Company to record and account for the grant of an Award of
restricted Common Stocks under Section&nbsp;10 of the Plan until the Award is paid, canceled, forfeited or terminated, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.34 &#147;SAR&#148;</B> is an Award that shall entitle the recipient to receive, with respect to each share of Common Stock encompassed by
the exercise of the SAR, a payment equal to the excess of the Fair Market Value on the date of exercise over the Fair Market Value on the date of grant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.35 &#147;Section 162(m)&#148;</B> means Section&nbsp;162(m) of the Code and the regulations promulgated thereunder and any successor
provision thereto as in effect from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.36 &#147;Section 162(m) Cash Maximum&#148;</B> means $5&nbsp;million. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.37 &#147;Section 162(m) Exemption&#148;</B> means the exemption from the limitation on deductibility imposed by Section&nbsp;162(m) that
is set forth in Section&nbsp;162(m)(4)(C) of the Code or any successor provision thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.38 &#147;Section 16&#148;</B> means
Section&nbsp;16 of the Exchange Act and the rules promulgated thereunder and any successor provision thereto as in effect from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.39 &#147;Section 16 Insider&#148;</B> means a Participant who is subject to the reporting requirements of Section&nbsp;16 as a result of
the Participant&#146;s position with the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.40 &#147;Stock Award&#148;</B> means an Award granted pursuant to Section&nbsp;10
in the form of shares of Common Stock or restricted shares of Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.41 &#147;Subsidiary&#148;</B> means a corporation or
other business entity in which the Company directly or indirectly has an ownership interest of 50% or more. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.</B><B><I> ADMINISTRATION</I></B><B>.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Plan shall be administered by the Committee. The Committee shall have the discretionary authority to: (a)&nbsp;interpret the Plan;
(b)&nbsp;establish any rules and regulations it deems necessary for the proper operation and administration of the Plan; (c)&nbsp;select persons to become Participants and receive Awards under the Plan; (d)&nbsp;determine the form of an Award,
whether an Option, SAR, Stock Award, cash bonus, or other incentive award established by the Committee, the number of shares subject to the Award, all the terms, conditions, restrictions and limitations, if any, of an Award, including the time and
conditions of exercise or vesting, and the terms of any Award Notice; (e)&nbsp;determine whether Awards should be granted singly, in combination or in tandem; (f)&nbsp;grant waivers of Plan terms, conditions, restrictions and limitations;
(g)&nbsp;accelerate the vesting, exercise or payment of an Award or the performance period of an Award in the event of a Participant&#146;s termination of employment or when that action or actions would be in the best interests of the Company;
(h)&nbsp;establish such other types of Awards, besides those specifically enumerated in Section&nbsp;2.3, which the Committee determines are consistent with the Plan&#146;s purpose; and (i)&nbsp;take all other action it deems necessary or advisable
for the proper operation or administration of the Plan. Subject to Section&nbsp;20, the Committee also shall have the authority to grant Awards in replacement of Awards previously granted under the Plan or any other executive compensation plan of
the Company or a Subsidiary. All determinations of the Committee shall be made by a majority of its members, and its determinations shall be final, binding and conclusive on all persons, including the Company and Participants. The Committee, in its
discretion, may delegate its authority and duties under the Plan to the Chief Executive Officer or to other senior officers of the Company under conditions and limitations the Committee may establish; however, only the Committee may select, grant,
and establish the terms of Awards to Section&nbsp;16 Insiders or Covered Employees, and only the Board shall have the authority to grant and establish the terms of awards under Section&nbsp;23. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.</B><B><I> ELIGIBILITY</I></B><B>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any Employee,
Director or Consultant shall be eligible to be designated a Participant; provided, however, that Non-Employee Directors shall only be eligible to receive Awards granted consistent with Section&nbsp;23. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. </B><B><I>NUMBER OF SHARES AVAILABLE</I></B><B>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to adjustment as provided in Section&nbsp;16 of the Plan, the maximum number of shares of Common Stock that shall be available for grant of Awards
under the Plan (including incentive stock options) during its term shall not exceed 5,462,459&nbsp;shares. Any shares of Common Stock related to Awards that are settled in cash in lieu of Common Stock shall be available again for grant under the
Plan. Similarly, any shares of Common Stock related to Awards that terminate by expiration, forfeiture, cancellation or otherwise without the issuance of the related </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares or are exchanged with the Committee&#146;s permission for Awards not involving Common Stock, shall be available again for grant under the Plan. Any shares of Common Stock related to Awards
that are cancelled on settlement of options or SARs in payment of the exercise price thereof and shares of Common Stock withheld to pay taxes shall not be available again for grant under the Plan. Finally, and notwithstanding the foregoing and
subject to adjustment as provided in Section&nbsp;16 of the Plan, the maximum number of shares of Common Stock with respect to which Awards may be granted under the Plan shall be increased by the number of shares of Common Stock with respect to
which options or other awards were granted under either the Company&#146;s 1998 Stock Option Plan (the &#147;1998 Plan&#148;) or the Directors Stock Option Plan (the &#147;Directors Plan&#148;) as of the record date for the meeting of stockholders
to approve this Plan, but which thereafter terminate, expire unexercised or are settled for cash, forfeited or cancelled without the delivery of Common Stock under the terms of the 1998 Plan or the Directors Plan (but excluding shares of Common
Stock cancelled on settlement of options or SARs in payment of the exercise price thereof or shares of Common Stock withheld to pay taxes); and any such shares shall again be available for grant as Awards under this Plan. Notwithstanding any
provision in the Plan to the contrary, and subject to adjustment as provided in Section&nbsp;16 hereof, no Participant may receive Options, SARs, Stock Awards or Restricted Share Units under the Plan during any one calendar year under the Plan that,
taken together, relate to more than 500,000&nbsp;shares of Common Stock. For purposes of this limitation, forfeited, canceled or repriced shares granted to a Participant in any given calendar year shall continue to be counted against the maximum
number of shares that may be granted to that Participant in that calendar year. The shares of Common Stock available for issuance under the Plan may be authorized and unissued shares. With the exception of Qualified Performance-Based Awards, which
are subject to a minimum one-year vesting period, effective for Awards issued on or after the Effective Date, no more than 5% of the total number of shares authorized for delivery under the Plan may be granted as SARs, Stock Awards or Restricted
Share Units which vest within one year after the date of grant. With respect to such Awards in excess of 5% of the Shares authorized for delivery under the Plan, the vesting period must exceed one year, with no more than one-third of the shares
becoming vested at the end of each of the twelve-month periods following the date of grant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. </B><B><I>EFFECTIVE DATE; TERM</I></B><B>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Plan originally became effective January 2008, and was most recently amended by the Committee and the Board effective April&nbsp;23, 2015 (the
&#147;Effective Date&#148;). This Plan shall remain in effect until terminated by action of the Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.</B><B><I> PARTICIPATION</I></B><B>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Committee shall select, from time to time, Participants from those Employees and Consultants who, in the opinion of the Committee, can further the
Plan&#146;s purposes. Once a Participant is selected, the Committee shall determine the type or types of Awards to be made to the Participant and shall establish in the related Award Notices the terms, conditions, restrictions and limitations, if
any, applicable to the Awards in addition to those set forth in the Plan and the administrative rules and regulations issued by the Committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.</B><B><I> STOCK OPTIONS. </I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1 Grants.</B> Awards may be granted in the form of Options. Options may be Incentive Stock Options, other tax-qualified stock options, or
Non-Qualified Stock Options, or a combination of any of those. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2 Terms and Conditions of Options.</B> An Option shall be exercisable
in whole or in such installments and at the times determined by the Committee. The Committee also shall determine the performance or other conditions, if any, which must be satisfied before all or part of an Option may be exercised. The price at
which Common Stock may be purchased upon exercise of a stock option shall be established by the Committee, but such price shall not be less than 110% of the Fair Market Value of the Common Stock on the date the Option is granted in the case of
Incentive Stock Options when the Employee to whom the option is to be granted owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any of its Subsidiaries (a &#147;Ten Percent Owner&#148;), and in the case of all Options other than Incentive Stock Options, not less than 100% of the Fair Market Value of the Common Stock on
the date the Option is granted. Each Option shall expire not later than 10 years (or, in the case of an Incentive Stock Option granted to a Ten Percent Owner, not later than 5&nbsp;years) from its date of grant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3 Restrictions Relating to Incentive Stock Options.</B> Incentive Stock Options shall, in addition to being subject to all applicable
terms, conditions, restrictions and limitations established by the Committee, comply with Section&nbsp;422 of the Code. Accordingly, Incentive Stock Options may only be granted to Employees who are employees of the Company or a Subsidiary, and the
aggregate market value (determined at the time the option was granted) of the Common Stock with respect to which Incentive Stock Options are exercisable for the first time by a Participant during any calendar year (under the Plan or any other plan
of the Company or any of its Subsidiaries) shall not exceed $100,000 (or other limit required by the Code). Except with respect to Ten Percent Owners, each Incentive Stock Option shall expire not later than 10 years from its date of grant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.4 Additional Terms and Conditions. </B>The Committee may, by way of the Award Notice or otherwise, establish other terms, conditions,
restrictions and limitations, if any, on any Option, provided they are not inconsistent with the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.5 Exercise.</B> The Committee
shall determine the methods by which the Exercise Price of an Option may be paid, the form of payment, including, without limitation, cash, shares of Common Stock, or other property (including &#147;cashless exercise&#148; arrangements, so long as
they do not in any way conflict with the requirements of applicable law), and the methods by which shares of Common Stock shall be delivered or deemed to be delivered by Participants. If, however, shares of Common Stock are used to pay the Exercise
Price of an Option, those shares must have been held by the Participant for at least 6 months (or any shorter or longer period necessary to avoid a charge to the Company&#146;s earnings for financial reporting purposes). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. </B><B><I>STOCK APPRECIATION RIGHTS</I></B><B>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1 Grants.</B> Awards may be granted in the form of SARs. The SAR may be granted in tandem with all or a portion of a related Option under
the Plan (&#147;Tandem SARs&#148;), or may be granted separately (&#147;Freestanding SARs&#148;). A Tandem SAR may be granted either at the time of the grant of the related Option or at any time thereafter during the term of the Option. In the case
of SARs granted in tandem with Options granted prior to the grant of the SARs, the appreciation in value is the difference between the option price of the related stock option and the Fair Market Value of the Common Stock on the date of exercise.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2 Terms and Conditions of Tandem SARs.</B> A Tandem SAR shall be exercisable to the extent, and only to the extent, that the related
Option is exercisable, and the &#147;exercise price&#148; of that SAR (the base from which the value of the SAR is measured at its exercise) shall be the Exercise Price under the related Option. If a related Option is exercised as to some or all of
the shares of Common Stock covered by the Award, the related Tandem SAR, if any, shall be canceled automatically to the extent of the number of shares of Common Stock covered by the Option exercise. Upon exercise of a Tandem SAR as to some or all of
the shares of Common Stock covered by the Award, the related Option shall be canceled automatically to the extent of the number of shares of Common Stock covered by the exercise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3 Terms and Conditions of Freestanding SARs. </B>Freestanding SARs shall be exercisable in whole or in the installments and at the times
determined by the Committee. Freestanding SARs shall have a term specified by the Committee, in no event to exceed 10 years. The Exercise Price of a Freestanding SAR shall also be determined by the Committee; however, that price shall not be less
than 100% of the Fair Market Value on the date of grant of the Freestanding SAR of the number of shares of Common Stock to which the Freestanding SAR relates. The Committee also shall determine the Qualified Performance Measures or other conditions,
if any, that must be satisfied before all or part of a Freestanding SAR may be exercised. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.4 Deemed Exercise.</B> The Committee may provide that an SAR shall be deemed to be exercised
at the close of business on the scheduled expiration date of the affected SAR if at that time the SAR by its terms remains exercisable and, if so exercised, would result in a payment to the holder of the SAR. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.5 Additional Terms and Conditions. </B>The Committee may, by way of the Award Notice or otherwise, determine such other terms, conditions,
restrictions and limitations, if any, of any SAR Award, provided they are not inconsistent with the Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. </B><B><I>STOCK AWARDS AND RESTRICTED
SHARE UNITS</I></B><B>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.1 Grants.</B> Awards may be granted in the form of Stock Awards and Restricted Share Units. Stock Awards
and Restricted Share Units shall be awarded in such numbers and at such times during the term of the Plan as the Committee shall determine. Stock Awards shall be made in actual shares of Common Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.2 Award Restrictions.</B> Stock Awards and Restricted Share Units shall be subject to terms, conditions, restrictions, and limitations,
if any, the Committee deems appropriate including, without limitation, restrictions on transferability and continued Employment of the Participant. The Committee also shall determine the Qualified Performance Measures or other conditions, if any,
that must be satisfied before all or part of the applicable restrictions lapse. The Committee may, at its discretion, waive all or any part of the restrictions applicable to any or all outstanding Stock Awards and Restricted Share Unit Awards. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.3 Rights as Stockholder.</B> During the period in which any restricted shares of Common Stock are subject to restrictions imposed
pursuant to Section&nbsp;10.2, the Participant to whom restricted shares have been awarded shall generally have the rights and privileges of a stockholder as to such Common Stock, including the right to receive dividends and the right to vote such
shares, subject to the following restrictions: (i)&nbsp;the Participant shall not be entitled to delivery of the stock certificate until the expiration of the restricted period and the fulfillment of any other restrictive conditions set forth in the
Award Notice with respect to such Common Stock; (ii)&nbsp;none of the Common Stock represented by the Award may be sold, assigned, transferred, pledged, hypothecated or otherwise encumbered or disposed of during such restricted period or until after
the fulfillment of any such other restrictive conditions; and (iii)&nbsp;except as otherwise determined by the Committee at or after grant, all of the shares of Common Stock subject to the Award shall be forfeited and all rights of the Participant
to such Common Stock shall terminate, without further obligation on the part of the Company, unless the Participant remains in the continuous Employment of the Company for the entire restricted period in relation to which such shares of Common Stock
were granted and unless any other restrictive conditions relating to the restricted Share Award are met. Unless otherwise provided in the applicable Award Notice, any shares of Common Stock, any other securities of the Company and any other property
(except for cash dividends) distributed with respect to the Common Stock subject to restricted Share Awards shall be subject to the same restrictions, terms and conditions as such restricted Share Award including the right vote such Common Stock.
Cash dividends with respect to the Common Stock subject to a restricted Share Award shall be currently paid to the Participant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.4
Evidence of Award. </B>Subject to Section&nbsp;10.5, any Stock Award granted under the Plan shall be evidenced by issuance of a stock certificate or certificates or, in the discretion of the Committee, through issuance of instructions to the
Company&#146;s transfer agent to issue the shares of Common Stock subject to the Award in book-entry (uncertificated) form on the books and records of the transfer agent through the Direct Registration System (&#147;DRS&#148;) or any successor
system. Any Restricted Share Unit shall be evidenced by an Award Notice that sets forth any other terms, conditions, restrictions and limitations, if any, established by the Committee with respect to any Restricted Share Unit Award that are
consistent with the terms of the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.5 Delivery of Shares and Transfer Restrictions.</B> Upon issuance of a certificate evidencing
a restricted Share Award, such certificate shall be held by the Company or any custodian appointed by the Company for the account of the Participant subject to the terms and conditions of the Plan, and shall bear such a legend setting forth the
restrictions imposed thereon as the Committee, in its discretion, may determine. Unless otherwise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provided in the applicable Award Notice, the grantee shall have all rights of a stockholder with respect to the Restricted Shares Upon the issuance of a restricted Share Award in book entry form,
the Company&#146;s transfer agent shall be apprised of and shall duly note any restrictions such as those set forth above that are applicable to the restricted Share Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.6 Termination of Restrictions.</B> At the end of the restricted period and provided that any other restrictive conditions of the
restricted Share Award are met, or at such earlier time as otherwise determined by the Committee, all restrictions set forth in the Award Notice relating to the restricted Share Award or in the Plan shall lapse as to the restricted shares of Common
Stock subject thereto, and either: (i)&nbsp;a stock certificate for the appropriate number of shares of Common Stock, free of the restrictions and restricted stock legend, shall be delivered to the Participant or the Participant&#146;s beneficiary
or estate, as the case may be; or (ii)&nbsp;in the event the Share Award was evidenced in book entry form, the Company&#146;s transfer agent shall be notified of the lapse and or termination of the restrictions and to remove all references thereto
in its books and records. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.7 Payment of Restricted Share Units.</B> Each Restricted Share Unit shall have a value equal to the Fair
Market Value of a share of Common Stock. Restricted Share Units shall be paid in cash, Shares, other securities or other property, as determined in the sole discretion of the Committee, upon the lapse of the restrictions applicable thereto, or
otherwise in accordance with the applicable Award Notice. Unless otherwise provided in the applicable Award Notice, a Participant shall receive dividend rights in respect of any vested Restricted Share Units at the time of any payment of dividends
to stockholders on the Common Stock. The amount of any such dividend right shall equal the amount that would be payable to the Participant as a stockholder in respect of a number of shares of Common Stock equal to the number of vested Restricted
Share Units then credited to the Participant. Other than pursuant to Section&nbsp;15 (but no transfers for consideration shall be permitted), Restricted Share Units may not be sold, assigned, transferred, pledged, hypothecated or otherwise
encumbered or disposed of, and all Restricted Share Units and all rights of the grantee to such Restricted Share Units shall terminate, without further obligation on the part of the Company, unless the Participant remains in continuous Employment of
the Company for the entire restricted period in relation to which such Restricted Share Units were granted and unless any other restrictive conditions relating to the Restricted Share Unit Award are met. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. </B><B><I>PLAN CASH BONUSES</I></B><B>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While cash
bonuses may be granted at any time outside this Plan, cash awards may also be granted in addition to other Awards granted under the Plan and in addition to cash awards made outside of the Plan. Subject to the provisions of the Plan, the Committee
shall have authority to determine the persons to whom cash bonuses under the Plan shall be granted and the amount, terms and conditions of those cash bonuses. Notwithstanding anything to the contrary in this Plan, no Covered Employee shall be
eligible to receive a cash bonus granted under the Plan in excess of the Section&nbsp;162(m) Cash Maximum in any fiscal year; no cash bonus shall be granted pursuant to this Plan to any Covered Employee unless the cash bonus constitutes a Qualified
Performance-Based Award, and no cash bonus awarded pursuant to the Plan shall be paid later than 2<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;1</SUP>/<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB> months after the end of the
calendar year in which such bonus was earned. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. </B><B><I>PERFORMANCE GOALS FOR CERTAIN SECTION 162(m) AWARDS</I></B><B>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.1 162(m) Exemption.</B> This Plan shall be operated to ensure that all stock options and SARs granted hereunder to any Covered Employee
qualify for the Section&nbsp;162(m) Exemption. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.2 Qualified Performance-Based Awards.</B> When granting any Award other than stock
options or SARs, the Committee may designate the Award as a Qualified Performance-Based Award, based upon a determination that the recipient is or may be a Covered Employee with respect to that Award, and the Committee wishes the Award to qualify
for the Section&nbsp;162(m) Exemption. If an Award is so designated, the Committee shall establish performance goals for the Award within the time period prescribed by Section&nbsp;162(m) of the Code based on one </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or more of the following Qualified Performance Measures, which may be expressed in terms of Company-wide objectives or in terms of objectives that relate to the performance of a Subsidiary or a
division, region, department or function within the Company or a Subsidiary: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">return on capital, equity, or assets (including economic value created), </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">productivity or operating efficiencies, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">cost improvements, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">cash flow, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">sales revenue growth, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">net income, earnings per share, or earnings from operations, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">quality, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">customer satisfaction, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">comparable store sales, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top">stock price or total stockholder return, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top">EBITDA or EBITDAR, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top">after tax operating income, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top">book value per Share, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top">debt reduction, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top">strategic business objectives, consisting of one or more objectives based on meeting specified cost targets, business expansion goals and goals relating to acquisitions or divestitures, or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top">any combination of the foregoing. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each goal may be expressed on an absolute and/or relative basis, may be
based on or otherwise employ comparisons based on internal targets, the past performance of the Company or any Subsidiary, operating unit, business segment or division of the Company and/or the past or current performance of other companies, and in
the case of earnings-based measures, may use or employ comparisons relating to capital, stockholders&#146; equity and/or Common Stock outstanding, or to assets or net assets. The Committee may appropriately adjust any evaluation of performance under
criteria set forth in this Section&nbsp;12.2 to exclude any of the following events that occurs during a performance period: (i)&nbsp;asset write-downs, (ii)&nbsp;litigation or claim judgments or settlements, (iii)&nbsp;the effect of changes in tax
law, accounting principles or other such laws or provisions affecting reported results, (iv)&nbsp;accruals for reorganization and restructuring programs and (v)&nbsp;with respect to fiscal years beginning prior to December&nbsp;16, 2015,
&#147;extraordinary items&#148; described in Accounting Principles Board Opinion No.&nbsp;30, and/or with respect to fiscal years beginning after December&nbsp;15, 2015, events of an &#147;unusual nature&#148; and/or of a type that indicate
&#147;infrequency of occurrence,&#148; as defined in FASB Accounting Standards Update <FONT STYLE="white-space:nowrap">2015&nbsp;-&nbsp;01,</FONT> and appearing in the Company&#146;s financial statements or notes thereto appearing in the
Company&#146;s Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,</FONT> and/or in management&#146;s discussion and analysis of financial performance appearing in such Annual Report. Measurement of the Company&#146;s performance
against the goals established by the Committee shall be objectively determinable, and to the extent goals are expressed in standard accounting terms, performance shall be measured according to generally accepted accounting principles as in existence
on the date on which the performance goals are established and without regard to any changes in those principles after that date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.3
Performance Goal Conditions.</B> Each Qualified Performance-Based Award (other than an Option or SAR) shall be earned, vested and payable (as applicable) only upon the achievement of performance goals established by the Committee based upon one or
more of the Qualified Performance Measures, together with the satisfaction of any other conditions, such as continued Employment, the Committee may determine to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
appropriate; however, (i)&nbsp;the Committee may provide, either in connection with the grant of an Award or by later amendment, that achievement of the performance goals will be waived upon the
death or Disability of the Participant, and (ii)&nbsp;the provisions of Section&nbsp;22 shall apply notwithstanding this sentence. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.4
Certification of Goal Achievement.</B> Any payment of a Qualified Performance-Based Award granted with performance goals shall be conditioned on the written certification of the Committee in each case that the performance goals and any other
material conditions were satisfied. Except as specifically provided in Section&nbsp;12.3, no Qualified Performance-Based Award may be amended, nor may the Committee exercise any discretionary authority it may otherwise have under the Plan with
respect to a Qualified Performance-Based Award, in any manner to waive the achievement of the applicable performance goal based on Qualified Performance Measures or to increase the amount payable under, or the value of, the Award, or otherwise in a
manner that would cause the Qualified Performance-Based Award to cease to qualify for the Section&nbsp;162(m) Exemption. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. </B><B><I>PAYMENT OF
AWARDS</I></B><B>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the discretion of the Committee, payment of Awards may be made in cash, Common Stock, a combination of cash and Common Stock, or
any other form of property the Committee shall determine. In addition, payment of Awards may include terms, conditions, restrictions and limitations, if any, the Committee deems appropriate, including, in the case of Awards paid in the form of
Common Stock, restrictions on transfer and forfeiture provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. </B><B><I>TERMINATION OF EMPLOYMENT.</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms in this Section&nbsp;14 describe a Participant&#146;s rights upon termination of Employment with respect to Awards granted under the Plan, provided,
however, that the terms provided in a Participant&#146;s Award Notice may supplement or modify the results of termination of Employment under this Section&nbsp;14 and, provided further, in the event of a Change in Control, the Participant&#146;s
rights under an Award will be determined in accordance with Section&nbsp;22. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.1 Options.</B> The portion of an Option that has become
vested under the terms of an Award Notice or this Plan following termination of Employment, based on the conditions for such termination, shall be exercisable for the period described in this Section&nbsp;14.1. Upon the expiration of such right to
exercise the Option, the unexercised portion of the Option will be forfeited. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">a. Death and Disability. If the Participant&#146;s
Employment is terminated due to death or Disability, the Option shall become fully vested. The right to exercise the Option will expire one year after death or Disability or, if sooner ten years after the Option was granted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">b. Termination for Cause. If the Participant&#146;s employment is terminated for Cause, the Participant shall immediately forfeit the
unexercised portion of the Option, whether vested or unvested. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">c. Other Termination of Employment. If the Participant&#146;s Employment is
terminated for any reason not described above in this Section&nbsp;14.1, the Participant shall immediately forfeit any portion of the Option that is unvested as of the date of termination of Employment. The right to exercise the vested portion of
the Option will expire three months following such termination of Employment or, if sooner ten years after the Grant Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.2 Other
Awards.</B> Awards of Qualified Performance-Based Awards, Restricted Share Units, SARs, and Stock Awards that have not become vested under the terms of an Award Notice or this Plan will be forfeited upon the termination of the Participant&#146;s
Employment, except as described in this Section&nbsp;14.2. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">a. Time Vested Awards. With respect to Awards that condition vesting solely
with respect to continued employment, upon termination of Employment that is due to death or Disability, the Participant&#146;s rights under an Award that shall become fully vested. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">b. Performance Vested Awards. With respect to Awards that condition vesting upon achievement of performance measures, which may be stated in
the Award Notice, upon termination of Employment that is due to death or Disability, the Participant&#146;s rights under an Award that shall become fully vested with respect to the portion of the Award that is earned by achievement of such
performance measures on or prior to the date of death or Disability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.</B><B><I> NO ASSIGNMENT. </I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No Awards (other than unrestricted Stock Awards) or any other payment under the Plan shall be subject in any manner to alienation, anticipation, sale, transfer
(except by will or the laws of descent and distribution), assignment, pledge, or encumbrance; however, the Committee may (but need not) permit other transfers where the Committee concludes that transferability (i)&nbsp;does not result in accelerated
taxation, (ii)&nbsp;does not cause any option intended to be an incentive stock option to fail to be described in Code Section&nbsp;422(b), and (iii)&nbsp;is otherwise appropriate and desirable, taking into account any state or federal securities
laws applicable to transferable Awards. During the lifetime of the Participant no Award shall be payable to or exercisable by anyone other than the Participant to whom it was granted, other than (a)&nbsp;the duly appointed conservator or other
lawfully designated representative of the Participant in the case of a permanent Disability involving a mental incapacity or (b)&nbsp;the transferee in the case of an Award transferred in accordance with the preceding sentence. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. </B><B><I>CAPITAL ADJUSTMENTS</I></B><B>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number
and price of shares of Common Stock covered by each Award and Outside Director Award and the total number of shares of Common Stock that may be awarded under the Plan shall be proportionately adjusted to reflect any stock dividend, stock split or
share combination of the Common Stock or any recapitalization of the Company. In the event of any merger, consolidation, reorganization, liquidation or dissolution of the Company, or any exchange of shares involving the Common Stock, any Award or
Outside Director Award granted under the Plan shall automatically be deemed to pertain to the securities and other property to which a holder of the number of shares of Common Stock covered by the Award or Outside Director Award would have been
entitled to receive in connection with any such event. The Committee shall have the sole discretion to make all interpretations and determinations required under this section to the extent it deems equitable and appropriate. It is the intent of any
such adjustment that the value of the Awards or Outside Director Awards held by the Participants or Outside Directors, as the case may be, immediately following the change is the same as that value immediately prior to the change. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. </B><B><I>WITHHOLDING TAXES</I></B><B>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
shall have the power and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy Federal, state, and local taxes (including the Participant&#146;s FICA obligation) required by law to be
withheld with respect to any taxable event arising as a result of this Plan. With respect to withholding required upon any taxable event, the Company may elect in its discretion, and Participants may elect, subject to the approval of the Committee,
to satisfy the withholding requirement, in whole or in part, by withholding or having the Company withhold shares of Common Stock having a Fair Market Value on the date the tax is to be determined equal to (and shall not exceed) the maximum
statutory total tax which could be imposed on the transaction. All elections by Participants shall be irrevocable, made in writing, and signed by the Participant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. </B><B><I>REGULATORY APPROVALS AND LISTINGS</I></B><B>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything contained in the Plan to the contrary, the Company shall have no obligation to issue or deliver certificates of Common Stock
evidencing Stock Awards or any other Award resulting in the payment of shares of Common Stock prior to (a)&nbsp;the obtaining of any approval from any governmental agency which the Company shall, in its sole discretion, determine to be necessary or
advisable, (b)&nbsp;the admission of the shares to quotation or listing on the automated quotation system or stock exchange on which the Common Stock may be listed, and (c)&nbsp;the completion of any registration or other qualification of the shares
under any State or Federal law or ruling of any governmental body that the Company shall, in its sole discretion, determine to be necessary or advisable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19.</B><B><I> PLAN AMENDMENT. </I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as provided in Section&nbsp;22, the Board or the Committee may, at any time and from time to time, suspend, amend, modify, or terminate the Plan without
stockholder approval; however, if an amendment to the Plan would, in the reasonable opinion of the Board or the Committee, either (i)&nbsp;result in repricing stock options or otherwise increase the benefits accruing to Participants or Outside
Directors, (ii)&nbsp;increase the number of shares of Common Stock issuable under the Plan, or (iii)&nbsp;modify the requirements for eligibility, then that amendment shall be subject to stockholder approval; and, the Board or Committee may
condition any amendment or modification on the approval of stockholders of the Company if that approval is necessary or deemed advisable to (i)&nbsp;permit Awards to be exempt from liability under Section&nbsp;16(b), (ii)&nbsp;to comply with the
listing or other requirements of an automated quotation system or stock exchange, or (iii)&nbsp;to satisfy any other tax, securities or other applicable laws, policies or regulations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. </B><B><I>AWARD AMENDMENTS</I></B><B>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as
provided in Section&nbsp;22, the Committee may amend, modify or terminate any outstanding Award or Outside Director Award without approval of the Participant or Outside Director, as applicable; however: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">subject to the terms of the applicable Award Notice, an amendment, modification or termination shall not, without the Participant&#146;s or Outside Director&#146;s consent, as applicable, reduce or diminish the value of
the Award or Outside Director Award determined as if the Award or Outside Director Award had been exercised, vested, cashed in (at the spread value in the case of stock options or SARs) or otherwise settled on the date of that amendment or
termination; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">the original term of any stock option or SAR may not be extended without the prior approval of the stockholders of the Company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">except as otherwise provided in Section&nbsp;16 of the Plan, the exercise price of any outstanding stock option or SAR may not be reduced, directly or indirectly, and outstanding stock options or SARs may not be
cancelled in exchange for cash or replaced by other awards or stock options or SARs with an exercise price that is less than the exercise price of the cancelled stock options or SARs, without the prior approval of the stockholders of the Company;
and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">no termination, amendment, or modification of the Plan shall adversely affect any Award or Outside Director Awards previously granted under the Plan, without the written consent of the affected Participant or Outside
Director. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.</B><B><I> GOVERNING LAW. </I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Plan shall be governed by and construed in accordance with the laws of the State of Delaware, except as superseded by applicable Federal law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22. </B><B><I>CHANGE IN CONTROL</I></B><B>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to
the limitations set forth in this Section&nbsp;22, (i)&nbsp;with respect to Awards granted on or after the Effective Date, in the event (A)&nbsp;a Participant has a Qualifying Termination within one year following a Change in Control of the Company,
or (B)&nbsp;a Change in Control occurs in which outstanding Awards are not assumed or honored by the successor entity or corporation or replaced with an Alternative Award (as defined below), and (ii)&nbsp;with respect to Awards granted prior to the
Effective Date, in connection with a Change in Control, if and to the extent determined by the Committee or the Board at or after the affected award or grant and subject to any right of approval expressly reserved by the Committee or the Board at
the time of the determination, the following provisions shall apply to any Award which has not previously terminated or expired: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">any SAR and any stock option or Outside Director Award awarded under this Plan that is not previously vested and exercisable shall become fully vested and exercisable; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">the restrictions applicable to any Award which are not already vested under the Plan shall lapse, and those existing shares and awards shall be deemed fully vested; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">unless otherwise determined by the Board or by the Committee in its sole discretion prior to any Change in Control, the value of all vested outstanding stock options, SARs, Outside Director Awards and other Awards,
shall be cashed out on the basis of the Change in Control Price as of the date the Change in Control is determined to have occurred (or other date determined by the Board or Committee prior to the Change in Control); and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">the Board or the Committee may impose additional conditions on the acceleration or valuation of any Award in any applicable Award Notice. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To qualify as an &#147;Alternative Award,&#148; the Committee must determine that the existing Awards are to be assumed, honored or new rights substituted by
the successor corporation or entity and further must: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">be based on shares of common stock that are traded on an established U.S. securities market or another public market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">provide the Participant (or each Participant in a class of Participants) with rights and entitlements substantially equivalent to or better than the rights, terms and conditions applicable under such Award, including,
but not limited to, an identical or better exercise or vesting schedule and identical or better timing and methods of payment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">have substantially equivalent economic value to such Award; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">contain terms and conditions which provide that in the event that the Participant&#146;s employment is terminated for death or Disability or is terminated without Cause within 90&nbsp;days following a Change of Control,
any conditions on the Participant&#146;s rights under, or any restrictions on transfer, vesting or exercisability applicable to, each such Award shall lapse; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top">be on terms and conditions that do not result in adverse tax consequences to the Participant under Section&nbsp;409A of the Code. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23. </B><B><I>AWARDS TO OUTSIDE DIRECTORS</I></B><B>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>23.1 </B>The independent members of the Board may provide that all or a portion of an Outside Director&#146;s annual retainer, meeting fees
and/or other awards or compensation as determined by such independent members of the Board, be payable (either automatically or at the election of an Outside Director) in the form of Non-Qualified Stock Options, Restricted Shares, Restricted Share
Units and/or Other Stock-Based Awards, including unrestricted Shares. The Board shall determine the terms and conditions of any such Awards, including the terms and conditions which shall apply upon a termination of the Non-Employee Director&#146;s
service as a member of the Board, and shall have full power and authority in its discretion to administer such Awards, subject to the terms of the Plan and applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>23.2 </B>The Board may also grant Awards to Outside Directors pursuant to the terms of the Plan, including any Award described in
Sections&nbsp;8, 9 and 10 above. With respect to such Awards, all references in the Plan to the Committee shall be deemed to be references to the independent members of the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>24. </B><B><I>NO RIGHT TO EMPLOYMENT OR PARTICIPATION</I></B><B>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The grant of an Award under this Plan shall not confer any rights upon the Participant holding such Award other than such terms, and subject to such
conditions, as are specified in this Plan as being applicable to such type of Award (or to all Awards) or as are expressly set forth in the Award Notice or other document evidencing such Award. Participation in the Plan shall not give any
Participant any right to remain in the employ, or to serve as a director, of the Company or any Subsidiary or Affiliate of the Company or, in the case of employment with a Subsidiary or Affiliate, the Subsidiary or Affiliate reserves the right to
terminate the employment of any Participant at any time. Further, the adoption of this Plan shall not be deemed to give any Employee or any other individual any right to be selected as a Participant or to be granted an Award. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>25. </B><B><I>NO RIGHT, TITLE OR INTEREST IN COMPANY ASSETS</I></B><B>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Plan is intended to constitute an &#147;unfunded&#148; plan for incentive compensation. No Participant shall have any rights as a stockholder as a result
of participation in the Plan until the date of issuance of a stock certificate in the Participant&#146;s name, and, in the case of restricted shares of Common Stock, such rights are granted to the Participant under Section&nbsp;10.3 hereof. To the
extent any person acquires a right to receive payments from the Company under the Plan, those rights shall be no greater than the rights of an unsecured creditor of the Company. In its sole discretion, the Committee may authorize the creation of
trusts or other arrangements to meet the obligations created under the Plan to deliver Common Stock or to make payments in lieu of, or with respect to, Plan awards. However, unless the Committee determines otherwise with the express consent of the
affected Participant, the existence of any such trusts or other arrangements is consistent with this &#147;unfunded&#148; status of the Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.
</B><B><I>SECURITIES LAWS</I></B><B>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to Section&nbsp;16 Insiders, transactions under this Plan are intended to comply with all
applicable conditions of <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3</FONT> or its successors under the Exchange Act. To the extent any provision of the Plan or action by the Committee fails so to comply, it shall be deemed null and void, to
the extent permitted by law and deemed advisable by the Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>27. </B><B><I>REQUIRED WRITTEN REPRESENTATIONS</I></B><B>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Committee may require each person purchasing shares pursuant to a stock option or other award under the Plan to represent to and agree with the Company in
writing that the optionee or Participant is acquiring any shares of Common Stock without a view to their distribution. The certificates for shares may include any legend which the Committee deems appropriate to reflect any restrictions on transfer.
All certificates for shares of Common Stock or other securities delivered under the Plan shall be subject to stop transfer orders and other restrictions the Committee deems advisable under the rules, regulations and other requirements of the
Securities and Exchange Commission, any stock exchange upon which the Common Stock is then listed, and any applicable Federal or state securities laws, and the Committee may cause a legend or legends to be put on any certificates to make appropriate
reference to the applicable restrictions. Each Participant is responsible for fully complying with all applicable state and federal securities laws and rules and the Company assumes no responsibility for compliance with any such laws or rules
pertaining to a Participant&#146;s resale of any shares of Common Stock acquired pursuant to this Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>28. </B><B><I>NON-EXCLUSIVE
ARRANGEMENT</I></B><B>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nothing contained in this Plan shall prevent the Board from adopting other or additional compensation arrangements, subject to
stockholder approval if required; and those arrangements may be either generally applicable or applicable only in specific cases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>29. LIMITS ON LIABILITY AND INDEMNIFICATION. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The members of the Committee and the Board shall not be liable to any employee or other person with respect to any determination made under the Plan in a
manner that is not inconsistent with their legal obligations as members of the Board. In addition to all other rights of indemnification they may have as directors or as members of the Committee, the members of the Committee shall be indemnified by
the Company against reasonable expenses, including attorneys&#146; fees actually and necessarily incurred in connection with the defense of any action, suit or proceeding, or in connection with any appeal therein, to which they or any of them may be
a party because of any action taken or failure to act under or in connection with the Plan or any Award granted under it, and against all amounts paid by them in settlement (provided the settlement is approved by independent legal counsel selected
by the Company) or paid to them in satisfaction of a judgment in that action, suit or proceeding, except in relation to matters as to which it shall be adjudged in the action, suit or proceeding that the Committee member is liable for negligence or
misconduct in the performance of his or her duties. Within 60&nbsp;days after institution of any action, suit or proceeding covered by this Section&nbsp;29, the Committee member must inform the Company in writing of the claim and offer the Company
the opportunity, at its own expense, to handle and defend the matter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>3
<FILENAME>d332070dex1015.htm
<DESCRIPTION>EX-10.15
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.15</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.15 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMEDISYS HOLDING, L.L.C. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEVERANCE PLAN FOR KEY EXECUTIVES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">APRIL 30, 2015 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Inclusive of all
Amendments to Sections 2 and 4 dated on or before December&nbsp;31, 2016 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1. Purpose</B>. The purpose of this Amedisys Holding, L.L.C.
Severance Plan for Key Employees (this &#147;Plan&#148;) is to provide a fair framework in the event of the termination of employment in certain circumstances of certain key executive employees of the Company. This document supersedes any prior
plan, program or arrangement that provides severance benefits to a Covered Executive (as defined below) eligible for benefits under this Plan. This document is intended to serve both as the official plan document and the summary plan description for
this Plan. The Plan is sponsored by Amedisys Holding, L.L.C. (&#147;Company&#148;). The Company is the Plan Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2. Covered
Executives</B>. To be eligible for benefits under this Plan an executive must (1)&nbsp;be employed by the Company with any of the following job titles: Chief Operating Officer, Chief Financial Officer, Vice Chairman, Chief Human Resources Officer,
General Counsel, Chief Information Officer, Chief Strategy Officer, Chief Clinical Operations Officer, or the Chief Compliance Officer; (2)&nbsp;have been designated in writing by the Board of Directors (the &#147;Board&#148;) of Amedisys, Inc. or
the Compensation Committee of the Board (the &#147;Committee&#148;), as appropriate, as being covered by this Plan; and (3)&nbsp;have executed and delivered to the Company (and not have revoked or attempted to revoke) the Company&#146;s Executive
Protective Covenants Agreement (&#147;EPCA&#148; or other similarly named agreement) (a &#147;Covered Executive&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Plan shall
not be applicable to any employee who is a party to a separate employment agreement, change of control agreement, or similar agreement with the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a Covered Executive under this Plan is or becomes eligible to participate in the April 2013 Severance Plan for Senior Management Leaders or
the Severance Plan for Senior Vice Presidents, then such employee will only be eligible for severance benefits under the terms of the April 2013 Severance Plan for Senior Management Leaders or the Severance Plan for Senior Vice Presidents, except in
the event of a &#147;Change in Control&#148; (as such term is defined in Section&nbsp;3, below), in which case the terms of this Plan (including, without limitation, the provisions of Section&nbsp;5, herein) shall control, regardless of whether such
employee still qualifies as a Covered Executive. In no event will a Covered Executive be entitled to simultaneously receive benefits under the April 2013 Severance Plan for Senior Management Leaders, the Severance Plan for Senior Vice Presidents and
this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3. Definitions. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <B>Cause</B>. &#147;Cause,&#148; as it applies to the determination by the Company to terminate the employment of a Covered Executive,
shall mean any one or more of the following: (i)&nbsp;Covered Executive&#146;s willful, material, and irreparable breach of Covered Executive&#146;s duties to the Company; (ii)&nbsp;Covered Executive&#146;s gross negligence in the performance or
intentional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
nonperformance of any of Covered Executive&#146;s material duties and responsibilities to the Company; (iii)&nbsp;Covered Executive&#146;s willful dishonesty, fraud, or misconduct with respect to
the business or affairs of the Company, which materially and adversely affects the operations or reputation of the Company; (iv)&nbsp;Covered Executive&#146;s conviction or plea of nolo contendere to a felony crime; and (v)&nbsp;Covered Executive
engages in an act or series of acts constituting misconduct resulting in a misstatement of a Company&#146;s financial statements due to material non-compliance with any financial reporting requirement within the meaning of Section&nbsp;304 of The
Sarbanes Oxley Act of 2002. In the event of a termination by the Company for Cause, Covered Executive shall have no right to any severance benefits under this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <B>Code. </B>&#147;Code&#148; shall mean the United States Internal Revenue Code of 1986, as amended, or any successor provision of law,
and the regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <B>Good Reason</B>. &#147;Good Reason,&#148; as it applies to the determination by a
Covered Executive to terminate Covered Executive&#146;s employment with the Company at his or her initiative shall mean the occurrence of any of the following events without Covered Executive&#146;s written consent: (i)&nbsp;Covered Executive
suffers a material diminution in authority, responsibilities, or duties; or (ii)&nbsp;Covered Executive suffers a material reduction in base salary other than in connection with a proportionate reduction in the base salaries of all similarly
situated senior officer-level employees. Good Reason shall not be deemed to have occurred unless (i)&nbsp;Covered Executive provides the Company with notice of one of the conditions described above within 90 days of the existence of the condition,
(ii)&nbsp;the Company is provided at least 30 days to cure the condition and fails to cure same within such 30 day period and (iii)&nbsp;Covered Executive terminates employment within at least 150 days of the existence of the condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <B>Employment Termination</B>. &#147;Employment Termination&#148; shall mean a Covered Executive no longer being an employee of the
Company as a result of a termination by the Company without Cause or by Covered Executive with Good Reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <B>Change in Control.
</B>A &#147;Change in Control&#148; shall be deemed to have occurred if: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. any person or entity, including a
&#147;group&#148; as defined in Section&nbsp;13(d)(3) of the Exchange Act, other than the Company or a wholly-owned Subsidiary, or any employee benefit plan of the Company or any Subsidiary, becomes the beneficial owner of the Company&#146;s
securities having 50% or more of the combined voting power of the then outstanding securities of the Company that may be cast for the election of directors of the Company (other than as a result of an issuance of securities initiated by the Company
in the ordinary course of business); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b. as the result of, or in connection with, any cash tender or exchange offer,
merger or other business combination, sales of assets or contested election, or any combination of the foregoing transactions, after the transaction less than a majority of the combined voting power of the then outstanding securities of the Company,
or any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
successor corporation or cooperative or entity, entitled to vote generally in the election of the directors of the Company, or other successor corporation or other entity, are held in the
aggregate by the holders of the Company&#146;s securities who immediately prior to the transaction had been entitled to vote generally in the election of directors of the Company; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c. during any period of 2 consecutive years, individuals who at the beginning of the period constitute the Board cease for any
reason to constitute at least a majority of the Board, unless the election, or the nomination for election by the Company&#146;s stockholders, of each director of the Company first elected during the relevant 2-year period was approved by a vote of
at least 2/3 of the directors of the Company then still in office who were directors of the Company at the beginning of that period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4. Result of Termination by the Company without Cause or by Covered Executive with Good Reason Prior to a Change in Control</B>. The
following provisions shall apply should the Company terminate a Covered Executive&#146;s employment without Cause or should a Covered Executive terminate Covered Executive&#146;s employment with Good Reason: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <B>Salary and Bonus</B>. The Company shall pay to Covered Executive an amount equal to one (1)&nbsp;times the sum of (A)&nbsp;the Covered
Executive&#146;s base salary, as in effect on the date of Employment Termination (or in the event a reduction in base salary is a basis for a termination with Good Reason, then the base salary in effect immediately prior to such reduction) and
(B)&nbsp;the greater of (x)&nbsp;an amount equal to the cash bonus earned by the Covered Executive for the previous fiscal year or (y)&nbsp;an amount equal to twenty-five (25)&nbsp;percent of the Covered Executive&#146;s base salary, as in effect on
the date of Employment Termination (or, in the event a reduction in base salary is a basis for termination for Good Reason, then the base salary in effect immediately prior to such reduction), which amount shall be payable in substantially equal
monthly installments in accordance with the Company&#146;s normal payroll practices for a period of 12 months and which payments shall commence in accordance with the provisions of Section&nbsp;6, herein (unless otherwise required to be paid in
accordance with Section&nbsp;7 below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <B>Stock Vesting. </B>Any unvested equity awards issued in the name of Covered Employee as of
the date of termination, will vest in accordance with the terms contained in the applicable Award Agreement for such awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.
Termination by the Company without Cause or Termination by Covered Executive with Good Reason Following a Change in Control. </B>The following provisions shall apply should the Company terminate a Covered Executive&#146;s employment without Cause or
should a Covered Executive terminate Covered Executive&#146;s employment with Good Reason, in either case within one year following a Change in Control (as defined above): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <B>Salary and Bonus.</B> The Company shall pay to Covered Executive (i)&nbsp;an amount equal to two (2)&nbsp;times the sum of (A)&nbsp;the
Covered Executive&#146;s base salary, as in effect on the date of Employment Termination (or in the event a reduction in base salary is a basis for a termination with Good Reason, then the base salary in effect immediately prior to such reduction)
and (B)&nbsp;the greater of (x)&nbsp;an amount equal to the cash bonus earned by the Covered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Executive for the previous fiscal year or (y)&nbsp;an amount equal to twenty-five (25)&nbsp;percent of the Covered Executive&#146;s base salary, as in effect on the date of Employment Termination
(or, in the event a reduction in base salary is a basis for termination for Good Reason, then the base salary in effect immediately prior to such reduction), which amount shall be payable in a lump sum on the date or dates specified in
Section&nbsp;6, herein (unless otherwise required to be paid in accordance with Section&nbsp;7 below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <B>Stock Vesting. </B>Any
unvested equity awards issued in the name of Covered Employee as of the occurrence of a Change in Control will vest in accordance with the provisions of the Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan, as the same may be amended from
time to time, or any successor plan thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6. Release of Claims</B>. The Company&#146;s obligations under this Plan are contingent
upon Covered Executive&#146;s executing (and not revoking during any applicable revocation period) a valid, enforceable, full and unconditional release of all claims Covered Executive may have against the Company, Amedisys, Inc. and their respective
directors, officers, employees, subsidiaries, stockholders, successors, assigns, agents, representatives subsidiaries and affiliates (whether known or unknown) as of the date of Employment Termination in such form as provided by the Company no later
than 60 days after the date of Employment Termination. If the foregoing release is executed and delivered and no longer subject to revocation within 60 days after the date of Employment Termination, then the following shall apply: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) To the extent any payments due to Covered Executive under this Plan are not &#147;deferred compensation&#148; for purposes of
Section&nbsp;409A of the Code then such payments shall commence upon the first regularly-scheduled payment date immediately following the date the release is executed and no longer subject to revocation (the &#147;Release Effective Date&#148;). The
first such cash payment shall include payment of all amounts that otherwise would have been due prior to the Release Effective Date under the terms of this Plan had such payments commenced after the date of Employment Termination, and any payments
to be made thereafter shall continue as provided herein. The delayed payments shall in any event expire at the time such payments would have expired had such payments commenced after the date of Employment Termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) To the extent any payments due to Covered Executive under this Plan above are &#147;deferred compensation&#148; for purposes of
Section&nbsp;409A, then such payments shall commence upon the 60th day following the date of Employment Termination. The first such cash payment shall include payment of all amounts that otherwise would have been due prior thereto under the terms of
this Plan had such payments commenced after the date of Employment Termination, and any payments to be made thereafter shall continue as provided herein. The delayed payments shall in any event expire at the time such payments would have expired had
such payments commenced immediately following the date of Employment Termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7. Section&nbsp;409A</B>. Notwithstanding any
provisions in this Plan to the contrary, if at the time of the Employment Termination the Covered Executive is a &#147;specified employee&#148; as defined in Section&nbsp;409A and the deferral of the commencement of any payments or benefits
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise payable as a result of such Employment Termination is necessary to avoid the additional tax under Section&nbsp;409A, the Company will defer the payment or commencement of the payment of
any such payments or benefits (without any reduction in such payments or benefits ultimately paid or provided to Covered Executive) until one day after the day which is six months from the date of Employment Termination. Any monthly payment amounts
deferred will be accumulated and paid to Covered Executive (without interest) six months after the date of Employment Termination in a lump sum, and the balance of payments due to Covered Executive will be paid as otherwise provided in this Plan.
Each monthly payment described in this Plan is designated as a &#147;separate payment&#148; for purposes of Section&nbsp;409A and, subject to the six month delay, if applicable, and the first monthly payment shall commence on the payroll date as in
effect on termination following the termination. For purposes of this Plan, a termination of employment means a separation from service as defined in Section&nbsp;409A. No reimbursement payable to Covered Executive pursuant to any provisions of this
Plan or pursuant to any plan or arrangement of the Company shall be paid later than the last day of the calendar year following the calendar year in which the related expense was incurred, and no such reimbursement during any calendar year shall
affect the amounts eligible for reimbursement in any other calendar year, except, in each case, to the extent that the right to reimbursement does not provide for a &#147;deferral of compensation&#148; within the meaning of Section&nbsp;409A. This
Plan will be interpreted, administered and operated in accordance with Section&nbsp;409A, although nothing herein will be construed as an entitlement to or guarantee of any particular tax treatment to Covered Executive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8. Claims Procedure</B>. If a Covered Executive does not receive a benefit to which the Covered Executive believes he or she is entitled
under the Plan, or if the Covered Executive believes that the Covered Executive is entitled to a greater benefit than was approved, the Covered Executive must, within 60 days following the date of Employment Termination, file a written claim with
the Plan Administrator. The Plan Administrator will investigate the claim and will send the Covered Executive a written decision within 60 days from the date upon which it receives the claim. If the claim is denied, the written decision will specify
the reasons for the denial (including the pertinent Plan provisions upon which the denial is based), as well as an explanation of how the Covered Executive may obtain a further review by the Plan Administrator. If the Covered Executive does not
receive a notice regarding his or her claim within these time periods, the claim will be considered denied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Covered Executive
disagrees with the Plan Administrator&#146;s decision, in whole or in part, the Covered Executive has 60 days following receipt of written notice from the Plan Administrator to request a review in writing. The request must describe the reasons why
the Covered Executive believes the denial was wrong and whatever evidence the Covered Executive believes supports his or her position. If the Covered Executive wishes to examine any Company documents, he or she must request an examination and
specify the documents requested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within 60 days following a request for review, the Plan Administrator will send the Covered Executive
its written decision specifying the reasons for the decision, including the pertinent Plan provisions upon which it is based. This decision shall be final and binding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If special circumstances require an extension of time for the Plan Administrator to render a decision, the Plan Administrator will send the
Covered Executive a written notice of the extension prior to the commencement of the extension and will explain the reasons for the delay. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, as Plan Administrator, has the exclusive discretionary authority to construe and
interpret the Plan, to decide all questions of eligibility for severance benefits under the Plan and to determine the amount of any such severance benefits, and its decisions on such matters are final and conclusive. Any interpretations or
determinations made pursuant to such discretionary authority will be upheld on judicial review, unless it is shown that the interpretation or determination was an abuse of discretion (i.e., arbitrary and capricious). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9. Your Rights Under ERISA</B>. As a participant in the Plan, a Covered Executive is entitled to certain rights and protection under the
Employee Retirement Income Security Act of 1974, as amended (&#147;ERISA&#148;). ERISA provides that all Plan participants shall be entitled to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Examine, without charge, at the Plan Administrator&#146;s office and at other specified locations, such as worksites, all documents governing the Plan, including a copy of the latest annual report (Form 5500 Series)
filed by the Plan with the U.S. Department of Labor. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Obtain, upon written request to the Plan Administrator, copies of documents governing the operation of the Plan, including a copy of the latest annual report (Form 5500 Series) and updated summary plan description. The
Administrator may make a reasonable charge for the copies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Receive a summary of the Plan&#146;s annual financial report. The Plan Administrator is required by law to furnish each participant with a copy of this summary annual report. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to creating rights for Plan participants, ERISA imposes duties upon the people who are responsible for the operation of the
employee benefit plan. The people who operate the Plan, called &#147;fiduciaries&#148; of the Plan, have a duty to do so prudently and in the interest of the Covered Executive and other Plan participants and beneficiaries. No one, including the
employer, or any other person, may fire the Covered Executive or otherwise discriminate against the Covered Executive in any way to prevent the Covered Executive from obtaining a welfare benefit or exercising his or her rights under ERISA. If the
Covered Executive&#146;s claim for a welfare benefit is denied, in whole or in part, he or she must receive a written explanation of the reason for the denial. The Covered Executive has the right to have the Plan review and reconsider his or her
claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under ERISA, there are steps a Covered Executive can take to enforce the above rights. For instance, if the Covered Executive
requests materials from the Plan and does not receive them within 30 days, he or she may file suit in a Federal court. In such a case, the court may require the Plan Administrator to provide the materials and pay the Covered Executive up to $110 a
day until he or she receives the materials, unless the materials were not sent because of reasons beyond the control of the Plan Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Covered Executive has a claim tor benefits which is denied or ignored, in whole or in part, the Covered Executive may file suit in a
state or Federal court. In addition, if the Covered Executive disagrees with the Plan&#146;s decision or lack thereof concerning the qualified status of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
medical child support order, he or she may file suit in Federal court. If it should happen that Plan fiduciaries misuse the Plan&#146;s money, or if the Covered Executive is discriminated against
for asserting his or her rights, the Covered Executive may seek assistance from the U.S. Department of Labor, or may file suit in a Federal court. The court will decide who should pay court costs and legal fees. If the Covered Executive is
successful, the court may order the person the Covered Executive has sued to pay these costs and fees. If the Covered Executive loses, the court may order him or her to pay these costs and fees &#151; for example, if the court finds the Covered
Executive&#146;s claim is frivolous. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Covered Executive has any questions about the Plan, he or she should contact the Plan
Administrator. If the Covered Executive has any questions about this statement or about his or her rights under ERISA, the Covered Executive should contact the nearest office of the Pension and Welfare Benefits Administration, U.S. Department of
Labor, listed in the telephone directory or the Division of Technical Assistance and Inquiries, Pension and Welfare Benefits Administration, U.S. Department of Labor, 200 Constitution Avenue, N.W., Washington, D.C. 20210. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10. Additional Important Information</B>. The name of the Plan is the Amedisys Holding, L.L.C. Severance Plan for Key Executives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sponsor of the Plan is Amedisys Holding, L.L.C. and its employer identification number is 36-4576454. The sponsor&#146;s address and
telephone number is 209 10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Avenue South, Suite 512, Nashville, TN 37203, (615)&nbsp;928-5458. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amedisys Holding, L.L.C. also serves as the Plan Administrator under ERISA for the Plan, and can be contacted at 209 10<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Avenue South, Suite 512, Nashville, TN 37203, (615)&nbsp;928-5458. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agent for
service of process for the Plan is Secretary, Amedisys Holding, L.L.C., 209 10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Avenue South, Suite 512, Nashville, TN 37203, (615)&nbsp;928-5458. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan is an employee welfare benefit plan providing severance pay and benefits as described in this Plan document. All Severance Benefits
under the Plan shall be paid directly by the Company from its general assets, and the rights of an eligible employee to any benefits hereunder shall not be superior to those of an unsecured general creditor of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan year shall be the calendar year. The Plan number is 1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Severance benefits under the Plan may not be assigned, transferred or pledged to a third party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11. At-Will Employment.</B> No provision of the Plan is intended to provide any Covered Executive with any right to continue as an employee
or in any other capacity with the Company, for any specific period of time, or otherwise affect the right of the Company to terminate the employment or service of any individual at any time for any reason with or without cause. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12. Amendment and Termination</B>. The Company reserves the right in its discretion to
terminate the Plan and to amend the Plan in any manner at any time, subject to the prior approval of the Board and/or the Committee, as applicable. Any such action will be in writing and signed by the Chief Executive Officer or the Chief Human
Resources Officer of the Company or such other persons as he or she shall designate. Oral or other informal communications made by the Company or its representatives shall not give rise to any rights or benefits other than those contained in the
Plan described herein, and such communications will not diminish the Company&#146;s rights to amend or terminate the Plan in any manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document is executed as of this 10th day of January 2017. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AMEDISYS HOLDING, L.L.C.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AMEDISYS, INC.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;Its Sole Member and Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Larry Pernosky</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Larry Pernosky</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Human Resources Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>d332070dex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIST OF SUBSIDIARIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>CORPORATIONS
</U></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS HOME HEALTH, INC. OF SOUTH CAROLINA, a South Carolina corporation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">HI-TECH</FONT> CARE, INC., a Florida Corporation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HMR ACQUISITION, INC., a Delaware corporation </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INFINITY HOME CARE
ACQUISITION CORP., a Florida corporation </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>LIMITED LIABILITY COMPANIES </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACCUMED HEALTH SERVICES, L.L.C., a Texas limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACCUMED HOLDING, L.L.C., a Delaware limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACCUMED HOME HEALTH OF GEORGIA, L.L.C.., a Georgia limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ADVENTA HOSPICE, L.L.C., a Florida limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ALBERT GALLATIN HOME CARE AND HOSPICE SERVICES, LLC, a Delaware limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS AIR, L.L.C., a Louisiana limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS ALABAMA, L.L.C., an Alabama limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS ALASKA, LLC, an Alaska limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS ARIZONA, L.L.C., an Arizona limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS ARKANSAS, LLC, an Arkansas limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS BA, LLC, a Delaware limited liability company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS
DELAWARE, L.L.C., a Delaware limited liability company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS FLORIDA, L.L.C., a Florida limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS GEORGIA, L.L.C., a Georgia limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS HEALTH CARE WEST, L.L.C., a Delaware limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS HOLDING, L.L.C., a Louisiana limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS HOME HEALTH OF ALABAMA, L.L.C. an Alabama limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS HOME HEALTH OF VIRGINIA, L.L.C. a Virginia limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS HOSPICE, L.L.C., a Louisiana limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS IDAHO, L.L.C., an Idaho limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS ILLINOIS, L.L.C., an Illinois limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS INDIANA, L.L.C., an Indiana limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS IOWA, L.L.C., an Iowa limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS KANSAS, L.L.C., a Kansas limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS LA ACQUISITIONS, L.L.C., a Louisiana limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS LOUISIANA, L.L.C., a Louisiana limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS MAINE, P.L.L.C., a Maine professional limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS MARYLAND, L.L.C., a Maryland limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS MICHIGAN, L.L.C., a Michigan limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS MISSISSIPPI, L.L.C., a Mississippi limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS MISSOURI, L.L.C., a Missouri limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS NEW HAMPSHIRE, L.L.C., a New Hampshire limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS NEW JERSEY, L.L.C., a New Jersey limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS NEW MEXICO, L.L.C., a New Mexico limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS NORTH CAROLINA, L.L.C., a North Carolina limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS NORTHWEST, L.L.C., a Georgia limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS OHIO, L.L.C., an Ohio limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS OKLAHOMA, L.L.C., an Oklahoma limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS OREGON, L.L.C., an Oregon limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS PENNSYLVANIA, L.L.C., a Pennsylvania limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS PERSONAL CARE, LLC, a Delaware limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS PROPERTY, L.L.C., a Louisiana limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS RHODE ISLAND, L.L.C., a Rhode Island limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS SC, L.L.C., a South Carolina limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS SOUTH FLORIDA, L.L.C., a Florida limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS SPECIALIZED MEDICAL SERVICES, L.L.C., a Louisiana limited liability company </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS <FONT STYLE="white-space:nowrap">SP-IN,</FONT> L.L.C., an Indiana limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS <FONT STYLE="white-space:nowrap">SP-KY,</FONT> L.L.C., a Kentucky limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS <FONT STYLE="white-space:nowrap">SP-OH,</FONT> L.L.C., an Ohio limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS <FONT STYLE="white-space:nowrap">SP-TN,</FONT> L.L.C., a Tennessee limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS TENNESSEE, L.L.C., a Tennessee limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS TEXAS, L.L.C., a Texas limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS TLC ACQUISITION, L.L.C., a Louisiana limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS WASHINGTON, L.L.C., a Washington limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS WEST VIRGINIA, L.L.C., a West Virginia limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS WISCONSIN, L.L.C., a Wisconsin limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ANGEL WATCH HOME CARE, L.L.C., a Florida limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ANMC VENTURES, L.L.C., a Louisiana liability company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASSOCIATED
HOME CARE, L.C.C., a Massachusetts limited liability company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AVENIR VENTURES, L.L.C., a Louisiana limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BEACON HOSPICE, L.L.C., a Delaware limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BROOKSIDE HOME HEALTH, LLC, a Virginia limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CH HOLDINGS, LLC, a Louisiana limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">COMPREHENSIVE HOME HEALTHCARE SERVICES, L.L.C., a Tennessee limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ELDER HOME OPTIONS, L.C.C., a Massachusetts limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EMERALD CARE, L.L.C., a North Carolina limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FAMILY HOME HEALTH CARE, L.L.C., a Kentucky limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HHC, L.L.C., a Tennessee limited liability company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HOME HEALTH
OF ALEXANDRIA, L.L.C., a Louisiana limited liability company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HOME HOSPITALISTS OF AMERICA, LLC, a Delaware limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HORIZONS HOSPICE CARE, L.L.C., an Alabama limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HOUSECALL, L.L.C., a Tennessee limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HOUSECALL HOME HEALTH, L.L.C., a Tennessee limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HOUSECALL MEDICAL RESOURCES, L.L.C., a Delaware limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HOUSECALL MEDICAL SERVICES, L.L.C., a Tennessee limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INFINITY HOME CARE, L.L.C., a Florida limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INFINITY HOME CARE OF BROWARD, LLC, a Florida limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INFINITY HOME CARE OF LAKELAND, LLC, a Florida limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INFINITY HOME CARE OF OCALA, LLC, a Florida limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INFINITY HOME CARE OF PINELLAS, LLC, a Florida limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INFINITY HOME CARE OF PORT CHARLOTTE, LLC, a Florida limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INFINITY HOME CARE OF JACKSONVILLE, LLC, a Florida limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INFINITY HOMECARE OF DISTRICT 9, LLC, a Florida limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MC VENTURES, LLC, a Mississippi limited liability company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NINE
PALMS 1, L.L.C., a Virginia limited liability company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TENDER LOVING CARE HEALTH CARE SERVICES INTERNATIONAL, LLC, a Delaware limited liability company
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TENDER LOVING CARE HEALTH CARE SERVICES OF BROWARD, LLC, a Delaware limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TENDER LOVING CARE HEALTH CARE SERVICES OF ERIE NIAGARA, LLC, a New York limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TENDER LOVING CARE HEALTH CARE SERVICES OF GEORGIA, LLC, a Delaware limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TENDER LOVING CARE HEALTH CARE SERVICES OF NASSAU SUFFOLK, LLC, a New York limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TENDER LOVING CARE HEALTH CARE SERVICES OF NEW ENGLAND, LLC, a Delaware limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TENDER LOVING CARE HEALTH CARE SERVICES OF WEST VIRGINIA, LLC, a Delaware limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TENDER LOVING CARE HEALTH CARE SERVICES SOUTHEAST, LLC, a Delaware limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TENDER LOVING CARE HEALTH CARE SERVICES WESTERN, LLC, a Delaware limited liability company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TLC HOLDINGS I, L.L.C., a Delaware limited liability company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TLC
HEALTH CARE SERVICES, L.L.C., a Delaware limited liability company </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>LIMITED PARTNERSHIPS/LIMITED LIABILITY PARTNERSHIPS </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NINE PALMS 2, LLP, a Mississippi limited liability partnership </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>JOINT VENTURES </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS HOME HEALTH, A LAWRENCE
MEDICAL CENTER PARTNER, L.L.C, a Delaware limited liability company <B>(66.67% ownership)</B> </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AMEDISYS PRIVATE DUTY, LLC, a Delaware limited liability company <B>(50% ownership)</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GEORGETOWN HOSPITAL HOME HEALTH, LLC, a Delaware limited liability company <B>(70% ownership)</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MARIETTA HOME HEALTH AND HOSPICE, L.L.C., an Ohio limited liability company <B>(50% ownership)</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MORGANTOWN HOSPICE, LLC, a Delaware limited liability company <B>(80% ownership)</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">TRI-CITIES</FONT> HOME HEALTH, LLC, a Delaware limited liability company <B>(50% ownership)</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TUCSON HOME HEALTH, LLC, a Delaware limited liability company<B> (70% ownership)</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WENTWORTH HOME CARE AND HOSPICE, LLC, a New Hampshire limited liability company <B>(50% ownership)</B> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>d332070dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amedisys, Inc.: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in the registration statements (Nos. <FONT STYLE="white-space:nowrap">333-138255</FONT> and <FONT
STYLE="white-space:nowrap">333-145582)</FONT> on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and <FONT STYLE="white-space:nowrap">(Nos.&nbsp;333-60525,</FONT> <FONT STYLE="white-space:nowrap">333-51704,</FONT>
<FONT STYLE="white-space:nowrap">333-53786,</FONT> <FONT STYLE="white-space:nowrap">333-143967,</FONT> <FONT STYLE="white-space:nowrap">333-152359,</FONT> <FONT STYLE="white-space:nowrap">333-182347</FONT> and
<FONT STYLE="white-space:nowrap">333-205267)</FONT> on Form <FONT STYLE="white-space:nowrap">S-8</FONT> of Amedisys, Inc. and subsidiaries of our reports dated March&nbsp;1, 2017, with respect to the consolidated balance sheets of Amedisys, Inc. and
subsidiaries as of December&nbsp;31, 2016 and 2015, and the related consolidated statements of operations, comprehensive income (loss), stockholders&#146; equity and cash flows for each of the years in the three-year period ended December&nbsp;31,
2016, and the effectiveness of internal control over financial reporting as of December&nbsp;31, 2016, which reports appear in the December&nbsp;31, 2016 Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Amedisys, Inc. and
subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our report dated March 1, 2017, on the effectiveness of internal control over financial reporting as of December 31, 2016, contains an
explanatory paragraph that states Amedisys, Inc. acquired Associated Home Care on March 1, 2016 and the assets of Professional Profiles, Inc. on September 1, 2016, and management excluded from its assessment of the effectiveness of Amedisys,
Inc.&#146;s internal control over financial reporting as of December 31, 2016, Associated Home Care&#146;s and Professional Profiles, Inc.&#146;s internal control over financial reporting associated with approximately 1% of total assets and 2% of
revenue included in the consolidated financial statements of Amedisys, Inc. as of and for the year ended December 31, 2016. Our audit of internal control over financial reporting of Amedisys, Inc. also excluded an evaluation of the internal control
over financial reporting of Associated Home Care and Professional Profiles, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ KPMG LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Baton Rouge, Louisiana </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;1, 2017 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>d332070dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Paul B. Kusserow,
certify that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1. I have reviewed this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2016, of Amedisys, Inc.; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4. The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules
<FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is
made known to us by others within those entities, particularly during the period in which this report is being prepared; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">b. Designed such
internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">c. Evaluated the effectiveness of
the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">d. Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the
registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
financial reporting; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5. The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March&nbsp;1, 2017 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/S/&nbsp;Paul B. Kusserow</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Paul B. Kusserow</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>President and Chief Executive Officer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>(Principal Executive Officer)</B></P></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>d332070dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Gary D. Willis, certify
that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1. I have reviewed this Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31,
2016, of Amedisys, Inc.; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4. The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act Rules
<FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is
made known to us by others within those entities, particularly during the period in which this report is being prepared; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">b. Designed such
internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">c. Evaluated the effectiveness of
the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">d. Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the
registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over
financial reporting; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5. The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March&nbsp;1, 2017 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/S/&nbsp;Gary D. Willis</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gary D. Willis</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Chief Financial
Officer</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>(Principal Financial Officer)</B></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>d332070dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Annual Report of Amedisys, Inc. (the &#147;Company&#148;) on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2016 (the &#147;Report&#148;), I, Paul B. Kusserow, President and Chief Executive Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the
Sarbanes-Oxley Act of 2002, that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(1) The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities
Exchange Act of 1934; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) The information contained in the Report fairly presents, in all material respects, the financial condition
and results of operations of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March&nbsp;1, 2017 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/S/&nbsp;Paul B. Kusserow</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Paul B. Kusserow</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>President and Chief
Executive Officer</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>(Principal Executive Officer)</B></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>d332070dex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Annual Report of Amedisys, Inc. (the &#147;Company&#148;) on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2016 (the &#147;Report&#148;), I, Gary D. Willis, Chief Financial Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of
2002, that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(1) The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March&nbsp;1, 2017 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/S/&nbsp;Gary D. Willis</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gary D. Willis</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Chief Financial
Officer</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>(Principal Financial Officer)</B></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>10
<FILENAME>amed-20161231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Prepared by IBM Cognos FSR v6.7.4.14 using Fujitsu Interstage XWand -->
<xbrli:xbrl xmlns:amed="http://www.amedisys.com/20161231" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-roles="http://fasb.org/us-roles/2015-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:negated="http://www.xbrl.org/2009/role/negated">
  <link:schemaRef xlink:type="simple" xlink:href="amed-20161231.xsd" />
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Feb24_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Jun30_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2013_us-gaap_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2013_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2013_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2013_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2013_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2013_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2014_us-gaap_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2014_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2014">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2014_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2014_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_StatementEquityComponentsAxis_CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Sep30_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_amed_CapYearAxis_CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_amed_CapYearAxis_CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_AcquiredNamesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BuildingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndFurnitureMember_us-gaap_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:EquipmentAndFurnitureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndFurnitureMember_us-gaap_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:EquipmentAndFurnitureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_VehiclesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ComputerSoftwareMember_us-gaap_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:ComputerSoftwareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ComputerSoftwareMember_us-gaap_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:ComputerSoftwareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Mar31_2015_amed_AssetImpairmentAxis_Ams3HomecareAndHospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:AssetImpairmentAxis">amed:Ams3HomecareAndHospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Oct01_2015_TO_Dec31_2015_amed_AssetImpairmentAxis_CorporateHeadquartersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:AssetImpairmentAxis">amed:CorporateHeadquartersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-10-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Oct01_2016_TO_Dec31_2016_amed_AssetImpairmentAxis_HomecareHomebaseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:AssetImpairmentAxis">amed:HomecareHomebaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-10-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LongtermDebtTypeAxis_DeferredDebtIssuanceCostsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:DeferredDebtIssuanceCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_LongtermDebtTypeAxis_DeferredDebtIssuanceCostsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:DeferredDebtIssuanceCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_LongtermDebtTypeAxis_DeferredDebtIssuanceCostsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:DeferredDebtIssuanceCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Jul24_2015_amed_StateAxis_TennesseeMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:TennesseeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-07-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_amed_StateAxis_FloridaMember_us-gaap_BusinessAcquisitionAxis_InfinityHomeCareMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:FloridaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Jul24_2015_amed_StateAxis_TennesseeMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:TennesseeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-07-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_amed_StateAxis_FloridaMember_us-gaap_BusinessAcquisitionAxis_InfinityHomeCareMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:FloridaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Oct03_2015_amed_StateAxis_GeorgiaMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:GeorgiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-10-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Mar01_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_AssociatedHomecareMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssociatedHomecareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Mar01_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_AssociatedHomecareMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssociatedHomecareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Mar31_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_AssociatedHomecareMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssociatedHomecareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Mar31_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_AssociatedHomecareMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssociatedHomecareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Jun30_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_AssociatedHomecareMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_AcquiredNameOfBusinessMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssociatedHomecareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNameOfBusinessMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Jun30_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_AssociatedHomecareMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssociatedHomecareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Jun30_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_AssociatedHomecareMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssociatedHomecareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Sep01_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_ProfessionalProfilesMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ProfessionalProfilesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-09-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jul01_2016_TO_Sep30_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_ProfessionalProfilesMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ProfessionalProfilesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>
      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Sep30_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_ProfessionalProfilesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ProfessionalProfilesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Apr01_2016_TO_Jun30_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_AssociatedHomecareMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssociatedHomecareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Sep01_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_ProfessionalProfilesMember_us-gaap_LongtermDebtTypeAxis_PromissoryNotesMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ProfessionalProfilesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-09-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Oct20_2016_amed_StateAxis_NewYorkMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:NewYorkMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-10-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Oct01_2016_TO_Dec31_2016_amed_StateAxis_NewYorkMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:NewYorkMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-10-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_amed_StateAxis_NewYorkMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CertificatesOfNeedAndLicensesMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:NewYorkMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_AssociatedHomecareMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssociatedHomecareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_ProfessionalProfilesMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ProfessionalProfilesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_amed_StateAxis_NewYorkMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:NewYorkMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2013_TO_Dec31_2013_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_DiscontinuedOperationsHeldforsaleMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongLivedAssetsHeldForSaleByAssetTypeAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_DiscontinuedOperationsHeldforsaleMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongLivedAssetsHeldForSaleByAssetTypeAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_amed_GoodwillAndIntangibleAssetsImpairmentAxis_CareCentersClosedOrConsolidatedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:GoodwillAndIntangibleAssetsImpairmentAxis">amed:CareCentersClosedOrConsolidatedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_amed_GoodwillAndIntangibleAssetsImpairmentAxis_AnnualImpairmentTestStepOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:GoodwillAndIntangibleAssetsImpairmentAxis">amed:AnnualImpairmentTestStepOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2013_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2013_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2013_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_amed_StateAxis_FloridaMember_us-gaap_BusinessAcquisitionAxis_InfinityHomeCareMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:FloridaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2014_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2013_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CertificatesOfNeedAndLicensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2013_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_AcquiredNamesOfBusinessMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesOfBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2013_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CertificatesOfNeedAndLicensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_AcquiredNamesOfBusinessMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesOfBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2014_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CertificatesOfNeedAndLicensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2014_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_AcquiredNamesOfBusinessMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesOfBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CertificatesOfNeedAndLicensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_AcquiredNamesOfBusinessMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesOfBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CertificatesOfNeedAndLicensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_AcquiredNamesOfBusinessMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesOfBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CertificatesOfNeedAndLicensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_AcquiredNamesOfBusinessMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesOfBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CertificatesOfNeedAndLicensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_AcquiredNamesOfBusinessMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesOfBusinessMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:OneHundredMillionTermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:OneHundredMillionTermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:TwoHundredMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:TwoHundredMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Aug28_2015_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:TwoHundredMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-08-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LongtermDebtTypeAxis_CreditAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:CreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:OneHundredMillionTermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Aug28_2015_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:OneHundredMillionTermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-08-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:TwoHundredMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Aug28_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-08-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_amed_TimePeriodAxis_OneMonthMember_us-gaap_LongtermDebtTypeAxis_CreditAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:TimePeriodAxis">amed:OneMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:CreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_amed_TimePeriodAxis_TwoMonthMember_us-gaap_LongtermDebtTypeAxis_CreditAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:TimePeriodAxis">amed:TwoMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:CreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_amed_TimePeriodAxis_ThreeMonthMember_us-gaap_LongtermDebtTypeAxis_CreditAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:TimePeriodAxis">amed:ThreeMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:CreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_amed_TimePeriodAxis_SixMonthMember_us-gaap_LongtermDebtTypeAxis_CreditAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:TimePeriodAxis">amed:SixMonthMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:CreditAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_amed_TimePeriodAxis_FourRemainingQuarterlyPaymentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:TimePeriodAxis">amed:FourRemainingQuarterlyPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_amed_TimePeriodAxis_SecondEightQuarterlyPaymentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:TimePeriodAxis">amed:SecondEightQuarterlyPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_amed_TimePeriodAxis_FinalTwoQuarterlyPaymentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:TimePeriodAxis">amed:FinalTwoQuarterlyPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_amed_TimePeriodAxis_FourRemainingQuarterlyPaymentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:TimePeriodAxis">amed:FourRemainingQuarterlyPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_amed_TimePeriodAxis_SecondEightQuarterlyPaymentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:TimePeriodAxis">amed:SecondEightQuarterlyPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_amed_TimePeriodAxis_FinalTwoQuarterlyPaymentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:TimePeriodAxis">amed:FinalTwoQuarterlyPaymentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Aug28_2015_us-gaap_LongtermDebtTypeAxis_SwingLineLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SwingLineLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-08-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Aug28_2015_us-gaap_LongtermDebtTypeAxis_LetterOfCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-08-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Aug28_2015_us-gaap_LongtermDebtTypeAxis_TermLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:TermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-08-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Aug28_2015_us-gaap_LongtermDebtTypeAxis_SecondLienCreditAgreementTermLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondLienCreditAgreementTermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-08-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jul01_2015_TO_Sep30_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Aug28_2015_us-gaap_LongtermDebtTypeAxis_SecondLienCreditAgreementTermLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondLienCreditAgreementTermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-08-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_LongtermDebtTypeAxis_PromissoryNotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_LongtermDebtTypeAxis_PromissoryNotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Aug31_2015_TO_Dec31_2015_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:OneHundredMillionTermLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-08-31</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LineOfCreditFacilityAxis_AbrLoansMember_us-gaap_RangeAxis_RangeFourMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">amed:AbrLoansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">amed:RangeFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LineOfCreditFacilityAxis_AbrLoansMember_us-gaap_RangeAxis_RangeOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">amed:AbrLoansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">amed:RangeOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LineOfCreditFacilityAxis_AbrLoansMember_us-gaap_RangeAxis_RangeTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">amed:AbrLoansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">amed:RangeTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LineOfCreditFacilityAxis_AbrLoansMember_us-gaap_RangeAxis_RangeThreeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">amed:AbrLoansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">amed:RangeThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LineOfCreditFacilityAxis_EurodollarLoansMember_us-gaap_RangeAxis_RangeOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">amed:EurodollarLoansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">amed:RangeOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LineOfCreditFacilityAxis_EurodollarLoansMember_us-gaap_RangeAxis_RangeTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">amed:EurodollarLoansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">amed:RangeTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LineOfCreditFacilityAxis_EurodollarLoansMember_us-gaap_RangeAxis_RangeThreeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">amed:EurodollarLoansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">amed:RangeThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LineOfCreditFacilityAxis_EurodollarLoansMember_us-gaap_RangeAxis_RangeFourMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">amed:EurodollarLoansMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">amed:RangeFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RangeAxis_RangeTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">amed:RangeTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RangeAxis_RangeOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">amed:RangeOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RangeAxis_RangeThreeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">amed:RangeThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RangeAxis_RangeFourMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">amed:RangeFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_IncomeTaxAuthorityAxis_DomesticCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_amed_UnrecognizedTaxBenefitsAxis_NetOperatingLossMember_us-gaap_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:UnrecognizedTaxBenefitsAxis">amed:NetOperatingLossMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_TaxCreditCarryforwardAxis_StateTaxCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">amed:StateTaxCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_TaxCreditCarryforwardAxis_AlternativeMinimumTaxCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">amed:AlternativeMinimumTaxCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_TaxCreditCarryforwardAxis_EmploymentTaxCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">amed:EmploymentTaxCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_TaxCreditCarryforwardAxis_ResearchAndDevelopmentTaxCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">amed:ResearchAndDevelopmentTaxCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_amed_UnrecognizedTaxBenefitsAxis_NetOperatingLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:UnrecognizedTaxBenefitsAxis">amed:NetOperatingLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_amed_UnrecognizedTaxBenefitsAxis_NetOperatingLossMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:UnrecognizedTaxBenefitsAxis">amed:NetOperatingLossMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_amed_UnrecognizedTaxBenefitsAxis_TaxCreditCarryforwardMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:UnrecognizedTaxBenefitsAxis">amed:TaxCreditCarryforwardMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_amed_UnrecognizedTaxBenefitsAxis_TaxCreditCarryforwardMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:UnrecognizedTaxBenefitsAxis">amed:TaxCreditCarryforwardMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_BalanceSheetLocationAxis_OtherLongTermObligationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amed:OtherLongTermObligationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_BalanceSheetLocationAxis_DeferredIncomeTaxesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amed:DeferredIncomeTaxesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2017_TO_Dec31_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_ShareBasedAwardsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ShareBasedAwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_ShareBasedAwardsToMoreThanTenPercentOwnerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ShareBasedAwardsToMoreThanTenPercentOwnerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Jun07_2012_us-gaap_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-06-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_PriorToTwoThousandFourteenMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">amed:PriorToTwoThousandFourteenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_January12015ToMarch312015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">amed:January12015ToMarch312015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_April12015ToJune302015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">amed:April12015ToJune302015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_July12015ToSeptember302015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">amed:July12015ToSeptember302015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_October12015ToDecember312015Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">amed:October12015ToDecember312015Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_January12016ToMarch312016Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">amed:January12016ToMarch312016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_April12016ToJune302016Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">amed:April12016ToJune302016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_July12016ToSeptember302016Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">amed:July12016ToSeptember302016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_October12016ToDecember312016Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">amed:October12016ToDecember312016Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_AwardTypeAxis_StockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember_us-gaap_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember_us-gaap_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_AwardTypeAxis_StockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_AwardTypeAxis_StockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_AwardTypeAxis_NonVestedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2013_TO_Dec31_2013_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndMarketBasedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndMarketBasedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndMarketBasedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndMarketBasedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndMarketBasedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndMarketBasedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Mar03_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndMarketBasedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2012_TO_Jul25_2012_amed_StateAxis_ConnecticutMember_us-gaap_LitigationStatusAxis_PendingLitigationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:ConnecticutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-07-25</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2012_TO_Sep13_2012_amed_StateAxis_IllinoisMember_us-gaap_LitigationStatusAxis_PendingLitigationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:IllinoisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan02_2008_TO_Nov10_2009_amed_StateAxis_OhioMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:OhioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2008-01-02</xbrli:startDate>
      <xbrli:endDate>2009-11-10</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2011_TO_Mar09_2011_amed_StateAxis_OhioMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_ExtrapolatedMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:OhioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:ExtrapolatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-03-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Mar09_2011_amed_StateAxis_OhioMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_ExtrapolatedMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:OhioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:ExtrapolatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2011_TO_Jun06_2011_amed_StateAxis_SouthCarolinaMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_ExtrapolatedMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:SouthCarolinaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:ExtrapolatedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-06-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2008_TO_Mar31_2010_amed_StateAxis_SouthCarolinaMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:SouthCarolinaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2008-01-01</xbrli:startDate>
      <xbrli:endDate>2010-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Jan31_2014_amed_StateAxis_OhioMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_FavorableInFullMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:OhioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:FavorableInFullMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Jan31_2014_amed_StateAxis_OhioMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_FavorableInPartMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:OhioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:FavorableInPartMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Jan31_2014_amed_StateAxis_OhioMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:OhioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Mar01_2015_TO_Mar02_2015_us-gaap_LitigationStatusAxis_ComputerInventoryAndDataSecurityReportingMember_us-gaap_RangeAxis_MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:ComputerInventoryAndDataSecurityReportingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>
      <xbrli:endDate>2015-03-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Mar01_2015_TO_Mar02_2015_us-gaap_LitigationStatusAxis_ComputerInventoryAndDataSecurityReportingMember_us-gaap_RangeAxis_MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:ComputerInventoryAndDataSecurityReportingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>
      <xbrli:endDate>2015-03-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Mar01_2015_TO_Mar02_2015_us-gaap_LitigationStatusAxis_ComputerInventoryAndDataSecurityReportingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:ComputerInventoryAndDataSecurityReportingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-01</xbrli:startDate>
      <xbrli:endDate>2015-03-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Apr01_2014_TO_Apr30_2014_us-gaap_LitigationStatusAxis_FrontierLitigationMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:FrontierLitigationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Apr01_2014_TO_Apr30_2014_us-gaap_LitigationStatusAxis_FrontierLitigationMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:FrontierLitigationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-04-01</xbrli:startDate>
      <xbrli:endDate>2014-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_May21_2015_amed_StateAxis_MassachusettsMember_us-gaap_LitigationStatusAxis_UsDepartmentOfJusticeMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MassachusettsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-05-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Nov03_2015_amed_StateAxis_MorgantownWestVirginiaMember_us-gaap_LitigationStatusAxis_UsDepartmentOfJusticeMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:MorgantownWestVirginiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-11-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_LitigationStatusAxis_PendingLitigationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_May05_2016_us-gaap_LitigationStatusAxis_OigSelfDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:OigSelfDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-05-05</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Jan18_2016_amed_StateAxis_SouthCarolinaMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:SouthCarolinaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-01-18</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Jan18_2016_amed_StateAxis_SouthCarolinaMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:SouthCarolinaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-01-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Sep30_2015_us-gaap_LitigationStatusAxis_PendingLitigationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Jun10_2015_us-gaap_LitigationStatusAxis_PendingLitigationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-10</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Mar31_2016_amed_StateAxis_ConnecticutMember_us-gaap_LitigationStatusAxis_PendingLitigationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:ConnecticutMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Jul13_2016_amed_StateAxis_OhioMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:OhioMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-07-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Jul13_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-07-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Jun30_2016_amed_StateAxis_SouthCarolinaMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:SouthCarolinaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_LitigationStatusAxis_OigSelfDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:OigSelfDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Apr01_2016_TO_Jun30_2016_us-gaap_LitigationStatusAxis_OigSelfDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:OigSelfDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Jun27_2016_amed_StateAxis_ParkersburgWestVirginiaMember_us-gaap_LitigationStatusAxis_UsDepartmentOfJusticeMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:ParkersburgWestVirginiaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Sep30_2016_amed_StateAxis_IllinoisMember_us-gaap_LitigationStatusAxis_PendingLitigationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:IllinoisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Aug04_2016_amed_StateAxis_IllinoisMember_us-gaap_LitigationStatusAxis_PendingLitigationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:IllinoisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-08-04</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LitigationStatusAxis_FrontierLitigationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:FrontierLitigationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Nov21_2016_amed_StateAxis_IllinoisMember_us-gaap_LitigationStatusAxis_PendingLitigationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:StateAxis">amed:IllinoisMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-11-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LitigationStatusAxis_OigSelfDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:OigSelfDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Sep09_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_amed_TypeOfBusinessSoldAxis_AvailableForSaleMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:TypeOfBusinessSoldAxis">amed:AvailableForSaleMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_amed_TypeOfBusinessSoldAxis_WyomingAndIdahoCareCentersMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:TypeOfBusinessSoldAxis">amed:WyomingAndIdahoCareCentersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_amed_TypeOfBusinessSoldAxis_WyomingAndIdahoCareCentersMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:TypeOfBusinessSoldAxis">amed:WyomingAndIdahoCareCentersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_amed_TypeOfBusinessSoldAxis_WyomingAndIdahoCareCentersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:TypeOfBusinessSoldAxis">amed:WyomingAndIdahoCareCentersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_amed_TypeOfBusinessSoldAxis_HospiceInpatientUnitMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:TypeOfBusinessSoldAxis">amed:HospiceInpatientUnitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_IntangiblesWriteOffMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:OtherRestructuringCostsAxis">amed:TwoThousandAndFourteenExitActivityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">amed:IntangiblesWriteOffMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_LeaseTerminationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:OtherRestructuringCostsAxis">amed:TwoThousandAndFourteenExitActivityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">amed:LeaseTerminationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_RestructuringCostAndReserveAxis_SeveranceForFormerExecutiveMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">amed:SeveranceForFormerExecutiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_RestructuringCostAndReserveAxis_SeveranceForRegionalLeadershipAndCorporateSupportMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">amed:SeveranceForRegionalLeadershipAndCorporateSupportMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_EmployeeSeveranceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:OtherRestructuringCostsAxis">amed:TwoThousandAndFourteenExitActivityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2014_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_LeaseTerminationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:OtherRestructuringCostsAxis">amed:TwoThousandAndFourteenExitActivityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">amed:LeaseTerminationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2013_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_LeaseTerminationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:OtherRestructuringCostsAxis">amed:TwoThousandAndFourteenExitActivityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">amed:LeaseTerminationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2013_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_EmployeeSeveranceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:OtherRestructuringCostsAxis">amed:TwoThousandAndFourteenExitActivityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_LeaseTerminationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:OtherRestructuringCostsAxis">amed:TwoThousandAndFourteenExitActivityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">amed:LeaseTerminationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_EmployeeSeveranceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:OtherRestructuringCostsAxis">amed:TwoThousandAndFourteenExitActivityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_LeaseTerminationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:OtherRestructuringCostsAxis">amed:TwoThousandAndFourteenExitActivityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">amed:LeaseTerminationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_EmployeeSeveranceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:OtherRestructuringCostsAxis">amed:TwoThousandAndFourteenExitActivityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_LeaseTerminationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:OtherRestructuringCostsAxis">amed:TwoThousandAndFourteenExitActivityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">amed:LeaseTerminationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_EmployeeSeveranceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:OtherRestructuringCostsAxis">amed:TwoThousandAndFourteenExitActivityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_LeaseTerminationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:OtherRestructuringCostsAxis">amed:TwoThousandAndFourteenExitActivityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">amed:LeaseTerminationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_EmployeeSeveranceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:OtherRestructuringCostsAxis">amed:TwoThousandAndFourteenExitActivityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2014_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_EmployeeSeveranceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:OtherRestructuringCostsAxis">amed:TwoThousandAndFourteenExitActivityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_ValuationAllowancesAndReservesTypeAxis_AllowanceForDoubtfulAccountsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForDoubtfulAccountsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_ValuationAllowancesAndReservesTypeAxis_AllowanceForDoubtfulAccountsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForDoubtfulAccountsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_ValuationAllowancesAndReservesTypeAxis_EstimatedRevenueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amed:EstimatedRevenueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_us-gaap_ValuationAllowancesAndReservesTypeAxis_EstimatedRevenueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amed:EstimatedRevenueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_ValuationAllowancesAndReservesTypeAxis_AllowanceForDoubtfulAccountsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForDoubtfulAccountsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_ValuationAllowancesAndReservesTypeAxis_AllowanceForDoubtfulAccountsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForDoubtfulAccountsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_us-gaap_ValuationAllowancesAndReservesTypeAxis_EstimatedRevenueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amed:EstimatedRevenueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_ValuationAllowancesAndReservesTypeAxis_EstimatedRevenueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amed:EstimatedRevenueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2014_us-gaap_ValuationAllowancesAndReservesTypeAxis_EstimatedRevenueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amed:EstimatedRevenueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_ValuationAllowancesAndReservesTypeAxis_AllowanceForDoubtfulAccountsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForDoubtfulAccountsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2013_us-gaap_ValuationAllowancesAndReservesTypeAxis_AllowanceForDoubtfulAccountsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForDoubtfulAccountsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2014_us-gaap_ValuationAllowancesAndReservesTypeAxis_AllowanceForDoubtfulAccountsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForDoubtfulAccountsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_ValuationAllowancesAndReservesTypeAxis_EstimatedRevenueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amed:EstimatedRevenueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2013_us-gaap_ValuationAllowancesAndReservesTypeAxis_EstimatedRevenueAdjustmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amed:EstimatedRevenueAdjustmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_ValuationAllowancesAndReservesTypeAxis_EstimatedRevenueAdjustmentsDiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">amed:EstimatedRevenueAdjustmentsDiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_ValuationAllowancesAndReservesTypeAxis_AllowanceForDoubtfulAccountsDiscontinuedOperationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForDoubtfulAccountsDiscontinuedOperationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Apr01_2016_TO_Jun30_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jul01_2016_TO_Sep30_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>
      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Apr01_2015_TO_Jun30_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Oct01_2015_TO_Dec31_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-10-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Oct01_2016_TO_Dec31_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-10-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Mar31_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Mar31_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Mar31_2016_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:QuarterlyFinancialInformationAxis">amed:NetOfTaxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Apr01_2016_TO_Jun30_2016_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:QuarterlyFinancialInformationAxis">amed:NetOfTaxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jul01_2016_TO_Sep30_2016_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:QuarterlyFinancialInformationAxis">amed:NetOfTaxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>
      <xbrli:endDate>2016-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Oct01_2016_TO_Dec31_2016_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:QuarterlyFinancialInformationAxis">amed:NetOfTaxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-10-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jul01_2015_TO_Sep30_2015_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:QuarterlyFinancialInformationAxis">amed:NetOfTaxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Oct01_2015_TO_Dec31_2015_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:QuarterlyFinancialInformationAxis">amed:NetOfTaxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-10-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Mar31_2015_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:QuarterlyFinancialInformationAxis">amed:NetOfTaxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Apr01_2015_TO_Jun30_2015_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:QuarterlyFinancialInformationAxis">amed:NetOfTaxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Oct01_2015_TO_Dec31_2015_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember_us-gaap_LitigationStatusAxis_OigSelfDisclosureMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:QuarterlyFinancialInformationAxis">amed:NetOfTaxMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">amed:OigSelfDisclosureMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-10-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Mar31_2016_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:QuarterlyFinancialInformationAxis">amed:NetOfTaxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Jun30_2016_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:QuarterlyFinancialInformationAxis">amed:NetOfTaxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Sep30_2016_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:QuarterlyFinancialInformationAxis">amed:NetOfTaxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2016_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:QuarterlyFinancialInformationAxis">amed:NetOfTaxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="AS_OF_Dec31_2015_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="amed:QuarterlyFinancialInformationAxis">amed:NetOfTaxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RelatedPartyTransactionAxis_CareInnovationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amed:CareInnovationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2015_TO_Oct22_2015_us-gaap_RelatedPartyTransactionAxis_CareInnovationsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amed:CareInnovationsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-10-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RelatedPartyTransactionAxis_KKRConsultingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amed:KKRConsultingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="FROM_Jan01_2017_TO_Feb01_2017_us-gaap_BusinessAcquisitionAxis_HomeStaffLlcMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:HomeStaffLlcMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-02-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="Shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USDollar">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USDperShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="Pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Agencies">
    <xbrli:measure>amed:Agencies</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="States">
    <xbrli:measure>amed:States</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Day">
    <xbrli:measure>amed:D</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Number_of_Visits">
    <xbrli:measure>amed:Number_of_Visits</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Year">
    <xbrli:measure>amed:Y</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Installment">
    <xbrli:measure>amed:Installment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Employee">
    <xbrli:measure>amed:Employee</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Claims">
    <xbrli:measure>amed:Claims</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Beneficiary">
    <xbrli:measure>amed:Beneficiary</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Computers">
    <xbrli:measure>amed:Computers</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Residents">
    <xbrli:measure>amed:Residents</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Segments">
    <xbrli:measure>amed:Segments</xbrli:measure>
  </xbrli:unit>
  <dei:DocumentType id="ID_0" contextRef="FROM_Jan01_2016_TO_Dec31_2016">10-K</dei:DocumentType>
  <dei:DocumentPeriodEndDate id="ID_1" contextRef="FROM_Jan01_2016_TO_Dec31_2016">2016-12-31</dei:DocumentPeriodEndDate>
  <dei:AmendmentFlag id="ID_2" contextRef="FROM_Jan01_2016_TO_Dec31_2016">false</dei:AmendmentFlag>
  <dei:DocumentFiscalPeriodFocus id="ID_3" contextRef="FROM_Jan01_2016_TO_Dec31_2016">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus id="ID_4" contextRef="FROM_Jan01_2016_TO_Dec31_2016">2016</dei:DocumentFiscalYearFocus>
  <dei:TradingSymbol id="ID_5" contextRef="FROM_Jan01_2016_TO_Dec31_2016">AMED</dei:TradingSymbol>
  <dei:CurrentFiscalYearEndDate id="ID_6" contextRef="FROM_Jan01_2016_TO_Dec31_2016">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityCentralIndexKey id="ID_7" contextRef="FROM_Jan01_2016_TO_Dec31_2016">0000896262</dei:EntityCentralIndexKey>
  <dei:EntityFilerCategory id="ID_8" contextRef="FROM_Jan01_2016_TO_Dec31_2016">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName id="ID_9" contextRef="FROM_Jan01_2016_TO_Dec31_2016">AMEDISYS INC</dei:EntityRegistrantName>
  <dei:EntityCommonStockSharesOutstanding id="ID_10" decimals="0" contextRef="AS_OF_Feb24_2017" unitRef="Shares">33607420</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus id="ID_11" contextRef="FROM_Jan01_2016_TO_Dec31_2016">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityVoluntaryFilers id="ID_12" contextRef="FROM_Jan01_2016_TO_Dec31_2016">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer id="ID_13" contextRef="FROM_Jan01_2016_TO_Dec31_2016">Yes</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityPublicFloat id="ID_14" decimals="0" contextRef="AS_OF_Jun30_2016" unitRef="USDollar">1010513839</dei:EntityPublicFloat>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="ID_15" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">30197000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent id="ID_16" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">166056000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:PrepaidExpenseCurrent id="ID_17" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">7397000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:OtherAssetsCurrent id="ID_18" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">11260000</us-gaap:OtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="ID_19" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">214910000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="ID_20" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">36999000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Goodwill id="ID_21" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">288957000</us-gaap:Goodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="ID_22" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">46755000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:DeferredTaxAssetsNetNoncurrent id="ID_23" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">107940000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="ID_24" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">38468000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets id="ID_25" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">734029000</us-gaap:Assets>
  <us-gaap:PropertyPlantAndEquipmentNet id="ID_26" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">42695000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="ID_27" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">44047000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:OtherAssetsNoncurrent id="ID_28" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">32802000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:AccountsReceivableNetCurrent id="ID_29" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">125010000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:DeferredTaxAssetsNetNoncurrent id="ID_30" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">125245000</us-gaap:DeferredTaxAssetsNetNoncurrent>
  <us-gaap:Goodwill id="ID_31" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">261663000</us-gaap:Goodwill>
  <us-gaap:AssetsCurrent id="ID_32" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">175263000</us-gaap:AssetsCurrent>
  <us-gaap:Assets id="ID_33" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">681715000</us-gaap:Assets>
  <us-gaap:PrepaidExpenseCurrent id="ID_34" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">8110000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:OtherAssetsCurrent id="ID_35" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">14641000</us-gaap:OtherAssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="ID_36" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">27502000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsPayableCurrent id="ID_37" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">25682000</us-gaap:AccountsPayableCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="ID_38" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">72546000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="ID_39" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">71965000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent id="ID_40" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">5000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
  <us-gaap:LiabilitiesCurrent id="ID_41" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">175193000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermDebtAndCapitalLeaseObligations id="ID_42" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">91630000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
  <us-gaap:OtherLiabilitiesNoncurrent id="ID_43" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">4456000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:Liabilities id="ID_44" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">271279000</us-gaap:Liabilities>
  <us-gaap:OtherLiabilitiesNoncurrent id="ID_45" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">3730000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:LongTermDebtAndCapitalLeaseObligations id="ID_46" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">87809000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
  <us-gaap:LiabilitiesCurrent id="ID_47" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">181348000</us-gaap:LiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="ID_48" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">82480000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AccountsPayableCurrent id="ID_49" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">30358000</us-gaap:AccountsPayableCurrent>
  <us-gaap:Liabilities id="ID_50" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">272887000</us-gaap:Liabilities>
  <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent id="ID_51" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">5220000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="ID_52" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">63290000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:PreferredStockValueOutstanding id="ID_53" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">0</us-gaap:PreferredStockValueOutstanding>
  <us-gaap:CommonStockValueOutstanding id="ID_54" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">35000</us-gaap:CommonStockValueOutstanding>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="ID_55" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">537472000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:TreasuryStockValue id="ID_56" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">46774000</us-gaap:TreasuryStockValue>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="ID_57" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">15000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="ID_58" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">-30545000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="ID_59" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">460203000</us-gaap:StockholdersEquity>
  <us-gaap:MinorityInterest id="ID_60" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">939000</us-gaap:MinorityInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_61" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">461142000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:LiabilitiesAndStockholdersEquity id="ID_62" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">734029000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="ID_63" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">504290000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:MinorityInterest id="ID_64" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">868000</us-gaap:MinorityInterest>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="ID_65" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">-67806000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="ID_66" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">409568000</us-gaap:StockholdersEquity>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="ID_67" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">15000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:LiabilitiesAndStockholdersEquity id="ID_68" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">681715000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CommonStockValueOutstanding id="ID_69" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">35000</us-gaap:CommonStockValueOutstanding>
  <us-gaap:TreasuryStockValue id="ID_70" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">26966000</us-gaap:TreasuryStockValue>
  <us-gaap:PreferredStockValueOutstanding id="ID_71" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">0</us-gaap:PreferredStockValueOutstanding>
  <us-gaap:CommitmentsAndContingencies id="ID_72" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">0</us-gaap:CommitmentsAndContingencies>
  <us-gaap:CommitmentsAndContingencies id="ID_73" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">0</us-gaap:CommitmentsAndContingencies>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent id="ID_74" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">17716000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent id="ID_75" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">16526000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="ID_76" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">138650000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="ID_77" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">141793000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization id="ID_78" decimals="-3" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">27864000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization id="ID_79" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">25386000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="ID_80" decimals="3" contextRef="AS_OF_Dec31_2016" unitRef="USDperShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="ID_81" decimals="3" contextRef="AS_OF_Dec31_2015" unitRef="USDperShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="ID_82" decimals="0" contextRef="AS_OF_Dec31_2016" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="ID_83" decimals="0" contextRef="AS_OF_Dec31_2015" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="ID_84" decimals="0" contextRef="AS_OF_Dec31_2016" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="ID_85" decimals="0" contextRef="AS_OF_Dec31_2016" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="ID_86" decimals="3" contextRef="AS_OF_Dec31_2016" unitRef="USDperShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="ID_87" decimals="0" contextRef="AS_OF_Dec31_2016" unitRef="Shares">60000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="ID_88" decimals="0" contextRef="AS_OF_Dec31_2016" unitRef="Shares">35253577</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="ID_89" decimals="0" contextRef="AS_OF_Dec31_2016" unitRef="Shares">33597215</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:TreasuryStockShares id="ID_90" decimals="0" contextRef="AS_OF_Dec31_2016" unitRef="Shares">1656362</us-gaap:TreasuryStockShares>
  <us-gaap:CommonStockParOrStatedValuePerShare id="ID_91" decimals="3" contextRef="AS_OF_Dec31_2015" unitRef="USDperShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued id="ID_92" decimals="0" contextRef="AS_OF_Dec31_2015" unitRef="Shares">34786966</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="ID_93" decimals="0" contextRef="AS_OF_Dec31_2015" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesIssued id="ID_94" decimals="0" contextRef="AS_OF_Dec31_2015" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="ID_95" decimals="0" contextRef="AS_OF_Dec31_2015" unitRef="Shares">33607282</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesAuthorized id="ID_96" decimals="0" contextRef="AS_OF_Dec31_2015" unitRef="Shares">60000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:TreasuryStockShares id="ID_97" decimals="0" contextRef="AS_OF_Dec31_2015" unitRef="Shares">1179684</us-gaap:TreasuryStockShares>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_98" decimals="-3" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">410436000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_99" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">1437454000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_100" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">1280541000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_101" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">1204554000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:CostOfServices id="ID_102" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">833055000</us-gaap:CostOfServices>
  <us-gaap:CostOfServices id="ID_103" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">725915000</us-gaap:CostOfServices>
  <us-gaap:CostOfServices id="ID_104" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">691061000</us-gaap:CostOfServices>
  <us-gaap:LaborAndRelatedExpense id="ID_105" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">306981000</us-gaap:LaborAndRelatedExpense>
  <us-gaap:LaborAndRelatedExpense id="ID_106" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">279425000</us-gaap:LaborAndRelatedExpense>
  <us-gaap:LaborAndRelatedExpense id="ID_107" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">292497000</us-gaap:LaborAndRelatedExpense>
  <us-gaap:ShareBasedCompensation id="ID_108" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">16401000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="ID_109" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">11824000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="ID_110" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">5597000</us-gaap:ShareBasedCompensation>
  <us-gaap:OtherGeneralAndAdministrativeExpense id="ID_111" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">180048000</us-gaap:OtherGeneralAndAdministrativeExpense>
  <us-gaap:OtherGeneralAndAdministrativeExpense id="ID_112" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">161186000</us-gaap:OtherGeneralAndAdministrativeExpense>
  <us-gaap:OtherGeneralAndAdministrativeExpense id="ID_113" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">143644000</us-gaap:OtherGeneralAndAdministrativeExpense>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_114" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">19519000</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_115" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">14053000</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_116" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">16294000</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_117" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">19678000</amed:DepreciationAndAmortizationForContinuingOperations>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_118" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">20036000</amed:DepreciationAndAmortizationForContinuingOperations>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_119" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">28307000</amed:DepreciationAndAmortizationForContinuingOperations>
  <us-gaap:CostsAndExpenses id="ID_120" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">1380114000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses id="ID_121" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">1180507000</us-gaap:CostsAndExpenses>
  <us-gaap:OperatingIncomeLoss id="ID_122" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">57340000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="ID_123" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">24047000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InvestmentIncomeInterestAndDividend id="ID_124" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">75000</us-gaap:InvestmentIncomeInterestAndDividend>
  <us-gaap:InvestmentIncomeInterestAndDividend id="ID_125" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">71000</us-gaap:InvestmentIncomeInterestAndDividend>
  <us-gaap:InvestmentIncomeInterestAndDividend id="ID_126" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">94000</us-gaap:InvestmentIncomeInterestAndDividend>
  <us-gaap:InterestExpense id="ID_127" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">5164000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="ID_128" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">10783000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="ID_129" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">8217000</us-gaap:InterestExpense>
  <us-gaap:IncomeLossFromEquityMethodInvestments id="ID_130" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">5588000</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromEquityMethodInvestments id="ID_131" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">9823000</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromEquityMethodInvestments id="ID_132" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">2991000</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:OtherNonoperatingIncomeExpense id="ID_133" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">3727000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="ID_134" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">9747000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="ID_135" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">2061000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="ID_136" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">4226000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="ID_137" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">8858000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="ID_138" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">-3071000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="ID_139" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">61566000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="ID_140" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-308000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="ID_141" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">20976000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxExpenseBenefit id="ID_142" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">23935000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit id="ID_143" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">2004000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit id="ID_144" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">7671000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest id="ID_145" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">37631000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest id="ID_146" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-2312000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest id="ID_147" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">13305000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="ID_148" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="ID_149" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax id="ID_150" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">-216000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
  <us-gaap:ProfitLoss id="ID_151" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">37631000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="ID_152" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-2312000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="ID_153" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">13089000</us-gaap:ProfitLoss>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest id="ID_154" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">370000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest id="ID_155" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">709000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest id="ID_156" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">313000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
  <us-gaap:NetIncomeLoss id="ID_157" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">37261000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="ID_158" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-3021000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="ID_159" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">12776000</us-gaap:NetIncomeLoss>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare id="ID_160" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDperShare">1.12</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare id="ID_161" decimals="2" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDperShare">-0.09</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare id="ID_162" decimals="2" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDperShare">0.40</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="ID_163" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Shares">33198000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="ID_164" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="Shares">33018000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="ID_165" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="Shares">32301000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:EarningsPerShareBasic id="ID_166" decimals="2" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDperShare">-0.09</us-gaap:EarningsPerShareBasic>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare id="ID_167" decimals="2" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDperShare">0.00</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare id="ID_168" decimals="2" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDperShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare id="ID_169" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDperShare">0.00</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
  <us-gaap:EarningsPerShareBasic id="ID_170" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDperShare">1.12</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic id="ID_171" decimals="2" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDperShare">0.39</us-gaap:EarningsPerShareBasic>
  <us-gaap:IncomeLossFromContinuingOperations id="ID_172" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">37261000</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:IncomeLossFromContinuingOperations id="ID_173" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-3021000</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:IncomeLossFromContinuingOperations id="ID_174" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">12992000</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity id="ID_175" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity id="ID_176" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity id="ID_177" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">-216000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
  <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare id="ID_178" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDperShare">1.10</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare id="ID_179" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDperShare">0.00</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
  <us-gaap:EarningsPerShareDiluted id="ID_180" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDperShare">1.10</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="ID_181" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Shares">33741000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare id="ID_182" decimals="2" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDperShare">-0.09</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare id="ID_183" decimals="2" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDperShare">0.00</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="ID_184" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="Shares">33018000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:EarningsPerShareDiluted id="ID_185" decimals="2" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDperShare">-0.09</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted id="ID_186" decimals="2" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDperShare">0.39</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="ID_187" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="Shares">32823000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare id="ID_188" decimals="2" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDperShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
  <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare id="ID_189" decimals="2" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDperShare">0.40</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
  <us-gaap:AssetImpairmentCharges id="ID_190" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">4432000</us-gaap:AssetImpairmentCharges>
  <us-gaap:AssetImpairmentCharges id="ID_191" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">77268000</us-gaap:AssetImpairmentCharges>
  <us-gaap:AssetImpairmentCharges id="ID_192" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">3107000</us-gaap:AssetImpairmentCharges>
  <us-gaap:OperatingIncomeLoss id="ID_193" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-9166000</us-gaap:OperatingIncomeLoss>
  <us-gaap:CostsAndExpenses id="ID_194" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">1289707000</us-gaap:CostsAndExpenses>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax id="ID_195" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest id="ID_196" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">13089000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:ComprehensiveIncomeNetOfTax id="ID_197" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">12776000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax id="ID_198" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="ID_199" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">37261000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest id="ID_200" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">37631000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax id="ID_201" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest id="ID_202" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-2312000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:ComprehensiveIncomeNetOfTax id="ID_203" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-3021000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_204" decimals="-3" contextRef="AS_OF_Dec31_2013" unitRef="USDollar">372479000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_205" decimals="-3" contextRef="AS_OF_Dec31_2013_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">33000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_206" decimals="-3" contextRef="AS_OF_Dec31_2013_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">467890000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_207" decimals="-3" contextRef="AS_OF_Dec31_2013_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">-18176000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_208" decimals="-3" contextRef="AS_OF_Dec31_2013_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_209" decimals="-3" contextRef="AS_OF_Dec31_2013_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">-77561000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_210" decimals="-3" contextRef="AS_OF_Dec31_2013_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">278000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:SharesOutstanding id="ID_211" decimals="0" contextRef="AS_OF_Dec31_2013_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">33413970</us-gaap:SharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="ID_212" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">2433000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="ID_213" decimals="0" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">176796</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="ID_214" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="ID_215" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">2433000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="ID_216" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="ID_217" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="ID_218" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="ID_219" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch id="ID_220" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">7062000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
  <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch id="ID_221" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">1000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
  <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch id="ID_222" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">7061000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
  <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch id="ID_223" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
  <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch id="ID_224" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
  <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch id="ID_225" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
  <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch id="ID_226" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
  <amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch id="ID_227" decimals="0" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">430919</amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="ID_228" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">564000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="ID_229" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="ID_230" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">564000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="ID_231" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="ID_232" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="ID_233" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="ID_234" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="ID_235" decimals="0" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">28229</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="ID_236" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="ID_237" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="ID_238" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="ID_239" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="ID_240" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="ID_241" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="ID_242" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures id="ID_243" decimals="0" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">519612</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_244" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">5597000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_245" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_246" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">5597000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_247" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_248" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_249" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_250" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation id="ID_251" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">579000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation id="ID_252" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation id="ID_253" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">579000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation id="ID_254" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation id="ID_255" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation id="ID_256" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation id="ID_257" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation>
  <us-gaap:ProfitLoss id="ID_258" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="ID_259" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">0</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="ID_260" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="ID_261" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="ID_262" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">12776000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="ID_263" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">313000</us-gaap:ProfitLoss>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="ID_264" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">2204000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="ID_265" decimals="0" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">79323</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="ID_266" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="ID_267" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">2204000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="ID_268" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="ID_269" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="ID_270" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="ID_271" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch id="ID_272" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">6032000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
  <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch id="ID_273" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
  <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch id="ID_274" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">6032000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
  <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch id="ID_275" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
  <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch id="ID_276" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
  <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch id="ID_277" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
  <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch id="ID_278" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
  <amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch id="ID_279" decimals="0" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">184412</amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch>
  <amed:SurrenderedShares id="ID_280" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">1684000</amed:SurrenderedShares>
  <amed:SurrenderedShares id="ID_281" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</amed:SurrenderedShares>
  <amed:SurrenderedShares id="ID_282" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">0</amed:SurrenderedShares>
  <amed:SurrenderedShares id="ID_283" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">1684000</amed:SurrenderedShares>
  <amed:SurrenderedShares id="ID_284" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</amed:SurrenderedShares>
  <amed:SurrenderedShares id="ID_285" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</amed:SurrenderedShares>
  <amed:SurrenderedShares id="ID_286" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</amed:SurrenderedShares>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="ID_287" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">399000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="ID_288" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="ID_289" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">399000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="ID_290" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="ID_291" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="ID_292" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="ID_293" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="ID_294" decimals="0" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">15380</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures id="ID_295" decimals="0" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">-61675</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="ID_296" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="ID_297" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="ID_298" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="ID_299" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="ID_300" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="ID_301" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="ID_302" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_303" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">11824000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_304" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_305" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">11824000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_306" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_307" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_308" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_309" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation id="ID_310" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">4000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation id="ID_311" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation id="ID_312" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">4000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation id="ID_313" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation id="ID_314" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation id="ID_315" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation id="ID_316" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation>
  <amed:SurrenderedShares id="ID_317" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">2525000</amed:SurrenderedShares>
  <amed:SurrenderedShares id="ID_318" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</amed:SurrenderedShares>
  <amed:SurrenderedShares id="ID_319" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">0</amed:SurrenderedShares>
  <amed:SurrenderedShares id="ID_320" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">2525000</amed:SurrenderedShares>
  <amed:SurrenderedShares id="ID_321" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</amed:SurrenderedShares>
  <amed:SurrenderedShares id="ID_322" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</amed:SurrenderedShares>
  <amed:SurrenderedShares id="ID_323" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</amed:SurrenderedShares>
  <us-gaap:ProfitLoss id="ID_324" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="ID_325" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">0</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="ID_326" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="ID_327" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="ID_328" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">-3021000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="ID_329" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">709000</us-gaap:ProfitLoss>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="ID_330" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">2483000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="ID_331" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="ID_332" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">2483000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="ID_333" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="ID_334" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="ID_335" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="ID_336" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="ID_337" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">63688</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch id="ID_338" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">6682000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
  <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch id="ID_339" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
  <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch id="ID_340" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">6682000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
  <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch id="ID_341" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
  <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch id="ID_342" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
  <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch id="ID_343" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
  <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch id="ID_344" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
  <amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch id="ID_345" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">145660</amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="ID_346" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="ID_347" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="ID_348" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="ID_349" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="ID_350" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="ID_351" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures id="ID_352" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures id="ID_353" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">257263</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_354" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">16401000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_355" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_356" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">16401000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_357" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_358" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_359" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="ID_360" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation id="ID_361" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">7241000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation id="ID_362" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation id="ID_363" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">7241000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation id="ID_364" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation id="ID_365" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation id="ID_366" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation id="ID_367" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <amed:SurrenderedShares id="ID_368" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">7493000</amed:SurrenderedShares>
  <amed:SurrenderedShares id="ID_369" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</amed:SurrenderedShares>
  <amed:SurrenderedShares id="ID_370" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">0</amed:SurrenderedShares>
  <amed:SurrenderedShares id="ID_371" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">7493000</amed:SurrenderedShares>
  <amed:SurrenderedShares id="ID_372" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</amed:SurrenderedShares>
  <amed:SurrenderedShares id="ID_373" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</amed:SurrenderedShares>
  <amed:SurrenderedShares id="ID_374" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</amed:SurrenderedShares>
  <us-gaap:TreasuryStockValueAcquiredCostMethod id="ID_375" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">12315000</us-gaap:TreasuryStockValueAcquiredCostMethod>
  <us-gaap:TreasuryStockValueAcquiredCostMethod id="ID_376" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
  <us-gaap:TreasuryStockValueAcquiredCostMethod id="ID_377" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
  <us-gaap:TreasuryStockValueAcquiredCostMethod id="ID_378" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">12315000</us-gaap:TreasuryStockValueAcquiredCostMethod>
  <us-gaap:TreasuryStockValueAcquiredCostMethod id="ID_379" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
  <us-gaap:TreasuryStockValueAcquiredCostMethod id="ID_380" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
  <us-gaap:TreasuryStockValueAcquiredCostMethod id="ID_381" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
  <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders id="ID_382" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">329000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
  <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders id="ID_383" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
  <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders id="ID_384" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
  <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders id="ID_385" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
  <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders id="ID_386" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
  <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders id="ID_387" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
  <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders id="ID_388" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">329000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
  <us-gaap:ProfitLoss id="ID_389" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="ID_390" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">0</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="ID_391" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="ID_392" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="ID_393" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">37261000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="ID_394" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">370000</us-gaap:ProfitLoss>
  <us-gaap:SharesOutstanding id="ID_395" decimals="0" contextRef="AS_OF_Dec31_2014_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">34569526</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_396" decimals="-3" contextRef="AS_OF_Dec31_2014_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_397" decimals="-3" contextRef="AS_OF_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">481762000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_398" decimals="-3" contextRef="AS_OF_Dec31_2014_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">-19860000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_399" decimals="-3" contextRef="AS_OF_Dec31_2014" unitRef="USDollar">397762000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_400" decimals="-3" contextRef="AS_OF_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_401" decimals="-3" contextRef="AS_OF_Dec31_2014_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">-64785000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_402" decimals="-3" contextRef="AS_OF_Dec31_2014_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">595000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_403" decimals="-3" contextRef="AS_OF_Dec31_2015_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:SharesOutstanding id="ID_404" decimals="0" contextRef="AS_OF_Dec31_2015_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">34786966</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_405" decimals="-3" contextRef="AS_OF_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">504290000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_406" decimals="-3" contextRef="AS_OF_Dec31_2015_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">-26966000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_407" decimals="-3" contextRef="AS_OF_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_408" decimals="-3" contextRef="AS_OF_Dec31_2015_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">-67806000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_409" decimals="-3" contextRef="AS_OF_Dec31_2015_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">868000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:SharesOutstanding id="ID_410" decimals="0" contextRef="AS_OF_Dec31_2016_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="Shares">35253577</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_411" decimals="-3" contextRef="AS_OF_Dec31_2016_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_412" decimals="-3" contextRef="AS_OF_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">537472000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_413" decimals="-3" contextRef="AS_OF_Dec31_2016_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">-46774000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_414" decimals="-3" contextRef="AS_OF_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_415" decimals="-3" contextRef="AS_OF_Dec31_2016_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">-30545000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest id="ID_416" decimals="-3" contextRef="AS_OF_Dec31_2016_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">939000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation id="ID_417" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">2073000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation id="ID_418" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">2073000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation id="ID_419" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation id="ID_420" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation id="ID_421" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation id="ID_422" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation id="ID_423" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
  <us-gaap:TreasuryStockValueAcquiredCostMethod id="ID_424" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">4581000</us-gaap:TreasuryStockValueAcquiredCostMethod>
  <us-gaap:TreasuryStockValueAcquiredCostMethod id="ID_425" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
  <us-gaap:TreasuryStockValueAcquiredCostMethod id="ID_426" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
  <us-gaap:TreasuryStockValueAcquiredCostMethod id="ID_427" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">4581000</us-gaap:TreasuryStockValueAcquiredCostMethod>
  <us-gaap:TreasuryStockValueAcquiredCostMethod id="ID_428" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
  <us-gaap:TreasuryStockValueAcquiredCostMethod id="ID_429" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
  <us-gaap:TreasuryStockValueAcquiredCostMethod id="ID_430" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
  <amed:IncreaseDecreaseInAssetsOfEquityMethodInvestment id="ID_431" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</amed:IncreaseDecreaseInAssetsOfEquityMethodInvestment>
  <amed:IncreaseDecreaseInAssetsOfEquityMethodInvestment id="ID_432" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">375000</amed:IncreaseDecreaseInAssetsOfEquityMethodInvestment>
  <amed:IncreaseDecreaseInAssetsOfEquityMethodInvestment id="ID_433" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</amed:IncreaseDecreaseInAssetsOfEquityMethodInvestment>
  <amed:IncreaseDecreaseInAssetsOfEquityMethodInvestment id="ID_434" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</amed:IncreaseDecreaseInAssetsOfEquityMethodInvestment>
  <amed:IncreaseDecreaseInAssetsOfEquityMethodInvestment id="ID_435" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</amed:IncreaseDecreaseInAssetsOfEquityMethodInvestment>
  <amed:IncreaseDecreaseInAssetsOfEquityMethodInvestment id="ID_436" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">30000</amed:IncreaseDecreaseInAssetsOfEquityMethodInvestment>
  <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation id="ID_437" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">1549000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
  <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation id="ID_438" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
  <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation id="ID_439" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">493000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
  <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation id="ID_440" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
  <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation id="ID_441" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
  <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation id="ID_442" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
  <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation id="ID_443" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">1056000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
  <us-gaap:MinorityInterestPeriodIncreaseDecrease id="ID_444" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">350000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
  <us-gaap:MinorityInterestPeriodIncreaseDecrease id="ID_445" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
  <us-gaap:MinorityInterestPeriodIncreaseDecrease id="ID_446" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">-710000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
  <us-gaap:MinorityInterestPeriodIncreaseDecrease id="ID_447" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
  <us-gaap:MinorityInterestPeriodIncreaseDecrease id="ID_448" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
  <us-gaap:MinorityInterestPeriodIncreaseDecrease id="ID_449" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
  <us-gaap:MinorityInterestPeriodIncreaseDecrease id="ID_450" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">1060000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
  <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders id="ID_451" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">436000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
  <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders id="ID_452" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_CommonStockMember" unitRef="USDollar">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
  <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders id="ID_453" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USDollar">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
  <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders id="ID_454" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USDollar">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
  <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders id="ID_455" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USDollar">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
  <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders id="ID_456" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USDollar">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
  <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders id="ID_457" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USDollar">436000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
  <us-gaap:DepreciationDepletionAndAmortization id="ID_458" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">19678000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="ID_459" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">20036000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="ID_460" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">28347000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:ProceedsFromDivestitureOfBusinesses id="ID_461" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
  <us-gaap:ProceedsFromDivestitureOfBusinesses id="ID_462" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">4233000</us-gaap:ProceedsFromDivestitureOfBusinesses>
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired id="ID_463" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">35522000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired id="ID_464" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired id="ID_465" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">69130000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <us-gaap:ProceedsFromDivestitureOfBusinesses id="ID_466" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">413000</us-gaap:ProceedsFromDivestitureOfBusinesses>
  <us-gaap:ProvisionForDoubtfulAccounts id="ID_467" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">19519000</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:ProvisionForDoubtfulAccounts id="ID_468" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">14053000</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:ProvisionForDoubtfulAccounts id="ID_469" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">16369000</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:PensionExpense id="ID_470" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">6875000</us-gaap:PensionExpense>
  <us-gaap:PensionExpense id="ID_471" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">6089000</us-gaap:PensionExpense>
  <us-gaap:PensionExpense id="ID_472" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">6216000</us-gaap:PensionExpense>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="ID_473" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">-582000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="ID_474" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-775000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="ID_475" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">-4592000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="ID_476" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">740000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="ID_477" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">959000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="ID_478" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">797000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:EquityMethodInvestmentDividendsOrDistributions id="ID_479" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">4323000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
  <us-gaap:EquityMethodInvestmentDividendsOrDistributions id="ID_480" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">5610000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
  <us-gaap:EquityMethodInvestmentDividendsOrDistributions id="ID_481" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">2025000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="ID_482" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">55519000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="ID_483" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">36493000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="ID_484" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">5290000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="ID_485" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">-4231000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="ID_486" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-6455000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="ID_487" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">-1694000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="ID_488" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">6269000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="ID_489" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">3970000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="ID_490" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">7639000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="ID_491" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">-3168000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="ID_492" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">-7618000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="ID_493" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">8406000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="ID_494" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">3495000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities id="ID_495" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">-726000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities id="ID_496" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-829000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities id="ID_497" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">-3226000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="ID_498" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">62259000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="ID_499" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">107785000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="ID_500" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">-65534000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:ProceedsFromSaleOfRestrictedInvestments id="ID_501" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">230000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
  <us-gaap:ProceedsFromSaleOfRestrictedInvestments id="ID_502" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">1229000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
  <us-gaap:ProceedsFromSaleOfRestrictedInvestments id="ID_503" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">11000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="ID_504" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="ID_505" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">20000000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="ID_506" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">3000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquireRestrictedInvestments id="ID_507" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</us-gaap:PaymentsToAcquireRestrictedInvestments>
  <us-gaap:PaymentsToAcquireRestrictedInvestments id="ID_508" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">19000</us-gaap:PaymentsToAcquireRestrictedInvestments>
  <us-gaap:PaymentsToAcquireRestrictedInvestments id="ID_509" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">132000</us-gaap:PaymentsToAcquireRestrictedInvestments>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="ID_510" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">15717000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="ID_511" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">21429000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="ID_512" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">12008000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsForProceedsFromInvestments id="ID_513" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">1040000</us-gaap:PaymentsForProceedsFromInvestments>
  <us-gaap:PaymentsForProceedsFromInvestments id="ID_514" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">3485000</us-gaap:PaymentsForProceedsFromInvestments>
  <us-gaap:PaymentsForProceedsFromInvestments id="ID_515" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">6407000</us-gaap:PaymentsForProceedsFromInvestments>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="ID_516" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">-52049000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="ID_517" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-67421000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="ID_518" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">-14300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromStockOptionsExercised id="ID_519" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="ID_520" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">399000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="ID_521" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">564000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockPlans id="ID_522" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">2483000</us-gaap:ProceedsFromStockPlans>
  <us-gaap:ProceedsFromStockPlans id="ID_523" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">2204000</us-gaap:ProceedsFromStockPlans>
  <us-gaap:ProceedsFromStockPlans id="ID_524" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">2433000</us-gaap:ProceedsFromStockPlans>
  <amed:CashDistributionToNoncontrollingInterest id="ID_525" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">329000</amed:CashDistributionToNoncontrollingInterest>
  <amed:CashDistributionToNoncontrollingInterest id="ID_526" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">436000</amed:CashDistributionToNoncontrollingInterest>
  <amed:CashDistributionToNoncontrollingInterest id="ID_527" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">0</amed:CashDistributionToNoncontrollingInterest>
  <us-gaap:ProceedsFromShortTermDebt id="ID_528" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">134500000</us-gaap:ProceedsFromShortTermDebt>
  <us-gaap:ProceedsFromShortTermDebt id="ID_529" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">63400000</us-gaap:ProceedsFromShortTermDebt>
  <us-gaap:ProceedsFromShortTermDebt id="ID_530" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">241800000</us-gaap:ProceedsFromShortTermDebt>
  <us-gaap:RepaymentsOfShortTermDebt id="ID_531" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">134500000</us-gaap:RepaymentsOfShortTermDebt>
  <us-gaap:RepaymentsOfShortTermDebt id="ID_532" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">78400000</us-gaap:RepaymentsOfShortTermDebt>
  <us-gaap:RepaymentsOfShortTermDebt id="ID_533" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">226800000</us-gaap:RepaymentsOfShortTermDebt>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="ID_534" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-20894000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="ID_535" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">70563000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="ID_536" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">2695000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="ID_537" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">19470000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="ID_538" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">-9271000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="ID_539" decimals="-3" contextRef="AS_OF_Dec31_2013" unitRef="USDollar">17303000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt id="ID_540" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt id="ID_541" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">68250000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:PaymentsOfFinancingCosts id="ID_542" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</us-gaap:PaymentsOfFinancingCosts>
  <us-gaap:PaymentsOfFinancingCosts id="ID_543" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">1780000</us-gaap:PaymentsOfFinancingCosts>
  <us-gaap:InterestPaid id="ID_544" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">2897000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid id="ID_545" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">7602000</us-gaap:InterestPaid>
  <us-gaap:IncomeTaxesPaidNet id="ID_546" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">755000</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:IncomeTaxesPaidNet id="ID_547" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">-1766000</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt id="ID_548" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">100000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:IncomeTaxesPaidNet id="ID_549" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-12185000</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:PaymentsOfFinancingCosts id="ID_550" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">2553000</us-gaap:PaymentsOfFinancingCosts>
  <us-gaap:InterestPaid id="ID_551" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">6175000</us-gaap:InterestPaid>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="ID_552" decimals="-3" contextRef="AS_OF_Dec31_2014" unitRef="USDollar">8032000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:GainsLossesOnSalesOfAssets id="ID_553" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</us-gaap:GainsLossesOnSalesOfAssets>
  <us-gaap:GainsLossesOnSalesOfAssets id="ID_554" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">184000</us-gaap:GainsLossesOnSalesOfAssets>
  <us-gaap:GainsLossesOnSalesOfAssets id="ID_555" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">2967000</us-gaap:GainsLossesOnSalesOfAssets>
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="ID_556" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">24547000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="ID_557" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-677000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="ID_558" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">22561000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities id="ID_559" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">7241000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities id="ID_560" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">2073000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities id="ID_561" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">0</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <us-gaap:RepaymentsOfLongTermDebt id="ID_562" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">13904000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:RepaymentsOfLongTermDebt id="ID_563" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">103000000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:RepaymentsOfLongTermDebt id="ID_564" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">5000000</us-gaap:RepaymentsOfLongTermDebt>
  <amed:DeferredDebtIssuanceCostsWrittenOff id="ID_565" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</amed:DeferredDebtIssuanceCostsWrittenOff>
  <amed:DeferredDebtIssuanceCostsWrittenOff id="ID_566" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">2512000</amed:DeferredDebtIssuanceCostsWrittenOff>
  <amed:DeferredDebtIssuanceCostsWrittenOff id="ID_567" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">488000</amed:DeferredDebtIssuanceCostsWrittenOff>
  <amed:IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual id="ID_568" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</amed:IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual>
  <amed:IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual id="ID_569" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">0</amed:IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="ID_570" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">11415000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets id="ID_571" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">3523000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <amed:NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests id="ID_572" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</amed:NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests>
  <amed:NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests id="ID_573" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">0</amed:NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests>
  <amed:NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests id="ID_574" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">-1549000</amed:NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests>
  <us-gaap:PaymentsForRepurchaseOfCommonStock id="ID_575" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">12315000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:PaymentsForRepurchaseOfCommonStock id="ID_576" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">4581000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:PaymentsForRepurchaseOfCommonStock id="ID_577" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:ProceedsFromSaleOfOtherInvestments id="ID_578" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</us-gaap:ProceedsFromSaleOfOtherInvestments>
  <us-gaap:ProceedsFromSaleOfOtherInvestments id="ID_579" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">5000000</us-gaap:ProceedsFromSaleOfOtherInvestments>
  <us-gaap:ProceedsFromSaleOfOtherInvestments id="ID_580" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">0</us-gaap:ProceedsFromSaleOfOtherInvestments>
  <amed:IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual id="ID_581" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">-150000000</amed:IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual>
  <amed:WriteOffOfInvestment id="ID_582" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">0</amed:WriteOffOfInvestment>
  <amed:WriteOffOfInvestment id="ID_583" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">0</amed:WriteOffOfInvestment>
  <amed:WriteOffOfInvestment id="ID_584" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">196000</amed:WriteOffOfInvestment>
  <amed:IncreaseDecreaseInAssetsOfEquityMethodInvestment id="ID_585" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">405000</amed:IncreaseDecreaseInAssetsOfEquityMethodInvestment>
  <amed:IncreaseDecreaseInAssetsOfEquityMethodInvestment id="ID_586" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">0</amed:IncreaseDecreaseInAssetsOfEquityMethodInvestment>
  <amed:IncreaseDecreaseInAssetsOfEquityMethodInvestment id="ID_587" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">0</amed:IncreaseDecreaseInAssetsOfEquityMethodInvestment>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="ID_588" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">-7515000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:UseOfEstimates id="ID_589" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Use of Estimates &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Our accounting and reporting policies conform with U.S.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;G&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;enerally Accepted Accounting Principles (&amp;#8220;U.S. G&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;AAP&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. In preparing the consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&amp;#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:EquityMethodInvestmentsPolicy id="ID_590" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Equity Investments &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%. Third party equity interests in our consolidated joint ventures are reflected as &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;noncontrolling&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; interests in our consolidated financial statements. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;During the three-month period ended September 30, 2016, we sold a 30% interest in one of our care centers while maintaining controlling interest in the newly formed joint venture.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. The book value of investments that we accounted for under the equity method of accounting w&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;as $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;27&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;December 31&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;25.7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;m&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;illion&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; as&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;We account for investments in entities in which we have less than a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;20&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% ownership interest under the cost method of accounting if we do not have the ability to exercise signific&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ant influence over the investee&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsPolicy>
  <us-gaap:ConsolidationPolicyTextBlock id="ID_591" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Principles of Consolidation &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;These consolidated financial statements include the accounts of Amedisys, Inc.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated financial statements, and business combinations accounted for as purchases have been included in our&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;accounted for as set forth below&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:ComparabilityOfPriorYearFinancialData id="ID_592" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Reclassifications and Comparability &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Certain &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;reclassifications have been made to prior periods' financial statements in order to conform to the current period'&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; presentation&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;In compliance with Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2015-03, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Interest &amp;#8211; Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of De&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;bt Issuance Costs, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;we have reclassified 2015 amounts related to unamortized debt issuance costs from other assets, net &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;long-term obligations, less current portion&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&amp;#160;&lt;/p&gt;</us-gaap:ComparabilityOfPriorYearFinancialData>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock id="ID_593" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:13pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;. NATURE OF OPERATIONS&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;CONSOLIDATION &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;AND PRESENTATION &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;OF FINANCIAL STATEMENTS &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Amedisys, Inc., a Delaware corporation, and its consolidated subsidiaries (&amp;#8220;Amedisys,&amp;#8221; &amp;#8220;we,&amp;#8221; &amp;#8220;us,&amp;#8221; or &amp;#8220;our&amp;#8221;) &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;are&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; a multi-state provider of home health&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, hospice and personal care&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; services with &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;approximately&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;78%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;80%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;82%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;of our revenue derived from Medicare for&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, respectively&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;December 31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;owned and operated&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;327&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; Medicare-ce&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;rtified home health care centers,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;79&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; Medicare-certified hospice &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;care centers&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and 14&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; personal-care care centers&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;in &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;34&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; states within the United States and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;the District of Columbia&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Use of Estimates &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Our accounting and reporting policies conform with U.S.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;G&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;enerally Accepted Accounting Principles (&amp;#8220;U.S. G&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;AAP&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. In preparing the consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Reclassifications and Comparability &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Certain &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;reclassifications have been made to prior periods' financial statements in order to conform to the current period'&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; presentation&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;In compliance with Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2015-03, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Interest &amp;#8211; Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of De&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;bt Issuance Costs, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;we have reclassified 2015 amounts related to unamortized debt issuance costs from other assets, net &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;long-term obligations, less current portion&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Principles of Consolidation &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;These consolidated financial statements include the accounts of Amedisys, Inc.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated financial statements, and business combinations accounted for as purchases have been included in our&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;accounted for as set forth below&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Equity Investments &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%. Third party equity interests in our consolidated joint ventures are reflected as &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;noncontrolling&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; interests in our consolidated financial statements. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;During the three-month period ended September 30, 2016, we sold a 30% interest in one of our care centers while maintaining controlling interest in the newly formed joint venture.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. The book value of investments that we accounted for under the equity method of accounting w&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;as $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;27&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;December 31&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;25.7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;m&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;illion&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; as&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;We account for investments in entities in which we have less than a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;20&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% ownership interest under the cost method of accounting if we do not have the ability to exercise signific&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ant influence over the investee&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;  &lt;/font&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <amed:MinimumPercentOwnershipForControllingInterestPercent id="ID_594" decimals="2" contextRef="AS_OF_Dec31_2016" unitRef="Pure">0.50</amed:MinimumPercentOwnershipForControllingInterestPercent>
  <amed:OperatingCareCenters id="ID_595" decimals="0" contextRef="AS_OF_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Agencies">327</amed:OperatingCareCenters>
  <amed:OperatingCareCenters id="ID_596" decimals="0" contextRef="AS_OF_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="Agencies">79</amed:OperatingCareCenters>
  <us-gaap:ConcentrationRiskPercentage1 id="ID_597" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Pure">0.78</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="ID_598" decimals="2" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="Pure">0.80</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="ID_599" decimals="2" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="Pure">0.82</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:NumberOfStatesInWhichEntityOperates id="ID_600" decimals="0" contextRef="AS_OF_Dec31_2016" unitRef="States">34</us-gaap:NumberOfStatesInWhichEntityOperates>
  <us-gaap:EquityMethodInvestmentAggregateCost id="ID_601" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">25700000</us-gaap:EquityMethodInvestmentAggregateCost>
  <amed:MaximumPercentOwnershipForCostMethodPercent id="ID_602" decimals="2" contextRef="AS_OF_Dec31_2016" unitRef="Pure">0.20</amed:MaximumPercentOwnershipForCostMethodPercent>
  <amed:MaximumPercentOwnershipForEquityMethodPercent id="ID_603" decimals="2" contextRef="AS_OF_Dec31_2016" unitRef="Pure">0.50</amed:MaximumPercentOwnershipForEquityMethodPercent>
  <us-gaap:EquityMethodInvestmentAggregateCost id="ID_604" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">27800000</us-gaap:EquityMethodInvestmentAggregateCost>
  <amed:OperatingCareCenters id="ID_605" decimals="0" contextRef="AS_OF_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="Agencies">14</amed:OperatingCareCenters>
  <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners id="ID_606" decimals="2" contextRef="AS_OF_Sep30_2016" unitRef="Pure">0.30</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
  <amed:EpisodeOfCareAsEpisodicBasedRevenue id="ID_607" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Day">60</amed:EpisodeOfCareAsEpisodicBasedRevenue>
  <amed:EpisodesInProgressThatBeginDuringReportingPeriod id="ID_608" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Day">60</amed:EpisodesInProgressThatBeginDuringReportingPeriod>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="ID_609" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:13pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;"&gt;2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Revenue Recognition&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We earn net service &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;revenue through our home health, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;hospice &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and personal-care &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;care center&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s by providing a variety of services almost exclusively in the homes of our patients. This net service revenue is earned and billed either on an episode of care basis, on a per visit basis or on a daily basis depending upon the payment terms and conditions established with each &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; for services provided. We refer to home health revenue earned and billed on a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;-day episode of care as episodic-based revenue. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;When we record our service revenue, we record it net of estimated revenue adjustments and contractual adjustments to reflect amounts we estimate to be realizable for services provided, as discussed below. We believe, based on information currently available to us and based on our judgment, that changes to one or more factors that impact the accounting estimates (such as our estimates related to revenue adjustments, contractual adjustments and episodes in progress) we make in determining net service revenue, which changes are likely to occur from period to period, will not materially impact our reported consolidated financial condition, results of operations, cash flows or our future financial results. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Home Health Revenue Recognition&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;"&gt;Medicare Revenue &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Net service revenue is recorded under the Medicare prospective payment system (&amp;#8220;PPS&amp;#8221;) based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a)&amp;#160;an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&amp;#160;a low utilization payment adjustment (&amp;#8220;LUPA&amp;#8221;) if the number of visits was fewer than five; (c)&amp;#160;a partial payment if our patient transferred to another provider or we received a patient from another provider before completing the episode; (d)&amp;#160;a payment adjustment based upon the level of therapy services required (with various incremental adjustments made for additional visits, with larger payment increases associated with the sixth, fourteenth and twentieth visit thresholds); (e) adjustments to payments if we are unable to perform periodic therapy assessments; (f)&amp;#160;the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (g)&amp;#160;changes in the base episode payments established by the Medicare Program; (h)&amp;#160;adjustments to the base episode payments for case mix and geographic wages; and (i&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&amp;#160;recoveries of overpayments. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;In addition, we make adjustments to Medicare revenue if we &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;find that we &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;are unable to produce &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;appropriate &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;documentation of a face to face encounter between the patient and physician.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;   &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We make adjustments to Medicare revenue &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;reflect&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; differences between estimated and actual payment amounts, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;our&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;discovered &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;inability to obtain appropriate billing documentation or authorizations and other reasons unrelated to credit risk. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;over &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;99&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; on&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; Medicare claims, and record this estimate during the period in which services are rendered as an estimated revenue adjustment and a corresponding reduction&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; to patient accounts receivable. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Therefore, we believe that our reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In addition to revenue recognized on completed episodes, we also recognize a portion of revenue associated with episodes in progress. Episodes in progress are &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;-day episodes of care that begin during the reporting period, but were not completed as of the end of the period. We estimate this revenue on a monthly basis based upon historical trends. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and our estimate of the average percentage complete based on &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;the number of days elapsed during an episodes of care. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;December 31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, the difference between the cash received from Medicare for a request for anticipated payment (&amp;#8220;RAP&amp;#8221;) on episodes in progress and the associated estimated revenue was immaterial and, therefore, the resulting credits were recorded as a reduction to our outstanding pa&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;tient accounts receivable in our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated balance sheets for such periods. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;"&gt;Non-Medicare Revenue &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Episodic-based Revenue. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Non-episodic &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;b&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;ased Revenue. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates, as applicable. Contractual adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue and are also recorded as a reduction to our outstanding patient accounts receivable. In addition, we receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Hospice Revenue Recognition &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;"&gt;Hospice Medicare Revenue &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates.  The estimated payment rates are daily or hourly rates for each of the four levels of care &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;we deliver.  The four levels of care&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;are routine care, general inpatient care, continuo&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;us home care and respite care. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Routine care accounts for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;99&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%, 9&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%, and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;of our total net Medic&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;are hospice service revenue for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; 2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and 2014, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;respectively&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Beginning January 1, 2016, CMS has provided for two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, beginning January 1, 2016, Medicare is also reimbursing for a service intensity add-on (&amp;#8220;SIA&amp;#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse (&amp;#8220;RN&amp;#8221;) or medical social worker (&amp;#8220;MSW&amp;#8221;) for patients in a routine level of care.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We make adjustments to Medicare revenue for an inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes our historical collection rate on Medicare claims, and record it during the period services are rendered as an estimated revenue adjustment and as a reduction to our outstanding patient accounts receivable&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap for each provider number, we monitor these caps and estimate amounts due back to Medicare if &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;we estimate &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;a cap has been exceeded.&amp;#160;We record these adjustments as a reduction to revenue and an increase &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;in other accrued liabilities. Beginning for the cap year ending October 31, 2014, providers are &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;required to self-report and pay their estimated cap liability by March 31&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;st&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of the following year.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;As of December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; have settled our Medicare hospice reimbursements for all fiscal years through October 31, 20&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;12 and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;we have recorded &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million for estimated amounts due back to Medicare in other accrued liabilities for the Federal &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;cap y&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ears ended October 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; through October 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. As of December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;had&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; recorded $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1.4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million for estimated amounts due back to Medicare in other accrued liabilities for the Federa&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;l &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;cap years ended October 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; through October 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;"&gt;Hospice Non-Medicare Revenue &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;day &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients, third parties and others for services provided and are deducted from gross revenue to determine our net service revenue and patient accounts receiv&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;able&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Personal Care Revenue Recognition &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;"&gt;Personal Care Non-Medicare Revenue &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We generate net service revenues by providing our services directly to patients primarily on a per hour, visit or unit basis. We receive payment for providing such services from our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; clients, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Net service revenues are principally provided based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; which are recognized as net service revenue at the time services are rendered&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Cash and Cash Equivalents &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Patient Accounts Receivable &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other t&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;hird-party &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payors&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and patients. As of December 31, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, there is one s&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ingle &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, other than Medicare, that accounts for more than &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% of our total outstanding patient receivables&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; (approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%). T&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;hus&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We fully reserve for accounts which are aged at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;36&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; days or greater. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We believe the credit risk associated with our Medicare accounts&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;which &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;represent &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% of our net patient accounts receivable at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;December 31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;December 31, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2015, respectively, is limited&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; due to our historical collection rate of over &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;99&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;from Medicare and the fact that Medicare is a U.S. government &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. Accordingly, we do not record an allowance for doubtful accounts for our Medicare patient accounts receivable, which are recorded at their net realizable value after recording estimated revenue &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;adjustments as discussed above. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;During &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;recorded $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million, $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million and $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million, respectively, in estimated revenue adjustments to Medicare revenue.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We believe there is a certain level of credit risk associated with non-Medicare &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payors&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. To provide for our non-Medicare patient accounts receivable that could become uncollectible in the future, we establish an allowance for doubtful accounts to reduce the carrying amount to its estimated net realizable value.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Medicare Home Health &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients.  Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% of our estimated payment for the initial episode at the start of care or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% of the estimated payment for any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed (&amp;#8220;final billed&amp;#8221;). The RAP received for that particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;120&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; days from the start of the episode, or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; days from the date the RAP was paid, any RAPs received for that episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be resubmitted. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Medicare Hospice &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services t&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;hat we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Once each patient has been confirmed for eligibility, we will bill Medicare on a monthly basis for the services provided to the patient. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Non-Medicare Home Health,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt; Hospice,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt; and Personal Care&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient's eligibility for services with the applicable &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. Once the patient has been confirmed for eligibility, we will provide services to the patient &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and bill the applicable &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.  &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payors&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; or groups of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payors&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; with similar characteristics that would subject us to any significant credit risk.  &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;We estimate an allowance for doubtful accounts&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; based upon our assessment of historical and expected net collections, business and economic conditions, trends in payment and an evaluation of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;collectability&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; based upon the date that the service was provided. Based upon our best judgment, we believe the allowance for doubtful accounts adequately provides for accounts that will not be collected due to credit risk&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Property and Equipment &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Property and equipment is stated at cost and we depreciate it on a straight-line basis over the estimated useful lives of the assets. Additionally, we have internally developed c&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;omputer software for our own use&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Additions and improvements (including interest costs for construction of qualifying long-lived assets) are capitalized. Maintenance and repair expenses are charged to expense as incurred. The cost of property and equipment sold or disposed of and the related accumulated depreciation are eliminated from the property and related accumulated depreciation accounts, and any gain or loss is credited or charged to other &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;general and administrative expenses&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.  &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:4.5pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We consider our reporting units to represent asset groups for purposes of testing long-lived assets for impairment.  We assess the impairment of a long-lived asset group whenever events or changes in circumstances indicate that the asset's carrying value may not be recoverable. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Factors we consider important that could trigger an impairment review include but are not limited to the following:&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:0pt'&gt;&lt;/p&gt;&lt;ul&gt;&lt;li style="margin-left:72px;list-style:disc;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;A significant change in the extent or manner in which the long-lived asset group is being used&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/li&gt;&lt;li style="margin-left:72px;list-style:disc;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;A significant change in the business climate that could affect the value of the long-lived asset group&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/li&gt;&lt;li style="margin-left:72px;list-style:disc;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;A significant change in the market value of the assets included in the asset group&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/li&gt;&lt;/ul&gt;&lt;p style='margin-top:4.5pt; margin-bottom:4.5pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;If we determine that the carrying value of long-lived assets may not be recoverable, we compare the carrying value of the asset group to the undiscounted cash flows expected to be generated by the asset group. If the carrying value exceeds the undiscounted cash flows, an impairment charge is indicated. An impairment charge is recognized to the extent that the carrying value of the asset group exceeds its fair value. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We generally provide for depreciation over the following estimated usef&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ul service lives&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 250px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:250px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Years&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Building&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 250px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:250px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;39&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Lesser of life or lease or expected useful life&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Equipment and furniture&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;3 to 7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Vehicles&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Computer software&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;3 to 5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;As of December 31, 2014, we had $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million of internally developed software costs related to the development of AMS3 Home Health&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Hospice&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; (&amp;#8220;AMS3&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. Expanded beta testing to additional sites in February of 2015 demonstrated that AMS3 was disruptive to operations. Additional analysis of the system determined that the system was not ready to be fully implemented and would require significant time and investment to redesign. Therefore, during the three-month period ended March 31, 2015, we made the decision to discontinue AMS3 and recorded a non-cash &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;asset impairment charge of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;75.2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; to write-off the software costs incurred related to the development of AMS3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.  &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;During 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;began &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;transition&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of all our care centers from our proprietary operating system &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Homecare &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Homebase&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; (&amp;#8220;HCHB&amp;#8221;), a leading home health and hospice platform, with all of our care centers operating on HCHB as of December 31,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; 2016. As part of our conversion process, we determined that a number of assets (primarily laptops) were not compatible with HCHB&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and had no other alternative or secondary use&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. As a result, we recorded a non-cash asset impairment charge of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4.4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million to write-off these assets during the three-month period ended December 31, 2016.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:4.5pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;During the three-month period ended September 30, 2015, we commenced an active program to sell our corporate headquarters located in Baton Rouge, Louisiana. In accordance with U.S. GAAP, we classified this asset as held for sale and reduced the carrying value of the asset to its estimated fair value less estimated costs to sell the asset; no further depreciation expense for the asset &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;was&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; recorded. As a result, we recorded a non-cash asset &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;impairment&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; charge of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million during the three-month period ended September 30, 2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;The asset was sold during the three-month period ended December 31, 2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and the Company now leases &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;equivalent&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; office space&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="7"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following table summarizes the balances related to our property and equipment for 2016 and 2015 (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4"  style="width: 160px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:160px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;As of December 31,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Building and leasehold improvements&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.3&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Equipment and furniture&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;71.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;89.6&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Computer software&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;96.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;92.6&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;175.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;184.5&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(138.6)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(141.8)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;37.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;42.7&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="7"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Depreciation expense for 2016, 2015 and 2014 was $17.2 million, $20.0 million and $28.0 million, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Goodwill and Other Intangible Assets&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Goodwill represents the amount of the purchase price in excess of the fair values assigned to the underlying identifiable net assets of acquired businesses. Goodwill is not amortized, but is subject to an annual impairment test. Tests are performed more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; These events or circumstances include but are not limited to, a significant adverse change in the business environment; regulatory environment or legal factors; or a substantial decline in market capitalization of our stock.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; To determine whether goodwill is impaired, we perform a two-step impairment test. In the first step of the test, the fair values of the reporting units are compared to their aggregate carrying values, including goodwill. If the fair value of the reporting unit is greater than its carrying amount, goodwill is not considered impaired and no further testing is required. If the fair value of the reporting unit is less than its carrying amount, we would proceed to step two of the test. In step two of the test, the implied fair value of the goodwill of the reporting unit is determined by a hypothetical allocation of the fair value calculated in step one to all of the assets and liabilities of that reporting unit (including any recognized and unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value was reflective of the price paid to acquire the reporting unit. The implied fair value of goodwill is the excess, if any, of the calculated fair value after hypothetical allocation to the reporting unit's assets and liabilities. If the implied fair value of the goodwill is greater than the carrying amount of the goodwill at the analysis date, goodwill is not impaired and the analysis is complete. If the implied fair value of the goodwill is less than the carrying value of goodwill at the analysis date, goodwill is deemed impaired by the amount of that variance.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We calculate the estimated fair value of our reporting units using discounted cash flows &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;as well as a market approach that compares our reporting units' earnings and revenue multiples to those of comparable public companies.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;To determine fair value we must make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; in particular expected organic growth rates, future Medicare reimbursement rates&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;capital requirements and income taxes), long-term growth rates for determining terminal value, and discount rates. Our estimates of discounted cash flows may differ from actual cash flows due to, among other things, economic conditions, changes to our business model or changes in operating performance. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;These factors increase the risk of differences between projected and actual performance that could impact future estimates of fair value of all reporting units. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Significant differences between these estimates and actual cash flows could &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;result in additional impairment in future periods.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Each of our operating segments described in &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Note 1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &amp;#8211; Segment Information &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;is considered to represent an individual reporting unit for goodwill impairment testing purposes. We consider each of our home health care centers to constitute an individual business for which discrete financial information is available. However, since these care centers have substantially similar operating and economic characteristics and resource allocation and significant investment decisions concerning these businesses are centralized and the benefits broadly distributed, we have aggregated these care centers and deemed them to constitute a single reporting unit. We have applied this same aggregation principle to our hospice care centers &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and personal-care care centers &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and have also deemed them to be a single reporting unit.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;During 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we did not record any goodwill impairment charges &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;as a result of our annual impairment test &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and none of the goodwill associated with our various reporting units w&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;as&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; considered at risk of impairment as of October 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. Since&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; the date of our last annual goodwill impairment test, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than its carrying amount.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Intangible assets consist of Certificates of&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; Need, licenses, acquired names and&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; non-&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;compete&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; agreements. We amortize non-compete agreements&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; acquired names that we do not intend to use in the future on a straight-line basis over their estimated useful lives, which is generally three years for non-compete agreements and up to five years for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;acquired names. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Debt Issuance Costs&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We amortize deferred debt issuance costs related to our long-term obligations over its term through interest expense, unless the debt is extinguished, in which case unamortized balances are immediately expensed. We &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;a&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;mortized $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, $0.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million and $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million in deferred debt issuance costs in &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, respectively. As of December 31, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;we had unamortized debt issuance costs of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million and $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; respectively&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; recorded as &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;long-term obligations, less current portion&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; in our accompanying consolidated balance sheets. The unamortized debt issuance costs of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million at December 31, 2016, will be amortize&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;d over a weighted-average amortization period of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;years.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 18px"&gt;&lt;td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 8px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="11"  style="width: 445px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:445px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Fair Value at Reporting Date Using&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 51px"&gt;&lt;td   style="width: 255px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:255px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Financial Instrument&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 95px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;As of
December 31,
2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 114px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:114px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Quoted Prices in Active Markets for Identical Items
(Level 1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 102px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:102px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Significant Other Observable Inputs (Level 2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 104px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:104px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Significant Unobservable Inputs (Level 3)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 255px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:255px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Long-term obligations&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;95.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 102px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:102px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;97.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 92px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:92px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;The &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;fair value hierarchy&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; is&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;/p&gt;&lt;ul&gt;&lt;li style="margin-left:36px;list-style:disc;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 1 &amp;#8211; Quoted prices in active markets for identical assets and liabilities.&lt;/font&gt;&lt;/li&gt;&lt;li style="margin-left:36px;list-style:disc;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 2 &amp;#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/font&gt;&lt;/li&gt;&lt;li style="margin-left:36px;list-style:disc;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 3 &amp;#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/li&gt;&lt;/ul&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, payroll and employee benefits &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and accrued expenses&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; we estimate the carrying amounts' approximate fair value. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Income Taxes&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We use the asset and liability approach for measuring deferred tax assets and liabilities based on temporary differences existing at each balance sheet date using currently enacted tax rates. Our deferred tax calculation requires us to make certain estimates about future operations. Deferred tax &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;assets are reduced by a valuation allowance when we believe it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect of a change in tax rate is recognized as income or expense in the period that includes the enactment date. As of December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;net &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;deferred tax asset&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; w&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ere&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;107.9&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;125&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million, respectively&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Management regularly assesses the ability to realize deferred tax assets recorded in the Company's entities based upon the weight of available evidence, including such factors as the recent earnings history and expected future taxable income&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;In the event future taxable income is below management's estimates or is generated in tax jurisdictions different than projected, we could be required to increase the valuation allowance for deferred tax assets. This would result in an increase in our effective tax rate.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Share-Based Compensation&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We record all share-based compensation as expense in the financial statements measured at the fair value of the award. We recognize compensation cost on a straight-line basis over the requisite service period for each separately vesting portion of the award. We reflect the excess tax benefits related to stock option exercises as financing cash flows. Share-based compensation expense for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;was $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million, $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;11&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million and $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million, respectively, and the total income tax benefit&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;recognized for these expenses was $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million, $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million and $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million, respectively.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Weighted-Average Shares Outstanding&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Net&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;income&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; (loss)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calc&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ulate our basic and diluted net &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;income (loss)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;attributable to Amedisys, Inc. common stockholders (amounts in thousands):&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 16px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5"  style="width: 234px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:234px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Years Ended December 31, &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Weighted average number of shares outstanding - basic&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;33,198&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;33,018&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;32,301&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; text-align:left;border-color:#000000;min-width:68px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; text-align:left;border-color:#000000;min-width:68px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; text-align:left;border-color:#000000;min-width:68px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Stock options&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;162&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Non-vested stock and stock units&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;381&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;521&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Weighted average number of shares outstanding - diluted&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;33,741&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;33,018&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;32,823&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Anti-dilutive securities&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;221&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;922&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;106&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Advertising Costs&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We expense advertising costs as incurred. Advertising expense for 2016, 2015 and 2014 was $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million, $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Recently Issued Accounting Pronouncements&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&amp;#160;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2014-09, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, which requires an entity to recognize the amount of revenue for which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP. In August 2015, the FASB issued ASU 2015-14,&lt;/font&gt;&lt;font style="font-family:Georgia;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date&lt;/font&gt;&lt;font style="font-family:Georgia;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; to defer the effective date of the standard from January 1, 2017, to January 1, 2018, with an option that permits companies to adopt the standard as early as the original effective date. The new ASU reflects the decisions reached by the FASB at its meeting in July 2015. Early application prior to the original effective date is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Co&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;mpany does not expect an impact on its consolidated financial statements upon &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;implementation&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of ASU 2014-09 and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ASU 2015-14 on January 1, 2018, but is still evaluating the effect the standard will have on its related disclosures.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In April 2015, the FASB issued ASU 2015-03, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Interest - Imputation of Interest&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;(Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&amp;#160;The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. ASU 2015-03 is effective for annual and interim periods beginning on or after December 15, 2015. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;We adopted this ASU during the three-month period ended March 31, 2016, and applied the change retrospectively for prior period balances of unamortized debt issuance costs, resulting &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;in a $3.4 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; reduction in other assets, net and long-term obligations, less current portion, on our consolidated balance sheet as of December 31, 2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;), &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;whic&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;h will require lessees to recognize a lease liability and right-of-use asset for all leases (with the exception of short-term leases) at the commencement date&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. The ASU is effective for annual and interim periods beginning on or after December 15, 2018. Early adoption is permitted. The standard requires a modified retrospective transition method which requires application of the new guid&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ance for all periods presented. While the Company expects adoption of this standard to lead to a material increase in the assets and liabilities recorded on our balance sheet, we are still &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;evaluating the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;overall impact on our&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; consolidated financial statements and related disclosures and the effect of the standard on &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;our&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; ongoing financial reporting&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In March 2016, the FASB issued ASU 2016-09, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Compensation &amp;#8211; Stock Compensation (Topic 718): Improvement to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, which will simplify the accounting for share-based payment award transactions, including income tax consequences, classification of awards as either equity or liability, and classification on the statement of cash flows. The ASU is effective for annual and interim periods beginning after December 15, 2016. Early adoption is permitted. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;The element of the new standard that will have the most impact on our consolidated financial statements will be income tax consequences. Excess tax benefits and tax deficiencies on share-based compensation awards will now be included in our tax provision within our consolidated statement of operations as discrete items in the reporting period in &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;which they occur, rather than our current accounting of recording in additional paid-in capital on our consolidated balance sheets&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In August 2016, the FASB issued ASU 2016-15, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, which provides specific guidance on eight cash flow classification issues not specifically addressed by U.S. GAAP. The ASU is effective for annual and interim periods beginning after December 15, 2017. Early adoption is permitted. The standard should be applied using a retrospective transition method unless it is impractical to do so for some of the issues. In such case, the amendments for those issues would be applied prospectively as of the earliest date practicable. The Company is evaluating the effect that ASU 2016-15 will have on its consolidated financial statements and related disclosures and the effect of the standard on its ongoing financial reporting&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:0pt'&gt;&amp;#160;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="ID_610" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Revenue Recognition&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We earn net service &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;revenue through our home health, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;hospice &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and personal-care &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;care center&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s by providing a variety of services almost exclusively in the homes of our patients. This net service revenue is earned and billed either on an episode of care basis, on a per visit basis or on a daily basis depending upon the payment terms and conditions established with each &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; for services provided. We refer to home health revenue earned and billed on a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;-day episode of care as episodic-based revenue. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;When we record our service revenue, we record it net of estimated revenue adjustments and contractual adjustments to reflect amounts we estimate to be realizable for services provided, as discussed below. We believe, based on information currently available to us and based on our judgment, that changes to one or more factors that impact the accounting estimates (such as our estimates related to revenue adjustments, contractual adjustments and episodes in progress) we make in determining net service revenue, which changes are likely to occur from period to period, will not materially impact our reported consolidated financial condition, results of operations, cash flows or our future financial results. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Home Health Revenue Recognition&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;"&gt;Medicare Revenue &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Net service revenue is recorded under the Medicare prospective payment system (&amp;#8220;PPS&amp;#8221;) based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a)&amp;#160;an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&amp;#160;a low utilization payment adjustment (&amp;#8220;LUPA&amp;#8221;) if the number of visits was fewer than five; (c)&amp;#160;a partial payment if our patient transferred to another provider or we received a patient from another provider before completing the episode; (d)&amp;#160;a payment adjustment based upon the level of therapy services required (with various incremental adjustments made for additional visits, with larger payment increases associated with the sixth, fourteenth and twentieth visit thresholds); (e) adjustments to payments if we are unable to perform periodic therapy assessments; (f)&amp;#160;the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (g)&amp;#160;changes in the base episode payments established by the Medicare Program; (h)&amp;#160;adjustments to the base episode payments for case mix and geographic wages; and (i&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&amp;#160;recoveries of overpayments. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;In addition, we make adjustments to Medicare revenue if we &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;find that we &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;are unable to produce &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;appropriate &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;documentation of a face to face encounter between the patient and physician.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;   &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We make adjustments to Medicare revenue &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;reflect&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; differences between estimated and actual payment amounts, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;our&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;discovered &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;inability to obtain appropriate billing documentation or authorizations and other reasons unrelated to credit risk. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;over &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;99&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; on&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; Medicare claims, and record this estimate during the period in which services are rendered as an estimated revenue adjustment and a corresponding reduction&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; to patient accounts receivable. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Therefore, we believe that our reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In addition to revenue recognized on completed episodes, we also recognize a portion of revenue associated with episodes in progress. Episodes in progress are &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;-day episodes of care that begin during the reporting period, but were not completed as of the end of the period. We estimate this revenue on a monthly basis based upon historical trends. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and our estimate of the average percentage complete based on &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;the number of days elapsed during an episodes of care. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;December 31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, the difference between the cash received from Medicare for a request for anticipated payment (&amp;#8220;RAP&amp;#8221;) on episodes in progress and the associated estimated revenue was immaterial and, therefore, the resulting credits were recorded as a reduction to our outstanding pa&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;tient accounts receivable in our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated balance sheets for such periods. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;"&gt;Non-Medicare Revenue &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Episodic-based Revenue. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Non-episodic &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;b&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;ased Revenue. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates, as applicable. Contractual adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue and are also recorded as a reduction to our outstanding patient accounts receivable. In addition, we receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Hospice Revenue Recognition &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;"&gt;Hospice Medicare Revenue &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates.  The estimated payment rates are daily or hourly rates for each of the four levels of care &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;we deliver.  The four levels of care&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;are routine care, general inpatient care, continuo&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;us home care and respite care. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Routine care accounts for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;99&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%, 9&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%, and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;of our total net Medic&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;are hospice service revenue for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; 2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and 2014, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;respectively&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Beginning January 1, 2016, CMS has provided for two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, beginning January 1, 2016, Medicare is also reimbursing for a service intensity add-on (&amp;#8220;SIA&amp;#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse (&amp;#8220;RN&amp;#8221;) or medical social worker (&amp;#8220;MSW&amp;#8221;) for patients in a routine level of care.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We make adjustments to Medicare revenue for an inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes our historical collection rate on Medicare claims, and record it during the period services are rendered as an estimated revenue adjustment and as a reduction to our outstanding patient accounts receivable&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap for each provider number, we monitor these caps and estimate amounts due back to Medicare if &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;we estimate &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;a cap has been exceeded.&amp;#160;We record these adjustments as a reduction to revenue and an increase &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;in other accrued liabilities. Beginning for the cap year ending October 31, 2014, providers are &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;required to self-report and pay their estimated cap liability by March 31&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;st&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of the following year.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;As of December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; have settled our Medicare hospice reimbursements for all fiscal years through October 31, 20&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;12 and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;we have recorded &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million for estimated amounts due back to Medicare in other accrued liabilities for the Federal &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;cap y&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ears ended October 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; through October 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. As of December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;had&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; recorded $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1.4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million for estimated amounts due back to Medicare in other accrued liabilities for the Federa&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;l &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;cap years ended October 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; through October 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;"&gt;Hospice Non-Medicare Revenue &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;day &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients, third parties and others for services provided and are deducted from gross revenue to determine our net service revenue and patient accounts receiv&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;able&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Personal Care Revenue Recognition &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;"&gt;Personal Care Non-Medicare Revenue &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We generate net service revenues by providing our services directly to patients primarily on a per hour, visit or unit basis. We receive payment for providing such services from our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; clients, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Net service revenues are principally provided based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; which are recognized as net service revenue at the time services are rendered&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <amed:FirstThresholdOfTherapyServicesRequired id="ID_611" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Number_of_Visits">6</amed:FirstThresholdOfTherapyServicesRequired>
  <amed:ThirdThresholdOfTherapyServicesRequired id="ID_612" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Number_of_Visits">20</amed:ThirdThresholdOfTherapyServicesRequired>
  <amed:LowUtilizationPaymentAdjustmentNumberOfVisits id="ID_613" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Number_of_Visits">5</amed:LowUtilizationPaymentAdjustmentNumberOfVisits>
  <amed:HospiceMedicareRevenueRateAccountedForRoutineCare id="ID_614" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Pure">0.99</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
  <amed:HospiceMedicareRevenueRateAccountedForRoutineCare id="ID_615" decimals="2" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="Pure">0.99</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
  <amed:HospiceMedicareRevenueRateAccountedForRoutineCare id="ID_616" decimals="2" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="Pure">0.98</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
  <amed:PercentageOfTotalReimbursementOfOutlierPayment id="ID_617" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Pure">0.10</amed:PercentageOfTotalReimbursementOfOutlierPayment>
  <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities id="ID_618" decimals="-5" contextRef="AS_OF_Dec31_2016_amed_CapYearAxis_CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember" unitRef="USDollar">800000</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
  <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities id="ID_619" decimals="-5" contextRef="AS_OF_Dec31_2015_amed_CapYearAxis_CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember" unitRef="USDollar">1400000</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
  <amed:SecondThresholdOfServicesRequired id="ID_620" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Number_of_Visits">14</amed:SecondThresholdOfServicesRequired>
  <amed:HistoricalCollectionRateFromMedicare id="ID_621" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Pure">0.99</amed:HistoricalCollectionRateFromMedicare>
  <amed:EstimatedUsefulLifeOfIntangibleAssets id="ID_622" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember">P3Y</amed:EstimatedUsefulLifeOfIntangibleAssets>
  <amed:EstimatedUsefulLifeOfIntangibleAssets id="ID_623" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_AcquiredNamesMember">P5Y</amed:EstimatedUsefulLifeOfIntangibleAssets>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="ID_624" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Cash and Cash Equivalents &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <amed:MinimumDaysAccountsReceivableOutstandingFullyReserved id="ID_625" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Day">365</amed:MinimumDaysAccountsReceivableOutstandingFullyReserved>
  <amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare id="ID_626" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Pure">0.6</amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare>
  <amed:RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare id="ID_627" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Pure">0.5</amed:RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare>
  <amed:MaximumDaysToSubmitFinalBillFromStartOfEpisode id="ID_628" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Day">120</amed:MaximumDaysToSubmitFinalBillFromStartOfEpisode>
  <amed:PercentageOfPatientReceivablesOutstanding id="ID_629" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Pure">0.1</amed:PercentageOfPatientReceivablesOutstanding>
  <amed:MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid id="ID_630" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Day">60</amed:MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid>
  <amed:RevenueAdjustmentToMedicareRevenue id="ID_631" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">7900000</amed:RevenueAdjustmentToMedicareRevenue>
  <amed:RevenueAdjustmentToMedicareRevenue id="ID_632" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">5100000</amed:RevenueAdjustmentToMedicareRevenue>
  <us-gaap:TradeAndOtherAccountsReceivablePolicy id="ID_633" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Patient Accounts Receivable &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other t&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;hird-party &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payors&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and patients. As of December 31, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, there is one s&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ingle &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, other than Medicare, that accounts for more than &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% of our total outstanding patient receivables&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; (approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%). T&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;hus&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We fully reserve for accounts which are aged at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;36&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; days or greater. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We believe the credit risk associated with our Medicare accounts&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;which &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;represent &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% of our net patient accounts receivable at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;December 31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;December 31, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2015, respectively, is limited&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; due to our historical collection rate of over &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;99&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;from Medicare and the fact that Medicare is a U.S. government &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. Accordingly, we do not record an allowance for doubtful accounts for our Medicare patient accounts receivable, which are recorded at their net realizable value after recording estimated revenue &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;adjustments as discussed above. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;During &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;recorded $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million, $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million and $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million, respectively, in estimated revenue adjustments to Medicare revenue.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We believe there is a certain level of credit risk associated with non-Medicare &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payors&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. To provide for our non-Medicare patient accounts receivable that could become uncollectible in the future, we establish an allowance for doubtful accounts to reduce the carrying amount to its estimated net realizable value.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Medicare Home Health &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients.  Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% of our estimated payment for the initial episode at the start of care or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% of the estimated payment for any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed (&amp;#8220;final billed&amp;#8221;). The RAP received for that particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;120&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; days from the start of the episode, or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; days from the date the RAP was paid, any RAPs received for that episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be resubmitted. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Medicare Hospice &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services t&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;hat we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Once each patient has been confirmed for eligibility, we will bill Medicare on a monthly basis for the services provided to the patient. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Non-Medicare Home Health,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt; Hospice,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt; and Personal Care&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient's eligibility for services with the applicable &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. Once the patient has been confirmed for eligibility, we will provide services to the patient &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and bill the applicable &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payor&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.  &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payors&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; or groups of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;payors&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; with similar characteristics that would subject us to any significant credit risk.  &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;We estimate an allowance for doubtful accounts&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; based upon our assessment of historical and expected net collections, business and economic conditions, trends in payment and an evaluation of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;collectability&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; based upon the date that the service was provided. Based upon our best judgment, we believe the allowance for doubtful accounts adequately provides for accounts that will not be collected due to credit risk&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
  <amed:RevenueAdjustmentToMedicareRevenue id="ID_634" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">6100000</amed:RevenueAdjustmentToMedicareRevenue>
  <amed:PortionOfPatientAccountsReceivableDerivedFromMedicare id="ID_635" decimals="2" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="Pure">0.64</amed:PortionOfPatientAccountsReceivableDerivedFromMedicare>
  <amed:PortionOfPatientAccountsReceivableDerivedFromMedicare id="ID_636" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Pure">0.61</amed:PortionOfPatientAccountsReceivableDerivedFromMedicare>
  <amed:PercentageOfPatientReceivablesOutstandingOverTenPercent id="ID_637" decimals="3" contextRef="AS_OF_Dec31_2016" unitRef="Pure">0.101</amed:PercentageOfPatientReceivablesOutstandingOverTenPercent>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="ID_638" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Property and Equipment &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Property and equipment is stated at cost and we depreciate it on a straight-line basis over the estimated useful lives of the assets. Additionally, we have internally developed c&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;omputer software for our own use&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Additions and improvements (including interest costs for construction of qualifying long-lived assets) are capitalized. Maintenance and repair expenses are charged to expense as incurred. The cost of property and equipment sold or disposed of and the related accumulated depreciation are eliminated from the property and related accumulated depreciation accounts, and any gain or loss is credited or charged to other &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;general and administrative expenses&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.  &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:4.5pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We consider our reporting units to represent asset groups for purposes of testing long-lived assets for impairment.  We assess the impairment of a long-lived asset group whenever events or changes in circumstances indicate that the asset's carrying value may not be recoverable. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Factors we consider important that could trigger an impairment review include but are not limited to the following:&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:0pt'&gt;&lt;/p&gt;&lt;ul&gt;&lt;li style="margin-left:72px;list-style:disc;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;A significant change in the extent or manner in which the long-lived asset group is being used&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/li&gt;&lt;li style="margin-left:72px;list-style:disc;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;A significant change in the business climate that could affect the value of the long-lived asset group&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/li&gt;&lt;li style="margin-left:72px;list-style:disc;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;A significant change in the market value of the assets included in the asset group&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/li&gt;&lt;/ul&gt;&lt;p style='margin-top:4.5pt; margin-bottom:4.5pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;If we determine that the carrying value of long-lived assets may not be recoverable, we compare the carrying value of the asset group to the undiscounted cash flows expected to be generated by the asset group. If the carrying value exceeds the undiscounted cash flows, an impairment charge is indicated. An impairment charge is recognized to the extent that the carrying value of the asset group exceeds its fair value. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We generally provide for depreciation over the following estimated usef&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ul service lives&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 250px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:250px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Years&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Building&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 250px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:250px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;39&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Lesser of life or lease or expected useful life&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Equipment and furniture&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;3 to 7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Vehicles&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Computer software&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;3 to 5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;As of December 31, 2014, we had $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million of internally developed software costs related to the development of AMS3 Home Health&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Hospice&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; (&amp;#8220;AMS3&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. Expanded beta testing to additional sites in February of 2015 demonstrated that AMS3 was disruptive to operations. Additional analysis of the system determined that the system was not ready to be fully implemented and would require significant time and investment to redesign. Therefore, during the three-month period ended March 31, 2015, we made the decision to discontinue AMS3 and recorded a non-cash &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;asset impairment charge of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;75.2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; to write-off the software costs incurred related to the development of AMS3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.  &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;During 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;began &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;transition&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of all our care centers from our proprietary operating system &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Homecare &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Homebase&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; (&amp;#8220;HCHB&amp;#8221;), a leading home health and hospice platform, with all of our care centers operating on HCHB as of December 31,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; 2016. As part of our conversion process, we determined that a number of assets (primarily laptops) were not compatible with HCHB&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and had no other alternative or secondary use&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. As a result, we recorded a non-cash asset impairment charge of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4.4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million to write-off these assets during the three-month period ended December 31, 2016.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:4.5pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;During the three-month period ended September 30, 2015, we commenced an active program to sell our corporate headquarters located in Baton Rouge, Louisiana. In accordance with U.S. GAAP, we classified this asset as held for sale and reduced the carrying value of the asset to its estimated fair value less estimated costs to sell the asset; no further depreciation expense for the asset &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;was&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; recorded. As a result, we recorded a non-cash asset &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;impairment&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; charge of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million during the three-month period ended September 30, 2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;The asset was sold during the three-month period ended December 31, 2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and the Company now leases &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;equivalent&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; office space&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="7"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following table summarizes the balances related to our property and equipment for 2016 and 2015 (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4"  style="width: 160px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:160px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;As of December 31,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Building and leasehold improvements&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.3&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Equipment and furniture&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;71.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;89.6&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Computer software&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;96.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;92.6&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;175.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;184.5&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(138.6)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(141.8)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;37.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;42.7&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="7"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Depreciation expense for 2016, 2015 and 2014 was $17.2 million, $20.0 million and $28.0 million, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <amed:EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock id="ID_639" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 250px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:250px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Years&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Building&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 250px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:250px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;39&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Lesser of life or lease or expected useful life&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Equipment and furniture&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;3 to 7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Vehicles&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Computer software&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;3 to 5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="ID_640" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_BuildingMember">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="ID_641" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndFurnitureMember_us-gaap_RangeAxis_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="ID_642" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndFurnitureMember_us-gaap_RangeAxis_MaximumMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="ID_643" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_VehiclesMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="ID_644" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ComputerSoftwareMember_us-gaap_RangeAxis_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="ID_645" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ComputerSoftwareMember_us-gaap_RangeAxis_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives id="ID_646" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">Lesser of life or lease or expected useful life</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <amed:InternallyDevelopedComputerSoftware id="ID_647" decimals="-5" contextRef="AS_OF_Dec31_2014" unitRef="USDollar">75800000</amed:InternallyDevelopedComputerSoftware>
  <us-gaap:AssetImpairmentCharges id="ID_648" decimals="-5" contextRef="FROM_Jan01_2015_TO_Mar31_2015_amed_AssetImpairmentAxis_Ams3HomecareAndHospiceMember" unitRef="USDollar">75200000</us-gaap:AssetImpairmentCharges>
  <us-gaap:AssetImpairmentCharges id="ID_649" decimals="-5" contextRef="FROM_Oct01_2015_TO_Dec31_2015_amed_AssetImpairmentAxis_CorporateHeadquartersMember" unitRef="USDollar">2100000</us-gaap:AssetImpairmentCharges>
  <us-gaap:AssetImpairmentCharges id="ID_650" decimals="-5" contextRef="FROM_Oct01_2016_TO_Dec31_2016_amed_AssetImpairmentAxis_HomecareHomebaseMember" unitRef="USDollar">4400000</us-gaap:AssetImpairmentCharges>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="ID_651" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="7"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following table summarizes the balances related to our property and equipment for 2016 and 2015 (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="4"  style="width: 160px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:160px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;As of December 31,&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Building and leasehold improvements&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.3&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Equipment and furniture&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;71.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;89.6&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Computer software&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;96.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;92.6&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;175.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;184.5&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(138.6)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(141.8)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;37.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;42.7&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="7"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Depreciation expense for 2016, 2015 and 2014 was $17.2 million, $20.0 million and $28.0 million, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <amed:BuildingAndLeaseholdImprovements id="ID_652" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">6900000</amed:BuildingAndLeaseholdImprovements>
  <amed:EquipmentAndFurniture id="ID_653" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">71900000</amed:EquipmentAndFurniture>
  <us-gaap:CapitalizedComputerSoftwareGross id="ID_654" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">96800000</us-gaap:CapitalizedComputerSoftwareGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="ID_655" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">175600000</us-gaap:PropertyPlantAndEquipmentGross>
  <amed:BuildingAndLeaseholdImprovements id="ID_656" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">2300000</amed:BuildingAndLeaseholdImprovements>
  <amed:EquipmentAndFurniture id="ID_657" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">89600000</amed:EquipmentAndFurniture>
  <us-gaap:CapitalizedComputerSoftwareGross id="ID_658" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">92600000</us-gaap:CapitalizedComputerSoftwareGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="ID_659" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">184500000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:Depreciation id="ID_660" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">17200000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="ID_661" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">20000000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="ID_662" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">28000000</us-gaap:Depreciation>
  <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy id="ID_663" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Goodwill and Other Intangible Assets&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Goodwill represents the amount of the purchase price in excess of the fair values assigned to the underlying identifiable net assets of acquired businesses. Goodwill is not amortized, but is subject to an annual impairment test. Tests are performed more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; These events or circumstances include but are not limited to, a significant adverse change in the business environment; regulatory environment or legal factors; or a substantial decline in market capitalization of our stock.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; To determine whether goodwill is impaired, we perform a two-step impairment test. In the first step of the test, the fair values of the reporting units are compared to their aggregate carrying values, including goodwill. If the fair value of the reporting unit is greater than its carrying amount, goodwill is not considered impaired and no further testing is required. If the fair value of the reporting unit is less than its carrying amount, we would proceed to step two of the test. In step two of the test, the implied fair value of the goodwill of the reporting unit is determined by a hypothetical allocation of the fair value calculated in step one to all of the assets and liabilities of that reporting unit (including any recognized and unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value was reflective of the price paid to acquire the reporting unit. The implied fair value of goodwill is the excess, if any, of the calculated fair value after hypothetical allocation to the reporting unit's assets and liabilities. If the implied fair value of the goodwill is greater than the carrying amount of the goodwill at the analysis date, goodwill is not impaired and the analysis is complete. If the implied fair value of the goodwill is less than the carrying value of goodwill at the analysis date, goodwill is deemed impaired by the amount of that variance.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We calculate the estimated fair value of our reporting units using discounted cash flows &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;as well as a market approach that compares our reporting units' earnings and revenue multiples to those of comparable public companies.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;To determine fair value we must make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; in particular expected organic growth rates, future Medicare reimbursement rates&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;capital requirements and income taxes), long-term growth rates for determining terminal value, and discount rates. Our estimates of discounted cash flows may differ from actual cash flows due to, among other things, economic conditions, changes to our business model or changes in operating performance. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;These factors increase the risk of differences between projected and actual performance that could impact future estimates of fair value of all reporting units. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Significant differences between these estimates and actual cash flows could &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;result in additional impairment in future periods.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Each of our operating segments described in &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Note 1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &amp;#8211; Segment Information &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;is considered to represent an individual reporting unit for goodwill impairment testing purposes. We consider each of our home health care centers to constitute an individual business for which discrete financial information is available. However, since these care centers have substantially similar operating and economic characteristics and resource allocation and significant investment decisions concerning these businesses are centralized and the benefits broadly distributed, we have aggregated these care centers and deemed them to constitute a single reporting unit. We have applied this same aggregation principle to our hospice care centers &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and personal-care care centers &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and have also deemed them to be a single reporting unit.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;During 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we did not record any goodwill impairment charges &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;as a result of our annual impairment test &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and none of the goodwill associated with our various reporting units w&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;as&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; considered at risk of impairment as of October 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. Since&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; the date of our last annual goodwill impairment test, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than its carrying amount.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Intangible assets consist of Certificates of&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; Need, licenses, acquired names and&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; non-&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;compete&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; agreements. We amortize non-compete agreements&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; acquired names that we do not intend to use in the future on a straight-line basis over their estimated useful lives, which is generally three years for non-compete agreements and up to five years for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;acquired names. &lt;/font&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
  <amed:DebtIssuanceCostsPolicyTextBlock id="ID_664" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Debt Issuance Costs&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We amortize deferred debt issuance costs related to our long-term obligations over its term through interest expense, unless the debt is extinguished, in which case unamortized balances are immediately expensed. We &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;a&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;mortized $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, $0.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million and $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million in deferred debt issuance costs in &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, respectively. As of December 31, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;we had unamortized debt issuance costs of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million and $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; respectively&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; recorded as &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;long-term obligations, less current portion&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; in our accompanying consolidated balance sheets. The unamortized debt issuance costs of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million at December 31, 2016, will be amortize&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;d over a weighted-average amortization period of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;years.&lt;/font&gt;&lt;/p&gt;</amed:DebtIssuanceCostsPolicyTextBlock>
  <us-gaap:UnamortizedDebtIssuanceExpense id="ID_665" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">2700000</us-gaap:UnamortizedDebtIssuanceExpense>
  <us-gaap:UnamortizedDebtIssuanceExpense id="ID_666" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">3400000</us-gaap:UnamortizedDebtIssuanceExpense>
  <amed:UnamortizedDebtIssuanceCostAmortizatinPeriod id="ID_667" contextRef="FROM_Jan01_2016_TO_Dec31_2016">P3Y8M12D</amed:UnamortizedDebtIssuanceCostAmortizatinPeriod>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="ID_668" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LongtermDebtTypeAxis_DeferredDebtIssuanceCostsMember" unitRef="USDollar">700000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="ID_669" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_LongtermDebtTypeAxis_DeferredDebtIssuanceCostsMember" unitRef="USDollar">800000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="ID_670" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_LongtermDebtTypeAxis_DeferredDebtIssuanceCostsMember" unitRef="USDollar">700000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <amed:FinancialInstrumentDetailsTextBlock id="ID_671" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 18px"&gt;&lt;td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 8px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="11"  style="width: 445px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:445px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Fair Value at Reporting Date Using&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 51px"&gt;&lt;td   style="width: 255px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:255px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Financial Instrument&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 95px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;As of
December 31,
2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 114px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:114px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Quoted Prices in Active Markets for Identical Items
(Level 1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 102px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:102px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Significant Other Observable Inputs (Level 2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 104px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:104px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Significant Unobservable Inputs (Level 3)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 255px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:255px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Long-term obligations&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;95.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 102px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:102px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;97.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 92px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:92px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:FinancialInstrumentDetailsTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="ID_672" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 18px"&gt;&lt;td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 8px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="11"  style="width: 445px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:445px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Fair Value at Reporting Date Using&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 51px"&gt;&lt;td   style="width: 255px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:255px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Financial Instrument&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 95px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;As of
December 31,
2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 114px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:114px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Quoted Prices in Active Markets for Identical Items
(Level 1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 102px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:102px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Significant Other Observable Inputs (Level 2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 104px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:104px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Significant Unobservable Inputs (Level 3)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 255px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:255px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Long-term obligations&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;95.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 102px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:102px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;97.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 92px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:92px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;The &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;fair value hierarchy&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; is&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;/p&gt;&lt;ul&gt;&lt;li style="margin-left:36px;list-style:disc;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 1 &amp;#8211; Quoted prices in active markets for identical assets and liabilities.&lt;/font&gt;&lt;/li&gt;&lt;li style="margin-left:36px;list-style:disc;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 2 &amp;#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/font&gt;&lt;/li&gt;&lt;li style="margin-left:36px;list-style:disc;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 3 &amp;#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/li&gt;&lt;/ul&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, payroll and employee benefits &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and accrued expenses&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; we estimate the carrying amounts' approximate fair value. &lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:LiabilitiesFairValueDisclosure id="ID_673" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">95700000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure id="ID_674" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USDollar">97800000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:IncomeTaxPolicyTextBlock id="ID_675" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Income Taxes&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We use the asset and liability approach for measuring deferred tax assets and liabilities based on temporary differences existing at each balance sheet date using currently enacted tax rates. Our deferred tax calculation requires us to make certain estimates about future operations. Deferred tax &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;assets are reduced by a valuation allowance when we believe it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect of a change in tax rate is recognized as income or expense in the period that includes the enactment date. As of December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;net &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;deferred tax asset&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; w&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ere&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;107.9&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;125&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million, respectively&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Management regularly assesses the ability to realize deferred tax assets recorded in the Company's entities based upon the weight of available evidence, including such factors as the recent earnings history and expected future taxable income&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;In the event future taxable income is below management's estimates or is generated in tax jurisdictions different than projected, we could be required to increase the valuation allowance for deferred tax assets. This would result in an increase in our effective tax rate.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="ID_676" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Share-Based Compensation&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We record all share-based compensation as expense in the financial statements measured at the fair value of the award. We recognize compensation cost on a straight-line basis over the requisite service period for each separately vesting portion of the award. We reflect the excess tax benefits related to stock option exercises as financing cash flows. Share-based compensation expense for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;was $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million, $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;11&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million and $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million, respectively, and the total income tax benefit&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;recognized for these expenses was $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million, $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million and $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million, respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense id="ID_677" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">4700000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
  <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense id="ID_678" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">2000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
  <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense id="ID_679" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">6400000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
  <us-gaap:EarningsPerSharePolicyTextBlock id="ID_680" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Weighted-Average Shares Outstanding&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Net&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;income&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; (loss)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calc&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ulate our basic and diluted net &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;income (loss)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;attributable to Amedisys, Inc. common stockholders (amounts in thousands):&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 16px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5"  style="width: 234px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:234px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Years Ended December 31, &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Weighted average number of shares outstanding - basic&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;33,198&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;33,018&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;32,301&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; text-align:left;border-color:#000000;min-width:68px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; text-align:left;border-color:#000000;min-width:68px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; text-align:left;border-color:#000000;min-width:68px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Stock options&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;162&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Non-vested stock and stock units&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;381&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;521&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Weighted average number of shares outstanding - diluted&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;33,741&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;33,018&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;32,823&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Anti-dilutive securities&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;221&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;922&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;106&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock id="ID_681" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 16px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5"  style="width: 234px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:234px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Years Ended December 31, &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Weighted average number of shares outstanding - basic&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;33,198&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;33,018&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;32,301&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; text-align:left;border-color:#000000;min-width:68px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; text-align:left;border-color:#000000;min-width:68px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; text-align:left;border-color:#000000;min-width:68px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Stock options&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;162&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Non-vested stock and stock units&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;381&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;521&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Weighted average number of shares outstanding - diluted&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;33,741&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;33,018&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;32,823&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Anti-dilutive securities&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;221&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;922&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 68px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;106&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="ID_682" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Shares">221000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="ID_683" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="Shares">922000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="ID_684" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="Shares">106000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements id="ID_685" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Shares">162000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <amed:NonVestedStockAndStockUnits id="ID_686" decimals="-3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Shares">381000</amed:NonVestedStockAndStockUnits>
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements id="ID_687" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="Shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <amed:NonVestedStockAndStockUnits id="ID_688" decimals="-3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="Shares">0</amed:NonVestedStockAndStockUnits>
  <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements id="ID_689" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="Shares">1000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
  <amed:NonVestedStockAndStockUnits id="ID_690" decimals="-3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="Shares">521000</amed:NonVestedStockAndStockUnits>
  <us-gaap:AdvertisingCostsPolicyTextBlock id="ID_691" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Advertising Costs&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We expense advertising costs as incurred. Advertising expense for 2016, 2015 and 2014 was $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million, $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
  <us-gaap:AdvertisingExpense id="ID_692" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">7800000</us-gaap:AdvertisingExpense>
  <us-gaap:AdvertisingExpense id="ID_693" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">6900000</us-gaap:AdvertisingExpense>
  <us-gaap:AdvertisingExpense id="ID_694" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">4700000</us-gaap:AdvertisingExpense>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="ID_695" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Recently Issued Accounting Pronouncements&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&amp;#160;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2014-09, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, which requires an entity to recognize the amount of revenue for which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP. In August 2015, the FASB issued ASU 2015-14,&lt;/font&gt;&lt;font style="font-family:Georgia;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date&lt;/font&gt;&lt;font style="font-family:Georgia;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; to defer the effective date of the standard from January 1, 2017, to January 1, 2018, with an option that permits companies to adopt the standard as early as the original effective date. The new ASU reflects the decisions reached by the FASB at its meeting in July 2015. Early application prior to the original effective date is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Co&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;mpany does not expect an impact on its consolidated financial statements upon &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;implementation&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of ASU 2014-09 and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ASU 2015-14 on January 1, 2018, but is still evaluating the effect the standard will have on its related disclosures.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In April 2015, the FASB issued ASU 2015-03, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Interest - Imputation of Interest&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;(Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&amp;#160;The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. ASU 2015-03 is effective for annual and interim periods beginning on or after December 15, 2015. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;We adopted this ASU during the three-month period ended March 31, 2016, and applied the change retrospectively for prior period balances of unamortized debt issuance costs, resulting &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;in a $3.4 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; reduction in other assets, net and long-term obligations, less current portion, on our consolidated balance sheet as of December 31, 2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;), &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;whic&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;h will require lessees to recognize a lease liability and right-of-use asset for all leases (with the exception of short-term leases) at the commencement date&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. The ASU is effective for annual and interim periods beginning on or after December 15, 2018. Early adoption is permitted. The standard requires a modified retrospective transition method which requires application of the new guid&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ance for all periods presented. While the Company expects adoption of this standard to lead to a material increase in the assets and liabilities recorded on our balance sheet, we are still &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;evaluating the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;overall impact on our&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; consolidated financial statements and related disclosures and the effect of the standard on &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;our&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; ongoing financial reporting&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In March 2016, the FASB issued ASU 2016-09, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Compensation &amp;#8211; Stock Compensation (Topic 718): Improvement to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, which will simplify the accounting for share-based payment award transactions, including income tax consequences, classification of awards as either equity or liability, and classification on the statement of cash flows. The ASU is effective for annual and interim periods beginning after December 15, 2016. Early adoption is permitted. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;The element of the new standard that will have the most impact on our consolidated financial statements will be income tax consequences. Excess tax benefits and tax deficiencies on share-based compensation awards will now be included in our tax provision within our consolidated statement of operations as discrete items in the reporting period in &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;which they occur, rather than our current accounting of recording in additional paid-in capital on our consolidated balance sheets&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In August 2016, the FASB issued ASU 2016-15, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, which provides specific guidance on eight cash flow classification issues not specifically addressed by U.S. GAAP. The ASU is effective for annual and interim periods beginning after December 15, 2017. Early adoption is permitted. The standard should be applied using a retrospective transition method unless it is impractical to do so for some of the issues. In such case, the amendments for those issues would be applied prospectively as of the earliest date practicable. The Company is evaluating the effect that ASU 2016-15 will have on its consolidated financial statements and related disclosures and the effect of the standard on its ongoing financial reporting&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:0pt'&gt;&amp;#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:BusinessCombinationDisclosureTextBlock id="ID_696" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:13pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;"&gt;3. ACQUISITIONS &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, hospice&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;personal care &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;services. The purchase price paid for acquisitions is negotiated through arm's length transactions, with consideration based on our analysis of, among other things, comparable acqu&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;isitions and expected cash flows&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets. Preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuation and liabilities assumed&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt; Acquisitions &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Personal Care Division&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;March 1, 2016, we acquired Associated Home Care which owns and operates 9 personal-care care centers servicing the state of Massachusetts for a total purchase price of $27.7 million, net of cash acquired (subject to certain adjustments), of which $0.5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million was placed in escrow for indemnification purposes and working capital price adjustments. The purchase price was paid with cash on hand on the date of the transaction. Based on our preliminary purchase price allocation, in connection with the acquisition, we recorded goodwill ($23.5 million) and other assets and liabilities, net ($4.2 million) during the three-month period ended March 31, 2016. During the three-month period ended June 30, 2016, we received the final report from our outside appraisal firm. As a result, we reduced our preliminary goodwill by $5.0 million and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;recorded corresponding increases&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;in the fair value of assets acquired ($0.2 million), other intangibles &amp;#8211; acquired names of business ($3.5 million) and other intangibles &amp;#8211; non-compete agreements ($1.3 million). &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;We expect the entire amount of goodwill recorded &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;for this acquisition &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;to be deductible for income tax purposes over approximately 15 years. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;September 1, 2016, we acquired the assets of Professional Profiles, Inc. which owns and operates 4 personal-care care centers servicing the state of Massachusetts for a total purchase price of $4.4 million, (subject to certain adjustments), of which $0.7 million was placed in a promissory note to be paid over 24 months, subject to any offsets or withholds for indemnification purposes. The purchase price was paid with cash on hand on the date of the transaction. During the three-month period ended September 30, 2016, we recorded goodwill ($4.2 million) and other intangibles &amp;#8211; non-compete agreements ($0.2 million)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; in connection with the acquisition&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;We expect the entire amount of goodwill recorded &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;for this acquisition &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;to be deductible for income tax purposes over approximately 15 years.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Home Health&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt; Division&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On Oc&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;tober 20, 2016, we acquired the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;assets of&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; a former nonprofit organization in New York for a purchase price of $4.6 million. During the three-month period ended December 31, 2016, we recorded goodwill ($4.4 million) and other intangibles &amp;#8211; cer&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;tificate of need ($0.2 million)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; in connection with the acquisition&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. We expect the entire amount of goodwill recorded &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;for this acquisition &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;to be deductible for income tax purposes over approximately 15 years.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;The following table contains unaudited pro forma condensed consolidated statement of operations information assuming that &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;our 2016 acquisitions &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;closed on January 1, 2015, for the years ended December 31, 2016 and 2015 (amounts in millions, except per share data):&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&amp;#160;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:center;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Net service revenue&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;1,449.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;1,322.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Operating income (loss)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;53.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(7.8)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Net income&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;35.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Basic earnings (loss) per share&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;1.04&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(0.01)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Diluted earnings (loss) per share&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;1.03&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(0.01)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="7" rowspan="5" style="width: 620px; text-align:left;border-color:#000000;min-width:620px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;The pro forma information presented above includes adjustments for (i) amortization of identifiable intangible assets and (ii) income tax provision using the Company&amp;#8217;s statutory tax rate. This pro forma information is presented for illustrative purposes only and may not be indicative of the results of operations that would have actually occurred. In addition, future results may vary significantly from the results reflected in the pro forma information.&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 19px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 30px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt; Acquisitions &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Hospice Division&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On July 24, 2015, we acquired one hospice care center in Tennessee for a total purchase price of $5.8 million. The purchase price was paid with cash on hand on the date of the transaction. In connection with the acquisition, we recorded goodwill ($5.5 million) and other intangibles ($0.3 million).&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Home Health Division&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On Octo&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ber 2, 2015, we acquired the&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; assets of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;home health care center in Georgia for a total purchase price of $0.3 million. The purchase price was paid with cash on hand on the date of the transaction. In connection with the acquisition, we recorded goodwill ($0.3 million).&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On December 31, 2015, we acquired Infinity &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;HomeCare&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; (&amp;#8220;Infinity&amp;#8221;) for a total purchase price of $63 million, net of cash acquired (subject to certain &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;adjustments), of which $3.2 million was placed in escrow for indemnification purposes and working capital price adjustments. The purchase price was paid with cash on hand on the date of the transaction. Infinity owned and operated 15 home health care centers servicing the state of Florida. In connection with the acquisition, we recorded goodwill ($&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50.2 &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million), other intangibles ($10.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million) and other assets and liabilities, net ($&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million). Approximately&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; $47.6 million of the $50.2 recorded as goodwill is expected to be deductible for income tax purposes over approximately 15 year&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s.&lt;/font&gt;&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
  <us-gaap:BusinessAcquisitionsProFormaRevenue id="ID_697" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">1322200000</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <amed:Businessacquisitionproformaoperatingincomeloss id="ID_698" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-7800000</amed:Businessacquisitionproformaoperatingincomeloss>
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss id="ID_699" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">400000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <us-gaap:BusinessAcquisitionsProFormaRevenue id="ID_700" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">1449700000</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <amed:Businessacquisitionproformaoperatingincomeloss id="ID_701" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">53900000</amed:Businessacquisitionproformaoperatingincomeloss>
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss id="ID_702" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">35000000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic id="ID_703" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDperShare">1.04</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
  <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted id="ID_704" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDperShare">1.03</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
  <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic id="ID_705" decimals="2" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDperShare">-0.01</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
  <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted id="ID_706" decimals="2" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDperShare">-0.01</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
  <us-gaap:BusinessAcquisitionProFormaInformationTextBlock id="ID_707" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:center;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Net service revenue&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;1,449.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;1,322.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Operating income (loss)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;53.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(7.8)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Net income&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;35.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Basic earnings (loss) per share&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;1.04&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(0.01)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Diluted earnings (loss) per share&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;1.03&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(0.01)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="7" rowspan="5" style="width: 620px; text-align:left;border-color:#000000;min-width:620px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;The pro forma information presented above includes adjustments for (i) amortization of identifiable intangible assets and (ii) income tax provision using the Company&amp;#8217;s statutory tax rate. This pro forma information is presented for illustrative purposes only and may not be indicative of the results of operations that would have actually occurred. In addition, future results may vary significantly from the results reflected in the pro forma information.&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 19px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 30px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
  <us-gaap:NumberOfBusinessesAcquired id="ID_708" decimals="0" contextRef="FROM_Jan01_2015_TO_Jul24_2015_amed_StateAxis_TennesseeMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="Agencies">1</us-gaap:NumberOfBusinessesAcquired>
  <us-gaap:NumberOfBusinessesAcquired id="ID_709" decimals="0" contextRef="FROM_Jan01_2015_TO_Dec31_2015_amed_StateAxis_FloridaMember_us-gaap_BusinessAcquisitionAxis_InfinityHomeCareMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Agencies">15</us-gaap:NumberOfBusinessesAcquired>
  <us-gaap:BusinessCombinationConsiderationTransferred1 id="ID_710" decimals="-5" contextRef="FROM_Jan01_2015_TO_Jul24_2015_amed_StateAxis_TennesseeMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">5800000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <us-gaap:BusinessCombinationConsiderationTransferred1 id="ID_711" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_amed_StateAxis_FloridaMember_us-gaap_BusinessAcquisitionAxis_InfinityHomeCareMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">63000000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill id="ID_712" decimals="-5" contextRef="AS_OF_Jul24_2015_amed_StateAxis_TennesseeMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill id="ID_713" decimals="-5" contextRef="AS_OF_Dec31_2015_amed_StateAxis_FloridaMember_us-gaap_BusinessAcquisitionAxis_InfinityHomeCareMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">10900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet id="ID_714" decimals="-5" contextRef="AS_OF_Dec31_2015_amed_StateAxis_FloridaMember_us-gaap_BusinessAcquisitionAxis_InfinityHomeCareMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">1900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
  <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount id="ID_715" decimals="-5" contextRef="AS_OF_Dec31_2015_amed_StateAxis_FloridaMember_us-gaap_BusinessAcquisitionAxis_InfinityHomeCareMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">47600000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
  <us-gaap:GoodwillAcquiredDuringPeriod id="ID_716" decimals="-5" contextRef="FROM_Jan01_2015_TO_Jul24_2015_amed_StateAxis_TennesseeMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">5500000</us-gaap:GoodwillAcquiredDuringPeriod>
  <us-gaap:GoodwillAcquiredDuringPeriod id="ID_717" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_amed_StateAxis_FloridaMember_us-gaap_BusinessAcquisitionAxis_InfinityHomeCareMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">50200000</us-gaap:GoodwillAcquiredDuringPeriod>
  <amed:Goodwillisexpectedtobedeductibleforincometaxpurposesyears id="ID_718" decimals="0" contextRef="FROM_Jan01_2015_TO_Dec31_2015_amed_StateAxis_FloridaMember_us-gaap_BusinessAcquisitionAxis_InfinityHomeCareMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Year">15</amed:Goodwillisexpectedtobedeductibleforincometaxpurposesyears>
  <us-gaap:EscrowDeposit id="ID_719" decimals="-5" contextRef="AS_OF_Dec31_2015_amed_StateAxis_FloridaMember_us-gaap_BusinessAcquisitionAxis_InfinityHomeCareMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">3200000</us-gaap:EscrowDeposit>
  <us-gaap:NumberOfBusinessesAcquired id="ID_720" decimals="0" contextRef="FROM_Jan01_2015_TO_Oct03_2015_amed_StateAxis_GeorgiaMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Agencies">1</us-gaap:NumberOfBusinessesAcquired>
  <us-gaap:BusinessCombinationConsiderationTransferred1 id="ID_721" decimals="-5" contextRef="FROM_Jan01_2015_TO_Oct03_2015_amed_StateAxis_GeorgiaMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">300000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <us-gaap:GoodwillAcquiredDuringPeriod id="ID_722" decimals="-5" contextRef="FROM_Jan01_2015_TO_Oct03_2015_amed_StateAxis_GeorgiaMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">300000</us-gaap:GoodwillAcquiredDuringPeriod>
  <us-gaap:NumberOfBusinessesAcquired id="ID_723" decimals="0" contextRef="FROM_Jan01_2016_TO_Mar01_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_AssociatedHomecareMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="Agencies">9</us-gaap:NumberOfBusinessesAcquired>
  <us-gaap:BusinessCombinationConsiderationTransferred1 id="ID_724" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar01_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_AssociatedHomecareMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">27700000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <us-gaap:EscrowDeposit id="ID_725" decimals="-5" contextRef="AS_OF_Mar01_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_AssociatedHomecareMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">500000</us-gaap:EscrowDeposit>
  <us-gaap:GoodwillAcquiredDuringPeriod id="ID_726" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_AssociatedHomecareMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">23500000</us-gaap:GoodwillAcquiredDuringPeriod>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet id="ID_727" decimals="-5" contextRef="AS_OF_Mar31_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_AssociatedHomecareMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">4200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill id="ID_728" decimals="-5" contextRef="AS_OF_Jun30_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_AssociatedHomecareMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_AcquiredNameOfBusinessMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">3500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill id="ID_729" decimals="-5" contextRef="AS_OF_Jun30_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_AssociatedHomecareMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">1300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet id="ID_730" decimals="-5" contextRef="AS_OF_Jun30_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_AssociatedHomecareMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
  <us-gaap:NumberOfBusinessesAcquired id="ID_731" decimals="0" contextRef="FROM_Jan01_2016_TO_Sep01_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_ProfessionalProfilesMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="Agencies">4</us-gaap:NumberOfBusinessesAcquired>
  <us-gaap:BusinessCombinationConsiderationTransferred1 id="ID_732" decimals="-5" contextRef="FROM_Jan01_2016_TO_Sep01_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_ProfessionalProfilesMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">4400000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <us-gaap:GoodwillAcquiredDuringPeriod id="ID_733" decimals="-5" contextRef="FROM_Jul01_2016_TO_Sep30_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_ProfessionalProfilesMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">4200000</us-gaap:GoodwillAcquiredDuringPeriod>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill id="ID_734" decimals="-5" contextRef="AS_OF_Sep30_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_ProfessionalProfilesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <us-gaap:GoodwillPurchaseAccountingAdjustments id="ID_735" decimals="-5" contextRef="FROM_Apr01_2016_TO_Jun30_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_AssociatedHomecareMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">-5000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
  <us-gaap:LongTermDebt id="ID_736" decimals="-5" contextRef="AS_OF_Sep01_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_ProfessionalProfilesMember_us-gaap_LongtermDebtTypeAxis_PromissoryNotesMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">700000</us-gaap:LongTermDebt>
  <us-gaap:NumberOfBusinessesAcquired id="ID_737" decimals="0" contextRef="FROM_Jan01_2016_TO_Oct20_2016_amed_StateAxis_NewYorkMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Agencies">1</us-gaap:NumberOfBusinessesAcquired>
  <us-gaap:BusinessCombinationConsiderationTransferred1 id="ID_738" decimals="-5" contextRef="FROM_Jan01_2016_TO_Oct20_2016_amed_StateAxis_NewYorkMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">4600000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <us-gaap:BusinessCombinationConsiderationTransferred1 id="ID_739" decimals="-5" contextRef="FROM_Oct01_2016_TO_Dec31_2016_amed_StateAxis_NewYorkMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">4400000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill id="ID_740" decimals="-5" contextRef="AS_OF_Dec31_2016_amed_StateAxis_NewYorkMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_CertificatesOfNeedAndLicensesMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <amed:Goodwillisexpectedtobedeductibleforincometaxpurposesyears id="ID_741" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_AssociatedHomecareMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="Year">15</amed:Goodwillisexpectedtobedeductibleforincometaxpurposesyears>
  <amed:Goodwillisexpectedtobedeductibleforincometaxpurposesyears id="ID_742" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_amed_StateAxis_MassachusettsMember_us-gaap_BusinessAcquisitionAxis_ProfessionalProfilesMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="Year">15</amed:Goodwillisexpectedtobedeductibleforincometaxpurposesyears>
  <amed:Goodwillisexpectedtobedeductibleforincometaxpurposesyears id="ID_743" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_amed_StateAxis_NewYorkMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Year">15</amed:Goodwillisexpectedtobedeductibleforincometaxpurposesyears>
  <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock id="ID_744" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:13pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;"&gt;4. DISCONTINUED OPERATIONS&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt; AND ASSETS HELD FOR SALE&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;As &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;of December 31, 2013, we had three care &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;centers classified as held for sale&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. During &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2014, we sold assets associated with two of these care centers and consolidated one of these care centers with a care center servicing the same m&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;arket. There were no care centers &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;classified as held for sale as of December 31, 2014&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;As we &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;exited&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; certain geographical areas and in accordance with applicable accounting guidance, the care centers which were &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;cl&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;assified as held for sale &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;as of December 31, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and subsequently sold in 2014 &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;are presented as discontinued operations in our cons&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;olidated financial statements. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;The care center consolidated with &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;care center servicing the same markets &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;is&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; presented in continuing operations as we expect continuing cash flows from these markets. For additional information on the care center&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; consolidated with care centers servicing the same markets and the care centers sold&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; see Note 1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &amp;#8211; Exit Activities&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and Restructuring &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Activitie&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;O&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;perating results for the twelve-month period ended December 31, 2014 for those care centers classified as discontinued operations are as follows: loss before income taxes of $0.3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million, income tax benefit of $0.1 million and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;net loss from &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;discontinued operations of $0.2 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&amp;#160;&lt;/p&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
  <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax id="ID_745" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">-300000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
  <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation id="ID_746" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">-100000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
  <amed:NumberOfCareCentersAvailableForSale id="ID_747" decimals="0" contextRef="FROM_Jan01_2013_TO_Dec31_2013_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_DiscontinuedOperationsHeldforsaleMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Agencies">3</amed:NumberOfCareCentersAvailableForSale>
  <amed:NumberOfCareCentersSold id="ID_748" decimals="0" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_DiscontinuedOperationsHeldforsaleMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Agencies">2</amed:NumberOfCareCentersSold>
  <amed:NumberOfCareCentersConsolidated id="ID_749" decimals="0" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_DiscontinuedOperationsHeldforsaleMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Agencies">1</amed:NumberOfCareCentersConsolidated>
  <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock id="ID_750" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:13pt; margin-bottom:9pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;"&gt;5. GOODWILL AND OTHER INTANGIBLE ASSETS, NET&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;During &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we did not record any goodwill impairment charges&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; as a result of our annual impairment test&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and none of the goodwill associated with our various reporting units were considered at risk of impairment as of October 31,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; Since the date of our last annual goodwill impairment test, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would b&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;e less than its carrying amount. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;During &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;the fiscal year &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2015, we did not record any goodwill impairment charges as a result of our annual impairment test and none of the goodwill associated with our various reporting units were considered at risk of impairment.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;During the fiscal year 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;we recognized &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;a non&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;-cash other intangible impairment charge of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.9 &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million during step one of our 2014 annual goodwill impairment test&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. In addition, we recorded &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;non-cash impairment charges of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2.2 &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million related to those care centers that were closed or consolidated during 2014 as discussed in Note 1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &amp;#8211; Exit and Restructuring Activities&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:10pt'&gt;&amp;#160;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 21px"&gt;&lt;td colspan="14"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;The following table summarizes the activity related to our goodwill for 2016, 2015 and 2014 (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 78px; text-align:left;border-color:#000000;min-width:78px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:left;border-color:#000000;min-width:64px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:left;border-color:#000000;min-width:64px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:left;border-color:#000000;min-width:64px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="11"  style="width: 346px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:346px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Goodwill&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 33px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 88px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:88px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Home Health&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 74px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:74px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Hospice&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 74px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:74px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Personal Care&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 74px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:74px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 352px; text-align:left;border-color:#000000;min-width:352px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Balances at December 31, 2013&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 78px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:78px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;16.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;192.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;208.9&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Write-off (1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 78px; text-align:right;border-color:#000000;min-width:78px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(3.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(3.3)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 352px; text-align:left;border-color:#000000;min-width:352px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Balances at December 31, 2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 78px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:78px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;16.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;189.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;205.6&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Additions&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 78px; text-align:right;border-color:#000000;min-width:78px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;50.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;5.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;56.1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 352px; text-align:left;border-color:#000000;min-width:352px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Balances at December 31, 2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 78px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:78px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;67.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;194.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;261.7&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Additions&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 78px; text-align:right;border-color:#000000;min-width:78px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;22.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;27.1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Adjustments related to acquisitions&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 78px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:78px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 352px; text-align:left;border-color:#000000;min-width:352px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Balances at December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 78px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:78px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;71.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;194.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;22.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;288.9&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 78px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:78px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:64px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:64px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:64px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;/p&gt;&lt;ul&gt;&lt;li style="margin-left:18px;list-style:decimal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Write-off of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;goodwill r&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;elated to the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;sale&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of care&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; centers as discussed in Note 1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &amp;#8211; Exit&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and Restructuring&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; Activities&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/li&gt;&lt;/ul&gt;&lt;p style='margin-top:0pt; margin-bottom:0pt'&gt;&amp;#160;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;During 2016, we adjusted goodwill by $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.1 &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;as a result of our completion of the purchase price accounting &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;for our 2015 acquisition of Infinity&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 30px"&gt;&lt;td colspan="14"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following table summarizes the activity related to our other intangible assets, net for 2016, 2015 and 2014 (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 95px; text-align:left;border-color:#000000;min-width:95px;"&gt;&amp;#160;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:left;border-color:#000000;min-width:64px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="11"  style="width: 380px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:380px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Other Intangible Assets, Net&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 10px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Certificates of&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Acquired &lt;/font&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 105px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:105px;"&gt;&amp;#160;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:64px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 10px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 85px; text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Need and&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 80px; text-align:center;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Names of&lt;/font&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Non-Compete&lt;/font&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:center;border-color:#000000;min-width:64px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 10px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Licenses&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Business&lt;/font&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 105px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Agreements (2)&lt;/font&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 74px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:74px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 16px"&gt;&lt;td colspan="2"  style="width: 318px; text-align:left;border-color:#000000;min-width:318px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Balances at December 31, 2013&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;25.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;11.1&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 95px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.2&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;36.7&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Write-off (1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(0.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.0&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 95px; text-align:right;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.0&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(0.2)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Impairment&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(2.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(1.0)&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 95px; text-align:right;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.0&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(3.1)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.0&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 95px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(0.2)&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(0.2)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td colspan="2"  style="width: 318px; text-align:left;border-color:#000000;min-width:318px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Balances at December 31, 2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;23.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;10.1&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 95px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.0&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;33.2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Additions&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;1.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;4.1&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 95px; text-align:right;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;5.9&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;11.1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Write-off&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(0.3)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.0&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 95px; text-align:right;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.0&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(0.3)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td colspan="2"  style="width: 318px; text-align:left;border-color:#000000;min-width:318px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Balances at December 31, 2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;23.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;14.2&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 95px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;5.9&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;44.0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Additions&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;3.5&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 95px; text-align:right;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;1.5&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;5.2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.0&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 95px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(2.5)&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(2.5)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td colspan="2"  style="width: 318px; text-align:left;border-color:#000000;min-width:318px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Balances at December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 75px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;24.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;17.7&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 95px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;4.9&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;46.7&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 95px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:95px;"&gt;&amp;#160;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:64px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;/p&gt;&lt;ul&gt;&lt;li style="margin-left:18px;list-style:decimal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Write-off of intangible assets related to the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;sale&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of care&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; centers as discussed in Note 1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &amp;#8211; Exit&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and Restructuring&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; Activities&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/li&gt;&lt;li style="margin-left:18px;list-style:decimal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;The weighted average amortization period of our non-compete agreements is &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; years&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/li&gt;&lt;/ul&gt;&lt;p style='margin-top:0pt; margin-bottom:0pt'&gt;&amp;#160;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;See Note 3 &amp;#8211; Acquisitions for further details on additions to goodwill and other intangible assets, net&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:0pt'&gt;&amp;#160;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:0pt'&gt;&amp;#160;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="6"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The estimated aggregate amortization expense related to intangible assets for each of the five succeeding years is as follows (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 11px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2021&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
  <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill id="ID_751" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_amed_GoodwillAndIntangibleAssetsImpairmentAxis_CareCentersClosedOrConsolidatedMember" unitRef="USDollar">-2200000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
  <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill id="ID_752" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_amed_GoodwillAndIntangibleAssetsImpairmentAxis_AnnualImpairmentTestStepOneMember" unitRef="USDollar">-900000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
  <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock id="ID_753" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 21px"&gt;&lt;td colspan="14"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;The following table summarizes the activity related to our goodwill for 2016, 2015 and 2014 (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 78px; text-align:left;border-color:#000000;min-width:78px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:left;border-color:#000000;min-width:64px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:left;border-color:#000000;min-width:64px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:left;border-color:#000000;min-width:64px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="11"  style="width: 346px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:346px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Goodwill&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 33px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 88px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:88px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Home Health&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 74px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:74px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Hospice&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 74px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:74px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Personal Care&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 74px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:74px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 352px; text-align:left;border-color:#000000;min-width:352px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Balances at December 31, 2013&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 78px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:78px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;16.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;192.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;208.9&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Write-off (1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 78px; text-align:right;border-color:#000000;min-width:78px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(3.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(3.3)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 352px; text-align:left;border-color:#000000;min-width:352px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Balances at December 31, 2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 78px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:78px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;16.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;189.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;205.6&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Additions&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 78px; text-align:right;border-color:#000000;min-width:78px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;50.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;5.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;56.1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 352px; text-align:left;border-color:#000000;min-width:352px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Balances at December 31, 2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 78px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:78px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;67.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;194.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;261.7&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Additions&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 78px; text-align:right;border-color:#000000;min-width:78px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;22.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;27.1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Adjustments related to acquisitions&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 78px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:78px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 352px; text-align:left;border-color:#000000;min-width:352px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Balances at December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 78px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:78px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;71.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;194.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;22.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;288.9&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 78px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:78px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:64px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:64px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:64px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 30px"&gt;&lt;td colspan="14"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following table summarizes the activity related to our other intangible assets, net for 2016, 2015 and 2014 (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 95px; text-align:left;border-color:#000000;min-width:95px;"&gt;&amp;#160;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:left;border-color:#000000;min-width:64px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="11"  style="width: 380px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:380px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Other Intangible Assets, Net&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 10px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Certificates of&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Acquired &lt;/font&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 105px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:105px;"&gt;&amp;#160;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:64px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 10px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 85px; text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Need and&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 80px; text-align:center;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Names of&lt;/font&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Non-Compete&lt;/font&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:center;border-color:#000000;min-width:64px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 10px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Licenses&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Business&lt;/font&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 105px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Agreements (2)&lt;/font&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 74px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:74px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 16px"&gt;&lt;td colspan="2"  style="width: 318px; text-align:left;border-color:#000000;min-width:318px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Balances at December 31, 2013&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;25.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;11.1&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 95px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.2&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;36.7&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Write-off (1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(0.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.0&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 95px; text-align:right;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.0&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(0.2)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Impairment&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(2.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(1.0)&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 95px; text-align:right;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.0&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(3.1)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.0&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 95px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(0.2)&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(0.2)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td colspan="2"  style="width: 318px; text-align:left;border-color:#000000;min-width:318px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Balances at December 31, 2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;23.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;10.1&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 95px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.0&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;33.2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Additions&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;1.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;4.1&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 95px; text-align:right;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;5.9&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;11.1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Write-off&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(0.3)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.0&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 95px; text-align:right;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.0&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(0.3)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td colspan="2"  style="width: 318px; text-align:left;border-color:#000000;min-width:318px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Balances at December 31, 2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;23.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;14.2&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 95px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;5.9&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;44.0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Additions&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;3.5&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 95px; text-align:right;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;1.5&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;5.2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;0.0&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 95px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(2.5)&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(2.5)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td colspan="2"  style="width: 318px; text-align:left;border-color:#000000;min-width:318px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Balances at December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 75px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;24.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;17.7&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 95px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:95px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;4.9&lt;/font&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:64px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;46.7&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 95px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:95px;"&gt;&amp;#160;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 64px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:64px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="6"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The estimated aggregate amortization expense related to intangible assets for each of the five succeeding years is as follows (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 11px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2021&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
  <us-gaap:Goodwill id="ID_754" decimals="-5" contextRef="AS_OF_Dec31_2013" unitRef="USDollar">208900000</us-gaap:Goodwill>
  <us-gaap:Goodwill id="ID_755" decimals="-5" contextRef="AS_OF_Dec31_2014" unitRef="USDollar">205600000</us-gaap:Goodwill>
  <us-gaap:GoodwillAcquiredDuringPeriod id="ID_756" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">27100000</us-gaap:GoodwillAcquiredDuringPeriod>
  <us-gaap:GoodwillAcquiredDuringPeriod id="ID_757" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">56100000</us-gaap:GoodwillAcquiredDuringPeriod>
  <us-gaap:Goodwill id="ID_758" decimals="-5" contextRef="AS_OF_Dec31_2013_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">16600000</us-gaap:Goodwill>
  <us-gaap:Goodwill id="ID_759" decimals="-5" contextRef="AS_OF_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">16500000</us-gaap:Goodwill>
  <us-gaap:GoodwillAcquiredDuringPeriod id="ID_760" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">50600000</us-gaap:GoodwillAcquiredDuringPeriod>
  <us-gaap:Goodwill id="ID_761" decimals="-5" contextRef="AS_OF_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">67100000</us-gaap:Goodwill>
  <us-gaap:GoodwillAcquiredDuringPeriod id="ID_762" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">4400000</us-gaap:GoodwillAcquiredDuringPeriod>
  <us-gaap:Goodwill id="ID_763" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">71600000</us-gaap:Goodwill>
  <us-gaap:Goodwill id="ID_764" decimals="-5" contextRef="AS_OF_Dec31_2013_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">192300000</us-gaap:Goodwill>
  <us-gaap:Goodwill id="ID_765" decimals="-5" contextRef="AS_OF_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">189100000</us-gaap:Goodwill>
  <us-gaap:GoodwillAcquiredDuringPeriod id="ID_766" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">5500000</us-gaap:GoodwillAcquiredDuringPeriod>
  <us-gaap:Goodwill id="ID_767" decimals="-5" contextRef="AS_OF_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">194600000</us-gaap:Goodwill>
  <us-gaap:GoodwillAcquiredDuringPeriod id="ID_768" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">0</us-gaap:GoodwillAcquiredDuringPeriod>
  <us-gaap:Goodwill id="ID_769" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">194600000</us-gaap:Goodwill>
  <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit id="ID_770" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">-100000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
  <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit id="ID_771" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">-3200000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
  <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit id="ID_772" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">-3300000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
  <us-gaap:Goodwill id="ID_773" decimals="-5" contextRef="AS_OF_Dec31_2013_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</us-gaap:Goodwill>
  <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit id="ID_774" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
  <us-gaap:Goodwill id="ID_775" decimals="-5" contextRef="AS_OF_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</us-gaap:Goodwill>
  <us-gaap:GoodwillAcquiredDuringPeriod id="ID_776" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</us-gaap:GoodwillAcquiredDuringPeriod>
  <us-gaap:Goodwill id="ID_777" decimals="-5" contextRef="AS_OF_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</us-gaap:Goodwill>
  <us-gaap:GoodwillAcquiredDuringPeriod id="ID_778" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">22700000</us-gaap:GoodwillAcquiredDuringPeriod>
  <us-gaap:GoodwillPurchaseAccountingAdjustments id="ID_779" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">100000</us-gaap:GoodwillPurchaseAccountingAdjustments>
  <us-gaap:GoodwillPurchaseAccountingAdjustments id="ID_780" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">0</us-gaap:GoodwillPurchaseAccountingAdjustments>
  <us-gaap:GoodwillPurchaseAccountingAdjustments id="ID_781" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</us-gaap:GoodwillPurchaseAccountingAdjustments>
  <us-gaap:GoodwillPurchaseAccountingAdjustments id="ID_782" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">100000</us-gaap:GoodwillPurchaseAccountingAdjustments>
  <us-gaap:Goodwill id="ID_783" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">22700000</us-gaap:Goodwill>
  <us-gaap:GoodwillPurchaseAccountingAdjustments id="ID_784" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_amed_StateAxis_FloridaMember_us-gaap_BusinessAcquisitionAxis_InfinityHomeCareMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">100000</us-gaap:GoodwillPurchaseAccountingAdjustments>
  <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill id="ID_785" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">3100000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
  <us-gaap:AmortizationOfIntangibleAssets id="ID_786" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">200000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="ID_787" decimals="-5" contextRef="AS_OF_Dec31_2014" unitRef="USDollar">33200000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <amed:OtherIntangibleAssetsAdditions id="ID_788" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">11100000</amed:OtherIntangibleAssetsAdditions>
  <amed:OtherIntangibleAssetsAdditions id="ID_789" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">5200000</amed:OtherIntangibleAssetsAdditions>
  <us-gaap:AmortizationOfIntangibleAssets id="ID_790" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">2500000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill id="ID_791" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember" unitRef="USDollar">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
  <us-gaap:AmortizationOfIntangibleAssets id="ID_792" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember" unitRef="USDollar">200000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="ID_793" decimals="-5" contextRef="AS_OF_Dec31_2014_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember" unitRef="USDollar">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <amed:OtherIntangibleAssetsAdditions id="ID_794" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember" unitRef="USDollar">5900000</amed:OtherIntangibleAssetsAdditions>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="ID_795" decimals="-5" contextRef="AS_OF_Dec31_2015_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember" unitRef="USDollar">5900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <amed:OtherIntangibleAssetsAdditions id="ID_796" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember" unitRef="USDollar">1500000</amed:OtherIntangibleAssetsAdditions>
  <us-gaap:AmortizationOfIntangibleAssets id="ID_797" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember" unitRef="USDollar">2500000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="ID_798" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember" unitRef="USDollar">4900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="ID_799" decimals="-5" contextRef="AS_OF_Dec31_2013" unitRef="USDollar">36700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <amed:OtherIntangiblesWriteOffs id="ID_800" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember" unitRef="USDollar">0</amed:OtherIntangiblesWriteOffs>
  <amed:OtherIntangiblesWriteOffs id="ID_801" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">300000</amed:OtherIntangiblesWriteOffs>
  <amed:OtherIntangiblesWriteOffs id="ID_802" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember" unitRef="USDollar">0</amed:OtherIntangiblesWriteOffs>
  <amed:OtherIntangiblesWriteOffs id="ID_803" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">200000</amed:OtherIntangiblesWriteOffs>
  <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife id="ID_804" contextRef="FROM_Jan01_2016_TO_Dec31_2016">P1Y10M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="ID_805" decimals="-5" contextRef="AS_OF_Dec31_2013_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CertificatesOfNeedAndLicensesMember" unitRef="USDollar">25400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="ID_806" decimals="-5" contextRef="AS_OF_Dec31_2013_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_AcquiredNamesOfBusinessMember" unitRef="USDollar">11100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="ID_807" decimals="-5" contextRef="AS_OF_Dec31_2013_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_NoncompeteAgreementsMember" unitRef="USDollar">200000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <amed:OtherIntangiblesWriteOffs id="ID_808" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CertificatesOfNeedAndLicensesMember" unitRef="USDollar">200000</amed:OtherIntangiblesWriteOffs>
  <amed:OtherIntangiblesWriteOffs id="ID_809" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_AcquiredNamesOfBusinessMember" unitRef="USDollar">0</amed:OtherIntangiblesWriteOffs>
  <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill id="ID_810" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CertificatesOfNeedAndLicensesMember" unitRef="USDollar">2100000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
  <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill id="ID_811" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_AcquiredNamesOfBusinessMember" unitRef="USDollar">1000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
  <us-gaap:AmortizationOfIntangibleAssets id="ID_812" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CertificatesOfNeedAndLicensesMember" unitRef="USDollar">0</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets id="ID_813" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_AcquiredNamesOfBusinessMember" unitRef="USDollar">0</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="ID_814" decimals="-5" contextRef="AS_OF_Dec31_2014_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CertificatesOfNeedAndLicensesMember" unitRef="USDollar">23100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="ID_815" decimals="-5" contextRef="AS_OF_Dec31_2014_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_AcquiredNamesOfBusinessMember" unitRef="USDollar">10100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <amed:OtherIntangibleAssetsAdditions id="ID_816" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CertificatesOfNeedAndLicensesMember" unitRef="USDollar">1100000</amed:OtherIntangibleAssetsAdditions>
  <amed:OtherIntangibleAssetsAdditions id="ID_817" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_AcquiredNamesOfBusinessMember" unitRef="USDollar">4100000</amed:OtherIntangibleAssetsAdditions>
  <amed:OtherIntangiblesWriteOffs id="ID_818" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CertificatesOfNeedAndLicensesMember" unitRef="USDollar">300000</amed:OtherIntangiblesWriteOffs>
  <amed:OtherIntangiblesWriteOffs id="ID_819" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_AcquiredNamesOfBusinessMember" unitRef="USDollar">0</amed:OtherIntangiblesWriteOffs>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="ID_820" decimals="-5" contextRef="AS_OF_Dec31_2015_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CertificatesOfNeedAndLicensesMember" unitRef="USDollar">23900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="ID_821" decimals="-5" contextRef="AS_OF_Dec31_2015_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_AcquiredNamesOfBusinessMember" unitRef="USDollar">14200000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <amed:OtherIntangibleAssetsAdditions id="ID_822" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CertificatesOfNeedAndLicensesMember" unitRef="USDollar">200000</amed:OtherIntangibleAssetsAdditions>
  <amed:OtherIntangibleAssetsAdditions id="ID_823" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_AcquiredNamesOfBusinessMember" unitRef="USDollar">3500000</amed:OtherIntangibleAssetsAdditions>
  <us-gaap:AmortizationOfIntangibleAssets id="ID_824" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CertificatesOfNeedAndLicensesMember" unitRef="USDollar">0</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets id="ID_825" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_AcquiredNamesOfBusinessMember" unitRef="USDollar">0</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="ID_826" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CertificatesOfNeedAndLicensesMember" unitRef="USDollar">24100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="ID_827" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_AcquiredNamesOfBusinessMember" unitRef="USDollar">17700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths id="ID_828" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">2700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo id="ID_829" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">2200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree id="ID_830" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour id="ID_831" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive id="ID_832" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
  <us-gaap:FiniteLivedIntangibleAssetsNet id="ID_833" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">4900000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <amed:DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock id="ID_834" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 20px"&gt;&lt;td colspan="10"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;6. DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 15px"&gt;&lt;td colspan="9"  style="width: 690px; text-align:left;border-color:#000000;min-width:690px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Additional information regarding certain balance sheet accounts is presented below (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5"  style="width: 180px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:180px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;As of December 31, &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 75px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 75px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Other current assets:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Payroll tax escrow&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Income tax receivable&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Due from joint ventures&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Other&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;11.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;14.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Other assets:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Workers' compensation deposits&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Health insurance deposits&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Other miscellaneous deposits&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Investments&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;27.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;25.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Other&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;8.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;38.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;32.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Accrued expenses:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Health insurance&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;11.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Workers' compensation&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;26.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;23.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Legal and other settlements&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;5.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Lease liability&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Charity care&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Estimated Medicare cap liability&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Hospice cost of revenue&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;7.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;OIG self-disclosure accrual&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Patient liability&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;5.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Other&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;63.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;72.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Other long-term obligations:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Reserve for uncertain tax positions&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Deferred compensation plan liability&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Other&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock>
  <amed:PayrollTaxEscrow id="ID_835" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">6700000</amed:PayrollTaxEscrow>
  <amed:PayrollTaxEscrow id="ID_836" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">6200000</amed:PayrollTaxEscrow>
  <us-gaap:IncomeTaxesReceivable id="ID_837" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">500000</us-gaap:IncomeTaxesReceivable>
  <us-gaap:DueFromJointVenturesCurrent id="ID_838" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">1800000</us-gaap:DueFromJointVenturesCurrent>
  <us-gaap:OtherAssetsMiscellaneousCurrent id="ID_839" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">6100000</us-gaap:OtherAssetsMiscellaneousCurrent>
  <us-gaap:IncomeTaxesReceivable id="ID_840" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">1300000</us-gaap:IncomeTaxesReceivable>
  <us-gaap:DueFromJointVenturesCurrent id="ID_841" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">1700000</us-gaap:DueFromJointVenturesCurrent>
  <us-gaap:OtherAssetsMiscellaneousCurrent id="ID_842" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">1600000</us-gaap:OtherAssetsMiscellaneousCurrent>
  <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock id="ID_843" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 20px"&gt;&lt;td colspan="10"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;6. DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 15px"&gt;&lt;td colspan="9"  style="width: 690px; text-align:left;border-color:#000000;min-width:690px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Additional information regarding certain balance sheet accounts is presented below (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5"  style="width: 180px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:180px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;As of December 31, &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 75px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 75px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Other current assets:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Payroll tax escrow&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Income tax receivable&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Due from joint ventures&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Other&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;11.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;14.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
  <us-gaap:ScheduleOfOtherAssetsTableTextBlock id="ID_844" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Other assets:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Workers' compensation deposits&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Health insurance deposits&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Other miscellaneous deposits&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Investments&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;27.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;25.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Other&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;8.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;38.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;32.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
  <amed:WorkersCompensationDeposits id="ID_845" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">400000</amed:WorkersCompensationDeposits>
  <amed:WorkersCompensationDeposits id="ID_846" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">300000</amed:WorkersCompensationDeposits>
  <amed:HealthInsuranceDeposits id="ID_847" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">500000</amed:HealthInsuranceDeposits>
  <amed:HealthInsuranceDeposits id="ID_848" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">1200000</amed:HealthInsuranceDeposits>
  <amed:OtherMiscellaneousDeposits id="ID_849" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">1500000</amed:OtherMiscellaneousDeposits>
  <amed:OtherMiscellaneousDeposits id="ID_850" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">900000</amed:OtherMiscellaneousDeposits>
  <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures id="ID_851" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">25700000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
  <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures id="ID_852" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">27800000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
  <us-gaap:OtherAssetsMiscellaneousNoncurrent id="ID_853" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">8900000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
  <us-gaap:OtherAssetsMiscellaneousNoncurrent id="ID_854" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">4100000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="ID_855" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Accrued expenses:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Health insurance&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;11.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Workers' compensation&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;26.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;23.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Legal and other settlements&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;5.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Lease liability&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Charity care&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Estimated Medicare cap liability&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Hospice cost of revenue&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;7.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;OIG self-disclosure accrual&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Patient liability&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;5.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Other&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;63.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;72.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:AccruedInsuranceCurrent id="ID_856" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">10600000</us-gaap:AccruedInsuranceCurrent>
  <amed:LegalAndOtherSettlements id="ID_857" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">5700000</amed:LegalAndOtherSettlements>
  <amed:LeaseLiability id="ID_858" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">400000</amed:LeaseLiability>
  <amed:CharityCare id="ID_859" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">1400000</amed:CharityCare>
  <amed:EstimatedMedicareCapLiability id="ID_860" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">800000</amed:EstimatedMedicareCapLiability>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="ID_861" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">6100000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:AccruedInsuranceCurrent id="ID_862" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">11700000</us-gaap:AccruedInsuranceCurrent>
  <us-gaap:WorkersCompensationLiabilityCurrent id="ID_863" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">23900000</us-gaap:WorkersCompensationLiabilityCurrent>
  <amed:LegalAndOtherSettlements id="ID_864" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">10500000</amed:LegalAndOtherSettlements>
  <amed:LeaseLiability id="ID_865" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">600000</amed:LeaseLiability>
  <amed:CharityCare id="ID_866" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">700000</amed:CharityCare>
  <amed:EstimatedMedicareCapLiability id="ID_867" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">1400000</amed:EstimatedMedicareCapLiability>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="ID_868" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">6600000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <amed:HospiceCostOfRevenue id="ID_869" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">7200000</amed:HospiceCostOfRevenue>
  <amed:HospiceCostOfRevenue id="ID_870" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">6800000</amed:HospiceCostOfRevenue>
  <amed:OigSelfDisclsoureAccrual id="ID_871" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">0</amed:OigSelfDisclsoureAccrual>
  <amed:OigSelfDisclsoureAccrual id="ID_872" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">4700000</amed:OigSelfDisclsoureAccrual>
  <amed:PatientLiability id="ID_873" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">5100000</amed:PatientLiability>
  <amed:PatientLiability id="ID_874" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">4300000</amed:PatientLiability>
  <us-gaap:WorkersCompensationLiabilityCurrent id="ID_875" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">26800000</us-gaap:WorkersCompensationLiabilityCurrent>
  <us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock id="ID_876" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Other long-term obligations:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Reserve for uncertain tax positions&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Deferred compensation plan liability&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Other&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock>
  <amed:DeferredCompensationPlanLiability id="ID_877" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">1800000</amed:DeferredCompensationPlanLiability>
  <amed:DeferredCompensationPlanLiability id="ID_878" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">2800000</amed:DeferredCompensationPlanLiability>
  <us-gaap:OtherSundryLiabilitiesNoncurrent id="ID_879" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">1600000</us-gaap:OtherSundryLiabilitiesNoncurrent>
  <us-gaap:OtherSundryLiabilitiesNoncurrent id="ID_880" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">900000</us-gaap:OtherSundryLiabilitiesNoncurrent>
  <amed:UncertainTaxBenefitsInLongTermObligations id="ID_881" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">300000</amed:UncertainTaxBenefitsInLongTermObligations>
  <amed:UncertainTaxBenefitsInLongTermObligations id="ID_882" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">700000</amed:UncertainTaxBenefitsInLongTermObligations>
  <us-gaap:DebtDisclosureTextBlock id="ID_883" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;7. LONG-TERM OBLIGATIONS&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Long-term debt consisted of the following for the periods indicated (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5"  style="width: 205px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:205px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;As  of December 31, &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 90px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 100px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:100px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$100.0 million Term Loan;  principal payments plus accrued interest payable
quarterly; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the
applicable percentage (2.77% at December 31, 2016); due August 28, 2020&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;95.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;100.0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$200.0 million Revolving Credit Facility; interest only quarterly payments; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the applicable percentage; due August 28, 2020&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Promissory notes&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Deferred debt issuance costs&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(2.7)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(3.4)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;93.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;96.6&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Current portion of long-term obligations&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(5.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(5.0)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;87.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;91.6&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="6"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Maturities of debt as of December 31, 2016 are as follows (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 25px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 75px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Long-term obligations&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;5.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;70.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2021&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;95.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Credit Agreement&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; August 28, 2015, we entered into a Credit Agreement that provides for senior secured facilities in an initial aggregate principal amount of up to $300 million (the &amp;#8220;Credit Facilities&amp;#8221;).&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;The Credit Facilities are comprised of (a) a term loan facility in an initial aggregate principal amount of $100 million (the &amp;#8220;Term Loan&amp;#8221;); and (b) a revolving credit facility in an initial aggregate principal amount of up to $200 million (the &amp;#8220;Revolving Credit Facility&amp;#8221;). The Revolving Credit Facility provides for and includes within its $200 million limit a $25 million &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;swingline&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; facility and commitments for up to $50 million in letters of credit. Upon lender approval, we may increase the aggregate loan amount under the Credit Facilities by a maximum amount of $150 million. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;The net proceeds of the Term Loan and existing cash on hand were used to pay off (i) our existing term loan under our prior Credit Agreement, dated as of October 22, 2012, as amended (the &amp;#8220;Prior Credit Agreement&amp;#8221;) with a principal balance of $27 million and (ii) our existing term loan under our prior Second Lien Credit Agreement dated July 28, 2014 (the &amp;#8220;Second Lien Credit Agreement&amp;#8221;), with a principal balance of $70 million.  The final ma&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;turity of the Term Loan is August 28, 2020. The Term Loan &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;began amortizing&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; on March 31, 2016 &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and will continue amortizing  over 14 quarterly instalments&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;four remaining&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; quarterly &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;installments&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of $1.25 million followed by eight quarterly &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;installments&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of $2.5 million, followed by two quarterly &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;installments&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of $3.1 million, subject to adjustment for prepayments), with the remaining balance due upon maturity.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;The Revolving Credit Facility may be used to provide ongoing working capital and for general corporate purposes of the Company and our subsidiaries, including permitted acquisitions, as defined in the Credit Agreement.  The final maturity of the Revolving Credit Facility is August 28, 2020 and will be payable in full at that time.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;The interest rate in connection with the Credit Facilities shall be selected from the following by us: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The &amp;#8220;Base Rate&amp;#8221; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate for an interest period of one month plus 1% per annum. The &amp;#8220;Eurodollar Rate&amp;#8221; means the rate at which Eur&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;odollar deposits in the London interbank market for an interest period of one, two, three or six months (as selected by us) are quoted. The &amp;#8220;Applicable Rate&amp;#8221; is based on the consolidated leverage ratio and is presented in the table below. As of December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, the Applicable Rate is &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;00&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% per annum for Base Rate Loans and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; per annum for Eurodollar Rate Loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Credit Facilities, as presented in the table below&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 29px"&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 160px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:160px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Consolidated  Leverage Ratio&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:center;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Margin for ABR Loans&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Margin for Eurodollar Loans&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Commitment Fee&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:center;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Letter of Credit Fee&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:center;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 160px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:160px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;&amp;#8805; 2.75 to 1.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.00%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.00%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.40%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.00%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 23px"&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 160px; text-align:center;border-color:#000000;min-width:160px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;&amp;lt; 2.75 to 1.0 but &amp;#8805; 1.75 to 1.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.50%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:right;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.50%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.35%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.50%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 25px"&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 160px; text-align:center;border-color:#000000;min-width:160px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;&amp;lt; 1.75 to 1.0 but &amp;#8805; 0.75 to 1.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.00%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:right;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.00%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.30%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.00%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 160px; text-align:center;border-color:#000000;min-width:160px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;&amp;lt; 0.75 to 1.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.50%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:right;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.50%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.25%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.50%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 160px; text-align:center;border-color:#000000;min-width:160px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:left;border-color:#000000;min-width:105px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Our&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;weighted average interest rate for our $100.0 million Term Loan, under our Credit Agreement, was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2.5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% for&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2.7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;for the period August 28, 2015 to December 31, 2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. Our weighted average interest rate for our $200.0 million Revolving Credit Facility was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3.5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% for 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;As of December 31,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; 2016,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; our availability under our $200.0 million Revolving Credit Facility was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;173.3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million as we had $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;26.7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million outstanding in letters of credit.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;The Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to EBITDA, as defined in the Credit Agreem&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ent, and (ii) a consolidated fixed charge coverage ratio of EBITDA plus rent expense (less cash taxes less capital expenditures) to scheduled debt repayments plus interest expense plus rent expense, all as defined in the Credit Agreement.  Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;December 31&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, our consolidated &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;leverage ratio was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and our consolidated fixed charge coverage ratio was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and we are in compliance with the Credit Agreement. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;The Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens; incurrence of additional debt; sales of assets and other fundamental corporate changes; investments; and declarations of dividends. These covenants contain customary exclusions and baskets. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;The Credit Facilities are guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than 70% of consolidated adjusted EBITDA, subject to certain exceptions. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In connection with entering into the Credit Agreement, we entered into (i) a Security Agreement with the Administrative Agent dated August 28, 2015 and (ii) a Pledge Agreement with the Administrative Agent dated as of August 28, 2015 for the purpose of securing the payment of our obligations under the Credit Agreement.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Pursuant to the Security Agreement and the Pledge Agreement, as of the effective date of the Credit Agreement, our obligations under the Credit Agreement are secured by (i) the grant of a first lien security interest in the non-real estate assets of substantially all of our direct and indirect, wholly-owned subsidiaries (subject to exceptions) and (ii) the pledge of the equity interests in (a) substantially all of our direct and indirect, wholly-owned corporate, limited liability company and limited partnership subsidiaries and (b) those joint ventures which constitute subsidiaries under the Credit Agreement (subject, in the case of the Pledge Agreement, to exceptions).&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In connection with our entry into the Credit Agreement, on August 28, 2015, each of the Prior Credit Agreement and the Second Lien Credit Agreement &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;were terminated. The Company paid a call premium of $700,000 associated with the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;termination of the Second Lien Credit Agreement and the voluntary prepayment of the amounts owed thereunder as of August 28, 2015, and expensed $2.5 million in deferred debt issuance costs during the three-month period ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;September 30&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, 2015. Also in connection with our entry into the Credit Agreement, we recorded $2.4 million in deferred debt issuance costs as other assets in our consolidated balance sheet&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; during 2015 which was reclassified to long-term obligations, less current portion during 2016 in accordance with ASU 2015-03&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Promissory Notes&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Our promissory note outstanding of $0.7 million, issued in conjunction with an acquisition, bears an interest rate of 2.6%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&amp;#160;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:ScheduleOfDebtInstrumentsTextBlock id="ID_884" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;7. LONG-TERM OBLIGATIONS&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Long-term debt consisted of the following for the periods indicated (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5"  style="width: 205px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:205px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;As  of December 31, &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 90px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 100px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:100px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$100.0 million Term Loan;  principal payments plus accrued interest payable
quarterly; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the
applicable percentage (2.77% at December 31, 2016); due August 28, 2020&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;95.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;100.0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$200.0 million Revolving Credit Facility; interest only quarterly payments; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the applicable percentage; due August 28, 2020&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Promissory notes&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Deferred debt issuance costs&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(2.7)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(3.4)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;93.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;96.6&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Current portion of long-term obligations&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(5.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(5.0)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;87.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;91.6&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
  <us-gaap:LongTermDebt id="ID_885" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember" unitRef="USDollar">95000000</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebt id="ID_886" decimals="-5" contextRef="AS_OF_Dec31_2015_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember" unitRef="USDollar">100000000</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebt id="ID_887" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">96600000</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebt id="ID_888" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember" unitRef="USDollar">0</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebt id="ID_889" decimals="-5" contextRef="AS_OF_Dec31_2015_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember" unitRef="USDollar">0</us-gaap:LongTermDebt>
  <amed:RevolvingCreditFacilityTotal id="ID_890" decimals="-6" contextRef="AS_OF_Aug28_2015_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember" unitRef="USDollar">200000000</amed:RevolvingCreditFacilityTotal>
  <amed:DebtInstrumentNumberOfPeriodicPayments id="ID_891" decimals="0" contextRef="AS_OF_Dec31_2016_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember" unitRef="Installment">14</amed:DebtInstrumentNumberOfPeriodicPayments>
  <amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate id="ID_892" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LongtermDebtTypeAxis_CreditAgreementMember" unitRef="Pure">0.0050</amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate>
  <amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate id="ID_893" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LongtermDebtTypeAxis_CreditAgreementMember" unitRef="Pure">0.0100</amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate>
  <amed:ApplicableMarginRateOnEurodollarRate id="ID_894" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LongtermDebtTypeAxis_CreditAgreementMember" unitRef="Pure">0.0200</amed:ApplicableMarginRateOnEurodollarRate>
  <amed:WeightedAverageInterestRate id="ID_895" decimals="3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember" unitRef="Pure">0.0250</amed:WeightedAverageInterestRate>
  <amed:TotalLeverageRatio id="ID_896" decimals="1" contextRef="AS_OF_Dec31_2016" unitRef="Pure">1.0</amed:TotalLeverageRatio>
  <amed:FixedChargeCoverageRatio id="ID_897" decimals="1" contextRef="AS_OF_Dec31_2016" unitRef="Pure">3.8</amed:FixedChargeCoverageRatio>
  <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity id="ID_898" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember" unitRef="USDollar">173300000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
  <us-gaap:LettersOfCreditOutstandingAmount id="ID_899" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember" unitRef="USDollar">26700000</us-gaap:LettersOfCreditOutstandingAmount>
  <us-gaap:LongTermDebtNoncurrent id="ID_900" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">87800000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="ID_901" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">91600000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity id="ID_902" decimals="-6" contextRef="AS_OF_Aug28_2015_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember" unitRef="USDollar">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:DebtInstrumentFaceAmount id="ID_903" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember" unitRef="USDollar">200000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentMaturityDate id="ID_904" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember">2020-08-28</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity id="ID_905" decimals="-6" contextRef="AS_OF_Aug28_2015" unitRef="USDollar">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <amed:EurodollarDepositsInterestPeriod id="ID_906" contextRef="FROM_Jan01_2016_TO_Dec31_2016_amed_TimePeriodAxis_OneMonthMember_us-gaap_LongtermDebtTypeAxis_CreditAgreementMember">P1M</amed:EurodollarDepositsInterestPeriod>
  <amed:EurodollarDepositsInterestPeriod id="ID_907" contextRef="FROM_Jan01_2016_TO_Dec31_2016_amed_TimePeriodAxis_TwoMonthMember_us-gaap_LongtermDebtTypeAxis_CreditAgreementMember">P2M</amed:EurodollarDepositsInterestPeriod>
  <amed:EurodollarDepositsInterestPeriod id="ID_908" contextRef="FROM_Jan01_2016_TO_Dec31_2016_amed_TimePeriodAxis_ThreeMonthMember_us-gaap_LongtermDebtTypeAxis_CreditAgreementMember">P3M</amed:EurodollarDepositsInterestPeriod>
  <amed:EurodollarDepositsInterestPeriod id="ID_909" contextRef="FROM_Jan01_2016_TO_Dec31_2016_amed_TimePeriodAxis_SixMonthMember_us-gaap_LongtermDebtTypeAxis_CreditAgreementMember">P6M</amed:EurodollarDepositsInterestPeriod>
  <amed:InterestRateOnNotesPayableToBank id="ID_910" decimals="4" contextRef="AS_OF_Dec31_2016_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember" unitRef="Pure">0.0277</amed:InterestRateOnNotesPayableToBank>
  <us-gaap:DebtInstrumentMaturityDate id="ID_911" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember">2020-08-28</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentFaceAmount id="ID_912" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember" unitRef="USDollar">100000000</us-gaap:DebtInstrumentFaceAmount>
  <amed:DebtInstrumentNumberOfPeriodicPayments id="ID_913" decimals="0" contextRef="AS_OF_Dec31_2016_amed_TimePeriodAxis_FourRemainingQuarterlyPaymentsMember" unitRef="Installment">4</amed:DebtInstrumentNumberOfPeriodicPayments>
  <amed:DebtInstrumentNumberOfPeriodicPayments id="ID_914" decimals="0" contextRef="AS_OF_Dec31_2016_amed_TimePeriodAxis_SecondEightQuarterlyPaymentsMember" unitRef="Installment">8</amed:DebtInstrumentNumberOfPeriodicPayments>
  <amed:DebtInstrumentNumberOfPeriodicPayments id="ID_915" decimals="0" contextRef="AS_OF_Dec31_2016_amed_TimePeriodAxis_FinalTwoQuarterlyPaymentsMember" unitRef="Installment">2</amed:DebtInstrumentNumberOfPeriodicPayments>
  <us-gaap:DebtInstrumentPeriodicPaymentPrincipal id="ID_916" decimals="-4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_amed_TimePeriodAxis_FourRemainingQuarterlyPaymentsMember" unitRef="USDollar">1250000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
  <us-gaap:DebtInstrumentPeriodicPaymentPrincipal id="ID_917" decimals="-4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_amed_TimePeriodAxis_SecondEightQuarterlyPaymentsMember" unitRef="USDollar">2500000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
  <us-gaap:DebtInstrumentPeriodicPaymentPrincipal id="ID_918" decimals="-4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_amed_TimePeriodAxis_FinalTwoQuarterlyPaymentsMember" unitRef="USDollar">3100000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
  <amed:RevolvingCreditFacilityTotal id="ID_919" decimals="-6" contextRef="AS_OF_Aug28_2015_us-gaap_LongtermDebtTypeAxis_SwingLineLoanMember" unitRef="USDollar">25000000</amed:RevolvingCreditFacilityTotal>
  <amed:RevolvingCreditFacilityTotal id="ID_920" decimals="-6" contextRef="AS_OF_Aug28_2015_us-gaap_LongtermDebtTypeAxis_LetterOfCreditMember" unitRef="USDollar">50000000</amed:RevolvingCreditFacilityTotal>
  <us-gaap:DebtInstrumentFaceAmount id="ID_921" decimals="-6" contextRef="AS_OF_Aug28_2015_us-gaap_LongtermDebtTypeAxis_TermLoanMember" unitRef="USDollar">27000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount id="ID_922" decimals="-6" contextRef="AS_OF_Aug28_2015_us-gaap_LongtermDebtTypeAxis_SecondLienCreditAgreementTermLoanMember" unitRef="USDollar">70000000</us-gaap:DebtInstrumentFaceAmount>
  <amed:LineOfCreditFacilityAdditionalBorrowingCapacity id="ID_923" decimals="-6" contextRef="AS_OF_Aug28_2015_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember" unitRef="USDollar">150000000</amed:LineOfCreditFacilityAdditionalBorrowingCapacity>
  <amed:ApplicableMarginRateOnBaseRate id="ID_924" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LongtermDebtTypeAxis_CreditAgreementMember" unitRef="Pure">0.0100</amed:ApplicableMarginRateOnBaseRate>
  <amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries id="ID_925" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LongtermDebtTypeAxis_CreditAgreementMember" unitRef="Pure">0.700</amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries>
  <amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries id="ID_926" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LongtermDebtTypeAxis_CreditAgreementMember" unitRef="Pure">0.9500</amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries>
  <us-gaap:DebtIssuanceCosts id="ID_927" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">2400000</us-gaap:DebtIssuanceCosts>
  <us-gaap:WriteOffOfDeferredDebtIssuanceCost id="ID_928" decimals="-5" contextRef="FROM_Jul01_2015_TO_Sep30_2015" unitRef="USDollar">2500000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
  <amed:CallPremiumPayment id="ID_929" decimals="0" contextRef="FROM_Jan01_2015_TO_Aug28_2015_us-gaap_LongtermDebtTypeAxis_SecondLienCreditAgreementTermLoanMember" unitRef="USDollar">700000</amed:CallPremiumPayment>
  <us-gaap:LongTermDebt id="ID_930" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_LongtermDebtTypeAxis_PromissoryNotesMember" unitRef="USDollar">700000</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebt id="ID_931" decimals="-5" contextRef="AS_OF_Dec31_2015_us-gaap_LongtermDebtTypeAxis_PromissoryNotesMember" unitRef="USDollar">0</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebt id="ID_932" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">93000000</us-gaap:LongTermDebt>
  <amed:WeightedAverageInterestRate id="ID_933" decimals="3" contextRef="FROM_Aug31_2015_TO_Dec31_2015_us-gaap_LongtermDebtTypeAxis_OneHundredMillionTermLoanMember" unitRef="Pure">0.0270</amed:WeightedAverageInterestRate>
  <amed:WeightedAverageInterestRate id="ID_934" decimals="3" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LongtermDebtTypeAxis_TwoHundredMillionRevolvingCreditFacilityMember" unitRef="Pure">0.0350</amed:WeightedAverageInterestRate>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage id="ID_935" decimals="4" contextRef="AS_OF_Dec31_2016_us-gaap_LongtermDebtTypeAxis_PromissoryNotesMember" unitRef="Pure">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock id="ID_936" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="6"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Maturities of debt as of December 31, 2016 are as follows (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 25px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 75px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Long-term obligations&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;5.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;70.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2021&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;95.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths id="ID_937" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">5200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo id="ID_938" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">10500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree id="ID_939" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">10000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour id="ID_940" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">70000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
  <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive id="ID_941" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
  <us-gaap:DebtLongtermAndShorttermCombinedAmount id="ID_942" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">95700000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
  <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock id="ID_943" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 29px"&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 160px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:160px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Consolidated  Leverage Ratio&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:center;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Margin for ABR Loans&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Margin for Eurodollar Loans&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Commitment Fee&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:center;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Letter of Credit Fee&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:center;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 160px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:160px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;&amp;#8805; 2.75 to 1.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.00%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.00%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.40%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.00%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 23px"&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 160px; text-align:center;border-color:#000000;min-width:160px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;&amp;lt; 2.75 to 1.0 but &amp;#8805; 1.75 to 1.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.50%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:right;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.50%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.35%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.50%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 25px"&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 160px; text-align:center;border-color:#000000;min-width:160px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;&amp;lt; 1.75 to 1.0 but &amp;#8805; 0.75 to 1.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.00%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:right;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.00%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.30%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.00%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 160px; text-align:center;border-color:#000000;min-width:160px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;&amp;lt; 0.75 to 1.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.50%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:right;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.50%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.25%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.50%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 160px; text-align:center;border-color:#000000;min-width:160px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:left;border-color:#000000;min-width:105px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 id="ID_944" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LineOfCreditFacilityAxis_AbrLoansMember_us-gaap_RangeAxis_RangeFourMember" unitRef="Pure">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 id="ID_945" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LineOfCreditFacilityAxis_AbrLoansMember_us-gaap_RangeAxis_RangeOneMember" unitRef="Pure">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 id="ID_946" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LineOfCreditFacilityAxis_AbrLoansMember_us-gaap_RangeAxis_RangeTwoMember" unitRef="Pure">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 id="ID_947" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LineOfCreditFacilityAxis_AbrLoansMember_us-gaap_RangeAxis_RangeThreeMember" unitRef="Pure">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 id="ID_948" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LineOfCreditFacilityAxis_EurodollarLoansMember_us-gaap_RangeAxis_RangeOneMember" unitRef="Pure">0.0300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 id="ID_949" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LineOfCreditFacilityAxis_EurodollarLoansMember_us-gaap_RangeAxis_RangeTwoMember" unitRef="Pure">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 id="ID_950" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LineOfCreditFacilityAxis_EurodollarLoansMember_us-gaap_RangeAxis_RangeThreeMember" unitRef="Pure">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 id="ID_951" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LineOfCreditFacilityAxis_EurodollarLoansMember_us-gaap_RangeAxis_RangeFourMember" unitRef="Pure">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:LineOfCreditFacilityCommitmentFeePercentage id="ID_952" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RangeAxis_RangeTwoMember" unitRef="Pure">0.0035</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
  <us-gaap:LineOfCreditFacilityCommitmentFeePercentage id="ID_953" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RangeAxis_RangeOneMember" unitRef="Pure">0.0040</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
  <us-gaap:LineOfCreditFacilityCommitmentFeePercentage id="ID_954" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RangeAxis_RangeThreeMember" unitRef="Pure">0.0030</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
  <us-gaap:LineOfCreditFacilityCommitmentFeePercentage id="ID_955" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RangeAxis_RangeFourMember" unitRef="Pure">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
  <amed:LetterOfCreditFee id="ID_956" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RangeAxis_RangeTwoMember" unitRef="Pure">0.0250</amed:LetterOfCreditFee>
  <amed:LetterOfCreditFee id="ID_957" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RangeAxis_RangeOneMember" unitRef="Pure">0.0300</amed:LetterOfCreditFee>
  <amed:LetterOfCreditFee id="ID_958" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RangeAxis_RangeThreeMember" unitRef="Pure">0.0200</amed:LetterOfCreditFee>
  <amed:LetterOfCreditFee id="ID_959" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RangeAxis_RangeFourMember" unitRef="Pure">0.0150</amed:LetterOfCreditFee>
  <us-gaap:IncomeTaxDisclosureTextBlock id="ID_960" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:13pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;"&gt;8. INCOME TAXES&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:9pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="12"  style="width: 665px; text-align:left;border-color:#000000;min-width:665px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Income taxes attributable to continuing operations consist of the following (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="8"  style="width: 219px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:219px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Years Ended December 31, &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Current income tax expense/(benefit):&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Federal&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.5)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(13.9)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;State and local&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(1.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.6)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(15.0)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Deferred income tax expense/(benefit):&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Federal &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;22.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.5)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;21.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;State and local&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Foreign&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;24.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.7)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;22.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 391px; text-align:center;border-color:#000000;min-width:391px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Income tax expense/(benefit) from continuing operations&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;23.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;7.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:center;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:center;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="12" rowspan="2" style="width: 665px; text-align:left;border-color:#000000;min-width:665px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Total income tax expense for the years ended December 31, 2016, 2015 and 2014 was allocated as follows (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="8"  style="width: 219px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:219px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Years Ended December 31, &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Income from continuing operations &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;23.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;7.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Income from discontinued operations &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Interest expense&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Goodwill&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Stockholders' equity &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(7.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(2.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;16.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;8.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;A reconciliation of significant differences between the reported amount of income tax expense and the expected amount of income tax expense that would result from applying the U.S. federal &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;statutory&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; income tax rate of 35 percent to income before taxes from continuing operations is as follo&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ws:&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="8"  style="width: 237px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:237px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Years Ended December 31,&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 71px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:71px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 71px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:71px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015 (1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 71px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:71px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 7px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 16px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 16px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 16px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Income tax expense at U.S. federal statutory rate&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;35.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;35.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;35.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;State and local income taxes, net of federal income tax benefit&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(7.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;5.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;79.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Tax credits&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.6)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;136.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(8.4)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Uncertain tax positions &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(1.0)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(230.3)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Other items, net (2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(663.3)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Income tax expense/(benefit)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;38.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:16px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(650.6)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:16px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;36.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:16px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;/p&gt;&lt;ul&gt;&lt;li style="margin-left:36px;list-style:decimal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;The information provided for the year ended December 31, 2015 does not provide a meaningful reconciliation of the effective tax rate or comparable to other periods. The effective tax rate for the year is influenced by the relationship of the amount of &amp;#8220;effective tax rate drivers&amp;#8221; (i.e. non-deductible expenses, non-taxable income, tax credits, valuation allowance, uncertain tax positions, etc.) to income or loss before taxes. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;A significant&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; asset impairment was recorded in the first quarter, resulting in a scenario where the company's loss before tax for the year was near zero. Consequently, for 2015, the relationship between &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;the &amp;#8220;effective tax rate drivers&amp;#8221;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and loss before taxes is distorted. &lt;/font&gt;&lt;/li&gt;&lt;li style="margin-left:36px;list-style:decimal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Includes various items such as, non-deductible expenses, non-taxable income, return-to-accrual adjustments, and foreign tax rate differential.&lt;/font&gt;&lt;/li&gt;&lt;/ul&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;As of December 31,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, the Company had income taxes receivable of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million and $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million, respectively, included in other current &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;assets&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 533px; text-align:left;border-color:#000000;min-width:533px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Deferred tax assets (liabilities) consist of the following components (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5"  style="width: 142px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:142px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;As of December 31,&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Allowance for doubtful accounts&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Accrued payroll &amp;amp; employee benefits&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;11.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;5.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Workers' compensation&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;9.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Amortization of intangible assets&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;56.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;72.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Share-based compensation&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;7.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;5.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Net operating loss carryforwards (1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;44.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;48.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Tax credit carryforwards (2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Other&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Gross deferred tax assets&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;143.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;155.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Less: valuation allowance&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.4)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.3)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Net deferred tax assets&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;143.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;155.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Deferred tax (liabilities):&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Property and equipment&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(7.8)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(9.5)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Deferred revenue&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(23.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(18.5)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Investment in partnerships&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(3.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Other liabilities &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.9)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(2.0)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Gross deferred tax (liabilities)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(35.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(30.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Net deferred tax assets (liabilities)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; $ &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;107.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; $ &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;125.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;(1)&lt;/font&gt;&lt;/td&gt;&lt;td colspan="7" rowspan="4" style="width: 660px; text-align:left;border-color:#000000;min-width:660px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The net operating loss ("NOL") carry forwards in the income tax returns include unrecognized tax benefits resulting from uncertain tax positions. Accordingly, the deferred tax assets recognized for the NOL carry forwards, as of December 31, 2016 and 2015, are presented net of unrecognized tax benefits of $3.1 million.&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;(2)&lt;/font&gt;&lt;/td&gt;&lt;td colspan="7" rowspan="4" style="width: 660px; text-align:left;border-color:#000000;min-width:660px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The tax credit carry forwards in the income tax returns include unrecognized tax benefits resulting from uncertain tax positions. Accordingly, the deferred tax assets recognized for the tax credit carry forwards are presented net of unrecognized tax benefits of $0.7 million for each of the years ended December 31, 2016 and 2015.&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;As of December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we have U.S. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;net operating loss (&amp;#8220;NOL&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; carry forward&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;102.1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million that &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;are&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;available to reduce future taxable income&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and begin&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; to expire in 2034&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. In addition, we have&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; r&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;esearch &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;d&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;evelopment tax credits, employment tax credits, and alternative minimum tax credits&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of $1.9 million, $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million and $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;respectively, available to reduce future U.S. federal income taxes. The &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;r&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;esearch &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;d&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;evelopment tax credits and employment tax credits begin to expire in 2032, and the alternative minimum tax credits are available indefinitely&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;As of December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we have state NOL carry forwards of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;268.4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million that are available to reduce future taxable income. In addition, we have $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3.1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million of various state tax credits available to reduce future taxable income. The state NOL and tax credit carry forwards begin to expire at various times.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;The&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; valuation allowance &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;for deferred &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;tax assets as of December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; was $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million and $0.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million, respectively. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;The net change in the total valuation allowance for the year ended December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and December 31&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;a&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;n&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;increase&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;decrease &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;of $0.3 million, respectively&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. The valuation allowance during 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; was primarily related to certain state NOL and state tax credit carry forwards&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In assessing the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;realizability&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those jurisdictions during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities (including the impact of available carry back and carry forward periods), projected future taxable income, and tax-planning strategies in making this assessment. In order to fully realize the deferred tax assets, the Company will need to generate future taxable income before the expiration of the carry forwards governed by the tax code. Based on the current level of pretax earnings&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;the Company will generate the minimum amount of future taxable income to support the realization of the deferred tax assets. As a result, management believes that it is more likely than not that we will realize the benefits of these deferred tax assets, net of the existing valuation allowances at December&amp;#160;31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. The amount of the deferred tax asset considered realizable, however, could be reduced in the near term if estimates of future taxable income during the carry forward period are reduced&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 10px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="10"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Uncertain Tax Positions&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td colspan="10"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;We account for uncertain tax positions in accordance with the authoritative guidance for uncertain tax positions. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 23px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5"  style="width: 142px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:142px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Years Ended December 31, &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 468px; text-align:left;border-color:#000000;min-width:468px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Balance at beginning of period&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Additions for tax positions related to current year&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Additions for tax positions related to prior year&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Reductions for tax positions related to prior years&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Lapse of statute of limitations&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.6)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.3)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Settlements&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 468px; text-align:left;border-color:#000000;min-width:468px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Balance at end of period&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;As of December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, there are $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3.8 &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million of unrecognized tax benefits recorded in &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;accrued&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;other long-term obligations and deferred income taxes, respectively, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;within the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;consolidated balance sheet&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Included in the balance of unrecognized tax benefits at December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; is $4.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million of tax benefits that, if recognized in future periods, would impact our effective tax rate. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;During the years ended December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we recognized interest and penalties of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(0.1)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million and $0.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million, respectively, as components of p&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;enalties or interest expense in connection with our reserve for uncertain tax positions. Interest and penalties, related to uncertain tax positions, included in the consolidated balance sheet at December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; were less than &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$0.1 and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$0.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, respectively&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.  &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We are subject to income taxes in the U.S. and in many of the 50 individual states, with significant operations in Louisiana, Alabama, Georgia, and Tennessee. We are open to examination in the U.S. and in various individual states for tax years ended December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; through December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. We are also open to examination in various states for the years ended 200&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &amp;#8211; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; resulting from net operating losses generated and available for carry forward from those years&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We believe that it is reasonab&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ly possible that decrease&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;up to $0.3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million in unrecognized tax benefits, each of which are individually insignificant, may be recognized by the end of December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; as a result of an anticipated settlement and lapse of the statute of limitations&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <amed:ProvisionForIncomeTaxesTextBlock id="ID_961" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="12"  style="width: 665px; text-align:left;border-color:#000000;min-width:665px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Income taxes attributable to continuing operations consist of the following (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="8"  style="width: 219px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:219px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Years Ended December 31, &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Current income tax expense/(benefit):&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Federal&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.5)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(13.9)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;State and local&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(1.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.6)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(15.0)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Deferred income tax expense/(benefit):&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Federal &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;22.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.5)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;21.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;State and local&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Foreign&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;24.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.7)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;22.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 391px; text-align:center;border-color:#000000;min-width:391px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Income tax expense/(benefit) from continuing operations&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;23.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;7.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:center;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:center;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="12" rowspan="2" style="width: 665px; text-align:left;border-color:#000000;min-width:665px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Total income tax expense for the years ended December 31, 2016, 2015 and 2014 was allocated as follows (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="8"  style="width: 219px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:219px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Years Ended December 31, &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Income from continuing operations &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;23.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;7.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Income from discontinued operations &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Interest expense&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Goodwill&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Stockholders' equity &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(7.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(2.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;16.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;8.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:ProvisionForIncomeTaxesTextBlock>
  <us-gaap:CurrentFederalTaxExpenseBenefit id="ID_962" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">-500000</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit id="ID_963" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">-100000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit id="ID_964" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">-600000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit id="ID_965" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">22100000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit id="ID_966" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">2400000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit id="ID_967" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">500000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:CurrentFederalTaxExpenseBenefit id="ID_968" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">2200000</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit id="ID_969" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">2700000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit id="ID_970" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-100000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit id="ID_971" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-500000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit id="ID_972" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">21000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit id="ID_973" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">1600000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit id="ID_974" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">-15000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit id="ID_975" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">-1100000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:CurrentFederalTaxExpenseBenefit id="ID_976" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">-13900000</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit id="ID_977" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">100000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit id="ID_978" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit id="ID_979" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-100000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <amed:DeferredIncomeTaxesForContinuingOperations id="ID_980" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">24500000</amed:DeferredIncomeTaxesForContinuingOperations>
  <amed:DeferredIncomeTaxesForContinuingOperations id="ID_981" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-700000</amed:DeferredIncomeTaxesForContinuingOperations>
  <amed:DeferredIncomeTaxesForContinuingOperations id="ID_982" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">22700000</amed:DeferredIncomeTaxesForContinuingOperations>
  <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation id="ID_983" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
  <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation id="ID_984" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">0</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
  <amed:IncomeTaxEffectsAllocatedToInterestExpense id="ID_985" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">-100000</amed:IncomeTaxEffectsAllocatedToInterestExpense>
  <amed:IncomeTaxEffectsAllocatedToInterestExpense id="ID_986" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">200000</amed:IncomeTaxEffectsAllocatedToInterestExpense>
  <amed:IncomeTaxEffectsAllocatedToInterestExpense id="ID_987" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">-100000</amed:IncomeTaxEffectsAllocatedToInterestExpense>
  <us-gaap:IncomeTaxEffectsAllocatedDirectlyToEquityOther id="ID_988" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">-7200000</us-gaap:IncomeTaxEffectsAllocatedDirectlyToEquityOther>
  <us-gaap:IncomeTaxEffectsAllocatedDirectlyToEquityOther id="ID_989" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-2100000</us-gaap:IncomeTaxEffectsAllocatedDirectlyToEquityOther>
  <us-gaap:IncomeTaxEffectsAllocatedDirectlyToEquityOther id="ID_990" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">600000</us-gaap:IncomeTaxEffectsAllocatedDirectlyToEquityOther>
  <amed:IncomeTaxEffectsAllocatedToGoodwill id="ID_991" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</amed:IncomeTaxEffectsAllocatedToGoodwill>
  <amed:IncomeTaxEffectsAllocatedToGoodwill id="ID_992" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-100000</amed:IncomeTaxEffectsAllocatedToGoodwill>
  <amed:IncomeTaxEffectsAllocatedToGoodwill id="ID_993" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">0</amed:IncomeTaxEffectsAllocatedToGoodwill>
  <us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation id="ID_994" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">16600000</us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation>
  <us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation id="ID_995" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">0</us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation>
  <us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation id="ID_996" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">8100000</us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation>
  <amed:ReconciliationOfStatutoryTaxEffectsTextBlock id="ID_997" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="8"  style="width: 237px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:237px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Years Ended December 31,&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 71px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:71px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 71px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:71px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015 (1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 71px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:71px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 7px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 16px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 16px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 16px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Income tax expense at U.S. federal statutory rate&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;35.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;35.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;35.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;State and local income taxes, net of federal income tax benefit&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(7.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;5.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;79.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Tax credits&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.6)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;136.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(8.4)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Uncertain tax positions &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(1.0)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(230.3)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Other items, net (2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(663.3)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Income tax expense/(benefit)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;38.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:16px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(650.6)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:16px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;36.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 16px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:16px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:ReconciliationOfStatutoryTaxEffectsTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="ID_998" decimals="3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Pure">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="ID_999" decimals="3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Pure">0.048</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="ID_1000" decimals="3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits id="ID_1001" decimals="3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Pure">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="ID_1002" decimals="3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Pure">0.389</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits id="ID_1003" decimals="3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="Pure">1.360</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="ID_1004" decimals="3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="Pure">0.791</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="ID_1005" decimals="3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="Pure">-0.071</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="ID_1006" decimals="3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="Pure">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="ID_1007" decimals="3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="Pure">-6.506</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="ID_1008" decimals="3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="Pure">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="ID_1009" decimals="3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="Pure">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits id="ID_1010" decimals="3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="Pure">-0.084</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="ID_1011" decimals="3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="Pure">0.058</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="ID_1012" decimals="3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="Pure">0.366</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments id="ID_1013" decimals="3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments id="ID_1014" decimals="3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="Pure">-2.303</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments id="ID_1015" decimals="3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="Pure">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense id="ID_1016" decimals="3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Pure">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense id="ID_1017" decimals="3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="Pure">-6.633</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense id="ID_1018" decimals="3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="Pure">0.021</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="ID_1019" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 533px; text-align:left;border-color:#000000;min-width:533px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Deferred tax assets (liabilities) consist of the following components (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5"  style="width: 142px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:142px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;As of December 31,&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Allowance for doubtful accounts&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Accrued payroll &amp;amp; employee benefits&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;11.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;5.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Workers' compensation&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;9.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Amortization of intangible assets&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;56.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;72.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Share-based compensation&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;7.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;5.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Net operating loss carryforwards (1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;44.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;48.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Tax credit carryforwards (2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Other&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Gross deferred tax assets&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;143.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;155.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Less: valuation allowance&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.4)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.3)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Net deferred tax assets&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;143.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;155.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Deferred tax (liabilities):&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Property and equipment&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(7.8)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(9.5)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Deferred revenue&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(23.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(18.5)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Investment in partnerships&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(3.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Other liabilities &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.9)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(2.0)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Gross deferred tax (liabilities)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(35.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(30.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Net deferred tax assets (liabilities)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; $ &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;107.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; $ &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;125.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;(1)&lt;/font&gt;&lt;/td&gt;&lt;td colspan="7" rowspan="4" style="width: 660px; text-align:left;border-color:#000000;min-width:660px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The net operating loss ("NOL") carry forwards in the income tax returns include unrecognized tax benefits resulting from uncertain tax positions. Accordingly, the deferred tax assets recognized for the NOL carry forwards, as of December 31, 2016 and 2015, are presented net of unrecognized tax benefits of $3.1 million.&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;(2)&lt;/font&gt;&lt;/td&gt;&lt;td colspan="7" rowspan="4" style="width: 660px; text-align:left;border-color:#000000;min-width:660px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The tax credit carry forwards in the income tax returns include unrecognized tax benefits resulting from uncertain tax positions. Accordingly, the deferred tax assets recognized for the tax credit carry forwards are presented net of unrecognized tax benefits of $0.7 million for each of the years ended December 31, 2016 and 2015.&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts id="ID_1020" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">6900000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
  <amed:DeferredTaxAssetsOtherCurrent id="ID_1021" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">1100000</amed:DeferredTaxAssetsOtherCurrent>
  <amed:DeferredTaxAssetsOtherCurrent id="ID_1022" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">4000000</amed:DeferredTaxAssetsOtherCurrent>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts id="ID_1023" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">6400000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment id="ID_1024" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">7800000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet id="ID_1025" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">107900000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment id="ID_1026" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">9500000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet id="ID_1027" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">125200000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <amed:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation id="ID_1028" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">10900000</amed:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation>
  <amed:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation id="ID_1029" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">9800000</amed:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation>
  <amed:DeferredTaxAssetsGoodwillAndIntangibleAssets1 id="ID_1030" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">72200000</amed:DeferredTaxAssetsGoodwillAndIntangibleAssets1>
  <amed:DeferredTaxAssetsGoodwillAndIntangibleAssets1 id="ID_1031" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">56300000</amed:DeferredTaxAssetsGoodwillAndIntangibleAssets1>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="ID_1032" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">7800000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="ID_1033" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">5000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsOtherLossCarryforwards id="ID_1034" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">48500000</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOtherLossCarryforwards id="ID_1035" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">44200000</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
  <us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome id="ID_1036" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">23200000</us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome>
  <us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome id="ID_1037" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">18500000</us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="ID_1038" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">300000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="ID_1039" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">400000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards id="ID_1040" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">4800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards id="ID_1041" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">4700000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsGross id="ID_1042" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">155700000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross id="ID_1043" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">143400000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsNet id="ID_1044" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">143000000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet id="ID_1045" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">155400000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxLiabilities id="ID_1046" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">30200000</us-gaap:DeferredTaxLiabilities>
  <us-gaap:DeferredTaxLiabilities id="ID_1047" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">35100000</us-gaap:DeferredTaxLiabilities>
  <us-gaap:DeferredTaxLiabilitiesOther id="ID_1048" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">2000000</us-gaap:DeferredTaxLiabilitiesOther>
  <us-gaap:DeferredTaxLiabilitiesOther id="ID_1049" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">900000</us-gaap:DeferredTaxLiabilitiesOther>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther id="ID_1050" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">11400000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther id="ID_1051" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">5100000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther>
  <us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates id="ID_1052" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">200000</us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates>
  <us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates id="ID_1053" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">3200000</us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates>
  <us-gaap:OperatingLossCarryforwards id="ID_1054" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_IncomeTaxAuthorityAxis_DomesticCountryMember" unitRef="USDollar">102100000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="ID_1055" decimals="-5" contextRef="AS_OF_Dec31_2016_amed_UnrecognizedTaxBenefitsAxis_NetOperatingLossMember_us-gaap_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember" unitRef="USDollar">268400000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:IncomeTaxCreditsAndAdjustments id="ID_1056" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_TaxCreditCarryforwardAxis_StateTaxCreditMember" unitRef="USDollar">3100000</us-gaap:IncomeTaxCreditsAndAdjustments>
  <us-gaap:IncomeTaxCreditsAndAdjustments id="ID_1057" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_TaxCreditCarryforwardAxis_AlternativeMinimumTaxCreditMember" unitRef="USDollar">1400000</us-gaap:IncomeTaxCreditsAndAdjustments>
  <us-gaap:IncomeTaxCreditsAndAdjustments id="ID_1058" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_TaxCreditCarryforwardAxis_EmploymentTaxCreditMember" unitRef="USDollar">200000</us-gaap:IncomeTaxCreditsAndAdjustments>
  <us-gaap:IncomeTaxCreditsAndAdjustments id="ID_1059" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_TaxCreditCarryforwardAxis_ResearchAndDevelopmentTaxCreditMember" unitRef="USDollar">1900000</us-gaap:IncomeTaxCreditsAndAdjustments>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="ID_1060" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="ID_1061" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:UnrecognizedTaxBenefits id="ID_1062" decimals="-5" contextRef="AS_OF_Dec31_2016_amed_UnrecognizedTaxBenefitsAxis_NetOperatingLossMember" unitRef="USDollar">3100000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits id="ID_1063" decimals="-5" contextRef="AS_OF_Dec31_2015_amed_UnrecognizedTaxBenefitsAxis_NetOperatingLossMember" unitRef="USDollar">3100000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits id="ID_1064" decimals="-5" contextRef="AS_OF_Dec31_2015_amed_UnrecognizedTaxBenefitsAxis_TaxCreditCarryforwardMember" unitRef="USDollar">700000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits id="ID_1065" decimals="-5" contextRef="AS_OF_Dec31_2016_amed_UnrecognizedTaxBenefitsAxis_TaxCreditCarryforwardMember" unitRef="USDollar">700000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock id="ID_1066" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 10px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="10"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Uncertain Tax Positions&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td colspan="10"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;We account for uncertain tax positions in accordance with the authoritative guidance for uncertain tax positions. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 23px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5"  style="width: 142px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:142px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Years Ended December 31, &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 468px; text-align:left;border-color:#000000;min-width:468px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Balance at beginning of period&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Additions for tax positions related to current year&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Additions for tax positions related to prior year&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Reductions for tax positions related to prior years&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Lapse of statute of limitations&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.6)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.3)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Settlements&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 468px; text-align:left;border-color:#000000;min-width:468px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Balance at end of period&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions id="ID_1067" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions id="ID_1068" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions id="ID_1069" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions id="ID_1070" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">1000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefits id="ID_1071" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">4700000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits id="ID_1072" decimals="-5" contextRef="AS_OF_Dec31_2014" unitRef="USDollar">4000000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued id="ID_1073" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <amed:NumberOfIndividualStatesSubjectToIncomeTax id="ID_1074" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="States">50</amed:NumberOfIndividualStatesSubjectToIncomeTax>
  <us-gaap:OpenTaxYear id="ID_1075" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RangeAxis_MinimumMember">2001</us-gaap:OpenTaxYear>
  <us-gaap:OpenTaxYear id="ID_1076" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RangeAxis_MaximumMember">2016</us-gaap:OpenTaxYear>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions id="ID_1077" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions id="ID_1078" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations id="ID_1079" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">300000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
  <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations id="ID_1080" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">600000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities id="ID_1081" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities id="ID_1082" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued id="ID_1083" decimals="-5" contextRef="AS_OF_Dec31_2015" unitRef="USDollar">200000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense id="ID_1084" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">-100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense id="ID_1085" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">200000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:UnrecognizedTaxBenefits id="ID_1086" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">4100000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits id="ID_1087" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_BalanceSheetLocationAxis_OtherLongTermObligationsMember" unitRef="USDollar">300000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits id="ID_1088" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_BalanceSheetLocationAxis_DeferredIncomeTaxesMember" unitRef="USDollar">3800000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease id="ID_1089" decimals="-5" contextRef="FROM_Jan01_2017_TO_Dec31_2017" unitRef="USDollar">-300000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="ID_1090" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:13pt; margin-bottom:4.5pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;"&gt;9. CAPITAL STOCK AND SHARE-BASED COMPENSATION&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We are authorized by our Certificate of Incorporation to issue 60,000,000 shares of common stock, $0.001 par value and 5,000,000 shares of preferred stock, $0.001 par value&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.  As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;December 31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;there &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;were &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;35&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;253&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;577&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;597&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;215&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;shares&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of common stock &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;issued and outstanding, respectively&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and no shares of preferred stock issued &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;outstanding. Our Board of Directors is authorized to fix the dividend rights and terms, conversion and voting rights, redemption rights and other privileges and restrictions applicable to our preferred stock.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:4.5pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Share-Based Awards&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Our 2008 Omnibus Incentive Compensation Plan (the &amp;#8220;Plan&amp;#8221;) authorizes the grant of various types of equity-based awards, such as stock awards, restricted stock units, stock appreciation rights and stock options to eligible participants, which include all of our employees and all employees of our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% or more owned subsidiaries, our non-employee directors and certain consultants. The vesting terms of the awards may be tied to continued employment (or, for our non-employee directors, continued service on the Board of Directors) and/or achievement of certain pre-determined performance goals. We refer to stock awards subject to service-based vesting conditions as &amp;#8220;non-vested stock&amp;#8221; and restricted stock units subject to service-based and performance-based &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;or market-based &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;vesting conditions as &amp;#8220;non-vested stock units.&amp;#8221; The Plan is administered by the Compensation Committee of our Board of Directors, which determines, within the provisions of the Plan, those eligible employees to whom, and the times at which, awards shall be granted. The Compensation Committee, in its discretion, may delegate its authority and duties under the Plan to specified officers; however, only the Compensation Committee may approve the terms of awards to our executive officers.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Equity-based awards may be granted for a number of shares not to exceed, in the aggregate, approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; shares of common stock, and we had &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; shares available at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;December 31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. The price per share for stock options shall be of no less than the greater of (a) &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;100&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% of the fair value of a share of common stock on the date the option is granted or (b) the aggregate par value of the shares of our common stock on the date the option is granted. If a stock option is granted to any owner of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% or more of our total combined voting power of us and our subsidiaries, the price is to be at least &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;110&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% of the fair value of a share of our common stock on the date the award is granted. Each equity-based award vests ratably over a 12 month&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;to&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; year period, with the exception of those issued under contractual arrangements that specify otherwise, that may be exercised during a period as determined by our Compensation Committee or as otherwise approved by our Compensation Committee. The contractual terms of stock options exercised shall not exceed &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; years from the date such option is granted.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:4.5pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Employee Stock Purchase Plan (&amp;#8220;ESPP&amp;#8221;)&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:9pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We have a plan whereby our eligible employees may purchase our common stock at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;85&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;% of the market price at the time of purchase. On June 7, 20&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;12&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, our stockholders ratified an amendment adopted by our Board of Directors to increase the total number of shares of our common stock &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;authorized for the issuance under our ESPP from &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;500&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; shares to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,500,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; shares, and as of December 31, 2016, there were &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;460&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;00&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;shares available for future issuance. The following is a detail of the purchases that were made or pending Board of Director approval under the plan:&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:10pt'&gt;&amp;#160;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&lt;font style="FONT-WEIGHT: bold;TEXT-DECORATION: underline;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;"&gt;Employee Stock Purchase Plan Period&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Shares Issued&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Price&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 16px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2014 and Prior&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2,899,528&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;13.78&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;January 1, 2015 to March 31, 2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;24,368&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;22.76&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;April 1, 2015 to June 30, 2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;15,750&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;33.77&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;July 1, 2015 to September 30, 2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;18,984&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;32.27&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;October 1, 2015 to December 31, 2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;19,082&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;33.42&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;January 1, 2016 to March 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;13,850&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;41.09&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;April 1, 2016 to June 30, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;14,236&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;42.91&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;July 1, 2016 to September 30, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;16,520&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;40.32&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;October 1, 2016 to December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;16,882&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;36.24&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3,039,200&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:4pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;ESPP expense included in general and administrative expense in our accompanying consolidated statements&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of operations&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; was $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; for each of&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 18px"&gt;&lt;td colspan="5"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Stock Options&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:left;border-color:#000000;min-width:105px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td colspan="5"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;We use the Black-Scholes option pricing model to estimate the fair value of our stock options. There were 268,538, 590,647 and 250,000 options granted during 2016, 2015 and 2014, respectively. Stock option compensation expense included in general and administrative expense in our accompanying consolidated statements of operations was $6.3 million, $3.8 million and $0.1 million for 2016, 2015 and 2014, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:center;border-color:#000000;min-width:395px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="5"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The fair value of the 2016 awards were estimated using the following assumptions:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 15px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:left;border-color:#000000;min-width:105px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Risk Free Rate&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;1.19% - 1.58%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Expected Volatility&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;53.44 % -  54.89%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Expected Term&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;5.86 - 6.25  years&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Weighted Average Fair Value&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;$25.99&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="5"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;We used the simplified method to estimate the expected term for the stock options granted during 2016.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:left;border-color:#000000;min-width:105px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="9"  style="width: 692px; text-align:left;border-color:#000000;min-width:692px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following table presents our stock option activity for 2016:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 40px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 97px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:97px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Weighted Average Contractual Life (Years)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 406px; text-align:center;border-color:#000000;min-width:406px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Outstanding options at January 1, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 838,494&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 87px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:87px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;30.18&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;9.31&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;268,538&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 87px; text-align:right;border-color:#000000;min-width:87px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;37.21&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 87px; text-align:right;border-color:#000000;min-width:87px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Canceled, forfeited or expired&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(98,875)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 87px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:87px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;35.45&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 406px; text-align:center;border-color:#000000;min-width:406px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Outstanding options at December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 1,008,157&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 87px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:87px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;31.54&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;8.42&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 406px; text-align:center;border-color:#000000;min-width:406px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Exercisable options at December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 281,458&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 87px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:87px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;28.86&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;8.21&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 87px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:87px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 31px"&gt;&lt;td colspan="10"  style="width: 727px; text-align:left;border-color:#000000;min-width:727px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The aggregate intrinsic value of our outstanding options and exercisable options at December 31, 2016 was $11.9 million and $3.9 million, respectively.  There were no options exercised during 2016. Total intrinsic value of options exercised was $0.2 million and $0.1 million for 2015 and 2014, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 18px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 87px; text-align:left;border-color:#000000;min-width:87px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 18px"&gt;&lt;td colspan="9"  style="width: 692px; text-align:left;border-color:#000000;min-width:692px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following table presents our non-vested stock option award activity for 2016:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 18px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td  rowspan="2" style="width: 85px; text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" rowspan="2" style="width: 97px; text-align:center;border-color:#000000;min-width:97px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Weighted Average Grant Date Fair Value&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 26px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 87px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:87px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 406px; text-align:left;border-color:#000000;min-width:406px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Non-vested stock options at January 1, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;775,994&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 87px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:87px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;30.47&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;268,538&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 87px; text-align:right;border-color:#000000;min-width:87px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;37.21&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Vested&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(219,872)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 87px; text-align:right;border-color:#000000;min-width:87px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;29.55&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(97,961)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 87px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:87px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;35.38&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 406px; text-align:left;border-color:#000000;min-width:406px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Non-vested stock options at December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 726,699&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 87px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:87px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 32.58&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 10px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 87px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:87px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 39px"&gt;&lt;td colspan="10"  style="width: 727px; text-align:left;border-color:#000000;min-width:727px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;At December 31, 2016, there was $7.2 million of unrecognized compensation cost related to stock options that we expect to be recognized over a weighted-average period of 2.1 years.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 18px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Non-Vested Stock&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 68px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;We issue shares of non-vested stock with vesting terms ranging from one to six years. The compensation expense is determined based on the market price of our common stock at the date of grant applied to the total number of shares that are anticipated to fully vest. Non-vested stock compensation expense included in general and administrative expenses in our accompanying consolidated statements of operations was $2.3 million, $5.0 million and $4.6 million for 2016, 2015 and 2014, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following table presents our non-vested stock award activity for 2016:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Weighted Average Grant Date Fair Value&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Non-vested stock at January 1, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 500,888&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;18.24&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 21,202&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;50.55&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Vested&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(222,783)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;18.00&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Canceled, forfeited or expired&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(89,929)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;17.26&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Non-vested stock at December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 209,378&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;22.20&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The weighted average grant date fair value of non-vested stock granted was $50.55, $28.48 and $16.38 in 2016, 2015, and 2014, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 11px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;At December 31, 2016, there was $1.4 million of unrecognized compensation cost related to non-vested stock award payments that we expect to be recognized over a  weighted average period of 0.9 years. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:4.5pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Non-Vested Stock Units&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:10pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We issue non-vested stock unit awards that are service-based, performance-based or a combination of both with vesting terms ranging from one to six years. Based on the terms and conditions of these awards, we determine if the awards should be recorded as either equity or liability instruments. The compensation expense is determined based on the market price of our common stock at the date of grant, applied to the total number of units that are anticipated to vest, unless the award specifies differently. We account for such awards similar to our non-vested stock awards; however, no shares of stock are issued to the recipient until the stock unit awards have vested and after the pre-determined delivery date has occurred.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 18px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Non-Vested Stock Units - Service-Based &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 44px"&gt;&lt;td colspan="8" rowspan="2" style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Service-based non-vested stock unit compensation expense included in general and administrative expenses in our accompanying consolidated statements of operations was $3.6 million and $1.0 million for 2016 and 2015, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 19px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following table presents our service-based non-vested stock units activity for 2016:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Weighted Average Grant Date Fair Value&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Non-vested stock units at January 1, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 183,332&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;37.89&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 147,896&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;45.60&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Vested&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(32,607)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;38.81&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Canceled, forfeited or expired&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(49,192)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;39.38&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Non-vested stock units at December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 249,429&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;42.05&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The weighted average grant date fair value of service-based non-vested stock units granted was $45.60 and $37.98 in 2016 and 2015, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 11px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;At December 31, 2016, there was $6.7 million of unrecognized compensation cost related to our service-based non-vested stock units that we expect to be recognized over a  weighted average period of 2.2 years. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:4.5pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Non-&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt;V&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt;ested Stock Units &amp;#8211; Service-&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt;B&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt;ased and Performance-&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt;B&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt;ased Awards&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:10pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;During 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we awarded performance-based awards to certain employees. The target level established by the award, which is based &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;on the Company's 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; adjusted earnings before interest, taxes and depreciation (&amp;#8220;EBITDA&amp;#8221;), provided for the recipients to receive &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;182,796&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;non&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;-vested stock units if the target was achieved.  The target number of shares to be potentially awarded has been reduced by forfeitures as indicated in the table below. Performance-based non-vested stock units compensation expense included in general and administrative expenses in our consolidated statements of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;operations was $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and $1.3 million &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;for&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; 2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, respectively&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:4.5pt'&gt;&amp;#160;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following table presents our performance-based non-vested stock units activity for 2016:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 31px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Weighted Average Grant Date Fair Value&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Non-vested stock units at January 1, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 151,063&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;39.44&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 182,796&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;46.29&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Vested&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; (44,729)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;34.83&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Canceled, forfeited or expired&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; (64,273)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;42.41&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Non-vested stock units at December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 224,857&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;45.08&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;The weighted average grant date fair value of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;performance-based &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;non-vested stock &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;units &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;granted was&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;46&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;29&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and $39.54 &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;in&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, respectively&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;At December 31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, there were $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6.4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million in&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;unrecognized compensation cost&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; related to our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;performance&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;-based &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;non-vested stock units&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; that we expect to be recognized over &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;a weighted average period of 2.0&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; years&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:10pt'&gt;&amp;#160;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:4.5pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Non-&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt;Vested Stock Units &amp;#8211; Service-Based and Market-Based Awards&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:4.5pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;During 2013&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we awarded market-based awards to certain employees. The target level e&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;stablished by the award, which wa&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s based on &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;our&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; average December 2015 stock price, provide&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;d&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; for the recipients to receive &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;417,330&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;non-vested stock units if the target is ach&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ieved. If the target objective wa&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s surpassed to the point of achieving the projected maximum payout, the recipients &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;would&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; receive &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;667,728&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;non-vested stock units. The target number of shares to be potentially awarded &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;was&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; reduced by forfeitures &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;as indicated in the table below. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;March 3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, 2016, it was determined that the market-based objective established by the award was satisfied at maximum payout and as a result, 248,654 stock units were awarded to the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;recipients&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; on April 1, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:9pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;For market-based awards, the effect of the market condition is reflected in the fair value of the awards at the date of grant using a&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; Monte-Carlo simulation model. A Monte-Carlo simulation model estimates the fair value of the market-based award based upon the expected term, risk-free interest rate and expected volatility. Compensation expense for market-based awards is recognized over the vesting period regardless of whether the market conditions are expected to be achieved.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; Market-based n&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;on-&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;vested stock units &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;compensation expense included in general and administrative expenses in our accompanying consolidated statements&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of operations&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$0.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and $0.5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, respectively&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;The fair value of the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; award was estimated using the following&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; assumptions&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Forward Interest Rate&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;0.327 % - 1.460%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Expected Volatility&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;54.38%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Requisite Service Period&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;3 years&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Fair Value&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;$ 10.51&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following table presents our market-based non-vested stock units activity for 2016:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 31px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Weighted Average Grant Date Fair Value&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Non-vested stock units at January 1, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 164,534&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.51&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Granted (1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 93,257&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.51&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Vested&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; (248,654)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.51&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Canceled, forfeited or expired&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; (9,137)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.51&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Non-vested stock units at December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; -&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:center;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:center;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:center;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:center;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:right;border-color:#000000;min-width:35px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(1) &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Represents shares awarded upon achievement of maximum payout. &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;The weighted average grant date fair value of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;market-based &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;non-vested stock &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;units &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;granted was&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;10.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;51 &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;in&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;A&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ll of our outstanding market-based non-vested stock units were fully vested as of April 1, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <amed:Percentageofownershipinsubsidiaries id="ID_1091" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Pure">0.5</amed:Percentageofownershipinsubsidiaries>
  <amed:Fairvalueofshareofcommonstockpercentage id="ID_1092" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_ShareBasedAwardsMember" unitRef="Pure">1</amed:Fairvalueofshareofcommonstockpercentage>
  <amed:Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries id="ID_1093" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Pure">0.1</amed:Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries>
  <amed:Fairvalueofshareofcommonstockpercentage id="ID_1094" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_ShareBasedAwardsToMoreThanTenPercentOwnerMember" unitRef="Pure">1.1</amed:Fairvalueofshareofcommonstockpercentage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="ID_1095" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="Shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="ID_1096" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="Shares">5500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward id="ID_1097" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RangeAxis_MaximumMember">ten</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="ID_1098" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RangeAxis_MinimumMember">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="ID_1099" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RangeAxis_MaximumMember">P6Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate id="ID_1100" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
  <amed:CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan id="ID_1101" decimals="0" contextRef="AS_OF_Jun07_2012_us-gaap_RangeAxis_MaximumMember" unitRef="Shares">2500000</amed:CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan>
  <amed:CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan id="ID_1102" decimals="0" contextRef="AS_OF_Dec31_2015_us-gaap_RangeAxis_MaximumMember" unitRef="Shares">4500000</amed:CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan>
  <amed:CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan id="ID_1103" decimals="0" contextRef="AS_OF_Dec31_2016" unitRef="Shares">1460800</amed:CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan>
  <us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock id="ID_1104" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&lt;font style="FONT-WEIGHT: bold;TEXT-DECORATION: underline;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;"&gt;Employee Stock Purchase Plan Period&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Shares Issued&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Price&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 16px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2014 and Prior&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2,899,528&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;13.78&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;January 1, 2015 to March 31, 2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;24,368&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;22.76&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;April 1, 2015 to June 30, 2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;15,750&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;33.77&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;July 1, 2015 to September 30, 2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;18,984&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;32.27&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;October 1, 2015 to December 31, 2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;19,082&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;33.42&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;January 1, 2016 to March 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;13,850&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;41.09&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;April 1, 2016 to June 30, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;14,236&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;42.91&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;July 1, 2016 to September 30, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;16,520&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;40.32&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;October 1, 2016 to December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;16,882&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;36.24&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3,039,200&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock>
  <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense id="ID_1105" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">400000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
  <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense id="ID_1106" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">400000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="ID_1107" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Shares">3039200</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="ID_1108" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_PriorToTwoThousandFourteenMember" unitRef="Shares">2899528</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <amed:StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare id="ID_1109" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_PriorToTwoThousandFourteenMember" unitRef="USDperShare">13.78</amed:StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="ID_1110" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_January12015ToMarch312015Member" unitRef="Shares">24368</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <amed:StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare id="ID_1111" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_January12015ToMarch312015Member" unitRef="USDperShare">22.76</amed:StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="ID_1112" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_April12015ToJune302015Member" unitRef="Shares">15750</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <amed:StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare id="ID_1113" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_April12015ToJune302015Member" unitRef="USDperShare">33.77</amed:StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="ID_1114" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_July12015ToSeptember302015Member" unitRef="Shares">18984</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <amed:StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare id="ID_1115" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_July12015ToSeptember302015Member" unitRef="USDperShare">32.27</amed:StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="ID_1116" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_October12015ToDecember312015Member" unitRef="Shares">19082</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <amed:StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare id="ID_1117" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_October12015ToDecember312015Member" unitRef="USDperShare">33.42</amed:StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare>
  <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense id="ID_1118" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">400000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="ID_1119" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_January12016ToMarch312016Member" unitRef="Shares">13850</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <amed:StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare id="ID_1120" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_January12016ToMarch312016Member" unitRef="USDperShare">41.09</amed:StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare>
  <amed:StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare id="ID_1121" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_April12016ToJune302016Member" unitRef="USDperShare">42.91</amed:StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare>
  <amed:StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare id="ID_1122" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_July12016ToSeptember302016Member" unitRef="USDperShare">40.32</amed:StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare>
  <amed:StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare id="ID_1123" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_October12016ToDecember312016Member" unitRef="USDperShare">36.24</amed:StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="ID_1124" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_April12016ToJune302016Member" unitRef="Shares">14236</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="ID_1125" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_July12016ToSeptember302016Member" unitRef="Shares">16520</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="ID_1126" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_October12016ToDecember312016Member" unitRef="Shares">16882</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="ID_1127" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 18px"&gt;&lt;td colspan="5"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Stock Options&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:left;border-color:#000000;min-width:105px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td colspan="5"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;We use the Black-Scholes option pricing model to estimate the fair value of our stock options. There were 268,538, 590,647 and 250,000 options granted during 2016, 2015 and 2014, respectively. Stock option compensation expense included in general and administrative expense in our accompanying consolidated statements of operations was $6.3 million, $3.8 million and $0.1 million for 2016, 2015 and 2014, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:center;border-color:#000000;min-width:395px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="5"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The fair value of the 2016 awards were estimated using the following assumptions:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 15px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:left;border-color:#000000;min-width:105px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Risk Free Rate&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;1.19% - 1.58%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Expected Volatility&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;53.44 % -  54.89%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Expected Term&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;5.86 - 6.25  years&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Weighted Average Fair Value&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;$25.99&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="5"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;We used the simplified method to estimate the expected term for the stock options granted during 2016.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:left;border-color:#000000;min-width:105px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="9"  style="width: 692px; text-align:left;border-color:#000000;min-width:692px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following table presents our stock option activity for 2016:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 40px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 97px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:97px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Weighted Average Contractual Life (Years)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 406px; text-align:center;border-color:#000000;min-width:406px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Outstanding options at January 1, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 838,494&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 87px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:87px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;30.18&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;9.31&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;268,538&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 87px; text-align:right;border-color:#000000;min-width:87px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;37.21&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 87px; text-align:right;border-color:#000000;min-width:87px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Canceled, forfeited or expired&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(98,875)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 87px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:87px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;35.45&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 406px; text-align:center;border-color:#000000;min-width:406px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Outstanding options at December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 1,008,157&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 87px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:87px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;31.54&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;8.42&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 406px; text-align:center;border-color:#000000;min-width:406px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Exercisable options at December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 281,458&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 87px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:87px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;28.86&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:70px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;8.21&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 87px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:87px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 31px"&gt;&lt;td colspan="10"  style="width: 727px; text-align:left;border-color:#000000;min-width:727px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The aggregate intrinsic value of our outstanding options and exercisable options at December 31, 2016 was $11.9 million and $3.9 million, respectively.  There were no options exercised during 2016. Total intrinsic value of options exercised was $0.2 million and $0.1 million for 2015 and 2014, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 18px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 87px; text-align:left;border-color:#000000;min-width:87px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 18px"&gt;&lt;td colspan="9"  style="width: 692px; text-align:left;border-color:#000000;min-width:692px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following table presents our non-vested stock option award activity for 2016:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 18px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td  rowspan="2" style="width: 85px; text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" rowspan="2" style="width: 97px; text-align:center;border-color:#000000;min-width:97px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Weighted Average Grant Date Fair Value&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 26px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 87px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:87px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 406px; text-align:left;border-color:#000000;min-width:406px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Non-vested stock options at January 1, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;775,994&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 87px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:87px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;30.47&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;268,538&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 87px; text-align:right;border-color:#000000;min-width:87px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;37.21&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Vested&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(219,872)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 87px; text-align:right;border-color:#000000;min-width:87px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;29.55&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(97,961)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 87px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:87px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;35.38&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="2"  style="width: 406px; text-align:left;border-color:#000000;min-width:406px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Non-vested stock options at December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 726,699&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 87px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:87px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 32.58&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 10px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 87px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:87px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 39px"&gt;&lt;td colspan="10"  style="width: 727px; text-align:left;border-color:#000000;min-width:727px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;At December 31, 2016, there was $7.2 million of unrecognized compensation cost related to stock options that we expect to be recognized over a weighted-average period of 2.1 years.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod id="ID_1128" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="Shares">268538</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod id="ID_1129" decimals="0" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="Shares">590647</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="ID_1130" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember_us-gaap_RangeAxis_MinimumMember">P5Y10M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue id="ID_1131" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="USDperShare">25.99</amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="ID_1132" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="Pure">0.0158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="ID_1133" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="Pure">0.0119</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="ID_1134" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="Pure">0.5344</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="ID_1135" decimals="4" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="Pure">0.5489</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="ID_1136" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember_us-gaap_RangeAxis_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod id="ID_1137" decimals="0" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="Shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:AllocatedShareBasedCompensationExpense id="ID_1138" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="USDollar">6300000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="ID_1139" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="USDollar">3800000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="ID_1140" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="USDollar">100000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="ID_1141" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod id="ID_1142" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="Shares">98875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="ID_1143" decimals="0" contextRef="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="Shares">281458</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="ID_1144" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="ID_1145" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="ID_1146" decimals="0" contextRef="AS_OF_Dec31_2015_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="Shares">838494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="ID_1147" decimals="2" contextRef="AS_OF_Dec31_2015_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="USDperShare">30.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="ID_1148" decimals="0" contextRef="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="Shares">1008157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="ID_1149" decimals="2" contextRef="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="USDperShare">31.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="ID_1150" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember">P8Y2M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="ID_1151" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="USDperShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="ID_1152" decimals="2" contextRef="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="USDperShare">28.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice id="ID_1153" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="USDperShare">35.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="ID_1154" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">11900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="ID_1155" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">3900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="ID_1156" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_AwardTypeAxis_StockOptionMember">P9Y3M22D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="ID_1157" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember">P8Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="ID_1158" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="USDperShare">37.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="ID_1159" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares id="ID_1160" decimals="0" contextRef="AS_OF_Dec31_2015_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="Shares">775994</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="ID_1161" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="Shares">268538</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares id="ID_1162" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="Shares">219872</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares id="ID_1163" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="Shares">97961</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue id="ID_1164" decimals="2" contextRef="AS_OF_Dec31_2015_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="USDperShare">30.47</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="ID_1165" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="USDperShare">37.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue id="ID_1166" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="USDperShare">29.55</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue id="ID_1167" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="USDperShare">35.38</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue id="ID_1168" decimals="2" contextRef="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="USDperShare">32.58</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares id="ID_1169" decimals="0" contextRef="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="Shares">726699</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="ID_1170" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember" unitRef="USDollar">7200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="ID_1171" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_StockOptionMember">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock id="ID_1172" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 18px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Non-Vested Stock&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 68px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;We issue shares of non-vested stock with vesting terms ranging from one to six years. The compensation expense is determined based on the market price of our common stock at the date of grant applied to the total number of shares that are anticipated to fully vest. Non-vested stock compensation expense included in general and administrative expenses in our accompanying consolidated statements of operations was $2.3 million, $5.0 million and $4.6 million for 2016, 2015 and 2014, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following table presents our non-vested stock award activity for 2016:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Weighted Average Grant Date Fair Value&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Non-vested stock at January 1, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 500,888&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;18.24&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 21,202&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;50.55&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Vested&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(222,783)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;18.00&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Canceled, forfeited or expired&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(89,929)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;17.26&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Non-vested stock at December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 209,378&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;22.20&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The weighted average grant date fair value of non-vested stock granted was $50.55, $28.48 and $16.38 in 2016, 2015, and 2014, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 11px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;At December 31, 2016, there was $1.4 million of unrecognized compensation cost related to non-vested stock award payments that we expect to be recognized over a  weighted average period of 0.9 years. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
  <us-gaap:AllocatedShareBasedCompensationExpense id="ID_1173" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockMember" unitRef="USDollar">5000000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="ID_1174" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_AwardTypeAxis_NonVestedStockMember" unitRef="USDollar">4600000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="ID_1175" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockMember" unitRef="USDollar">2300000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="ID_1176" decimals="2" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockMember" unitRef="USDperShare">28.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="ID_1177" decimals="2" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_AwardTypeAxis_NonVestedStockMember" unitRef="USDperShare">16.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="ID_1178" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockMember" unitRef="USDollar">1400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="ID_1179" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockMember">P10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="ID_1180" decimals="0" contextRef="AS_OF_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockMember" unitRef="Shares">500888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="ID_1181" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockMember" unitRef="Shares">21202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="ID_1182" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockMember" unitRef="Shares">222783</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="ID_1183" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockMember" unitRef="Shares">89929</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="ID_1184" decimals="0" contextRef="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockMember" unitRef="Shares">209378</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="ID_1185" decimals="2" contextRef="AS_OF_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockMember" unitRef="USDperShare">18.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="ID_1186" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockMember" unitRef="USDperShare">50.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue id="ID_1187" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockMember" unitRef="USDperShare">18.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue id="ID_1188" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockMember" unitRef="USDperShare">17.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="ID_1189" decimals="2" contextRef="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockMember" unitRef="USDperShare">22.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="ID_1190" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceMember" unitRef="Shares">147896</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock id="ID_1191" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 18px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Non-Vested Stock Units - Service-Based &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 44px"&gt;&lt;td colspan="8" rowspan="2" style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Service-based non-vested stock unit compensation expense included in general and administrative expenses in our accompanying consolidated statements of operations was $3.6 million and $1.0 million for 2016 and 2015, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 19px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following table presents our service-based non-vested stock units activity for 2016:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Weighted Average Grant Date Fair Value&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Non-vested stock units at January 1, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 183,332&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;37.89&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 147,896&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;45.60&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Vested&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(32,607)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;38.81&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Canceled, forfeited or expired&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(49,192)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;39.38&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Non-vested stock units at December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 249,429&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;42.05&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The weighted average grant date fair value of service-based non-vested stock units granted was $45.60 and $37.98 in 2016 and 2015, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 11px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;At December 31, 2016, there was $6.7 million of unrecognized compensation cost related to our service-based non-vested stock units that we expect to be recognized over a  weighted average period of 2.2 years. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following table presents our performance-based non-vested stock units activity for 2016:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 31px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Weighted Average Grant Date Fair Value&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Non-vested stock units at January 1, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 151,063&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;39.44&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 182,796&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;46.29&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Vested&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; (44,729)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;34.83&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Canceled, forfeited or expired&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; (64,273)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;42.41&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Non-vested stock units at December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 224,857&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;45.08&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Forward Interest Rate&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;0.327 % - 1.460%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Expected Volatility&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;54.38%&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Requisite Service Period&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;3 years&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Fair Value&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;$ 10.51&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following table presents our market-based non-vested stock units activity for 2016:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 31px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Weighted Average Grant Date Fair Value&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Non-vested stock units at January 1, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 164,534&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.51&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Granted (1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 93,257&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.51&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Vested&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; (248,654)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.51&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Canceled, forfeited or expired&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; (9,137)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.51&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Non-vested stock units at December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; -&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:center;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:center;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:center;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 443px; text-align:center;border-color:#000000;min-width:443px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 35px; text-align:right;border-color:#000000;min-width:35px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;"&gt;(1) &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Represents shares awarded upon achievement of maximum payout. &lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="ID_1192" decimals="0" contextRef="AS_OF_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceMember" unitRef="Shares">183332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="ID_1193" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceMember" unitRef="Shares">32607</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="ID_1194" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceMember" unitRef="Shares">49192</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="ID_1195" decimals="0" contextRef="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceMember" unitRef="Shares">249429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="ID_1196" decimals="2" contextRef="AS_OF_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceMember" unitRef="USDperShare">37.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="ID_1197" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceMember" unitRef="USDperShare">45.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue id="ID_1198" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceMember" unitRef="USDperShare">38.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue id="ID_1199" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceMember" unitRef="USDperShare">39.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="ID_1200" decimals="2" contextRef="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceMember" unitRef="USDperShare">42.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:AllocatedShareBasedCompensationExpense id="ID_1201" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceMember" unitRef="USDollar">3600000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="ID_1202" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceMember" unitRef="USDollar">6700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="ID_1203" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceMember">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:AllocatedShareBasedCompensationExpense id="ID_1204" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceMember" unitRef="USDollar">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="ID_1205" decimals="2" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceMember" unitRef="USDperShare">37.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="ID_1206" decimals="0" contextRef="AS_OF_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" unitRef="Shares">151063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:AllocatedShareBasedCompensationExpense id="ID_1207" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" unitRef="USDollar">3700000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="ID_1208" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" unitRef="USDperShare">46.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="ID_1209" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" unitRef="USDollar">6400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="ID_1210" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="ID_1211" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" unitRef="Shares">182796</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="ID_1212" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" unitRef="Shares">44729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="ID_1213" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" unitRef="Shares">64273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="ID_1214" decimals="0" contextRef="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" unitRef="Shares">224857</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="ID_1215" decimals="2" contextRef="AS_OF_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" unitRef="USDperShare">39.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue id="ID_1216" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" unitRef="USDperShare">34.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue id="ID_1217" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" unitRef="USDperShare">42.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="ID_1218" decimals="2" contextRef="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" unitRef="USDperShare">45.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <amed:Performancebasedawardtargetshareamount id="ID_1219" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" unitRef="Shares">182796</amed:Performancebasedawardtargetshareamount>
  <us-gaap:AllocatedShareBasedCompensationExpense id="ID_1220" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" unitRef="USDollar">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="ID_1221" decimals="2" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" unitRef="USDperShare">39.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="ID_1222" decimals="5" contextRef="FROM_Jan01_2013_TO_Dec31_2013_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember" unitRef="Pure">0.01460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRequisiteServicePeriod id="ID_1223" contextRef="FROM_Jan01_2013_TO_Dec31_2013_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember">P3Y</amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRequisiteServicePeriod>
  <amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue id="ID_1224" decimals="2" contextRef="FROM_Jan01_2013_TO_Dec31_2013_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember" unitRef="USDperShare">10.51</amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue>
  <amed:MarketBasedAwardTargetShareAmount id="ID_1225" decimals="0" contextRef="FROM_Jan01_2013_TO_Dec31_2013_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember" unitRef="Shares">417330</amed:MarketBasedAwardTargetShareAmount>
  <amed:MarketBasedAwardMaximumShareAmount id="ID_1226" decimals="0" contextRef="FROM_Jan01_2013_TO_Dec31_2013_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember" unitRef="Shares">667728</amed:MarketBasedAwardMaximumShareAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="ID_1227" decimals="0" contextRef="AS_OF_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember" unitRef="Shares">164534</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="ID_1228" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember" unitRef="Shares">93257</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod id="ID_1229" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember" unitRef="Shares">248654</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="ID_1230" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember" unitRef="Shares">9137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="ID_1231" decimals="0" contextRef="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember" unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="ID_1232" decimals="2" contextRef="AS_OF_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember" unitRef="USDperShare">10.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="ID_1233" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember" unitRef="USDperShare">10.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue id="ID_1234" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember" unitRef="USDperShare">10.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue id="ID_1235" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember" unitRef="USDperShare">10.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue id="ID_1236" decimals="2" contextRef="AS_OF_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember" unitRef="USDperShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:AllocatedShareBasedCompensationExpense id="ID_1237" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember" unitRef="USDollar">500000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="ID_1238" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember" unitRef="USDollar">100000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="ID_1239" decimals="5" contextRef="FROM_Jan01_2013_TO_Dec31_2013_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember" unitRef="Pure">0.00327</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="ID_1240" decimals="4" contextRef="FROM_Jan01_2013_TO_Dec31_2013_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember" unitRef="Pure">0.5438</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:AllocatedShareBasedCompensationExpense id="ID_1241" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember" unitRef="USDollar">300000</us-gaap:AllocatedShareBasedCompensationExpense>
  <amed:MarketBasedAwardMaximumShareAmount id="ID_1242" decimals="0" contextRef="FROM_Jan01_2016_TO_Mar03_2016_us-gaap_AwardTypeAxis_NonVestedStockUnitsServiceBasedAndMarketBasedMember" unitRef="Shares">248654</amed:MarketBasedAwardMaximumShareAmount>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="ID_1243" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:13pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;"&gt;10&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Legal Proceedings &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt;&amp;#8211; Ongoing&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;are involved in the following legal actions: &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Securities Class Action Lawsuits &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On June&amp;#160;10, 2010, a putative securities class action complaint was filed in the United States District Court for the Middle District of Louisiana (the &amp;#8220;District Court&amp;#8221;) against the Company and certain of our current and former senior executives. Additional putative securities class actions were filed in the District Court on July&amp;#160;14,&amp;#160;July&amp;#160;16, and July&amp;#160;28, 2010.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On January&amp;#160;18, 2011, the Co-Lead Plaintiffs filed an amended, consolidated&amp;#160;class action complaint (the &amp;#8220;Securities Complaint&amp;#8221;) which supersedes the earlier-filed securities class action complaints.&amp;#160;The Securities Complaint alleges that the defendants made false and/or misleading statements and failed to disclose material facts about our business, financial condition, operations and prospects, particularly relating to our policies and practices regarding home therapy visits under the Medicare home health prospective payment system and the related alleged impact on our business, financial condition, operations and prospects. The Securities Complaint seeks a determination that the action may be maintained as a class action on behalf of all persons who purchased the Company's securities between August&amp;#160;2, 2005 and September&amp;#160;28, 2010 and an unspecified amount of damages.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;All defendants moved to dismiss the Securities Complaint. On June&amp;#160;28, 2012, the District Court granted the defendants' motion to dismiss the Securities Complaint. On July&amp;#160;26, 2012, the Co-Lead Plaintiffs filed a motion for reconsideration, which the District Court denied on April&amp;#160;9, 2013.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On May&amp;#160;3, 2013, the Co-Lead Plaintiffs appealed the dismissal of the Securities Complaint to the United States Court of Appeals for the Fifth Circuit (the &amp;#8220;Fifth Circuit&amp;#8221;). On October 2, 2014, a three-judge panel of the Fifth Circuit issued a decision reversing the District Court's dismissal of the Securities Complaint. On October 16, 2014, all defendants filed a petition with the Fifth Circuit to review the three-judge panel's decision &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;en banc&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, or as a whole court. On December 29, 2014, the Fifth Circuit denied the defendants' motion for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;en banc&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; review of the Fifth Circuit panel's decision reversing the District Court's dismissal of the Securities Complaint.&amp;#160; The case then returned to the District Court for further proceedings. On March 30, 2015, the defendants filed a Petition for Writ of Certiorari (the &amp;#8220;Petition&amp;#8221;) with the United States Supreme Court asking the Supreme Court to consider whether the Fifth Circuit erred in reversing the District Court's dismissal of the Securities Complaint. The Supreme Court denied the Petition on June 29, 2015, which did not affect the ongoing proceedings before the District Court, including the District Court's consideration of a motion filed on April 3, 2015, by the Co-Lead Plaintiffs for leave to amend the Securities Complaint, which motion was granted by the District Court. On December 15, 2015, the defendants filed a motion to dismiss the Co-Lead Plaintiffs' First Amended Consolidated Complaint. All discovery in the case is currently stayed pursuant to federal law. The parties agreed to explore the possibility of a mediated settlement of this matter, and a mediation was held on June 21, 2016. The parties were unable to resolve this matter during the mediation. On August 19, 2016, the District Court denied the defendants motion to dismiss the Co-Lead &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Plantiffs&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;' First Amended Consolidated Complaint. The Defendants filed an Answer to the Complaint on October 20, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. The case is currently in discovery&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We are unable to assess the probable outcome or reasonably estimate the potential liability, if any, arising from the securities litigation described above.&amp;#160; The Company intends to continue to vigorously defend itself in the securities litigation matter but, if decided adverse to the Company, its impact could be material.&amp;#160; No assurances can be given as to the timing or outcome of the securities matter described above or the impact of any of the inquiry or litigation matters on the Company, its consolidated financial condition, results of operations or cash flows, which could be material, individually or in the aggregate&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Subpoena &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Duces&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Tecum&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt; Issued by the U.S. Department of Justice&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On May 21, 2015, we received a Subpoena &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Duces&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Tecum&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; (&amp;#8220;Subpoena&amp;#8221;) issued by the U.S. Department of Justice. The Subpoena requests the delivery of information regarding 53 identified hospice patients to the United States Attorney's Office for the District of Massachusetts. It also requests the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covers the period from January 1, 2011, through the present. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. Based on the information currently available to us, we cannot predict the timing or outcome of this investigation or reasonably estimate the amount or range of potential losses, if any, which may arise from this matter.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Civil Investigative Demand Issued by the U.S. Department of Justice&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On November 3, 2015, we received a civil investigative demand (&amp;#8220;CID&amp;#8221;) issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requests the delivery of information to the United States Attorney's Office for the Northern District of West Virginia regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covers the period from January 1, 2009 through August 31, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. Based on the information currently available to us, we cannot predict the timing or outcome of this investigation or reasonably estimate the amount or range of potential losses, if any, which may arise from this matter.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On June 27, 2016, we received a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;CID &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requests the delivery of information to the United States Attorney's Office for the Southern District of West Virginia regarding 68 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covers the period from January 1, 2011 through June 20, 2016. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. Based on the information currently available to us, we cannot predict the timing or outcome of this investigation or reasonably estimate the amount or range of potential losses, if any, which may arise from this matter.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In addition to the matters referenced in this note, we are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. We do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Legal Proceedings &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt;&amp;#8211; Settled&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Wage and Hour Litigation &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On July 25, 2012, a putative collective and class action complaint was filed in the United States District Court for the District of Connecticut against us in which three former employees allege wage and hour law violations.&amp;#160; The former employees claim that they were not paid overtime for all hours worked over 40 hours in violation of the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Federal Fair Labor Standards Act (&amp;#8220;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;FLSA&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, as well as the Pennsylvania Minimum Wage Act. More specifically, they allege they were paid on both a per-visit and an hourly basis, and that such a pay scheme resulted in their misclassification as exempt employees, thereby denying them overtime pay. Moreover, in response to a Company motion arguing that plaintiffs' complaint was deficient in that it was ambiguous and failed to provide fair notice of the claims asserted and plaintiffs' opposition thereto, the Court, on April 8, 2013, held that the complaint adequately raises general allegations that the plaintiffs were not paid overtime for all hours worked in a week over 40, which may include claims for unpaid overtime under other theories of liability, such as alleged off-the-clock work, in addition to plaintiffs' more clearly stated allegations based on misclassification. On behalf of themselves and a class of current and former employees they allege are similarly situated, plaintiffs seek attorneys' fees, back wages and liquidated damages going back three years under the FLSA and three years under the Pennsylvania statute.  On October 8, 2013, the Court granted plaintiffs' motion for equitable tolling requesting that the statute of limitations for claims under the FLSA for plaintiffs who opt-in to the lawsuit be tolled from September 24, 2012, the date upon which plaintiffs filed their original motion for conditional certification, until 90 days after any notice of this lawsuit is issued following conditional certification. Following a motion for reconsideration filed by the Company, on December 3, 2013, the Court modified this order, holding that putative class members' FLSA claims are tolled from October 29, 2012 through the date of the Court's order on plaintiffs' motion for conditional certification. On January 13, 2014, the Court granted plaintiffs' July 10, 2013 motion for conditional certification of their FLSA claims and authorized issuance of notice to putative class members to provide them an opportunity to opt in to the action.  On April 17, 2014, that notice was mailed to putative class members. The period within which putative class members were permitted to opt into the action expired on July 16, 2014.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On September 10, 2014, the plaintiffs in the Connecticut case filed a motion for leave to amend their complaint to add a new claim under the Kentucky Wage and Hour Act (&amp;#8220;KWHA&amp;#8221;) alleging that the Company did not pay certain home health clinicians working in the Commonwealth of Kentucky all of the overtime wages they were owed, either because the Company misclassified them as exempt from overtime or, while treating them as overtime eligible, did not properly pay them overtime for all hours worked over 40 in a week. On behalf of themselves and a class of current and former employees they allege are similarly situated, plaintiffs seek attorneys' fees, back wages and liquidated damages going back five years before the filing of their original complaint under the KWHA. On October 1, 2014, the Company filed an opposition to the plaintiffs' motion to amend. On October 15, 2014, plaintiffs filed a reply brief in support of their motion.  On December 12, 2014, the Court granted the plaintiffs' motion to amend the complaint to add the claims under the KWHA. The Company and the plaintiffs agreed to explore the possibility of a mediated settlement of the Connecticut case, and on February 23, 2015 filed a joint motion to stay proceedings for six months to pursue that process, which was granted by the Court on February 24, 2015. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On June 10, 2015, the Company and plaintiffs participated in a mediation whereby they agreed to fully resolve all of plaintiffs' claims in the lawsuit for $8.0 million, subject to approval by the Court.&amp;#160; The settlement agreement was submitted to the Court for preliminary approval and plaintiffs requested certification of Pennsylvania and Kentucky classes for the sole purpose of this proposed settlement.&amp;#160; The Court granted preliminary approval, notice was issued to members of the settlement classes to provide them with an opportunity to object to the settlement and, in the case of members of the Pennsylvania and Kentucky classes, opt out of the settlement.&amp;#160; Following this notice period, the Court held a final fairness hearing for the&amp;#160;purpose of considering objections and deciding whether to grant final approval of the settlement. As of September 30, 2015, we had an accrual of $8.0 million for this matter. On January 29, 2016, the Court approved the final settlement of this case. The settlement became effective on February 26, 2016. As a result of the final amount calculated by the settlement administrator based on claims timely submitted, we reduced our accrual to $5.3 million as of December 31, 2015; this amount was paid during the three-month period ended March 31, 2016.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On September 13, 2012, a putative collective and class action complaint was filed in the United States District Court for the Northern District of Illinois against us in which a former employee alleges wage and hour law violations.&amp;#160; The former employee claims she was paid on both a per-visit and an hourly basis, and that such a pay scheme resulted in her misclassification as an exempt employee, thereby denying her overtime. The plaintiff alleges violations of federal and state law and seeks damages under the FLSA and the Illinois Minimum Wage Law. &amp;#160;Plaintiff seeks class certification of similar employees who were or are employed in Illinois and seeks &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;attorneys' fees, back wages and liquidated damages going back three years under the FLSA and three years under the Illinois statute. On May 28, 2013, the Court granted the Company's motion to stay the case pending resolution of class certification issues and dispositive motions in the earlier-filed Connecticut case. On December 23, 2015, the parties agreed to explore the possibility of a mediated settlement of the Illinois case, and a mediation occurred on April 18, 2016. The parties agreed to settle the case for $0.8 million, subject to court approval, which the Company ha&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;d&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; accrued as of September 30, 2016. On August 4, 2016, the Court approved the final settlement of this case&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. The final payment of $0.6 million was paid on November 21, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Frontier Litigation &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On April 2, 2015, Frontier Home Health and Hospice, L.L.C. (&amp;#8220;Frontier&amp;#8221;) &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;filed a complaint against the Company in the United States District Court for the District of Connecticut alleging breach of contract, negligent misrepresentation and unfair and deceptive trade practices under Conn. Gen. Stat. &amp;#167;42-110b.&amp;#160; Frontier acquired our interest in five home health and four hospice care centers in Wyoming and Idaho in April 2014.&amp;#160; The complaint alleges that certain of the hospice patients on service at the time of the acquisition did not meet Medicare eligibility requirements and that we breached certain of the representations and warranties under the purchase agreement and therefore, the businesses were worth less than the purchase price. Under the complaint, Frontier seeks declaratory judgment from the District Court that, under the terms of the purchase agreement with Frontier, we are obligated to determine the amount of the alleged Medicare overpayments and reimburse the government for the same in a timely manner, as well as unspecified compensatory and punitive damages, attorneys' fees and pre- and post-judgment interest.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:11pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;The Company resolved the Frontier litigation for $2.9 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; during the three-month period ended December 31, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Other Investigative Matters&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"&gt; - Ongoing&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Corporate Integrity Agreement&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On April 23, 2014, with no admissions of liability on our part, we entered into a settlement agreement with the U.S. Department of&lt;/font&gt;&lt;font style="font-family:Calibri;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Justice relating to certain of our clinical and business operations.  Concurrently with our entry into this agreement, we entered into a corporate integrity agreement (&amp;#8220;CIA&amp;#8221;) with the Office of Inspector General-HHS (&amp;#8220;OIG&amp;#8221;). The CIA formalizes various aspects of our already existing ethics and compliance programs and contains other requirements designed to help ensure our ongoing compliance with federal health care program requirements. Among other things, the CIA requires us to maintain our existing compliance program, executive compliance committee and compliance committee of the Board of Directors; provide certain compliance training; continue screening new and current employees to ensure they are eligible to participate in federal health care programs; engage an independent review organization to perform certain auditing and reviews and prepare certain reports regarding our compliance with federal health care programs, our billing submissions to federal health care programs and our compliance and risk mitigation programs; and provide certain reports and management certifications to the OIG. Additionally, the CIA specifically requires that we report substantial overpayments that we discover we have received from federal health care programs, as well as probable violations of federal health care laws. Upon breach of the CIA, we could become liable for payment of certain stipulated penalties, or could be excluded from participation in federal health care programs.  The corporate integrity agreement has a term of five years.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Computer Inventory and Data Security Reporting&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On March 1 and March 2, 2015, we provided official notice under federal and state data privacy laws concerning the outcome of an &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;extensive risk management process to locate and verify our large computer inventory. The process identified approximately 142 encrypted computers and laptops for which reports were required under federal and state data privacy laws. The devices at issue were originally assigned to Company clinicians and other team members&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; who left the Company between 2011 and 2014. We reported these devices to the U.S. Department of Health and Human Services, state agencies, and individuals whose information may be involved, as required under applicable law because we could not rule out unauthorized access to patient data on the devices. The Office of Civil Rights, U.S. Department of Health and Human Services (&amp;#8220;OCR&amp;#8221;) is reviewing our compliance with applicable laws, as is typical for any data breach involving more than 500 individuals. We are cooperating with OCR in its review and if any other regulatory reviews are formally commenced, will cooperate with applicable regulatory authorities. In accordance with our CIA, we have notified the OIG of this matter.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Frontier &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Litigation&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Separate from the Frontier litigation described above under &amp;#8220;Legal Proceedings - Settled&amp;#8221;, the Company engaged an independent auditing firm to perform a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;clinical&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; audit &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;of the hospice care centers acquired by Frontier. N&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;o assurances can be given as to the timing or outcome of the audit on the Company, its consolidated financial condition, results of operations or cash flows, which could be material, individually or in the aggregate&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Other Investigative Matters - Settled&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;"&gt;Corporate Integrity Agreement&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;During the course of our compliance with the CIA, the Company identified several reportable events and notified the OIG as required. As of December 31, 2015, the Company had an accrual of $4.7 million for these matters. On May 5, 2016, the company entered into a settlement agreement with the OIG and the matters were fully resolved for $4.7 million; this amount was paid during the three-month period ended June 30, 2016.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Third Party Audits - Ongoing&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by the Centers for Medicare and Medicaid Services (&amp;#8220;CMS&amp;#8221;) conduct extensive review of claims data to identify potential improper payments under the Medicare program.  &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a Zone Program Integrity Contractor (&amp;#8220;ZPIC&amp;#8221;) a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January 1, 2008 through March 31, 2010 (the &amp;#8220;Review Period&amp;#8221;) to determine whether the underlying services met pertinent Medicare payment requirements.&amp;#160; We acquired the hospice operations subject to this review on August 1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&amp;#160; Based on the ZPIC's findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June 6, 2011, the MAC for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment.  We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An ALJ hearing was held in early January 2015. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;On January 18, 2016 we received a letter dated January 6, 2016 referencing the ALJ hearing decision for the overpayment issued on June 6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million with a balance owed of $5.6 million including interest based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid.&amp;#160; No assurances can be given as to the timing or outcome of the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Medicare Appeals Council decision. As of June 30, 2016, Medicare has withheld payments of $5.7 million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;the event we are not able to recoup this alleged overpayment, we are indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August 1, 2009.  As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;December 31&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, 2016, we have an indemnity&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; receivable for the amount withheld related to the period prior to August 1, 2009&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In July 2016, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;the Company received a request for medical records from &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;SafeGuard&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; Services, L.L.C. (&amp;#8220;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;SafeGuard&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8221;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December 31, 2015. Subsequent to the initial ZPIC letter, on September 16, 2016, the Company received a letter from &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;SafeGuard&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; notifying the Company&amp;#160;that the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Winterhaven&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, Bradenton, and Tampa care centers were on a prepayment review.&amp;#160; On October 28, 2016, the company received a &amp;#8220;Notice of Suspension of Medicare Payments&amp;#8221; for up to 180 days for these three care centers.&amp;#160; On January 10, 2017, the Company received a letter from &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;SafeGuard&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; notifying the Company&amp;#160;that the Clearwater care center was on a prepayment review.&amp;#160; Subsequently, on February 2, 2017, the Company received a &amp;#8220;Notice of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Suspension of Medicare Payments&amp;#8221; for up to 180 days for the Clearwater care center.&amp;#160; Based on the information currently available to the Company, the Company cannot predict the timing or outcome of this audit or reasonably estimate the amount or range of potential losses, which may arise from this matter.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:6pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Third Party Audits &amp;#8211; Settled&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In January 2010, our subsidiary that provides home health services in Dayton, Ohio received from a Medicare Program Safeguard Contractor (&amp;#8220;PSC&amp;#8221;) a request for records regarding 137 claims submitted by the subsidiary paid from January 2, 2008 through November 10, 2009 (the &amp;#8220;Claim Period&amp;#8221;) to determine whether the underlying services met pertinent Medicare payment requirements.  Based on the PSC's findings for 114 of the claims, which were extrapolated to all claims for home health services provided by the Dayton subsidiary paid during the Claim Period, on March 9, 2011, the Medicare Administrative Contractor (&amp;#8220;MAC&amp;#8221;) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment of approximately $5.6 million. We disputed these findings, and our Dayton subsidiary filed appeals through the Original Medicare Standard Appeals Process, in which we were seeking to have those findings overturned. A consolidated administrative law judge (&amp;#8220;ALJ&amp;#8221;) hearing was held in late March 2013. In January 2014, the ALJ found fully in favor of our Dayton subsidiary on 74 appeals and partially in favor of our Dayton subsidiary on eight appeals. Taking into account the ALJ's decision, certain determinations that our Dayton subsidiary decided not to appeal as well as certain determinations made by the MAC, of the 114 claims that were originally extrapolated by the MAC, 76 claims were decided in favor of our Dayton subsidiary in full, 10 claims were decided in favor of our Dayton subsidiary in part, and 28 claims were decided against or not appealed by our Dayton subsidiary.  The ALJ ordered the MAC to recalculate the extrapolation amount based on the ALJ's decision.  The Medicare Appeals Council could decide on its own motion to review the ALJ's decisions.  As of July 13, 2016, we were notified that the PSC elected not to re-extrapolate the overpayment and instead issued a new calculated overpayment in the amount of $0.2 million. The overpayment has been paid in full and the matter is fully resolved&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Operating Leases&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:9pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We have leased office space at various locations under non-cancelable agreements that &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;expire between &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and 20&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and require various minimum annual rentals. Our typical operating leases are for lease terms &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; to seven years&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and may include, in addition to base rental amounts, certain landlord pass-through costs for our pro-rata share of the lessor's real estate taxes, utilities and common area maintenance costs. Some of our operating leases contain escalation clauses, in which annual minimum base rentals increase over the term of the lease. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="6"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Total minimum rental commitments as of December 31, 2016 are as follows (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;23.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;17.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;13.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;9.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;2021&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Future years&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;72.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 10px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td colspan="6"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Rent expense for non-cancelable operating leases was $27.5 million, $23.7 million and $26.5 million for 2016, 2015 and 2014.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Insurance &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We are obligated for certain costs associated with our insurance programs, including employee health, workers' compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;up to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;specified deductible limits&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; reported&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:9pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;The following table presents details of our insurance programs, including amounts accrued for the periods indicated (amounts in millions) in accrued expenses in our accompanying balance sheets. The amounts accrued below represent our total estimated liability for individual claims that are less than our noted insurance coverage amounts, which can include outstanding claims and claims incurred but not reported.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;  &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5"  style="width: 160px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:160px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;As of December 31,&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"&gt;&lt;font style="FONT-WEIGHT: bold;TEXT-DECORATION: underline;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;"&gt;Type of Insurance&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Health insurance&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;11.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Workers' compensation&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;26.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;23.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Professional liability&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;42.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;39.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Less: long-term portion&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.8)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.9)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;41.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;38.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td colspan="9"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The retention limit per claim for our health insurance, worker's compensation and professional liability is $0.9 million, $0.5 million and $0.3 million, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Employment Contracts &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We have commitments related to employment contracts with a number of our senior executives. These contracts generally commit us to pay severance benefits under certain circumstances. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Other &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We are subject to various other types of claims and disputes arising in the ordinary course of our business. While the resolution of such issues is not presently determinable, we believe that the ultimate resolution of such matters will not have a significant effect on our consolidated financial condition, results of operations and cash flows.&lt;/font&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:LossContingencyNumberOfPlaintiffs id="ID_1244" decimals="0" contextRef="FROM_Jan01_2012_TO_Jul25_2012_amed_StateAxis_ConnecticutMember_us-gaap_LitigationStatusAxis_PendingLitigationMember" unitRef="Employee">3</us-gaap:LossContingencyNumberOfPlaintiffs>
  <us-gaap:LossContingencyNumberOfPlaintiffs id="ID_1245" decimals="0" contextRef="FROM_Jan01_2012_TO_Sep13_2012_amed_StateAxis_IllinoisMember_us-gaap_LitigationStatusAxis_PendingLitigationMember" unitRef="Employee">1</us-gaap:LossContingencyNumberOfPlaintiffs>
  <amed:NumberOfClaimsSubmittedBySubsidiary id="ID_1246" decimals="0" contextRef="FROM_Jan02_2008_TO_Nov10_2009_amed_StateAxis_OhioMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Claims">137</amed:NumberOfClaimsSubmittedBySubsidiary>
  <amed:NumberOfClaimsSubmittedBySubsidiary id="ID_1247" decimals="0" contextRef="FROM_Jan01_2011_TO_Mar09_2011_amed_StateAxis_OhioMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_ExtrapolatedMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Claims">114</amed:NumberOfClaimsSubmittedBySubsidiary>
  <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary id="ID_1248" decimals="-5" contextRef="AS_OF_Mar09_2011_amed_StateAxis_OhioMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_ExtrapolatedMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">5600000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
  <amed:NumberOfBeneficiaries id="ID_1249" decimals="0" contextRef="FROM_Jan01_2011_TO_Jun06_2011_amed_StateAxis_SouthCarolinaMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_ExtrapolatedMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="Beneficiary">16</amed:NumberOfBeneficiaries>
  <amed:NumberOfBeneficiaries id="ID_1250" decimals="0" contextRef="FROM_Jan01_2008_TO_Mar31_2010_amed_StateAxis_SouthCarolinaMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="Beneficiary">30</amed:NumberOfBeneficiaries>
  <amed:NumberOfClaimsSubmittedBySubsidiary id="ID_1251" decimals="0" contextRef="FROM_Jan01_2014_TO_Jan31_2014_amed_StateAxis_OhioMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_FavorableInFullMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Claims">76</amed:NumberOfClaimsSubmittedBySubsidiary>
  <amed:NumberOfClaimsAppealed id="ID_1252" decimals="0" contextRef="FROM_Jan01_2014_TO_Jan31_2014_amed_StateAxis_OhioMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_FavorableInFullMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Claims">74</amed:NumberOfClaimsAppealed>
  <amed:NumberOfClaimsSubmittedBySubsidiary id="ID_1253" decimals="0" contextRef="FROM_Jan01_2014_TO_Jan31_2014_amed_StateAxis_OhioMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_FavorableInPartMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Claims">10</amed:NumberOfClaimsSubmittedBySubsidiary>
  <amed:NumberOfClaimsAppealed id="ID_1254" decimals="0" contextRef="FROM_Jan01_2014_TO_Jan31_2014_amed_StateAxis_OhioMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_FavorableInPartMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Claims">8</amed:NumberOfClaimsAppealed>
  <amed:NumberOfClaimsSubmittedBySubsidiary id="ID_1255" decimals="0" contextRef="FROM_Jan01_2014_TO_Jan31_2014_amed_StateAxis_OhioMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Claims">28</amed:NumberOfClaimsSubmittedBySubsidiary>
  <amed:CorporateIntegrityAgreementTerm id="ID_1256" contextRef="FROM_Jan01_2016_TO_Dec31_2016">P5Y</amed:CorporateIntegrityAgreementTerm>
  <amed:YearOfDeparture id="ID_1257" contextRef="FROM_Mar01_2015_TO_Mar02_2015_us-gaap_LitigationStatusAxis_ComputerInventoryAndDataSecurityReportingMember_us-gaap_RangeAxis_MinimumMember">2011</amed:YearOfDeparture>
  <amed:YearOfDeparture id="ID_1258" contextRef="FROM_Mar01_2015_TO_Mar02_2015_us-gaap_LitigationStatusAxis_ComputerInventoryAndDataSecurityReportingMember_us-gaap_RangeAxis_MaximumMember">2014</amed:YearOfDeparture>
  <amed:NumberOfMissingComputersAndLaptops id="ID_1259" decimals="0" contextRef="FROM_Mar01_2015_TO_Mar02_2015_us-gaap_LitigationStatusAxis_ComputerInventoryAndDataSecurityReportingMember" unitRef="Computers">142</amed:NumberOfMissingComputersAndLaptops>
  <amed:ThresholdOfIndividualsInDataBreach id="ID_1260" decimals="0" contextRef="FROM_Mar01_2015_TO_Mar02_2015_us-gaap_LitigationStatusAxis_ComputerInventoryAndDataSecurityReportingMember" unitRef="Residents">500</amed:ThresholdOfIndividualsInDataBreach>
  <amed:NumberOfCareCentersSold id="ID_1261" decimals="0" contextRef="FROM_Apr01_2014_TO_Apr30_2014_us-gaap_LitigationStatusAxis_FrontierLitigationMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Agencies">5</amed:NumberOfCareCentersSold>
  <amed:NumberOfCareCentersSold id="ID_1262" decimals="0" contextRef="FROM_Apr01_2014_TO_Apr30_2014_us-gaap_LitigationStatusAxis_FrontierLitigationMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="Agencies">4</amed:NumberOfCareCentersSold>
  <amed:Numberofpatients id="ID_1263" decimals="0" contextRef="FROM_Jan01_2015_TO_May21_2015_amed_StateAxis_MassachusettsMember_us-gaap_LitigationStatusAxis_UsDepartmentOfJusticeMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="Pure">53</amed:Numberofpatients>
  <amed:Numberofpatients id="ID_1264" decimals="0" contextRef="FROM_Jan01_2015_TO_Nov03_2015_amed_StateAxis_MorgantownWestVirginiaMember_us-gaap_LitigationStatusAxis_UsDepartmentOfJusticeMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="Pure">66</amed:Numberofpatients>
  <us-gaap:LossContingencyAccrualProvision id="ID_1265" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_LitigationStatusAxis_PendingLitigationMember" unitRef="USDollar">5300000</us-gaap:LossContingencyAccrualProvision>
  <us-gaap:LossContingencyAccrualProvision id="ID_1266" decimals="-5" contextRef="FROM_Jan01_2016_TO_May05_2016_us-gaap_LitigationStatusAxis_OigSelfDisclosureMember" unitRef="USDollar">4700000</us-gaap:LossContingencyAccrualProvision>
  <amed:NumberOfClaimsSubmittedBySubsidiary id="ID_1267" decimals="0" contextRef="FROM_Jan01_2016_TO_Jan18_2016_amed_StateAxis_SouthCarolinaMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="Claims">9</amed:NumberOfClaimsSubmittedBySubsidiary>
  <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary id="ID_1268" decimals="-5" contextRef="AS_OF_Jan18_2016_amed_StateAxis_SouthCarolinaMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">3700000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
  <amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest id="ID_1269" decimals="-5" contextRef="AS_OF_Jan18_2016_amed_StateAxis_SouthCarolinaMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">5600000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest>
  <us-gaap:LossContingencyAccrualProvision id="ID_1270" decimals="-5" contextRef="FROM_Jan01_2015_TO_Sep30_2015_us-gaap_LitigationStatusAxis_PendingLitigationMember" unitRef="USDollar">8000000</us-gaap:LossContingencyAccrualProvision>
  <us-gaap:LitigationSettlementAmount id="ID_1271" decimals="-5" contextRef="FROM_Jan01_2015_TO_Jun10_2015_us-gaap_LitigationStatusAxis_PendingLitigationMember" unitRef="USDollar">8000000</us-gaap:LitigationSettlementAmount>
  <us-gaap:PaymentsForLegalSettlements id="ID_1272" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_amed_StateAxis_ConnecticutMember_us-gaap_LitigationStatusAxis_PendingLitigationMember" unitRef="USDollar">5300000</us-gaap:PaymentsForLegalSettlements>
  <amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest id="ID_1273" decimals="-5" contextRef="AS_OF_Jul13_2016_amed_StateAxis_OhioMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">200000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest>
  <us-gaap:PaymentsForLegalSettlements id="ID_1274" decimals="-5" contextRef="FROM_Jan01_2016_TO_Jul13_2016" unitRef="USDollar">200000</us-gaap:PaymentsForLegalSettlements>
  <amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld id="ID_1275" decimals="-5" contextRef="AS_OF_Jun30_2016_amed_StateAxis_SouthCarolinaMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_UnfavorableMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">5700000</amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld>
  <us-gaap:LossContingencyAccrualProvision id="ID_1276" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_LitigationStatusAxis_OigSelfDisclosureMember" unitRef="USDollar">4700000</us-gaap:LossContingencyAccrualProvision>
  <us-gaap:PaymentsForLegalSettlements id="ID_1277" decimals="-5" contextRef="FROM_Apr01_2016_TO_Jun30_2016_us-gaap_LitigationStatusAxis_OigSelfDisclosureMember" unitRef="USDollar">4700000</us-gaap:PaymentsForLegalSettlements>
  <amed:Numberofpatients id="ID_1278" decimals="0" contextRef="FROM_Jan01_2016_TO_Jun27_2016_amed_StateAxis_ParkersburgWestVirginiaMember_us-gaap_LitigationStatusAxis_UsDepartmentOfJusticeMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="Pure">68</amed:Numberofpatients>
  <us-gaap:LossContingencyAccrualProvision id="ID_1279" decimals="-5" contextRef="FROM_Jan01_2016_TO_Sep30_2016_amed_StateAxis_IllinoisMember_us-gaap_LitigationStatusAxis_PendingLitigationMember" unitRef="USDollar">800000</us-gaap:LossContingencyAccrualProvision>
  <us-gaap:LitigationSettlementAmount id="ID_1280" decimals="-5" contextRef="FROM_Jan01_2016_TO_Aug04_2016_amed_StateAxis_IllinoisMember_us-gaap_LitigationStatusAxis_PendingLitigationMember" unitRef="USDollar">800000</us-gaap:LitigationSettlementAmount>
  <us-gaap:PaymentsForLegalSettlements id="ID_1281" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LitigationStatusAxis_FrontierLitigationMember" unitRef="USDollar">2900000</us-gaap:PaymentsForLegalSettlements>
  <us-gaap:PaymentsForLegalSettlements id="ID_1282" decimals="-5" contextRef="FROM_Jan01_2016_TO_Nov21_2016_amed_StateAxis_IllinoisMember_us-gaap_LitigationStatusAxis_PendingLitigationMember" unitRef="USDollar">600000</us-gaap:PaymentsForLegalSettlements>
  <us-gaap:PaymentsForLegalSettlements id="ID_1283" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_LitigationStatusAxis_OigSelfDisclosureMember" unitRef="USDollar">400000</us-gaap:PaymentsForLegalSettlements>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock id="ID_1284" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 14px"&gt;&lt;td colspan="6"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Total minimum rental commitments as of December 31, 2016 are as follows (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;23.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;17.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;13.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;9.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;2021&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Future years&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;72.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 10px"&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td colspan="6"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Rent expense for non-cancelable operating leases was $27.5 million, $23.7 million and $26.5 million for 2016, 2015 and 2014.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent id="ID_1285" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">23500000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears id="ID_1286" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">17500000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears id="ID_1287" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">13000000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears id="ID_1288" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">9100000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears id="ID_1289" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">4300000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter id="ID_1290" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">4600000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue id="ID_1291" decimals="-5" contextRef="AS_OF_Dec31_2016" unitRef="USDollar">72000000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <amed:OperatingLeasesRentExpenseNetForContinuingOperations id="ID_1292" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">27500000</amed:OperatingLeasesRentExpenseNetForContinuingOperations>
  <amed:OperatingLeasesRentExpenseNetForContinuingOperations id="ID_1293" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">23700000</amed:OperatingLeasesRentExpenseNetForContinuingOperations>
  <amed:OperatingLeasesRentExpenseNetForContinuingOperations id="ID_1294" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">26500000</amed:OperatingLeasesRentExpenseNetForContinuingOperations>
  <amed:OperatingLeaseTermYears id="ID_1295" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RangeAxis_MinimumMember">P1Y</amed:OperatingLeaseTermYears>
  <amed:OperatingLeaseTermYears id="ID_1296" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RangeAxis_MaximumMember">P7Y</amed:OperatingLeaseTermYears>
  <amed:InsuranceProgramsTableTextBlock id="ID_1297" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5"  style="width: 160px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:160px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;As of December 31,&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"&gt;&lt;font style="FONT-WEIGHT: bold;TEXT-DECORATION: underline;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;"&gt;Type of Insurance&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Health insurance&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;11.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Workers' compensation&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;26.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;23.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Professional liability&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;42.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;39.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Less: long-term portion&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.8)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.9)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;41.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;38.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td colspan="9"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The retention limit per claim for our health insurance, worker's compensation and professional liability is $0.9 million, $0.5 million and $0.3 million, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:InsuranceProgramsTableTextBlock>
  <amed:HealthInsurance id="ID_1298" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">10600000</amed:HealthInsurance>
  <amed:WokersCompensation id="ID_1299" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">26800000</amed:WokersCompensation>
  <amed:ProfessionalLiability id="ID_1300" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">4700000</amed:ProfessionalLiability>
  <amed:EstimatedInsuranceTotal id="ID_1301" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">42100000</amed:EstimatedInsuranceTotal>
  <amed:EstimatedInsuranceLongTermPortion id="ID_1302" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">-800000</amed:EstimatedInsuranceLongTermPortion>
  <amed:EstimatedInsuranceExcludingLongTermPortion id="ID_1303" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">41300000</amed:EstimatedInsuranceExcludingLongTermPortion>
  <amed:HealthInsurance id="ID_1304" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">11700000</amed:HealthInsurance>
  <amed:WokersCompensation id="ID_1305" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">23900000</amed:WokersCompensation>
  <amed:ProfessionalLiability id="ID_1306" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">4100000</amed:ProfessionalLiability>
  <amed:EstimatedInsuranceTotal id="ID_1307" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">39700000</amed:EstimatedInsuranceTotal>
  <amed:EstimatedInsuranceLongTermPortion id="ID_1308" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">-900000</amed:EstimatedInsuranceLongTermPortion>
  <amed:EstimatedInsuranceExcludingLongTermPortion id="ID_1309" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">38800000</amed:EstimatedInsuranceExcludingLongTermPortion>
  <amed:HealthInsuranceRetentionLimit id="ID_1310" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">900000</amed:HealthInsuranceRetentionLimit>
  <amed:WorkersCompensationInsuranceRetentionLimit id="ID_1311" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">500000</amed:WorkersCompensationInsuranceRetentionLimit>
  <amed:ProfessionalLiabilityInsuranceRetentionLimit id="ID_1312" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">300000</amed:ProfessionalLiabilityInsuranceRetentionLimit>
  <amed:MinimumEligibleAgeForEmployeesToContributeToBenefitPlan id="ID_1313" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Year">21</amed:MinimumEligibleAgeForEmployeesToContributeToBenefitPlan>
  <us-gaap:DefinedContributionPlanCostRecognized id="ID_1314" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">6900000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock id="ID_1315" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:13pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;"&gt;11. EMPLOYEE BENEFIT PLANS&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;401(K) Benefit Plan&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We maintain a plan qualified under Section 401(k) of the Internal Revenue Code for all employees who have reached &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; years of age, effective the first month after hire date. Under the plan, eligible employees may elect to defer a portion of their compensation, subject to Internal Revenue Service limits.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;During &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and  &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;our match of contributions to be made to each eligible employee contribution &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$0.375 for every $1.00 of contribution made up to&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; the first 6%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of their salary. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Effective January 1, 2017, our match of contributions to be made to each eligible employee contribution is $0.44 for every $1.00 of contribution made up to the first 6% of their salary. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;The match is discretionary and thus is subject to change at the discretion of management. These contributions are made in the form of our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;common stock, valued based upon the fair value of the stock as of the end of each calendar quarter end. We expensed approximately $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;m&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;illion, $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million and $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6.2&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;million for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Deferred Compensation Plan&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;We h&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ad&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; a Deferred Compensation Plan for additional tax-deferred savings to a select group of management or highly compensated employees.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Amounts credited under the Deferred Compensation Plan &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;were&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; funded into a rabbi trust, which is managed by a trustee. The trustee has the discretion to manage the assets of the Deferred Compensation Plan as deemed fit, thus the assets are not necessarily reflective of the same investment choices made by the participants.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Effective January 1, 2015, all prospective salary deferrals &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ceased&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. Participants will be allowed to make transactions with any remaining account balances as they wish per plan guidelines.&lt;/font&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:DefinedContributionPlanCostRecognized id="ID_1316" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">6100000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:DefinedContributionPlanCostRecognized id="ID_1317" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">6200000</us-gaap:DefinedContributionPlanCostRecognized>
  <amed:DefinedContributionPlanEmployerMatchingContribution id="ID_1318" decimals="3" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">0.375</amed:DefinedContributionPlanEmployerMatchingContribution>
  <amed:DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram id="ID_1319" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">1.00</amed:DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram>
  <amed:DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage id="ID_1320" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Pure">0.06</amed:DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage>
  <amed:DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage id="ID_1321" decimals="2" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="Pure">0.06</amed:DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage>
  <amed:DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram id="ID_1322" decimals="2" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">1.00</amed:DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram>
  <amed:DefinedContributionPlanEmployerMatchingContribution id="ID_1323" decimals="3" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">0.375</amed:DefinedContributionPlanEmployerMatchingContribution>
  <amed:DefinedContributionPlanEmployerMatchingContribution id="ID_1324" decimals="3" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">0.375</amed:DefinedContributionPlanEmployerMatchingContribution>
  <amed:DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram id="ID_1325" decimals="2" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">1.00</amed:DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram>
  <amed:DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage id="ID_1326" decimals="2" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="Pure">0.06</amed:DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage>
  <amed:DefinedContributionPlanEmployerMatchingContribution id="ID_1327" decimals="3" contextRef="FROM_Jan01_2017_TO_Dec31_2017" unitRef="USDollar">0.440</amed:DefinedContributionPlanEmployerMatchingContribution>
  <amed:DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram id="ID_1328" decimals="2" contextRef="FROM_Jan01_2017_TO_Dec31_2017" unitRef="USDollar">1.00</amed:DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram>
  <amed:DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage id="ID_1329" decimals="2" contextRef="FROM_Jan01_2017_TO_Dec31_2017" unitRef="Pure">0.06</amed:DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage>
  <us-gaap:TreasuryStockTextBlock id="ID_1330" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:13pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;"&gt;12. S&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;TOCK&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt; REPURCHASE PROGRAM&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;September 9, 2015&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;75&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million of our outstanding common stock&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; on or before September 6, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Under the terms of the program, we could repurchase shares from time to time in open market transactions, block purchases or in private transactions in accordance with &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;applicable federal securities laws and other legal requirements. We &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;could&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; enter into Rule 10b5-1 plans to effect some or all of the repurchases. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;The timing and the amount of the repurchases, if any, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;was&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;P&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;ursuant to this program, we repurchased &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;324,141&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; shares of our common stock at a weighted average price of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;37.96 &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;per share and a total cost of approximately $12.3 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; during 2016 and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;116,859&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;shares of our common stock at a weighted average price of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;39.20&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;per share and a total cost of approximately $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4.6&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million. The repurchased shares are classified as treasury shares&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. The stock repurchase program expired on September 6, 2016&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;</us-gaap:TreasuryStockTextBlock>
  <us-gaap:StockRepurchaseProgramAuthorizedAmount1 id="ID_1331" decimals="-6" contextRef="AS_OF_Sep09_2015" unitRef="USDollar">75000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
  <us-gaap:TreasuryStockSharesAcquired id="ID_1332" decimals="0" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="Shares">116859</us-gaap:TreasuryStockSharesAcquired>
  <us-gaap:TreasuryStockAcquiredAverageCostPerShare id="ID_1333" decimals="2" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDperShare">39.20</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
  <us-gaap:TreasuryStockSharesAcquired id="ID_1334" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Shares">324141</us-gaap:TreasuryStockSharesAcquired>
  <us-gaap:TreasuryStockAcquiredAverageCostPerShare id="ID_1335" decimals="2" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDperShare">37.96</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
  <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock id="ID_1336" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:13pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;"&gt;13&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;EXIT &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;AND RESTRUCTURING ACTIVITIES &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:4.5pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;As of December 31, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we reported three home health care &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;centers &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;as held for sale. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;During 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we sold assets associated with two of these care centers for cash consideration of approximately $0.8 million and recognized a gain of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$0.8 million which is included in discontinued operations. The remaining care center classified as held for sale was consolidated with a care center servicing the same market during 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:4.5pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;During 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, the Company sold its interest in five home health and four hospice care c&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;enters in Wyoming and Idaho for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;approximately $5.0 million and recognized a gain of $2.1 million. We also exited our hospice inpatient unit in New Hampshire and recognized a loss of $0.5 million.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:4.5pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;In addition to the exit activity related to the care centers mentioned above, we consolidated 21 operating home health care centers and four operating hospice care centers with care centers servicing the same markets and closed 22 home health care centers and four hospice care centers during 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. In connection with these care centers, we recorded non-cash charges of $2.2 million in other intangibles impairment expense related to the write-off of intangible assets, $2.1 million in other general and administrative expenses related to lease termination costs and $2.1 million in salaries and benefits related to severance costs. These care centers were not concentrated in certain selected geographical areas and did not meet the criteria to be classified as discontinued operations in accordance with applicable accounting guidance&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;"&gt;Restructuring Activity&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:9pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;During &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we restructured our regional leadership and corporate support functions.  As such, we recorded charges of $3.4 million in salaries and benefits related to severance &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;costs. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;In addition, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;during 2014&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, William F. Borne stepped down from his positions as Chief Executive Officer, Chairman and a member of our Board of Directors and we recorded charges of $2.3 million in salaries and benefits related to severance costs.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:4.5pt'&gt;&amp;#160;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="15"  style="width: 646px; text-align:left;border-color:#000000;min-width:646px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Our reserve activity for our 2014 exit and restructuring activity is as follows (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6"  style="width: 169px; text-align:center;border-color:#000000;min-width:169px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5"  style="width: 159px; text-align:center;border-color:#000000;min-width:159px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5"  style="width: 159px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:159px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2014 Exit Activity&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5"  style="width: 159px; text-align:center;border-color:#000000;min-width:159px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 25px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 76px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:76px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Lease Termination&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 7px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 76px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:76px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Severance&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 76px; text-align:center;border-color:#000000;min-width:76px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:center;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 76px; text-align:center;border-color:#000000;min-width:76px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Balances at December 31, 2013&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 7px; text-align:center;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:center;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Charge in 2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;7.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Cash expenditures in 2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(1.6)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(5.5)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Balances at December 31, 2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 7px; text-align:center;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:center;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Charge in 2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Cash expenditures in 2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.4)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(1.9)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Balances at December 31, 2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Charge in 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Cash expenditures in 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.4)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Balances at December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 66px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 66px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
  <amed:NumberOfCareCentersSold id="ID_1337" decimals="0" contextRef="FROM_Jan01_2014_TO_Dec31_2014_amed_TypeOfBusinessSoldAxis_AvailableForSaleMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Agencies">2</amed:NumberOfCareCentersSold>
  <us-gaap:ProceedsFromDivestitureOfBusinesses id="ID_1338" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_amed_TypeOfBusinessSoldAxis_AvailableForSaleMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">800000</us-gaap:ProceedsFromDivestitureOfBusinesses>
  <us-gaap:GainsLossesOnSalesOfAssets id="ID_1339" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_amed_TypeOfBusinessSoldAxis_AvailableForSaleMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">800000</us-gaap:GainsLossesOnSalesOfAssets>
  <amed:NumberOfCareCentersSold id="ID_1340" decimals="0" contextRef="FROM_Jan01_2014_TO_Dec31_2014_amed_TypeOfBusinessSoldAxis_WyomingAndIdahoCareCentersMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Agencies">5</amed:NumberOfCareCentersSold>
  <amed:NumberOfCareCentersSold id="ID_1341" decimals="0" contextRef="FROM_Jan01_2014_TO_Dec31_2014_amed_TypeOfBusinessSoldAxis_WyomingAndIdahoCareCentersMember_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="Agencies">4</amed:NumberOfCareCentersSold>
  <us-gaap:ProceedsFromDivestitureOfBusinesses id="ID_1342" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_amed_TypeOfBusinessSoldAxis_WyomingAndIdahoCareCentersMember" unitRef="USDollar">5000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
  <us-gaap:GainsLossesOnSalesOfAssets id="ID_1343" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_amed_TypeOfBusinessSoldAxis_WyomingAndIdahoCareCentersMember" unitRef="USDollar">2100000</us-gaap:GainsLossesOnSalesOfAssets>
  <amed:NumberOfCareCentersClosed id="ID_1344" decimals="0" contextRef="FROM_Jan01_2014_TO_Dec31_2014_amed_TypeOfBusinessSoldAxis_HospiceInpatientUnitMember" unitRef="Agencies">1</amed:NumberOfCareCentersClosed>
  <us-gaap:GainsLossesOnSalesOfAssets id="ID_1345" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_amed_TypeOfBusinessSoldAxis_HospiceInpatientUnitMember" unitRef="USDollar">-500000</us-gaap:GainsLossesOnSalesOfAssets>
  <amed:NumberOfCareCentersClosed id="ID_1346" decimals="0" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Agencies">22</amed:NumberOfCareCentersClosed>
  <amed:NumberOfCareCentersClosed id="ID_1347" decimals="0" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="Agencies">4</amed:NumberOfCareCentersClosed>
  <amed:NumberOfCareCentersConsolidated id="ID_1348" decimals="0" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Agencies">21</amed:NumberOfCareCentersConsolidated>
  <amed:NumberOfCareCentersConsolidated id="ID_1349" decimals="0" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="Agencies">4</amed:NumberOfCareCentersConsolidated>
  <us-gaap:OtherRestructuringCosts id="ID_1350" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_IntangiblesWriteOffMember" unitRef="USDollar">2200000</us-gaap:OtherRestructuringCosts>
  <us-gaap:OtherRestructuringCosts id="ID_1351" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_LeaseTerminationMember" unitRef="USDollar">2100000</us-gaap:OtherRestructuringCosts>
  <us-gaap:OtherRestructuringCosts id="ID_1352" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_RestructuringCostAndReserveAxis_SeveranceForFormerExecutiveMember" unitRef="USDollar">2300000</us-gaap:OtherRestructuringCosts>
  <us-gaap:OtherRestructuringCosts id="ID_1353" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_RestructuringCostAndReserveAxis_SeveranceForRegionalLeadershipAndCorporateSupportMember" unitRef="USDollar">3400000</us-gaap:OtherRestructuringCosts>
  <amed:NumberOfCareCentersConsolidated id="ID_1354" decimals="0" contextRef="FROM_Jan01_2014_TO_Dec31_2014_amed_TypeOfBusinessSoldAxis_AvailableForSaleMember_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="Agencies">1</amed:NumberOfCareCentersConsolidated>
  <us-gaap:OtherRestructuringCosts id="ID_1355" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="USDollar">2100000</us-gaap:OtherRestructuringCosts>
  <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock id="ID_1356" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="15"  style="width: 646px; text-align:left;border-color:#000000;min-width:646px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Our reserve activity for our 2014 exit and restructuring activity is as follows (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="6"  style="width: 169px; text-align:center;border-color:#000000;min-width:169px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5"  style="width: 159px; text-align:center;border-color:#000000;min-width:159px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5"  style="width: 159px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:159px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;2014 Exit Activity&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5"  style="width: 159px; text-align:center;border-color:#000000;min-width:159px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 25px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 76px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:76px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Lease Termination&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 7px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 76px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:76px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Severance&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 76px; text-align:center;border-color:#000000;min-width:76px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:center;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 76px; text-align:center;border-color:#000000;min-width:76px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Balances at December 31, 2013&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 7px; text-align:center;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:center;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Charge in 2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;7.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Cash expenditures in 2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(1.6)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(5.5)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Balances at December 31, 2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 7px; text-align:center;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:center;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Charge in 2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Cash expenditures in 2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.4)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(1.9)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Balances at December 31, 2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Charge in 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Cash expenditures in 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.4)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Balances at December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 66px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 66px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:66px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
  <us-gaap:RestructuringReserve id="ID_1357" decimals="-5" contextRef="AS_OF_Dec31_2014_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_LeaseTerminationMember" unitRef="USDollar">500000</us-gaap:RestructuringReserve>
  <us-gaap:RestructuringReserve id="ID_1358" decimals="-5" contextRef="AS_OF_Dec31_2013_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_LeaseTerminationMember" unitRef="USDollar">0</us-gaap:RestructuringReserve>
  <us-gaap:RestructuringReserve id="ID_1359" decimals="-5" contextRef="AS_OF_Dec31_2013_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="USDollar">0</us-gaap:RestructuringReserve>
  <us-gaap:RestructuringReserve id="ID_1360" decimals="-5" contextRef="AS_OF_Dec31_2015_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_LeaseTerminationMember" unitRef="USDollar">100000</us-gaap:RestructuringReserve>
  <us-gaap:RestructuringReserve id="ID_1361" decimals="-5" contextRef="AS_OF_Dec31_2015_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="USDollar">400000</us-gaap:RestructuringReserve>
  <us-gaap:RestructuringReserve id="ID_1362" decimals="-5" contextRef="AS_OF_Dec31_2016_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_LeaseTerminationMember" unitRef="USDollar">0</us-gaap:RestructuringReserve>
  <us-gaap:RestructuringReserve id="ID_1363" decimals="-5" contextRef="AS_OF_Dec31_2016_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="USDollar">0</us-gaap:RestructuringReserve>
  <us-gaap:RestructuringCharges id="ID_1364" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_LeaseTerminationMember" unitRef="USDollar">2100000</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringCharges id="ID_1365" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="USDollar">7800000</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringCharges id="ID_1366" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_LeaseTerminationMember" unitRef="USDollar">0</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringCharges id="ID_1367" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="USDollar">0</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringCharges id="ID_1368" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_LeaseTerminationMember" unitRef="USDollar">0</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringCharges id="ID_1369" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="USDollar">0</us-gaap:RestructuringCharges>
  <us-gaap:PaymentsForRestructuring id="ID_1370" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_LeaseTerminationMember" unitRef="USDollar">100000</us-gaap:PaymentsForRestructuring>
  <us-gaap:PaymentsForRestructuring id="ID_1371" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="USDollar">400000</us-gaap:PaymentsForRestructuring>
  <us-gaap:PaymentsForRestructuring id="ID_1372" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="USDollar">5500000</us-gaap:PaymentsForRestructuring>
  <us-gaap:PaymentsForRestructuring id="ID_1373" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_LeaseTerminationMember" unitRef="USDollar">1600000</us-gaap:PaymentsForRestructuring>
  <us-gaap:PaymentsForRestructuring id="ID_1374" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_LeaseTerminationMember" unitRef="USDollar">400000</us-gaap:PaymentsForRestructuring>
  <us-gaap:PaymentsForRestructuring id="ID_1375" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="USDollar">1900000</us-gaap:PaymentsForRestructuring>
  <us-gaap:RestructuringReserve id="ID_1376" decimals="-5" contextRef="AS_OF_Dec31_2014_amed_OtherRestructuringCostsAxis_TwoThousandAndFourteenExitActivityMember_us-gaap_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="USDollar">2300000</us-gaap:RestructuringReserve>
  <us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock id="ID_1377" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="18"  style="width: 709px; text-align:left;border-color:#000000;min-width:709px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;14. VALUATION AND QUALIFYING ACCOUNTS&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td colspan="18"  style="width: 709px; text-align:left;border-color:#000000;min-width:709px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following table summarizes the activity and ending balances in our allowance for doubtful accounts and estimated revenue adjustments (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 18px"&gt;&lt;td colspan="18"  style="width: 709px; text-align:left;border-color:#000000;min-width:709px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Allowance for Doubtful Accounts&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:center;border-color:#000000;min-width:69px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 81px; text-align:center;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 51px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:165px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Year End&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Balance at Beginning of Year&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Provision for Doubtful Accounts (1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Write-Offs&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 79px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:79px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Balance at End of Year&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:165px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;16.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;19.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(18.3)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 69px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:69px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;17.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;14.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;14.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(11.9)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:right;border-color:#000000;min-width:69px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;16.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;14.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;16.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(16.3)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:right;border-color:#000000;min-width:69px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;14.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 8px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="16"  style="width: 547px; text-align:left;border-color:#000000;min-width:547px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;(1) Includes $0.1 million from discontinued operations for the year ended December 31, 2014.&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="18"  style="width: 709px; text-align:left;border-color:#000000;min-width:709px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Estimated Revenue Adjustments&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:center;border-color:#000000;min-width:69px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 81px; text-align:center;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 63px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:165px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Year End&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Balance at Beginning of Year&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Provision for Estimated Revenue Adjustments (1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Write-Offs&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 79px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:79px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Balance at End of Year&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:165px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;7.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(7.8)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 69px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:69px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(5.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:right;border-color:#000000;min-width:69px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;5.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(5.9)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:right;border-color:#000000;min-width:69px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 8px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 36px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="16"  style="width: 547px; text-align:left;border-color:#000000;min-width:547px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;(1) Includes $0.1 million from discontinued operations for the year ended December 31, 2014.&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
  <amed:ValuationAndQualifyingAccountsTableTextBlock id="ID_1378" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="18"  style="width: 709px; text-align:left;border-color:#000000;min-width:709px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;14. VALUATION AND QUALIFYING ACCOUNTS&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td colspan="18"  style="width: 709px; text-align:left;border-color:#000000;min-width:709px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;The following table summarizes the activity and ending balances in our allowance for doubtful accounts and estimated revenue adjustments (amounts in millions):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 18px"&gt;&lt;td colspan="18"  style="width: 709px; text-align:left;border-color:#000000;min-width:709px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Allowance for Doubtful Accounts&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:center;border-color:#000000;min-width:69px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 81px; text-align:center;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 51px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:165px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Year End&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Balance at Beginning of Year&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Provision for Doubtful Accounts (1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Write-Offs&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 79px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:79px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Balance at End of Year&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:165px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;16.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;19.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(18.3)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 69px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:69px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;17.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;14.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;14.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(11.9)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:right;border-color:#000000;min-width:69px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;16.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;14.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;16.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(16.3)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:right;border-color:#000000;min-width:69px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;14.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 8px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 34px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="16"  style="width: 547px; text-align:left;border-color:#000000;min-width:547px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;(1) Includes $0.1 million from discontinued operations for the year ended December 31, 2014.&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="18"  style="width: 709px; text-align:left;border-color:#000000;min-width:709px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;Estimated Revenue Adjustments&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:center;border-color:#000000;min-width:69px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 81px; text-align:center;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 63px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:165px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Year End&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Balance at Beginning of Year&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Provision for Estimated Revenue Adjustments (1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Write-Offs&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 79px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:79px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Balance at End of Year&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:165px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;7.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(7.8)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 69px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:69px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(5.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:right;border-color:#000000;min-width:69px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;5.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(5.9)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:right;border-color:#000000;min-width:69px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 8px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 36px"&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="16"  style="width: 547px; text-align:left;border-color:#000000;min-width:547px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;(1) Includes $0.1 million from discontinued operations for the year ended December 31, 2014.&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:ValuationAndQualifyingAccountsTableTextBlock>
  <us-gaap:ProvisionForDoubtfulAccounts id="ID_1379" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_ValuationAllowancesAndReservesTypeAxis_AllowanceForDoubtfulAccountsMember" unitRef="USDollar">19500000</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:ValuationAllowancesAndReservesBalance id="ID_1380" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_ValuationAllowancesAndReservesTypeAxis_AllowanceForDoubtfulAccountsMember" unitRef="USDollar">17700000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesDeductions id="ID_1381" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_ValuationAllowancesAndReservesTypeAxis_AllowanceForDoubtfulAccountsMember" unitRef="USDollar">-18300000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <us-gaap:ValuationAllowancesAndReservesDeductions id="ID_1382" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_ValuationAllowancesAndReservesTypeAxis_EstimatedRevenueAdjustmentsMember" unitRef="USDollar">-7800000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <us-gaap:ValuationAllowancesAndReservesAdjustments id="ID_1383" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_ValuationAllowancesAndReservesTypeAxis_EstimatedRevenueAdjustmentsMember" unitRef="USDollar">7900000</us-gaap:ValuationAllowancesAndReservesAdjustments>
  <us-gaap:ValuationAllowancesAndReservesBalance id="ID_1384" decimals="-5" contextRef="AS_OF_Dec31_2016_us-gaap_ValuationAllowancesAndReservesTypeAxis_EstimatedRevenueAdjustmentsMember" unitRef="USDollar">4100000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance id="ID_1385" decimals="-5" contextRef="AS_OF_Dec31_2015_us-gaap_ValuationAllowancesAndReservesTypeAxis_AllowanceForDoubtfulAccountsMember" unitRef="USDollar">16500000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ProvisionForDoubtfulAccounts id="ID_1386" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_ValuationAllowancesAndReservesTypeAxis_AllowanceForDoubtfulAccountsMember" unitRef="USDollar">14100000</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:ValuationAllowancesAndReservesDeductions id="ID_1387" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_ValuationAllowancesAndReservesTypeAxis_AllowanceForDoubtfulAccountsMember" unitRef="USDollar">-11900000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <us-gaap:ValuationAllowancesAndReservesBalance id="ID_1388" decimals="-5" contextRef="AS_OF_Dec31_2015_us-gaap_ValuationAllowancesAndReservesTypeAxis_EstimatedRevenueAdjustmentsMember" unitRef="USDollar">4000000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesAdjustments id="ID_1389" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_ValuationAllowancesAndReservesTypeAxis_EstimatedRevenueAdjustmentsMember" unitRef="USDollar">6100000</us-gaap:ValuationAllowancesAndReservesAdjustments>
  <us-gaap:ValuationAllowancesAndReservesDeductions id="ID_1390" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_ValuationAllowancesAndReservesTypeAxis_EstimatedRevenueAdjustmentsMember" unitRef="USDollar">-5200000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <us-gaap:ValuationAllowancesAndReservesBalance id="ID_1391" decimals="-5" contextRef="AS_OF_Dec31_2014_us-gaap_ValuationAllowancesAndReservesTypeAxis_EstimatedRevenueAdjustmentsMember" unitRef="USDollar">3100000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesDeductions id="ID_1392" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_ValuationAllowancesAndReservesTypeAxis_AllowanceForDoubtfulAccountsMember" unitRef="USDollar">-16300000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <us-gaap:ProvisionForDoubtfulAccounts id="ID_1393" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_ValuationAllowancesAndReservesTypeAxis_AllowanceForDoubtfulAccountsMember" unitRef="USDollar">16400000</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:ValuationAllowancesAndReservesBalance id="ID_1394" decimals="-5" contextRef="AS_OF_Dec31_2013_us-gaap_ValuationAllowancesAndReservesTypeAxis_AllowanceForDoubtfulAccountsMember" unitRef="USDollar">14200000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance id="ID_1395" decimals="-5" contextRef="AS_OF_Dec31_2014_us-gaap_ValuationAllowancesAndReservesTypeAxis_AllowanceForDoubtfulAccountsMember" unitRef="USDollar">14300000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesAdjustments id="ID_1396" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_ValuationAllowancesAndReservesTypeAxis_EstimatedRevenueAdjustmentsMember" unitRef="USDollar">5100000</us-gaap:ValuationAllowancesAndReservesAdjustments>
  <us-gaap:ValuationAllowancesAndReservesBalance id="ID_1397" decimals="-5" contextRef="AS_OF_Dec31_2013_us-gaap_ValuationAllowancesAndReservesTypeAxis_EstimatedRevenueAdjustmentsMember" unitRef="USDollar">3900000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesDeductions id="ID_1398" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_ValuationAllowancesAndReservesTypeAxis_EstimatedRevenueAdjustmentsMember" unitRef="USDollar">-5900000</us-gaap:ValuationAllowancesAndReservesDeductions>
  <us-gaap:ValuationAllowancesAndReservesAdjustments id="ID_1399" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_ValuationAllowancesAndReservesTypeAxis_EstimatedRevenueAdjustmentsDiscontinuedOperationsMember" unitRef="USDollar">100000</us-gaap:ValuationAllowancesAndReservesAdjustments>
  <us-gaap:ProvisionForDoubtfulAccounts id="ID_1400" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_ValuationAllowancesAndReservesTypeAxis_AllowanceForDoubtfulAccountsDiscontinuedOperationsMember" unitRef="USDollar">100000</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:SegmentReportingDisclosureTextBlock id="ID_1401" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:13pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman Bold;font-size:10pt;font-weight:bold;margin-left:0px;"&gt;15&lt;/font&gt;&lt;font style="font-family:Times New Roman Bold;font-size:10pt;font-weight:bold;"&gt;. Segment Information&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:9pt; margin-bottom:4.5pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Our operations involve servicing patients through our t&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;hree&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; reportable &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;business segments:&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;home health, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;hospice&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and personal care&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.  Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with the essenti&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;al activities of daily living. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Our hospice segment provides palliative care and comfort to terminally il&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;l patients and their families. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Our personal care segment, which was established with the acquisition of Associated Home Care during the three-month period ended March 31, 2016, provides patients with assistance with the essential activities of daily living. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;The &amp;#8220;other&amp;#8221; column in the following tables consist&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;s&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; of costs relating to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;executive management &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and administrative support functions&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.  &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:4.5pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;M&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;anagement&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;evaluates performance and allocates resources based on the operating income of the reportable segments, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;which &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;includes an allocation of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;corporate expenses&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; directly attribu&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;table to the specific segment&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; and includes revenues and all other costs directly attributable to the specific segment&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Segment assets are not reviewed by the company's chief operating decision maker and therefore are not disclosed below (amounts in millions).  &lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:9pt'&gt;&amp;#160;&lt;/p&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="13"  style="width: 375px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:375px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Year Ended December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Home Health&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Hospice&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Personal Care&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Other&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Net service revenue&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1,085.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;316.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;35.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1,437.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Cost of service, excluding depreciation and amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;643.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;163.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;26.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;833.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;General and administrative expenses&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;283.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;70.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;7.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;141.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;503.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Provision for doubtful accounts&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;13.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;5.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;19.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Depreciation and amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;12.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;19.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Asset impairment charge&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Operating expenses&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;946.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;240.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;34.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;158.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1,380.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Operating income (loss)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;138.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;75.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(158.7)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;57.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="13"  style="width: 375px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:375px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Year Ended December 31, 2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Home Health&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Hospice&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Personal Care&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Other&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Net service revenue&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1,005.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;275.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1,280.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Cost of service, excluding depreciation and amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;584.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;141.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;725.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;General and administrative expenses&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;263.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;62.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;126.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;452.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Provision for doubtful accounts&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;12.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;14.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Depreciation and amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;5.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;13.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;20.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Asset impairment charge&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;77.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;77.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Operating expenses&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;864.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;207.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;217.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1,289.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Operating income (loss)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;140.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;67.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(217.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(9.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="13"  style="width: 375px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:375px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Year Ended December 31, 2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Home Health&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Hospice&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Personal Care&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Other&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Net service revenue&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;956.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;247.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1,204.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Cost of service, excluding depreciation and amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;559.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;131.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;691.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;General and administrative expenses&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;269.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;58.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;114.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;441.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Provision for doubtful accounts&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;14.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;16.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Depreciation and amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;9.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;17.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;28.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Asset impairment charge&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Operating expenses&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;853.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;195.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;131.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1,180.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Operating income (loss)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;103.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;52.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(131.6)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;24.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
  <us-gaap:NumberOfReportableSegments id="ID_1402" decimals="0" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="Segments">3</us-gaap:NumberOfReportableSegments>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_1403" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">1085500000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_1404" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">316000000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_1405" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">0</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_1406" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">1005100000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_1407" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">275400000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_1408" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">0</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_1409" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">956900000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_1410" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">247600000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_1411" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">0</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock id="ID_1412" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="13"  style="width: 375px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:375px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Year Ended December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Home Health&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Hospice&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Personal Care&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Other&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Net service revenue&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1,085.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;316.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;35.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1,437.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Cost of service, excluding depreciation and amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;643.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;163.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;26.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;833.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;General and administrative expenses&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;283.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;70.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;7.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;141.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;503.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Provision for doubtful accounts&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;13.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;5.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;19.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Depreciation and amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;12.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;19.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Asset impairment charge&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Operating expenses&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;946.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;240.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;34.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;158.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1,380.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Operating income (loss)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;138.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;75.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(158.7)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;57.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="13"  style="width: 375px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:375px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Year Ended December 31, 2015&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Home Health&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Hospice&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Personal Care&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Other&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Net service revenue&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1,005.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;275.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1,280.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Cost of service, excluding depreciation and amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;584.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;141.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;725.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;General and administrative expenses&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;263.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;62.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;126.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;452.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Provision for doubtful accounts&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;12.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;14.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Depreciation and amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;5.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;13.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;20.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Asset impairment charge&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;77.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;77.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Operating expenses&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;864.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;207.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;217.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1,289.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Operating income (loss)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;140.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;67.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(217.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(9.2)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="13"  style="width: 375px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:375px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;For the Year Ended December 31, 2014&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Home Health&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Hospice&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Personal Care&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Other&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Net service revenue&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;956.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;247.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1,204.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Cost of service, excluding depreciation and amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;559.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;131.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;691.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;General and administrative expenses&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;269.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;58.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;114.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;441.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Provision for doubtful accounts&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;14.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;16.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Depreciation and amortization&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;9.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;17.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;28.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Asset impairment charge&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Operating expenses&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;853.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;195.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;131.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1,180.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;Operating income (loss)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;103.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;52.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(131.6)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;24.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 9px"&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
  <us-gaap:CostOfServices id="ID_1413" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">584200000</us-gaap:CostOfServices>
  <us-gaap:CostOfServices id="ID_1414" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">141700000</us-gaap:CostOfServices>
  <us-gaap:CostOfServices id="ID_1415" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">0</us-gaap:CostOfServices>
  <us-gaap:CostOfServices id="ID_1416" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">559400000</us-gaap:CostOfServices>
  <us-gaap:CostOfServices id="ID_1417" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">131700000</us-gaap:CostOfServices>
  <us-gaap:CostOfServices id="ID_1418" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">0</us-gaap:CostOfServices>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_1419" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016" unitRef="USDollar">503400000</amed:GeneralAndAdministrativeExpenseSegment>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_1420" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">263200000</amed:GeneralAndAdministrativeExpenseSegment>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_1421" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">62700000</amed:GeneralAndAdministrativeExpenseSegment>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_1422" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">126500000</amed:GeneralAndAdministrativeExpenseSegment>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_1423" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015" unitRef="USDollar">452400000</amed:GeneralAndAdministrativeExpenseSegment>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_1424" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">269000000</amed:GeneralAndAdministrativeExpenseSegment>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_1425" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">58300000</amed:GeneralAndAdministrativeExpenseSegment>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_1426" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">114400000</amed:GeneralAndAdministrativeExpenseSegment>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_1427" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014" unitRef="USDollar">441700000</amed:GeneralAndAdministrativeExpenseSegment>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_1428" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">12200000</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_1429" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">1900000</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_1430" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">0</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_1431" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">14800000</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_1432" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">1500000</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_1433" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">0</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_1434" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">5200000</amed:DepreciationAndAmortizationForContinuingOperations>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_1435" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">1400000</amed:DepreciationAndAmortizationForContinuingOperations>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_1436" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">13400000</amed:DepreciationAndAmortizationForContinuingOperations>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_1437" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">9000000</amed:DepreciationAndAmortizationForContinuingOperations>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_1438" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">2100000</amed:DepreciationAndAmortizationForContinuingOperations>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_1439" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">17200000</amed:DepreciationAndAmortizationForContinuingOperations>
  <us-gaap:CostsAndExpenses id="ID_1440" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">864800000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses id="ID_1441" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">207700000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses id="ID_1442" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">217200000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses id="ID_1443" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">853800000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses id="ID_1444" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">195100000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses id="ID_1445" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">131600000</us-gaap:CostsAndExpenses>
  <us-gaap:OperatingIncomeLoss id="ID_1446" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">140300000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="ID_1447" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">67700000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="ID_1448" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">-217200000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="ID_1449" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">103100000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="ID_1450" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">52500000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="ID_1451" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">-131600000</us-gaap:OperatingIncomeLoss>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_1452" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">283400000</amed:GeneralAndAdministrativeExpenseSegment>
  <us-gaap:CostOfServices id="ID_1453" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">643700000</us-gaap:CostOfServices>
  <us-gaap:OperatingIncomeLoss id="ID_1454" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">138600000</us-gaap:OperatingIncomeLoss>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_1455" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">6000000</amed:DepreciationAndAmortizationForContinuingOperations>
  <us-gaap:CostsAndExpenses id="ID_1456" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">946900000</us-gaap:CostsAndExpenses>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_1457" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">13800000</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_1458" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">141900000</amed:GeneralAndAdministrativeExpenseSegment>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_1459" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">0</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <us-gaap:CostOfServices id="ID_1460" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">0</us-gaap:CostOfServices>
  <us-gaap:OperatingIncomeLoss id="ID_1461" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">-158700000</us-gaap:OperatingIncomeLoss>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_1462" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">12400000</amed:DepreciationAndAmortizationForContinuingOperations>
  <us-gaap:CostsAndExpenses id="ID_1463" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">158700000</us-gaap:CostsAndExpenses>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_1464" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">1300000</amed:DepreciationAndAmortizationForContinuingOperations>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_1465" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">70200000</amed:GeneralAndAdministrativeExpenseSegment>
  <us-gaap:OperatingIncomeLoss id="ID_1466" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">75900000</us-gaap:OperatingIncomeLoss>
  <us-gaap:CostsAndExpenses id="ID_1467" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">240100000</us-gaap:CostsAndExpenses>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_1468" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">5500000</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <us-gaap:CostOfServices id="ID_1469" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">163100000</us-gaap:CostOfServices>
  <us-gaap:AssetImpairmentCharges id="ID_1470" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">0</us-gaap:AssetImpairmentCharges>
  <us-gaap:AssetImpairmentCharges id="ID_1471" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">0</us-gaap:AssetImpairmentCharges>
  <us-gaap:AssetImpairmentCharges id="ID_1472" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">4400000</us-gaap:AssetImpairmentCharges>
  <us-gaap:AssetImpairmentCharges id="ID_1473" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">0</us-gaap:AssetImpairmentCharges>
  <us-gaap:AssetImpairmentCharges id="ID_1474" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">0</us-gaap:AssetImpairmentCharges>
  <us-gaap:AssetImpairmentCharges id="ID_1475" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">77300000</us-gaap:AssetImpairmentCharges>
  <us-gaap:AssetImpairmentCharges id="ID_1476" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HomeHealthMember" unitRef="USDollar">1600000</us-gaap:AssetImpairmentCharges>
  <us-gaap:AssetImpairmentCharges id="ID_1477" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_HospiceMember" unitRef="USDollar">1500000</us-gaap:AssetImpairmentCharges>
  <us-gaap:AssetImpairmentCharges id="ID_1478" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_AllOtherSegmentsMember" unitRef="USDollar">0</us-gaap:AssetImpairmentCharges>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_1479" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">35900000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:CostOfServices id="ID_1480" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">26300000</us-gaap:CostOfServices>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_1481" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">7900000</amed:GeneralAndAdministrativeExpenseSegment>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_1482" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">200000</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_1483" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</amed:DepreciationAndAmortizationForContinuingOperations>
  <us-gaap:AssetImpairmentCharges id="ID_1484" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</us-gaap:AssetImpairmentCharges>
  <us-gaap:CostsAndExpenses id="ID_1485" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">34400000</us-gaap:CostsAndExpenses>
  <us-gaap:OperatingIncomeLoss id="ID_1486" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">1500000</us-gaap:OperatingIncomeLoss>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_1487" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:CostOfServices id="ID_1488" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</us-gaap:CostOfServices>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_1489" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</amed:GeneralAndAdministrativeExpenseSegment>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_1490" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_1491" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</amed:DepreciationAndAmortizationForContinuingOperations>
  <us-gaap:AssetImpairmentCharges id="ID_1492" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</us-gaap:AssetImpairmentCharges>
  <us-gaap:CostsAndExpenses id="ID_1493" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</us-gaap:CostsAndExpenses>
  <us-gaap:OperatingIncomeLoss id="ID_1494" decimals="-5" contextRef="FROM_Jan01_2015_TO_Dec31_2015_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</us-gaap:OperatingIncomeLoss>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_1495" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:CostOfServices id="ID_1496" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</us-gaap:CostOfServices>
  <amed:GeneralAndAdministrativeExpenseSegment id="ID_1497" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</amed:GeneralAndAdministrativeExpenseSegment>
  <amed:ProvisionForDoubtfulAccountsForContinuingOperations id="ID_1498" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</amed:ProvisionForDoubtfulAccountsForContinuingOperations>
  <amed:DepreciationAndAmortizationForContinuingOperations id="ID_1499" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</amed:DepreciationAndAmortizationForContinuingOperations>
  <us-gaap:AssetImpairmentCharges id="ID_1500" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</us-gaap:AssetImpairmentCharges>
  <us-gaap:CostsAndExpenses id="ID_1501" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</us-gaap:CostsAndExpenses>
  <us-gaap:OperatingIncomeLoss id="ID_1502" decimals="-5" contextRef="FROM_Jan01_2014_TO_Dec31_2014_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">0</us-gaap:OperatingIncomeLoss>
  <us-gaap:QuarterlyFinancialInformationTextBlock id="ID_1503" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="15"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;16. UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 20px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5"  style="width: 154px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:154px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 7.5pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Net Income (Loss) Attributable to Amedisys, Inc. Common Stockholders (1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 77px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:77px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 7.5pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Revenue&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 102px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:102px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 7.5pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Net Income (Loss) Attributable to Amedisys, Inc.&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 72px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:72px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 7.5pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Basic&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 72px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:72px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 7.5pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Diluted&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2016:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:60px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:60px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1st Quarter (2) (3) (4)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;348.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.19&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.19&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2nd Quarter (2) (3) (4)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;360.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.32&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.32&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3rd Quarter (2) (3) (4)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;361.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;11.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.34&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.34&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4th Quarter (2) (3) (4) (5)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;366.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;8.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.27&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.26&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 1,437.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;37.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.12&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.10&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2015:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1st Quarter (6) (7)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;301.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(35.0)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(1.07)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(1.07)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2nd Quarter (7)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;314.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.32&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.32&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3rd Quarter (6) (7) (9)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;326.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;8.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.25&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.25&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4th Quarter (7) (8) (9)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;338.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;12.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.39&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.38&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 1,280.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.09)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.09)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style='margin-top: 0pt; margin-bottom: 0pt;'&gt;&lt;/p&gt;&lt;p style='margin-top:12pt; margin-bottom:10pt'&gt;&lt;/p&gt;&lt;ul&gt;&lt;li style="margin-left:54px;list-style:decimal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Because of the method used in calculating per share data, the quarterly per share data may not necessarily total to the per share data as computed for the entire year.&lt;/font&gt;&lt;/li&gt;&lt;li style="margin-left:54px;list-style:decimal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;During each of the four quarters of 2016, we incurred certain costs associated with the implementation of Homecare &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Homebase&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. Net of income taxes, these costs amounted to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$1.5 million, $1.6 million, $1.2 million and $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million for the three-month periods ended March 31, 2016, June 30, 2016, September 30, 2016 and December 31, 2016, respectively.&lt;/font&gt;&lt;/li&gt;&lt;li style="margin-left:54px;list-style:decimal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;During each of the four quarters of 2016, we incurred certain costs associated with various legal matters. Net of income taxes, these costs amounted to $0.9 million, $0.3 million, $0.2 million &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;and $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; for the three-month periods ended March 31, 2016, June 30, 2016, September 30, 2016 and December 31, 2016, respectively.&lt;/font&gt;&lt;/li&gt;&lt;li style="margin-left:54px;list-style:decimal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;During each of the four quarters of 2016, we incurred certain costs associated with various acquisition costs. Net of income taxes, these costs amounted to $1.0 million, $0.2 million, $0.3 million and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;0&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million for the three-month periods ended March 31, 2016, June 30, 2016, September 30, 2016 and December 31, 2016, respectively.&lt;/font&gt;&lt;/li&gt;&lt;li style="margin-left:54px;list-style:decimal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;During the fourth quarter of 2016, we recorded a non-cash asset impairment charge to write-off assets as a result of our conversion from our proprietary operating system to Homecare &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Homebase&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; in the amount of $2.7 million, net of income taxes.&lt;/font&gt;&lt;/li&gt;&lt;li style="margin-left:54px;list-style:decimal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;During the first quarter of 2015,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; we rec&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;orded&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; a n&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;on-cash asset impairment charge to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;write-off the software costs incurred related to the development of AMS3 Home Health and Hospice&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; in the amount of $45.5 million, net of income taxes. During the third quarter of 2015, we recorded a non-cash asset impairment charge &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;related to our corporate headquarters in the amount of $1.2 million, net of income taxes.&lt;/font&gt;&lt;/li&gt;&lt;li style="margin-left:54px;list-style:decimal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;During each of the four quarters of 2015, we incurred certain costs associate&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;d&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; with various legal matters. Net of income taxes, these costs amounted to $1.3 million, $4.8 million, $0.2 million and $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million for the three-month periods ended March 31, 2015, June 30, 2015, September 30, 2015 and December 31, 2015, respectively.&lt;/font&gt;&lt;/li&gt;&lt;li style="margin-left:54px;list-style:decimal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;During the fourth quarter of 2015, we recorded an accrual related to an OIG Self-Disclosure matter. Net of income taxes, this charge amounted to $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million.&lt;/font&gt;&lt;/li&gt;&lt;li style="margin-left:54px;list-style:decimal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;During the third and fourth quarters of 2015, we incurred certain costs associated with the implementation of Homecare &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Homebase&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. Net of income taxes, these costs a&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;mounted to $1.2 million and $1.4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million for the three-month periods ended September 30, 2015 and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;December 31, 2015, respectively&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/li&gt;&lt;/ul&gt;&lt;p style='margin-top:0pt; margin-bottom:10pt'&gt;&amp;#160;&lt;/p&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock id="ID_1504" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;div&gt;&lt;table style="border-collapse:collapse;margin-top:20px;"&gt;&lt;tr style="height: 13px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td colspan="15"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;"&gt;16. UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 17px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 20px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5"  style="width: 154px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:154px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 7.5pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Net Income (Loss) Attributable to Amedisys, Inc. Common Stockholders (1)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 12px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 77px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:77px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 7.5pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Revenue&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 102px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:102px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 7.5pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Net Income (Loss) Attributable to Amedisys, Inc.&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 72px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:72px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 7.5pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Basic&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"  style="width: 72px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:72px;"&gt;&lt;font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 7.5pt;COLOR: #000000;TEXT-ALIGN: center;"&gt;Diluted&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2016:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:60px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:60px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1st Quarter (2) (3) (4)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;348.8&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;6.2&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.19&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.19&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2nd Quarter (2) (3) (4)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;360.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.7&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.32&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.32&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3rd Quarter (2) (3) (4)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;361.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;11.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.34&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.34&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4th Quarter (2) (3) (4) (5)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;366.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;8.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.27&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.26&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 1,437.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;37.3&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.12&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1.10&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2015:&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:90px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;1st Quarter (6) (7)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;301.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(35.0)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(1.07)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(1.07)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;2nd Quarter (7)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;314.1&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;10.6&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.32&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.32&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3rd Quarter (6) (7) (9)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;326.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;8.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.25&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.25&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;4th Quarter (7) (8) (9)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;338.4&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;12.9&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.39&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;0.38&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height: 14px"&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt; 1,280.5&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 90px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:90px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;3.0&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.09)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"&gt;&lt;font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"&gt;(0.09)&lt;/font&gt;&lt;/td&gt;&lt;td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <us-gaap:EarningsPerShareBasic id="ID_1505" decimals="2" contextRef="FROM_Apr01_2016_TO_Jun30_2016" unitRef="USDperShare">0.32</us-gaap:EarningsPerShareBasic>
  <us-gaap:NetIncomeLoss id="ID_1506" decimals="-5" contextRef="FROM_Apr01_2016_TO_Jun30_2016" unitRef="USDollar">10700000</us-gaap:NetIncomeLoss>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_1507" decimals="-5" contextRef="FROM_Apr01_2016_TO_Jun30_2016" unitRef="USDollar">360700000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:EarningsPerShareDiluted id="ID_1508" decimals="2" contextRef="FROM_Apr01_2016_TO_Jun30_2016" unitRef="USDperShare">0.32</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic id="ID_1509" decimals="2" contextRef="FROM_Jul01_2016_TO_Sep30_2016" unitRef="USDperShare">0.34</us-gaap:EarningsPerShareBasic>
  <us-gaap:NetIncomeLoss id="ID_1510" decimals="-5" contextRef="FROM_Jul01_2016_TO_Sep30_2016" unitRef="USDollar">11400000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareDiluted id="ID_1511" decimals="2" contextRef="FROM_Jul01_2016_TO_Sep30_2016" unitRef="USDperShare">0.34</us-gaap:EarningsPerShareDiluted>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_1512" decimals="-5" contextRef="FROM_Jul01_2016_TO_Sep30_2016" unitRef="USDollar">361600000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:EarningsPerShareBasic id="ID_1513" decimals="2" contextRef="FROM_Apr01_2015_TO_Jun30_2015" unitRef="USDperShare">0.32</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted id="ID_1514" decimals="2" contextRef="FROM_Apr01_2015_TO_Jun30_2015" unitRef="USDperShare">0.32</us-gaap:EarningsPerShareDiluted>
  <us-gaap:NetIncomeLoss id="ID_1515" decimals="-5" contextRef="FROM_Apr01_2015_TO_Jun30_2015" unitRef="USDollar">10600000</us-gaap:NetIncomeLoss>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_1516" decimals="-5" contextRef="FROM_Apr01_2015_TO_Jun30_2015" unitRef="USDollar">314100000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:NetIncomeLoss id="ID_1517" decimals="-5" contextRef="FROM_Jul01_2015_TO_Sep30_2015" unitRef="USDollar">8400000</us-gaap:NetIncomeLoss>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_1518" decimals="-5" contextRef="FROM_Jul01_2015_TO_Sep30_2015" unitRef="USDollar">326400000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:EarningsPerShareDiluted id="ID_1519" decimals="2" contextRef="FROM_Jul01_2015_TO_Sep30_2015" unitRef="USDperShare">0.25</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic id="ID_1520" decimals="2" contextRef="FROM_Jul01_2015_TO_Sep30_2015" unitRef="USDperShare">0.25</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted id="ID_1521" decimals="2" contextRef="FROM_Oct01_2015_TO_Dec31_2015" unitRef="USDperShare">0.38</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic id="ID_1522" decimals="2" contextRef="FROM_Oct01_2015_TO_Dec31_2015" unitRef="USDperShare">0.39</us-gaap:EarningsPerShareBasic>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_1523" decimals="-5" contextRef="FROM_Oct01_2015_TO_Dec31_2015" unitRef="USDollar">338400000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:NetIncomeLoss id="ID_1524" decimals="-5" contextRef="FROM_Oct01_2015_TO_Dec31_2015" unitRef="USDollar">12900000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareDiluted id="ID_1525" decimals="2" contextRef="FROM_Oct01_2016_TO_Dec31_2016" unitRef="USDperShare">0.26</us-gaap:EarningsPerShareDiluted>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_1526" decimals="-5" contextRef="FROM_Oct01_2016_TO_Dec31_2016" unitRef="USDollar">366300000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:NetIncomeLoss id="ID_1527" decimals="-5" contextRef="FROM_Oct01_2016_TO_Dec31_2016" unitRef="USDollar">8900000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasic id="ID_1528" decimals="2" contextRef="FROM_Oct01_2016_TO_Dec31_2016" unitRef="USDperShare">0.27</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic id="ID_1529" decimals="2" contextRef="FROM_Jan01_2015_TO_Mar31_2015" unitRef="USDperShare">-1.07</us-gaap:EarningsPerShareBasic>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_1530" decimals="-5" contextRef="FROM_Jan01_2015_TO_Mar31_2015" unitRef="USDollar">301600000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:NetIncomeLoss id="ID_1531" decimals="-5" contextRef="FROM_Jan01_2015_TO_Mar31_2015" unitRef="USDollar">-35000000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareDiluted id="ID_1532" decimals="2" contextRef="FROM_Jan01_2015_TO_Mar31_2015" unitRef="USDperShare">-1.07</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareBasic id="ID_1533" decimals="2" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDperShare">0.19</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted id="ID_1534" decimals="2" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDperShare">0.19</us-gaap:EarningsPerShareDiluted>
  <us-gaap:HealthCareOrganizationPatientServiceRevenue id="ID_1535" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">348800000</us-gaap:HealthCareOrganizationPatientServiceRevenue>
  <us-gaap:NetIncomeLoss id="ID_1536" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016" unitRef="USDollar">6200000</us-gaap:NetIncomeLoss>
  <amed:SoftwareImplementationCosts id="ID_1537" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember" unitRef="USDollar">1500000</amed:SoftwareImplementationCosts>
  <amed:SoftwareImplementationCosts id="ID_1538" decimals="-5" contextRef="FROM_Apr01_2016_TO_Jun30_2016_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember" unitRef="USDollar">1600000</amed:SoftwareImplementationCosts>
  <amed:SoftwareImplementationCosts id="ID_1539" decimals="-5" contextRef="FROM_Jul01_2016_TO_Sep30_2016_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember" unitRef="USDollar">1200000</amed:SoftwareImplementationCosts>
  <amed:SoftwareImplementationCosts id="ID_1540" decimals="-5" contextRef="FROM_Oct01_2016_TO_Dec31_2016_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember" unitRef="USDollar">800000</amed:SoftwareImplementationCosts>
  <amed:SoftwareImplementationCosts id="ID_1541" decimals="-5" contextRef="FROM_Jul01_2015_TO_Sep30_2015_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember" unitRef="USDollar">1200000</amed:SoftwareImplementationCosts>
  <amed:SoftwareImplementationCosts id="ID_1542" decimals="-5" contextRef="FROM_Oct01_2015_TO_Dec31_2015_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember" unitRef="USDollar">1400000</amed:SoftwareImplementationCosts>
  <us-gaap:LegalFees id="ID_1543" decimals="-5" contextRef="FROM_Jan01_2016_TO_Mar31_2016_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember" unitRef="USDollar">900000</us-gaap:LegalFees>
  <us-gaap:LegalFees id="ID_1544" decimals="-5" contextRef="FROM_Jan01_2015_TO_Mar31_2015_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember" unitRef="USDollar">1300000</us-gaap:LegalFees>
  <us-gaap:LegalFees id="ID_1545" decimals="-5" contextRef="FROM_Apr01_2016_TO_Jun30_2016_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember" unitRef="USDollar">300000</us-gaap:LegalFees>
  <us-gaap:LegalFees id="ID_1546" decimals="-5" contextRef="FROM_Apr01_2015_TO_Jun30_2015_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember" unitRef="USDollar">4800000</us-gaap:LegalFees>
  <us-gaap:LegalFees id="ID_1547" decimals="-5" contextRef="FROM_Jul01_2016_TO_Sep30_2016_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember" unitRef="USDollar">200000</us-gaap:LegalFees>
  <us-gaap:LegalFees id="ID_1548" decimals="-5" contextRef="FROM_Jul01_2015_TO_Sep30_2015_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember" unitRef="USDollar">200000</us-gaap:LegalFees>
  <us-gaap:LegalFees id="ID_1549" decimals="-5" contextRef="FROM_Oct01_2016_TO_Dec31_2016_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember" unitRef="USDollar">1800000</us-gaap:LegalFees>
  <us-gaap:AssetImpairmentCharges id="ID_1550" decimals="-5" contextRef="FROM_Jan01_2015_TO_Mar31_2015_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember" unitRef="USDollar">45500000</us-gaap:AssetImpairmentCharges>
  <us-gaap:AssetImpairmentCharges id="ID_1551" decimals="-5" contextRef="FROM_Jul01_2015_TO_Sep30_2015_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember" unitRef="USDollar">1200000</us-gaap:AssetImpairmentCharges>
  <us-gaap:AssetImpairmentCharges id="ID_1552" decimals="-5" contextRef="FROM_Oct01_2016_TO_Dec31_2016_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember" unitRef="USDollar">2700000</us-gaap:AssetImpairmentCharges>
  <us-gaap:LossContingencyAccrualProvision id="ID_1553" decimals="-5" contextRef="FROM_Oct01_2015_TO_Dec31_2015_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember_us-gaap_LitigationStatusAxis_OigSelfDisclosureMember" unitRef="USDollar">3400000</us-gaap:LossContingencyAccrualProvision>
  <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts id="ID_1554" decimals="-5" contextRef="AS_OF_Mar31_2016_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember" unitRef="USDollar">1000000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
  <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts id="ID_1555" decimals="-5" contextRef="AS_OF_Jun30_2016_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember" unitRef="USDollar">200000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
  <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts id="ID_1556" decimals="-5" contextRef="AS_OF_Sep30_2016_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember" unitRef="USDollar">300000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
  <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts id="ID_1557" decimals="-5" contextRef="AS_OF_Dec31_2016_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember" unitRef="USDollar">500000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
  <amed:ReversalOfLegalAccrual id="ID_1558" decimals="-5" contextRef="AS_OF_Dec31_2015_amed_QuarterlyFinancialInformationAxis_NetOfTaxMember" unitRef="USDollar">-1100000</amed:ReversalOfLegalAccrual>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="ID_1559" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;"&gt;17&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;.&amp;#160; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;RELATED PARTY TRANSACTIONS&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On November &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;20, 2015, we engaged KKR Consulting, LLC (&amp;#8220;KKR Capstone&amp;#8221;), a consulting company of operational professionals that works exclusively with portfolio companies of Kohlberg Kravis Roberts &amp;amp; Co. Nathaniel M. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Zilkha&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, a member of our Board of Directors, is a member of KKR Management, LLC, which is an affiliate of KKR Asset Management LLC (&amp;#8220;KAM&amp;#8221;), a substantial stockholder of our Company, and an affiliate of Kohlberg Kravis Roberts &amp;amp; Co. KKR Capstone will receive a fee in connection with providing consulting services to the Company in the ordinary course of business. Mr. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Zilkha&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; will not receive any direct compensation or direct financial benefit from the engagement of KKR Capstone. During 2016, we incurred costs of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;approximately $1.6 million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; related to this related party engagement&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Effective October 22, 2015, we entered into a contract for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;telemonitoring&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; services with Care Innovations, LLC (&amp;#8220;Care Innovations&amp;#8221;). Paul Kusserow, our President and Chief Executive Officer, is a member of the Advisory Board to Care Innovations. Care Innovations will receive an annual fee of approximately $1.8 million in connection with our contract for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;telemonitoring&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; services for the Company. Care Innovations has confirmed to us that Mr. Kusserow will not receive any direct compensation or direct financial benefit from the engagement of Care Innovations as our &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;telemonitoring&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; partner. During 2016 we incurred costs of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;approximately $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; related to this related party engagement.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:8pt'&gt;&amp;#160;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty id="ID_1560" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RelatedPartyTransactionAxis_CareInnovationsMember" unitRef="USDollar">1500000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction id="ID_1561" decimals="-5" contextRef="FROM_Jan01_2015_TO_Oct22_2015_us-gaap_RelatedPartyTransactionAxis_CareInnovationsMember" unitRef="USDollar">1800000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty id="ID_1562" decimals="-5" contextRef="FROM_Jan01_2016_TO_Dec31_2016_us-gaap_RelatedPartyTransactionAxis_KKRConsultingMember" unitRef="USDollar">1600000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:SubsequentEventsTextBlock id="ID_1563" contextRef="FROM_Jan01_2016_TO_Dec31_2016">&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;"&gt;18.&amp;#160; SUBSEQUENT EVENT&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;On &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;February &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, 201&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, we acquired &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Home Staff, LLC&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;a&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;personal care provider&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; with &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;care centers &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;for a purchase price of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.0&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt; million&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:4.5pt; margin-bottom:0pt'&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"&gt;Unaudited - O&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;n February 28, 2017, we signed a definitive agreement to acquire Tenet Healthcare's home health and hospice operations in Arizona, Illinois, Massachusetts and Texas&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;. We do not believe that the closing of this acquisition will have a material impact on our 2017 results of operations&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style='margin-top:0pt; margin-bottom:8pt'&gt;&amp;#160;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:NumberOfBusinessesAcquired id="ID_1564" decimals="0" contextRef="FROM_Jan01_2017_TO_Feb01_2017_us-gaap_BusinessAcquisitionAxis_HomeStaffLlcMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="Agencies">3</us-gaap:NumberOfBusinessesAcquired>
  <us-gaap:BusinessCombinationConsiderationTransferred1 id="ID_1565" decimals="-5" contextRef="FROM_Jan01_2017_TO_Feb01_2017_us-gaap_BusinessAcquisitionAxis_HomeStaffLlcMember_us-gaap_StatementBusinessSegmentsAxis_PersonalCareMember" unitRef="USDollar">4000000</us-gaap:BusinessCombinationConsiderationTransferred1>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>amed-20161231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Prepared by IBM Cognos FSR v6.7.4.14 using Fujitsu Interstage XWand -->
<schema targetNamespace="http://www.amedisys.com/20161231" elementFormDefault="qualified" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:amed="http://www.amedisys.com/20161231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:us-types="http://fasb.org/us-types/2015-01-31">
    <annotation>
        <appinfo>
            <link:linkbaseRef xlink:type="simple" xlink:href="amed-20161231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
            <link:linkbaseRef xlink:type="simple" xlink:href="amed-20161231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
            <link:linkbaseRef xlink:type="simple" xlink:href="amed-20161231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
            <link:linkbaseRef xlink:type="simple" xlink:href="amed-20161231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
            <link:roleType roleURI="http://www.amedisys.com/role/DocumentAndEntityInformation" id="amed_ELRID_DocumentAndEntityInformation">
                <link:definition>000101 - Document - Document and Entity Information</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDBALANCESHEETS" id="amed_ELRID_CONSOLIDATEDBALANCESHEETS">
                <link:definition>000103 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" id="amed_ELRID_CONSOLIDATEDBALANCESHEETSParenthetical">
                <link:definition>000104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" id="amed_ELRID_CONSOLIDATEDSTATEMENTSOFOPERATIONS">
                <link:definition>000105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" id="amed_ELRID_CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
                <link:definition>000108 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" id="amed_ELRID_NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS">
                <link:definition>010109 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" id="amed_ELRID_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
                <link:definition>010110 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/ACQUISITIONS" id="amed_ELRID_ACQUISITIONS">
                <link:definition>010111 - Disclosure - ACQUISITIONS</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DISCONTINUEDOPERATIONSANDASSETSHELDFORSALE" id="amed_ELRID_DISCONTINUEDOPERATIONSANDASSETSHELDFORSALE">
                <link:definition>010112 - Disclosure - DISCONTINUED OPERATIONS AND ASSETS HELD FOR SALE</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET" id="amed_ELRID_GOODWILLANDOTHERINTANGIBLEASSETSNET">
                <link:definition>010113 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" id="amed_ELRID_LONGTERMOBLIGATIONS">
                <link:definition>010115 - Disclosure - LONG-TERM OBLIGATIONS</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" id="amed_ELRID_COMMITMENTSANDCONTINGENCIES">
                <link:definition>010118 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/SEGMENTINFORMATION" id="amed_ELRID_SEGMENTINFORMATION">
                <link:definition>010123 - Disclosure - SEGMENT INFORMATION</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureNATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSPolicies" id="amed_ELRID_NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSPolicies">
                <link:definition>020010 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS (Policies)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" id="amed_ELRID_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
                <link:definition>030010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DISCONTINUEDOPERATIONSANDASSETSHELDFORSALETables" id="amed_ELRID_DISCONTINUEDOPERATIONSANDASSETSHELDFORSALETables">
                <link:definition>030020 - Disclosure - DISCONTINUED OPERATIONS AND ASSETS HELD FOR SALE (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureGOODWILLANDOTHERINTANGIBLEASSETSNETTables" id="amed_ELRID_GOODWILLANDOTHERINTANGIBLEASSETSNETTables">
                <link:definition>030030 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables" id="amed_ELRID_LONGTERMOBLIGATIONSTables">
                <link:definition>030050 - Disclosure - LONG-TERM OBLIGATIONS (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" id="amed_ELRID_SEGMENTINFORMATIONTables">
                <link:definition>030110 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationDetail" id="amed_ELRID_NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationDetail">
                <link:definition>040010 - Disclosure - Nature of Operations Consolidation and Presentation of Financial Statements - Additional Information (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="amed_ELRID_SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
                <link:definition>040020 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/ScheduleOfFinancialInstrumentsWhereCarryingValueAndFairValueDifferDetail" id="amed_ELRID_ScheduleOfFinancialInstrumentsWhereCarryingValueAndFairValueDifferDetail">
                <link:definition>040023 - Disclosure - Schedule of Financial Instruments Where Carrying Value and Fair Value Differ (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/ScheduleOfWeightedAverageSharesOutstandingDetail" id="amed_ELRID_ScheduleOfWeightedAverageSharesOutstandingDetail">
                <link:definition>040024 - Disclosure - Schedule of Weighted Average Shares Outstanding (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureDiscontinuedOperationsAndAssetsHeldForSaleAdditionalInformationDetail" id="amed_ELRID_DiscontinuedOperationsAndAssetsHeldForSaleAdditionalInformationDetail">
                <link:definition>040040 - Disclosure - Discontinued Operations and Assets Held For Sale - Additional Information (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/NetRevenuesAndOperatingResultsDetail" id="amed_ELRID_NetRevenuesAndOperatingResultsDetail">
                <link:definition>040041 - Disclosure - Net Revenues and Operating Results (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureLongTermDebtDetail" id="amed_ELRID_LongTermDebtDetail">
                <link:definition>040070 - Disclosure - Long Term Debt (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureLongTermDebtParentheticalDetail" id="amed_ELRID_LongTermDebtParentheticalDetail">
                <link:definition>040072 - Disclosure - Long Term Debt (Parenthetical) (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureLongTermDebtAdditionalInformationDetail" id="amed_ELRID_LongTermDebtAdditionalInformationDetail">
                <link:definition>040071 - Disclosure - Long Term Debt - Additional Information (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureCommitmentsAndContigenciesDetail" id="amed_ELRID_CommitmentsAndContigenciesDetail">
                <link:definition>040100 - Disclosure - Commitments and Contigencies (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/SegmentInformationAdditionalInformationDetail" id="amed_ELRID_SegmentInformationAdditionalInformationDetail">
                <link:definition>040140 - Disclosure - Segment Information - Additional Information (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureOperatingIncomeOfReportableSegmentsDetail" id="amed_ELRID_OperatingIncomeOfReportableSegmentsDetail">
                <link:definition>040141 - Disclosure - Operating Income of Reportable Segments (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" id="amed_ELRID_CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME">
                <link:definition>000106 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/EXITACTIVITIES" id="amed_ELRID_EXITACTIVITIES">
                <link:definition>010121 - Disclosure - EXIT ACTIVITIES</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureExitActivitiesDetail" id="amed_ELRID_ExitActivitiesDetail">
                <link:definition>040120 - Disclosure - Exit Activities (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENT" id="amed_ELRID_SUBSEQUENTEVENT">
                <link:definition>010126 - Disclosure - SUBSEQUENT EVENT</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureSubsequentEventDetail" id="amed_ELRID_SubsequentEventDetail">
                <link:definition>040170 - Disclosure - Subsequent Event (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" id="amed_ELRID_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
                <link:definition>000107 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS" id="amed_ELRID_DETAILSOFCERTAINBALANCESHEETACCOUNTS">
                <link:definition>010114 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/INCOMETAXES" id="amed_ELRID_INCOMETAXES">
                <link:definition>010116 - Disclosure - INCOME TAXES</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION" id="amed_ELRID_CAPITALSTOCKANDSHAREBASEDCOMPENSATION">
                <link:definition>010117 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS" id="amed_ELRID_EMPLOYEEBENEFITPLANS">
                <link:definition>010119 - Disclosure - EMPLOYEE BENEFIT PLANS</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/VALUATIONANDQUALIFYINGACCOUNTS" id="amed_ELRID_VALUATIONANDQUALIFYINGACCOUNTS">
                <link:definition>010122 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION" id="amed_ELRID_UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION">
                <link:definition>010124 - Disclosure - UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables" id="amed_ELRID_DETAILSOFCERTAINBALANCESHEETACCOUNTSTables">
                <link:definition>030040 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/INCOMETAXESTables" id="amed_ELRID_INCOMETAXESTables">
                <link:definition>030060 - Disclosure - INCOME TAXES (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureCAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables" id="amed_ELRID_CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables">
                <link:definition>030070 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureCOMMITMENTSANDCONTINGENCIESTables" id="amed_ELRID_COMMITMENTSANDCONTINGENCIESTables">
                <link:definition>030080 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/EXITACTIVITIESTables" id="amed_ELRID_EXITACTIVITIESTables">
                <link:definition>030090 - Disclosure - EXIT ACTIVITIES (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureVALUATIONANDQUALIFYINGACCOUNTSTables" id="amed_ELRID_VALUATIONANDQUALIFYINGACCOUNTSTables">
                <link:definition>030100 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables" id="amed_ELRID_UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables">
                <link:definition>030120 - Disclosure - UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureAcquisitionsDetail" id="amed_ELRID_AcquisitionsDetail">
                <link:definition>040030 - Disclosure - Acquisitions (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureGoodwillAndOtherIntangibleAssetsNetDetail" id="amed_ELRID_GoodwillAndOtherIntangibleAssetsNetDetail">
                <link:definition>040050 - Disclosure - Goodwill and Other Intangible Assets, Net (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsOtherCurrentAssetsDetail" id="amed_ELRID_DetailsOfCertainBalanceSheetAccountsOtherCurrentAssetsDetail">
                <link:definition>040060 - Disclosure - Details of Certain Balance Sheet Accounts - Other Current Assets (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureIncomeTaxesDetail" id="amed_ELRID_IncomeTaxesDetail">
                <link:definition>040080 - Disclosure - Income Taxes (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureCapitalStockAndShareBasedCompensationDetail" id="amed_ELRID_CapitalStockAndShareBasedCompensationDetail">
                <link:definition>040090 - Disclosure - Capital Stock and Share-Based Compensation (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/EmployeeBenefitPlansDetail" id="amed_ELRID_EmployeeBenefitPlansDetail">
                <link:definition>040110 - Disclosure - Employee Benefit Plans (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureValuationAndQualifyingAccountsDetail" id="amed_ELRID_ValuationAndQualifyingAccountsDetail">
                <link:definition>040130 - Disclosure - Valuation and Qualifying Accounts (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureUnauditedSummarizedQuarterlyFinancialInformationDetail" id="amed_ELRID_UnauditedSummarizedQuarterlyFinancialInformationDetail">
                <link:definition>040150 - Disclosure - Unaudited Summarized Quarterly Financial Information (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/FutureMinimumRentalCommitmentsDetail" id="amed_ELRID_FutureMinimumRentalCommitmentsDetail">
                <link:definition>040101 - Disclosure - Future Minimum Rental Commitments (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureInsuranceProgramsDetails" id="amed_ELRID_InsuranceProgramsDetails">
                <link:definition>040102 - Disclosure - Insurance Programs (Details)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureEmployeeStockPurchasePlanDetail" id="amed_ELRID_EmployeeStockPurchasePlanDetail">
                <link:definition>040091 - Disclosure - Employee Stock Purchase Plan (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureStockOptionActivityDetail" id="amed_ELRID_StockOptionActivityDetail">
                <link:definition>040092 - Disclosure - Stock Option Activity (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureNonVestedStockActivityDetail" id="amed_ELRID_NonVestedStockActivityDetail">
                <link:definition>040094 - Disclosure - Non-Vested Stock Activity (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureNonVestedStockUnitsDetail" id="amed_ELRID_NonVestedStockUnitsDetail">
                <link:definition>040095 - Disclosure - Non-Vested Stock Units (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureTotalProvisionForIncomeTaxesDetail" id="amed_ELRID_TotalProvisionForIncomeTaxesDetail">
                <link:definition>040081 - Disclosure - Total Provision For Income Taxes (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureComponentsOfNetDeferredTaxAssetsDetail" id="amed_ELRID_ComponentsOfNetDeferredTaxAssetsDetail">
                <link:definition>040084 - Disclosure - Components of Net Deferred Tax Assets (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/SourcesOfTaxEffectDetail" id="amed_ELRID_SourcesOfTaxEffectDetail">
                <link:definition>040083 - Disclosure - Sources of Tax Effect (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureReconciliationOfUnrecognizedTaxBenefitsDetail" id="amed_ELRID_ReconciliationOfUnrecognizedTaxBenefitsDetail">
                <link:definition>040086 - Disclosure - Reconciliation of Unrecognized Tax Benefits (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsOtherAssetsDetail" id="amed_ELRID_DetailsOfCertainBalanceSheetAccountsOtherAssetsDetail">
                <link:definition>040061 - Disclosure - Details of Certain Balance Sheet Accounts - Other Assets (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsAccruedExpensesDetail" id="amed_ELRID_DetailsOfCertainBalanceSheetAccountsAccruedExpensesDetail">
                <link:definition>040062 - Disclosure - Details of Certain Balance Sheet Accounts - Accrued Expenses (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsOtherLongTermObligationsDetail" id="amed_ELRID_DetailsOfCertainBalanceSheetAccountsOtherLongTermObligationsDetail">
                <link:definition>040063 - Disclosure - Details of Certain Balance Sheet Accounts - Other Long-Term Obligations (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureSummaryOfActivityRelatedToGoodwillDetail" id="amed_ELRID_SummaryOfActivityRelatedToGoodwillDetail">
                <link:definition>040051 - Disclosure - Summary of Activity Related to Goodwill (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureSummaryOfActivityRelatedToOtherIntangibleAssetsNetDetail" id="amed_ELRID_SummaryOfActivityRelatedToOtherIntangibleAssetsNetDetail">
                <link:definition>040052 - Disclosure - Summary of Activity Related to Other Intangible Assets, Net (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/SummaryOfActivityRelatedToOtherIntangibleAssetsNetParentheticalDetail" id="amed_ELRID_SummaryOfActivityRelatedToOtherIntangibleAssetsNetParentheticalDetail">
                <link:definition>040053 - Disclosure - Summary of Activity Related to Other Intangible Assets, Net (Parenthetical) (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" id="amed_ELRID_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail">
                <link:definition>040021 - Disclosure - Schedule of Estimated Useful Lives of Property and Equipment (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/ScheduleOfBalancesRelatedToPropertyAndEquipmentDetails" id="amed_ELRID_ScheduleOfBalancesRelatedToPropertyAndEquipmentDetails">
                <link:definition>040022 - Disclosure - Schedule of Balances Related to Property and Equipment (Details)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureMaturitiesOfDebtDetail" id="amed_ELRID_MaturitiesOfDebtDetail">
                <link:definition>040073 - Disclosure - Maturities of Debt (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureCommitmentFeeUnderCreditFacilitiesDetail" id="amed_ELRID_CommitmentFeeUnderCreditFacilitiesDetail">
                <link:definition>040074 - Disclosure - Commitment Fee Under Credit Facilities (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureExitActivitiesReserveActivityDetail" id="amed_ELRID_ExitActivitiesReserveActivityDetail">
                <link:definition>040121 - Disclosure - Exit Activities - Reserve Activity (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/ClassificationOfDeferredTaxAssetsAndLiabilitiesDetail" id="amed_ELRID_ClassificationOfDeferredTaxAssetsAndLiabilitiesDetail">
                <link:definition>040085 - Disclosure - Classification of Deferred Tax Assets and Liabilities (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureNonVestedStockOptionActivityDetail" id="amed_ELRID_NonVestedStockOptionActivityDetail">
                <link:definition>040093 - Disclosure - Non-Vested Stock Option Activity (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/SHAREREPURCHASEPROGRAM" id="amed_ELRID_SHAREREPURCHASEPROGRAM">
                <link:definition>010120 - Disclosure - SHARE REPURCHASE PROGRAM</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/ShareRepurchaseProgramDetail" id="amed_ELRID_ShareRepurchaseProgramDetail">
                <link:definition>040115 - Disclosure - Share Repurchase Program (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureACQUISITIONSPROFORMACONDENSEDCONSOLIDATEDINCOMESTATEMENTTables" id="amed_ELRID_ACQUISITIONSPROFORMACONDENSEDCONSOLIDATEDINCOMESTATEMENTTables">
                <link:definition>030015 - Disclosure - ACQUISITIONS - PRO FORMA CONDENSED CONSOLIDATED INCOME STATEMENT (Tables)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/DisclosureAcquisitionsProFormaCondensedConsolidatedIncomeStatementDetail" id="amed_ELRID_AcquisitionsProFormaCondensedConsolidatedIncomeStatementDetail">
                <link:definition>040035 - Disclosure - Acquisitions - Pro Forma Condensed Consolidated Income Statement (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/IncomeTaxExpenseAllocationDetail" id="amed_ELRID_IncomeTaxExpenseAllocationDetail">
                <link:definition>040082 - Disclosure - Income Tax Expense Allocation (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/RelatedPartyTransactionDetail" id="amed_ELRID_RelatedPartyTransactionDetail">
                <link:definition>040160 - Disclosure - Related Party Transaction (Detail)</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
            <link:roleType roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS" id="amed_ELRID_RELATEDPARTYTRANSACTIONS">
                <link:definition>010125 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
                <link:usedOn>link:presentationLink</link:usedOn>
                <link:usedOn>link:calculationLink</link:usedOn>
                <link:usedOn>link:definitionLink</link:usedOn>
            </link:roleType>
        </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd" />
    <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://fasb.org/us-types/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-types-2015-01-31.xsd" />
    <element name="CapYearAxis" id="amed_CapYearAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CapYearDomain" id="amed_CapYearDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember" id="amed_CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CashDistributionToNoncontrollingInterest" id="amed_CashDistributionToNoncontrollingInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="CmsHospiceFaceToFaceRequirementPriorToThirdBenefitPeriod" id="amed_CmsHospiceFaceToFaceRequirementPriorToThirdBenefitPeriod" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="CmsTherapyAssessmentRequirementIntervalMinimum" id="amed_CmsTherapyAssessmentRequirementIntervalMinimum" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="CommimentsAndContingenciesTable" id="amed_CommimentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CommitmentsAndContingenciesDisclosureLineItems" id="amed_CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="DaysInHospiceRecertificationThirdBenefitPeriod" id="amed_DaysInHospiceRecertificationThirdBenefitPeriod" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="DepreciationAndAmortizationForContinuingOperations" id="amed_DepreciationAndAmortizationForContinuingOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationAbstract" id="amed_DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="DocumentDocumentandEntityInformationAbstract" id="amed_DocumentDocumentandEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="EpisodeOfCareAsEpisodicBasedRevenue" id="amed_EpisodeOfCareAsEpisodicBasedRevenue" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="EpisodesInProgressThatBeginDuringReportingPeriod" id="amed_EpisodesInProgressThatBeginDuringReportingPeriod" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" id="amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="FavorableMember" id="amed_FavorableMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="FinancialInstrumentDetailsTextBlock" id="amed_FinancialInstrumentDetailsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="FirstThresholdOfTherapyServicesRequired" id="amed_FirstThresholdOfTherapyServicesRequired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="FixedChargeCoverageRatio" id="amed_FixedChargeCoverageRatio" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="GeneralAndAdministrativeExpenseSegment" id="amed_GeneralAndAdministrativeExpenseSegment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="HealthInsuranceRetentionLimit" id="amed_HealthInsuranceRetentionLimit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="HistoricalCollectionRateFromMedicare" id="amed_HistoricalCollectionRateFromMedicare" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="HomeHealthMember" id="amed_HomeHealthMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="HospiceMedicareRevenueRateAccountedForRoutineCare" id="amed_HospiceMedicareRevenueRateAccountedForRoutineCare" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="HospiceMember" id="amed_HospiceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="InterestRateOnNotesPayableToBank" id="amed_InterestRateOnNotesPayableToBank" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="LowUtilizationPaymentAdjustmentNumberOfVisits" id="amed_LowUtilizationPaymentAdjustmentNumberOfVisits" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="MassproAndHospiceMember" id="amed_MassproAndHospiceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" id="amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="MaximumDaysToSubmitFinalBillFromStartOfEpisode" id="amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="MaximusFederalServicesAndHospiceMember" id="amed_MaximusFederalServicesAndHospiceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MaximusFederalServicesMember" id="amed_MaximusFederalServicesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MedicareAdministrativeContractorMacMember" id="amed_MedicareAdministrativeContractorMacMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MinimumDaysAccountsReceivableOutstandingFullyReserved" id="amed_MinimumDaysAccountsReceivableOutstandingFullyReserved" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="MinimumPercentOwnershipForControllingInterestPercent" id="amed_MinimumPercentOwnershipForControllingInterestPercent" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="NonVestedStockAndStockUnits" id="amed_NonVestedStockAndStockUnits" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfCareCentersClosed" id="amed_NumberOfCareCentersClosed" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfCareCentersConsolidated" id="amed_NumberOfCareCentersConsolidated" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfCareCentersExited" id="amed_NumberOfCareCentersExited" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfClaimsSubmittedBySubsidiary" id="amed_NumberOfClaimsSubmittedBySubsidiary" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfRedeterminationDecisions" id="amed_NumberOfRedeterminationDecisions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="PercentageOfPatientReceivablesOutstanding" id="amed_PercentageOfPatientReceivablesOutstanding" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="PercentageOfTotalReimbursementOfOutlierPayment" id="amed_PercentageOfTotalReimbursementOfOutlierPayment" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="PortionOfPatientAccountsReceivableDerivedFromMedicare" id="amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="ProfessionalLiabilityInsuranceRetentionLimit" id="amed_ProfessionalLiabilityInsuranceRetentionLimit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="ProvisionForDoubtfulAccountsForContinuingOperations" id="amed_ProvisionForDoubtfulAccountsForContinuingOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare" id="amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" id="amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="RecoveryAmountOfOverpaymentMadeToSubsidiary" id="amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="RelatedPartyMember" id="amed_RelatedPartyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="RevenueAdjustmentToMedicareRevenue" id="amed_RevenueAdjustmentToMedicareRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="RevolvingCreditFacilitiesMember" id="amed_RevolvingCreditFacilitiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="SecondThresholdOfServicesRequired" id="amed_SecondThresholdOfServicesRequired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="SeriesBNotesMember" id="amed_SeriesBNotesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="SeriesCNotesMember" id="amed_SeriesCNotesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="SeriesANotesMember" id="amed_SeriesANotesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="TermLoanMember" id="amed_TermLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="ThirdThresholdOfTherapyServicesRequired" id="amed_ThirdThresholdOfTherapyServicesRequired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="TotalLeverageRatio" id="amed_TotalLeverageRatio" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="WorkersCompensationInsuranceRetentionLimit" id="amed_WorkersCompensationInsuranceRetentionLimit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="NumberOfEmployeesInWageHourLitigationMember" id="amed_NumberOfEmployeesInWageHourLitigationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MaximusFederalServicesAndHomeHealthMember" id="amed_MaximusFederalServicesAndHomeHealthMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="OperatingCareCenters" id="amed_OperatingCareCenters" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="OrganizationAndNatureOfOperationsTable" id="amed_OrganizationAndNatureOfOperationsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="HospiceInpatientMember" id="amed_HospiceInpatientMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="OrganizationAndNatureOfOperationsLineItems" id="amed_OrganizationAndNatureOfOperationsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="StateAxis" id="amed_StateAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="StateDomain" id="amed_StateDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="IllinoisMember" id="amed_IllinoisMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="ConnecticutMember" id="amed_ConnecticutMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="OhioMember" id="amed_OhioMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="SouthCarolinaMember" id="amed_SouthCarolinaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MassachusettsMember" id="amed_MassachusettsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfBeneficiaries" id="amed_NumberOfBeneficiaries" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="FinalLitigationSettlmentMember" id="amed_FinalLitigationSettlmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MedicareRevenue" id="amed_MedicareRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="ExtrapolatedMember" id="amed_ExtrapolatedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MaximumPercentOwnershipForEquityMethodPercent" id="amed_MaximumPercentOwnershipForEquityMethodPercent" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="MaximumPercentOwnershipForCostMethodPercent" id="amed_MaximumPercentOwnershipForCostMethodPercent" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="NumberOfCareCentersAvailableForSale" id="amed_NumberOfCareCentersAvailableForSale" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfCareCentersSold" id="amed_NumberOfCareCentersSold" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfCareCentersIncludedInDivestiturePlan" id="amed_NumberOfCareCentersIncludedInDivestiturePlan" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="FederalDerivativeActionsMember" id="amed_FederalDerivativeActionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="LineOfCreditFacilityEffectiveyBorrowingCapacity" id="amed_LineOfCreditFacilityEffectiveyBorrowingCapacity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="LineOfCreditFacilityDebtRestrictions" id="amed_LineOfCreditFacilityDebtRestrictions" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="DeferredDebtIssuanceCostsWrittenOff" id="amed_DeferredDebtIssuanceCostsWrittenOff" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="OtherRestructuringCostsAxis" id="amed_OtherRestructuringCostsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="OtherRestructuringDomain" id="amed_OtherRestructuringDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="TypeOfBusinessSoldAxis" id="amed_TypeOfBusinessSoldAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="BusinessSoldDomain" id="amed_BusinessSoldDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="AlaskaAndWashingtonCareCentersMember" id="amed_AlaskaAndWashingtonCareCentersMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="UnconsolidatedJointVentureMember" id="amed_UnconsolidatedJointVentureMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="UnfavorableMember" id="amed_UnfavorableMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MaximumLeverageRatio" id="amed_MaximumLeverageRatio" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="MinimumFixedChargeCoverageRatio" id="amed_MinimumFixedChargeCoverageRatio" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="WeightedAverageInterestRate" id="amed_WeightedAverageInterestRate" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfCareCentersRemovedFromAvailableForSale" id="amed_NumberOfCareCentersRemovedFromAvailableForSale" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" id="amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="NetRevenueForCareCentersRemovedFromAvailableForSale" id="amed_NetRevenueForCareCentersRemovedFromAvailableForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale" id="amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale" id="amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale" id="amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="InsuranceProceedsForReimbursementOfLegalFees" id="amed_InsuranceProceedsForReimbursementOfLegalFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="AccruedChargeRelatedToUsDepartmentOfJusticeSettlement" id="amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="UsDepartmentOfJusticeSettlement" id="amed_UsDepartmentOfJusticeSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="IncomeTaxesLineItems" id="amed_IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="IncomeTaxesTable" id="amed_IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="IncomeTaxesAxis" id="amed_IncomeTaxesAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="IncomeTaxesDomain" id="amed_IncomeTaxesDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="UsDepartmentOfJusticeSettlementMember" id="amed_UsDepartmentOfJusticeSettlementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="InterestRateOnUsDepartmentOfJusticeSettlement" id="amed_InterestRateOnUsDepartmentOfJusticeSettlement" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="PaymentUponExecutionOfUsDepartmentOfJusticeSettlement" id="amed_PaymentUponExecutionOfUsDepartmentOfJusticeSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="FinalPaymentOfUsDepartmentOfJusticeSettlement" id="amed_FinalPaymentOfUsDepartmentOfJusticeSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement" id="amed_PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="OigSelfDisclosureMember" id="amed_OigSelfDisclosureMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="ErisaClassActionLawsuitMember" id="amed_ErisaClassActionLawsuitMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable" id="amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CareCenterStatusAxis" id="amed_CareCenterStatusAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CareCenterStatusDomain" id="amed_CareCenterStatusDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CareCentersRemovedFromAvailableForSaleMember" id="amed_CareCentersRemovedFromAvailableForSaleMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="DetailsOfCertainBalanceSheetAccountsAbstract" id="amed_DetailsOfCertainBalanceSheetAccountsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" id="amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="PensionAndOtherPostretirementBenefitsDisclosureAbstract" id="amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="ProvisionForIncomeTaxesTextBlock" id="amed_ProvisionForIncomeTaxesTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="ReconciliationOfStatutoryTaxEffectsTextBlock" id="amed_ReconciliationOfStatutoryTaxEffectsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="InsuranceProgramsTableTextBlock" id="amed_InsuranceProgramsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="ValuationAndQualifyingAccountsTableTextBlock" id="amed_ValuationAndQualifyingAccountsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="EstimatedRevenueAdjustmentsMember" id="amed_EstimatedRevenueAdjustmentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="EstimatedRevenueAdjustmentsDiscontinuedOperationsMember" id="amed_EstimatedRevenueAdjustmentsDiscontinuedOperationsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MinimumEligibleAgeForEmployeesToContributeToBenefitPlan" id="amed_MinimumEligibleAgeForEmployeesToContributeToBenefitPlan" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="DefinedContributionPlanEmployerMatchingContribution" id="amed_DefinedContributionPlanEmployerMatchingContribution" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" id="amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" id="amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="DeferredCompensationArrangementMaximumPercentageOfSalaryDeferment" id="amed_DeferredCompensationArrangementMaximumPercentageOfSalaryDeferment" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="DeferredCompensationArrangementMaximumPercentageOfAnnualBonusDeferment" id="amed_DeferredCompensationArrangementMaximumPercentageOfAnnualBonusDeferment" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="QuarterlyFinancialInformationLineItems" id="amed_QuarterlyFinancialInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="LineOfCreditFacilityLoanCost" id="amed_LineOfCreditFacilityLoanCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="OperatingLeaseObligationsLineItems" id="amed_OperatingLeaseObligationsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="HealthInsurance" id="amed_HealthInsurance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="WokersCompensation" id="amed_WokersCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="ProfessionalLiability" id="amed_ProfessionalLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="EstimatedInsuranceTotal" id="amed_EstimatedInsuranceTotal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="EstimatedInsuranceLongTermPortion" id="amed_EstimatedInsuranceLongTermPortion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="EstimatedInsuranceExcludingLongTermPortion" id="amed_EstimatedInsuranceExcludingLongTermPortion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="Percentageofownershipinsubsidiaries" id="amed_Percentageofownershipinsubsidiaries" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="Fairvalueofshareofcommonstockpercentage" id="amed_Fairvalueofshareofcommonstockpercentage" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" id="amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="EquityBasedAwardsTable" id="amed_EquityBasedAwardsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="ShareBasedAwardsMember" id="amed_ShareBasedAwardsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="ShareBasedAwardsToMoreThanTenPercentOwnerMember" id="amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" id="amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="StockAvailableForFutureIssuanceUnderEmployeePurchasePlan" id="amed_StockAvailableForFutureIssuanceUnderEmployeePurchasePlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NonVestedStockMember" id="amed_NonVestedStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" id="amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="NonVestedStockUnitsServiceBasedAndMarketBasedMember" id="amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MarketBasedAwardTargetShareAmount" id="amed_MarketBasedAwardTargetShareAmount" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="MarketBasedAwardMaximumShareAmount" id="amed_MarketBasedAwardMaximumShareAmount" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare" id="amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare" type="num:perShareItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" id="amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" type="num:perShareItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRequisiteServicePeriod" id="amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRequisiteServicePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="IncomeTaxDisclosureLineItems" id="amed_IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfIndividualStatesSubjectToIncomeTax" id="amed_NumberOfIndividualStatesSubjectToIncomeTax" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual" id="amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" id="amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="DeferredTaxAssetsOtherCurrent" id="amed_DeferredTaxAssetsOtherCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="PayrollTaxEscrow" id="amed_PayrollTaxEscrow" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="MedicareWithholds" id="amed_MedicareWithholds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="WorkersCompensationDeposits" id="amed_WorkersCompensationDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="HealthInsuranceDeposits" id="amed_HealthInsuranceDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="OtherMiscellaneousDeposits" id="amed_OtherMiscellaneousDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="LegalAndOtherSettlements" id="amed_LegalAndOtherSettlements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="LeaseLiability" id="amed_LeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="CharityCare" id="amed_CharityCare" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="EstimatedMedicareCapLiability" id="amed_EstimatedMedicareCapLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="DeferredCompensationPlanLiability" id="amed_DeferredCompensationPlanLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" id="amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" id="amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="IncreaseDecreaseInAssetsOfEquityMethodInvestment" id="amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="GoodwillAndIntangibleAssetsLineItems" id="amed_GoodwillAndIntangibleAssetsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CareCentersClosedOrConsolidatedMember" id="amed_CareCentersClosedOrConsolidatedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="OtherIntangibleAssetsAdditions" id="amed_OtherIntangibleAssetsAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="OtherIntangiblesWriteOffs" id="amed_OtherIntangiblesWriteOffs" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="UnamortizedAcquiredNames" id="amed_UnamortizedAcquiredNames" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="AmortizedAcquiredNames" id="amed_AmortizedAcquiredNames" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="AcquiredNameOfBusinessMember" id="amed_AcquiredNameOfBusinessMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CertificatesOfNeedAndLicensesMember" id="amed_CertificatesOfNeedAndLicensesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="AcquiredNamesOfBusinessMember" id="amed_AcquiredNamesOfBusinessMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="QuarterlyFinancialInformationTable" id="amed_QuarterlyFinancialInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="QuarterlyFinancialInformationAxis" id="amed_QuarterlyFinancialInformationAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="QuarterlyFinancialInformationDomain" id="amed_QuarterlyFinancialInformationDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="NetOfTaxMember" id="amed_NetOfTaxMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="TwoThousandAndThirteenExitActivityMember" id="amed_TwoThousandAndThirteenExitActivityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="RestructuringCostAndReserveDomain" id="amed_RestructuringCostAndReserveDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="LeaseTerminationMember" id="amed_LeaseTerminationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="IntangiblesWriteOffMember" id="amed_IntangiblesWriteOffMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" id="amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="DebtIssuanceCostsPolicyTextBlock" id="amed_DebtIssuanceCostsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="EquipmentAndFurnitureMember" id="amed_EquipmentAndFurnitureMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="ComputerSoftwareMember" id="amed_ComputerSoftwareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="InternallyDevelopedComputerSoftwareAmortizationPeriod" id="amed_InternallyDevelopedComputerSoftwareAmortizationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="UnamortizedDebtIssuanceCostAmortizatinPeriod" id="amed_UnamortizedDebtIssuanceCostAmortizatinPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="BuildingAndLeaseholdImprovements" id="amed_BuildingAndLeaseholdImprovements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="EquipmentAndFurniture" id="amed_EquipmentAndFurniture" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="InternallyDevelopedComputerSoftware" id="amed_InternallyDevelopedComputerSoftware" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="AvailableForSaleMember" id="amed_AvailableForSaleMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="PriorToTwoThousandFourteenMember" id="amed_PriorToTwoThousandFourteenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="January12015ToMarch312015Member" id="amed_January12015ToMarch312015Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="April12015ToJune302015Member" id="amed_April12015ToJune302015Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="July12015ToSeptember302015Member" id="amed_July12015ToSeptember302015Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="October12015ToDecember312015Member" id="amed_October12015ToDecember312015Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="January12016ToMarch312016Member" id="amed_January12016ToMarch312016Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="April12016ToJune302016Member" id="amed_April12016ToJune302016Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="July12016ToSeptember302016Member" id="amed_July12016ToSeptember302016Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="October12016ToDecember312016Member" id="amed_October12016ToDecember312016Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" id="amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid" id="amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="AlabamaMember" id="amed_AlabamaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="NorthCarolinaMember" id="amed_NorthCarolinaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="WestVirginiaMember" id="amed_WestVirginiaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="LouisianaMember" id="amed_LouisianaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="FloridaMember" id="amed_FloridaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="BusinessAcquisitionAcquiredDomain" id="amed_BusinessAcquisitionAcquiredDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="InHousePhysiciansPracticeMember" id="amed_InHousePhysiciansPracticeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="RevolvingCreditFacilityTotal" id="amed_RevolvingCreditFacilityTotal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="LineOfCreditFacilityAdditionalBorrowingCapacity" id="amed_LineOfCreditFacilityAdditionalBorrowingCapacity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="SwingLineLoanMember" id="amed_SwingLineLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="DebtInstrumentNumberOfPeriodicPayments" id="amed_DebtInstrumentNumberOfPeriodicPayments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="RangeOneMember" id="amed_RangeOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="RangeTwoMember" id="amed_RangeTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="RangeThreeMember" id="amed_RangeThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="RangeFourMember" id="amed_RangeFourMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" id="amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" id="amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="ApplicableMarginRateOnBaseRate" id="amed_ApplicableMarginRateOnBaseRate" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="ApplicableMarginRateOnEurodollarRate" id="amed_ApplicableMarginRateOnEurodollarRate" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="AbrLoansMember" id="amed_AbrLoansMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="EurodollarLoansMember" id="amed_EurodollarLoansMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="OperatingLeaseCommitmentsForDiscontinuedOperations" id="amed_OperatingLeaseCommitmentsForDiscontinuedOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="OperatingLeasesRentExpenseNetForContinuingOperations" id="amed_OperatingLeasesRentExpenseNetForContinuingOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="OperatingLeaseTermYears" id="amed_OperatingLeaseTermYears" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="OperatingLeasesAgreementExpirationYear" id="amed_OperatingLeasesAgreementExpirationYear" type="invest:dateStringItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="LineOfCreditFacilityDomain" id="amed_LineOfCreditFacilityDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" id="amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="PromissoryNotesMember" id="amed_PromissoryNotesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfCareCentersIncludedInDiscontinuedOperations" id="amed_NumberOfCareCentersIncludedInDiscontinuedOperations" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="GoodwillAndOtherIntangiblesImpairmentMember" id="amed_GoodwillAndOtherIntangiblesImpairmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="FutureRentalCommitmentsTable" id="amed_FutureRentalCommitmentsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="AssetWriteOffMember" id="amed_AssetWriteOffMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" id="amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="CapYearTwoThousandThirteenThroughTwoThousandFifteenMember" id="amed_CapYearTwoThousandThirteenThroughTwoThousandFifteenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="EstimatedUsefulLifeOfIntangibleAssets" id="amed_EstimatedUsefulLifeOfIntangibleAssets" type="us-types:durationStringItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="AcquiredNamesMember" id="amed_AcquiredNamesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="FavorableInFullMember" id="amed_FavorableInFullMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="FavorableInPartMember" id="amed_FavorableInPartMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfClaimsAppealed" id="amed_NumberOfClaimsAppealed" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" id="amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NotIncludedInAvailableForSaleMember" id="amed_NotIncludedInAvailableForSaleMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="GoodwillAndIntangibleAssetsImpairmentAxis" id="amed_GoodwillAndIntangibleAssetsImpairmentAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="GoodwillAndIntangibleAssetsDomain" id="amed_GoodwillAndIntangibleAssetsDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="SecondLienCreditAgreementTermLoanMember" id="amed_SecondLienCreditAgreementTermLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="SeniorSecuredLeverageRatio" id="amed_SeniorSecuredLeverageRatio" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="SecondLienCreditAgreementRevolvingCreditFacilityMember" id="amed_SecondLienCreditAgreementRevolvingCreditFacilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="DebtInstrumentInterestAdditionalInterestAboveABRRate" id="amed_DebtInstrumentInterestAdditionalInterestAboveABRRate" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate" id="amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="DebtInstrumentInterestABRFlatRate" id="amed_DebtInstrumentInterestABRFlatRate" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="EurodollarDepositsInterestPeriod" id="amed_EurodollarDepositsInterestPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="DebtInstrumentInterestLiborFloor" id="amed_DebtInstrumentInterestLiborFloor" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="CreditAgreementMember" id="amed_CreditAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="OtherLongTermObligationsMember" id="amed_OtherLongTermObligationsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="DeferredIncomeTaxesMember" id="amed_DeferredIncomeTaxesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="TwoThousandAndFourteenExitActivityMember" id="amed_TwoThousandAndFourteenExitActivityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="WyomingAndIdahoCareCentersMember" id="amed_WyomingAndIdahoCareCentersMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="HospiceInpatientUnitMember" id="amed_HospiceInpatientUnitMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="SeveranceForRegionalLeadershipAndCorporateSupportMember" id="amed_SeveranceForRegionalLeadershipAndCorporateSupportMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="SeveranceForFormerExecutiveMember" id="amed_SeveranceForFormerExecutiveMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="DebtIssuanceCostsLineItems" id="amed_DebtIssuanceCostsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CorporateIntegrityAgreementTerm" id="amed_CorporateIntegrityAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="TimePeriodAxis" id="amed_TimePeriodAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="TimePeriodDomain" id="amed_TimePeriodDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="OneMonthMember" id="amed_OneMonthMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="TwoMonthMember" id="amed_TwoMonthMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="ThreeMonthMember" id="amed_ThreeMonthMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="SixMonthMember" id="amed_SixMonthMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="OneYearMember" id="amed_OneYearMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="TwoYearMember" id="amed_TwoYearMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="AnnualImpairmentTestStepOneMember" id="amed_AnnualImpairmentTestStepOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="PrepaymentPenaltyPercentage" id="amed_PrepaymentPenaltyPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual" id="amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="ClassificationOfDeferredTaxAssetsLiabilitiesTextBlock" id="amed_ClassificationOfDeferredTaxAssetsLiabilitiesTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="UncertainTaxBenefitsInLongTermObligations" id="amed_UncertainTaxBenefitsInLongTermObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="DeferredIncomeTaxesForContinuingOperations" id="amed_DeferredIncomeTaxesForContinuingOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests" id="amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="FeeTypeAxis" id="amed_FeeTypeAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="FeeTypeDomain" id="amed_FeeTypeDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="ArrangerFeeMember" id="amed_ArrangerFeeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="ComputerInventoryAndDataSecurityReportingMember" id="amed_ComputerInventoryAndDataSecurityReportingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfIndividualsWithInformationOnMissingDevices" id="amed_NumberOfIndividualsWithInformationOnMissingDevices" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NumberOfMissingComputersAndLaptops" id="amed_NumberOfMissingComputersAndLaptops" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="ThresholdOfIndividualsInDataBreach" id="amed_ThresholdOfIndividualsInDataBreach" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="PercentageOfCompanyDevicesUsed" id="amed_PercentageOfCompanyDevicesUsed" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="YearOfDeparture" id="amed_YearOfDeparture" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="OneHundredMillionTermLoanMember" id="amed_OneHundredMillionTermLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CallPremiumPayment" id="amed_CallPremiumPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="MarginAdjustmentOnBaseRate" id="amed_MarginAdjustmentOnBaseRate" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="MarginAdjustmentOnEuroDollarLoans" id="amed_MarginAdjustmentOnEuroDollarLoans" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="TwoHundredMillionRevolvingCreditFacilityMember" id="amed_TwoHundredMillionRevolvingCreditFacilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="MiddleMember" id="amed_MiddleMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="FourRemainingQuarterlyPaymentsMember" id="amed_FourRemainingQuarterlyPaymentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="SecondEightQuarterlyPaymentsMember" id="amed_SecondEightQuarterlyPaymentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="FinalTwoQuarterlyPaymentsMember" id="amed_FinalTwoQuarterlyPaymentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="LetterOfCreditFee" id="amed_LetterOfCreditFee" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="NonVestedStockUnitsServiceMember" id="amed_NonVestedStockUnitsServiceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="SoftwareImplementationCosts" id="amed_SoftwareImplementationCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="Performancebasedawardtargetshareamount" id="amed_Performancebasedawardtargetshareamount" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="TennesseeMember" id="amed_TennesseeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="GeorgiaMember" id="amed_GeorgiaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="Goodwillisexpectedtobedeductibleforincometaxpurposesyears" id="amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="Businessacquisitionproformaoperatingincomeloss" id="amed_Businessacquisitionproformaoperatingincomeloss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="IncomeTaxEffectsAllocatedToInterestExpense" id="amed_IncomeTaxEffectsAllocatedToInterestExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="ResearchAndDevelopmentTaxCreditMember" id="amed_ResearchAndDevelopmentTaxCreditMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="EmploymentTaxCreditMember" id="amed_EmploymentTaxCreditMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="AlternativeMinimumTaxCreditMember" id="amed_AlternativeMinimumTaxCreditMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="StateTaxCreditMember" id="amed_StateTaxCreditMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="UnrecognizedTaxBenefitsAxis" id="amed_UnrecognizedTaxBenefitsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="UnrecognizedTaxBenefitsDomain" id="amed_UnrecognizedTaxBenefitsDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="NetOperatingLossMember" id="amed_NetOperatingLossMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="TaxCreditCarryforwardMember" id="amed_TaxCreditCarryforwardMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="AccruedExpensesMember" id="amed_AccruedExpensesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="HospiceCostOfRevenue" id="amed_HospiceCostOfRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="OigSelfDisclsoureAccrual" id="amed_OigSelfDisclsoureAccrual" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="PatientLiability" id="amed_PatientLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="Numberofpatients" id="amed_Numberofpatients" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
    <element name="FrontierLitigationMember" id="amed_FrontierLitigationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="UsDepartmentOfJusticeMember" id="amed_UsDepartmentOfJusticeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="DeferredDebtIssuanceCostsMember" id="amed_DeferredDebtIssuanceCostsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="AssetImpairmentAxis" id="amed_AssetImpairmentAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="AssetImpairmentDomain" id="amed_AssetImpairmentDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CorporateHeadquartersMember" id="amed_CorporateHeadquartersMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="Ams3HomecareAndHospiceMember" id="amed_Ams3HomecareAndHospiceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="SurrenderedShares" id="amed_SurrenderedShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="IncomeTaxEffectsAllocatedToGoodwill" id="amed_IncomeTaxEffectsAllocatedToGoodwill" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="PercentageOfPatientReceivablesOutstandingOverTenPercent" id="amed_PercentageOfPatientReceivablesOutstandingOverTenPercent" type="num:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
    <element name="RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" id="amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome" id="amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses" id="amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations" id="amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
    <element name="HeritageHealthcareInnovationFundMember" id="amed_HeritageHealthcareInnovationFundMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="PersonalCareMember" id="amed_PersonalCareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="AssociatedHomecareMember" id="amed_AssociatedHomecareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="ProfessionalProfilesMember" id="amed_ProfessionalProfilesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" id="amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="MorgantownWestVirginiaMember" id="amed_MorgantownWestVirginiaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="ParkersburgWestVirginiaMember" id="amed_ParkersburgWestVirginiaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="RelatedPartyTransactionTable" id="amed_RelatedPartyTransactionTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CompanyNameDomain" id="amed_CompanyNameDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="KKRConsultingMember" id="amed_KKRConsultingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="CareInnovationsMember" id="amed_CareInnovationsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="WriteOffOfInvestment" id="amed_WriteOffOfInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
    <element name="NewYorkMember" id="amed_NewYorkMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="InfinityHomeCareMember" id="amed_InfinityHomeCareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="HomeStaffLlcMember" id="amed_HomeStaffLlcMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
    <element name="DeferredTaxAssetsGoodwillAndIntangibleAssets1" id="amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
    <element name="ReversalOfLegalAccrual" id="amed_ReversalOfLegalAccrual" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
    <element name="HomecareHomebaseMember" id="amed_HomecareHomebaseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>amed-20161231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Prepared by IBM Cognos FSR v6.7.4.14 using Fujitsu Interstage XWand -->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/instance http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
    <roleRef roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_CONSOLIDATEDBALANCESHEETS" />
    <roleRef roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_CONSOLIDATEDSTATEMENTSOFOPERATIONS" />
    <roleRef roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_CONSOLIDATEDSTATEMENTSOFCASHFLOWS" />
    <roleRef roleURI="http://www.amedisys.com/role/ScheduleOfWeightedAverageSharesOutstandingDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_ScheduleOfWeightedAverageSharesOutstandingDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/NetRevenuesAndOperatingResultsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_NetRevenuesAndOperatingResultsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureOperatingIncomeOfReportableSegmentsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_OperatingIncomeOfReportableSegmentsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsOtherCurrentAssetsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_DetailsOfCertainBalanceSheetAccountsOtherCurrentAssetsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureInsuranceProgramsDetails" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_InsuranceProgramsDetails" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureComponentsOfNetDeferredTaxAssetsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_ComponentsOfNetDeferredTaxAssetsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsOtherAssetsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_DetailsOfCertainBalanceSheetAccountsOtherAssetsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsAccruedExpensesDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_DetailsOfCertainBalanceSheetAccountsAccruedExpensesDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsOtherLongTermObligationsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_DetailsOfCertainBalanceSheetAccountsOtherLongTermObligationsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/ScheduleOfBalancesRelatedToPropertyAndEquipmentDetails" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_ScheduleOfBalancesRelatedToPropertyAndEquipmentDetails" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureMaturitiesOfDebtDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_MaturitiesOfDebtDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/IncomeTaxExpenseAllocationDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_IncomeTaxExpenseAllocationDetail" />
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/StatementCONSOLIDATEDBALANCESHEETS">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="Locator_us-gaap_Assets_157" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="Locator_us-gaap_AssetsCurrent_158" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_Assets_157" xlink:to="Locator_us-gaap_AssetsCurrent_158" order="10.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="Locator_us-gaap_AssetsCurrent_169" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="Locator_us-gaap_CashAndCashEquivalentsAtCarryingValue_170" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_AssetsCurrent_169" xlink:to="Locator_us-gaap_CashAndCashEquivalentsAtCarryingValue_170" order="4.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="Locator_us-gaap_AssetsCurrent_171" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="Locator_us-gaap_AccountsReceivableNetCurrent_172" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_AssetsCurrent_171" xlink:to="Locator_us-gaap_AccountsReceivableNetCurrent_172" order="5.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="Locator_us-gaap_AssetsCurrent_173" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="Locator_us-gaap_PrepaidExpenseCurrent_174" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_AssetsCurrent_173" xlink:to="Locator_us-gaap_PrepaidExpenseCurrent_174" order="6.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="Locator_us-gaap_AssetsCurrent_175" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="Locator_us-gaap_OtherAssetsCurrent_176" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_AssetsCurrent_175" xlink:to="Locator_us-gaap_OtherAssetsCurrent_176" order="8.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="Locator_us-gaap_AssetsCurrent_177" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="Locator_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_178" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_AssetsCurrent_177" xlink:to="Locator_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_178" order="9.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="Locator_us-gaap_AssetsCurrent_179" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="Locator_us-gaap_DeferredTaxAssetsNetCurrent_180" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_AssetsCurrent_179" xlink:to="Locator_us-gaap_DeferredTaxAssetsNetCurrent_180" order="7.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="Locator_us-gaap_Assets_159" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentNet_160" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_Assets_159" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentNet_160" order="11.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="Locator_us-gaap_Assets_161" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="Locator_us-gaap_Goodwill_162" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_Assets_161" xlink:to="Locator_us-gaap_Goodwill_162" order="12.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="Locator_us-gaap_Assets_163" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="Locator_us-gaap_IntangibleAssetsNetExcludingGoodwill_164" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_Assets_163" xlink:to="Locator_us-gaap_IntangibleAssetsNetExcludingGoodwill_164" order="13.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="Locator_us-gaap_Assets_165" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="Locator_us-gaap_DeferredTaxAssetsNetNoncurrent_166" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_Assets_165" xlink:to="Locator_us-gaap_DeferredTaxAssetsNetNoncurrent_166" order="14.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="Locator_us-gaap_Assets_167" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="Locator_us-gaap_OtherAssetsNoncurrent_168" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_Assets_167" xlink:to="Locator_us-gaap_OtherAssetsNoncurrent_168" order="15.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquity_181" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="Locator_us-gaap_Liabilities_182" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquity_181" xlink:to="Locator_us-gaap_Liabilities_182" order="28.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="Locator_us-gaap_Liabilities_185" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="Locator_us-gaap_LiabilitiesCurrent_186" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_Liabilities_185" xlink:to="Locator_us-gaap_LiabilitiesCurrent_186" order="25.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="Locator_us-gaap_LiabilitiesCurrent_191" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="Locator_us-gaap_AccountsPayableCurrent_192" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_LiabilitiesCurrent_191" xlink:to="Locator_us-gaap_AccountsPayableCurrent_192" order="19.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="Locator_us-gaap_LiabilitiesCurrent_193" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="Locator_us-gaap_EmployeeRelatedLiabilitiesCurrent_194" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_LiabilitiesCurrent_193" xlink:to="Locator_us-gaap_EmployeeRelatedLiabilitiesCurrent_194" order="21.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="Locator_us-gaap_LiabilitiesCurrent_195" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="Locator_us-gaap_AccruedLiabilitiesCurrent_196" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_LiabilitiesCurrent_195" xlink:to="Locator_us-gaap_AccruedLiabilitiesCurrent_196" order="22.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="Locator_us-gaap_LiabilitiesCurrent_197" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_198" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_LiabilitiesCurrent_197" xlink:to="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_198" order="23.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="Locator_us-gaap_LiabilitiesCurrent_199" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="Locator_us-gaap_DeferredTaxLiabilitiesCurrent_200" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_LiabilitiesCurrent_199" xlink:to="Locator_us-gaap_DeferredTaxLiabilitiesCurrent_200" order="24.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="Locator_us-gaap_LiabilitiesCurrent_201" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement_202" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_LiabilitiesCurrent_201" xlink:to="Locator_amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement_202" order="20.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="Locator_us-gaap_Liabilities_187" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligations_188" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_Liabilities_187" xlink:to="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligations_188" order="26.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="Locator_us-gaap_Liabilities_189" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="Locator_us-gaap_OtherLiabilitiesNoncurrent_190" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_Liabilities_189" xlink:to="Locator_us-gaap_OtherLiabilitiesNoncurrent_190" order="27.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquity_183" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_184" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquity_183" xlink:to="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_184" order="39.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_203" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="Locator_us-gaap_StockholdersEquity_204" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_203" xlink:to="Locator_us-gaap_StockholdersEquity_204" order="37.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="Locator_us-gaap_StockholdersEquity_207" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="Locator_us-gaap_PreferredStockValueOutstanding_208" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_StockholdersEquity_207" xlink:to="Locator_us-gaap_PreferredStockValueOutstanding_208" order="31.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="Locator_us-gaap_StockholdersEquity_209" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="Locator_us-gaap_CommonStockValueOutstanding_210" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_StockholdersEquity_209" xlink:to="Locator_us-gaap_CommonStockValueOutstanding_210" order="32.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="Locator_us-gaap_StockholdersEquity_211" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="Locator_us-gaap_AdditionalPaidInCapitalCommonStock_212" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_StockholdersEquity_211" xlink:to="Locator_us-gaap_AdditionalPaidInCapitalCommonStock_212" order="33.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="Locator_us-gaap_StockholdersEquity_213" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="Locator_us-gaap_TreasuryStockValue_214" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_StockholdersEquity_213" xlink:to="Locator_us-gaap_TreasuryStockValue_214" order="34.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="Locator_us-gaap_StockholdersEquity_215" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="Locator_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_216" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_StockholdersEquity_215" xlink:to="Locator_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_216" order="35.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="Locator_us-gaap_StockholdersEquity_217" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="Locator_us-gaap_RetainedEarningsAccumulatedDeficit_218" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_StockholdersEquity_217" xlink:to="Locator_us-gaap_RetainedEarningsAccumulatedDeficit_218" order="36.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_205" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterest" xlink:label="Locator_us-gaap_MinorityInterest_206" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_205" xlink:to="Locator_us-gaap_MinorityInterest_206" order="38.0" weight="1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="Locator_us-gaap_ProfitLoss_453" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_454" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_ProfitLoss_453" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_454" order="22.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_457" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_458" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_457" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_458" order="20.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_461" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="Locator_us-gaap_OperatingIncomeLoss_462" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_461" xlink:to="Locator_us-gaap_OperatingIncomeLoss_462" order="13.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="Locator_us-gaap_OperatingIncomeLoss_465" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationPatientServiceRevenue" xlink:label="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_466" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_OperatingIncomeLoss_465" xlink:to="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_466" order="2.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="Locator_us-gaap_OperatingIncomeLoss_467" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_468" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_OperatingIncomeLoss_467" xlink:to="Locator_us-gaap_CostsAndExpenses_468" order="12.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_469" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="Locator_us-gaap_LaborAndRelatedExpense_470" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_469" xlink:to="Locator_us-gaap_LaborAndRelatedExpense_470" order="5.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_471" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="Locator_us-gaap_ShareBasedCompensation_472" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_471" xlink:to="Locator_us-gaap_ShareBasedCompensation_472" order="6.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_473" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="Locator_us-gaap_OtherGeneralAndAdministrativeExpense_474" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_473" xlink:to="Locator_us-gaap_OtherGeneralAndAdministrativeExpense_474" order="7.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_475" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfServices" xlink:label="Locator_us-gaap_CostOfServices_476" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_475" xlink:to="Locator_us-gaap_CostOfServices_476" order="3.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_477" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProvisionForDoubtfulAccountsForContinuingOperations" xlink:label="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_478" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_477" xlink:to="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_478" order="8.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_479" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DepreciationAndAmortizationForContinuingOperations" xlink:label="Locator_amed_DepreciationAndAmortizationForContinuingOperations_480" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_479" xlink:to="Locator_amed_DepreciationAndAmortizationForContinuingOperations_480" order="9.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_481" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_UsDepartmentOfJusticeSettlement_482" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_481" xlink:to="Locator_amed_UsDepartmentOfJusticeSettlement_482" order="10.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_483" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="Locator_us-gaap_AssetImpairmentCharges_484" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_483" xlink:to="Locator_us-gaap_AssetImpairmentCharges_484" order="11.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_463" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="Locator_us-gaap_NonoperatingIncomeExpense_464" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_463" xlink:to="Locator_us-gaap_NonoperatingIncomeExpense_464" order="19.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="Locator_us-gaap_NonoperatingIncomeExpense_485" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="Locator_us-gaap_InvestmentIncomeInterestAndDividend_486" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NonoperatingIncomeExpense_485" xlink:to="Locator_us-gaap_InvestmentIncomeInterestAndDividend_486" order="15.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="Locator_us-gaap_NonoperatingIncomeExpense_487" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="Locator_us-gaap_InterestExpense_488" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NonoperatingIncomeExpense_487" xlink:to="Locator_us-gaap_InterestExpense_488" order="16.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="Locator_us-gaap_NonoperatingIncomeExpense_489" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="Locator_us-gaap_IncomeLossFromEquityMethodInvestments_490" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NonoperatingIncomeExpense_489" xlink:to="Locator_us-gaap_IncomeLossFromEquityMethodInvestments_490" order="17.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="Locator_us-gaap_NonoperatingIncomeExpense_491" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="Locator_us-gaap_OtherNonoperatingIncomeExpense_492" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NonoperatingIncomeExpense_491" xlink:to="Locator_us-gaap_OtherNonoperatingIncomeExpense_492" order="18.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_459" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="Locator_us-gaap_IncomeTaxExpenseBenefit_460" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_459" xlink:to="Locator_us-gaap_IncomeTaxExpenseBenefit_460" order="21.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="Locator_us-gaap_ProfitLoss_455" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_456" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_ProfitLoss_455" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_456" order="23.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="Locator_us-gaap_EarningsPerShareBasic_493" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_494" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_EarningsPerShareBasic_493" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_494" order="28.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="Locator_us-gaap_EarningsPerShareBasic_495" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_496" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_EarningsPerShareBasic_495" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_496" order="29.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="Locator_us-gaap_EarningsPerShareDiluted_497" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_498" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_EarningsPerShareDiluted_497" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_498" order="33.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="Locator_us-gaap_EarningsPerShareDiluted_499" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_500" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_EarningsPerShareDiluted_499" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_500" order="34.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="Locator_us-gaap_NetIncomeLoss_501" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="Locator_us-gaap_ProfitLoss_502" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetIncomeLoss_501" xlink:to="Locator_us-gaap_ProfitLoss_502" order="24.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="Locator_us-gaap_NetIncomeLoss_503" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_504" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetIncomeLoss_503" xlink:to="Locator_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_504" order="25.0" weight="-1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="Locator_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_707" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_708" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_707" xlink:to="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_708" order="25.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_713" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="Locator_us-gaap_ProfitLoss_714" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_713" xlink:to="Locator_us-gaap_ProfitLoss_714" order="2.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_715" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="Locator_us-gaap_DepreciationDepletionAndAmortization_716" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_715" xlink:to="Locator_us-gaap_DepreciationDepletionAndAmortization_716" order="4.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_717" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="Locator_us-gaap_ProvisionForDoubtfulAccounts_718" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_717" xlink:to="Locator_us-gaap_ProvisionForDoubtfulAccounts_718" order="5.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_719" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="Locator_us-gaap_ShareBasedCompensation_720" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_719" xlink:to="Locator_us-gaap_ShareBasedCompensation_720" order="6.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_721" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionExpense" xlink:label="Locator_us-gaap_PensionExpense_722" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_721" xlink:to="Locator_us-gaap_PensionExpense_722" order="7.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_723" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="Locator_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_724" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_723" xlink:to="Locator_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_724" order="9.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_725" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="Locator_us-gaap_DeferredIncomeTaxExpenseBenefit_726" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_725" xlink:to="Locator_us-gaap_DeferredIncomeTaxExpenseBenefit_726" order="11.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_727" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="Locator_us-gaap_IncomeLossFromEquityMethodInvestments_728" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_727" xlink:to="Locator_us-gaap_IncomeLossFromEquityMethodInvestments_728" order="13.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_729" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="Locator_us-gaap_AmortizationOfFinancingCostsAndDiscounts_730" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_729" xlink:to="Locator_us-gaap_AmortizationOfFinancingCostsAndDiscounts_730" order="14.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_731" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:label="Locator_us-gaap_EquityMethodInvestmentDividendsOrDistributions_732" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_731" xlink:to="Locator_us-gaap_EquityMethodInvestmentDividendsOrDistributions_732" order="15.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_733" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="Locator_us-gaap_IncreaseDecreaseInAccountsReceivable_734" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_733" xlink:to="Locator_us-gaap_IncreaseDecreaseInAccountsReceivable_734" order="18.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_735" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="Locator_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_736" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_735" xlink:to="Locator_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_736" order="19.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_737" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="Locator_us-gaap_IncreaseDecreaseInOtherOperatingAssets_738" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_737" xlink:to="Locator_us-gaap_IncreaseDecreaseInOtherOperatingAssets_738" order="20.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_739" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="Locator_us-gaap_IncreaseDecreaseInAccountsPayable_740" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_739" xlink:to="Locator_us-gaap_IncreaseDecreaseInAccountsPayable_740" order="21.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_741" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="Locator_us-gaap_IncreaseDecreaseInAccruedLiabilities_742" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_741" xlink:to="Locator_us-gaap_IncreaseDecreaseInAccruedLiabilities_742" order="23.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_743" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="Locator_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_744" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_743" xlink:to="Locator_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_744" order="24.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_745" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="Locator_us-gaap_AssetImpairmentCharges_746" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_745" xlink:to="Locator_us-gaap_AssetImpairmentCharges_746" order="16.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_747" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredDebtIssuanceCostsWrittenOff" xlink:label="Locator_amed_DeferredDebtIssuanceCostsWrittenOff_748" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_747" xlink:to="Locator_amed_DeferredDebtIssuanceCostsWrittenOff_748" order="12.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_749" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="Locator_us-gaap_GainsLossesOnSalesOfAssets_750" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_749" xlink:to="Locator_us-gaap_GainsLossesOnSalesOfAssets_750" order="10.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_751" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual" xlink:label="Locator_amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual_752" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_751" xlink:to="Locator_amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual_752" order="22.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_753" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WriteOffOfInvestment" xlink:label="Locator_amed_WriteOffOfInvestment_754" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_753" xlink:to="Locator_amed_WriteOffOfInvestment_754" order="8.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="Locator_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_709" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivities_710" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_709" xlink:to="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivities_710" order="35.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivities_755" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:label="Locator_us-gaap_ProceedsFromSaleOfRestrictedInvestments_756" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivities_755" xlink:to="Locator_us-gaap_ProceedsFromSaleOfRestrictedInvestments_756" order="27.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivities_757" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="Locator_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_758" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivities_757" xlink:to="Locator_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_758" order="28.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivities_759" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="Locator_us-gaap_PaymentsToAcquireRestrictedInvestments_760" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivities_759" xlink:to="Locator_us-gaap_PaymentsToAcquireRestrictedInvestments_760" order="29.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivities_761" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="Locator_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_762" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivities_761" xlink:to="Locator_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_762" order="30.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivities_763" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="Locator_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_764" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivities_763" xlink:to="Locator_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_764" order="33.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivities_765" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="Locator_us-gaap_PaymentsForProceedsFromInvestments_766" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivities_765" xlink:to="Locator_us-gaap_PaymentsForProceedsFromInvestments_766" order="31.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivities_767" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="Locator_us-gaap_ProceedsFromDivestitureOfBusinesses_768" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivities_767" xlink:to="Locator_us-gaap_ProceedsFromDivestitureOfBusinesses_768" order="34.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivities_769" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:label="Locator_us-gaap_ProceedsFromSaleOfOtherInvestments_770" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivities_769" xlink:to="Locator_us-gaap_ProceedsFromSaleOfOtherInvestments_770" order="32.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="Locator_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_711" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_712" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_711" xlink:to="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_712" order="48.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_771" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="Locator_us-gaap_ProceedsFromStockOptionsExercised_772" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_771" xlink:to="Locator_us-gaap_ProceedsFromStockOptionsExercised_772" order="37.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_773" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="Locator_us-gaap_ProceedsFromStockPlans_774" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_773" xlink:to="Locator_us-gaap_ProceedsFromStockPlans_774" order="38.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_775" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="Locator_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_776" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_775" xlink:to="Locator_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_776" order="39.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_777" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="Locator_us-gaap_RepaymentsOfShortTermDebt_778" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_777" xlink:to="Locator_us-gaap_RepaymentsOfShortTermDebt_778" order="42.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_779" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="Locator_us-gaap_RepaymentsOfLongTermDebt_780" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_779" xlink:to="Locator_us-gaap_RepaymentsOfLongTermDebt_780" order="44.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_781" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="Locator_us-gaap_ProceedsFromShortTermDebt_782" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_781" xlink:to="Locator_us-gaap_ProceedsFromShortTermDebt_782" order="41.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_783" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CashDistributionToNoncontrollingInterest" xlink:label="Locator_amed_CashDistributionToNoncontrollingInterest_784" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_783" xlink:to="Locator_amed_CashDistributionToNoncontrollingInterest_784" order="40.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_785" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="Locator_us-gaap_ProceedsFromIssuanceOfLongTermDebt_786" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_785" xlink:to="Locator_us-gaap_ProceedsFromIssuanceOfLongTermDebt_786" order="43.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_787" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="Locator_us-gaap_PaymentsOfFinancingCosts_788" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_787" xlink:to="Locator_us-gaap_PaymentsOfFinancingCosts_788" order="45.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_789" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="Locator_us-gaap_PaymentsForRepurchaseOfCommonStock_790" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_789" xlink:to="Locator_us-gaap_PaymentsForRepurchaseOfCommonStock_790" order="46.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_791" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment" xlink:label="Locator_amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment_792" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_791" xlink:to="Locator_amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment_792" order="47.0" weight="1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/ScheduleOfWeightedAverageSharesOutstandingDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1347" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="Locator_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1348" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1347" xlink:to="Locator_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1348" order="1.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1349" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="Locator_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1350" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1349" xlink:to="Locator_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1350" order="2.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1351" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockAndStockUnits" xlink:label="Locator_amed_NonVestedStockAndStockUnits_1352" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1351" xlink:to="Locator_amed_NonVestedStockAndStockUnits_1352" order="3.0" weight="1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/NetRevenuesAndOperatingResultsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1445" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="Locator_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1446" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1445" xlink:to="Locator_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1446" order="2.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1447" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="Locator_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1448" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1447" xlink:to="Locator_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1448" order="3.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_1449" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale_1450" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_1449" xlink:to="Locator_amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale_1450" order="7.0" weight="1" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_1451" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale_1452" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_1451" xlink:to="Locator_amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale_1452" order="8.0" weight="-1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureOperatingIncomeOfReportableSegmentsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_2321" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfServices" xlink:label="Locator_us-gaap_CostOfServices_2322" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_2321" xlink:to="Locator_us-gaap_CostOfServices_2322" order="3.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_2323" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GeneralAndAdministrativeExpenseSegment" xlink:label="Locator_amed_GeneralAndAdministrativeExpenseSegment_2324" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_2323" xlink:to="Locator_amed_GeneralAndAdministrativeExpenseSegment_2324" order="4.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_2325" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProvisionForDoubtfulAccountsForContinuingOperations" xlink:label="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_2326" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_2325" xlink:to="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_2326" order="5.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_2327" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DepreciationAndAmortizationForContinuingOperations" xlink:label="Locator_amed_DepreciationAndAmortizationForContinuingOperations_2328" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_2327" xlink:to="Locator_amed_DepreciationAndAmortizationForContinuingOperations_2328" order="6.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_2329" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_UsDepartmentOfJusticeSettlement_2330" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_2329" xlink:to="Locator_amed_UsDepartmentOfJusticeSettlement_2330" order="7.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_2331" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="Locator_us-gaap_AssetImpairmentCharges_2332" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_CostsAndExpenses_2331" xlink:to="Locator_us-gaap_AssetImpairmentCharges_2332" order="8.0" weight="1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="Locator_us-gaap_ComprehensiveIncomeNetOfTax_2389" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2390" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_ComprehensiveIncomeNetOfTax_2389" xlink:to="Locator_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2390" order="4.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2393" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="Locator_us-gaap_ProfitLoss_2394" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2393" xlink:to="Locator_us-gaap_ProfitLoss_2394" order="1.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2395" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="Locator_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2396" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2395" xlink:to="Locator_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2396" order="3.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="Locator_us-gaap_ComprehensiveIncomeNetOfTax_2391" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2392" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_ComprehensiveIncomeNetOfTax_2391" xlink:to="Locator_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2392" order="5.0" weight="-1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsOtherCurrentAssetsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="Locator_us-gaap_OtherAssetsCurrent_3027" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PayrollTaxEscrow" xlink:label="Locator_amed_PayrollTaxEscrow_3028" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_OtherAssetsCurrent_3027" xlink:to="Locator_amed_PayrollTaxEscrow_3028" order="1.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="Locator_us-gaap_OtherAssetsCurrent_3029" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MedicareWithholds" xlink:label="Locator_amed_MedicareWithholds_3030" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_OtherAssetsCurrent_3029" xlink:to="Locator_amed_MedicareWithholds_3030" order="2.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="Locator_us-gaap_OtherAssetsCurrent_3031" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="Locator_us-gaap_IncomeTaxesReceivable_3032" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_OtherAssetsCurrent_3031" xlink:to="Locator_us-gaap_IncomeTaxesReceivable_3032" order="3.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="Locator_us-gaap_OtherAssetsCurrent_3033" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueFromJointVenturesCurrent" xlink:label="Locator_us-gaap_DueFromJointVenturesCurrent_3034" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_OtherAssetsCurrent_3033" xlink:to="Locator_us-gaap_DueFromJointVenturesCurrent_3034" order="4.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="Locator_us-gaap_OtherAssetsCurrent_3035" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsMiscellaneousCurrent" xlink:label="Locator_us-gaap_OtherAssetsMiscellaneousCurrent_3036" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_OtherAssetsCurrent_3035" xlink:to="Locator_us-gaap_OtherAssetsMiscellaneousCurrent_3036" order="5.0" weight="1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureInsuranceProgramsDetails">
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedInsuranceTotal" xlink:label="Locator_amed_EstimatedInsuranceTotal_3633" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HealthInsurance" xlink:label="Locator_amed_HealthInsurance_3634" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_amed_EstimatedInsuranceTotal_3633" xlink:to="Locator_amed_HealthInsurance_3634" order="1.0" weight="1" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedInsuranceTotal" xlink:label="Locator_amed_EstimatedInsuranceTotal_3635" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WokersCompensation" xlink:label="Locator_amed_WokersCompensation_3636" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_amed_EstimatedInsuranceTotal_3635" xlink:to="Locator_amed_WokersCompensation_3636" order="2.0" weight="1" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedInsuranceTotal" xlink:label="Locator_amed_EstimatedInsuranceTotal_3637" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProfessionalLiability" xlink:label="Locator_amed_ProfessionalLiability_3638" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_amed_EstimatedInsuranceTotal_3637" xlink:to="Locator_amed_ProfessionalLiability_3638" order="3.0" weight="1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureComponentsOfNetDeferredTaxAssetsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNet_4051" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="Locator_us-gaap_DeferredTaxAssetsNet_4052" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNet_4051" xlink:to="Locator_us-gaap_DeferredTaxAssetsNet_4052" order="14.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="Locator_us-gaap_DeferredTaxAssetsNet_4055" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_4056" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsNet_4055" xlink:to="Locator_us-gaap_DeferredTaxAssetsGross_4056" order="12.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_4059" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_4060" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsGross_4059" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_4060" order="1.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_4061" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_4062" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsGross_4061" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_4062" order="2.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_4063" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual" xlink:label="Locator_amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual_4064" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsGross_4063" xlink:to="Locator_amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual_4064" order="5.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_4065" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" xlink:label="Locator_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_4066" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsGross_4065" xlink:to="Locator_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_4066" order="6.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_4067" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4068" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsGross_4067" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4068" order="8.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_4069" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="Locator_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_4070" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsGross_4069" xlink:to="Locator_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_4070" order="9.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_4071" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredTaxAssetsOtherCurrent" xlink:label="Locator_amed_DeferredTaxAssetsOtherCurrent_4072" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsGross_4071" xlink:to="Locator_amed_DeferredTaxAssetsOtherCurrent_4072" order="11.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_4073" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4074" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsGross_4073" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4074" order="10.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_4075" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_4076" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsGross_4075" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_4076" order="4.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_4077" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_4078" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsGross_4077" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_4078" order="3.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_4079" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1" xlink:label="Locator_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1_4080" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsGross_4079" xlink:to="Locator_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1_4080" order="7.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="Locator_us-gaap_DeferredTaxAssetsNet_4057" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="Locator_us-gaap_DeferredTaxAssetsValuationAllowance_4058" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsNet_4057" xlink:to="Locator_us-gaap_DeferredTaxAssetsValuationAllowance_4058" order="13.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNet_4053" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="Locator_us-gaap_DeferredTaxLiabilities_4054" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNet_4053" xlink:to="Locator_us-gaap_DeferredTaxLiabilities_4054" order="19.0" weight="-1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="Locator_us-gaap_DeferredTaxLiabilities_4081" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="Locator_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4082" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxLiabilities_4081" xlink:to="Locator_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4082" order="15.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="Locator_us-gaap_DeferredTaxLiabilities_4083" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:label="Locator_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_4084" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxLiabilities_4083" xlink:to="Locator_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_4084" order="16.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="Locator_us-gaap_DeferredTaxLiabilities_4085" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="Locator_us-gaap_DeferredTaxLiabilitiesOther_4086" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxLiabilities_4085" xlink:to="Locator_us-gaap_DeferredTaxLiabilitiesOther_4086" order="18.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="Locator_us-gaap_DeferredTaxLiabilities_4087" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:label="Locator_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_4088" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DeferredTaxLiabilities_4087" xlink:to="Locator_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_4088" order="17.0" weight="1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsOtherAssetsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="Locator_us-gaap_OtherAssetsNoncurrent_4133" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WorkersCompensationDeposits" xlink:label="Locator_amed_WorkersCompensationDeposits_4134" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_OtherAssetsNoncurrent_4133" xlink:to="Locator_amed_WorkersCompensationDeposits_4134" order="1.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="Locator_us-gaap_OtherAssetsNoncurrent_4135" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HealthInsuranceDeposits" xlink:label="Locator_amed_HealthInsuranceDeposits_4136" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_OtherAssetsNoncurrent_4135" xlink:to="Locator_amed_HealthInsuranceDeposits_4136" order="2.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="Locator_us-gaap_OtherAssetsNoncurrent_4137" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherMiscellaneousDeposits" xlink:label="Locator_amed_OtherMiscellaneousDeposits_4138" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_OtherAssetsNoncurrent_4137" xlink:to="Locator_amed_OtherMiscellaneousDeposits_4138" order="3.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="Locator_us-gaap_OtherAssetsNoncurrent_4139" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="Locator_us-gaap_DeferredFinanceCostsNoncurrentNet_4140" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_OtherAssetsNoncurrent_4139" xlink:to="Locator_us-gaap_DeferredFinanceCostsNoncurrentNet_4140" order="4.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="Locator_us-gaap_OtherAssetsNoncurrent_4141" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="Locator_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4142" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_OtherAssetsNoncurrent_4141" xlink:to="Locator_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4142" order="5.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="Locator_us-gaap_OtherAssetsNoncurrent_4143" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:label="Locator_us-gaap_OtherAssetsMiscellaneousNoncurrent_4144" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_OtherAssetsNoncurrent_4143" xlink:to="Locator_us-gaap_OtherAssetsMiscellaneousNoncurrent_4144" order="6.0" weight="1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsAccruedExpensesDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="Locator_us-gaap_AccruedLiabilitiesCurrent_4167" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedInsuranceCurrent" xlink:label="Locator_us-gaap_AccruedInsuranceCurrent_4168" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_AccruedLiabilitiesCurrent_4167" xlink:to="Locator_us-gaap_AccruedInsuranceCurrent_4168" order="1.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="Locator_us-gaap_AccruedLiabilitiesCurrent_4169" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="Locator_us-gaap_WorkersCompensationLiabilityCurrent_4170" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_AccruedLiabilitiesCurrent_4169" xlink:to="Locator_us-gaap_WorkersCompensationLiabilityCurrent_4170" order="2.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="Locator_us-gaap_AccruedLiabilitiesCurrent_4171" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LegalAndOtherSettlements" xlink:label="Locator_amed_LegalAndOtherSettlements_4172" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_AccruedLiabilitiesCurrent_4171" xlink:to="Locator_amed_LegalAndOtherSettlements_4172" order="3.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="Locator_us-gaap_AccruedLiabilitiesCurrent_4173" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LeaseLiability" xlink:label="Locator_amed_LeaseLiability_4174" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_AccruedLiabilitiesCurrent_4173" xlink:to="Locator_amed_LeaseLiability_4174" order="4.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="Locator_us-gaap_AccruedLiabilitiesCurrent_4175" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CharityCare" xlink:label="Locator_amed_CharityCare_4176" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_AccruedLiabilitiesCurrent_4175" xlink:to="Locator_amed_CharityCare_4176" order="5.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="Locator_us-gaap_AccruedLiabilitiesCurrent_4177" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedMedicareCapLiability" xlink:label="Locator_amed_EstimatedMedicareCapLiability_4178" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_AccruedLiabilitiesCurrent_4177" xlink:to="Locator_amed_EstimatedMedicareCapLiability_4178" order="6.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="Locator_us-gaap_AccruedLiabilitiesCurrent_4179" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="Locator_us-gaap_OtherAccruedLiabilitiesCurrent_4180" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_AccruedLiabilitiesCurrent_4179" xlink:to="Locator_us-gaap_OtherAccruedLiabilitiesCurrent_4180" order="10.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="Locator_us-gaap_AccruedLiabilitiesCurrent_4181" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceCostOfRevenue" xlink:label="Locator_amed_HospiceCostOfRevenue_4182" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_AccruedLiabilitiesCurrent_4181" xlink:to="Locator_amed_HospiceCostOfRevenue_4182" order="7.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="Locator_us-gaap_AccruedLiabilitiesCurrent_4183" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OigSelfDisclsoureAccrual" xlink:label="Locator_amed_OigSelfDisclsoureAccrual_4184" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_AccruedLiabilitiesCurrent_4183" xlink:to="Locator_amed_OigSelfDisclsoureAccrual_4184" order="8.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="Locator_us-gaap_AccruedLiabilitiesCurrent_4185" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PatientLiability" xlink:label="Locator_amed_PatientLiability_4186" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_AccruedLiabilitiesCurrent_4185" xlink:to="Locator_amed_PatientLiability_4186" order="9.0" weight="1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsOtherLongTermObligationsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="Locator_us-gaap_OtherLiabilitiesNoncurrent_4195" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredCompensationPlanLiability" xlink:label="Locator_amed_DeferredCompensationPlanLiability_4196" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_OtherLiabilitiesNoncurrent_4195" xlink:to="Locator_amed_DeferredCompensationPlanLiability_4196" order="2.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="Locator_us-gaap_OtherLiabilitiesNoncurrent_4197" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:label="Locator_us-gaap_OtherSundryLiabilitiesNoncurrent_4198" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_OtherLiabilitiesNoncurrent_4197" xlink:to="Locator_us-gaap_OtherSundryLiabilitiesNoncurrent_4198" order="3.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="Locator_us-gaap_OtherLiabilitiesNoncurrent_4199" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UncertainTaxBenefitsInLongTermObligations" xlink:label="Locator_amed_UncertainTaxBenefitsInLongTermObligations_4200" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_OtherLiabilitiesNoncurrent_4199" xlink:to="Locator_amed_UncertainTaxBenefitsInLongTermObligations_4200" order="1.0" weight="1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/ScheduleOfBalancesRelatedToPropertyAndEquipmentDetails">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentNet_4441" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentGross_4442" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentNet_4441" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentGross_4442" order="5.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentGross_4445" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Land" xlink:label="Locator_us-gaap_Land_4446" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentGross_4445" xlink:to="Locator_us-gaap_Land_4446" order="1.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentGross_4447" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BuildingAndLeaseholdImprovements" xlink:label="Locator_amed_BuildingAndLeaseholdImprovements_4448" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentGross_4447" xlink:to="Locator_amed_BuildingAndLeaseholdImprovements_4448" order="2.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentGross_4449" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquipmentAndFurniture" xlink:label="Locator_amed_EquipmentAndFurniture_4450" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentGross_4449" xlink:to="Locator_amed_EquipmentAndFurniture_4450" order="3.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentGross_4451" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="Locator_us-gaap_CapitalizedComputerSoftwareGross_4452" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentGross_4451" xlink:to="Locator_us-gaap_CapitalizedComputerSoftwareGross_4452" order="4.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentNet_4443" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="Locator_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4444" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentNet_4443" xlink:to="Locator_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4444" order="6.0" weight="-1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureMaturitiesOfDebtDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_4467" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4468" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_4467" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4468" order="1.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_4469" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_4470" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_4469" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_4470" order="2.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_4471" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_4472" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_4471" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_4472" order="3.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_4473" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4474" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_4473" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4474" order="4.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_4475" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_4476" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_4475" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_4476" order="5.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_4477" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_4478" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_4477" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_4478" order="6.0" weight="1" />
    </calculationLink>
    <calculationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/IncomeTaxExpenseAllocationDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:label="Locator_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_4687" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="Locator_us-gaap_IncomeTaxExpenseBenefit_4688" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_4687" xlink:to="Locator_us-gaap_IncomeTaxExpenseBenefit_4688" order="1.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:label="Locator_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_4689" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="Locator_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_4690" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_4689" xlink:to="Locator_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_4690" order="2.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:label="Locator_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_4691" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxEffectsAllocatedToInterestExpense" xlink:label="Locator_amed_IncomeTaxEffectsAllocatedToInterestExpense_4692" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_4691" xlink:to="Locator_amed_IncomeTaxEffectsAllocatedToInterestExpense_4692" order="3.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:label="Locator_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_4693" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityOther" xlink:label="Locator_us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityOther_4694" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_4693" xlink:to="Locator_us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityOther_4694" order="5.0" weight="1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:label="Locator_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_4695" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxEffectsAllocatedToGoodwill" xlink:label="Locator_amed_IncomeTaxEffectsAllocatedToGoodwill_4696" />
        <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Locator_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_4695" xlink:to="Locator_amed_IncomeTaxEffectsAllocatedToGoodwill_4696" order="4.0" weight="1" />
    </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>amed-20161231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Prepared by IBM Cognos FSR v6.7.4.14 using Fujitsu Interstage XWand -->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/instance http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
    <roleRef roleURI="http://www.amedisys.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_DocumentAndEntityInformation" />
    <roleRef roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_CONSOLIDATEDBALANCESHEETS" />
    <roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_CONSOLIDATEDBALANCESHEETSParenthetical" />
    <roleRef roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_CONSOLIDATEDSTATEMENTSOFOPERATIONS" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/ScheduleOfFinancialInstrumentsWhereCarryingValueAndFairValueDifferDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_ScheduleOfFinancialInstrumentsWhereCarryingValueAndFairValueDifferDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureDiscontinuedOperationsAndAssetsHeldForSaleAdditionalInformationDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_DiscontinuedOperationsAndAssetsHeldForSaleAdditionalInformationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/NetRevenuesAndOperatingResultsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_NetRevenuesAndOperatingResultsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureLongTermDebtDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_LongTermDebtDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureLongTermDebtParentheticalDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_LongTermDebtParentheticalDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureLongTermDebtAdditionalInformationDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_LongTermDebtAdditionalInformationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureCommitmentsAndContigenciesDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_CommitmentsAndContigenciesDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureOperatingIncomeOfReportableSegmentsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_OperatingIncomeOfReportableSegmentsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureExitActivitiesDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_ExitActivitiesDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureSubsequentEventDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_SubsequentEventDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureAcquisitionsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_AcquisitionsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureGoodwillAndOtherIntangibleAssetsNetDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_GoodwillAndOtherIntangibleAssetsNetDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureIncomeTaxesDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_IncomeTaxesDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureCapitalStockAndShareBasedCompensationDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_CapitalStockAndShareBasedCompensationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureValuationAndQualifyingAccountsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_ValuationAndQualifyingAccountsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureUnauditedSummarizedQuarterlyFinancialInformationDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_UnauditedSummarizedQuarterlyFinancialInformationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/FutureMinimumRentalCommitmentsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_FutureMinimumRentalCommitmentsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureEmployeeStockPurchasePlanDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_EmployeeStockPurchasePlanDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureStockOptionActivityDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_StockOptionActivityDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureNonVestedStockActivityDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_NonVestedStockActivityDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureNonVestedStockUnitsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_NonVestedStockUnitsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureSummaryOfActivityRelatedToGoodwillDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_SummaryOfActivityRelatedToGoodwillDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureSummaryOfActivityRelatedToOtherIntangibleAssetsNetDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_SummaryOfActivityRelatedToOtherIntangibleAssetsNetDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/SummaryOfActivityRelatedToOtherIntangibleAssetsNetParentheticalDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_SummaryOfActivityRelatedToOtherIntangibleAssetsNetParentheticalDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureCommitmentFeeUnderCreditFacilitiesDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_CommitmentFeeUnderCreditFacilitiesDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureExitActivitiesReserveActivityDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_ExitActivitiesReserveActivityDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureNonVestedStockOptionActivityDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_NonVestedStockOptionActivityDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/RelatedPartyTransactionDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_RelatedPartyTransactionDetail" />
    <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
    <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
    <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
    <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
    <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DocumentAndEntityInformation">
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_37" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_38" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_dei_LegalEntityAxis_37" xlink:to="Locator_dei_EntityDomain_38" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_31" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntitiesTable" xlink:label="Locator_dei_EntitiesTable_32" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_dei_DocumentInformationLineItems_31" xlink:to="Locator_dei_EntitiesTable_32" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntitiesTable" xlink:label="Locator_dei_EntitiesTable_35" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_36" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_dei_EntitiesTable_35" xlink:to="Locator_dei_LegalEntityAxis_36" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_39" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="Locator_dei_DocumentType_40" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_39" xlink:to="Locator_dei_DocumentType_40" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_41" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="Locator_dei_AmendmentFlag_42" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_41" xlink:to="Locator_dei_AmendmentFlag_42" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_43" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="Locator_dei_DocumentPeriodEndDate_44" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_43" xlink:to="Locator_dei_DocumentPeriodEndDate_44" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_45" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="Locator_dei_DocumentFiscalYearFocus_46" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_45" xlink:to="Locator_dei_DocumentFiscalYearFocus_46" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_47" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="Locator_dei_DocumentFiscalPeriodFocus_48" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_47" xlink:to="Locator_dei_DocumentFiscalPeriodFocus_48" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_49" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="Locator_dei_TradingSymbol_50" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_49" xlink:to="Locator_dei_TradingSymbol_50" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_51" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="Locator_dei_EntityRegistrantName_52" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_51" xlink:to="Locator_dei_EntityRegistrantName_52" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_53" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="Locator_dei_EntityCentralIndexKey_54" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_53" xlink:to="Locator_dei_EntityCentralIndexKey_54" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_55" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="Locator_dei_CurrentFiscalYearEndDate_56" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_55" xlink:to="Locator_dei_CurrentFiscalYearEndDate_56" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_57" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="Locator_dei_EntityFilerCategory_58" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_57" xlink:to="Locator_dei_EntityFilerCategory_58" order="10.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_59" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="Locator_dei_EntityCommonStockSharesOutstanding_60" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_59" xlink:to="Locator_dei_EntityCommonStockSharesOutstanding_60" order="11.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_61" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="Locator_dei_EntityPublicFloat_62" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_61" xlink:to="Locator_dei_EntityPublicFloat_62" order="12.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_63" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="Locator_dei_EntityVoluntaryFilers_64" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_63" xlink:to="Locator_dei_EntityVoluntaryFilers_64" order="13.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_65" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="Locator_dei_EntityCurrentReportingStatus_66" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_65" xlink:to="Locator_dei_EntityCurrentReportingStatus_66" order="14.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_67" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="Locator_dei_EntityWellKnownSeasonedIssuer_68" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_DocumentInformationLineItems_67" xlink:to="Locator_dei_EntityWellKnownSeasonedIssuer_68" order="15.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/StatementCONSOLIDATEDBALANCESHEETS">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_223" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_224" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_223" xlink:to="Locator_us-gaap_AssetsAbstract_224" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_225" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_226" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsAbstract_225" xlink:to="Locator_us-gaap_AssetsCurrentAbstract_226" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_227" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="Locator_us-gaap_CashAndCashEquivalentsAtCarryingValue_228" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_227" xlink:to="Locator_us-gaap_CashAndCashEquivalentsAtCarryingValue_228" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_229" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="Locator_us-gaap_AccountsReceivableNetCurrent_230" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_229" xlink:to="Locator_us-gaap_AccountsReceivableNetCurrent_230" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_231" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="Locator_us-gaap_PrepaidExpenseCurrent_232" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_231" xlink:to="Locator_us-gaap_PrepaidExpenseCurrent_232" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_233" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="Locator_us-gaap_DeferredTaxAssetsNetCurrent_234" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_233" xlink:to="Locator_us-gaap_DeferredTaxAssetsNetCurrent_234" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_235" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="Locator_us-gaap_OtherAssetsCurrent_236" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_235" xlink:to="Locator_us-gaap_OtherAssetsCurrent_236" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_237" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="Locator_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_238" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_237" xlink:to="Locator_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_238" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_239" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="Locator_us-gaap_AssetsCurrent_240" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_239" xlink:to="Locator_us-gaap_AssetsCurrent_240" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_241" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentNet_242" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsAbstract_241" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentNet_242" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_243" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="Locator_us-gaap_Goodwill_244" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsAbstract_243" xlink:to="Locator_us-gaap_Goodwill_244" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_245" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="Locator_us-gaap_IntangibleAssetsNetExcludingGoodwill_246" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsAbstract_245" xlink:to="Locator_us-gaap_IntangibleAssetsNetExcludingGoodwill_246" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_247" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="Locator_us-gaap_DeferredTaxAssetsNetNoncurrent_248" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsAbstract_247" xlink:to="Locator_us-gaap_DeferredTaxAssetsNetNoncurrent_248" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_249" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="Locator_us-gaap_OtherAssetsNoncurrent_250" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsAbstract_249" xlink:to="Locator_us-gaap_OtherAssetsNoncurrent_250" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_251" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="Locator_us-gaap_Assets_252" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_AssetsAbstract_251" xlink:to="Locator_us-gaap_Assets_252" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_253" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_254" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_253" xlink:to="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_254" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_255" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_256" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_255" xlink:to="Locator_us-gaap_LiabilitiesCurrentAbstract_256" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_257" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="Locator_us-gaap_AccountsPayableCurrent_258" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_257" xlink:to="Locator_us-gaap_AccountsPayableCurrent_258" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_259" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement_260" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_259" xlink:to="Locator_amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement_260" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_261" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="Locator_us-gaap_EmployeeRelatedLiabilitiesCurrent_262" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_261" xlink:to="Locator_us-gaap_EmployeeRelatedLiabilitiesCurrent_262" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_263" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="Locator_us-gaap_AccruedLiabilitiesCurrent_264" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_263" xlink:to="Locator_us-gaap_AccruedLiabilitiesCurrent_264" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_265" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_266" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_265" xlink:to="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_266" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_267" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="Locator_us-gaap_DeferredTaxLiabilitiesCurrent_268" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_267" xlink:to="Locator_us-gaap_DeferredTaxLiabilitiesCurrent_268" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_269" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="Locator_us-gaap_LiabilitiesCurrent_270" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_269" xlink:to="Locator_us-gaap_LiabilitiesCurrent_270" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_271" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligations_272" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_271" xlink:to="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligations_272" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_273" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="Locator_us-gaap_OtherLiabilitiesNoncurrent_274" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_273" xlink:to="Locator_us-gaap_OtherLiabilitiesNoncurrent_274" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_275" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="Locator_us-gaap_Liabilities_276" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_275" xlink:to="Locator_us-gaap_Liabilities_276" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_277" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="Locator_us-gaap_CommitmentsAndContingencies_278" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_277" xlink:to="Locator_us-gaap_CommitmentsAndContingencies_278" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_279" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_280" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_279" xlink:to="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_280" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_281" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="Locator_us-gaap_PreferredStockValueOutstanding_282" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_281" xlink:to="Locator_us-gaap_PreferredStockValueOutstanding_282" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_283" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="Locator_us-gaap_CommonStockValueOutstanding_284" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_283" xlink:to="Locator_us-gaap_CommonStockValueOutstanding_284" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_285" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="Locator_us-gaap_AdditionalPaidInCapitalCommonStock_286" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_285" xlink:to="Locator_us-gaap_AdditionalPaidInCapitalCommonStock_286" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_287" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="Locator_us-gaap_TreasuryStockValue_288" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_287" xlink:to="Locator_us-gaap_TreasuryStockValue_288" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_289" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="Locator_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_290" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_289" xlink:to="Locator_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_290" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_291" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="Locator_us-gaap_RetainedEarningsAccumulatedDeficit_292" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_291" xlink:to="Locator_us-gaap_RetainedEarningsAccumulatedDeficit_292" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_293" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="Locator_us-gaap_StockholdersEquity_294" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_293" xlink:to="Locator_us-gaap_StockholdersEquity_294" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_295" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterest" xlink:label="Locator_us-gaap_MinorityInterest_296" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_295" xlink:to="Locator_us-gaap_MinorityInterest_296" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_297" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_298" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_297" xlink:to="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_298" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_299" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquity_300" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_299" xlink:to="Locator_us-gaap_LiabilitiesAndStockholdersEquity_300" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_79" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_80" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_StatementLineItems_79" xlink:to="Locator_us-gaap_StatementTable_80" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_219" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_220" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_StatementTable_219" xlink:to="Locator_dei_LegalEntityAxis_220" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_221" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_222" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_dei_LegalEntityAxis_221" xlink:to="Locator_dei_EntityDomain_222" order="1.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_339" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="Locator_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_340" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_339" xlink:to="Locator_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_340" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_341" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="Locator_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_342" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_341" xlink:to="Locator_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_342" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_343" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_344" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_343" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_344" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_345" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="Locator_us-gaap_PreferredStockParOrStatedValuePerShare_346" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_345" xlink:to="Locator_us-gaap_PreferredStockParOrStatedValuePerShare_346" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_347" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="Locator_us-gaap_PreferredStockSharesAuthorized_348" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_347" xlink:to="Locator_us-gaap_PreferredStockSharesAuthorized_348" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_349" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="Locator_us-gaap_PreferredStockSharesIssued_350" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_349" xlink:to="Locator_us-gaap_PreferredStockSharesIssued_350" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_351" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="Locator_us-gaap_PreferredStockSharesOutstanding_352" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_351" xlink:to="Locator_us-gaap_PreferredStockSharesOutstanding_352" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_353" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="Locator_us-gaap_CommonStockParOrStatedValuePerShare_354" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_353" xlink:to="Locator_us-gaap_CommonStockParOrStatedValuePerShare_354" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_355" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="Locator_us-gaap_CommonStockSharesAuthorized_356" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_355" xlink:to="Locator_us-gaap_CommonStockSharesAuthorized_356" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_357" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="Locator_us-gaap_CommonStockSharesIssued_358" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_357" xlink:to="Locator_us-gaap_CommonStockSharesIssued_358" order="10.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_359" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="Locator_us-gaap_CommonStockSharesOutstanding_360" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_359" xlink:to="Locator_us-gaap_CommonStockSharesOutstanding_360" order="11.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_361" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="Locator_us-gaap_TreasuryStockShares_362" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_361" xlink:to="Locator_us-gaap_TreasuryStockShares_362" order="12.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_331" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_332" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_StatementLineItems_331" xlink:to="Locator_us-gaap_StatementTable_332" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_335" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_336" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_StatementTable_335" xlink:to="Locator_dei_LegalEntityAxis_336" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_337" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_338" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_dei_LegalEntityAxis_337" xlink:to="Locator_dei_EntityDomain_338" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_363" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_364" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_dei_LegalEntityAxis_363" xlink:to="Locator_dei_EntityDomain_364" order="1.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_509" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationPatientServiceRevenue" xlink:label="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_510" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_509" xlink:to="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_510" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_511" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfServices" xlink:label="Locator_us-gaap_CostOfServices_512" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_511" xlink:to="Locator_us-gaap_CostOfServices_512" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_513" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_514" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_513" xlink:to="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_514" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_515" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="Locator_us-gaap_LaborAndRelatedExpense_516" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_515" xlink:to="Locator_us-gaap_LaborAndRelatedExpense_516" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_517" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="Locator_us-gaap_ShareBasedCompensation_518" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_517" xlink:to="Locator_us-gaap_ShareBasedCompensation_518" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_519" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="Locator_us-gaap_OtherGeneralAndAdministrativeExpense_520" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_519" xlink:to="Locator_us-gaap_OtherGeneralAndAdministrativeExpense_520" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_521" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProvisionForDoubtfulAccountsForContinuingOperations" xlink:label="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_522" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_521" xlink:to="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_522" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_523" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DepreciationAndAmortizationForContinuingOperations" xlink:label="Locator_amed_DepreciationAndAmortizationForContinuingOperations_524" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_523" xlink:to="Locator_amed_DepreciationAndAmortizationForContinuingOperations_524" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_525" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_UsDepartmentOfJusticeSettlement_526" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_525" xlink:to="Locator_amed_UsDepartmentOfJusticeSettlement_526" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_527" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="Locator_us-gaap_AssetImpairmentCharges_528" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_527" xlink:to="Locator_us-gaap_AssetImpairmentCharges_528" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_529" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_530" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_529" xlink:to="Locator_us-gaap_CostsAndExpenses_530" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_531" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="Locator_us-gaap_OperatingIncomeLoss_532" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_531" xlink:to="Locator_us-gaap_OperatingIncomeLoss_532" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_533" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_534" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_533" xlink:to="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_534" order="10.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_535" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="Locator_us-gaap_InvestmentIncomeInterestAndDividend_536" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_535" xlink:to="Locator_us-gaap_InvestmentIncomeInterestAndDividend_536" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_537" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="Locator_us-gaap_InterestExpense_538" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_537" xlink:to="Locator_us-gaap_InterestExpense_538" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_539" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="Locator_us-gaap_IncomeLossFromEquityMethodInvestments_540" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_539" xlink:to="Locator_us-gaap_IncomeLossFromEquityMethodInvestments_540" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_541" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="Locator_us-gaap_OtherNonoperatingIncomeExpense_542" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_541" xlink:to="Locator_us-gaap_OtherNonoperatingIncomeExpense_542" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_543" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="Locator_us-gaap_NonoperatingIncomeExpense_544" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_543" xlink:to="Locator_us-gaap_NonoperatingIncomeExpense_544" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_545" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_546" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_545" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_546" order="11.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_547" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="Locator_us-gaap_IncomeTaxExpenseBenefit_548" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_547" xlink:to="Locator_us-gaap_IncomeTaxExpenseBenefit_548" order="12.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_549" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_550" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_549" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_550" order="13.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_551" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_552" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_551" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_552" order="14.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_555" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_556" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_555" xlink:to="Locator_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_556" order="16.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_557" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="Locator_us-gaap_EarningsPerShareBasicAbstract_558" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_557" xlink:to="Locator_us-gaap_EarningsPerShareBasicAbstract_558" order="18.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="Locator_us-gaap_EarningsPerShareBasicAbstract_559" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_560" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EarningsPerShareBasicAbstract_559" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_560" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="Locator_us-gaap_EarningsPerShareBasicAbstract_561" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_562" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EarningsPerShareBasicAbstract_561" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_562" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="Locator_us-gaap_EarningsPerShareBasicAbstract_563" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="Locator_us-gaap_EarningsPerShareBasic_564" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EarningsPerShareBasicAbstract_563" xlink:to="Locator_us-gaap_EarningsPerShareBasic_564" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_565" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="Locator_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_566" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_565" xlink:to="Locator_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_566" order="19.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_567" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="Locator_us-gaap_EarningsPerShareDilutedAbstract_568" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_567" xlink:to="Locator_us-gaap_EarningsPerShareDilutedAbstract_568" order="20.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="Locator_us-gaap_EarningsPerShareDilutedAbstract_569" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_570" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EarningsPerShareDilutedAbstract_569" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_570" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="Locator_us-gaap_EarningsPerShareDilutedAbstract_571" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_572" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EarningsPerShareDilutedAbstract_571" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_572" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="Locator_us-gaap_EarningsPerShareDilutedAbstract_573" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="Locator_us-gaap_EarningsPerShareDiluted_574" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EarningsPerShareDilutedAbstract_573" xlink:to="Locator_us-gaap_EarningsPerShareDiluted_574" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_575" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_576" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_575" xlink:to="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_576" order="21.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_577" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_578" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_577" xlink:to="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_578" order="22.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_579" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperations_580" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_579" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperations_580" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_581" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_582" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_581" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_582" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_583" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="Locator_us-gaap_NetIncomeLoss_584" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_583" xlink:to="Locator_us-gaap_NetIncomeLoss_584" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_415" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_416" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_StatementLineItems_415" xlink:to="Locator_us-gaap_StatementTable_416" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_505" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_506" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_StatementTable_505" xlink:to="Locator_dei_LegalEntityAxis_506" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_507" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_508" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_dei_LegalEntityAxis_507" xlink:to="Locator_dei_EntityDomain_508" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_553" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="Locator_us-gaap_ProfitLoss_554" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_553" xlink:to="Locator_us-gaap_ProfitLoss_554" order="15.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_909" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_910" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_909" xlink:to="Locator_us-gaap_SegmentDomain_910" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_965" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_966" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_965" xlink:to="Locator_us-gaap_SegmentDomain_966" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_915" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceInpatientMember" xlink:label="Locator_amed_HospiceInpatientMember_916" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_915" xlink:to="Locator_amed_HospiceInpatientMember_916" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_911" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_912" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_911" xlink:to="Locator_amed_HomeHealthMember_912" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_913" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_914" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_913" xlink:to="Locator_amed_HospiceMember_914" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_917" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PersonalCareMember" xlink:label="Locator_amed_PersonalCareMember_918" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_917" xlink:to="Locator_amed_PersonalCareMember_918" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_897" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsTable_898" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_897" xlink:to="Locator_amed_OrganizationAndNatureOfOperationsTable_898" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsTable_901" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_902" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsTable_901" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_902" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsTable_903" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="Locator_us-gaap_ConcentrationRiskByTypeAxis_904" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsTable_903" xlink:to="Locator_us-gaap_ConcentrationRiskByTypeAxis_904" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="Locator_us-gaap_ConcentrationRiskByTypeAxis_919" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="Locator_us-gaap_ConcentrationRiskTypeDomain_920" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_ConcentrationRiskByTypeAxis_919" xlink:to="Locator_us-gaap_ConcentrationRiskTypeDomain_920" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="Locator_us-gaap_ConcentrationRiskByTypeAxis_967" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="Locator_us-gaap_ConcentrationRiskTypeDomain_968" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_ConcentrationRiskByTypeAxis_967" xlink:to="Locator_us-gaap_ConcentrationRiskTypeDomain_968" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="Locator_us-gaap_ConcentrationRiskTypeDomain_921" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="Locator_us-gaap_CustomerConcentrationRiskMember_922" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ConcentrationRiskTypeDomain_921" xlink:to="Locator_us-gaap_CustomerConcentrationRiskMember_922" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsTable_905" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_906" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsTable_905" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_906" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_923" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_924" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_923" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsDomain_924" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_925" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentsMember" xlink:label="Locator_us-gaap_EquityMethodInvestmentsMember_926" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsDomain_925" xlink:to="Locator_us-gaap_EquityMethodInvestmentsMember_926" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsTable_907" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="Locator_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_908" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsTable_907" xlink:to="Locator_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_908" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="Locator_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_927" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="Locator_us-gaap_EquityMethodInvesteeNameDomain_928" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_927" xlink:to="Locator_us-gaap_EquityMethodInvesteeNameDomain_928" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="Locator_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_969" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="Locator_us-gaap_EquityMethodInvesteeNameDomain_970" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_969" xlink:to="Locator_us-gaap_EquityMethodInvesteeNameDomain_970" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="Locator_us-gaap_EquityMethodInvesteeNameDomain_929" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HeritageHealthcareInnovationFundMember" xlink:label="Locator_amed_HeritageHealthcareInnovationFundMember_930" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EquityMethodInvesteeNameDomain_929" xlink:to="Locator_amed_HeritageHealthcareInnovationFundMember_930" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_931" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="Locator_us-gaap_ConcentrationRiskPercentage1_932" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_931" xlink:to="Locator_us-gaap_ConcentrationRiskPercentage1_932" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_933" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingCareCenters" xlink:label="Locator_amed_OperatingCareCenters_934" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_933" xlink:to="Locator_amed_OperatingCareCenters_934" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_935" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates" xlink:label="Locator_us-gaap_NumberOfStatesInWhichEntityOperates_936" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_935" xlink:to="Locator_us-gaap_NumberOfStatesInWhichEntityOperates_936" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_937" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:label="Locator_amed_MinimumPercentOwnershipForControllingInterestPercent_938" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_937" xlink:to="Locator_amed_MinimumPercentOwnershipForControllingInterestPercent_938" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_939" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="Locator_us-gaap_EquityMethodInvestmentAggregateCost_940" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_939" xlink:to="Locator_us-gaap_EquityMethodInvestmentAggregateCost_940" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_941" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostMethodInvestments" xlink:label="Locator_us-gaap_CostMethodInvestments_942" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_941" xlink:to="Locator_us-gaap_CostMethodInvestments_942" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_943" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:label="Locator_amed_MaximumPercentOwnershipForEquityMethodPercent_944" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_943" xlink:to="Locator_amed_MaximumPercentOwnershipForEquityMethodPercent_944" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_945" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumPercentOwnershipForCostMethodPercent" xlink:label="Locator_amed_MaximumPercentOwnershipForCostMethodPercent_946" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_945" xlink:to="Locator_amed_MaximumPercentOwnershipForCostMethodPercent_946" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_947" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="Locator_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_948" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_947" xlink:to="Locator_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_948" order="9.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_949" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="Locator_us-gaap_GoodwillImpairmentLoss_950" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_949" xlink:to="Locator_us-gaap_GoodwillImpairmentLoss_950" order="10.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_951" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets" xlink:label="Locator_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets_952" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_951" xlink:to="Locator_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets_952" order="11.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_953" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" xlink:label="Locator_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_954" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_953" xlink:to="Locator_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_954" order="12.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_955" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" xlink:label="Locator_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_956" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_955" xlink:to="Locator_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_956" order="13.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_957" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities" xlink:label="Locator_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities_958" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_957" xlink:to="Locator_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities_958" order="14.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_959" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome" xlink:label="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome_960" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_959" xlink:to="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome_960" order="15.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_961" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses" xlink:label="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses_962" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_961" xlink:to="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses_962" order="16.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_963" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations" xlink:label="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations_964" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_963" xlink:to="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations_964" order="17.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1111" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1112" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_DebtInstrumentTable_1111" xlink:to="Locator_us-gaap_LongtermDebtTypeAxis_1112" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1115" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1116" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_LongtermDebtTypeAxis_1115" xlink:to="Locator_us-gaap_LongtermDebtTypeDomain_1116" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1123" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredDebtIssuanceCostsMember" xlink:label="Locator_amed_DeferredDebtIssuanceCostsMember_1124" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1123" xlink:to="Locator_amed_DeferredDebtIssuanceCostsMember_1124" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1117" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondLienCreditAgreementTermLoanMember" xlink:label="Locator_amed_SecondLienCreditAgreementTermLoanMember_1118" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1117" xlink:to="Locator_amed_SecondLienCreditAgreementTermLoanMember_1118" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1119" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CreditAgreementMember" xlink:label="Locator_amed_CreditAgreementMember_1120" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1119" xlink:to="Locator_amed_CreditAgreementMember_1120" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1121" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondLienCreditAgreementRevolvingCreditFacilityMember" xlink:label="Locator_amed_SecondLienCreditAgreementRevolvingCreditFacilityMember_1122" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1121" xlink:to="Locator_amed_SecondLienCreditAgreementRevolvingCreditFacilityMember_1122" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_1125" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1126" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_1125" xlink:to="Locator_us-gaap_SegmentDomain_1126" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1127" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_1128" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_1127" xlink:to="Locator_amed_HomeHealthMember_1128" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1129" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_1130" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_1129" xlink:to="Locator_amed_HospiceMember_1130" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1225" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InternallyDevelopedComputerSoftware" xlink:label="Locator_amed_InternallyDevelopedComputerSoftware_1226" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1225" xlink:to="Locator_amed_InternallyDevelopedComputerSoftware_1226" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1227" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InternallyDevelopedComputerSoftwareAmortizationPeriod" xlink:label="Locator_amed_InternallyDevelopedComputerSoftwareAmortizationPeriod_1228" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1227" xlink:to="Locator_amed_InternallyDevelopedComputerSoftwareAmortizationPeriod_1228" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1229" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="Locator_us-gaap_Depreciation_1230" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1229" xlink:to="Locator_us-gaap_Depreciation_1230" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1083" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1084" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1083" xlink:to="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1084" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1113" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_1114" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1113" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_1114" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1051" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1052" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1051" xlink:to="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1052" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1101" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearAxis" xlink:label="Locator_amed_CapYearAxis_1102" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1101" xlink:to="Locator_amed_CapYearAxis_1102" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearAxis" xlink:label="Locator_amed_CapYearAxis_1131" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearDomain" xlink:label="Locator_amed_CapYearDomain_1132" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_CapYearAxis_1131" xlink:to="Locator_amed_CapYearDomain_1132" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearAxis" xlink:label="Locator_amed_CapYearAxis_1231" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearDomain" xlink:label="Locator_amed_CapYearDomain_1232" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_amed_CapYearAxis_1231" xlink:to="Locator_amed_CapYearDomain_1232" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearDomain" xlink:label="Locator_amed_CapYearDomain_1133" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember" xlink:label="Locator_amed_CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember_1134" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CapYearDomain_1133" xlink:to="Locator_amed_CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember_1134" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearDomain" xlink:label="Locator_amed_CapYearDomain_1135" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandFifteenMember" xlink:label="Locator_amed_CapYearTwoThousandThirteenThroughTwoThousandFifteenMember_1136" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CapYearDomain_1135" xlink:to="Locator_amed_CapYearTwoThousandThirteenThroughTwoThousandFifteenMember_1136" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1103" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssetImpairmentAxis" xlink:label="Locator_amed_AssetImpairmentAxis_1104" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1103" xlink:to="Locator_amed_AssetImpairmentAxis_1104" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssetImpairmentAxis" xlink:label="Locator_amed_AssetImpairmentAxis_1137" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssetImpairmentDomain" xlink:label="Locator_amed_AssetImpairmentDomain_1138" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_AssetImpairmentAxis_1137" xlink:to="Locator_amed_AssetImpairmentDomain_1138" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssetImpairmentAxis" xlink:label="Locator_amed_AssetImpairmentAxis_1233" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssetImpairmentDomain" xlink:label="Locator_amed_AssetImpairmentDomain_1234" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_amed_AssetImpairmentAxis_1233" xlink:to="Locator_amed_AssetImpairmentDomain_1234" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssetImpairmentDomain" xlink:label="Locator_amed_AssetImpairmentDomain_1139" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Ams3HomecareAndHospiceMember" xlink:label="Locator_amed_Ams3HomecareAndHospiceMember_1140" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_AssetImpairmentDomain_1139" xlink:to="Locator_amed_Ams3HomecareAndHospiceMember_1140" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssetImpairmentDomain" xlink:label="Locator_amed_AssetImpairmentDomain_1141" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CorporateHeadquartersMember" xlink:label="Locator_amed_CorporateHeadquartersMember_1142" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_AssetImpairmentDomain_1141" xlink:to="Locator_amed_CorporateHeadquartersMember_1142" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssetImpairmentDomain" xlink:label="Locator_amed_AssetImpairmentDomain_1143" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomecareHomebaseMember" xlink:label="Locator_amed_HomecareHomebaseMember_1144" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_AssetImpairmentDomain_1143" xlink:to="Locator_amed_HomecareHomebaseMember_1144" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1159" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenue" xlink:label="Locator_amed_EpisodeOfCareAsEpisodicBasedRevenue_1160" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1159" xlink:to="Locator_amed_EpisodeOfCareAsEpisodicBasedRevenue_1160" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1161" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:label="Locator_amed_PercentageOfTotalReimbursementOfOutlierPayment_1162" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1161" xlink:to="Locator_amed_PercentageOfTotalReimbursementOfOutlierPayment_1162" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1163" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:label="Locator_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1164" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1163" xlink:to="Locator_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1164" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1165" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FirstThresholdOfTherapyServicesRequired" xlink:label="Locator_amed_FirstThresholdOfTherapyServicesRequired_1166" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1165" xlink:to="Locator_amed_FirstThresholdOfTherapyServicesRequired_1166" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1167" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondThresholdOfServicesRequired" xlink:label="Locator_amed_SecondThresholdOfServicesRequired_1168" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1167" xlink:to="Locator_amed_SecondThresholdOfServicesRequired_1168" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1169" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ThirdThresholdOfTherapyServicesRequired" xlink:label="Locator_amed_ThirdThresholdOfTherapyServicesRequired_1170" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1169" xlink:to="Locator_amed_ThirdThresholdOfTherapyServicesRequired_1170" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1171" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CmsTherapyAssessmentRequirementIntervalMinimum" xlink:label="Locator_amed_CmsTherapyAssessmentRequirementIntervalMinimum_1172" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1171" xlink:to="Locator_amed_CmsTherapyAssessmentRequirementIntervalMinimum_1172" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1173" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HistoricalCollectionRateFromMedicare" xlink:label="Locator_amed_HistoricalCollectionRateFromMedicare_1174" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1173" xlink:to="Locator_amed_HistoricalCollectionRateFromMedicare_1174" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1175" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EpisodesInProgressThatBeginDuringReportingPeriod" xlink:label="Locator_amed_EpisodesInProgressThatBeginDuringReportingPeriod_1176" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1175" xlink:to="Locator_amed_EpisodesInProgressThatBeginDuringReportingPeriod_1176" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1177" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:label="Locator_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_1178" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1177" xlink:to="Locator_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_1178" order="10.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1179" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:label="Locator_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_1180" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1179" xlink:to="Locator_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_1180" order="11.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1181" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CmsHospiceFaceToFaceRequirementPriorToThirdBenefitPeriod" xlink:label="Locator_amed_CmsHospiceFaceToFaceRequirementPriorToThirdBenefitPeriod_1182" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1181" xlink:to="Locator_amed_CmsHospiceFaceToFaceRequirementPriorToThirdBenefitPeriod_1182" order="12.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1183" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DaysInHospiceRecertificationThirdBenefitPeriod" xlink:label="Locator_amed_DaysInHospiceRecertificationThirdBenefitPeriod_1184" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1183" xlink:to="Locator_amed_DaysInHospiceRecertificationThirdBenefitPeriod_1184" order="13.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1185" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfPatientReceivablesOutstanding" xlink:label="Locator_amed_PercentageOfPatientReceivablesOutstanding_1186" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1185" xlink:to="Locator_amed_PercentageOfPatientReceivablesOutstanding_1186" order="14.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1187" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfPatientReceivablesOutstandingOverTenPercent" xlink:label="Locator_amed_PercentageOfPatientReceivablesOutstandingOverTenPercent_1188" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1187" xlink:to="Locator_amed_PercentageOfPatientReceivablesOutstandingOverTenPercent_1188" order="15.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1189" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MinimumDaysAccountsReceivableOutstandingFullyReserved" xlink:label="Locator_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved_1190" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1189" xlink:to="Locator_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved_1190" order="16.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1191" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" xlink:label="Locator_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_1192" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1191" xlink:to="Locator_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_1192" order="17.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1193" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RevenueAdjustmentToMedicareRevenue" xlink:label="Locator_amed_RevenueAdjustmentToMedicareRevenue_1194" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1193" xlink:to="Locator_amed_RevenueAdjustmentToMedicareRevenue_1194" order="18.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1195" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare" xlink:label="Locator_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_1196" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1195" xlink:to="Locator_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_1196" order="19.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1197" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:label="Locator_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_1198" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1197" xlink:to="Locator_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_1198" order="20.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1199" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode" xlink:label="Locator_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_1200" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1199" xlink:to="Locator_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_1200" order="21.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1201" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:label="Locator_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_1202" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1201" xlink:to="Locator_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_1202" order="22.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1203" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="Locator_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1204" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1203" xlink:to="Locator_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1204" order="23.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1205" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="Locator_us-gaap_AssetImpairmentCharges_1206" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1205" xlink:to="Locator_us-gaap_AssetImpairmentCharges_1206" order="24.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1145" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1146" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1145" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1146" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1147" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AcquiredNamesMember" xlink:label="Locator_amed_AcquiredNamesMember_1148" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1147" xlink:to="Locator_amed_AcquiredNamesMember_1148" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1149" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="Locator_us-gaap_NoncompeteAgreementsMember_1150" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1149" xlink:to="Locator_us-gaap_NoncompeteAgreementsMember_1150" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_1151" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_1152" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_1151" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsDomain_1152" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_1153" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AnnualImpairmentTestStepOneMember" xlink:label="Locator_amed_AnnualImpairmentTestStepOneMember_1154" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsDomain_1153" xlink:to="Locator_amed_AnnualImpairmentTestStepOneMember_1154" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesLineItems" xlink:label="Locator_amed_IncomeTaxesLineItems_1059" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesTable" xlink:label="Locator_amed_IncomeTaxesTable_1060" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_amed_IncomeTaxesLineItems_1059" xlink:to="Locator_amed_IncomeTaxesTable_1060" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesTable" xlink:label="Locator_amed_IncomeTaxesTable_1105" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesAxis" xlink:label="Locator_amed_IncomeTaxesAxis_1106" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_IncomeTaxesTable_1105" xlink:to="Locator_amed_IncomeTaxesAxis_1106" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesAxis" xlink:label="Locator_amed_IncomeTaxesAxis_1155" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesDomain" xlink:label="Locator_amed_IncomeTaxesDomain_1156" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_IncomeTaxesAxis_1155" xlink:to="Locator_amed_IncomeTaxesDomain_1156" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesAxis" xlink:label="Locator_amed_IncomeTaxesAxis_1235" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesDomain" xlink:label="Locator_amed_IncomeTaxesDomain_1236" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_amed_IncomeTaxesAxis_1235" xlink:to="Locator_amed_IncomeTaxesDomain_1236" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesDomain" xlink:label="Locator_amed_IncomeTaxesDomain_1157" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UsDepartmentOfJusticeSettlementMember" xlink:label="Locator_amed_UsDepartmentOfJusticeSettlementMember_1158" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxesDomain_1157" xlink:to="Locator_amed_UsDepartmentOfJusticeSettlementMember_1158" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesLineItems" xlink:label="Locator_amed_IncomeTaxesLineItems_1207" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent" xlink:label="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent_1208" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxesLineItems_1207" xlink:to="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent_1208" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesLineItems" xlink:label="Locator_amed_IncomeTaxesLineItems_1209" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_1210" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxesLineItems_1209" xlink:to="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_1210" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesLineItems" xlink:label="Locator_amed_IncomeTaxesLineItems_1211" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNet_1212" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxesLineItems_1211" xlink:to="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNet_1212" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_1213" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedUsefulLifeOfIntangibleAssets" xlink:label="Locator_amed_EstimatedUsefulLifeOfIntangibleAssets_1214" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_1213" xlink:to="Locator_amed_EstimatedUsefulLifeOfIntangibleAssets_1214" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_1063" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_1064" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_1063" xlink:to="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_1064" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_1109" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_1110" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_1109" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_1110" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_1107" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1108" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_1107" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1108" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtIssuanceCostsLineItems" xlink:label="Locator_amed_DebtIssuanceCostsLineItems_1075" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1076" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_amed_DebtIssuanceCostsLineItems_1075" xlink:to="Locator_us-gaap_DebtInstrumentTable_1076" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtIssuanceCostsLineItems" xlink:label="Locator_amed_DebtIssuanceCostsLineItems_1215" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="Locator_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1216" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_DebtIssuanceCostsLineItems_1215" xlink:to="Locator_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1216" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtIssuanceCostsLineItems" xlink:label="Locator_amed_DebtIssuanceCostsLineItems_1217" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="Locator_us-gaap_WriteOffOfDeferredDebtIssuanceCost_1218" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_DebtIssuanceCostsLineItems_1217" xlink:to="Locator_us-gaap_WriteOffOfDeferredDebtIssuanceCost_1218" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtIssuanceCostsLineItems" xlink:label="Locator_amed_DebtIssuanceCostsLineItems_1219" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="Locator_us-gaap_DebtIssuanceCosts_1220" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_DebtIssuanceCostsLineItems_1219" xlink:to="Locator_us-gaap_DebtIssuanceCosts_1220" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtIssuanceCostsLineItems" xlink:label="Locator_amed_DebtIssuanceCostsLineItems_1221" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="Locator_us-gaap_UnamortizedDebtIssuanceExpense_1222" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_DebtIssuanceCostsLineItems_1221" xlink:to="Locator_us-gaap_UnamortizedDebtIssuanceExpense_1222" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtIssuanceCostsLineItems" xlink:label="Locator_amed_DebtIssuanceCostsLineItems_1223" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnamortizedDebtIssuanceCostAmortizatinPeriod" xlink:label="Locator_amed_UnamortizedDebtIssuanceCostAmortizatinPeriod_1224" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_DebtIssuanceCostsLineItems_1223" xlink:to="Locator_amed_UnamortizedDebtIssuanceCostAmortizatinPeriod_1224" order="5.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/ScheduleOfFinancialInstrumentsWhereCarryingValueAndFairValueDifferDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1307" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1308" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1307" xlink:to="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1308" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1311" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="Locator_us-gaap_FairValueByFairValueHierarchyLevelAxis_1312" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1311" xlink:to="Locator_us-gaap_FairValueByFairValueHierarchyLevelAxis_1312" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="Locator_us-gaap_FairValueByFairValueHierarchyLevelAxis_1313" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1314" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_FairValueByFairValueHierarchyLevelAxis_1313" xlink:to="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1314" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="Locator_us-gaap_FairValueByFairValueHierarchyLevelAxis_1323" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1324" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_FairValueByFairValueHierarchyLevelAxis_1323" xlink:to="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1324" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1315" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="Locator_us-gaap_FairValueInputsLevel1Member_1316" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1315" xlink:to="Locator_us-gaap_FairValueInputsLevel1Member_1316" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1317" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="Locator_us-gaap_FairValueInputsLevel2Member_1318" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1317" xlink:to="Locator_us-gaap_FairValueInputsLevel2Member_1318" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1319" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="Locator_us-gaap_FairValueInputsLevel3Member_1320" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1319" xlink:to="Locator_us-gaap_FairValueInputsLevel3Member_1320" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1321" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="Locator_us-gaap_LiabilitiesFairValueDisclosure_1322" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1321" xlink:to="Locator_us-gaap_LiabilitiesFairValueDisclosure_1322" order="1.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureDiscontinuedOperationsAndAssetsHeldForSaleAdditionalInformationDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1371" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1372" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1371" xlink:to="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1372" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1375" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_1376" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1375" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_1376" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_1379" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1380" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_1379" xlink:to="Locator_us-gaap_SegmentDomain_1380" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1381" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_1382" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_1381" xlink:to="Locator_amed_HomeHealthMember_1382" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1383" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_1384" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_1383" xlink:to="Locator_amed_HospiceMember_1384" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1377" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:label="Locator_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1378" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1377" xlink:to="Locator_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1378" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:label="Locator_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1385" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="Locator_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1386" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1385" xlink:to="Locator_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1386" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:label="Locator_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1407" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="Locator_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1408" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1407" xlink:to="Locator_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1408" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="Locator_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1387" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="Locator_us-gaap_DiscontinuedOperationsHeldforsaleMember_1388" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1387" xlink:to="Locator_us-gaap_DiscontinuedOperationsHeldforsaleMember_1388" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1389" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersConsolidated" xlink:label="Locator_amed_NumberOfCareCentersConsolidated_1390" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1389" xlink:to="Locator_amed_NumberOfCareCentersConsolidated_1390" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1391" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersClosed" xlink:label="Locator_amed_NumberOfCareCentersClosed_1392" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1391" xlink:to="Locator_amed_NumberOfCareCentersClosed_1392" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1393" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" xlink:label="Locator_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_1394" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1393" xlink:to="Locator_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_1394" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1395" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersExited" xlink:label="Locator_amed_NumberOfCareCentersExited_1396" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1395" xlink:to="Locator_amed_NumberOfCareCentersExited_1396" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1397" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersAvailableForSale" xlink:label="Locator_amed_NumberOfCareCentersAvailableForSale_1398" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1397" xlink:to="Locator_amed_NumberOfCareCentersAvailableForSale_1398" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1399" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersSold" xlink:label="Locator_amed_NumberOfCareCentersSold_1400" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1399" xlink:to="Locator_amed_NumberOfCareCentersSold_1400" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1401" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersIncludedInDivestiturePlan" xlink:label="Locator_amed_NumberOfCareCentersIncludedInDivestiturePlan_1402" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1401" xlink:to="Locator_amed_NumberOfCareCentersIncludedInDivestiturePlan_1402" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1403" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersIncludedInDiscontinuedOperations" xlink:label="Locator_amed_NumberOfCareCentersIncludedInDiscontinuedOperations_1404" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1403" xlink:to="Locator_amed_NumberOfCareCentersIncludedInDiscontinuedOperations_1404" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1405" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_NumberOfCareCentersRemovedFromAvailableForSale_1406" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1405" xlink:to="Locator_amed_NumberOfCareCentersRemovedFromAvailableForSale_1406" order="9.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/NetRevenuesAndOperatingResultsDetail">
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1443" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_1444" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1443" xlink:to="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_1444" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_1453" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareCenterStatusAxis" xlink:label="Locator_amed_CareCenterStatusAxis_1454" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_1453" xlink:to="Locator_amed_CareCenterStatusAxis_1454" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareCenterStatusAxis" xlink:label="Locator_amed_CareCenterStatusAxis_1455" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareCenterStatusDomain" xlink:label="Locator_amed_CareCenterStatusDomain_1456" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_CareCenterStatusAxis_1455" xlink:to="Locator_amed_CareCenterStatusDomain_1456" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareCenterStatusAxis" xlink:label="Locator_amed_CareCenterStatusAxis_1467" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareCenterStatusDomain" xlink:label="Locator_amed_CareCenterStatusDomain_1468" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_amed_CareCenterStatusAxis_1467" xlink:to="Locator_amed_CareCenterStatusDomain_1468" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareCenterStatusDomain" xlink:label="Locator_amed_CareCenterStatusDomain_1457" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareCentersRemovedFromAvailableForSaleMember" xlink:label="Locator_amed_CareCentersRemovedFromAvailableForSaleMember_1458" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CareCenterStatusDomain_1457" xlink:to="Locator_amed_CareCentersRemovedFromAvailableForSaleMember_1458" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1459" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NetRevenueForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_NetRevenueForCareCentersRemovedFromAvailableForSale_1460" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1459" xlink:to="Locator_amed_NetRevenueForCareCentersRemovedFromAvailableForSale_1460" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1461" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale_1462" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1461" xlink:to="Locator_amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale_1462" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1463" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale_1464" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1463" xlink:to="Locator_amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale_1464" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1465" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_1466" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1465" xlink:to="Locator_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_1466" order="4.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureLongTermDebtDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1519" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_1520" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1519" xlink:to="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_1520" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1521" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="Locator_us-gaap_DebtInstrumentUnamortizedDiscount_1522" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1521" xlink:to="Locator_us-gaap_DebtInstrumentUnamortizedDiscount_1522" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1523" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="Locator_us-gaap_UnamortizedDebtIssuanceExpense_1524" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1523" xlink:to="Locator_us-gaap_UnamortizedDebtIssuanceExpense_1524" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1525" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="Locator_us-gaap_LongTermDebtNoncurrent_1526" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1525" xlink:to="Locator_us-gaap_LongTermDebtNoncurrent_1526" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1487" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1488" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1487" xlink:to="Locator_us-gaap_DebtInstrumentTable_1488" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1491" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1492" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_DebtInstrumentTable_1491" xlink:to="Locator_us-gaap_LongtermDebtTypeAxis_1492" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1493" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1494" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_LongtermDebtTypeAxis_1493" xlink:to="Locator_us-gaap_LongtermDebtTypeDomain_1494" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1495" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TermLoanMember" xlink:label="Locator_amed_TermLoanMember_1496" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1495" xlink:to="Locator_amed_TermLoanMember_1496" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1497" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RevolvingCreditFacilitiesMember" xlink:label="Locator_amed_RevolvingCreditFacilitiesMember_1498" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1497" xlink:to="Locator_amed_RevolvingCreditFacilitiesMember_1498" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1499" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SwingLineLoanMember" xlink:label="Locator_amed_SwingLineLoanMember_1500" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1499" xlink:to="Locator_amed_SwingLineLoanMember_1500" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1501" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="Locator_us-gaap_LetterOfCreditMember_1502" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1501" xlink:to="Locator_us-gaap_LetterOfCreditMember_1502" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1503" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesANotesMember" xlink:label="Locator_amed_SeriesANotesMember_1504" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1503" xlink:to="Locator_amed_SeriesANotesMember_1504" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1505" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesBNotesMember" xlink:label="Locator_amed_SeriesBNotesMember_1506" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1505" xlink:to="Locator_amed_SeriesBNotesMember_1506" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1507" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesCNotesMember" xlink:label="Locator_amed_SeriesCNotesMember_1508" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1507" xlink:to="Locator_amed_SeriesCNotesMember_1508" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1509" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondLienCreditAgreementTermLoanMember" xlink:label="Locator_amed_SecondLienCreditAgreementTermLoanMember_1510" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1509" xlink:to="Locator_amed_SecondLienCreditAgreementTermLoanMember_1510" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1513" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OneHundredMillionTermLoanMember" xlink:label="Locator_amed_OneHundredMillionTermLoanMember_1514" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1513" xlink:to="Locator_amed_OneHundredMillionTermLoanMember_1514" order="10.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1515" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1516" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1515" xlink:to="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1516" order="11.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1511" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PromissoryNotesMember" xlink:label="Locator_amed_PromissoryNotesMember_1512" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1511" xlink:to="Locator_amed_PromissoryNotesMember_1512" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1517" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="Locator_us-gaap_LongTermDebt_1518" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1517" xlink:to="Locator_us-gaap_LongTermDebt_1518" order="1.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureLongTermDebtParentheticalDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1609" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="Locator_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_1610" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1609" xlink:to="Locator_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_1610" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1613" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InterestRateOnNotesPayableToBank" xlink:label="Locator_amed_InterestRateOnNotesPayableToBank_1614" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1613" xlink:to="Locator_amed_InterestRateOnNotesPayableToBank_1614" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1617" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="Locator_us-gaap_DebtInstrumentPeriodicPaymentInterest_1618" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1617" xlink:to="Locator_us-gaap_DebtInstrumentPeriodicPaymentInterest_1618" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1569" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1570" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1569" xlink:to="Locator_us-gaap_DebtInstrumentTable_1570" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1573" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1574" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_DebtInstrumentTable_1573" xlink:to="Locator_us-gaap_LongtermDebtTypeAxis_1574" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1577" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1578" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_LongtermDebtTypeAxis_1577" xlink:to="Locator_us-gaap_LongtermDebtTypeDomain_1578" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1621" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1622" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_LongtermDebtTypeAxis_1621" xlink:to="Locator_us-gaap_LongtermDebtTypeDomain_1622" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1579" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TermLoanMember" xlink:label="Locator_amed_TermLoanMember_1580" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1579" xlink:to="Locator_amed_TermLoanMember_1580" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1581" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RevolvingCreditFacilitiesMember" xlink:label="Locator_amed_RevolvingCreditFacilitiesMember_1582" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1581" xlink:to="Locator_amed_RevolvingCreditFacilitiesMember_1582" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1583" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SwingLineLoanMember" xlink:label="Locator_amed_SwingLineLoanMember_1584" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1583" xlink:to="Locator_amed_SwingLineLoanMember_1584" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1585" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="Locator_us-gaap_LetterOfCreditMember_1586" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1585" xlink:to="Locator_us-gaap_LetterOfCreditMember_1586" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1587" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesANotesMember" xlink:label="Locator_amed_SeriesANotesMember_1588" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1587" xlink:to="Locator_amed_SeriesANotesMember_1588" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1589" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesBNotesMember" xlink:label="Locator_amed_SeriesBNotesMember_1590" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1589" xlink:to="Locator_amed_SeriesBNotesMember_1590" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1591" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesCNotesMember" xlink:label="Locator_amed_SeriesCNotesMember_1592" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1591" xlink:to="Locator_amed_SeriesCNotesMember_1592" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1595" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondLienCreditAgreementTermLoanMember" xlink:label="Locator_amed_SecondLienCreditAgreementTermLoanMember_1596" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1595" xlink:to="Locator_amed_SecondLienCreditAgreementTermLoanMember_1596" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1597" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OneHundredMillionTermLoanMember" xlink:label="Locator_amed_OneHundredMillionTermLoanMember_1598" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1597" xlink:to="Locator_amed_OneHundredMillionTermLoanMember_1598" order="10.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1599" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1600" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1599" xlink:to="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1600" order="11.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1593" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PromissoryNotesMember" xlink:label="Locator_amed_PromissoryNotesMember_1594" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1593" xlink:to="Locator_amed_PromissoryNotesMember_1594" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1575" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_1576" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_DebtInstrumentTable_1575" xlink:to="Locator_us-gaap_RangeAxis_1576" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_1601" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1602" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_RangeAxis_1601" xlink:to="Locator_us-gaap_RangeMember_1602" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_1623" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1624" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_RangeAxis_1623" xlink:to="Locator_us-gaap_RangeMember_1624" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1605" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_1606" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_1605" xlink:to="Locator_us-gaap_MinimumMember_1606" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1603" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_1604" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_1603" xlink:to="Locator_us-gaap_MaximumMember_1604" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1607" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="Locator_us-gaap_DebtInstrumentFaceAmount_1608" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1607" xlink:to="Locator_us-gaap_DebtInstrumentFaceAmount_1608" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1615" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="Locator_us-gaap_DebtInstrumentMaturityDate_1616" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1615" xlink:to="Locator_us-gaap_DebtInstrumentMaturityDate_1616" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1619" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="Locator_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_1620" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1619" xlink:to="Locator_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_1620" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1611" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="Locator_us-gaap_DebtInstrumentInterestRateStatedPercentage_1612" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1611" xlink:to="Locator_us-gaap_DebtInstrumentInterestRateStatedPercentage_1612" order="3.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureLongTermDebtAdditionalInformationDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1743" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1744" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1743" xlink:to="Locator_us-gaap_DebtInstrumentTable_1744" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1747" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1748" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_DebtInstrumentTable_1747" xlink:to="Locator_us-gaap_LongtermDebtTypeAxis_1748" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1755" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1756" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_LongtermDebtTypeAxis_1755" xlink:to="Locator_us-gaap_LongtermDebtTypeDomain_1756" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1757" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TermLoanMember" xlink:label="Locator_amed_TermLoanMember_1758" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1757" xlink:to="Locator_amed_TermLoanMember_1758" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1759" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RevolvingCreditFacilitiesMember" xlink:label="Locator_amed_RevolvingCreditFacilitiesMember_1760" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1759" xlink:to="Locator_amed_RevolvingCreditFacilitiesMember_1760" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1761" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SwingLineLoanMember" xlink:label="Locator_amed_SwingLineLoanMember_1762" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1761" xlink:to="Locator_amed_SwingLineLoanMember_1762" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1763" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="Locator_us-gaap_LetterOfCreditMember_1764" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1763" xlink:to="Locator_us-gaap_LetterOfCreditMember_1764" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1765" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesANotesMember" xlink:label="Locator_amed_SeriesANotesMember_1766" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1765" xlink:to="Locator_amed_SeriesANotesMember_1766" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1767" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesBNotesMember" xlink:label="Locator_amed_SeriesBNotesMember_1768" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1767" xlink:to="Locator_amed_SeriesBNotesMember_1768" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1769" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesCNotesMember" xlink:label="Locator_amed_SeriesCNotesMember_1770" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1769" xlink:to="Locator_amed_SeriesCNotesMember_1770" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1771" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondLienCreditAgreementTermLoanMember" xlink:label="Locator_amed_SecondLienCreditAgreementTermLoanMember_1772" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1771" xlink:to="Locator_amed_SecondLienCreditAgreementTermLoanMember_1772" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1775" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CreditAgreementMember" xlink:label="Locator_amed_CreditAgreementMember_1776" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1775" xlink:to="Locator_amed_CreditAgreementMember_1776" order="10.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1777" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondLienCreditAgreementRevolvingCreditFacilityMember" xlink:label="Locator_amed_SecondLienCreditAgreementRevolvingCreditFacilityMember_1778" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1777" xlink:to="Locator_amed_SecondLienCreditAgreementRevolvingCreditFacilityMember_1778" order="11.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1779" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OneHundredMillionTermLoanMember" xlink:label="Locator_amed_OneHundredMillionTermLoanMember_1780" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1779" xlink:to="Locator_amed_OneHundredMillionTermLoanMember_1780" order="12.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1781" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1782" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1781" xlink:to="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1782" order="13.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1773" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PromissoryNotesMember" xlink:label="Locator_amed_PromissoryNotesMember_1774" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1773" xlink:to="Locator_amed_PromissoryNotesMember_1774" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1749" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_1750" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_DebtInstrumentTable_1749" xlink:to="Locator_us-gaap_RangeAxis_1750" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_1783" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1784" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_RangeAxis_1783" xlink:to="Locator_us-gaap_RangeMember_1784" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1789" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MiddleMember" xlink:label="Locator_amed_MiddleMember_1790" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_1789" xlink:to="Locator_amed_MiddleMember_1790" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1787" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_1788" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_1787" xlink:to="Locator_us-gaap_MinimumMember_1788" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1785" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_1786" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_1785" xlink:to="Locator_us-gaap_MaximumMember_1786" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1751" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodAxis" xlink:label="Locator_amed_TimePeriodAxis_1752" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_DebtInstrumentTable_1751" xlink:to="Locator_amed_TimePeriodAxis_1752" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodAxis" xlink:label="Locator_amed_TimePeriodAxis_1791" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1792" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_TimePeriodAxis_1791" xlink:to="Locator_amed_TimePeriodDomain_1792" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodAxis" xlink:label="Locator_amed_TimePeriodAxis_1897" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1898" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_amed_TimePeriodAxis_1897" xlink:to="Locator_amed_TimePeriodDomain_1898" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1793" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OneMonthMember" xlink:label="Locator_amed_OneMonthMember_1794" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_TimePeriodDomain_1793" xlink:to="Locator_amed_OneMonthMember_1794" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1795" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoMonthMember" xlink:label="Locator_amed_TwoMonthMember_1796" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_TimePeriodDomain_1795" xlink:to="Locator_amed_TwoMonthMember_1796" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1797" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ThreeMonthMember" xlink:label="Locator_amed_ThreeMonthMember_1798" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_TimePeriodDomain_1797" xlink:to="Locator_amed_ThreeMonthMember_1798" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1799" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SixMonthMember" xlink:label="Locator_amed_SixMonthMember_1800" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_TimePeriodDomain_1799" xlink:to="Locator_amed_SixMonthMember_1800" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1801" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OneYearMember" xlink:label="Locator_amed_OneYearMember_1802" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_TimePeriodDomain_1801" xlink:to="Locator_amed_OneYearMember_1802" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1803" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoYearMember" xlink:label="Locator_amed_TwoYearMember_1804" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_TimePeriodDomain_1803" xlink:to="Locator_amed_TwoYearMember_1804" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1805" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FourRemainingQuarterlyPaymentsMember" xlink:label="Locator_amed_FourRemainingQuarterlyPaymentsMember_1806" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_TimePeriodDomain_1805" xlink:to="Locator_amed_FourRemainingQuarterlyPaymentsMember_1806" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1807" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondEightQuarterlyPaymentsMember" xlink:label="Locator_amed_SecondEightQuarterlyPaymentsMember_1808" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_TimePeriodDomain_1807" xlink:to="Locator_amed_SecondEightQuarterlyPaymentsMember_1808" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1809" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FinalTwoQuarterlyPaymentsMember" xlink:label="Locator_amed_FinalTwoQuarterlyPaymentsMember_1810" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_TimePeriodDomain_1809" xlink:to="Locator_amed_FinalTwoQuarterlyPaymentsMember_1810" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1753" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FeeTypeAxis" xlink:label="Locator_amed_FeeTypeAxis_1754" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_DebtInstrumentTable_1753" xlink:to="Locator_amed_FeeTypeAxis_1754" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FeeTypeAxis" xlink:label="Locator_amed_FeeTypeAxis_1811" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FeeTypeDomain" xlink:label="Locator_amed_FeeTypeDomain_1812" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_FeeTypeAxis_1811" xlink:to="Locator_amed_FeeTypeDomain_1812" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FeeTypeAxis" xlink:label="Locator_amed_FeeTypeAxis_1899" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FeeTypeDomain" xlink:label="Locator_amed_FeeTypeDomain_1900" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_amed_FeeTypeAxis_1899" xlink:to="Locator_amed_FeeTypeDomain_1900" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FeeTypeDomain" xlink:label="Locator_amed_FeeTypeDomain_1813" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ArrangerFeeMember" xlink:label="Locator_amed_ArrangerFeeMember_1814" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_FeeTypeDomain_1813" xlink:to="Locator_amed_ArrangerFeeMember_1814" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1815" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="Locator_us-gaap_DebtInstrumentTerm_1816" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1815" xlink:to="Locator_us-gaap_DebtInstrumentTerm_1816" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1817" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WeightedAverageInterestRate" xlink:label="Locator_amed_WeightedAverageInterestRate_1818" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1817" xlink:to="Locator_amed_WeightedAverageInterestRate_1818" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1819" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TotalLeverageRatio" xlink:label="Locator_amed_TotalLeverageRatio_1820" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1819" xlink:to="Locator_amed_TotalLeverageRatio_1820" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1821" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FixedChargeCoverageRatio" xlink:label="Locator_amed_FixedChargeCoverageRatio_1822" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1821" xlink:to="Locator_amed_FixedChargeCoverageRatio_1822" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1823" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="Locator_us-gaap_DebtInstrumentFaceAmount_1824" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1823" xlink:to="Locator_us-gaap_DebtInstrumentFaceAmount_1824" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1825" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="Locator_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1826" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1825" xlink:to="Locator_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1826" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1827" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="Locator_us-gaap_LettersOfCreditOutstandingAmount_1828" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1827" xlink:to="Locator_us-gaap_LettersOfCreditOutstandingAmount_1828" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1829" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityEffectiveyBorrowingCapacity" xlink:label="Locator_amed_LineOfCreditFacilityEffectiveyBorrowingCapacity_1830" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1829" xlink:to="Locator_amed_LineOfCreditFacilityEffectiveyBorrowingCapacity_1830" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1831" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityDebtRestrictions" xlink:label="Locator_amed_LineOfCreditFacilityDebtRestrictions_1832" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1831" xlink:to="Locator_amed_LineOfCreditFacilityDebtRestrictions_1832" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1833" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumLeverageRatio" xlink:label="Locator_amed_MaximumLeverageRatio_1834" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1833" xlink:to="Locator_amed_MaximumLeverageRatio_1834" order="10.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1835" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MinimumFixedChargeCoverageRatio" xlink:label="Locator_amed_MinimumFixedChargeCoverageRatio_1836" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1835" xlink:to="Locator_amed_MinimumFixedChargeCoverageRatio_1836" order="11.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1837" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="Locator_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1838" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1837" xlink:to="Locator_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1838" order="12.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1839" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RevolvingCreditFacilityTotal" xlink:label="Locator_amed_RevolvingCreditFacilityTotal_1840" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1839" xlink:to="Locator_amed_RevolvingCreditFacilityTotal_1840" order="13.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1841" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:label="Locator_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_1842" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1841" xlink:to="Locator_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_1842" order="14.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1843" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="Locator_us-gaap_DebtInstrumentMaturityDate_1844" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1843" xlink:to="Locator_us-gaap_DebtInstrumentMaturityDate_1844" order="15.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1845" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentNumberOfPeriodicPayments" xlink:label="Locator_amed_DebtInstrumentNumberOfPeriodicPayments_1846" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1845" xlink:to="Locator_amed_DebtInstrumentNumberOfPeriodicPayments_1846" order="16.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1847" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="Locator_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_1848" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1847" xlink:to="Locator_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_1848" order="17.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1849" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="Locator_us-gaap_DebtIssuanceCosts_1850" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1849" xlink:to="Locator_us-gaap_DebtIssuanceCosts_1850" order="18.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1851" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:label="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_1852" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1851" xlink:to="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_1852" order="19.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1853" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:label="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_1854" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1853" xlink:to="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_1854" order="20.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1855" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveABRRate" xlink:label="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveABRRate_1856" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1855" xlink:to="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveABRRate_1856" order="21.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1857" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestABRFlatRate" xlink:label="Locator_amed_DebtInstrumentInterestABRFlatRate_1858" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1857" xlink:to="Locator_amed_DebtInstrumentInterestABRFlatRate_1858" order="22.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1859" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate" xlink:label="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate_1860" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1859" xlink:to="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate_1860" order="23.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1861" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ApplicableMarginRateOnBaseRate" xlink:label="Locator_amed_ApplicableMarginRateOnBaseRate_1862" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1861" xlink:to="Locator_amed_ApplicableMarginRateOnBaseRate_1862" order="24.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1863" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ApplicableMarginRateOnEurodollarRate" xlink:label="Locator_amed_ApplicableMarginRateOnEurodollarRate_1864" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1863" xlink:to="Locator_amed_ApplicableMarginRateOnEurodollarRate_1864" order="25.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1865" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EurodollarDepositsInterestPeriod" xlink:label="Locator_amed_EurodollarDepositsInterestPeriod_1866" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1865" xlink:to="Locator_amed_EurodollarDepositsInterestPeriod_1866" order="26.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1867" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestLiborFloor" xlink:label="Locator_amed_DebtInstrumentInterestLiborFloor_1868" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1867" xlink:to="Locator_amed_DebtInstrumentInterestLiborFloor_1868" order="27.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1869" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PrepaymentPenaltyPercentage" xlink:label="Locator_amed_PrepaymentPenaltyPercentage_1870" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1869" xlink:to="Locator_amed_PrepaymentPenaltyPercentage_1870" order="28.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1871" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:label="Locator_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_1872" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1871" xlink:to="Locator_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_1872" order="29.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1873" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:label="Locator_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_1874" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1873" xlink:to="Locator_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_1874" order="30.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1875" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="Locator_us-gaap_LongTermDebt_1876" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1875" xlink:to="Locator_us-gaap_LongTermDebt_1876" order="31.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1877" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNotesPayable" xlink:label="Locator_us-gaap_OtherNotesPayable_1878" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1877" xlink:to="Locator_us-gaap_OtherNotesPayable_1878" order="32.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1879" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="Locator_us-gaap_DebtInstrumentInterestRateStatedPercentage_1880" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1879" xlink:to="Locator_us-gaap_DebtInstrumentInterestRateStatedPercentage_1880" order="33.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1881" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="Locator_us-gaap_RepaymentsOfLinesOfCredit_1882" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1881" xlink:to="Locator_us-gaap_RepaymentsOfLinesOfCredit_1882" order="34.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1883" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="Locator_us-gaap_ProceedsFromIssuanceOfDebt_1884" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1883" xlink:to="Locator_us-gaap_ProceedsFromIssuanceOfDebt_1884" order="35.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1885" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="Locator_us-gaap_DebtWeightedAverageInterestRate_1886" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1885" xlink:to="Locator_us-gaap_DebtWeightedAverageInterestRate_1886" order="36.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1887" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeniorSecuredLeverageRatio" xlink:label="Locator_amed_SeniorSecuredLeverageRatio_1888" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1887" xlink:to="Locator_amed_SeniorSecuredLeverageRatio_1888" order="37.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1889" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="Locator_us-gaap_WriteOffOfDeferredDebtIssuanceCost_1890" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1889" xlink:to="Locator_us-gaap_WriteOffOfDeferredDebtIssuanceCost_1890" order="38.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1891" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CallPremiumPayment" xlink:label="Locator_amed_CallPremiumPayment_1892" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1891" xlink:to="Locator_amed_CallPremiumPayment_1892" order="39.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1893" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MarginAdjustmentOnBaseRate" xlink:label="Locator_amed_MarginAdjustmentOnBaseRate_1894" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1893" xlink:to="Locator_amed_MarginAdjustmentOnBaseRate_1894" order="40.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1895" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MarginAdjustmentOnEuroDollarLoans" xlink:label="Locator_amed_MarginAdjustmentOnEuroDollarLoans_1896" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1895" xlink:to="Locator_amed_MarginAdjustmentOnEuroDollarLoans_1896" order="41.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureCommitmentsAndContigenciesDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_2053" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2054" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_RangeAxis_2053" xlink:to="Locator_us-gaap_RangeMember_2054" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2055" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_2056" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_2055" xlink:to="Locator_us-gaap_MinimumMember_2056" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2057" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_2058" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_2057" xlink:to="Locator_us-gaap_MaximumMember_2058" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2059" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2060" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_2059" xlink:to="Locator_us-gaap_SegmentDomain_2060" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2063" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximusFederalServicesMember" xlink:label="Locator_amed_MaximusFederalServicesMember_2064" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2063" xlink:to="Locator_amed_MaximusFederalServicesMember_2064" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2067" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximusFederalServicesAndHospiceMember" xlink:label="Locator_amed_MaximusFederalServicesAndHospiceMember_2068" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2067" xlink:to="Locator_amed_MaximusFederalServicesAndHospiceMember_2068" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2069" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MassproAndHospiceMember" xlink:label="Locator_amed_MassproAndHospiceMember_2070" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2069" xlink:to="Locator_amed_MassproAndHospiceMember_2070" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2071" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfEmployeesInWageHourLitigationMember" xlink:label="Locator_amed_NumberOfEmployeesInWageHourLitigationMember_2072" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2071" xlink:to="Locator_amed_NumberOfEmployeesInWageHourLitigationMember_2072" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2073" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximusFederalServicesAndHomeHealthMember" xlink:label="Locator_amed_MaximusFederalServicesAndHomeHealthMember_2074" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2073" xlink:to="Locator_amed_MaximusFederalServicesAndHomeHealthMember_2074" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2061" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_2062" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2061" xlink:to="Locator_amed_HomeHealthMember_2062" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2065" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_2066" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2065" xlink:to="Locator_amed_HospiceMember_2066" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_2075" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_2076" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_dei_LegalEntityAxis_2075" xlink:to="Locator_dei_EntityDomain_2076" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_2077" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MedicareAdministrativeContractorMacMember" xlink:label="Locator_amed_MedicareAdministrativeContractorMacMember_2078" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_dei_EntityDomain_2077" xlink:to="Locator_amed_MedicareAdministrativeContractorMacMember_2078" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateAxis" xlink:label="Locator_amed_StateAxis_2079" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2080" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_StateAxis_2079" xlink:to="Locator_amed_StateDomain_2080" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateAxis" xlink:label="Locator_amed_StateAxis_2195" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2196" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_amed_StateAxis_2195" xlink:to="Locator_amed_StateDomain_2196" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2081" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IllinoisMember" xlink:label="Locator_amed_IllinoisMember_2082" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2081" xlink:to="Locator_amed_IllinoisMember_2082" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2083" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ConnecticutMember" xlink:label="Locator_amed_ConnecticutMember_2084" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2083" xlink:to="Locator_amed_ConnecticutMember_2084" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2085" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OhioMember" xlink:label="Locator_amed_OhioMember_2086" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2085" xlink:to="Locator_amed_OhioMember_2086" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2087" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SouthCarolinaMember" xlink:label="Locator_amed_SouthCarolinaMember_2088" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2087" xlink:to="Locator_amed_SouthCarolinaMember_2088" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2093" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MorgantownWestVirginiaMember" xlink:label="Locator_amed_MorgantownWestVirginiaMember_2094" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2093" xlink:to="Locator_amed_MorgantownWestVirginiaMember_2094" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2095" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ParkersburgWestVirginiaMember" xlink:label="Locator_amed_ParkersburgWestVirginiaMember_2096" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2095" xlink:to="Locator_amed_ParkersburgWestVirginiaMember_2096" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2091" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WestVirginiaMember" xlink:label="Locator_amed_WestVirginiaMember_2092" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2091" xlink:to="Locator_amed_WestVirginiaMember_2092" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2089" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MassachusettsMember" xlink:label="Locator_amed_MassachusettsMember_2090" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2089" xlink:to="Locator_amed_MassachusettsMember_2090" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2035" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2036" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2035" xlink:to="Locator_amed_CommimentsAndContingenciesTable_2036" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2039" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2040" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2039" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_2040" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2041" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_2042" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2041" xlink:to="Locator_dei_LegalEntityAxis_2042" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2043" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="Locator_us-gaap_LitigationStatusAxis_2044" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2043" xlink:to="Locator_us-gaap_LitigationStatusAxis_2044" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="Locator_us-gaap_LitigationStatusAxis_2097" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2098" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_LitigationStatusAxis_2097" xlink:to="Locator_us-gaap_LitigationStatusDomain_2098" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="Locator_us-gaap_LitigationStatusAxis_2197" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2198" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_LitigationStatusAxis_2197" xlink:to="Locator_us-gaap_LitigationStatusDomain_2198" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2099" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="Locator_us-gaap_PendingLitigationMember_2100" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LitigationStatusDomain_2099" xlink:to="Locator_us-gaap_PendingLitigationMember_2100" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2101" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FinalLitigationSettlmentMember" xlink:label="Locator_amed_FinalLitigationSettlmentMember_2102" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LitigationStatusDomain_2101" xlink:to="Locator_amed_FinalLitigationSettlmentMember_2102" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2103" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FederalDerivativeActionsMember" xlink:label="Locator_amed_FederalDerivativeActionsMember_2104" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LitigationStatusDomain_2103" xlink:to="Locator_amed_FederalDerivativeActionsMember_2104" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2107" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ErisaClassActionLawsuitMember" xlink:label="Locator_amed_ErisaClassActionLawsuitMember_2108" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LitigationStatusDomain_2107" xlink:to="Locator_amed_ErisaClassActionLawsuitMember_2108" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2109" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ComputerInventoryAndDataSecurityReportingMember" xlink:label="Locator_amed_ComputerInventoryAndDataSecurityReportingMember_2110" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LitigationStatusDomain_2109" xlink:to="Locator_amed_ComputerInventoryAndDataSecurityReportingMember_2110" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2111" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FrontierLitigationMember" xlink:label="Locator_amed_FrontierLitigationMember_2112" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LitigationStatusDomain_2111" xlink:to="Locator_amed_FrontierLitigationMember_2112" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2113" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UsDepartmentOfJusticeMember" xlink:label="Locator_amed_UsDepartmentOfJusticeMember_2114" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LitigationStatusDomain_2113" xlink:to="Locator_amed_UsDepartmentOfJusticeMember_2114" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2105" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OigSelfDisclosureMember" xlink:label="Locator_amed_OigSelfDisclosureMember_2106" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LitigationStatusDomain_2105" xlink:to="Locator_amed_OigSelfDisclosureMember_2106" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2045" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="Locator_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2046" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2045" xlink:to="Locator_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2046" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="Locator_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2115" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="Locator_us-gaap_HealthCareOrganizationRevenueSourcesDomain_2116" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2115" xlink:to="Locator_us-gaap_HealthCareOrganizationRevenueSourcesDomain_2116" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="Locator_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2199" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="Locator_us-gaap_HealthCareOrganizationRevenueSourcesDomain_2200" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2199" xlink:to="Locator_us-gaap_HealthCareOrganizationRevenueSourcesDomain_2200" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="Locator_us-gaap_HealthCareOrganizationRevenueSourcesDomain_2117" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RelatedPartyMember" xlink:label="Locator_amed_RelatedPartyMember_2118" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_HealthCareOrganizationRevenueSourcesDomain_2117" xlink:to="Locator_amed_RelatedPartyMember_2118" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2047" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="Locator_us-gaap_LossContingenciesByNatureOfContingencyAxis_2048" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2047" xlink:to="Locator_us-gaap_LossContingenciesByNatureOfContingencyAxis_2048" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="Locator_us-gaap_LossContingenciesByNatureOfContingencyAxis_2119" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_2120" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_LossContingenciesByNatureOfContingencyAxis_2119" xlink:to="Locator_us-gaap_LossContingencyNatureDomain_2120" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="Locator_us-gaap_LossContingenciesByNatureOfContingencyAxis_2201" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_2202" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_LossContingenciesByNatureOfContingencyAxis_2201" xlink:to="Locator_us-gaap_LossContingencyNatureDomain_2202" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_2121" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ExtrapolatedMember" xlink:label="Locator_amed_ExtrapolatedMember_2122" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LossContingencyNatureDomain_2121" xlink:to="Locator_amed_ExtrapolatedMember_2122" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_2123" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FavorableMember" xlink:label="Locator_amed_FavorableMember_2124" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LossContingencyNatureDomain_2123" xlink:to="Locator_amed_FavorableMember_2124" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_2125" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnfavorableMember" xlink:label="Locator_amed_UnfavorableMember_2126" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LossContingencyNatureDomain_2125" xlink:to="Locator_amed_UnfavorableMember_2126" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_2127" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FavorableInFullMember" xlink:label="Locator_amed_FavorableInFullMember_2128" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LossContingencyNatureDomain_2127" xlink:to="Locator_amed_FavorableInFullMember_2128" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_2129" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FavorableInPartMember" xlink:label="Locator_amed_FavorableInPartMember_2130" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LossContingencyNatureDomain_2129" xlink:to="Locator_amed_FavorableInPartMember_2130" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2049" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateAxis" xlink:label="Locator_amed_StateAxis_2050" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2049" xlink:to="Locator_amed_StateAxis_2050" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2051" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_2052" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2051" xlink:to="Locator_us-gaap_RangeAxis_2052" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2131" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MedicareRevenue" xlink:label="Locator_amed_MedicareRevenue_2132" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2131" xlink:to="Locator_amed_MedicareRevenue_2132" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2133" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs" xlink:label="Locator_us-gaap_LossContingencyNumberOfPlaintiffs_2134" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2133" xlink:to="Locator_us-gaap_LossContingencyNumberOfPlaintiffs_2134" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2135" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyActionsTakenByPlaintiff" xlink:label="Locator_us-gaap_LossContingencyActionsTakenByPlaintiff_2136" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2135" xlink:to="Locator_us-gaap_LossContingencyActionsTakenByPlaintiff_2136" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2137" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfClaimsSubmittedBySubsidiary" xlink:label="Locator_amed_NumberOfClaimsSubmittedBySubsidiary_2138" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2137" xlink:to="Locator_amed_NumberOfClaimsSubmittedBySubsidiary_2138" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2139" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:label="Locator_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_2140" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2139" xlink:to="Locator_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_2140" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2141" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:label="Locator_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_2142" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2141" xlink:to="Locator_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_2142" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2143" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfClaimsAppealed" xlink:label="Locator_amed_NumberOfClaimsAppealed_2144" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2143" xlink:to="Locator_amed_NumberOfClaimsAppealed_2144" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2145" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfRedeterminationDecisions" xlink:label="Locator_amed_NumberOfRedeterminationDecisions_2146" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2145" xlink:to="Locator_amed_NumberOfRedeterminationDecisions_2146" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2147" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HealthInsuranceRetentionLimit" xlink:label="Locator_amed_HealthInsuranceRetentionLimit_2148" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2147" xlink:to="Locator_amed_HealthInsuranceRetentionLimit_2148" order="9.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2149" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WorkersCompensationInsuranceRetentionLimit" xlink:label="Locator_amed_WorkersCompensationInsuranceRetentionLimit_2150" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2149" xlink:to="Locator_amed_WorkersCompensationInsuranceRetentionLimit_2150" order="10.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2151" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:label="Locator_amed_ProfessionalLiabilityInsuranceRetentionLimit_2152" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2151" xlink:to="Locator_amed_ProfessionalLiabilityInsuranceRetentionLimit_2152" order="11.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2153" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfBeneficiaries" xlink:label="Locator_amed_NumberOfBeneficiaries_2154" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2153" xlink:to="Locator_amed_NumberOfBeneficiaries_2154" order="12.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2155" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="Locator_us-gaap_LitigationSettlementAmount_2156" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2155" xlink:to="Locator_us-gaap_LitigationSettlementAmount_2156" order="13.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2157" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="Locator_us-gaap_LossContingencyAccrualAtCarryingValue_2158" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2157" xlink:to="Locator_us-gaap_LossContingencyAccrualAtCarryingValue_2158" order="14.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2159" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InsuranceProceedsForReimbursementOfLegalFees" xlink:label="Locator_amed_InsuranceProceedsForReimbursementOfLegalFees_2160" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2159" xlink:to="Locator_amed_InsuranceProceedsForReimbursementOfLegalFees_2160" order="15.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2161" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PaymentUponExecutionOfUsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_PaymentUponExecutionOfUsDepartmentOfJusticeSettlement_2162" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2161" xlink:to="Locator_amed_PaymentUponExecutionOfUsDepartmentOfJusticeSettlement_2162" order="16.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2163" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InterestRateOnUsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_InterestRateOnUsDepartmentOfJusticeSettlement_2164" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2163" xlink:to="Locator_amed_InterestRateOnUsDepartmentOfJusticeSettlement_2164" order="17.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2165" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FinalPaymentOfUsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_FinalPaymentOfUsDepartmentOfJusticeSettlement_2166" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2165" xlink:to="Locator_amed_FinalPaymentOfUsDepartmentOfJusticeSettlement_2166" order="18.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2167" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement_2168" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2167" xlink:to="Locator_amed_PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement_2168" order="19.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2169" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="Locator_us-gaap_LossContingencyEstimateOfPossibleLoss_2170" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2169" xlink:to="Locator_us-gaap_LossContingencyEstimateOfPossibleLoss_2170" order="20.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2171" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="Locator_us-gaap_LossContingencyAccrualProvision_2172" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2171" xlink:to="Locator_us-gaap_LossContingencyAccrualProvision_2172" order="21.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2173" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CorporateIntegrityAgreementTerm" xlink:label="Locator_amed_CorporateIntegrityAgreementTerm_2174" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2173" xlink:to="Locator_amed_CorporateIntegrityAgreementTerm_2174" order="22.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2175" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates" xlink:label="Locator_us-gaap_NumberOfStatesInWhichEntityOperates_2176" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2175" xlink:to="Locator_us-gaap_NumberOfStatesInWhichEntityOperates_2176" order="23.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2177" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfIndividualsWithInformationOnMissingDevices" xlink:label="Locator_amed_NumberOfIndividualsWithInformationOnMissingDevices_2178" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2177" xlink:to="Locator_amed_NumberOfIndividualsWithInformationOnMissingDevices_2178" order="24.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2179" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfMissingComputersAndLaptops" xlink:label="Locator_amed_NumberOfMissingComputersAndLaptops_2180" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2179" xlink:to="Locator_amed_NumberOfMissingComputersAndLaptops_2180" order="25.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2181" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ThresholdOfIndividualsInDataBreach" xlink:label="Locator_amed_ThresholdOfIndividualsInDataBreach_2182" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2181" xlink:to="Locator_amed_ThresholdOfIndividualsInDataBreach_2182" order="26.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2183" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfCompanyDevicesUsed" xlink:label="Locator_amed_PercentageOfCompanyDevicesUsed_2184" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2183" xlink:to="Locator_amed_PercentageOfCompanyDevicesUsed_2184" order="27.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2185" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_YearOfDeparture" xlink:label="Locator_amed_YearOfDeparture_2186" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2185" xlink:to="Locator_amed_YearOfDeparture_2186" order="28.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2187" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersSold" xlink:label="Locator_amed_NumberOfCareCentersSold_2188" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2187" xlink:to="Locator_amed_NumberOfCareCentersSold_2188" order="29.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2189" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Numberofpatients" xlink:label="Locator_amed_Numberofpatients_2190" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2189" xlink:to="Locator_amed_Numberofpatients_2190" order="30.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2191" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="Locator_us-gaap_PaymentsForLegalSettlements_2192" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2191" xlink:to="Locator_us-gaap_PaymentsForLegalSettlements_2192" order="31.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2193" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:label="Locator_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_2194" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2193" xlink:to="Locator_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_2194" order="32.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureOperatingIncomeOfReportableSegmentsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2335" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2336" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_2335" xlink:to="Locator_us-gaap_SegmentDomain_2336" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2343" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="Locator_us-gaap_AllOtherSegmentsMember_2344" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2343" xlink:to="Locator_us-gaap_AllOtherSegmentsMember_2344" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2337" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_2338" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2337" xlink:to="Locator_amed_HomeHealthMember_2338" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2339" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_2340" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2339" xlink:to="Locator_amed_HospiceMember_2340" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2341" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PersonalCareMember" xlink:label="Locator_amed_PersonalCareMember_2342" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2341" xlink:to="Locator_amed_PersonalCareMember_2342" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2317" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2318" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2317" xlink:to="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2318" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2333" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2334" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2333" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_2334" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2345" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationPatientServiceRevenue" xlink:label="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_2346" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2345" xlink:to="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_2346" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2347" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfServices" xlink:label="Locator_us-gaap_CostOfServices_2348" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2347" xlink:to="Locator_us-gaap_CostOfServices_2348" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2349" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GeneralAndAdministrativeExpenseSegment" xlink:label="Locator_amed_GeneralAndAdministrativeExpenseSegment_2350" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2349" xlink:to="Locator_amed_GeneralAndAdministrativeExpenseSegment_2350" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2351" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProvisionForDoubtfulAccountsForContinuingOperations" xlink:label="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_2352" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2351" xlink:to="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_2352" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2353" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DepreciationAndAmortizationForContinuingOperations" xlink:label="Locator_amed_DepreciationAndAmortizationForContinuingOperations_2354" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2353" xlink:to="Locator_amed_DepreciationAndAmortizationForContinuingOperations_2354" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2355" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_UsDepartmentOfJusticeSettlement_2356" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2355" xlink:to="Locator_amed_UsDepartmentOfJusticeSettlement_2356" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2357" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="Locator_us-gaap_AssetImpairmentCharges_2358" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2357" xlink:to="Locator_us-gaap_AssetImpairmentCharges_2358" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2359" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_2360" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2359" xlink:to="Locator_us-gaap_CostsAndExpenses_2360" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2361" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="Locator_us-gaap_OperatingIncomeLoss_2362" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2361" xlink:to="Locator_us-gaap_OperatingIncomeLoss_2362" order="9.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureExitActivitiesDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2429" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2430" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_2429" xlink:to="Locator_us-gaap_SegmentDomain_2430" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2431" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_2432" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2431" xlink:to="Locator_amed_HomeHealthMember_2432" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2433" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_2434" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2433" xlink:to="Locator_amed_HospiceMember_2434" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2471" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherRestructuringCosts" xlink:label="Locator_us-gaap_OtherRestructuringCosts_2472" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2471" xlink:to="Locator_us-gaap_OtherRestructuringCosts_2472" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2473" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="Locator_us-gaap_GainsLossesOnSalesOfAssets_2474" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2473" xlink:to="Locator_us-gaap_GainsLossesOnSalesOfAssets_2474" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2475" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="Locator_us-gaap_ProceedsFromDivestitureOfBusinesses_2476" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2475" xlink:to="Locator_us-gaap_ProceedsFromDivestitureOfBusinesses_2476" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2477" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersAvailableForSale" xlink:label="Locator_amed_NumberOfCareCentersAvailableForSale_2478" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2477" xlink:to="Locator_amed_NumberOfCareCentersAvailableForSale_2478" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2479" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersConsolidated" xlink:label="Locator_amed_NumberOfCareCentersConsolidated_2480" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2479" xlink:to="Locator_amed_NumberOfCareCentersConsolidated_2480" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2481" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersSold" xlink:label="Locator_amed_NumberOfCareCentersSold_2482" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2481" xlink:to="Locator_amed_NumberOfCareCentersSold_2482" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2483" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersClosed" xlink:label="Locator_amed_NumberOfCareCentersClosed_2484" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2483" xlink:to="Locator_amed_NumberOfCareCentersClosed_2484" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2485" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" xlink:label="Locator_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_2486" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2485" xlink:to="Locator_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_2486" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2487" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="Locator_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_2488" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2487" xlink:to="Locator_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_2488" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2417" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2418" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2417" xlink:to="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2418" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2423" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TypeOfBusinessSoldAxis" xlink:label="Locator_amed_TypeOfBusinessSoldAxis_2424" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2423" xlink:to="Locator_amed_TypeOfBusinessSoldAxis_2424" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TypeOfBusinessSoldAxis" xlink:label="Locator_amed_TypeOfBusinessSoldAxis_2435" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessSoldDomain" xlink:label="Locator_amed_BusinessSoldDomain_2436" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_TypeOfBusinessSoldAxis_2435" xlink:to="Locator_amed_BusinessSoldDomain_2436" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TypeOfBusinessSoldAxis" xlink:label="Locator_amed_TypeOfBusinessSoldAxis_2489" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessSoldDomain" xlink:label="Locator_amed_BusinessSoldDomain_2490" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_amed_TypeOfBusinessSoldAxis_2489" xlink:to="Locator_amed_BusinessSoldDomain_2490" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessSoldDomain" xlink:label="Locator_amed_BusinessSoldDomain_2437" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AlaskaAndWashingtonCareCentersMember" xlink:label="Locator_amed_AlaskaAndWashingtonCareCentersMember_2438" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_BusinessSoldDomain_2437" xlink:to="Locator_amed_AlaskaAndWashingtonCareCentersMember_2438" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessSoldDomain" xlink:label="Locator_amed_BusinessSoldDomain_2439" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WyomingAndIdahoCareCentersMember" xlink:label="Locator_amed_WyomingAndIdahoCareCentersMember_2440" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_BusinessSoldDomain_2439" xlink:to="Locator_amed_WyomingAndIdahoCareCentersMember_2440" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessSoldDomain" xlink:label="Locator_amed_BusinessSoldDomain_2441" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnconsolidatedJointVentureMember" xlink:label="Locator_amed_UnconsolidatedJointVentureMember_2442" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_BusinessSoldDomain_2441" xlink:to="Locator_amed_UnconsolidatedJointVentureMember_2442" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessSoldDomain" xlink:label="Locator_amed_BusinessSoldDomain_2443" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AvailableForSaleMember" xlink:label="Locator_amed_AvailableForSaleMember_2444" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_BusinessSoldDomain_2443" xlink:to="Locator_amed_AvailableForSaleMember_2444" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessSoldDomain" xlink:label="Locator_amed_BusinessSoldDomain_2445" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NotIncludedInAvailableForSaleMember" xlink:label="Locator_amed_NotIncludedInAvailableForSaleMember_2446" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_BusinessSoldDomain_2445" xlink:to="Locator_amed_NotIncludedInAvailableForSaleMember_2446" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessSoldDomain" xlink:label="Locator_amed_BusinessSoldDomain_2447" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceInpatientUnitMember" xlink:label="Locator_amed_HospiceInpatientUnitMember_2448" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_BusinessSoldDomain_2447" xlink:to="Locator_amed_HospiceInpatientUnitMember_2448" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2427" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2428" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2427" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_2428" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2421" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringCostsAxis" xlink:label="Locator_amed_OtherRestructuringCostsAxis_2422" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2421" xlink:to="Locator_amed_OtherRestructuringCostsAxis_2422" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringCostsAxis" xlink:label="Locator_amed_OtherRestructuringCostsAxis_2449" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_2450" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_OtherRestructuringCostsAxis_2449" xlink:to="Locator_amed_OtherRestructuringDomain_2450" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringCostsAxis" xlink:label="Locator_amed_OtherRestructuringCostsAxis_2491" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_2492" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_amed_OtherRestructuringCostsAxis_2491" xlink:to="Locator_amed_OtherRestructuringDomain_2492" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_2451" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoThousandAndThirteenExitActivityMember" xlink:label="Locator_amed_TwoThousandAndThirteenExitActivityMember_2452" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OtherRestructuringDomain_2451" xlink:to="Locator_amed_TwoThousandAndThirteenExitActivityMember_2452" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_2453" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoThousandAndFourteenExitActivityMember" xlink:label="Locator_amed_TwoThousandAndFourteenExitActivityMember_2454" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OtherRestructuringDomain_2453" xlink:to="Locator_amed_TwoThousandAndFourteenExitActivityMember_2454" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2425" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="Locator_us-gaap_RestructuringCostAndReserveAxis_2426" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2425" xlink:to="Locator_us-gaap_RestructuringCostAndReserveAxis_2426" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="Locator_us-gaap_RestructuringCostAndReserveAxis_2455" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_2456" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_RestructuringCostAndReserveAxis_2455" xlink:to="Locator_amed_RestructuringCostAndReserveDomain_2456" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="Locator_us-gaap_RestructuringCostAndReserveAxis_2493" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_2494" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_RestructuringCostAndReserveAxis_2493" xlink:to="Locator_amed_RestructuringCostAndReserveDomain_2494" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_2461" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IntangiblesWriteOffMember" xlink:label="Locator_amed_IntangiblesWriteOffMember_2462" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_RestructuringCostAndReserveDomain_2461" xlink:to="Locator_amed_IntangiblesWriteOffMember_2462" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_2463" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndOtherIntangiblesImpairmentMember" xlink:label="Locator_amed_GoodwillAndOtherIntangiblesImpairmentMember_2464" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_RestructuringCostAndReserveDomain_2463" xlink:to="Locator_amed_GoodwillAndOtherIntangiblesImpairmentMember_2464" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_2465" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssetWriteOffMember" xlink:label="Locator_amed_AssetWriteOffMember_2466" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_RestructuringCostAndReserveDomain_2465" xlink:to="Locator_amed_AssetWriteOffMember_2466" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_2467" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeveranceForRegionalLeadershipAndCorporateSupportMember" xlink:label="Locator_amed_SeveranceForRegionalLeadershipAndCorporateSupportMember_2468" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_RestructuringCostAndReserveDomain_2467" xlink:to="Locator_amed_SeveranceForRegionalLeadershipAndCorporateSupportMember_2468" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_2469" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeveranceForFormerExecutiveMember" xlink:label="Locator_amed_SeveranceForFormerExecutiveMember_2470" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_RestructuringCostAndReserveDomain_2469" xlink:to="Locator_amed_SeveranceForFormerExecutiveMember_2470" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_2457" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LeaseTerminationMember" xlink:label="Locator_amed_LeaseTerminationMember_2458" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_RestructuringCostAndReserveDomain_2457" xlink:to="Locator_amed_LeaseTerminationMember_2458" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_2459" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="Locator_us-gaap_EmployeeSeveranceMember_2460" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_RestructuringCostAndReserveDomain_2459" xlink:to="Locator_us-gaap_EmployeeSeveranceMember_2460" order="2.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureSubsequentEventDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2561" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2562" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_2561" xlink:to="Locator_us-gaap_SegmentDomain_2562" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2563" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PersonalCareMember" xlink:label="Locator_amed_PersonalCareMember_2564" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2563" xlink:to="Locator_amed_PersonalCareMember_2564" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="Locator_us-gaap_SubsequentEventLineItems_2553" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2554" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_SubsequentEventLineItems_2553" xlink:to="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2554" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2559" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="Locator_us-gaap_BusinessAcquisitionAxis_2560" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2559" xlink:to="Locator_us-gaap_BusinessAcquisitionAxis_2560" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="Locator_us-gaap_BusinessAcquisitionAxis_2565" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionAcquiredDomain" xlink:label="Locator_amed_BusinessAcquisitionAcquiredDomain_2566" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_BusinessAcquisitionAxis_2565" xlink:to="Locator_amed_BusinessAcquisitionAcquiredDomain_2566" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionAcquiredDomain" xlink:label="Locator_amed_BusinessAcquisitionAcquiredDomain_2567" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeStaffLlcMember" xlink:label="Locator_amed_HomeStaffLlcMember_2568" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_BusinessAcquisitionAcquiredDomain_2567" xlink:to="Locator_amed_HomeStaffLlcMember_2568" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2557" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2558" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2557" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_2558" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="Locator_us-gaap_SubsequentEventLineItems_2569" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="Locator_us-gaap_BusinessCombinationConsiderationTransferred1_2570" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SubsequentEventLineItems_2569" xlink:to="Locator_us-gaap_BusinessCombinationConsiderationTransferred1_2570" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="Locator_us-gaap_SubsequentEventLineItems_2571" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfBusinessesAcquired" xlink:label="Locator_us-gaap_NumberOfBusinessesAcquired_2572" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SubsequentEventLineItems_2571" xlink:to="Locator_us-gaap_NumberOfBusinessesAcquired_2572" order="2.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2635" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_2636" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_StatementLineItems_2635" xlink:to="Locator_us-gaap_StatementTable_2636" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_2639" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="Locator_us-gaap_StatementEquityComponentsAxis_2640" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_StatementTable_2639" xlink:to="Locator_us-gaap_StatementEquityComponentsAxis_2640" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="Locator_us-gaap_StatementEquityComponentsAxis_2641" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="Locator_us-gaap_EquityComponentDomain_2642" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_StatementEquityComponentsAxis_2641" xlink:to="Locator_us-gaap_EquityComponentDomain_2642" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="Locator_us-gaap_StatementEquityComponentsAxis_2699" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="Locator_us-gaap_EquityComponentDomain_2700" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_StatementEquityComponentsAxis_2699" xlink:to="Locator_us-gaap_EquityComponentDomain_2700" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="Locator_us-gaap_EquityComponentDomain_2643" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="Locator_us-gaap_CommonStockMember_2644" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EquityComponentDomain_2643" xlink:to="Locator_us-gaap_CommonStockMember_2644" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="Locator_us-gaap_EquityComponentDomain_2645" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="Locator_us-gaap_AdditionalPaidInCapitalMember_2646" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EquityComponentDomain_2645" xlink:to="Locator_us-gaap_AdditionalPaidInCapitalMember_2646" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="Locator_us-gaap_EquityComponentDomain_2647" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="Locator_us-gaap_TreasuryStockMember_2648" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EquityComponentDomain_2647" xlink:to="Locator_us-gaap_TreasuryStockMember_2648" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="Locator_us-gaap_EquityComponentDomain_2649" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="Locator_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2650" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EquityComponentDomain_2649" xlink:to="Locator_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2650" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="Locator_us-gaap_EquityComponentDomain_2651" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="Locator_us-gaap_RetainedEarningsMember_2652" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EquityComponentDomain_2651" xlink:to="Locator_us-gaap_RetainedEarningsMember_2652" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="Locator_us-gaap_EquityComponentDomain_2653" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="Locator_us-gaap_NoncontrollingInterestMember_2654" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EquityComponentDomain_2653" xlink:to="Locator_us-gaap_NoncontrollingInterestMember_2654" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2655" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2656" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_2655" xlink:to="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2656" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2657" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="Locator_us-gaap_SharesOutstanding_2658" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_2657" xlink:to="Locator_us-gaap_SharesOutstanding_2658" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2659" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="Locator_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2660" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_2659" xlink:to="Locator_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2660" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2661" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="Locator_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2662" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_2661" xlink:to="Locator_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2662" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2663" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:label="Locator_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_2664" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_2663" xlink:to="Locator_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_2664" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2665" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:label="Locator_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_2666" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_2665" xlink:to="Locator_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_2666" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2667" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="Locator_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2668" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_2667" xlink:to="Locator_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2668" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2669" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="Locator_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2670" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_2669" xlink:to="Locator_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2670" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2671" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="Locator_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_2672" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_2671" xlink:to="Locator_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_2672" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2673" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="Locator_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2674" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_2673" xlink:to="Locator_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2674" order="10.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2675" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="Locator_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2676" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_2675" xlink:to="Locator_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2676" order="11.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2677" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="Locator_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_2678" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_2677" xlink:to="Locator_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_2678" order="12.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2679" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation" xlink:label="Locator_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation_2680" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_2679" xlink:to="Locator_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation_2680" order="13.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2681" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SurrenderedShares" xlink:label="Locator_amed_SurrenderedShares_2682" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_2681" xlink:to="Locator_amed_SurrenderedShares_2682" order="14.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2683" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="Locator_us-gaap_TreasuryStockValueAcquiredCostMethod_2684" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_2683" xlink:to="Locator_us-gaap_TreasuryStockValueAcquiredCostMethod_2684" order="15.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2685" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="Locator_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_2686" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_2685" xlink:to="Locator_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_2686" order="16.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2687" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:label="Locator_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_2688" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_2687" xlink:to="Locator_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_2688" order="17.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2689" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="Locator_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_2690" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_2689" xlink:to="Locator_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_2690" order="18.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2691" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="Locator_us-gaap_MinorityInterestPeriodIncreaseDecrease_2692" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_2691" xlink:to="Locator_us-gaap_MinorityInterestPeriodIncreaseDecrease_2692" order="19.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2693" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment" xlink:label="Locator_amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment_2694" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_2693" xlink:to="Locator_amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment_2694" order="20.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2695" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="Locator_us-gaap_ProfitLoss_2696" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_2695" xlink:to="Locator_us-gaap_ProfitLoss_2696" order="21.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2697" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="Locator_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2698" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_StatementLineItems_2697" xlink:to="Locator_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2698" order="22.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureAcquisitionsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_2811" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_2812" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_LongtermDebtTypeAxis_2811" xlink:to="Locator_us-gaap_LongtermDebtTypeDomain_2812" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_2813" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PromissoryNotesMember" xlink:label="Locator_amed_PromissoryNotesMember_2814" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_2813" xlink:to="Locator_amed_PromissoryNotesMember_2814" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2815" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2816" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_2815" xlink:to="Locator_us-gaap_SegmentDomain_2816" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2817" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_2818" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2817" xlink:to="Locator_amed_HomeHealthMember_2818" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2819" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_2820" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2819" xlink:to="Locator_amed_HospiceMember_2820" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2821" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PersonalCareMember" xlink:label="Locator_amed_PersonalCareMember_2822" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2821" xlink:to="Locator_amed_PersonalCareMember_2822" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2801" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateAxis" xlink:label="Locator_amed_StateAxis_2802" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2801" xlink:to="Locator_amed_StateAxis_2802" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateAxis" xlink:label="Locator_amed_StateAxis_2823" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2824" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_StateAxis_2823" xlink:to="Locator_amed_StateDomain_2824" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2825" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AlabamaMember" xlink:label="Locator_amed_AlabamaMember_2826" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2825" xlink:to="Locator_amed_AlabamaMember_2826" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2827" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NorthCarolinaMember" xlink:label="Locator_amed_NorthCarolinaMember_2828" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2827" xlink:to="Locator_amed_NorthCarolinaMember_2828" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2829" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WestVirginiaMember" xlink:label="Locator_amed_WestVirginiaMember_2830" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2829" xlink:to="Locator_amed_WestVirginiaMember_2830" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2831" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LouisianaMember" xlink:label="Locator_amed_LouisianaMember_2832" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2831" xlink:to="Locator_amed_LouisianaMember_2832" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2833" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FloridaMember" xlink:label="Locator_amed_FloridaMember_2834" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2833" xlink:to="Locator_amed_FloridaMember_2834" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2835" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TennesseeMember" xlink:label="Locator_amed_TennesseeMember_2836" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2835" xlink:to="Locator_amed_TennesseeMember_2836" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2837" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GeorgiaMember" xlink:label="Locator_amed_GeorgiaMember_2838" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2837" xlink:to="Locator_amed_GeorgiaMember_2838" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2839" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MassachusettsMember" xlink:label="Locator_amed_MassachusettsMember_2840" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2839" xlink:to="Locator_amed_MassachusettsMember_2840" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2841" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NewYorkMember" xlink:label="Locator_amed_NewYorkMember_2842" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_StateDomain_2841" xlink:to="Locator_amed_NewYorkMember_2842" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2803" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="Locator_us-gaap_BusinessAcquisitionAxis_2804" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2803" xlink:to="Locator_us-gaap_BusinessAcquisitionAxis_2804" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="Locator_us-gaap_BusinessAcquisitionAxis_2843" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionAcquiredDomain" xlink:label="Locator_amed_BusinessAcquisitionAcquiredDomain_2844" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_BusinessAcquisitionAxis_2843" xlink:to="Locator_amed_BusinessAcquisitionAcquiredDomain_2844" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="Locator_us-gaap_BusinessAcquisitionAxis_2893" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionAcquiredDomain" xlink:label="Locator_amed_BusinessAcquisitionAcquiredDomain_2894" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_BusinessAcquisitionAxis_2893" xlink:to="Locator_amed_BusinessAcquisitionAcquiredDomain_2894" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionAcquiredDomain" xlink:label="Locator_amed_BusinessAcquisitionAcquiredDomain_2845" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InHousePhysiciansPracticeMember" xlink:label="Locator_amed_InHousePhysiciansPracticeMember_2846" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_BusinessAcquisitionAcquiredDomain_2845" xlink:to="Locator_amed_InHousePhysiciansPracticeMember_2846" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionAcquiredDomain" xlink:label="Locator_amed_BusinessAcquisitionAcquiredDomain_2847" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentsMember" xlink:label="Locator_us-gaap_EquityMethodInvestmentsMember_2848" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_BusinessAcquisitionAcquiredDomain_2847" xlink:to="Locator_us-gaap_EquityMethodInvestmentsMember_2848" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionAcquiredDomain" xlink:label="Locator_amed_BusinessAcquisitionAcquiredDomain_2849" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssociatedHomecareMember" xlink:label="Locator_amed_AssociatedHomecareMember_2850" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_BusinessAcquisitionAcquiredDomain_2849" xlink:to="Locator_amed_AssociatedHomecareMember_2850" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionAcquiredDomain" xlink:label="Locator_amed_BusinessAcquisitionAcquiredDomain_2851" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProfessionalProfilesMember" xlink:label="Locator_amed_ProfessionalProfilesMember_2852" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_BusinessAcquisitionAcquiredDomain_2851" xlink:to="Locator_amed_ProfessionalProfilesMember_2852" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionAcquiredDomain" xlink:label="Locator_amed_BusinessAcquisitionAcquiredDomain_2853" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InfinityHomeCareMember" xlink:label="Locator_amed_InfinityHomeCareMember_2854" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_BusinessAcquisitionAcquiredDomain_2853" xlink:to="Locator_amed_InfinityHomeCareMember_2854" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2805" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2806" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2805" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_2806" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2807" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2808" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2807" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2808" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2855" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2856" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2855" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2856" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2861" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CertificatesOfNeedAndLicensesMember" xlink:label="Locator_amed_CertificatesOfNeedAndLicensesMember_2862" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2861" xlink:to="Locator_amed_CertificatesOfNeedAndLicensesMember_2862" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2857" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AcquiredNameOfBusinessMember" xlink:label="Locator_amed_AcquiredNameOfBusinessMember_2858" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2857" xlink:to="Locator_amed_AcquiredNameOfBusinessMember_2858" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2859" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="Locator_us-gaap_NoncompeteAgreementsMember_2860" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2859" xlink:to="Locator_us-gaap_NoncompeteAgreementsMember_2860" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2809" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_2810" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2809" xlink:to="Locator_us-gaap_LongtermDebtTypeAxis_2810" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2797" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2798" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2797" xlink:to="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2798" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2863" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="Locator_us-gaap_BusinessCombinationConsiderationTransferred1_2864" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2863" xlink:to="Locator_us-gaap_BusinessCombinationConsiderationTransferred1_2864" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2865" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfBusinessesAcquired" xlink:label="Locator_us-gaap_NumberOfBusinessesAcquired_2866" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2865" xlink:to="Locator_us-gaap_NumberOfBusinessesAcquired_2866" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2867" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="Locator_us-gaap_GoodwillAcquiredDuringPeriod_2868" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2867" xlink:to="Locator_us-gaap_GoodwillAcquiredDuringPeriod_2868" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2869" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2870" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2869" xlink:to="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2870" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2871" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2872" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2871" xlink:to="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2872" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2873" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_2874" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2873" xlink:to="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_2874" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2875" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid" xlink:label="Locator_amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid_2876" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2875" xlink:to="Locator_amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid_2876" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2877" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2878" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2877" xlink:to="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2878" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2879" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="Locator_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_2880" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2879" xlink:to="Locator_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_2880" order="9.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2881" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears" xlink:label="Locator_amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears_2882" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2881" xlink:to="Locator_amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears_2882" order="10.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2883" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="Locator_us-gaap_EscrowDeposit_2884" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2883" xlink:to="Locator_us-gaap_EscrowDeposit_2884" order="11.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2885" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="Locator_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_2886" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2885" xlink:to="Locator_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_2886" order="12.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2887" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="Locator_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2888" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2887" xlink:to="Locator_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2888" order="13.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2889" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="Locator_us-gaap_GoodwillPurchaseAccountingAdjustments_2890" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2889" xlink:to="Locator_us-gaap_GoodwillPurchaseAccountingAdjustments_2890" order="14.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2891" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="Locator_us-gaap_LongTermDebt_2892" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2891" xlink:to="Locator_us-gaap_LongTermDebt_2892" order="15.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureGoodwillAndOtherIntangibleAssetsNetDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2973" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2974" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_2973" xlink:to="Locator_us-gaap_SegmentDomain_2974" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2975" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_2976" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2975" xlink:to="Locator_amed_HomeHealthMember_2976" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2977" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_2978" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_2977" xlink:to="Locator_amed_HospiceMember_2978" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_2979" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_2980" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_2979" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsDomain_2980" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_2993" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_2994" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_2993" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsDomain_2994" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_2981" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentsMember" xlink:label="Locator_us-gaap_EquityMethodInvestmentsMember_2982" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsDomain_2981" xlink:to="Locator_us-gaap_EquityMethodInvestmentsMember_2982" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_2983" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareCentersClosedOrConsolidatedMember" xlink:label="Locator_amed_CareCentersClosedOrConsolidatedMember_2984" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsDomain_2983" xlink:to="Locator_amed_CareCentersClosedOrConsolidatedMember_2984" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_2985" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AnnualImpairmentTestStepOneMember" xlink:label="Locator_amed_AnnualImpairmentTestStepOneMember_2986" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsDomain_2985" xlink:to="Locator_amed_AnnualImpairmentTestStepOneMember_2986" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2991" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_2992" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2991" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_2992" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2965" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="Locator_us-gaap_ScheduleOfGoodwillTable_2966" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2965" xlink:to="Locator_us-gaap_ScheduleOfGoodwillTable_2966" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="Locator_us-gaap_ScheduleOfGoodwillTable_2969" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_2970" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfGoodwillTable_2969" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_2970" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="Locator_us-gaap_ScheduleOfGoodwillTable_2971" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2972" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfGoodwillTable_2971" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_2972" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2989" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="Locator_us-gaap_GoodwillImpairmentLoss_2990" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2989" xlink:to="Locator_us-gaap_GoodwillImpairmentLoss_2990" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2987" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="Locator_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2988" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2987" xlink:to="Locator_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2988" order="1.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureIncomeTaxesDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_3077" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3078" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_RangeAxis_3077" xlink:to="Locator_us-gaap_RangeMember_3078" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3079" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_3080" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_3079" xlink:to="Locator_us-gaap_MinimumMember_3080" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3081" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_3082" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_3081" xlink:to="Locator_us-gaap_MaximumMember_3082" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3063" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="Locator_us-gaap_IncomeTaxExaminationTable_3064" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3063" xlink:to="Locator_us-gaap_IncomeTaxExaminationTable_3064" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="Locator_us-gaap_IncomeTaxExaminationTable_3067" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="Locator_us-gaap_IncomeTaxAuthorityAxis_3068" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_IncomeTaxExaminationTable_3067" xlink:to="Locator_us-gaap_IncomeTaxAuthorityAxis_3068" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="Locator_us-gaap_IncomeTaxAuthorityAxis_3083" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="Locator_us-gaap_IncomeTaxAuthorityDomain_3084" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_IncomeTaxAuthorityAxis_3083" xlink:to="Locator_us-gaap_IncomeTaxAuthorityDomain_3084" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="Locator_us-gaap_IncomeTaxAuthorityAxis_3141" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="Locator_us-gaap_IncomeTaxAuthorityDomain_3142" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_IncomeTaxAuthorityAxis_3141" xlink:to="Locator_us-gaap_IncomeTaxAuthorityDomain_3142" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="Locator_us-gaap_IncomeTaxAuthorityDomain_3085" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="Locator_us-gaap_StateAndLocalJurisdictionMember_3086" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeTaxAuthorityDomain_3085" xlink:to="Locator_us-gaap_StateAndLocalJurisdictionMember_3086" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="Locator_us-gaap_IncomeTaxAuthorityDomain_3087" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="Locator_us-gaap_DomesticCountryMember_3088" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeTaxAuthorityDomain_3087" xlink:to="Locator_us-gaap_DomesticCountryMember_3088" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="Locator_us-gaap_IncomeTaxAuthorityDomain_3089" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="Locator_us-gaap_ForeignCountryMember_3090" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IncomeTaxAuthorityDomain_3089" xlink:to="Locator_us-gaap_ForeignCountryMember_3090" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="Locator_us-gaap_IncomeTaxExaminationTable_3069" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_3070" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_IncomeTaxExaminationTable_3069" xlink:to="Locator_us-gaap_RangeAxis_3070" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="Locator_us-gaap_IncomeTaxExaminationTable_3071" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="Locator_us-gaap_BalanceSheetLocationAxis_3072" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_IncomeTaxExaminationTable_3071" xlink:to="Locator_us-gaap_BalanceSheetLocationAxis_3072" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="Locator_us-gaap_BalanceSheetLocationAxis_3091" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="Locator_us-gaap_BalanceSheetLocationDomain_3092" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_BalanceSheetLocationAxis_3091" xlink:to="Locator_us-gaap_BalanceSheetLocationDomain_3092" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="Locator_us-gaap_BalanceSheetLocationAxis_3143" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="Locator_us-gaap_BalanceSheetLocationDomain_3144" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_BalanceSheetLocationAxis_3143" xlink:to="Locator_us-gaap_BalanceSheetLocationDomain_3144" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="Locator_us-gaap_BalanceSheetLocationDomain_3093" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherLongTermObligationsMember" xlink:label="Locator_amed_OtherLongTermObligationsMember_3094" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_BalanceSheetLocationDomain_3093" xlink:to="Locator_amed_OtherLongTermObligationsMember_3094" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="Locator_us-gaap_BalanceSheetLocationDomain_3095" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredIncomeTaxesMember" xlink:label="Locator_amed_DeferredIncomeTaxesMember_3096" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_BalanceSheetLocationDomain_3095" xlink:to="Locator_amed_DeferredIncomeTaxesMember_3096" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="Locator_us-gaap_BalanceSheetLocationDomain_3097" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AccruedExpensesMember" xlink:label="Locator_amed_AccruedExpensesMember_3098" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_BalanceSheetLocationDomain_3097" xlink:to="Locator_amed_AccruedExpensesMember_3098" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="Locator_us-gaap_IncomeTaxExaminationTable_3073" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="Locator_us-gaap_TaxCreditCarryforwardAxis_3074" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_IncomeTaxExaminationTable_3073" xlink:to="Locator_us-gaap_TaxCreditCarryforwardAxis_3074" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="Locator_us-gaap_TaxCreditCarryforwardAxis_3099" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="Locator_us-gaap_TaxCreditCarryforwardNameDomain_3100" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_TaxCreditCarryforwardAxis_3099" xlink:to="Locator_us-gaap_TaxCreditCarryforwardNameDomain_3100" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="Locator_us-gaap_TaxCreditCarryforwardAxis_3145" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="Locator_us-gaap_TaxCreditCarryforwardNameDomain_3146" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_TaxCreditCarryforwardAxis_3145" xlink:to="Locator_us-gaap_TaxCreditCarryforwardNameDomain_3146" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="Locator_us-gaap_TaxCreditCarryforwardNameDomain_3101" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ResearchAndDevelopmentTaxCreditMember" xlink:label="Locator_amed_ResearchAndDevelopmentTaxCreditMember_3102" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_TaxCreditCarryforwardNameDomain_3101" xlink:to="Locator_amed_ResearchAndDevelopmentTaxCreditMember_3102" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="Locator_us-gaap_TaxCreditCarryforwardNameDomain_3103" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EmploymentTaxCreditMember" xlink:label="Locator_amed_EmploymentTaxCreditMember_3104" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_TaxCreditCarryforwardNameDomain_3103" xlink:to="Locator_amed_EmploymentTaxCreditMember_3104" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="Locator_us-gaap_TaxCreditCarryforwardNameDomain_3105" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AlternativeMinimumTaxCreditMember" xlink:label="Locator_amed_AlternativeMinimumTaxCreditMember_3106" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_TaxCreditCarryforwardNameDomain_3105" xlink:to="Locator_amed_AlternativeMinimumTaxCreditMember_3106" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="Locator_us-gaap_TaxCreditCarryforwardNameDomain_3107" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateTaxCreditMember" xlink:label="Locator_amed_StateTaxCreditMember_3108" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_TaxCreditCarryforwardNameDomain_3107" xlink:to="Locator_amed_StateTaxCreditMember_3108" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="Locator_us-gaap_IncomeTaxExaminationTable_3075" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnrecognizedTaxBenefitsAxis" xlink:label="Locator_amed_UnrecognizedTaxBenefitsAxis_3076" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_IncomeTaxExaminationTable_3075" xlink:to="Locator_amed_UnrecognizedTaxBenefitsAxis_3076" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnrecognizedTaxBenefitsAxis" xlink:label="Locator_amed_UnrecognizedTaxBenefitsAxis_3109" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnrecognizedTaxBenefitsDomain" xlink:label="Locator_amed_UnrecognizedTaxBenefitsDomain_3110" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_UnrecognizedTaxBenefitsAxis_3109" xlink:to="Locator_amed_UnrecognizedTaxBenefitsDomain_3110" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnrecognizedTaxBenefitsAxis" xlink:label="Locator_amed_UnrecognizedTaxBenefitsAxis_3147" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnrecognizedTaxBenefitsDomain" xlink:label="Locator_amed_UnrecognizedTaxBenefitsDomain_3148" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_amed_UnrecognizedTaxBenefitsAxis_3147" xlink:to="Locator_amed_UnrecognizedTaxBenefitsDomain_3148" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnrecognizedTaxBenefitsDomain" xlink:label="Locator_amed_UnrecognizedTaxBenefitsDomain_3111" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NetOperatingLossMember" xlink:label="Locator_amed_NetOperatingLossMember_3112" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_UnrecognizedTaxBenefitsDomain_3111" xlink:to="Locator_amed_NetOperatingLossMember_3112" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnrecognizedTaxBenefitsDomain" xlink:label="Locator_amed_UnrecognizedTaxBenefitsDomain_3113" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TaxCreditCarryforwardMember" xlink:label="Locator_amed_TaxCreditCarryforwardMember_3114" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_UnrecognizedTaxBenefitsDomain_3113" xlink:to="Locator_amed_TaxCreditCarryforwardMember_3114" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3115" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="Locator_us-gaap_IncomeTaxesReceivable_3116" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3115" xlink:to="Locator_us-gaap_IncomeTaxesReceivable_3116" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3117" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="Locator_us-gaap_OperatingLossCarryforwards_3118" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3117" xlink:to="Locator_us-gaap_OperatingLossCarryforwards_3118" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3119" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="Locator_us-gaap_IncomeTaxCreditsAndAdjustments_3120" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3119" xlink:to="Locator_us-gaap_IncomeTaxCreditsAndAdjustments_3120" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3121" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="Locator_us-gaap_DeferredTaxAssetsValuationAllowance_3122" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3121" xlink:to="Locator_us-gaap_DeferredTaxAssetsValuationAllowance_3122" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3123" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="Locator_us-gaap_OperatingLossCarryforwardsValuationAllowance_3124" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3123" xlink:to="Locator_us-gaap_OperatingLossCarryforwardsValuationAllowance_3124" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3125" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:label="Locator_us-gaap_TaxCreditCarryforwardValuationAllowance_3126" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3125" xlink:to="Locator_us-gaap_TaxCreditCarryforwardValuationAllowance_3126" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3127" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="Locator_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3128" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3127" xlink:to="Locator_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3128" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3129" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefits_3130" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3129" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefits_3130" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3131" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_3132" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3131" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_3132" order="9.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3133" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3134" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3133" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3134" order="10.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3135" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfIndividualStatesSubjectToIncomeTax" xlink:label="Locator_amed_NumberOfIndividualStatesSubjectToIncomeTax_3136" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3135" xlink:to="Locator_amed_NumberOfIndividualStatesSubjectToIncomeTax_3136" order="11.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3137" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="Locator_us-gaap_OpenTaxYear_3138" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3137" xlink:to="Locator_us-gaap_OpenTaxYear_3138" order="12.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3139" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_3140" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3139" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_3140" order="13.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureCapitalStockAndShareBasedCompensationDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_3265" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3266" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_RangeAxis_3265" xlink:to="Locator_us-gaap_RangeMember_3266" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3267" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_3268" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_3267" xlink:to="Locator_us-gaap_MinimumMember_3268" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3269" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_3270" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_3269" xlink:to="Locator_us-gaap_MaximumMember_3270" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3287" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="Locator_us-gaap_CommonStockSharesAuthorized_3288" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3287" xlink:to="Locator_us-gaap_CommonStockSharesAuthorized_3288" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3289" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="Locator_us-gaap_CommonStockParOrStatedValuePerShare_3290" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3289" xlink:to="Locator_us-gaap_CommonStockParOrStatedValuePerShare_3290" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3291" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="Locator_us-gaap_PreferredStockSharesAuthorized_3292" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3291" xlink:to="Locator_us-gaap_PreferredStockSharesAuthorized_3292" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3293" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="Locator_us-gaap_PreferredStockParOrStatedValuePerShare_3294" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3293" xlink:to="Locator_us-gaap_PreferredStockParOrStatedValuePerShare_3294" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3295" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="Locator_us-gaap_CommonStockSharesIssued_3296" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3295" xlink:to="Locator_us-gaap_CommonStockSharesIssued_3296" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3297" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="Locator_us-gaap_CommonStockSharesOutstanding_3298" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3297" xlink:to="Locator_us-gaap_CommonStockSharesOutstanding_3298" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3299" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="Locator_us-gaap_PreferredStockSharesIssued_3300" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3299" xlink:to="Locator_us-gaap_PreferredStockSharesIssued_3300" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3301" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="Locator_us-gaap_PreferredStockSharesOutstanding_3302" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3301" xlink:to="Locator_us-gaap_PreferredStockSharesOutstanding_3302" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3303" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Percentageofownershipinsubsidiaries" xlink:label="Locator_amed_Percentageofownershipinsubsidiaries_3304" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3303" xlink:to="Locator_amed_Percentageofownershipinsubsidiaries_3304" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3305" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3306" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3305" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3306" order="10.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3307" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3308" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3307" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3308" order="11.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3309" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Fairvalueofshareofcommonstockpercentage" xlink:label="Locator_amed_Fairvalueofshareofcommonstockpercentage_3310" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3309" xlink:to="Locator_amed_Fairvalueofshareofcommonstockpercentage_3310" order="12.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3311" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" xlink:label="Locator_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries_3312" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3311" xlink:to="Locator_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries_3312" order="13.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3313" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3314" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3313" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3314" order="14.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3315" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_3316" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3315" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_3316" order="15.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3317" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3318" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3317" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3318" order="16.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3319" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" xlink:label="Locator_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan_3320" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3319" xlink:to="Locator_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan_3320" order="17.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3321" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StockAvailableForFutureIssuanceUnderEmployeePurchasePlan" xlink:label="Locator_amed_StockAvailableForFutureIssuanceUnderEmployeePurchasePlan_3322" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3321" xlink:to="Locator_amed_StockAvailableForFutureIssuanceUnderEmployeePurchasePlan_3322" order="18.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3323" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_3324" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3323" xlink:to="Locator_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_3324" order="19.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3325" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3326" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3325" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3326" order="20.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3327" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3328" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3327" xlink:to="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3328" order="21.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3329" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3330" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3329" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3330" order="22.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3339" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MarketBasedAwardTargetShareAmount" xlink:label="Locator_amed_MarketBasedAwardTargetShareAmount_3340" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3339" xlink:to="Locator_amed_MarketBasedAwardTargetShareAmount_3340" order="27.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3341" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MarketBasedAwardMaximumShareAmount" xlink:label="Locator_amed_MarketBasedAwardMaximumShareAmount_3342" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3341" xlink:to="Locator_amed_MarketBasedAwardMaximumShareAmount_3342" order="28.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3343" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Performancebasedawardtargetshareamount" xlink:label="Locator_amed_Performancebasedawardtargetshareamount_3344" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3343" xlink:to="Locator_amed_Performancebasedawardtargetshareamount_3344" order="29.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3335" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="Locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3336" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3335" xlink:to="Locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3336" order="25.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3337" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="Locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3338" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3337" xlink:to="Locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3338" order="26.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3331" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="Locator_us-gaap_AllocatedShareBasedCompensationExpense_3332" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3331" xlink:to="Locator_us-gaap_AllocatedShareBasedCompensationExpense_3332" order="23.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3333" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3334" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3333" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3334" order="24.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3257" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3258" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3257" xlink:to="Locator_amed_EquityBasedAwardsTable_3258" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3261" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_3262" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_EquityBasedAwardsTable_3261" xlink:to="Locator_us-gaap_RangeAxis_3262" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3263" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="Locator_us-gaap_AwardTypeAxis_3264" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_EquityBasedAwardsTable_3263" xlink:to="Locator_us-gaap_AwardTypeAxis_3264" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="Locator_us-gaap_AwardTypeAxis_3271" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3272" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_AwardTypeAxis_3271" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3272" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="Locator_us-gaap_AwardTypeAxis_3345" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3346" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_AwardTypeAxis_3345" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3346" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3273" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedAwardsMember" xlink:label="Locator_amed_ShareBasedAwardsMember_3274" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3273" xlink:to="Locator_amed_ShareBasedAwardsMember_3274" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3275" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" xlink:label="Locator_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_3276" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3275" xlink:to="Locator_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_3276" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3277" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockMember" xlink:label="Locator_amed_NonVestedStockMember_3278" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3277" xlink:to="Locator_amed_NonVestedStockMember_3278" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3279" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" xlink:label="Locator_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_3280" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3279" xlink:to="Locator_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_3280" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3281" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember" xlink:label="Locator_amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember_3282" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3281" xlink:to="Locator_amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember_3282" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3283" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceMember" xlink:label="Locator_amed_NonVestedStockUnitsServiceMember_3284" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3283" xlink:to="Locator_amed_NonVestedStockUnitsServiceMember_3284" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3285" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockOptionMember" xlink:label="Locator_us-gaap_StockOptionMember_3286" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3285" xlink:to="Locator_us-gaap_StockOptionMember_3286" order="7.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureValuationAndQualifyingAccountsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_3399" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3400" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_3399" xlink:to="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3400" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3403" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesTypeAxis_3404" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3403" xlink:to="Locator_us-gaap_ValuationAllowancesAndReservesTypeAxis_3404" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesTypeAxis_3405" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesDomain_3406" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_ValuationAllowancesAndReservesTypeAxis_3405" xlink:to="Locator_us-gaap_ValuationAllowancesAndReservesDomain_3406" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesTypeAxis_3423" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesDomain_3424" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_ValuationAllowancesAndReservesTypeAxis_3423" xlink:to="Locator_us-gaap_ValuationAllowancesAndReservesDomain_3424" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesDomain_3407" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsMember" xlink:label="Locator_us-gaap_AllowanceForDoubtfulAccountsMember_3408" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ValuationAllowancesAndReservesDomain_3407" xlink:to="Locator_us-gaap_AllowanceForDoubtfulAccountsMember_3408" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesDomain_3409" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsDiscontinuedOperationsMember" xlink:label="Locator_us-gaap_AllowanceForDoubtfulAccountsDiscontinuedOperationsMember_3410" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ValuationAllowancesAndReservesDomain_3409" xlink:to="Locator_us-gaap_AllowanceForDoubtfulAccountsDiscontinuedOperationsMember_3410" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesDomain_3411" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedRevenueAdjustmentsMember" xlink:label="Locator_amed_EstimatedRevenueAdjustmentsMember_3412" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ValuationAllowancesAndReservesDomain_3411" xlink:to="Locator_amed_EstimatedRevenueAdjustmentsMember_3412" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesDomain_3413" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedRevenueAdjustmentsDiscontinuedOperationsMember" xlink:label="Locator_amed_EstimatedRevenueAdjustmentsDiscontinuedOperationsMember_3414" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ValuationAllowancesAndReservesDomain_3413" xlink:to="Locator_amed_EstimatedRevenueAdjustmentsDiscontinuedOperationsMember_3414" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_3415" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesBalance_3416" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_3415" xlink:to="Locator_us-gaap_ValuationAllowancesAndReservesBalance_3416" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_3417" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="Locator_us-gaap_ProvisionForDoubtfulAccounts_3418" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_3417" xlink:to="Locator_us-gaap_ProvisionForDoubtfulAccounts_3418" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_3419" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesAdjustments_3420" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_3419" xlink:to="Locator_us-gaap_ValuationAllowancesAndReservesAdjustments_3420" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_3421" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesDeductions_3422" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_3421" xlink:to="Locator_us-gaap_ValuationAllowancesAndReservesDeductions_3422" order="4.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureUnauditedSummarizedQuarterlyFinancialInformationDetail">
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TypeOfBusinessSoldAxis" xlink:label="Locator_amed_TypeOfBusinessSoldAxis_3485" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessSoldDomain" xlink:label="Locator_amed_BusinessSoldDomain_3486" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_TypeOfBusinessSoldAxis_3485" xlink:to="Locator_amed_BusinessSoldDomain_3486" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessSoldDomain" xlink:label="Locator_amed_BusinessSoldDomain_3487" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceInpatientUnitMember" xlink:label="Locator_amed_HospiceInpatientUnitMember_3488" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_BusinessSoldDomain_3487" xlink:to="Locator_amed_HospiceInpatientUnitMember_3488" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="Locator_us-gaap_LitigationStatusAxis_3489" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_3490" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_LitigationStatusAxis_3489" xlink:to="Locator_us-gaap_LitigationStatusDomain_3490" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_3491" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OigSelfDisclosureMember" xlink:label="Locator_amed_OigSelfDisclosureMember_3492" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LitigationStatusDomain_3491" xlink:to="Locator_amed_OigSelfDisclosureMember_3492" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3475" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationTable" xlink:label="Locator_amed_QuarterlyFinancialInformationTable_3476" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3475" xlink:to="Locator_amed_QuarterlyFinancialInformationTable_3476" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationTable" xlink:label="Locator_amed_QuarterlyFinancialInformationTable_3479" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationAxis" xlink:label="Locator_amed_QuarterlyFinancialInformationAxis_3480" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_QuarterlyFinancialInformationTable_3479" xlink:to="Locator_amed_QuarterlyFinancialInformationAxis_3480" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationAxis" xlink:label="Locator_amed_QuarterlyFinancialInformationAxis_3493" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationDomain" xlink:label="Locator_amed_QuarterlyFinancialInformationDomain_3494" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_QuarterlyFinancialInformationAxis_3493" xlink:to="Locator_amed_QuarterlyFinancialInformationDomain_3494" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationAxis" xlink:label="Locator_amed_QuarterlyFinancialInformationAxis_3533" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationDomain" xlink:label="Locator_amed_QuarterlyFinancialInformationDomain_3534" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_amed_QuarterlyFinancialInformationAxis_3533" xlink:to="Locator_amed_QuarterlyFinancialInformationDomain_3534" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationDomain" xlink:label="Locator_amed_QuarterlyFinancialInformationDomain_3495" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NetOfTaxMember" xlink:label="Locator_amed_NetOfTaxMember_3496" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_QuarterlyFinancialInformationDomain_3495" xlink:to="Locator_amed_NetOfTaxMember_3496" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationTable" xlink:label="Locator_amed_QuarterlyFinancialInformationTable_3481" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="Locator_us-gaap_LitigationStatusAxis_3482" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_QuarterlyFinancialInformationTable_3481" xlink:to="Locator_us-gaap_LitigationStatusAxis_3482" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationTable" xlink:label="Locator_amed_QuarterlyFinancialInformationTable_3483" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TypeOfBusinessSoldAxis" xlink:label="Locator_amed_TypeOfBusinessSoldAxis_3484" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_QuarterlyFinancialInformationTable_3483" xlink:to="Locator_amed_TypeOfBusinessSoldAxis_3484" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3497" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationPatientServiceRevenue" xlink:label="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_3498" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3497" xlink:to="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_3498" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3499" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="Locator_us-gaap_NetIncomeLoss_3500" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3499" xlink:to="Locator_us-gaap_NetIncomeLoss_3500" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3501" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="Locator_us-gaap_EarningsPerShareBasic_3502" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3501" xlink:to="Locator_us-gaap_EarningsPerShareBasic_3502" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3503" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="Locator_us-gaap_EarningsPerShareDiluted_3504" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3503" xlink:to="Locator_us-gaap_EarningsPerShareDiluted_3504" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3505" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="Locator_us-gaap_AssetImpairmentCharges_3506" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3505" xlink:to="Locator_us-gaap_AssetImpairmentCharges_3506" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3507" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="Locator_us-gaap_RestructuringCharges_3508" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3507" xlink:to="Locator_us-gaap_RestructuringCharges_3508" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3509" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalFees" xlink:label="Locator_us-gaap_LegalFees_3510" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3509" xlink:to="Locator_us-gaap_LegalFees_3510" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3511" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ReversalOfLegalAccrual" xlink:label="Locator_amed_ReversalOfLegalAccrual_3512" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3511" xlink:to="Locator_amed_ReversalOfLegalAccrual_3512" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3513" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="Locator_us-gaap_LossContingencyAccrualProvision_3514" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3513" xlink:to="Locator_us-gaap_LossContingencyAccrualProvision_3514" order="9.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3515" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalizedComputerSoftwareImpairments" xlink:label="Locator_us-gaap_CapitalizedComputerSoftwareImpairments_3516" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3515" xlink:to="Locator_us-gaap_CapitalizedComputerSoftwareImpairments_3516" order="10.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3517" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="Locator_us-gaap_WriteOffOfDeferredDebtIssuanceCost_3518" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3517" xlink:to="Locator_us-gaap_WriteOffOfDeferredDebtIssuanceCost_3518" order="11.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3519" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="Locator_us-gaap_GainsLossesOnSalesOfAssets_3520" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3519" xlink:to="Locator_us-gaap_GainsLossesOnSalesOfAssets_3520" order="12.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3521" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_UsDepartmentOfJusticeSettlement_3522" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3521" xlink:to="Locator_amed_UsDepartmentOfJusticeSettlement_3522" order="13.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3523" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InsuranceProceedsForReimbursementOfLegalFees" xlink:label="Locator_amed_InsuranceProceedsForReimbursementOfLegalFees_3524" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3523" xlink:to="Locator_amed_InsuranceProceedsForReimbursementOfLegalFees_3524" order="14.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3525" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityLoanCost" xlink:label="Locator_amed_LineOfCreditFacilityLoanCost_3526" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3525" xlink:to="Locator_amed_LineOfCreditFacilityLoanCost_3526" order="15.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3527" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="Locator_us-gaap_ProceedsFromLegalSettlements_3528" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3527" xlink:to="Locator_us-gaap_ProceedsFromLegalSettlements_3528" order="16.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3529" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SoftwareImplementationCosts" xlink:label="Locator_amed_SoftwareImplementationCosts_3530" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3529" xlink:to="Locator_amed_SoftwareImplementationCosts_3530" order="17.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3531" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="Locator_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_3532" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3531" xlink:to="Locator_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_3532" order="18.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/FutureMinimumRentalCommitmentsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_3583" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3584" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_RangeAxis_3583" xlink:to="Locator_us-gaap_RangeMember_3584" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3585" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_3586" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_3585" xlink:to="Locator_us-gaap_MinimumMember_3586" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3587" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_3588" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_3587" xlink:to="Locator_us-gaap_MaximumMember_3588" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3577" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FutureRentalCommitmentsTable" xlink:label="Locator_amed_FutureRentalCommitmentsTable_3578" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3577" xlink:to="Locator_amed_FutureRentalCommitmentsTable_3578" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FutureRentalCommitmentsTable" xlink:label="Locator_amed_FutureRentalCommitmentsTable_3581" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_3582" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_FutureRentalCommitmentsTable_3581" xlink:to="Locator_us-gaap_RangeAxis_3582" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3589" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3590" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3589" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3590" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3591" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_3592" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3591" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_3592" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3593" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3594" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3593" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3594" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3595" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3596" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3595" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3596" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3597" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_3598" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3597" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_3598" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3599" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_3600" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3599" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_3600" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3601" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_3602" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3601" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_3602" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3603" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseCommitmentsForDiscontinuedOperations" xlink:label="Locator_amed_OperatingLeaseCommitmentsForDiscontinuedOperations_3604" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3603" xlink:to="Locator_amed_OperatingLeaseCommitmentsForDiscontinuedOperations_3604" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3605" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeasesRentExpenseNetForContinuingOperations" xlink:label="Locator_amed_OperatingLeasesRentExpenseNetForContinuingOperations_3606" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3605" xlink:to="Locator_amed_OperatingLeasesRentExpenseNetForContinuingOperations_3606" order="9.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3607" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseTermYears" xlink:label="Locator_amed_OperatingLeaseTermYears_3608" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3607" xlink:to="Locator_amed_OperatingLeaseTermYears_3608" order="10.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3609" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeasesAgreementExpirationYear" xlink:label="Locator_amed_OperatingLeasesAgreementExpirationYear_3610" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3609" xlink:to="Locator_amed_OperatingLeasesAgreementExpirationYear_3610" order="11.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureEmployeeStockPurchasePlanDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3643" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="Locator_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_3644" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3643" xlink:to="Locator_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_3644" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="Locator_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_3645" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_3646" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_3645" xlink:to="Locator_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_3646" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_3647" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3648" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_3647" xlink:to="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3648" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_3671" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3672" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_3671" xlink:to="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3672" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3649" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PriorToTwoThousandFourteenMember" xlink:label="Locator_amed_PriorToTwoThousandFourteenMember_3650" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3649" xlink:to="Locator_amed_PriorToTwoThousandFourteenMember_3650" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3651" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_January12015ToMarch312015Member" xlink:label="Locator_amed_January12015ToMarch312015Member_3652" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3651" xlink:to="Locator_amed_January12015ToMarch312015Member_3652" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3653" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_April12015ToJune302015Member" xlink:label="Locator_amed_April12015ToJune302015Member_3654" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3653" xlink:to="Locator_amed_April12015ToJune302015Member_3654" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3655" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_July12015ToSeptember302015Member" xlink:label="Locator_amed_July12015ToSeptember302015Member_3656" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3655" xlink:to="Locator_amed_July12015ToSeptember302015Member_3656" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3657" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_October12015ToDecember312015Member" xlink:label="Locator_amed_October12015ToDecember312015Member_3658" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3657" xlink:to="Locator_amed_October12015ToDecember312015Member_3658" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3659" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_January12016ToMarch312016Member" xlink:label="Locator_amed_January12016ToMarch312016Member_3660" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3659" xlink:to="Locator_amed_January12016ToMarch312016Member_3660" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3661" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_April12016ToJune302016Member" xlink:label="Locator_amed_April12016ToJune302016Member_3662" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3661" xlink:to="Locator_amed_April12016ToJune302016Member_3662" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3663" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_July12016ToSeptember302016Member" xlink:label="Locator_amed_July12016ToSeptember302016Member_3664" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3663" xlink:to="Locator_amed_July12016ToSeptember302016Member_3664" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3665" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_October12016ToDecember312016Member" xlink:label="Locator_amed_October12016ToDecember312016Member_3666" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3665" xlink:to="Locator_amed_October12016ToDecember312016Member_3666" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3667" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="Locator_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3668" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3667" xlink:to="Locator_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3668" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3669" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare" xlink:label="Locator_amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare_3670" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3669" xlink:to="Locator_amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare_3670" order="2.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureStockOptionActivityDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_3755" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3756" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_RangeAxis_3755" xlink:to="Locator_us-gaap_RangeMember_3756" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3759" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_3760" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_3759" xlink:to="Locator_us-gaap_MinimumMember_3760" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3757" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_3758" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_3757" xlink:to="Locator_us-gaap_MaximumMember_3758" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3765" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3766" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3765" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3766" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3767" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_3768" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3767" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_3768" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3769" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="Locator_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3770" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3769" xlink:to="Locator_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3770" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3771" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3772" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3771" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3772" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3773" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3774" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3773" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3774" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3775" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3776" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3775" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3776" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3777" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3778" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3777" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3778" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3779" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3780" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3779" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3780" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3781" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_3782" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3781" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_3782" order="10.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3783" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3784" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3783" xlink:to="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3784" order="12.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3785" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3786" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3785" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3786" order="13.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3787" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3788" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3787" xlink:to="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3788" order="14.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3789" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3790" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3789" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3790" order="15.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3791" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="Locator_us-gaap_FairValueAssumptionsExpectedVolatilityRate_3792" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3791" xlink:to="Locator_us-gaap_FairValueAssumptionsExpectedVolatilityRate_3792" order="16.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3793" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3794" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3793" xlink:to="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3794" order="17.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3801" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_3802" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3801" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_3802" order="21.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3803" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_3804" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3803" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_3804" order="22.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3805" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="Locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3806" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3805" xlink:to="Locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3806" order="23.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3807" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="Locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3808" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3807" xlink:to="Locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3808" order="24.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3809" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="Locator_us-gaap_AllocatedShareBasedCompensationExpense_3810" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3809" xlink:to="Locator_us-gaap_AllocatedShareBasedCompensationExpense_3810" order="25.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3797" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3798" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3797" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3798" order="19.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3799" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_3800" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3799" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_3800" order="20.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3795" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" xlink:label="Locator_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_3796" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3795" xlink:to="Locator_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_3796" order="18.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3747" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3748" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3747" xlink:to="Locator_amed_EquityBasedAwardsTable_3748" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3753" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_3754" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_EquityBasedAwardsTable_3753" xlink:to="Locator_us-gaap_RangeAxis_3754" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3751" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="Locator_us-gaap_AwardTypeAxis_3752" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_EquityBasedAwardsTable_3751" xlink:to="Locator_us-gaap_AwardTypeAxis_3752" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="Locator_us-gaap_AwardTypeAxis_3761" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3762" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_AwardTypeAxis_3761" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3762" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3763" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockOptionMember" xlink:label="Locator_us-gaap_StockOptionMember_3764" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3763" xlink:to="Locator_us-gaap_StockOptionMember_3764" order="1.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureNonVestedStockActivityDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3867" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3868" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3867" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3868" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3869" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3870" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3869" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3870" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3871" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3872" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3871" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3872" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3873" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3874" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3873" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3874" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3875" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3876" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3875" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3876" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3877" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3878" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3877" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3878" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3879" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3880" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3879" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3880" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3881" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3882" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3881" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3882" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3847" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3848" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3847" xlink:to="Locator_amed_EquityBasedAwardsTable_3848" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3851" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="Locator_us-gaap_AwardTypeAxis_3852" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_EquityBasedAwardsTable_3851" xlink:to="Locator_us-gaap_AwardTypeAxis_3852" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="Locator_us-gaap_AwardTypeAxis_3853" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3854" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_AwardTypeAxis_3853" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3854" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3855" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedAwardsMember" xlink:label="Locator_amed_ShareBasedAwardsMember_3856" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3855" xlink:to="Locator_amed_ShareBasedAwardsMember_3856" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3857" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" xlink:label="Locator_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_3858" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3857" xlink:to="Locator_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_3858" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3859" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockMember" xlink:label="Locator_amed_NonVestedStockMember_3860" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3859" xlink:to="Locator_amed_NonVestedStockMember_3860" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3861" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" xlink:label="Locator_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_3862" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3861" xlink:to="Locator_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_3862" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3863" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember" xlink:label="Locator_amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember_3864" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3863" xlink:to="Locator_amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember_3864" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3865" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceMember" xlink:label="Locator_amed_NonVestedStockUnitsServiceMember_3866" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3865" xlink:to="Locator_amed_NonVestedStockUnitsServiceMember_3866" order="6.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureNonVestedStockUnitsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3951" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3952" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3951" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3952" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3953" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3954" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3953" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3954" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3955" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3956" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3955" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3956" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3957" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3958" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3957" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3958" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3959" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3960" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3959" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3960" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3961" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3962" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3961" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3962" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3963" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3964" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3963" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3964" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3965" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3966" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3965" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3966" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3967" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3968" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3967" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3968" order="11.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3969" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_3970" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3969" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_3970" order="12.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3971" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3972" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3971" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3972" order="13.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3973" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRequisiteServicePeriod" xlink:label="Locator_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRequisiteServicePeriod_3974" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3973" xlink:to="Locator_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRequisiteServicePeriod_3974" order="14.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3975" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" xlink:label="Locator_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_3976" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3975" xlink:to="Locator_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_3976" order="15.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3931" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3932" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3931" xlink:to="Locator_amed_EquityBasedAwardsTable_3932" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3935" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="Locator_us-gaap_AwardTypeAxis_3936" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_EquityBasedAwardsTable_3935" xlink:to="Locator_us-gaap_AwardTypeAxis_3936" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="Locator_us-gaap_AwardTypeAxis_3937" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3938" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_AwardTypeAxis_3937" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3938" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3939" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedAwardsMember" xlink:label="Locator_amed_ShareBasedAwardsMember_3940" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3939" xlink:to="Locator_amed_ShareBasedAwardsMember_3940" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3941" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" xlink:label="Locator_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_3942" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3941" xlink:to="Locator_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_3942" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3943" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockMember" xlink:label="Locator_amed_NonVestedStockMember_3944" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3943" xlink:to="Locator_amed_NonVestedStockMember_3944" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3945" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" xlink:label="Locator_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_3946" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3945" xlink:to="Locator_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_3946" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3947" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember" xlink:label="Locator_amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember_3948" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3947" xlink:to="Locator_amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember_3948" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3949" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceMember" xlink:label="Locator_amed_NonVestedStockUnitsServiceMember_3950" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3949" xlink:to="Locator_amed_NonVestedStockUnitsServiceMember_3950" order="6.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureSummaryOfActivityRelatedToGoodwillDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_4219" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_4220" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_4219" xlink:to="Locator_us-gaap_SegmentDomain_4220" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_4221" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_4222" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_4221" xlink:to="Locator_amed_HomeHealthMember_4222" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_4223" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_4224" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_4223" xlink:to="Locator_amed_HospiceMember_4224" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_4225" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PersonalCareMember" xlink:label="Locator_amed_PersonalCareMember_4226" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_SegmentDomain_4225" xlink:to="Locator_amed_PersonalCareMember_4226" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4213" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="Locator_us-gaap_ScheduleOfGoodwillTable_4214" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4213" xlink:to="Locator_us-gaap_ScheduleOfGoodwillTable_4214" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="Locator_us-gaap_ScheduleOfGoodwillTable_4217" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_4218" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfGoodwillTable_4217" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_4218" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4227" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="Locator_us-gaap_Goodwill_4228" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4227" xlink:to="Locator_us-gaap_Goodwill_4228" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4229" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="Locator_us-gaap_GoodwillAcquiredDuringPeriod_4230" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4229" xlink:to="Locator_us-gaap_GoodwillAcquiredDuringPeriod_4230" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4231" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:label="Locator_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_4232" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4231" xlink:to="Locator_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_4232" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4233" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="Locator_us-gaap_GoodwillImpairmentLoss_4234" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4233" xlink:to="Locator_us-gaap_GoodwillImpairmentLoss_4234" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4235" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="Locator_us-gaap_GoodwillPurchaseAccountingAdjustments_4236" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4235" xlink:to="Locator_us-gaap_GoodwillPurchaseAccountingAdjustments_4236" order="5.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureSummaryOfActivityRelatedToOtherIntangibleAssetsNetDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4269" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4270" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4269" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4270" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4271" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="Locator_us-gaap_NoncompeteAgreementsMember_4272" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4271" xlink:to="Locator_us-gaap_NoncompeteAgreementsMember_4272" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4261" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_4262" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4261" xlink:to="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_4262" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_4265" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4266" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_4265" xlink:to="Locator_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4266" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4273" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4274" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4273" xlink:to="Locator_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4274" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4289" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4290" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4289" xlink:to="Locator_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4290" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4275" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CertificatesOfNeedAndLicensesMember" xlink:label="Locator_amed_CertificatesOfNeedAndLicensesMember_4276" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4275" xlink:to="Locator_amed_CertificatesOfNeedAndLicensesMember_4276" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4277" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AcquiredNamesOfBusinessMember" xlink:label="Locator_amed_AcquiredNamesOfBusinessMember_4278" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4277" xlink:to="Locator_amed_AcquiredNamesOfBusinessMember_4278" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_4267" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4268" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_4267" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4268" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4279" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="Locator_us-gaap_IntangibleAssetsNetExcludingGoodwill_4280" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4279" xlink:to="Locator_us-gaap_IntangibleAssetsNetExcludingGoodwill_4280" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4281" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherIntangibleAssetsAdditions" xlink:label="Locator_amed_OtherIntangibleAssetsAdditions_4282" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4281" xlink:to="Locator_amed_OtherIntangibleAssetsAdditions_4282" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4283" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherIntangiblesWriteOffs" xlink:label="Locator_amed_OtherIntangiblesWriteOffs_4284" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4283" xlink:to="Locator_amed_OtherIntangiblesWriteOffs_4284" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4285" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="Locator_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_4286" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4285" xlink:to="Locator_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_4286" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4287" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="Locator_us-gaap_AmortizationOfIntangibleAssets_4288" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4287" xlink:to="Locator_us-gaap_AmortizationOfIntangibleAssets_4288" order="5.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/SummaryOfActivityRelatedToOtherIntangibleAssetsNetParentheticalDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4331" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4332" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4331" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4332" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4355" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4356" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4355" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4356" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4333" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AcquiredNameOfBusinessMember" xlink:label="Locator_amed_AcquiredNameOfBusinessMember_4334" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4333" xlink:to="Locator_amed_AcquiredNameOfBusinessMember_4334" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4335" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="Locator_us-gaap_NoncompeteAgreementsMember_4336" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4335" xlink:to="Locator_us-gaap_NoncompeteAgreementsMember_4336" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4325" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="Locator_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4326" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4325" xlink:to="Locator_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4326" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="Locator_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4329" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4330" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4329" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4330" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4337" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnamortizedAcquiredNames" xlink:label="Locator_amed_UnamortizedAcquiredNames_4338" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4337" xlink:to="Locator_amed_UnamortizedAcquiredNames_4338" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4339" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AmortizedAcquiredNames" xlink:label="Locator_amed_AmortizedAcquiredNames_4340" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4339" xlink:to="Locator_amed_AmortizedAcquiredNames_4340" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4341" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="Locator_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4342" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4341" xlink:to="Locator_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4342" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4343" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4344" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4343" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4344" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4345" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4346" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4345" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4346" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4347" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4348" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4347" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4348" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4349" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4350" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4349" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4350" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4351" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4352" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4351" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4352" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4353" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsNet_4354" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4353" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsNet_4354" order="9.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_4379" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_4380" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_RangeAxis_4379" xlink:to="Locator_us-gaap_RangeMember_4380" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_4381" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_4382" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_4381" xlink:to="Locator_us-gaap_MinimumMember_4382" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_4383" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_4384" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_4383" xlink:to="Locator_us-gaap_MaximumMember_4384" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_4371" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4372" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_4371" xlink:to="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4372" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4375" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4376" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4375" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4376" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4385" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4386" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4385" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4386" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4401" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4402" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4401" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4402" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4387" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingMember" xlink:label="Locator_us-gaap_BuildingMember_4388" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4387" xlink:to="Locator_us-gaap_BuildingMember_4388" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4389" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="Locator_us-gaap_LeaseholdImprovementsMember_4390" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4389" xlink:to="Locator_us-gaap_LeaseholdImprovementsMember_4390" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4391" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquipmentAndFurnitureMember" xlink:label="Locator_amed_EquipmentAndFurnitureMember_4392" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4391" xlink:to="Locator_amed_EquipmentAndFurnitureMember_4392" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4393" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VehiclesMember" xlink:label="Locator_us-gaap_VehiclesMember_4394" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4393" xlink:to="Locator_us-gaap_VehiclesMember_4394" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4395" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ComputerSoftwareMember" xlink:label="Locator_amed_ComputerSoftwareMember_4396" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4395" xlink:to="Locator_amed_ComputerSoftwareMember_4396" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4377" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_4378" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4377" xlink:to="Locator_us-gaap_RangeAxis_4378" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_4397" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentUsefulLife_4398" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_4397" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentUsefulLife_4398" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_4399" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_4400" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_4399" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_4400" order="2.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureCommitmentFeeUnderCreditFacilitiesDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_4493" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_4494" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_RangeAxis_4493" xlink:to="Locator_us-gaap_RangeMember_4494" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_4495" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RangeOneMember" xlink:label="Locator_amed_RangeOneMember_4496" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_4495" xlink:to="Locator_amed_RangeOneMember_4496" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_4497" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RangeTwoMember" xlink:label="Locator_amed_RangeTwoMember_4498" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_4497" xlink:to="Locator_amed_RangeTwoMember_4498" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_4499" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RangeThreeMember" xlink:label="Locator_amed_RangeThreeMember_4500" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_4499" xlink:to="Locator_amed_RangeThreeMember_4500" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_4501" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RangeFourMember" xlink:label="Locator_amed_RangeFourMember_4502" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RangeMember_4501" xlink:to="Locator_amed_RangeFourMember_4502" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="Locator_us-gaap_LineOfCreditFacilityLineItems_4485" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="Locator_us-gaap_LineOfCreditFacilityTable_4486" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_LineOfCreditFacilityLineItems_4485" xlink:to="Locator_us-gaap_LineOfCreditFacilityTable_4486" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="Locator_us-gaap_LineOfCreditFacilityTable_4489" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_4490" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_LineOfCreditFacilityTable_4489" xlink:to="Locator_us-gaap_RangeAxis_4490" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="Locator_us-gaap_LineOfCreditFacilityTable_4491" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="Locator_us-gaap_LineOfCreditFacilityAxis_4492" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_LineOfCreditFacilityTable_4491" xlink:to="Locator_us-gaap_LineOfCreditFacilityAxis_4492" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="Locator_us-gaap_LineOfCreditFacilityAxis_4503" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityDomain" xlink:label="Locator_amed_LineOfCreditFacilityDomain_4504" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_LineOfCreditFacilityAxis_4503" xlink:to="Locator_amed_LineOfCreditFacilityDomain_4504" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="Locator_us-gaap_LineOfCreditFacilityAxis_4515" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityDomain" xlink:label="Locator_amed_LineOfCreditFacilityDomain_4516" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_LineOfCreditFacilityAxis_4515" xlink:to="Locator_amed_LineOfCreditFacilityDomain_4516" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityDomain" xlink:label="Locator_amed_LineOfCreditFacilityDomain_4505" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AbrLoansMember" xlink:label="Locator_amed_AbrLoansMember_4506" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_LineOfCreditFacilityDomain_4505" xlink:to="Locator_amed_AbrLoansMember_4506" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityDomain" xlink:label="Locator_amed_LineOfCreditFacilityDomain_4507" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EurodollarLoansMember" xlink:label="Locator_amed_EurodollarLoansMember_4508" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_LineOfCreditFacilityDomain_4507" xlink:to="Locator_amed_EurodollarLoansMember_4508" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="Locator_us-gaap_LineOfCreditFacilityLineItems_4509" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="Locator_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_4510" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LineOfCreditFacilityLineItems_4509" xlink:to="Locator_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_4510" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="Locator_us-gaap_LineOfCreditFacilityLineItems_4511" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="Locator_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4512" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LineOfCreditFacilityLineItems_4511" xlink:to="Locator_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4512" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="Locator_us-gaap_LineOfCreditFacilityLineItems_4513" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LetterOfCreditFee" xlink:label="Locator_amed_LetterOfCreditFee_4514" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_LineOfCreditFacilityLineItems_4513" xlink:to="Locator_amed_LetterOfCreditFee_4514" order="3.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureExitActivitiesReserveActivityDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_4545" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4546" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_4545" xlink:to="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4546" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4549" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringCostsAxis" xlink:label="Locator_amed_OtherRestructuringCostsAxis_4550" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4549" xlink:to="Locator_amed_OtherRestructuringCostsAxis_4550" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringCostsAxis" xlink:label="Locator_amed_OtherRestructuringCostsAxis_4553" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_4554" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_amed_OtherRestructuringCostsAxis_4553" xlink:to="Locator_amed_OtherRestructuringDomain_4554" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_4555" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoThousandAndThirteenExitActivityMember" xlink:label="Locator_amed_TwoThousandAndThirteenExitActivityMember_4556" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OtherRestructuringDomain_4555" xlink:to="Locator_amed_TwoThousandAndThirteenExitActivityMember_4556" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_4557" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoThousandAndFourteenExitActivityMember" xlink:label="Locator_amed_TwoThousandAndFourteenExitActivityMember_4558" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_OtherRestructuringDomain_4557" xlink:to="Locator_amed_TwoThousandAndFourteenExitActivityMember_4558" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4551" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="Locator_us-gaap_RestructuringCostAndReserveAxis_4552" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4551" xlink:to="Locator_us-gaap_RestructuringCostAndReserveAxis_4552" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="Locator_us-gaap_RestructuringCostAndReserveAxis_4559" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_4560" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_RestructuringCostAndReserveAxis_4559" xlink:to="Locator_amed_RestructuringCostAndReserveDomain_4560" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_4561" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LeaseTerminationMember" xlink:label="Locator_amed_LeaseTerminationMember_4562" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_RestructuringCostAndReserveDomain_4561" xlink:to="Locator_amed_LeaseTerminationMember_4562" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_4563" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="Locator_us-gaap_EmployeeSeveranceMember_4564" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_RestructuringCostAndReserveDomain_4563" xlink:to="Locator_us-gaap_EmployeeSeveranceMember_4564" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_4565" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="Locator_us-gaap_RestructuringReserve_4566" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_4565" xlink:to="Locator_us-gaap_RestructuringReserve_4566" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_4567" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="Locator_us-gaap_RestructuringCharges_4568" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_4567" xlink:to="Locator_us-gaap_RestructuringCharges_4568" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_4569" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="Locator_us-gaap_PaymentsForRestructuring_4570" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_4569" xlink:to="Locator_us-gaap_PaymentsForRestructuring_4570" order="3.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureNonVestedStockOptionActivityDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4619" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_4620" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4619" xlink:to="Locator_amed_EquityBasedAwardsTable_4620" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_4623" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="Locator_us-gaap_AwardTypeAxis_4624" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_EquityBasedAwardsTable_4623" xlink:to="Locator_us-gaap_AwardTypeAxis_4624" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="Locator_us-gaap_AwardTypeAxis_4625" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4626" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_AwardTypeAxis_4625" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4626" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4627" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockOptionMember" xlink:label="Locator_us-gaap_StockOptionMember_4628" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4627" xlink:to="Locator_us-gaap_StockOptionMember_4628" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4629" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_4630" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4629" xlink:to="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_4630" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4631" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4632" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4631" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4632" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4633" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_4634" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4633" xlink:to="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_4634" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4635" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_4636" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4635" xlink:to="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_4636" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4637" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_4638" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4637" xlink:to="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_4638" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4639" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4640" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4639" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4640" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4641" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_4642" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4641" xlink:to="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_4642" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4643" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_4644" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4643" xlink:to="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_4644" order="9.0" />
    </definitionLink>
    <definitionLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/RelatedPartyTransactionDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="Locator_us-gaap_RelatedPartyTransactionLineItems_4701" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RelatedPartyTransactionTable" xlink:label="Locator_amed_RelatedPartyTransactionTable_4702" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="Locator_us-gaap_RelatedPartyTransactionLineItems_4701" xlink:to="Locator_amed_RelatedPartyTransactionTable_4702" order="-1.0" xbrldt:contextElement="segment" xbrldt:closed="true" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RelatedPartyTransactionTable" xlink:label="Locator_amed_RelatedPartyTransactionTable_4705" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="Locator_us-gaap_RelatedPartyTransactionAxis_4706" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="Locator_amed_RelatedPartyTransactionTable_4705" xlink:to="Locator_us-gaap_RelatedPartyTransactionAxis_4706" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="Locator_us-gaap_RelatedPartyTransactionAxis_4707" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CompanyNameDomain" xlink:label="Locator_amed_CompanyNameDomain_4708" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="Locator_us-gaap_RelatedPartyTransactionAxis_4707" xlink:to="Locator_amed_CompanyNameDomain_4708" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="Locator_us-gaap_RelatedPartyTransactionAxis_4717" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CompanyNameDomain" xlink:label="Locator_amed_CompanyNameDomain_4718" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="Locator_us-gaap_RelatedPartyTransactionAxis_4717" xlink:to="Locator_amed_CompanyNameDomain_4718" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CompanyNameDomain" xlink:label="Locator_amed_CompanyNameDomain_4709" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_KKRConsultingMember" xlink:label="Locator_amed_KKRConsultingMember_4710" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CompanyNameDomain_4709" xlink:to="Locator_amed_KKRConsultingMember_4710" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CompanyNameDomain" xlink:label="Locator_amed_CompanyNameDomain_4711" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareInnovationsMember" xlink:label="Locator_amed_CareInnovationsMember_4712" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_amed_CompanyNameDomain_4711" xlink:to="Locator_amed_CareInnovationsMember_4712" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="Locator_us-gaap_RelatedPartyTransactionLineItems_4713" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="Locator_us-gaap_RelatedPartyTransactionAmountsOfTransaction_4714" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RelatedPartyTransactionLineItems_4713" xlink:to="Locator_us-gaap_RelatedPartyTransactionAmountsOfTransaction_4714" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="Locator_us-gaap_RelatedPartyTransactionLineItems_4715" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="Locator_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_4716" />
        <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="Locator_us-gaap_RelatedPartyTransactionLineItems_4715" xlink:to="Locator_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_4716" order="2.0" />
    </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>amed-20161231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Prepared by IBM Cognos FSR v6.7.4.14 using Fujitsu Interstage XWand -->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/instance http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
    <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
    <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="element1" />
        <label xlink:type="resource" xlink:label="label1" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AwardTypeAxis_en-US">Award Type [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1" xlink:to="label1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="element2" />
        <label xlink:type="resource" xlink:label="label2" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AccountingPoliciesAbstract_en-US">Accounting Policies [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element2" xlink:to="label2" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="element3" />
        <label xlink:type="resource" xlink:label="label3" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AccountsPayableCurrent_en-US">Accounts Payable Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element3" xlink:to="label3" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="element4" />
        <label xlink:type="resource" xlink:label="label4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AccountsPayableCurrent_en-US">Accounts payable</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element4" xlink:to="label4" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="element5" />
        <label xlink:type="resource" xlink:label="label5" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AccountsReceivableNetCurrent_en-US">Accounts Receivable Net Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element5" xlink:to="label5" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="element6" />
        <label xlink:type="resource" xlink:label="label6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AccountsReceivableNetCurrent_en-US">Patient accounts receivable, net of allowance for doubtful accounts of $17,716, and $16,526</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element6" xlink:to="label6" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedInsuranceCurrent" xlink:label="element7" />
        <label xlink:type="resource" xlink:label="label7" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AccruedInsuranceCurrent_en-US">AccruedInsuranceCurrent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element7" xlink:to="label7" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedInsuranceCurrent" xlink:label="element8" />
        <label xlink:type="resource" xlink:label="label8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AccruedInsuranceCurrent_en-US">Health insurance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element8" xlink:to="label8" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="element9" />
        <label xlink:type="resource" xlink:label="label9" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AccruedLiabilitiesCurrent_en-US">Accrued Liabilities Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element9" xlink:to="label9" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="element10" />
        <label xlink:type="resource" xlink:label="label10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AccruedLiabilitiesCurrent_en-US">Accrued expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element10" xlink:to="label10" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="element11" />
        <label xlink:type="resource" xlink:label="label11" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_AccruedLiabilitiesCurrent_en-US">Accrued expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element11" xlink:to="label11" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="element12" />
        <label xlink:type="resource" xlink:label="label12" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_en-US">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element12" xlink:to="label12" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="element13" />
        <label xlink:type="resource" xlink:label="label13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_en-US">Property and equipment, accumulated depreciation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element13" xlink:to="label13" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="element14" />
        <label xlink:type="resource" xlink:label="label14" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_en-US">Less accumulated depreciation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element14" xlink:to="label14" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="element15" />
        <label xlink:type="resource" xlink:label="label15" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AccumulatedOtherComprehensiveIncomeMember_en-US">Accumulated Other Comprehensive Income (Loss) [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element15" xlink:to="label15" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="element16" />
        <label xlink:type="resource" xlink:label="label16" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_en-US">Accumulated Other Comprehensive Income Loss Net Of Tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element16" xlink:to="label16" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="element17" />
        <label xlink:type="resource" xlink:label="label17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_en-US">Accumulated other comprehensive income</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element17" xlink:to="label17" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="element18" />
        <label xlink:type="resource" xlink:label="label18" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_en-US">Acquired Finite Lived Intangible Assets Weighted Average Useful Life</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element18" xlink:to="label18" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="element19" />
        <label xlink:type="resource" xlink:label="label19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_en-US">Weighted-average amortization period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element19" xlink:to="label19" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="element20" />
        <label xlink:type="resource" xlink:label="label20" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AdditionalPaidInCapitalCommonStock_en-US">Additional Paid In Capital Common Stock</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element20" xlink:to="label20" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="element21" />
        <label xlink:type="resource" xlink:label="label21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AdditionalPaidInCapitalCommonStock_en-US">Additional paid-in capital</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element21" xlink:to="label21" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="element22" />
        <label xlink:type="resource" xlink:label="label22" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AdditionalPaidInCapitalMember_en-US">Additional Paid-in Capital [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element22" xlink:to="label22" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="element23" />
        <label xlink:type="resource" xlink:label="label23" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_en-US">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element23" xlink:to="label23" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="element24" />
        <label xlink:type="resource" xlink:label="label24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_en-US">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element24" xlink:to="label24" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation" xlink:label="element25" />
        <label xlink:type="resource" xlink:label="label25" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation_en-US">Adjustments To Additional Paid In Capital Income Tax Deficiency From Share Based Compensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element25" xlink:to="label25" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation" xlink:label="element26" />
        <label xlink:type="resource" xlink:label="label26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation_en-US">Tax deficit from stock options exercised and restricted stock vesting</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element26" xlink:to="label26" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation" xlink:label="element27" />
        <label xlink:type="resource" xlink:label="label27" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation_en-US">Tax deficit from stock options exercised and restricted stock vesting</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element27" xlink:to="label27" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="element28" />
        <label xlink:type="resource" xlink:label="label28" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_en-US">AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element28" xlink:to="label28" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="element29" />
        <label xlink:type="resource" xlink:label="label29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_en-US">Non-cash compensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element29" xlink:to="label29" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="element30" />
        <label xlink:type="resource" xlink:label="label30" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_en-US">AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element30" xlink:to="label30" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="element31" />
        <label xlink:type="resource" xlink:label="label31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_en-US">Tax benefit from stock options exercised and restricted stock vesting</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element31" xlink:to="label31" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="element32" />
        <label xlink:type="resource" xlink:label="label32" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AdvertisingCostsPolicyTextBlock_en-US">Advertising Costs Policy Text Block</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element32" xlink:to="label32" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="element33" />
        <label xlink:type="resource" xlink:label="label33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AdvertisingCostsPolicyTextBlock_en-US">Advertising Costs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element33" xlink:to="label33" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="element34" />
        <label xlink:type="resource" xlink:label="label34" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AdvertisingExpense_en-US">Advertising Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element34" xlink:to="label34" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="element35" />
        <label xlink:type="resource" xlink:label="label35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AdvertisingExpense_en-US">Advertising expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element35" xlink:to="label35" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="element36" />
        <label xlink:type="resource" xlink:label="label36" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AllOtherSegmentsMember_en-US">All Other Segments [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element36" xlink:to="label36" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="element37" />
        <label xlink:type="resource" xlink:label="label37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AllOtherSegmentsMember_en-US">Other</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element37" xlink:to="label37" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="element38" />
        <label xlink:type="resource" xlink:label="label38" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AllocatedShareBasedCompensationExpense_en-US">Allocated Share-based Compensation Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element38" xlink:to="label38" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="element39" />
        <label xlink:type="resource" xlink:label="label39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AllocatedShareBasedCompensationExpense_en-US">Stock Compensation Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element39" xlink:to="label39" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsMember" xlink:label="element40" />
        <label xlink:type="resource" xlink:label="label40" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AllowanceForDoubtfulAccountsMember_en-US">Allowance for Doubtful Accounts [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element40" xlink:to="label40" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="element41" />
        <label xlink:type="resource" xlink:label="label41" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_en-US">Allowance For Doubtful Accounts Receivable Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element41" xlink:to="label41" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="element42" />
        <label xlink:type="resource" xlink:label="label42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_en-US">Patient accounts receivable, allowance for doubtful accounts</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element42" xlink:to="label42" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsDiscontinuedOperationsMember" xlink:label="element43" />
        <label xlink:type="resource" xlink:label="label43" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AllowanceForDoubtfulAccountsDiscontinuedOperationsMember_en-US">Allowance for Doubtful Accounts - Discontinued Operations [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element43" xlink:to="label43" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="element44" />
        <label xlink:type="resource" xlink:label="label44" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AmortizationOfFinancingCostsAndDiscounts_en-US">Amortization Of Financing Costs And Discounts</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element44" xlink:to="label44" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="element45" />
        <label xlink:type="resource" xlink:label="label45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AmortizationOfFinancingCostsAndDiscounts_en-US">Amortization of deferred debt issuance costs/debt discount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element45" xlink:to="label45" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="element46" />
        <label xlink:type="resource" xlink:label="label46" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AmortizationOfIntangibleAssets_en-US">Amortization Of Intangible Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element46" xlink:to="label46" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="element47" />
        <label xlink:type="resource" xlink:label="label47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AmortizationOfIntangibleAssets_en-US">Amortization</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element47" xlink:to="label47" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="element48" />
        <label xlink:type="resource" xlink:label="label48" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_AmortizationOfIntangibleAssets_en-US">Amortization</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element48" xlink:to="label48" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="element49" />
        <label xlink:type="resource" xlink:label="label49" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element49" xlink:to="label49" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="element50" />
        <label xlink:type="resource" xlink:label="label50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_en-US">Anti-dilutive securities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element50" xlink:to="label50" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="element51" />
        <label xlink:type="resource" xlink:label="label51" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AssetImpairmentCharges_en-US">Asset Impairment Charges</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element51" xlink:to="label51" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="element52" />
        <label xlink:type="resource" xlink:label="label52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AssetImpairmentCharges_en-US">Asset impairment charge</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element52" xlink:to="label52" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="element53" />
        <label xlink:type="resource" xlink:label="label53" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_en-US">Assets Of Disposal Group Including Discontinued Operation Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element53" xlink:to="label53" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="element54" />
        <label xlink:type="resource" xlink:label="label54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_en-US">Assets held for sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element54" xlink:to="label54" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="element55" />
        <label xlink:type="resource" xlink:label="label55" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AssetsAbstract_en-US">Assets [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element55" xlink:to="label55" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="element56" />
        <label xlink:type="resource" xlink:label="label56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AssetsAbstract_en-US">ASSETS</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element56" xlink:to="label56" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="element57" />
        <label xlink:type="resource" xlink:label="label57" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_Assets_en-US">Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element57" xlink:to="label57" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="element58" />
        <label xlink:type="resource" xlink:label="label58" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_Assets_en-US">Total assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element58" xlink:to="label58" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="element59" />
        <label xlink:type="resource" xlink:label="label59" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AssetsCurrent_en-US">Assets Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element59" xlink:to="label59" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="element60" />
        <label xlink:type="resource" xlink:label="label60" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_AssetsCurrent_en-US">Total current assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element60" xlink:to="label60" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="element61" />
        <label xlink:type="resource" xlink:label="label61" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_AssetsCurrentAbstract_en-US">Assets Current [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element61" xlink:to="label61" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="element62" />
        <label xlink:type="resource" xlink:label="label62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_AssetsCurrentAbstract_en-US">Current assets:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element62" xlink:to="label62" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="element63" />
        <label xlink:type="resource" xlink:label="label63" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BalanceSheetLocationAxis_en-US">Balance Sheet [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element63" xlink:to="label63" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="element64" />
        <label xlink:type="resource" xlink:label="label64" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BalanceSheetLocationDomain_en-US">Balance Sheet [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element64" xlink:to="label64" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="element65" />
        <label xlink:type="resource" xlink:label="label65" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_en-US">Basis Of Accounting Policy Policy [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element65" xlink:to="label65" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="element66" />
        <label xlink:type="resource" xlink:label="label66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_en-US">Basis of Presentation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element66" xlink:to="label66" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingMember" xlink:label="element67" />
        <label xlink:type="resource" xlink:label="label67" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BuildingMember_en-US">Building [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element67" xlink:to="label67" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="element68" />
        <label xlink:type="resource" xlink:label="label68" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_en-US">Business Acquisition Cost Of Acquired Entity Transaction Costs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element68" xlink:to="label68" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="element69" />
        <label xlink:type="resource" xlink:label="label69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_en-US">Transaction-related expenses for aquisitions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element69" xlink:to="label69" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="element70" />
        <label xlink:type="resource" xlink:label="label70" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessCombinationConsiderationTransferred1_en-US">Business Acquisition Cost Of Acquired Entity Purchase Price</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element70" xlink:to="label70" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="element71" />
        <label xlink:type="resource" xlink:label="label71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BusinessCombinationConsiderationTransferred1_en-US">Acquisition, total purchase price</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element71" xlink:to="label71" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:label="element72" />
        <label xlink:type="resource" xlink:label="label72" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_en-US">Business Acquisition Pro Forma Earnings Per Share Diluted</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element72" xlink:to="label72" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:label="element73" />
        <label xlink:type="resource" xlink:label="label73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_en-US">Diluted earnings (loss) per share</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element73" xlink:to="label73" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="element74" />
        <label xlink:type="resource" xlink:label="label74" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_en-US">Business Acquisition Contingent Consideration Potential Cash Payment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element74" xlink:to="label74" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="element75" />
        <label xlink:type="resource" xlink:label="label75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_en-US">Accrued liability resulting from acquisition</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element75" xlink:to="label75" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="element76" />
        <label xlink:type="resource" xlink:label="label76" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_en-US">Business Acquisition Pro Forma Earnings Per Share Basic</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element76" xlink:to="label76" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="element77" />
        <label xlink:type="resource" xlink:label="label77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_en-US">Basic earnings (loss) per share</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element77" xlink:to="label77" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="element78" />
        <label xlink:type="resource" xlink:label="label78" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessAcquisitionProFormaInformationAbstract_en-US">Business Acquisition Pro Forma Information [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element78" xlink:to="label78" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="element79" />
        <label xlink:type="resource" xlink:label="label79" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_en-US">Business Acquisition Purchase Price Allocation Current Assets Cash And Cash Equivalents</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element79" xlink:to="label79" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="element80" />
        <label xlink:type="resource" xlink:label="label80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_en-US">Acquisition, cash recorded</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element80" xlink:to="label80" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="element81" />
        <label xlink:type="resource" xlink:label="label81" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessAcquisitionsProFormaRevenue_en-US">Business Acquisitions Pro Forma Revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element81" xlink:to="label81" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="element82" />
        <label xlink:type="resource" xlink:label="label82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BusinessAcquisitionsProFormaRevenue_en-US">Net service revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element82" xlink:to="label82" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="element83" />
        <label xlink:type="resource" xlink:label="label83" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_en-US">Business Acquisition Pro Forma Information Text Block</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element83" xlink:to="label83" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="element84" />
        <label xlink:type="resource" xlink:label="label84" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_en-US">Business Acquisitions Pro Forma Net Income Loss</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element84" xlink:to="label84" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="element85" />
        <label xlink:type="resource" xlink:label="label85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_en-US">Net income (loss)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element85" xlink:to="label85" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="element86" />
        <label xlink:type="resource" xlink:label="label86" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_en-US">Business Acquisition Purchase Price Allocation Intangible Assets Other Than Goodwill</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element86" xlink:to="label86" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="element87" />
        <label xlink:type="resource" xlink:label="label87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_en-US">Acquisition, other intangibles recorded</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element87" xlink:to="label87" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="element88" />
        <label xlink:type="resource" xlink:label="label88" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessAcquisitionAxis_en-US">Business Acquisition [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element88" xlink:to="label88" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="element89" />
        <label xlink:type="resource" xlink:label="label89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BusinessAcquisitionAxis_en-US">Business Acquisition [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element89" xlink:to="label89" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="element90" />
        <label xlink:type="resource" xlink:label="label90" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessCombinationsAbstract_en-US">Business Combinations [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element90" xlink:to="label90" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="element91" />
        <label xlink:type="resource" xlink:label="label91" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessCombinationDisclosureTextBlock_en-US">Business Combination Disclosure [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element91" xlink:to="label91" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="element92" />
        <label xlink:type="resource" xlink:label="label92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BusinessCombinationDisclosureTextBlock_en-US">ACQUISITIONS</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element92" xlink:to="label92" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="element93" />
        <label xlink:type="resource" xlink:label="label93" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_en-US">Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element93" xlink:to="label93" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="element94" />
        <label xlink:type="resource" xlink:label="label94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_en-US">Goodwill deductible for income tax purposes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element94" xlink:to="label94" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="element95" />
        <label xlink:type="resource" xlink:label="label95" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_en-US">Business Acquisition Purchase Price Allocation Assets Acquired Liabilities Assumed Net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element95" xlink:to="label95" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="element96" />
        <label xlink:type="resource" xlink:label="label96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_en-US">Acquisition, recorded other assets and liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element96" xlink:to="label96" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalizedComputerSoftwareImpairments" xlink:label="element97" />
        <label xlink:type="resource" xlink:label="label97" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CapitalizedComputerSoftwareImpairments_en-US">Capitalized Computer Software Impairments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element97" xlink:to="label97" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalizedComputerSoftwareImpairments" xlink:label="element98" />
        <label xlink:type="resource" xlink:label="label98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CapitalizedComputerSoftwareImpairments_en-US">Software Write off</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element98" xlink:to="label98" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="element99" />
        <label xlink:type="resource" xlink:label="label99" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CapitalizedComputerSoftwareGross_en-US">Capitalized Computer Software, Gross</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element99" xlink:to="label99" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="element100" />
        <label xlink:type="resource" xlink:label="label100" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CapitalizedComputerSoftwareGross_en-US">Computer software</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element100" xlink:to="label100" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="element101" />
        <label xlink:type="resource" xlink:label="label101" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock_en-US">Cash And Cash Equivalents Policy Text Block</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element101" xlink:to="label101" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="element102" />
        <label xlink:type="resource" xlink:label="label102" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CashAndCashEquivalentsPolicyTextBlock_en-US">Cash and Cash Equivalents</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element102" xlink:to="label102" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="element103" />
        <label xlink:type="resource" xlink:label="label103" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_en-US">Cash And Cash Equivalents At Carrying Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element103" xlink:to="label103" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="element104" />
        <label xlink:type="resource" xlink:label="label104" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US" id="periodEnd_us-gaap_CashAndCashEquivalentsAtCarryingValue_en-US">Cash and cash equivalents at end of period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element104" xlink:to="label104" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="element105" />
        <label xlink:type="resource" xlink:label="label105" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US" id="periodStart_us-gaap_CashAndCashEquivalentsAtCarryingValue_en-US">Cash and cash equivalents at beginning of period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element105" xlink:to="label105" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="element106" />
        <label xlink:type="resource" xlink:label="label106" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CashAndCashEquivalentsAtCarryingValue_en-US">Cash and cash equivalents</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element106" xlink:to="label106" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="element107" />
        <label xlink:type="resource" xlink:label="label107" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_en-US">Cash And Cash Equivalents Period Increase Decrease</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element107" xlink:to="label107" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="element108" />
        <label xlink:type="resource" xlink:label="label108" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_en-US">Net increase (decrease) in cash and cash equivalents</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element108" xlink:to="label108" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="element109" />
        <label xlink:type="resource" xlink:label="label109" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_en-US">CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element109" xlink:to="label109" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="element110" />
        <label xlink:type="resource" xlink:label="label110" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_en-US">Supplemental Disclosures of Non-Cash Financing and Investing Activities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element110" xlink:to="label110" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="element111" />
        <label xlink:type="resource" xlink:label="label111" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CommitmentsAndContingencies_en-US">Commitments And Contingencies</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element111" xlink:to="label111" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="element112" />
        <label xlink:type="resource" xlink:label="label112" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CommitmentsAndContingencies_en-US">Commitments and Contingencies - Note 10</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element112" xlink:to="label112" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="element113" />
        <label xlink:type="resource" xlink:label="label113" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_en-US">Commitments And Contingencies Disclosure [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element113" xlink:to="label113" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="element114" />
        <label xlink:type="resource" xlink:label="label114" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_en-US">COMMITMENTS AND CONTINGENCIES</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element114" xlink:to="label114" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="element115" />
        <label xlink:type="resource" xlink:label="label115" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_en-US">Commitments and Contingencies Disclosure [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element115" xlink:to="label115" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="element116" />
        <label xlink:type="resource" xlink:label="label116" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CommonStockSharesIssued_en-US">Common Stock Shares Issued</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element116" xlink:to="label116" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="element117" />
        <label xlink:type="resource" xlink:label="label117" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CommonStockSharesIssued_en-US">Common Stock, shares issued</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element117" xlink:to="label117" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="element118" />
        <label xlink:type="resource" xlink:label="label118" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CommonStockValueOutstanding_en-US">Common Stock Value Outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element118" xlink:to="label118" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="element119" />
        <label xlink:type="resource" xlink:label="label119" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CommonStockValueOutstanding_en-US">Common Stock, $0.001 par value, 60,000,000 shares authorized; 35,253,577, and 34,786,966 shares issued; and 33,597,215 and 33,607,282 shares outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element119" xlink:to="label119" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="element120" />
        <label xlink:type="resource" xlink:label="label120" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CommonStockSharesAuthorized_en-US">Common Stock Shares Authorized</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element120" xlink:to="label120" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="element121" />
        <label xlink:type="resource" xlink:label="label121" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CommonStockSharesAuthorized_en-US">Common Stock, shares authorized</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element121" xlink:to="label121" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="element122" />
        <label xlink:type="resource" xlink:label="label122" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CommonStockParOrStatedValuePerShare_en-US">Common Stock Par Or Stated Value Per Share</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element122" xlink:to="label122" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="element123" />
        <label xlink:type="resource" xlink:label="label123" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CommonStockParOrStatedValuePerShare_en-US">Common Stock, par value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element123" xlink:to="label123" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="element124" />
        <label xlink:type="resource" xlink:label="label124" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CommonStockMember_en-US">Common Stock [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element124" xlink:to="label124" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="element125" />
        <label xlink:type="resource" xlink:label="label125" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CommonStockSharesOutstanding_en-US">Common Stock Shares Outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element125" xlink:to="label125" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="element126" />
        <label xlink:type="resource" xlink:label="label126" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CommonStockSharesOutstanding_en-US">Common Stock, shares outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element126" xlink:to="label126" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComparabilityOfPriorYearFinancialData" xlink:label="element127" />
        <label xlink:type="resource" xlink:label="label127" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ComparabilityOfPriorYearFinancialData_en-US">Comparability Of Prior Year Financial Data</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element127" xlink:to="label127" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComparabilityOfPriorYearFinancialData" xlink:label="element128" />
        <label xlink:type="resource" xlink:label="label128" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ComparabilityOfPriorYearFinancialData_en-US">Reclassifications and Comparability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element128" xlink:to="label128" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="element129" />
        <label xlink:type="resource" xlink:label="label129" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_en-US">Comprehensive income</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element129" xlink:to="label129" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="element130" />
        <label xlink:type="resource" xlink:label="label130" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_en-US">Comprehensive income (loss)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element130" xlink:to="label130" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="element131" />
        <label xlink:type="resource" xlink:label="label131" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ComprehensiveIncomeNetOfTax_en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element131" xlink:to="label131" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="element132" />
        <label xlink:type="resource" xlink:label="label132" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_ComprehensiveIncomeNetOfTax_en-US">Comprehensive income (loss) attributable to Amedisys, Inc.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element132" xlink:to="label132" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="element133" />
        <label xlink:type="resource" xlink:label="label133" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ConcentrationRiskTypeDomain_en-US">Concentration Risk Type [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element133" xlink:to="label133" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="element134" />
        <label xlink:type="resource" xlink:label="label134" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ConcentrationRiskByTypeAxis_en-US">Concentration Risk Type [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element134" xlink:to="label134" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="element135" />
        <label xlink:type="resource" xlink:label="label135" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ConcentrationRiskPercentage1_en-US">Percent Of Net Services Revenue Provided By Medicare</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element135" xlink:to="label135" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="element136" />
        <label xlink:type="resource" xlink:label="label136" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ConsolidationPolicyTextBlock_en-US">Consolidation Policy [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element136" xlink:to="label136" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="element137" />
        <label xlink:type="resource" xlink:label="label137" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ConsolidationPolicyTextBlock_en-US">Principles of Consolidation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element137" xlink:to="label137" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostMethodInvestments" xlink:label="element138" />
        <label xlink:type="resource" xlink:label="label138" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CostMethodInvestments_en-US">Cost Method Investments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element138" xlink:to="label138" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostMethodInvestments" xlink:label="element139" />
        <label xlink:type="resource" xlink:label="label139" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CostMethodInvestments_en-US">Cost method investment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element139" xlink:to="label139" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfServices" xlink:label="element140" />
        <label xlink:type="resource" xlink:label="label140" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CostOfServices_en-US">Cost Of Services</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element140" xlink:to="label140" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfServices" xlink:label="element141" />
        <label xlink:type="resource" xlink:label="label141" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CostOfServices_en-US">Cost of service, excluding depreciation and amortization</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element141" xlink:to="label141" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="element142" />
        <label xlink:type="resource" xlink:label="label142" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CostsAndExpenses_en-US">Costs And Expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element142" xlink:to="label142" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="element143" />
        <label xlink:type="resource" xlink:label="label143" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_CostsAndExpenses_en-US">Operating expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element143" xlink:to="label143" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="element144" />
        <label xlink:type="resource" xlink:label="label144" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CurrentIncomeTaxExpenseBenefit_en-US">CurrentIncomeTaxExpenseBenefit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element144" xlink:to="label144" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="element145" />
        <label xlink:type="resource" xlink:label="label145" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CurrentIncomeTaxExpenseBenefit_en-US">Current income tax expense/(benefit)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element145" xlink:to="label145" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="element146" />
        <label xlink:type="resource" xlink:label="label146" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CurrentFederalTaxExpenseBenefit_en-US">CurrentFederalTaxExpenseBenefit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element146" xlink:to="label146" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="element147" />
        <label xlink:type="resource" xlink:label="label147" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CurrentFederalTaxExpenseBenefit_en-US">Federal, current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element147" xlink:to="label147" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="element148" />
        <label xlink:type="resource" xlink:label="label148" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_en-US">CurrentStateAndLocalTaxExpenseBenefit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element148" xlink:to="label148" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="element149" />
        <label xlink:type="resource" xlink:label="label149" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_en-US">State and local, current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element149" xlink:to="label149" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="element150" />
        <label xlink:type="resource" xlink:label="label150" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_CustomerConcentrationRiskMember_en-US">Customer Concentration Risk [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element150" xlink:to="label150" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="element151" />
        <label xlink:type="resource" xlink:label="label151" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtInstrumentLineItems_en-US">Debt Instrument [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element151" xlink:to="label151" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="element152" />
        <label xlink:type="resource" xlink:label="label152" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DebtInstrumentLineItems_en-US">Debt Instrument [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element152" xlink:to="label152" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="element153" />
        <label xlink:type="resource" xlink:label="label153" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtInstrumentTerm_en-US">Debt Instrument Term</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element153" xlink:to="label153" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="element154" />
        <label xlink:type="resource" xlink:label="label154" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DebtInstrumentTerm_en-US">Term loan, period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element154" xlink:to="label154" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="element155" />
        <label xlink:type="resource" xlink:label="label155" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtDisclosureAbstract_en-US">Debt Disclosure [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element155" xlink:to="label155" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="element156" />
        <label xlink:type="resource" xlink:label="label156" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtWeightedAverageInterestRate_en-US">Debt Weighted Average Interest Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element156" xlink:to="label156" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="element157" />
        <label xlink:type="resource" xlink:label="label157" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtInstrumentTable_en-US">Debt Instrument [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element157" xlink:to="label157" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="element158" />
        <label xlink:type="resource" xlink:label="label158" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DebtInstrumentTable_en-US">Schedule of Long-term Debt Instruments [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element158" xlink:to="label158" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="element159" />
        <label xlink:type="resource" xlink:label="label159" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtLongtermAndShorttermCombinedAmount_en-US">Debt Longterm And Shortterm Combined Amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element159" xlink:to="label159" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="element160" />
        <label xlink:type="resource" xlink:label="label160" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DebtLongtermAndShorttermCombinedAmount_en-US">Total longterm and shortterm debt</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element160" xlink:to="label160" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="element161" />
        <label xlink:type="resource" xlink:label="label161" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_DebtLongtermAndShorttermCombinedAmount_en-US">Total longterm and shortterm debt</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element161" xlink:to="label161" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="element162" />
        <label xlink:type="resource" xlink:label="label162" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_en-US">Debt Instrument Basis Spread On Variable Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element162" xlink:to="label162" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="element163" />
        <label xlink:type="resource" xlink:label="label163" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_en-US">Margin on Loans</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element163" xlink:to="label163" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="element164" />
        <label xlink:type="resource" xlink:label="label164" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtDisclosureTextBlock_en-US">Debt Disclosure [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element164" xlink:to="label164" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="element165" />
        <label xlink:type="resource" xlink:label="label165" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DebtDisclosureTextBlock_en-US">LONG-TERM OBLIGATIONS</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element165" xlink:to="label165" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="element166" />
        <label xlink:type="resource" xlink:label="label166" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtIssuanceCosts_en-US">Debt Issuance Cost</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element166" xlink:to="label166" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="element167" />
        <label xlink:type="resource" xlink:label="label167" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DebtIssuanceCosts_en-US">Deferred debt issuance cost</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element167" xlink:to="label167" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="element168" />
        <label xlink:type="resource" xlink:label="label168" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtInstrumentUnamortizedDiscount_en-US">Debt Instrument Unamortized Discount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element168" xlink:to="label168" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="element169" />
        <label xlink:type="resource" xlink:label="label169" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DebtInstrumentUnamortizedDiscount_en-US">Discount on long-term debt</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element169" xlink:to="label169" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="element170" />
        <label xlink:type="resource" xlink:label="label170" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtInstrumentMaturityDate_en-US">Debt Instrument Maturity Date</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element170" xlink:to="label170" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="element171" />
        <label xlink:type="resource" xlink:label="label171" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DebtInstrumentMaturityDate_en-US">Maturity date</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element171" xlink:to="label171" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="element172" />
        <label xlink:type="resource" xlink:label="label172" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_en-US">Debt Instrument, Frequency of Periodic Payment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element172" xlink:to="label172" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="element173" />
        <label xlink:type="resource" xlink:label="label173" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtInstrumentPeriodicPaymentInterest_en-US">Debt Instrument Periodic Payment Interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element173" xlink:to="label173" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="element174" />
        <label xlink:type="resource" xlink:label="label174" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtInstrumentFaceAmount_en-US">Debt Instrument Face Amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element174" xlink:to="label174" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="element175" />
        <label xlink:type="resource" xlink:label="label175" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DebtInstrumentFaceAmount_en-US">Principal amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element175" xlink:to="label175" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="element176" />
        <label xlink:type="resource" xlink:label="label176" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtInstrumentInterestRateStatedPercentage_en-US">Debt Instrument Interest Rate Stated Percentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element176" xlink:to="label176" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="element177" />
        <label xlink:type="resource" xlink:label="label177" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DebtInstrumentInterestRateStatedPercentage_en-US">Senior long-term notes, interest rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element177" xlink:to="label177" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="element178" />
        <label xlink:type="resource" xlink:label="label178" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US" id="verbose_us-gaap_DebtInstrumentInterestRateStatedPercentage_en-US">Promissory notes, interest rate percentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element178" xlink:to="label178" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="element179" />
        <label xlink:type="resource" xlink:label="label179" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_en-US">Debt Instrument Periodic Payment Principal</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element179" xlink:to="label179" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="element180" />
        <label xlink:type="resource" xlink:label="label180" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_en-US">DeferredFederalIncomeTaxExpenseBenefit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element180" xlink:to="label180" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="element181" />
        <label xlink:type="resource" xlink:label="label181" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_en-US">Federal, deferred</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element181" xlink:to="label181" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="element182" />
        <label xlink:type="resource" xlink:label="label182" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredFinanceCostsNoncurrentNet_en-US">DeferredFinanceCostsNoncurrentNet</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element182" xlink:to="label182" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="element183" />
        <label xlink:type="resource" xlink:label="label183" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredFinanceCostsNoncurrentNet_en-US">Deferred financing fees</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element183" xlink:to="label183" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="element184" />
        <label xlink:type="resource" xlink:label="label184" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredIncomeTaxExpenseBenefit_en-US">Deferred Income Tax Expense Benefit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element184" xlink:to="label184" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="element185" />
        <label xlink:type="resource" xlink:label="label185" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredIncomeTaxExpenseBenefit_en-US">Deferred income taxes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element185" xlink:to="label185" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="element186" />
        <label xlink:type="resource" xlink:label="label186" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_en-US">DeferredForeignIncomeTaxExpenseBenefit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element186" xlink:to="label186" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="element187" />
        <label xlink:type="resource" xlink:label="label187" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_en-US">Foreign, deferred</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element187" xlink:to="label187" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:label="element188" />
        <label xlink:type="resource" xlink:label="label188" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_en-US">Deferred Tax Assets Liabilities Net [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element188" xlink:to="label188" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="element189" />
        <label xlink:type="resource" xlink:label="label189" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsLiabilitiesNet_en-US">Deferred Tax Assets Liabilities Net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element189" xlink:to="label189" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="element190" />
        <label xlink:type="resource" xlink:label="label190" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsLiabilitiesNet_en-US">Net deferred tax assets (liabilities)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element190" xlink:to="label190" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="element191" />
        <label xlink:type="resource" xlink:label="label191" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_DeferredTaxAssetsLiabilitiesNet_en-US">Net deferred tax assets (liabilities)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element191" xlink:to="label191" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="element192" />
        <label xlink:type="resource" xlink:label="label192" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_en-US">Deferred Tax Assets Liabilities Net Noncurrent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element192" xlink:to="label192" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="element193" />
        <label xlink:type="resource" xlink:label="label193" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_en-US">Noncurrent portion of deferred tax assets (liabilities)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element193" xlink:to="label193" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="element194" />
        <label xlink:type="resource" xlink:label="label194" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_en-US">DeferredStateAndLocalIncomeTaxExpenseBenefit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element194" xlink:to="label194" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="element195" />
        <label xlink:type="resource" xlink:label="label195" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_en-US">State and local, deferred</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element195" xlink:to="label195" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent" xlink:label="element196" />
        <label xlink:type="resource" xlink:label="label196" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent_en-US">Deferred Tax Assets Liabilities Net Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element196" xlink:to="label196" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent" xlink:label="element197" />
        <label xlink:type="resource" xlink:label="label197" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent_en-US">Current portion of deferred tax assets (liabilities)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element197" xlink:to="label197" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:label="element198" />
        <label xlink:type="resource" xlink:label="label198" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_en-US">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element198" xlink:to="label198" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:label="element199" />
        <label xlink:type="resource" xlink:label="label199" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_en-US">Accrued bonus</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element199" xlink:to="label199" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="element200" />
        <label xlink:type="resource" xlink:label="label200" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_en-US">Deferred Tax Assets Tax Credit Carryforwards</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element200" xlink:to="label200" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="element201" />
        <label xlink:type="resource" xlink:label="label201" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_en-US">Tax credit carryforwards</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element201" xlink:to="label201" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="element202" />
        <label xlink:type="resource" xlink:label="label202" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_en-US">Deferred Tax Assets Other Loss Carryforwards</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element202" xlink:to="label202" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="element203" />
        <label xlink:type="resource" xlink:label="label203" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_en-US">Net operating loss carryforwards</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element203" xlink:to="label203" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="element204" />
        <label xlink:type="resource" xlink:label="label204" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsNetCurrent_en-US">Deferred Tax Assets, Net of Valuation Allowance, Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element204" xlink:to="label204" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="element205" />
        <label xlink:type="resource" xlink:label="label205" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsNetCurrent_en-US">Deferred income taxes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element205" xlink:to="label205" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="element206" />
        <label xlink:type="resource" xlink:label="label206" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US" id="verbose_us-gaap_DeferredTaxAssetsNetCurrent_en-US">Current deferred tax assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element206" xlink:to="label206" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="element207" />
        <label xlink:type="resource" xlink:label="label207" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsNetNoncurrent_en-US">Deferred Tax Assets Net Noncurrent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element207" xlink:to="label207" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="element208" />
        <label xlink:type="resource" xlink:label="label208" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsNetNoncurrent_en-US">Deferred income taxes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element208" xlink:to="label208" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="element209" />
        <label xlink:type="resource" xlink:label="label209" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US" id="verbose_us-gaap_DeferredTaxAssetsNetNoncurrent_en-US">Noncurrent deferred tax assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element209" xlink:to="label209" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:label="element210" />
        <label xlink:type="resource" xlink:label="label210" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_en-US">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element210" xlink:to="label210" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:label="element211" />
        <label xlink:type="resource" xlink:label="label211" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_en-US">Accrued payroll &amp; employee benefits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element211" xlink:to="label211" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="element212" />
        <label xlink:type="resource" xlink:label="label212" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsNet_en-US">Deferred Tax Assets Net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element212" xlink:to="label212" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="element213" />
        <label xlink:type="resource" xlink:label="label213" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsNet_en-US">Net deferred tax assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element213" xlink:to="label213" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="element214" />
        <label xlink:type="resource" xlink:label="label214" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_DeferredTaxAssetsNet_en-US">Net deferred tax assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element214" xlink:to="label214" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="element215" />
        <label xlink:type="resource" xlink:label="label215" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsGross_en-US">Deferred Tax Assets Gross</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element215" xlink:to="label215" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="element216" />
        <label xlink:type="resource" xlink:label="label216" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsGross_en-US">Gross deferred tax assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element216" xlink:to="label216" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="element217" />
        <label xlink:type="resource" xlink:label="label217" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_DeferredTaxAssetsGross_en-US">Gross deferred tax assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element217" xlink:to="label217" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="element218" />
        <label xlink:type="resource" xlink:label="label218" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_en-US">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element218" xlink:to="label218" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="element219" />
        <label xlink:type="resource" xlink:label="label219" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_en-US">Allowance for doubtful accounts</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element219" xlink:to="label219" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="element220" />
        <label xlink:type="resource" xlink:label="label220" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_en-US">DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element220" xlink:to="label220" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="element221" />
        <label xlink:type="resource" xlink:label="label221" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_en-US">Deferred tax benefit as result of impairment charges</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element221" xlink:to="label221" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:label="element222" />
        <label xlink:type="resource" xlink:label="label222" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_en-US">Deferred Tax Liabilities Investment In Noncontrolled Affiliates</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element222" xlink:to="label222" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:label="element223" />
        <label xlink:type="resource" xlink:label="label223" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_en-US">Investment in partnerships</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element223" xlink:to="label223" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="element224" />
        <label xlink:type="resource" xlink:label="label224" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxLiabilitiesCurrent_en-US">Deferred Tax Liabilities Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element224" xlink:to="label224" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="element225" />
        <label xlink:type="resource" xlink:label="label225" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxLiabilitiesCurrent_en-US">Current portion of deferred income taxes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element225" xlink:to="label225" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="element226" />
        <label xlink:type="resource" xlink:label="label226" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US" id="verbose_us-gaap_DeferredTaxLiabilitiesCurrent_en-US">Current deferred tax liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element226" xlink:to="label226" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="element227" />
        <label xlink:type="resource" xlink:label="label227" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxLiabilities_en-US">Deferred Tax Liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element227" xlink:to="label227" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="element228" />
        <label xlink:type="resource" xlink:label="label228" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxLiabilities_en-US">Gross deferred tax (liabilities)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element228" xlink:to="label228" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="element229" />
        <label xlink:type="resource" xlink:label="label229" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_DeferredTaxLiabilities_en-US">Gross deferred tax (liabilities)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element229" xlink:to="label229" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="element230" />
        <label xlink:type="resource" xlink:label="label230" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsValuationAllowance_en-US">Deferred Tax Assets Valuation Allowance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element230" xlink:to="label230" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="element231" />
        <label xlink:type="resource" xlink:label="label231" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsValuationAllowance_en-US">Valuation Allowance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element231" xlink:to="label231" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="element232" />
        <label xlink:type="resource" xlink:label="label232" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_en-US">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element232" xlink:to="label232" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="element233" />
        <label xlink:type="resource" xlink:label="label233" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_en-US">Share-based compensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element233" xlink:to="label233" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="element234" />
        <label xlink:type="resource" xlink:label="label234" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_en-US">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element234" xlink:to="label234" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="element235" />
        <label xlink:type="resource" xlink:label="label235" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_en-US">Accrued expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element235" xlink:to="label235" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="element236" />
        <label xlink:type="resource" xlink:label="label236" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_en-US">Deferred Tax Liabilities Property Plant And Equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element236" xlink:to="label236" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="element237" />
        <label xlink:type="resource" xlink:label="label237" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_en-US">Property and equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element237" xlink:to="label237" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="element238" />
        <label xlink:type="resource" xlink:label="label238" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxLiabilitiesNoncurrent_en-US">Deferred Tax Liabilities Noncurrent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element238" xlink:to="label238" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="element239" />
        <label xlink:type="resource" xlink:label="label239" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxLiabilitiesNoncurrent_en-US">Noncurrent deferred tax liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element239" xlink:to="label239" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:label="element240" />
        <label xlink:type="resource" xlink:label="label240" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_en-US">Deferred Tax Liabilities Tax Deferred Income</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element240" xlink:to="label240" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:label="element241" />
        <label xlink:type="resource" xlink:label="label241" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_en-US">Deferred revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element241" xlink:to="label241" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:label="element242" />
        <label xlink:type="resource" xlink:label="label242" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_en-US">Deferred revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element242" xlink:to="label242" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="element243" />
        <label xlink:type="resource" xlink:label="label243" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DeferredTaxLiabilitiesOther_en-US">Deferred Tax Liabilities Other</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element243" xlink:to="label243" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="element244" />
        <label xlink:type="resource" xlink:label="label244" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DeferredTaxLiabilitiesOther_en-US">Other liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element244" xlink:to="label244" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="element245" />
        <label xlink:type="resource" xlink:label="label245" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DefinedContributionPlanCostRecognized_en-US">DefinedContributionPlanCostRecognized</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element245" xlink:to="label245" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="element246" />
        <label xlink:type="resource" xlink:label="label246" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DefinedContributionPlanCostRecognized_en-US">401 (k) Expense Recognized by Company</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element246" xlink:to="label246" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="element247" />
        <label xlink:type="resource" xlink:label="label247" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DepreciationDepletionAndAmortization_en-US">Depreciation Depletion And Amortization</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element247" xlink:to="label247" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="element248" />
        <label xlink:type="resource" xlink:label="label248" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DepreciationDepletionAndAmortization_en-US">Depreciation and amortization</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element248" xlink:to="label248" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="element249" />
        <label xlink:type="resource" xlink:label="label249" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_Depreciation_en-US">Depreciation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element249" xlink:to="label249" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="element250" />
        <label xlink:type="resource" xlink:label="label250" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_en-US">Disclosure of Compensation Related Costs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element250" xlink:to="label250" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="element251" />
        <label xlink:type="resource" xlink:label="label251" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_en-US">CAPITAL SOCK AND SHARE-BASED COMPENSATION</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element251" xlink:to="label251" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="element252" />
        <label xlink:type="resource" xlink:label="label252" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element252" xlink:to="label252" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="element253" />
        <label xlink:type="resource" xlink:label="label253" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_en-US">Discontinued Operation Tax Effect Of Discontinued Operation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element253" xlink:to="label253" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="element254" />
        <label xlink:type="resource" xlink:label="label254" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_en-US">Income tax benefit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element254" xlink:to="label254" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="element255" />
        <label xlink:type="resource" xlink:label="label255" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US" id="verbose_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_en-US">Income from discontinued operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element255" xlink:to="label255" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="element256" />
        <label xlink:type="resource" xlink:label="label256" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_en-US">Discontinued Operation Income Loss From Discontinued Operation Before Income Tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element256" xlink:to="label256" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="element257" />
        <label xlink:type="resource" xlink:label="label257" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_en-US">(Loss) before income taxes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element257" xlink:to="label257" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:label="element258" />
        <label xlink:type="resource" xlink:label="label258" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_en-US">Discontinued Operation, Additional Disclosures [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element258" xlink:to="label258" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="element259" />
        <label xlink:type="resource" xlink:label="label259" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DiscontinuedOperationsHeldforsaleMember_en-US">Discontinued Operations, Held-for-sale [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element259" xlink:to="label259" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="element260" />
        <label xlink:type="resource" xlink:label="label260" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DiscontinuedOperationsHeldforsaleMember_en-US">Assets Held-for-sale [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element260" xlink:to="label260" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="element261" />
        <label xlink:type="resource" xlink:label="label261" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_en-US">Disposal Group Including Discontinued Operation Accrued Liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element261" xlink:to="label261" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="element262" />
        <label xlink:type="resource" xlink:label="label262" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_en-US">Discontinued Operations Liability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element262" xlink:to="label262" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="element263" />
        <label xlink:type="resource" xlink:label="label263" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_en-US">Disposal Group Including Discontinued Operation Revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element263" xlink:to="label263" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="element264" />
        <label xlink:type="resource" xlink:label="label264" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_en-US">Net revenues</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element264" xlink:to="label264" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="element265" />
        <label xlink:type="resource" xlink:label="label265" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_en-US">Disposal Groups Including Discontinued Operations Disclosure [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element265" xlink:to="label265" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="element266" />
        <label xlink:type="resource" xlink:label="label266" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_en-US">DISCONTINUED OPERATIONS</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element266" xlink:to="label266" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="element267" />
        <label xlink:type="resource" xlink:label="label267" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DomesticCountryMember_en-US">Domestic [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element267" xlink:to="label267" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="element268" />
        <label xlink:type="resource" xlink:label="label268" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DomesticCountryMember_en-US">Federal [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element268" xlink:to="label268" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueFromJointVenturesCurrent" xlink:label="element269" />
        <label xlink:type="resource" xlink:label="label269" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_DueFromJointVenturesCurrent_en-US">DueFromJointVenturesCurrent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element269" xlink:to="label269" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueFromJointVenturesCurrent" xlink:label="element270" />
        <label xlink:type="resource" xlink:label="label270" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_DueFromJointVenturesCurrent_en-US">Due from joint ventures</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element270" xlink:to="label270" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="element271" />
        <label xlink:type="resource" xlink:label="label271" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasicAbstract_en-US">Earnings Per Share Basic [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element271" xlink:to="label271" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="element272" />
        <label xlink:type="resource" xlink:label="label272" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EarningsPerShareBasicAbstract_en-US">Basic earnings per common share:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element272" xlink:to="label272" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="element273" />
        <label xlink:type="resource" xlink:label="label273" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EarningsPerShareDilutedAbstract_en-US">Earnings Per Share Diluted [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element273" xlink:to="label273" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="element274" />
        <label xlink:type="resource" xlink:label="label274" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EarningsPerShareDilutedAbstract_en-US">Diluted earnings per common share:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element274" xlink:to="label274" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="element275" />
        <label xlink:type="resource" xlink:label="label275" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EarningsPerSharePolicyTextBlock_en-US">Earnings Per Share Policy [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element275" xlink:to="label275" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="element276" />
        <label xlink:type="resource" xlink:label="label276" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EarningsPerSharePolicyTextBlock_en-US">Weighted-Average Shares Outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element276" xlink:to="label276" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="element277" />
        <label xlink:type="resource" xlink:label="label277" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasic_en-US">Earnings Per Share Basic</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element277" xlink:to="label277" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="element278" />
        <label xlink:type="resource" xlink:label="label278" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_EarningsPerShareBasic_en-US">Income (loss) attributable to Amedisys, Inc. common stockholders</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element278" xlink:to="label278" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="element279" />
        <label xlink:type="resource" xlink:label="label279" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EarningsPerShareDiluted_en-US">Earnings Per Share Diluted</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element279" xlink:to="label279" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="element280" />
        <label xlink:type="resource" xlink:label="label280" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_EarningsPerShareDiluted_en-US">Income (loss) attributable to Amedisys, Inc. common stockholders</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element280" xlink:to="label280" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="element281" />
        <label xlink:type="resource" xlink:label="label281" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_en-US">Effective Income Tax Rate Reconciliation Other Adjustments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element281" xlink:to="label281" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="element282" />
        <label xlink:type="resource" xlink:label="label282" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_en-US">Uncertain tax positions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element282" xlink:to="label282" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="element283" />
        <label xlink:type="resource" xlink:label="label283" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_en-US">EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element283" xlink:to="label283" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="element284" />
        <label xlink:type="resource" xlink:label="label284" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_en-US">State and local income taxes and other, net of federal income tax benefit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element284" xlink:to="label284" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="element285" />
        <label xlink:type="resource" xlink:label="label285" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_en-US">EffectiveIncomeTaxRateReconciliationNondeductibleExpense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element285" xlink:to="label285" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="element286" />
        <label xlink:type="resource" xlink:label="label286" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_en-US">Other items, net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element286" xlink:to="label286" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="element287" />
        <label xlink:type="resource" xlink:label="label287" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_en-US">EffectiveIncomeTaxRateReconciliationTaxCredits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element287" xlink:to="label287" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="element288" />
        <label xlink:type="resource" xlink:label="label288" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_en-US">Tax credits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element288" xlink:to="label288" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="element289" />
        <label xlink:type="resource" xlink:label="label289" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_en-US">EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element289" xlink:to="label289" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="element290" />
        <label xlink:type="resource" xlink:label="label290" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_en-US">Valuation allowance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element290" xlink:to="label290" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="element291" />
        <label xlink:type="resource" xlink:label="label291" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateContinuingOperations_en-US">EffectiveIncomeTaxRateContinuingOperations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element291" xlink:to="label291" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="element292" />
        <label xlink:type="resource" xlink:label="label292" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EffectiveIncomeTaxRateContinuingOperations_en-US">Continuing operations effective income tax rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element292" xlink:to="label292" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="element293" />
        <label xlink:type="resource" xlink:label="label293" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_en-US">Statutory Tax Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element293" xlink:to="label293" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="element294" />
        <label xlink:type="resource" xlink:label="label294" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element294" xlink:to="label294" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="element295" />
        <label xlink:type="resource" xlink:label="label295" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_en-US">EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element295" xlink:to="label295" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="element296" />
        <label xlink:type="resource" xlink:label="label296" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_en-US">Goodwill impairment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element296" xlink:to="label296" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="element297" />
        <label xlink:type="resource" xlink:label="label297" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_en-US">EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element297" xlink:to="label297" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="element298" />
        <label xlink:type="resource" xlink:label="label298" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_en-US">Non-vested stock award compensation expense weighted-average period, years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element298" xlink:to="label298" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="element299" />
        <label xlink:type="resource" xlink:label="label299" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_en-US">Employee Stock Ownership Plan ESOP Compensation Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element299" xlink:to="label299" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="element300" />
        <label xlink:type="resource" xlink:label="label300" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_en-US">Employee Stock Purchase Plan expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element300" xlink:to="label300" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="element301" />
        <label xlink:type="resource" xlink:label="label301" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_en-US">EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element301" xlink:to="label301" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="element302" />
        <label xlink:type="resource" xlink:label="label302" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_en-US">Unrecognized compensation expense related to non-vested stock awards</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element302" xlink:to="label302" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="element303" />
        <label xlink:type="resource" xlink:label="label303" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_en-US">Employee Service Share Based Compensation Tax Benefit From Compensation Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element303" xlink:to="label303" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="element304" />
        <label xlink:type="resource" xlink:label="label304" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_en-US">Share-based compensation, tax benefit recognized</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element304" xlink:to="label304" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="element305" />
        <label xlink:type="resource" xlink:label="label305" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EmployeeSeveranceMember_en-US">Severance [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element305" xlink:to="label305" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="element306" />
        <label xlink:type="resource" xlink:label="label306" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EmployeeSeveranceMember_en-US">Severance [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element306" xlink:to="label306" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="element307" />
        <label xlink:type="resource" xlink:label="label307" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_en-US">Employee Stock Ownership Plan (ESOP) Name [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element307" xlink:to="label307" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="element308" />
        <label xlink:type="resource" xlink:label="label308" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EmployeeRelatedLiabilitiesCurrent_en-US">Employee Related Liabilities Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element308" xlink:to="label308" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="element309" />
        <label xlink:type="resource" xlink:label="label309" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EmployeeRelatedLiabilitiesCurrent_en-US">Payroll and employee benefits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element309" xlink:to="label309" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="element310" />
        <label xlink:type="resource" xlink:label="label310" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_en-US">Employee Stock Ownership Plan (ESOP), Plan [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element310" xlink:to="label310" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="element311" />
        <label xlink:type="resource" xlink:label="label311" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EquityAbstract_en-US">EquityAbstract</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element311" xlink:to="label311" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="element312" />
        <label xlink:type="resource" xlink:label="label312" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EquityMethodInvesteeNameDomain_en-US">Equity Method Name</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element312" xlink:to="label312" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" xlink:label="element313" />
        <label xlink:type="resource" xlink:label="label313" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_en-US">Equity Method Investment Summarized Financial Information Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element313" xlink:to="label313" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" xlink:label="element314" />
        <label xlink:type="resource" xlink:label="label314" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_en-US">Equity method investment total assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element314" xlink:to="label314" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:label="element315" />
        <label xlink:type="resource" xlink:label="label315" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EquityMethodInvestmentDividendsOrDistributions_en-US">Equity Method Investment Dividends Or Distributions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element315" xlink:to="label315" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:label="element316" />
        <label xlink:type="resource" xlink:label="label316" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EquityMethodInvestmentDividendsOrDistributions_en-US">Return on equity investment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element316" xlink:to="label316" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets" xlink:label="element317" />
        <label xlink:type="resource" xlink:label="label317" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets_en-US">Equity Method Investment Summarized Financial Information Current Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element317" xlink:to="label317" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets" xlink:label="element318" />
        <label xlink:type="resource" xlink:label="label318" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets_en-US">Equity method investment current assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element318" xlink:to="label318" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" xlink:label="element319" />
        <label xlink:type="resource" xlink:label="label319" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_en-US">Equity Method Investment Summarized Financial Information Current Liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element319" xlink:to="label319" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" xlink:label="element320" />
        <label xlink:type="resource" xlink:label="label320" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_en-US">Equity method investment current liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element320" xlink:to="label320" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="element321" />
        <label xlink:type="resource" xlink:label="label321" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EquityComponentDomain_en-US">Equity Component [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element321" xlink:to="label321" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="element322" />
        <label xlink:type="resource" xlink:label="label322" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EquityMethodInvestmentAggregateCost_en-US">Equity Method Investment Aggregate Cost</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element322" xlink:to="label322" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities" xlink:label="element323" />
        <label xlink:type="resource" xlink:label="label323" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities_en-US">EquityMethodInvestmentSummarizedFinancialInformationLiabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element323" xlink:to="label323" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities" xlink:label="element324" />
        <label xlink:type="resource" xlink:label="label324" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities_en-US">Equity method investment total liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element324" xlink:to="label324" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentsMember" xlink:label="element325" />
        <label xlink:type="resource" xlink:label="label325" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EquityMethodInvestmentsMember_en-US">Equity Method Investments [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element325" xlink:to="label325" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="element326" />
        <label xlink:type="resource" xlink:label="label326" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EquityMethodInvestmentsPolicy_en-US">Equity Method Investments Policy</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element326" xlink:to="label326" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="element327" />
        <label xlink:type="resource" xlink:label="label327" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EquityMethodInvestmentsPolicy_en-US">Equity Investments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element327" xlink:to="label327" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="element328" />
        <label xlink:type="resource" xlink:label="label328" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_EscrowDeposit_en-US">Escrow Deposit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element328" xlink:to="label328" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="element329" />
        <label xlink:type="resource" xlink:label="label329" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_EscrowDeposit_en-US">Escrow deposit for indemnification purposes and working capital price adjustments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element329" xlink:to="label329" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="element330" />
        <label xlink:type="resource" xlink:label="label330" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_en-US">Excess Tax Benefit From Share Based Compensation Financing Activities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element330" xlink:to="label330" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="element331" />
        <label xlink:type="resource" xlink:label="label331" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_en-US">Tax benefit from stock options exercised and restricted stock vesting</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element331" xlink:to="label331" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="element332" />
        <label xlink:type="resource" xlink:label="label332" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FairValueAssumptionsExpectedVolatilityRate_en-US">Expected Volatility</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element332" xlink:to="label332" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="element333" />
        <label xlink:type="resource" xlink:label="label333" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FairValueAssumptionsExpectedVolatilityRate_en-US">Expected Volatility</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element333" xlink:to="label333" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="element334" />
        <label xlink:type="resource" xlink:label="label334" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element334" xlink:to="label334" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="element335" />
        <label xlink:type="resource" xlink:label="label335" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element335" xlink:to="label335" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="element336" />
        <label xlink:type="resource" xlink:label="label336" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element336" xlink:to="label336" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="element337" />
        <label xlink:type="resource" xlink:label="label337" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element337" xlink:to="label337" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="element338" />
        <label xlink:type="resource" xlink:label="label338" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FairValueByFairValueHierarchyLevelAxis_en-US">Fair Value By Fair Value Hierarchy Level [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element338" xlink:to="label338" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="element339" />
        <label xlink:type="resource" xlink:label="label339" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FairValueByFairValueHierarchyLevelAxis_en-US">Fair Value, Hierarchy [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element339" xlink:to="label339" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="element340" />
        <label xlink:type="resource" xlink:label="label340" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FairValueOfFinancialInstrumentsPolicy_en-US">Fair Value Of Financial Instruments Policy</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element340" xlink:to="label340" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="element341" />
        <label xlink:type="resource" xlink:label="label341" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FairValueOfFinancialInstrumentsPolicy_en-US">Fair Value of Financial Instruments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element341" xlink:to="label341" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="element342" />
        <label xlink:type="resource" xlink:label="label342" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element342" xlink:to="label342" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="element343" />
        <label xlink:type="resource" xlink:label="label343" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element343" xlink:to="label343" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="element344" />
        <label xlink:type="resource" xlink:label="label344" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FairValueInputsLevel3Member_en-US">Fair Value, Inputs, Level 3 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element344" xlink:to="label344" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="element345" />
        <label xlink:type="resource" xlink:label="label345" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FairValueInputsLevel1Member_en-US">Fair Value, Inputs, Level 1 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element345" xlink:to="label345" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="element346" />
        <label xlink:type="resource" xlink:label="label346" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FairValueInputsLevel2Member_en-US">Fair Value Inputs Level 2 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element346" xlink:to="label346" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="element347" />
        <label xlink:type="resource" xlink:label="label347" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FairValueInputsLevel2Member_en-US">Significant Other Observable Inputs (Level 2)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element347" xlink:to="label347" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="element348" />
        <label xlink:type="resource" xlink:label="label348" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_en-US">Finite Lived Intangible Assets Accumulated Amortization</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element348" xlink:to="label348" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="element349" />
        <label xlink:type="resource" xlink:label="label349" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_en-US">Intangible assets, accumulated amortization</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element349" xlink:to="label349" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="element350" />
        <label xlink:type="resource" xlink:label="label350" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FiniteLivedIntangibleAssetsNet_en-US">Finite Lived Intangible Assets Net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element350" xlink:to="label350" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="element351" />
        <label xlink:type="resource" xlink:label="label351" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_en-US">Finite Lived Intangible Assets Amortization Expense Year Three</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element351" xlink:to="label351" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="element352" />
        <label xlink:type="resource" xlink:label="label352" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_en-US">2019</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element352" xlink:to="label352" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="element353" />
        <label xlink:type="resource" xlink:label="label353" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_en-US">Finite Lived Intangible Assets Major Class Name [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element353" xlink:to="label353" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="element354" />
        <label xlink:type="resource" xlink:label="label354" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element354" xlink:to="label354" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="element355" />
        <label xlink:type="resource" xlink:label="label355" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_en-US">Finite Lived Intangible Assets By Major Class [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element355" xlink:to="label355" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="element356" />
        <label xlink:type="resource" xlink:label="label356" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element356" xlink:to="label356" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="element357" />
        <label xlink:type="resource" xlink:label="label357" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_en-US">Finite Lived Intangible Assets Amortization Expense Year Four</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element357" xlink:to="label357" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="element358" />
        <label xlink:type="resource" xlink:label="label358" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_en-US">2020</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element358" xlink:to="label358" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="element359" />
        <label xlink:type="resource" xlink:label="label359" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_en-US">Finite Lived Intangible Assets Amortization Expense Year Five</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element359" xlink:to="label359" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="element360" />
        <label xlink:type="resource" xlink:label="label360" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_en-US">2021</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element360" xlink:to="label360" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="element361" />
        <label xlink:type="resource" xlink:label="label361" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_en-US">Finite Lived Intangible Assets Amortization Expense Year Two</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element361" xlink:to="label361" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="element362" />
        <label xlink:type="resource" xlink:label="label362" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_en-US">2018</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element362" xlink:to="label362" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="element363" />
        <label xlink:type="resource" xlink:label="label363" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_en-US">FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element363" xlink:to="label363" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="element364" />
        <label xlink:type="resource" xlink:label="label364" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_en-US">2017</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element364" xlink:to="label364" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="element365" />
        <label xlink:type="resource" xlink:label="label365" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ForeignCountryMember_en-US">Foreign [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element365" xlink:to="label365" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="element366" />
        <label xlink:type="resource" xlink:label="label366" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ForeignCountryMember_en-US">Puerto Rico [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element366" xlink:to="label366" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="element367" />
        <label xlink:type="resource" xlink:label="label367" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_en-US">Gain Loss On Sale Of Property Plant Equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element367" xlink:to="label367" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="element368" />
        <label xlink:type="resource" xlink:label="label368" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_en-US">Loss on disposal of property and equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element368" xlink:to="label368" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="element369" />
        <label xlink:type="resource" xlink:label="label369" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_GainsLossesOnSalesOfAssets_en-US">Gains (Losses) on Sales of Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element369" xlink:to="label369" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="element370" />
        <label xlink:type="resource" xlink:label="label370" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_GainsLossesOnSalesOfAssets_en-US">Gain on sale of care centers</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element370" xlink:to="label370" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="element371" />
        <label xlink:type="resource" xlink:label="label371" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_GainsLossesOnSalesOfAssets_en-US">Gain on sale of care centers</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element371" xlink:to="label371" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="element372" />
        <label xlink:type="resource" xlink:label="label372" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_GeneralAndAdministrativeExpenseAbstract_en-US">General And Administrative Expense [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element372" xlink:to="label372" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="element373" />
        <label xlink:type="resource" xlink:label="label373" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_GeneralAndAdministrativeExpenseAbstract_en-US">General and administrative expenses:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element373" xlink:to="label373" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="element374" />
        <label xlink:type="resource" xlink:label="label374" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_Goodwill_en-US">Goodwill</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element374" xlink:to="label374" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="element375" />
        <label xlink:type="resource" xlink:label="label375" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US" id="periodEnd_us-gaap_Goodwill_en-US">Ending balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element375" xlink:to="label375" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="element376" />
        <label xlink:type="resource" xlink:label="label376" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US" id="periodStart_us-gaap_Goodwill_en-US">Beginning balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element376" xlink:to="label376" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="element377" />
        <label xlink:type="resource" xlink:label="label377" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_Goodwill_en-US">Goodwill</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element377" xlink:to="label377" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="element378" />
        <label xlink:type="resource" xlink:label="label378" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_GoodwillPurchaseAccountingAdjustments_en-US">Goodwill Purchase Accounting Adjustments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element378" xlink:to="label378" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="element379" />
        <label xlink:type="resource" xlink:label="label379" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_GoodwillPurchaseAccountingAdjustments_en-US">Adjustments related to acquisitions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element379" xlink:to="label379" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="element380" />
        <label xlink:type="resource" xlink:label="label380" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_en-US">Goodwill And Intangible Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element380" xlink:to="label380" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="element381" />
        <label xlink:type="resource" xlink:label="label381" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_en-US">Goodwill And Intangible Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element381" xlink:to="label381" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:label="element382" />
        <label xlink:type="resource" xlink:label="label382" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_en-US">Goodwill, Written off Related to Sale of Business Unit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element382" xlink:to="label382" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:label="element383" />
        <label xlink:type="resource" xlink:label="label383" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_en-US">Write-Off</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element383" xlink:to="label383" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="element384" />
        <label xlink:type="resource" xlink:label="label384" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_GoodwillAcquiredDuringPeriod_en-US">GoodwillAcquiredDuringPeriod</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element384" xlink:to="label384" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="element385" />
        <label xlink:type="resource" xlink:label="label385" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_GoodwillAcquiredDuringPeriod_en-US">Additions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element385" xlink:to="label385" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="element386" />
        <label xlink:type="resource" xlink:label="label386" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_en-US">Goodwill And Intangible Assets Disclosure [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element386" xlink:to="label386" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="element387" />
        <label xlink:type="resource" xlink:label="label387" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_en-US">GOODWILL AND OTHER INTANGIBLE ASSETS, NET</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element387" xlink:to="label387" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="element388" />
        <label xlink:type="resource" xlink:label="label388" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_GoodwillImpairmentLoss_en-US">Goodwill, Impairment Loss</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element388" xlink:to="label388" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="element389" />
        <label xlink:type="resource" xlink:label="label389" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_GoodwillImpairmentLoss_en-US">Goodwill impairment loss</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element389" xlink:to="label389" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="element390" />
        <label xlink:type="resource" xlink:label="label390" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element390" xlink:to="label390" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="element391" />
        <label xlink:type="resource" xlink:label="label391" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_HealthCareOrganizationRevenueSourcesDomain_en-US">Health Care Organization Revenue Sources [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element391" xlink:to="label391" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="element392" />
        <label xlink:type="resource" xlink:label="label392" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_HealthCareOrganizationRevenueSourcesDomain_en-US">Health Care Organization, Revenue Sources [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element392" xlink:to="label392" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="element393" />
        <label xlink:type="resource" xlink:label="label393" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_HealthCareOrganizationRevenueSourcesAxis_en-US">Health Care Organization Revenue Sources [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element393" xlink:to="label393" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="element394" />
        <label xlink:type="resource" xlink:label="label394" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_HealthCareOrganizationRevenueSourcesAxis_en-US">Health Care Organization, Revenue Sources [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element394" xlink:to="label394" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationPatientServiceRevenue" xlink:label="element395" />
        <label xlink:type="resource" xlink:label="label395" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_HealthCareOrganizationPatientServiceRevenue_en-US">Health Care Organization Patient Service Revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element395" xlink:to="label395" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationPatientServiceRevenue" xlink:label="element396" />
        <label xlink:type="resource" xlink:label="label396" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_HealthCareOrganizationPatientServiceRevenue_en-US">Net service revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element396" xlink:to="label396" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="element397" />
        <label xlink:type="resource" xlink:label="label397" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_en-US">ImpairmentOfIntangibleAssetsExcludingGoodwill</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element397" xlink:to="label397" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="element398" />
        <label xlink:type="resource" xlink:label="label398" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_en-US">Other intangibles impairment charge</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element398" xlink:to="label398" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="element399" />
        <label xlink:type="resource" xlink:label="label399" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_en-US">Other intangibles impairment charge</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element399" xlink:to="label399" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="element400" />
        <label xlink:type="resource" xlink:label="label400" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_en-US">Income Loss From Continuing Operations Per Basic Share</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element400" xlink:to="label400" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="element401" />
        <label xlink:type="resource" xlink:label="label401" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_en-US">Income (loss) from continuing operations attributable to Amedisys, Inc. common stockholders</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element401" xlink:to="label401" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="element402" />
        <label xlink:type="resource" xlink:label="label402" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeLossFromEquityMethodInvestments_en-US">Income Loss From Equity Method Investments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element402" xlink:to="label402" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="element403" />
        <label xlink:type="resource" xlink:label="label403" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeLossFromEquityMethodInvestments_en-US">Equity in earnings from equity method investments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element403" xlink:to="label403" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="element404" />
        <label xlink:type="resource" xlink:label="label404" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_IncomeLossFromEquityMethodInvestments_en-US">Equity in earnings from equity method investments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element404" xlink:to="label404" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="element405" />
        <label xlink:type="resource" xlink:label="label405" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_en-US">Income Loss From Discontinued Operations Net Of Tax Per Diluted Share</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element405" xlink:to="label405" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="element406" />
        <label xlink:type="resource" xlink:label="label406" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_en-US">Discontinued operations, net of tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element406" xlink:to="label406" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="element407" />
        <label xlink:type="resource" xlink:label="label407" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_en-US">Income Loss From Discontinued Operations Net Of Tax Per Basic Share</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element407" xlink:to="label407" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="element408" />
        <label xlink:type="resource" xlink:label="label408" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_en-US">Discontinued operations, net of tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element408" xlink:to="label408" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="element409" />
        <label xlink:type="resource" xlink:label="label409" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeStatementAbstract_en-US">Income Statement [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element409" xlink:to="label409" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="element410" />
        <label xlink:type="resource" xlink:label="label410" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeStatementAbstract_en-US">Income Statement [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element410" xlink:to="label410" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="element411" />
        <label xlink:type="resource" xlink:label="label411" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeTaxDisclosureAbstract_en-US">Income Tax Disclosure [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element411" xlink:to="label411" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="element412" />
        <label xlink:type="resource" xlink:label="label412" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_en-US">Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element412" xlink:to="label412" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="element413" />
        <label xlink:type="resource" xlink:label="label413" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element413" xlink:to="label413" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="element414" />
        <label xlink:type="resource" xlink:label="label414" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_en-US">Income Loss From Continuing Operations Per Diluted Share</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element414" xlink:to="label414" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="element415" />
        <label xlink:type="resource" xlink:label="label415" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_en-US">Income (loss) from continuing operations attributable to Amedisys, Inc. common stockholders</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element415" xlink:to="label415" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="element416" />
        <label xlink:type="resource" xlink:label="label416" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeTaxAuthorityAxis_en-US">Income Tax Authority [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element416" xlink:to="label416" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="element417" />
        <label xlink:type="resource" xlink:label="label417" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_en-US">Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element417" xlink:to="label417" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="element418" />
        <label xlink:type="resource" xlink:label="label418" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_en-US">Income (loss) before income taxes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element418" xlink:to="label418" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="element419" />
        <label xlink:type="resource" xlink:label="label419" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_en-US">Income Loss From Discontinued Operations Net Of Tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element419" xlink:to="label419" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="element420" />
        <label xlink:type="resource" xlink:label="label420" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_en-US">Discontinued operations, net of tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element420" xlink:to="label420" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="element421" />
        <label xlink:type="resource" xlink:label="label421" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_en-US">Discontinued operations, net of tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element421" xlink:to="label421" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="element422" />
        <label xlink:type="resource" xlink:label="label422" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeLossFromContinuingOperations_en-US">Income Loss From Continuing Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element422" xlink:to="label422" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="element423" />
        <label xlink:type="resource" xlink:label="label423" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeLossFromContinuingOperations_en-US">Income (loss) from continuing operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element423" xlink:to="label423" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="element424" />
        <label xlink:type="resource" xlink:label="label424" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeTaxCreditsAndAdjustments_en-US">Income Tax Credits And Adjustments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element424" xlink:to="label424" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="element425" />
        <label xlink:type="resource" xlink:label="label425" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeTaxCreditsAndAdjustments_en-US">Tax credits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element425" xlink:to="label425" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="element426" />
        <label xlink:type="resource" xlink:label="label426" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_en-US">Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element426" xlink:to="label426" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="element427" />
        <label xlink:type="resource" xlink:label="label427" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element427" xlink:to="label427" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="element428" />
        <label xlink:type="resource" xlink:label="label428" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeTaxExpenseBenefit_en-US">Income Tax Expense Benefit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element428" xlink:to="label428" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="element429" />
        <label xlink:type="resource" xlink:label="label429" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_IncomeTaxExpenseBenefit_en-US">Income tax expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element429" xlink:to="label429" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="element430" />
        <label xlink:type="resource" xlink:label="label430" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US" id="verbose_us-gaap_IncomeTaxExpenseBenefit_en-US">Income tax expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element430" xlink:to="label430" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="element431" />
        <label xlink:type="resource" xlink:label="label431" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeTaxAuthorityDomain_en-US">Income Tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element431" xlink:to="label431" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:label="element432" />
        <label xlink:type="resource" xlink:label="label432" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_en-US">Income Tax Expense Benefit Intraperiod Tax Allocation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element432" xlink:to="label432" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:label="element433" />
        <label xlink:type="resource" xlink:label="label433" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_en-US">Total income tax expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element433" xlink:to="label433" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityOther" xlink:label="element434" />
        <label xlink:type="resource" xlink:label="label434" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityOther_en-US">Income Tax Effects Allocated Directly To Equity Other</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element434" xlink:to="label434" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityOther" xlink:label="element435" />
        <label xlink:type="resource" xlink:label="label435" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityOther_en-US">Stockholders' equity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element435" xlink:to="label435" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="element436" />
        <label xlink:type="resource" xlink:label="label436" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeTaxDisclosureTextBlock_en-US">Income Tax Disclosure [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element436" xlink:to="label436" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="element437" />
        <label xlink:type="resource" xlink:label="label437" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeTaxDisclosureTextBlock_en-US">INCOME TAXES</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element437" xlink:to="label437" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="element438" />
        <label xlink:type="resource" xlink:label="label438" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeTaxExaminationTable_en-US">Income Tax Examination [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element438" xlink:to="label438" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="element439" />
        <label xlink:type="resource" xlink:label="label439" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeTaxPolicyTextBlock_en-US">Income Taxes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element439" xlink:to="label439" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="element440" />
        <label xlink:type="resource" xlink:label="label440" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeTaxPolicyTextBlock_en-US">Income Tax, Policy</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element440" xlink:to="label440" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="element441" />
        <label xlink:type="resource" xlink:label="label441" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeTaxesPaidNet_en-US">Income Taxes Paid Net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element441" xlink:to="label441" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="element442" />
        <label xlink:type="resource" xlink:label="label442" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeTaxesPaidNet_en-US">Cash paid for income taxes, net of refunds received</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element442" xlink:to="label442" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="element443" />
        <label xlink:type="resource" xlink:label="label443" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeTaxesReceivable_en-US">IncomeTaxesReceivable</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element443" xlink:to="label443" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="element444" />
        <label xlink:type="resource" xlink:label="label444" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeTaxesReceivable_en-US">Income tax receivable</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element444" xlink:to="label444" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="element445" />
        <label xlink:type="resource" xlink:label="label445" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_en-US">Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element445" xlink:to="label445" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="element446" />
        <label xlink:type="resource" xlink:label="label446" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_en-US">Income (loss) from continuing operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element446" xlink:to="label446" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="element447" />
        <label xlink:type="resource" xlink:label="label447" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_en-US">Income Amounts Attributable To Reporting Entity Disclosures [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element447" xlink:to="label447" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="element448" />
        <label xlink:type="resource" xlink:label="label448" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_en-US">Amounts attributable to Amedisys, Inc. common stockholders:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element448" xlink:to="label448" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="element449" />
        <label xlink:type="resource" xlink:label="label449" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_en-US">Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element449" xlink:to="label449" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="element450" />
        <label xlink:type="resource" xlink:label="label450" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_en-US">Discontinued operations, net of tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element450" xlink:to="label450" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="element451" />
        <label xlink:type="resource" xlink:label="label451" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsReceivable_en-US">Increase Decrease In Accounts Receivable</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element451" xlink:to="label451" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="element452" />
        <label xlink:type="resource" xlink:label="label452" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_IncreaseDecreaseInAccountsReceivable_en-US">Patient accounts receivable</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element452" xlink:to="label452" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="element453" />
        <label xlink:type="resource" xlink:label="label453" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsPayable_en-US">Increase Decrease In Accounts Payable</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element453" xlink:to="label453" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="element454" />
        <label xlink:type="resource" xlink:label="label454" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncreaseDecreaseInAccountsPayable_en-US">Accounts payable</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element454" xlink:to="label454" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="element455" />
        <label xlink:type="resource" xlink:label="label455" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_en-US">IncreaseDecreaseinOtherCurrentLiabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element455" xlink:to="label455" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="element456" />
        <label xlink:type="resource" xlink:label="label456" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_en-US">Settlement of the Federal Cap</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element456" xlink:to="label456" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="element457" />
        <label xlink:type="resource" xlink:label="label457" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_en-US">Other long-term obligations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element457" xlink:to="label457" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="element458" />
        <label xlink:type="resource" xlink:label="label458" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccruedLiabilities_en-US">Increase Decrease In Accrued Liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element458" xlink:to="label458" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="element459" />
        <label xlink:type="resource" xlink:label="label459" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncreaseDecreaseInAccruedLiabilities_en-US">Accrued expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element459" xlink:to="label459" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="element460" />
        <label xlink:type="resource" xlink:label="label460" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_en-US">Increase Decrease In Operating Capital [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element460" xlink:to="label460" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="element461" />
        <label xlink:type="resource" xlink:label="label461" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_en-US">Changes in operating assets and liabilities, net of impact of acquisitions:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element461" xlink:to="label461" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="element462" />
        <label xlink:type="resource" xlink:label="label462" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInOtherOperatingAssets_en-US">Increase Decrease In Other Operating Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element462" xlink:to="label462" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="element463" />
        <label xlink:type="resource" xlink:label="label463" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_IncreaseDecreaseInOtherOperatingAssets_en-US">Other assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element463" xlink:to="label463" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="element464" />
        <label xlink:type="resource" xlink:label="label464" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_en-US">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element464" xlink:to="label464" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="element465" />
        <label xlink:type="resource" xlink:label="label465" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_en-US">Other current assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element465" xlink:to="label465" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="element466" />
        <label xlink:type="resource" xlink:label="label466" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_en-US">Incremental Common Shares Attributable To Share Based Payment Arrangements</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element466" xlink:to="label466" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="element467" />
        <label xlink:type="resource" xlink:label="label467" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_en-US">Stock options</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element467" xlink:to="label467" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="element468" />
        <label xlink:type="resource" xlink:label="label468" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_en-US">Intangible Assets Class [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element468" xlink:to="label468" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="element469" />
        <label xlink:type="resource" xlink:label="label469" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_en-US">Intangible Assets By Major Class [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element469" xlink:to="label469" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="element470" />
        <label xlink:type="resource" xlink:label="label470" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_IntangibleAssetsNetExcludingGoodwill_en-US">Intangible Assets Net Excluding Goodwill</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element470" xlink:to="label470" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="element471" />
        <label xlink:type="resource" xlink:label="label471" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US" id="periodEnd_us-gaap_IntangibleAssetsNetExcludingGoodwill_en-US">Ending balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element471" xlink:to="label471" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="element472" />
        <label xlink:type="resource" xlink:label="label472" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US" id="periodStart_us-gaap_IntangibleAssetsNetExcludingGoodwill_en-US">Beginning balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element472" xlink:to="label472" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="element473" />
        <label xlink:type="resource" xlink:label="label473" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_IntangibleAssetsNetExcludingGoodwill_en-US">Intangible assets, net of accumulated amortization of $27,864 and $25,386</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element473" xlink:to="label473" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="element474" />
        <label xlink:type="resource" xlink:label="label474" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_InterestExpense_en-US">Interest Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element474" xlink:to="label474" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="element475" />
        <label xlink:type="resource" xlink:label="label475" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_InterestExpense_en-US">Interest expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element475" xlink:to="label475" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="element476" />
        <label xlink:type="resource" xlink:label="label476" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_InterestPaid_en-US">Interest Paid</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element476" xlink:to="label476" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="element477" />
        <label xlink:type="resource" xlink:label="label477" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_InterestPaid_en-US">Cash paid for interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element477" xlink:to="label477" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="element478" />
        <label xlink:type="resource" xlink:label="label478" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_InvestmentIncomeInterestAndDividend_en-US">Investment Income Interest And Dividend</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element478" xlink:to="label478" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="element479" />
        <label xlink:type="resource" xlink:label="label479" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_InvestmentIncomeInterestAndDividend_en-US">Interest income</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element479" xlink:to="label479" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="element480" />
        <label xlink:type="resource" xlink:label="label480" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_en-US">InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element480" xlink:to="label480" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="element481" />
        <label xlink:type="resource" xlink:label="label481" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_en-US">Investments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element481" xlink:to="label481" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="element482" />
        <label xlink:type="resource" xlink:label="label482" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LettersOfCreditOutstandingAmount_en-US">Letters Of Credit Outstanding Amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element482" xlink:to="label482" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="element483" />
        <label xlink:type="resource" xlink:label="label483" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LettersOfCreditOutstandingAmount_en-US">Outstanding letters of credit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element483" xlink:to="label483" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="element484" />
        <label xlink:type="resource" xlink:label="label484" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongtermDebtTypeAxis_en-US">Longterm Debt Type [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element484" xlink:to="label484" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="element485" />
        <label xlink:type="resource" xlink:label="label485" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongtermDebtTypeAxis_en-US">Long-term Debt, Type [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element485" xlink:to="label485" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="element486" />
        <label xlink:type="resource" xlink:label="label486" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongtermDebtTypeDomain_en-US">Longterm Debt Type [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element486" xlink:to="label486" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="element487" />
        <label xlink:type="resource" xlink:label="label487" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongtermDebtTypeDomain_en-US">Long-term Debt, Type [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element487" xlink:to="label487" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="element488" />
        <label xlink:type="resource" xlink:label="label488" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LaborAndRelatedExpense_en-US">Labor And Related Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element488" xlink:to="label488" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="element489" />
        <label xlink:type="resource" xlink:label="label489" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LaborAndRelatedExpense_en-US">Salaries and benefits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element489" xlink:to="label489" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Land" xlink:label="element490" />
        <label xlink:type="resource" xlink:label="label490" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_Land_en-US">Land</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element490" xlink:to="label490" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="element491" />
        <label xlink:type="resource" xlink:label="label491" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LeaseholdImprovementsMember_en-US">Leasehold Improvements [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element491" xlink:to="label491" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalFees" xlink:label="element492" />
        <label xlink:type="resource" xlink:label="label492" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LegalFees_en-US">Legal Fees</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element492" xlink:to="label492" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalFees" xlink:label="element493" />
        <label xlink:type="resource" xlink:label="label493" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LegalFees_en-US">Legal fees</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element493" xlink:to="label493" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="element494" />
        <label xlink:type="resource" xlink:label="label494" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LetterOfCreditMember_en-US">Letter Of Credit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element494" xlink:to="label494" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="element495" />
        <label xlink:type="resource" xlink:label="label495" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrent_en-US">Liabilities Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element495" xlink:to="label495" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="element496" />
        <label xlink:type="resource" xlink:label="label496" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_LiabilitiesCurrent_en-US">Total current liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element496" xlink:to="label496" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="element497" />
        <label xlink:type="resource" xlink:label="label497" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrentAbstract_en-US">Liabilities Current [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element497" xlink:to="label497" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="element498" />
        <label xlink:type="resource" xlink:label="label498" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LiabilitiesCurrentAbstract_en-US">Current liabilities:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element498" xlink:to="label498" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="element499" />
        <label xlink:type="resource" xlink:label="label499" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_Liabilities_en-US">Liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element499" xlink:to="label499" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="element500" />
        <label xlink:type="resource" xlink:label="label500" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_Liabilities_en-US">Total liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element500" xlink:to="label500" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="element501" />
        <label xlink:type="resource" xlink:label="label501" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_en-US">Liabilities And Stockholders Equity [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element501" xlink:to="label501" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="element502" />
        <label xlink:type="resource" xlink:label="label502" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LiabilitiesAndStockholdersEquityAbstract_en-US">LIABILITIES AND EQUITY</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element502" xlink:to="label502" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="element503" />
        <label xlink:type="resource" xlink:label="label503" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LiabilitiesFairValueDisclosure_en-US">Liabilities Fair Value Disclosure</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element503" xlink:to="label503" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="element504" />
        <label xlink:type="resource" xlink:label="label504" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LiabilitiesFairValueDisclosure_en-US">Long-term obligations, excluding capital leases</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element504" xlink:to="label504" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="element505" />
        <label xlink:type="resource" xlink:label="label505" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquity_en-US">Liabilities And Stockholders Equity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element505" xlink:to="label505" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="element506" />
        <label xlink:type="resource" xlink:label="label506" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_LiabilitiesAndStockholdersEquity_en-US">Total liabilities and equity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element506" xlink:to="label506" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="element507" />
        <label xlink:type="resource" xlink:label="label507" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LineOfCreditFacilityTable_en-US">Line of Credit Facility [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element507" xlink:to="label507" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="element508" />
        <label xlink:type="resource" xlink:label="label508" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_en-US">Line Of Credit Facility Commitment Fee Percentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element508" xlink:to="label508" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="element509" />
        <label xlink:type="resource" xlink:label="label509" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_en-US">Commitment Fee</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element509" xlink:to="label509" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="element510" />
        <label xlink:type="resource" xlink:label="label510" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LineOfCreditFacilityAxis_en-US">Line Of Credit Facility [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element510" xlink:to="label510" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="element511" />
        <label xlink:type="resource" xlink:label="label511" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_en-US">Line Of Credit Facility Maximum Borrowing Capacity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element511" xlink:to="label511" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="element512" />
        <label xlink:type="resource" xlink:label="label512" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_en-US">Credit facility, maximum borrowing capacity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element512" xlink:to="label512" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="element513" />
        <label xlink:type="resource" xlink:label="label513" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LineOfCreditFacilityLineItems_en-US">Line of Credit Facility [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element513" xlink:to="label513" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="element514" />
        <label xlink:type="resource" xlink:label="label514" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_en-US">Line Of Credit Facility Remaining Borrowing Capacity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element514" xlink:to="label514" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="element515" />
        <label xlink:type="resource" xlink:label="label515" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_en-US">Availability under the revolving credit facility</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element515" xlink:to="label515" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="element516" />
        <label xlink:type="resource" xlink:label="label516" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LitigationStatusDomain_en-US">Litigation Status [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element516" xlink:to="label516" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="element517" />
        <label xlink:type="resource" xlink:label="label517" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LitigationSettlementAmount_en-US">Loss Contingency, Settlement Agreement, Consideration</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element517" xlink:to="label517" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="element518" />
        <label xlink:type="resource" xlink:label="label518" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LitigationStatusAxis_en-US">Litigation Status [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element518" xlink:to="label518" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="element519" />
        <label xlink:type="resource" xlink:label="label519" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongLivedAssetsHeldForSaleNameDomain_en-US">Long Lived Assets Held-for-sale, Name [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element519" xlink:to="label519" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="element520" />
        <label xlink:type="resource" xlink:label="label520" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongTermDebt_en-US">Long Term Debt</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element520" xlink:to="label520" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="element521" />
        <label xlink:type="resource" xlink:label="label521" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongTermDebt_en-US">Long-term debt including current portion</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element521" xlink:to="label521" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="element522" />
        <label xlink:type="resource" xlink:label="label522" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_LongTermDebt_en-US">Long-term debt including current portion</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element522" xlink:to="label522" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:label="element523" />
        <label xlink:type="resource" xlink:label="label523" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_en-US">Long Lived Assets Held-for-sale by Asset Type [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element523" xlink:to="label523" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="element524" />
        <label xlink:type="resource" xlink:label="label524" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_en-US">Long Term Debt Maturities Repayments Of Principal In Year Four</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element524" xlink:to="label524" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="element525" />
        <label xlink:type="resource" xlink:label="label525" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_en-US">2020</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element525" xlink:to="label525" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="element526" />
        <label xlink:type="resource" xlink:label="label526" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongTermDebtAndCapitalLeaseObligations_en-US">Long Term Debt And Capital Lease Obligations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element526" xlink:to="label526" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="element527" />
        <label xlink:type="resource" xlink:label="label527" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongTermDebtAndCapitalLeaseObligations_en-US">Long-term obligations, less current portion</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element527" xlink:to="label527" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="element528" />
        <label xlink:type="resource" xlink:label="label528" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_en-US">Long Term Debt Maturities Repayments Of Principal In Year Five</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element528" xlink:to="label528" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="element529" />
        <label xlink:type="resource" xlink:label="label529" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_en-US">2021</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element529" xlink:to="label529" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAbstract" xlink:label="element530" />
        <label xlink:type="resource" xlink:label="label530" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongTermDebtAbstract_en-US">Long-term Debt [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element530" xlink:to="label530" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="element531" />
        <label xlink:type="resource" xlink:label="label531" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_en-US">Long Term Debt Maturities Repayments Of Principal In Year Three</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element531" xlink:to="label531" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="element532" />
        <label xlink:type="resource" xlink:label="label532" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_en-US">2019</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element532" xlink:to="label532" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="element533" />
        <label xlink:type="resource" xlink:label="label533" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_en-US">Long Term Debt And Capital Lease Obligations Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element533" xlink:to="label533" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="element534" />
        <label xlink:type="resource" xlink:label="label534" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_en-US">Current portion of long-term obligations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element534" xlink:to="label534" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="element535" />
        <label xlink:type="resource" xlink:label="label535" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_en-US">Current portion of long-term obligations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element535" xlink:to="label535" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="element536" />
        <label xlink:type="resource" xlink:label="label536" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_en-US">Long Term Debt Maturities Repayments Of Principal After Year Five</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element536" xlink:to="label536" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="element537" />
        <label xlink:type="resource" xlink:label="label537" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_en-US">Future Years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element537" xlink:to="label537" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="element538" />
        <label xlink:type="resource" xlink:label="label538" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_en-US">Long Term Debt Maturities Repayments Of Principal In Next Twelve Months</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element538" xlink:to="label538" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="element539" />
        <label xlink:type="resource" xlink:label="label539" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_en-US">2017</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element539" xlink:to="label539" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="element540" />
        <label xlink:type="resource" xlink:label="label540" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_en-US">Long Term Debt Maturities Repayments Of Principal In Year Two</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element540" xlink:to="label540" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="element541" />
        <label xlink:type="resource" xlink:label="label541" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_en-US">2018</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element541" xlink:to="label541" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="element542" />
        <label xlink:type="resource" xlink:label="label542" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LongTermDebtNoncurrent_en-US">Long Term Debt Noncurrent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element542" xlink:to="label542" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="element543" />
        <label xlink:type="resource" xlink:label="label543" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LongTermDebtNoncurrent_en-US">Total</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element543" xlink:to="label543" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="element544" />
        <label xlink:type="resource" xlink:label="label544" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LossContingencyEstimateOfPossibleLoss_en-US">Loss Contingency, Estimate of Possible Loss</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element544" xlink:to="label544" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="element545" />
        <label xlink:type="resource" xlink:label="label545" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LossContingencyAccrualAtCarryingValue_en-US">Loss Contingency Accrual, at Carrying Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element545" xlink:to="label545" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs" xlink:label="element546" />
        <label xlink:type="resource" xlink:label="label546" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LossContingencyNumberOfPlaintiffs_en-US">Loss Contingency Number Of Plaintiffs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element546" xlink:to="label546" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs" xlink:label="element547" />
        <label xlink:type="resource" xlink:label="label547" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LossContingencyNumberOfPlaintiffs_en-US">Number of former employees who filled a putative collective and class action complaint</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element547" xlink:to="label547" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="element548" />
        <label xlink:type="resource" xlink:label="label548" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LossContingenciesByNatureOfContingencyAxis_en-US">Loss Contingencies By Nature Of Contingency [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element548" xlink:to="label548" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="element549" />
        <label xlink:type="resource" xlink:label="label549" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LossContingenciesByNatureOfContingencyAxis_en-US">Loss Contingency Nature [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element549" xlink:to="label549" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyActionsTakenByPlaintiff" xlink:label="element550" />
        <label xlink:type="resource" xlink:label="label550" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LossContingencyActionsTakenByPlaintiff_en-US">Loss Contingency Actions Taken By Plaintiff</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element550" xlink:to="label550" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyActionsTakenByPlaintiff" xlink:label="element551" />
        <label xlink:type="resource" xlink:label="label551" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LossContingencyActionsTakenByPlaintiff_en-US">Description of plaintiffs class certification request</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element551" xlink:to="label551" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="element552" />
        <label xlink:type="resource" xlink:label="label552" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LossContingencyAccrualProvision_en-US">LossContingencyAccrual</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element552" xlink:to="label552" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="element553" />
        <label xlink:type="resource" xlink:label="label553" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LossContingencyAccrualProvision_en-US">Loss Contingency Accrual</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element553" xlink:to="label553" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="element554" />
        <label xlink:type="resource" xlink:label="label554" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_LossContingencyNatureDomain_en-US">Loss Contingency Nature [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element554" xlink:to="label554" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="element555" />
        <label xlink:type="resource" xlink:label="label555" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_LossContingencyNatureDomain_en-US">Loss Contingency, Nature [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element555" xlink:to="label555" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="element556" />
        <label xlink:type="resource" xlink:label="label556" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_MaturitiesOfLongTermDebtAbstract_en-US">Maturities of Long-term Debt [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element556" xlink:to="label556" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="element557" />
        <label xlink:type="resource" xlink:label="label557" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_MaximumMember_en-US">Maximum [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element557" xlink:to="label557" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="element558" />
        <label xlink:type="resource" xlink:label="label558" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_MinimumMember_en-US">Minimum [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element558" xlink:to="label558" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="element559" />
        <label xlink:type="resource" xlink:label="label559" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_MinorityInterestPeriodIncreaseDecrease_en-US">Minority Interest Period Increase Decrease</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element559" xlink:to="label559" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="element560" />
        <label xlink:type="resource" xlink:label="label560" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_MinorityInterestPeriodIncreaseDecrease_en-US">Decrease in noncontrolling interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element560" xlink:to="label560" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="element561" />
        <label xlink:type="resource" xlink:label="label561" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_en-US">MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element561" xlink:to="label561" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="element562" />
        <label xlink:type="resource" xlink:label="label562" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_en-US">Noncontrolling interest distribution</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element562" xlink:to="label562" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="element563" />
        <label xlink:type="resource" xlink:label="label563" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_en-US">Noncontrolling interest distribution</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element563" xlink:to="label563" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="element564" />
        <label xlink:type="resource" xlink:label="label564" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element564" xlink:to="label564" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterest" xlink:label="element565" />
        <label xlink:type="resource" xlink:label="label565" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_MinorityInterest_en-US">Minority Interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element565" xlink:to="label565" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterest" xlink:label="element566" />
        <label xlink:type="resource" xlink:label="label566" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_MinorityInterest_en-US">Noncontrolling interests</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element566" xlink:to="label566" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="element567" />
        <label xlink:type="resource" xlink:label="label567" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivities_en-US">Net Cash Provided By Used In Financing Activities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element567" xlink:to="label567" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="element568" />
        <label xlink:type="resource" xlink:label="label568" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_NetCashProvidedByUsedInFinancingActivities_en-US">Net cash (used in) provided by financing activities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element568" xlink:to="label568" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="element569" />
        <label xlink:type="resource" xlink:label="label569" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_en-US">Net Cash Provided By Used In Financing Activities [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element569" xlink:to="label569" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="element570" />
        <label xlink:type="resource" xlink:label="label570" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_en-US">Cash Flows from Financing Activities:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element570" xlink:to="label570" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="element571" />
        <label xlink:type="resource" xlink:label="label571" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivities_en-US">Net Cash Provided By Used In Investing Activities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element571" xlink:to="label571" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="element572" />
        <label xlink:type="resource" xlink:label="label572" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_NetCashProvidedByUsedInInvestingActivities_en-US">Net cash used in investing activities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element572" xlink:to="label572" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="element573" />
        <label xlink:type="resource" xlink:label="label573" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivities_en-US">Net Cash Provided By Used In Operating Activities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element573" xlink:to="label573" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="element574" />
        <label xlink:type="resource" xlink:label="label574" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_NetCashProvidedByUsedInOperatingActivities_en-US">Net cash provided by (used in) operating activities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element574" xlink:to="label574" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="element575" />
        <label xlink:type="resource" xlink:label="label575" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss_en-US">Net Income Loss</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element575" xlink:to="label575" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="element576" />
        <label xlink:type="resource" xlink:label="label576" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_NetIncomeLoss_en-US">Net income (loss) attributable to Amedisys, Inc.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element576" xlink:to="label576" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="element577" />
        <label xlink:type="resource" xlink:label="label577" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_en-US">Net Cash Provided By Used In Investing Activities [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element577" xlink:to="label577" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="element578" />
        <label xlink:type="resource" xlink:label="label578" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_en-US">Cash Flows from Investing Activities:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element578" xlink:to="label578" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="element579" />
        <label xlink:type="resource" xlink:label="label579" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_en-US">Net Cash Provided By Used In Operating Activities [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element579" xlink:to="label579" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="element580" />
        <label xlink:type="resource" xlink:label="label580" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_en-US">Cash Flows from Operating Activities:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element580" xlink:to="label580" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="element581" />
        <label xlink:type="resource" xlink:label="label581" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_en-US">Net Income Loss Attributable To Noncontrolling Interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element581" xlink:to="label581" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="element582" />
        <label xlink:type="resource" xlink:label="label582" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_en-US">Net income attributable to noncontrolling interests</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element582" xlink:to="label582" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="element583" />
        <label xlink:type="resource" xlink:label="label583" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_en-US">Comprehensive (income) loss attributable to non-controlling interests</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element583" xlink:to="label583" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="element584" />
        <label xlink:type="resource" xlink:label="label584" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_en-US">Accounting Pronouncements</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element584" xlink:to="label584" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="element585" />
        <label xlink:type="resource" xlink:label="label585" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_en-US">Recently Issued Accounting Pronouncements</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element585" xlink:to="label585" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1" xlink:label="element586" />
        <label xlink:type="resource" xlink:label="label586" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1_en-US">NoncashOrPartNoncashAcquisitionDebtAssumed1</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element586" xlink:to="label586" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1" xlink:label="element587" />
        <label xlink:type="resource" xlink:label="label587" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1_en-US">Notes payable issued for/assumed in acquisitions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element587" xlink:to="label587" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="element588" />
        <label xlink:type="resource" xlink:label="label588" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NoncompeteAgreementsMember_en-US">Noncompete Agreements [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element588" xlink:to="label588" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="element589" />
        <label xlink:type="resource" xlink:label="label589" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NonoperatingIncomeExpense_en-US">Nonoperating Income Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element589" xlink:to="label589" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="element590" />
        <label xlink:type="resource" xlink:label="label590" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_NonoperatingIncomeExpense_en-US">Total other income (expense), net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element590" xlink:to="label590" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="element591" />
        <label xlink:type="resource" xlink:label="label591" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NonoperatingIncomeExpenseAbstract_en-US">Nonoperating Income Expense [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element591" xlink:to="label591" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="element592" />
        <label xlink:type="resource" xlink:label="label592" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_NonoperatingIncomeExpenseAbstract_en-US">Other income (expense):</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element592" xlink:to="label592" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesIssued1" xlink:label="element593" />
        <label xlink:type="resource" xlink:label="label593" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NotesIssued1_en-US">NotesIssued1</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element593" xlink:to="label593" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesIssued1" xlink:label="element594" />
        <label xlink:type="resource" xlink:label="label594" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_NotesIssued1_en-US">Notes payable issued for software licenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element594" xlink:to="label594" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates" xlink:label="element595" />
        <label xlink:type="resource" xlink:label="label595" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NumberOfStatesInWhichEntityOperates_en-US">Number Of States With Facilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element595" xlink:to="label595" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfBusinessesAcquired" xlink:label="element596" />
        <label xlink:type="resource" xlink:label="label596" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NumberOfBusinessesAcquired_en-US">Number Of Businesses Acquired</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element596" xlink:to="label596" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfBusinessesAcquired" xlink:label="element597" />
        <label xlink:type="resource" xlink:label="label597" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_NumberOfBusinessesAcquired_en-US">Acquisition, number of care centers acquired</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element597" xlink:to="label597" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="element598" />
        <label xlink:type="resource" xlink:label="label598" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NumberOfReportableSegments_en-US">Number Of Reportable Segments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element598" xlink:to="label598" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="element599" />
        <label xlink:type="resource" xlink:label="label599" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_NumberOfReportableSegments_en-US">Number of reportable business segments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element599" xlink:to="label599" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:label="element600" />
        <label xlink:type="resource" xlink:label="label600" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_en-US">Noncontrolling Interest Decrease From Deconsolidation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element600" xlink:to="label600" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:label="element601" />
        <label xlink:type="resource" xlink:label="label601" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_en-US">Sale of noncontrolling interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element601" xlink:to="label601" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:label="element602" />
        <label xlink:type="resource" xlink:label="label602" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_en-US">Sale of noncontrolling interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element602" xlink:to="label602" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="element603" />
        <label xlink:type="resource" xlink:label="label603" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NoncontrollingInterestMember_en-US">Noncontrolling Interest [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element603" xlink:to="label603" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="element604" />
        <label xlink:type="resource" xlink:label="label604" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_en-US">Acquired Noncontrolling Interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element604" xlink:to="label604" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="element605" />
        <label xlink:type="resource" xlink:label="label605" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_en-US">Acquired noncontrolling interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element605" xlink:to="label605" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="element606" />
        <label xlink:type="resource" xlink:label="label606" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OpenTaxYear_en-US">OpenTaxYear</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element606" xlink:to="label606" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="element607" />
        <label xlink:type="resource" xlink:label="label607" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OpenTaxYear_en-US">Tax years open to examination</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element607" xlink:to="label607" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="element608" />
        <label xlink:type="resource" xlink:label="label608" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_en-US">OperatingLeasesFutureMinimumPaymentsDueCurrent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element608" xlink:to="label608" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="element609" />
        <label xlink:type="resource" xlink:label="label609" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_en-US">2017</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element609" xlink:to="label609" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="element610" />
        <label xlink:type="resource" xlink:label="label610" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OperatingLossCarryforwardsValuationAllowance_en-US">Operating Loss Carryforwards Valuation Allowance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element610" xlink:to="label610" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="element611" />
        <label xlink:type="resource" xlink:label="label611" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OperatingLossCarryforwardsValuationAllowance_en-US">Net operating loss carryforwards valuation allowance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element611" xlink:to="label611" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="element612" />
        <label xlink:type="resource" xlink:label="label612" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_en-US">OperatingLeasesFutureMinimumPaymentsDueInTwoYears</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element612" xlink:to="label612" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="element613" />
        <label xlink:type="resource" xlink:label="label613" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_en-US">2018</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element613" xlink:to="label613" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="element614" />
        <label xlink:type="resource" xlink:label="label614" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OperatingIncomeLoss_en-US">Operating Income Loss</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element614" xlink:to="label614" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="element615" />
        <label xlink:type="resource" xlink:label="label615" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OperatingIncomeLoss_en-US">Operating loss</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element615" xlink:to="label615" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="element616" />
        <label xlink:type="resource" xlink:label="label616" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_OperatingIncomeLoss_en-US">Operating income (loss)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element616" xlink:to="label616" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="element617" />
        <label xlink:type="resource" xlink:label="label617" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US" id="verbose_us-gaap_OperatingIncomeLoss_en-US">Operating income (loss)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element617" xlink:to="label617" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="element618" />
        <label xlink:type="resource" xlink:label="label618" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_en-US">OperatingLeasesFutureMinimumPaymentsDueThereafter</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element618" xlink:to="label618" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="element619" />
        <label xlink:type="resource" xlink:label="label619" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_en-US">Future years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element619" xlink:to="label619" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="element620" />
        <label xlink:type="resource" xlink:label="label620" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_en-US">OperatingLeasesFutureMinimumPaymentsDue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element620" xlink:to="label620" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="element621" />
        <label xlink:type="resource" xlink:label="label621" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_en-US">Total</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element621" xlink:to="label621" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="element622" />
        <label xlink:type="resource" xlink:label="label622" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_en-US">OperatingLeasesFutureMinimumPaymentsDueInFourYears</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element622" xlink:to="label622" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="element623" />
        <label xlink:type="resource" xlink:label="label623" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_en-US">2020</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element623" xlink:to="label623" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="element624" />
        <label xlink:type="resource" xlink:label="label624" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_en-US">OperatingLeasesFutureMinimumPaymentsDueInFiveYears</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element624" xlink:to="label624" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="element625" />
        <label xlink:type="resource" xlink:label="label625" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_en-US">2021</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element625" xlink:to="label625" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="element626" />
        <label xlink:type="resource" xlink:label="label626" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OperatingLossCarryforwards_en-US">Operating Loss Carryforwards</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element626" xlink:to="label626" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="element627" />
        <label xlink:type="resource" xlink:label="label627" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OperatingLossCarryforwards_en-US">Net operating loss carryforwards</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element627" xlink:to="label627" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="element628" />
        <label xlink:type="resource" xlink:label="label628" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_en-US">OperatingLeasesFutureMinimumPaymentsDueInThreeYears</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element628" xlink:to="label628" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="element629" />
        <label xlink:type="resource" xlink:label="label629" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_en-US">2019</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element629" xlink:to="label629" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="element630" />
        <label xlink:type="resource" xlink:label="label630" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_en-US">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element630" xlink:to="label630" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="element631" />
        <label xlink:type="resource" xlink:label="label631" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_en-US">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element631" xlink:to="label631" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="element632" />
        <label xlink:type="resource" xlink:label="label632" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element632" xlink:to="label632" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="element633" />
        <label xlink:type="resource" xlink:label="label633" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OtherComprehensiveIncomeLossNetOfTax_en-US">Other Comprehensive Income Loss Net Of Tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element633" xlink:to="label633" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="element634" />
        <label xlink:type="resource" xlink:label="label634" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OtherComprehensiveIncomeLossNetOfTax_en-US">Other comprehensive income (loss)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element634" xlink:to="label634" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="element635" />
        <label xlink:type="resource" xlink:label="label635" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OtherAssetsNoncurrent_en-US">Other Assets Noncurrent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element635" xlink:to="label635" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="element636" />
        <label xlink:type="resource" xlink:label="label636" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OtherAssetsNoncurrent_en-US">Other assets, net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element636" xlink:to="label636" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="element637" />
        <label xlink:type="resource" xlink:label="label637" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_OtherAssetsNoncurrent_en-US">Other assets, net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element637" xlink:to="label637" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsMiscellaneousCurrent" xlink:label="element638" />
        <label xlink:type="resource" xlink:label="label638" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OtherAssetsMiscellaneousCurrent_en-US">OtherAssetsMiscellaneousCurrent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element638" xlink:to="label638" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsMiscellaneousCurrent" xlink:label="element639" />
        <label xlink:type="resource" xlink:label="label639" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OtherAssetsMiscellaneousCurrent_en-US">Other</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element639" xlink:to="label639" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:label="element640" />
        <label xlink:type="resource" xlink:label="label640" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OtherAssetsMiscellaneousNoncurrent_en-US">OtherAssetsMiscellaneousNoncurrent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element640" xlink:to="label640" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:label="element641" />
        <label xlink:type="resource" xlink:label="label641" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OtherAssetsMiscellaneousNoncurrent_en-US">Other</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element641" xlink:to="label641" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:label="element642" />
        <label xlink:type="resource" xlink:label="label642" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OtherSundryLiabilitiesNoncurrent_en-US">Other Sundry Liabilities, Noncurrent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element642" xlink:to="label642" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:label="element643" />
        <label xlink:type="resource" xlink:label="label643" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OtherSundryLiabilitiesNoncurrent_en-US">Other</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element643" xlink:to="label643" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="element644" />
        <label xlink:type="resource" xlink:label="label644" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_en-US">Other comprehensive income</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element644" xlink:to="label644" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="element645" />
        <label xlink:type="resource" xlink:label="label645" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OtherAssetsCurrent_en-US">Other Assets Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element645" xlink:to="label645" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="element646" />
        <label xlink:type="resource" xlink:label="label646" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OtherAssetsCurrent_en-US">Other current assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element646" xlink:to="label646" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="element647" />
        <label xlink:type="resource" xlink:label="label647" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_OtherAssetsCurrent_en-US">Other current assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element647" xlink:to="label647" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="element648" />
        <label xlink:type="resource" xlink:label="label648" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OtherLiabilitiesNoncurrent_en-US">Other Liabilities Noncurrent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element648" xlink:to="label648" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="element649" />
        <label xlink:type="resource" xlink:label="label649" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OtherLiabilitiesNoncurrent_en-US">Other long-term obligations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element649" xlink:to="label649" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="element650" />
        <label xlink:type="resource" xlink:label="label650" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_OtherLiabilitiesNoncurrent_en-US">Other long-term obligations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element650" xlink:to="label650" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="element651" />
        <label xlink:type="resource" xlink:label="label651" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OtherGeneralAndAdministrativeExpense_en-US">Other General And Administrative Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element651" xlink:to="label651" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="element652" />
        <label xlink:type="resource" xlink:label="label652" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OtherGeneralAndAdministrativeExpense_en-US">Other</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element652" xlink:to="label652" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherRestructuringCosts" xlink:label="element653" />
        <label xlink:type="resource" xlink:label="label653" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OtherRestructuringCosts_en-US">Other Restructuring Costs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element653" xlink:to="label653" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="element654" />
        <label xlink:type="resource" xlink:label="label654" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OtherNonoperatingIncomeExpense_en-US">Other Nonoperating Income Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element654" xlink:to="label654" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="element655" />
        <label xlink:type="resource" xlink:label="label655" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OtherNonoperatingIncomeExpense_en-US">Miscellaneous, net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element655" xlink:to="label655" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNotesPayable" xlink:label="element656" />
        <label xlink:type="resource" xlink:label="label656" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OtherNotesPayable_en-US">Other Notes Payable</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element656" xlink:to="label656" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNotesPayable" xlink:label="element657" />
        <label xlink:type="resource" xlink:label="label657" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OtherNotesPayable_en-US">Promissory notes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element657" xlink:to="label657" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="element658" />
        <label xlink:type="resource" xlink:label="label658" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_OtherAccruedLiabilitiesCurrent_en-US">OtherAccruedLiabilitiesCurrent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element658" xlink:to="label658" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="element659" />
        <label xlink:type="resource" xlink:label="label659" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_OtherAccruedLiabilitiesCurrent_en-US">Other</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element659" xlink:to="label659" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="element660" />
        <label xlink:type="resource" xlink:label="label660" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PaymentsForProceedsFromInvestments_en-US">PaymentsForProceedsFromInvestments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element660" xlink:to="label660" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="element661" />
        <label xlink:type="resource" xlink:label="label661" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PaymentsForProceedsFromInvestments_en-US">Purchase of Investment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element661" xlink:to="label661" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="element662" />
        <label xlink:type="resource" xlink:label="label662" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_PaymentsForProceedsFromInvestments_en-US">Purchase of investments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element662" xlink:to="label662" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="element663" />
        <label xlink:type="resource" xlink:label="label663" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PaymentsForRepurchaseOfCommonStock_en-US">Payments For Repurchase Of Common Stock</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element663" xlink:to="label663" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="element664" />
        <label xlink:type="resource" xlink:label="label664" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PaymentsForRepurchaseOfCommonStock_en-US">Purchase of company stock</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element664" xlink:to="label664" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="element665" />
        <label xlink:type="resource" xlink:label="label665" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_PaymentsForRepurchaseOfCommonStock_en-US">Purchase of company stock</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element665" xlink:to="label665" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="element666" />
        <label xlink:type="resource" xlink:label="label666" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PaymentsForLegalSettlements_en-US">PaymentsForLegalSettlements</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element666" xlink:to="label666" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="element667" />
        <label xlink:type="resource" xlink:label="label667" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PaymentsForLegalSettlements_en-US">Payments for Legal Settlements</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element667" xlink:to="label667" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="element668" />
        <label xlink:type="resource" xlink:label="label668" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_en-US">Payments To Acquire Businesses Net Of Cash Acquired</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element668" xlink:to="label668" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="element669" />
        <label xlink:type="resource" xlink:label="label669" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_en-US">Acquisitions of businesses, net of cash acquired</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element669" xlink:to="label669" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="element670" />
        <label xlink:type="resource" xlink:label="label670" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PaymentsForRestructuring_en-US">RestructuringReserveSettledWithCash</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element670" xlink:to="label670" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="element671" />
        <label xlink:type="resource" xlink:label="label671" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PaymentsForRestructuring_en-US">Cash Expenditure</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element671" xlink:to="label671" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="element672" />
        <label xlink:type="resource" xlink:label="label672" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_PaymentsForRestructuring_en-US">Cash Expenditure</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element672" xlink:to="label672" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="element673" />
        <label xlink:type="resource" xlink:label="label673" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_en-US">Payments To Acquire Property Plant And Equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element673" xlink:to="label673" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="element674" />
        <label xlink:type="resource" xlink:label="label674" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_en-US">Purchases of property and equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element674" xlink:to="label674" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="element675" />
        <label xlink:type="resource" xlink:label="label675" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PaymentsOfFinancingCosts_en-US">Payment of deferred financing fees</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element675" xlink:to="label675" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="element676" />
        <label xlink:type="resource" xlink:label="label676" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_PaymentsOfFinancingCosts_en-US">Debt issuance costs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element676" xlink:to="label676" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="element677" />
        <label xlink:type="resource" xlink:label="label677" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PaymentsOfFinancingCosts_en-US">Debt issuance costs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element677" xlink:to="label677" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="element678" />
        <label xlink:type="resource" xlink:label="label678" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PaymentsToAcquireRestrictedInvestments_en-US">Payments To Acquire Restricted Investments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element678" xlink:to="label678" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="element679" />
        <label xlink:type="resource" xlink:label="label679" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_PaymentsToAcquireRestrictedInvestments_en-US">Purchases of deferred compensation plan assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element679" xlink:to="label679" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="element680" />
        <label xlink:type="resource" xlink:label="label680" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PendingLitigationMember_en-US">Pending Litigation [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element680" xlink:to="label680" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="element681" />
        <label xlink:type="resource" xlink:label="label681" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PendingLitigationMember_en-US">Wage and Hour Litigation [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element681" xlink:to="label681" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionExpense" xlink:label="element682" />
        <label xlink:type="resource" xlink:label="label682" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PensionExpense_en-US">401(k) employer match</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element682" xlink:to="label682" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionExpense" xlink:label="element683" />
        <label xlink:type="resource" xlink:label="label683" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PensionExpense_en-US">Pension Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element683" xlink:to="label683" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="element684" />
        <label xlink:type="resource" xlink:label="label684" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_en-US">Pension And Other Postretirement Benefits DisclosureText Block</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element684" xlink:to="label684" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="element685" />
        <label xlink:type="resource" xlink:label="label685" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_en-US">EMPLOYEE BENEFIT PLANS</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element685" xlink:to="label685" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="element686" />
        <label xlink:type="resource" xlink:label="label686" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PreferredStockParOrStatedValuePerShare_en-US">Preferred Stock Par Or Stated Value Per Share</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element686" xlink:to="label686" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="element687" />
        <label xlink:type="resource" xlink:label="label687" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PreferredStockParOrStatedValuePerShare_en-US">Preferred stock, par value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element687" xlink:to="label687" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="element688" />
        <label xlink:type="resource" xlink:label="label688" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PreferredStockValueOutstanding_en-US">Preferred Stock Value Outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element688" xlink:to="label688" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="element689" />
        <label xlink:type="resource" xlink:label="label689" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PreferredStockValueOutstanding_en-US">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element689" xlink:to="label689" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="element690" />
        <label xlink:type="resource" xlink:label="label690" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PreferredStockSharesIssued_en-US">Preferred Stock Shares Issued</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element690" xlink:to="label690" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="element691" />
        <label xlink:type="resource" xlink:label="label691" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PreferredStockSharesIssued_en-US">Preferred stock, issued</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element691" xlink:to="label691" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="element692" />
        <label xlink:type="resource" xlink:label="label692" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PreferredStockSharesAuthorized_en-US">Preferred Stock Shares Authorized</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element692" xlink:to="label692" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="element693" />
        <label xlink:type="resource" xlink:label="label693" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PreferredStockSharesAuthorized_en-US">Preferred stock, shares authorized</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element693" xlink:to="label693" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="element694" />
        <label xlink:type="resource" xlink:label="label694" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PreferredStockSharesOutstanding_en-US">Preferred Stock Shares Outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element694" xlink:to="label694" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="element695" />
        <label xlink:type="resource" xlink:label="label695" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PreferredStockSharesOutstanding_en-US">Preferred stock, outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element695" xlink:to="label695" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="element696" />
        <label xlink:type="resource" xlink:label="label696" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PrepaidExpenseCurrent_en-US">Prepaid Expense Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element696" xlink:to="label696" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="element697" />
        <label xlink:type="resource" xlink:label="label697" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PrepaidExpenseCurrent_en-US">Prepaid expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element697" xlink:to="label697" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="element698" />
        <label xlink:type="resource" xlink:label="label698" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ProceedsFromIssuanceOfDebt_en-US">Proceeds From Issuance Of Debt</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element698" xlink:to="label698" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="element699" />
        <label xlink:type="resource" xlink:label="label699" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ProceedsFromLegalSettlements_en-US">Proceeds From Legal Settlements</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element699" xlink:to="label699" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="element700" />
        <label xlink:type="resource" xlink:label="label700" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ProceedsFromLegalSettlements_en-US">Settlement of lawsuit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element700" xlink:to="label700" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="element701" />
        <label xlink:type="resource" xlink:label="label701" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ProceedsFromIssuanceOfLongTermDebt_en-US">Proceeds from issuance of long-term obligations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element701" xlink:to="label701" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="element702" />
        <label xlink:type="resource" xlink:label="label702" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ProceedsFromDivestitureOfBusinesses_en-US">Proceeds from Divestiture of Business</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element702" xlink:to="label702" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="element703" />
        <label xlink:type="resource" xlink:label="label703" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ProceedsFromDivestitureOfBusinesses_en-US">Proceeds from disposition of care centers</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element703" xlink:to="label703" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="element704" />
        <label xlink:type="resource" xlink:label="label704" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ProceedsFromStockOptionsExercised_en-US">Proceeds From Stock Options Exercised</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element704" xlink:to="label704" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="element705" />
        <label xlink:type="resource" xlink:label="label705" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ProceedsFromStockOptionsExercised_en-US">Proceeds from issuance of stock upon exercise of stock options and warrants</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element705" xlink:to="label705" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="element706" />
        <label xlink:type="resource" xlink:label="label706" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ProceedsFromShortTermDebt_en-US">Proceeds from revolving line of credit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element706" xlink:to="label706" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:label="element707" />
        <label xlink:type="resource" xlink:label="label707" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ProceedsFromSaleOfOtherInvestments_en-US">Proceeds From Sale of Investment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element707" xlink:to="label707" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:label="element708" />
        <label xlink:type="resource" xlink:label="label708" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ProceedsFromSaleOfOtherInvestments_en-US">Proceeds from sale of investment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element708" xlink:to="label708" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:label="element709" />
        <label xlink:type="resource" xlink:label="label709" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ProceedsFromSaleOfRestrictedInvestments_en-US">Proceeds From Sale Of Restricted Investments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element709" xlink:to="label709" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:label="element710" />
        <label xlink:type="resource" xlink:label="label710" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ProceedsFromSaleOfRestrictedInvestments_en-US">Proceeds from sale of deferred compensation plan assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element710" xlink:to="label710" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="element711" />
        <label xlink:type="resource" xlink:label="label711" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_en-US">Proceeds From Sale Of Property Plant And Equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element711" xlink:to="label711" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="element712" />
        <label xlink:type="resource" xlink:label="label712" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_en-US">Proceeds from the sale of property and equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element712" xlink:to="label712" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="element713" />
        <label xlink:type="resource" xlink:label="label713" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ProceedsFromStockPlans_en-US">Proceeds From Stock Plans</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element713" xlink:to="label713" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="element714" />
        <label xlink:type="resource" xlink:label="label714" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ProceedsFromStockPlans_en-US">Proceeds from issuance of stock to employee stock purchase plan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element714" xlink:to="label714" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="element715" />
        <label xlink:type="resource" xlink:label="label715" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ProfitLoss_en-US">Profit Loss</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element715" xlink:to="label715" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="element716" />
        <label xlink:type="resource" xlink:label="label716" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ProfitLoss_en-US">Net income (loss)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element716" xlink:to="label716" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="element717" />
        <label xlink:type="resource" xlink:label="label717" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_ProfitLoss_en-US">Net income (loss)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element717" xlink:to="label717" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="element718" />
        <label xlink:type="resource" xlink:label="label718" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US" id="verbose_us-gaap_ProfitLoss_en-US">Net income (loss)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element718" xlink:to="label718" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="element719" />
        <label xlink:type="resource" xlink:label="label719" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentTextBlock_en-US">Property Plant And Equipment Text Block</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element719" xlink:to="label719" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="element720" />
        <label xlink:type="resource" xlink:label="label720" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PropertyPlantAndEquipmentTextBlock_en-US">Property Plant and Equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element720" xlink:to="label720" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="element721" />
        <label xlink:type="resource" xlink:label="label721" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentByTypeAxis_en-US">Property Plant And Equipment By Type [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element721" xlink:to="label721" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="element722" />
        <label xlink:type="resource" xlink:label="label722" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_en-US">Property Plant And Equipment Policy</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element722" xlink:to="label722" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="element723" />
        <label xlink:type="resource" xlink:label="label723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_en-US">Property Plant And Equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element723" xlink:to="label723" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="element724" />
        <label xlink:type="resource" xlink:label="label724" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentAbstract_en-US">Property Plant And Equipment [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element724" xlink:to="label724" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="element725" />
        <label xlink:type="resource" xlink:label="label725" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentUsefulLife_en-US">Property Plant And Equipment Useful Life</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element725" xlink:to="label725" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="element726" />
        <label xlink:type="resource" xlink:label="label726" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PropertyPlantAndEquipmentUsefulLife_en-US">Useful Life</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element726" xlink:to="label726" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="element727" />
        <label xlink:type="resource" xlink:label="label727" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentTypeDomain_en-US">Property Plant And Equipment By Type [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element727" xlink:to="label727" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="element728" />
        <label xlink:type="resource" xlink:label="label728" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_en-US">Property Plant And Equipment Estimated Useful Lives</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element728" xlink:to="label728" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="element729" />
        <label xlink:type="resource" xlink:label="label729" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_en-US">Estimated Useful Life</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element729" xlink:to="label729" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="element730" />
        <label xlink:type="resource" xlink:label="label730" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentNet_en-US">Property Plant And Equipment Net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element730" xlink:to="label730" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="element731" />
        <label xlink:type="resource" xlink:label="label731" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_PropertyPlantAndEquipmentNet_en-US">Property and equipment, net of accumulated depreciation of $138,650 and $141,793</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element731" xlink:to="label731" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="element732" />
        <label xlink:type="resource" xlink:label="label732" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_PropertyPlantAndEquipmentNet_en-US">Property and equipment, net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element732" xlink:to="label732" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="element733" />
        <label xlink:type="resource" xlink:label="label733" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentGross_en-US">Property Plant And Equipment Gross</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element733" xlink:to="label733" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="element734" />
        <label xlink:type="resource" xlink:label="label734" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_PropertyPlantAndEquipmentGross_en-US">Property and Equipment, Gross</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element734" xlink:to="label734" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="element735" />
        <label xlink:type="resource" xlink:label="label735" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentLineItems_en-US">Property Plant And Equipment [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element735" xlink:to="label735" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="element736" />
        <label xlink:type="resource" xlink:label="label736" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ProvisionForDoubtfulAccounts_en-US">Provision For Doubtful Accounts</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element736" xlink:to="label736" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="element737" />
        <label xlink:type="resource" xlink:label="label737" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ProvisionForDoubtfulAccounts_en-US">Provision for doubtful accounts</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element737" xlink:to="label737" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="element738" />
        <label xlink:type="resource" xlink:label="label738" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_QuarterlyFinancialInformationTextBlock_en-US">Quarterly Financial Information [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element738" xlink:to="label738" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="element739" />
        <label xlink:type="resource" xlink:label="label739" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_QuarterlyFinancialInformationTextBlock_en-US">UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element739" xlink:to="label739" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="element740" />
        <label xlink:type="resource" xlink:label="label740" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_en-US">Quarterly Financial Information [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element740" xlink:to="label740" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="element741" />
        <label xlink:type="resource" xlink:label="label741" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RangeMember_en-US">Range [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element741" xlink:to="label741" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="element742" />
        <label xlink:type="resource" xlink:label="label742" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RangeAxis_en-US">Range [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element742" xlink:to="label742" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="element743" />
        <label xlink:type="resource" xlink:label="label743" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_en-US">Related Party Transactions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element743" xlink:to="label743" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="element744" />
        <label xlink:type="resource" xlink:label="label744" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_en-US">RELATED PARTY TRANSACTION</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element744" xlink:to="label744" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="element745" />
        <label xlink:type="resource" xlink:label="label745" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RelatedPartyTransactionLineItems_en-US">Related Party Transaction [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element745" xlink:to="label745" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="element746" />
        <label xlink:type="resource" xlink:label="label746" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RelatedPartyTransactionLineItems_en-US">Related Party Transaction [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element746" xlink:to="label746" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="element747" />
        <label xlink:type="resource" xlink:label="label747" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RelatedPartyTransactionAmountsOfTransaction_en-US">Related Party Transaction Amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element747" xlink:to="label747" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="element748" />
        <label xlink:type="resource" xlink:label="label748" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RelatedPartyTransactionAmountsOfTransaction_en-US">Related party transaction amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element748" xlink:to="label748" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="element749" />
        <label xlink:type="resource" xlink:label="label749" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RelatedPartyTransactionAxis_en-US">Related Party [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element749" xlink:to="label749" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="element750" />
        <label xlink:type="resource" xlink:label="label750" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_en-US">RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element750" xlink:to="label750" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="element751" />
        <label xlink:type="resource" xlink:label="label751" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_en-US">Related party transaction expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element751" xlink:to="label751" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="element752" />
        <label xlink:type="resource" xlink:label="label752" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RelatedPartyTransactionsAbstract_en-US">Related Party Transaction</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element752" xlink:to="label752" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="element753" />
        <label xlink:type="resource" xlink:label="label753" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RepaymentsOfShortTermDebt_en-US">Repayments Of Short Term Debt</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element753" xlink:to="label753" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="element754" />
        <label xlink:type="resource" xlink:label="label754" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_RepaymentsOfShortTermDebt_en-US">Repayments of revolving line of credit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element754" xlink:to="label754" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="element755" />
        <label xlink:type="resource" xlink:label="label755" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RepaymentsOfLongTermDebt_en-US">Repayments Of Long Term Debt</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element755" xlink:to="label755" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="element756" />
        <label xlink:type="resource" xlink:label="label756" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_RepaymentsOfLongTermDebt_en-US">Principal payments of long-term obligations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element756" xlink:to="label756" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="element757" />
        <label xlink:type="resource" xlink:label="label757" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RepaymentsOfLongTermDebt_en-US">Principal amount of existing term loan paid off</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element757" xlink:to="label757" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="element758" />
        <label xlink:type="resource" xlink:label="label758" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RepaymentsOfLinesOfCredit_en-US">Line Of Credit Facility Decrease Repayments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element758" xlink:to="label758" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="element759" />
        <label xlink:type="resource" xlink:label="label759" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RepaymentsOfLinesOfCredit_en-US">Repayments of lines of credit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element759" xlink:to="label759" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="element760" />
        <label xlink:type="resource" xlink:label="label760" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RestructuringCharges_en-US">Restructuring Charges</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element760" xlink:to="label760" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="element761" />
        <label xlink:type="resource" xlink:label="label761" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RestructuringCharges_en-US">Charge</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element761" xlink:to="label761" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="element762" />
        <label xlink:type="resource" xlink:label="label762" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US" id="verbose_us-gaap_RestructuringCharges_en-US">Exit activity costs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element762" xlink:to="label762" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="element763" />
        <label xlink:type="resource" xlink:label="label763" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RestructuringReserve_en-US">Restructuring Reserve</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element763" xlink:to="label763" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="element764" />
        <label xlink:type="resource" xlink:label="label764" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RestructuringReserve_en-US">Reserve Balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element764" xlink:to="label764" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="element765" />
        <label xlink:type="resource" xlink:label="label765" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RestructuringAndRelatedActivitiesAbstract_en-US">Restructuring and Related Activities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element765" xlink:to="label765" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="element766" />
        <label xlink:type="resource" xlink:label="label766" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_en-US">Restructuring and Related Activities Disclosure</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element766" xlink:to="label766" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="element767" />
        <label xlink:type="resource" xlink:label="label767" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_en-US">EXIT ACTIVITIES</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element767" xlink:to="label767" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="element768" />
        <label xlink:type="resource" xlink:label="label768" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RestructuringCostAndReserveAxis_en-US">Restructuring Cost And Reserve [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element768" xlink:to="label768" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="element769" />
        <label xlink:type="resource" xlink:label="label769" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RestructuringCostAndReserveLineItems_en-US">Restructuring Cost and Reserve [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element769" xlink:to="label769" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="element770" />
        <label xlink:type="resource" xlink:label="label770" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RetainedEarningsMember_en-US">Retained Earnings [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element770" xlink:to="label770" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="element771" />
        <label xlink:type="resource" xlink:label="label771" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RetainedEarningsAccumulatedDeficit_en-US">Retained Earnings Accumulated Deficit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element771" xlink:to="label771" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="element772" />
        <label xlink:type="resource" xlink:label="label772" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RetainedEarningsAccumulatedDeficit_en-US">Retained earnings</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element772" xlink:to="label772" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="element773" />
        <label xlink:type="resource" xlink:label="label773" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_en-US">Revenue Recognition Multiple Deliverable Arrangements [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element773" xlink:to="label773" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="element774" />
        <label xlink:type="resource" xlink:label="label774" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element774" xlink:to="label774" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="element775" />
        <label xlink:type="resource" xlink:label="label775" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RevenueRecognitionPolicyTextBlock_en-US">Revenue Recognition Policy [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element775" xlink:to="label775" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="element776" />
        <label xlink:type="resource" xlink:label="label776" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RevenueRecognitionPolicyTextBlock_en-US">Revenue Recognition</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element776" xlink:to="label776" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="element777" />
        <label xlink:type="resource" xlink:label="label777" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_en-US">Revenue Recognition Multiple Deliverable Arrangements [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element777" xlink:to="label777" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="element778" />
        <label xlink:type="resource" xlink:label="label778" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element778" xlink:to="label778" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="element779" />
        <label xlink:type="resource" xlink:label="label779" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element779" xlink:to="label779" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="element780" />
        <label xlink:type="resource" xlink:label="label780" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_en-US">Expected Term</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element780" xlink:to="label780" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="element781" />
        <label xlink:type="resource" xlink:label="label781" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element781" xlink:to="label781" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="element782" />
        <label xlink:type="resource" xlink:label="label782" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_en-US">Options Outstanding, Weighted Average Contractual Life</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element782" xlink:to="label782" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="element783" />
        <label xlink:type="resource" xlink:label="label783" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US" id="periodStart_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_en-US">Options Outstanding, Beginning Balance, Weighted Average Contractual Life</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element783" xlink:to="label783" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="element784" />
        <label xlink:type="resource" xlink:label="label784" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US" id="periodEnd_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_en-US">Options Outstanding, Ending Balance, Weighted Average Contractual Life</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element784" xlink:to="label784" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="element785" />
        <label xlink:type="resource" xlink:label="label785" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element785" xlink:to="label785" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="element786" />
        <label xlink:type="resource" xlink:label="label786" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US" id="periodStart_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_en-US">Non-vested stock options beginning balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element786" xlink:to="label786" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="element787" />
        <label xlink:type="resource" xlink:label="label787" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US" id="periodEnd_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_en-US">Non-vested stock options ending balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element787" xlink:to="label787" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="element788" />
        <label xlink:type="resource" xlink:label="label788" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element788" xlink:to="label788" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="element789" />
        <label xlink:type="resource" xlink:label="label789" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_en-US">Non-Vested Stock Options Vested, Weighted Average Grant Date Fair Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element789" xlink:to="label789" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="element790" />
        <label xlink:type="resource" xlink:label="label790" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element790" xlink:to="label790" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="element791" />
        <label xlink:type="resource" xlink:label="label791" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_en-US">Intrinsic Value of Stock Options Exerciseable</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element791" xlink:to="label791" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="element792" />
        <label xlink:type="resource" xlink:label="label792" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element792" xlink:to="label792" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="element793" />
        <label xlink:type="resource" xlink:label="label793" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US" id="periodStart_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_en-US">Non-Vested Stock Options Begining Balance, Weighted Average Grant Date Fair Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element793" xlink:to="label793" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="element794" />
        <label xlink:type="resource" xlink:label="label794" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US" id="periodEnd_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_en-US">Non-Vested Stock Options Ending Balance, Weighted Average Grant Date Fair Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element794" xlink:to="label794" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="element795" />
        <label xlink:type="resource" xlink:label="label795" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element795" xlink:to="label795" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="element796" />
        <label xlink:type="resource" xlink:label="label796" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_en-US">Vested</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element796" xlink:to="label796" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="element797" />
        <label xlink:type="resource" xlink:label="label797" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_en-US">Vested</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element797" xlink:to="label797" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="element798" />
        <label xlink:type="resource" xlink:label="label798" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element798" xlink:to="label798" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="element799" />
        <label xlink:type="resource" xlink:label="label799" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_en-US">Non-Vested Stock Options Forfeited, Weighted Average Grant Date Fair Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element799" xlink:to="label799" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="element800" />
        <label xlink:type="resource" xlink:label="label800" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element800" xlink:to="label800" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="element801" />
        <label xlink:type="resource" xlink:label="label801" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_en-US">Forfeited</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element801" xlink:to="label801" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="element802" />
        <label xlink:type="resource" xlink:label="label802" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_en-US">Forfeited</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element802" xlink:to="label802" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="element803" />
        <label xlink:type="resource" xlink:label="label803" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_en-US">Share-based Compensation Arrangement By Share-based Payment Award Options Exercisable Weighted Average Remaining Contractual Term 1</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element803" xlink:to="label803" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="element804" />
        <label xlink:type="resource" xlink:label="label804" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_en-US">Stock Options Exerciseable, Weighted Average Contractual Life</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element804" xlink:to="label804" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:label="element805" />
        <label xlink:type="resource" xlink:label="label805" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_en-US">OtherLiabilitiesTableTextBlock</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element805" xlink:to="label805" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:label="element806" />
        <label xlink:type="resource" xlink:label="label806" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_en-US">Other Liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element806" xlink:to="label806" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:label="element807" />
        <label xlink:type="resource" xlink:label="label807" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_en-US">Employee Stock Purchase Plan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element807" xlink:to="label807" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:label="element808" />
        <label xlink:type="resource" xlink:label="label808" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_en-US">Employee Stock Purchase Plan Activity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element808" xlink:to="label808" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="element809" />
        <label xlink:type="resource" xlink:label="label809" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_en-US">Schedule of Nonvested Share Activity [Table Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element809" xlink:to="label809" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="element810" />
        <label xlink:type="resource" xlink:label="label810" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_en-US">Non-Vested Stock Activity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element810" xlink:to="label810" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="element811" />
        <label xlink:type="resource" xlink:label="label811" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_en-US">Stock Option</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element811" xlink:to="label811" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="element812" />
        <label xlink:type="resource" xlink:label="label812" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_en-US">Stock Options Activity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element812" xlink:to="label812" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="element813" />
        <label xlink:type="resource" xlink:label="label813" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_en-US">Schedule of Maturities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element813" xlink:to="label813" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="element814" />
        <label xlink:type="resource" xlink:label="label814" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_en-US">Maturities of Long-Term Debt</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element814" xlink:to="label814" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="element815" />
        <label xlink:type="resource" xlink:label="label815" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_en-US">Schedule of Intangible Assets [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element815" xlink:to="label815" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="element816" />
        <label xlink:type="resource" xlink:label="label816" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_en-US">Components of Net Deferred Tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element816" xlink:to="label816" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="element817" />
        <label xlink:type="resource" xlink:label="label817" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_en-US">Net Deferred Tax Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element817" xlink:to="label817" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="element818" />
        <label xlink:type="resource" xlink:label="label818" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_en-US">Schedule of Nonvested Restricted Stock Units Activity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element818" xlink:to="label818" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="element819" />
        <label xlink:type="resource" xlink:label="label819" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_en-US">Non-Vested Stock Unity Activity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element819" xlink:to="label819" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="element820" />
        <label xlink:type="resource" xlink:label="label820" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_en-US">Schedule of Accrued Liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element820" xlink:to="label820" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="element821" />
        <label xlink:type="resource" xlink:label="label821" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_en-US">Accrued Expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element821" xlink:to="label821" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="element822" />
        <label xlink:type="resource" xlink:label="label822" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_en-US">Schedule of Future Minimum Rental Payments for Operating Leases</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element822" xlink:to="label822" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="element823" />
        <label xlink:type="resource" xlink:label="label823" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_en-US">Future Minimum Rental Commitments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element823" xlink:to="label823" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="element824" />
        <label xlink:type="resource" xlink:label="label824" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_en-US">Schedule of Quarterly Financial Information</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element824" xlink:to="label824" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="element825" />
        <label xlink:type="resource" xlink:label="label825" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_en-US">Unaudited Summarized Quarterly Financial Information</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element825" xlink:to="label825" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="element826" />
        <label xlink:type="resource" xlink:label="label826" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element826" xlink:to="label826" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="element827" />
        <label xlink:type="resource" xlink:label="label827" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_en-US">Schedule Of Intangible Assets And Goodwill Table [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element827" xlink:to="label827" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="element828" />
        <label xlink:type="resource" xlink:label="label828" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_en-US">Summary of Activity Related to Goodwill and Other Intangible Assets Net</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element828" xlink:to="label828" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="element829" />
        <label xlink:type="resource" xlink:label="label829" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfOtherAssetsTableTextBlock_en-US">Schedule of Other Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element829" xlink:to="label829" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="element830" />
        <label xlink:type="resource" xlink:label="label830" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfOtherAssetsTableTextBlock_en-US">Other Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element830" xlink:to="label830" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="element831" />
        <label xlink:type="resource" xlink:label="label831" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_en-US">Unrecognized Tax Benefits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element831" xlink:to="label831" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="element832" />
        <label xlink:type="resource" xlink:label="label832" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_en-US">Uncertain Tax Positions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element832" xlink:to="label832" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="element833" />
        <label xlink:type="resource" xlink:label="label833" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_en-US">Schedule Of Weighted Average Number Of Shares Table [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element833" xlink:to="label833" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="element834" />
        <label xlink:type="resource" xlink:label="label834" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_en-US">Weighted-Average Shares Outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element834" xlink:to="label834" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="element835" />
        <label xlink:type="resource" xlink:label="label835" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element835" xlink:to="label835" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="element836" />
        <label xlink:type="resource" xlink:label="label836" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_en-US">Schedule of Other Current Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element836" xlink:to="label836" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="element837" />
        <label xlink:type="resource" xlink:label="label837" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_en-US">Other Current Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element837" xlink:to="label837" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="element838" />
        <label xlink:type="resource" xlink:label="label838" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfDebtInstrumentsTextBlock_en-US">Schedule Of Debt Instruments [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element838" xlink:to="label838" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="element839" />
        <label xlink:type="resource" xlink:label="label839" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfDebtInstrumentsTextBlock_en-US">Long-Term Debt</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element839" xlink:to="label839" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="element840" />
        <label xlink:type="resource" xlink:label="label840" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_en-US">Schedule Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element840" xlink:to="label840" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="element841" />
        <label xlink:type="resource" xlink:label="label841" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_en-US">Net Revenues and Operating Results</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element841" xlink:to="label841" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="element842" />
        <label xlink:type="resource" xlink:label="label842" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_en-US">Employee Stock Purchase Plan [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element842" xlink:to="label842" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="element843" />
        <label xlink:type="resource" xlink:label="label843" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_en-US">Equity Method Investee Name [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element843" xlink:to="label843" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="element844" />
        <label xlink:type="resource" xlink:label="label844" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfGoodwillTable_en-US">Schedule of Goodwill [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element844" xlink:to="label844" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="element845" />
        <label xlink:type="resource" xlink:label="label845" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_en-US">Schedule Of Property Plant And Equipment [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element845" xlink:to="label845" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="element846" />
        <label xlink:type="resource" xlink:label="label846" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_en-US">Restructuring Costs [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element846" xlink:to="label846" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:label="element847" />
        <label xlink:type="resource" xlink:label="label847" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_en-US">Schedule of Line of Credit Facilities [Table Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element847" xlink:to="label847" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:label="element848" />
        <label xlink:type="resource" xlink:label="label848" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_en-US">Commitment Fee Under Credit Facilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element848" xlink:to="label848" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="element849" />
        <label xlink:type="resource" xlink:label="label849" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_en-US">Schedule of Restructuring and Related Costs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element849" xlink:to="label849" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="element850" />
        <label xlink:type="resource" xlink:label="label850" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_en-US">Exit Activity Reserves</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element850" xlink:to="label850" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="element851" />
        <label xlink:type="resource" xlink:label="label851" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_en-US">Schedule Of Segment Reporting Information By Segment [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element851" xlink:to="label851" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="element852" />
        <label xlink:type="resource" xlink:label="label852" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element852" xlink:to="label852" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="element853" />
        <label xlink:type="resource" xlink:label="label853" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_en-US">Schedule Of Segment Reporting Information By Segment [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element853" xlink:to="label853" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="element854" />
        <label xlink:type="resource" xlink:label="label854" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_en-US">Operating Income of Reportable Segments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element854" xlink:to="label854" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="element855" />
        <label xlink:type="resource" xlink:label="label855" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_en-US">Schedule Of Valuation And Qualifying Accounts Disclosure Text Block</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element855" xlink:to="label855" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="element856" />
        <label xlink:type="resource" xlink:label="label856" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_en-US">VALUATION AND QUALIFYING ACCOUNTS</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element856" xlink:to="label856" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="element857" />
        <label xlink:type="resource" xlink:label="label857" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SegmentReportingAbstract_en-US">Segment Reporting [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element857" xlink:to="label857" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="element858" />
        <label xlink:type="resource" xlink:label="label858" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SegmentDomain_en-US">Segment [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element858" xlink:to="label858" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="element859" />
        <label xlink:type="resource" xlink:label="label859" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_SegmentDomain_en-US">Segment [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element859" xlink:to="label859" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="element860" />
        <label xlink:type="resource" xlink:label="label860" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SegmentReportingInformationLineItems_en-US">Segment Reporting Information [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element860" xlink:to="label860" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="element861" />
        <label xlink:type="resource" xlink:label="label861" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_SegmentReportingInformationLineItems_en-US">Segment Reporting Information [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element861" xlink:to="label861" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="element862" />
        <label xlink:type="resource" xlink:label="label862" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SegmentReportingDisclosureTextBlock_en-US">Segment Reporting Disclosure [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element862" xlink:to="label862" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="element863" />
        <label xlink:type="resource" xlink:label="label863" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_SegmentReportingDisclosureTextBlock_en-US">SEGMENT INFORMATION</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element863" xlink:to="label863" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="element864" />
        <label xlink:type="resource" xlink:label="label864" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element864" xlink:to="label864" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="element865" />
        <label xlink:type="resource" xlink:label="label865" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_en-US">Vesting Period of Equity-based Awards</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element865" xlink:to="label865" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="element866" />
        <label xlink:type="resource" xlink:label="label866" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element866" xlink:to="label866" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="element867" />
        <label xlink:type="resource" xlink:label="label867" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_en-US">Non-vested Stock Granted, Number of Shares</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element867" xlink:to="label867" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="element868" />
        <label xlink:type="resource" xlink:label="label868" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element868" xlink:to="label868" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="element869" />
        <label xlink:type="resource" xlink:label="label869" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_en-US">Non-vested Stock Granted, Weighted Average Grant Date Fair Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element869" xlink:to="label869" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="element870" />
        <label xlink:type="resource" xlink:label="label870" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element870" xlink:to="label870" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="element871" />
        <label xlink:type="resource" xlink:label="label871" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_en-US">Non-vested Stock Outstanding, Number of Shares</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element871" xlink:to="label871" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="element872" />
        <label xlink:type="resource" xlink:label="label872" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US" id="periodStart_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_en-US">Non-vested Stock Outstanding, Beginning Balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element872" xlink:to="label872" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="element873" />
        <label xlink:type="resource" xlink:label="label873" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US" id="periodEnd_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_en-US">Non-vested Stock Outstanding, Ending Balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element873" xlink:to="label873" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="element874" />
        <label xlink:type="resource" xlink:label="label874" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element874" xlink:to="label874" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="element875" />
        <label xlink:type="resource" xlink:label="label875" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_en-US">Stock Options Exercised, Weighted Average Exercise Price</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element875" xlink:to="label875" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="element876" />
        <label xlink:type="resource" xlink:label="label876" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element876" xlink:to="label876" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="element877" />
        <label xlink:type="resource" xlink:label="label877" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_en-US">Expected Volatility Rate, Maximum</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element877" xlink:to="label877" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="element878" />
        <label xlink:type="resource" xlink:label="label878" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationAbstract_en-US">Share Based Compensation [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element878" xlink:to="label878" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="element879" />
        <label xlink:type="resource" xlink:label="label879" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element879" xlink:to="label879" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="element880" />
        <label xlink:type="resource" xlink:label="label880" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_en-US">Expected Volatility Rate, Minimum</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element880" xlink:to="label880" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="element881" />
        <label xlink:type="resource" xlink:label="label881" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensation_en-US">Share Based Compensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element881" xlink:to="label881" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="element882" />
        <label xlink:type="resource" xlink:label="label882" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensation_en-US">Non-cash compensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element882" xlink:to="label882" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="element883" />
        <label xlink:type="resource" xlink:label="label883" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element883" xlink:to="label883" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="element884" />
        <label xlink:type="resource" xlink:label="label884" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_en-US">Non-vested Stock Outstanding, Weighted Average Grant Date Fair Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element884" xlink:to="label884" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="element885" />
        <label xlink:type="resource" xlink:label="label885" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US" id="periodStart_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_en-US">Non-vested Stock Outstanding, Beginning Balance, Weighted Average Grant Date Fair Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element885" xlink:to="label885" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="element886" />
        <label xlink:type="resource" xlink:label="label886" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US" id="periodEnd_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_en-US">Non-vested Stock Outstanding, Ending Balance, Weighted Average Grant Date Fair Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element886" xlink:to="label886" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="element887" />
        <label xlink:type="resource" xlink:label="label887" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element887" xlink:to="label887" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="element888" />
        <label xlink:type="resource" xlink:label="label888" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_en-US">Forward Interest Rate, Maximum</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element888" xlink:to="label888" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="element889" />
        <label xlink:type="resource" xlink:label="label889" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_en-US">ShareBased Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element889" xlink:to="label889" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="element890" />
        <label xlink:type="resource" xlink:label="label890" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_en-US">Granted</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element890" xlink:to="label890" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="element891" />
        <label xlink:type="resource" xlink:label="label891" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element891" xlink:to="label891" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="element892" />
        <label xlink:type="resource" xlink:label="label892" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_en-US">Share Based Compensation [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element892" xlink:to="label892" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="element893" />
        <label xlink:type="resource" xlink:label="label893" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element893" xlink:to="label893" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="element894" />
        <label xlink:type="resource" xlink:label="label894" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_en-US">Percentage of Market Value at Which Eligible Employees May Purchase Shares of Common Stock</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element894" xlink:to="label894" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="element895" />
        <label xlink:type="resource" xlink:label="label895" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element895" xlink:to="label895" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="element896" />
        <label xlink:type="resource" xlink:label="label896" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_en-US">Non-vested Stock Canceled, Forfeited or Expired, Weighted Average Grant Date Fair Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element896" xlink:to="label896" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="element897" />
        <label xlink:type="resource" xlink:label="label897" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element897" xlink:to="label897" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="element898" />
        <label xlink:type="resource" xlink:label="label898" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_en-US">Non-vested Stock Canceled, Forfeited or Expired, Number of Shares</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element898" xlink:to="label898" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="element899" />
        <label xlink:type="resource" xlink:label="label899" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_en-US">Non-vested Stock Canceled, Forfeited or Expired, Number of Shares</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element899" xlink:to="label899" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="element900" />
        <label xlink:type="resource" xlink:label="label900" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element900" xlink:to="label900" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="element901" />
        <label xlink:type="resource" xlink:label="label901" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_en-US">Forward Interest Rate, Minimum</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element901" xlink:to="label901" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="element902" />
        <label xlink:type="resource" xlink:label="label902" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element902" xlink:to="label902" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="element903" />
        <label xlink:type="resource" xlink:label="label903" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_en-US">Stock Options Granted, Weighted Average Exercise Price</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element903" xlink:to="label903" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="element904" />
        <label xlink:type="resource" xlink:label="label904" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element904" xlink:to="label904" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="element905" />
        <label xlink:type="resource" xlink:label="label905" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_en-US">Stock Options Granted, Number of Shares</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element905" xlink:to="label905" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="element906" />
        <label xlink:type="resource" xlink:label="label906" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element906" xlink:to="label906" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="element907" />
        <label xlink:type="resource" xlink:label="label907" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_en-US">Stock Options Exerciseable, Weighted Average Exercise Price</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element907" xlink:to="label907" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="element908" />
        <label xlink:type="resource" xlink:label="label908" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element908" xlink:to="label908" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="element909" />
        <label xlink:type="resource" xlink:label="label909" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_en-US">Non-vested Stock Vested, Weighted Average Grant Date Fair Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element909" xlink:to="label909" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="element910" />
        <label xlink:type="resource" xlink:label="label910" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element910" xlink:to="label910" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="element911" />
        <label xlink:type="resource" xlink:label="label911" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_en-US">Stock Options Exerciseable, Number of Shares</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element911" xlink:to="label911" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="element912" />
        <label xlink:type="resource" xlink:label="label912" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element912" xlink:to="label912" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="element913" />
        <label xlink:type="resource" xlink:label="label913" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_en-US">Stock Options Canceled, Forfeited or Expired, Weighted Average Exercise Price</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element913" xlink:to="label913" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="element914" />
        <label xlink:type="resource" xlink:label="label914" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element914" xlink:to="label914" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="element915" />
        <label xlink:type="resource" xlink:label="label915" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_en-US">Equity-based Awards, Shares Available for Grant</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element915" xlink:to="label915" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="element916" />
        <label xlink:type="resource" xlink:label="label916" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element916" xlink:to="label916" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="element917" />
        <label xlink:type="resource" xlink:label="label917" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_en-US">Non-vested Stock Vested, Number of Shares</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element917" xlink:to="label917" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="element918" />
        <label xlink:type="resource" xlink:label="label918" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_en-US">Non-vested Stock Vested, Number of Shares</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element918" xlink:to="label918" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="element919" />
        <label xlink:type="resource" xlink:label="label919" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element919" xlink:to="label919" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="element920" />
        <label xlink:type="resource" xlink:label="label920" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_en-US">Expected Volatility</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element920" xlink:to="label920" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="element921" />
        <label xlink:type="resource" xlink:label="label921" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element921" xlink:to="label921" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="element922" />
        <label xlink:type="resource" xlink:label="label922" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_en-US">Equity-based Awards, Maximum Number of Shares Granted</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element922" xlink:to="label922" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="element923" />
        <label xlink:type="resource" xlink:label="label923" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element923" xlink:to="label923" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="element924" />
        <label xlink:type="resource" xlink:label="label924" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_en-US">Risk Free Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element924" xlink:to="label924" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="element925" />
        <label xlink:type="resource" xlink:label="label925" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element925" xlink:to="label925" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="element926" />
        <label xlink:type="resource" xlink:label="label926" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_en-US">Stock Options Canceled, Forfeited or Expired, Number of Shares</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element926" xlink:to="label926" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="element927" />
        <label xlink:type="resource" xlink:label="label927" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_en-US">Stock Options Canceled, Forfeited or Expired, Number of Shares</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element927" xlink:to="label927" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="element928" />
        <label xlink:type="resource" xlink:label="label928" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element928" xlink:to="label928" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="element929" />
        <label xlink:type="resource" xlink:label="label929" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_en-US">Intrinsic Value of Stock Options Exercised</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element929" xlink:to="label929" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="element930" />
        <label xlink:type="resource" xlink:label="label930" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_en-US">Share Based Compensation Option And Incentive Plans Policy</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element930" xlink:to="label930" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="element931" />
        <label xlink:type="resource" xlink:label="label931" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_en-US">Share-Based Compensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element931" xlink:to="label931" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="element932" />
        <label xlink:type="resource" xlink:label="label932" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element932" xlink:to="label932" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="element933" />
        <label xlink:type="resource" xlink:label="label933" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_en-US">Intrinsic Value of Stock Options Outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element933" xlink:to="label933" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="element934" />
        <label xlink:type="resource" xlink:label="label934" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_en-US">Award Type [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element934" xlink:to="label934" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="element935" />
        <label xlink:type="resource" xlink:label="label935" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element935" xlink:to="label935" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="element936" />
        <label xlink:type="resource" xlink:label="label936" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_en-US">Number of Options Outstanding, Number of Shares</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element936" xlink:to="label936" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="element937" />
        <label xlink:type="resource" xlink:label="label937" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US" id="periodStart_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_en-US">Number of Options Outstanding, Beginning Balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element937" xlink:to="label937" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="element938" />
        <label xlink:type="resource" xlink:label="label938" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US" id="periodEnd_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_en-US">Number of Options Outstanding, Ending Balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element938" xlink:to="label938" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="element939" />
        <label xlink:type="resource" xlink:label="label939" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element939" xlink:to="label939" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="element940" />
        <label xlink:type="resource" xlink:label="label940" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_en-US">Options Outstanding, Weighted Average Exercise Price</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element940" xlink:to="label940" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="element941" />
        <label xlink:type="resource" xlink:label="label941" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US" id="periodStart_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_en-US">Options Outstanding, Beginning Balance, Weighted Average Exercise Price</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element941" xlink:to="label941" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="element942" />
        <label xlink:type="resource" xlink:label="label942" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US" id="periodEnd_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_en-US">Options Outstanding, Ending Balance, Weighted Average Exercise Price</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element942" xlink:to="label942" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="element943" />
        <label xlink:type="resource" xlink:label="label943" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element943" xlink:to="label943" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="element944" />
        <label xlink:type="resource" xlink:label="label944" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_en-US">Contractual Term of Stock Options Exercised</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element944" xlink:to="label944" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="element945" />
        <label xlink:type="resource" xlink:label="label945" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element945" xlink:to="label945" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="element946" />
        <label xlink:type="resource" xlink:label="label946" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_en-US">Non-Vested Stock Options Granted, Weighted Average Grant Date Fair Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element946" xlink:to="label946" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="element947" />
        <label xlink:type="resource" xlink:label="label947" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SharesOutstanding_en-US">SharesOutstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element947" xlink:to="label947" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="element948" />
        <label xlink:type="resource" xlink:label="label948" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_SharesOutstanding_en-US">Balance (in shares)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element948" xlink:to="label948" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="element949" />
        <label xlink:type="resource" xlink:label="label949" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US" id="periodStart_us-gaap_SharesOutstanding_en-US">Balance (in shares)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element949" xlink:to="label949" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="element950" />
        <label xlink:type="resource" xlink:label="label950" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US" id="periodEnd_us-gaap_SharesOutstanding_en-US">Balance (in shares)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element950" xlink:to="label950" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="element951" />
        <label xlink:type="resource" xlink:label="label951" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SignificantAccountingPoliciesTextBlock_en-US">Significant Accounting Policies [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element951" xlink:to="label951" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="element952" />
        <label xlink:type="resource" xlink:label="label952" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_SignificantAccountingPoliciesTextBlock_en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element952" xlink:to="label952" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="element953" />
        <label xlink:type="resource" xlink:label="label953" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StateAndLocalJurisdictionMember_en-US">State and Local Jurisdiction [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element953" xlink:to="label953" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="element954" />
        <label xlink:type="resource" xlink:label="label954" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StatementLineItems_en-US">Statement [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element954" xlink:to="label954" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="element955" />
        <label xlink:type="resource" xlink:label="label955" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_StatementLineItems_en-US">Statement [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element955" xlink:to="label955" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="element956" />
        <label xlink:type="resource" xlink:label="label956" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StatementOfStockholdersEquityAbstract_en-US">Statement of Stockholders' Equity [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element956" xlink:to="label956" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="element957" />
        <label xlink:type="resource" xlink:label="label957" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StatementOfCashFlowsAbstract_en-US">Statement Of Cash Flows [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element957" xlink:to="label957" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="element958" />
        <label xlink:type="resource" xlink:label="label958" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_StatementOfCashFlowsAbstract_en-US">Statement of Cash Flows [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element958" xlink:to="label958" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="element959" />
        <label xlink:type="resource" xlink:label="label959" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_en-US">Statement of Other Comprehensive Income (Loss) [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element959" xlink:to="label959" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="element960" />
        <label xlink:type="resource" xlink:label="label960" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StatementEquityComponentsAxis_en-US">Statement Equity Components [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element960" xlink:to="label960" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="element961" />
        <label xlink:type="resource" xlink:label="label961" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StatementTable_en-US">Statement [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element961" xlink:to="label961" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="element962" />
        <label xlink:type="resource" xlink:label="label962" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_StatementTable_en-US">Statement [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element962" xlink:to="label962" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="element963" />
        <label xlink:type="resource" xlink:label="label963" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StatementBusinessSegmentsAxis_en-US">Statement Business Segments [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element963" xlink:to="label963" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="element964" />
        <label xlink:type="resource" xlink:label="label964" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_StatementBusinessSegmentsAxis_en-US">Business Segments [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element964" xlink:to="label964" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="element965" />
        <label xlink:type="resource" xlink:label="label965" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StatementOfFinancialPositionAbstract_en-US">Statement Of Financial Position [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element965" xlink:to="label965" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="element966" />
        <label xlink:type="resource" xlink:label="label966" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_StatementOfFinancialPositionAbstract_en-US">Statement of Financial Position [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element966" xlink:to="label966" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="element967" />
        <label xlink:type="resource" xlink:label="label967" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StockRepurchaseProgramAuthorizedAmount1_en-US">StockRepurchaseProgramAuthorizedAmount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element967" xlink:to="label967" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="element968" />
        <label xlink:type="resource" xlink:label="label968" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_StockRepurchaseProgramAuthorizedAmount1_en-US">Share Repurchase Program authorized amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element968" xlink:to="label968" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="element969" />
        <label xlink:type="resource" xlink:label="label969" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_en-US">Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element969" xlink:to="label969" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="element970" />
        <label xlink:type="resource" xlink:label="label970" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_en-US">Issuance/(cancellation) of non-vested stock</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element970" xlink:to="label970" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="element971" />
        <label xlink:type="resource" xlink:label="label971" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_en-US">StockIssuedDuringPeriodValueStockOptionsExercised</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element971" xlink:to="label971" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="element972" />
        <label xlink:type="resource" xlink:label="label972" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_en-US">Exercise of stock options</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element972" xlink:to="label972" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="element973" />
        <label xlink:type="resource" xlink:label="label973" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_en-US">Stock Issued During Period Shares Stock Options Exercised</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element973" xlink:to="label973" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="element974" />
        <label xlink:type="resource" xlink:label="label974" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_en-US">Stock Options Exercised, Number of Shares</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element974" xlink:to="label974" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="element975" />
        <label xlink:type="resource" xlink:label="label975" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US" id="verbose_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_en-US">Exercise of stock options (in shares)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element975" xlink:to="label975" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="element976" />
        <label xlink:type="resource" xlink:label="label976" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_en-US">StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element976" xlink:to="label976" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="element977" />
        <label xlink:type="resource" xlink:label="label977" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_en-US">Issuance/(cancellation) of non-vested stock (in shares)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element977" xlink:to="label977" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockOptionMember" xlink:label="element978" />
        <label xlink:type="resource" xlink:label="label978" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StockOptionMember_en-US">Stock Option [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element978" xlink:to="label978" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="element979" />
        <label xlink:type="resource" xlink:label="label979" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_en-US">Stock Issued During Period Shares Employee Stock Purchase Plans</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element979" xlink:to="label979" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="element980" />
        <label xlink:type="resource" xlink:label="label980" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_en-US">ESPP Shares Issued</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element980" xlink:to="label980" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="element981" />
        <label xlink:type="resource" xlink:label="label981" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US" id="verbose_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_en-US">Issuance of stock - employee stock purchase plan (in shares)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element981" xlink:to="label981" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="element982" />
        <label xlink:type="resource" xlink:label="label982" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_en-US">StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element982" xlink:to="label982" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="element983" />
        <label xlink:type="resource" xlink:label="label983" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_en-US">Issuance of stock - employee stock purchase plan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element983" xlink:to="label983" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="element984" />
        <label xlink:type="resource" xlink:label="label984" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_en-US">Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element984" xlink:to="label984" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="element985" />
        <label xlink:type="resource" xlink:label="label985" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_en-US">Equity:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element985" xlink:to="label985" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="element986" />
        <label xlink:type="resource" xlink:label="label986" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_en-US">Stockholders Equity Including Portion Attributable To Noncontrolling Interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element986" xlink:to="label986" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="element987" />
        <label xlink:type="resource" xlink:label="label987" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_en-US">Total equity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element987" xlink:to="label987" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="element988" />
        <label xlink:type="resource" xlink:label="label988" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_en-US">Balance, Stockholders Equity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element988" xlink:to="label988" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="element989" />
        <label xlink:type="resource" xlink:label="label989" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US" id="periodStart_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_en-US">Balance, Stockholders Equity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element989" xlink:to="label989" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="element990" />
        <label xlink:type="resource" xlink:label="label990" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US" id="periodEnd_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_en-US">Balance, Stockholders Equity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element990" xlink:to="label990" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="element991" />
        <label xlink:type="resource" xlink:label="label991" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_StockholdersEquity_en-US">Stockholders Equity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element991" xlink:to="label991" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="element992" />
        <label xlink:type="resource" xlink:label="label992" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_StockholdersEquity_en-US">Total Amedisys, Inc. stockholders' equity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element992" xlink:to="label992" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="element993" />
        <label xlink:type="resource" xlink:label="label993" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SubsequentEventLineItems_en-US">Subsequent Event [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element993" xlink:to="label993" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="element994" />
        <label xlink:type="resource" xlink:label="label994" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_SubsequentEventsTextBlock_en-US">SUBSEQUENT EVENT</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element994" xlink:to="label994" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="element995" />
        <label xlink:type="resource" xlink:label="label995" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SubsequentEventsTextBlock_en-US">Subsequent Events [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element995" xlink:to="label995" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="element996" />
        <label xlink:type="resource" xlink:label="label996" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SubsequentEventsAbstract_en-US">Subsequent Events [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element996" xlink:to="label996" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="element997" />
        <label xlink:type="resource" xlink:label="label997" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_SupplementalCashFlowInformationAbstract_en-US">Supplemental Cash Flow Information [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element997" xlink:to="label997" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="element998" />
        <label xlink:type="resource" xlink:label="label998" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_SupplementalCashFlowInformationAbstract_en-US">Supplemental Disclosures of Cash Flow Information:</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element998" xlink:to="label998" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="element999" />
        <label xlink:type="resource" xlink:label="label999" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_TaxCreditCarryforwardAxis_en-US">Tax Credit Carryforward [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element999" xlink:to="label999" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="element1000" />
        <label xlink:type="resource" xlink:label="label1000" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_TaxCreditCarryforwardNameDomain_en-US">Tax Credit Carryforward [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1000" xlink:to="label1000" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:label="element1001" />
        <label xlink:type="resource" xlink:label="label1001" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_TaxCreditCarryforwardValuationAllowance_en-US">Tax Credit Carryforward Valuation Allowance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1001" xlink:to="label1001" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:label="element1002" />
        <label xlink:type="resource" xlink:label="label1002" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_TaxCreditCarryforwardValuationAllowance_en-US">Tax credit carryforwards valuation allowance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1002" xlink:to="label1002" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="element1003" />
        <label xlink:type="resource" xlink:label="label1003" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_TradeAndOtherAccountsReceivablePolicy_en-US">Trade And Other Accounts Receivable Policy</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1003" xlink:to="label1003" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="element1004" />
        <label xlink:type="resource" xlink:label="label1004" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_TradeAndOtherAccountsReceivablePolicy_en-US">Patient Accounts Receivable</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1004" xlink:to="label1004" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="element1005" />
        <label xlink:type="resource" xlink:label="label1005" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_TreasuryStockSharesAcquired_en-US">Treasury Stock Shares Acquired</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1005" xlink:to="label1005" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="element1006" />
        <label xlink:type="resource" xlink:label="label1006" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_TreasuryStockSharesAcquired_en-US">Treasury Stock Shares Repurchased</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1006" xlink:to="label1006" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="element1007" />
        <label xlink:type="resource" xlink:label="label1007" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_TreasuryStockShares_en-US">Treasury Stock Shares</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1007" xlink:to="label1007" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="element1008" />
        <label xlink:type="resource" xlink:label="label1008" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_TreasuryStockShares_en-US">Treasury Stock at cost, shares</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1008" xlink:to="label1008" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockTextBlock" xlink:label="element1009" />
        <label xlink:type="resource" xlink:label="label1009" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_TreasuryStockTextBlock_en-US">Treasury Stock</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1009" xlink:to="label1009" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockTextBlock" xlink:label="element1010" />
        <label xlink:type="resource" xlink:label="label1010" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_TreasuryStockTextBlock_en-US">SHARE REPURCHASE PROGRAM</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1010" xlink:to="label1010" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="element1011" />
        <label xlink:type="resource" xlink:label="label1011" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_TreasuryStockMember_en-US">Treasury Stock [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1011" xlink:to="label1011" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="element1012" />
        <label xlink:type="resource" xlink:label="label1012" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_TreasuryStockValueAcquiredCostMethod_en-US">Treasury Stock Value Acquired Cost Method</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1012" xlink:to="label1012" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="element1013" />
        <label xlink:type="resource" xlink:label="label1013" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_TreasuryStockValueAcquiredCostMethod_en-US">Shares repurchased</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1013" xlink:to="label1013" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="element1014" />
        <label xlink:type="resource" xlink:label="label1014" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_TreasuryStockValueAcquiredCostMethod_en-US">Shares repurchased</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1014" xlink:to="label1014" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="element1015" />
        <label xlink:type="resource" xlink:label="label1015" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_TreasuryStockAcquiredAverageCostPerShare_en-US">Treasury Stock Acquired Average Cost Per Share</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1015" xlink:to="label1015" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="element1016" />
        <label xlink:type="resource" xlink:label="label1016" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_TreasuryStockAcquiredAverageCostPerShare_en-US">Treasury Stock Weighted Average Price</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1016" xlink:to="label1016" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="element1017" />
        <label xlink:type="resource" xlink:label="label1017" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_TreasuryStockValue_en-US">Treasury Stock Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1017" xlink:to="label1017" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="element1018" />
        <label xlink:type="resource" xlink:label="label1018" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_TreasuryStockValue_en-US">Treasury Stock at cost 1,656,362, and 1,179,684 shares of common stock</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1018" xlink:to="label1018" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="element1019" />
        <label xlink:type="resource" xlink:label="label1019" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_UnamortizedDebtIssuanceExpense_en-US">Unamortized Debt Issuance Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1019" xlink:to="label1019" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="element1020" />
        <label xlink:type="resource" xlink:label="label1020" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_UnamortizedDebtIssuanceExpense_en-US">Unamortized debt issuance costs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1020" xlink:to="label1020" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="element1021" />
        <label xlink:type="resource" xlink:label="label1021" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_en-US">nrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1021" xlink:to="label1021" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="element1022" />
        <label xlink:type="resource" xlink:label="label1022" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_en-US">Additions for tax positions related to prior years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1022" xlink:to="label1022" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="element1023" />
        <label xlink:type="resource" xlink:label="label1023" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_en-US">Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1023" xlink:to="label1023" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="element1024" />
        <label xlink:type="resource" xlink:label="label1024" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_en-US">Settlements</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1024" xlink:to="label1024" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="element1025" />
        <label xlink:type="resource" xlink:label="label1025" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_en-US">Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1025" xlink:to="label1025" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="element1026" />
        <label xlink:type="resource" xlink:label="label1026" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_en-US">Lapse of statute of limitations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1026" xlink:to="label1026" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="element1027" />
        <label xlink:type="resource" xlink:label="label1027" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_en-US">Lapse of statute of limitations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1027" xlink:to="label1027" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="element1028" />
        <label xlink:type="resource" xlink:label="label1028" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_en-US">Unrecognized Tax Benefits Income Tax Penalties And Interest Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1028" xlink:to="label1028" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="element1029" />
        <label xlink:type="resource" xlink:label="label1029" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_en-US">Interest and penalties recognized related to uncertain income tax positions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1029" xlink:to="label1029" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="element1030" />
        <label xlink:type="resource" xlink:label="label1030" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_UnrecognizedTaxBenefits_en-US">UnrecognizedTaxBenefits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1030" xlink:to="label1030" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="element1031" />
        <label xlink:type="resource" xlink:label="label1031" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_UnrecognizedTaxBenefits_en-US">Uncertain tax benefits accrued</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1031" xlink:to="label1031" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="element1032" />
        <label xlink:type="resource" xlink:label="label1032" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US" id="periodStart_us-gaap_UnrecognizedTaxBenefits_en-US">Uncertain tax benefits accrued, beginning balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1032" xlink:to="label1032" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="element1033" />
        <label xlink:type="resource" xlink:label="label1033" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US" id="periodEnd_us-gaap_UnrecognizedTaxBenefits_en-US">Uncertain tax benefits accrued, ending balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1033" xlink:to="label1033" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="element1034" />
        <label xlink:type="resource" xlink:label="label1034" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_en-US">UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1034" xlink:to="label1034" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="element1035" />
        <label xlink:type="resource" xlink:label="label1035" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_en-US">Interest and penalties accrued related to uncertain income tax positions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1035" xlink:to="label1035" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="element1036" />
        <label xlink:type="resource" xlink:label="label1036" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_en-US">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1036" xlink:to="label1036" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="element1037" />
        <label xlink:type="resource" xlink:label="label1037" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_en-US">Additions for tax positions related to current year</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1037" xlink:to="label1037" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="element1038" />
        <label xlink:type="resource" xlink:label="label1038" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_en-US">UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1038" xlink:to="label1038" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="element1039" />
        <label xlink:type="resource" xlink:label="label1039" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_en-US">Reductions for tax positions related to prior years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1039" xlink:to="label1039" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="element1040" />
        <label xlink:type="resource" xlink:label="label1040" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_en-US">Unrecognized Tax Benefits Period Increase Decrease</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1040" xlink:to="label1040" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="element1041" />
        <label xlink:type="resource" xlink:label="label1041" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_UseOfEstimates_en-US">Use Of Estimates</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1041" xlink:to="label1041" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="element1042" />
        <label xlink:type="resource" xlink:label="label1042" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_UseOfEstimates_en-US">Use of Estimates</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1042" xlink:to="label1042" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="element1043" />
        <label xlink:type="resource" xlink:label="label1043" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_en-US">Valuation and Qualifying Accounts Disclosure [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1043" xlink:to="label1043" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="element1044" />
        <label xlink:type="resource" xlink:label="label1044" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ValuationAllowancesAndReservesDomain_en-US">Valuation Allowances</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1044" xlink:to="label1044" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:label="element1045" />
        <label xlink:type="resource" xlink:label="label1045" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ValuationAllowancesAndReservesAdjustments_en-US">ValuationAllowancesAndReservesAdjustments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1045" xlink:to="label1045" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:label="element1046" />
        <label xlink:type="resource" xlink:label="label1046" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ValuationAllowancesAndReservesAdjustments_en-US">Provision for Estimated Revenue Adjustments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1046" xlink:to="label1046" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="element1047" />
        <label xlink:type="resource" xlink:label="label1047" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ValuationAllowancesAndReservesBalance_en-US">ValuationAllowancesAndReservesBalance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1047" xlink:to="label1047" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="element1048" />
        <label xlink:type="resource" xlink:label="label1048" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ValuationAllowancesAndReservesBalance_en-US">Allowance for Doubtful Accounts Balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1048" xlink:to="label1048" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="element1049" />
        <label xlink:type="resource" xlink:label="label1049" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xml:lang="en-US" id="periodStart_us-gaap_ValuationAllowancesAndReservesBalance_en-US">Valuation Allowances and Reserves, Balance, Beginning Balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1049" xlink:to="label1049" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="element1050" />
        <label xlink:type="resource" xlink:label="label1050" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xml:lang="en-US" id="periodEnd_us-gaap_ValuationAllowancesAndReservesBalance_en-US">Valuation Allowances and Reserves, Balance, Ending Balance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1050" xlink:to="label1050" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="element1051" />
        <label xlink:type="resource" xlink:label="label1051" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ValuationAllowancesAndReservesDeductions_en-US">ValuationAllowancesAndReservesDeductions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1051" xlink:to="label1051" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="element1052" />
        <label xlink:type="resource" xlink:label="label1052" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ValuationAllowancesAndReservesDeductions_en-US">Write-Offs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1052" xlink:to="label1052" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="element1053" />
        <label xlink:type="resource" xlink:label="label1053" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_us-gaap_ValuationAllowancesAndReservesDeductions_en-US">Write-Offs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1053" xlink:to="label1053" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="element1054" />
        <label xlink:type="resource" xlink:label="label1054" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_en-US">Net change in total valuation allowance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1054" xlink:to="label1054" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="element1055" />
        <label xlink:type="resource" xlink:label="label1055" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_en-US">ValuationAllowanceDeferredTaxAssetChangeInAmount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1055" xlink:to="label1055" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="element1056" />
        <label xlink:type="resource" xlink:label="label1056" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ValuationAllowancesAndReservesTypeAxis_en-US">Valuation Allowances And Reserves Type [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1056" xlink:to="label1056" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:label="element1057" />
        <label xlink:type="resource" xlink:label="label1057" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ValuationAndQualifyingAccountsAbstract_en-US">Valuation And Qualifying Accounts [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1057" xlink:to="label1057" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="element1058" />
        <label xlink:type="resource" xlink:label="label1058" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1058" xlink:to="label1058" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="element1059" />
        <label xlink:type="resource" xlink:label="label1059" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1059" xlink:to="label1059" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VehiclesMember" xlink:label="element1060" />
        <label xlink:type="resource" xlink:label="label1060" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_VehiclesMember_en-US">Vehicles [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1060" xlink:to="label1060" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="element1061" />
        <label xlink:type="resource" xlink:label="label1061" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_en-US">Weighted Average Number Of Shares Outstanding Basic</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1061" xlink:to="label1061" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="element1062" />
        <label xlink:type="resource" xlink:label="label1062" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_en-US">Weighted average number of shares outstanding - basic</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1062" xlink:to="label1062" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="element1063" />
        <label xlink:type="resource" xlink:label="label1063" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US" id="verbose_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_en-US">Weighted average shares outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1063" xlink:to="label1063" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="element1064" />
        <label xlink:type="resource" xlink:label="label1064" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_en-US">Weighted Average Number Of Diluted Shares Outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1064" xlink:to="label1064" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="element1065" />
        <label xlink:type="resource" xlink:label="label1065" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_en-US">Weighted average shares outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1065" xlink:to="label1065" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="element1066" />
        <label xlink:type="resource" xlink:label="label1066" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_en-US">Weighted average number of shares outstanding - diluted</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1066" xlink:to="label1066" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="element1067" />
        <label xlink:type="resource" xlink:label="label1067" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_WorkersCompensationLiabilityCurrent_en-US">WorkersCompensationLiabilityCurrent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1067" xlink:to="label1067" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="element1068" />
        <label xlink:type="resource" xlink:label="label1068" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_WorkersCompensationLiabilityCurrent_en-US">Workers' compensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1068" xlink:to="label1068" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="element1069" />
        <label xlink:type="resource" xlink:label="label1069" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_us-gaap_WriteOffOfDeferredDebtIssuanceCost_en-US">Write Off Of Deferred Debt Issuance Cost</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1069" xlink:to="label1069" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="element1070" />
        <label xlink:type="resource" xlink:label="label1070" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_us-gaap_WriteOffOfDeferredDebtIssuanceCost_en-US">Write-off of deferred debt issuance cost</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1070" xlink:to="label1070" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="element1071" />
        <label xlink:type="resource" xlink:label="label1071" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_AmendmentFlag_en-US">Amendment Flag</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1071" xlink:to="label1071" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="element1072" />
        <label xlink:type="resource" xlink:label="label1072" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_AmendmentFlag_en-US">Amendment Flag</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1072" xlink:to="label1072" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="element1073" />
        <label xlink:type="resource" xlink:label="label1073" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_CurrentFiscalYearEndDate_en-US">Current Fiscal Year End Date</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1073" xlink:to="label1073" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="element1074" />
        <label xlink:type="resource" xlink:label="label1074" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_CurrentFiscalYearEndDate_en-US">Current Fiscal Year End Date</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1074" xlink:to="label1074" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="element1075" />
        <label xlink:type="resource" xlink:label="label1075" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_DocumentInformationLineItems_en-US">Document Information [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1075" xlink:to="label1075" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="element1076" />
        <label xlink:type="resource" xlink:label="label1076" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_DocumentInformationLineItems_en-US">Document Information [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1076" xlink:to="label1076" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="element1077" />
        <label xlink:type="resource" xlink:label="label1077" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_DocumentPeriodEndDate_en-US">Document Period End Date</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1077" xlink:to="label1077" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="element1078" />
        <label xlink:type="resource" xlink:label="label1078" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_DocumentPeriodEndDate_en-US">Document Period End Date</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1078" xlink:to="label1078" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntitiesTable" xlink:label="element1079" />
        <label xlink:type="resource" xlink:label="label1079" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_EntitiesTable_en-US">Entities [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1079" xlink:to="label1079" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntitiesTable" xlink:label="element1080" />
        <label xlink:type="resource" xlink:label="label1080" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_EntitiesTable_en-US">Entities [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1080" xlink:to="label1080" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="element1081" />
        <label xlink:type="resource" xlink:label="label1081" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_EntityDomain_en-US">Entity [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1081" xlink:to="label1081" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="element1082" />
        <label xlink:type="resource" xlink:label="label1082" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_EntityDomain_en-US">Entity [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1082" xlink:to="label1082" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="element1083" />
        <label xlink:type="resource" xlink:label="label1083" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_TradingSymbol_en-US">Trading Symbol</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1083" xlink:to="label1083" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="element1084" />
        <label xlink:type="resource" xlink:label="label1084" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_TradingSymbol_en-US">Trading Symbol</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1084" xlink:to="label1084" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="element1085" />
        <label xlink:type="resource" xlink:label="label1085" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_EntityWellKnownSeasonedIssuer_en-US">Entity Well-known Seasoned Issuer</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1085" xlink:to="label1085" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="element1086" />
        <label xlink:type="resource" xlink:label="label1086" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_EntityVoluntaryFilers_en-US">Entity Voluntary Filers</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1086" xlink:to="label1086" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="element1087" />
        <label xlink:type="resource" xlink:label="label1087" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_EntityCurrentReportingStatus_en-US">Entity Current Reporting Status</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1087" xlink:to="label1087" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="element1088" />
        <label xlink:type="resource" xlink:label="label1088" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_EntityFilerCategory_en-US">Entity Filer Category</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1088" xlink:to="label1088" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="element1089" />
        <label xlink:type="resource" xlink:label="label1089" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_EntityFilerCategory_en-US">Entity Filer Category</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1089" xlink:to="label1089" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="element1090" />
        <label xlink:type="resource" xlink:label="label1090" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_EntityPublicFloat_en-US">Entity Public Float</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1090" xlink:to="label1090" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="element1091" />
        <label xlink:type="resource" xlink:label="label1091" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_EntityRegistrantName_en-US">Entity Registrant Name</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1091" xlink:to="label1091" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="element1092" />
        <label xlink:type="resource" xlink:label="label1092" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_EntityRegistrantName_en-US">Entity Registrant Name</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1092" xlink:to="label1092" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="element1093" />
        <label xlink:type="resource" xlink:label="label1093" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_EntityCentralIndexKey_en-US">Entity Central Index Key</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1093" xlink:to="label1093" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="element1094" />
        <label xlink:type="resource" xlink:label="label1094" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_EntityCentralIndexKey_en-US">Entity Central Index Key</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1094" xlink:to="label1094" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="element1095" />
        <label xlink:type="resource" xlink:label="label1095" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_EntityCommonStockSharesOutstanding_en-US">Entity Common Stock Shares Outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1095" xlink:to="label1095" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="element1096" />
        <label xlink:type="resource" xlink:label="label1096" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_EntityCommonStockSharesOutstanding_en-US">Entity Common Stock, Shares Outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1096" xlink:to="label1096" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="element1097" />
        <label xlink:type="resource" xlink:label="label1097" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_DocumentFiscalYearFocus_en-US">Document Fiscal Year Focus</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1097" xlink:to="label1097" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="element1098" />
        <label xlink:type="resource" xlink:label="label1098" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_DocumentFiscalYearFocus_en-US">Document Fiscal Year Focus</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1098" xlink:to="label1098" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="element1099" />
        <label xlink:type="resource" xlink:label="label1099" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_DocumentFiscalPeriodFocus_en-US">Document Fiscal Period Focus</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1099" xlink:to="label1099" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="element1100" />
        <label xlink:type="resource" xlink:label="label1100" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_DocumentFiscalPeriodFocus_en-US">Document Fiscal Period Focus</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1100" xlink:to="label1100" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="element1101" />
        <label xlink:type="resource" xlink:label="label1101" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_LegalEntityAxis_en-US">Legal Entity [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1101" xlink:to="label1101" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="element1102" />
        <label xlink:type="resource" xlink:label="label1102" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_LegalEntityAxis_en-US">Legal Entity [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1102" xlink:to="label1102" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="element1103" />
        <label xlink:type="resource" xlink:label="label1103" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_dei_DocumentType_en-US">Document Type</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1103" xlink:to="label1103" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="element1104" />
        <label xlink:type="resource" xlink:label="label1104" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_dei_DocumentType_en-US">Document Type</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1104" xlink:to="label1104" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearAxis" xlink:label="element1105" />
        <label xlink:type="resource" xlink:label="label1105" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CapYearAxis_en-US">Cap Year [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1105" xlink:to="label1105" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearAxis" xlink:label="element1106" />
        <label xlink:type="resource" xlink:label="label1106" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CapYearAxis_en-US">Cap Year [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1106" xlink:to="label1106" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearAxis" xlink:label="element1107" />
        <label xlink:type="resource" xlink:label="label1107" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_CapYearAxis_en-US">Cap Year [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1107" xlink:to="label1107" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearDomain" xlink:label="element1108" />
        <label xlink:type="resource" xlink:label="label1108" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CapYearDomain_en-US">Cap Year [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1108" xlink:to="label1108" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearDomain" xlink:label="element1109" />
        <label xlink:type="resource" xlink:label="label1109" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CapYearDomain_en-US">Cap Year [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1109" xlink:to="label1109" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearDomain" xlink:label="element1110" />
        <label xlink:type="resource" xlink:label="label1110" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_CapYearDomain_en-US">Cap Year [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1110" xlink:to="label1110" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember" xlink:label="element1111" />
        <label xlink:type="resource" xlink:label="label1111" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember_en-US">Cap Year Two Thousand Thirteen Through Two Thousand Sixteen [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1111" xlink:to="label1111" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember" xlink:label="element1112" />
        <label xlink:type="resource" xlink:label="label1112" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember_en-US">Cap Year Two Thousand Thirteen Through Two Thousand Sixteen [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1112" xlink:to="label1112" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember" xlink:label="element1113" />
        <label xlink:type="resource" xlink:label="label1113" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember_en-US">Cap Year 2013 - 2016</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1113" xlink:to="label1113" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CashDistributionToNoncontrollingInterest" xlink:label="element1114" />
        <label xlink:type="resource" xlink:label="label1114" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CashDistributionToNoncontrollingInterest_en-US">Payment of dividends or other distributions to noncontrolling interest holders.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1114" xlink:to="label1114" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CashDistributionToNoncontrollingInterest" xlink:label="element1115" />
        <label xlink:type="resource" xlink:label="label1115" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CashDistributionToNoncontrollingInterest_en-US">Cash Distribution To Noncontrolling Interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1115" xlink:to="label1115" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CashDistributionToNoncontrollingInterest" xlink:label="element1116" />
        <label xlink:type="resource" xlink:label="label1116" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_amed_CashDistributionToNoncontrollingInterest_en-US">Non-controlling interest distribution</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1116" xlink:to="label1116" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CmsHospiceFaceToFaceRequirementPriorToThirdBenefitPeriod" xlink:label="element1117" />
        <label xlink:type="resource" xlink:label="label1117" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CmsHospiceFaceToFaceRequirementPriorToThirdBenefitPeriod_en-US">Description of the number of days before a Hospice patient's third benefit period within which the CMS Face to Face Requirement must be met.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1117" xlink:to="label1117" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CmsHospiceFaceToFaceRequirementPriorToThirdBenefitPeriod" xlink:label="element1118" />
        <label xlink:type="resource" xlink:label="label1118" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CmsHospiceFaceToFaceRequirementPriorToThirdBenefitPeriod_en-US">Cms Hospice Face To Face Requirement Prior To Third Benefit Period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1118" xlink:to="label1118" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CmsHospiceFaceToFaceRequirementPriorToThirdBenefitPeriod" xlink:label="element1119" />
        <label xlink:type="resource" xlink:label="label1119" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_CmsHospiceFaceToFaceRequirementPriorToThirdBenefitPeriod_en-US">CMS hospice face-to-face requirement prior to third benefit period, days</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1119" xlink:to="label1119" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CmsTherapyAssessmentRequirementIntervalMinimum" xlink:label="element1120" />
        <label xlink:type="resource" xlink:label="label1120" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CmsTherapyAssessmentRequirementIntervalMinimum_en-US">Description of the number of days in which a therapy assessment is required during a therapy patient's course of treatment.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1120" xlink:to="label1120" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CmsTherapyAssessmentRequirementIntervalMinimum" xlink:label="element1121" />
        <label xlink:type="resource" xlink:label="label1121" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CmsTherapyAssessmentRequirementIntervalMinimum_en-US">Cms Therapy Assessment Requirement Interval Minimum</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1121" xlink:to="label1121" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CmsTherapyAssessmentRequirementIntervalMinimum" xlink:label="element1122" />
        <label xlink:type="resource" xlink:label="label1122" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_CmsTherapyAssessmentRequirementIntervalMinimum_en-US">CMS therapy assessment requirement interval minimum, days</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1122" xlink:to="label1122" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommimentsAndContingenciesTable" xlink:label="element1123" />
        <label xlink:type="resource" xlink:label="label1123" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CommimentsAndContingenciesTable_en-US">Commiments And Contingencies [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1123" xlink:to="label1123" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommimentsAndContingenciesTable" xlink:label="element1124" />
        <label xlink:type="resource" xlink:label="label1124" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CommimentsAndContingenciesTable_en-US">Commiments And Contingencies [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1124" xlink:to="label1124" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommimentsAndContingenciesTable" xlink:label="element1125" />
        <label xlink:type="resource" xlink:label="label1125" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_CommimentsAndContingenciesTable_en-US">Commiments And Contingencies [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1125" xlink:to="label1125" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="element1126" />
        <label xlink:type="resource" xlink:label="label1126" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CommitmentsAndContingenciesDisclosureLineItems_en-US">Commitments and Contingencies Disclosure [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1126" xlink:to="label1126" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="element1127" />
        <label xlink:type="resource" xlink:label="label1127" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CommitmentsAndContingenciesDisclosureLineItems_en-US">Commitments And Contingencies Disclosure [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1127" xlink:to="label1127" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="element1128" />
        <label xlink:type="resource" xlink:label="label1128" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_CommitmentsAndContingenciesDisclosureLineItems_en-US">Commitments and Contingencies Disclosure [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1128" xlink:to="label1128" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DaysInHospiceRecertificationThirdBenefitPeriod" xlink:label="element1129" />
        <label xlink:type="resource" xlink:label="label1129" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DaysInHospiceRecertificationThirdBenefitPeriod_en-US">Description containing the number of days within the third benefit period for Hospice.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1129" xlink:to="label1129" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DaysInHospiceRecertificationThirdBenefitPeriod" xlink:label="element1130" />
        <label xlink:type="resource" xlink:label="label1130" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DaysInHospiceRecertificationThirdBenefitPeriod_en-US">Days In Hospice Recertification Third Benefit Period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1130" xlink:to="label1130" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DaysInHospiceRecertificationThirdBenefitPeriod" xlink:label="element1131" />
        <label xlink:type="resource" xlink:label="label1131" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DaysInHospiceRecertificationThirdBenefitPeriod_en-US">Days in hospice recertification third benefit period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1131" xlink:to="label1131" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DepreciationAndAmortizationForContinuingOperations" xlink:label="element1132" />
        <label xlink:type="resource" xlink:label="label1132" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DepreciationAndAmortizationForContinuingOperations_en-US">Depreciation And Amortization For Continuing Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1132" xlink:to="label1132" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DepreciationAndAmortizationForContinuingOperations" xlink:label="element1133" />
        <label xlink:type="resource" xlink:label="label1133" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DepreciationAndAmortizationForContinuingOperations_en-US">Depreciation And Amortization For Continuing Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1133" xlink:to="label1133" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DepreciationAndAmortizationForContinuingOperations" xlink:label="element1134" />
        <label xlink:type="resource" xlink:label="label1134" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DepreciationAndAmortizationForContinuingOperations_en-US">Depreciation and amortization</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1134" xlink:to="label1134" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationAbstract" xlink:label="element1135" />
        <label xlink:type="resource" xlink:label="label1135" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationAbstract_en-US">Disclosure - Nature of Operations Consolidation and Presentation of Financial Statements - Additional Information [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1135" xlink:to="label1135" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationAbstract" xlink:label="element1136" />
        <label xlink:type="resource" xlink:label="label1136" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationAbstract_en-US">Disclosure Nature Of Operations Consolidation And Presentation Of Financial Statements Additional Information [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1136" xlink:to="label1136" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationAbstract" xlink:label="element1137" />
        <label xlink:type="resource" xlink:label="label1137" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationAbstract_en-US">Disclosure - Nature of Operations Consolidation and Presentation of Financial Statements - Additional Information [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1137" xlink:to="label1137" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DocumentDocumentandEntityInformationAbstract" xlink:label="element1138" />
        <label xlink:type="resource" xlink:label="label1138" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DocumentDocumentandEntityInformationAbstract_en-US">Document - Document and Entity Information [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1138" xlink:to="label1138" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DocumentDocumentandEntityInformationAbstract" xlink:label="element1139" />
        <label xlink:type="resource" xlink:label="label1139" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DocumentDocumentandEntityInformationAbstract_en-US">Document Documentand Entity Information [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1139" xlink:to="label1139" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DocumentDocumentandEntityInformationAbstract" xlink:label="element1140" />
        <label xlink:type="resource" xlink:label="label1140" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DocumentDocumentandEntityInformationAbstract_en-US">Document - Document and Entity Information [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1140" xlink:to="label1140" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenue" xlink:label="element1141" />
        <label xlink:type="resource" xlink:label="label1141" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EpisodeOfCareAsEpisodicBasedRevenue_en-US">Description containing the number of days in a home health episode of care.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1141" xlink:to="label1141" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenue" xlink:label="element1142" />
        <label xlink:type="resource" xlink:label="label1142" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EpisodeOfCareAsEpisodicBasedRevenue_en-US">Episode Of Care As Episodic Based Revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1142" xlink:to="label1142" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenue" xlink:label="element1143" />
        <label xlink:type="resource" xlink:label="label1143" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EpisodeOfCareAsEpisodicBasedRevenue_en-US">Episode of care as episodic-based revenue, days</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1143" xlink:to="label1143" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EpisodesInProgressThatBeginDuringReportingPeriod" xlink:label="element1144" />
        <label xlink:type="resource" xlink:label="label1144" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EpisodesInProgressThatBeginDuringReportingPeriod_en-US">Description containing the number of days in an episode of care.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1144" xlink:to="label1144" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EpisodesInProgressThatBeginDuringReportingPeriod" xlink:label="element1145" />
        <label xlink:type="resource" xlink:label="label1145" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EpisodesInProgressThatBeginDuringReportingPeriod_en-US">Episodes In Progress That Begin During Reporting Period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1145" xlink:to="label1145" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EpisodesInProgressThatBeginDuringReportingPeriod" xlink:label="element1146" />
        <label xlink:type="resource" xlink:label="label1146" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EpisodesInProgressThatBeginDuringReportingPeriod_en-US">Episodes in progress that begin during reporting period, days</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1146" xlink:to="label1146" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:label="element1147" />
        <label xlink:type="resource" xlink:label="label1147" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_en-US">Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1147" xlink:to="label1147" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:label="element1148" />
        <label xlink:type="resource" xlink:label="label1148" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_en-US">Estimated Amount Due Back To Medicare In Other Accrued Liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1148" xlink:to="label1148" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:label="element1149" />
        <label xlink:type="resource" xlink:label="label1149" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_en-US">Estimated amounts due back to Medicare</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1149" xlink:to="label1149" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FavorableMember" xlink:label="element1150" />
        <label xlink:type="resource" xlink:label="label1150" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FavorableMember_en-US">Favorable [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1150" xlink:to="label1150" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FavorableMember" xlink:label="element1151" />
        <label xlink:type="resource" xlink:label="label1151" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FavorableMember_en-US">Favorable [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1151" xlink:to="label1151" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FavorableMember" xlink:label="element1152" />
        <label xlink:type="resource" xlink:label="label1152" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_FavorableMember_en-US">Favorable</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1152" xlink:to="label1152" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FinancialInstrumentDetailsTextBlock" xlink:label="element1153" />
        <label xlink:type="resource" xlink:label="label1153" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FinancialInstrumentDetailsTextBlock_en-US">Financial instrument details, table.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1153" xlink:to="label1153" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FinancialInstrumentDetailsTextBlock" xlink:label="element1154" />
        <label xlink:type="resource" xlink:label="label1154" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FinancialInstrumentDetailsTextBlock_en-US">Financial Instrument Details [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1154" xlink:to="label1154" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FinancialInstrumentDetailsTextBlock" xlink:label="element1155" />
        <label xlink:type="resource" xlink:label="label1155" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_FinancialInstrumentDetailsTextBlock_en-US">Financial Instruments Where Carrying Value and Fair Value Differ</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1155" xlink:to="label1155" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FirstThresholdOfTherapyServicesRequired" xlink:label="element1156" />
        <label xlink:type="resource" xlink:label="label1156" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FirstThresholdOfTherapyServicesRequired_en-US">Description containing the number of visits related to the first threshold of therapy services required.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1156" xlink:to="label1156" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FirstThresholdOfTherapyServicesRequired" xlink:label="element1157" />
        <label xlink:type="resource" xlink:label="label1157" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FirstThresholdOfTherapyServicesRequired_en-US">First Threshold Of Therapy Services Required</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1157" xlink:to="label1157" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FirstThresholdOfTherapyServicesRequired" xlink:label="element1158" />
        <label xlink:type="resource" xlink:label="label1158" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_FirstThresholdOfTherapyServicesRequired_en-US">First threshold of therapy services required, visits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1158" xlink:to="label1158" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FixedChargeCoverageRatio" xlink:label="element1159" />
        <label xlink:type="resource" xlink:label="label1159" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FixedChargeCoverageRatio_en-US">Ratio of adjusted earnings before interest, taxes , depreciation and amortization plus rent expense to certain fixed charges (interest expense, required principal payments and capital expenditures).</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1159" xlink:to="label1159" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FixedChargeCoverageRatio" xlink:label="element1160" />
        <label xlink:type="resource" xlink:label="label1160" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FixedChargeCoverageRatio_en-US">Fixed Charge Coverage Ratio</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1160" xlink:to="label1160" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FixedChargeCoverageRatio" xlink:label="element1161" />
        <label xlink:type="resource" xlink:label="label1161" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_FixedChargeCoverageRatio_en-US">Fixed charge coverage ratio</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1161" xlink:to="label1161" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GeneralAndAdministrativeExpenseSegment" xlink:label="element1162" />
        <label xlink:type="resource" xlink:label="label1162" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_GeneralAndAdministrativeExpenseSegment_en-US">The aggregate total of expenses of managing and administering the affairs of each segment of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1162" xlink:to="label1162" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GeneralAndAdministrativeExpenseSegment" xlink:label="element1163" />
        <label xlink:type="resource" xlink:label="label1163" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_GeneralAndAdministrativeExpenseSegment_en-US">General And Administrative Expense Segment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1163" xlink:to="label1163" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GeneralAndAdministrativeExpenseSegment" xlink:label="element1164" />
        <label xlink:type="resource" xlink:label="label1164" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_GeneralAndAdministrativeExpenseSegment_en-US">General and administrative expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1164" xlink:to="label1164" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HealthInsuranceRetentionLimit" xlink:label="element1165" />
        <label xlink:type="resource" xlink:label="label1165" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_HealthInsuranceRetentionLimit_en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1165" xlink:to="label1165" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HealthInsuranceRetentionLimit" xlink:label="element1166" />
        <label xlink:type="resource" xlink:label="label1166" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_HealthInsuranceRetentionLimit_en-US">Health Insurance Retention Limit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1166" xlink:to="label1166" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HealthInsuranceRetentionLimit" xlink:label="element1167" />
        <label xlink:type="resource" xlink:label="label1167" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_HealthInsuranceRetentionLimit_en-US">Health insurance retention limit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1167" xlink:to="label1167" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HistoricalCollectionRateFromMedicare" xlink:label="element1168" />
        <label xlink:type="resource" xlink:label="label1168" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_HistoricalCollectionRateFromMedicare_en-US">Historical collection rate from Medicare.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1168" xlink:to="label1168" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HistoricalCollectionRateFromMedicare" xlink:label="element1169" />
        <label xlink:type="resource" xlink:label="label1169" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_HistoricalCollectionRateFromMedicare_en-US">Historical Collection Rate From Medicare</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1169" xlink:to="label1169" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HistoricalCollectionRateFromMedicare" xlink:label="element1170" />
        <label xlink:type="resource" xlink:label="label1170" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_HistoricalCollectionRateFromMedicare_en-US">Historical collection rate from Medicare</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1170" xlink:to="label1170" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeHealthMember" xlink:label="element1171" />
        <label xlink:type="resource" xlink:label="label1171" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_HomeHealthMember_en-US">Home Health [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1171" xlink:to="label1171" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeHealthMember" xlink:label="element1172" />
        <label xlink:type="resource" xlink:label="label1172" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_HomeHealthMember_en-US">Home Health [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1172" xlink:to="label1172" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeHealthMember" xlink:label="element1173" />
        <label xlink:type="resource" xlink:label="label1173" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_HomeHealthMember_en-US">Home Health</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1173" xlink:to="label1173" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:label="element1174" />
        <label xlink:type="resource" xlink:label="label1174" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_en-US">Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1174" xlink:to="label1174" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:label="element1175" />
        <label xlink:type="resource" xlink:label="label1175" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_en-US">Hospice Medicare Revenue Rate Accounted For Routine Care</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1175" xlink:to="label1175" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:label="element1176" />
        <label xlink:type="resource" xlink:label="label1176" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_en-US">Hospice Medicare revenue rate accounted for routine care</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1176" xlink:to="label1176" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMember" xlink:label="element1177" />
        <label xlink:type="resource" xlink:label="label1177" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_HospiceMember_en-US">Hospice [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1177" xlink:to="label1177" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMember" xlink:label="element1178" />
        <label xlink:type="resource" xlink:label="label1178" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_HospiceMember_en-US">Hospice [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1178" xlink:to="label1178" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMember" xlink:label="element1179" />
        <label xlink:type="resource" xlink:label="label1179" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_HospiceMember_en-US">Hospice care centers</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1179" xlink:to="label1179" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InterestRateOnNotesPayableToBank" xlink:label="element1180" />
        <label xlink:type="resource" xlink:label="label1180" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_InterestRateOnNotesPayableToBank_en-US">Interest rate for the amounts borrowed under the Term Loan, including the terms and method for determining the interest rate at the balance sheet date.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1180" xlink:to="label1180" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InterestRateOnNotesPayableToBank" xlink:label="element1181" />
        <label xlink:type="resource" xlink:label="label1181" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_InterestRateOnNotesPayableToBank_en-US">Interest Rate On Notes Payable To Bank</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1181" xlink:to="label1181" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InterestRateOnNotesPayableToBank" xlink:label="element1182" />
        <label xlink:type="resource" xlink:label="label1182" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_InterestRateOnNotesPayableToBank_en-US">Eurodollar Rate plus the applicable percentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1182" xlink:to="label1182" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:label="element1183" />
        <label xlink:type="resource" xlink:label="label1183" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_en-US">Description containing the visit threshold for a low utilization payment adjustment.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1183" xlink:to="label1183" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:label="element1184" />
        <label xlink:type="resource" xlink:label="label1184" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_en-US">Low Utilization Payment Adjustment Number Of Visits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1184" xlink:to="label1184" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:label="element1185" />
        <label xlink:type="resource" xlink:label="label1185" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_en-US">Low utilization payment adjustment, maximum number of visits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1185" xlink:to="label1185" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MassproAndHospiceMember" xlink:label="element1186" />
        <label xlink:type="resource" xlink:label="label1186" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MassproAndHospiceMember_en-US">MassPro and Hospice [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1186" xlink:to="label1186" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MassproAndHospiceMember" xlink:label="element1187" />
        <label xlink:type="resource" xlink:label="label1187" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MassproAndHospiceMember_en-US">Masspro And Hospice [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1187" xlink:to="label1187" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MassproAndHospiceMember" xlink:label="element1188" />
        <label xlink:type="resource" xlink:label="label1188" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MassproAndHospiceMember_en-US">Masspro and Hospice</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1188" xlink:to="label1188" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:label="element1189" />
        <label xlink:type="resource" xlink:label="label1189" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1189" xlink:to="label1189" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:label="element1190" />
        <label xlink:type="resource" xlink:label="label1190" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_en-US">Maximum Days To Submit Final Bill From Date Request For Anticipated Payment Was Paid</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1190" xlink:to="label1190" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:label="element1191" />
        <label xlink:type="resource" xlink:label="label1191" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_en-US">Maximum days to submit final bill from the date the request for anticipated payment was paid</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1191" xlink:to="label1191" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode" xlink:label="element1192" />
        <label xlink:type="resource" xlink:label="label1192" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_en-US">Description containing the number of days from the start of the episode in which the final bill must be submitted to Medicare.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1192" xlink:to="label1192" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode" xlink:label="element1193" />
        <label xlink:type="resource" xlink:label="label1193" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_en-US">Maximum Days To Submit Final Bill From Start Of Episode</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1193" xlink:to="label1193" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode" xlink:label="element1194" />
        <label xlink:type="resource" xlink:label="label1194" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_en-US">Maximum days to submit final bill from the start of episode</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1194" xlink:to="label1194" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximusFederalServicesAndHospiceMember" xlink:label="element1195" />
        <label xlink:type="resource" xlink:label="label1195" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MaximusFederalServicesAndHospiceMember_en-US">MAXIMUS Federal Services and Hospice [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1195" xlink:to="label1195" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximusFederalServicesAndHospiceMember" xlink:label="element1196" />
        <label xlink:type="resource" xlink:label="label1196" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MaximusFederalServicesAndHospiceMember_en-US">Maximus Federal Services And Hospice [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1196" xlink:to="label1196" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximusFederalServicesAndHospiceMember" xlink:label="element1197" />
        <label xlink:type="resource" xlink:label="label1197" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MaximusFederalServicesAndHospiceMember_en-US">Maximus Federal Services And Hospice</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1197" xlink:to="label1197" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximusFederalServicesMember" xlink:label="element1198" />
        <label xlink:type="resource" xlink:label="label1198" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MaximusFederalServicesMember_en-US">MAXIMUS Federal Services [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1198" xlink:to="label1198" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximusFederalServicesMember" xlink:label="element1199" />
        <label xlink:type="resource" xlink:label="label1199" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MaximusFederalServicesMember_en-US">Maximus Federal Services [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1199" xlink:to="label1199" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximusFederalServicesMember" xlink:label="element1200" />
        <label xlink:type="resource" xlink:label="label1200" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MaximusFederalServicesMember_en-US">Maximus Federal Services</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1200" xlink:to="label1200" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MedicareAdministrativeContractorMacMember" xlink:label="element1201" />
        <label xlink:type="resource" xlink:label="label1201" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MedicareAdministrativeContractorMacMember_en-US">Medicare Administrative Contractor (MAC) [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1201" xlink:to="label1201" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MedicareAdministrativeContractorMacMember" xlink:label="element1202" />
        <label xlink:type="resource" xlink:label="label1202" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MedicareAdministrativeContractorMacMember_en-US">Medicare Administrative Contractor Mac [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1202" xlink:to="label1202" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MedicareAdministrativeContractorMacMember" xlink:label="element1203" />
        <label xlink:type="resource" xlink:label="label1203" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MedicareAdministrativeContractorMacMember_en-US">Medicare Administrative Contractor (MAC)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1203" xlink:to="label1203" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MinimumDaysAccountsReceivableOutstandingFullyReserved" xlink:label="element1204" />
        <label xlink:type="resource" xlink:label="label1204" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved_en-US">The number of days required before a patient accounts receivable must be outstanding to be fully reserved.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1204" xlink:to="label1204" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MinimumDaysAccountsReceivableOutstandingFullyReserved" xlink:label="element1205" />
        <label xlink:type="resource" xlink:label="label1205" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved_en-US">Minimum Days Accounts Receivable Outstanding Fully Reserved</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1205" xlink:to="label1205" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MinimumDaysAccountsReceivableOutstandingFullyReserved" xlink:label="element1206" />
        <label xlink:type="resource" xlink:label="label1206" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved_en-US">Minimum days for accounts receivable outstanding to be fully reserved</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1206" xlink:to="label1206" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:label="element1207" />
        <label xlink:type="resource" xlink:label="label1207" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MinimumPercentOwnershipForControllingInterestPercent_en-US">Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1207" xlink:to="label1207" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:label="element1208" />
        <label xlink:type="resource" xlink:label="label1208" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MinimumPercentOwnershipForControllingInterestPercent_en-US">Minimum Percent Ownership For Controlling Interest Percent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1208" xlink:to="label1208" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:label="element1209" />
        <label xlink:type="resource" xlink:label="label1209" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MinimumPercentOwnershipForControllingInterestPercent_en-US">Minimum percent ownership for controlling interest percent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1209" xlink:to="label1209" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockAndStockUnits" xlink:label="element1210" />
        <label xlink:type="resource" xlink:label="label1210" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NonVestedStockAndStockUnits_en-US">Non vested stock and stock units.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1210" xlink:to="label1210" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockAndStockUnits" xlink:label="element1211" />
        <label xlink:type="resource" xlink:label="label1211" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NonVestedStockAndStockUnits_en-US">Non Vested Stock And Stock Units</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1211" xlink:to="label1211" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockAndStockUnits" xlink:label="element1212" />
        <label xlink:type="resource" xlink:label="label1212" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NonVestedStockAndStockUnits_en-US">Non-vested stock and stock units</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1212" xlink:to="label1212" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersClosed" xlink:label="element1213" />
        <label xlink:type="resource" xlink:label="label1213" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfCareCentersClosed_en-US">Number of operating care centers that were closed during the period.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1213" xlink:to="label1213" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersClosed" xlink:label="element1214" />
        <label xlink:type="resource" xlink:label="label1214" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfCareCentersClosed_en-US">Number Of Care Centers Closed</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1214" xlink:to="label1214" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersClosed" xlink:label="element1215" />
        <label xlink:type="resource" xlink:label="label1215" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfCareCentersClosed_en-US">Number of care centers closed</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1215" xlink:to="label1215" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersConsolidated" xlink:label="element1216" />
        <label xlink:type="resource" xlink:label="label1216" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfCareCentersConsolidated_en-US">Number of operating care centers that were consolidated with care centers servicing the same market during the period.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1216" xlink:to="label1216" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersConsolidated" xlink:label="element1217" />
        <label xlink:type="resource" xlink:label="label1217" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfCareCentersConsolidated_en-US">Number Of Care Centers Consolidated</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1217" xlink:to="label1217" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersConsolidated" xlink:label="element1218" />
        <label xlink:type="resource" xlink:label="label1218" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfCareCentersConsolidated_en-US">Number of care centers consolidated</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1218" xlink:to="label1218" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersExited" xlink:label="element1219" />
        <label xlink:type="resource" xlink:label="label1219" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfCareCentersExited_en-US">Number of Care Centers that were exited during the period though closure, consolidation or discontinued start-up process.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1219" xlink:to="label1219" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersExited" xlink:label="element1220" />
        <label xlink:type="resource" xlink:label="label1220" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfCareCentersExited_en-US">Number Of Care Centers Exited</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1220" xlink:to="label1220" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersExited" xlink:label="element1221" />
        <label xlink:type="resource" xlink:label="label1221" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfCareCentersExited_en-US">Number of care centers exited</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1221" xlink:to="label1221" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfClaimsSubmittedBySubsidiary" xlink:label="element1222" />
        <label xlink:type="resource" xlink:label="label1222" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfClaimsSubmittedBySubsidiary_en-US">Number of claims submitted by subsidiary.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1222" xlink:to="label1222" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfClaimsSubmittedBySubsidiary" xlink:label="element1223" />
        <label xlink:type="resource" xlink:label="label1223" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfClaimsSubmittedBySubsidiary_en-US">Number Of Claims Submitted By Subsidiary</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1223" xlink:to="label1223" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfClaimsSubmittedBySubsidiary" xlink:label="element1224" />
        <label xlink:type="resource" xlink:label="label1224" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfClaimsSubmittedBySubsidiary_en-US">Number of claims submitted by subsidiary</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1224" xlink:to="label1224" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfRedeterminationDecisions" xlink:label="element1225" />
        <label xlink:type="resource" xlink:label="label1225" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfRedeterminationDecisions_en-US">Number of redetermination decisions.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1225" xlink:to="label1225" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfRedeterminationDecisions" xlink:label="element1226" />
        <label xlink:type="resource" xlink:label="label1226" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfRedeterminationDecisions_en-US">Number Of Redetermination Decisions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1226" xlink:to="label1226" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfRedeterminationDecisions" xlink:label="element1227" />
        <label xlink:type="resource" xlink:label="label1227" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfRedeterminationDecisions_en-US">Number of redetermination decisions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1227" xlink:to="label1227" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfPatientReceivablesOutstanding" xlink:label="element1228" />
        <label xlink:type="resource" xlink:label="label1228" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PercentageOfPatientReceivablesOutstanding_en-US">Percentage of patient receivables outstanding.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1228" xlink:to="label1228" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfPatientReceivablesOutstanding" xlink:label="element1229" />
        <label xlink:type="resource" xlink:label="label1229" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PercentageOfPatientReceivablesOutstanding_en-US">Percentage Of Patient Receivables Outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1229" xlink:to="label1229" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfPatientReceivablesOutstanding" xlink:label="element1230" />
        <label xlink:type="resource" xlink:label="label1230" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_PercentageOfPatientReceivablesOutstanding_en-US">Percentage of patient receivables outstanding</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1230" xlink:to="label1230" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:label="element1231" />
        <label xlink:type="resource" xlink:label="label1231" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PercentageOfTotalReimbursementOfOutlierPayment_en-US">Percentage at which total reimbursement is capped if cost of care is unusually costly.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1231" xlink:to="label1231" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:label="element1232" />
        <label xlink:type="resource" xlink:label="label1232" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PercentageOfTotalReimbursementOfOutlierPayment_en-US">Percentage Of Total Reimbursement Of Outlier Payment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1232" xlink:to="label1232" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:label="element1233" />
        <label xlink:type="resource" xlink:label="label1233" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_PercentageOfTotalReimbursementOfOutlierPayment_en-US">Percentage of total reimbursement of outlier payment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1233" xlink:to="label1233" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" xlink:label="element1234" />
        <label xlink:type="resource" xlink:label="label1234" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_en-US">Description containing the percentage of the entity's net patient accounts receivable that is derived from Medicare.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1234" xlink:to="label1234" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" xlink:label="element1235" />
        <label xlink:type="resource" xlink:label="label1235" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_en-US">Portion Of Patient Accounts Receivable Derived From Medicare</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1235" xlink:to="label1235" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" xlink:label="element1236" />
        <label xlink:type="resource" xlink:label="label1236" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_en-US">Portion of accounts receivable derived from Medicare</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1236" xlink:to="label1236" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:label="element1237" />
        <label xlink:type="resource" xlink:label="label1237" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ProfessionalLiabilityInsuranceRetentionLimit_en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1237" xlink:to="label1237" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:label="element1238" />
        <label xlink:type="resource" xlink:label="label1238" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ProfessionalLiabilityInsuranceRetentionLimit_en-US">Professional Liability Insurance Retention Limit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1238" xlink:to="label1238" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:label="element1239" />
        <label xlink:type="resource" xlink:label="label1239" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ProfessionalLiabilityInsuranceRetentionLimit_en-US">Professional liability insurance retention limit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1239" xlink:to="label1239" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProvisionForDoubtfulAccountsForContinuingOperations" xlink:label="element1240" />
        <label xlink:type="resource" xlink:label="label1240" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ProvisionForDoubtfulAccountsForContinuingOperations_en-US">Provision For Doubtful Accounts For Continuing Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1240" xlink:to="label1240" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProvisionForDoubtfulAccountsForContinuingOperations" xlink:label="element1241" />
        <label xlink:type="resource" xlink:label="label1241" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ProvisionForDoubtfulAccountsForContinuingOperations_en-US">Provision For Doubtful Accounts For Continuing Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1241" xlink:to="label1241" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProvisionForDoubtfulAccountsForContinuingOperations" xlink:label="element1242" />
        <label xlink:type="resource" xlink:label="label1242" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ProvisionForDoubtfulAccountsForContinuingOperations_en-US">Provision for doubtful accounts</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1242" xlink:to="label1242" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare" xlink:label="element1243" />
        <label xlink:type="resource" xlink:label="label1243" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_en-US">Description containing the percentage of estimated payment that is requested at the start of care for an initial episode of care.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1243" xlink:to="label1243" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare" xlink:label="element1244" />
        <label xlink:type="resource" xlink:label="label1244" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_en-US">Rate Of Request For Anticipated Payment Submitted For Initial Episode Of Care</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1244" xlink:to="label1244" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare" xlink:label="element1245" />
        <label xlink:type="resource" xlink:label="label1245" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_en-US">Rate of request for anticipated payment submitted for the initial episode of care</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1245" xlink:to="label1245" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:label="element1246" />
        <label xlink:type="resource" xlink:label="label1246" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_en-US">Description containing the percentage of estimated payment that is requested at the start of care for any subsequent episodes of care.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1246" xlink:to="label1246" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:label="element1247" />
        <label xlink:type="resource" xlink:label="label1247" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_en-US">Rate Of Request For Anticipated Payment Submitted For Subsequent Episodes Of Care</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1247" xlink:to="label1247" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:label="element1248" />
        <label xlink:type="resource" xlink:label="label1248" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_en-US">Rate of request for anticipated payment submitted for subsequent episodes of care</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1248" xlink:to="label1248" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:label="element1249" />
        <label xlink:type="resource" xlink:label="label1249" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_en-US">Recovery amount of the overpayment made to the subsidiary.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1249" xlink:to="label1249" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:label="element1250" />
        <label xlink:type="resource" xlink:label="label1250" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_en-US">Recovery Amount Of Overpayment Made To Subsidiary</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1250" xlink:to="label1250" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:label="element1251" />
        <label xlink:type="resource" xlink:label="label1251" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_en-US">Recovery amount of the overpayment made to the subsidiary</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1251" xlink:to="label1251" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RelatedPartyMember" xlink:label="element1252" />
        <label xlink:type="resource" xlink:label="label1252" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_RelatedPartyMember_en-US">Related Party [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1252" xlink:to="label1252" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RelatedPartyMember" xlink:label="element1253" />
        <label xlink:type="resource" xlink:label="label1253" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_RelatedPartyMember_en-US">Related Party [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1253" xlink:to="label1253" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RelatedPartyMember" xlink:label="element1254" />
        <label xlink:type="resource" xlink:label="label1254" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_RelatedPartyMember_en-US">Large physician group</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1254" xlink:to="label1254" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RevenueAdjustmentToMedicareRevenue" xlink:label="element1255" />
        <label xlink:type="resource" xlink:label="label1255" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_RevenueAdjustmentToMedicareRevenue_en-US">Description of the provisions that reduce the amount of Medicare revenue recognized by the entity.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1255" xlink:to="label1255" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RevenueAdjustmentToMedicareRevenue" xlink:label="element1256" />
        <label xlink:type="resource" xlink:label="label1256" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_RevenueAdjustmentToMedicareRevenue_en-US">Revenue Adjustment To Medicare Revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1256" xlink:to="label1256" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RevenueAdjustmentToMedicareRevenue" xlink:label="element1257" />
        <label xlink:type="resource" xlink:label="label1257" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_RevenueAdjustmentToMedicareRevenue_en-US">Revenue adjustment to Medicare revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1257" xlink:to="label1257" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RevolvingCreditFacilitiesMember" xlink:label="element1258" />
        <label xlink:type="resource" xlink:label="label1258" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_RevolvingCreditFacilitiesMember_en-US">Revolving Credit Facilities [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1258" xlink:to="label1258" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RevolvingCreditFacilitiesMember" xlink:label="element1259" />
        <label xlink:type="resource" xlink:label="label1259" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_RevolvingCreditFacilitiesMember_en-US">Revolving Credit Facilities [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1259" xlink:to="label1259" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RevolvingCreditFacilitiesMember" xlink:label="element1260" />
        <label xlink:type="resource" xlink:label="label1260" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_RevolvingCreditFacilitiesMember_en-US">Revolving Credit Facilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1260" xlink:to="label1260" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondThresholdOfServicesRequired" xlink:label="element1261" />
        <label xlink:type="resource" xlink:label="label1261" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SecondThresholdOfServicesRequired_en-US">Description containing the number of visits related to the second threshold of therapy services required.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1261" xlink:to="label1261" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondThresholdOfServicesRequired" xlink:label="element1262" />
        <label xlink:type="resource" xlink:label="label1262" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SecondThresholdOfServicesRequired_en-US">Second Threshold Of Services Required</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1262" xlink:to="label1262" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondThresholdOfServicesRequired" xlink:label="element1263" />
        <label xlink:type="resource" xlink:label="label1263" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_SecondThresholdOfServicesRequired_en-US">Second threshold of services required, visits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1263" xlink:to="label1263" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesBNotesMember" xlink:label="element1264" />
        <label xlink:type="resource" xlink:label="label1264" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SeriesBNotesMember_en-US">Series B Notes [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1264" xlink:to="label1264" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesBNotesMember" xlink:label="element1265" />
        <label xlink:type="resource" xlink:label="label1265" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SeriesBNotesMember_en-US">Series B Notes [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1265" xlink:to="label1265" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesBNotesMember" xlink:label="element1266" />
        <label xlink:type="resource" xlink:label="label1266" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_SeriesBNotesMember_en-US">Series B Notes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1266" xlink:to="label1266" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesCNotesMember" xlink:label="element1267" />
        <label xlink:type="resource" xlink:label="label1267" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SeriesCNotesMember_en-US">Series C Notes [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1267" xlink:to="label1267" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesCNotesMember" xlink:label="element1268" />
        <label xlink:type="resource" xlink:label="label1268" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SeriesCNotesMember_en-US">Series C Notes [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1268" xlink:to="label1268" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesCNotesMember" xlink:label="element1269" />
        <label xlink:type="resource" xlink:label="label1269" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_SeriesCNotesMember_en-US">Series C Notes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1269" xlink:to="label1269" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesANotesMember" xlink:label="element1270" />
        <label xlink:type="resource" xlink:label="label1270" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SeriesANotesMember_en-US">Series A Notes [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1270" xlink:to="label1270" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesANotesMember" xlink:label="element1271" />
        <label xlink:type="resource" xlink:label="label1271" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SeriesANotesMember_en-US">Series A Notes [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1271" xlink:to="label1271" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesANotesMember" xlink:label="element1272" />
        <label xlink:type="resource" xlink:label="label1272" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_SeriesANotesMember_en-US">Series A Notes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1272" xlink:to="label1272" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TermLoanMember" xlink:label="element1273" />
        <label xlink:type="resource" xlink:label="label1273" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_TermLoanMember_en-US">Term Loan [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1273" xlink:to="label1273" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TermLoanMember" xlink:label="element1274" />
        <label xlink:type="resource" xlink:label="label1274" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TermLoanMember_en-US">Term Loan [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1274" xlink:to="label1274" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TermLoanMember" xlink:label="element1275" />
        <label xlink:type="resource" xlink:label="label1275" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_TermLoanMember_en-US">Term Loan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1275" xlink:to="label1275" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ThirdThresholdOfTherapyServicesRequired" xlink:label="element1276" />
        <label xlink:type="resource" xlink:label="label1276" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ThirdThresholdOfTherapyServicesRequired_en-US">Description containing the number of visits related to the third threshold of therapy services required.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1276" xlink:to="label1276" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ThirdThresholdOfTherapyServicesRequired" xlink:label="element1277" />
        <label xlink:type="resource" xlink:label="label1277" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ThirdThresholdOfTherapyServicesRequired_en-US">Third Threshold Of Therapy Services Required</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1277" xlink:to="label1277" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ThirdThresholdOfTherapyServicesRequired" xlink:label="element1278" />
        <label xlink:type="resource" xlink:label="label1278" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ThirdThresholdOfTherapyServicesRequired_en-US">Third threshold of therapy services required, visits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1278" xlink:to="label1278" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TotalLeverageRatio" xlink:label="element1279" />
        <label xlink:type="resource" xlink:label="label1279" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_TotalLeverageRatio_en-US">Ratio of debt to earnings before interest, taxes, depreciation and amortization.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1279" xlink:to="label1279" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TotalLeverageRatio" xlink:label="element1280" />
        <label xlink:type="resource" xlink:label="label1280" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TotalLeverageRatio_en-US">Total Leverage Ratio</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1280" xlink:to="label1280" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TotalLeverageRatio" xlink:label="element1281" />
        <label xlink:type="resource" xlink:label="label1281" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_TotalLeverageRatio_en-US">Total leverage ratio</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1281" xlink:to="label1281" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WorkersCompensationInsuranceRetentionLimit" xlink:label="element1282" />
        <label xlink:type="resource" xlink:label="label1282" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_WorkersCompensationInsuranceRetentionLimit_en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1282" xlink:to="label1282" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WorkersCompensationInsuranceRetentionLimit" xlink:label="element1283" />
        <label xlink:type="resource" xlink:label="label1283" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_WorkersCompensationInsuranceRetentionLimit_en-US">Workers Compensation Insurance Retention Limit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1283" xlink:to="label1283" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WorkersCompensationInsuranceRetentionLimit" xlink:label="element1284" />
        <label xlink:type="resource" xlink:label="label1284" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_WorkersCompensationInsuranceRetentionLimit_en-US">Workers' compensation insurance retention limit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1284" xlink:to="label1284" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfEmployeesInWageHourLitigationMember" xlink:label="element1285" />
        <label xlink:type="resource" xlink:label="label1285" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfEmployeesInWageHourLitigationMember_en-US">Number Of Employees In Wage Hour Litigation [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1285" xlink:to="label1285" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximusFederalServicesAndHomeHealthMember" xlink:label="element1286" />
        <label xlink:type="resource" xlink:label="label1286" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MaximusFederalServicesAndHomeHealthMember_en-US">Maximus Federal Services And Home Health [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1286" xlink:to="label1286" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximusFederalServicesAndHomeHealthMember" xlink:label="element1287" />
        <label xlink:type="resource" xlink:label="label1287" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MaximusFederalServicesAndHomeHealthMember_en-US">Maximus Federal Services And Home Health</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1287" xlink:to="label1287" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximusFederalServicesAndHomeHealthMember" xlink:label="element1288" />
        <label xlink:type="resource" xlink:label="label1288" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MaximusFederalServicesAndHomeHealthMember_en-US">Maximus Federal Services And Home Health</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1288" xlink:to="label1288" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingCareCenters" xlink:label="element1289" />
        <label xlink:type="resource" xlink:label="label1289" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OperatingCareCenters_en-US">Description containing the number of care centers owned by the entity as of the balance sheet date.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1289" xlink:to="label1289" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingCareCenters" xlink:label="element1290" />
        <label xlink:type="resource" xlink:label="label1290" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OperatingCareCenters_en-US">Operating Care Centers</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1290" xlink:to="label1290" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingCareCenters" xlink:label="element1291" />
        <label xlink:type="resource" xlink:label="label1291" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_OperatingCareCenters_en-US">Operating Care Centers</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1291" xlink:to="label1291" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="element1292" />
        <label xlink:type="resource" xlink:label="label1292" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OrganizationAndNatureOfOperationsTable_en-US">Organization And Nature Of Operations [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1292" xlink:to="label1292" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceInpatientMember" xlink:label="element1293" />
        <label xlink:type="resource" xlink:label="label1293" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_HospiceInpatientMember_en-US">Hospice Inpatient [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1293" xlink:to="label1293" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="element1294" />
        <label xlink:type="resource" xlink:label="label1294" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OrganizationAndNatureOfOperationsLineItems_en-US">Organization And Nature Of Operations [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1294" xlink:to="label1294" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateAxis" xlink:label="element1295" />
        <label xlink:type="resource" xlink:label="label1295" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_StateAxis_en-US">State [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1295" xlink:to="label1295" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="element1296" />
        <label xlink:type="resource" xlink:label="label1296" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_StateDomain_en-US">State [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1296" xlink:to="label1296" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IllinoisMember" xlink:label="element1297" />
        <label xlink:type="resource" xlink:label="label1297" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IllinoisMember_en-US">Illinois [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1297" xlink:to="label1297" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ConnecticutMember" xlink:label="element1298" />
        <label xlink:type="resource" xlink:label="label1298" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ConnecticutMember_en-US">Connecticut [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1298" xlink:to="label1298" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OhioMember" xlink:label="element1299" />
        <label xlink:type="resource" xlink:label="label1299" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OhioMember_en-US">Ohio [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1299" xlink:to="label1299" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SouthCarolinaMember" xlink:label="element1300" />
        <label xlink:type="resource" xlink:label="label1300" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SouthCarolinaMember_en-US">South Carolina [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1300" xlink:to="label1300" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MassachusettsMember" xlink:label="element1301" />
        <label xlink:type="resource" xlink:label="label1301" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MassachusettsMember_en-US">Massachusetts [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1301" xlink:to="label1301" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MassachusettsMember" xlink:label="element1302" />
        <label xlink:type="resource" xlink:label="label1302" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MassachusettsMember_en-US">Massachusetts [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1302" xlink:to="label1302" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfBeneficiaries" xlink:label="element1303" />
        <label xlink:type="resource" xlink:label="label1303" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfBeneficiaries_en-US">Number of beneficiaries</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1303" xlink:to="label1303" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfBeneficiaries" xlink:label="element1304" />
        <label xlink:type="resource" xlink:label="label1304" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfBeneficiaries_en-US">Number of beneficiaries who received services</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1304" xlink:to="label1304" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FinalLitigationSettlmentMember" xlink:label="element1305" />
        <label xlink:type="resource" xlink:label="label1305" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FinalLitigationSettlmentMember_en-US">Final Litigation Settlment [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1305" xlink:to="label1305" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FinalLitigationSettlmentMember" xlink:label="element1306" />
        <label xlink:type="resource" xlink:label="label1306" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FinalLitigationSettlmentMember_en-US">Amount of litigation settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1306" xlink:to="label1306" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MedicareRevenue" xlink:label="element1307" />
        <label xlink:type="resource" xlink:label="label1307" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MedicareRevenue_en-US">Medicare Revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1307" xlink:to="label1307" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MedicareRevenue" xlink:label="element1308" />
        <label xlink:type="resource" xlink:label="label1308" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MedicareRevenue_en-US">Amount of net service revenue derived from Medicare</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1308" xlink:to="label1308" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ExtrapolatedMember" xlink:label="element1309" />
        <label xlink:type="resource" xlink:label="label1309" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ExtrapolatedMember_en-US">Extrapolated [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1309" xlink:to="label1309" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ExtrapolatedMember" xlink:label="element1310" />
        <label xlink:type="resource" xlink:label="label1310" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ExtrapolatedMember_en-US">Extrapolated [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1310" xlink:to="label1310" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ExtrapolatedMember" xlink:label="element1311" />
        <label xlink:type="resource" xlink:label="label1311" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ExtrapolatedMember_en-US">Extrapolated</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1311" xlink:to="label1311" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:label="element1312" />
        <label xlink:type="resource" xlink:label="label1312" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MaximumPercentOwnershipForEquityMethodPercent_en-US">Maximum Percent Ownership For Equity Method Percent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1312" xlink:to="label1312" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:label="element1313" />
        <label xlink:type="resource" xlink:label="label1313" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MaximumPercentOwnershipForEquityMethodPercent_en-US">Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1313" xlink:to="label1313" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumPercentOwnershipForCostMethodPercent" xlink:label="element1314" />
        <label xlink:type="resource" xlink:label="label1314" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MaximumPercentOwnershipForCostMethodPercent_en-US">Maximum Percent Ownership For Cost Method Percent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1314" xlink:to="label1314" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumPercentOwnershipForCostMethodPercent" xlink:label="element1315" />
        <label xlink:type="resource" xlink:label="label1315" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MaximumPercentOwnershipForCostMethodPercent_en-US">Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1315" xlink:to="label1315" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersAvailableForSale" xlink:label="element1316" />
        <label xlink:type="resource" xlink:label="label1316" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfCareCentersAvailableForSale_en-US">Number Of Care Centers Available For Sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1316" xlink:to="label1316" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersAvailableForSale" xlink:label="element1317" />
        <label xlink:type="resource" xlink:label="label1317" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfCareCentersAvailableForSale_en-US">Number of care centers available for sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1317" xlink:to="label1317" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersAvailableForSale" xlink:label="element1318" />
        <label xlink:type="resource" xlink:label="label1318" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfCareCentersAvailableForSale_en-US">Number of care centers that were classified as available for sale during the period.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1318" xlink:to="label1318" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersSold" xlink:label="element1319" />
        <label xlink:type="resource" xlink:label="label1319" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfCareCentersSold_en-US">Number Of Care Centers Sold</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1319" xlink:to="label1319" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersSold" xlink:label="element1320" />
        <label xlink:type="resource" xlink:label="label1320" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfCareCentersSold_en-US">Number of care centers sold</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1320" xlink:to="label1320" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersSold" xlink:label="element1321" />
        <label xlink:type="resource" xlink:label="label1321" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfCareCentersSold_en-US">Number of care centers sold during the period.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1321" xlink:to="label1321" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersIncludedInDivestiturePlan" xlink:label="element1322" />
        <label xlink:type="resource" xlink:label="label1322" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfCareCentersIncludedInDivestiturePlan_en-US">Number of Care Centers Included in Divestiture Plan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1322" xlink:to="label1322" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersIncludedInDivestiturePlan" xlink:label="element1323" />
        <label xlink:type="resource" xlink:label="label1323" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfCareCentersIncludedInDivestiturePlan_en-US">Number of care centers included in divestiture plan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1323" xlink:to="label1323" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersIncludedInDivestiturePlan" xlink:label="element1324" />
        <label xlink:type="resource" xlink:label="label1324" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfCareCentersIncludedInDivestiturePlan_en-US">The number of care centers that were included in the divestiture plan during the period.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1324" xlink:to="label1324" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FederalDerivativeActionsMember" xlink:label="element1325" />
        <label xlink:type="resource" xlink:label="label1325" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FederalDerivativeActionsMember_en-US">Federal Derivative Actions [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1325" xlink:to="label1325" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FederalDerivativeActionsMember" xlink:label="element1326" />
        <label xlink:type="resource" xlink:label="label1326" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FederalDerivativeActionsMember_en-US">Federal Derivative Actions [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1326" xlink:to="label1326" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FederalDerivativeActionsMember" xlink:label="element1327" />
        <label xlink:type="resource" xlink:label="label1327" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_FederalDerivativeActionsMember_en-US">Federal Derivative Actions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1327" xlink:to="label1327" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityEffectiveyBorrowingCapacity" xlink:label="element1328" />
        <label xlink:type="resource" xlink:label="label1328" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_LineOfCreditFacilityEffectiveyBorrowingCapacity_en-US">Line Of Credit Facility Effectivey Borrowing Capacity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1328" xlink:to="label1328" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityEffectiveyBorrowingCapacity" xlink:label="element1329" />
        <label xlink:type="resource" xlink:label="label1329" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_LineOfCreditFacilityEffectiveyBorrowingCapacity_en-US">Effective availability under the revolving credit facility</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1329" xlink:to="label1329" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityEffectiveyBorrowingCapacity" xlink:label="element1330" />
        <label xlink:type="resource" xlink:label="label1330" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_LineOfCreditFacilityEffectiveyBorrowingCapacity_en-US">Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed less the amount of borrowings outstanding.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1330" xlink:to="label1330" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityDebtRestrictions" xlink:label="element1331" />
        <label xlink:type="resource" xlink:label="label1331" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_LineOfCreditFacilityDebtRestrictions_en-US">Line of Credit Facility Debt Restrictions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1331" xlink:to="label1331" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityDebtRestrictions" xlink:label="element1332" />
        <label xlink:type="resource" xlink:label="label1332" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_LineOfCreditFacilityDebtRestrictions_en-US">Line of Credit Facility Debt Restrictions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1332" xlink:to="label1332" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityDebtRestrictions" xlink:label="element1333" />
        <label xlink:type="resource" xlink:label="label1333" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_LineOfCreditFacilityDebtRestrictions_en-US">The amount by which overall debt must be less than earnings before interest, taxes, depreciation and amortization.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1333" xlink:to="label1333" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredDebtIssuanceCostsWrittenOff" xlink:label="element1334" />
        <label xlink:type="resource" xlink:label="label1334" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DeferredDebtIssuanceCostsWrittenOff_en-US">Deferred Debt Issuance Costs Written Off</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1334" xlink:to="label1334" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredDebtIssuanceCostsWrittenOff" xlink:label="element1335" />
        <label xlink:type="resource" xlink:label="label1335" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DeferredDebtIssuanceCostsWrittenOff_en-US">The amount of deferred debt issuance costs written off during the period.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1335" xlink:to="label1335" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredDebtIssuanceCostsWrittenOff" xlink:label="element1336" />
        <label xlink:type="resource" xlink:label="label1336" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DeferredDebtIssuanceCostsWrittenOff_en-US">Write off of deferred debt issuance costs/debt discount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1336" xlink:to="label1336" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringCostsAxis" xlink:label="element1337" />
        <label xlink:type="resource" xlink:label="label1337" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OtherRestructuringCostsAxis_en-US">Other Restructuring Costs [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1337" xlink:to="label1337" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringDomain" xlink:label="element1338" />
        <label xlink:type="resource" xlink:label="label1338" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OtherRestructuringDomain_en-US">Other Restructuring [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1338" xlink:to="label1338" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringDomain" xlink:label="element1339" />
        <label xlink:type="resource" xlink:label="label1339" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OtherRestructuringDomain_en-US">Other Restructuring [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1339" xlink:to="label1339" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TypeOfBusinessSoldAxis" xlink:label="element1340" />
        <label xlink:type="resource" xlink:label="label1340" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TypeOfBusinessSoldAxis_en-US">Type of Business Sold [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1340" xlink:to="label1340" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessSoldDomain" xlink:label="element1341" />
        <label xlink:type="resource" xlink:label="label1341" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_BusinessSoldDomain_en-US">Business Sold [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1341" xlink:to="label1341" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AlaskaAndWashingtonCareCentersMember" xlink:label="element1342" />
        <label xlink:type="resource" xlink:label="label1342" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AlaskaAndWashingtonCareCentersMember_en-US">Alaska and Washington Care Centers [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1342" xlink:to="label1342" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnconsolidatedJointVentureMember" xlink:label="element1343" />
        <label xlink:type="resource" xlink:label="label1343" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_UnconsolidatedJointVentureMember_en-US">Unconsolidated Joint Venture [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1343" xlink:to="label1343" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnfavorableMember" xlink:label="element1344" />
        <label xlink:type="resource" xlink:label="label1344" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_UnfavorableMember_en-US">Unfavorable [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1344" xlink:to="label1344" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumLeverageRatio" xlink:label="element1345" />
        <label xlink:type="resource" xlink:label="label1345" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MaximumLeverageRatio_en-US">Maximum Leverage Ratio</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1345" xlink:to="label1345" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumLeverageRatio" xlink:label="element1346" />
        <label xlink:type="resource" xlink:label="label1346" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MaximumLeverageRatio_en-US">Maximum leverage ratio</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1346" xlink:to="label1346" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumLeverageRatio" xlink:label="element1347" />
        <label xlink:type="resource" xlink:label="label1347" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MaximumLeverageRatio_en-US">The maximum total leverage ratio allowed as defined by the Company's Credit Agreement.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1347" xlink:to="label1347" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MinimumFixedChargeCoverageRatio" xlink:label="element1348" />
        <label xlink:type="resource" xlink:label="label1348" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MinimumFixedChargeCoverageRatio_en-US">Minimum Fixed Charge Coverage Ratio</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1348" xlink:to="label1348" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MinimumFixedChargeCoverageRatio" xlink:label="element1349" />
        <label xlink:type="resource" xlink:label="label1349" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MinimumFixedChargeCoverageRatio_en-US">The minumum fixed charge ratio allowed as defined by the Company's Credit Agreement.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1349" xlink:to="label1349" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MinimumFixedChargeCoverageRatio" xlink:label="element1350" />
        <label xlink:type="resource" xlink:label="label1350" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MinimumFixedChargeCoverageRatio_en-US">Minimum fixed charge coverage ratio</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1350" xlink:to="label1350" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WeightedAverageInterestRate" xlink:label="element1351" />
        <label xlink:type="resource" xlink:label="label1351" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_WeightedAverageInterestRate_en-US">Weighted Average Interest Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1351" xlink:to="label1351" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WeightedAverageInterestRate" xlink:label="element1352" />
        <label xlink:type="resource" xlink:label="label1352" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_WeightedAverageInterestRate_en-US">Weighted-average interest rate for five year Term Loan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1352" xlink:to="label1352" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersRemovedFromAvailableForSale" xlink:label="element1353" />
        <label xlink:type="resource" xlink:label="label1353" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfCareCentersRemovedFromAvailableForSale_en-US">Number Of Care Centers Removed From Available For Sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1353" xlink:to="label1353" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersRemovedFromAvailableForSale" xlink:label="element1354" />
        <label xlink:type="resource" xlink:label="label1354" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfCareCentersRemovedFromAvailableForSale_en-US">Number of care centers removed from available for sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1354" xlink:to="label1354" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersRemovedFromAvailableForSale" xlink:label="element1355" />
        <label xlink:type="resource" xlink:label="label1355" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfCareCentersRemovedFromAvailableForSale_en-US">Number of care centers that were removed from available for sale classification during the period.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1355" xlink:to="label1355" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="element1356" />
        <label xlink:type="resource" xlink:label="label1356" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_en-US">Income Statement Disclosures For Care Centers Removed From Available For Sale [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1356" xlink:to="label1356" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="element1357" />
        <label xlink:type="resource" xlink:label="label1357" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_en-US">Income Statement Disclosures For Care Centers Removed From Available For Sale [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1357" xlink:to="label1357" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NetRevenueForCareCentersRemovedFromAvailableForSale" xlink:label="element1358" />
        <label xlink:type="resource" xlink:label="label1358" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NetRevenueForCareCentersRemovedFromAvailableForSale_en-US">Net Revenue For Care Centers Removed From Available For Sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1358" xlink:to="label1358" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NetRevenueForCareCentersRemovedFromAvailableForSale" xlink:label="element1359" />
        <label xlink:type="resource" xlink:label="label1359" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NetRevenueForCareCentersRemovedFromAvailableForSale_en-US">Net Revenue For Care Centers Removed From Available For Sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1359" xlink:to="label1359" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NetRevenueForCareCentersRemovedFromAvailableForSale" xlink:label="element1360" />
        <label xlink:type="resource" xlink:label="label1360" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NetRevenueForCareCentersRemovedFromAvailableForSale_en-US">Net revenues</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1360" xlink:to="label1360" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale" xlink:label="element1361" />
        <label xlink:type="resource" xlink:label="label1361" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale_en-US">Income (Loss) Before Income Taxes For Care Centers Removed From Available For Sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1361" xlink:to="label1361" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale" xlink:label="element1362" />
        <label xlink:type="resource" xlink:label="label1362" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale_en-US">Income (Loss) Before Income Taxes For Care Centers Removed From Available For Sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1362" xlink:to="label1362" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale" xlink:label="element1363" />
        <label xlink:type="resource" xlink:label="label1363" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale_en-US">Income before income taxes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1363" xlink:to="label1363" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale" xlink:label="element1364" />
        <label xlink:type="resource" xlink:label="label1364" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale_en-US">Income Tax Benefit (Expense) For Care Centers Removed From Available For Sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1364" xlink:to="label1364" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale" xlink:label="element1365" />
        <label xlink:type="resource" xlink:label="label1365" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale_en-US">Income Tax Benefit (Expense) For Care Centers Removed From Available For Sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1365" xlink:to="label1365" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale" xlink:label="element1366" />
        <label xlink:type="resource" xlink:label="label1366" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale_en-US">Income tax expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1366" xlink:to="label1366" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale" xlink:label="element1367" />
        <label xlink:type="resource" xlink:label="label1367" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_en-US">Income From Continuing Operations For Care Centers Removed From Available For Sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1367" xlink:to="label1367" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale" xlink:label="element1368" />
        <label xlink:type="resource" xlink:label="label1368" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_en-US">Income From Continuing Operations For Care Centers Removed From Available For Sale</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1368" xlink:to="label1368" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale" xlink:label="element1369" />
        <label xlink:type="resource" xlink:label="label1369" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_en-US">Income from continuing operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1369" xlink:to="label1369" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale" xlink:label="element1370" />
        <label xlink:type="resource" xlink:label="label1370" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_en-US">Income from continuing operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1370" xlink:to="label1370" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InsuranceProceedsForReimbursementOfLegalFees" xlink:label="element1371" />
        <label xlink:type="resource" xlink:label="label1371" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_InsuranceProceedsForReimbursementOfLegalFees_en-US">Insurance Proceeds For Reimbursement Of Legal Fees</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1371" xlink:to="label1371" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InsuranceProceedsForReimbursementOfLegalFees" xlink:label="element1372" />
        <label xlink:type="resource" xlink:label="label1372" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_InsuranceProceedsForReimbursementOfLegalFees_en-US">Insurance proceeds for reimbursement of legal fees</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1372" xlink:to="label1372" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InsuranceProceedsForReimbursementOfLegalFees" xlink:label="element1373" />
        <label xlink:type="resource" xlink:label="label1373" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_InsuranceProceedsForReimbursementOfLegalFees_en-US">Proceeds received for insurance carrier for the reimbursement of legal fees related to current litigation activities.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1373" xlink:to="label1373" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement" xlink:label="element1374" />
        <label xlink:type="resource" xlink:label="label1374" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement_en-US">Accrued Charge Related To U.S. Department Of Justice Settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1374" xlink:to="label1374" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement" xlink:label="element1375" />
        <label xlink:type="resource" xlink:label="label1375" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement_en-US">Accrued charge related to U.S. Department of Justice settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1375" xlink:to="label1375" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement" xlink:label="element1376" />
        <label xlink:type="resource" xlink:label="label1376" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement_en-US">Accrued charge related to U.S. Department of Justice settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1376" xlink:to="label1376" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UsDepartmentOfJusticeSettlement" xlink:label="element1377" />
        <label xlink:type="resource" xlink:label="label1377" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_UsDepartmentOfJusticeSettlement_en-US">U.S. Department Of Justice Settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1377" xlink:to="label1377" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UsDepartmentOfJusticeSettlement" xlink:label="element1378" />
        <label xlink:type="resource" xlink:label="label1378" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_UsDepartmentOfJusticeSettlement_en-US">Charge related to U.S. Department of Justice setlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1378" xlink:to="label1378" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UsDepartmentOfJusticeSettlement" xlink:label="element1379" />
        <label xlink:type="resource" xlink:label="label1379" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_UsDepartmentOfJusticeSettlement_en-US">U.S. Department of Justice settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1379" xlink:to="label1379" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesLineItems" xlink:label="element1380" />
        <label xlink:type="resource" xlink:label="label1380" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IncomeTaxesLineItems_en-US">Income Taxes [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1380" xlink:to="label1380" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesLineItems" xlink:label="element1381" />
        <label xlink:type="resource" xlink:label="label1381" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_IncomeTaxesLineItems_en-US">Income Taxes Line Items</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1381" xlink:to="label1381" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesTable" xlink:label="element1382" />
        <label xlink:type="resource" xlink:label="label1382" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IncomeTaxesTable_en-US">Income Taxes [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1382" xlink:to="label1382" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesAxis" xlink:label="element1383" />
        <label xlink:type="resource" xlink:label="label1383" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IncomeTaxesAxis_en-US">Income Taxes [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1383" xlink:to="label1383" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesDomain" xlink:label="element1384" />
        <label xlink:type="resource" xlink:label="label1384" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IncomeTaxesDomain_en-US">Income Taxes [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1384" xlink:to="label1384" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UsDepartmentOfJusticeSettlementMember" xlink:label="element1385" />
        <label xlink:type="resource" xlink:label="label1385" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_UsDepartmentOfJusticeSettlementMember_en-US">U.S. Department of Justice Settlement [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1385" xlink:to="label1385" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UsDepartmentOfJusticeSettlementMember" xlink:label="element1386" />
        <label xlink:type="resource" xlink:label="label1386" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_UsDepartmentOfJusticeSettlementMember_en-US">U.S. Department of Justice Settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1386" xlink:to="label1386" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InterestRateOnUsDepartmentOfJusticeSettlement" xlink:label="element1387" />
        <label xlink:type="resource" xlink:label="label1387" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_InterestRateOnUsDepartmentOfJusticeSettlement_en-US">Interest Rate On U.S. Department of Justice Settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1387" xlink:to="label1387" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InterestRateOnUsDepartmentOfJusticeSettlement" xlink:label="element1388" />
        <label xlink:type="resource" xlink:label="label1388" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_InterestRateOnUsDepartmentOfJusticeSettlement_en-US">Interest rate on U.S. Department of Justice Settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1388" xlink:to="label1388" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PaymentUponExecutionOfUsDepartmentOfJusticeSettlement" xlink:label="element1389" />
        <label xlink:type="resource" xlink:label="label1389" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PaymentUponExecutionOfUsDepartmentOfJusticeSettlement_en-US">Payment Upon Execution Of U.S. Department Of Justice Settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1389" xlink:to="label1389" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PaymentUponExecutionOfUsDepartmentOfJusticeSettlement" xlink:label="element1390" />
        <label xlink:type="resource" xlink:label="label1390" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PaymentUponExecutionOfUsDepartmentOfJusticeSettlement_en-US">Payment upon execution of U.S. Department of Justice settlement documents.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1390" xlink:to="label1390" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FinalPaymentOfUsDepartmentOfJusticeSettlement" xlink:label="element1391" />
        <label xlink:type="resource" xlink:label="label1391" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FinalPaymentOfUsDepartmentOfJusticeSettlement_en-US">Final Payment Of U.S. Department Of Justice Settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1391" xlink:to="label1391" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FinalPaymentOfUsDepartmentOfJusticeSettlement" xlink:label="element1392" />
        <label xlink:type="resource" xlink:label="label1392" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FinalPaymentOfUsDepartmentOfJusticeSettlement_en-US">Final payment of U.S. Department of Justice settlement.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1392" xlink:to="label1392" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement" xlink:label="element1393" />
        <label xlink:type="resource" xlink:label="label1393" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement_en-US">Period Of Time For Final Payment Of U.S. Department of Justice Settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1393" xlink:to="label1393" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement" xlink:label="element1394" />
        <label xlink:type="resource" xlink:label="label1394" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement_en-US">Period of time final payment of U.S. Department of Justice payment is due after initial payment.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1394" xlink:to="label1394" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OigSelfDisclosureMember" xlink:label="element1395" />
        <label xlink:type="resource" xlink:label="label1395" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OigSelfDisclosureMember_en-US">OIG Self-Disclosure [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1395" xlink:to="label1395" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OigSelfDisclosureMember" xlink:label="element1396" />
        <label xlink:type="resource" xlink:label="label1396" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OigSelfDisclosureMember_en-US">OIG Self-Disclosure matters</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1396" xlink:to="label1396" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ErisaClassActionLawsuitMember" xlink:label="element1397" />
        <label xlink:type="resource" xlink:label="label1397" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ErisaClassActionLawsuitMember_en-US">ERISA Class Action Lawsuit [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1397" xlink:to="label1397" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ErisaClassActionLawsuitMember" xlink:label="element1398" />
        <label xlink:type="resource" xlink:label="label1398" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ErisaClassActionLawsuitMember_en-US">ERISA Class Action Lawsuit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1398" xlink:to="label1398" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable" xlink:label="element1399" />
        <label xlink:type="resource" xlink:label="label1399" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_en-US">Income Statement Disclosures For Care Centers Removed From Available For Sale [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1399" xlink:to="label1399" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable" xlink:label="element1400" />
        <label xlink:type="resource" xlink:label="label1400" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_en-US">Income Statement Disclosures For Care Centers Removed From Available For Sale [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1400" xlink:to="label1400" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareCenterStatusAxis" xlink:label="element1401" />
        <label xlink:type="resource" xlink:label="label1401" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CareCenterStatusAxis_en-US">Care Center Status [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1401" xlink:to="label1401" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareCenterStatusAxis" xlink:label="element1402" />
        <label xlink:type="resource" xlink:label="label1402" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CareCenterStatusAxis_en-US">Care Center Status [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1402" xlink:to="label1402" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareCenterStatusDomain" xlink:label="element1403" />
        <label xlink:type="resource" xlink:label="label1403" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CareCenterStatusDomain_en-US">Care Center Status [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1403" xlink:to="label1403" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareCenterStatusDomain" xlink:label="element1404" />
        <label xlink:type="resource" xlink:label="label1404" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CareCenterStatusDomain_en-US">Care Center Status [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1404" xlink:to="label1404" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareCentersRemovedFromAvailableForSaleMember" xlink:label="element1405" />
        <label xlink:type="resource" xlink:label="label1405" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CareCentersRemovedFromAvailableForSaleMember_en-US">Care Centers Removed From Available For Sale [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1405" xlink:to="label1405" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareCentersRemovedFromAvailableForSaleMember" xlink:label="element1406" />
        <label xlink:type="resource" xlink:label="label1406" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CareCentersRemovedFromAvailableForSaleMember_en-US">Care Centers Removed From Available For Sale [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1406" xlink:to="label1406" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="element1407" />
        <label xlink:type="resource" xlink:label="label1407" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DetailsOfCertainBalanceSheetAccountsAbstract_en-US">Details Of Certain Balance Sheet Accounts [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1407" xlink:to="label1407" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" xlink:label="element1408" />
        <label xlink:type="resource" xlink:label="label1408" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock_en-US">Details of Certain Balance Sheet Accounts Disclosure [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1408" xlink:to="label1408" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" xlink:label="element1409" />
        <label xlink:type="resource" xlink:label="label1409" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock_en-US">DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1409" xlink:to="label1409" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract" xlink:label="element1410" />
        <label xlink:type="resource" xlink:label="label1410" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_en-US">Pension and Other Postretirement Benefits Disclosure [Abstract]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1410" xlink:to="label1410" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProvisionForIncomeTaxesTextBlock" xlink:label="element1411" />
        <label xlink:type="resource" xlink:label="label1411" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ProvisionForIncomeTaxesTextBlock_en-US">Provision for Income Taxes [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1411" xlink:to="label1411" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProvisionForIncomeTaxesTextBlock" xlink:label="element1412" />
        <label xlink:type="resource" xlink:label="label1412" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ProvisionForIncomeTaxesTextBlock_en-US">Provision for Income Taxes Table</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1412" xlink:to="label1412" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProvisionForIncomeTaxesTextBlock" xlink:label="element1413" />
        <label xlink:type="resource" xlink:label="label1413" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ProvisionForIncomeTaxesTextBlock_en-US">Income Tax Provision</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1413" xlink:to="label1413" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ReconciliationOfStatutoryTaxEffectsTextBlock" xlink:label="element1414" />
        <label xlink:type="resource" xlink:label="label1414" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ReconciliationOfStatutoryTaxEffectsTextBlock_en-US">Reconciliation of Statutory Tax Effects [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1414" xlink:to="label1414" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ReconciliationOfStatutoryTaxEffectsTextBlock" xlink:label="element1415" />
        <label xlink:type="resource" xlink:label="label1415" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ReconciliationOfStatutoryTaxEffectsTextBlock_en-US">Reconciliation of Statutory Tax Effects Table</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1415" xlink:to="label1415" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ReconciliationOfStatutoryTaxEffectsTextBlock" xlink:label="element1416" />
        <label xlink:type="resource" xlink:label="label1416" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ReconciliationOfStatutoryTaxEffectsTextBlock_en-US">Sources of Tax Effects</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1416" xlink:to="label1416" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InsuranceProgramsTableTextBlock" xlink:label="element1417" />
        <label xlink:type="resource" xlink:label="label1417" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_InsuranceProgramsTableTextBlock_en-US">Insurance Programs Table [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1417" xlink:to="label1417" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InsuranceProgramsTableTextBlock" xlink:label="element1418" />
        <label xlink:type="resource" xlink:label="label1418" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_InsuranceProgramsTableTextBlock_en-US">Insurance Programs Details, Table</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1418" xlink:to="label1418" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InsuranceProgramsTableTextBlock" xlink:label="element1419" />
        <label xlink:type="resource" xlink:label="label1419" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_InsuranceProgramsTableTextBlock_en-US">Insurance Programs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1419" xlink:to="label1419" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ValuationAndQualifyingAccountsTableTextBlock" xlink:label="element1420" />
        <label xlink:type="resource" xlink:label="label1420" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ValuationAndQualifyingAccountsTableTextBlock_en-US">Valuation and Qualifying Accounts Table [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1420" xlink:to="label1420" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ValuationAndQualifyingAccountsTableTextBlock" xlink:label="element1421" />
        <label xlink:type="resource" xlink:label="label1421" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ValuationAndQualifyingAccountsTableTextBlock_en-US">A schedule of allowance and reserve accounts including their beginning and ending balances, as well as a reconciliation by type of activity during the period.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1421" xlink:to="label1421" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ValuationAndQualifyingAccountsTableTextBlock" xlink:label="element1422" />
        <label xlink:type="resource" xlink:label="label1422" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ValuationAndQualifyingAccountsTableTextBlock_en-US">Valuation and Qualifying Accounts</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1422" xlink:to="label1422" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedRevenueAdjustmentsMember" xlink:label="element1423" />
        <label xlink:type="resource" xlink:label="label1423" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EstimatedRevenueAdjustmentsMember_en-US">Estimated Revenue Adjustments [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1423" xlink:to="label1423" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedRevenueAdjustmentsMember" xlink:label="element1424" />
        <label xlink:type="resource" xlink:label="label1424" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EstimatedRevenueAdjustmentsMember_en-US">Estimated Revenue Adjustments [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1424" xlink:to="label1424" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedRevenueAdjustmentsMember" xlink:label="element1425" />
        <label xlink:type="resource" xlink:label="label1425" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EstimatedRevenueAdjustmentsMember_en-US">Estimated Revenue Adjustments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1425" xlink:to="label1425" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedRevenueAdjustmentsDiscontinuedOperationsMember" xlink:label="element1426" />
        <label xlink:type="resource" xlink:label="label1426" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EstimatedRevenueAdjustmentsDiscontinuedOperationsMember_en-US">Estimated Revenue Adjustments, Discontinued Operations [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1426" xlink:to="label1426" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedRevenueAdjustmentsDiscontinuedOperationsMember" xlink:label="element1427" />
        <label xlink:type="resource" xlink:label="label1427" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EstimatedRevenueAdjustmentsDiscontinuedOperationsMember_en-US">Estimated Revenue Adjustments, Discontinued Operations [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1427" xlink:to="label1427" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedRevenueAdjustmentsDiscontinuedOperationsMember" xlink:label="element1428" />
        <label xlink:type="resource" xlink:label="label1428" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EstimatedRevenueAdjustmentsDiscontinuedOperationsMember_en-US">Estimated Revenue Adjustments - Discontinued Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1428" xlink:to="label1428" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MinimumEligibleAgeForEmployeesToContributeToBenefitPlan" xlink:label="element1429" />
        <label xlink:type="resource" xlink:label="label1429" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MinimumEligibleAgeForEmployeesToContributeToBenefitPlan_en-US">Minimum Eligible Age For Employees To Contribute To Benefit Plan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1429" xlink:to="label1429" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MinimumEligibleAgeForEmployeesToContributeToBenefitPlan" xlink:label="element1430" />
        <label xlink:type="resource" xlink:label="label1430" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MinimumEligibleAgeForEmployeesToContributeToBenefitPlan_en-US">Minimum eligible age for employees to contribute to benefit plan, years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1430" xlink:to="label1430" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DefinedContributionPlanEmployerMatchingContribution" xlink:label="element1431" />
        <label xlink:type="resource" xlink:label="label1431" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DefinedContributionPlanEmployerMatchingContribution_en-US">Defined Contribution Plan Employer Matching Contribution</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1431" xlink:to="label1431" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DefinedContributionPlanEmployerMatchingContribution" xlink:label="element1432" />
        <label xlink:type="resource" xlink:label="label1432" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DefinedContributionPlanEmployerMatchingContribution_en-US">Defined contribution plan employer matching contribution.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1432" xlink:to="label1432" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DefinedContributionPlanEmployerMatchingContribution" xlink:label="element1433" />
        <label xlink:type="resource" xlink:label="label1433" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DefinedContributionPlanEmployerMatchingContribution_en-US">Employer Match Amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1433" xlink:to="label1433" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" xlink:label="element1434" />
        <label xlink:type="resource" xlink:label="label1434" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram_en-US">Defined Contribution Plan Employee Contribution For Employee Matching Program</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1434" xlink:to="label1434" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" xlink:label="element1435" />
        <label xlink:type="resource" xlink:label="label1435" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram_en-US">Defined Contribution Plan Employee Contribution For Employer Matching Program</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1435" xlink:to="label1435" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" xlink:label="element1436" />
        <label xlink:type="resource" xlink:label="label1436" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram_en-US">Employee Contribution Amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1436" xlink:to="label1436" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" xlink:label="element1437" />
        <label xlink:type="resource" xlink:label="label1437" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage_en-US">Defind Contribution Plan Maximum Annual Match Per Employee Salary Percentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1437" xlink:to="label1437" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" xlink:label="element1438" />
        <label xlink:type="resource" xlink:label="label1438" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage_en-US">Maximum Percentage of Employee Salary Eligible for Employer Match</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1438" xlink:to="label1438" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" xlink:label="element1439" />
        <label xlink:type="resource" xlink:label="label1439" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage_en-US">Maximum Percentage of Employee Salary Eligible for Employer Match</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1439" xlink:to="label1439" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredCompensationArrangementMaximumPercentageOfSalaryDeferment" xlink:label="element1440" />
        <label xlink:type="resource" xlink:label="label1440" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DeferredCompensationArrangementMaximumPercentageOfSalaryDeferment_en-US">Deferred Compensation Arrangement Maximum Percentage Of Salary Deferment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1440" xlink:to="label1440" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredCompensationArrangementMaximumPercentageOfSalaryDeferment" xlink:label="element1441" />
        <label xlink:type="resource" xlink:label="label1441" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DeferredCompensationArrangementMaximumPercentageOfSalaryDeferment_en-US">Maximum percentage of annual salary that participant is allowed to defer per terms of the Company's Deferred Compensation Plan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1441" xlink:to="label1441" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredCompensationArrangementMaximumPercentageOfSalaryDeferment" xlink:label="element1442" />
        <label xlink:type="resource" xlink:label="label1442" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DeferredCompensationArrangementMaximumPercentageOfSalaryDeferment_en-US">Permitted deferment of annual salary, percentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1442" xlink:to="label1442" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredCompensationArrangementMaximumPercentageOfAnnualBonusDeferment" xlink:label="element1443" />
        <label xlink:type="resource" xlink:label="label1443" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DeferredCompensationArrangementMaximumPercentageOfAnnualBonusDeferment_en-US">Deferred Compensation Arrangement Maximum Percentage Of Annual Bonus Deferment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1443" xlink:to="label1443" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredCompensationArrangementMaximumPercentageOfAnnualBonusDeferment" xlink:label="element1444" />
        <label xlink:type="resource" xlink:label="label1444" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DeferredCompensationArrangementMaximumPercentageOfAnnualBonusDeferment_en-US">Permitted deferment of annual bonus, percentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1444" xlink:to="label1444" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredCompensationArrangementMaximumPercentageOfAnnualBonusDeferment" xlink:label="element1445" />
        <label xlink:type="resource" xlink:label="label1445" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DeferredCompensationArrangementMaximumPercentageOfAnnualBonusDeferment_en-US">Maximum percentage of annual bonus that participant is allowed to defer per terms of the Company's Deferred Compensation Plan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1445" xlink:to="label1445" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="element1446" />
        <label xlink:type="resource" xlink:label="label1446" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_QuarterlyFinancialInformationLineItems_en-US">Quarterly Financial Information [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1446" xlink:to="label1446" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="element1447" />
        <label xlink:type="resource" xlink:label="label1447" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_QuarterlyFinancialInformationLineItems_en-US">Quarterly Financial Information [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1447" xlink:to="label1447" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityLoanCost" xlink:label="element1448" />
        <label xlink:type="resource" xlink:label="label1448" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_LineOfCreditFacilityLoanCost_en-US">Line Of Credit Facility Loan Cost</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1448" xlink:to="label1448" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityLoanCost" xlink:label="element1449" />
        <label xlink:type="resource" xlink:label="label1449" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_LineOfCreditFacilityLoanCost_en-US">Line Of Credit Facility Loan Cost</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1449" xlink:to="label1449" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityLoanCost" xlink:label="element1450" />
        <label xlink:type="resource" xlink:label="label1450" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_LineOfCreditFacilityLoanCost_en-US">Cost associated with prepayment of loans</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1450" xlink:to="label1450" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="element1451" />
        <label xlink:type="resource" xlink:label="label1451" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OperatingLeaseObligationsLineItems_en-US">Operating Lease Obligations [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1451" xlink:to="label1451" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="element1452" />
        <label xlink:type="resource" xlink:label="label1452" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_OperatingLeaseObligationsLineItems_en-US">Operating Lease Obligations [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1452" xlink:to="label1452" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HealthInsurance" xlink:label="element1453" />
        <label xlink:type="resource" xlink:label="label1453" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_HealthInsurance_en-US">Health Insurance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1453" xlink:to="label1453" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HealthInsurance" xlink:label="element1454" />
        <label xlink:type="resource" xlink:label="label1454" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_HealthInsurance_en-US">Health insurance, estimated liability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1454" xlink:to="label1454" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HealthInsurance" xlink:label="element1455" />
        <label xlink:type="resource" xlink:label="label1455" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_HealthInsurance_en-US">Health insurance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1455" xlink:to="label1455" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WokersCompensation" xlink:label="element1456" />
        <label xlink:type="resource" xlink:label="label1456" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_WokersCompensation_en-US">Wokers Compensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1456" xlink:to="label1456" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WokersCompensation" xlink:label="element1457" />
        <label xlink:type="resource" xlink:label="label1457" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_WokersCompensation_en-US">Workers' Compensation insurance, estimated liability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1457" xlink:to="label1457" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WokersCompensation" xlink:label="element1458" />
        <label xlink:type="resource" xlink:label="label1458" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_WokersCompensation_en-US">Wokers compensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1458" xlink:to="label1458" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProfessionalLiability" xlink:label="element1459" />
        <label xlink:type="resource" xlink:label="label1459" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ProfessionalLiability_en-US">Professional Liability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1459" xlink:to="label1459" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProfessionalLiability" xlink:label="element1460" />
        <label xlink:type="resource" xlink:label="label1460" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ProfessionalLiability_en-US">Professional liability insurance, estimated liability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1460" xlink:to="label1460" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProfessionalLiability" xlink:label="element1461" />
        <label xlink:type="resource" xlink:label="label1461" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ProfessionalLiability_en-US">Professional liability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1461" xlink:to="label1461" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedInsuranceTotal" xlink:label="element1462" />
        <label xlink:type="resource" xlink:label="label1462" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EstimatedInsuranceTotal_en-US">Estimated Insurance Total</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1462" xlink:to="label1462" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedInsuranceTotal" xlink:label="element1463" />
        <label xlink:type="resource" xlink:label="label1463" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EstimatedInsuranceTotal_en-US">Estimated insurance, total</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1463" xlink:to="label1463" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedInsuranceTotal" xlink:label="element1464" />
        <label xlink:type="resource" xlink:label="label1464" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US" id="total_amed_EstimatedInsuranceTotal_en-US">Estimated Insurance Total</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1464" xlink:to="label1464" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedInsuranceLongTermPortion" xlink:label="element1465" />
        <label xlink:type="resource" xlink:label="label1465" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EstimatedInsuranceLongTermPortion_en-US">Estimated Insurance Long Term Portion</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1465" xlink:to="label1465" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedInsuranceLongTermPortion" xlink:label="element1466" />
        <label xlink:type="resource" xlink:label="label1466" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EstimatedInsuranceLongTermPortion_en-US">Long term portion of estimated insurance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1466" xlink:to="label1466" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedInsuranceLongTermPortion" xlink:label="element1467" />
        <label xlink:type="resource" xlink:label="label1467" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EstimatedInsuranceLongTermPortion_en-US">Estimated Insurance Long Term Portion</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1467" xlink:to="label1467" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedInsuranceExcludingLongTermPortion" xlink:label="element1468" />
        <label xlink:type="resource" xlink:label="label1468" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EstimatedInsuranceExcludingLongTermPortion_en-US">Estimated Insurance Excluding Long Term Portion</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1468" xlink:to="label1468" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedInsuranceExcludingLongTermPortion" xlink:label="element1469" />
        <label xlink:type="resource" xlink:label="label1469" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EstimatedInsuranceExcludingLongTermPortion_en-US">Estimated insurance liability, excluding long-term</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1469" xlink:to="label1469" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedInsuranceExcludingLongTermPortion" xlink:label="element1470" />
        <label xlink:type="resource" xlink:label="label1470" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EstimatedInsuranceExcludingLongTermPortion_en-US">Estimated Insurance Excluding Long Term Portion</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1470" xlink:to="label1470" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Percentageofownershipinsubsidiaries" xlink:label="element1471" />
        <label xlink:type="resource" xlink:label="label1471" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_Percentageofownershipinsubsidiaries_en-US">Percentageofownershipinsubsidiaries</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1471" xlink:to="label1471" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Percentageofownershipinsubsidiaries" xlink:label="element1472" />
        <label xlink:type="resource" xlink:label="label1472" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_Percentageofownershipinsubsidiaries_en-US">Percentage of Ownership in Subsidiaries</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1472" xlink:to="label1472" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Percentageofownershipinsubsidiaries" xlink:label="element1473" />
        <label xlink:type="resource" xlink:label="label1473" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_Percentageofownershipinsubsidiaries_en-US">Percentage of ownership in subsidiaries</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1473" xlink:to="label1473" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Fairvalueofshareofcommonstockpercentage" xlink:label="element1474" />
        <label xlink:type="resource" xlink:label="label1474" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_Fairvalueofshareofcommonstockpercentage_en-US">Fairvalueofshareofcommonstockpercentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1474" xlink:to="label1474" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Fairvalueofshareofcommonstockpercentage" xlink:label="element1475" />
        <label xlink:type="resource" xlink:label="label1475" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_Fairvalueofshareofcommonstockpercentage_en-US">Fair value of a share of common stock, percentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1475" xlink:to="label1475" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Fairvalueofshareofcommonstockpercentage" xlink:label="element1476" />
        <label xlink:type="resource" xlink:label="label1476" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_Fairvalueofshareofcommonstockpercentage_en-US">Fair Value of Share of Common Stock, Percentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1476" xlink:to="label1476" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" xlink:label="element1477" />
        <label xlink:type="resource" xlink:label="label1477" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries_en-US">Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1477" xlink:to="label1477" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" xlink:label="element1478" />
        <label xlink:type="resource" xlink:label="label1478" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries_en-US">Percentage of total combined voting power of the Company and our subsidiaries</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1478" xlink:to="label1478" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" xlink:label="element1479" />
        <label xlink:type="resource" xlink:label="label1479" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries_en-US">Percentage of Total Combined Voting Power of the Ccompany and Our Subsidiaries</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1479" xlink:to="label1479" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="element1480" />
        <label xlink:type="resource" xlink:label="label1480" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EquityBasedAwardsTable_en-US">Equity Based Awards [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1480" xlink:to="label1480" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="element1481" />
        <label xlink:type="resource" xlink:label="label1481" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EquityBasedAwardsTable_en-US">Equity Based Awards [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1481" xlink:to="label1481" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedAwardsMember" xlink:label="element1482" />
        <label xlink:type="resource" xlink:label="label1482" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ShareBasedAwardsMember_en-US">Share-Based Awards [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1482" xlink:to="label1482" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedAwardsMember" xlink:label="element1483" />
        <label xlink:type="resource" xlink:label="label1483" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ShareBasedAwardsMember_en-US">Share-Based Awards</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1483" xlink:to="label1483" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" xlink:label="element1484" />
        <label xlink:type="resource" xlink:label="label1484" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_en-US">Share Based Awards To More Than Ten Percent Owner [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1484" xlink:to="label1484" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" xlink:label="element1485" />
        <label xlink:type="resource" xlink:label="label1485" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_en-US">Share-based awards to any owner of 10% or more of our total combined voting power of us and our subsidiaries</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1485" xlink:to="label1485" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" xlink:label="element1486" />
        <label xlink:type="resource" xlink:label="label1486" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan_en-US">Common Stock Shares Authorized For Issuance To Employee Stock Purchase Plan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1486" xlink:to="label1486" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" xlink:label="element1487" />
        <label xlink:type="resource" xlink:label="label1487" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan_en-US">Number of shares authorized for issuance to the Company's employee stock purchase plan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1487" xlink:to="label1487" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StockAvailableForFutureIssuanceUnderEmployeePurchasePlan" xlink:label="element1488" />
        <label xlink:type="resource" xlink:label="label1488" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_StockAvailableForFutureIssuanceUnderEmployeePurchasePlan_en-US">Stock Available For Future Issuance Under Employee Purchase Plan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1488" xlink:to="label1488" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StockAvailableForFutureIssuanceUnderEmployeePurchasePlan" xlink:label="element1489" />
        <label xlink:type="resource" xlink:label="label1489" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_StockAvailableForFutureIssuanceUnderEmployeePurchasePlan_en-US">Stock Available For Future Issuance Under Employee Purchase Plan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1489" xlink:to="label1489" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockMember" xlink:label="element1490" />
        <label xlink:type="resource" xlink:label="label1490" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NonVestedStockMember_en-US">Non-Vested Stock [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1490" xlink:to="label1490" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockMember" xlink:label="element1491" />
        <label xlink:type="resource" xlink:label="label1491" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NonVestedStockMember_en-US">Service-Based Non-Vested Stock</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1491" xlink:to="label1491" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" xlink:label="element1492" />
        <label xlink:type="resource" xlink:label="label1492" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_en-US">Non-Vested Stock Units - Service-Based and Performance-Based [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1492" xlink:to="label1492" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" xlink:label="element1493" />
        <label xlink:type="resource" xlink:label="label1493" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_en-US">Non-Vested Stock Units - Service-Based and Performance-Based</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1493" xlink:to="label1493" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember" xlink:label="element1494" />
        <label xlink:type="resource" xlink:label="label1494" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember_en-US">Non-Vested Stock Units - Service-Based and Market-Based [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1494" xlink:to="label1494" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember" xlink:label="element1495" />
        <label xlink:type="resource" xlink:label="label1495" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember_en-US">Non-Vested Stock Units - Service-Based and Market-Based</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1495" xlink:to="label1495" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MarketBasedAwardTargetShareAmount" xlink:label="element1496" />
        <label xlink:type="resource" xlink:label="label1496" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MarketBasedAwardTargetShareAmount_en-US">Market Based Award Target Share Amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1496" xlink:to="label1496" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MarketBasedAwardTargetShareAmount" xlink:label="element1497" />
        <label xlink:type="resource" xlink:label="label1497" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MarketBasedAwardTargetShareAmount_en-US">Market-based award, target number of shares to be received</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1497" xlink:to="label1497" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MarketBasedAwardTargetShareAmount" xlink:label="element1498" />
        <label xlink:type="resource" xlink:label="label1498" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MarketBasedAwardTargetShareAmount_en-US">Number of stock units authorized for achievement of targeted performance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1498" xlink:to="label1498" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MarketBasedAwardMaximumShareAmount" xlink:label="element1499" />
        <label xlink:type="resource" xlink:label="label1499" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MarketBasedAwardMaximumShareAmount_en-US">Market Based Award Maximum Share Amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1499" xlink:to="label1499" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MarketBasedAwardMaximumShareAmount" xlink:label="element1500" />
        <label xlink:type="resource" xlink:label="label1500" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MarketBasedAwardMaximumShareAmount_en-US">Market-based award, maximum number of shares authorized to be received</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1500" xlink:to="label1500" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MarketBasedAwardMaximumShareAmount" xlink:label="element1501" />
        <label xlink:type="resource" xlink:label="label1501" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MarketBasedAwardMaximumShareAmount_en-US">Number of stock units authorized for exceeding targeted performance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1501" xlink:to="label1501" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare" xlink:label="element1502" />
        <label xlink:type="resource" xlink:label="label1502" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare_en-US">Stock Issued Under Employee Stock Purchase Plan Discounted Value Per Share</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1502" xlink:to="label1502" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare" xlink:label="element1503" />
        <label xlink:type="resource" xlink:label="label1503" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare_en-US">Stock issued under employee stock purchase plan discounted value per share</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1503" xlink:to="label1503" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare" xlink:label="element1504" />
        <label xlink:type="resource" xlink:label="label1504" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare_en-US">Price per ESPP Share Issued</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1504" xlink:to="label1504" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" xlink:label="element1505" />
        <label xlink:type="resource" xlink:label="label1505" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1505" xlink:to="label1505" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" xlink:label="element1506" />
        <label xlink:type="resource" xlink:label="label1506" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_en-US">Fair Value</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1506" xlink:to="label1506" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" xlink:label="element1507" />
        <label xlink:type="resource" xlink:label="label1507" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_en-US">The calculated fair value of a stock-based compensation award</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1507" xlink:to="label1507" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRequisiteServicePeriod" xlink:label="element1508" />
        <label xlink:type="resource" xlink:label="label1508" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRequisiteServicePeriod_en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Requisite Service Period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1508" xlink:to="label1508" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRequisiteServicePeriod" xlink:label="element1509" />
        <label xlink:type="resource" xlink:label="label1509" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRequisiteServicePeriod_en-US">The requisite service period that was used in the calculation of the fair value of a stock-based compensation award</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1509" xlink:to="label1509" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRequisiteServicePeriod" xlink:label="element1510" />
        <label xlink:type="resource" xlink:label="label1510" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRequisiteServicePeriod_en-US">Requisite Service Period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1510" xlink:to="label1510" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="element1511" />
        <label xlink:type="resource" xlink:label="label1511" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IncomeTaxDisclosureLineItems_en-US">Income Tax Disclosure [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1511" xlink:to="label1511" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="element1512" />
        <label xlink:type="resource" xlink:label="label1512" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_IncomeTaxDisclosureLineItems_en-US">Income Tax Disclosure [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1512" xlink:to="label1512" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfIndividualStatesSubjectToIncomeTax" xlink:label="element1513" />
        <label xlink:type="resource" xlink:label="label1513" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfIndividualStatesSubjectToIncomeTax_en-US">Number of Individual States Subject To Income Tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1513" xlink:to="label1513" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfIndividualStatesSubjectToIncomeTax" xlink:label="element1514" />
        <label xlink:type="resource" xlink:label="label1514" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfIndividualStatesSubjectToIncomeTax_en-US">Number of individual states subject to income tax</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1514" xlink:to="label1514" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfIndividualStatesSubjectToIncomeTax" xlink:label="element1515" />
        <label xlink:type="resource" xlink:label="label1515" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfIndividualStatesSubjectToIncomeTax_en-US">Number of individual states subject to income taxes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1515" xlink:to="label1515" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual" xlink:label="element1516" />
        <label xlink:type="resource" xlink:label="label1516" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual_en-US">Deferred Tax Assets Deferred Expense US Department Of Justice Settlement Accrual</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1516" xlink:to="label1516" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual" xlink:label="element1517" />
        <label xlink:type="resource" xlink:label="label1517" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual_en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from U.S. Department of Justice settlement accrual</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1517" xlink:to="label1517" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual" xlink:label="element1518" />
        <label xlink:type="resource" xlink:label="label1518" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual_en-US">Settlement accrual</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1518" xlink:to="label1518" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" xlink:label="element1519" />
        <label xlink:type="resource" xlink:label="label1519" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_en-US">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Workers Compensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1519" xlink:to="label1519" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" xlink:label="element1520" />
        <label xlink:type="resource" xlink:label="label1520" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_en-US">Deferred tax assets tax deferred expense compensation and benefits workers compensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1520" xlink:to="label1520" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" xlink:label="element1521" />
        <label xlink:type="resource" xlink:label="label1521" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_en-US">Workers' compensation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1521" xlink:to="label1521" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredTaxAssetsOtherCurrent" xlink:label="element1522" />
        <label xlink:type="resource" xlink:label="label1522" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DeferredTaxAssetsOtherCurrent_en-US">Deferred Tax Assets Other Current</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1522" xlink:to="label1522" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredTaxAssetsOtherCurrent" xlink:label="element1523" />
        <label xlink:type="resource" xlink:label="label1523" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DeferredTaxAssetsOtherCurrent_en-US">Amount before allocation of valuation allowances of current deferred tax asset attributable to deductible temporary differences not separately disclosed</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1523" xlink:to="label1523" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredTaxAssetsOtherCurrent" xlink:label="element1524" />
        <label xlink:type="resource" xlink:label="label1524" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DeferredTaxAssetsOtherCurrent_en-US">Other</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1524" xlink:to="label1524" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PayrollTaxEscrow" xlink:label="element1525" />
        <label xlink:type="resource" xlink:label="label1525" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PayrollTaxEscrow_en-US">Payroll tax escrow</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1525" xlink:to="label1525" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PayrollTaxEscrow" xlink:label="element1526" />
        <label xlink:type="resource" xlink:label="label1526" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PayrollTaxEscrow_en-US">Payroll tax escrow</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1526" xlink:to="label1526" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MedicareWithholds" xlink:label="element1527" />
        <label xlink:type="resource" xlink:label="label1527" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MedicareWithholds_en-US">Medicare Withholds</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1527" xlink:to="label1527" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WorkersCompensationDeposits" xlink:label="element1528" />
        <label xlink:type="resource" xlink:label="label1528" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_WorkersCompensationDeposits_en-US">Workers Compensation Deposits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1528" xlink:to="label1528" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WorkersCompensationDeposits" xlink:label="element1529" />
        <label xlink:type="resource" xlink:label="label1529" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_WorkersCompensationDeposits_en-US">Workers Compensation Deposits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1529" xlink:to="label1529" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WorkersCompensationDeposits" xlink:label="element1530" />
        <label xlink:type="resource" xlink:label="label1530" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_WorkersCompensationDeposits_en-US">Workers compensation deposits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1530" xlink:to="label1530" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HealthInsuranceDeposits" xlink:label="element1531" />
        <label xlink:type="resource" xlink:label="label1531" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_HealthInsuranceDeposits_en-US">Health Insurance Deposits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1531" xlink:to="label1531" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HealthInsuranceDeposits" xlink:label="element1532" />
        <label xlink:type="resource" xlink:label="label1532" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_HealthInsuranceDeposits_en-US">Health Insurance Deposits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1532" xlink:to="label1532" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HealthInsuranceDeposits" xlink:label="element1533" />
        <label xlink:type="resource" xlink:label="label1533" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_HealthInsuranceDeposits_en-US">Health insurance deposits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1533" xlink:to="label1533" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherMiscellaneousDeposits" xlink:label="element1534" />
        <label xlink:type="resource" xlink:label="label1534" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OtherMiscellaneousDeposits_en-US">Other Miscellaneous Deposits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1534" xlink:to="label1534" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherMiscellaneousDeposits" xlink:label="element1535" />
        <label xlink:type="resource" xlink:label="label1535" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OtherMiscellaneousDeposits_en-US">Other Miscellaneous Deposits</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1535" xlink:to="label1535" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherMiscellaneousDeposits" xlink:label="element1536" />
        <label xlink:type="resource" xlink:label="label1536" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_OtherMiscellaneousDeposits_en-US">Other miscellaneous deposit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1536" xlink:to="label1536" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LegalAndOtherSettlements" xlink:label="element1537" />
        <label xlink:type="resource" xlink:label="label1537" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_LegalAndOtherSettlements_en-US">Legal And Other Settlements</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1537" xlink:to="label1537" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LegalAndOtherSettlements" xlink:label="element1538" />
        <label xlink:type="resource" xlink:label="label1538" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_LegalAndOtherSettlements_en-US">Amount of accrued expenses related to legal and other settlements</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1538" xlink:to="label1538" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LegalAndOtherSettlements" xlink:label="element1539" />
        <label xlink:type="resource" xlink:label="label1539" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_LegalAndOtherSettlements_en-US">Legal and other settlements</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1539" xlink:to="label1539" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LeaseLiability" xlink:label="element1540" />
        <label xlink:type="resource" xlink:label="label1540" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_LeaseLiability_en-US">Lease Liability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1540" xlink:to="label1540" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LeaseLiability" xlink:label="element1541" />
        <label xlink:type="resource" xlink:label="label1541" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_LeaseLiability_en-US">Amount of accrued expenses related to lease liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1541" xlink:to="label1541" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LeaseLiability" xlink:label="element1542" />
        <label xlink:type="resource" xlink:label="label1542" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_LeaseLiability_en-US">Lease liability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1542" xlink:to="label1542" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CharityCare" xlink:label="element1543" />
        <label xlink:type="resource" xlink:label="label1543" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CharityCare_en-US">Charity Care</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1543" xlink:to="label1543" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CharityCare" xlink:label="element1544" />
        <label xlink:type="resource" xlink:label="label1544" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CharityCare_en-US">Amount of accrued expenses related to charity care</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1544" xlink:to="label1544" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CharityCare" xlink:label="element1545" />
        <label xlink:type="resource" xlink:label="label1545" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_CharityCare_en-US">Charity care</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1545" xlink:to="label1545" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedMedicareCapLiability" xlink:label="element1546" />
        <label xlink:type="resource" xlink:label="label1546" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EstimatedMedicareCapLiability_en-US">Estimated Medicare Cap Liability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1546" xlink:to="label1546" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedMedicareCapLiability" xlink:label="element1547" />
        <label xlink:type="resource" xlink:label="label1547" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EstimatedMedicareCapLiability_en-US">Amount of accrued expenses related to the estimated Medicare CAP liability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1547" xlink:to="label1547" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedMedicareCapLiability" xlink:label="element1548" />
        <label xlink:type="resource" xlink:label="label1548" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EstimatedMedicareCapLiability_en-US">Estimated Medicare CAP liability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1548" xlink:to="label1548" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredCompensationPlanLiability" xlink:label="element1549" />
        <label xlink:type="resource" xlink:label="label1549" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DeferredCompensationPlanLiability_en-US">Deferred Compensation Plan Liability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1549" xlink:to="label1549" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredCompensationPlanLiability" xlink:label="element1550" />
        <label xlink:type="resource" xlink:label="label1550" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DeferredCompensationPlanLiability_en-US">Deferred Compensation Plan Liability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1550" xlink:to="label1550" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredCompensationPlanLiability" xlink:label="element1551" />
        <label xlink:type="resource" xlink:label="label1551" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DeferredCompensationPlanLiability_en-US">Deferred compensation plan liability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1551" xlink:to="label1551" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:label="element1552" />
        <label xlink:type="resource" xlink:label="label1552" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_en-US">Stock Issued During Period Value Four Zero One K Employer Match</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1552" xlink:to="label1552" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:label="element1553" />
        <label xlink:type="resource" xlink:label="label1553" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_en-US">Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1553" xlink:to="label1553" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:label="element1554" />
        <label xlink:type="resource" xlink:label="label1554" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_en-US">Issuance of stock - 401 (k) plan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1554" xlink:to="label1554" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:label="element1555" />
        <label xlink:type="resource" xlink:label="label1555" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_en-US">Stock Issued During Period Shares Four Zero One K Employer Match</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1555" xlink:to="label1555" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:label="element1556" />
        <label xlink:type="resource" xlink:label="label1556" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_en-US">Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1556" xlink:to="label1556" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:label="element1557" />
        <label xlink:type="resource" xlink:label="label1557" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_en-US">Issuance of stock - 401 (k) plan (in shares)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1557" xlink:to="label1557" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment" xlink:label="element1558" />
        <label xlink:type="resource" xlink:label="label1558" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment_en-US">Increase Decrease In Assets Of Equity Method Investment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1558" xlink:to="label1558" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment" xlink:label="element1559" />
        <label xlink:type="resource" xlink:label="label1559" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment_en-US">Increase Decrease In Assets of Equity Method Investment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1559" xlink:to="label1559" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment" xlink:label="element1560" />
        <label xlink:type="resource" xlink:label="label1560" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment_en-US">Assets contributed to equity investment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1560" xlink:to="label1560" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="element1561" />
        <label xlink:type="resource" xlink:label="label1561" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_GoodwillAndIntangibleAssetsLineItems_en-US">Goodwill and Intangible Assets [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1561" xlink:to="label1561" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="element1562" />
        <label xlink:type="resource" xlink:label="label1562" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_GoodwillAndIntangibleAssetsLineItems_en-US">Goodwill and Intangible Assets [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1562" xlink:to="label1562" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareCentersClosedOrConsolidatedMember" xlink:label="element1563" />
        <label xlink:type="resource" xlink:label="label1563" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CareCentersClosedOrConsolidatedMember_en-US">Care Centers Closed Or Consolidated [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1563" xlink:to="label1563" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareCentersClosedOrConsolidatedMember" xlink:label="element1564" />
        <label xlink:type="resource" xlink:label="label1564" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CareCentersClosedOrConsolidatedMember_en-US">Care Centers Closed Or Consolidated [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1564" xlink:to="label1564" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherIntangibleAssetsAdditions" xlink:label="element1565" />
        <label xlink:type="resource" xlink:label="label1565" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OtherIntangibleAssetsAdditions_en-US">Other Intangible Assets Additions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1565" xlink:to="label1565" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherIntangibleAssetsAdditions" xlink:label="element1566" />
        <label xlink:type="resource" xlink:label="label1566" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OtherIntangibleAssetsAdditions_en-US">Additions to Other Intangible Assets that occurred during the period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1566" xlink:to="label1566" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherIntangibleAssetsAdditions" xlink:label="element1567" />
        <label xlink:type="resource" xlink:label="label1567" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_OtherIntangibleAssetsAdditions_en-US">Additions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1567" xlink:to="label1567" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherIntangiblesWriteOffs" xlink:label="element1568" />
        <label xlink:type="resource" xlink:label="label1568" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OtherIntangiblesWriteOffs_en-US">Other Intangibles Write Offs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1568" xlink:to="label1568" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherIntangiblesWriteOffs" xlink:label="element1569" />
        <label xlink:type="resource" xlink:label="label1569" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OtherIntangiblesWriteOffs_en-US">Write-off of intangible asets that occurred during the period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1569" xlink:to="label1569" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherIntangiblesWriteOffs" xlink:label="element1570" />
        <label xlink:type="resource" xlink:label="label1570" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_OtherIntangiblesWriteOffs_en-US">Write-off</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1570" xlink:to="label1570" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherIntangiblesWriteOffs" xlink:label="element1571" />
        <label xlink:type="resource" xlink:label="label1571" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_amed_OtherIntangiblesWriteOffs_en-US">Write-off</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1571" xlink:to="label1571" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnamortizedAcquiredNames" xlink:label="element1572" />
        <label xlink:type="resource" xlink:label="label1572" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_UnamortizedAcquiredNames_en-US">Unamortized Acquired Names</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1572" xlink:to="label1572" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnamortizedAcquiredNames" xlink:label="element1573" />
        <label xlink:type="resource" xlink:label="label1573" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_UnamortizedAcquiredNames_en-US">The sum of the carrying amounts as of the balance sheet date of the entity's acquired names of business having a projected indefinite period of benefit.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1573" xlink:to="label1573" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnamortizedAcquiredNames" xlink:label="element1574" />
        <label xlink:type="resource" xlink:label="label1574" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_UnamortizedAcquiredNames_en-US">Unamortized Acquired Names</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1574" xlink:to="label1574" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AmortizedAcquiredNames" xlink:label="element1575" />
        <label xlink:type="resource" xlink:label="label1575" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AmortizedAcquiredNames_en-US">Amortized Acquired Names</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1575" xlink:to="label1575" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AmortizedAcquiredNames" xlink:label="element1576" />
        <label xlink:type="resource" xlink:label="label1576" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AmortizedAcquiredNames_en-US">The sum of the carrying amounts as of the balance sheet date of the entity's acquired names of business having a definite period of benefit.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1576" xlink:to="label1576" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AmortizedAcquiredNames" xlink:label="element1577" />
        <label xlink:type="resource" xlink:label="label1577" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_AmortizedAcquiredNames_en-US">Amortized Acquired Names</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1577" xlink:to="label1577" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AcquiredNameOfBusinessMember" xlink:label="element1578" />
        <label xlink:type="resource" xlink:label="label1578" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AcquiredNameOfBusinessMember_en-US">Acquired Name Of Business [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1578" xlink:to="label1578" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AcquiredNameOfBusinessMember" xlink:label="element1579" />
        <label xlink:type="resource" xlink:label="label1579" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AcquiredNameOfBusinessMember_en-US">Acquired Name Of Business [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1579" xlink:to="label1579" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CertificatesOfNeedAndLicensesMember" xlink:label="element1580" />
        <label xlink:type="resource" xlink:label="label1580" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CertificatesOfNeedAndLicensesMember_en-US">Certificates Of Need And Licenses [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1580" xlink:to="label1580" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CertificatesOfNeedAndLicensesMember" xlink:label="element1581" />
        <label xlink:type="resource" xlink:label="label1581" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CertificatesOfNeedAndLicensesMember_en-US">Certificates Of Need And Licenses [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1581" xlink:to="label1581" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AcquiredNamesOfBusinessMember" xlink:label="element1582" />
        <label xlink:type="resource" xlink:label="label1582" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AcquiredNamesOfBusinessMember_en-US">Acquired Names Of Business [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1582" xlink:to="label1582" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AcquiredNamesOfBusinessMember" xlink:label="element1583" />
        <label xlink:type="resource" xlink:label="label1583" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AcquiredNamesOfBusinessMember_en-US">Acquired Names Of Business [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1583" xlink:to="label1583" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationTable" xlink:label="element1584" />
        <label xlink:type="resource" xlink:label="label1584" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_QuarterlyFinancialInformationTable_en-US">Quarterly Financial Information [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1584" xlink:to="label1584" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationTable" xlink:label="element1585" />
        <label xlink:type="resource" xlink:label="label1585" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_QuarterlyFinancialInformationTable_en-US">Quarterly Financial Information [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1585" xlink:to="label1585" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationAxis" xlink:label="element1586" />
        <label xlink:type="resource" xlink:label="label1586" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_QuarterlyFinancialInformationAxis_en-US">Quarterly Financial Information [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1586" xlink:to="label1586" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationAxis" xlink:label="element1587" />
        <label xlink:type="resource" xlink:label="label1587" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_QuarterlyFinancialInformationAxis_en-US">Quarterly Financial Information [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1587" xlink:to="label1587" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationDomain" xlink:label="element1588" />
        <label xlink:type="resource" xlink:label="label1588" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_QuarterlyFinancialInformationDomain_en-US">Quarterly Financial Information [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1588" xlink:to="label1588" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationDomain" xlink:label="element1589" />
        <label xlink:type="resource" xlink:label="label1589" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_QuarterlyFinancialInformationDomain_en-US">Quarterly Financial Information [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1589" xlink:to="label1589" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NetOfTaxMember" xlink:label="element1590" />
        <label xlink:type="resource" xlink:label="label1590" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NetOfTaxMember_en-US">Net Of Tax [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1590" xlink:to="label1590" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NetOfTaxMember" xlink:label="element1591" />
        <label xlink:type="resource" xlink:label="label1591" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NetOfTaxMember_en-US">Net Of Tax [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1591" xlink:to="label1591" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoThousandAndThirteenExitActivityMember" xlink:label="element1592" />
        <label xlink:type="resource" xlink:label="label1592" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TwoThousandAndThirteenExitActivityMember_en-US">Two Thousand And Thirteen Exit Activity [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1592" xlink:to="label1592" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoThousandAndThirteenExitActivityMember" xlink:label="element1593" />
        <label xlink:type="resource" xlink:label="label1593" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_TwoThousandAndThirteenExitActivityMember_en-US">Two Thousand And Thirteen Exit Activity [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1593" xlink:to="label1593" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoThousandAndThirteenExitActivityMember" xlink:label="element1594" />
        <label xlink:type="resource" xlink:label="label1594" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_TwoThousandAndThirteenExitActivityMember_en-US">2013 Exit Activity [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1594" xlink:to="label1594" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="element1595" />
        <label xlink:type="resource" xlink:label="label1595" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_RestructuringCostAndReserveDomain_en-US">Restructuring Cost And Reserve [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1595" xlink:to="label1595" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="element1596" />
        <label xlink:type="resource" xlink:label="label1596" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_RestructuringCostAndReserveDomain_en-US">Restructuring Cost And Reserve [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1596" xlink:to="label1596" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LeaseTerminationMember" xlink:label="element1597" />
        <label xlink:type="resource" xlink:label="label1597" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_LeaseTerminationMember_en-US">Lease Termination [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1597" xlink:to="label1597" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LeaseTerminationMember" xlink:label="element1598" />
        <label xlink:type="resource" xlink:label="label1598" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_LeaseTerminationMember_en-US">Lease Termination [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1598" xlink:to="label1598" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IntangiblesWriteOffMember" xlink:label="element1599" />
        <label xlink:type="resource" xlink:label="label1599" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IntangiblesWriteOffMember_en-US">Intangibles Write Off [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1599" xlink:to="label1599" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IntangiblesWriteOffMember" xlink:label="element1600" />
        <label xlink:type="resource" xlink:label="label1600" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_IntangiblesWriteOffMember_en-US">Intangibles Write Off [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1600" xlink:to="label1600" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" xlink:label="element1601" />
        <label xlink:type="resource" xlink:label="label1601" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock_en-US">Estimated Useful Lives Of Property And Equipment [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1601" xlink:to="label1601" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" xlink:label="element1602" />
        <label xlink:type="resource" xlink:label="label1602" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock_en-US">stimated Useful Lives Of Property And Equipment, table</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1602" xlink:to="label1602" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" xlink:label="element1603" />
        <label xlink:type="resource" xlink:label="label1603" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock_en-US">Estimated Useful Lives Of Property And Equipment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1603" xlink:to="label1603" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtIssuanceCostsPolicyTextBlock" xlink:label="element1604" />
        <label xlink:type="resource" xlink:label="label1604" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DebtIssuanceCostsPolicyTextBlock_en-US">Debt Issuance Costs Policy [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1604" xlink:to="label1604" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtIssuanceCostsPolicyTextBlock" xlink:label="element1605" />
        <label xlink:type="resource" xlink:label="label1605" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DebtIssuanceCostsPolicyTextBlock_en-US">Disclosure of accounting policy for debt issuance costs.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1605" xlink:to="label1605" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtIssuanceCostsPolicyTextBlock" xlink:label="element1606" />
        <label xlink:type="resource" xlink:label="label1606" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DebtIssuanceCostsPolicyTextBlock_en-US">Debt Issuance Costs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1606" xlink:to="label1606" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquipmentAndFurnitureMember" xlink:label="element1607" />
        <label xlink:type="resource" xlink:label="label1607" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EquipmentAndFurnitureMember_en-US">Equipment And Furniture [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1607" xlink:to="label1607" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquipmentAndFurnitureMember" xlink:label="element1608" />
        <label xlink:type="resource" xlink:label="label1608" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EquipmentAndFurnitureMember_en-US">Equipment And Furniture [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1608" xlink:to="label1608" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ComputerSoftwareMember" xlink:label="element1609" />
        <label xlink:type="resource" xlink:label="label1609" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ComputerSoftwareMember_en-US">Computer Software [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1609" xlink:to="label1609" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ComputerSoftwareMember" xlink:label="element1610" />
        <label xlink:type="resource" xlink:label="label1610" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ComputerSoftwareMember_en-US">Computer Software [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1610" xlink:to="label1610" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InternallyDevelopedComputerSoftwareAmortizationPeriod" xlink:label="element1611" />
        <label xlink:type="resource" xlink:label="label1611" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_InternallyDevelopedComputerSoftwareAmortizationPeriod_en-US">Internally Developed Computer Software Amortization Period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1611" xlink:to="label1611" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InternallyDevelopedComputerSoftwareAmortizationPeriod" xlink:label="element1612" />
        <label xlink:type="resource" xlink:label="label1612" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_InternallyDevelopedComputerSoftwareAmortizationPeriod_en-US">Internally developed computer software amortization period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1612" xlink:to="label1612" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InternallyDevelopedComputerSoftwareAmortizationPeriod" xlink:label="element1613" />
        <label xlink:type="resource" xlink:label="label1613" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_InternallyDevelopedComputerSoftwareAmortizationPeriod_en-US">Expected amortization period of internally developed AMS3 software once placed in service</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1613" xlink:to="label1613" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnamortizedDebtIssuanceCostAmortizatinPeriod" xlink:label="element1614" />
        <label xlink:type="resource" xlink:label="label1614" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_UnamortizedDebtIssuanceCostAmortizatinPeriod_en-US">Unamortized Debt Issuance Cost Amortizatin Period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1614" xlink:to="label1614" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnamortizedDebtIssuanceCostAmortizatinPeriod" xlink:label="element1615" />
        <label xlink:type="resource" xlink:label="label1615" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_UnamortizedDebtIssuanceCostAmortizatinPeriod_en-US">Expected amortization period of debt issuance cost</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1615" xlink:to="label1615" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnamortizedDebtIssuanceCostAmortizatinPeriod" xlink:label="element1616" />
        <label xlink:type="resource" xlink:label="label1616" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_UnamortizedDebtIssuanceCostAmortizatinPeriod_en-US">Unamortized debt issuance costs, weighted average amortization period, years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1616" xlink:to="label1616" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BuildingAndLeaseholdImprovements" xlink:label="element1617" />
        <label xlink:type="resource" xlink:label="label1617" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_BuildingAndLeaseholdImprovements_en-US">Building And Leasehold Improvements</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1617" xlink:to="label1617" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BuildingAndLeaseholdImprovements" xlink:label="element1618" />
        <label xlink:type="resource" xlink:label="label1618" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_BuildingAndLeaseholdImprovements_en-US">Building And Leasehold Improvements</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1618" xlink:to="label1618" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BuildingAndLeaseholdImprovements" xlink:label="element1619" />
        <label xlink:type="resource" xlink:label="label1619" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_BuildingAndLeaseholdImprovements_en-US">Building and leasehold improvements</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1619" xlink:to="label1619" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquipmentAndFurniture" xlink:label="element1620" />
        <label xlink:type="resource" xlink:label="label1620" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EquipmentAndFurniture_en-US">Equipment And Furniture</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1620" xlink:to="label1620" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquipmentAndFurniture" xlink:label="element1621" />
        <label xlink:type="resource" xlink:label="label1621" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EquipmentAndFurniture_en-US">Equipment And Furniture</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1621" xlink:to="label1621" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquipmentAndFurniture" xlink:label="element1622" />
        <label xlink:type="resource" xlink:label="label1622" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EquipmentAndFurniture_en-US">Equipment and furniture</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1622" xlink:to="label1622" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InternallyDevelopedComputerSoftware" xlink:label="element1623" />
        <label xlink:type="resource" xlink:label="label1623" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_InternallyDevelopedComputerSoftware_en-US">Internally Developed Computer Software</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1623" xlink:to="label1623" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InternallyDevelopedComputerSoftware" xlink:label="element1624" />
        <label xlink:type="resource" xlink:label="label1624" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_InternallyDevelopedComputerSoftware_en-US">Internally developed computer software</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1624" xlink:to="label1624" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InternallyDevelopedComputerSoftware" xlink:label="element1625" />
        <label xlink:type="resource" xlink:label="label1625" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_InternallyDevelopedComputerSoftware_en-US">Internally developed AMS3 computer software</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1625" xlink:to="label1625" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AvailableForSaleMember" xlink:label="element1626" />
        <label xlink:type="resource" xlink:label="label1626" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AvailableForSaleMember_en-US">Available For Sale [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1626" xlink:to="label1626" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AvailableForSaleMember" xlink:label="element1627" />
        <label xlink:type="resource" xlink:label="label1627" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AvailableForSaleMember_en-US">Available For Sale [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1627" xlink:to="label1627" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PriorToTwoThousandFourteenMember" xlink:label="element1628" />
        <label xlink:type="resource" xlink:label="label1628" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PriorToTwoThousandFourteenMember_en-US">Prior To Two Thousand Fourteen [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1628" xlink:to="label1628" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PriorToTwoThousandFourteenMember" xlink:label="element1629" />
        <label xlink:type="resource" xlink:label="label1629" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PriorToTwoThousandFourteenMember_en-US">Prior To Two Thousand Fourteen [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1629" xlink:to="label1629" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_January12015ToMarch312015Member" xlink:label="element1630" />
        <label xlink:type="resource" xlink:label="label1630" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_January12015ToMarch312015Member_en-US">January 1 2015 To March 31 2015 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1630" xlink:to="label1630" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_January12015ToMarch312015Member" xlink:label="element1631" />
        <label xlink:type="resource" xlink:label="label1631" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_January12015ToMarch312015Member_en-US">January 1 2015 To March 31 2015 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1631" xlink:to="label1631" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_April12015ToJune302015Member" xlink:label="element1632" />
        <label xlink:type="resource" xlink:label="label1632" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_April12015ToJune302015Member_en-US">April 1 2015 To June 30 2015 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1632" xlink:to="label1632" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_April12015ToJune302015Member" xlink:label="element1633" />
        <label xlink:type="resource" xlink:label="label1633" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_April12015ToJune302015Member_en-US">April 1 2015 To June 30 2015 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1633" xlink:to="label1633" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_July12015ToSeptember302015Member" xlink:label="element1634" />
        <label xlink:type="resource" xlink:label="label1634" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_July12015ToSeptember302015Member_en-US">July 1 2015 To September 30 2015 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1634" xlink:to="label1634" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_July12015ToSeptember302015Member" xlink:label="element1635" />
        <label xlink:type="resource" xlink:label="label1635" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_July12015ToSeptember302015Member_en-US">July 1 2015 To September 30 2015 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1635" xlink:to="label1635" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_October12015ToDecember312015Member" xlink:label="element1636" />
        <label xlink:type="resource" xlink:label="label1636" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_October12015ToDecember312015Member_en-US">October 1 2015 To December 31 2015 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1636" xlink:to="label1636" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_October12015ToDecember312015Member" xlink:label="element1637" />
        <label xlink:type="resource" xlink:label="label1637" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_October12015ToDecember312015Member_en-US">October 1 2015 To December 31 2015 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1637" xlink:to="label1637" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_January12016ToMarch312016Member" xlink:label="element1638" />
        <label xlink:type="resource" xlink:label="label1638" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_January12016ToMarch312016Member_en-US">January 1 2016 To March 31 2016 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1638" xlink:to="label1638" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_January12016ToMarch312016Member" xlink:label="element1639" />
        <label xlink:type="resource" xlink:label="label1639" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_January12016ToMarch312016Member_en-US">January 1 2016 To March 31 2016 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1639" xlink:to="label1639" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_April12016ToJune302016Member" xlink:label="element1640" />
        <label xlink:type="resource" xlink:label="label1640" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_April12016ToJune302016Member_en-US">April 1 2016 To June 30 2016 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1640" xlink:to="label1640" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_April12016ToJune302016Member" xlink:label="element1641" />
        <label xlink:type="resource" xlink:label="label1641" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_April12016ToJune302016Member_en-US">April 1 2016 To June 30 2016 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1641" xlink:to="label1641" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_July12016ToSeptember302016Member" xlink:label="element1642" />
        <label xlink:type="resource" xlink:label="label1642" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_July12016ToSeptember302016Member_en-US">July 1 2016 To September 30 2016 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1642" xlink:to="label1642" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_July12016ToSeptember302016Member" xlink:label="element1643" />
        <label xlink:type="resource" xlink:label="label1643" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_July12016ToSeptember302016Member_en-US">July 1 2016 To September 30 2016 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1643" xlink:to="label1643" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_October12016ToDecember312016Member" xlink:label="element1644" />
        <label xlink:type="resource" xlink:label="label1644" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_October12016ToDecember312016Member_en-US">October 1 2016 To December 31 2016 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1644" xlink:to="label1644" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_October12016ToDecember312016Member" xlink:label="element1645" />
        <label xlink:type="resource" xlink:label="label1645" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_October12016ToDecember312016Member_en-US">October 1 2016 To December 31 2016 [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1645" xlink:to="label1645" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="element1646" />
        <label xlink:type="resource" xlink:label="label1646" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_en-US">Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1646" xlink:to="label1646" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="element1647" />
        <label xlink:type="resource" xlink:label="label1647" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_en-US">Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1647" xlink:to="label1647" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid" xlink:label="element1648" />
        <label xlink:type="resource" xlink:label="label1648" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid_en-US">Business Acquisition Cost Of Acquired Entity Liabilities Paid</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1648" xlink:to="label1648" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid" xlink:label="element1649" />
        <label xlink:type="resource" xlink:label="label1649" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid_en-US">Accrued liability paid to seller</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1649" xlink:to="label1649" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid" xlink:label="element1650" />
        <label xlink:type="resource" xlink:label="label1650" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid_en-US">Accrued liability paid to seller</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1650" xlink:to="label1650" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AlabamaMember" xlink:label="element1651" />
        <label xlink:type="resource" xlink:label="label1651" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AlabamaMember_en-US">Alabama [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1651" xlink:to="label1651" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AlabamaMember" xlink:label="element1652" />
        <label xlink:type="resource" xlink:label="label1652" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AlabamaMember_en-US">Alabama [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1652" xlink:to="label1652" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NorthCarolinaMember" xlink:label="element1653" />
        <label xlink:type="resource" xlink:label="label1653" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NorthCarolinaMember_en-US">North Carolina [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1653" xlink:to="label1653" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NorthCarolinaMember" xlink:label="element1654" />
        <label xlink:type="resource" xlink:label="label1654" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NorthCarolinaMember_en-US">North Carolina [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1654" xlink:to="label1654" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WestVirginiaMember" xlink:label="element1655" />
        <label xlink:type="resource" xlink:label="label1655" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_WestVirginiaMember_en-US">West Virginia [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1655" xlink:to="label1655" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WestVirginiaMember" xlink:label="element1656" />
        <label xlink:type="resource" xlink:label="label1656" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_WestVirginiaMember_en-US">West Virginia [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1656" xlink:to="label1656" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LouisianaMember" xlink:label="element1657" />
        <label xlink:type="resource" xlink:label="label1657" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_LouisianaMember_en-US">Louisiana [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1657" xlink:to="label1657" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LouisianaMember" xlink:label="element1658" />
        <label xlink:type="resource" xlink:label="label1658" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_LouisianaMember_en-US">Louisiana [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1658" xlink:to="label1658" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FloridaMember" xlink:label="element1659" />
        <label xlink:type="resource" xlink:label="label1659" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FloridaMember_en-US">Florida [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1659" xlink:to="label1659" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FloridaMember" xlink:label="element1660" />
        <label xlink:type="resource" xlink:label="label1660" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FloridaMember_en-US">Florida [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1660" xlink:to="label1660" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionAcquiredDomain" xlink:label="element1661" />
        <label xlink:type="resource" xlink:label="label1661" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_BusinessAcquisitionAcquiredDomain_en-US">Business Acquisition Acquired [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1661" xlink:to="label1661" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionAcquiredDomain" xlink:label="element1662" />
        <label xlink:type="resource" xlink:label="label1662" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_BusinessAcquisitionAcquiredDomain_en-US">Business Acquisition Acquired [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1662" xlink:to="label1662" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InHousePhysiciansPracticeMember" xlink:label="element1663" />
        <label xlink:type="resource" xlink:label="label1663" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_InHousePhysiciansPracticeMember_en-US">In House Physicians Practice [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1663" xlink:to="label1663" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InHousePhysiciansPracticeMember" xlink:label="element1664" />
        <label xlink:type="resource" xlink:label="label1664" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_InHousePhysiciansPracticeMember_en-US">In House Physicians Practice [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1664" xlink:to="label1664" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RevolvingCreditFacilityTotal" xlink:label="element1665" />
        <label xlink:type="resource" xlink:label="label1665" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_RevolvingCreditFacilityTotal_en-US">Revolving Credit Facility Total</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1665" xlink:to="label1665" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RevolvingCreditFacilityTotal" xlink:label="element1666" />
        <label xlink:type="resource" xlink:label="label1666" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_RevolvingCreditFacilityTotal_en-US">Amount of Revolving Credit Facility</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1666" xlink:to="label1666" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:label="element1667" />
        <label xlink:type="resource" xlink:label="label1667" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_en-US">Line Of Credit Facility Additional Borrowing Capacity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1667" xlink:to="label1667" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:label="element1668" />
        <label xlink:type="resource" xlink:label="label1668" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_en-US">Line Of Credit Facility Additional Borrowing Capacity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1668" xlink:to="label1668" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:label="element1669" />
        <label xlink:type="resource" xlink:label="label1669" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_en-US">Credit facility, maximum additional borrowing capacity</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1669" xlink:to="label1669" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SwingLineLoanMember" xlink:label="element1670" />
        <label xlink:type="resource" xlink:label="label1670" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SwingLineLoanMember_en-US">Swing Line Loan [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1670" xlink:to="label1670" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SwingLineLoanMember" xlink:label="element1671" />
        <label xlink:type="resource" xlink:label="label1671" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SwingLineLoanMember_en-US">Swing Line Loan [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1671" xlink:to="label1671" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentNumberOfPeriodicPayments" xlink:label="element1672" />
        <label xlink:type="resource" xlink:label="label1672" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DebtInstrumentNumberOfPeriodicPayments_en-US">Debt Instrument Number Of Periodic Payments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1672" xlink:to="label1672" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentNumberOfPeriodicPayments" xlink:label="element1673" />
        <label xlink:type="resource" xlink:label="label1673" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DebtInstrumentNumberOfPeriodicPayments_en-US">Debt instrument, number of quarterly installments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1673" xlink:to="label1673" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentNumberOfPeriodicPayments" xlink:label="element1674" />
        <label xlink:type="resource" xlink:label="label1674" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DebtInstrumentNumberOfPeriodicPayments_en-US">Debt instrument, number of quarterly installments</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1674" xlink:to="label1674" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RangeOneMember" xlink:label="element1675" />
        <label xlink:type="resource" xlink:label="label1675" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_RangeOneMember_en-US">Range One [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1675" xlink:to="label1675" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RangeOneMember" xlink:label="element1676" />
        <label xlink:type="resource" xlink:label="label1676" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_RangeOneMember_en-US">Range One [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1676" xlink:to="label1676" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RangeTwoMember" xlink:label="element1677" />
        <label xlink:type="resource" xlink:label="label1677" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_RangeTwoMember_en-US">Range Two [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1677" xlink:to="label1677" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RangeThreeMember" xlink:label="element1678" />
        <label xlink:type="resource" xlink:label="label1678" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_RangeThreeMember_en-US">Range Three [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1678" xlink:to="label1678" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RangeFourMember" xlink:label="element1679" />
        <label xlink:type="resource" xlink:label="label1679" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_RangeFourMember_en-US">Range Four [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1679" xlink:to="label1679" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:label="element1680" />
        <label xlink:type="resource" xlink:label="label1680" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_en-US">Debt Instrument Interest Additional Interest Above Federal Fund Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1680" xlink:to="label1680" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:label="element1681" />
        <label xlink:type="resource" xlink:label="label1681" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_en-US">Debt Instrument Interest Additional Interest Above Federal Fund Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1681" xlink:to="label1681" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:label="element1682" />
        <label xlink:type="resource" xlink:label="label1682" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_en-US">Credit facility, additional interest rate over Federal Funds rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1682" xlink:to="label1682" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:label="element1683" />
        <label xlink:type="resource" xlink:label="label1683" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_en-US">Debt Instrument Interest Additional Interest Above Eurodollar Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1683" xlink:to="label1683" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:label="element1684" />
        <label xlink:type="resource" xlink:label="label1684" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_en-US">Debt Instrument Interest Additional Interest Above Eurodollar Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1684" xlink:to="label1684" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:label="element1685" />
        <label xlink:type="resource" xlink:label="label1685" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_en-US">Credit Facility, additional interest rate over Eurodollar Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1685" xlink:to="label1685" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ApplicableMarginRateOnBaseRate" xlink:label="element1686" />
        <label xlink:type="resource" xlink:label="label1686" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ApplicableMarginRateOnBaseRate_en-US">Applicable Margin Rate On Base Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1686" xlink:to="label1686" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ApplicableMarginRateOnBaseRate" xlink:label="element1687" />
        <label xlink:type="resource" xlink:label="label1687" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ApplicableMarginRateOnBaseRate_en-US">Applicable Margin Rate On Base Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1687" xlink:to="label1687" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ApplicableMarginRateOnBaseRate" xlink:label="element1688" />
        <label xlink:type="resource" xlink:label="label1688" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ApplicableMarginRateOnBaseRate_en-US">Credit Facility, applicable margin on Base Rate Advances</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1688" xlink:to="label1688" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ApplicableMarginRateOnEurodollarRate" xlink:label="element1689" />
        <label xlink:type="resource" xlink:label="label1689" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ApplicableMarginRateOnEurodollarRate_en-US">Applicable Margin Rate On Eurodollar Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1689" xlink:to="label1689" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ApplicableMarginRateOnEurodollarRate" xlink:label="element1690" />
        <label xlink:type="resource" xlink:label="label1690" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ApplicableMarginRateOnEurodollarRate_en-US">Applicable Margin Rate On Eurodollar Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1690" xlink:to="label1690" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ApplicableMarginRateOnEurodollarRate" xlink:label="element1691" />
        <label xlink:type="resource" xlink:label="label1691" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ApplicableMarginRateOnEurodollarRate_en-US">Credit Facility, applicable margin on Eurodollar Rate Advances</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1691" xlink:to="label1691" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AbrLoansMember" xlink:label="element1692" />
        <label xlink:type="resource" xlink:label="label1692" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AbrLoansMember_en-US">Abr Loans [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1692" xlink:to="label1692" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AbrLoansMember" xlink:label="element1693" />
        <label xlink:type="resource" xlink:label="label1693" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AbrLoansMember_en-US">Abr Loans [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1693" xlink:to="label1693" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EurodollarLoansMember" xlink:label="element1694" />
        <label xlink:type="resource" xlink:label="label1694" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EurodollarLoansMember_en-US">Eurodollar Loans [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1694" xlink:to="label1694" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EurodollarLoansMember" xlink:label="element1695" />
        <label xlink:type="resource" xlink:label="label1695" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EurodollarLoansMember_en-US">Eurodollar Loans [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1695" xlink:to="label1695" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseCommitmentsForDiscontinuedOperations" xlink:label="element1696" />
        <label xlink:type="resource" xlink:label="label1696" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OperatingLeaseCommitmentsForDiscontinuedOperations_en-US">Operating Lease Commitments For Discontinued Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1696" xlink:to="label1696" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseCommitmentsForDiscontinuedOperations" xlink:label="element1697" />
        <label xlink:type="resource" xlink:label="label1697" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OperatingLeaseCommitmentsForDiscontinuedOperations_en-US">Operating Lease Commitments For Discontinued Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1697" xlink:to="label1697" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseCommitmentsForDiscontinuedOperations" xlink:label="element1698" />
        <label xlink:type="resource" xlink:label="label1698" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_OperatingLeaseCommitmentsForDiscontinuedOperations_en-US">Future rental commitments for discontinued operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1698" xlink:to="label1698" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeasesRentExpenseNetForContinuingOperations" xlink:label="element1699" />
        <label xlink:type="resource" xlink:label="label1699" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OperatingLeasesRentExpenseNetForContinuingOperations_en-US">Operating Leases Rent Expense Net For Continuing Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1699" xlink:to="label1699" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeasesRentExpenseNetForContinuingOperations" xlink:label="element1700" />
        <label xlink:type="resource" xlink:label="label1700" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OperatingLeasesRentExpenseNetForContinuingOperations_en-US">Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income for continuing operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1700" xlink:to="label1700" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeasesRentExpenseNetForContinuingOperations" xlink:label="element1701" />
        <label xlink:type="resource" xlink:label="label1701" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_OperatingLeasesRentExpenseNetForContinuingOperations_en-US">Rent expense for non-cancelable operating leases</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1701" xlink:to="label1701" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseTermYears" xlink:label="element1702" />
        <label xlink:type="resource" xlink:label="label1702" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OperatingLeaseTermYears_en-US">Operating Lease Term Years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1702" xlink:to="label1702" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseTermYears" xlink:label="element1703" />
        <label xlink:type="resource" xlink:label="label1703" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_OperatingLeaseTermYears_en-US">Operating lease term, years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1703" xlink:to="label1703" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseTermYears" xlink:label="element1704" />
        <label xlink:type="resource" xlink:label="label1704" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OperatingLeaseTermYears_en-US">Operating lease term, years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1704" xlink:to="label1704" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeasesAgreementExpirationYear" xlink:label="element1705" />
        <label xlink:type="resource" xlink:label="label1705" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OperatingLeasesAgreementExpirationYear_en-US">Operating Leases Agreement Expiration Year</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1705" xlink:to="label1705" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeasesAgreementExpirationYear" xlink:label="element1706" />
        <label xlink:type="resource" xlink:label="label1706" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OperatingLeasesAgreementExpirationYear_en-US">Operating lease agreement year</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1706" xlink:to="label1706" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeasesAgreementExpirationYear" xlink:label="element1707" />
        <label xlink:type="resource" xlink:label="label1707" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_OperatingLeasesAgreementExpirationYear_en-US">Operating lease agreement year</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1707" xlink:to="label1707" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityDomain" xlink:label="element1708" />
        <label xlink:type="resource" xlink:label="label1708" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_LineOfCreditFacilityDomain_en-US">Line Of Credit Facility [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1708" xlink:to="label1708" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityDomain" xlink:label="element1709" />
        <label xlink:type="resource" xlink:label="label1709" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_LineOfCreditFacilityDomain_en-US">Line Of Credit Facility [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1709" xlink:to="label1709" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:label="element1710" />
        <label xlink:type="resource" xlink:label="label1710" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_en-US">Percentage Of Revenue And Of Earnings Before Interest Taxes Depreciation And Amortization From Wholly Owned Subsidiaries</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1710" xlink:to="label1710" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:label="element1711" />
        <label xlink:type="resource" xlink:label="label1711" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_en-US">Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1711" xlink:to="label1711" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:label="element1712" />
        <label xlink:type="resource" xlink:label="label1712" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_en-US">Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1712" xlink:to="label1712" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PromissoryNotesMember" xlink:label="element1713" />
        <label xlink:type="resource" xlink:label="label1713" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PromissoryNotesMember_en-US">Promissory Notes [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1713" xlink:to="label1713" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PromissoryNotesMember" xlink:label="element1714" />
        <label xlink:type="resource" xlink:label="label1714" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PromissoryNotesMember_en-US">Promissory Notes [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1714" xlink:to="label1714" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersIncludedInDiscontinuedOperations" xlink:label="element1715" />
        <label xlink:type="resource" xlink:label="label1715" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfCareCentersIncludedInDiscontinuedOperations_en-US">Number Of Care Centers Included In Discontinued Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1715" xlink:to="label1715" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersIncludedInDiscontinuedOperations" xlink:label="element1716" />
        <label xlink:type="resource" xlink:label="label1716" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfCareCentersIncludedInDiscontinuedOperations_en-US">Number of care centers included in discontinued operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1716" xlink:to="label1716" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersIncludedInDiscontinuedOperations" xlink:label="element1717" />
        <label xlink:type="resource" xlink:label="label1717" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfCareCentersIncludedInDiscontinuedOperations_en-US">The number of care centers included in discontinued operations during the period.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1717" xlink:to="label1717" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndOtherIntangiblesImpairmentMember" xlink:label="element1718" />
        <label xlink:type="resource" xlink:label="label1718" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_GoodwillAndOtherIntangiblesImpairmentMember_en-US">Goodwill And Other Intangibles Impairment [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1718" xlink:to="label1718" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndOtherIntangiblesImpairmentMember" xlink:label="element1719" />
        <label xlink:type="resource" xlink:label="label1719" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_GoodwillAndOtherIntangiblesImpairmentMember_en-US">Goodwill And Other Intangibles Impairment [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1719" xlink:to="label1719" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FutureRentalCommitmentsTable" xlink:label="element1720" />
        <label xlink:type="resource" xlink:label="label1720" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FutureRentalCommitmentsTable_en-US">Future Rental Commitments [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1720" xlink:to="label1720" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssetWriteOffMember" xlink:label="element1721" />
        <label xlink:type="resource" xlink:label="label1721" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AssetWriteOffMember_en-US">Asset Write Off [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1721" xlink:to="label1721" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssetWriteOffMember" xlink:label="element1722" />
        <label xlink:type="resource" xlink:label="label1722" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AssetWriteOffMember_en-US">Asset Write Off [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1722" xlink:to="label1722" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:label="element1723" />
        <label xlink:type="resource" xlink:label="label1723" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_en-US">Percentage Of Earnings Before Interest Taxes Depreciation And Amortization From Subsidiaries</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1723" xlink:to="label1723" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:label="element1724" />
        <label xlink:type="resource" xlink:label="label1724" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_en-US">Percentage of adjusted EBITDA that guarantor subsidiaries represent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1724" xlink:to="label1724" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:label="element1725" />
        <label xlink:type="resource" xlink:label="label1725" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_en-US">Percentage of adjusted EBITDA that guarantor subsidiaries represent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1725" xlink:to="label1725" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandFifteenMember" xlink:label="element1726" />
        <label xlink:type="resource" xlink:label="label1726" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CapYearTwoThousandThirteenThroughTwoThousandFifteenMember_en-US">Cap Year Two Thousand Thirteen Through Two Thousand Fifteen [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1726" xlink:to="label1726" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandFifteenMember" xlink:label="element1727" />
        <label xlink:type="resource" xlink:label="label1727" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CapYearTwoThousandThirteenThroughTwoThousandFifteenMember_en-US">Cap Year Two Thousand Thirteen Through Two Thousand Fifteen [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1727" xlink:to="label1727" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandFifteenMember" xlink:label="element1728" />
        <label xlink:type="resource" xlink:label="label1728" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_CapYearTwoThousandThirteenThroughTwoThousandFifteenMember_en-US">2013 - 2015</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1728" xlink:to="label1728" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedUsefulLifeOfIntangibleAssets" xlink:label="element1729" />
        <label xlink:type="resource" xlink:label="label1729" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EstimatedUsefulLifeOfIntangibleAssets_en-US">Estimated Useful Life of Intangible Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1729" xlink:to="label1729" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedUsefulLifeOfIntangibleAssets" xlink:label="element1730" />
        <label xlink:type="resource" xlink:label="label1730" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EstimatedUsefulLifeOfIntangibleAssets_en-US">The estimated useful life of the company's intangible assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1730" xlink:to="label1730" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedUsefulLifeOfIntangibleAssets" xlink:label="element1731" />
        <label xlink:type="resource" xlink:label="label1731" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EstimatedUsefulLifeOfIntangibleAssets_en-US">Estimated useful life of intangible assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1731" xlink:to="label1731" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AcquiredNamesMember" xlink:label="element1732" />
        <label xlink:type="resource" xlink:label="label1732" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AcquiredNamesMember_en-US">Acquired Names [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1732" xlink:to="label1732" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AcquiredNamesMember" xlink:label="element1733" />
        <label xlink:type="resource" xlink:label="label1733" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AcquiredNamesMember_en-US">Acquired Names [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1733" xlink:to="label1733" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FavorableInFullMember" xlink:label="element1734" />
        <label xlink:type="resource" xlink:label="label1734" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FavorableInFullMember_en-US">Favorable In Full [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1734" xlink:to="label1734" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FavorableInFullMember" xlink:label="element1735" />
        <label xlink:type="resource" xlink:label="label1735" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FavorableInFullMember_en-US">Favorable In Full [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1735" xlink:to="label1735" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FavorableInPartMember" xlink:label="element1736" />
        <label xlink:type="resource" xlink:label="label1736" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FavorableInPartMember_en-US">Favorable In Part [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1736" xlink:to="label1736" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FavorableInPartMember" xlink:label="element1737" />
        <label xlink:type="resource" xlink:label="label1737" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FavorableInPartMember_en-US">Favorable In Part [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1737" xlink:to="label1737" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfClaimsAppealed" xlink:label="element1738" />
        <label xlink:type="resource" xlink:label="label1738" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfClaimsAppealed_en-US">Number Of Claims Appealed</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1738" xlink:to="label1738" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfClaimsAppealed" xlink:label="element1739" />
        <label xlink:type="resource" xlink:label="label1739" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfClaimsAppealed_en-US">Number of claims appealed</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1739" xlink:to="label1739" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfClaimsAppealed" xlink:label="element1740" />
        <label xlink:type="resource" xlink:label="label1740" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfClaimsAppealed_en-US">Number of claims appealed</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1740" xlink:to="label1740" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" xlink:label="element1741" />
        <label xlink:type="resource" xlink:label="label1741" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_en-US">Number Of Prospective Unopened Care Centers Start Up Process Discontinued</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1741" xlink:to="label1741" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" xlink:label="element1742" />
        <label xlink:type="resource" xlink:label="label1742" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_en-US">Number of care centers start-up process discontinued</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1742" xlink:to="label1742" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" xlink:label="element1743" />
        <label xlink:type="resource" xlink:label="label1743" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_en-US">The number of prospective unopened care centers for which the start-up process was discontinued during the period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1743" xlink:to="label1743" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NotIncludedInAvailableForSaleMember" xlink:label="element1744" />
        <label xlink:type="resource" xlink:label="label1744" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NotIncludedInAvailableForSaleMember_en-US">Not Included In Available For Sale [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1744" xlink:to="label1744" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NotIncludedInAvailableForSaleMember" xlink:label="element1745" />
        <label xlink:type="resource" xlink:label="label1745" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NotIncludedInAvailableForSaleMember_en-US">Not Included In Available For Sale [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1745" xlink:to="label1745" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="element1746" />
        <label xlink:type="resource" xlink:label="label1746" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_GoodwillAndIntangibleAssetsImpairmentAxis_en-US">Goodwill And Intangible Assets Impairment [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1746" xlink:to="label1746" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="element1747" />
        <label xlink:type="resource" xlink:label="label1747" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_GoodwillAndIntangibleAssetsDomain_en-US">Goodwill And Intangible Assets [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1747" xlink:to="label1747" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondLienCreditAgreementTermLoanMember" xlink:label="element1748" />
        <label xlink:type="resource" xlink:label="label1748" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SecondLienCreditAgreementTermLoanMember_en-US">Second Lien Credit Agreement Term Loan [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1748" xlink:to="label1748" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondLienCreditAgreementTermLoanMember" xlink:label="element1749" />
        <label xlink:type="resource" xlink:label="label1749" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SecondLienCreditAgreementTermLoanMember_en-US">Second Lien Credit Agreement Term Loan [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1749" xlink:to="label1749" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeniorSecuredLeverageRatio" xlink:label="element1750" />
        <label xlink:type="resource" xlink:label="label1750" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SeniorSecuredLeverageRatio_en-US">Senior Secured Leverage Ratio</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1750" xlink:to="label1750" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeniorSecuredLeverageRatio" xlink:label="element1751" />
        <label xlink:type="resource" xlink:label="label1751" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SeniorSecuredLeverageRatio_en-US">Senior secured leverage ratio</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1751" xlink:to="label1751" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeniorSecuredLeverageRatio" xlink:label="element1752" />
        <label xlink:type="resource" xlink:label="label1752" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_SeniorSecuredLeverageRatio_en-US">Senior secured leverage ratio</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1752" xlink:to="label1752" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondLienCreditAgreementRevolvingCreditFacilityMember" xlink:label="element1753" />
        <label xlink:type="resource" xlink:label="label1753" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SecondLienCreditAgreementRevolvingCreditFacilityMember_en-US">Second Lien Credit Agreement Revolving Credit Facility [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1753" xlink:to="label1753" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondLienCreditAgreementRevolvingCreditFacilityMember" xlink:label="element1754" />
        <label xlink:type="resource" xlink:label="label1754" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SecondLienCreditAgreementRevolvingCreditFacilityMember_en-US">Second Lien Credit Agreement Revolving Credit Facility [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1754" xlink:to="label1754" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveABRRate" xlink:label="element1755" />
        <label xlink:type="resource" xlink:label="label1755" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DebtInstrumentInterestAdditionalInterestAboveABRRate_en-US">Debt Instrument Interest Additional Interest Above ABR Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1755" xlink:to="label1755" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveABRRate" xlink:label="element1756" />
        <label xlink:type="resource" xlink:label="label1756" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DebtInstrumentInterestAdditionalInterestAboveABRRate_en-US">Credit Facility, additional interest rate over ABR Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1756" xlink:to="label1756" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveABRRate" xlink:label="element1757" />
        <label xlink:type="resource" xlink:label="label1757" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DebtInstrumentInterestAdditionalInterestAboveABRRate_en-US">Debt Instrument Interest Additional Interest Above ABR Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1757" xlink:to="label1757" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate" xlink:label="element1758" />
        <label xlink:type="resource" xlink:label="label1758" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate_en-US">Debt Instrument Interest Additional Interest Above One Month Eurodollar Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1758" xlink:to="label1758" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate" xlink:label="element1759" />
        <label xlink:type="resource" xlink:label="label1759" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate_en-US">Credit Facility, additional interest rate over One Month Eurodollar Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1759" xlink:to="label1759" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate" xlink:label="element1760" />
        <label xlink:type="resource" xlink:label="label1760" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate_en-US">Debt Instrument Interest Additional Interest Above One Month Eurodollar Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1760" xlink:to="label1760" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestABRFlatRate" xlink:label="element1761" />
        <label xlink:type="resource" xlink:label="label1761" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DebtInstrumentInterestABRFlatRate_en-US">Debt Instrument Interest ABR Flat Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1761" xlink:to="label1761" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestABRFlatRate" xlink:label="element1762" />
        <label xlink:type="resource" xlink:label="label1762" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DebtInstrumentInterestABRFlatRate_en-US">Debt Instrument Interest ABR Flat Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1762" xlink:to="label1762" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestABRFlatRate" xlink:label="element1763" />
        <label xlink:type="resource" xlink:label="label1763" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DebtInstrumentInterestABRFlatRate_en-US">Credit Facility, ABR Flat Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1763" xlink:to="label1763" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EurodollarDepositsInterestPeriod" xlink:label="element1764" />
        <label xlink:type="resource" xlink:label="label1764" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EurodollarDepositsInterestPeriod_en-US">Eurodollar Deposits Interest Period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1764" xlink:to="label1764" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EurodollarDepositsInterestPeriod" xlink:label="element1765" />
        <label xlink:type="resource" xlink:label="label1765" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EurodollarDepositsInterestPeriod_en-US">Eurodollar Deposits Interest Period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1765" xlink:to="label1765" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EurodollarDepositsInterestPeriod" xlink:label="element1766" />
        <label xlink:type="resource" xlink:label="label1766" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EurodollarDepositsInterestPeriod_en-US">Eurodollar deposits interest period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1766" xlink:to="label1766" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestLiborFloor" xlink:label="element1767" />
        <label xlink:type="resource" xlink:label="label1767" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DebtInstrumentInterestLiborFloor_en-US">Debt Instrument Interest LIBOR Floor</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1767" xlink:to="label1767" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestLiborFloor" xlink:label="element1768" />
        <label xlink:type="resource" xlink:label="label1768" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DebtInstrumentInterestLiborFloor_en-US">Debt Instrument Interest LIBOR Floor</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1768" xlink:to="label1768" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestLiborFloor" xlink:label="element1769" />
        <label xlink:type="resource" xlink:label="label1769" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DebtInstrumentInterestLiborFloor_en-US">Credit Facility, LIBOR floor</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1769" xlink:to="label1769" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CreditAgreementMember" xlink:label="element1770" />
        <label xlink:type="resource" xlink:label="label1770" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CreditAgreementMember_en-US">Credit Agreement [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1770" xlink:to="label1770" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CreditAgreementMember" xlink:label="element1771" />
        <label xlink:type="resource" xlink:label="label1771" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CreditAgreementMember_en-US">Credit Agreement [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1771" xlink:to="label1771" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherLongTermObligationsMember" xlink:label="element1772" />
        <label xlink:type="resource" xlink:label="label1772" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OtherLongTermObligationsMember_en-US">Other Long Term Obligations [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1772" xlink:to="label1772" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherLongTermObligationsMember" xlink:label="element1773" />
        <label xlink:type="resource" xlink:label="label1773" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OtherLongTermObligationsMember_en-US">Other Long Term Obligations [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1773" xlink:to="label1773" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredIncomeTaxesMember" xlink:label="element1774" />
        <label xlink:type="resource" xlink:label="label1774" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DeferredIncomeTaxesMember_en-US">Deferred Income Taxes [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1774" xlink:to="label1774" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredIncomeTaxesMember" xlink:label="element1775" />
        <label xlink:type="resource" xlink:label="label1775" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DeferredIncomeTaxesMember_en-US">Deferred Income Taxes [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1775" xlink:to="label1775" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoThousandAndFourteenExitActivityMember" xlink:label="element1776" />
        <label xlink:type="resource" xlink:label="label1776" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TwoThousandAndFourteenExitActivityMember_en-US">Two Thousand And Fourteen Exit Activity [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1776" xlink:to="label1776" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoThousandAndFourteenExitActivityMember" xlink:label="element1777" />
        <label xlink:type="resource" xlink:label="label1777" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_TwoThousandAndFourteenExitActivityMember_en-US">Two Thousand And Fourteen Exit Activity [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1777" xlink:to="label1777" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoThousandAndFourteenExitActivityMember" xlink:label="element1778" />
        <label xlink:type="resource" xlink:label="label1778" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_TwoThousandAndFourteenExitActivityMember_en-US">2014 Exit Activity [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1778" xlink:to="label1778" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WyomingAndIdahoCareCentersMember" xlink:label="element1779" />
        <label xlink:type="resource" xlink:label="label1779" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_WyomingAndIdahoCareCentersMember_en-US">Wyoming and Idaho Care Centers [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1779" xlink:to="label1779" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceInpatientUnitMember" xlink:label="element1780" />
        <label xlink:type="resource" xlink:label="label1780" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_HospiceInpatientUnitMember_en-US">Hospice Inpatient Unit [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1780" xlink:to="label1780" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeveranceForRegionalLeadershipAndCorporateSupportMember" xlink:label="element1781" />
        <label xlink:type="resource" xlink:label="label1781" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SeveranceForRegionalLeadershipAndCorporateSupportMember_en-US">Severance For Regional Leadership And Corporate Support [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1781" xlink:to="label1781" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeveranceForRegionalLeadershipAndCorporateSupportMember" xlink:label="element1782" />
        <label xlink:type="resource" xlink:label="label1782" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SeveranceForRegionalLeadershipAndCorporateSupportMember_en-US">Severance For Regional Leadership And Corporate Support [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1782" xlink:to="label1782" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeveranceForFormerExecutiveMember" xlink:label="element1783" />
        <label xlink:type="resource" xlink:label="label1783" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SeveranceForFormerExecutiveMember_en-US">Severance For Former Executive [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1783" xlink:to="label1783" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeveranceForFormerExecutiveMember" xlink:label="element1784" />
        <label xlink:type="resource" xlink:label="label1784" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SeveranceForFormerExecutiveMember_en-US">Severance For Former Executive [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1784" xlink:to="label1784" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtIssuanceCostsLineItems" xlink:label="element1785" />
        <label xlink:type="resource" xlink:label="label1785" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DebtIssuanceCostsLineItems_en-US">Debt Issuance Costs [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1785" xlink:to="label1785" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtIssuanceCostsLineItems" xlink:label="element1786" />
        <label xlink:type="resource" xlink:label="label1786" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DebtIssuanceCostsLineItems_en-US">Debt Issuance Costs [Line Items]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1786" xlink:to="label1786" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CorporateIntegrityAgreementTerm" xlink:label="element1787" />
        <label xlink:type="resource" xlink:label="label1787" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CorporateIntegrityAgreementTerm_en-US">Corporate Integrity Agreement Term</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1787" xlink:to="label1787" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CorporateIntegrityAgreementTerm" xlink:label="element1788" />
        <label xlink:type="resource" xlink:label="label1788" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_CorporateIntegrityAgreementTerm_en-US">Corporate Integrity Agreement Term</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1788" xlink:to="label1788" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CorporateIntegrityAgreementTerm" xlink:label="element1789" />
        <label xlink:type="resource" xlink:label="label1789" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CorporateIntegrityAgreementTerm_en-US">Corporate Integrity Agreement Term</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1789" xlink:to="label1789" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodAxis" xlink:label="element1790" />
        <label xlink:type="resource" xlink:label="label1790" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TimePeriodAxis_en-US">Time Period [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1790" xlink:to="label1790" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodDomain" xlink:label="element1791" />
        <label xlink:type="resource" xlink:label="label1791" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TimePeriodDomain_en-US">Time Period [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1791" xlink:to="label1791" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OneMonthMember" xlink:label="element1792" />
        <label xlink:type="resource" xlink:label="label1792" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OneMonthMember_en-US">One Month [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1792" xlink:to="label1792" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OneMonthMember" xlink:label="element1793" />
        <label xlink:type="resource" xlink:label="label1793" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OneMonthMember_en-US">One Month [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1793" xlink:to="label1793" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoMonthMember" xlink:label="element1794" />
        <label xlink:type="resource" xlink:label="label1794" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TwoMonthMember_en-US">Two Month [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1794" xlink:to="label1794" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoMonthMember" xlink:label="element1795" />
        <label xlink:type="resource" xlink:label="label1795" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_TwoMonthMember_en-US">Two Month [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1795" xlink:to="label1795" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ThreeMonthMember" xlink:label="element1796" />
        <label xlink:type="resource" xlink:label="label1796" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ThreeMonthMember_en-US">Three Month [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1796" xlink:to="label1796" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ThreeMonthMember" xlink:label="element1797" />
        <label xlink:type="resource" xlink:label="label1797" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ThreeMonthMember_en-US">Three Month [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1797" xlink:to="label1797" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SixMonthMember" xlink:label="element1798" />
        <label xlink:type="resource" xlink:label="label1798" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SixMonthMember_en-US">Six Month [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1798" xlink:to="label1798" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SixMonthMember" xlink:label="element1799" />
        <label xlink:type="resource" xlink:label="label1799" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SixMonthMember_en-US">Six Month [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1799" xlink:to="label1799" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OneYearMember" xlink:label="element1800" />
        <label xlink:type="resource" xlink:label="label1800" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OneYearMember_en-US">One Year [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1800" xlink:to="label1800" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoYearMember" xlink:label="element1801" />
        <label xlink:type="resource" xlink:label="label1801" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TwoYearMember_en-US">Two Year [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1801" xlink:to="label1801" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AnnualImpairmentTestStepOneMember" xlink:label="element1802" />
        <label xlink:type="resource" xlink:label="label1802" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AnnualImpairmentTestStepOneMember_en-US">Annual Impairment Test Step One [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1802" xlink:to="label1802" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AnnualImpairmentTestStepOneMember" xlink:label="element1803" />
        <label xlink:type="resource" xlink:label="label1803" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AnnualImpairmentTestStepOneMember_en-US">Annual Impairment Test Step One [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1803" xlink:to="label1803" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PrepaymentPenaltyPercentage" xlink:label="element1804" />
        <label xlink:type="resource" xlink:label="label1804" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PrepaymentPenaltyPercentage_en-US">Prepayment Penalty Percentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1804" xlink:to="label1804" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PrepaymentPenaltyPercentage" xlink:label="element1805" />
        <label xlink:type="resource" xlink:label="label1805" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PrepaymentPenaltyPercentage_en-US">Prepayment Penalty Percentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1805" xlink:to="label1805" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PrepaymentPenaltyPercentage" xlink:label="element1806" />
        <label xlink:type="resource" xlink:label="label1806" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_PrepaymentPenaltyPercentage_en-US">Prepayment penalty percentage</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1806" xlink:to="label1806" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual" xlink:label="element1807" />
        <label xlink:type="resource" xlink:label="label1807" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual_en-US">Increase Decrease In U.S. Department of Justice Settlement Accrual</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1807" xlink:to="label1807" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual" xlink:label="element1808" />
        <label xlink:type="resource" xlink:label="label1808" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual_en-US">Increase Decrease In U.S. Department of Justice Settlement Accrual</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1808" xlink:to="label1808" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual" xlink:label="element1809" />
        <label xlink:type="resource" xlink:label="label1809" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual_en-US">U.S. Department of Justice settlement</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1809" xlink:to="label1809" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ClassificationOfDeferredTaxAssetsLiabilitiesTextBlock" xlink:label="element1810" />
        <label xlink:type="resource" xlink:label="label1810" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ClassificationOfDeferredTaxAssetsLiabilitiesTextBlock_en-US">Classification Of Deferred Tax Assets Liabilities [Text Block]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1810" xlink:to="label1810" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ClassificationOfDeferredTaxAssetsLiabilitiesTextBlock" xlink:label="element1811" />
        <label xlink:type="resource" xlink:label="label1811" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ClassificationOfDeferredTaxAssetsLiabilitiesTextBlock_en-US">Classification Of Deferred Tax Assets Liabilities Table</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1811" xlink:to="label1811" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ClassificationOfDeferredTaxAssetsLiabilitiesTextBlock" xlink:label="element1812" />
        <label xlink:type="resource" xlink:label="label1812" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ClassificationOfDeferredTaxAssetsLiabilitiesTextBlock_en-US">Classification of Deferred Tax Assets and Liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1812" xlink:to="label1812" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UncertainTaxBenefitsInLongTermObligations" xlink:label="element1813" />
        <label xlink:type="resource" xlink:label="label1813" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_UncertainTaxBenefitsInLongTermObligations_en-US">Uncertain Tax Benefits In Long Term Obligations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1813" xlink:to="label1813" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UncertainTaxBenefitsInLongTermObligations" xlink:label="element1814" />
        <label xlink:type="resource" xlink:label="label1814" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_UncertainTaxBenefitsInLongTermObligations_en-US">Uncertain Tax Benefits In Long Term Obligations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1814" xlink:to="label1814" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UncertainTaxBenefitsInLongTermObligations" xlink:label="element1815" />
        <label xlink:type="resource" xlink:label="label1815" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_UncertainTaxBenefitsInLongTermObligations_en-US">Reserve for uncertain tax positions</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1815" xlink:to="label1815" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredIncomeTaxesForContinuingOperations" xlink:label="element1816" />
        <label xlink:type="resource" xlink:label="label1816" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DeferredIncomeTaxesForContinuingOperations_en-US">Deferred Income Taxes For Continuing Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1816" xlink:to="label1816" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredIncomeTaxesForContinuingOperations" xlink:label="element1817" />
        <label xlink:type="resource" xlink:label="label1817" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DeferredIncomeTaxesForContinuingOperations_en-US">Deferred Income Taxes For Continuing Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1817" xlink:to="label1817" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredIncomeTaxesForContinuingOperations" xlink:label="element1818" />
        <label xlink:type="resource" xlink:label="label1818" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DeferredIncomeTaxesForContinuingOperations_en-US">Deferred income taxes</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1818" xlink:to="label1818" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests" xlink:label="element1819" />
        <label xlink:type="resource" xlink:label="label1819" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests_en-US">Noncash Or Part Noncash Sale Acquisition Of Noncontrolling Interests</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1819" xlink:to="label1819" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests" xlink:label="element1820" />
        <label xlink:type="resource" xlink:label="label1820" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests_en-US">(Sale) acquistion of noncontrolling interests</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1820" xlink:to="label1820" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests" xlink:label="element1821" />
        <label xlink:type="resource" xlink:label="label1821" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests_en-US">Noncash Or Part Noncash Sale Acquisition Of Noncontrolling Interests</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1821" xlink:to="label1821" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FeeTypeAxis" xlink:label="element1822" />
        <label xlink:type="resource" xlink:label="label1822" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FeeTypeAxis_en-US">Fee Type [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1822" xlink:to="label1822" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FeeTypeAxis" xlink:label="element1823" />
        <label xlink:type="resource" xlink:label="label1823" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FeeTypeAxis_en-US">Fee Type [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1823" xlink:to="label1823" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FeeTypeDomain" xlink:label="element1824" />
        <label xlink:type="resource" xlink:label="label1824" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FeeTypeDomain_en-US">Fee Type [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1824" xlink:to="label1824" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ArrangerFeeMember" xlink:label="element1825" />
        <label xlink:type="resource" xlink:label="label1825" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ArrangerFeeMember_en-US">Arranger Fee [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1825" xlink:to="label1825" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ArrangerFeeMember" xlink:label="element1826" />
        <label xlink:type="resource" xlink:label="label1826" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ArrangerFeeMember_en-US">Arranger Fee [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1826" xlink:to="label1826" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ComputerInventoryAndDataSecurityReportingMember" xlink:label="element1827" />
        <label xlink:type="resource" xlink:label="label1827" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ComputerInventoryAndDataSecurityReportingMember_en-US">Computer Inventory And Data Security Reporting [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1827" xlink:to="label1827" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ComputerInventoryAndDataSecurityReportingMember" xlink:label="element1828" />
        <label xlink:type="resource" xlink:label="label1828" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ComputerInventoryAndDataSecurityReportingMember_en-US">Computer Inventory And Data Security Reporting</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1828" xlink:to="label1828" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfIndividualsWithInformationOnMissingDevices" xlink:label="element1829" />
        <label xlink:type="resource" xlink:label="label1829" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfIndividualsWithInformationOnMissingDevices_en-US">Number of Individuals With Information on Missing Devices</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1829" xlink:to="label1829" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfIndividualsWithInformationOnMissingDevices" xlink:label="element1830" />
        <label xlink:type="resource" xlink:label="label1830" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfIndividualsWithInformationOnMissingDevices_en-US">Number of individuals whose information was on reported missing devices</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1830" xlink:to="label1830" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfMissingComputersAndLaptops" xlink:label="element1831" />
        <label xlink:type="resource" xlink:label="label1831" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NumberOfMissingComputersAndLaptops_en-US">Number of Missing Computers and Laptops</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1831" xlink:to="label1831" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfMissingComputersAndLaptops" xlink:label="element1832" />
        <label xlink:type="resource" xlink:label="label1832" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NumberOfMissingComputersAndLaptops_en-US">Number of missing computers and laptops</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1832" xlink:to="label1832" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ThresholdOfIndividualsInDataBreach" xlink:label="element1833" />
        <label xlink:type="resource" xlink:label="label1833" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ThresholdOfIndividualsInDataBreach_en-US">Threshold of Individuals in Data Breach</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1833" xlink:to="label1833" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ThresholdOfIndividualsInDataBreach" xlink:label="element1834" />
        <label xlink:type="resource" xlink:label="label1834" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ThresholdOfIndividualsInDataBreach_en-US">Threshold of number of individuals involved in a data breach</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1834" xlink:to="label1834" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfCompanyDevicesUsed" xlink:label="element1835" />
        <label xlink:type="resource" xlink:label="label1835" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PercentageOfCompanyDevicesUsed_en-US">Percentage Of Company Devices Used</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1835" xlink:to="label1835" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfCompanyDevicesUsed" xlink:label="element1836" />
        <label xlink:type="resource" xlink:label="label1836" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PercentageOfCompanyDevicesUsed_en-US">Percentage of devices used by the Company</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1836" xlink:to="label1836" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_YearOfDeparture" xlink:label="element1837" />
        <label xlink:type="resource" xlink:label="label1837" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_YearOfDeparture_en-US">Year of Departure</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1837" xlink:to="label1837" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_YearOfDeparture" xlink:label="element1838" />
        <label xlink:type="resource" xlink:label="label1838" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_YearOfDeparture_en-US">Year of departure from the company</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1838" xlink:to="label1838" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OneHundredMillionTermLoanMember" xlink:label="element1839" />
        <label xlink:type="resource" xlink:label="label1839" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OneHundredMillionTermLoanMember_en-US">One Hundred Million Term Loan [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1839" xlink:to="label1839" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OneHundredMillionTermLoanMember" xlink:label="element1840" />
        <label xlink:type="resource" xlink:label="label1840" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OneHundredMillionTermLoanMember_en-US">100 Million Term Loan [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1840" xlink:to="label1840" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CallPremiumPayment" xlink:label="element1841" />
        <label xlink:type="resource" xlink:label="label1841" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CallPremiumPayment_en-US">Call Premium Payment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1841" xlink:to="label1841" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CallPremiumPayment" xlink:label="element1842" />
        <label xlink:type="resource" xlink:label="label1842" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CallPremiumPayment_en-US">Call premium paid during the period</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1842" xlink:to="label1842" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MarginAdjustmentOnBaseRate" xlink:label="element1843" />
        <label xlink:type="resource" xlink:label="label1843" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MarginAdjustmentOnBaseRate_en-US">Margin Adjustment On Base Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1843" xlink:to="label1843" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MarginAdjustmentOnBaseRate" xlink:label="element1844" />
        <label xlink:type="resource" xlink:label="label1844" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MarginAdjustmentOnBaseRate_en-US">Margin Adjustment On Base Rate</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1844" xlink:to="label1844" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MarginAdjustmentOnBaseRate" xlink:label="element1845" />
        <label xlink:type="resource" xlink:label="label1845" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MarginAdjustmentOnBaseRate_en-US">Credit Facility, margin adjustment on Base Rate Loans</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1845" xlink:to="label1845" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MarginAdjustmentOnEuroDollarLoans" xlink:label="element1846" />
        <label xlink:type="resource" xlink:label="label1846" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MarginAdjustmentOnEuroDollarLoans_en-US">Margin Adjustment On Eurodollar Loans</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1846" xlink:to="label1846" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MarginAdjustmentOnEuroDollarLoans" xlink:label="element1847" />
        <label xlink:type="resource" xlink:label="label1847" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MarginAdjustmentOnEuroDollarLoans_en-US">Margin Adjustment On Eurodollar Loans</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1847" xlink:to="label1847" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MarginAdjustmentOnEuroDollarLoans" xlink:label="element1848" />
        <label xlink:type="resource" xlink:label="label1848" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_MarginAdjustmentOnEuroDollarLoans_en-US">Credit Facility, margin adjustment on Eurodollar Loans</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1848" xlink:to="label1848" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="element1849" />
        <label xlink:type="resource" xlink:label="label1849" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TwoHundredMillionRevolvingCreditFacilityMember_en-US">Two Hundred Million Revolving Credit Facility [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1849" xlink:to="label1849" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="element1850" />
        <label xlink:type="resource" xlink:label="label1850" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_TwoHundredMillionRevolvingCreditFacilityMember_en-US">Two Hundred Million Revolving Credit Facility [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1850" xlink:to="label1850" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MiddleMember" xlink:label="element1851" />
        <label xlink:type="resource" xlink:label="label1851" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MiddleMember_en-US">Middle [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1851" xlink:to="label1851" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MiddleMember" xlink:label="element1852" />
        <label xlink:type="resource" xlink:label="label1852" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MiddleMember_en-US">Middle [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1852" xlink:to="label1852" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FourRemainingQuarterlyPaymentsMember" xlink:label="element1853" />
        <label xlink:type="resource" xlink:label="label1853" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FourRemainingQuarterlyPaymentsMember_en-US">Four Remaining Quarterly Payments [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1853" xlink:to="label1853" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FourRemainingQuarterlyPaymentsMember" xlink:label="element1854" />
        <label xlink:type="resource" xlink:label="label1854" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FourRemainingQuarterlyPaymentsMember_en-US">Four Remaining Quarterly Payments [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1854" xlink:to="label1854" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondEightQuarterlyPaymentsMember" xlink:label="element1855" />
        <label xlink:type="resource" xlink:label="label1855" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SecondEightQuarterlyPaymentsMember_en-US">Second Eight Quarterly Payments [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1855" xlink:to="label1855" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondEightQuarterlyPaymentsMember" xlink:label="element1856" />
        <label xlink:type="resource" xlink:label="label1856" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SecondEightQuarterlyPaymentsMember_en-US">Second Eight Quarterly Payments [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1856" xlink:to="label1856" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FinalTwoQuarterlyPaymentsMember" xlink:label="element1857" />
        <label xlink:type="resource" xlink:label="label1857" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FinalTwoQuarterlyPaymentsMember_en-US">Final Two Quarterly Payments [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1857" xlink:to="label1857" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FinalTwoQuarterlyPaymentsMember" xlink:label="element1858" />
        <label xlink:type="resource" xlink:label="label1858" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FinalTwoQuarterlyPaymentsMember_en-US">Final Two Quarterly Payments [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1858" xlink:to="label1858" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LetterOfCreditFee" xlink:label="element1859" />
        <label xlink:type="resource" xlink:label="label1859" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_LetterOfCreditFee_en-US">Letter Of Credit Fee</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1859" xlink:to="label1859" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LetterOfCreditFee" xlink:label="element1860" />
        <label xlink:type="resource" xlink:label="label1860" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_LetterOfCreditFee_en-US">The fee, expressed as a percentage of the letters of credit, for the letters of credit</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1860" xlink:to="label1860" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceMember" xlink:label="element1861" />
        <label xlink:type="resource" xlink:label="label1861" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NonVestedStockUnitsServiceMember_en-US">Non Vested Stock Units Service [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1861" xlink:to="label1861" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SoftwareImplementationCosts" xlink:label="element1862" />
        <label xlink:type="resource" xlink:label="label1862" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SoftwareImplementationCosts_en-US">Software Implementation Costs</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1862" xlink:to="label1862" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SoftwareImplementationCosts" xlink:label="element1863" />
        <label xlink:type="resource" xlink:label="label1863" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SoftwareImplementationCosts_en-US">Costs Incurred For Software Implementation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1863" xlink:to="label1863" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Performancebasedawardtargetshareamount" xlink:label="element1864" />
        <label xlink:type="resource" xlink:label="label1864" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_Performancebasedawardtargetshareamount_en-US">Performance Based Award Target Share Amount</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1864" xlink:to="label1864" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Performancebasedawardtargetshareamount" xlink:label="element1865" />
        <label xlink:type="resource" xlink:label="label1865" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_Performancebasedawardtargetshareamount_en-US">Performance-based award, target number of shares to be received</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1865" xlink:to="label1865" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Performancebasedawardtargetshareamount" xlink:label="element1866" />
        <label xlink:type="resource" xlink:label="label1866" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_Performancebasedawardtargetshareamount_en-US">Number of stock units authorized for achievement of targeted performance</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1866" xlink:to="label1866" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TennesseeMember" xlink:label="element1867" />
        <label xlink:type="resource" xlink:label="label1867" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TennesseeMember_en-US">Tennessee [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1867" xlink:to="label1867" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TennesseeMember" xlink:label="element1868" />
        <label xlink:type="resource" xlink:label="label1868" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_TennesseeMember_en-US">Tennessee [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1868" xlink:to="label1868" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GeorgiaMember" xlink:label="element1869" />
        <label xlink:type="resource" xlink:label="label1869" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_GeorgiaMember_en-US">Georgia [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1869" xlink:to="label1869" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GeorgiaMember" xlink:label="element1870" />
        <label xlink:type="resource" xlink:label="label1870" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_GeorgiaMember_en-US">Georgia [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1870" xlink:to="label1870" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears" xlink:label="element1871" />
        <label xlink:type="resource" xlink:label="label1871" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears_en-US">Goodwill Is Expected To Be Deductible For Income Tax Purposes Years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1871" xlink:to="label1871" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears" xlink:label="element1872" />
        <label xlink:type="resource" xlink:label="label1872" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears_en-US">Period in which goodwill is expected to be deductible for income tax purposes, in years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1872" xlink:to="label1872" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears" xlink:label="element1873" />
        <label xlink:type="resource" xlink:label="label1873" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears_en-US">Period in which goodwill is expected to be deductible for income tax purposes, in years</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1873" xlink:to="label1873" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Businessacquisitionproformaoperatingincomeloss" xlink:label="element1874" />
        <label xlink:type="resource" xlink:label="label1874" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_Businessacquisitionproformaoperatingincomeloss_en-US">Business Acquisition Pro Forma Operating Income Loss</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1874" xlink:to="label1874" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Businessacquisitionproformaoperatingincomeloss" xlink:label="element1875" />
        <label xlink:type="resource" xlink:label="label1875" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_Businessacquisitionproformaoperatingincomeloss_en-US">Operating income (loss)</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1875" xlink:to="label1875" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxEffectsAllocatedToInterestExpense" xlink:label="element1876" />
        <label xlink:type="resource" xlink:label="label1876" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IncomeTaxEffectsAllocatedToInterestExpense_en-US">Income Tax Effects Allocated to Interest Expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1876" xlink:to="label1876" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxEffectsAllocatedToInterestExpense" xlink:label="element1877" />
        <label xlink:type="resource" xlink:label="label1877" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_IncomeTaxEffectsAllocatedToInterestExpense_en-US">The tax effect of items occuring during the period that have been charged or credited directly to interest expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1877" xlink:to="label1877" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxEffectsAllocatedToInterestExpense" xlink:label="element1878" />
        <label xlink:type="resource" xlink:label="label1878" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_IncomeTaxEffectsAllocatedToInterestExpense_en-US">Interest expense</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1878" xlink:to="label1878" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ResearchAndDevelopmentTaxCreditMember" xlink:label="element1879" />
        <label xlink:type="resource" xlink:label="label1879" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ResearchAndDevelopmentTaxCreditMember_en-US">Research And Development Tax Credit [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1879" xlink:to="label1879" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ResearchAndDevelopmentTaxCreditMember" xlink:label="element1880" />
        <label xlink:type="resource" xlink:label="label1880" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ResearchAndDevelopmentTaxCreditMember_en-US">Research And Development Tax Credit [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1880" xlink:to="label1880" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EmploymentTaxCreditMember" xlink:label="element1881" />
        <label xlink:type="resource" xlink:label="label1881" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EmploymentTaxCreditMember_en-US">Employment Tax Credit [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1881" xlink:to="label1881" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EmploymentTaxCreditMember" xlink:label="element1882" />
        <label xlink:type="resource" xlink:label="label1882" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EmploymentTaxCreditMember_en-US">Employment Tax Credit [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1882" xlink:to="label1882" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AlternativeMinimumTaxCreditMember" xlink:label="element1883" />
        <label xlink:type="resource" xlink:label="label1883" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AlternativeMinimumTaxCreditMember_en-US">Alternative Minimum Tax Credit [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1883" xlink:to="label1883" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AlternativeMinimumTaxCreditMember" xlink:label="element1884" />
        <label xlink:type="resource" xlink:label="label1884" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AlternativeMinimumTaxCreditMember_en-US">Alternative Minimum Tax Credit [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1884" xlink:to="label1884" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateTaxCreditMember" xlink:label="element1885" />
        <label xlink:type="resource" xlink:label="label1885" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_StateTaxCreditMember_en-US">State Tax Credit [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1885" xlink:to="label1885" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateTaxCreditMember" xlink:label="element1886" />
        <label xlink:type="resource" xlink:label="label1886" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_StateTaxCreditMember_en-US">State Tax Credit [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1886" xlink:to="label1886" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnrecognizedTaxBenefitsAxis" xlink:label="element1887" />
        <label xlink:type="resource" xlink:label="label1887" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_UnrecognizedTaxBenefitsAxis_en-US">Unrecognized Tax Benefits [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1887" xlink:to="label1887" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnrecognizedTaxBenefitsAxis" xlink:label="element1888" />
        <label xlink:type="resource" xlink:label="label1888" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_UnrecognizedTaxBenefitsAxis_en-US">Unrecognized Tax Benefits [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1888" xlink:to="label1888" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnrecognizedTaxBenefitsDomain" xlink:label="element1889" />
        <label xlink:type="resource" xlink:label="label1889" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_UnrecognizedTaxBenefitsDomain_en-US">Unrecognized Tax Benefits [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1889" xlink:to="label1889" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnrecognizedTaxBenefitsDomain" xlink:label="element1890" />
        <label xlink:type="resource" xlink:label="label1890" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_UnrecognizedTaxBenefitsDomain_en-US">Unrecognized Tax Benefits [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1890" xlink:to="label1890" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NetOperatingLossMember" xlink:label="element1891" />
        <label xlink:type="resource" xlink:label="label1891" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NetOperatingLossMember_en-US">Net Operating Loss [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1891" xlink:to="label1891" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NetOperatingLossMember" xlink:label="element1892" />
        <label xlink:type="resource" xlink:label="label1892" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NetOperatingLossMember_en-US">Net Operating Loss [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1892" xlink:to="label1892" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TaxCreditCarryforwardMember" xlink:label="element1893" />
        <label xlink:type="resource" xlink:label="label1893" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_TaxCreditCarryforwardMember_en-US">Tax Credit Carryforward [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1893" xlink:to="label1893" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TaxCreditCarryforwardMember" xlink:label="element1894" />
        <label xlink:type="resource" xlink:label="label1894" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_TaxCreditCarryforwardMember_en-US">Tax Credit Carryforward [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1894" xlink:to="label1894" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AccruedExpensesMember" xlink:label="element1895" />
        <label xlink:type="resource" xlink:label="label1895" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AccruedExpensesMember_en-US">Accrued Expenses [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1895" xlink:to="label1895" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AccruedExpensesMember" xlink:label="element1896" />
        <label xlink:type="resource" xlink:label="label1896" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AccruedExpensesMember_en-US">Accrued Expenses [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1896" xlink:to="label1896" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceCostOfRevenue" xlink:label="element1897" />
        <label xlink:type="resource" xlink:label="label1897" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_HospiceCostOfRevenue_en-US">Hospice Cost of Revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1897" xlink:to="label1897" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceCostOfRevenue" xlink:label="element1898" />
        <label xlink:type="resource" xlink:label="label1898" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_HospiceCostOfRevenue_en-US">Hospice cost of revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1898" xlink:to="label1898" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceCostOfRevenue" xlink:label="element1899" />
        <label xlink:type="resource" xlink:label="label1899" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_HospiceCostOfRevenue_en-US">Amount of accrued expenses related to Hospice cost of revenue</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1899" xlink:to="label1899" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OigSelfDisclsoureAccrual" xlink:label="element1900" />
        <label xlink:type="resource" xlink:label="label1900" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_OigSelfDisclsoureAccrual_en-US">OIG Self-Disclsoure Accrual</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1900" xlink:to="label1900" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OigSelfDisclsoureAccrual" xlink:label="element1901" />
        <label xlink:type="resource" xlink:label="label1901" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_OigSelfDisclsoureAccrual_en-US">OIG self-disclsoure accrual</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1901" xlink:to="label1901" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OigSelfDisclsoureAccrual" xlink:label="element1902" />
        <label xlink:type="resource" xlink:label="label1902" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_OigSelfDisclsoureAccrual_en-US">Amount of accrued expenses related to the OIG self-disclsoure accrual</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1902" xlink:to="label1902" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PatientLiability" xlink:label="element1903" />
        <label xlink:type="resource" xlink:label="label1903" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PatientLiability_en-US">Patient Liability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1903" xlink:to="label1903" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PatientLiability" xlink:label="element1904" />
        <label xlink:type="resource" xlink:label="label1904" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_PatientLiability_en-US">Patient liability</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1904" xlink:to="label1904" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PatientLiability" xlink:label="element1905" />
        <label xlink:type="resource" xlink:label="label1905" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PatientLiability_en-US">Amount of accrued expenses related to Patient liabilities</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1905" xlink:to="label1905" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Numberofpatients" xlink:label="element1906" />
        <label xlink:type="resource" xlink:label="label1906" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_Numberofpatients_en-US">Number of patients</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1906" xlink:to="label1906" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Numberofpatients" xlink:label="element1907" />
        <label xlink:type="resource" xlink:label="label1907" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_Numberofpatients_en-US">Number of patients</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1907" xlink:to="label1907" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FrontierLitigationMember" xlink:label="element1908" />
        <label xlink:type="resource" xlink:label="label1908" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_FrontierLitigationMember_en-US">Frontier Litigation [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1908" xlink:to="label1908" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FrontierLitigationMember" xlink:label="element1909" />
        <label xlink:type="resource" xlink:label="label1909" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_FrontierLitigationMember_en-US">Frontier Litigation</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1909" xlink:to="label1909" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UsDepartmentOfJusticeMember" xlink:label="element1910" />
        <label xlink:type="resource" xlink:label="label1910" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_UsDepartmentOfJusticeMember_en-US">US Department of Justice [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1910" xlink:to="label1910" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UsDepartmentOfJusticeMember" xlink:label="element1911" />
        <label xlink:type="resource" xlink:label="label1911" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_UsDepartmentOfJusticeMember_en-US">US Department of Justice</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1911" xlink:to="label1911" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredDebtIssuanceCostsMember" xlink:label="element1912" />
        <label xlink:type="resource" xlink:label="label1912" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DeferredDebtIssuanceCostsMember_en-US">Deferred Debt Issuance Costs [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1912" xlink:to="label1912" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredDebtIssuanceCostsMember" xlink:label="element1913" />
        <label xlink:type="resource" xlink:label="label1913" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DeferredDebtIssuanceCostsMember_en-US">Deferred Debt Issuance Costs [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1913" xlink:to="label1913" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssetImpairmentAxis" xlink:label="element1914" />
        <label xlink:type="resource" xlink:label="label1914" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AssetImpairmentAxis_en-US">Asset Impairment [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1914" xlink:to="label1914" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssetImpairmentAxis" xlink:label="element1915" />
        <label xlink:type="resource" xlink:label="label1915" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AssetImpairmentAxis_en-US">Asset Impairment [Axis]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1915" xlink:to="label1915" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssetImpairmentDomain" xlink:label="element1916" />
        <label xlink:type="resource" xlink:label="label1916" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AssetImpairmentDomain_en-US">Asset Impairment [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1916" xlink:to="label1916" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssetImpairmentDomain" xlink:label="element1917" />
        <label xlink:type="resource" xlink:label="label1917" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AssetImpairmentDomain_en-US">Asset Impairment [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1917" xlink:to="label1917" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CorporateHeadquartersMember" xlink:label="element1918" />
        <label xlink:type="resource" xlink:label="label1918" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CorporateHeadquartersMember_en-US">Corporate Headquarters [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1918" xlink:to="label1918" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CorporateHeadquartersMember" xlink:label="element1919" />
        <label xlink:type="resource" xlink:label="label1919" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_CorporateHeadquartersMember_en-US">Corporate Headquarters [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1919" xlink:to="label1919" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Ams3HomecareAndHospiceMember" xlink:label="element1920" />
        <label xlink:type="resource" xlink:label="label1920" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_Ams3HomecareAndHospiceMember_en-US">AMS3 Homecare and Hospice [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1920" xlink:to="label1920" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Ams3HomecareAndHospiceMember" xlink:label="element1921" />
        <label xlink:type="resource" xlink:label="label1921" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_Ams3HomecareAndHospiceMember_en-US">AMS3 Homecare and Hospice [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1921" xlink:to="label1921" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SurrenderedShares" xlink:label="element1922" />
        <label xlink:type="resource" xlink:label="label1922" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_SurrenderedShares_en-US">Surrendered Shares</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1922" xlink:to="label1922" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SurrenderedShares" xlink:label="element1923" />
        <label xlink:type="resource" xlink:label="label1923" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_SurrenderedShares_en-US">Surrendered shares</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1923" xlink:to="label1923" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SurrenderedShares" xlink:label="element1924" />
        <label xlink:type="resource" xlink:label="label1924" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_SurrenderedShares_en-US">Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1924" xlink:to="label1924" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SurrenderedShares" xlink:label="element1925" />
        <label xlink:type="resource" xlink:label="label1925" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US" id="Negated_amed_SurrenderedShares_en-US">Surrendered shares</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1925" xlink:to="label1925" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxEffectsAllocatedToGoodwill" xlink:label="element1926" />
        <label xlink:type="resource" xlink:label="label1926" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_IncomeTaxEffectsAllocatedToGoodwill_en-US">Income Tax Effects Allocated to Goodwill</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1926" xlink:to="label1926" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxEffectsAllocatedToGoodwill" xlink:label="element1927" />
        <label xlink:type="resource" xlink:label="label1927" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_IncomeTaxEffectsAllocatedToGoodwill_en-US">The tax effect of items occuring during the period that have been charged or credited directly to goodwill</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1927" xlink:to="label1927" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxEffectsAllocatedToGoodwill" xlink:label="element1928" />
        <label xlink:type="resource" xlink:label="label1928" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_IncomeTaxEffectsAllocatedToGoodwill_en-US">Goodwill</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1928" xlink:to="label1928" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfPatientReceivablesOutstandingOverTenPercent" xlink:label="element1929" />
        <label xlink:type="resource" xlink:label="label1929" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PercentageOfPatientReceivablesOutstandingOverTenPercent_en-US">Percentage of Patient Receivables Outstanding Over Ten Percent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1929" xlink:to="label1929" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfPatientReceivablesOutstandingOverTenPercent" xlink:label="element1930" />
        <label xlink:type="resource" xlink:label="label1930" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_PercentageOfPatientReceivablesOutstandingOverTenPercent_en-US">Percentage of Patient Receivables Outstanding Over Ten Percent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1930" xlink:to="label1930" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfPatientReceivablesOutstandingOverTenPercent" xlink:label="element1931" />
        <label xlink:type="resource" xlink:label="label1931" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PercentageOfPatientReceivablesOutstandingOverTenPercent_en-US">Percentage of patient receivables outstanding over ten percent</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1931" xlink:to="label1931" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:label="element1932" />
        <label xlink:type="resource" xlink:label="label1932" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_en-US">Recovery Amount of Overpayment Made To Subsidiary Including Interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1932" xlink:to="label1932" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:label="element1933" />
        <label xlink:type="resource" xlink:label="label1933" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_en-US">Recovery amount of overpayment made to subsidiary including interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1933" xlink:to="label1933" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:label="element1934" />
        <label xlink:type="resource" xlink:label="label1934" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_en-US">Recovery amount of overpayment made to subsidiary including interest</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1934" xlink:to="label1934" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome" xlink:label="element1935" />
        <label xlink:type="resource" xlink:label="label1935" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome_en-US">Equity Method Investment Summarized Financial Information Total Investment Income</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1935" xlink:to="label1935" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome" xlink:label="element1936" />
        <label xlink:type="resource" xlink:label="label1936" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome_en-US">Equity method investment total investment income</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1936" xlink:to="label1936" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome" xlink:label="element1937" />
        <label xlink:type="resource" xlink:label="label1937" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome_en-US">Investment income of equity method investee</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1937" xlink:to="label1937" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses" xlink:label="element1938" />
        <label xlink:type="resource" xlink:label="label1938" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses_en-US">Equity Method Investment Summarized Financial Information Total Expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1938" xlink:to="label1938" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses" xlink:label="element1939" />
        <label xlink:type="resource" xlink:label="label1939" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses_en-US">Equity method investment summarized financial information total expenses</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1939" xlink:to="label1939" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses" xlink:label="element1940" />
        <label xlink:type="resource" xlink:label="label1940" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses_en-US">Total expenses of equity method investee</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1940" xlink:to="label1940" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations" xlink:label="element1941" />
        <label xlink:type="resource" xlink:label="label1941" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations_en-US">Equity Method Investment Summarized Financial Information Net Increase In Partners' Capital From Operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1941" xlink:to="label1941" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations" xlink:label="element1942" />
        <label xlink:type="resource" xlink:label="label1942" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations_en-US">Equity method investment summarized financial information net increase in partners' capital from operations</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1942" xlink:to="label1942" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations" xlink:label="element1943" />
        <label xlink:type="resource" xlink:label="label1943" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations_en-US">Net increase in partner's capital from operations of equity method investee</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1943" xlink:to="label1943" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HeritageHealthcareInnovationFundMember" xlink:label="element1944" />
        <label xlink:type="resource" xlink:label="label1944" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_HeritageHealthcareInnovationFundMember_en-US">Heritage Healthcare Innovation Fund [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1944" xlink:to="label1944" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PersonalCareMember" xlink:label="element1945" />
        <label xlink:type="resource" xlink:label="label1945" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_PersonalCareMember_en-US">Personal Care [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1945" xlink:to="label1945" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PersonalCareMember" xlink:label="element1946" />
        <label xlink:type="resource" xlink:label="label1946" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_PersonalCareMember_en-US">Personal Care [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1946" xlink:to="label1946" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PersonalCareMember" xlink:label="element1947" />
        <label xlink:type="resource" xlink:label="label1947" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_PersonalCareMember_en-US">Personal Care</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1947" xlink:to="label1947" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssociatedHomecareMember" xlink:label="element1948" />
        <label xlink:type="resource" xlink:label="label1948" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_AssociatedHomecareMember_en-US">Associated Homecare [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1948" xlink:to="label1948" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssociatedHomecareMember" xlink:label="element1949" />
        <label xlink:type="resource" xlink:label="label1949" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_AssociatedHomecareMember_en-US">Associated Homecare [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1949" xlink:to="label1949" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProfessionalProfilesMember" xlink:label="element1950" />
        <label xlink:type="resource" xlink:label="label1950" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ProfessionalProfilesMember_en-US">Professional Profiles [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1950" xlink:to="label1950" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProfessionalProfilesMember" xlink:label="element1951" />
        <label xlink:type="resource" xlink:label="label1951" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ProfessionalProfilesMember_en-US">Professional Profiles [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1951" xlink:to="label1951" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:label="element1952" />
        <label xlink:type="resource" xlink:label="label1952" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_en-US">Recovery Amount Of Over Payment Made To Subsidiary Including Interest Withheld</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1952" xlink:to="label1952" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:label="element1953" />
        <label xlink:type="resource" xlink:label="label1953" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_en-US">Recovery amount of over payment made to subsidiary including interest withheld</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1953" xlink:to="label1953" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:label="element1954" />
        <label xlink:type="resource" xlink:label="label1954" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_en-US">Recovery amount of over payment made to subsidiary including interest withheld</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1954" xlink:to="label1954" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MorgantownWestVirginiaMember" xlink:label="element1955" />
        <label xlink:type="resource" xlink:label="label1955" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_MorgantownWestVirginiaMember_en-US">Morgantown, West Virginia [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1955" xlink:to="label1955" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MorgantownWestVirginiaMember" xlink:label="element1956" />
        <label xlink:type="resource" xlink:label="label1956" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_MorgantownWestVirginiaMember_en-US">Morgantown, West Virginia [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1956" xlink:to="label1956" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ParkersburgWestVirginiaMember" xlink:label="element1957" />
        <label xlink:type="resource" xlink:label="label1957" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ParkersburgWestVirginiaMember_en-US">Parkersburg, West Virginia [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1957" xlink:to="label1957" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ParkersburgWestVirginiaMember" xlink:label="element1958" />
        <label xlink:type="resource" xlink:label="label1958" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ParkersburgWestVirginiaMember_en-US">Parkersburg, West Virginia [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1958" xlink:to="label1958" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RelatedPartyTransactionTable" xlink:label="element1959" />
        <label xlink:type="resource" xlink:label="label1959" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_RelatedPartyTransactionTable_en-US">Related Party Transaction [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1959" xlink:to="label1959" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RelatedPartyTransactionTable" xlink:label="element1960" />
        <label xlink:type="resource" xlink:label="label1960" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_RelatedPartyTransactionTable_en-US">Related Party Transaction [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1960" xlink:to="label1960" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RelatedPartyTransactionTable" xlink:label="element1961" />
        <label xlink:type="resource" xlink:label="label1961" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_RelatedPartyTransactionTable_en-US">Related Party Transaction [Table]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1961" xlink:to="label1961" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CompanyNameDomain" xlink:label="element1962" />
        <label xlink:type="resource" xlink:label="label1962" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CompanyNameDomain_en-US">Company Name [Domain]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1962" xlink:to="label1962" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_KKRConsultingMember" xlink:label="element1963" />
        <label xlink:type="resource" xlink:label="label1963" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_KKRConsultingMember_en-US">KKR Consulting [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1963" xlink:to="label1963" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareInnovationsMember" xlink:label="element1964" />
        <label xlink:type="resource" xlink:label="label1964" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_CareInnovationsMember_en-US">Care Innovations [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1964" xlink:to="label1964" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WriteOffOfInvestment" xlink:label="element1965" />
        <label xlink:type="resource" xlink:label="label1965" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_WriteOffOfInvestment_en-US">Write Off Of Investment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1965" xlink:to="label1965" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WriteOffOfInvestment" xlink:label="element1966" />
        <label xlink:type="resource" xlink:label="label1966" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_WriteOffOfInvestment_en-US">Write-off of investment</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1966" xlink:to="label1966" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WriteOffOfInvestment" xlink:label="element1967" />
        <label xlink:type="resource" xlink:label="label1967" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_WriteOffOfInvestment_en-US">Write-off of investment. This element refers to the loss in earnings resulting from the investment write-off.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1967" xlink:to="label1967" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NewYorkMember" xlink:label="element1968" />
        <label xlink:type="resource" xlink:label="label1968" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_NewYorkMember_en-US">New York [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1968" xlink:to="label1968" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NewYorkMember" xlink:label="element1969" />
        <label xlink:type="resource" xlink:label="label1969" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_NewYorkMember_en-US">New York [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1969" xlink:to="label1969" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InfinityHomeCareMember" xlink:label="element1970" />
        <label xlink:type="resource" xlink:label="label1970" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_InfinityHomeCareMember_en-US">Infinity HomeCare [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1970" xlink:to="label1970" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InfinityHomeCareMember" xlink:label="element1971" />
        <label xlink:type="resource" xlink:label="label1971" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_InfinityHomeCareMember_en-US">Infinity HomeCare [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1971" xlink:to="label1971" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeStaffLlcMember" xlink:label="element1972" />
        <label xlink:type="resource" xlink:label="label1972" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_HomeStaffLlcMember_en-US">Home Staff LLC [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1972" xlink:to="label1972" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeStaffLlcMember" xlink:label="element1973" />
        <label xlink:type="resource" xlink:label="label1973" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_HomeStaffLlcMember_en-US">Home Staff LLC [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1973" xlink:to="label1973" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1" xlink:label="element1974" />
        <label xlink:type="resource" xlink:label="label1974" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1_en-US">Deferred Tax Assets Goodwill And Intangible Assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1974" xlink:to="label1974" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1" xlink:label="element1975" />
        <label xlink:type="resource" xlink:label="label1975" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1_en-US">Amortization of intangible assets</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1975" xlink:to="label1975" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1" xlink:label="element1976" />
        <label xlink:type="resource" xlink:label="label1976" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1_en-US">The cumulative amount of the estimated future tax effects attributable to the difference between the tax basis of intangible assets and the basis of intangible assets computed in accordance with generally accepted accounting principles. The difference in basis, whether due to amortization or other reasons, will increase future taxable income when such difference reverses.</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1976" xlink:to="label1976" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ReversalOfLegalAccrual" xlink:label="element1977" />
        <label xlink:type="resource" xlink:label="label1977" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_ReversalOfLegalAccrual_en-US">Reversal of Legal Accrual</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1977" xlink:to="label1977" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ReversalOfLegalAccrual" xlink:label="element1978" />
        <label xlink:type="resource" xlink:label="label1978" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US" id="terse_amed_ReversalOfLegalAccrual_en-US">Legal fee accrual reversal</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1978" xlink:to="label1978" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ReversalOfLegalAccrual" xlink:label="element1979" />
        <label xlink:type="resource" xlink:label="label1979" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_ReversalOfLegalAccrual_en-US">Reversal of legal fee accrual</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1979" xlink:to="label1979" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomecareHomebaseMember" xlink:label="element1980" />
        <label xlink:type="resource" xlink:label="label1980" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US" id="label_amed_HomecareHomebaseMember_en-US">Homecare Homebase [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1980" xlink:to="label1980" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomecareHomebaseMember" xlink:label="element1981" />
        <label xlink:type="resource" xlink:label="label1981" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" id="documentation_amed_HomecareHomebaseMember_en-US">Homecare Homebase [Member]</label>
        <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="element1981" xlink:to="label1981" />
    </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>amed-20161231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Prepared by IBM Cognos FSR v6.7.4.14 using Fujitsu Interstage XWand -->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/instance http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
    <roleRef roleURI="http://www.amedisys.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_DocumentAndEntityInformation" />
    <roleRef roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_CONSOLIDATEDBALANCESHEETS" />
    <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
    <roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_CONSOLIDATEDBALANCESHEETSParenthetical" />
    <roleRef roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_CONSOLIDATEDSTATEMENTSOFOPERATIONS" />
    <roleRef roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_CONSOLIDATEDSTATEMENTSOFCASHFLOWS" />
    <roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" />
    <roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" />
    <roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_ACQUISITIONS" />
    <roleRef roleURI="http://www.amedisys.com/role/DISCONTINUEDOPERATIONSANDASSETSHELDFORSALE" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_DISCONTINUEDOPERATIONSANDASSETSHELDFORSALE" />
    <roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_GOODWILLANDOTHERINTANGIBLEASSETSNET" />
    <roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_LONGTERMOBLIGATIONS" />
    <roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_COMMITMENTSANDCONTINGENCIES" />
    <roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_SEGMENTINFORMATION" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureNATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSPolicies" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSPolicies" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" />
    <roleRef roleURI="http://www.amedisys.com/role/DISCONTINUEDOPERATIONSANDASSETSHELDFORSALETables" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_DISCONTINUEDOPERATIONSANDASSETSHELDFORSALETables" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureGOODWILLANDOTHERINTANGIBLEASSETSNETTables" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_GOODWILLANDOTHERINTANGIBLEASSETSNETTables" />
    <roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_LONGTERMOBLIGATIONSTables" />
    <roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_SEGMENTINFORMATIONTables" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_NatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/ScheduleOfFinancialInstrumentsWhereCarryingValueAndFairValueDifferDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_ScheduleOfFinancialInstrumentsWhereCarryingValueAndFairValueDifferDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/ScheduleOfWeightedAverageSharesOutstandingDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_ScheduleOfWeightedAverageSharesOutstandingDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureDiscontinuedOperationsAndAssetsHeldForSaleAdditionalInformationDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_DiscontinuedOperationsAndAssetsHeldForSaleAdditionalInformationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/NetRevenuesAndOperatingResultsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_NetRevenuesAndOperatingResultsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureLongTermDebtDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_LongTermDebtDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureLongTermDebtParentheticalDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_LongTermDebtParentheticalDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureLongTermDebtAdditionalInformationDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_LongTermDebtAdditionalInformationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureCommitmentsAndContigenciesDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_CommitmentsAndContigenciesDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/SegmentInformationAdditionalInformationDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_SegmentInformationAdditionalInformationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureOperatingIncomeOfReportableSegmentsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_OperatingIncomeOfReportableSegmentsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME" />
    <roleRef roleURI="http://www.amedisys.com/role/EXITACTIVITIES" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_EXITACTIVITIES" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureExitActivitiesDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_ExitActivitiesDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENT" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_SUBSEQUENTEVENT" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureSubsequentEventDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_SubsequentEventDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" />
    <roleRef roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_DETAILSOFCERTAINBALANCESHEETACCOUNTS" />
    <roleRef roleURI="http://www.amedisys.com/role/INCOMETAXES" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_INCOMETAXES" />
    <roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_CAPITALSTOCKANDSHAREBASEDCOMPENSATION" />
    <roleRef roleURI="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_EMPLOYEEBENEFITPLANS" />
    <roleRef roleURI="http://www.amedisys.com/role/VALUATIONANDQUALIFYINGACCOUNTS" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_VALUATIONANDQUALIFYINGACCOUNTS" />
    <roleRef roleURI="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION" />
    <roleRef roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_DETAILSOFCERTAINBALANCESHEETACCOUNTSTables" />
    <roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_INCOMETAXESTables" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureCAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureCOMMITMENTSANDCONTINGENCIESTables" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_COMMITMENTSANDCONTINGENCIESTables" />
    <roleRef roleURI="http://www.amedisys.com/role/EXITACTIVITIESTables" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_EXITACTIVITIESTables" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureVALUATIONANDQUALIFYINGACCOUNTSTables" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_VALUATIONANDQUALIFYINGACCOUNTSTables" />
    <roleRef roleURI="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureAcquisitionsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_AcquisitionsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureGoodwillAndOtherIntangibleAssetsNetDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_GoodwillAndOtherIntangibleAssetsNetDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsOtherCurrentAssetsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_DetailsOfCertainBalanceSheetAccountsOtherCurrentAssetsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureIncomeTaxesDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_IncomeTaxesDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureCapitalStockAndShareBasedCompensationDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_CapitalStockAndShareBasedCompensationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/EmployeeBenefitPlansDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_EmployeeBenefitPlansDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureValuationAndQualifyingAccountsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_ValuationAndQualifyingAccountsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureUnauditedSummarizedQuarterlyFinancialInformationDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_UnauditedSummarizedQuarterlyFinancialInformationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/FutureMinimumRentalCommitmentsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_FutureMinimumRentalCommitmentsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureInsuranceProgramsDetails" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_InsuranceProgramsDetails" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureEmployeeStockPurchasePlanDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_EmployeeStockPurchasePlanDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureStockOptionActivityDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_StockOptionActivityDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureNonVestedStockActivityDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_NonVestedStockActivityDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureNonVestedStockUnitsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_NonVestedStockUnitsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureTotalProvisionForIncomeTaxesDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_TotalProvisionForIncomeTaxesDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureComponentsOfNetDeferredTaxAssetsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_ComponentsOfNetDeferredTaxAssetsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/SourcesOfTaxEffectDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_SourcesOfTaxEffectDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureReconciliationOfUnrecognizedTaxBenefitsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_ReconciliationOfUnrecognizedTaxBenefitsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsOtherAssetsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_DetailsOfCertainBalanceSheetAccountsOtherAssetsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsAccruedExpensesDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_DetailsOfCertainBalanceSheetAccountsAccruedExpensesDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsOtherLongTermObligationsDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_DetailsOfCertainBalanceSheetAccountsOtherLongTermObligationsDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureSummaryOfActivityRelatedToGoodwillDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_SummaryOfActivityRelatedToGoodwillDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureSummaryOfActivityRelatedToOtherIntangibleAssetsNetDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_SummaryOfActivityRelatedToOtherIntangibleAssetsNetDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/SummaryOfActivityRelatedToOtherIntangibleAssetsNetParentheticalDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_SummaryOfActivityRelatedToOtherIntangibleAssetsNetParentheticalDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/ScheduleOfBalancesRelatedToPropertyAndEquipmentDetails" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_ScheduleOfBalancesRelatedToPropertyAndEquipmentDetails" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureMaturitiesOfDebtDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_MaturitiesOfDebtDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureCommitmentFeeUnderCreditFacilitiesDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_CommitmentFeeUnderCreditFacilitiesDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureExitActivitiesReserveActivityDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_ExitActivitiesReserveActivityDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/ClassificationOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_ClassificationOfDeferredTaxAssetsAndLiabilitiesDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureNonVestedStockOptionActivityDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_NonVestedStockOptionActivityDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASEPROGRAM" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_SHAREREPURCHASEPROGRAM" />
    <roleRef roleURI="http://www.amedisys.com/role/ShareRepurchaseProgramDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_ShareRepurchaseProgramDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureACQUISITIONSPROFORMACONDENSEDCONSOLIDATEDINCOMESTATEMENTTables" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_ACQUISITIONSPROFORMACONDENSEDCONSOLIDATEDINCOMESTATEMENTTables" />
    <roleRef roleURI="http://www.amedisys.com/role/DisclosureAcquisitionsProFormaCondensedConsolidatedIncomeStatementDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_AcquisitionsProFormaCondensedConsolidatedIncomeStatementDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/IncomeTaxExpenseAllocationDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_IncomeTaxExpenseAllocationDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/RelatedPartyTransactionDetail" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_RelatedPartyTransactionDetail" />
    <roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="amed-20161231.xsd#amed_ELRID_RELATEDPARTYTRANSACTIONS" />
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DocumentAndEntityInformation">
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_73" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_74" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_LegalEntityAxis_73" xlink:to="Locator_dei_EntityDomain_74" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DocumentDocumentandEntityInformationAbstract" xlink:label="Locator_amed_DocumentDocumentandEntityInformationAbstract_33" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntitiesTable" xlink:label="Locator_dei_EntitiesTable_34" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DocumentDocumentandEntityInformationAbstract_33" xlink:to="Locator_dei_EntitiesTable_34" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntitiesTable" xlink:label="Locator_dei_EntitiesTable_69" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_70" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_EntitiesTable_69" xlink:to="Locator_dei_DocumentInformationLineItems_70" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_1" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="Locator_dei_DocumentType_2" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_1" xlink:to="Locator_dei_DocumentType_2" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_3" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="Locator_dei_AmendmentFlag_4" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_3" xlink:to="Locator_dei_AmendmentFlag_4" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_5" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="Locator_dei_DocumentPeriodEndDate_6" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_5" xlink:to="Locator_dei_DocumentPeriodEndDate_6" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_7" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="Locator_dei_DocumentFiscalYearFocus_8" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_7" xlink:to="Locator_dei_DocumentFiscalYearFocus_8" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_9" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="Locator_dei_DocumentFiscalPeriodFocus_10" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_9" xlink:to="Locator_dei_DocumentFiscalPeriodFocus_10" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_11" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="Locator_dei_TradingSymbol_12" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_11" xlink:to="Locator_dei_TradingSymbol_12" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_13" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="Locator_dei_EntityRegistrantName_14" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_13" xlink:to="Locator_dei_EntityRegistrantName_14" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_15" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="Locator_dei_EntityCentralIndexKey_16" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_15" xlink:to="Locator_dei_EntityCentralIndexKey_16" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_17" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="Locator_dei_CurrentFiscalYearEndDate_18" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_17" xlink:to="Locator_dei_CurrentFiscalYearEndDate_18" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_19" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="Locator_dei_EntityFilerCategory_20" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_19" xlink:to="Locator_dei_EntityFilerCategory_20" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_21" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="Locator_dei_EntityCommonStockSharesOutstanding_22" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_21" xlink:to="Locator_dei_EntityCommonStockSharesOutstanding_22" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_23" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="Locator_dei_EntityPublicFloat_24" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_23" xlink:to="Locator_dei_EntityPublicFloat_24" order="12.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_25" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="Locator_dei_EntityVoluntaryFilers_26" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_25" xlink:to="Locator_dei_EntityVoluntaryFilers_26" order="13.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_27" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="Locator_dei_EntityCurrentReportingStatus_28" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_27" xlink:to="Locator_dei_EntityCurrentReportingStatus_28" order="14.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="Locator_dei_DocumentInformationLineItems_29" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="Locator_dei_EntityWellKnownSeasonedIssuer_30" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_DocumentInformationLineItems_29" xlink:to="Locator_dei_EntityWellKnownSeasonedIssuer_30" order="15.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntitiesTable" xlink:label="Locator_dei_EntitiesTable_71" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_72" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_EntitiesTable_71" xlink:to="Locator_dei_LegalEntityAxis_72" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/StatementCONSOLIDATEDBALANCESHEETS">
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_305" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_306" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_LegalEntityAxis_305" xlink:to="Locator_dei_EntityDomain_306" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_303" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_304" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementTable_303" xlink:to="Locator_dei_LegalEntityAxis_304" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_301" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_302" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementTable_301" xlink:to="Locator_us-gaap_StatementLineItems_302" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_75" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_76" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_75" xlink:to="Locator_us-gaap_AssetsAbstract_76" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_81" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_82" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsAbstract_81" xlink:to="Locator_us-gaap_AssetsCurrentAbstract_82" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_95" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="Locator_us-gaap_CashAndCashEquivalentsAtCarryingValue_96" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_95" xlink:to="Locator_us-gaap_CashAndCashEquivalentsAtCarryingValue_96" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_97" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="Locator_us-gaap_AccountsReceivableNetCurrent_98" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_97" xlink:to="Locator_us-gaap_AccountsReceivableNetCurrent_98" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_99" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="Locator_us-gaap_PrepaidExpenseCurrent_100" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_99" xlink:to="Locator_us-gaap_PrepaidExpenseCurrent_100" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_101" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="Locator_us-gaap_DeferredTaxAssetsNetCurrent_102" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_101" xlink:to="Locator_us-gaap_DeferredTaxAssetsNetCurrent_102" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_103" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="Locator_us-gaap_OtherAssetsCurrent_104" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_103" xlink:to="Locator_us-gaap_OtherAssetsCurrent_104" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_105" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="Locator_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_106" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_105" xlink:to="Locator_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_106" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="Locator_us-gaap_AssetsCurrentAbstract_107" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="Locator_us-gaap_AssetsCurrent_108" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsCurrentAbstract_107" xlink:to="Locator_us-gaap_AssetsCurrent_108" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_83" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentNet_84" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsAbstract_83" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentNet_84" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_85" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="Locator_us-gaap_Goodwill_86" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsAbstract_85" xlink:to="Locator_us-gaap_Goodwill_86" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_87" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="Locator_us-gaap_IntangibleAssetsNetExcludingGoodwill_88" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsAbstract_87" xlink:to="Locator_us-gaap_IntangibleAssetsNetExcludingGoodwill_88" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_89" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="Locator_us-gaap_DeferredTaxAssetsNetNoncurrent_90" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsAbstract_89" xlink:to="Locator_us-gaap_DeferredTaxAssetsNetNoncurrent_90" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_91" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="Locator_us-gaap_OtherAssetsNoncurrent_92" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsAbstract_91" xlink:to="Locator_us-gaap_OtherAssetsNoncurrent_92" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="Locator_us-gaap_AssetsAbstract_93" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="Locator_us-gaap_Assets_94" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AssetsAbstract_93" xlink:to="Locator_us-gaap_Assets_94" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_77" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_78" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_77" xlink:to="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_78" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_109" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_110" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_109" xlink:to="Locator_us-gaap_LiabilitiesCurrentAbstract_110" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_123" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="Locator_us-gaap_AccountsPayableCurrent_124" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_123" xlink:to="Locator_us-gaap_AccountsPayableCurrent_124" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_125" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement_126" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_125" xlink:to="Locator_amed_AccruedChargeRelatedToUsDepartmentOfJusticeSettlement_126" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_127" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="Locator_us-gaap_EmployeeRelatedLiabilitiesCurrent_128" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_127" xlink:to="Locator_us-gaap_EmployeeRelatedLiabilitiesCurrent_128" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_129" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="Locator_us-gaap_AccruedLiabilitiesCurrent_130" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_129" xlink:to="Locator_us-gaap_AccruedLiabilitiesCurrent_130" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_131" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_132" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_131" xlink:to="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_132" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_133" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="Locator_us-gaap_DeferredTaxLiabilitiesCurrent_134" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_133" xlink:to="Locator_us-gaap_DeferredTaxLiabilitiesCurrent_134" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="Locator_us-gaap_LiabilitiesCurrentAbstract_135" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="Locator_us-gaap_LiabilitiesCurrent_136" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesCurrentAbstract_135" xlink:to="Locator_us-gaap_LiabilitiesCurrent_136" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_111" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligations_112" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_111" xlink:to="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligations_112" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_113" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="Locator_us-gaap_OtherLiabilitiesNoncurrent_114" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_113" xlink:to="Locator_us-gaap_OtherLiabilitiesNoncurrent_114" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_115" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="Locator_us-gaap_Liabilities_116" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_115" xlink:to="Locator_us-gaap_Liabilities_116" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_117" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="Locator_us-gaap_CommitmentsAndContingencies_118" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_117" xlink:to="Locator_us-gaap_CommitmentsAndContingencies_118" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_119" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_120" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_119" xlink:to="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_120" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_137" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="Locator_us-gaap_PreferredStockValueOutstanding_138" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_137" xlink:to="Locator_us-gaap_PreferredStockValueOutstanding_138" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_139" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValueOutstanding" xlink:label="Locator_us-gaap_CommonStockValueOutstanding_140" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_139" xlink:to="Locator_us-gaap_CommonStockValueOutstanding_140" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_141" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="Locator_us-gaap_AdditionalPaidInCapitalCommonStock_142" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_141" xlink:to="Locator_us-gaap_AdditionalPaidInCapitalCommonStock_142" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_143" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="Locator_us-gaap_TreasuryStockValue_144" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_143" xlink:to="Locator_us-gaap_TreasuryStockValue_144" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_145" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="Locator_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_146" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_145" xlink:to="Locator_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_146" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_147" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="Locator_us-gaap_RetainedEarningsAccumulatedDeficit_148" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_147" xlink:to="Locator_us-gaap_RetainedEarningsAccumulatedDeficit_148" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_149" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="Locator_us-gaap_StockholdersEquity_150" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_149" xlink:to="Locator_us-gaap_StockholdersEquity_150" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_151" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterest" xlink:label="Locator_us-gaap_MinorityInterest_152" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_151" xlink:to="Locator_us-gaap_MinorityInterest_152" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_153" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_154" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_153" xlink:to="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_154" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="Locator_us-gaap_LiabilitiesAndStockholdersEquity_122" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LiabilitiesAndStockholdersEquityAbstract_121" xlink:to="Locator_us-gaap_LiabilitiesAndStockholdersEquity_122" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="Locator_us-gaap_StatementOfFinancialPositionAbstract_155" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_156" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfFinancialPositionAbstract_155" xlink:to="Locator_us-gaap_StatementTable_156" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_369" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_370" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_LegalEntityAxis_369" xlink:to="Locator_dei_EntityDomain_370" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_367" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_368" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementTable_367" xlink:to="Locator_dei_LegalEntityAxis_368" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_365" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_366" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementTable_365" xlink:to="Locator_us-gaap_StatementLineItems_366" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_307" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="Locator_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_308" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_307" xlink:to="Locator_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_308" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_309" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="Locator_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_310" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_309" xlink:to="Locator_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_310" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_311" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_312" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_311" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_312" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_313" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="Locator_us-gaap_PreferredStockParOrStatedValuePerShare_314" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_313" xlink:to="Locator_us-gaap_PreferredStockParOrStatedValuePerShare_314" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_315" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="Locator_us-gaap_PreferredStockSharesAuthorized_316" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_315" xlink:to="Locator_us-gaap_PreferredStockSharesAuthorized_316" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_317" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="Locator_us-gaap_PreferredStockSharesIssued_318" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_317" xlink:to="Locator_us-gaap_PreferredStockSharesIssued_318" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_319" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="Locator_us-gaap_PreferredStockSharesOutstanding_320" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_319" xlink:to="Locator_us-gaap_PreferredStockSharesOutstanding_320" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_321" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="Locator_us-gaap_CommonStockParOrStatedValuePerShare_322" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_321" xlink:to="Locator_us-gaap_CommonStockParOrStatedValuePerShare_322" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_323" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="Locator_us-gaap_CommonStockSharesAuthorized_324" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_323" xlink:to="Locator_us-gaap_CommonStockSharesAuthorized_324" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_325" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="Locator_us-gaap_CommonStockSharesIssued_326" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_325" xlink:to="Locator_us-gaap_CommonStockSharesIssued_326" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_327" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="Locator_us-gaap_CommonStockSharesOutstanding_328" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_327" xlink:to="Locator_us-gaap_CommonStockSharesOutstanding_328" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_329" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="Locator_us-gaap_TreasuryStockShares_330" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_329" xlink:to="Locator_us-gaap_TreasuryStockShares_330" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="Locator_us-gaap_StatementOfFinancialPositionAbstract_333" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_334" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfFinancialPositionAbstract_333" xlink:to="Locator_us-gaap_StatementTable_334" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_589" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_590" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_LegalEntityAxis_589" xlink:to="Locator_dei_EntityDomain_590" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="Locator_us-gaap_IncomeStatementAbstract_451" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_452" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementAbstract_451" xlink:to="Locator_us-gaap_StatementTable_452" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_587" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_588" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementTable_587" xlink:to="Locator_dei_LegalEntityAxis_588" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_585" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_586" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementTable_585" xlink:to="Locator_us-gaap_StatementLineItems_586" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_371" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationPatientServiceRevenue" xlink:label="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_372" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_371" xlink:to="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_372" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_373" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfServices" xlink:label="Locator_us-gaap_CostOfServices_374" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_373" xlink:to="Locator_us-gaap_CostOfServices_374" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_375" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_376" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_375" xlink:to="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_376" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_417" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="Locator_us-gaap_LaborAndRelatedExpense_418" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_417" xlink:to="Locator_us-gaap_LaborAndRelatedExpense_418" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_419" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="Locator_us-gaap_ShareBasedCompensation_420" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_419" xlink:to="Locator_us-gaap_ShareBasedCompensation_420" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_421" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="Locator_us-gaap_OtherGeneralAndAdministrativeExpense_422" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_GeneralAndAdministrativeExpenseAbstract_421" xlink:to="Locator_us-gaap_OtherGeneralAndAdministrativeExpense_422" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_377" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProvisionForDoubtfulAccountsForContinuingOperations" xlink:label="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_378" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_377" xlink:to="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_378" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_379" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DepreciationAndAmortizationForContinuingOperations" xlink:label="Locator_amed_DepreciationAndAmortizationForContinuingOperations_380" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_379" xlink:to="Locator_amed_DepreciationAndAmortizationForContinuingOperations_380" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_381" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_UsDepartmentOfJusticeSettlement_382" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_381" xlink:to="Locator_amed_UsDepartmentOfJusticeSettlement_382" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_383" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="Locator_us-gaap_AssetImpairmentCharges_384" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_383" xlink:to="Locator_us-gaap_AssetImpairmentCharges_384" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_385" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_386" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_385" xlink:to="Locator_us-gaap_CostsAndExpenses_386" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_387" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="Locator_us-gaap_OperatingIncomeLoss_388" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_387" xlink:to="Locator_us-gaap_OperatingIncomeLoss_388" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_389" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_390" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_389" xlink:to="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_390" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_423" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="Locator_us-gaap_InvestmentIncomeInterestAndDividend_424" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_423" xlink:to="Locator_us-gaap_InvestmentIncomeInterestAndDividend_424" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_425" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="Locator_us-gaap_InterestExpense_426" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_425" xlink:to="Locator_us-gaap_InterestExpense_426" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_427" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="Locator_us-gaap_IncomeLossFromEquityMethodInvestments_428" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_427" xlink:to="Locator_us-gaap_IncomeLossFromEquityMethodInvestments_428" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_429" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="Locator_us-gaap_OtherNonoperatingIncomeExpense_430" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_429" xlink:to="Locator_us-gaap_OtherNonoperatingIncomeExpense_430" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_431" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="Locator_us-gaap_NonoperatingIncomeExpense_432" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NonoperatingIncomeExpenseAbstract_431" xlink:to="Locator_us-gaap_NonoperatingIncomeExpense_432" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_391" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_392" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_391" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_392" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_393" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="Locator_us-gaap_IncomeTaxExpenseBenefit_394" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_393" xlink:to="Locator_us-gaap_IncomeTaxExpenseBenefit_394" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_395" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_396" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_395" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_396" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_397" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_398" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_397" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_398" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_401" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_402" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_401" xlink:to="Locator_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_402" order="16.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_403" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="Locator_us-gaap_NetIncomeLoss_404" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_403" xlink:to="Locator_us-gaap_NetIncomeLoss_404" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_405" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="Locator_us-gaap_EarningsPerShareBasicAbstract_406" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_405" xlink:to="Locator_us-gaap_EarningsPerShareBasicAbstract_406" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="Locator_us-gaap_EarningsPerShareBasicAbstract_433" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_434" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EarningsPerShareBasicAbstract_433" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_434" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="Locator_us-gaap_EarningsPerShareBasicAbstract_435" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_436" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EarningsPerShareBasicAbstract_435" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_436" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="Locator_us-gaap_EarningsPerShareBasicAbstract_437" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="Locator_us-gaap_EarningsPerShareBasic_438" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EarningsPerShareBasicAbstract_437" xlink:to="Locator_us-gaap_EarningsPerShareBasic_438" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_407" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="Locator_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_408" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_407" xlink:to="Locator_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_408" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_409" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="Locator_us-gaap_EarningsPerShareDilutedAbstract_410" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_409" xlink:to="Locator_us-gaap_EarningsPerShareDilutedAbstract_410" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="Locator_us-gaap_EarningsPerShareDilutedAbstract_439" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_440" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EarningsPerShareDilutedAbstract_439" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_440" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="Locator_us-gaap_EarningsPerShareDilutedAbstract_441" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_442" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EarningsPerShareDilutedAbstract_441" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_442" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="Locator_us-gaap_EarningsPerShareDilutedAbstract_443" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="Locator_us-gaap_EarningsPerShareDiluted_444" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EarningsPerShareDilutedAbstract_443" xlink:to="Locator_us-gaap_EarningsPerShareDiluted_444" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_411" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_412" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_411" xlink:to="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_412" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_413" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_414" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_413" xlink:to="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_414" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_445" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="Locator_us-gaap_IncomeLossFromContinuingOperations_446" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_445" xlink:to="Locator_us-gaap_IncomeLossFromContinuingOperations_446" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_447" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_448" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_447" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_448" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_449" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="Locator_us-gaap_NetIncomeLoss_450" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_449" xlink:to="Locator_us-gaap_NetIncomeLoss_450" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_399" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="Locator_us-gaap_ProfitLoss_400" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_399" xlink:to="Locator_us-gaap_ProfitLoss_400" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="Locator_us-gaap_StatementOfCashFlowsAbstract_591" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_592" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfCashFlowsAbstract_591" xlink:to="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_592" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_607" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="Locator_us-gaap_ProfitLoss_608" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_607" xlink:to="Locator_us-gaap_ProfitLoss_608" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_609" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_610" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_609" xlink:to="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_610" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_613" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="Locator_us-gaap_DepreciationDepletionAndAmortization_614" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_613" xlink:to="Locator_us-gaap_DepreciationDepletionAndAmortization_614" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_615" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="Locator_us-gaap_ProvisionForDoubtfulAccounts_616" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_615" xlink:to="Locator_us-gaap_ProvisionForDoubtfulAccounts_616" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_617" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="Locator_us-gaap_ShareBasedCompensation_618" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_617" xlink:to="Locator_us-gaap_ShareBasedCompensation_618" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionExpense" xlink:label="Locator_us-gaap_PensionExpense_620" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_619" xlink:to="Locator_us-gaap_PensionExpense_620" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_621" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WriteOffOfInvestment" xlink:label="Locator_amed_WriteOffOfInvestment_622" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_621" xlink:to="Locator_amed_WriteOffOfInvestment_622" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_623" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="Locator_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_624" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_623" xlink:to="Locator_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_624" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_625" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="Locator_us-gaap_GainsLossesOnSalesOfAssets_626" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_625" xlink:to="Locator_us-gaap_GainsLossesOnSalesOfAssets_626" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_627" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="Locator_us-gaap_DeferredIncomeTaxExpenseBenefit_628" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_627" xlink:to="Locator_us-gaap_DeferredIncomeTaxExpenseBenefit_628" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_629" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredDebtIssuanceCostsWrittenOff" xlink:label="Locator_amed_DeferredDebtIssuanceCostsWrittenOff_630" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_629" xlink:to="Locator_amed_DeferredDebtIssuanceCostsWrittenOff_630" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_631" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="Locator_us-gaap_IncomeLossFromEquityMethodInvestments_632" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_631" xlink:to="Locator_us-gaap_IncomeLossFromEquityMethodInvestments_632" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_633" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="Locator_us-gaap_AmortizationOfFinancingCostsAndDiscounts_634" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_633" xlink:to="Locator_us-gaap_AmortizationOfFinancingCostsAndDiscounts_634" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:label="Locator_us-gaap_EquityMethodInvestmentDividendsOrDistributions_636" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635" xlink:to="Locator_us-gaap_EquityMethodInvestmentDividendsOrDistributions_636" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="Locator_us-gaap_AssetImpairmentCharges_638" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637" xlink:to="Locator_us-gaap_AssetImpairmentCharges_638" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_640" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639" xlink:to="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_640" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_641" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="Locator_us-gaap_IncreaseDecreaseInAccountsReceivable_642" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_641" xlink:to="Locator_us-gaap_IncreaseDecreaseInAccountsReceivable_642" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_643" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="Locator_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_644" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_643" xlink:to="Locator_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_644" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_645" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="Locator_us-gaap_IncreaseDecreaseInOtherOperatingAssets_646" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_645" xlink:to="Locator_us-gaap_IncreaseDecreaseInOtherOperatingAssets_646" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_647" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="Locator_us-gaap_IncreaseDecreaseInAccountsPayable_648" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_647" xlink:to="Locator_us-gaap_IncreaseDecreaseInAccountsPayable_648" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_649" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual" xlink:label="Locator_amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual_650" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_649" xlink:to="Locator_amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual_650" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_651" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="Locator_us-gaap_IncreaseDecreaseInAccruedLiabilities_652" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_651" xlink:to="Locator_us-gaap_IncreaseDecreaseInAccruedLiabilities_652" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_653" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="Locator_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_654" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_653" xlink:to="Locator_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_654" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_611" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_612" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_611" xlink:to="Locator_us-gaap_NetCashProvidedByUsedInOperatingActivities_612" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="Locator_us-gaap_StatementOfCashFlowsAbstract_593" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_594" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfCashFlowsAbstract_593" xlink:to="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_594" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_655" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:label="Locator_us-gaap_ProceedsFromSaleOfRestrictedInvestments_656" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_655" xlink:to="Locator_us-gaap_ProceedsFromSaleOfRestrictedInvestments_656" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_657" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="Locator_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_658" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_657" xlink:to="Locator_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_658" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_659" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:label="Locator_us-gaap_PaymentsToAcquireRestrictedInvestments_660" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_659" xlink:to="Locator_us-gaap_PaymentsToAcquireRestrictedInvestments_660" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_661" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="Locator_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_662" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_661" xlink:to="Locator_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_662" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_663" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="Locator_us-gaap_PaymentsForProceedsFromInvestments_664" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_663" xlink:to="Locator_us-gaap_PaymentsForProceedsFromInvestments_664" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_665" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:label="Locator_us-gaap_ProceedsFromSaleOfOtherInvestments_666" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_665" xlink:to="Locator_us-gaap_ProceedsFromSaleOfOtherInvestments_666" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_667" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="Locator_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_668" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_667" xlink:to="Locator_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_668" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_669" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="Locator_us-gaap_ProceedsFromDivestitureOfBusinesses_670" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_669" xlink:to="Locator_us-gaap_ProceedsFromDivestitureOfBusinesses_670" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_671" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivities_672" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_671" xlink:to="Locator_us-gaap_NetCashProvidedByUsedInInvestingActivities_672" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="Locator_us-gaap_StatementOfCashFlowsAbstract_595" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfCashFlowsAbstract_595" xlink:to="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_673" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="Locator_us-gaap_ProceedsFromStockOptionsExercised_674" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_673" xlink:to="Locator_us-gaap_ProceedsFromStockOptionsExercised_674" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_675" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="Locator_us-gaap_ProceedsFromStockPlans_676" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_675" xlink:to="Locator_us-gaap_ProceedsFromStockPlans_676" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_677" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="Locator_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_678" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_677" xlink:to="Locator_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_678" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_679" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CashDistributionToNoncontrollingInterest" xlink:label="Locator_amed_CashDistributionToNoncontrollingInterest_680" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_679" xlink:to="Locator_amed_CashDistributionToNoncontrollingInterest_680" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_681" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="Locator_us-gaap_ProceedsFromShortTermDebt_682" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_681" xlink:to="Locator_us-gaap_ProceedsFromShortTermDebt_682" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_683" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="Locator_us-gaap_RepaymentsOfShortTermDebt_684" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_683" xlink:to="Locator_us-gaap_RepaymentsOfShortTermDebt_684" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_685" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="Locator_us-gaap_ProceedsFromIssuanceOfLongTermDebt_686" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_685" xlink:to="Locator_us-gaap_ProceedsFromIssuanceOfLongTermDebt_686" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_687" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="Locator_us-gaap_RepaymentsOfLongTermDebt_688" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_687" xlink:to="Locator_us-gaap_RepaymentsOfLongTermDebt_688" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_689" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="Locator_us-gaap_PaymentsOfFinancingCosts_690" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_689" xlink:to="Locator_us-gaap_PaymentsOfFinancingCosts_690" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_691" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="Locator_us-gaap_PaymentsForRepurchaseOfCommonStock_692" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_691" xlink:to="Locator_us-gaap_PaymentsForRepurchaseOfCommonStock_692" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_693" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment" xlink:label="Locator_amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment_694" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_693" xlink:to="Locator_amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment_694" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_695" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_696" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_695" xlink:to="Locator_us-gaap_NetCashProvidedByUsedInFinancingActivities_696" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="Locator_us-gaap_StatementOfCashFlowsAbstract_597" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="Locator_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_598" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfCashFlowsAbstract_597" xlink:to="Locator_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_598" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="Locator_us-gaap_StatementOfCashFlowsAbstract_599" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="Locator_us-gaap_CashAndCashEquivalentsAtCarryingValue_600" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfCashFlowsAbstract_599" xlink:to="Locator_us-gaap_CashAndCashEquivalentsAtCarryingValue_600" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="Locator_us-gaap_StatementOfCashFlowsAbstract_601" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="Locator_us-gaap_CashAndCashEquivalentsAtCarryingValue_602" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfCashFlowsAbstract_601" xlink:to="Locator_us-gaap_CashAndCashEquivalentsAtCarryingValue_602" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="Locator_us-gaap_StatementOfCashFlowsAbstract_603" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="Locator_us-gaap_SupplementalCashFlowInformationAbstract_604" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfCashFlowsAbstract_603" xlink:to="Locator_us-gaap_SupplementalCashFlowInformationAbstract_604" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="Locator_us-gaap_SupplementalCashFlowInformationAbstract_697" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="Locator_us-gaap_InterestPaid_698" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SupplementalCashFlowInformationAbstract_697" xlink:to="Locator_us-gaap_InterestPaid_698" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="Locator_us-gaap_SupplementalCashFlowInformationAbstract_699" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="Locator_us-gaap_IncomeTaxesPaidNet_700" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SupplementalCashFlowInformationAbstract_699" xlink:to="Locator_us-gaap_IncomeTaxesPaidNet_700" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="Locator_us-gaap_StatementOfCashFlowsAbstract_605" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="Locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_606" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfCashFlowsAbstract_605" xlink:to="Locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_606" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="Locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_701" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1" xlink:label="Locator_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1_702" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_701" xlink:to="Locator_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1_702" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="Locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_703" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesIssued1" xlink:label="Locator_us-gaap_NotesIssued1_704" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_703" xlink:to="Locator_us-gaap_NotesIssued1_704" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="Locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_705" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests" xlink:label="Locator_amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests_706" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_705" xlink:to="Locator_amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests_706" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_793" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_794" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_793" xlink:to="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_794" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_795" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="Locator_us-gaap_SignificantAccountingPoliciesTextBlock_796" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_795" xlink:to="Locator_us-gaap_SignificantAccountingPoliciesTextBlock_796" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/ACQUISITIONS">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="Locator_us-gaap_BusinessCombinationsAbstract_797" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="Locator_us-gaap_BusinessCombinationDisclosureTextBlock_798" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BusinessCombinationsAbstract_797" xlink:to="Locator_us-gaap_BusinessCombinationDisclosureTextBlock_798" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DISCONTINUEDOPERATIONSANDASSETSHELDFORSALE">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:label="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_799" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="Locator_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_800" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_799" xlink:to="Locator_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_800" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="Locator_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_801" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="Locator_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_802" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_801" xlink:to="Locator_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_802" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONS">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="Locator_us-gaap_DebtDisclosureAbstract_803" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="Locator_us-gaap_DebtDisclosureTextBlock_804" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtDisclosureAbstract_803" xlink:to="Locator_us-gaap_DebtDisclosureTextBlock_804" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_805" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_806" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_805" xlink:to="Locator_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_806" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATION">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="Locator_us-gaap_SegmentReportingAbstract_807" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="Locator_us-gaap_SegmentReportingDisclosureTextBlock_808" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingAbstract_807" xlink:to="Locator_us-gaap_SegmentReportingDisclosureTextBlock_808" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureNATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSPolicies">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_809" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="Locator_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_810" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_809" xlink:to="Locator_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_810" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_811" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="Locator_us-gaap_UseOfEstimates_812" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_811" xlink:to="Locator_us-gaap_UseOfEstimates_812" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_813" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComparabilityOfPriorYearFinancialData" xlink:label="Locator_us-gaap_ComparabilityOfPriorYearFinancialData_814" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_813" xlink:to="Locator_us-gaap_ComparabilityOfPriorYearFinancialData_814" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_815" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="Locator_us-gaap_ConsolidationPolicyTextBlock_816" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_815" xlink:to="Locator_us-gaap_ConsolidationPolicyTextBlock_816" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_817" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="Locator_us-gaap_EquityMethodInvestmentsPolicy_818" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_817" xlink:to="Locator_us-gaap_EquityMethodInvestmentsPolicy_818" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_819" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="Locator_us-gaap_RevenueRecognitionPolicyTextBlock_820" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_819" xlink:to="Locator_us-gaap_RevenueRecognitionPolicyTextBlock_820" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_821" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="Locator_us-gaap_CashAndCashEquivalentsPolicyTextBlock_822" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_821" xlink:to="Locator_us-gaap_CashAndCashEquivalentsPolicyTextBlock_822" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_823" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="Locator_us-gaap_TradeAndOtherAccountsReceivablePolicy_824" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_823" xlink:to="Locator_us-gaap_TradeAndOtherAccountsReceivablePolicy_824" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_825" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_826" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_825" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_826" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_827" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="Locator_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_828" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_827" xlink:to="Locator_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_828" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_829" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtIssuanceCostsPolicyTextBlock" xlink:label="Locator_amed_DebtIssuanceCostsPolicyTextBlock_830" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_829" xlink:to="Locator_amed_DebtIssuanceCostsPolicyTextBlock_830" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_831" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="Locator_us-gaap_FairValueOfFinancialInstrumentsPolicy_832" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_831" xlink:to="Locator_us-gaap_FairValueOfFinancialInstrumentsPolicy_832" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_833" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="Locator_us-gaap_IncomeTaxPolicyTextBlock_834" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_833" xlink:to="Locator_us-gaap_IncomeTaxPolicyTextBlock_834" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_835" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="Locator_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_836" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_835" xlink:to="Locator_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_836" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_837" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="Locator_us-gaap_EarningsPerSharePolicyTextBlock_838" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_837" xlink:to="Locator_us-gaap_EarningsPerSharePolicyTextBlock_838" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_839" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="Locator_us-gaap_AdvertisingCostsPolicyTextBlock_840" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_839" xlink:to="Locator_us-gaap_AdvertisingCostsPolicyTextBlock_840" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_841" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="Locator_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_842" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_841" xlink:to="Locator_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_842" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_843" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" xlink:label="Locator_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock_844" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_843" xlink:to="Locator_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock_844" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_845" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTextBlock_846" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_845" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentTextBlock_846" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_847" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FinancialInstrumentDetailsTextBlock" xlink:label="Locator_amed_FinancialInstrumentDetailsTextBlock_848" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_847" xlink:to="Locator_amed_FinancialInstrumentDetailsTextBlock_848" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_849" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_850" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_849" xlink:to="Locator_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_850" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DISCONTINUEDOPERATIONSANDASSETSHELDFORSALETables">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:label="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_851" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="Locator_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_852" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_851" xlink:to="Locator_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_852" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureGOODWILLANDOTHERINTANGIBLEASSETSNETTables">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="Locator_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_853" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_854" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_853" xlink:to="Locator_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_854" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="Locator_us-gaap_DebtDisclosureAbstract_855" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="Locator_us-gaap_ScheduleOfDebtInstrumentsTextBlock_856" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtDisclosureAbstract_855" xlink:to="Locator_us-gaap_ScheduleOfDebtInstrumentsTextBlock_856" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="Locator_us-gaap_DebtDisclosureAbstract_857" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_858" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtDisclosureAbstract_857" xlink:to="Locator_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_858" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="Locator_us-gaap_DebtDisclosureAbstract_859" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:label="Locator_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_860" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtDisclosureAbstract_859" xlink:to="Locator_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_860" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONTables">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="Locator_us-gaap_SegmentReportingAbstract_861" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_862" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingAbstract_861" xlink:to="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_862" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationDetail">
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_995" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_996" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_995" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsDomain_996" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_997" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentsMember" xlink:label="Locator_us-gaap_EquityMethodInvestmentsMember_998" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsDomain_997" xlink:to="Locator_us-gaap_EquityMethodInvestmentsMember_998" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_981" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_982" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_981" xlink:to="Locator_us-gaap_SegmentDomain_982" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_987" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceInpatientMember" xlink:label="Locator_amed_HospiceInpatientMember_988" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_987" xlink:to="Locator_amed_HospiceInpatientMember_988" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_983" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_984" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_983" xlink:to="Locator_amed_HomeHealthMember_984" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_985" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_986" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_985" xlink:to="Locator_amed_HospiceMember_986" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_989" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PersonalCareMember" xlink:label="Locator_amed_PersonalCareMember_990" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_989" xlink:to="Locator_amed_PersonalCareMember_990" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationAbstract" xlink:label="Locator_amed_DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationAbstract_899" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsTable_900" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationAbstract_899" xlink:to="Locator_amed_OrganizationAndNatureOfOperationsTable_900" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsTable_971" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_972" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsTable_971" xlink:to="Locator_amed_OrganizationAndNatureOfOperationsLineItems_972" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_863" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="Locator_us-gaap_ConcentrationRiskPercentage1_864" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_863" xlink:to="Locator_us-gaap_ConcentrationRiskPercentage1_864" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_865" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingCareCenters" xlink:label="Locator_amed_OperatingCareCenters_866" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_865" xlink:to="Locator_amed_OperatingCareCenters_866" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_867" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates" xlink:label="Locator_us-gaap_NumberOfStatesInWhichEntityOperates_868" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_867" xlink:to="Locator_us-gaap_NumberOfStatesInWhichEntityOperates_868" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_869" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:label="Locator_amed_MinimumPercentOwnershipForControllingInterestPercent_870" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_869" xlink:to="Locator_amed_MinimumPercentOwnershipForControllingInterestPercent_870" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_871" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="Locator_us-gaap_EquityMethodInvestmentAggregateCost_872" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_871" xlink:to="Locator_us-gaap_EquityMethodInvestmentAggregateCost_872" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_873" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostMethodInvestments" xlink:label="Locator_us-gaap_CostMethodInvestments_874" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_873" xlink:to="Locator_us-gaap_CostMethodInvestments_874" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_875" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:label="Locator_amed_MaximumPercentOwnershipForEquityMethodPercent_876" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_875" xlink:to="Locator_amed_MaximumPercentOwnershipForEquityMethodPercent_876" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_877" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumPercentOwnershipForCostMethodPercent" xlink:label="Locator_amed_MaximumPercentOwnershipForCostMethodPercent_878" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_877" xlink:to="Locator_amed_MaximumPercentOwnershipForCostMethodPercent_878" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_879" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="Locator_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_880" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_879" xlink:to="Locator_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_880" order="9.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_881" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="Locator_us-gaap_GoodwillImpairmentLoss_882" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_881" xlink:to="Locator_us-gaap_GoodwillImpairmentLoss_882" order="10.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_883" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets" xlink:label="Locator_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets_884" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_883" xlink:to="Locator_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets_884" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_885" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" xlink:label="Locator_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_886" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_885" xlink:to="Locator_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_886" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_887" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" xlink:label="Locator_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_888" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_887" xlink:to="Locator_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_888" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_889" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities" xlink:label="Locator_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities_890" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_889" xlink:to="Locator_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities_890" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_891" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome" xlink:label="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome_892" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_891" xlink:to="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalInvestmentIncome_892" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_893" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses" xlink:label="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses_894" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_893" xlink:to="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationTotalExpenses_894" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsLineItems" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsLineItems_895" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations" xlink:label="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations_896" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsLineItems_895" xlink:to="Locator_amed_EquityMethodInvestmentSummarizedFinancialInformationNetIncreaseInPartnersCapitalFromOperations_896" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsTable_973" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_974" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsTable_973" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_974" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsTable_975" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="Locator_us-gaap_ConcentrationRiskByTypeAxis_976" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsTable_975" xlink:to="Locator_us-gaap_ConcentrationRiskByTypeAxis_976" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="Locator_us-gaap_ConcentrationRiskByTypeAxis_991" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="Locator_us-gaap_ConcentrationRiskTypeDomain_992" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ConcentrationRiskByTypeAxis_991" xlink:to="Locator_us-gaap_ConcentrationRiskTypeDomain_992" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="Locator_us-gaap_ConcentrationRiskTypeDomain_993" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="Locator_us-gaap_CustomerConcentrationRiskMember_994" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ConcentrationRiskTypeDomain_993" xlink:to="Locator_us-gaap_CustomerConcentrationRiskMember_994" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsTable_977" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_978" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsTable_977" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_978" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OrganizationAndNatureOfOperationsTable" xlink:label="Locator_amed_OrganizationAndNatureOfOperationsTable_979" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="Locator_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_980" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OrganizationAndNatureOfOperationsTable_979" xlink:to="Locator_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_980" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="Locator_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_999" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="Locator_us-gaap_EquityMethodInvesteeNameDomain_1000" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_999" xlink:to="Locator_us-gaap_EquityMethodInvesteeNameDomain_1000" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="Locator_us-gaap_EquityMethodInvesteeNameDomain_1001" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HeritageHealthcareInnovationFundMember" xlink:label="Locator_amed_HeritageHealthcareInnovationFundMember_1002" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EquityMethodInvesteeNameDomain_1001" xlink:to="Locator_amed_HeritageHealthcareInnovationFundMember_1002" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1085" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1086" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1085" xlink:to="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1086" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1237" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1238" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1237" xlink:to="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1238" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1003" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenue" xlink:label="Locator_amed_EpisodeOfCareAsEpisodicBasedRevenue_1004" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1003" xlink:to="Locator_amed_EpisodeOfCareAsEpisodicBasedRevenue_1004" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1005" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:label="Locator_amed_PercentageOfTotalReimbursementOfOutlierPayment_1006" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1005" xlink:to="Locator_amed_PercentageOfTotalReimbursementOfOutlierPayment_1006" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1007" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:label="Locator_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1008" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1007" xlink:to="Locator_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_1008" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1009" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FirstThresholdOfTherapyServicesRequired" xlink:label="Locator_amed_FirstThresholdOfTherapyServicesRequired_1010" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1009" xlink:to="Locator_amed_FirstThresholdOfTherapyServicesRequired_1010" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1011" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondThresholdOfServicesRequired" xlink:label="Locator_amed_SecondThresholdOfServicesRequired_1012" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1011" xlink:to="Locator_amed_SecondThresholdOfServicesRequired_1012" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1013" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ThirdThresholdOfTherapyServicesRequired" xlink:label="Locator_amed_ThirdThresholdOfTherapyServicesRequired_1014" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1013" xlink:to="Locator_amed_ThirdThresholdOfTherapyServicesRequired_1014" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1015" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CmsTherapyAssessmentRequirementIntervalMinimum" xlink:label="Locator_amed_CmsTherapyAssessmentRequirementIntervalMinimum_1016" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1015" xlink:to="Locator_amed_CmsTherapyAssessmentRequirementIntervalMinimum_1016" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1017" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HistoricalCollectionRateFromMedicare" xlink:label="Locator_amed_HistoricalCollectionRateFromMedicare_1018" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1017" xlink:to="Locator_amed_HistoricalCollectionRateFromMedicare_1018" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1019" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EpisodesInProgressThatBeginDuringReportingPeriod" xlink:label="Locator_amed_EpisodesInProgressThatBeginDuringReportingPeriod_1020" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1019" xlink:to="Locator_amed_EpisodesInProgressThatBeginDuringReportingPeriod_1020" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1021" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:label="Locator_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_1022" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1021" xlink:to="Locator_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_1022" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1023" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:label="Locator_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_1024" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1023" xlink:to="Locator_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_1024" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1025" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CmsHospiceFaceToFaceRequirementPriorToThirdBenefitPeriod" xlink:label="Locator_amed_CmsHospiceFaceToFaceRequirementPriorToThirdBenefitPeriod_1026" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1025" xlink:to="Locator_amed_CmsHospiceFaceToFaceRequirementPriorToThirdBenefitPeriod_1026" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1027" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DaysInHospiceRecertificationThirdBenefitPeriod" xlink:label="Locator_amed_DaysInHospiceRecertificationThirdBenefitPeriod_1028" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1027" xlink:to="Locator_amed_DaysInHospiceRecertificationThirdBenefitPeriod_1028" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1029" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfPatientReceivablesOutstanding" xlink:label="Locator_amed_PercentageOfPatientReceivablesOutstanding_1030" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1029" xlink:to="Locator_amed_PercentageOfPatientReceivablesOutstanding_1030" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1031" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfPatientReceivablesOutstandingOverTenPercent" xlink:label="Locator_amed_PercentageOfPatientReceivablesOutstandingOverTenPercent_1032" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1031" xlink:to="Locator_amed_PercentageOfPatientReceivablesOutstandingOverTenPercent_1032" order="15.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1033" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MinimumDaysAccountsReceivableOutstandingFullyReserved" xlink:label="Locator_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved_1034" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1033" xlink:to="Locator_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved_1034" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1035" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" xlink:label="Locator_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_1036" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1035" xlink:to="Locator_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_1036" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1037" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RevenueAdjustmentToMedicareRevenue" xlink:label="Locator_amed_RevenueAdjustmentToMedicareRevenue_1038" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1037" xlink:to="Locator_amed_RevenueAdjustmentToMedicareRevenue_1038" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1039" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare" xlink:label="Locator_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_1040" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1039" xlink:to="Locator_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare_1040" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1041" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:label="Locator_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_1042" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1041" xlink:to="Locator_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_1042" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1043" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode" xlink:label="Locator_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_1044" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1043" xlink:to="Locator_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode_1044" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1045" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:label="Locator_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_1046" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1045" xlink:to="Locator_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_1046" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1047" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="Locator_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1048" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1047" xlink:to="Locator_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1048" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1049" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="Locator_us-gaap_AssetImpairmentCharges_1050" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1049" xlink:to="Locator_us-gaap_AssetImpairmentCharges_1050" order="24.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1247" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearAxis" xlink:label="Locator_amed_CapYearAxis_1248" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1247" xlink:to="Locator_amed_CapYearAxis_1248" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearAxis" xlink:label="Locator_amed_CapYearAxis_1277" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearDomain" xlink:label="Locator_amed_CapYearDomain_1278" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CapYearAxis_1277" xlink:to="Locator_amed_CapYearDomain_1278" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearDomain" xlink:label="Locator_amed_CapYearDomain_1279" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember" xlink:label="Locator_amed_CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember_1280" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CapYearDomain_1279" xlink:to="Locator_amed_CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember_1280" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearDomain" xlink:label="Locator_amed_CapYearDomain_1281" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CapYearTwoThousandThirteenThroughTwoThousandFifteenMember" xlink:label="Locator_amed_CapYearTwoThousandThirteenThroughTwoThousandFifteenMember_1282" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CapYearDomain_1281" xlink:to="Locator_amed_CapYearTwoThousandThirteenThroughTwoThousandFifteenMember_1282" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:label="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1249" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssetImpairmentAxis" xlink:label="Locator_amed_AssetImpairmentAxis_1250" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_1249" xlink:to="Locator_amed_AssetImpairmentAxis_1250" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssetImpairmentAxis" xlink:label="Locator_amed_AssetImpairmentAxis_1283" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssetImpairmentDomain" xlink:label="Locator_amed_AssetImpairmentDomain_1284" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_AssetImpairmentAxis_1283" xlink:to="Locator_amed_AssetImpairmentDomain_1284" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssetImpairmentDomain" xlink:label="Locator_amed_AssetImpairmentDomain_1285" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Ams3HomecareAndHospiceMember" xlink:label="Locator_amed_Ams3HomecareAndHospiceMember_1286" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_AssetImpairmentDomain_1285" xlink:to="Locator_amed_Ams3HomecareAndHospiceMember_1286" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssetImpairmentDomain" xlink:label="Locator_amed_AssetImpairmentDomain_1287" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CorporateHeadquartersMember" xlink:label="Locator_amed_CorporateHeadquartersMember_1288" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_AssetImpairmentDomain_1287" xlink:to="Locator_amed_CorporateHeadquartersMember_1288" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssetImpairmentDomain" xlink:label="Locator_amed_AssetImpairmentDomain_1289" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomecareHomebaseMember" xlink:label="Locator_amed_HomecareHomebaseMember_1290" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_AssetImpairmentDomain_1289" xlink:to="Locator_amed_HomecareHomebaseMember_1290" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1087" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesTable" xlink:label="Locator_amed_IncomeTaxesTable_1088" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1087" xlink:to="Locator_amed_IncomeTaxesTable_1088" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesTable" xlink:label="Locator_amed_IncomeTaxesTable_1239" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesLineItems" xlink:label="Locator_amed_IncomeTaxesLineItems_1240" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxesTable_1239" xlink:to="Locator_amed_IncomeTaxesLineItems_1240" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesLineItems" xlink:label="Locator_amed_IncomeTaxesLineItems_1053" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent" xlink:label="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent_1054" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxesLineItems_1053" xlink:to="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent_1054" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesLineItems" xlink:label="Locator_amed_IncomeTaxesLineItems_1055" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_1056" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxesLineItems_1055" xlink:to="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_1056" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesLineItems" xlink:label="Locator_amed_IncomeTaxesLineItems_1057" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNet_1058" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxesLineItems_1057" xlink:to="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNet_1058" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesTable" xlink:label="Locator_amed_IncomeTaxesTable_1251" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesAxis" xlink:label="Locator_amed_IncomeTaxesAxis_1252" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxesTable_1251" xlink:to="Locator_amed_IncomeTaxesAxis_1252" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesAxis" xlink:label="Locator_amed_IncomeTaxesAxis_1301" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesDomain" xlink:label="Locator_amed_IncomeTaxesDomain_1302" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxesAxis_1301" xlink:to="Locator_amed_IncomeTaxesDomain_1302" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxesDomain" xlink:label="Locator_amed_IncomeTaxesDomain_1303" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UsDepartmentOfJusticeSettlementMember" xlink:label="Locator_amed_UsDepartmentOfJusticeSettlementMember_1304" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxesDomain_1303" xlink:to="Locator_amed_UsDepartmentOfJusticeSettlementMember_1304" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1089" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_1090" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1089" xlink:to="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_1090" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_1255" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_1256" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_1255" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_1256" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_1297" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_1298" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_1297" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsDomain_1298" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_1299" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AnnualImpairmentTestStepOneMember" xlink:label="Locator_amed_AnnualImpairmentTestStepOneMember_1300" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsDomain_1299" xlink:to="Locator_amed_AnnualImpairmentTestStepOneMember_1300" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_1241" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_1242" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_1241" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsLineItems_1242" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_1061" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedUsefulLifeOfIntangibleAssets" xlink:label="Locator_amed_EstimatedUsefulLifeOfIntangibleAssets_1062" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_1061" xlink:to="Locator_amed_EstimatedUsefulLifeOfIntangibleAssets_1062" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_1253" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1254" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_1253" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1254" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1291" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1292" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1291" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1292" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1293" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AcquiredNamesMember" xlink:label="Locator_amed_AcquiredNamesMember_1294" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1293" xlink:to="Locator_amed_AcquiredNamesMember_1294" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1295" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="Locator_us-gaap_NoncompeteAgreementsMember_1296" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1295" xlink:to="Locator_us-gaap_NoncompeteAgreementsMember_1296" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1093" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1094" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1093" xlink:to="Locator_us-gaap_DebtInstrumentTable_1094" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1243" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtIssuanceCostsLineItems" xlink:label="Locator_amed_DebtIssuanceCostsLineItems_1244" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentTable_1243" xlink:to="Locator_amed_DebtIssuanceCostsLineItems_1244" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtIssuanceCostsLineItems" xlink:label="Locator_amed_DebtIssuanceCostsLineItems_1065" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="Locator_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1066" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DebtIssuanceCostsLineItems_1065" xlink:to="Locator_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1066" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtIssuanceCostsLineItems" xlink:label="Locator_amed_DebtIssuanceCostsLineItems_1067" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="Locator_us-gaap_WriteOffOfDeferredDebtIssuanceCost_1068" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DebtIssuanceCostsLineItems_1067" xlink:to="Locator_us-gaap_WriteOffOfDeferredDebtIssuanceCost_1068" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtIssuanceCostsLineItems" xlink:label="Locator_amed_DebtIssuanceCostsLineItems_1069" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="Locator_us-gaap_DebtIssuanceCosts_1070" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DebtIssuanceCostsLineItems_1069" xlink:to="Locator_us-gaap_DebtIssuanceCosts_1070" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtIssuanceCostsLineItems" xlink:label="Locator_amed_DebtIssuanceCostsLineItems_1071" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="Locator_us-gaap_UnamortizedDebtIssuanceExpense_1072" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DebtIssuanceCostsLineItems_1071" xlink:to="Locator_us-gaap_UnamortizedDebtIssuanceExpense_1072" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtIssuanceCostsLineItems" xlink:label="Locator_amed_DebtIssuanceCostsLineItems_1073" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnamortizedDebtIssuanceCostAmortizatinPeriod" xlink:label="Locator_amed_UnamortizedDebtIssuanceCostAmortizatinPeriod_1074" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DebtIssuanceCostsLineItems_1073" xlink:to="Locator_amed_UnamortizedDebtIssuanceCostAmortizatinPeriod_1074" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1257" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1258" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentTable_1257" xlink:to="Locator_us-gaap_LongtermDebtTypeAxis_1258" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1261" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1262" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeAxis_1261" xlink:to="Locator_us-gaap_LongtermDebtTypeDomain_1262" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1269" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredDebtIssuanceCostsMember" xlink:label="Locator_amed_DeferredDebtIssuanceCostsMember_1270" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1269" xlink:to="Locator_amed_DeferredDebtIssuanceCostsMember_1270" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1263" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondLienCreditAgreementTermLoanMember" xlink:label="Locator_amed_SecondLienCreditAgreementTermLoanMember_1264" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1263" xlink:to="Locator_amed_SecondLienCreditAgreementTermLoanMember_1264" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1265" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CreditAgreementMember" xlink:label="Locator_amed_CreditAgreementMember_1266" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1265" xlink:to="Locator_amed_CreditAgreementMember_1266" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1267" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondLienCreditAgreementRevolvingCreditFacilityMember" xlink:label="Locator_amed_SecondLienCreditAgreementRevolvingCreditFacilityMember_1268" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1267" xlink:to="Locator_amed_SecondLienCreditAgreementRevolvingCreditFacilityMember_1268" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1095" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="Locator_us-gaap_ShareBasedCompensation_1096" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1095" xlink:to="Locator_us-gaap_ShareBasedCompensation_1096" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1097" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="Locator_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1098" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1097" xlink:to="Locator_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1098" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1099" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="Locator_us-gaap_AdvertisingExpense_1100" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1099" xlink:to="Locator_us-gaap_AdvertisingExpense_1100" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1091" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1092" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1091" xlink:to="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1092" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1259" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_1260" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1259" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_1260" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_1271" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1272" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_1271" xlink:to="Locator_us-gaap_SegmentDomain_1272" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1273" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_1274" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_1273" xlink:to="Locator_amed_HomeHealthMember_1274" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1275" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_1276" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_1275" xlink:to="Locator_amed_HospiceMember_1276" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1245" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1246" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1245" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1246" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1077" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InternallyDevelopedComputerSoftware" xlink:label="Locator_amed_InternallyDevelopedComputerSoftware_1078" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1077" xlink:to="Locator_amed_InternallyDevelopedComputerSoftware_1078" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1079" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InternallyDevelopedComputerSoftwareAmortizationPeriod" xlink:label="Locator_amed_InternallyDevelopedComputerSoftwareAmortizationPeriod_1080" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1079" xlink:to="Locator_amed_InternallyDevelopedComputerSoftwareAmortizationPeriod_1080" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1081" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="Locator_us-gaap_Depreciation_1082" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_1081" xlink:to="Locator_us-gaap_Depreciation_1082" order="3.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/ScheduleOfFinancialInstrumentsWhereCarryingValueAndFairValueDifferDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1309" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1310" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1309" xlink:to="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1310" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1325" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1326" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1325" xlink:to="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1326" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1305" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="Locator_us-gaap_LiabilitiesFairValueDisclosure_1306" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1305" xlink:to="Locator_us-gaap_LiabilitiesFairValueDisclosure_1306" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1327" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="Locator_us-gaap_FairValueByFairValueHierarchyLevelAxis_1328" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1327" xlink:to="Locator_us-gaap_FairValueByFairValueHierarchyLevelAxis_1328" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="Locator_us-gaap_FairValueByFairValueHierarchyLevelAxis_1329" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1330" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FairValueByFairValueHierarchyLevelAxis_1329" xlink:to="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1330" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1331" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="Locator_us-gaap_FairValueInputsLevel1Member_1332" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1331" xlink:to="Locator_us-gaap_FairValueInputsLevel1Member_1332" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1333" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="Locator_us-gaap_FairValueInputsLevel2Member_1334" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1333" xlink:to="Locator_us-gaap_FairValueInputsLevel2Member_1334" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1335" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="Locator_us-gaap_FairValueInputsLevel3Member_1336" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1335" xlink:to="Locator_us-gaap_FairValueInputsLevel3Member_1336" order="3.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/ScheduleOfWeightedAverageSharesOutstandingDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1337" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="Locator_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1338" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1337" xlink:to="Locator_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1338" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1339" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="Locator_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1340" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1339" xlink:to="Locator_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1340" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1341" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockAndStockUnits" xlink:label="Locator_amed_NonVestedStockAndStockUnits_1342" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1341" xlink:to="Locator_amed_NonVestedStockAndStockUnits_1342" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1343" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1344" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1343" xlink:to="Locator_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1344" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_1345" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="Locator_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1346" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_1345" xlink:to="Locator_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1346" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureDiscontinuedOperationsAndAssetsHeldForSaleAdditionalInformationDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_1415" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1416" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_1415" xlink:to="Locator_us-gaap_SegmentDomain_1416" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1417" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_1418" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_1417" xlink:to="Locator_amed_HomeHealthMember_1418" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_1419" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_1420" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_1419" xlink:to="Locator_amed_HospiceMember_1420" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:label="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1373" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1374" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1373" xlink:to="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1374" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1409" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1410" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1409" xlink:to="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1410" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1353" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersConsolidated" xlink:label="Locator_amed_NumberOfCareCentersConsolidated_1354" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1353" xlink:to="Locator_amed_NumberOfCareCentersConsolidated_1354" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1355" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersClosed" xlink:label="Locator_amed_NumberOfCareCentersClosed_1356" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1355" xlink:to="Locator_amed_NumberOfCareCentersClosed_1356" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1357" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" xlink:label="Locator_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_1358" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1357" xlink:to="Locator_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_1358" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1359" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersExited" xlink:label="Locator_amed_NumberOfCareCentersExited_1360" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1359" xlink:to="Locator_amed_NumberOfCareCentersExited_1360" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1361" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersAvailableForSale" xlink:label="Locator_amed_NumberOfCareCentersAvailableForSale_1362" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1361" xlink:to="Locator_amed_NumberOfCareCentersAvailableForSale_1362" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1363" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersSold" xlink:label="Locator_amed_NumberOfCareCentersSold_1364" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1363" xlink:to="Locator_amed_NumberOfCareCentersSold_1364" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1365" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersIncludedInDivestiturePlan" xlink:label="Locator_amed_NumberOfCareCentersIncludedInDivestiturePlan_1366" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1365" xlink:to="Locator_amed_NumberOfCareCentersIncludedInDivestiturePlan_1366" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1367" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersIncludedInDiscontinuedOperations" xlink:label="Locator_amed_NumberOfCareCentersIncludedInDiscontinuedOperations_1368" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1367" xlink:to="Locator_amed_NumberOfCareCentersIncludedInDiscontinuedOperations_1368" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1369" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_NumberOfCareCentersRemovedFromAvailableForSale_1370" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1369" xlink:to="Locator_amed_NumberOfCareCentersRemovedFromAvailableForSale_1370" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1411" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_1412" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1411" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_1412" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1413" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:label="Locator_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1414" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_1413" xlink:to="Locator_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1414" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:label="Locator_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1421" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="Locator_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1422" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1421" xlink:to="Locator_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1422" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="Locator_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1423" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="Locator_us-gaap_DiscontinuedOperationsHeldforsaleMember_1424" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1423" xlink:to="Locator_us-gaap_DiscontinuedOperationsHeldforsaleMember_1424" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/NetRevenuesAndOperatingResultsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:label="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1425" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="Locator_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1426" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1425" xlink:to="Locator_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1426" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:label="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1427" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="Locator_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1428" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1427" xlink:to="Locator_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1428" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:label="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1429" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="Locator_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1430" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1429" xlink:to="Locator_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1430" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:label="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1431" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1432" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1431" xlink:to="Locator_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1432" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:label="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1433" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_1434" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_1433" xlink:to="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_1434" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_1469" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1470" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_1469" xlink:to="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1470" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1435" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NetRevenueForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_NetRevenueForCareCentersRemovedFromAvailableForSale_1436" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1435" xlink:to="Locator_amed_NetRevenueForCareCentersRemovedFromAvailableForSale_1436" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1437" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale_1438" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1437" xlink:to="Locator_amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale_1438" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1439" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale_1440" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1439" xlink:to="Locator_amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale_1440" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1441" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale" xlink:label="Locator_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_1442" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleLineItems_1441" xlink:to="Locator_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_1442" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable" xlink:label="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_1471" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareCenterStatusAxis" xlink:label="Locator_amed_CareCenterStatusAxis_1472" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeStatementDisclosuresForCareCentersRemovedFromAvailableForSaleTable_1471" xlink:to="Locator_amed_CareCenterStatusAxis_1472" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareCenterStatusAxis" xlink:label="Locator_amed_CareCenterStatusAxis_1473" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareCenterStatusDomain" xlink:label="Locator_amed_CareCenterStatusDomain_1474" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CareCenterStatusAxis_1473" xlink:to="Locator_amed_CareCenterStatusDomain_1474" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareCenterStatusDomain" xlink:label="Locator_amed_CareCenterStatusDomain_1475" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareCentersRemovedFromAvailableForSaleMember" xlink:label="Locator_amed_CareCentersRemovedFromAvailableForSaleMember_1476" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CareCenterStatusDomain_1475" xlink:to="Locator_amed_CareCentersRemovedFromAvailableForSaleMember_1476" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureLongTermDebtDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1527" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1528" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentTable_1527" xlink:to="Locator_us-gaap_DebtInstrumentLineItems_1528" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1479" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_1480" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1479" xlink:to="Locator_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_1480" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1481" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="Locator_us-gaap_DebtInstrumentUnamortizedDiscount_1482" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1481" xlink:to="Locator_us-gaap_DebtInstrumentUnamortizedDiscount_1482" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1483" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="Locator_us-gaap_UnamortizedDebtIssuanceExpense_1484" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1483" xlink:to="Locator_us-gaap_UnamortizedDebtIssuanceExpense_1484" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1485" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="Locator_us-gaap_LongTermDebtNoncurrent_1486" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1485" xlink:to="Locator_us-gaap_LongTermDebtNoncurrent_1486" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1477" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="Locator_us-gaap_LongTermDebt_1478" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1477" xlink:to="Locator_us-gaap_LongTermDebt_1478" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1529" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1530" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentTable_1529" xlink:to="Locator_us-gaap_LongtermDebtTypeAxis_1530" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1531" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1532" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeAxis_1531" xlink:to="Locator_us-gaap_LongtermDebtTypeDomain_1532" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1533" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TermLoanMember" xlink:label="Locator_amed_TermLoanMember_1534" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1533" xlink:to="Locator_amed_TermLoanMember_1534" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1535" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RevolvingCreditFacilitiesMember" xlink:label="Locator_amed_RevolvingCreditFacilitiesMember_1536" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1535" xlink:to="Locator_amed_RevolvingCreditFacilitiesMember_1536" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1537" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SwingLineLoanMember" xlink:label="Locator_amed_SwingLineLoanMember_1538" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1537" xlink:to="Locator_amed_SwingLineLoanMember_1538" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1539" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="Locator_us-gaap_LetterOfCreditMember_1540" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1539" xlink:to="Locator_us-gaap_LetterOfCreditMember_1540" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1541" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesANotesMember" xlink:label="Locator_amed_SeriesANotesMember_1542" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1541" xlink:to="Locator_amed_SeriesANotesMember_1542" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1543" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesBNotesMember" xlink:label="Locator_amed_SeriesBNotesMember_1544" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1543" xlink:to="Locator_amed_SeriesBNotesMember_1544" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1545" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesCNotesMember" xlink:label="Locator_amed_SeriesCNotesMember_1546" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1545" xlink:to="Locator_amed_SeriesCNotesMember_1546" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1547" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondLienCreditAgreementTermLoanMember" xlink:label="Locator_amed_SecondLienCreditAgreementTermLoanMember_1548" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1547" xlink:to="Locator_amed_SecondLienCreditAgreementTermLoanMember_1548" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1551" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OneHundredMillionTermLoanMember" xlink:label="Locator_amed_OneHundredMillionTermLoanMember_1552" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1551" xlink:to="Locator_amed_OneHundredMillionTermLoanMember_1552" order="10.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1553" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1554" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1553" xlink:to="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1554" order="11.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1549" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PromissoryNotesMember" xlink:label="Locator_amed_PromissoryNotesMember_1550" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1549" xlink:to="Locator_amed_PromissoryNotesMember_1550" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAbstract" xlink:label="Locator_us-gaap_LongTermDebtAbstract_1489" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1490" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongTermDebtAbstract_1489" xlink:to="Locator_us-gaap_DebtInstrumentTable_1490" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureLongTermDebtParentheticalDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1625" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1626" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentTable_1625" xlink:to="Locator_us-gaap_DebtInstrumentLineItems_1626" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1557" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="Locator_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_1558" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1557" xlink:to="Locator_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_1558" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1561" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InterestRateOnNotesPayableToBank" xlink:label="Locator_amed_InterestRateOnNotesPayableToBank_1562" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1561" xlink:to="Locator_amed_InterestRateOnNotesPayableToBank_1562" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1565" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="Locator_us-gaap_DebtInstrumentPeriodicPaymentInterest_1566" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1565" xlink:to="Locator_us-gaap_DebtInstrumentPeriodicPaymentInterest_1566" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1555" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="Locator_us-gaap_DebtInstrumentFaceAmount_1556" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1555" xlink:to="Locator_us-gaap_DebtInstrumentFaceAmount_1556" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1563" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="Locator_us-gaap_DebtInstrumentMaturityDate_1564" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1563" xlink:to="Locator_us-gaap_DebtInstrumentMaturityDate_1564" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1567" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="Locator_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_1568" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1567" xlink:to="Locator_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_1568" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1559" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="Locator_us-gaap_DebtInstrumentInterestRateStatedPercentage_1560" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1559" xlink:to="Locator_us-gaap_DebtInstrumentInterestRateStatedPercentage_1560" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1627" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1628" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentTable_1627" xlink:to="Locator_us-gaap_LongtermDebtTypeAxis_1628" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1631" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1632" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeAxis_1631" xlink:to="Locator_us-gaap_LongtermDebtTypeDomain_1632" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1633" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TermLoanMember" xlink:label="Locator_amed_TermLoanMember_1634" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1633" xlink:to="Locator_amed_TermLoanMember_1634" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1635" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RevolvingCreditFacilitiesMember" xlink:label="Locator_amed_RevolvingCreditFacilitiesMember_1636" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1635" xlink:to="Locator_amed_RevolvingCreditFacilitiesMember_1636" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1637" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SwingLineLoanMember" xlink:label="Locator_amed_SwingLineLoanMember_1638" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1637" xlink:to="Locator_amed_SwingLineLoanMember_1638" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1639" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="Locator_us-gaap_LetterOfCreditMember_1640" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1639" xlink:to="Locator_us-gaap_LetterOfCreditMember_1640" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1641" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesANotesMember" xlink:label="Locator_amed_SeriesANotesMember_1642" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1641" xlink:to="Locator_amed_SeriesANotesMember_1642" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1643" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesBNotesMember" xlink:label="Locator_amed_SeriesBNotesMember_1644" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1643" xlink:to="Locator_amed_SeriesBNotesMember_1644" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1645" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesCNotesMember" xlink:label="Locator_amed_SeriesCNotesMember_1646" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1645" xlink:to="Locator_amed_SeriesCNotesMember_1646" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1649" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondLienCreditAgreementTermLoanMember" xlink:label="Locator_amed_SecondLienCreditAgreementTermLoanMember_1650" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1649" xlink:to="Locator_amed_SecondLienCreditAgreementTermLoanMember_1650" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1651" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OneHundredMillionTermLoanMember" xlink:label="Locator_amed_OneHundredMillionTermLoanMember_1652" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1651" xlink:to="Locator_amed_OneHundredMillionTermLoanMember_1652" order="10.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1653" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1654" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1653" xlink:to="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1654" order="11.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1647" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PromissoryNotesMember" xlink:label="Locator_amed_PromissoryNotesMember_1648" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1647" xlink:to="Locator_amed_PromissoryNotesMember_1648" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1629" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_1630" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentTable_1629" xlink:to="Locator_us-gaap_RangeAxis_1630" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_1655" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1656" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeAxis_1655" xlink:to="Locator_us-gaap_RangeMember_1656" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1659" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_1660" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_1659" xlink:to="Locator_us-gaap_MinimumMember_1660" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1657" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_1658" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_1657" xlink:to="Locator_us-gaap_MaximumMember_1658" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAbstract" xlink:label="Locator_us-gaap_LongTermDebtAbstract_1571" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1572" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongTermDebtAbstract_1571" xlink:to="Locator_us-gaap_DebtInstrumentTable_1572" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureLongTermDebtAdditionalInformationDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1901" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1902" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentTable_1901" xlink:to="Locator_us-gaap_DebtInstrumentLineItems_1902" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1661" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="Locator_us-gaap_DebtInstrumentTerm_1662" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1661" xlink:to="Locator_us-gaap_DebtInstrumentTerm_1662" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1663" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WeightedAverageInterestRate" xlink:label="Locator_amed_WeightedAverageInterestRate_1664" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1663" xlink:to="Locator_amed_WeightedAverageInterestRate_1664" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1665" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TotalLeverageRatio" xlink:label="Locator_amed_TotalLeverageRatio_1666" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1665" xlink:to="Locator_amed_TotalLeverageRatio_1666" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1667" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FixedChargeCoverageRatio" xlink:label="Locator_amed_FixedChargeCoverageRatio_1668" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1667" xlink:to="Locator_amed_FixedChargeCoverageRatio_1668" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1669" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="Locator_us-gaap_DebtInstrumentFaceAmount_1670" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1669" xlink:to="Locator_us-gaap_DebtInstrumentFaceAmount_1670" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1671" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="Locator_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1672" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1671" xlink:to="Locator_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1672" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1673" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="Locator_us-gaap_LettersOfCreditOutstandingAmount_1674" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1673" xlink:to="Locator_us-gaap_LettersOfCreditOutstandingAmount_1674" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1675" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityEffectiveyBorrowingCapacity" xlink:label="Locator_amed_LineOfCreditFacilityEffectiveyBorrowingCapacity_1676" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1675" xlink:to="Locator_amed_LineOfCreditFacilityEffectiveyBorrowingCapacity_1676" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1677" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityDebtRestrictions" xlink:label="Locator_amed_LineOfCreditFacilityDebtRestrictions_1678" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1677" xlink:to="Locator_amed_LineOfCreditFacilityDebtRestrictions_1678" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1679" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximumLeverageRatio" xlink:label="Locator_amed_MaximumLeverageRatio_1680" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1679" xlink:to="Locator_amed_MaximumLeverageRatio_1680" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1681" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MinimumFixedChargeCoverageRatio" xlink:label="Locator_amed_MinimumFixedChargeCoverageRatio_1682" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1681" xlink:to="Locator_amed_MinimumFixedChargeCoverageRatio_1682" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1683" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="Locator_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1684" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1683" xlink:to="Locator_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1684" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1685" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RevolvingCreditFacilityTotal" xlink:label="Locator_amed_RevolvingCreditFacilityTotal_1686" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1685" xlink:to="Locator_amed_RevolvingCreditFacilityTotal_1686" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1687" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:label="Locator_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_1688" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1687" xlink:to="Locator_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_1688" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1689" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="Locator_us-gaap_DebtInstrumentMaturityDate_1690" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1689" xlink:to="Locator_us-gaap_DebtInstrumentMaturityDate_1690" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1691" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentNumberOfPeriodicPayments" xlink:label="Locator_amed_DebtInstrumentNumberOfPeriodicPayments_1692" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1691" xlink:to="Locator_amed_DebtInstrumentNumberOfPeriodicPayments_1692" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1693" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="Locator_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_1694" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1693" xlink:to="Locator_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_1694" order="17.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1695" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="Locator_us-gaap_DebtIssuanceCosts_1696" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1695" xlink:to="Locator_us-gaap_DebtIssuanceCosts_1696" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1697" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:label="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_1698" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1697" xlink:to="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_1698" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1699" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:label="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_1700" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1699" xlink:to="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_1700" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1701" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveABRRate" xlink:label="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveABRRate_1702" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1701" xlink:to="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveABRRate_1702" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1703" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestABRFlatRate" xlink:label="Locator_amed_DebtInstrumentInterestABRFlatRate_1704" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1703" xlink:to="Locator_amed_DebtInstrumentInterestABRFlatRate_1704" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1705" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate" xlink:label="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate_1706" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1705" xlink:to="Locator_amed_DebtInstrumentInterestAdditionalInterestAboveOneMonthEurodollarRate_1706" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1707" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ApplicableMarginRateOnBaseRate" xlink:label="Locator_amed_ApplicableMarginRateOnBaseRate_1708" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1707" xlink:to="Locator_amed_ApplicableMarginRateOnBaseRate_1708" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1709" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ApplicableMarginRateOnEurodollarRate" xlink:label="Locator_amed_ApplicableMarginRateOnEurodollarRate_1710" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1709" xlink:to="Locator_amed_ApplicableMarginRateOnEurodollarRate_1710" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1711" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EurodollarDepositsInterestPeriod" xlink:label="Locator_amed_EurodollarDepositsInterestPeriod_1712" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1711" xlink:to="Locator_amed_EurodollarDepositsInterestPeriod_1712" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1713" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DebtInstrumentInterestLiborFloor" xlink:label="Locator_amed_DebtInstrumentInterestLiborFloor_1714" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1713" xlink:to="Locator_amed_DebtInstrumentInterestLiborFloor_1714" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1715" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PrepaymentPenaltyPercentage" xlink:label="Locator_amed_PrepaymentPenaltyPercentage_1716" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1715" xlink:to="Locator_amed_PrepaymentPenaltyPercentage_1716" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1717" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:label="Locator_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_1718" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1717" xlink:to="Locator_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_1718" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1719" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:label="Locator_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_1720" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1719" xlink:to="Locator_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_1720" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1721" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="Locator_us-gaap_LongTermDebt_1722" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1721" xlink:to="Locator_us-gaap_LongTermDebt_1722" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1723" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNotesPayable" xlink:label="Locator_us-gaap_OtherNotesPayable_1724" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1723" xlink:to="Locator_us-gaap_OtherNotesPayable_1724" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1725" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="Locator_us-gaap_DebtInstrumentInterestRateStatedPercentage_1726" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1725" xlink:to="Locator_us-gaap_DebtInstrumentInterestRateStatedPercentage_1726" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1727" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="Locator_us-gaap_RepaymentsOfLinesOfCredit_1728" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1727" xlink:to="Locator_us-gaap_RepaymentsOfLinesOfCredit_1728" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1729" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="Locator_us-gaap_ProceedsFromIssuanceOfDebt_1730" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1729" xlink:to="Locator_us-gaap_ProceedsFromIssuanceOfDebt_1730" order="35.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1731" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="Locator_us-gaap_DebtWeightedAverageInterestRate_1732" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1731" xlink:to="Locator_us-gaap_DebtWeightedAverageInterestRate_1732" order="36.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1733" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeniorSecuredLeverageRatio" xlink:label="Locator_amed_SeniorSecuredLeverageRatio_1734" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1733" xlink:to="Locator_amed_SeniorSecuredLeverageRatio_1734" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1735" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="Locator_us-gaap_WriteOffOfDeferredDebtIssuanceCost_1736" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1735" xlink:to="Locator_us-gaap_WriteOffOfDeferredDebtIssuanceCost_1736" order="38.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1737" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CallPremiumPayment" xlink:label="Locator_amed_CallPremiumPayment_1738" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1737" xlink:to="Locator_amed_CallPremiumPayment_1738" order="39.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1739" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MarginAdjustmentOnBaseRate" xlink:label="Locator_amed_MarginAdjustmentOnBaseRate_1740" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1739" xlink:to="Locator_amed_MarginAdjustmentOnBaseRate_1740" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="Locator_us-gaap_DebtInstrumentLineItems_1741" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MarginAdjustmentOnEuroDollarLoans" xlink:label="Locator_amed_MarginAdjustmentOnEuroDollarLoans_1742" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentLineItems_1741" xlink:to="Locator_amed_MarginAdjustmentOnEuroDollarLoans_1742" order="41.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1903" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1904" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentTable_1903" xlink:to="Locator_us-gaap_LongtermDebtTypeAxis_1904" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_1911" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1912" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeAxis_1911" xlink:to="Locator_us-gaap_LongtermDebtTypeDomain_1912" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1913" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TermLoanMember" xlink:label="Locator_amed_TermLoanMember_1914" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1913" xlink:to="Locator_amed_TermLoanMember_1914" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1915" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RevolvingCreditFacilitiesMember" xlink:label="Locator_amed_RevolvingCreditFacilitiesMember_1916" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1915" xlink:to="Locator_amed_RevolvingCreditFacilitiesMember_1916" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1917" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SwingLineLoanMember" xlink:label="Locator_amed_SwingLineLoanMember_1918" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1917" xlink:to="Locator_amed_SwingLineLoanMember_1918" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1919" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="Locator_us-gaap_LetterOfCreditMember_1920" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1919" xlink:to="Locator_us-gaap_LetterOfCreditMember_1920" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1921" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesANotesMember" xlink:label="Locator_amed_SeriesANotesMember_1922" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1921" xlink:to="Locator_amed_SeriesANotesMember_1922" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1923" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesBNotesMember" xlink:label="Locator_amed_SeriesBNotesMember_1924" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1923" xlink:to="Locator_amed_SeriesBNotesMember_1924" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1925" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeriesCNotesMember" xlink:label="Locator_amed_SeriesCNotesMember_1926" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1925" xlink:to="Locator_amed_SeriesCNotesMember_1926" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1927" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondLienCreditAgreementTermLoanMember" xlink:label="Locator_amed_SecondLienCreditAgreementTermLoanMember_1928" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1927" xlink:to="Locator_amed_SecondLienCreditAgreementTermLoanMember_1928" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1931" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CreditAgreementMember" xlink:label="Locator_amed_CreditAgreementMember_1932" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1931" xlink:to="Locator_amed_CreditAgreementMember_1932" order="10.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1933" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondLienCreditAgreementRevolvingCreditFacilityMember" xlink:label="Locator_amed_SecondLienCreditAgreementRevolvingCreditFacilityMember_1934" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1933" xlink:to="Locator_amed_SecondLienCreditAgreementRevolvingCreditFacilityMember_1934" order="11.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1935" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OneHundredMillionTermLoanMember" xlink:label="Locator_amed_OneHundredMillionTermLoanMember_1936" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1935" xlink:to="Locator_amed_OneHundredMillionTermLoanMember_1936" order="12.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1937" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:label="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1938" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1937" xlink:to="Locator_amed_TwoHundredMillionRevolvingCreditFacilityMember_1938" order="13.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_1929" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PromissoryNotesMember" xlink:label="Locator_amed_PromissoryNotesMember_1930" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_1929" xlink:to="Locator_amed_PromissoryNotesMember_1930" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1905" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_1906" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentTable_1905" xlink:to="Locator_us-gaap_RangeAxis_1906" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_1939" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1940" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeAxis_1939" xlink:to="Locator_us-gaap_RangeMember_1940" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1945" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MiddleMember" xlink:label="Locator_amed_MiddleMember_1946" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_1945" xlink:to="Locator_amed_MiddleMember_1946" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1943" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_1944" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_1943" xlink:to="Locator_us-gaap_MinimumMember_1944" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_1941" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_1942" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_1941" xlink:to="Locator_us-gaap_MaximumMember_1942" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1907" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodAxis" xlink:label="Locator_amed_TimePeriodAxis_1908" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentTable_1907" xlink:to="Locator_amed_TimePeriodAxis_1908" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodAxis" xlink:label="Locator_amed_TimePeriodAxis_1947" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1948" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_TimePeriodAxis_1947" xlink:to="Locator_amed_TimePeriodDomain_1948" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1949" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OneMonthMember" xlink:label="Locator_amed_OneMonthMember_1950" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_TimePeriodDomain_1949" xlink:to="Locator_amed_OneMonthMember_1950" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1951" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoMonthMember" xlink:label="Locator_amed_TwoMonthMember_1952" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_TimePeriodDomain_1951" xlink:to="Locator_amed_TwoMonthMember_1952" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1953" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ThreeMonthMember" xlink:label="Locator_amed_ThreeMonthMember_1954" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_TimePeriodDomain_1953" xlink:to="Locator_amed_ThreeMonthMember_1954" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1955" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SixMonthMember" xlink:label="Locator_amed_SixMonthMember_1956" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_TimePeriodDomain_1955" xlink:to="Locator_amed_SixMonthMember_1956" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1957" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OneYearMember" xlink:label="Locator_amed_OneYearMember_1958" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_TimePeriodDomain_1957" xlink:to="Locator_amed_OneYearMember_1958" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1959" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoYearMember" xlink:label="Locator_amed_TwoYearMember_1960" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_TimePeriodDomain_1959" xlink:to="Locator_amed_TwoYearMember_1960" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1961" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FourRemainingQuarterlyPaymentsMember" xlink:label="Locator_amed_FourRemainingQuarterlyPaymentsMember_1962" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_TimePeriodDomain_1961" xlink:to="Locator_amed_FourRemainingQuarterlyPaymentsMember_1962" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1963" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SecondEightQuarterlyPaymentsMember" xlink:label="Locator_amed_SecondEightQuarterlyPaymentsMember_1964" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_TimePeriodDomain_1963" xlink:to="Locator_amed_SecondEightQuarterlyPaymentsMember_1964" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TimePeriodDomain" xlink:label="Locator_amed_TimePeriodDomain_1965" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FinalTwoQuarterlyPaymentsMember" xlink:label="Locator_amed_FinalTwoQuarterlyPaymentsMember_1966" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_TimePeriodDomain_1965" xlink:to="Locator_amed_FinalTwoQuarterlyPaymentsMember_1966" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1909" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FeeTypeAxis" xlink:label="Locator_amed_FeeTypeAxis_1910" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtInstrumentTable_1909" xlink:to="Locator_amed_FeeTypeAxis_1910" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FeeTypeAxis" xlink:label="Locator_amed_FeeTypeAxis_1967" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FeeTypeDomain" xlink:label="Locator_amed_FeeTypeDomain_1968" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_FeeTypeAxis_1967" xlink:to="Locator_amed_FeeTypeDomain_1968" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FeeTypeDomain" xlink:label="Locator_amed_FeeTypeDomain_1969" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ArrangerFeeMember" xlink:label="Locator_amed_ArrangerFeeMember_1970" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_FeeTypeDomain_1969" xlink:to="Locator_amed_ArrangerFeeMember_1970" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtAbstract" xlink:label="Locator_us-gaap_LongTermDebtAbstract_1745" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="Locator_us-gaap_DebtInstrumentTable_1746" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongTermDebtAbstract_1745" xlink:to="Locator_us-gaap_DebtInstrumentTable_1746" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureCommitmentsAndContigenciesDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_2219" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2220" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeAxis_2219" xlink:to="Locator_us-gaap_RangeMember_2220" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2221" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_2222" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_2221" xlink:to="Locator_us-gaap_MinimumMember_2222" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_2223" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_2224" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_2223" xlink:to="Locator_us-gaap_MaximumMember_2224" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2225" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2226" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_2225" xlink:to="Locator_us-gaap_SegmentDomain_2226" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2229" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximusFederalServicesMember" xlink:label="Locator_amed_MaximusFederalServicesMember_2230" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2229" xlink:to="Locator_amed_MaximusFederalServicesMember_2230" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2233" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximusFederalServicesAndHospiceMember" xlink:label="Locator_amed_MaximusFederalServicesAndHospiceMember_2234" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2233" xlink:to="Locator_amed_MaximusFederalServicesAndHospiceMember_2234" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2235" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MassproAndHospiceMember" xlink:label="Locator_amed_MassproAndHospiceMember_2236" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2235" xlink:to="Locator_amed_MassproAndHospiceMember_2236" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2237" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfEmployeesInWageHourLitigationMember" xlink:label="Locator_amed_NumberOfEmployeesInWageHourLitigationMember_2238" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2237" xlink:to="Locator_amed_NumberOfEmployeesInWageHourLitigationMember_2238" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2239" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MaximusFederalServicesAndHomeHealthMember" xlink:label="Locator_amed_MaximusFederalServicesAndHomeHealthMember_2240" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2239" xlink:to="Locator_amed_MaximusFederalServicesAndHomeHealthMember_2240" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2227" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_2228" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2227" xlink:to="Locator_amed_HomeHealthMember_2228" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2231" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_2232" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2231" xlink:to="Locator_amed_HospiceMember_2232" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateAxis" xlink:label="Locator_amed_StateAxis_2245" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2246" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateAxis_2245" xlink:to="Locator_amed_StateDomain_2246" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2247" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IllinoisMember" xlink:label="Locator_amed_IllinoisMember_2248" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2247" xlink:to="Locator_amed_IllinoisMember_2248" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2249" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ConnecticutMember" xlink:label="Locator_amed_ConnecticutMember_2250" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2249" xlink:to="Locator_amed_ConnecticutMember_2250" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2251" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OhioMember" xlink:label="Locator_amed_OhioMember_2252" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2251" xlink:to="Locator_amed_OhioMember_2252" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2253" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SouthCarolinaMember" xlink:label="Locator_amed_SouthCarolinaMember_2254" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2253" xlink:to="Locator_amed_SouthCarolinaMember_2254" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2259" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MorgantownWestVirginiaMember" xlink:label="Locator_amed_MorgantownWestVirginiaMember_2260" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2259" xlink:to="Locator_amed_MorgantownWestVirginiaMember_2260" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2261" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ParkersburgWestVirginiaMember" xlink:label="Locator_amed_ParkersburgWestVirginiaMember_2262" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2261" xlink:to="Locator_amed_ParkersburgWestVirginiaMember_2262" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2257" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WestVirginiaMember" xlink:label="Locator_amed_WestVirginiaMember_2258" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2257" xlink:to="Locator_amed_WestVirginiaMember_2258" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2255" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MassachusettsMember" xlink:label="Locator_amed_MassachusettsMember_2256" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2255" xlink:to="Locator_amed_MassachusettsMember_2256" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2037" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2038" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2037" xlink:to="Locator_amed_CommimentsAndContingenciesTable_2038" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2203" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2204" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2203" xlink:to="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2204" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1971" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MedicareRevenue" xlink:label="Locator_amed_MedicareRevenue_1972" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1971" xlink:to="Locator_amed_MedicareRevenue_1972" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1973" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs" xlink:label="Locator_us-gaap_LossContingencyNumberOfPlaintiffs_1974" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1973" xlink:to="Locator_us-gaap_LossContingencyNumberOfPlaintiffs_1974" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1975" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyActionsTakenByPlaintiff" xlink:label="Locator_us-gaap_LossContingencyActionsTakenByPlaintiff_1976" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1975" xlink:to="Locator_us-gaap_LossContingencyActionsTakenByPlaintiff_1976" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1977" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfClaimsSubmittedBySubsidiary" xlink:label="Locator_amed_NumberOfClaimsSubmittedBySubsidiary_1978" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1977" xlink:to="Locator_amed_NumberOfClaimsSubmittedBySubsidiary_1978" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1979" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:label="Locator_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_1980" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1979" xlink:to="Locator_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_1980" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1981" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:label="Locator_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_1982" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1981" xlink:to="Locator_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_1982" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1983" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfClaimsAppealed" xlink:label="Locator_amed_NumberOfClaimsAppealed_1984" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1983" xlink:to="Locator_amed_NumberOfClaimsAppealed_1984" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1985" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfRedeterminationDecisions" xlink:label="Locator_amed_NumberOfRedeterminationDecisions_1986" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1985" xlink:to="Locator_amed_NumberOfRedeterminationDecisions_1986" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1987" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HealthInsuranceRetentionLimit" xlink:label="Locator_amed_HealthInsuranceRetentionLimit_1988" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1987" xlink:to="Locator_amed_HealthInsuranceRetentionLimit_1988" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1989" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WorkersCompensationInsuranceRetentionLimit" xlink:label="Locator_amed_WorkersCompensationInsuranceRetentionLimit_1990" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1989" xlink:to="Locator_amed_WorkersCompensationInsuranceRetentionLimit_1990" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1991" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:label="Locator_amed_ProfessionalLiabilityInsuranceRetentionLimit_1992" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1991" xlink:to="Locator_amed_ProfessionalLiabilityInsuranceRetentionLimit_1992" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1993" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfBeneficiaries" xlink:label="Locator_amed_NumberOfBeneficiaries_1994" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1993" xlink:to="Locator_amed_NumberOfBeneficiaries_1994" order="12.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1995" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="Locator_us-gaap_LitigationSettlementAmount_1996" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1995" xlink:to="Locator_us-gaap_LitigationSettlementAmount_1996" order="13.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1997" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="Locator_us-gaap_LossContingencyAccrualAtCarryingValue_1998" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1997" xlink:to="Locator_us-gaap_LossContingencyAccrualAtCarryingValue_1998" order="14.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1999" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InsuranceProceedsForReimbursementOfLegalFees" xlink:label="Locator_amed_InsuranceProceedsForReimbursementOfLegalFees_2000" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_1999" xlink:to="Locator_amed_InsuranceProceedsForReimbursementOfLegalFees_2000" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2001" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PaymentUponExecutionOfUsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_PaymentUponExecutionOfUsDepartmentOfJusticeSettlement_2002" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2001" xlink:to="Locator_amed_PaymentUponExecutionOfUsDepartmentOfJusticeSettlement_2002" order="16.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2003" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InterestRateOnUsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_InterestRateOnUsDepartmentOfJusticeSettlement_2004" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2003" xlink:to="Locator_amed_InterestRateOnUsDepartmentOfJusticeSettlement_2004" order="17.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2005" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FinalPaymentOfUsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_FinalPaymentOfUsDepartmentOfJusticeSettlement_2006" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2005" xlink:to="Locator_amed_FinalPaymentOfUsDepartmentOfJusticeSettlement_2006" order="18.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2007" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement_2008" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2007" xlink:to="Locator_amed_PeriodOfTimeForFinalPaymentOfUsDepartmentOfJusticeSettlement_2008" order="19.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2009" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="Locator_us-gaap_LossContingencyEstimateOfPossibleLoss_2010" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2009" xlink:to="Locator_us-gaap_LossContingencyEstimateOfPossibleLoss_2010" order="20.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2011" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="Locator_us-gaap_LossContingencyAccrualProvision_2012" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2011" xlink:to="Locator_us-gaap_LossContingencyAccrualProvision_2012" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2013" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CorporateIntegrityAgreementTerm" xlink:label="Locator_amed_CorporateIntegrityAgreementTerm_2014" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2013" xlink:to="Locator_amed_CorporateIntegrityAgreementTerm_2014" order="22.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2015" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates" xlink:label="Locator_us-gaap_NumberOfStatesInWhichEntityOperates_2016" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2015" xlink:to="Locator_us-gaap_NumberOfStatesInWhichEntityOperates_2016" order="23.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2017" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfIndividualsWithInformationOnMissingDevices" xlink:label="Locator_amed_NumberOfIndividualsWithInformationOnMissingDevices_2018" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2017" xlink:to="Locator_amed_NumberOfIndividualsWithInformationOnMissingDevices_2018" order="24.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2019" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfMissingComputersAndLaptops" xlink:label="Locator_amed_NumberOfMissingComputersAndLaptops_2020" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2019" xlink:to="Locator_amed_NumberOfMissingComputersAndLaptops_2020" order="25.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2021" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ThresholdOfIndividualsInDataBreach" xlink:label="Locator_amed_ThresholdOfIndividualsInDataBreach_2022" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2021" xlink:to="Locator_amed_ThresholdOfIndividualsInDataBreach_2022" order="26.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2023" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PercentageOfCompanyDevicesUsed" xlink:label="Locator_amed_PercentageOfCompanyDevicesUsed_2024" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2023" xlink:to="Locator_amed_PercentageOfCompanyDevicesUsed_2024" order="27.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2025" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_YearOfDeparture" xlink:label="Locator_amed_YearOfDeparture_2026" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2025" xlink:to="Locator_amed_YearOfDeparture_2026" order="28.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2027" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersSold" xlink:label="Locator_amed_NumberOfCareCentersSold_2028" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2027" xlink:to="Locator_amed_NumberOfCareCentersSold_2028" order="29.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2029" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Numberofpatients" xlink:label="Locator_amed_Numberofpatients_2030" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2029" xlink:to="Locator_amed_Numberofpatients_2030" order="30.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2031" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="Locator_us-gaap_PaymentsForLegalSettlements_2032" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2031" xlink:to="Locator_us-gaap_PaymentsForLegalSettlements_2032" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2033" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:label="Locator_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_2034" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommitmentsAndContingenciesDisclosureLineItems_2033" xlink:to="Locator_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_2034" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2205" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2206" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2205" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_2206" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2207" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_2208" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2207" xlink:to="Locator_dei_LegalEntityAxis_2208" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="Locator_dei_LegalEntityAxis_2241" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_2242" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_LegalEntityAxis_2241" xlink:to="Locator_dei_EntityDomain_2242" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="Locator_dei_EntityDomain_2243" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MedicareAdministrativeContractorMacMember" xlink:label="Locator_amed_MedicareAdministrativeContractorMacMember_2244" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_dei_EntityDomain_2243" xlink:to="Locator_amed_MedicareAdministrativeContractorMacMember_2244" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2209" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="Locator_us-gaap_LitigationStatusAxis_2210" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2209" xlink:to="Locator_us-gaap_LitigationStatusAxis_2210" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="Locator_us-gaap_LitigationStatusAxis_2263" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2264" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LitigationStatusAxis_2263" xlink:to="Locator_us-gaap_LitigationStatusDomain_2264" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2265" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="Locator_us-gaap_PendingLitigationMember_2266" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LitigationStatusDomain_2265" xlink:to="Locator_us-gaap_PendingLitigationMember_2266" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2267" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FinalLitigationSettlmentMember" xlink:label="Locator_amed_FinalLitigationSettlmentMember_2268" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LitigationStatusDomain_2267" xlink:to="Locator_amed_FinalLitigationSettlmentMember_2268" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2269" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FederalDerivativeActionsMember" xlink:label="Locator_amed_FederalDerivativeActionsMember_2270" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LitigationStatusDomain_2269" xlink:to="Locator_amed_FederalDerivativeActionsMember_2270" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2273" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ErisaClassActionLawsuitMember" xlink:label="Locator_amed_ErisaClassActionLawsuitMember_2274" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LitigationStatusDomain_2273" xlink:to="Locator_amed_ErisaClassActionLawsuitMember_2274" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2275" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ComputerInventoryAndDataSecurityReportingMember" xlink:label="Locator_amed_ComputerInventoryAndDataSecurityReportingMember_2276" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LitigationStatusDomain_2275" xlink:to="Locator_amed_ComputerInventoryAndDataSecurityReportingMember_2276" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2277" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FrontierLitigationMember" xlink:label="Locator_amed_FrontierLitigationMember_2278" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LitigationStatusDomain_2277" xlink:to="Locator_amed_FrontierLitigationMember_2278" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2279" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UsDepartmentOfJusticeMember" xlink:label="Locator_amed_UsDepartmentOfJusticeMember_2280" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LitigationStatusDomain_2279" xlink:to="Locator_amed_UsDepartmentOfJusticeMember_2280" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_2271" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OigSelfDisclosureMember" xlink:label="Locator_amed_OigSelfDisclosureMember_2272" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LitigationStatusDomain_2271" xlink:to="Locator_amed_OigSelfDisclosureMember_2272" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2211" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="Locator_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2212" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2211" xlink:to="Locator_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2212" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="Locator_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2281" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="Locator_us-gaap_HealthCareOrganizationRevenueSourcesDomain_2282" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_HealthCareOrganizationRevenueSourcesAxis_2281" xlink:to="Locator_us-gaap_HealthCareOrganizationRevenueSourcesDomain_2282" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="Locator_us-gaap_HealthCareOrganizationRevenueSourcesDomain_2283" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RelatedPartyMember" xlink:label="Locator_amed_RelatedPartyMember_2284" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_HealthCareOrganizationRevenueSourcesDomain_2283" xlink:to="Locator_amed_RelatedPartyMember_2284" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2213" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="Locator_us-gaap_LossContingenciesByNatureOfContingencyAxis_2214" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2213" xlink:to="Locator_us-gaap_LossContingenciesByNatureOfContingencyAxis_2214" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="Locator_us-gaap_LossContingenciesByNatureOfContingencyAxis_2285" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_2286" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LossContingenciesByNatureOfContingencyAxis_2285" xlink:to="Locator_us-gaap_LossContingencyNatureDomain_2286" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_2287" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ExtrapolatedMember" xlink:label="Locator_amed_ExtrapolatedMember_2288" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LossContingencyNatureDomain_2287" xlink:to="Locator_amed_ExtrapolatedMember_2288" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_2289" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FavorableMember" xlink:label="Locator_amed_FavorableMember_2290" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LossContingencyNatureDomain_2289" xlink:to="Locator_amed_FavorableMember_2290" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_2291" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnfavorableMember" xlink:label="Locator_amed_UnfavorableMember_2292" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LossContingencyNatureDomain_2291" xlink:to="Locator_amed_UnfavorableMember_2292" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_2293" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FavorableInFullMember" xlink:label="Locator_amed_FavorableInFullMember_2294" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LossContingencyNatureDomain_2293" xlink:to="Locator_amed_FavorableInFullMember_2294" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="Locator_us-gaap_LossContingencyNatureDomain_2295" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FavorableInPartMember" xlink:label="Locator_amed_FavorableInPartMember_2296" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LossContingencyNatureDomain_2295" xlink:to="Locator_amed_FavorableInPartMember_2296" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2215" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateAxis" xlink:label="Locator_amed_StateAxis_2216" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2215" xlink:to="Locator_amed_StateAxis_2216" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommimentsAndContingenciesTable" xlink:label="Locator_amed_CommimentsAndContingenciesTable_2217" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_2218" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CommimentsAndContingenciesTable_2217" xlink:to="Locator_us-gaap_RangeAxis_2218" order="7.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/SegmentInformationAdditionalInformationDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="Locator_us-gaap_SegmentReportingAbstract_2297" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="Locator_us-gaap_NumberOfReportableSegments_2298" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingAbstract_2297" xlink:to="Locator_us-gaap_NumberOfReportableSegments_2298" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureOperatingIncomeOfReportableSegmentsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2367" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2368" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_2367" xlink:to="Locator_us-gaap_SegmentDomain_2368" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2375" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllOtherSegmentsMember" xlink:label="Locator_us-gaap_AllOtherSegmentsMember_2376" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2375" xlink:to="Locator_us-gaap_AllOtherSegmentsMember_2376" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2369" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_2370" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2369" xlink:to="Locator_amed_HomeHealthMember_2370" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2371" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_2372" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2371" xlink:to="Locator_amed_HospiceMember_2372" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2373" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PersonalCareMember" xlink:label="Locator_amed_PersonalCareMember_2374" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2373" xlink:to="Locator_amed_PersonalCareMember_2374" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="Locator_us-gaap_SegmentReportingAbstract_2319" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2320" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingAbstract_2319" xlink:to="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2320" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2363" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2364" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2363" xlink:to="Locator_us-gaap_SegmentReportingInformationLineItems_2364" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2299" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationPatientServiceRevenue" xlink:label="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_2300" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2299" xlink:to="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_2300" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2301" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfServices" xlink:label="Locator_us-gaap_CostOfServices_2302" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2301" xlink:to="Locator_us-gaap_CostOfServices_2302" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2303" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GeneralAndAdministrativeExpenseSegment" xlink:label="Locator_amed_GeneralAndAdministrativeExpenseSegment_2304" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2303" xlink:to="Locator_amed_GeneralAndAdministrativeExpenseSegment_2304" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2305" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProvisionForDoubtfulAccountsForContinuingOperations" xlink:label="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_2306" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2305" xlink:to="Locator_amed_ProvisionForDoubtfulAccountsForContinuingOperations_2306" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2307" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DepreciationAndAmortizationForContinuingOperations" xlink:label="Locator_amed_DepreciationAndAmortizationForContinuingOperations_2308" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2307" xlink:to="Locator_amed_DepreciationAndAmortizationForContinuingOperations_2308" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2309" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_UsDepartmentOfJusticeSettlement_2310" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2309" xlink:to="Locator_amed_UsDepartmentOfJusticeSettlement_2310" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2311" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="Locator_us-gaap_AssetImpairmentCharges_2312" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2311" xlink:to="Locator_us-gaap_AssetImpairmentCharges_2312" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2313" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="Locator_us-gaap_CostsAndExpenses_2314" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2313" xlink:to="Locator_us-gaap_CostsAndExpenses_2314" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="Locator_us-gaap_SegmentReportingInformationLineItems_2315" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="Locator_us-gaap_OperatingIncomeLoss_2316" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentReportingInformationLineItems_2315" xlink:to="Locator_us-gaap_OperatingIncomeLoss_2316" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2365" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2366" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2365" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_2366" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="Locator_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2377" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="Locator_us-gaap_ProfitLoss_2378" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2377" xlink:to="Locator_us-gaap_ProfitLoss_2378" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="Locator_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2379" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="Locator_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_2380" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2379" xlink:to="Locator_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_2380" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="Locator_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2381" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="Locator_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2382" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2381" xlink:to="Locator_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2382" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="Locator_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2383" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2384" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2383" xlink:to="Locator_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2384" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="Locator_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2385" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2386" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2385" xlink:to="Locator_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2386" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="Locator_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2387" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="Locator_us-gaap_ComprehensiveIncomeNetOfTax_2388" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2387" xlink:to="Locator_us-gaap_ComprehensiveIncomeNetOfTax_2388" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/EXITACTIVITIES">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="Locator_us-gaap_RestructuringAndRelatedActivitiesAbstract_2397" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="Locator_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_2398" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringAndRelatedActivitiesAbstract_2397" xlink:to="Locator_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_2398" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureExitActivitiesDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2505" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2506" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_2505" xlink:to="Locator_us-gaap_SegmentDomain_2506" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2507" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_2508" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2507" xlink:to="Locator_amed_HomeHealthMember_2508" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2509" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_2510" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2509" xlink:to="Locator_amed_HospiceMember_2510" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TypeOfBusinessSoldAxis" xlink:label="Locator_amed_TypeOfBusinessSoldAxis_2511" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessSoldDomain" xlink:label="Locator_amed_BusinessSoldDomain_2512" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_TypeOfBusinessSoldAxis_2511" xlink:to="Locator_amed_BusinessSoldDomain_2512" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessSoldDomain" xlink:label="Locator_amed_BusinessSoldDomain_2513" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AlaskaAndWashingtonCareCentersMember" xlink:label="Locator_amed_AlaskaAndWashingtonCareCentersMember_2514" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_BusinessSoldDomain_2513" xlink:to="Locator_amed_AlaskaAndWashingtonCareCentersMember_2514" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessSoldDomain" xlink:label="Locator_amed_BusinessSoldDomain_2515" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WyomingAndIdahoCareCentersMember" xlink:label="Locator_amed_WyomingAndIdahoCareCentersMember_2516" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_BusinessSoldDomain_2515" xlink:to="Locator_amed_WyomingAndIdahoCareCentersMember_2516" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessSoldDomain" xlink:label="Locator_amed_BusinessSoldDomain_2517" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnconsolidatedJointVentureMember" xlink:label="Locator_amed_UnconsolidatedJointVentureMember_2518" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_BusinessSoldDomain_2517" xlink:to="Locator_amed_UnconsolidatedJointVentureMember_2518" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessSoldDomain" xlink:label="Locator_amed_BusinessSoldDomain_2519" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AvailableForSaleMember" xlink:label="Locator_amed_AvailableForSaleMember_2520" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_BusinessSoldDomain_2519" xlink:to="Locator_amed_AvailableForSaleMember_2520" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessSoldDomain" xlink:label="Locator_amed_BusinessSoldDomain_2521" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NotIncludedInAvailableForSaleMember" xlink:label="Locator_amed_NotIncludedInAvailableForSaleMember_2522" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_BusinessSoldDomain_2521" xlink:to="Locator_amed_NotIncludedInAvailableForSaleMember_2522" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessSoldDomain" xlink:label="Locator_amed_BusinessSoldDomain_2523" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceInpatientUnitMember" xlink:label="Locator_amed_HospiceInpatientUnitMember_2524" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_BusinessSoldDomain_2523" xlink:to="Locator_amed_HospiceInpatientUnitMember_2524" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="Locator_us-gaap_RestructuringAndRelatedActivitiesAbstract_2419" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2420" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringAndRelatedActivitiesAbstract_2419" xlink:to="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2420" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2499" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TypeOfBusinessSoldAxis" xlink:label="Locator_amed_TypeOfBusinessSoldAxis_2500" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2499" xlink:to="Locator_amed_TypeOfBusinessSoldAxis_2500" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2503" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2504" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2503" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_2504" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2495" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2496" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2495" xlink:to="Locator_us-gaap_RestructuringCostAndReserveLineItems_2496" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2399" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherRestructuringCosts" xlink:label="Locator_us-gaap_OtherRestructuringCosts_2400" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2399" xlink:to="Locator_us-gaap_OtherRestructuringCosts_2400" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2401" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="Locator_us-gaap_GainsLossesOnSalesOfAssets_2402" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2401" xlink:to="Locator_us-gaap_GainsLossesOnSalesOfAssets_2402" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2403" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="Locator_us-gaap_ProceedsFromDivestitureOfBusinesses_2404" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2403" xlink:to="Locator_us-gaap_ProceedsFromDivestitureOfBusinesses_2404" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2405" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersAvailableForSale" xlink:label="Locator_amed_NumberOfCareCentersAvailableForSale_2406" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2405" xlink:to="Locator_amed_NumberOfCareCentersAvailableForSale_2406" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2407" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersConsolidated" xlink:label="Locator_amed_NumberOfCareCentersConsolidated_2408" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2407" xlink:to="Locator_amed_NumberOfCareCentersConsolidated_2408" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2409" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersSold" xlink:label="Locator_amed_NumberOfCareCentersSold_2410" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2409" xlink:to="Locator_amed_NumberOfCareCentersSold_2410" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2411" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfCareCentersClosed" xlink:label="Locator_amed_NumberOfCareCentersClosed_2412" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2411" xlink:to="Locator_amed_NumberOfCareCentersClosed_2412" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2413" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" xlink:label="Locator_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_2414" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2413" xlink:to="Locator_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_2414" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_2415" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:label="Locator_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_2416" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_2415" xlink:to="Locator_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_2416" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2497" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringCostsAxis" xlink:label="Locator_amed_OtherRestructuringCostsAxis_2498" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2497" xlink:to="Locator_amed_OtherRestructuringCostsAxis_2498" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringCostsAxis" xlink:label="Locator_amed_OtherRestructuringCostsAxis_2525" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_2526" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OtherRestructuringCostsAxis_2525" xlink:to="Locator_amed_OtherRestructuringDomain_2526" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_2527" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoThousandAndThirteenExitActivityMember" xlink:label="Locator_amed_TwoThousandAndThirteenExitActivityMember_2528" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OtherRestructuringDomain_2527" xlink:to="Locator_amed_TwoThousandAndThirteenExitActivityMember_2528" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_2529" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoThousandAndFourteenExitActivityMember" xlink:label="Locator_amed_TwoThousandAndFourteenExitActivityMember_2530" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OtherRestructuringDomain_2529" xlink:to="Locator_amed_TwoThousandAndFourteenExitActivityMember_2530" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2501" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="Locator_us-gaap_RestructuringCostAndReserveAxis_2502" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2501" xlink:to="Locator_us-gaap_RestructuringCostAndReserveAxis_2502" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="Locator_us-gaap_RestructuringCostAndReserveAxis_2531" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_2532" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringCostAndReserveAxis_2531" xlink:to="Locator_amed_RestructuringCostAndReserveDomain_2532" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_2537" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IntangiblesWriteOffMember" xlink:label="Locator_amed_IntangiblesWriteOffMember_2538" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_RestructuringCostAndReserveDomain_2537" xlink:to="Locator_amed_IntangiblesWriteOffMember_2538" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_2539" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndOtherIntangiblesImpairmentMember" xlink:label="Locator_amed_GoodwillAndOtherIntangiblesImpairmentMember_2540" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_RestructuringCostAndReserveDomain_2539" xlink:to="Locator_amed_GoodwillAndOtherIntangiblesImpairmentMember_2540" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_2541" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssetWriteOffMember" xlink:label="Locator_amed_AssetWriteOffMember_2542" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_RestructuringCostAndReserveDomain_2541" xlink:to="Locator_amed_AssetWriteOffMember_2542" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_2543" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeveranceForRegionalLeadershipAndCorporateSupportMember" xlink:label="Locator_amed_SeveranceForRegionalLeadershipAndCorporateSupportMember_2544" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_RestructuringCostAndReserveDomain_2543" xlink:to="Locator_amed_SeveranceForRegionalLeadershipAndCorporateSupportMember_2544" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_2545" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SeveranceForFormerExecutiveMember" xlink:label="Locator_amed_SeveranceForFormerExecutiveMember_2546" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_RestructuringCostAndReserveDomain_2545" xlink:to="Locator_amed_SeveranceForFormerExecutiveMember_2546" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_2533" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LeaseTerminationMember" xlink:label="Locator_amed_LeaseTerminationMember_2534" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_RestructuringCostAndReserveDomain_2533" xlink:to="Locator_amed_LeaseTerminationMember_2534" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_2535" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="Locator_us-gaap_EmployeeSeveranceMember_2536" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_RestructuringCostAndReserveDomain_2535" xlink:to="Locator_us-gaap_EmployeeSeveranceMember_2536" order="2.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENT">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="Locator_us-gaap_SubsequentEventsAbstract_2547" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="Locator_us-gaap_SubsequentEventsTextBlock_2548" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SubsequentEventsAbstract_2547" xlink:to="Locator_us-gaap_SubsequentEventsTextBlock_2548" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureSubsequentEventDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2579" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2580" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_2579" xlink:to="Locator_us-gaap_SegmentDomain_2580" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2581" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PersonalCareMember" xlink:label="Locator_amed_PersonalCareMember_2582" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2581" xlink:to="Locator_amed_PersonalCareMember_2582" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2573" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="Locator_us-gaap_SubsequentEventLineItems_2574" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2573" xlink:to="Locator_us-gaap_SubsequentEventLineItems_2574" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="Locator_us-gaap_SubsequentEventLineItems_2549" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="Locator_us-gaap_BusinessCombinationConsiderationTransferred1_2550" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SubsequentEventLineItems_2549" xlink:to="Locator_us-gaap_BusinessCombinationConsiderationTransferred1_2550" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="Locator_us-gaap_SubsequentEventLineItems_2551" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfBusinessesAcquired" xlink:label="Locator_us-gaap_NumberOfBusinessesAcquired_2552" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SubsequentEventLineItems_2551" xlink:to="Locator_us-gaap_NumberOfBusinessesAcquired_2552" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2577" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="Locator_us-gaap_BusinessAcquisitionAxis_2578" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2577" xlink:to="Locator_us-gaap_BusinessAcquisitionAxis_2578" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="Locator_us-gaap_BusinessAcquisitionAxis_2583" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionAcquiredDomain" xlink:label="Locator_amed_BusinessAcquisitionAcquiredDomain_2584" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BusinessAcquisitionAxis_2583" xlink:to="Locator_amed_BusinessAcquisitionAcquiredDomain_2584" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionAcquiredDomain" xlink:label="Locator_amed_BusinessAcquisitionAcquiredDomain_2585" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeStaffLlcMember" xlink:label="Locator_amed_HomeStaffLlcMember_2586" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_BusinessAcquisitionAcquiredDomain_2585" xlink:to="Locator_amed_HomeStaffLlcMember_2586" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2575" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2576" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2575" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_2576" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="Locator_us-gaap_SubsequentEventsAbstract_2555" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2556" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SubsequentEventsAbstract_2555" xlink:to="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2556" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_2701" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2702" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementTable_2701" xlink:to="Locator_us-gaap_StatementLineItems_2702" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2591" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="Locator_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2592" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2591" xlink:to="Locator_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2592" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2593" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="Locator_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2594" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2593" xlink:to="Locator_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2594" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2595" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:label="Locator_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_2596" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2595" xlink:to="Locator_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_2596" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2597" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:label="Locator_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_2598" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2597" xlink:to="Locator_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_2598" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2599" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="Locator_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2600" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2599" xlink:to="Locator_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2600" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2601" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="Locator_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2602" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2601" xlink:to="Locator_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2602" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2603" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="Locator_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_2604" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2603" xlink:to="Locator_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_2604" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2605" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="Locator_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2606" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2605" xlink:to="Locator_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2606" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2607" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="Locator_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2608" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2607" xlink:to="Locator_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2608" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2609" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="Locator_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_2610" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2609" xlink:to="Locator_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_2610" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2611" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation" xlink:label="Locator_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation_2612" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2611" xlink:to="Locator_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation_2612" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2613" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SurrenderedShares" xlink:label="Locator_amed_SurrenderedShares_2614" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2613" xlink:to="Locator_amed_SurrenderedShares_2614" order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2615" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="Locator_us-gaap_TreasuryStockValueAcquiredCostMethod_2616" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2615" xlink:to="Locator_us-gaap_TreasuryStockValueAcquiredCostMethod_2616" order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2617" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="Locator_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_2618" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2617" xlink:to="Locator_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_2618" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2619" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:label="Locator_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_2620" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2619" xlink:to="Locator_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_2620" order="17.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2621" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="Locator_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_2622" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2621" xlink:to="Locator_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_2622" order="18.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2623" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="Locator_us-gaap_MinorityInterestPeriodIncreaseDecrease_2624" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2623" xlink:to="Locator_us-gaap_MinorityInterestPeriodIncreaseDecrease_2624" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2625" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment" xlink:label="Locator_amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment_2626" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2625" xlink:to="Locator_amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment_2626" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2627" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss" xlink:label="Locator_us-gaap_ProfitLoss_2628" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2627" xlink:to="Locator_us-gaap_ProfitLoss_2628" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2629" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="Locator_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2630" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2629" xlink:to="Locator_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2630" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2587" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2588" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2587" xlink:to="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2588" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2631" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2632" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2631" xlink:to="Locator_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2632" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2589" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="Locator_us-gaap_SharesOutstanding_2590" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2589" xlink:to="Locator_us-gaap_SharesOutstanding_2590" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="Locator_us-gaap_StatementLineItems_2633" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="Locator_us-gaap_SharesOutstanding_2634" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementLineItems_2633" xlink:to="Locator_us-gaap_SharesOutstanding_2634" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_2703" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="Locator_us-gaap_StatementEquityComponentsAxis_2704" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementTable_2703" xlink:to="Locator_us-gaap_StatementEquityComponentsAxis_2704" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="Locator_us-gaap_StatementEquityComponentsAxis_2705" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="Locator_us-gaap_EquityComponentDomain_2706" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementEquityComponentsAxis_2705" xlink:to="Locator_us-gaap_EquityComponentDomain_2706" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="Locator_us-gaap_EquityComponentDomain_2707" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="Locator_us-gaap_CommonStockMember_2708" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EquityComponentDomain_2707" xlink:to="Locator_us-gaap_CommonStockMember_2708" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="Locator_us-gaap_EquityComponentDomain_2709" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="Locator_us-gaap_AdditionalPaidInCapitalMember_2710" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EquityComponentDomain_2709" xlink:to="Locator_us-gaap_AdditionalPaidInCapitalMember_2710" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="Locator_us-gaap_EquityComponentDomain_2711" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="Locator_us-gaap_TreasuryStockMember_2712" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EquityComponentDomain_2711" xlink:to="Locator_us-gaap_TreasuryStockMember_2712" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="Locator_us-gaap_EquityComponentDomain_2713" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="Locator_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2714" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EquityComponentDomain_2713" xlink:to="Locator_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2714" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="Locator_us-gaap_EquityComponentDomain_2715" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="Locator_us-gaap_RetainedEarningsMember_2716" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EquityComponentDomain_2715" xlink:to="Locator_us-gaap_RetainedEarningsMember_2716" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="Locator_us-gaap_EquityComponentDomain_2717" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="Locator_us-gaap_NoncontrollingInterestMember_2718" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EquityComponentDomain_2717" xlink:to="Locator_us-gaap_NoncontrollingInterestMember_2718" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="Locator_us-gaap_StatementOfStockholdersEquityAbstract_2637" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="Locator_us-gaap_StatementTable_2638" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementOfStockholdersEquityAbstract_2637" xlink:to="Locator_us-gaap_StatementTable_2638" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS">
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_2719" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock_2720" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_2719" xlink:to="Locator_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock_2720" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/INCOMETAXES">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2721" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="Locator_us-gaap_IncomeTaxDisclosureTextBlock_2722" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2721" xlink:to="Locator_us-gaap_IncomeTaxDisclosureTextBlock_2722" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="Locator_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2723" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="Locator_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2724" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2723" xlink:to="Locator_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2724" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS">
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract" xlink:label="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_2725" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="Locator_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2726" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_2725" xlink:to="Locator_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2726" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/VALUATIONANDQUALIFYINGACCOUNTS">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:label="Locator_us-gaap_ValuationAndQualifyingAccountsAbstract_2727" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="Locator_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_2728" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ValuationAndQualifyingAccountsAbstract_2727" xlink:to="Locator_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_2728" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="Locator_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_2729" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="Locator_us-gaap_QuarterlyFinancialInformationTextBlock_2730" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_2729" xlink:to="Locator_us-gaap_QuarterlyFinancialInformationTextBlock_2730" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables">
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_2731" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_2732" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_2731" xlink:to="Locator_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_2732" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_2733" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfOtherAssetsTableTextBlock_2734" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_2733" xlink:to="Locator_us-gaap_ScheduleOfOtherAssetsTableTextBlock_2734" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_2735" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2736" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_2735" xlink:to="Locator_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2736" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_2737" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_2738" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_2737" xlink:to="Locator_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_2738" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/INCOMETAXESTables">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2739" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProvisionForIncomeTaxesTextBlock" xlink:label="Locator_amed_ProvisionForIncomeTaxesTextBlock_2740" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2739" xlink:to="Locator_amed_ProvisionForIncomeTaxesTextBlock_2740" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2741" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ReconciliationOfStatutoryTaxEffectsTextBlock" xlink:label="Locator_amed_ReconciliationOfStatutoryTaxEffectsTextBlock_2742" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2741" xlink:to="Locator_amed_ReconciliationOfStatutoryTaxEffectsTextBlock_2742" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2743" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2744" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2743" xlink:to="Locator_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2744" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2745" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ClassificationOfDeferredTaxAssetsLiabilitiesTextBlock" xlink:label="Locator_amed_ClassificationOfDeferredTaxAssetsLiabilitiesTextBlock_2746" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2745" xlink:to="Locator_amed_ClassificationOfDeferredTaxAssetsLiabilitiesTextBlock_2746" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_2747" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_2748" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_2747" xlink:to="Locator_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_2748" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureCAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="Locator_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2749" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_2750" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2749" xlink:to="Locator_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_2750" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="Locator_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2751" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2752" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2751" xlink:to="Locator_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2752" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="Locator_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2753" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_2754" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2753" xlink:to="Locator_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_2754" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="Locator_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2755" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_2756" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2755" xlink:to="Locator_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_2756" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureCOMMITMENTSANDCONTINGENCIESTables">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2757" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2758" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2757" xlink:to="Locator_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2758" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2759" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InsuranceProgramsTableTextBlock" xlink:label="Locator_amed_InsuranceProgramsTableTextBlock_2760" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2759" xlink:to="Locator_amed_InsuranceProgramsTableTextBlock_2760" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/EXITACTIVITIESTables">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="Locator_us-gaap_RestructuringAndRelatedActivitiesAbstract_2761" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_2762" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringAndRelatedActivitiesAbstract_2761" xlink:to="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_2762" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureVALUATIONANDQUALIFYINGACCOUNTSTables">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:label="Locator_us-gaap_ValuationAndQualifyingAccountsAbstract_2763" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ValuationAndQualifyingAccountsTableTextBlock" xlink:label="Locator_amed_ValuationAndQualifyingAccountsTableTextBlock_2764" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ValuationAndQualifyingAccountsAbstract_2763" xlink:to="Locator_amed_ValuationAndQualifyingAccountsTableTextBlock_2764" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="Locator_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_2765" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="Locator_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2766" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_2765" xlink:to="Locator_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2766" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureAcquisitionsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2951" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2952" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2951" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2952" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2957" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CertificatesOfNeedAndLicensesMember" xlink:label="Locator_amed_CertificatesOfNeedAndLicensesMember_2958" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2957" xlink:to="Locator_amed_CertificatesOfNeedAndLicensesMember_2958" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2953" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AcquiredNameOfBusinessMember" xlink:label="Locator_amed_AcquiredNameOfBusinessMember_2954" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2953" xlink:to="Locator_amed_AcquiredNameOfBusinessMember_2954" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2955" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="Locator_us-gaap_NoncompeteAgreementsMember_2956" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2955" xlink:to="Locator_us-gaap_NoncompeteAgreementsMember_2956" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_2907" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_2908" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeAxis_2907" xlink:to="Locator_us-gaap_LongtermDebtTypeDomain_2908" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="Locator_us-gaap_LongtermDebtTypeDomain_2909" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PromissoryNotesMember" xlink:label="Locator_amed_PromissoryNotesMember_2910" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LongtermDebtTypeDomain_2909" xlink:to="Locator_amed_PromissoryNotesMember_2910" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2911" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2912" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_2911" xlink:to="Locator_us-gaap_SegmentDomain_2912" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2913" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_2914" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2913" xlink:to="Locator_amed_HomeHealthMember_2914" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2915" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_2916" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2915" xlink:to="Locator_amed_HospiceMember_2916" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_2917" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PersonalCareMember" xlink:label="Locator_amed_PersonalCareMember_2918" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_2917" xlink:to="Locator_amed_PersonalCareMember_2918" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="Locator_us-gaap_BusinessCombinationsAbstract_2799" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2800" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BusinessCombinationsAbstract_2799" xlink:to="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2800" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2895" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2896" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2895" xlink:to="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2896" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2767" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="Locator_us-gaap_BusinessCombinationConsiderationTransferred1_2768" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2767" xlink:to="Locator_us-gaap_BusinessCombinationConsiderationTransferred1_2768" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2769" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfBusinessesAcquired" xlink:label="Locator_us-gaap_NumberOfBusinessesAcquired_2770" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2769" xlink:to="Locator_us-gaap_NumberOfBusinessesAcquired_2770" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2771" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="Locator_us-gaap_GoodwillAcquiredDuringPeriod_2772" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2771" xlink:to="Locator_us-gaap_GoodwillAcquiredDuringPeriod_2772" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2773" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2774" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2773" xlink:to="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2774" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2775" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2776" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2775" xlink:to="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2776" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2777" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_2778" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2777" xlink:to="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_2778" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2779" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid" xlink:label="Locator_amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid_2780" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2779" xlink:to="Locator_amed_BusinessAcquisitionCostOfAcquiredEntityLiabilitiesPaid_2780" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2781" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2782" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2781" xlink:to="Locator_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2782" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2783" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="Locator_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_2784" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2783" xlink:to="Locator_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_2784" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2785" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears" xlink:label="Locator_amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears_2786" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2785" xlink:to="Locator_amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears_2786" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2787" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="Locator_us-gaap_EscrowDeposit_2788" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2787" xlink:to="Locator_us-gaap_EscrowDeposit_2788" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2789" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="Locator_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_2790" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2789" xlink:to="Locator_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_2790" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2791" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="Locator_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2792" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2791" xlink:to="Locator_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2792" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2793" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="Locator_us-gaap_GoodwillPurchaseAccountingAdjustments_2794" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2793" xlink:to="Locator_us-gaap_GoodwillPurchaseAccountingAdjustments_2794" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems" xlink:label="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2795" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebt" xlink:label="Locator_us-gaap_LongTermDebt_2796" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems_2795" xlink:to="Locator_us-gaap_LongTermDebt_2796" order="15.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2897" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateAxis" xlink:label="Locator_amed_StateAxis_2898" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2897" xlink:to="Locator_amed_StateAxis_2898" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateAxis" xlink:label="Locator_amed_StateAxis_2919" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2920" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateAxis_2919" xlink:to="Locator_amed_StateDomain_2920" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2921" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AlabamaMember" xlink:label="Locator_amed_AlabamaMember_2922" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2921" xlink:to="Locator_amed_AlabamaMember_2922" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2923" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NorthCarolinaMember" xlink:label="Locator_amed_NorthCarolinaMember_2924" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2923" xlink:to="Locator_amed_NorthCarolinaMember_2924" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2925" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WestVirginiaMember" xlink:label="Locator_amed_WestVirginiaMember_2926" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2925" xlink:to="Locator_amed_WestVirginiaMember_2926" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2927" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LouisianaMember" xlink:label="Locator_amed_LouisianaMember_2928" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2927" xlink:to="Locator_amed_LouisianaMember_2928" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2929" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FloridaMember" xlink:label="Locator_amed_FloridaMember_2930" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2929" xlink:to="Locator_amed_FloridaMember_2930" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2931" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TennesseeMember" xlink:label="Locator_amed_TennesseeMember_2932" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2931" xlink:to="Locator_amed_TennesseeMember_2932" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2933" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GeorgiaMember" xlink:label="Locator_amed_GeorgiaMember_2934" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2933" xlink:to="Locator_amed_GeorgiaMember_2934" order="7.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2935" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MassachusettsMember" xlink:label="Locator_amed_MassachusettsMember_2936" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2935" xlink:to="Locator_amed_MassachusettsMember_2936" order="8.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateDomain" xlink:label="Locator_amed_StateDomain_2937" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NewYorkMember" xlink:label="Locator_amed_NewYorkMember_2938" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_StateDomain_2937" xlink:to="Locator_amed_NewYorkMember_2938" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2899" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="Locator_us-gaap_BusinessAcquisitionAxis_2900" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2899" xlink:to="Locator_us-gaap_BusinessAcquisitionAxis_2900" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="Locator_us-gaap_BusinessAcquisitionAxis_2939" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionAcquiredDomain" xlink:label="Locator_amed_BusinessAcquisitionAcquiredDomain_2940" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BusinessAcquisitionAxis_2939" xlink:to="Locator_amed_BusinessAcquisitionAcquiredDomain_2940" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionAcquiredDomain" xlink:label="Locator_amed_BusinessAcquisitionAcquiredDomain_2941" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InHousePhysiciansPracticeMember" xlink:label="Locator_amed_InHousePhysiciansPracticeMember_2942" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_BusinessAcquisitionAcquiredDomain_2941" xlink:to="Locator_amed_InHousePhysiciansPracticeMember_2942" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionAcquiredDomain" xlink:label="Locator_amed_BusinessAcquisitionAcquiredDomain_2943" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentsMember" xlink:label="Locator_us-gaap_EquityMethodInvestmentsMember_2944" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_BusinessAcquisitionAcquiredDomain_2943" xlink:to="Locator_us-gaap_EquityMethodInvestmentsMember_2944" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionAcquiredDomain" xlink:label="Locator_amed_BusinessAcquisitionAcquiredDomain_2945" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AssociatedHomecareMember" xlink:label="Locator_amed_AssociatedHomecareMember_2946" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_BusinessAcquisitionAcquiredDomain_2945" xlink:to="Locator_amed_AssociatedHomecareMember_2946" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionAcquiredDomain" xlink:label="Locator_amed_BusinessAcquisitionAcquiredDomain_2947" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProfessionalProfilesMember" xlink:label="Locator_amed_ProfessionalProfilesMember_2948" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_BusinessAcquisitionAcquiredDomain_2947" xlink:to="Locator_amed_ProfessionalProfilesMember_2948" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessAcquisitionAcquiredDomain" xlink:label="Locator_amed_BusinessAcquisitionAcquiredDomain_2949" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InfinityHomeCareMember" xlink:label="Locator_amed_InfinityHomeCareMember_2950" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_BusinessAcquisitionAcquiredDomain_2949" xlink:to="Locator_amed_InfinityHomeCareMember_2950" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2901" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_2902" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2901" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_2902" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2903" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2904" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2903" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2904" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2905" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="Locator_us-gaap_LongtermDebtTypeAxis_2906" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2905" xlink:to="Locator_us-gaap_LongtermDebtTypeAxis_2906" order="5.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureGoodwillAndOtherIntangibleAssetsNetDetail">
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_3007" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_3008" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_3007" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsDomain_3008" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_3009" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityMethodInvestmentsMember" xlink:label="Locator_us-gaap_EquityMethodInvestmentsMember_3010" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsDomain_3009" xlink:to="Locator_us-gaap_EquityMethodInvestmentsMember_3010" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_3011" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareCentersClosedOrConsolidatedMember" xlink:label="Locator_amed_CareCentersClosedOrConsolidatedMember_3012" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsDomain_3011" xlink:to="Locator_amed_CareCentersClosedOrConsolidatedMember_3012" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsDomain" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsDomain_3013" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AnnualImpairmentTestStepOneMember" xlink:label="Locator_amed_AnnualImpairmentTestStepOneMember_3014" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsDomain_3013" xlink:to="Locator_amed_AnnualImpairmentTestStepOneMember_3014" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2963" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_2964" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2963" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_2964" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2961" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="Locator_us-gaap_GoodwillImpairmentLoss_2962" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2961" xlink:to="Locator_us-gaap_GoodwillImpairmentLoss_2962" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2959" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="Locator_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2960" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2959" xlink:to="Locator_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2960" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_3001" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_3002" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_3001" xlink:to="Locator_us-gaap_SegmentDomain_3002" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_3003" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_3004" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_3003" xlink:to="Locator_amed_HomeHealthMember_3004" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_3005" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_3006" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_3005" xlink:to="Locator_amed_HospiceMember_3006" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="Locator_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2967" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="Locator_us-gaap_ScheduleOfGoodwillTable_2968" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2967" xlink:to="Locator_us-gaap_ScheduleOfGoodwillTable_2968" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="Locator_us-gaap_ScheduleOfGoodwillTable_2997" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsImpairmentAxis" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_2998" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfGoodwillTable_2997" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsImpairmentAxis_2998" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="Locator_us-gaap_ScheduleOfGoodwillTable_2995" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2996" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfGoodwillTable_2995" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsLineItems_2996" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="Locator_us-gaap_ScheduleOfGoodwillTable_2999" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_3000" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfGoodwillTable_2999" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_3000" order="2.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsOtherCurrentAssetsDetail">
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_3015" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PayrollTaxEscrow" xlink:label="Locator_amed_PayrollTaxEscrow_3016" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_3015" xlink:to="Locator_amed_PayrollTaxEscrow_3016" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_3017" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MedicareWithholds" xlink:label="Locator_amed_MedicareWithholds_3018" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_3017" xlink:to="Locator_amed_MedicareWithholds_3018" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_3019" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="Locator_us-gaap_IncomeTaxesReceivable_3020" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_3019" xlink:to="Locator_us-gaap_IncomeTaxesReceivable_3020" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_3021" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueFromJointVenturesCurrent" xlink:label="Locator_us-gaap_DueFromJointVenturesCurrent_3022" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_3021" xlink:to="Locator_us-gaap_DueFromJointVenturesCurrent_3022" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_3023" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsMiscellaneousCurrent" xlink:label="Locator_us-gaap_OtherAssetsMiscellaneousCurrent_3024" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_3023" xlink:to="Locator_us-gaap_OtherAssetsMiscellaneousCurrent_3024" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_3025" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="Locator_us-gaap_OtherAssetsCurrent_3026" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_3025" xlink:to="Locator_us-gaap_OtherAssetsCurrent_3026" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureIncomeTaxesDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_3161" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3162" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeAxis_3161" xlink:to="Locator_us-gaap_RangeMember_3162" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3163" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_3164" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_3163" xlink:to="Locator_us-gaap_MinimumMember_3164" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3165" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_3166" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_3165" xlink:to="Locator_us-gaap_MaximumMember_3166" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_3065" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="Locator_us-gaap_IncomeTaxExaminationTable_3066" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_3065" xlink:to="Locator_us-gaap_IncomeTaxExaminationTable_3066" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="Locator_us-gaap_IncomeTaxExaminationTable_3149" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3150" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxExaminationTable_3149" xlink:to="Locator_amed_IncomeTaxDisclosureLineItems_3150" order="6.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3037" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="Locator_us-gaap_IncomeTaxesReceivable_3038" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3037" xlink:to="Locator_us-gaap_IncomeTaxesReceivable_3038" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3039" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="Locator_us-gaap_OperatingLossCarryforwards_3040" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3039" xlink:to="Locator_us-gaap_OperatingLossCarryforwards_3040" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3041" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="Locator_us-gaap_IncomeTaxCreditsAndAdjustments_3042" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3041" xlink:to="Locator_us-gaap_IncomeTaxCreditsAndAdjustments_3042" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3043" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="Locator_us-gaap_DeferredTaxAssetsValuationAllowance_3044" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3043" xlink:to="Locator_us-gaap_DeferredTaxAssetsValuationAllowance_3044" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3045" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="Locator_us-gaap_OperatingLossCarryforwardsValuationAllowance_3046" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3045" xlink:to="Locator_us-gaap_OperatingLossCarryforwardsValuationAllowance_3046" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3047" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:label="Locator_us-gaap_TaxCreditCarryforwardValuationAllowance_3048" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3047" xlink:to="Locator_us-gaap_TaxCreditCarryforwardValuationAllowance_3048" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3049" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="Locator_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3050" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3049" xlink:to="Locator_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3050" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3051" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefits_3052" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3051" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefits_3052" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3053" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_3054" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3053" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_3054" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3055" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3056" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3055" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3056" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3057" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NumberOfIndividualStatesSubjectToIncomeTax" xlink:label="Locator_amed_NumberOfIndividualStatesSubjectToIncomeTax_3058" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3057" xlink:to="Locator_amed_NumberOfIndividualStatesSubjectToIncomeTax_3058" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3059" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="Locator_us-gaap_OpenTaxYear_3060" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3059" xlink:to="Locator_us-gaap_OpenTaxYear_3060" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxDisclosureLineItems" xlink:label="Locator_amed_IncomeTaxDisclosureLineItems_3061" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_3062" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_IncomeTaxDisclosureLineItems_3061" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_3062" order="13.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="Locator_us-gaap_IncomeTaxExaminationTable_3151" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="Locator_us-gaap_IncomeTaxAuthorityAxis_3152" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxExaminationTable_3151" xlink:to="Locator_us-gaap_IncomeTaxAuthorityAxis_3152" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="Locator_us-gaap_IncomeTaxAuthorityAxis_3167" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="Locator_us-gaap_IncomeTaxAuthorityDomain_3168" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxAuthorityAxis_3167" xlink:to="Locator_us-gaap_IncomeTaxAuthorityDomain_3168" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="Locator_us-gaap_IncomeTaxAuthorityDomain_3169" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="Locator_us-gaap_StateAndLocalJurisdictionMember_3170" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxAuthorityDomain_3169" xlink:to="Locator_us-gaap_StateAndLocalJurisdictionMember_3170" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="Locator_us-gaap_IncomeTaxAuthorityDomain_3171" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="Locator_us-gaap_DomesticCountryMember_3172" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxAuthorityDomain_3171" xlink:to="Locator_us-gaap_DomesticCountryMember_3172" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="Locator_us-gaap_IncomeTaxAuthorityDomain_3173" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="Locator_us-gaap_ForeignCountryMember_3174" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxAuthorityDomain_3173" xlink:to="Locator_us-gaap_ForeignCountryMember_3174" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="Locator_us-gaap_IncomeTaxExaminationTable_3153" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_3154" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxExaminationTable_3153" xlink:to="Locator_us-gaap_RangeAxis_3154" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="Locator_us-gaap_IncomeTaxExaminationTable_3155" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="Locator_us-gaap_BalanceSheetLocationAxis_3156" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxExaminationTable_3155" xlink:to="Locator_us-gaap_BalanceSheetLocationAxis_3156" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="Locator_us-gaap_BalanceSheetLocationAxis_3175" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="Locator_us-gaap_BalanceSheetLocationDomain_3176" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BalanceSheetLocationAxis_3175" xlink:to="Locator_us-gaap_BalanceSheetLocationDomain_3176" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="Locator_us-gaap_BalanceSheetLocationDomain_3177" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherLongTermObligationsMember" xlink:label="Locator_amed_OtherLongTermObligationsMember_3178" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BalanceSheetLocationDomain_3177" xlink:to="Locator_amed_OtherLongTermObligationsMember_3178" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="Locator_us-gaap_BalanceSheetLocationDomain_3179" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredIncomeTaxesMember" xlink:label="Locator_amed_DeferredIncomeTaxesMember_3180" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BalanceSheetLocationDomain_3179" xlink:to="Locator_amed_DeferredIncomeTaxesMember_3180" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="Locator_us-gaap_BalanceSheetLocationDomain_3181" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AccruedExpensesMember" xlink:label="Locator_amed_AccruedExpensesMember_3182" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BalanceSheetLocationDomain_3181" xlink:to="Locator_amed_AccruedExpensesMember_3182" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="Locator_us-gaap_IncomeTaxExaminationTable_3157" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="Locator_us-gaap_TaxCreditCarryforwardAxis_3158" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxExaminationTable_3157" xlink:to="Locator_us-gaap_TaxCreditCarryforwardAxis_3158" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="Locator_us-gaap_TaxCreditCarryforwardAxis_3183" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="Locator_us-gaap_TaxCreditCarryforwardNameDomain_3184" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_TaxCreditCarryforwardAxis_3183" xlink:to="Locator_us-gaap_TaxCreditCarryforwardNameDomain_3184" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="Locator_us-gaap_TaxCreditCarryforwardNameDomain_3185" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ResearchAndDevelopmentTaxCreditMember" xlink:label="Locator_amed_ResearchAndDevelopmentTaxCreditMember_3186" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_TaxCreditCarryforwardNameDomain_3185" xlink:to="Locator_amed_ResearchAndDevelopmentTaxCreditMember_3186" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="Locator_us-gaap_TaxCreditCarryforwardNameDomain_3187" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EmploymentTaxCreditMember" xlink:label="Locator_amed_EmploymentTaxCreditMember_3188" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_TaxCreditCarryforwardNameDomain_3187" xlink:to="Locator_amed_EmploymentTaxCreditMember_3188" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="Locator_us-gaap_TaxCreditCarryforwardNameDomain_3189" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AlternativeMinimumTaxCreditMember" xlink:label="Locator_amed_AlternativeMinimumTaxCreditMember_3190" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_TaxCreditCarryforwardNameDomain_3189" xlink:to="Locator_amed_AlternativeMinimumTaxCreditMember_3190" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="Locator_us-gaap_TaxCreditCarryforwardNameDomain_3191" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StateTaxCreditMember" xlink:label="Locator_amed_StateTaxCreditMember_3192" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_TaxCreditCarryforwardNameDomain_3191" xlink:to="Locator_amed_StateTaxCreditMember_3192" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="Locator_us-gaap_IncomeTaxExaminationTable_3159" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnrecognizedTaxBenefitsAxis" xlink:label="Locator_amed_UnrecognizedTaxBenefitsAxis_3160" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxExaminationTable_3159" xlink:to="Locator_amed_UnrecognizedTaxBenefitsAxis_3160" order="5.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnrecognizedTaxBenefitsAxis" xlink:label="Locator_amed_UnrecognizedTaxBenefitsAxis_3193" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnrecognizedTaxBenefitsDomain" xlink:label="Locator_amed_UnrecognizedTaxBenefitsDomain_3194" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_UnrecognizedTaxBenefitsAxis_3193" xlink:to="Locator_amed_UnrecognizedTaxBenefitsDomain_3194" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnrecognizedTaxBenefitsDomain" xlink:label="Locator_amed_UnrecognizedTaxBenefitsDomain_3195" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NetOperatingLossMember" xlink:label="Locator_amed_NetOperatingLossMember_3196" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_UnrecognizedTaxBenefitsDomain_3195" xlink:to="Locator_amed_NetOperatingLossMember_3196" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnrecognizedTaxBenefitsDomain" xlink:label="Locator_amed_UnrecognizedTaxBenefitsDomain_3197" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TaxCreditCarryforwardMember" xlink:label="Locator_amed_TaxCreditCarryforwardMember_3198" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_UnrecognizedTaxBenefitsDomain_3197" xlink:to="Locator_amed_TaxCreditCarryforwardMember_3198" order="2.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureCapitalStockAndShareBasedCompensationDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_3353" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3354" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeAxis_3353" xlink:to="Locator_us-gaap_RangeMember_3354" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3355" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_3356" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_3355" xlink:to="Locator_us-gaap_MinimumMember_3356" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3357" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_3358" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_3357" xlink:to="Locator_us-gaap_MaximumMember_3358" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="Locator_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3259" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3260" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3259" xlink:to="Locator_amed_EquityBasedAwardsTable_3260" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3349" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_3350" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_EquityBasedAwardsTable_3349" xlink:to="Locator_us-gaap_RangeAxis_3350" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3347" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3348" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_EquityBasedAwardsTable_3347" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3348" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3199" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="Locator_us-gaap_CommonStockSharesAuthorized_3200" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3199" xlink:to="Locator_us-gaap_CommonStockSharesAuthorized_3200" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3201" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="Locator_us-gaap_CommonStockParOrStatedValuePerShare_3202" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3201" xlink:to="Locator_us-gaap_CommonStockParOrStatedValuePerShare_3202" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3203" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="Locator_us-gaap_PreferredStockSharesAuthorized_3204" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3203" xlink:to="Locator_us-gaap_PreferredStockSharesAuthorized_3204" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3205" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="Locator_us-gaap_PreferredStockParOrStatedValuePerShare_3206" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3205" xlink:to="Locator_us-gaap_PreferredStockParOrStatedValuePerShare_3206" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3207" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="Locator_us-gaap_CommonStockSharesIssued_3208" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3207" xlink:to="Locator_us-gaap_CommonStockSharesIssued_3208" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3209" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="Locator_us-gaap_CommonStockSharesOutstanding_3210" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3209" xlink:to="Locator_us-gaap_CommonStockSharesOutstanding_3210" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3211" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="Locator_us-gaap_PreferredStockSharesIssued_3212" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3211" xlink:to="Locator_us-gaap_PreferredStockSharesIssued_3212" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3213" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="Locator_us-gaap_PreferredStockSharesOutstanding_3214" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3213" xlink:to="Locator_us-gaap_PreferredStockSharesOutstanding_3214" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3215" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Percentageofownershipinsubsidiaries" xlink:label="Locator_amed_Percentageofownershipinsubsidiaries_3216" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3215" xlink:to="Locator_amed_Percentageofownershipinsubsidiaries_3216" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3217" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3218" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3217" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3218" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3219" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3220" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3219" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3220" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3221" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Fairvalueofshareofcommonstockpercentage" xlink:label="Locator_amed_Fairvalueofshareofcommonstockpercentage_3222" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3221" xlink:to="Locator_amed_Fairvalueofshareofcommonstockpercentage_3222" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3223" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" xlink:label="Locator_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries_3224" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3223" xlink:to="Locator_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries_3224" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3225" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3226" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3225" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3226" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3227" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_3228" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3227" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_3228" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3229" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3230" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3229" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_3230" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3231" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" xlink:label="Locator_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan_3232" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3231" xlink:to="Locator_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan_3232" order="17.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3233" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StockAvailableForFutureIssuanceUnderEmployeePurchasePlan" xlink:label="Locator_amed_StockAvailableForFutureIssuanceUnderEmployeePurchasePlan_3234" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3233" xlink:to="Locator_amed_StockAvailableForFutureIssuanceUnderEmployeePurchasePlan_3234" order="18.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3235" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_3236" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3235" xlink:to="Locator_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_3236" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3237" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3238" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3237" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3238" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3239" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3240" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3239" xlink:to="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3240" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3241" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3242" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3241" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3242" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3251" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MarketBasedAwardTargetShareAmount" xlink:label="Locator_amed_MarketBasedAwardTargetShareAmount_3252" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3251" xlink:to="Locator_amed_MarketBasedAwardTargetShareAmount_3252" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3253" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MarketBasedAwardMaximumShareAmount" xlink:label="Locator_amed_MarketBasedAwardMaximumShareAmount_3254" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3253" xlink:to="Locator_amed_MarketBasedAwardMaximumShareAmount_3254" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3255" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Performancebasedawardtargetshareamount" xlink:label="Locator_amed_Performancebasedawardtargetshareamount_3256" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3255" xlink:to="Locator_amed_Performancebasedawardtargetshareamount_3256" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3247" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="Locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3248" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3247" xlink:to="Locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3248" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3249" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="Locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3250" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3249" xlink:to="Locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3250" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3243" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="Locator_us-gaap_AllocatedShareBasedCompensationExpense_3244" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3243" xlink:to="Locator_us-gaap_AllocatedShareBasedCompensationExpense_3244" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3245" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3246" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3245" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3246" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3351" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="Locator_us-gaap_AwardTypeAxis_3352" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_EquityBasedAwardsTable_3351" xlink:to="Locator_us-gaap_AwardTypeAxis_3352" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="Locator_us-gaap_AwardTypeAxis_3359" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3360" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AwardTypeAxis_3359" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3360" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3361" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedAwardsMember" xlink:label="Locator_amed_ShareBasedAwardsMember_3362" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3361" xlink:to="Locator_amed_ShareBasedAwardsMember_3362" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3363" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" xlink:label="Locator_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_3364" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3363" xlink:to="Locator_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_3364" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3365" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockMember" xlink:label="Locator_amed_NonVestedStockMember_3366" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3365" xlink:to="Locator_amed_NonVestedStockMember_3366" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3367" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" xlink:label="Locator_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_3368" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3367" xlink:to="Locator_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_3368" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3369" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember" xlink:label="Locator_amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember_3370" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3369" xlink:to="Locator_amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember_3370" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3371" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceMember" xlink:label="Locator_amed_NonVestedStockUnitsServiceMember_3372" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3371" xlink:to="Locator_amed_NonVestedStockUnitsServiceMember_3372" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3373" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockOptionMember" xlink:label="Locator_us-gaap_StockOptionMember_3374" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3373" xlink:to="Locator_us-gaap_StockOptionMember_3374" order="7.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/EmployeeBenefitPlansDetail">
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract" xlink:label="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_3375" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_MinimumEligibleAgeForEmployeesToContributeToBenefitPlan" xlink:label="Locator_amed_MinimumEligibleAgeForEmployeesToContributeToBenefitPlan_3376" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_3375" xlink:to="Locator_amed_MinimumEligibleAgeForEmployeesToContributeToBenefitPlan_3376" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract" xlink:label="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_3377" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DefinedContributionPlanEmployerMatchingContribution" xlink:label="Locator_amed_DefinedContributionPlanEmployerMatchingContribution_3378" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_3377" xlink:to="Locator_amed_DefinedContributionPlanEmployerMatchingContribution_3378" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract" xlink:label="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_3379" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" xlink:label="Locator_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram_3380" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_3379" xlink:to="Locator_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram_3380" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract" xlink:label="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_3381" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" xlink:label="Locator_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage_3382" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_3381" xlink:to="Locator_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage_3382" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract" xlink:label="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_3383" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="Locator_us-gaap_DefinedContributionPlanCostRecognized_3384" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_3383" xlink:to="Locator_us-gaap_DefinedContributionPlanCostRecognized_3384" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract" xlink:label="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_3385" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredCompensationArrangementMaximumPercentageOfSalaryDeferment" xlink:label="Locator_amed_DeferredCompensationArrangementMaximumPercentageOfSalaryDeferment_3386" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_3385" xlink:to="Locator_amed_DeferredCompensationArrangementMaximumPercentageOfSalaryDeferment_3386" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract" xlink:label="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_3387" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredCompensationArrangementMaximumPercentageOfAnnualBonusDeferment" xlink:label="Locator_amed_DeferredCompensationArrangementMaximumPercentageOfAnnualBonusDeferment_3388" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract_3387" xlink:to="Locator_amed_DeferredCompensationArrangementMaximumPercentageOfAnnualBonusDeferment_3388" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureValuationAndQualifyingAccountsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:label="Locator_us-gaap_ValuationAndQualifyingAccountsAbstract_3401" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3402" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ValuationAndQualifyingAccountsAbstract_3401" xlink:to="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3402" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3425" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_3426" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3425" xlink:to="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_3426" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_3391" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="Locator_us-gaap_ProvisionForDoubtfulAccounts_3392" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_3391" xlink:to="Locator_us-gaap_ProvisionForDoubtfulAccounts_3392" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_3393" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesAdjustments_3394" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_3393" xlink:to="Locator_us-gaap_ValuationAllowancesAndReservesAdjustments_3394" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_3395" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesDeductions_3396" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_3395" xlink:to="Locator_us-gaap_ValuationAllowancesAndReservesDeductions_3396" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_3389" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesBalance_3390" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_3389" xlink:to="Locator_us-gaap_ValuationAllowancesAndReservesBalance_3390" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_3397" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesBalance_3398" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_3397" xlink:to="Locator_us-gaap_ValuationAllowancesAndReservesBalance_3398" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3427" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesTypeAxis_3428" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_3427" xlink:to="Locator_us-gaap_ValuationAllowancesAndReservesTypeAxis_3428" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesTypeAxis_3429" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesDomain_3430" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ValuationAllowancesAndReservesTypeAxis_3429" xlink:to="Locator_us-gaap_ValuationAllowancesAndReservesDomain_3430" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesDomain_3431" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsMember" xlink:label="Locator_us-gaap_AllowanceForDoubtfulAccountsMember_3432" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ValuationAllowancesAndReservesDomain_3431" xlink:to="Locator_us-gaap_AllowanceForDoubtfulAccountsMember_3432" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesDomain_3433" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsDiscontinuedOperationsMember" xlink:label="Locator_us-gaap_AllowanceForDoubtfulAccountsDiscontinuedOperationsMember_3434" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ValuationAllowancesAndReservesDomain_3433" xlink:to="Locator_us-gaap_AllowanceForDoubtfulAccountsDiscontinuedOperationsMember_3434" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesDomain_3435" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedRevenueAdjustmentsMember" xlink:label="Locator_amed_EstimatedRevenueAdjustmentsMember_3436" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ValuationAllowancesAndReservesDomain_3435" xlink:to="Locator_amed_EstimatedRevenueAdjustmentsMember_3436" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="Locator_us-gaap_ValuationAllowancesAndReservesDomain_3437" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedRevenueAdjustmentsDiscontinuedOperationsMember" xlink:label="Locator_amed_EstimatedRevenueAdjustmentsDiscontinuedOperationsMember_3438" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ValuationAllowancesAndReservesDomain_3437" xlink:to="Locator_amed_EstimatedRevenueAdjustmentsDiscontinuedOperationsMember_3438" order="4.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureUnauditedSummarizedQuarterlyFinancialInformationDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="Locator_us-gaap_LitigationStatusAxis_3547" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_3548" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LitigationStatusAxis_3547" xlink:to="Locator_us-gaap_LitigationStatusDomain_3548" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="Locator_us-gaap_LitigationStatusDomain_3549" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OigSelfDisclosureMember" xlink:label="Locator_amed_OigSelfDisclosureMember_3550" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LitigationStatusDomain_3549" xlink:to="Locator_amed_OigSelfDisclosureMember_3550" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="Locator_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_3477" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationTable" xlink:label="Locator_amed_QuarterlyFinancialInformationTable_3478" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_3477" xlink:to="Locator_amed_QuarterlyFinancialInformationTable_3478" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationTable" xlink:label="Locator_amed_QuarterlyFinancialInformationTable_3535" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3536" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationTable_3535" xlink:to="Locator_amed_QuarterlyFinancialInformationLineItems_3536" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3439" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_HealthCareOrganizationPatientServiceRevenue" xlink:label="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_3440" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3439" xlink:to="Locator_us-gaap_HealthCareOrganizationPatientServiceRevenue_3440" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3441" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="Locator_us-gaap_NetIncomeLoss_3442" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3441" xlink:to="Locator_us-gaap_NetIncomeLoss_3442" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3443" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="Locator_us-gaap_EarningsPerShareBasic_3444" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3443" xlink:to="Locator_us-gaap_EarningsPerShareBasic_3444" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3445" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="Locator_us-gaap_EarningsPerShareDiluted_3446" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3445" xlink:to="Locator_us-gaap_EarningsPerShareDiluted_3446" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3447" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="Locator_us-gaap_AssetImpairmentCharges_3448" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3447" xlink:to="Locator_us-gaap_AssetImpairmentCharges_3448" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3449" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="Locator_us-gaap_RestructuringCharges_3450" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3449" xlink:to="Locator_us-gaap_RestructuringCharges_3450" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3451" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalFees" xlink:label="Locator_us-gaap_LegalFees_3452" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3451" xlink:to="Locator_us-gaap_LegalFees_3452" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3453" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ReversalOfLegalAccrual" xlink:label="Locator_amed_ReversalOfLegalAccrual_3454" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3453" xlink:to="Locator_amed_ReversalOfLegalAccrual_3454" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3455" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="Locator_us-gaap_LossContingencyAccrualProvision_3456" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3455" xlink:to="Locator_us-gaap_LossContingencyAccrualProvision_3456" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3457" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalizedComputerSoftwareImpairments" xlink:label="Locator_us-gaap_CapitalizedComputerSoftwareImpairments_3458" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3457" xlink:to="Locator_us-gaap_CapitalizedComputerSoftwareImpairments_3458" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3459" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="Locator_us-gaap_WriteOffOfDeferredDebtIssuanceCost_3460" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3459" xlink:to="Locator_us-gaap_WriteOffOfDeferredDebtIssuanceCost_3460" order="11.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3461" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainsLossesOnSalesOfAssets" xlink:label="Locator_us-gaap_GainsLossesOnSalesOfAssets_3462" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3461" xlink:to="Locator_us-gaap_GainsLossesOnSalesOfAssets_3462" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3463" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UsDepartmentOfJusticeSettlement" xlink:label="Locator_amed_UsDepartmentOfJusticeSettlement_3464" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3463" xlink:to="Locator_amed_UsDepartmentOfJusticeSettlement_3464" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3465" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_InsuranceProceedsForReimbursementOfLegalFees" xlink:label="Locator_amed_InsuranceProceedsForReimbursementOfLegalFees_3466" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3465" xlink:to="Locator_amed_InsuranceProceedsForReimbursementOfLegalFees_3466" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3467" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityLoanCost" xlink:label="Locator_amed_LineOfCreditFacilityLoanCost_3468" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3467" xlink:to="Locator_amed_LineOfCreditFacilityLoanCost_3468" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3469" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="Locator_us-gaap_ProceedsFromLegalSettlements_3470" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3469" xlink:to="Locator_us-gaap_ProceedsFromLegalSettlements_3470" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3471" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_SoftwareImplementationCosts" xlink:label="Locator_amed_SoftwareImplementationCosts_3472" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3471" xlink:to="Locator_amed_SoftwareImplementationCosts_3472" order="17.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationLineItems" xlink:label="Locator_amed_QuarterlyFinancialInformationLineItems_3473" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="Locator_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_3474" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationLineItems_3473" xlink:to="Locator_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_3474" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationTable" xlink:label="Locator_amed_QuarterlyFinancialInformationTable_3537" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationAxis" xlink:label="Locator_amed_QuarterlyFinancialInformationAxis_3538" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationTable_3537" xlink:to="Locator_amed_QuarterlyFinancialInformationAxis_3538" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationAxis" xlink:label="Locator_amed_QuarterlyFinancialInformationAxis_3551" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationDomain" xlink:label="Locator_amed_QuarterlyFinancialInformationDomain_3552" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationAxis_3551" xlink:to="Locator_amed_QuarterlyFinancialInformationDomain_3552" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationDomain" xlink:label="Locator_amed_QuarterlyFinancialInformationDomain_3553" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NetOfTaxMember" xlink:label="Locator_amed_NetOfTaxMember_3554" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationDomain_3553" xlink:to="Locator_amed_NetOfTaxMember_3554" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationTable" xlink:label="Locator_amed_QuarterlyFinancialInformationTable_3539" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="Locator_us-gaap_LitigationStatusAxis_3540" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationTable_3539" xlink:to="Locator_us-gaap_LitigationStatusAxis_3540" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_QuarterlyFinancialInformationTable" xlink:label="Locator_amed_QuarterlyFinancialInformationTable_3541" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TypeOfBusinessSoldAxis" xlink:label="Locator_amed_TypeOfBusinessSoldAxis_3542" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_QuarterlyFinancialInformationTable_3541" xlink:to="Locator_amed_TypeOfBusinessSoldAxis_3542" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TypeOfBusinessSoldAxis" xlink:label="Locator_amed_TypeOfBusinessSoldAxis_3543" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessSoldDomain" xlink:label="Locator_amed_BusinessSoldDomain_3544" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_TypeOfBusinessSoldAxis_3543" xlink:to="Locator_amed_BusinessSoldDomain_3544" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BusinessSoldDomain" xlink:label="Locator_amed_BusinessSoldDomain_3545" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceInpatientUnitMember" xlink:label="Locator_amed_HospiceInpatientUnitMember_3546" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_BusinessSoldDomain_3545" xlink:to="Locator_amed_HospiceInpatientUnitMember_3546" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/FutureMinimumRentalCommitmentsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_3615" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3616" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeAxis_3615" xlink:to="Locator_us-gaap_RangeMember_3616" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3617" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_3618" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_3617" xlink:to="Locator_us-gaap_MinimumMember_3618" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3619" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_3620" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_3619" xlink:to="Locator_us-gaap_MaximumMember_3620" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3579" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FutureRentalCommitmentsTable" xlink:label="Locator_amed_FutureRentalCommitmentsTable_3580" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3579" xlink:to="Locator_amed_FutureRentalCommitmentsTable_3580" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FutureRentalCommitmentsTable" xlink:label="Locator_amed_FutureRentalCommitmentsTable_3611" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3612" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_FutureRentalCommitmentsTable_3611" xlink:to="Locator_amed_OperatingLeaseObligationsLineItems_3612" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3555" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3556" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3555" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3556" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3557" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_3558" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3557" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_3558" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3559" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3560" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3559" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3560" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3561" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3562" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3561" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_3562" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3563" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_3564" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3563" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_3564" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3565" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_3566" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3565" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_3566" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3567" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_3568" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3567" xlink:to="Locator_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_3568" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3569" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseCommitmentsForDiscontinuedOperations" xlink:label="Locator_amed_OperatingLeaseCommitmentsForDiscontinuedOperations_3570" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3569" xlink:to="Locator_amed_OperatingLeaseCommitmentsForDiscontinuedOperations_3570" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3571" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeasesRentExpenseNetForContinuingOperations" xlink:label="Locator_amed_OperatingLeasesRentExpenseNetForContinuingOperations_3572" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3571" xlink:to="Locator_amed_OperatingLeasesRentExpenseNetForContinuingOperations_3572" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3573" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseTermYears" xlink:label="Locator_amed_OperatingLeaseTermYears_3574" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3573" xlink:to="Locator_amed_OperatingLeaseTermYears_3574" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeaseObligationsLineItems" xlink:label="Locator_amed_OperatingLeaseObligationsLineItems_3575" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OperatingLeasesAgreementExpirationYear" xlink:label="Locator_amed_OperatingLeasesAgreementExpirationYear_3576" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OperatingLeaseObligationsLineItems_3575" xlink:to="Locator_amed_OperatingLeasesAgreementExpirationYear_3576" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_FutureRentalCommitmentsTable" xlink:label="Locator_amed_FutureRentalCommitmentsTable_3613" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_3614" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_FutureRentalCommitmentsTable_3613" xlink:to="Locator_us-gaap_RangeAxis_3614" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureInsuranceProgramsDetails">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3621" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HealthInsurance" xlink:label="Locator_amed_HealthInsurance_3622" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3621" xlink:to="Locator_amed_HealthInsurance_3622" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3623" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WokersCompensation" xlink:label="Locator_amed_WokersCompensation_3624" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3623" xlink:to="Locator_amed_WokersCompensation_3624" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3625" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ProfessionalLiability" xlink:label="Locator_amed_ProfessionalLiability_3626" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3625" xlink:to="Locator_amed_ProfessionalLiability_3626" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3627" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedInsuranceTotal" xlink:label="Locator_amed_EstimatedInsuranceTotal_3628" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3627" xlink:to="Locator_amed_EstimatedInsuranceTotal_3628" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3629" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedInsuranceLongTermPortion" xlink:label="Locator_amed_EstimatedInsuranceLongTermPortion_3630" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3629" xlink:to="Locator_amed_EstimatedInsuranceLongTermPortion_3630" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3631" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedInsuranceExcludingLongTermPortion" xlink:label="Locator_amed_EstimatedInsuranceExcludingLongTermPortion_3632" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3631" xlink:to="Locator_amed_EstimatedInsuranceExcludingLongTermPortion_3632" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureEmployeeStockPurchasePlanDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3639" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="Locator_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3640" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3639" xlink:to="Locator_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3640" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3641" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare" xlink:label="Locator_amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare_3642" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3641" xlink:to="Locator_amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare_3642" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="Locator_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_3673" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3674" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_3673" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3674" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="Locator_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_3675" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_3676" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_3675" xlink:to="Locator_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_3676" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_3677" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3678" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_3677" xlink:to="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3678" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3679" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PriorToTwoThousandFourteenMember" xlink:label="Locator_amed_PriorToTwoThousandFourteenMember_3680" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3679" xlink:to="Locator_amed_PriorToTwoThousandFourteenMember_3680" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3681" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_January12015ToMarch312015Member" xlink:label="Locator_amed_January12015ToMarch312015Member_3682" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3681" xlink:to="Locator_amed_January12015ToMarch312015Member_3682" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3683" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_April12015ToJune302015Member" xlink:label="Locator_amed_April12015ToJune302015Member_3684" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3683" xlink:to="Locator_amed_April12015ToJune302015Member_3684" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3685" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_July12015ToSeptember302015Member" xlink:label="Locator_amed_July12015ToSeptember302015Member_3686" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3685" xlink:to="Locator_amed_July12015ToSeptember302015Member_3686" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3687" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_October12015ToDecember312015Member" xlink:label="Locator_amed_October12015ToDecember312015Member_3688" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3687" xlink:to="Locator_amed_October12015ToDecember312015Member_3688" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3689" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_January12016ToMarch312016Member" xlink:label="Locator_amed_January12016ToMarch312016Member_3690" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3689" xlink:to="Locator_amed_January12016ToMarch312016Member_3690" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3691" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_April12016ToJune302016Member" xlink:label="Locator_amed_April12016ToJune302016Member_3692" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3691" xlink:to="Locator_amed_April12016ToJune302016Member_3692" order="7.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3693" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_July12016ToSeptember302016Member" xlink:label="Locator_amed_July12016ToSeptember302016Member_3694" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3693" xlink:to="Locator_amed_July12016ToSeptember302016Member_3694" order="8.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3695" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_October12016ToDecember312016Member" xlink:label="Locator_amed_October12016ToDecember312016Member_3696" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_3695" xlink:to="Locator_amed_October12016ToDecember312016Member_3696" order="9.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureStockOptionActivityDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_3817" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3818" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeAxis_3817" xlink:to="Locator_us-gaap_RangeMember_3818" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3821" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_3822" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_3821" xlink:to="Locator_us-gaap_MinimumMember_3822" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_3819" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_3820" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_3819" xlink:to="Locator_us-gaap_MaximumMember_3820" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3815" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_3816" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_EquityBasedAwardsTable_3815" xlink:to="Locator_us-gaap_RangeAxis_3816" order="2.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3811" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3812" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_EquityBasedAwardsTable_3811" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3812" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3699" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_3700" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3699" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_3700" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3701" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="Locator_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3702" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3701" xlink:to="Locator_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3702" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3703" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3704" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3703" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3704" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3697" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3698" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3697" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3698" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3705" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3706" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3705" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3706" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3707" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3708" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3707" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3708" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3711" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3712" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3711" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3712" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3713" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3714" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3713" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3714" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3715" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_3716" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3715" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_3716" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3709" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3710" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3709" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3710" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3717" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3718" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3717" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3718" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3719" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3720" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3719" xlink:to="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3720" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3721" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3722" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3721" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3722" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3723" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3724" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3723" xlink:to="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3724" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3725" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3726" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3725" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3726" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3727" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="Locator_us-gaap_FairValueAssumptionsExpectedVolatilityRate_3728" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3727" xlink:to="Locator_us-gaap_FairValueAssumptionsExpectedVolatilityRate_3728" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3729" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3730" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3729" xlink:to="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3730" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3737" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_3738" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3737" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_3738" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3739" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_3740" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3739" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_3740" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3741" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="Locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3742" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3741" xlink:to="Locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3742" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3743" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="Locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3744" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3743" xlink:to="Locator_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3744" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3745" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="Locator_us-gaap_AllocatedShareBasedCompensationExpense_3746" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3745" xlink:to="Locator_us-gaap_AllocatedShareBasedCompensationExpense_3746" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3733" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3734" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3733" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3734" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3735" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_3736" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3735" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_3736" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3731" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" xlink:label="Locator_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_3732" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3731" xlink:to="Locator_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_3732" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3813" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="Locator_us-gaap_AwardTypeAxis_3814" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_EquityBasedAwardsTable_3813" xlink:to="Locator_us-gaap_AwardTypeAxis_3814" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="Locator_us-gaap_AwardTypeAxis_3823" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3824" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AwardTypeAxis_3823" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3824" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3825" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockOptionMember" xlink:label="Locator_us-gaap_StockOptionMember_3826" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3825" xlink:to="Locator_us-gaap_StockOptionMember_3826" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="Locator_us-gaap_ShareBasedCompensationAbstract_3749" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3750" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationAbstract_3749" xlink:to="Locator_amed_EquityBasedAwardsTable_3750" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureNonVestedStockActivityDetail">
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3883" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3884" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_EquityBasedAwardsTable_3883" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3884" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3829" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3830" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3829" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3830" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3831" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3832" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3831" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3832" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3833" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3834" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3833" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3834" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3827" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3828" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3827" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3828" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3835" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3836" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3835" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3836" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3839" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3840" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3839" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3840" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3841" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3842" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3841" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3842" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3843" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3844" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3843" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3844" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3837" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3838" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3837" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3838" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3845" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3846" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3845" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3846" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3885" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="Locator_us-gaap_AwardTypeAxis_3886" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_EquityBasedAwardsTable_3885" xlink:to="Locator_us-gaap_AwardTypeAxis_3886" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="Locator_us-gaap_AwardTypeAxis_3887" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3888" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AwardTypeAxis_3887" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3888" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3889" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedAwardsMember" xlink:label="Locator_amed_ShareBasedAwardsMember_3890" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3889" xlink:to="Locator_amed_ShareBasedAwardsMember_3890" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3891" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" xlink:label="Locator_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_3892" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3891" xlink:to="Locator_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_3892" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3893" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockMember" xlink:label="Locator_amed_NonVestedStockMember_3894" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3893" xlink:to="Locator_amed_NonVestedStockMember_3894" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3895" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" xlink:label="Locator_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_3896" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3895" xlink:to="Locator_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_3896" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3897" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember" xlink:label="Locator_amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember_3898" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3897" xlink:to="Locator_amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember_3898" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3899" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceMember" xlink:label="Locator_amed_NonVestedStockUnitsServiceMember_3900" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3899" xlink:to="Locator_amed_NonVestedStockUnitsServiceMember_3900" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="Locator_us-gaap_ShareBasedCompensationAbstract_3849" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3850" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationAbstract_3849" xlink:to="Locator_amed_EquityBasedAwardsTable_3850" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureNonVestedStockUnitsDetail">
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3977" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3978" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_EquityBasedAwardsTable_3977" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3978" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3903" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3904" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3903" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3904" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3905" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3906" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3905" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3906" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3907" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3908" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3907" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3908" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3901" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3902" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3901" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3902" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3909" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3910" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3909" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3910" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3913" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3914" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3913" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3914" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3915" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3916" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3915" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3916" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3917" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3918" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3917" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3918" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3911" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3912" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3911" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3912" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3919" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3920" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3919" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3920" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3921" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3922" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3921" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3922" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3923" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_3924" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3923" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_3924" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3925" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3926" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3925" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3926" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3927" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRequisiteServicePeriod" xlink:label="Locator_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRequisiteServicePeriod_3928" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3927" xlink:to="Locator_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRequisiteServicePeriod_3928" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3929" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" xlink:label="Locator_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_3930" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3929" xlink:to="Locator_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_3930" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3979" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="Locator_us-gaap_AwardTypeAxis_3980" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_EquityBasedAwardsTable_3979" xlink:to="Locator_us-gaap_AwardTypeAxis_3980" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="Locator_us-gaap_AwardTypeAxis_3981" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3982" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AwardTypeAxis_3981" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3982" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3983" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedAwardsMember" xlink:label="Locator_amed_ShareBasedAwardsMember_3984" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3983" xlink:to="Locator_amed_ShareBasedAwardsMember_3984" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3985" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" xlink:label="Locator_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_3986" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3985" xlink:to="Locator_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_3986" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3987" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockMember" xlink:label="Locator_amed_NonVestedStockMember_3988" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3987" xlink:to="Locator_amed_NonVestedStockMember_3988" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3989" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" xlink:label="Locator_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_3990" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3989" xlink:to="Locator_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_3990" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3991" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember" xlink:label="Locator_amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember_3992" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3991" xlink:to="Locator_amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember_3992" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3993" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_NonVestedStockUnitsServiceMember" xlink:label="Locator_amed_NonVestedStockUnitsServiceMember_3994" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3993" xlink:to="Locator_amed_NonVestedStockUnitsServiceMember_3994" order="6.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="Locator_us-gaap_ShareBasedCompensationAbstract_3933" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_3934" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationAbstract_3933" xlink:to="Locator_amed_EquityBasedAwardsTable_3934" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureTotalProvisionForIncomeTaxesDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_3995" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="Locator_us-gaap_CurrentFederalTaxExpenseBenefit_3996" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_3995" xlink:to="Locator_us-gaap_CurrentFederalTaxExpenseBenefit_3996" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_3997" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="Locator_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3998" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_3997" xlink:to="Locator_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3998" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_3999" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="Locator_us-gaap_CurrentIncomeTaxExpenseBenefit_4000" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_3999" xlink:to="Locator_us-gaap_CurrentIncomeTaxExpenseBenefit_4000" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4001" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="Locator_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4002" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4001" xlink:to="Locator_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4002" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4003" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="Locator_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4004" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4003" xlink:to="Locator_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4004" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4005" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="Locator_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_4006" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4005" xlink:to="Locator_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_4006" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4007" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredIncomeTaxesForContinuingOperations" xlink:label="Locator_amed_DeferredIncomeTaxesForContinuingOperations_4008" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4007" xlink:to="Locator_amed_DeferredIncomeTaxesForContinuingOperations_4008" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4009" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="Locator_us-gaap_IncomeTaxExpenseBenefit_4010" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4009" xlink:to="Locator_us-gaap_IncomeTaxExpenseBenefit_4010" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureComponentsOfNetDeferredTaxAssetsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4011" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_4012" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4011" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_4012" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4013" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_4014" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4013" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_4014" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4015" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_4016" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4015" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_4016" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4017" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_4018" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4017" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_4018" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4019" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual" xlink:label="Locator_amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual_4020" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4019" xlink:to="Locator_amed_DeferredTaxAssetsDeferredExpenseUsDepartmentOfJusticeSettlementAccrual_4020" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4021" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" xlink:label="Locator_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_4022" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4021" xlink:to="Locator_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_4022" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4023" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1" xlink:label="Locator_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1_4024" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4023" xlink:to="Locator_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1_4024" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4025" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4026" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4025" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4026" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4027" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="Locator_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_4028" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4027" xlink:to="Locator_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_4028" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4029" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="Locator_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4030" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4029" xlink:to="Locator_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4030" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4031" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredTaxAssetsOtherCurrent" xlink:label="Locator_amed_DeferredTaxAssetsOtherCurrent_4032" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4031" xlink:to="Locator_amed_DeferredTaxAssetsOtherCurrent_4032" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4033" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="Locator_us-gaap_DeferredTaxAssetsGross_4034" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4033" xlink:to="Locator_us-gaap_DeferredTaxAssetsGross_4034" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4035" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="Locator_us-gaap_DeferredTaxAssetsValuationAllowance_4036" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4035" xlink:to="Locator_us-gaap_DeferredTaxAssetsValuationAllowance_4036" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4037" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="Locator_us-gaap_DeferredTaxAssetsNet_4038" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4037" xlink:to="Locator_us-gaap_DeferredTaxAssetsNet_4038" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4039" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="Locator_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4040" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4039" xlink:to="Locator_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4040" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4041" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:label="Locator_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_4042" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4041" xlink:to="Locator_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_4042" order="16.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4043" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:label="Locator_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_4044" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4043" xlink:to="Locator_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_4044" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4045" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="Locator_us-gaap_DeferredTaxLiabilitiesOther_4046" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4045" xlink:to="Locator_us-gaap_DeferredTaxLiabilitiesOther_4046" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4047" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="Locator_us-gaap_DeferredTaxLiabilities_4048" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4047" xlink:to="Locator_us-gaap_DeferredTaxLiabilities_4048" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4049" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNet_4050" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4049" xlink:to="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNet_4050" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/SourcesOfTaxEffectDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4089" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4090" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4089" xlink:to="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4090" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4091" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4092" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4091" xlink:to="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4092" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4093" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_4094" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4093" xlink:to="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_4094" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4095" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_4096" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4095" xlink:to="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_4096" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4097" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_4098" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4097" xlink:to="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_4098" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4099" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4100" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4099" xlink:to="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4100" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4101" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_4102" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4101" xlink:to="Locator_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_4102" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4103" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="Locator_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4104" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4103" xlink:to="Locator_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4104" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureReconciliationOfUnrecognizedTaxBenefitsDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4107" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_4108" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4107" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_4108" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4109" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_4110" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4109" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_4110" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4111" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_4112" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4111" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_4112" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4113" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_4114" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4113" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_4114" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4115" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_4116" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4115" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_4116" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4105" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefits_4106" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4105" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefits_4106" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4117" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="Locator_us-gaap_UnrecognizedTaxBenefits_4118" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4117" xlink:to="Locator_us-gaap_UnrecognizedTaxBenefits_4118" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsOtherAssetsDetail">
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4119" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_WorkersCompensationDeposits" xlink:label="Locator_amed_WorkersCompensationDeposits_4120" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4119" xlink:to="Locator_amed_WorkersCompensationDeposits_4120" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4121" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HealthInsuranceDeposits" xlink:label="Locator_amed_HealthInsuranceDeposits_4122" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4121" xlink:to="Locator_amed_HealthInsuranceDeposits_4122" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4123" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherMiscellaneousDeposits" xlink:label="Locator_amed_OtherMiscellaneousDeposits_4124" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4123" xlink:to="Locator_amed_OtherMiscellaneousDeposits_4124" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4125" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="Locator_us-gaap_DeferredFinanceCostsNoncurrentNet_4126" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4125" xlink:to="Locator_us-gaap_DeferredFinanceCostsNoncurrentNet_4126" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4127" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="Locator_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4128" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4127" xlink:to="Locator_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4128" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4129" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:label="Locator_us-gaap_OtherAssetsMiscellaneousNoncurrent_4130" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4129" xlink:to="Locator_us-gaap_OtherAssetsMiscellaneousNoncurrent_4130" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4131" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="Locator_us-gaap_OtherAssetsNoncurrent_4132" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4131" xlink:to="Locator_us-gaap_OtherAssetsNoncurrent_4132" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsAccruedExpensesDetail">
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4145" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedInsuranceCurrent" xlink:label="Locator_us-gaap_AccruedInsuranceCurrent_4146" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4145" xlink:to="Locator_us-gaap_AccruedInsuranceCurrent_4146" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4147" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="Locator_us-gaap_WorkersCompensationLiabilityCurrent_4148" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4147" xlink:to="Locator_us-gaap_WorkersCompensationLiabilityCurrent_4148" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4149" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LegalAndOtherSettlements" xlink:label="Locator_amed_LegalAndOtherSettlements_4150" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4149" xlink:to="Locator_amed_LegalAndOtherSettlements_4150" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4151" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LeaseLiability" xlink:label="Locator_amed_LeaseLiability_4152" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4151" xlink:to="Locator_amed_LeaseLiability_4152" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4153" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CharityCare" xlink:label="Locator_amed_CharityCare_4154" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4153" xlink:to="Locator_amed_CharityCare_4154" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4155" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EstimatedMedicareCapLiability" xlink:label="Locator_amed_EstimatedMedicareCapLiability_4156" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4155" xlink:to="Locator_amed_EstimatedMedicareCapLiability_4156" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4157" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceCostOfRevenue" xlink:label="Locator_amed_HospiceCostOfRevenue_4158" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4157" xlink:to="Locator_amed_HospiceCostOfRevenue_4158" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4159" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OigSelfDisclsoureAccrual" xlink:label="Locator_amed_OigSelfDisclsoureAccrual_4160" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4159" xlink:to="Locator_amed_OigSelfDisclsoureAccrual_4160" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4161" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PatientLiability" xlink:label="Locator_amed_PatientLiability_4162" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4161" xlink:to="Locator_amed_PatientLiability_4162" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4163" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="Locator_us-gaap_OtherAccruedLiabilitiesCurrent_4164" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4163" xlink:to="Locator_us-gaap_OtherAccruedLiabilitiesCurrent_4164" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4165" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="Locator_us-gaap_AccruedLiabilitiesCurrent_4166" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4165" xlink:to="Locator_us-gaap_AccruedLiabilitiesCurrent_4166" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsOtherLongTermObligationsDetail">
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4187" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UncertainTaxBenefitsInLongTermObligations" xlink:label="Locator_amed_UncertainTaxBenefitsInLongTermObligations_4188" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4187" xlink:to="Locator_amed_UncertainTaxBenefitsInLongTermObligations_4188" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4189" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DeferredCompensationPlanLiability" xlink:label="Locator_amed_DeferredCompensationPlanLiability_4190" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4189" xlink:to="Locator_amed_DeferredCompensationPlanLiability_4190" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4191" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:label="Locator_us-gaap_OtherSundryLiabilitiesNoncurrent_4192" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4191" xlink:to="Locator_us-gaap_OtherSundryLiabilitiesNoncurrent_4192" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:label="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4193" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="Locator_us-gaap_OtherLiabilitiesNoncurrent_4194" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_DetailsOfCertainBalanceSheetAccountsAbstract_4193" xlink:to="Locator_us-gaap_OtherLiabilitiesNoncurrent_4194" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureSummaryOfActivityRelatedToGoodwillDetail">
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4203" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="Locator_us-gaap_GoodwillAcquiredDuringPeriod_4204" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4203" xlink:to="Locator_us-gaap_GoodwillAcquiredDuringPeriod_4204" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4205" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:label="Locator_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_4206" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4205" xlink:to="Locator_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_4206" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4207" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="Locator_us-gaap_GoodwillImpairmentLoss_4208" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4207" xlink:to="Locator_us-gaap_GoodwillImpairmentLoss_4208" order="4.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4209" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="Locator_us-gaap_GoodwillPurchaseAccountingAdjustments_4210" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4209" xlink:to="Locator_us-gaap_GoodwillPurchaseAccountingAdjustments_4210" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4201" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="Locator_us-gaap_Goodwill_4202" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4201" xlink:to="Locator_us-gaap_Goodwill_4202" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4211" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="Locator_us-gaap_Goodwill_4212" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4211" xlink:to="Locator_us-gaap_Goodwill_4212" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_4241" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_4242" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_StatementBusinessSegmentsAxis_4241" xlink:to="Locator_us-gaap_SegmentDomain_4242" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_4243" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HomeHealthMember" xlink:label="Locator_amed_HomeHealthMember_4244" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_4243" xlink:to="Locator_amed_HomeHealthMember_4244" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_4245" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_HospiceMember" xlink:label="Locator_amed_HospiceMember_4246" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_4245" xlink:to="Locator_amed_HospiceMember_4246" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="Locator_us-gaap_SegmentDomain_4247" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_PersonalCareMember" xlink:label="Locator_amed_PersonalCareMember_4248" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_SegmentDomain_4247" xlink:to="Locator_amed_PersonalCareMember_4248" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="Locator_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4215" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="Locator_us-gaap_ScheduleOfGoodwillTable_4216" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4215" xlink:to="Locator_us-gaap_ScheduleOfGoodwillTable_4216" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="Locator_us-gaap_ScheduleOfGoodwillTable_4237" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4238" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfGoodwillTable_4237" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4238" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="Locator_us-gaap_ScheduleOfGoodwillTable_4239" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="Locator_us-gaap_StatementBusinessSegmentsAxis_4240" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfGoodwillTable_4239" xlink:to="Locator_us-gaap_StatementBusinessSegmentsAxis_4240" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureSummaryOfActivityRelatedToOtherIntangibleAssetsNetDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_4291" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4292" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_4291" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4292" order="3.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4251" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherIntangibleAssetsAdditions" xlink:label="Locator_amed_OtherIntangibleAssetsAdditions_4252" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4251" xlink:to="Locator_amed_OtherIntangibleAssetsAdditions_4252" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4253" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherIntangiblesWriteOffs" xlink:label="Locator_amed_OtherIntangiblesWriteOffs_4254" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4253" xlink:to="Locator_amed_OtherIntangiblesWriteOffs_4254" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4255" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="Locator_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_4256" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4255" xlink:to="Locator_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_4256" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4257" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="Locator_us-gaap_AmortizationOfIntangibleAssets_4258" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4257" xlink:to="Locator_us-gaap_AmortizationOfIntangibleAssets_4258" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4249" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="Locator_us-gaap_IntangibleAssetsNetExcludingGoodwill_4250" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4249" xlink:to="Locator_us-gaap_IntangibleAssetsNetExcludingGoodwill_4250" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4259" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="Locator_us-gaap_IntangibleAssetsNetExcludingGoodwill_4260" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4259" xlink:to="Locator_us-gaap_IntangibleAssetsNetExcludingGoodwill_4260" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_4293" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4294" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_4293" xlink:to="Locator_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4294" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4301" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4302" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4301" xlink:to="Locator_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4302" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4303" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CertificatesOfNeedAndLicensesMember" xlink:label="Locator_amed_CertificatesOfNeedAndLicensesMember_4304" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4303" xlink:to="Locator_amed_CertificatesOfNeedAndLicensesMember_4304" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4305" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AcquiredNamesOfBusinessMember" xlink:label="Locator_amed_AcquiredNamesOfBusinessMember_4306" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4305" xlink:to="Locator_amed_AcquiredNamesOfBusinessMember_4306" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_4295" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4296" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_4295" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4296" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4297" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4298" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4297" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4298" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4299" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="Locator_us-gaap_NoncompeteAgreementsMember_4300" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4299" xlink:to="Locator_us-gaap_NoncompeteAgreementsMember_4300" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="Locator_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4263" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_4264" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4263" xlink:to="Locator_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_4264" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/SummaryOfActivityRelatedToOtherIntangibleAssetsNetParentheticalDetail">
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4307" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_UnamortizedAcquiredNames" xlink:label="Locator_amed_UnamortizedAcquiredNames_4308" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4307" xlink:to="Locator_amed_UnamortizedAcquiredNames_4308" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4309" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AmortizedAcquiredNames" xlink:label="Locator_amed_AmortizedAcquiredNames_4310" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4309" xlink:to="Locator_amed_AmortizedAcquiredNames_4310" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4311" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="Locator_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4312" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4311" xlink:to="Locator_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4312" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4313" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4314" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4313" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4314" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4315" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4316" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4315" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4316" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4317" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4318" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4317" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4318" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4319" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4320" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4319" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4320" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4321" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4322" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4321" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4322" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4323" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsNet_4324" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4323" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsNet_4324" order="9.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4361" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4362" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4361" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4362" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4363" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AcquiredNameOfBusinessMember" xlink:label="Locator_amed_AcquiredNameOfBusinessMember_4364" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4363" xlink:to="Locator_amed_AcquiredNameOfBusinessMember_4364" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4365" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="Locator_us-gaap_NoncompeteAgreementsMember_4366" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4365" xlink:to="Locator_us-gaap_NoncompeteAgreementsMember_4366" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="Locator_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4327" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="Locator_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4328" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4327" xlink:to="Locator_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4328" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="Locator_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4357" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_GoodwillAndIntangibleAssetsLineItems" xlink:label="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4358" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4357" xlink:to="Locator_amed_GoodwillAndIntangibleAssetsLineItems_4358" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="Locator_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4359" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4360" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4359" xlink:to="Locator_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4360" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_4409" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_4410" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeAxis_4409" xlink:to="Locator_us-gaap_RangeMember_4410" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_4411" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="Locator_us-gaap_MinimumMember_4412" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_4411" xlink:to="Locator_us-gaap_MinimumMember_4412" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_4413" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="Locator_us-gaap_MaximumMember_4414" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_4413" xlink:to="Locator_us-gaap_MaximumMember_4414" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="Locator_us-gaap_AccountingPoliciesAbstract_4373" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4374" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AccountingPoliciesAbstract_4373" xlink:to="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4374" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4403" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_4404" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4403" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_4404" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_4367" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentUsefulLife_4368" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_4367" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentUsefulLife_4368" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_4369" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_4370" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentLineItems_4369" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_4370" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4405" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4406" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4405" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4406" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4415" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4416" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4415" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4416" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4417" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingMember" xlink:label="Locator_us-gaap_BuildingMember_4418" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4417" xlink:to="Locator_us-gaap_BuildingMember_4418" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4419" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="Locator_us-gaap_LeaseholdImprovementsMember_4420" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4419" xlink:to="Locator_us-gaap_LeaseholdImprovementsMember_4420" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4421" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquipmentAndFurnitureMember" xlink:label="Locator_amed_EquipmentAndFurnitureMember_4422" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4421" xlink:to="Locator_amed_EquipmentAndFurnitureMember_4422" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4423" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_VehiclesMember" xlink:label="Locator_us-gaap_VehiclesMember_4424" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4423" xlink:to="Locator_us-gaap_VehiclesMember_4424" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4425" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_ComputerSoftwareMember" xlink:label="Locator_amed_ComputerSoftwareMember_4426" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentTypeDomain_4425" xlink:to="Locator_amed_ComputerSoftwareMember_4426" order="5.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4407" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_4408" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4407" xlink:to="Locator_us-gaap_RangeAxis_4408" order="2.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/ScheduleOfBalancesRelatedToPropertyAndEquipmentDetails">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_4427" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Land" xlink:label="Locator_us-gaap_Land_4428" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_4427" xlink:to="Locator_us-gaap_Land_4428" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_4429" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_BuildingAndLeaseholdImprovements" xlink:label="Locator_amed_BuildingAndLeaseholdImprovements_4430" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_4429" xlink:to="Locator_amed_BuildingAndLeaseholdImprovements_4430" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_4431" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquipmentAndFurniture" xlink:label="Locator_amed_EquipmentAndFurniture_4432" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_4431" xlink:to="Locator_amed_EquipmentAndFurniture_4432" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_4433" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="Locator_us-gaap_CapitalizedComputerSoftwareGross_4434" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_4433" xlink:to="Locator_us-gaap_CapitalizedComputerSoftwareGross_4434" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_4435" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentGross_4436" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_4435" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentGross_4436" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_4437" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="Locator_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4438" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_4437" xlink:to="Locator_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4438" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_4439" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="Locator_us-gaap_PropertyPlantAndEquipmentNet_4440" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_PropertyPlantAndEquipmentAbstract_4439" xlink:to="Locator_us-gaap_PropertyPlantAndEquipmentNet_4440" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureMaturitiesOfDebtDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_4453" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4454" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_4453" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4454" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_4455" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_4456" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_4455" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_4456" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_4457" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_4458" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_4457" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_4458" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_4459" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4460" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_4459" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4460" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_4461" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_4462" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_4461" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_4462" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_4463" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_4464" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_4463" xlink:to="Locator_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_4464" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_4465" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_4466" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_MaturitiesOfLongTermDebtAbstract_4465" xlink:to="Locator_us-gaap_DebtLongtermAndShorttermCombinedAmount_4466" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureCommitmentFeeUnderCreditFacilitiesDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_4523" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_4524" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeAxis_4523" xlink:to="Locator_us-gaap_RangeMember_4524" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_4525" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RangeOneMember" xlink:label="Locator_amed_RangeOneMember_4526" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_4525" xlink:to="Locator_amed_RangeOneMember_4526" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_4527" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RangeTwoMember" xlink:label="Locator_amed_RangeTwoMember_4528" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_4527" xlink:to="Locator_amed_RangeTwoMember_4528" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_4529" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RangeThreeMember" xlink:label="Locator_amed_RangeThreeMember_4530" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_4529" xlink:to="Locator_amed_RangeThreeMember_4530" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="Locator_us-gaap_RangeMember_4531" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RangeFourMember" xlink:label="Locator_amed_RangeFourMember_4532" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RangeMember_4531" xlink:to="Locator_amed_RangeFourMember_4532" order="4.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="Locator_us-gaap_DebtDisclosureAbstract_4487" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="Locator_us-gaap_LineOfCreditFacilityTable_4488" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DebtDisclosureAbstract_4487" xlink:to="Locator_us-gaap_LineOfCreditFacilityTable_4488" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="Locator_us-gaap_LineOfCreditFacilityTable_4517" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="Locator_us-gaap_LineOfCreditFacilityLineItems_4518" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LineOfCreditFacilityTable_4517" xlink:to="Locator_us-gaap_LineOfCreditFacilityLineItems_4518" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="Locator_us-gaap_LineOfCreditFacilityLineItems_4479" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="Locator_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_4480" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LineOfCreditFacilityLineItems_4479" xlink:to="Locator_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_4480" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="Locator_us-gaap_LineOfCreditFacilityLineItems_4481" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="Locator_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4482" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LineOfCreditFacilityLineItems_4481" xlink:to="Locator_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_4482" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="Locator_us-gaap_LineOfCreditFacilityLineItems_4483" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LetterOfCreditFee" xlink:label="Locator_amed_LetterOfCreditFee_4484" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LineOfCreditFacilityLineItems_4483" xlink:to="Locator_amed_LetterOfCreditFee_4484" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="Locator_us-gaap_LineOfCreditFacilityTable_4519" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="Locator_us-gaap_RangeAxis_4520" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LineOfCreditFacilityTable_4519" xlink:to="Locator_us-gaap_RangeAxis_4520" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="Locator_us-gaap_LineOfCreditFacilityTable_4521" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="Locator_us-gaap_LineOfCreditFacilityAxis_4522" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LineOfCreditFacilityTable_4521" xlink:to="Locator_us-gaap_LineOfCreditFacilityAxis_4522" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="Locator_us-gaap_LineOfCreditFacilityAxis_4533" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityDomain" xlink:label="Locator_amed_LineOfCreditFacilityDomain_4534" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_LineOfCreditFacilityAxis_4533" xlink:to="Locator_amed_LineOfCreditFacilityDomain_4534" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityDomain" xlink:label="Locator_amed_LineOfCreditFacilityDomain_4535" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_AbrLoansMember" xlink:label="Locator_amed_AbrLoansMember_4536" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_LineOfCreditFacilityDomain_4535" xlink:to="Locator_amed_AbrLoansMember_4536" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LineOfCreditFacilityDomain" xlink:label="Locator_amed_LineOfCreditFacilityDomain_4537" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EurodollarLoansMember" xlink:label="Locator_amed_EurodollarLoansMember_4538" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_LineOfCreditFacilityDomain_4537" xlink:to="Locator_amed_EurodollarLoansMember_4538" order="2.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureExitActivitiesReserveActivityDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="Locator_us-gaap_RestructuringAndRelatedActivitiesAbstract_4547" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4548" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringAndRelatedActivitiesAbstract_4547" xlink:to="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4548" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4571" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_4572" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4571" xlink:to="Locator_us-gaap_RestructuringCostAndReserveLineItems_4572" order="3.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_4539" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="Locator_us-gaap_RestructuringReserve_4540" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_4539" xlink:to="Locator_us-gaap_RestructuringReserve_4540" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_4541" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="Locator_us-gaap_RestructuringCharges_4542" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_4541" xlink:to="Locator_us-gaap_RestructuringCharges_4542" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="Locator_us-gaap_RestructuringCostAndReserveLineItems_4543" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="Locator_us-gaap_PaymentsForRestructuring_4544" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringCostAndReserveLineItems_4543" xlink:to="Locator_us-gaap_PaymentsForRestructuring_4544" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4573" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringCostsAxis" xlink:label="Locator_amed_OtherRestructuringCostsAxis_4574" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4573" xlink:to="Locator_amed_OtherRestructuringCostsAxis_4574" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringCostsAxis" xlink:label="Locator_amed_OtherRestructuringCostsAxis_4577" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_4578" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OtherRestructuringCostsAxis_4577" xlink:to="Locator_amed_OtherRestructuringDomain_4578" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_4579" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoThousandAndThirteenExitActivityMember" xlink:label="Locator_amed_TwoThousandAndThirteenExitActivityMember_4580" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OtherRestructuringDomain_4579" xlink:to="Locator_amed_TwoThousandAndThirteenExitActivityMember_4580" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_OtherRestructuringDomain" xlink:label="Locator_amed_OtherRestructuringDomain_4581" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_TwoThousandAndFourteenExitActivityMember" xlink:label="Locator_amed_TwoThousandAndFourteenExitActivityMember_4582" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_OtherRestructuringDomain_4581" xlink:to="Locator_amed_TwoThousandAndFourteenExitActivityMember_4582" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4575" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="Locator_us-gaap_RestructuringCostAndReserveAxis_4576" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4575" xlink:to="Locator_us-gaap_RestructuringCostAndReserveAxis_4576" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="Locator_us-gaap_RestructuringCostAndReserveAxis_4583" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_4584" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RestructuringCostAndReserveAxis_4583" xlink:to="Locator_amed_RestructuringCostAndReserveDomain_4584" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_4585" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_LeaseTerminationMember" xlink:label="Locator_amed_LeaseTerminationMember_4586" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_RestructuringCostAndReserveDomain_4585" xlink:to="Locator_amed_LeaseTerminationMember_4586" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RestructuringCostAndReserveDomain" xlink:label="Locator_amed_RestructuringCostAndReserveDomain_4587" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="Locator_us-gaap_EmployeeSeveranceMember_4588" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_RestructuringCostAndReserveDomain_4587" xlink:to="Locator_us-gaap_EmployeeSeveranceMember_4588" order="2.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/ClassificationOfDeferredTaxAssetsAndLiabilitiesDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:label="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_4589" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="Locator_us-gaap_DeferredTaxAssetsNetCurrent_4590" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_4589" xlink:to="Locator_us-gaap_DeferredTaxAssetsNetCurrent_4590" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:label="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_4591" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="Locator_us-gaap_DeferredTaxLiabilitiesCurrent_4592" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_4591" xlink:to="Locator_us-gaap_DeferredTaxLiabilitiesCurrent_4592" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:label="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_4593" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="Locator_us-gaap_DeferredTaxAssetsNetNoncurrent_4594" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_4593" xlink:to="Locator_us-gaap_DeferredTaxAssetsNetNoncurrent_4594" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:label="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_4595" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="Locator_us-gaap_DeferredTaxLiabilitiesNoncurrent_4596" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_4595" xlink:to="Locator_us-gaap_DeferredTaxLiabilitiesNoncurrent_4596" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:label="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_4597" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNet_4598" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_4597" xlink:to="Locator_us-gaap_DeferredTaxAssetsLiabilitiesNet_4598" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureNonVestedStockOptionActivityDetail">
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_4645" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4646" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_EquityBasedAwardsTable_4645" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4646" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4601" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4602" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4601" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4602" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4603" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_4604" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4603" xlink:to="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_4604" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4605" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_4606" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4605" xlink:to="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_4606" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4599" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_4600" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4599" xlink:to="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_4600" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4607" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_4608" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4607" xlink:to="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_4608" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4611" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4612" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4611" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4612" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4613" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_4614" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4613" xlink:to="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_4614" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4615" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_4616" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4615" xlink:to="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_4616" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4609" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_4610" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4609" xlink:to="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_4610" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4617" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_4618" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4617" xlink:to="Locator_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_4618" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_4647" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="Locator_us-gaap_AwardTypeAxis_4648" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_EquityBasedAwardsTable_4647" xlink:to="Locator_us-gaap_AwardTypeAxis_4648" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="Locator_us-gaap_AwardTypeAxis_4649" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4650" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_AwardTypeAxis_4649" xlink:to="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4650" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4651" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockOptionMember" xlink:label="Locator_us-gaap_StockOptionMember_4652" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4651" xlink:to="Locator_us-gaap_StockOptionMember_4652" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="Locator_us-gaap_ShareBasedCompensationAbstract_4621" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_EquityBasedAwardsTable" xlink:label="Locator_amed_EquityBasedAwardsTable_4622" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_ShareBasedCompensationAbstract_4621" xlink:to="Locator_amed_EquityBasedAwardsTable_4622" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/SHAREREPURCHASEPROGRAM">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="Locator_us-gaap_EquityAbstract_4653" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockTextBlock" xlink:label="Locator_us-gaap_TreasuryStockTextBlock_4654" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EquityAbstract_4653" xlink:to="Locator_us-gaap_TreasuryStockTextBlock_4654" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/ShareRepurchaseProgramDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="Locator_us-gaap_EquityAbstract_4655" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="Locator_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4656" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EquityAbstract_4655" xlink:to="Locator_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4656" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="Locator_us-gaap_EquityAbstract_4657" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="Locator_us-gaap_TreasuryStockValueAcquiredCostMethod_4658" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EquityAbstract_4657" xlink:to="Locator_us-gaap_TreasuryStockValueAcquiredCostMethod_4658" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="Locator_us-gaap_EquityAbstract_4659" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="Locator_us-gaap_TreasuryStockSharesAcquired_4660" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EquityAbstract_4659" xlink:to="Locator_us-gaap_TreasuryStockSharesAcquired_4660" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="Locator_us-gaap_EquityAbstract_4661" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="Locator_us-gaap_TreasuryStockAcquiredAverageCostPerShare_4662" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_EquityAbstract_4661" xlink:to="Locator_us-gaap_TreasuryStockAcquiredAverageCostPerShare_4662" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureACQUISITIONSPROFORMACONDENSEDCONSOLIDATEDINCOMESTATEMENTTables">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="Locator_us-gaap_BusinessAcquisitionProFormaInformationAbstract_4663" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="Locator_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_4664" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BusinessAcquisitionProFormaInformationAbstract_4663" xlink:to="Locator_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_4664" order="1.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/DisclosureAcquisitionsProFormaCondensedConsolidatedIncomeStatementDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="Locator_us-gaap_BusinessAcquisitionProFormaInformationAbstract_4665" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="Locator_us-gaap_BusinessAcquisitionsProFormaRevenue_4666" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BusinessAcquisitionProFormaInformationAbstract_4665" xlink:to="Locator_us-gaap_BusinessAcquisitionsProFormaRevenue_4666" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="Locator_us-gaap_BusinessAcquisitionProFormaInformationAbstract_4667" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_Businessacquisitionproformaoperatingincomeloss" xlink:label="Locator_amed_Businessacquisitionproformaoperatingincomeloss_4668" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BusinessAcquisitionProFormaInformationAbstract_4667" xlink:to="Locator_amed_Businessacquisitionproformaoperatingincomeloss_4668" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="Locator_us-gaap_BusinessAcquisitionProFormaInformationAbstract_4669" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="Locator_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_4670" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BusinessAcquisitionProFormaInformationAbstract_4669" xlink:to="Locator_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_4670" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="Locator_us-gaap_BusinessAcquisitionProFormaInformationAbstract_4671" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="Locator_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_4672" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BusinessAcquisitionProFormaInformationAbstract_4671" xlink:to="Locator_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_4672" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="Locator_us-gaap_BusinessAcquisitionProFormaInformationAbstract_4673" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:label="Locator_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_4674" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_BusinessAcquisitionProFormaInformationAbstract_4673" xlink:to="Locator_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_4674" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/IncomeTaxExpenseAllocationDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4675" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="Locator_us-gaap_IncomeTaxExpenseBenefit_4676" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4675" xlink:to="Locator_us-gaap_IncomeTaxExpenseBenefit_4676" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4677" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="Locator_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_4678" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4677" xlink:to="Locator_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_4678" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4679" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxEffectsAllocatedToInterestExpense" xlink:label="Locator_amed_IncomeTaxEffectsAllocatedToInterestExpense_4680" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4679" xlink:to="Locator_amed_IncomeTaxEffectsAllocatedToInterestExpense_4680" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4681" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_IncomeTaxEffectsAllocatedToGoodwill" xlink:label="Locator_amed_IncomeTaxEffectsAllocatedToGoodwill_4682" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4681" xlink:to="Locator_amed_IncomeTaxEffectsAllocatedToGoodwill_4682" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4683" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityOther" xlink:label="Locator_us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityOther_4684" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4683" xlink:to="Locator_us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityOther_4684" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="Locator_us-gaap_IncomeTaxDisclosureAbstract_4685" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:label="Locator_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_4686" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_IncomeTaxDisclosureAbstract_4685" xlink:to="Locator_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_4686" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/RelatedPartyTransactionDetail">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="Locator_us-gaap_RelatedPartyTransactionsAbstract_4703" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RelatedPartyTransactionTable" xlink:label="Locator_amed_RelatedPartyTransactionTable_4704" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RelatedPartyTransactionsAbstract_4703" xlink:to="Locator_amed_RelatedPartyTransactionTable_4704" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RelatedPartyTransactionTable" xlink:label="Locator_amed_RelatedPartyTransactionTable_4719" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="Locator_us-gaap_RelatedPartyTransactionLineItems_4720" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_RelatedPartyTransactionTable_4719" xlink:to="Locator_us-gaap_RelatedPartyTransactionLineItems_4720" order="2.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="Locator_us-gaap_RelatedPartyTransactionLineItems_4697" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="Locator_us-gaap_RelatedPartyTransactionAmountsOfTransaction_4698" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RelatedPartyTransactionLineItems_4697" xlink:to="Locator_us-gaap_RelatedPartyTransactionAmountsOfTransaction_4698" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="Locator_us-gaap_RelatedPartyTransactionLineItems_4699" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="Locator_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_4700" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RelatedPartyTransactionLineItems_4699" xlink:to="Locator_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_4700" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_RelatedPartyTransactionTable" xlink:label="Locator_amed_RelatedPartyTransactionTable_4721" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="Locator_us-gaap_RelatedPartyTransactionAxis_4722" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_RelatedPartyTransactionTable_4721" xlink:to="Locator_us-gaap_RelatedPartyTransactionAxis_4722" order="1.0" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="Locator_us-gaap_RelatedPartyTransactionAxis_4723" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CompanyNameDomain" xlink:label="Locator_amed_CompanyNameDomain_4724" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RelatedPartyTransactionAxis_4723" xlink:to="Locator_amed_CompanyNameDomain_4724" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CompanyNameDomain" xlink:label="Locator_amed_CompanyNameDomain_4725" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_KKRConsultingMember" xlink:label="Locator_amed_KKRConsultingMember_4726" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CompanyNameDomain_4725" xlink:to="Locator_amed_KKRConsultingMember_4726" order="1.0" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CompanyNameDomain" xlink:label="Locator_amed_CompanyNameDomain_4727" />
        <loc xlink:type="locator" xlink:href="amed-20161231.xsd#amed_CareInnovationsMember" xlink:label="Locator_amed_CareInnovationsMember_4728" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_amed_CompanyNameDomain_4727" xlink:to="Locator_amed_CareInnovationsMember_4728" order="2.0" />
    </presentationLink>
    <presentationLink xlink:type="extended" xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS">
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="Locator_us-gaap_RelatedPartyTransactionsAbstract_4729" />
        <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="Locator_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_4730" />
        <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="Locator_us-gaap_RelatedPartyTransactionsAbstract_4729" xlink:to="Locator_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_4730" order="1.0" />
    </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g332070g58p88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332070g58p88.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ , !X P$1  (1 0,1 ?_$ !T   ,
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HV(?2>,X^J;LK)9;=MC/Z33]NAC5+4L))N;6Y=!A,)\+$?"(^$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g332070g66x66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g332070g66x66.jpg
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M(S,Y0ADD4F)Q@24T-39#4W*1)T158V2QEJ&B_\0 & $! 0$! 0
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M QA"+E>U^C>]K\O3RY4!S6+$;<E4+G!4F0H4A(U"M8L/*3)4Q!0;B,/4*#A
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MZMJY*2!0L+Z!UQE\^9"Z%X1?<.\0E-DU]:\%YW2;/%9B<67,%\*Q".;/:_\
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MG=CR9EH;$I)8Y1WL,MP-*7%26,O?3&<("HM\9E_(X"]-82S>_P#K;_\ %O\
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MO\17]9S^'JAT^GCR^3T?:/?>5Z@_1=P!^Z>)4,.]\7W)14(* 4 H!0"@% *
M4 H!0"@% ?%0G3JTYZ1602J2JB34ZE,H* <G4)S@"+.(/),"(LTDTL0BS2C
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M,\-R@?=6MR3EEKT*@5C49Y1O(5!&%QUK8CQ5XBNF+Q8U@1F-GQ*K1/D .B+
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M=LKC8;14>3K1"/VR$*+A.NHM&Q33P?XR"8;'WN=9GNY7;K'7N99/T[]*A#'
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MY/1]H]]Y7J#]%W '[IXE0P[WQ?<E%0@H!0"@% * 4 H!0"@% * 4 H!0"@%
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MSXAP+3&E$(S)U8LE1-%;04W+)6X)D;H_J'!R1I51(1<IW7<KLL*%UP? N/\
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M#*5T[U%2QBY=-](&V.A!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H#R/_93?XBOZSG\/5#I]/'E\GH^T>^\KU!^B[@#]T\2H8=[
MXON2BH04 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M$&N'U_@WECZ<O$9_UY;$T*[^2[(G+0@H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"#4(_XE6SOT'-%OW]<1&A<%Q?9&
M@3[*;_$5_6<_AZH;^GCR^3T?:/?>5Z@_1=P!^Z>)4,.]\7W(3\1W#>79UE#"
M\MP[AB09$E2&+Y'A[>XG%XHFN&GI4^0:=&I,<;!8[R7=G>&#'KV\A833\DXZ
MEC8ZE-RF1MR\HV3MV,VY[%LM0<73C)X;_+HF,LIZB;<.V:,R9,D47@&6VB:D
MX+?WLR-R#O-]G<%PON?!\P)]=VF-3E:TQYL27P/&GV)%,[HYMV/Y7*9 ]NTD
M?2G*?S)9<$UW4YJ:<\X0Q4+[BS%NIN>5BW-S@5KP[%I-CTKD@P&@,=<4 .TO
M?3MI)SE1=.I.5:;B)C1TN+DL,SNK#B8R9.:>4XW+C2X@$L+CJ9>$5+"%]\_%
M*^%)&]68MDC>8J_M40DX(7*'!K5I6&6&L:23%QYS-+N%*ZCCZ]0D1O 4AE[&
M70*5)!*CET!FAM?G0R:=]&\-;@.&*<G'L&Z;7'4)6Y&^J!2@'K+!7D:M\;=T
M\[M\C?\ OQ5+B!D DS\F<9"6T%E73L8',+.E/4ID)1Y@VW9C_'!8NB)E>0S=
MKKX-791QY[YT)&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[
M>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>
M^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#
M5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D
M,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&
MS[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<
M>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z
M^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K
M'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=
M!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V
M4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W
M:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[
M>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>
M^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#
M5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D
M,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&
MS[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<
M>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z
M^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K
M'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=
M!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V
M4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W:Z^#5V4<>>^=!&S[>K'D,W
M:Z^#5V4<>>^=!&S[>K*$^8TVTC)'?,DXB<-CR;HW%WP^:T8L:2.C;Y1=U7SM
M.7T;?AOTN5J0;N41M6%?9A_]B!F7MIL_XWR#'HA'=ZF7)#(,XN\VEL6UHQBJ
M;&!,I[G8D+"<GF"I'*7!, 0E3BG3+$J0@%BT1:\QP$J(0];/TK5I-W4CBS#^
MI934+,:^I]"?$>Q9N#*V)GDT=X@#&ZL3^VHW9H<DVJ6/KD+6]>0!2E4EV',0
M&!L:28$5P&@ :6*]RS0 ,"(-N3E)WHWM67-6>K*QY#-VNO@U=E''GOG01L^W
MJQY#-VNO@U=E''GOG01L^WJQY#-VNO@U=E''GOG01L^WJQY#-VNO@U=E''GO
MG01L^WJS$VM$3RG#^(/M8VY<RXGS+(E&F^CRY#)4V/67&P&]E,S7Q ""&*[(
MQN;JE5B3KDS@ONZF* *#K.04@B0EHBAF X04%";QCA9-+?V4W^(K^LY_#U0U
M]/'E\GH^T>^\KU!^B[@#]T\2H8=[XON2BH04 H!0$&N'U_@WECZ<O$9_UY;$
MT*[^2[(G+0@H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 7OR]-_1:WIO>
M_P""@,:R7,N(H;W2TLRAC^.F%<^D0\2]@0*N=OE !(H7@4F&?D++*&.]_18-
MZNRW<F^3)%569@"0[^:J,!ETX,F6D*[I= M#%HY)WL9XODL$A80T!:C!"OZ
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M^2_,/+E3:L*ZQ'_LWV$+3OM9>(_;:!0%[Y&9,RUGS*AH[VNH(EN1U)C8;?\
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M[^2[(G+0@H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M2B@/@J5)D2<Y6M4D)$B<L1JA4J.+3IR"@6YB,..-$ LHL-O2(8Q!#:WIO>U
M15R/M)&6I"Z-V/2%LP>BRS$=GI F,%&FA:>4:%.<:O&4.SD:6(%U!"=&4-(L
M"2,'?Y=K"O;I8^G%K:<%CYOS5##MX)1\ZF(<*3C/4U)/A['+&1M,8T8W#O\
MES0XN3LL2J5PK'=S6F$*BE/>9ZDDNQ:NY1H23R2R+FE$CL3OZEFQ9<4HIT=S
MSQ(MM[N*A\&?/)MG]Q_]JY]*0 O\I3) V:W+\M@*.Z-YW^5A"N*]OEY7KE&S
MA9S?^RPM.^UDO]#R#2Q;Z'K/F4U5K_=A:7$+$ 7Y;= DY4"UK_DN$5ORVO5V
MEA97F0V7C:</-X\UZ$J/2\RK)<AO?[NSQ+S#@CO?Y>=DZ%,+E?\ )TKWY?AO
M\M3;>"2X(;"JWS*DCU=P@CO80H<):9;Y3%S](3[BO^41=G4LB_/\/,G_ /N]
M-NU7HB[%GCYN+N180Q"W\N]\=1,?1^2ZQH3.-_\ SNX!5<__ #YU-JU5]NPV
M;*P^>Y=R*&0]MY>#HG&D'1Y='O)B:TO+E\G+N"4OER_!RI%N]LL%19%Q@  L
M-@%@"  ?0$  V"&UOR6"&UK6_P#*U0IRH!0"@% * 4 H!0"@(-0C_B5;._0<
MT6_?UQ$:%P7%]D:!/LIO\17]9S^'JAOZ>/+Y/1]H]]Y7J#]%W '[IXE0P[WQ
M?<@?Q,,1S^:97P1,<<X8?,J2]GCN2(S%D;Q%8CDC"TF>WB#S9P28_P ELSHL
MCDRQ.)Y>VV,";,T1.<Q=I9DZAP=)*%V>H/!$(A;.*<D[ZPW8=&\%)MF&LRZU
MY$EF97V38YU=D[!%FQ7+#\]0Y>SP@U+EJ-J]\M;<[SX,6R,9(4[OGM1L;BG&
MN1UZ?'$[)5QV%LCV/%:A7CTYW4Q-^%BDKYRG/VM0AN<%$MY9JUEI2KRLK2ZX
M20MLR\0Z)M+4-V:'$&::RD_:6;9'<YR\HQO(/(Z3+$[QCO.9?BX$;DD38Z\1
MW!(BG29BAZX2,(;KZ-0NNY=:LWYS)#+'**OZ""2%GB<Q5M:LB-260QE1,V-C
M>#"[A1N3K%$DCB"F0(DQO(P]K(E#":K!:Y87-+>_=+#)ITT;QKO<LQ7D\Z,[
M::]L;:#<??1(K0.VF$MD*E1(T.Z6=TDK>R'!/M^P!2M<ADI#J^,[ -$J/C+4
MX(X^H?)&>VF/SB-MV8W6KK/^2HOM9,OR6<0WKEZT=A6:?&U0D;'MM?DOT'DL
MXAO7+UH["LT^-J@C8]MK\E^@\EG$-ZY>M'85FGQM4$;'MM?DOT'DLXAO7+UH
M["LT^-J@C8]MK\E^@\EG$-ZY>M'85FGQM4$;'MM?DOT'DLXAO7+UH["LT^-J
M@C8]MK\E^@\EG$-ZY>M'85FGQM4$;'MM?DOT'DLXAO7+UH["LT^-J@C8]MK\
ME^@\EG$-ZY>M'85FGQM4$;'MM?DOT'DLXAO7+UH["LT^-J@C8]MK\E^@\EG$
M-ZY>M'85FGQM4$;'MM?DOT'DLXAO7+UH["LT^-J@C8]MK\E^@\EG$-ZY>M'8
M5FGQM4$;'MM?DOT'DLXAO7+UH["LT^-J@C8]MK\E^@\EG$-ZY>M'85FGQM4$
M;'MM?DOT'DLXAO7+UH["LT^-J@C8]MK\E^@\EG$-ZY>M'85FGQM4$;'MM?DO
MT'DLXAO7+UH["LT^-J@C8]MK\E^@\EG$-ZY>M'85FGQM4$;'MM?DOT'DLXAO
M7+UH["LT^-J@C8]MK\E^@\EG$-ZY>M'85FGQM4$;'MM?DOT'DLXAO7+UH["L
MT^-J@C8]MK\E^@\EG$-ZY>M'85FGQM4$;'MM?DOT'DLXAO7+UH["LT^-J@C8
M]MK\E^@\EG$-ZY>M'85FGQM4$;'MM?DOT'DLXAO7+UH["LT^-J@C8]MK\E^@
M\EG$-ZY>M'85FGQM4$;'MM?DOT'DLXAO7+UH["LT^-J@C8]MK\E^@\EG$-ZY
M>M'85FGQM4$;'MM?DOT'DLXAO7+UH["LT^-J@C8]MK\E^@\EG$-ZY>M'85FG
MQM4$;'MM?DOT'DLXAO7+UH["LT^-J@C8]MK\E^@\EG$-ZY>M'85FGQM4$;'M
MM?DOT'DLXAO7+UH["LT^-J@C8]MK\E^@\EG$-ZY>M'85FGQM4$;'MM?DOT'D
MLXAO7+UH["LT^-J@C8]MK\E^@\EG$-ZY>M'85FGQM4$;'MM?DOT'DLXAO7+U
MH["LT^-J@C8]MK\E^@\EG$-ZY>M'85FGQM4$;'MM?DOT'DLXAO7+UH["LT^-
MJ@C8]MK\E^@\EG$-ZY>M'85FGQM4$;'MM?DOT.(L7<0L 1#'N;K,   W$,8M
M%IF$(0AMS$(0K[M6L$(;6O>][WM:UK<[^B@C8]MK\E^A#K(NP6X<<>A0;&.W
M6 \]9-,N,I/#\9:'S9V2)C@"L 8GJ3IMU%;6WI2!\P+C4('=0W"#?O\ 2)B^
M9@=KZ;<WZ56U+)8_V9=NQ<K-IO=:4/\ P,K/&O>_FQN-?!F7=AX7@UT5M9!(
MH_!\=KY"UKU9G+OXZ6M#/DR,*S$IY=Q!)82,E/C<6'N(E KJ"SN[7:L6?XJ+
M]UKX1B#M/U12]J>'&[G!\"MXKT]VYPJT^",:[,:HQHLPH!:UP)T/FJI]=>AR
MO83L^K=W%#LX_;VN8 I2K&G($*]DQ)!?(%LNU:M7N)T2^FKK-K\E^AE;R6<0
MWKEZT=A6:?&U62QL>VU^2_0>2SB&]<O6CL*S3XVJ"-CVVOR7Z'2<<?;^M"(]
MQ==VM7&QO2@N8I7+]'I<D2)R[?*,Y0HW=+*+#^#F,=K7O>UK>F]!&Q2U^:_0
MPDVS/?-ZE2%J@.Q.$LOMJ1P)#)%#)IA*X"T 16%:ZA.DFCYMM)T:%:,%A6)4
MJ8VN37MR-3$N%N15][,/Y.&Z]^9F';LN5BS:;JVFO_%=T9=RQK1L_EHEC7!V
M-Q]$5B98-6[1B1X7DV38<858'_54;>DCV;<*FIS"17O=0N5!<59]@@*"I""P
MQG3:A*RH;\?/)$5F<;<;6Y.'=/L=AEP?OI'&\EJ8-M]66=M3VY$HF[0N7)$X
M;\K6$.Y9.ZX+#-'RM<PT?2--%]L8,0KWO6;YLZ+85UFU^2_0JODLXAO7+UH[
M"LT^-J@C8]MK\E^@\EG$-ZY>M'85FGQM4$;'MM?DOT'DLXAO7+UH["LT^-J@
MC8]MK\E^@\EG$-ZY>M'85FGQM4$;'MM?DOT'DLXAO7+UH["LT^-J@C8]MK\E
M^@\EG$-ZY>M'85FGQM4$;'MM?DOT'DLXAO7+UH["LT^-J@C8]MK\E^@\EG$-
MZY>M'85FGQM4$;'MM?DOT'DLXAO7+UH["LT^-J@C8]MK\E^@\EG$-ZY>M'85
MFGQM4$;'MM?DOT'DLXAO7+UH["LT^-J@C8]MK\E^@\EG$-ZY>M'85FGQM4$;
M'MM?DOT'DLXAO7+UH["LT^-J@C8]MK\E^@\EG$-ZY>M'85FGQM4$;'MM?DOT
M'DLXAO7+UH["LT^-J@C8]MK\E^@\EG$-ZY>M'85FGQM4$;'MM?DOT'DLXAO7
M+UH["LT^-J@C8]MK\E^ABC6B/YFCG$'VL19QR;!<JRHW3?1Y4W2" 8F=,.LZ
M*/CS9Q 2DS.JC3ME/+:A>Y$.)+HM-?"Y$A)4)5Z1 %E(&W&+G '""@FIN]QP
ML[EV-+?V4W^(K^LY_#U0U]/'E\GH^T>^\KU!^B[@#]T\2H8=[XON2BH04 H!
M0$&N'U_@WECZ<O$9_P!>6Q-"N_DNR)RT(* 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!9#WDJ 1N3L\,?YA'V
M:4O[:XN[0R.3DG2+%C:TAZ:]8 )PP +)* $XP%SQE74EI%YB6QP&Y<)/8.$8
M2NYLD4KV1<FV[4.\.'P/ T7?MA\BVYE^#X* 5X@U#N*Y=E+Y-!$G-I2$L=["
M$L;P+F[T")4N2$?VX=JQC::LK?>^"O([6%F;\\^2T@ZY9_S^(*_:3* XQ$%
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M%O3$HTA +?\ *2G3@+*+#S]-[!!;G>][W]-ZP;.]0"@% * 4 H!0"@% * 4
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M3#L"YH_N+4G59/42H\UH/)YQ(^MIIAV!<T?W%J3JLGJ)4>:T'D\XD?6TTP[
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M@\@VCM.Y26XJL)7S>\SO:UK6M:UK6M:UK6M:W*UK6]%K6M;T6M:WR6K)H_:
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * @U"/^)5L[]!S1;]_
M7$1H7!<7V1H$^RF_Q%?UG/X>J&_IX\OD]'VCWWE>H/T7< ?NGB5##O?%]R2R
MEP0(C4!"Q<C2'NBL2!L)4J22#7%<%&K<1(D!9HP#6*PMZ!<N$F3V,.LC1*U-
MP=Q3'# (=OI6YWMSMS#Z16YVYVY_)S_)S_SH#\Z0?M?M@_;_ '/IM]MZ+B^U
M_+]K:]_1S]%KW^2@.5 0:X?7^#>6/IR\1G_7EL30KOY+LB<M""@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0%'<I%'V:U[O#ZSM5
M@VYBNY.:)#:UORWNJ/*Y6_SO2#=RB2*JLS'CGGC#K1TN^\AQLRX.?2LVK!/-
M^=OEM:S.6NN*_P#D&U[\_1\M:V;5/CN3:LU++-VGQ:88(IB#+96:&][6+CT6
M<3ACO^"P0N%FV_I_!TK!IL/<N+)MK>S$RC<<<V<G>!X9A+@]Y%)(5EE)'BZ9
M2!@.3#[D>LD3,TK[G)R$9G^S,3KGAF"-6(I()84:8 (];$%&TX+=CP<ODFW@
MK,_,##L UWSX&?*<N9)C4>R9DTTX V.0Y1>$BACAZ8L5S4Y47AD<<S6]I,3'
MC&<F-O8VZ$SH'-Z=$K$J4JJ[5F$$W96*49X3<)^2(E:C&$7OAJ2W\6MH'7TK
M\CX_BP1_= CL;->!EVO_ ,MKOB(/IM;\-CK^GY!W^6LQL4;\W,U"W5><AY#I
MZY?^\NP.0581_P"]+CI2>*@%:_W0;62*E8.5[>CTE\OR@Y>BFTL+*[_ V7C:
M?]YU\1R!JSC50,)D@7S:6F6OS$.12M:?<=_P](2 MN%;G_W16O\ YU-MX07!
M#86\QV9IDREN1B]KG+DU "N&L;TY#.6;=M#91<]*22I.=1'F726Z "SS17.'
M<NQ@Q7'>]ZZ+ZS2ALJZ''_9-C?T_LF>G+-*3D%'GW4GEDE%G*;EA*NH-  (3
M#[E ^T+N:.US+E@^U!TNB'T6M7$Z'VH!0"@% * 4 H!0"@/RXK!M<0KV#:WR
MWO>UK6_\;W]% <0F 'SZ P#Y?+T16%RY_)SY7ORH(QN.= * Z*]T;&HFZET<
M4+:GMSYGKU:=&3;E\O,U086"W+\/,5 8F?-CM>8QT_&3/&&H_<OGT[/63X2U
MB#>WRV$%:^$"M>WY.7/GZ.56#H\F(JMUYAQ\XAFDD>Z??^S&*U'0Y]+P&_\
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M% * @UP^O\&\L?3EXC/^O+8FA7?R79$Y:$% * 4 H!0"@% * 4 H!0"@% *
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M4GW#8H@T81#L4 H!0$&N'U_@WECZ<O$9_P!>6Q-"N_DNR)RT(* 4 H!0"@%
M* 4 H!0"@% * 4 H"B#D;$6_@BYCHD!(#&LQZ U",Y*A-92BR4:SHWMT+%V/
MO<%K7'8P5@&#""Y91@@6#A&$HPCOO@-V):4BS!B^*=T"^SF/)3BN?=$9"\#D
MX Y?+83<UV6+K7_!:UT]N=_1;G>U%9;P,[5E8_/8QF+91J>!"*QYC_(60#>=
M[ 5MS$<WLM^7HM<UR5!,.3!Y^BXCV\ ;<_3?I?:UK8JTB;=$WYS./AG9Z5>A
MNBD$QJB-^V"?(70Z1.Y9=_DN6!K[NC[K:U^?<U;<5>XK6L+N7IYST*]M\H>9
MA[;N4//+AY#IS(_MLAYPFCH4;Z3VJ)%I8BW7M_\ )'9+W<E25^#F- 2*]ODL
M$7V]-I*ZRN<QLMWVN2EYD7.P:YX=CXPGEPY&[K.?2,62,]4_&'#^6XS4[B<<
MW]*]_3>Y:,NU[WYWM3:M/'SN56;*PCQ\@9C0MS>UIP)&Q"C;DA?W"9"F)2)P
M?@^T)3@++#Z+<O0&U9-0A<=R@% 42026.1)L/>Y5(&2,LR6W-2[R!U0,K8GM
MRO?F>O<CTR4JW*U[\S#0^BU[_):] 04R+Q0]+L?K+LZ/*MLGR89MR$<:P\R.
M>0EKD?;G:Q+>[M)-HD>:(5NB N\C+$9>_,%A L(0=;-JAG:7/@_/*FMG?+;W
M:+-F((^'$VLVT>!H8GR*T.1>4')2^PV72,%HY*TZ2-#AD8(\, 8G&RJ[T:[W
M?5[*%:RMB<81JE: VVK*49M.5U_G^Z&;3BKFIX\*%H</EHXEF26')A4,SPNQ
MPUHG>-EN;GGV.2G($@-4J$;J(J\(33=N=FXA*025>[T6$U/W4\QKN:$=@@$&
MVME0BLOFXEB,'!PU\OY&P%VT]VY6MJU]S'Q/,B-+0A3&K7@^!X^BF)V]L1DA
MN-2>8_M<@1D)B"@6N*Z@QN2@)M;I7M64UA8C'"_A W!J;M=H;K_.Y!/S-%.S
MTK%&\1YPVMRE"VIPNEFV=LX93<U<%/&5?_K+?"8P6T-[N]J[!$$7-4[FW,$(
ML"A.T(#2'D_I'87J23PLJ^>+O2_J:,0VG)O>WOPPR^#8WCKA*:.P5I;DSKB?
MRA/Z8H/A"33232U:>ZJKWN,TXQC2OR6-)2>F(024Y#3TPD6+ I4+#@C4F<G;
M?#=_LVK*6$2448U$U7AG<Q1G7/";4>5RZ"TK&<0.<K='Y.DZ*FD]Q'R^6UQJ
MA>GT_+Z:D75YLL%19&>&QH:65*%$S-;<THP<N@D;$29 E!RMRMT4Z4HHH/*W
MHMR!;T5"E1H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% 0:A'_$JV=^@YHM^_KB(T+@N+[(T"?93?XBOZSG\/5#?T\>7R
M>C[1[[RO4'Z+N /W3Q*AAWOB^YKZXH4#?G[+FNLMCF*9-EJ3QYJR,C@T.=L4
MRK)F+Y;+#X--G=#%FV88[=&:9ZT9<<7=GC1$;SPI>6B,18E8CG;A=T+Q.L3I
M!;-SG!2C6$878WW*<H8E_9XP.\J)YO0J-;,TK,?9>QOHN8M<VIAE.P@UHXUG
M;-RW,$=A6-)=*5!"^'L\&7L:F<XLQXG,((C4A=7"*XVF$K?0QB4!&ZZ3>ZD)
MJ&.,>A$$S$&3E;&J;3M>I$E4)H."&</M_@VO#UC%#C#);1M#D1]<LV32!,3(
ME;-69+.H@[89F,L?Y8BQTEET<A$T2C:V17(U>-!//.7B+'?_ -IS:@L<8.,H
M\KST!3(J8GQ5_)Q\OC37-S&M4"+.,R:71^BJ)Z$7>R%0_LS(]QMW<VLLWD)4
MC;GYI5G%\P$KDXKV'88-.NC3'Q"#<5Y/%%<H::H6H.X^^A:PJ08'S:ZN!LG*
MW2SN7,%B8]NV.9TQ#"NE(7A9&FTU.I<&F/GMK8Z.KTXI53LL&G"CN6.Y;B9?
MB]Q*OG=T;[.F>_BDH25'FM!XO<2KYW=&^SIGOXI*"5'FM!XO<2KYW=&^SIGO
MXI*"5'FM!XO<2KYW=&^SIGOXI*"5'FM!XO<2KYW=&^SIGOXI*"5'FM!XO<2K
MYW=&^SIGOXI*"5'FM!XO<2KYW=&^SIGOXI*"5'FM!XO<2KYW=&^SIGOXI*"5
M'FM!XO<2KYW=&^SIGOXI*"5'FM!XO<2KYW=&^SIGOXI*"5'FM!XO<2KYW=&^
MSIGOXI*"5'FM!XO<2KYW=&^SIGOXI*"5'FM!XO<2KYW=&^SIGOXI*"5'FM"V
M)$Z;^1$KNTGV"T 8@]'I@ Y8&SDE/.M__'3&;464J17Y7Y (*,'?E?D&_*]5
M)NY$=JRK^Z[0,+*,[<0%Q4B08]FNI^2EH3+ $..ZK[#$MA5_^:ZA<NV?)-(#
M:WIL9="(F]OMKFA!>PKZV'BTO,NIG;LW)6GP:T);Q$6YLF8$*>8J<2PEVN7S
M<7QBCKHD-.N.UN0VZ,N<OR.4BZ/IO<AQ?33;7O:PC B#<-YZ%6UT7F9/6[EL
MK?/X^#"3_K3GN2NZI\?7.-/KNHZ #5;J]+AIU0"0V+)(4$("6U2%ON  0&)$
M*IO-L1<8"#TQU['![?\ )]/9V4K2Y*3K?,SL6KWSG/@=>.:\;KQ:Q8F:1</H
M@\NP;@5*]:,].ZTL5N7I+<'?:18L#?G_ ,P307O^&UODKAM6JOMV.NS87^/6
M/=&3 QSB4 "$ ,MZ,A"&U@A"'7//80A#:W*U@VMM':UK6MZ+6M;E:U0LJ/-:
M'+Q>XE7SNZ-]G3/?Q24$J/-:#Q>XE7SNZ-]G3/?Q24$J/-:'0<T?$794*ET>
M<W:&-+8C+N<L<7/ &<T"%*5;Y35*M5M04G(+MSMS&:8$-OPWH)4>:T(19.XA
M>5L6&F(7/<SA]2Y\"9W A@QCK=L3D=P5*^ET.\BU<3V;<F),K[I_LNY.+PAY
M&_[$0K&_:5I6;3PSD9=JPJY_T6?C_=+B\94D!'DTUAQ=)H,;T1%2F<8.R5@T
MI>3<=K75(54SV=>FLY%W/F8 ]"J=%)G+N84'=[7*LV4K[2Y3&U&ZS:YM0QW;
MH$DI%A?BQ9E9UHY+L[A+7/OXJ]TD8Q!#'>1'INZ>BQ;E)WD),@0J$X;BO>\?
ME2@H\5@\E)?.URK&PKDWQ?\ 7=9$A:=[2X>4QZ$5V;A![)*GNTFS%GG FR4B
M"<8<6Z9PA&S#_<D0S.D$(28_M%&0J"K!L"QA#D->G.$&]QE="X2@3:>$%P1=
MFSCM/C:7Z[R<F.M==R\0H[(<6KN&_CY/<NQ1OBCJ5F%A/5!MRYW7*V_9<A6O
M,%>UKF'+3SSC!6Z1A@A>FLQ;O<2^E7*'-?J9+-8^)*268<=F'1@DDD S333=
M=\]%EE%EAN,9A@Q[2V"   VN(8Q7L$(;7O>]K6O>A94>:T,!YESINQA2/-SP
M_P"=M&7QUDB<@V$Q&*Z[9V>I)-!K.C9 )C1I=J!A&WJQC+"!X.,+;;],!9)Z
MA4:G2GZLV7:<%*K<DN/D2.U95<UH6Y*L [[;71F%27*$SPOC4A$I;G%5AA_A
M61UT*>@$(^D:ND<=BN4XY*6]:M7B+4I$#GD)V7,B0!J(13>K/5<][5FQ*Q-X
MVVO_ !H82=J=J,,$G#.3UX$C6.!<1",M#>P1W)&A;&R-28M&V-+5K3G1 WH$
MI5N19"5(FV@+()+#Z;]$ +6N*XA7YB%>]^48S<V=/31YK0JOB]Q*OG=T;[.F
M>_BDH)4>:T'B]Q*OG=T;[.F>_BDH)4>:T'B]Q*OG=T;[.F>_BDH)4>:T'B]Q
M*OG=T;[.F>_BDH)4>:T'B]Q*OG=T;[.F>_BDH)4>:T'B]Q*OG=T;[.F>_BDH
M)4>:T'B]Q*OG=T;[.F>_BDH)4>:T'B]Q*OG=T;[.F>_BDH)4>:T'B]Q*OG=T
M;[.F>_BDH)4>:T'B]Q*OG=T;[.F>_BDH)4>:T'B]Q*OG=T;[.F>_BDH)4>:T
M'B]Q*OG=T;[.F>_BDH)4>:T'B]Q*OG=T;[.F>_BDH)4>:T'B]Q*OG=T;[.F>
M_BDH)4>:T'B]Q*OG=T;[.F>_BDH)4>:T'B]Q*OG=T;[.F>_BDH)4>:T'B]Q*
MOG=T;[.F>_BDH)4>:T'B]Q*OG=T;[.F>_BDH)4>:T'B]Q*OG=T;[.F>_BDH)
M4>:T'B]Q*OG=T;[.F>_BDH)4>:T'B]Q*OG=T;[.F>_BDH)4>:T'B]Q*OG=T;
M[.F>_BDH)4>:T'B]Q*OG=T;[.F>_BDH)4>:T'B]Q*OG=T;[.F>_BDH)4>:T'
MB]Q*OG=T;[.F>_BDH)4>:T'B]Q*OG=T;[.F>_BDH)4>:T'B]Q*OG=T;[.F>_
MBDH)4>:T'B]Q*OG=T;[.F>_BDH)4>:T'B]Q*OG=T;[.F>_BDH)4>:T'B]Q*O
MG=T;[.F>_BDH)4>:T'B]Q*OG=T;[.F>_BDH)4>:T'B]Q*OG=T;[.F>_BDH)4
M>:T'B]Q*OG=T;[.F>_BDH)4>:T'B]Q*OG=T;[.F>_BDH)4>:T'B]Q*OG=T;[
M.F>_BDH)4>:T'B]Q*OG=T;[.F>_BDH)4>:T'B]Q*OG=T;[.F>_BDH)4>:T,3
MZT(\XH>(/M85GV1XHD\N%IOH\8V+\/PJ7P6-DQR^;.("%*D7M,TGV17-2]@<
MPNQRAP3O25 :@/;DQ;82H2J52P5P@H1O?:SN1I;^RF_Q%?UG/X>J&OIX\OD]
M'VCWWE>H/T7< ?NGB5##O?%]R45""@% * @UP^O\&\L?3EXC/^O+8FA7?R79
M$Y:$% * 4 H!0"@% * ^*A0G2$F*51Y*9.2&XS3U!H"22@6^41AI@@@ &WX1
M"%:UORT!A>1[$XDCAMTHI20_.-Q=S*;8L2;(%)YO/EW$L] $;=8WI?:]S-7%
M"Z7HY<[7Y:5FT\(<?(F7:LK&/#R!:OE8S!+OM<>897-J,STE/V1UH&1/8L7W
M!MV0LPA:<"]KV%82-<JZ5K^@-[6Z5["RK[4>'FA-JT[K.?B'DLS/+OML@9D4
M,J,S_>L.-D-F@NP!?=E6?C@)EXP<OM+@5)%816O>UQ='T"D;*NLY^?(V;3OM
M9>(N>.ZYXDCQME@XR"1N=Q=,USEJDZ0*#S/E[J:G67NV=TY_;=,MO+%<7IO?
MT!Y':M/&'#R)58LK?Q,U)4J5$06E1IB$B8D/0)3I22R""@V^0)9)00%@#;\@
M0VM_E631]Z 4!\5"E.C(.5*SR4J5.6,Y0I4&@((()+#<1AIQQH@EE%@#:XAC
M&((0AM>][VM:@(;93XAFF>'KJ");GR$+71-T@#8H4K/R"\V4A]%D9Z.%)WVS
M<I%?E;HNIJ !?.PCC"P7Z5:V;3P^.Y-I5ONA/L1[_P"D1RWE/_8:K:.9WR8F
M5?[)!-LF ;L.P,X0ON5B1X=[N:%S2!M>P[DFNS*JN"]KF=PO</2NRE?:2X39
M-J-R?/R? >3SBKYH^VF>;,&ZIQU9]J:SXGB*C(\W(37^4E8Y2<Y0W$++!Y6[
M^CTM2WN980P%D%\BAHV%@WT\R$+3Q2X3\CIO.^V<*?#,B7)GW8S*6>MH7\HR
MQYE\HY+?"8Z6?;Y/!C*P*$#DW)K<[V"B%(UB8)5^X!!8CF7>;;P27!>=ALK&
M+X^<_&3=QCKI@;"Y10,58@QY!#BB^YW<H]%6E&^'AZ/0_P"NO_>PWM>.X?M;
MF+G!09</HN*]JC;=[-))7&3'N2QR-)^^Y'(&2/I>5Q=\O;J@:D_1#]T+NR\\
M@OE;E?G?I<K?AJ0C<(I7N!@.3;CZOQ+NEG;-<)4"*YV&".KCY>9:]OE#8$23
M/8KBM>W*X;6YVOZ+\KUI6+3NLO(SM6:F)Q\07$[L,1&-X%FW+*BXK@(O!<<+
MU28TSGRM80W%4WK"PWOZ.8&\TRU^5NY?+RU_Q6E_)V;.,VO/C>3;6";.'G&[
M5RK[3'^F<@;BA^DMTR7/&:*]S#?Y!*&%<E:UENC\HRR7 PW_ )0E\_338L*_
MZBY*(VK3NLY^(Q%G6&\0G*V+I2W.Q6(HRRB174KX/CEQD8YK*$!%[C4L7A!=
M9R;E0#RKB,4($;LWB=[$6;K%J *A(U.K+^DK2_D][A!<N.1'MM4W*]]RL: Z
MJO&.6@_*N6&%O\=GY&VE0M ]HCU4F@T?3D*07N,U8H&2RKG@E24&[:F0E.36
M@( E5+2C%BUJ2/JVTW"RY8PN;^>./),MBS";4\//.ILWKB;% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * @U"
M/^)5L[]!S1;]_7$1H7!<7V1H$^RF_P 17]9S^'JAOZ>/+Y/1]H]]Y7J#]%W
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M$\%[?((*ASQ:ZGA':_R#"9T_^]3_ )+/L_\ V]!L?=A"Y=9SYF0&W1K<V/\
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M_P#RH#E0"@% * 4 H!0"@% * 4!Q",([<P""*W/ES#>PK<_R<[7OZ?3:@.5
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MG9<XFD\70]KE"%'@8G'JF:Q0;NY1B)327^"'U<[*TK(=,TR8AQBZUX>"HV0
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MSE&7K'.:69A'#OOEA'R.ZX@OCG$;$J)@\Z?]>LJ,6"E&1<0E[!:I7UCV$>2
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!Y'_LI
MO\17]9S^'JAT^GCR^3T?:/?>5Z@_1=P!^Z>)4,.]\7W)14(* 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * LG(F1H5B>)+IUD)^3QJ*MJY@;%3JI3K5=K.<JD
M+5$HVW)T;:E6N"UP?),^-#&V(D210I6.+BE3$E"&;:U 83\\S77US?O9=EKW
M&H!YYFNOKF_>R[+7N-0#SS-=?7-^]EV6O<:@'GF:Z^N;][+LM>XU //,UU]<
MW[V79:]QJ >>9KKZYOWLNRU[C4 \\S77US?O9=EKW&H!YYFNOKF_>R[+7N-0
M#SS-=?7-^]EV6O<:@'GF:Z^N;][+LM>XU //,UU]<W[V79:]QJ >>9KKZYOW
MLNRU[C4 \\S77US?O9=EKW&H!YYFNOKF_>R[+7N-0#SS-=?7-^]EV6O<:@'G
MF:Z^N;][+LM>XU //,UU]<W[V79:]QJ >>9KKZYOWLNRU[C4 \\S77US?O9=
MEKW&H!YYFNOKF_>R[+7N-0#SS-=?7-^]EV6O<:@'GF:Z^N;][+LM>XU //,U
MU]<W[V79:]QJ >>9KKZYOWLNRU[C4 \\S77US?O9=EKW&H!YYFNOKF_>R[+7
MN-0#SS-=?7-^]EV6O<:@'GF:Z^N;][+LM>XU //,UU]<W[V79:]QJ >>9KKZ
MYOWLNRU[C4 \\S77US?O9=EKW&H!YYFNOKF_>R[+7N-0#SS-=?7-^]EV6O<:
M@'GF:Z^N;][+LM>XU //,UU]<W[V79:]QJ [C;M_KPZNS*R)YXK3+Y"^L<99
M_#$&R&P(EC_)79&PQYI\*OL3;FI.L>GMQ;VAL+5+2._')<D1$7&I4DEC DM0
M"@% * 4 H!0"@% * 4 H!0"@% * 4!Y'_LIO\17]9S^'JAT^GCR^3T?:/?>5
MZ@_1=P!^Z>)4,.]\7W)14(* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * BON
M-_A)$?I4:+?ZW->Z%5_)]F2HH04 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@(N[??X3Q+Z46CW^M3 %"J_D^S)14(* 4
M H!0"@% * 4 H!0"@% * 4 H!0'D?^RF_P 17]9S^'JAT^GCR^3T?:/?>5Z@
M_1=P!^Z>)4,.]\7W)14(* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * BON-_
MA)$?I4:+?ZW->Z%5_)]F2HH0H;Q)XY'CV5,_/K2S*)&Z%,;"2YKTJ(QX>#RC
M3R6MM H,+NL7'%$&B*3$6&:9<-@ "(8@!$@(E<H#%^1,T8PQ.[8T8\AR]!&'
M7,$\0XSQRC5IW%0.239R0+W% S%C0(U9+:%44WF)271Y,;F83PK9F'PAX<?V
M)O<0A&.Z9?8WUD+472&/#4!78Y,FNE&X) J+*%IRE,C(N2(ZQECE:A$L3IBN
MCTSSDBDHH(S"#0A Y&/;,2%S&<[-A0&7HW>1F+TH M/3)"I!X3$(VUD'23C
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MJ=%P&02S &@ :4,!A9@ F%F%BL,!@!VL( P##>X1 $&]A!$&]["M>U[7O:]
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M19(>?#NIUOMHO;_ECWMH(*BR0\^'=3K?;1>W_+'O;005%DAY\.ZG6^VB]O\
MECWMH(*BR0\^'=3K?;1>W_+'O;005%DAY\.ZG6^VB]O^6/>V@@J+)#SX=U.M
M]M%[?\L>]M!!462'GP[J=;[:+V_Y8][:""HLD//AW4ZWVT7M_P L>]M!!462
M(-[GY\SKEOR;>5;-.6LF^+_CCX!\H61IA-/ GA7Q6\*>"/&1Y<O!OA+P:W=_
4]Y]Q[\[P1=\=T[U([F+!*Y0/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6793711904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Feb. 24, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMED<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMEDISYS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000896262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,607,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,010,513,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6794128272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 30,197<span></span>
</td>
<td class="nump">$ 27,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable, net of allowance for doubtful accounts of $17,716, and $16,526</a></td>
<td class="nump">166,056<span></span>
</td>
<td class="nump">125,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">7,397<span></span>
</td>
<td class="nump">8,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">11,260<span></span>
</td>
<td class="nump">14,641<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">214,910<span></span>
</td>
<td class="nump">175,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $138,650 and $141,793</a></td>
<td class="nump">36,999<span></span>
</td>
<td class="nump">42,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">288,957<span></span>
</td>
<td class="nump">261,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization of $27,864 and $25,386</a></td>
<td class="nump">46,755<span></span>
</td>
<td class="nump">44,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetNoncurrent', window );">Deferred income taxes</a></td>
<td class="nump">107,940<span></span>
</td>
<td class="nump">125,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, net</a></td>
<td class="nump">38,468<span></span>
</td>
<td class="nump">32,802<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">734,029<span></span>
</td>
<td class="nump">681,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">30,358<span></span>
</td>
<td class="nump">25,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="nump">82,480<span></span>
</td>
<td class="nump">72,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">63,290<span></span>
</td>
<td class="nump">71,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations</a></td>
<td class="nump">5,220<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">181,348<span></span>
</td>
<td class="nump">175,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term obligations, less current portion</a></td>
<td class="nump">87,809<span></span>
</td>
<td class="nump">91,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">3,730<span></span>
</td>
<td class="nump">4,456<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">272,887<span></span>
</td>
<td class="nump">271,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies - Note 10</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common Stock, $0.001 par value, 60,000,000 shares authorized; 35,253,577, and 34,786,966 shares issued; and 33,597,215 and 33,607,282 shares outstanding</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">537,472<span></span>
</td>
<td class="nump">504,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock at cost 1,656,362, and 1,179,684 shares of common stock</a></td>
<td class="num">(46,774)<span></span>
</td>
<td class="num">(26,966)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="num">(30,545)<span></span>
</td>
<td class="num">(67,806)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Amedisys, Inc. stockholders' equity</a></td>
<td class="nump">460,203<span></span>
</td>
<td class="nump">409,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">939<span></span>
</td>
<td class="nump">868<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">461,142<span></span>
</td>
<td class="nump">410,436<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 734,029<span></span>
</td>
<td class="nump">$ 681,715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3-4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3<br> -Subparagraph a(1)<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 4<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 12<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of noncurrent deferred tax asset attributable to deductible temporary differences and carryforwards. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31928-109318<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 25<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and capital lease obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section H<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and capital leases due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 27<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=51662447&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6793777440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Patient accounts receivable, allowance for doubtful accounts</a></td>
<td class="nump">$ 17,716<span></span>
</td>
<td class="nump">$ 16,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, accumulated depreciation</a></td>
<td class="nump">138,650<span></span>
</td>
<td class="nump">141,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="nump">$ 27,864<span></span>
</td>
<td class="nump">$ 25,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued</a></td>
<td class="nump">35,253,577<span></span>
</td>
<td class="nump">34,786,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding</a></td>
<td class="nump">33,597,215<span></span>
</td>
<td class="nump">33,607,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock at cost, shares</a></td>
<td class="nump">1,656,362<span></span>
</td>
<td class="nump">1,179,684<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6794357776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationPatientServiceRevenue', window );">Net service revenue</a></td>
<td class="nump">$ 1,437,454<span></span>
</td>
<td class="nump">$ 1,280,541<span></span>
</td>
<td class="nump">$ 1,204,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServices', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">833,055<span></span>
</td>
<td class="nump">725,915<span></span>
</td>
<td class="nump">691,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">306,981<span></span>
</td>
<td class="nump">279,425<span></span>
</td>
<td class="nump">292,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="nump">16,401<span></span>
</td>
<td class="nump">11,824<span></span>
</td>
<td class="nump">5,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other</a></td>
<td class="nump">180,048<span></span>
</td>
<td class="nump">161,186<span></span>
</td>
<td class="nump">143,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProvisionForDoubtfulAccountsForContinuingOperations', window );">Provision for doubtful accounts</a></td>
<td class="nump">19,519<span></span>
</td>
<td class="nump">14,053<span></span>
</td>
<td class="nump">16,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="nump">19,678<span></span>
</td>
<td class="nump">20,036<span></span>
</td>
<td class="nump">28,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charge</a></td>
<td class="nump">4,432<span></span>
</td>
<td class="nump">77,268<span></span>
</td>
<td class="nump">3,107<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">1,380,114<span></span>
</td>
<td class="nump">1,289,707<span></span>
</td>
<td class="nump">1,180,507<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">57,340<span></span>
</td>
<td class="num">(9,166)<span></span>
</td>
<td class="nump">24,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest income</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(5,164)<span></span>
</td>
<td class="num">(10,783)<span></span>
</td>
<td class="num">(8,217)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings from equity method investments</a></td>
<td class="nump">5,588<span></span>
</td>
<td class="nump">9,823<span></span>
</td>
<td class="nump">2,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Miscellaneous, net</a></td>
<td class="nump">3,727<span></span>
</td>
<td class="nump">9,747<span></span>
</td>
<td class="nump">2,061<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">4,226<span></span>
</td>
<td class="nump">8,858<span></span>
</td>
<td class="num">(3,071)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="nump">61,566<span></span>
</td>
<td class="num">(308)<span></span>
</td>
<td class="nump">20,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(23,935)<span></span>
</td>
<td class="num">(2,004)<span></span>
</td>
<td class="num">(7,671)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income (loss) from continuing operations</a></td>
<td class="nump">37,631<span></span>
</td>
<td class="num">(2,312)<span></span>
</td>
<td class="nump">13,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(216)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">37,631<span></span>
</td>
<td class="num">(2,312)<span></span>
</td>
<td class="nump">13,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="num">(370)<span></span>
</td>
<td class="num">(709)<span></span>
</td>
<td class="num">(313)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Amedisys, Inc.</a></td>
<td class="nump">$ 37,261<span></span>
</td>
<td class="num">$ (3,021)<span></span>
</td>
<td class="nump">$ 12,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Income (loss) from continuing operations attributable to Amedisys, Inc. common stockholders</a></td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations, net of tax</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Income (loss) attributable to Amedisys, Inc. common stockholders</a></td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding</a></td>
<td class="nump">33,198<span></span>
</td>
<td class="nump">33,018<span></span>
</td>
<td class="nump">32,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income (loss) from continuing operations attributable to Amedisys, Inc. common stockholders</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations, net of tax</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Income (loss) attributable to Amedisys, Inc. common stockholders</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding</a></td>
<td class="nump">33,741<span></span>
</td>
<td class="nump">33,018<span></span>
</td>
<td class="nump">32,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract', window );"><strong>Amounts attributable to Amedisys, Inc. common stockholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Income (loss) from continuing operations</a></td>
<td class="nump">$ 37,261<span></span>
</td>
<td class="num">$ (3,021)<span></span>
</td>
<td class="nump">$ 12,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Discontinued operations, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(216)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Amedisys, Inc.</a></td>
<td class="nump">$ 37,261<span></span>
</td>
<td class="num">$ (3,021)<span></span>
</td>
<td class="nump">$ 12,776<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DepreciationAndAmortizationForContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation And Amortization For Continuing Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DepreciationAndAmortizationForContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProvisionForDoubtfulAccountsForContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision For Doubtful Accounts For Continuing Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProvisionForDoubtfulAccountsForContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51824106&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to services rendered by an entity during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationPatientServiceRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized for providing services to patients, net of provisions for contractual allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51673510&amp;loc=d3e8184-115640<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51673510&amp;loc=d3e8195-115640<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51673510&amp;loc=SL9156442-115640<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51673531&amp;loc=SL9156464-115641<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51673510&amp;loc=SL9156442-115640<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationPatientServiceRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4613673-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=SL51721675-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=d3e1012-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=SL51721525-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=SL51721523-107759<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=d3e957-107759<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1361-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 13<br> -Article 7<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 15<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=SL51721675-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=SL51721525-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=SL51721523-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=d3e957-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=d3e1012-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1361-107760<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=SL51721673-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section E<br> -Paragraph Question 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35755396&amp;loc=d3e33749-111570<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 9<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 11<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of expenditures for salaries, wages, profit sharing and incentive compensation, and other employee benefits, including equity-based compensation, and pension and other postretirement benefit expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of expenses not otherwise specified in the taxonomy for managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6775962688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Other Comprehensive Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 37,631<span></span>
</td>
<td class="num">$ (2,312)<span></span>
</td>
<td class="nump">$ 13,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss)</a></td>
<td class="nump">37,631<span></span>
</td>
<td class="num">(2,312)<span></span>
</td>
<td class="nump">13,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="num">(370)<span></span>
</td>
<td class="num">(709)<span></span>
</td>
<td class="num">(313)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to Amedisys, Inc.</a></td>
<td class="nump">$ 37,261<span></span>
</td>
<td class="num">$ (3,021)<span></span>
</td>
<td class="nump">$ 12,776<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=51821188&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6796066208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2013</a></td>
<td class="nump">$ 372,479<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 467,890<span></span>
</td>
<td class="num">$ (18,176)<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="num">$ (77,561)<span></span>
</td>
<td class="nump">$ 278<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,413,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">2,433<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,433<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch', window );">Issuance of stock - 401 (k) plan</a></td>
<td class="nump">7,062<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">7,061<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch', window );">Issuance of stock - 401 (k) plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">564<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">564<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">519,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">5,597<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,597<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation', window );">Tax deficit from stock options exercised and restricted stock vesting</a></td>
<td class="num">(579)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(579)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered shares</a></td>
<td class="num">(1,684)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,684)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Sale of noncontrolling interest</a></td>
<td class="num">(1,549)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(493)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Decrease in noncontrolling interest</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(710)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment', window );">Assets contributed to equity investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">13,089<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,776<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2014</a></td>
<td class="nump">397,762<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">481,762<span></span>
</td>
<td class="num">(19,860)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="num">(64,785)<span></span>
</td>
<td class="nump">595<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,569,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">2,204<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,204<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch', window );">Issuance of stock - 401 (k) plan</a></td>
<td class="nump">6,032<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,032<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch', window );">Issuance of stock - 401 (k) plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">399<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">399<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,675)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">11,824<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">11,824<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Tax benefit from stock options exercised and restricted stock vesting</a></td>
<td class="nump">2,073<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,073<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation', window );">Tax deficit from stock options exercised and restricted stock vesting</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered shares</a></td>
<td class="num">(2,525)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,525)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Shares repurchased</a></td>
<td class="num">(4,581)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,581)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distribution</a></td>
<td class="num">(436)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(436)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment', window );">Assets contributed to equity investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(2,312)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,021)<span></span>
</td>
<td class="nump">709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2015</a></td>
<td class="nump">410,436<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">504,290<span></span>
</td>
<td class="num">(26,966)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="num">(67,806)<span></span>
</td>
<td class="nump">868<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,786,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">$ 2,483<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,483<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (in shares)</a></td>
<td class="nump">3,039,200<span></span>
</td>
<td class="nump">63,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch', window );">Issuance of stock - 401 (k) plan</a></td>
<td class="nump">$ 6,682<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,682<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch', window );">Issuance of stock - 401 (k) plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">16,401<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">16,401<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Tax benefit from stock options exercised and restricted stock vesting</a></td>
<td class="nump">7,241<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,241<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered shares</a></td>
<td class="num">(7,493)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,493)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Shares repurchased</a></td>
<td class="num">(12,315)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,315)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distribution</a></td>
<td class="num">(329)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(329)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment', window );">Assets contributed to equity investment</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">37,631<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,261<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2016</a></td>
<td class="nump">$ 461,142<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 537,472<span></span>
</td>
<td class="num">$ (46,774)<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="num">$ (30,545)<span></span>
</td>
<td class="nump">$ 939<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,253,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Assets of Equity Method Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SurrenderedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SurrenderedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from a tax deficiency associated with a share-based compensation plan other than an employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6419406&amp;loc=d3e23524-113945<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4568740-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=51821188&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6795132240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 37,631<span></span>
</td>
<td class="num">$ (2,312)<span></span>
</td>
<td class="nump">$ 13,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">19,678<span></span>
</td>
<td class="nump">20,036<span></span>
</td>
<td class="nump">28,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">19,519<span></span>
</td>
<td class="nump">14,053<span></span>
</td>
<td class="nump">16,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="nump">16,401<span></span>
</td>
<td class="nump">11,824<span></span>
</td>
<td class="nump">5,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionExpense', window );">401(k) employer match</a></td>
<td class="nump">6,875<span></span>
</td>
<td class="nump">6,089<span></span>
</td>
<td class="nump">6,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WriteOffOfInvestment', window );">Write-off of investment</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">582<span></span>
</td>
<td class="nump">775<span></span>
</td>
<td class="nump">4,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnSalesOfAssets', window );">Gain on sale of care centers</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(184)<span></span>
</td>
<td class="num">(2,967)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">24,547<span></span>
</td>
<td class="num">(677)<span></span>
</td>
<td class="nump">22,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DeferredDebtIssuanceCostsWrittenOff', window );">Write off of deferred debt issuance costs/debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,512<span></span>
</td>
<td class="nump">488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings from equity method investments</a></td>
<td class="num">(5,588)<span></span>
</td>
<td class="num">(9,823)<span></span>
</td>
<td class="num">(2,991)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred debt issuance costs/debt discount</a></td>
<td class="nump">740<span></span>
</td>
<td class="nump">959<span></span>
</td>
<td class="nump">797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Return on equity investment</a></td>
<td class="nump">4,323<span></span>
</td>
<td class="nump">5,610<span></span>
</td>
<td class="nump">2,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charge</a></td>
<td class="nump">4,432<span></span>
</td>
<td class="nump">77,268<span></span>
</td>
<td class="nump">3,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of impact of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Patient accounts receivable</a></td>
<td class="num">(55,519)<span></span>
</td>
<td class="num">(36,493)<span></span>
</td>
<td class="num">(5,290)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other current assets</a></td>
<td class="nump">4,231<span></span>
</td>
<td class="nump">6,455<span></span>
</td>
<td class="num">(6,269)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(11,415)<span></span>
</td>
<td class="num">(3,523)<span></span>
</td>
<td class="nump">1,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,970<span></span>
</td>
<td class="nump">7,639<span></span>
</td>
<td class="num">(3,168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual', window );">U.S. Department of Justice settlement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(150,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(7,618)<span></span>
</td>
<td class="nump">8,406<span></span>
</td>
<td class="nump">3,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term obligations</a></td>
<td class="num">(726)<span></span>
</td>
<td class="num">(829)<span></span>
</td>
<td class="num">(3,226)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">62,259<span></span>
</td>
<td class="nump">107,785<span></span>
</td>
<td class="num">(65,534)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments', window );">Proceeds from sale of deferred compensation plan assets</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">1,229<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchases of deferred compensation plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(15,717)<span></span>
</td>
<td class="num">(21,429)<span></span>
</td>
<td class="num">(12,008)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Purchase of investments</a></td>
<td class="num">(1,040)<span></span>
</td>
<td class="num">(3,485)<span></span>
</td>
<td class="num">(6,407)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherInvestments', window );">Proceeds from sale of investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions of businesses, net of cash acquired</a></td>
<td class="num">(35,522)<span></span>
</td>
<td class="num">(69,130)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from disposition of care centers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="nump">4,233<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(52,049)<span></span>
</td>
<td class="num">(67,421)<span></span>
</td>
<td class="num">(14,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of stock upon exercise of stock options and warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">399<span></span>
</td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of stock to employee stock purchase plan</a></td>
<td class="nump">2,483<span></span>
</td>
<td class="nump">2,204<span></span>
</td>
<td class="nump">2,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities', window );">Tax benefit from stock options exercised and restricted stock vesting</a></td>
<td class="nump">7,241<span></span>
</td>
<td class="nump">2,073<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CashDistributionToNoncontrollingInterest', window );">Non-controlling interest distribution</a></td>
<td class="num">(329)<span></span>
</td>
<td class="num">(436)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from revolving line of credit</a></td>
<td class="nump">134,500<span></span>
</td>
<td class="nump">63,400<span></span>
</td>
<td class="nump">241,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments of revolving line of credit</a></td>
<td class="num">(134,500)<span></span>
</td>
<td class="num">(78,400)<span></span>
</td>
<td class="num">(226,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">68,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments of long-term obligations</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(103,000)<span></span>
</td>
<td class="num">(13,904)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,553)<span></span>
</td>
<td class="num">(1,780)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="num">(12,315)<span></span>
</td>
<td class="num">(4,581)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment', window );">Assets contributed to equity investment</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(7,515)<span></span>
</td>
<td class="num">(20,894)<span></span>
</td>
<td class="nump">70,563<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">2,695<span></span>
</td>
<td class="nump">19,470<span></span>
</td>
<td class="num">(9,271)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">27,502<span></span>
</td>
<td class="nump">8,032<span></span>
</td>
<td class="nump">17,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">30,197<span></span>
</td>
<td class="nump">27,502<span></span>
</td>
<td class="nump">8,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="nump">2,897<span></span>
</td>
<td class="nump">6,175<span></span>
</td>
<td class="nump">7,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes, net of refunds received</a></td>
<td class="nump">755<span></span>
</td>
<td class="num">(12,185)<span></span>
</td>
<td class="num">(1,766)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosures of Non-Cash Financing and Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests', window );">(Sale) acquistion of noncontrolling interests</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,549)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashDistributionToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of dividends or other distributions to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashDistributionToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DeferredDebtIssuanceCostsWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred debt issuance costs written off during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DeferredDebtIssuanceCostsWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Assets of Equity Method Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncreaseDecreaseInAssetsOfEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In U.S. Department of Justice Settlement Accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncreaseDecreaseInUsDepartmentOfJusticeSettlementAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Or Part Noncash Sale Acquisition Of Noncontrolling Interests</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NoncashOrPartNoncashSaleAcquisitionOfNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WriteOffOfInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off of investment. This element refers to the loss in earnings resulting from the investment write-off.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WriteOffOfInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51824106&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section I<br> -Subsection 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents disclosure of the amount of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporation; these investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 13<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11374-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnSalesOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnSalesOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35755396&amp;loc=d3e33749-111570<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 9<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 11<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3098-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of pension benefit costs recognized during the period for (1) defined benefit plans and (2) defined contribution plans. For defined benefit plans, pension expense includes the following components: service cost, interest cost, expected return on plan assets, gain (loss) on plan assets, prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments. For defined contribution plans, the pension expense generally equals the firm's contribution to employees' accounts (if the firm contributes) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6783780656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</a></td>
<td class="text"><p style='margin-top:13pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;">1</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">. NATURE OF OPERATIONS</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">CONSOLIDATION </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">AND PRESENTATION </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">OF FINANCIAL STATEMENTS </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Amedisys, Inc., a Delaware corporation, and its consolidated subsidiaries (&#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) </font><font style="font-family:Times New Roman;font-size:10pt;">are</font><font style="font-family:Times New Roman;font-size:10pt;"> a multi-state provider of home health</font><font style="font-family:Times New Roman;font-size:10pt;">, hospice and personal care</font><font style="font-family:Times New Roman;font-size:10pt;"> services with </font><font style="font-family:Times New Roman;font-size:10pt;">approximately</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">78%</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">80%</font><font style="font-family:Times New Roman;font-size:10pt;"> and</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">82%</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">of our revenue derived from Medicare for</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">2015</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">2014</font><font style="font-family:Times New Roman;font-size:10pt;">, respectively</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">As of </font><font style="font-family:Times New Roman;font-size:10pt;">December 31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;">, we </font><font style="font-family:Times New Roman;font-size:10pt;">owned and operated</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">327</font><font style="font-family:Times New Roman;font-size:10pt;"> Medicare-ce</font><font style="font-family:Times New Roman;font-size:10pt;">rtified home health care centers,</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">79</font><font style="font-family:Times New Roman;font-size:10pt;"> Medicare-certified hospice </font><font style="font-family:Times New Roman;font-size:10pt;">care centers</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">and 14</font><font style="font-family:Times New Roman;font-size:10pt;"> personal-care care centers</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">in </font><font style="font-family:Times New Roman;font-size:10pt;">34</font><font style="font-family:Times New Roman;font-size:10pt;"> states within the United States and </font><font style="font-family:Times New Roman;font-size:10pt;">the District of Columbia</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Use of Estimates </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Our accounting and reporting policies conform with U.S.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">G</font><font style="font-family:Times New Roman;font-size:10pt;">enerally Accepted Accounting Principles (&#8220;U.S. G</font><font style="font-family:Times New Roman;font-size:10pt;">AAP</font><font style="font-family:Times New Roman;font-size:10pt;">&#8221;)</font><font style="font-family:Times New Roman;font-size:10pt;">. In preparing the consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Reclassifications and Comparability </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Certain </font><font style="font-family:Times New Roman;font-size:10pt;">reclassifications have been made to prior periods' financial statements in order to conform to the current period'</font><font style="font-family:Times New Roman;font-size:10pt;">s</font><font style="font-family:Times New Roman;font-size:10pt;"> presentation</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">In compliance with Accounting Standards Update (&#8220;ASU&#8221;) 2015-03, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Interest &#8211; Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of De</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">bt Issuance Costs, </font><font style="font-family:Times New Roman;font-size:10pt;">we have reclassified 2015 amounts related to unamortized debt issuance costs from other assets, net </font><font style="font-family:Times New Roman;font-size:10pt;">to </font><font style="font-family:Times New Roman;font-size:10pt;">long-term obligations, less current portion</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Principles of Consolidation </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">These consolidated financial statements include the accounts of Amedisys, Inc.</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated financial statements, and business combinations accounted for as purchases have been included in our</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are </font><font style="font-family:Times New Roman;font-size:10pt;">accounted for as set forth below</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Equity Investments </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of </font><font style="font-family:Times New Roman;font-size:10pt;">50</font><font style="font-family:Times New Roman;font-size:10pt;">%. Third party equity interests in our consolidated joint ventures are reflected as </font><font style="font-family:Times New Roman;font-size:10pt;">noncontrolling</font><font style="font-family:Times New Roman;font-size:10pt;"> interests in our consolidated financial statements. </font><font style="font-family:Times New Roman;font-size:10pt;">During the three-month period ended September 30, 2016, we sold a 30% interest in one of our care centers while maintaining controlling interest in the newly formed joint venture.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold </font><font style="font-family:Times New Roman;font-size:10pt;">50</font><font style="font-family:Times New Roman;font-size:10pt;">% or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. The book value of investments that we accounted for under the equity method of accounting w</font><font style="font-family:Times New Roman;font-size:10pt;">as $</font><font style="font-family:Times New Roman;font-size:10pt;">27</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">8</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million</font><font style="font-family:Times New Roman;font-size:10pt;"> as of </font><font style="font-family:Times New Roman;font-size:10pt;">December 31</font><font style="font-family:Times New Roman;font-size:10pt;">, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">$</font><font style="font-family:Times New Roman;font-size:10pt;">25.7</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">m</font><font style="font-family:Times New Roman;font-size:10pt;">illion</font><font style="font-family:Times New Roman;font-size:10pt;"> as</font><font style="font-family:Times New Roman;font-size:10pt;"> of December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">We account for investments in entities in which we have less than a </font><font style="font-family:Times New Roman;font-size:10pt;">20</font><font style="font-family:Times New Roman;font-size:10pt;">% ownership interest under the cost method of accounting if we do not have the ability to exercise signific</font><font style="font-family:Times New Roman;font-size:10pt;">ant influence over the investee</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">  </font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958256032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style='margin-top:13pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;">2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"> </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Revenue Recognition</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"> </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We earn net service </font><font style="font-family:Times New Roman;font-size:10pt;">revenue through our home health, </font><font style="font-family:Times New Roman;font-size:10pt;">hospice </font><font style="font-family:Times New Roman;font-size:10pt;">and personal-care </font><font style="font-family:Times New Roman;font-size:10pt;">care center</font><font style="font-family:Times New Roman;font-size:10pt;">s by providing a variety of services almost exclusively in the homes of our patients. This net service revenue is earned and billed either on an episode of care basis, on a per visit basis or on a daily basis depending upon the payment terms and conditions established with each </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;"> for services provided. We refer to home health revenue earned and billed on a </font><font style="font-family:Times New Roman;font-size:10pt;">60</font><font style="font-family:Times New Roman;font-size:10pt;">-day episode of care as episodic-based revenue. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">When we record our service revenue, we record it net of estimated revenue adjustments and contractual adjustments to reflect amounts we estimate to be realizable for services provided, as discussed below. We believe, based on information currently available to us and based on our judgment, that changes to one or more factors that impact the accounting estimates (such as our estimates related to revenue adjustments, contractual adjustments and episodes in progress) we make in determining net service revenue, which changes are likely to occur from period to period, will not materially impact our reported consolidated financial condition, results of operations, cash flows or our future financial results. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Home Health Revenue Recognition</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;">Medicare Revenue </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Net service revenue is recorded under the Medicare prospective payment system (&#8220;PPS&#8221;) based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a)&#160;an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits was fewer than five; (c)&#160;a partial payment if our patient transferred to another provider or we received a patient from another provider before completing the episode; (d)&#160;a payment adjustment based upon the level of therapy services required (with various incremental adjustments made for additional visits, with larger payment increases associated with the sixth, fourteenth and twentieth visit thresholds); (e) adjustments to payments if we are unable to perform periodic therapy assessments; (f)&#160;the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (g)&#160;changes in the base episode payments established by the Medicare Program; (h)&#160;adjustments to the base episode payments for case mix and geographic wages; and (i</font><font style="font-family:Times New Roman;font-size:10pt;">)&#160;recoveries of overpayments. </font><font style="font-family:Times New Roman;font-size:10pt;">In addition, we make adjustments to Medicare revenue if we </font><font style="font-family:Times New Roman;font-size:10pt;">find that we </font><font style="font-family:Times New Roman;font-size:10pt;">are unable to produce </font><font style="font-family:Times New Roman;font-size:10pt;">appropriate </font><font style="font-family:Times New Roman;font-size:10pt;">documentation of a face to face encounter between the patient and physician.</font><font style="font-family:Times New Roman;font-size:10pt;">   </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We make adjustments to Medicare revenue </font><font style="font-family:Times New Roman;font-size:10pt;">to </font><font style="font-family:Times New Roman;font-size:10pt;">reflect</font><font style="font-family:Times New Roman;font-size:10pt;"> differences between estimated and actual payment amounts, </font><font style="font-family:Times New Roman;font-size:10pt;">our</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">discovered </font><font style="font-family:Times New Roman;font-size:10pt;">inability to obtain appropriate billing documentation or authorizations and other reasons unrelated to credit risk. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of </font><font style="font-family:Times New Roman;font-size:10pt;">over </font><font style="font-family:Times New Roman;font-size:10pt;">99</font><font style="font-family:Times New Roman;font-size:10pt;">%</font><font style="font-family:Times New Roman;font-size:10pt;"> on</font><font style="font-family:Times New Roman;font-size:10pt;"> Medicare claims, and record this estimate during the period in which services are rendered as an estimated revenue adjustment and a corresponding reduction</font><font style="font-family:Times New Roman;font-size:10pt;"> to patient accounts receivable. </font><font style="font-family:Times New Roman;font-size:10pt;">Therefore, we believe that our reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In addition to revenue recognized on completed episodes, we also recognize a portion of revenue associated with episodes in progress. Episodes in progress are </font><font style="font-family:Times New Roman;font-size:10pt;">60</font><font style="font-family:Times New Roman;font-size:10pt;">-day episodes of care that begin during the reporting period, but were not completed as of the end of the period. We estimate this revenue on a monthly basis based upon historical trends. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and our estimate of the average percentage complete based on </font><font style="font-family:Times New Roman;font-size:10pt;">the number of days elapsed during an episodes of care. </font><font style="font-family:Times New Roman;font-size:10pt;">As of </font><font style="font-family:Times New Roman;font-size:10pt;">December 31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">2015</font><font style="font-family:Times New Roman;font-size:10pt;">, the difference between the cash received from Medicare for a request for anticipated payment (&#8220;RAP&#8221;) on episodes in progress and the associated estimated revenue was immaterial and, therefore, the resulting credits were recorded as a reduction to our outstanding pa</font><font style="font-family:Times New Roman;font-size:10pt;">tient accounts receivable in our </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated balance sheets for such periods. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;">Non-Medicare Revenue </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Episodic-based Revenue. </font><font style="font-family:Times New Roman;font-size:10pt;">We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Non-episodic </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">b</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">ased Revenue. </font><font style="font-family:Times New Roman;font-size:10pt;">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates, as applicable. Contractual adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue and are also recorded as a reduction to our outstanding patient accounts receivable. In addition, we receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Hospice Revenue Recognition </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;">Hospice Medicare Revenue </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates.  The estimated payment rates are daily or hourly rates for each of the four levels of care </font><font style="font-family:Times New Roman;font-size:10pt;">we deliver.  The four levels of care</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">are routine care, general inpatient care, continuo</font><font style="font-family:Times New Roman;font-size:10pt;">us home care and respite care. </font><font style="font-family:Times New Roman;font-size:10pt;">Routine care accounts for </font><font style="font-family:Times New Roman;font-size:10pt;">99</font><font style="font-family:Times New Roman;font-size:10pt;">%, 9</font><font style="font-family:Times New Roman;font-size:10pt;">9</font><font style="font-family:Times New Roman;font-size:10pt;">%, and </font><font style="font-family:Times New Roman;font-size:10pt;">9</font><font style="font-family:Times New Roman;font-size:10pt;">8</font><font style="font-family:Times New Roman;font-size:10pt;">% </font><font style="font-family:Times New Roman;font-size:10pt;">of our total net Medic</font><font style="font-family:Times New Roman;font-size:10pt;">are hospice service revenue for </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> 2015</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">and 2014, </font><font style="font-family:Times New Roman;font-size:10pt;">respectively</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">Beginning January 1, 2016, CMS has provided for two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, beginning January 1, 2016, Medicare is also reimbursing for a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse (&#8220;RN&#8221;) or medical social worker (&#8220;MSW&#8221;) for patients in a routine level of care.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We make adjustments to Medicare revenue for an inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes our historical collection rate on Medicare claims, and record it during the period services are rendered as an estimated revenue adjustment and as a reduction to our outstanding patient accounts receivable</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap for each provider number, we monitor these caps and estimate amounts due back to Medicare if </font><font style="font-family:Times New Roman;font-size:10pt;">we estimate </font><font style="font-family:Times New Roman;font-size:10pt;">a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase </font><font style="font-family:Times New Roman;font-size:10pt;">in other accrued liabilities. Beginning for the cap year ending October 31, 2014, providers are </font><font style="font-family:Times New Roman;font-size:10pt;">required to self-report and pay their estimated cap liability by March 31</font><font style="font-family:Times New Roman;font-size:10pt;">st</font><font style="font-family:Times New Roman;font-size:10pt;"> of the following year.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">As of December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">, we</font><font style="font-family:Times New Roman;font-size:10pt;"> have settled our Medicare hospice reimbursements for all fiscal years through October 31, 20</font><font style="font-family:Times New Roman;font-size:10pt;">12 and </font><font style="font-family:Times New Roman;font-size:10pt;">we have recorded </font><font style="font-family:Times New Roman;font-size:10pt;">$</font><font style="font-family:Times New Roman;font-size:10pt;">0.8</font><font style="font-family:Times New Roman;font-size:10pt;"> million for estimated amounts due back to Medicare in other accrued liabilities for the Federal </font><font style="font-family:Times New Roman;font-size:10pt;">cap y</font><font style="font-family:Times New Roman;font-size:10pt;">ears ended October 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;"> through October 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">. As of December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;">, we </font><font style="font-family:Times New Roman;font-size:10pt;">had</font><font style="font-family:Times New Roman;font-size:10pt;"> recorded $</font><font style="font-family:Times New Roman;font-size:10pt;">1.4</font><font style="font-family:Times New Roman;font-size:10pt;"> million for estimated amounts due back to Medicare in other accrued liabilities for the Federa</font><font style="font-family:Times New Roman;font-size:10pt;">l </font><font style="font-family:Times New Roman;font-size:10pt;">cap years ended October 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;"> through October 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;">Hospice Non-Medicare Revenue </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per </font><font style="font-family:Times New Roman;font-size:10pt;">day </font><font style="font-family:Times New Roman;font-size:10pt;">rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients, third parties and others for services provided and are deducted from gross revenue to determine our net service revenue and patient accounts receiv</font><font style="font-family:Times New Roman;font-size:10pt;">able</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Personal Care Revenue Recognition </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;">Personal Care Non-Medicare Revenue </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We generate net service revenues by providing our services directly to patients primarily on a per hour, visit or unit basis. We receive payment for providing such services from our </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;"> clients, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Net service revenues are principally provided based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> which are recognized as net service revenue at the time services are rendered</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Cash and Cash Equivalents </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Patient Accounts Receivable </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other t</font><font style="font-family:Times New Roman;font-size:10pt;">hird-party </font><font style="font-family:Times New Roman;font-size:10pt;">payors</font><font style="font-family:Times New Roman;font-size:10pt;"> and patients. As of December 31, </font><font style="font-family:Times New Roman;font-size:10pt;">201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">, there is one s</font><font style="font-family:Times New Roman;font-size:10pt;">ingle </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;">, other than Medicare, that accounts for more than </font><font style="font-family:Times New Roman;font-size:10pt;">10</font><font style="font-family:Times New Roman;font-size:10pt;">% of our total outstanding patient receivables</font><font style="font-family:Times New Roman;font-size:10pt;"> (approximately </font><font style="font-family:Times New Roman;font-size:10pt;">10</font><font style="font-family:Times New Roman;font-size:10pt;">.1</font><font style="font-family:Times New Roman;font-size:10pt;">%). T</font><font style="font-family:Times New Roman;font-size:10pt;">hus</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We fully reserve for accounts which are aged at </font><font style="font-family:Times New Roman;font-size:10pt;">36</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;"> days or greater. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We believe the credit risk associated with our Medicare accounts</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">which </font><font style="font-family:Times New Roman;font-size:10pt;">represent </font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;">% and </font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;">% of our net patient accounts receivable at </font><font style="font-family:Times New Roman;font-size:10pt;">December 31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">December 31, </font><font style="font-family:Times New Roman;font-size:10pt;">2015, respectively, is limited</font><font style="font-family:Times New Roman;font-size:10pt;"> due to our historical collection rate of over </font><font style="font-family:Times New Roman;font-size:10pt;">99</font><font style="font-family:Times New Roman;font-size:10pt;">% </font><font style="font-family:Times New Roman;font-size:10pt;">from Medicare and the fact that Medicare is a U.S. government </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;">. Accordingly, we do not record an allowance for doubtful accounts for our Medicare patient accounts receivable, which are recorded at their net realizable value after recording estimated revenue </font><font style="font-family:Times New Roman;font-size:10pt;">adjustments as discussed above. </font><font style="font-family:Times New Roman;font-size:10pt;">During </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">2015</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">2014</font><font style="font-family:Times New Roman;font-size:10pt;">, we </font><font style="font-family:Times New Roman;font-size:10pt;">recorded $</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">9</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million, $</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">.1</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million and $</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million, respectively, in estimated revenue adjustments to Medicare revenue.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We believe there is a certain level of credit risk associated with non-Medicare </font><font style="font-family:Times New Roman;font-size:10pt;">payors</font><font style="font-family:Times New Roman;font-size:10pt;">. To provide for our non-Medicare patient accounts receivable that could become uncollectible in the future, we establish an allowance for doubtful accounts to reduce the carrying amount to its estimated net realizable value.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Medicare Home Health </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients.  Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for </font><font style="font-family:Times New Roman;font-size:10pt;">60</font><font style="font-family:Times New Roman;font-size:10pt;">% of our estimated payment for the initial episode at the start of care or </font><font style="font-family:Times New Roman;font-size:10pt;">50</font><font style="font-family:Times New Roman;font-size:10pt;">% of the estimated payment for any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed (&#8220;final billed&#8221;). The RAP received for that particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of </font><font style="font-family:Times New Roman;font-size:10pt;">120</font><font style="font-family:Times New Roman;font-size:10pt;"> days from the start of the episode, or </font><font style="font-family:Times New Roman;font-size:10pt;">60</font><font style="font-family:Times New Roman;font-size:10pt;"> days from the date the RAP was paid, any RAPs received for that episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be resubmitted. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Medicare Hospice </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services t</font><font style="font-family:Times New Roman;font-size:10pt;">hat we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. </font><font style="font-family:Times New Roman;font-size:10pt;">Once each patient has been confirmed for eligibility, we will bill Medicare on a monthly basis for the services provided to the patient. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Non-Medicare Home Health,</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"> Hospice,</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"> and Personal Care</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient's eligibility for services with the applicable </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;">. Once the patient has been confirmed for eligibility, we will provide services to the patient </font><font style="font-family:Times New Roman;font-size:10pt;">and bill the applicable </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;">.  </font><font style="font-family:Times New Roman;font-size:10pt;">Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular </font><font style="font-family:Times New Roman;font-size:10pt;">payors</font><font style="font-family:Times New Roman;font-size:10pt;"> or groups of </font><font style="font-family:Times New Roman;font-size:10pt;">payors</font><font style="font-family:Times New Roman;font-size:10pt;"> with similar characteristics that would subject us to any significant credit risk.  </font><font style="font-family:Times New Roman;font-size:10pt;">We estimate an allowance for doubtful accounts</font><font style="font-family:Times New Roman;font-size:10pt;"> based upon our assessment of historical and expected net collections, business and economic conditions, trends in payment and an evaluation of </font><font style="font-family:Times New Roman;font-size:10pt;">collectability</font><font style="font-family:Times New Roman;font-size:10pt;"> based upon the date that the service was provided. Based upon our best judgment, we believe the allowance for doubtful accounts adequately provides for accounts that will not be collected due to credit risk</font><font style="font-family:Times New Roman;font-size:10pt;">. </font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Property and Equipment </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Property and equipment is stated at cost and we depreciate it on a straight-line basis over the estimated useful lives of the assets. Additionally, we have internally developed c</font><font style="font-family:Times New Roman;font-size:10pt;">omputer software for our own use</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">Additions and improvements (including interest costs for construction of qualifying long-lived assets) are capitalized. Maintenance and repair expenses are charged to expense as incurred. The cost of property and equipment sold or disposed of and the related accumulated depreciation are eliminated from the property and related accumulated depreciation accounts, and any gain or loss is credited or charged to other </font><font style="font-family:Times New Roman;font-size:10pt;">general and administrative expenses</font><font style="font-family:Times New Roman;font-size:10pt;">.  </font></p><p style='margin-top:4.5pt; margin-bottom:4.5pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We consider our reporting units to represent asset groups for purposes of testing long-lived assets for impairment.  We assess the impairment of a long-lived asset group whenever events or changes in circumstances indicate that the asset's carrying value may not be recoverable. </font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">Factors we consider important that could trigger an impairment review include but are not limited to the following:</font></p><p style='margin-top:0pt; margin-bottom:0pt'></p><ul><li style="margin-left:72px;list-style:disc;"><font style="font-family:Times New Roman;font-size:10pt;">A significant change in the extent or manner in which the long-lived asset group is being used</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></li><li style="margin-left:72px;list-style:disc;"><font style="font-family:Times New Roman;font-size:10pt;">A significant change in the business climate that could affect the value of the long-lived asset group</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></li><li style="margin-left:72px;list-style:disc;"><font style="font-family:Times New Roman;font-size:10pt;">A significant change in the market value of the assets included in the asset group</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></li></ul><p style='margin-top:4.5pt; margin-bottom:4.5pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">If we determine that the carrying value of long-lived assets may not be recoverable, we compare the carrying value of the asset group to the undiscounted cash flows expected to be generated by the asset group. If the carrying value exceeds the undiscounted cash flows, an impairment charge is indicated. An impairment charge is recognized to the extent that the carrying value of the asset group exceeds its fair value. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We generally provide for depreciation over the following estimated usef</font><font style="font-family:Times New Roman;font-size:10pt;">ul service lives</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 14px"><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 250px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:250px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Years</font></td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Building</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 250px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:250px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">39</font></td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Leasehold improvements</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Lesser of life or lease or expected useful life</font></td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Equipment and furniture</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">3 to 7</font></td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Vehicles</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">5</font></td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Computer software</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">3 to 5</font></td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">As of December 31, 2014, we had $</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">8</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million of internally developed software costs related to the development of AMS3 Home Health</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">Hospice</font><font style="font-family:Times New Roman;font-size:10pt;"> (&#8220;AMS3&#8221;)</font><font style="font-family:Times New Roman;font-size:10pt;">. Expanded beta testing to additional sites in February of 2015 demonstrated that AMS3 was disruptive to operations. Additional analysis of the system determined that the system was not ready to be fully implemented and would require significant time and investment to redesign. Therefore, during the three-month period ended March 31, 2015, we made the decision to discontinue AMS3 and recorded a non-cash </font><font style="font-family:Times New Roman;font-size:10pt;">asset impairment charge of $</font><font style="font-family:Times New Roman;font-size:10pt;">75.2</font><font style="font-family:Times New Roman;font-size:10pt;"> million</font><font style="font-family:Times New Roman;font-size:10pt;"> to write-off the software costs incurred related to the development of AMS3</font><font style="font-family:Times New Roman;font-size:10pt;">.  </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">During 201</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;">, we </font><font style="font-family:Times New Roman;font-size:10pt;">began </font><font style="font-family:Times New Roman;font-size:10pt;">the </font><font style="font-family:Times New Roman;font-size:10pt;">transition</font><font style="font-family:Times New Roman;font-size:10pt;"> of all our care centers from our proprietary operating system </font><font style="font-family:Times New Roman;font-size:10pt;">to </font><font style="font-family:Times New Roman;font-size:10pt;">Homecare </font><font style="font-family:Times New Roman;font-size:10pt;">Homebase</font><font style="font-family:Times New Roman;font-size:10pt;"> (&#8220;HCHB&#8221;), a leading home health and hospice platform, with all of our care centers operating on HCHB as of December 31,</font><font style="font-family:Times New Roman;font-size:10pt;"> 2016. As part of our conversion process, we determined that a number of assets (primarily laptops) were not compatible with HCHB</font><font style="font-family:Times New Roman;font-size:10pt;"> and had no other alternative or secondary use</font><font style="font-family:Times New Roman;font-size:10pt;">. As a result, we recorded a non-cash asset impairment charge of $</font><font style="font-family:Times New Roman;font-size:10pt;">4.4</font><font style="font-family:Times New Roman;font-size:10pt;"> million to write-off these assets during the three-month period ended December 31, 2016.</font></p><p style='margin-top:4.5pt; margin-bottom:4.5pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">During the three-month period ended September 30, 2015, we commenced an active program to sell our corporate headquarters located in Baton Rouge, Louisiana. In accordance with U.S. GAAP, we classified this asset as held for sale and reduced the carrying value of the asset to its estimated fair value less estimated costs to sell the asset; no further depreciation expense for the asset </font><font style="font-family:Times New Roman;font-size:10pt;">was</font><font style="font-family:Times New Roman;font-size:10pt;"> recorded. As a result, we recorded a non-cash asset </font><font style="font-family:Times New Roman;font-size:10pt;">impairment</font><font style="font-family:Times New Roman;font-size:10pt;"> charge of $</font><font style="font-family:Times New Roman;font-size:10pt;">2.1</font><font style="font-family:Times New Roman;font-size:10pt;"> million during the three-month period ended September 30, 2015</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">The asset was sold during the three-month period ended December 31, 2015</font><font style="font-family:Times New Roman;font-size:10pt;"> and the Company now leases </font><font style="font-family:Times New Roman;font-size:10pt;">equivalent</font><font style="font-family:Times New Roman;font-size:10pt;"> office space</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 14px"><td colspan="7"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following table summarizes the balances related to our property and equipment for 2016 and 2015 (amounts in millions):</font></td></tr><tr style="height: 9px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="4"  style="width: 160px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:160px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">As of December 31,</font></td></tr><tr style="height: 12px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 20px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015</font></td></tr><tr style="height: 14px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Building and leasehold improvements</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.9</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.3</font></td></tr><tr style="height: 14px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Equipment and furniture</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">71.9</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">89.6</font></td></tr><tr style="height: 14px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Computer software</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">96.8</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">92.6</font></td></tr><tr style="height: 14px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">175.6</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">184.5</font></td></tr><tr style="height: 14px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Less: accumulated depreciation</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(138.6)</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(141.8)</font></td></tr><tr style="height: 14px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">37.0</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">42.7</font></td></tr><tr style="height: 9px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;">&#160;</td></tr><tr style="height: 14px"><td colspan="7"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Depreciation expense for 2016, 2015 and 2014 was $17.2 million, $20.0 million and $28.0 million, respectively.</font></td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Goodwill and Other Intangible Assets</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Goodwill represents the amount of the purchase price in excess of the fair values assigned to the underlying identifiable net assets of acquired businesses. Goodwill is not amortized, but is subject to an annual impairment test. Tests are performed more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount.</font><font style="font-family:Times New Roman;font-size:10pt;"> These events or circumstances include but are not limited to, a significant adverse change in the business environment; regulatory environment or legal factors; or a substantial decline in market capitalization of our stock.</font><font style="font-family:Times New Roman;font-size:10pt;"> To determine whether goodwill is impaired, we perform a two-step impairment test. In the first step of the test, the fair values of the reporting units are compared to their aggregate carrying values, including goodwill. If the fair value of the reporting unit is greater than its carrying amount, goodwill is not considered impaired and no further testing is required. If the fair value of the reporting unit is less than its carrying amount, we would proceed to step two of the test. In step two of the test, the implied fair value of the goodwill of the reporting unit is determined by a hypothetical allocation of the fair value calculated in step one to all of the assets and liabilities of that reporting unit (including any recognized and unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value was reflective of the price paid to acquire the reporting unit. The implied fair value of goodwill is the excess, if any, of the calculated fair value after hypothetical allocation to the reporting unit's assets and liabilities. If the implied fair value of the goodwill is greater than the carrying amount of the goodwill at the analysis date, goodwill is not impaired and the analysis is complete. If the implied fair value of the goodwill is less than the carrying value of goodwill at the analysis date, goodwill is deemed impaired by the amount of that variance.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We calculate the estimated fair value of our reporting units using discounted cash flows </font><font style="font-family:Times New Roman;font-size:10pt;">as well as a market approach that compares our reporting units' earnings and revenue multiples to those of comparable public companies.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">To determine fair value we must make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> in particular expected organic growth rates, future Medicare reimbursement rates</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">capital requirements and income taxes), long-term growth rates for determining terminal value, and discount rates. Our estimates of discounted cash flows may differ from actual cash flows due to, among other things, economic conditions, changes to our business model or changes in operating performance. </font><font style="font-family:Times New Roman;font-size:10pt;">These factors increase the risk of differences between projected and actual performance that could impact future estimates of fair value of all reporting units. </font><font style="font-family:Times New Roman;font-size:10pt;">Significant differences between these estimates and actual cash flows could </font><font style="font-family:Times New Roman;font-size:10pt;">result in additional impairment in future periods.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Each of our operating segments described in </font><font style="font-family:Times New Roman;font-size:10pt;">Note 1</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;"> &#8211; Segment Information </font><font style="font-family:Times New Roman;font-size:10pt;">is considered to represent an individual reporting unit for goodwill impairment testing purposes. We consider each of our home health care centers to constitute an individual business for which discrete financial information is available. However, since these care centers have substantially similar operating and economic characteristics and resource allocation and significant investment decisions concerning these businesses are centralized and the benefits broadly distributed, we have aggregated these care centers and deemed them to constitute a single reporting unit. We have applied this same aggregation principle to our hospice care centers </font><font style="font-family:Times New Roman;font-size:10pt;">and personal-care care centers </font><font style="font-family:Times New Roman;font-size:10pt;">and have also deemed them to be a single reporting unit.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">During 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">, we did not record any goodwill impairment charges </font><font style="font-family:Times New Roman;font-size:10pt;">as a result of our annual impairment test </font><font style="font-family:Times New Roman;font-size:10pt;">and none of the goodwill associated with our various reporting units w</font><font style="font-family:Times New Roman;font-size:10pt;">as</font><font style="font-family:Times New Roman;font-size:10pt;"> considered at risk of impairment as of October 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">. Since</font><font style="font-family:Times New Roman;font-size:10pt;"> the date of our last annual goodwill impairment test, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than its carrying amount.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Intangible assets consist of Certificates of</font><font style="font-family:Times New Roman;font-size:10pt;"> Need, licenses, acquired names and</font><font style="font-family:Times New Roman;font-size:10pt;"> non-</font><font style="font-family:Times New Roman;font-size:10pt;">compete</font><font style="font-family:Times New Roman;font-size:10pt;"> agreements. We amortize non-compete agreements</font><font style="font-family:Times New Roman;font-size:10pt;"> and</font><font style="font-family:Times New Roman;font-size:10pt;"> acquired names that we do not intend to use in the future on a straight-line basis over their estimated useful lives, which is generally three years for non-compete agreements and up to five years for </font><font style="font-family:Times New Roman;font-size:10pt;">acquired names. </font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Debt Issuance Costs</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We amortize deferred debt issuance costs related to our long-term obligations over its term through interest expense, unless the debt is extinguished, in which case unamortized balances are immediately expensed. We </font><font style="font-family:Times New Roman;font-size:10pt;">a</font><font style="font-family:Times New Roman;font-size:10pt;">mortized $</font><font style="font-family:Times New Roman;font-size:10pt;">0.</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;"> million</font><font style="font-family:Times New Roman;font-size:10pt;">, $0.</font><font style="font-family:Times New Roman;font-size:10pt;">8</font><font style="font-family:Times New Roman;font-size:10pt;"> million and $</font><font style="font-family:Times New Roman;font-size:10pt;">0.7</font><font style="font-family:Times New Roman;font-size:10pt;"> million in deferred debt issuance costs in </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">2015</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">2014</font><font style="font-family:Times New Roman;font-size:10pt;">, respectively. As of December 31, </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">2015</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">we had unamortized debt issuance costs of $</font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million and $</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> respectively</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> recorded as </font><font style="font-family:Times New Roman;font-size:10pt;">long-term obligations, less current portion</font><font style="font-family:Times New Roman;font-size:10pt;"> in our accompanying consolidated balance sheets. The unamortized debt issuance costs of $</font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;"> million at December 31, 2016, will be amortize</font><font style="font-family:Times New Roman;font-size:10pt;">d over a weighted-average amortization period of </font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">years.</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 9px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;">&#160;</td></tr><tr style="height: 18px"><td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Fair Value of Financial Instruments</font></td></tr><tr style="height: 8px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;">&#160;</td></tr><tr style="height: 17px"><td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</font></td></tr><tr style="height: 9px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="11"  style="width: 445px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:445px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Fair Value at Reporting Date Using</font></td></tr><tr style="height: 51px"><td   style="width: 255px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:255px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;">Financial Instrument</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 95px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:95px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">As of
December 31,
2016</font></td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 114px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:114px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Quoted Prices in Active Markets for Identical Items
(Level 1)</font></td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 102px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:102px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Significant Other Observable Inputs (Level 2)</font></td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 104px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:104px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Significant Unobservable Inputs (Level 3)</font></td></tr><tr style="height: 14px"><td   style="width: 255px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:255px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Long-term obligations</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">95.7</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 102px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:102px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">0</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">97.8</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 92px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:92px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">0</font></td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">The </font><font style="font-family:Times New Roman;font-size:10pt;">fair value hierarchy</font><font style="font-family:Times New Roman;font-size:10pt;"> is</font><font style="font-family:Times New Roman;font-size:10pt;"> based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'></p><ul><li style="margin-left:36px;list-style:disc;"><font style="font-family:Times New Roman;font-size:10pt;">Level 1 &#8211; Quoted prices in active markets for identical assets and liabilities.</font></li><li style="margin-left:36px;list-style:disc;"><font style="font-family:Times New Roman;font-size:10pt;">Level 2 &#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></li><li style="margin-left:36px;list-style:disc;"><font style="font-family:Times New Roman;font-size:10pt;">Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</font></li></ul><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. </font><font style="font-family:Times New Roman;font-size:10pt;">For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable</font><font style="font-family:Times New Roman;font-size:10pt;">, payroll and employee benefits </font><font style="font-family:Times New Roman;font-size:10pt;">and accrued expenses</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> we estimate the carrying amounts' approximate fair value. </font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Income Taxes</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We use the asset and liability approach for measuring deferred tax assets and liabilities based on temporary differences existing at each balance sheet date using currently enacted tax rates. Our deferred tax calculation requires us to make certain estimates about future operations. Deferred tax </font><font style="font-family:Times New Roman;font-size:10pt;">assets are reduced by a valuation allowance when we believe it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect of a change in tax rate is recognized as income or expense in the period that includes the enactment date. As of December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">and 201</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">our </font><font style="font-family:Times New Roman;font-size:10pt;">net </font><font style="font-family:Times New Roman;font-size:10pt;">deferred tax asset</font><font style="font-family:Times New Roman;font-size:10pt;">s</font><font style="font-family:Times New Roman;font-size:10pt;"> w</font><font style="font-family:Times New Roman;font-size:10pt;">ere</font><font style="font-family:Times New Roman;font-size:10pt;"> $</font><font style="font-family:Times New Roman;font-size:10pt;">107.9</font><font style="font-family:Times New Roman;font-size:10pt;"> million</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">$</font><font style="font-family:Times New Roman;font-size:10pt;">125</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;"> million, respectively</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Management regularly assesses the ability to realize deferred tax assets recorded in the Company's entities based upon the weight of available evidence, including such factors as the recent earnings history and expected future taxable income</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">In the event future taxable income is below management's estimates or is generated in tax jurisdictions different than projected, we could be required to increase the valuation allowance for deferred tax assets. This would result in an increase in our effective tax rate.</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Share-Based Compensation</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We record all share-based compensation as expense in the financial statements measured at the fair value of the award. We recognize compensation cost on a straight-line basis over the requisite service period for each separately vesting portion of the award. We reflect the excess tax benefits related to stock option exercises as financing cash flows. Share-based compensation expense for </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">2015</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">2014</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">was $</font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;"> million, $</font><font style="font-family:Times New Roman;font-size:10pt;">11</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">8</font><font style="font-family:Times New Roman;font-size:10pt;"> million and $</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;"> million, respectively, and the total income tax benefit</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">recognized for these expenses was $</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million, $</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million and $</font><font style="font-family:Times New Roman;font-size:10pt;">2.</font><font style="font-family:Times New Roman;font-size:10pt;">0</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million, respectively.</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Weighted-Average Shares Outstanding</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Net</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">income</font><font style="font-family:Times New Roman;font-size:10pt;"> (loss)</font><font style="font-family:Times New Roman;font-size:10pt;"> per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calc</font><font style="font-family:Times New Roman;font-size:10pt;">ulate our basic and diluted net </font><font style="font-family:Times New Roman;font-size:10pt;">income (loss)</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">attributable to Amedisys, Inc. common stockholders (amounts in thousands):</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 16px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="5"  style="width: 234px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:234px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Years Ended December 31, </font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:68px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 15px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:68px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015</font></td><td   style="width: 15px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:68px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2014</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Weighted average number of shares outstanding - basic</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">33,198</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">33,018</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">32,301</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Effect of dilutive securities:</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 68px; text-align:left;border-color:#000000;min-width:68px;">&#160;</td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; text-align:left;border-color:#000000;min-width:68px;">&#160;</td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; text-align:left;border-color:#000000;min-width:68px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Stock options</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 68px; text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">162</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Non-vested stock and stock units</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 68px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">381</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">521</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Weighted average number of shares outstanding - diluted</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">33,741</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">33,018</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">32,823</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Anti-dilutive securities</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 68px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">221</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">922</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">106</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Advertising Costs</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We expense advertising costs as incurred. Advertising expense for 2016, 2015 and 2014 was $</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">8</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million, $</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">9</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million </font><font style="font-family:Times New Roman;font-size:10pt;">and $</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million</font><font style="font-family:Times New Roman;font-size:10pt;">, respectively.</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Recently Issued Accounting Pronouncements</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'>&#160;</p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Times New Roman;font-size:10pt;">, which requires an entity to recognize the amount of revenue for which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP. In August 2015, the FASB issued ASU 2015-14,</font><font style="font-family:Georgia;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font><font style="font-family:Georgia;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> to defer the effective date of the standard from January 1, 2017, to January 1, 2018, with an option that permits companies to adopt the standard as early as the original effective date. The new ASU reflects the decisions reached by the FASB at its meeting in July 2015. Early application prior to the original effective date is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Co</font><font style="font-family:Times New Roman;font-size:10pt;">mpany does not expect an impact on its consolidated financial statements upon </font><font style="font-family:Times New Roman;font-size:10pt;">implementation</font><font style="font-family:Times New Roman;font-size:10pt;"> of ASU 2014-09 and </font><font style="font-family:Times New Roman;font-size:10pt;">ASU 2015-14 on January 1, 2018, but is still evaluating the effect the standard will have on its related disclosures.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In April 2015, the FASB issued ASU 2015-03, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Interest - Imputation of Interest</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">(Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</font><font style="font-family:Times New Roman;font-size:10pt;">.&#160;The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. ASU 2015-03 is effective for annual and interim periods beginning on or after December 15, 2015. </font><font style="font-family:Times New Roman;font-size:10pt;">We adopted this ASU during the three-month period ended March 31, 2016, and applied the change retrospectively for prior period balances of unamortized debt issuance costs, resulting </font><font style="font-family:Times New Roman;font-size:10pt;">in a $3.4 million</font><font style="font-family:Times New Roman;font-size:10pt;"> reduction in other assets, net and long-term obligations, less current portion, on our consolidated balance sheet as of December 31, 2015</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In February 2016, the FASB issued ASU 2016-02, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Leases (Topic 842</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">), </font><font style="font-family:Times New Roman;font-size:10pt;">whic</font><font style="font-family:Times New Roman;font-size:10pt;">h will require lessees to recognize a lease liability and right-of-use asset for all leases (with the exception of short-term leases) at the commencement date</font><font style="font-family:Times New Roman;font-size:10pt;">. The ASU is effective for annual and interim periods beginning on or after December 15, 2018. Early adoption is permitted. The standard requires a modified retrospective transition method which requires application of the new guid</font><font style="font-family:Times New Roman;font-size:10pt;">ance for all periods presented. While the Company expects adoption of this standard to lead to a material increase in the assets and liabilities recorded on our balance sheet, we are still </font><font style="font-family:Times New Roman;font-size:10pt;">evaluating the </font><font style="font-family:Times New Roman;font-size:10pt;">overall impact on our</font><font style="font-family:Times New Roman;font-size:10pt;"> consolidated financial statements and related disclosures and the effect of the standard on </font><font style="font-family:Times New Roman;font-size:10pt;">our</font><font style="font-family:Times New Roman;font-size:10pt;"> ongoing financial reporting</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In March 2016, the FASB issued ASU 2016-09, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Compensation &#8211; Stock Compensation (Topic 718): Improvement to Employee Share-Based Payment Accounting</font><font style="font-family:Times New Roman;font-size:10pt;">, which will simplify the accounting for share-based payment award transactions, including income tax consequences, classification of awards as either equity or liability, and classification on the statement of cash flows. The ASU is effective for annual and interim periods beginning after December 15, 2016. Early adoption is permitted. </font><font style="font-family:Times New Roman;font-size:10pt;">The element of the new standard that will have the most impact on our consolidated financial statements will be income tax consequences. Excess tax benefits and tax deficiencies on share-based compensation awards will now be included in our tax provision within our consolidated statement of operations as discrete items in the reporting period in </font><font style="font-family:Times New Roman;font-size:10pt;">which they occur, rather than our current accounting of recording in additional paid-in capital on our consolidated balance sheets</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In August 2016, the FASB issued ASU 2016-15, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:Times New Roman;font-size:10pt;">, which provides specific guidance on eight cash flow classification issues not specifically addressed by U.S. GAAP. The ASU is effective for annual and interim periods beginning after December 15, 2017. Early adoption is permitted. The standard should be applied using a retrospective transition method unless it is impractical to do so for some of the issues. In such case, the amendments for those issues would be applied prospectively as of the earliest date practicable. The Company is evaluating the effect that ASU 2016-15 will have on its consolidated financial statements and related disclosures and the effect of the standard on its ongoing financial reporting</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:0pt; margin-bottom:0pt'>&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6783843712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITIONS</a></td>
<td class="text"><p style='margin-top:13pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;">3. ACQUISITIONS </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health</font><font style="font-family:Times New Roman;font-size:10pt;">, hospice</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">personal care </font><font style="font-family:Times New Roman;font-size:10pt;">services. The purchase price paid for acquisitions is negotiated through arm's length transactions, with consideration based on our analysis of, among other things, comparable acqu</font><font style="font-family:Times New Roman;font-size:10pt;">isitions and expected cash flows</font><font style="font-family:Times New Roman;font-size:10pt;">. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy</font><font style="font-family:Times New Roman;font-size:10pt;">. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets. Preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuation and liabilities assumed</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">2016</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"> Acquisitions </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Personal Care Division</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On </font><font style="font-family:Times New Roman;font-size:10pt;">March 1, 2016, we acquired Associated Home Care which owns and operates 9 personal-care care centers servicing the state of Massachusetts for a total purchase price of $27.7 million, net of cash acquired (subject to certain adjustments), of which $0.5</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million was placed in escrow for indemnification purposes and working capital price adjustments. The purchase price was paid with cash on hand on the date of the transaction. Based on our preliminary purchase price allocation, in connection with the acquisition, we recorded goodwill ($23.5 million) and other assets and liabilities, net ($4.2 million) during the three-month period ended March 31, 2016. During the three-month period ended June 30, 2016, we received the final report from our outside appraisal firm. As a result, we reduced our preliminary goodwill by $5.0 million and </font><font style="font-family:Times New Roman;font-size:10pt;">recorded corresponding increases</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">in the fair value of assets acquired ($0.2 million), other intangibles &#8211; acquired names of business ($3.5 million) and other intangibles &#8211; non-compete agreements ($1.3 million). </font><font style="font-family:Times New Roman;font-size:10pt;">We expect the entire amount of goodwill recorded </font><font style="font-family:Times New Roman;font-size:10pt;">for this acquisition </font><font style="font-family:Times New Roman;font-size:10pt;">to be deductible for income tax purposes over approximately 15 years. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On </font><font style="font-family:Times New Roman;font-size:10pt;">September 1, 2016, we acquired the assets of Professional Profiles, Inc. which owns and operates 4 personal-care care centers servicing the state of Massachusetts for a total purchase price of $4.4 million, (subject to certain adjustments), of which $0.7 million was placed in a promissory note to be paid over 24 months, subject to any offsets or withholds for indemnification purposes. The purchase price was paid with cash on hand on the date of the transaction. During the three-month period ended September 30, 2016, we recorded goodwill ($4.2 million) and other intangibles &#8211; non-compete agreements ($0.2 million)</font><font style="font-family:Times New Roman;font-size:10pt;"> in connection with the acquisition</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">We expect the entire amount of goodwill recorded </font><font style="font-family:Times New Roman;font-size:10pt;">for this acquisition </font><font style="font-family:Times New Roman;font-size:10pt;">to be deductible for income tax purposes over approximately 15 years.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Home Health</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"> Division</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On Oc</font><font style="font-family:Times New Roman;font-size:10pt;">tober 20, 2016, we acquired the </font><font style="font-family:Times New Roman;font-size:10pt;">assets of</font><font style="font-family:Times New Roman;font-size:10pt;"> a former nonprofit organization in New York for a purchase price of $4.6 million. During the three-month period ended December 31, 2016, we recorded goodwill ($4.4 million) and other intangibles &#8211; cer</font><font style="font-family:Times New Roman;font-size:10pt;">tificate of need ($0.2 million)</font><font style="font-family:Times New Roman;font-size:10pt;"> in connection with the acquisition</font><font style="font-family:Times New Roman;font-size:10pt;">. We expect the entire amount of goodwill recorded </font><font style="font-family:Times New Roman;font-size:10pt;">for this acquisition </font><font style="font-family:Times New Roman;font-size:10pt;">to be deductible for income tax purposes over approximately 15 years.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">The following table contains unaudited pro forma condensed consolidated statement of operations information assuming that </font><font style="font-family:Times New Roman;font-size:10pt;">our 2016 acquisitions </font><font style="font-family:Times New Roman;font-size:10pt;">closed on January 1, 2015, for the years ended December 31, 2016 and 2015 (amounts in millions, except per share data):</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'>&#160;</p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015</font></td><td   style="width: 45px; text-align:center;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Net service revenue</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">1,449.7</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">1,322.2</font></td><td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Operating income (loss)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">53.9</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(7.8)</font></td><td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Net income</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">35.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.4</font></td><td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Basic earnings (loss) per share</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">1.04</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(0.01)</font></td><td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Diluted earnings (loss) per share</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">1.03</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(0.01)</font></td><td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td colspan="7" rowspan="5" style="width: 620px; text-align:left;border-color:#000000;min-width:620px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">The pro forma information presented above includes adjustments for (i) amortization of identifiable intangible assets and (ii) income tax provision using the Company&#8217;s statutory tax rate. This pro forma information is presented for illustrative purposes only and may not be indicative of the results of operations that would have actually occurred. In addition, future results may vary significantly from the results reflected in the pro forma information.</font></td><td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 19px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 30px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">2015</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"> Acquisitions </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Hospice Division</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On July 24, 2015, we acquired one hospice care center in Tennessee for a total purchase price of $5.8 million. The purchase price was paid with cash on hand on the date of the transaction. In connection with the acquisition, we recorded goodwill ($5.5 million) and other intangibles ($0.3 million).</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Home Health Division</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On Octo</font><font style="font-family:Times New Roman;font-size:10pt;">ber 2, 2015, we acquired the</font><font style="font-family:Times New Roman;font-size:10pt;"> assets of </font><font style="font-family:Times New Roman;font-size:10pt;">a </font><font style="font-family:Times New Roman;font-size:10pt;">home health care center in Georgia for a total purchase price of $0.3 million. The purchase price was paid with cash on hand on the date of the transaction. In connection with the acquisition, we recorded goodwill ($0.3 million).</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On December 31, 2015, we acquired Infinity </font><font style="font-family:Times New Roman;font-size:10pt;">HomeCare</font><font style="font-family:Times New Roman;font-size:10pt;"> (&#8220;Infinity&#8221;) for a total purchase price of $63 million, net of cash acquired (subject to certain </font><font style="font-family:Times New Roman;font-size:10pt;">adjustments), of which $3.2 million was placed in escrow for indemnification purposes and working capital price adjustments. The purchase price was paid with cash on hand on the date of the transaction. Infinity owned and operated 15 home health care centers servicing the state of Florida. In connection with the acquisition, we recorded goodwill ($</font><font style="font-family:Times New Roman;font-size:10pt;">50.2 </font><font style="font-family:Times New Roman;font-size:10pt;">million), other intangibles ($10.</font><font style="font-family:Times New Roman;font-size:10pt;">9</font><font style="font-family:Times New Roman;font-size:10pt;"> million) and other assets and liabilities, net ($</font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">9</font><font style="font-family:Times New Roman;font-size:10pt;"> million). Approximately</font><font style="font-family:Times New Roman;font-size:10pt;"> $47.6 million of the $50.2 recorded as goodwill is expected to be deductible for income tax purposes over approximately 15 year</font><font style="font-family:Times New Roman;font-size:10pt;">s.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1497-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1490-128463<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1486-128463<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1500-128463<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1524-128463<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7000-128479<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4922-128472<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4934-128472<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4926-128472<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1383-128463<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6996-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958362848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATIONS AND ASSETS HELD FOR SALE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract', window );"><strong>Discontinued Operation, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">DISCONTINUED OPERATIONS</a></td>
<td class="text"><p style='margin-top:13pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;">4. DISCONTINUED OPERATIONS</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"> AND ASSETS HELD FOR SALE</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">As </font><font style="font-family:Times New Roman;font-size:10pt;">of December 31, 2013, we had three care </font><font style="font-family:Times New Roman;font-size:10pt;">centers classified as held for sale</font><font style="font-family:Times New Roman;font-size:10pt;">. During </font><font style="font-family:Times New Roman;font-size:10pt;">2014, we sold assets associated with two of these care centers and consolidated one of these care centers with a care center servicing the same m</font><font style="font-family:Times New Roman;font-size:10pt;">arket. There were no care centers </font><font style="font-family:Times New Roman;font-size:10pt;">classified as held for sale as of December 31, 2014</font><font style="font-family:Times New Roman;font-size:10pt;">. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">As we </font><font style="font-family:Times New Roman;font-size:10pt;">exited</font><font style="font-family:Times New Roman;font-size:10pt;"> certain geographical areas and in accordance with applicable accounting guidance, the care centers which were </font><font style="font-family:Times New Roman;font-size:10pt;">cl</font><font style="font-family:Times New Roman;font-size:10pt;">assified as held for sale </font><font style="font-family:Times New Roman;font-size:10pt;">as of December 31, </font><font style="font-family:Times New Roman;font-size:10pt;">2013</font><font style="font-family:Times New Roman;font-size:10pt;"> and subsequently sold in 2014 </font><font style="font-family:Times New Roman;font-size:10pt;">are presented as discontinued operations in our cons</font><font style="font-family:Times New Roman;font-size:10pt;">olidated financial statements. </font><font style="font-family:Times New Roman;font-size:10pt;">The care center consolidated with </font><font style="font-family:Times New Roman;font-size:10pt;">a </font><font style="font-family:Times New Roman;font-size:10pt;">care center servicing the same markets </font><font style="font-family:Times New Roman;font-size:10pt;">is</font><font style="font-family:Times New Roman;font-size:10pt;"> presented in continuing operations as we expect continuing cash flows from these markets. For additional information on the care center</font><font style="font-family:Times New Roman;font-size:10pt;">s</font><font style="font-family:Times New Roman;font-size:10pt;"> consolidated with care centers servicing the same markets and the care centers sold</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> see Note 1</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;"> &#8211; Exit Activities</font><font style="font-family:Times New Roman;font-size:10pt;"> and Restructuring </font><font style="font-family:Times New Roman;font-size:10pt;">Activitie</font><font style="font-family:Times New Roman;font-size:10pt;">s.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">O</font><font style="font-family:Times New Roman;font-size:10pt;">perating results for the twelve-month period ended December 31, 2014 for those care centers classified as discontinued operations are as follows: loss before income taxes of $0.3</font><font style="font-family:Times New Roman;font-size:10pt;"> million, income tax benefit of $0.1 million and </font><font style="font-family:Times New Roman;font-size:10pt;">net loss from </font><font style="font-family:Times New Roman;font-size:10pt;">discontinued operations of $0.2 million</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'>&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=SL51721533-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=SL51721665-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=SL51721675-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=51719941&amp;loc=SL51724579-110230<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=SL51721663-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51719941&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1361-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=SL51721659-107760<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=SL51721671-107760<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=SL51721677-107760<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1474-107760<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958169728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL AND OTHER INTANGIBLE ASSETS, NET</a></td>
<td class="text"><p style='margin-top:13pt; margin-bottom:9pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;">5. GOODWILL AND OTHER INTANGIBLE ASSETS, NET</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">During </font><font style="font-family:Times New Roman;font-size:10pt;">201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">, we did not record any goodwill impairment charges</font><font style="font-family:Times New Roman;font-size:10pt;"> as a result of our annual impairment test</font><font style="font-family:Times New Roman;font-size:10pt;"> and none of the goodwill associated with our various reporting units were considered at risk of impairment as of October 31,</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> Since the date of our last annual goodwill impairment test, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would b</font><font style="font-family:Times New Roman;font-size:10pt;">e less than its carrying amount. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">During </font><font style="font-family:Times New Roman;font-size:10pt;">the fiscal year </font><font style="font-family:Times New Roman;font-size:10pt;">2015, we did not record any goodwill impairment charges as a result of our annual impairment test and none of the goodwill associated with our various reporting units were considered at risk of impairment.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">During the fiscal year 201</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">we recognized </font><font style="font-family:Times New Roman;font-size:10pt;">a non</font><font style="font-family:Times New Roman;font-size:10pt;">-cash other intangible impairment charge of $</font><font style="font-family:Times New Roman;font-size:10pt;">0.9 </font><font style="font-family:Times New Roman;font-size:10pt;">million during step one of our 2014 annual goodwill impairment test</font><font style="font-family:Times New Roman;font-size:10pt;">. In addition, we recorded </font><font style="font-family:Times New Roman;font-size:10pt;">non-cash impairment charges of </font><font style="font-family:Times New Roman;font-size:10pt;">$</font><font style="font-family:Times New Roman;font-size:10pt;">2.2 </font><font style="font-family:Times New Roman;font-size:10pt;">million related to those care centers that were closed or consolidated during 2014 as discussed in Note 1</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;"> &#8211; Exit and Restructuring Activities</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:10pt'>&#160;</p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 21px"><td colspan="14"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">The following table summarizes the activity related to our goodwill for 2016, 2015 and 2014 (amounts in millions):</font></td></tr><tr style="height: 9px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 78px; text-align:left;border-color:#000000;min-width:78px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:left;border-color:#000000;min-width:64px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:left;border-color:#000000;min-width:64px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:left;border-color:#000000;min-width:64px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="11"  style="width: 346px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:346px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Goodwill</font></td></tr><tr style="height: 33px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;">&#160;</td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 88px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:88px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Home Health</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 74px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:74px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Hospice</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 74px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:74px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Personal Care</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 74px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:74px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Total</font></td></tr><tr style="height: 14px"><td colspan="2"  style="width: 352px; text-align:left;border-color:#000000;min-width:352px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Balances at December 31, 2013</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 78px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:78px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">16.6</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">192.3</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">208.9</font></td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Write-off (1)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 78px; text-align:right;border-color:#000000;min-width:78px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.1)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(3.2)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(3.3)</font></td></tr><tr style="height: 14px"><td colspan="2"  style="width: 352px; text-align:left;border-color:#000000;min-width:352px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Balances at December 31, 2014</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 78px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:78px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">16.5</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">189.1</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">205.6</font></td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Additions</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 78px; text-align:right;border-color:#000000;min-width:78px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">50.6</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">5.5</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">56.1</font></td></tr><tr style="height: 14px"><td colspan="2"  style="width: 352px; text-align:left;border-color:#000000;min-width:352px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Balances at December 31, 2015</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 78px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:78px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">67.1</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">194.6</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">261.7</font></td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Additions</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 78px; text-align:right;border-color:#000000;min-width:78px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.4</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">22.7</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">27.1</font></td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Adjustments related to acquisitions</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 78px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:78px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.1</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.1</font></td></tr><tr style="height: 14px"><td colspan="2"  style="width: 352px; text-align:left;border-color:#000000;min-width:352px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Balances at December 31, 2016</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 78px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:78px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">71.6</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">194.6</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">22.7</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">288.9</font></td></tr><tr style="height: 9px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 78px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:78px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:64px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:64px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:64px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'></p><ul><li style="margin-left:18px;list-style:decimal;"><font style="font-family:Times New Roman;font-size:10pt;">Write-off of </font><font style="font-family:Times New Roman;font-size:10pt;">goodwill r</font><font style="font-family:Times New Roman;font-size:10pt;">elated to the </font><font style="font-family:Times New Roman;font-size:10pt;">sale</font><font style="font-family:Times New Roman;font-size:10pt;"> of care</font><font style="font-family:Times New Roman;font-size:10pt;"> centers as discussed in Note 1</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;"> &#8211; Exit</font><font style="font-family:Times New Roman;font-size:10pt;"> and Restructuring</font><font style="font-family:Times New Roman;font-size:10pt;"> Activities</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></li></ul><p style='margin-top:0pt; margin-bottom:0pt'>&#160;</p><p style='margin-top:0pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">During 2016, we adjusted goodwill by $</font><font style="font-family:Times New Roman;font-size:10pt;">0.1 </font><font style="font-family:Times New Roman;font-size:10pt;">million </font><font style="font-family:Times New Roman;font-size:10pt;">as a result of our completion of the purchase price accounting </font><font style="font-family:Times New Roman;font-size:10pt;">for our 2015 acquisition of Infinity</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 30px"><td colspan="14"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following table summarizes the activity related to our other intangible assets, net for 2016, 2015 and 2014 (amounts in millions):</font></td></tr><tr style="height: 9px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;<font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;" /></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 95px; text-align:left;border-color:#000000;min-width:95px;">&#160;<font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;" /></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:left;border-color:#000000;min-width:64px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="11"  style="width: 380px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:380px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Other Intangible Assets, Net</font></td></tr><tr style="height: 10px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;">&#160;</td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Certificates of</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:80px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Acquired </font><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 105px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:105px;">&#160;<font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:64px;">&#160;</td></tr><tr style="height: 10px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;">&#160;</td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 85px; text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Need and</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 80px; text-align:center;border-color:#000000;min-width:80px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Names of</font><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Non-Compete</font><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:center;border-color:#000000;min-width:64px;">&#160;</td></tr><tr style="height: 10px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;">&#160;</td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Licenses</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:80px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Business</font><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 105px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:105px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Agreements (2)</font><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 74px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:74px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Total</font></td></tr><tr style="height: 16px"><td colspan="2"  style="width: 318px; text-align:left;border-color:#000000;min-width:318px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Balances at December 31, 2013</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">25.4</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">$</font></td><td   style="width: 70px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">11.1</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">$</font></td><td   style="width: 95px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:95px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.2</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">$</font></td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">36.7</font></td></tr><tr style="height: 13px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Write-off (1)</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(0.2)</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 70px; text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.0</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 95px; text-align:right;border-color:#000000;min-width:95px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.0</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(0.2)</font></td></tr><tr style="height: 13px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Impairment</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(2.1)</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 70px; text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(1.0)</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 95px; text-align:right;border-color:#000000;min-width:95px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.0</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(3.1)</font></td></tr><tr style="height: 13px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Amortization</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.0</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 70px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.0</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 95px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:95px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(0.2)</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(0.2)</font></td></tr><tr style="height: 13px"><td colspan="2"  style="width: 318px; text-align:left;border-color:#000000;min-width:318px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Balances at December 31, 2014</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">23.1</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 70px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">10.1</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 95px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:95px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.0</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">33.2</font></td></tr><tr style="height: 13px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Additions</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">1.1</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 70px; text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">4.1</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 95px; text-align:right;border-color:#000000;min-width:95px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">5.9</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">11.1</font></td></tr><tr style="height: 13px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Write-off</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(0.3)</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 70px; text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.0</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 95px; text-align:right;border-color:#000000;min-width:95px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.0</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(0.3)</font></td></tr><tr style="height: 13px"><td colspan="2"  style="width: 318px; text-align:left;border-color:#000000;min-width:318px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Balances at December 31, 2015</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">23.9</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 70px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">14.2</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 95px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:95px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">5.9</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">44.0</font></td></tr><tr style="height: 13px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Additions</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.2</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 70px; text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">3.5</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 95px; text-align:right;border-color:#000000;min-width:95px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">1.5</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">5.2</font></td></tr><tr style="height: 13px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Amortization</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.0</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 70px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.0</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 95px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:95px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(2.5)</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(2.5)</font></td></tr><tr style="height: 13px"><td colspan="2"  style="width: 318px; text-align:left;border-color:#000000;min-width:318px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Balances at December 31, 2016</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 75px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">24.1</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">$</font></td><td   style="width: 70px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">17.7</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">$</font></td><td   style="width: 95px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:95px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">4.9</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">$</font></td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">46.7</font></td></tr><tr style="height: 13px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;">&#160;</td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 70px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:70px;">&#160;<font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 95px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:95px;">&#160;<font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:64px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'></p><ul><li style="margin-left:18px;list-style:decimal;"><font style="font-family:Times New Roman;font-size:10pt;">Write-off of intangible assets related to the </font><font style="font-family:Times New Roman;font-size:10pt;">sale</font><font style="font-family:Times New Roman;font-size:10pt;"> of care</font><font style="font-family:Times New Roman;font-size:10pt;"> centers as discussed in Note 1</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;"> &#8211; Exit</font><font style="font-family:Times New Roman;font-size:10pt;"> and Restructuring</font><font style="font-family:Times New Roman;font-size:10pt;"> Activities</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></li><li style="margin-left:18px;list-style:decimal;"><font style="font-family:Times New Roman;font-size:10pt;">The weighted average amortization period of our non-compete agreements is </font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">9</font><font style="font-family:Times New Roman;font-size:10pt;"> years</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></li></ul><p style='margin-top:0pt; margin-bottom:0pt'>&#160;</p><p style='margin-top:0pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">See Note 3 &#8211; Acquisitions for further details on additions to goodwill and other intangible assets, net</font><font style="font-family:Times New Roman;font-size:10pt;">. </font></p><p style='margin-top:0pt; margin-bottom:0pt'>&#160;</p><p style='margin-top:0pt; margin-bottom:0pt'>&#160;</p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td colspan="6"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The estimated aggregate amortization expense related to intangible assets for each of the five succeeding years is as follows (amounts in millions):</font></td></tr><tr style="height: 11px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2017</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.7</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2018</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.2</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2019</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2020</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2021</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.9</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958288672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DetailsOfCertainBalanceSheetAccountsAbstract', window );"><strong>Details Of Certain Balance Sheet Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock', window );">DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 20px"><td colspan="10"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">6. DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS</font></td></tr><tr style="height: 9px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 15px"><td colspan="9"  style="width: 690px; text-align:left;border-color:#000000;min-width:690px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Additional information regarding certain balance sheet accounts is presented below (amounts in millions):</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="5"  style="width: 180px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:180px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">As of December 31, </font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 75px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:75px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 30px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:30px;">&#160;</td><td colspan="2"  style="width: 75px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:75px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td colspan="2"  style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Other current assets:</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Payroll tax escrow</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.7</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.2</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Income tax receivable</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.3</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.5</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Due from joint ventures</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.7</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.8</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Other</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.6</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.1</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">11.3</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">14.6</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 9px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td colspan="2"  style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Other assets:</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Workers' compensation deposits</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.4</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.3</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Health insurance deposits</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.5</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.2</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Other miscellaneous deposits</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.9</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.5</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Investments</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">27.8</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">25.7</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Other</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">8.9</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.1</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">38.5</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">32.8</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 9px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td colspan="2"  style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Accrued expenses:</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Health insurance</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.6</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">11.7</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Workers' compensation</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">26.8</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">23.9</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Legal and other settlements</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">5.7</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.5</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Lease liability</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.4</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.6</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Charity care</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.4</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.7</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Estimated Medicare cap liability</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.8</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.4</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Hospice cost of revenue</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">7.2</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.8</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">OIG self-disclosure accrual</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.7</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Patient liability</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.3</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">5.1</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Other</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.1</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.6</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">63.3</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">72.0</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 9px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td colspan="2"  style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Other long-term obligations:</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Reserve for uncertain tax positions</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.3</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.7</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Deferred compensation plan liability</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.8</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.8</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Other</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.6</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.9</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.7</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.4</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DetailsOfCertainBalanceSheetAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DetailsOfCertainBalanceSheetAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958345184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">LONG-TERM OBLIGATIONS</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">7. LONG-TERM OBLIGATIONS</font></td></tr><tr style="height: 9px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td></tr><tr style="height: 17px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Long-term debt consisted of the following for the periods indicated (amounts in millions):</font></td></tr><tr style="height: 9px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="5"  style="width: 205px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:205px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">As  of December 31, </font></td></tr><tr style="height: 12px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 90px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 15px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td colspan="2"  style="width: 100px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:100px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015</font></td></tr><tr style="height: 17px"><td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$100.0 million Term Loan;  principal payments plus accrued interest payable
quarterly; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the
applicable percentage (2.77% at December 31, 2016); due August 28, 2020</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">95.0</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">100.0</font></td></tr><tr style="height: 17px"><td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$200.0 million Revolving Credit Facility; interest only quarterly payments; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the applicable percentage; due August 28, 2020</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td></tr><tr style="height: 17px"><td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Promissory notes</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.7</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td></tr><tr style="height: 17px"><td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Deferred debt issuance costs</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(2.7)</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(3.4)</font></td></tr><tr style="height: 17px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">93.0</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">96.6</font></td></tr><tr style="height: 17px"><td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Current portion of long-term obligations</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(5.2)</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(5.0)</font></td></tr><tr style="height: 17px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Total</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">87.8</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 90px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">91.6</font></td></tr><tr style="height: 17px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:90px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td colspan="6"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Maturities of debt as of December 31, 2016 are as follows (amounts in millions):</font></td></tr><tr style="height: 12px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 25px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 75px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:75px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Long-term obligations</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2017</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">5.2</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2018</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.5</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2019</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.0</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2020</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">70.0</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2021</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">95.7</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Credit Agreement</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On</font><font style="font-family:Times New Roman;font-size:10pt;"> August 28, 2015, we entered into a Credit Agreement that provides for senior secured facilities in an initial aggregate principal amount of up to $300 million (the &#8220;Credit Facilities&#8221;).</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">The Credit Facilities are comprised of (a) a term loan facility in an initial aggregate principal amount of $100 million (the &#8220;Term Loan&#8221;); and (b) a revolving credit facility in an initial aggregate principal amount of up to $200 million (the &#8220;Revolving Credit Facility&#8221;). The Revolving Credit Facility provides for and includes within its $200 million limit a $25 million </font><font style="font-family:Times New Roman;font-size:10pt;">swingline</font><font style="font-family:Times New Roman;font-size:10pt;"> facility and commitments for up to $50 million in letters of credit. Upon lender approval, we may increase the aggregate loan amount under the Credit Facilities by a maximum amount of $150 million. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">The net proceeds of the Term Loan and existing cash on hand were used to pay off (i) our existing term loan under our prior Credit Agreement, dated as of October 22, 2012, as amended (the &#8220;Prior Credit Agreement&#8221;) with a principal balance of $27 million and (ii) our existing term loan under our prior Second Lien Credit Agreement dated July 28, 2014 (the &#8220;Second Lien Credit Agreement&#8221;), with a principal balance of $70 million.  The final ma</font><font style="font-family:Times New Roman;font-size:10pt;">turity of the Term Loan is August 28, 2020. The Term Loan </font><font style="font-family:Times New Roman;font-size:10pt;">began amortizing</font><font style="font-family:Times New Roman;font-size:10pt;"> on March 31, 2016 </font><font style="font-family:Times New Roman;font-size:10pt;">and will continue amortizing  over 14 quarterly instalments</font><font style="font-family:Times New Roman;font-size:10pt;"> (</font><font style="font-family:Times New Roman;font-size:10pt;">four remaining</font><font style="font-family:Times New Roman;font-size:10pt;"> quarterly </font><font style="font-family:Times New Roman;font-size:10pt;">installments</font><font style="font-family:Times New Roman;font-size:10pt;"> of $1.25 million followed by eight quarterly </font><font style="font-family:Times New Roman;font-size:10pt;">installments</font><font style="font-family:Times New Roman;font-size:10pt;"> of $2.5 million, followed by two quarterly </font><font style="font-family:Times New Roman;font-size:10pt;">installments</font><font style="font-family:Times New Roman;font-size:10pt;"> of $3.1 million, subject to adjustment for prepayments), with the remaining balance due upon maturity.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">The Revolving Credit Facility may be used to provide ongoing working capital and for general corporate purposes of the Company and our subsidiaries, including permitted acquisitions, as defined in the Credit Agreement.  The final maturity of the Revolving Credit Facility is August 28, 2020 and will be payable in full at that time.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">The interest rate in connection with the Credit Facilities shall be selected from the following by us: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The &#8220;Base Rate&#8221; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate for an interest period of one month plus 1% per annum. The &#8220;Eurodollar Rate&#8221; means the rate at which Eur</font><font style="font-family:Times New Roman;font-size:10pt;">odollar deposits in the London interbank market for an interest period of one, two, three or six months (as selected by us) are quoted. The &#8220;Applicable Rate&#8221; is based on the consolidated leverage ratio and is presented in the table below. As of December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">, the Applicable Rate is </font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">00</font><font style="font-family:Times New Roman;font-size:10pt;">% per annum for Base Rate Loans and </font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">0</font><font style="font-family:Times New Roman;font-size:10pt;">0</font><font style="font-family:Times New Roman;font-size:10pt;">%</font><font style="font-family:Times New Roman;font-size:10pt;"> per annum for Eurodollar Rate Loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Credit Facilities, as presented in the table below</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 29px"><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td><td   style="width: 160px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:160px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Consolidated  Leverage Ratio</font></td><td   style="width: 19px; text-align:center;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:80px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Margin for ABR Loans</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 105px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:105px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Margin for Eurodollar Loans</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:80px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Commitment Fee</font></td><td   style="width: 19px; text-align:center;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:80px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Letter of Credit Fee</font></td><td   style="width: 19px; text-align:center;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td><td   style="width: 160px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:160px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">&#8805; 2.75 to 1.0</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.00%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 105px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.00%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.40%</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.00%</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td></tr><tr style="height: 23px"><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td><td   style="width: 160px; text-align:center;border-color:#000000;min-width:160px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">&lt; 2.75 to 1.0 but &#8805; 1.75 to 1.0</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.50%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 105px; text-align:right;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.50%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.35%</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.50%</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td></tr><tr style="height: 25px"><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td><td   style="width: 160px; text-align:center;border-color:#000000;min-width:160px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">&lt; 1.75 to 1.0 but &#8805; 0.75 to 1.0</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.00%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 105px; text-align:right;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.00%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.30%</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.00%</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td><td   style="width: 160px; text-align:center;border-color:#000000;min-width:160px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">&lt; 0.75 to 1.0</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.50%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 105px; text-align:right;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.50%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.25%</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.50%</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td><td   style="width: 160px; text-align:center;border-color:#000000;min-width:160px;">&#160;</td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 105px; text-align:left;border-color:#000000;min-width:105px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Our</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">weighted average interest rate for our $100.0 million Term Loan, under our Credit Agreement, was </font><font style="font-family:Times New Roman;font-size:10pt;">2.5</font><font style="font-family:Times New Roman;font-size:10pt;">% for</font><font style="font-family:Times New Roman;font-size:10pt;"> 2016</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">2.7</font><font style="font-family:Times New Roman;font-size:10pt;">% </font><font style="font-family:Times New Roman;font-size:10pt;">for the period August 28, 2015 to December 31, 2015</font><font style="font-family:Times New Roman;font-size:10pt;">. Our weighted average interest rate for our $200.0 million Revolving Credit Facility was </font><font style="font-family:Times New Roman;font-size:10pt;">3.5</font><font style="font-family:Times New Roman;font-size:10pt;">% for 2016</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">As of December 31,</font><font style="font-family:Times New Roman;font-size:10pt;"> 2016,</font><font style="font-family:Times New Roman;font-size:10pt;"> our availability under our $200.0 million Revolving Credit Facility was </font><font style="font-family:Times New Roman;font-size:10pt;">$</font><font style="font-family:Times New Roman;font-size:10pt;">173.3</font><font style="font-family:Times New Roman;font-size:10pt;"> million as we had $</font><font style="font-family:Times New Roman;font-size:10pt;">26.7</font><font style="font-family:Times New Roman;font-size:10pt;"> million outstanding in letters of credit.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">The Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to EBITDA, as defined in the Credit Agreem</font><font style="font-family:Times New Roman;font-size:10pt;">ent, and (ii) a consolidated fixed charge coverage ratio of EBITDA plus rent expense (less cash taxes less capital expenditures) to scheduled debt repayments plus interest expense plus rent expense, all as defined in the Credit Agreement.  Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. </font><font style="font-family:Times New Roman;font-size:10pt;">As of </font><font style="font-family:Times New Roman;font-size:10pt;">December 31</font><font style="font-family:Times New Roman;font-size:10pt;">, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">, our consolidated </font><font style="font-family:Times New Roman;font-size:10pt;">leverage ratio was </font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">0</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">and our consolidated fixed charge coverage ratio was </font><font style="font-family:Times New Roman;font-size:10pt;">3.</font><font style="font-family:Times New Roman;font-size:10pt;">8</font><font style="font-family:Times New Roman;font-size:10pt;"> and we are in compliance with the Credit Agreement. </font><font style="font-family:Times New Roman;font-size:10pt;">The Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens; incurrence of additional debt; sales of assets and other fundamental corporate changes; investments; and declarations of dividends. These covenants contain customary exclusions and baskets. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">The Credit Facilities are guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than 70% of consolidated adjusted EBITDA, subject to certain exceptions. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In connection with entering into the Credit Agreement, we entered into (i) a Security Agreement with the Administrative Agent dated August 28, 2015 and (ii) a Pledge Agreement with the Administrative Agent dated as of August 28, 2015 for the purpose of securing the payment of our obligations under the Credit Agreement.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">Pursuant to the Security Agreement and the Pledge Agreement, as of the effective date of the Credit Agreement, our obligations under the Credit Agreement are secured by (i) the grant of a first lien security interest in the non-real estate assets of substantially all of our direct and indirect, wholly-owned subsidiaries (subject to exceptions) and (ii) the pledge of the equity interests in (a) substantially all of our direct and indirect, wholly-owned corporate, limited liability company and limited partnership subsidiaries and (b) those joint ventures which constitute subsidiaries under the Credit Agreement (subject, in the case of the Pledge Agreement, to exceptions).</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In connection with our entry into the Credit Agreement, on August 28, 2015, each of the Prior Credit Agreement and the Second Lien Credit Agreement </font><font style="font-family:Times New Roman;font-size:10pt;">were terminated. The Company paid a call premium of $700,000 associated with the </font><font style="font-family:Times New Roman;font-size:10pt;">termination of the Second Lien Credit Agreement and the voluntary prepayment of the amounts owed thereunder as of August 28, 2015, and expensed $2.5 million in deferred debt issuance costs during the three-month period ended </font><font style="font-family:Times New Roman;font-size:10pt;">September 30</font><font style="font-family:Times New Roman;font-size:10pt;">, 2015. Also in connection with our entry into the Credit Agreement, we recorded $2.4 million in deferred debt issuance costs as other assets in our consolidated balance sheet</font><font style="font-family:Times New Roman;font-size:10pt;"> during 2015 which was reclassified to long-term obligations, less current portion during 2016 in accordance with ASU 2015-03</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Promissory Notes</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Our promissory note outstanding of $0.7 million, issued in conjunction with an acquisition, bears an interest rate of 2.6%</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'>&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6783779136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style='margin-top:13pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;">8. INCOME TAXES</font></p><p style='margin-top:9pt; margin-bottom:9pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;"> </font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td colspan="12"  style="width: 665px; text-align:left;border-color:#000000;min-width:665px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Income taxes attributable to continuing operations consist of the following (amounts in millions):</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="8"  style="width: 219px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:219px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Years Ended December 31, </font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2014</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Current income tax expense/(benefit):</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Federal</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.5)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.2</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(13.9)</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">State and local</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.1)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.5</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(1.1)</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.6)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.7</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(15.0)</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Deferred income tax expense/(benefit):</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Federal </font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">22.1</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.5)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">21.0</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">State and local</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.4</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.1)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.6</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Foreign</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.1)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.1</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">24.5</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.7)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">22.7</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td colspan="2"  style="width: 391px; text-align:center;border-color:#000000;min-width:391px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Income tax expense/(benefit) from continuing operations</font></td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">23.9</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">7.7</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:center;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:center;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td colspan="12" rowspan="2" style="width: 665px; text-align:left;border-color:#000000;min-width:665px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Total income tax expense for the years ended December 31, 2016, 2015 and 2014 was allocated as follows (amounts in millions):</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="8"  style="width: 219px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:219px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Years Ended December 31, </font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2014</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Income from continuing operations </font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">23.9</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">7.7</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Income from discontinued operations </font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.1)</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Interest expense</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.1)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.2</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.1)</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Goodwill</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.1)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Stockholders' equity </font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(7.2)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(2.1)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.6</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">16.6</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">8.1</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">A reconciliation of significant differences between the reported amount of income tax expense and the expected amount of income tax expense that would result from applying the U.S. federal </font><font style="font-family:Times New Roman;font-size:10pt;">statutory</font><font style="font-family:Times New Roman;font-size:10pt;"> income tax rate of 35 percent to income before taxes from continuing operations is as follo</font><font style="font-family:Times New Roman;font-size:10pt;">ws:</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 12px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="8"  style="width: 237px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:237px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Years Ended December 31,</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 71px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:71px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 71px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:71px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015 (1)</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 71px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:71px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2014</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 7px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 16px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 16px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 16px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Income tax expense at U.S. federal statutory rate</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">35.0</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">35.0</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">35.0</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">%</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">State and local income taxes, net of federal income tax benefit</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.8</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(7.1)</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">5.8</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Valuation allowance</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.1</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">79.1</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.5</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Tax credits</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.6)</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">136.0</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(8.4)</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Uncertain tax positions </font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(1.0)</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(230.3)</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.6</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Other items, net (2)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.6</font></td><td   style="width: 16px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(663.3)</font></td><td   style="width: 16px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.1</font></td><td   style="width: 16px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Income tax expense/(benefit)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">38.9</font></td><td   style="width: 16px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:16px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(650.6)</font></td><td   style="width: 16px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:16px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">36.6</font></td><td   style="width: 16px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:16px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">%</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'></p><ul><li style="margin-left:36px;list-style:decimal;"><font style="font-family:Times New Roman;font-size:10pt;">The information provided for the year ended December 31, 2015 does not provide a meaningful reconciliation of the effective tax rate or comparable to other periods. The effective tax rate for the year is influenced by the relationship of the amount of &#8220;effective tax rate drivers&#8221; (i.e. non-deductible expenses, non-taxable income, tax credits, valuation allowance, uncertain tax positions, etc.) to income or loss before taxes. </font><font style="font-family:Times New Roman;font-size:10pt;">A significant</font><font style="font-family:Times New Roman;font-size:10pt;"> asset impairment was recorded in the first quarter, resulting in a scenario where the company's loss before tax for the year was near zero. Consequently, for 2015, the relationship between </font><font style="font-family:Times New Roman;font-size:10pt;">the &#8220;effective tax rate drivers&#8221;</font><font style="font-family:Times New Roman;font-size:10pt;"> and loss before taxes is distorted. </font></li><li style="margin-left:36px;list-style:decimal;"><font style="font-family:Times New Roman;font-size:10pt;">Includes various items such as, non-deductible expenses, non-taxable income, return-to-accrual adjustments, and foreign tax rate differential.</font></li></ul><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">As of December 31,</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">2015</font><font style="font-family:Times New Roman;font-size:10pt;">, the Company had income taxes receivable of $</font><font style="font-family:Times New Roman;font-size:10pt;">1.3</font><font style="font-family:Times New Roman;font-size:10pt;"> million and $</font><font style="font-family:Times New Roman;font-size:10pt;">0</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million, respectively, included in other current </font><font style="font-family:Times New Roman;font-size:10pt;">assets</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td colspan="2"  style="width: 533px; text-align:left;border-color:#000000;min-width:533px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Deferred tax assets (liabilities) consist of the following components (amounts in millions):</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="5"  style="width: 142px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:142px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">As of December 31,</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:55px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:55px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Deferred tax assets:</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Allowance for doubtful accounts</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.9</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.4</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Accrued payroll &amp; employee benefits</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">11.4</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">5.1</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Workers' compensation</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.9</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">9.8</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Amortization of intangible assets</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">56.3</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">72.2</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Share-based compensation</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">7.8</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">5.0</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Net operating loss carryforwards (1)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">44.2</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">48.5</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Tax credit carryforwards (2)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.8</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.7</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Other</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.1</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.0</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Gross deferred tax assets</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">143.4</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">155.7</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Less: valuation allowance</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.4)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.3)</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Net deferred tax assets</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">143.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">155.4</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Deferred tax (liabilities):</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Property and equipment</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(7.8)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(9.5)</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Deferred revenue</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(23.2)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(18.5)</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Investment in partnerships</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(3.2)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.2)</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Other liabilities </font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.9)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(2.0)</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Gross deferred tax (liabilities)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(35.1)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(30.2)</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Net deferred tax assets (liabilities)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> $ </font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">107.9</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> $ </font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">125.2</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">(1)</font></td><td colspan="7" rowspan="4" style="width: 660px; text-align:left;border-color:#000000;min-width:660px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The net operating loss ("NOL") carry forwards in the income tax returns include unrecognized tax benefits resulting from uncertain tax positions. Accordingly, the deferred tax assets recognized for the NOL carry forwards, as of December 31, 2016 and 2015, are presented net of unrecognized tax benefits of $3.1 million.</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">(2)</font></td><td colspan="7" rowspan="4" style="width: 660px; text-align:left;border-color:#000000;min-width:660px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The tax credit carry forwards in the income tax returns include unrecognized tax benefits resulting from uncertain tax positions. Accordingly, the deferred tax assets recognized for the tax credit carry forwards are presented net of unrecognized tax benefits of $0.7 million for each of the years ended December 31, 2016 and 2015.</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">As of December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">, we have U.S. </font><font style="font-family:Times New Roman;font-size:10pt;">net operating loss (&#8220;NOL&#8221;)</font><font style="font-family:Times New Roman;font-size:10pt;"> carry forward</font><font style="font-family:Times New Roman;font-size:10pt;">s</font><font style="font-family:Times New Roman;font-size:10pt;"> of $</font><font style="font-family:Times New Roman;font-size:10pt;">102.1</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million that </font><font style="font-family:Times New Roman;font-size:10pt;">are</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">available to reduce future taxable income</font><font style="font-family:Times New Roman;font-size:10pt;"> and begin</font><font style="font-family:Times New Roman;font-size:10pt;"> to expire in 2034</font><font style="font-family:Times New Roman;font-size:10pt;">. In addition, we have</font><font style="font-family:Times New Roman;font-size:10pt;"> r</font><font style="font-family:Times New Roman;font-size:10pt;">esearch </font><font style="font-family:Times New Roman;font-size:10pt;">and</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">d</font><font style="font-family:Times New Roman;font-size:10pt;">evelopment tax credits, employment tax credits, and alternative minimum tax credits</font><font style="font-family:Times New Roman;font-size:10pt;"> of $1.9 million, $</font><font style="font-family:Times New Roman;font-size:10pt;">0.2</font><font style="font-family:Times New Roman;font-size:10pt;"> million and $</font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;"> million, </font><font style="font-family:Times New Roman;font-size:10pt;">respectively, available to reduce future U.S. federal income taxes. The </font><font style="font-family:Times New Roman;font-size:10pt;">r</font><font style="font-family:Times New Roman;font-size:10pt;">esearch </font><font style="font-family:Times New Roman;font-size:10pt;">and</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">d</font><font style="font-family:Times New Roman;font-size:10pt;">evelopment tax credits and employment tax credits begin to expire in 2032, and the alternative minimum tax credits are available indefinitely</font><font style="font-family:Times New Roman;font-size:10pt;">. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">As of December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">, we have state NOL carry forwards of $</font><font style="font-family:Times New Roman;font-size:10pt;">268.4</font><font style="font-family:Times New Roman;font-size:10pt;"> million that are available to reduce future taxable income. In addition, we have $</font><font style="font-family:Times New Roman;font-size:10pt;">3.1</font><font style="font-family:Times New Roman;font-size:10pt;"> million of various state tax credits available to reduce future taxable income. The state NOL and tax credit carry forwards begin to expire at various times.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">The</font><font style="font-family:Times New Roman;font-size:10pt;"> valuation allowance </font><font style="font-family:Times New Roman;font-size:10pt;">for deferred </font><font style="font-family:Times New Roman;font-size:10pt;">tax assets as of December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;"> and 201</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;"> was $</font><font style="font-family:Times New Roman;font-size:10pt;">0.4</font><font style="font-family:Times New Roman;font-size:10pt;"> million and $0.</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;"> million, respectively. </font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">The net change in the total valuation allowance for the year ended December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;"> and December 31</font><font style="font-family:Times New Roman;font-size:10pt;">, 201</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;"> was </font><font style="font-family:Times New Roman;font-size:10pt;">a</font><font style="font-family:Times New Roman;font-size:10pt;">n</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">increase</font><font style="font-family:Times New Roman;font-size:10pt;"> of $</font><font style="font-family:Times New Roman;font-size:10pt;">0.</font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;"> million</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">a </font><font style="font-family:Times New Roman;font-size:10pt;">decrease </font><font style="font-family:Times New Roman;font-size:10pt;">of $0.3 million, respectively</font><font style="font-family:Times New Roman;font-size:10pt;">. The valuation allowance during 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;"> and 201</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;"> was primarily related to certain state NOL and state tax credit carry forwards</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In assessing the </font><font style="font-family:Times New Roman;font-size:10pt;">realizability</font><font style="font-family:Times New Roman;font-size:10pt;"> of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those jurisdictions during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities (including the impact of available carry back and carry forward periods), projected future taxable income, and tax-planning strategies in making this assessment. In order to fully realize the deferred tax assets, the Company will need to generate future taxable income before the expiration of the carry forwards governed by the tax code. Based on the current level of pretax earnings</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">the Company will generate the minimum amount of future taxable income to support the realization of the deferred tax assets. As a result, management believes that it is more likely than not that we will realize the benefits of these deferred tax assets, net of the existing valuation allowances at December&#160;31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">. The amount of the deferred tax asset considered realizable, however, could be reduced in the near term if estimates of future taxable income during the carry forward period are reduced</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 10px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 17px"><td colspan="10"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Uncertain Tax Positions</font></td></tr><tr style="height: 9px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 34px"><td colspan="10"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">We account for uncertain tax positions in accordance with the authoritative guidance for uncertain tax positions. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (amounts in millions):</font></td></tr><tr style="height: 9px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 23px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="5"  style="width: 142px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:142px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Years Ended December 31, </font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td colspan="2"  style="width: 468px; text-align:left;border-color:#000000;min-width:468px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Balance at beginning of period</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.7</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.0</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Additions for tax positions related to current year</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Additions for tax positions related to prior year</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.0</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Reductions for tax positions related to prior years</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Lapse of statute of limitations</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.6)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.3)</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Settlements</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td colspan="2"  style="width: 468px; text-align:left;border-color:#000000;min-width:468px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Balance at end of period</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.1</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.7</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">As of December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">, there are $</font><font style="font-family:Times New Roman;font-size:10pt;">0.</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;"> million</font><font style="font-family:Times New Roman;font-size:10pt;"> and $</font><font style="font-family:Times New Roman;font-size:10pt;">3.8 </font><font style="font-family:Times New Roman;font-size:10pt;">million of unrecognized tax benefits recorded in </font><font style="font-family:Times New Roman;font-size:10pt;">accrued</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">other long-term obligations and deferred income taxes, respectively, </font><font style="font-family:Times New Roman;font-size:10pt;">within the </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated balance sheet</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Included in the balance of unrecognized tax benefits at December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;"> is $4.</font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;"> million of tax benefits that, if recognized in future periods, would impact our effective tax rate. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">During the years ended December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;"> and 201</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;">, we recognized interest and penalties of $</font><font style="font-family:Times New Roman;font-size:10pt;">(0.1)</font><font style="font-family:Times New Roman;font-size:10pt;"> million and $0.</font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;"> million, respectively, as components of p</font><font style="font-family:Times New Roman;font-size:10pt;">enalties or interest expense in connection with our reserve for uncertain tax positions. Interest and penalties, related to uncertain tax positions, included in the consolidated balance sheet at December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;"> and 201</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;"> were less than </font><font style="font-family:Times New Roman;font-size:10pt;">$0.1 and </font><font style="font-family:Times New Roman;font-size:10pt;">$0.</font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;"> million</font><font style="font-family:Times New Roman;font-size:10pt;">, respectively</font><font style="font-family:Times New Roman;font-size:10pt;">.  </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We are subject to income taxes in the U.S. and in many of the 50 individual states, with significant operations in Louisiana, Alabama, Georgia, and Tennessee. We are open to examination in the U.S. and in various individual states for tax years ended December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;"> through December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">. We are also open to examination in various states for the years ended 200</font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;"> &#8211; </font><font style="font-family:Times New Roman;font-size:10pt;">201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;"> resulting from net operating losses generated and available for carry forward from those years</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We believe that it is reasonab</font><font style="font-family:Times New Roman;font-size:10pt;">ly possible that decrease</font><font style="font-family:Times New Roman;font-size:10pt;">s</font><font style="font-family:Times New Roman;font-size:10pt;"> of </font><font style="font-family:Times New Roman;font-size:10pt;">up to $0.3</font><font style="font-family:Times New Roman;font-size:10pt;"> million in unrecognized tax benefits, each of which are individually insignificant, may be recognized by the end of December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;"> as a result of an anticipated settlement and lapse of the statute of limitations</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958299136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">CAPITAL SOCK AND SHARE-BASED COMPENSATION</a></td>
<td class="text"><p style='margin-top:13pt; margin-bottom:4.5pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;">9. CAPITAL STOCK AND SHARE-BASED COMPENSATION</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We are authorized by our Certificate of Incorporation to issue 60,000,000 shares of common stock, $0.001 par value and 5,000,000 shares of preferred stock, $0.001 par value</font><font style="font-family:Times New Roman;font-size:10pt;">.  As of </font><font style="font-family:Times New Roman;font-size:10pt;">December 31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">there </font><font style="font-family:Times New Roman;font-size:10pt;">were </font><font style="font-family:Times New Roman;font-size:10pt;">35</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;">253</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;">577</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">and </font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;">597</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;">215</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">shares</font><font style="font-family:Times New Roman;font-size:10pt;"> of common stock </font><font style="font-family:Times New Roman;font-size:10pt;">issued and outstanding, respectively</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">and no shares of preferred stock issued </font><font style="font-family:Times New Roman;font-size:10pt;">or </font><font style="font-family:Times New Roman;font-size:10pt;">outstanding. Our Board of Directors is authorized to fix the dividend rights and terms, conversion and voting rights, redemption rights and other privileges and restrictions applicable to our preferred stock.</font></p><p style='margin-top:9pt; margin-bottom:4.5pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Share-Based Awards</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Our 2008 Omnibus Incentive Compensation Plan (the &#8220;Plan&#8221;) authorizes the grant of various types of equity-based awards, such as stock awards, restricted stock units, stock appreciation rights and stock options to eligible participants, which include all of our employees and all employees of our </font><font style="font-family:Times New Roman;font-size:10pt;">50</font><font style="font-family:Times New Roman;font-size:10pt;">% or more owned subsidiaries, our non-employee directors and certain consultants. The vesting terms of the awards may be tied to continued employment (or, for our non-employee directors, continued service on the Board of Directors) and/or achievement of certain pre-determined performance goals. We refer to stock awards subject to service-based vesting conditions as &#8220;non-vested stock&#8221; and restricted stock units subject to service-based and performance-based </font><font style="font-family:Times New Roman;font-size:10pt;">or market-based </font><font style="font-family:Times New Roman;font-size:10pt;">vesting conditions as &#8220;non-vested stock units.&#8221; The Plan is administered by the Compensation Committee of our Board of Directors, which determines, within the provisions of the Plan, those eligible employees to whom, and the times at which, awards shall be granted. The Compensation Committee, in its discretion, may delegate its authority and duties under the Plan to specified officers; however, only the Compensation Committee may approve the terms of awards to our executive officers.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Equity-based awards may be granted for a number of shares not to exceed, in the aggregate, approximately </font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million</font><font style="font-family:Times New Roman;font-size:10pt;"> shares of common stock, and we had </font><font style="font-family:Times New Roman;font-size:10pt;">approximately </font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million</font><font style="font-family:Times New Roman;font-size:10pt;"> shares available at </font><font style="font-family:Times New Roman;font-size:10pt;">December 31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;">. The price per share for stock options shall be of no less than the greater of (a) </font><font style="font-family:Times New Roman;font-size:10pt;">100</font><font style="font-family:Times New Roman;font-size:10pt;">% of the fair value of a share of common stock on the date the option is granted or (b) the aggregate par value of the shares of our common stock on the date the option is granted. If a stock option is granted to any owner of </font><font style="font-family:Times New Roman;font-size:10pt;">10</font><font style="font-family:Times New Roman;font-size:10pt;">% or more of our total combined voting power of us and our subsidiaries, the price is to be at least </font><font style="font-family:Times New Roman;font-size:10pt;">110</font><font style="font-family:Times New Roman;font-size:10pt;">% of the fair value of a share of our common stock on the date the award is granted. Each equity-based award vests ratably over a 12 month</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">to</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">six</font><font style="font-family:Times New Roman;font-size:10pt;"> year period, with the exception of those issued under contractual arrangements that specify otherwise, that may be exercised during a period as determined by our Compensation Committee or as otherwise approved by our Compensation Committee. The contractual terms of stock options exercised shall not exceed </font><font style="font-family:Times New Roman;font-size:10pt;">ten</font><font style="font-family:Times New Roman;font-size:10pt;"> years from the date such option is granted.</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:4.5pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Employee Stock Purchase Plan (&#8220;ESPP&#8221;)</font></p><p style='margin-top:0pt; margin-bottom:9pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We have a plan whereby our eligible employees may purchase our common stock at </font><font style="font-family:Times New Roman;font-size:10pt;">85</font><font style="font-family:Times New Roman;font-size:10pt;">% of the market price at the time of purchase. On June 7, 20</font><font style="font-family:Times New Roman;font-size:10pt;">12</font><font style="font-family:Times New Roman;font-size:10pt;">, our stockholders ratified an amendment adopted by our Board of Directors to increase the total number of shares of our common stock </font><font style="font-family:Times New Roman;font-size:10pt;">authorized for the issuance under our ESPP from </font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;">500</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;">000</font><font style="font-family:Times New Roman;font-size:10pt;"> shares to </font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;">,500,000</font><font style="font-family:Times New Roman;font-size:10pt;"> shares, and as of December 31, 2016, there were </font><font style="font-family:Times New Roman;font-size:10pt;">1,</font><font style="font-family:Times New Roman;font-size:10pt;">460</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;">8</font><font style="font-family:Times New Roman;font-size:10pt;">00</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">shares available for future issuance. The following is a detail of the purchases that were made or pending Board of Director approval under the plan:</font></p><p style='margin-top:0pt; margin-bottom:10pt'>&#160;</p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"><font style="FONT-WEIGHT: bold;TEXT-DECORATION: underline;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;">Employee Stock Purchase Plan Period</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Shares Issued</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Price</font></td></tr><tr style="height: 16px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2014 and Prior</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2,899,528</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">13.78</font></td></tr><tr style="height: 14px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">January 1, 2015 to March 31, 2015</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">24,368</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">22.76</font></td></tr><tr style="height: 14px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">April 1, 2015 to June 30, 2015</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">15,750</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">33.77</font></td></tr><tr style="height: 14px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">July 1, 2015 to September 30, 2015</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">18,984</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">32.27</font></td></tr><tr style="height: 14px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">October 1, 2015 to December 31, 2015</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">19,082</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">33.42</font></td></tr><tr style="height: 14px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">January 1, 2016 to March 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">13,850</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">41.09</font></td></tr><tr style="height: 14px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">April 1, 2016 to June 30, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">14,236</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">42.91</font></td></tr><tr style="height: 14px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">July 1, 2016 to September 30, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">16,520</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">40.32</font></td></tr><tr style="height: 14px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">October 1, 2016 to December 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">16,882</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">36.24</font></td></tr><tr style="height: 14px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3,039,200</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:4pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">ESPP expense included in general and administrative expense in our accompanying consolidated statements</font><font style="font-family:Times New Roman;font-size:10pt;"> of operations</font><font style="font-family:Times New Roman;font-size:10pt;"> was $</font><font style="font-family:Times New Roman;font-size:10pt;">0.4</font><font style="font-family:Times New Roman;font-size:10pt;"> million</font><font style="font-family:Times New Roman;font-size:10pt;"> for each of</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">201</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">201</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;">, respectively.</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 18px"><td colspan="5"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Stock Options</font></td></tr><tr style="height: 17px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:left;border-color:#000000;min-width:105px;">&#160;</td><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td></tr><tr style="height: 34px"><td colspan="5"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">We use the Black-Scholes option pricing model to estimate the fair value of our stock options. There were 268,538, 590,647 and 250,000 options granted during 2016, 2015 and 2014, respectively. Stock option compensation expense included in general and administrative expense in our accompanying consolidated statements of operations was $6.3 million, $3.8 million and $0.1 million for 2016, 2015 and 2014, respectively.</font></td></tr><tr style="height: 9px"><td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:center;border-color:#000000;min-width:395px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;">&#160;</td><td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;">&#160;</td></tr><tr style="height: 17px"><td colspan="5"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The fair value of the 2016 awards were estimated using the following assumptions:</font></td></tr><tr style="height: 15px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:left;border-color:#000000;min-width:105px;">&#160;</td><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Risk Free Rate</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">1.19% - 1.58%</font></td><td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Expected Volatility</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">53.44 % -  54.89%</font></td><td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Expected Term</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">5.86 - 6.25  years</font></td><td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Weighted Average Fair Value</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">$25.99</font></td><td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;">&#160;</td><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td></tr><tr style="height: 14px"><td colspan="5"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">We used the simplified method to estimate the expected term for the stock options granted during 2016.</font></td></tr><tr style="height: 14px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:left;border-color:#000000;min-width:105px;">&#160;</td><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td colspan="9"  style="width: 692px; text-align:left;border-color:#000000;min-width:692px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following table presents our stock option activity for 2016:</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 40px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Number of Shares</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 97px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:97px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Weighted Average Exercise Price</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:70px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Weighted Average Contractual Life (Years)</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td colspan="2"  style="width: 406px; text-align:center;border-color:#000000;min-width:406px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Outstanding options at January 1, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 838,494</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 87px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:87px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">30.18</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">9.31</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Granted</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">268,538</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 87px; text-align:right;border-color:#000000;min-width:87px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">37.21</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Exercised</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 87px; text-align:right;border-color:#000000;min-width:87px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Canceled, forfeited or expired</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(98,875)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 87px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:87px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">35.45</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td colspan="2"  style="width: 406px; text-align:center;border-color:#000000;min-width:406px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Outstanding options at December 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 1,008,157</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 87px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:87px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">31.54</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">8.42</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td colspan="2"  style="width: 406px; text-align:center;border-color:#000000;min-width:406px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Exercisable options at December 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 281,458</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 87px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:87px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">28.86</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">8.21</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 87px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:87px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 31px"><td colspan="10"  style="width: 727px; text-align:left;border-color:#000000;min-width:727px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The aggregate intrinsic value of our outstanding options and exercisable options at December 31, 2016 was $11.9 million and $3.9 million, respectively.  There were no options exercised during 2016. Total intrinsic value of options exercised was $0.2 million and $0.1 million for 2015 and 2014, respectively.</font></td></tr><tr style="height: 18px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 87px; text-align:left;border-color:#000000;min-width:87px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 18px"><td colspan="9"  style="width: 692px; text-align:left;border-color:#000000;min-width:692px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following table presents our non-vested stock option award activity for 2016:</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 18px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td  rowspan="2" style="width: 85px; text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Number of Shares</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2" rowspan="2" style="width: 97px; text-align:center;border-color:#000000;min-width:97px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Weighted Average Grant Date Fair Value</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 26px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 87px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:87px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 17px"><td colspan="2"  style="width: 406px; text-align:left;border-color:#000000;min-width:406px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Non-vested stock options at January 1, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">775,994</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 87px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:87px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">30.47</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Granted</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">268,538</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 87px; text-align:right;border-color:#000000;min-width:87px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">37.21</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Vested</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(219,872)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 87px; text-align:right;border-color:#000000;min-width:87px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">29.55</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Forfeited</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(97,961)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 87px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:87px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">35.38</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 17px"><td colspan="2"  style="width: 406px; text-align:left;border-color:#000000;min-width:406px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Non-vested stock options at December 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 726,699</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 87px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:87px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 32.58</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 10px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 87px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:87px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 39px"><td colspan="10"  style="width: 727px; text-align:left;border-color:#000000;min-width:727px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">At December 31, 2016, there was $7.2 million of unrecognized compensation cost related to stock options that we expect to be recognized over a weighted-average period of 2.1 years.</font></td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 18px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Non-Vested Stock</font></td></tr><tr style="height: 9px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 68px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">We issue shares of non-vested stock with vesting terms ranging from one to six years. The compensation expense is determined based on the market price of our common stock at the date of grant applied to the total number of shares that are anticipated to fully vest. Non-vested stock compensation expense included in general and administrative expenses in our accompanying consolidated statements of operations was $2.3 million, $5.0 million and $4.6 million for 2016, 2015 and 2014, respectively.</font></td></tr><tr style="height: 9px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 17px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following table presents our non-vested stock award activity for 2016:</font></td></tr><tr style="height: 34px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Number of Shares</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Weighted Average Grant Date Fair Value</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Non-vested stock at January 1, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 500,888</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">18.24</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Granted</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 21,202</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">50.55</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Vested</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(222,783)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">18.00</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Canceled, forfeited or expired</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(89,929)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">17.26</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Non-vested stock at December 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 209,378</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">22.20</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 34px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The weighted average grant date fair value of non-vested stock granted was $50.55, $28.48 and $16.38 in 2016, 2015, and 2014, respectively.</font></td></tr><tr style="height: 11px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 34px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">At December 31, 2016, there was $1.4 million of unrecognized compensation cost related to non-vested stock award payments that we expect to be recognized over a  weighted average period of 0.9 years. </font></td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:4.5pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Non-Vested Stock Units</font></p><p style='margin-top:0pt; margin-bottom:10pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We issue non-vested stock unit awards that are service-based, performance-based or a combination of both with vesting terms ranging from one to six years. Based on the terms and conditions of these awards, we determine if the awards should be recorded as either equity or liability instruments. The compensation expense is determined based on the market price of our common stock at the date of grant, applied to the total number of units that are anticipated to vest, unless the award specifies differently. We account for such awards similar to our non-vested stock awards; however, no shares of stock are issued to the recipient until the stock unit awards have vested and after the pre-determined delivery date has occurred.</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 18px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Non-Vested Stock Units - Service-Based </font></td></tr><tr style="height: 9px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 44px"><td colspan="8" rowspan="2" style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Service-based non-vested stock unit compensation expense included in general and administrative expenses in our accompanying consolidated statements of operations was $3.6 million and $1.0 million for 2016 and 2015, respectively.</font></td></tr><tr style="height: 17px"><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 19px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 17px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following table presents our service-based non-vested stock units activity for 2016:</font></td></tr><tr style="height: 34px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Number of Shares</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Weighted Average Grant Date Fair Value</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Non-vested stock units at January 1, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 183,332</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">37.89</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Granted</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 147,896</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">45.60</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Vested</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(32,607)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">38.81</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Canceled, forfeited or expired</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(49,192)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">39.38</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Non-vested stock units at December 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 249,429</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">42.05</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 34px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The weighted average grant date fair value of service-based non-vested stock units granted was $45.60 and $37.98 in 2016 and 2015, respectively.</font></td></tr><tr style="height: 11px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 34px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">At December 31, 2016, there was $6.7 million of unrecognized compensation cost related to our service-based non-vested stock units that we expect to be recognized over a  weighted average period of 2.2 years. </font></td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:4.5pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Non-</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;">V</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;">ested Stock Units &#8211; Service-</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;">B</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;">ased and Performance-</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;">B</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;">ased Awards</font></p><p style='margin-top:0pt; margin-bottom:10pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">During 2016</font><font style="font-family:Times New Roman;font-size:10pt;">, we awarded performance-based awards to certain employees. The target level established by the award, which is based </font><font style="font-family:Times New Roman;font-size:10pt;">on the Company's 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;"> adjusted earnings before interest, taxes and depreciation (&#8220;EBITDA&#8221;), provided for the recipients to receive </font><font style="font-family:Times New Roman;font-size:10pt;">182,796</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">non</font><font style="font-family:Times New Roman;font-size:10pt;">-vested stock units if the target was achieved.  The target number of shares to be potentially awarded has been reduced by forfeitures as indicated in the table below. Performance-based non-vested stock units compensation expense included in general and administrative expenses in our consolidated statements of </font><font style="font-family:Times New Roman;font-size:10pt;">operations was $</font><font style="font-family:Times New Roman;font-size:10pt;">3.</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;"> million </font><font style="font-family:Times New Roman;font-size:10pt;">and $1.3 million </font><font style="font-family:Times New Roman;font-size:10pt;">for</font><font style="font-family:Times New Roman;font-size:10pt;"> 2016</font><font style="font-family:Times New Roman;font-size:10pt;"> and</font><font style="font-family:Times New Roman;font-size:10pt;"> 2015</font><font style="font-family:Times New Roman;font-size:10pt;">, respectively</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:0pt; margin-bottom:4.5pt'>&#160;</p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 17px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following table presents our performance-based non-vested stock units activity for 2016:</font></td></tr><tr style="height: 31px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Number of Shares</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Weighted Average Grant Date Fair Value</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Non-vested stock units at January 1, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 151,063</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">39.44</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Granted</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 182,796</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">46.29</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Vested</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> (44,729)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">34.83</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Canceled, forfeited or expired</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> (64,273)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">42.41</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Non-vested stock units at December 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 224,857</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">45.08</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">The weighted average grant date fair value of </font><font style="font-family:Times New Roman;font-size:10pt;">performance-based </font><font style="font-family:Times New Roman;font-size:10pt;">non-vested stock </font><font style="font-family:Times New Roman;font-size:10pt;">units </font><font style="font-family:Times New Roman;font-size:10pt;">granted was</font><font style="font-family:Times New Roman;font-size:10pt;"> $</font><font style="font-family:Times New Roman;font-size:10pt;">46</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">29</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">and $39.54 </font><font style="font-family:Times New Roman;font-size:10pt;">in</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">201</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;">, respectively</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">At December 31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;">, there were $</font><font style="font-family:Times New Roman;font-size:10pt;">6.4</font><font style="font-family:Times New Roman;font-size:10pt;"> million in</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">unrecognized compensation cost</font><font style="font-family:Times New Roman;font-size:10pt;">s</font><font style="font-family:Times New Roman;font-size:10pt;"> related to our </font><font style="font-family:Times New Roman;font-size:10pt;">performance</font><font style="font-family:Times New Roman;font-size:10pt;">-based </font><font style="font-family:Times New Roman;font-size:10pt;">non-vested stock units</font><font style="font-family:Times New Roman;font-size:10pt;"> that we expect to be recognized over </font><font style="font-family:Times New Roman;font-size:10pt;">a weighted average period of 2.0</font><font style="font-family:Times New Roman;font-size:10pt;"> years</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:0pt; margin-bottom:10pt'>&#160;</p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:4.5pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Non-</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;">Vested Stock Units &#8211; Service-Based and Market-Based Awards</font></p><p style='margin-top:0pt; margin-bottom:4.5pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">During 2013</font><font style="font-family:Times New Roman;font-size:10pt;">, we awarded market-based awards to certain employees. The target level e</font><font style="font-family:Times New Roman;font-size:10pt;">stablished by the award, which wa</font><font style="font-family:Times New Roman;font-size:10pt;">s based on </font><font style="font-family:Times New Roman;font-size:10pt;">our</font><font style="font-family:Times New Roman;font-size:10pt;"> average December 2015 stock price, provide</font><font style="font-family:Times New Roman;font-size:10pt;">d</font><font style="font-family:Times New Roman;font-size:10pt;"> for the recipients to receive </font><font style="font-family:Times New Roman;font-size:10pt;">417,330</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">non-vested stock units if the target is ach</font><font style="font-family:Times New Roman;font-size:10pt;">ieved. If the target objective wa</font><font style="font-family:Times New Roman;font-size:10pt;">s surpassed to the point of achieving the projected maximum payout, the recipients </font><font style="font-family:Times New Roman;font-size:10pt;">would</font><font style="font-family:Times New Roman;font-size:10pt;"> receive </font><font style="font-family:Times New Roman;font-size:10pt;">667,728</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">non-vested stock units. The target number of shares to be potentially awarded </font><font style="font-family:Times New Roman;font-size:10pt;">was</font><font style="font-family:Times New Roman;font-size:10pt;"> reduced by forfeitures </font><font style="font-family:Times New Roman;font-size:10pt;">as indicated in the table below. As of </font><font style="font-family:Times New Roman;font-size:10pt;">March 3</font><font style="font-family:Times New Roman;font-size:10pt;">, 2016, it was determined that the market-based objective established by the award was satisfied at maximum payout and as a result, 248,654 stock units were awarded to the </font><font style="font-family:Times New Roman;font-size:10pt;">recipients</font><font style="font-family:Times New Roman;font-size:10pt;"> on April 1, 2016</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:0pt; margin-bottom:9pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">For market-based awards, the effect of the market condition is reflected in the fair value of the awards at the date of grant using a</font><font style="font-family:Times New Roman;font-size:10pt;"> Monte-Carlo simulation model. A Monte-Carlo simulation model estimates the fair value of the market-based award based upon the expected term, risk-free interest rate and expected volatility. Compensation expense for market-based awards is recognized over the vesting period regardless of whether the market conditions are expected to be achieved.</font><font style="font-family:Times New Roman;font-size:10pt;"> Market-based n</font><font style="font-family:Times New Roman;font-size:10pt;">on-</font><font style="font-family:Times New Roman;font-size:10pt;">vested stock units </font><font style="font-family:Times New Roman;font-size:10pt;">compensation expense included in general and administrative expenses in our accompanying consolidated statements</font><font style="font-family:Times New Roman;font-size:10pt;"> of operations</font><font style="font-family:Times New Roman;font-size:10pt;"> was </font><font style="font-family:Times New Roman;font-size:10pt;">$</font><font style="font-family:Times New Roman;font-size:10pt;">0.</font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;"> million, </font><font style="font-family:Times New Roman;font-size:10pt;">$0.</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;"> million</font><font style="font-family:Times New Roman;font-size:10pt;"> and $0.5</font><font style="font-family:Times New Roman;font-size:10pt;"> million</font><font style="font-family:Times New Roman;font-size:10pt;"> for </font><font style="font-family:Times New Roman;font-size:10pt;">201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">, 201</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">201</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;">, respectively</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">The fair value of the </font><font style="font-family:Times New Roman;font-size:10pt;">2013</font><font style="font-family:Times New Roman;font-size:10pt;"> award was estimated using the following</font><font style="font-family:Times New Roman;font-size:10pt;"> assumptions</font><font style="font-family:Times New Roman;font-size:10pt;">:</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 14px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Forward Interest Rate</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">0.327 % - 1.460%</font></td><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Expected Volatility</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">54.38%</font></td><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Requisite Service Period</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">3 years</font></td><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Fair Value</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">$ 10.51</font></td><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 17px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following table presents our market-based non-vested stock units activity for 2016:</font></td></tr><tr style="height: 31px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Number of Shares</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Weighted Average Grant Date Fair Value</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Non-vested stock units at January 1, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 164,534</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.51</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Granted (1)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 93,257</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.51</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Vested</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> (248,654)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.51</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Canceled, forfeited or expired</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> (9,137)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.51</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Non-vested stock units at December 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> -</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:center;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:center;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:center;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:center;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:right;border-color:#000000;min-width:35px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(1) </font></td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Represents shares awarded upon achievement of maximum payout. </font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">The weighted average grant date fair value of </font><font style="font-family:Times New Roman;font-size:10pt;">market-based </font><font style="font-family:Times New Roman;font-size:10pt;">non-vested stock </font><font style="font-family:Times New Roman;font-size:10pt;">units </font><font style="font-family:Times New Roman;font-size:10pt;">granted was</font><font style="font-family:Times New Roman;font-size:10pt;"> $</font><font style="font-family:Times New Roman;font-size:10pt;">10.</font><font style="font-family:Times New Roman;font-size:10pt;">51 </font><font style="font-family:Times New Roman;font-size:10pt;">in</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">201</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">A</font><font style="font-family:Times New Roman;font-size:10pt;">ll of our outstanding market-based non-vested stock units were fully vested as of April 1, 2016</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958272304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style='margin-top:13pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;">10</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">COMMITMENTS AND CONTINGENCIES</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"> </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Legal Proceedings </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;">&#8211; Ongoing</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We </font><font style="font-family:Times New Roman;font-size:10pt;">are involved in the following legal actions: </font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Securities Class Action Lawsuits </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On June&#160;10, 2010, a putative securities class action complaint was filed in the United States District Court for the Middle District of Louisiana (the &#8220;District Court&#8221;) against the Company and certain of our current and former senior executives. Additional putative securities class actions were filed in the District Court on July&#160;14,&#160;July&#160;16, and July&#160;28, 2010.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On January&#160;18, 2011, the Co-Lead Plaintiffs filed an amended, consolidated&#160;class action complaint (the &#8220;Securities Complaint&#8221;) which supersedes the earlier-filed securities class action complaints.&#160;The Securities Complaint alleges that the defendants made false and/or misleading statements and failed to disclose material facts about our business, financial condition, operations and prospects, particularly relating to our policies and practices regarding home therapy visits under the Medicare home health prospective payment system and the related alleged impact on our business, financial condition, operations and prospects. The Securities Complaint seeks a determination that the action may be maintained as a class action on behalf of all persons who purchased the Company's securities between August&#160;2, 2005 and September&#160;28, 2010 and an unspecified amount of damages.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">All defendants moved to dismiss the Securities Complaint. On June&#160;28, 2012, the District Court granted the defendants' motion to dismiss the Securities Complaint. On July&#160;26, 2012, the Co-Lead Plaintiffs filed a motion for reconsideration, which the District Court denied on April&#160;9, 2013.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On May&#160;3, 2013, the Co-Lead Plaintiffs appealed the dismissal of the Securities Complaint to the United States Court of Appeals for the Fifth Circuit (the &#8220;Fifth Circuit&#8221;). On October 2, 2014, a three-judge panel of the Fifth Circuit issued a decision reversing the District Court's dismissal of the Securities Complaint. On October 16, 2014, all defendants filed a petition with the Fifth Circuit to review the three-judge panel's decision </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">en banc</font><font style="font-family:Times New Roman;font-size:10pt;">, or as a whole court. On December 29, 2014, the Fifth Circuit denied the defendants' motion for </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">en banc</font><font style="font-family:Times New Roman;font-size:10pt;"> review of the Fifth Circuit panel's decision reversing the District Court's dismissal of the Securities Complaint.&#160; The case then returned to the District Court for further proceedings. On March 30, 2015, the defendants filed a Petition for Writ of Certiorari (the &#8220;Petition&#8221;) with the United States Supreme Court asking the Supreme Court to consider whether the Fifth Circuit erred in reversing the District Court's dismissal of the Securities Complaint. The Supreme Court denied the Petition on June 29, 2015, which did not affect the ongoing proceedings before the District Court, including the District Court's consideration of a motion filed on April 3, 2015, by the Co-Lead Plaintiffs for leave to amend the Securities Complaint, which motion was granted by the District Court. On December 15, 2015, the defendants filed a motion to dismiss the Co-Lead Plaintiffs' First Amended Consolidated Complaint. All discovery in the case is currently stayed pursuant to federal law. The parties agreed to explore the possibility of a mediated settlement of this matter, and a mediation was held on June 21, 2016. The parties were unable to resolve this matter during the mediation. On August 19, 2016, the District Court denied the defendants motion to dismiss the Co-Lead </font><font style="font-family:Times New Roman;font-size:10pt;">Plantiffs</font><font style="font-family:Times New Roman;font-size:10pt;">' First Amended Consolidated Complaint. The Defendants filed an Answer to the Complaint on October 20, 2016</font><font style="font-family:Times New Roman;font-size:10pt;">. The case is currently in discovery</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We are unable to assess the probable outcome or reasonably estimate the potential liability, if any, arising from the securities litigation described above.&#160; The Company intends to continue to vigorously defend itself in the securities litigation matter but, if decided adverse to the Company, its impact could be material.&#160; No assurances can be given as to the timing or outcome of the securities matter described above or the impact of any of the inquiry or litigation matters on the Company, its consolidated financial condition, results of operations or cash flows, which could be material, individually or in the aggregate</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Subpoena </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Duces</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Tecum</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"> Issued by the U.S. Department of Justice</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On May 21, 2015, we received a Subpoena </font><font style="font-family:Times New Roman;font-size:10pt;">Duces</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">Tecum</font><font style="font-family:Times New Roman;font-size:10pt;"> (&#8220;Subpoena&#8221;) issued by the U.S. Department of Justice. The Subpoena requests the delivery of information regarding 53 identified hospice patients to the United States Attorney's Office for the District of Massachusetts. It also requests the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covers the period from January 1, 2011, through the present. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. Based on the information currently available to us, we cannot predict the timing or outcome of this investigation or reasonably estimate the amount or range of potential losses, if any, which may arise from this matter.</font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Civil Investigative Demand Issued by the U.S. Department of Justice</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On November 3, 2015, we received a civil investigative demand (&#8220;CID&#8221;) issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requests the delivery of information to the United States Attorney's Office for the Northern District of West Virginia regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covers the period from January 1, 2009 through August 31, 2015. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. Based on the information currently available to us, we cannot predict the timing or outcome of this investigation or reasonably estimate the amount or range of potential losses, if any, which may arise from this matter.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On June 27, 2016, we received a </font><font style="font-family:Times New Roman;font-size:10pt;">CID </font><font style="font-family:Times New Roman;font-size:10pt;">issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requests the delivery of information to the United States Attorney's Office for the Southern District of West Virginia regarding 68 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covers the period from January 1, 2011 through June 20, 2016. We are fully cooperating with the U.S. Department of Justice with respect to this investigation. Based on the information currently available to us, we cannot predict the timing or outcome of this investigation or reasonably estimate the amount or range of potential losses, if any, which may arise from this matter.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In addition to the matters referenced in this note, we are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. We do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Legal Proceedings </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;">&#8211; Settled</font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Wage and Hour Litigation </font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On July 25, 2012, a putative collective and class action complaint was filed in the United States District Court for the District of Connecticut against us in which three former employees allege wage and hour law violations.&#160; The former employees claim that they were not paid overtime for all hours worked over 40 hours in violation of the </font><font style="font-family:Times New Roman;font-size:10pt;">Federal Fair Labor Standards Act (&#8220;</font><font style="font-family:Times New Roman;font-size:10pt;">FLSA</font><font style="font-family:Times New Roman;font-size:10pt;">&#8221;)</font><font style="font-family:Times New Roman;font-size:10pt;">, as well as the Pennsylvania Minimum Wage Act. More specifically, they allege they were paid on both a per-visit and an hourly basis, and that such a pay scheme resulted in their misclassification as exempt employees, thereby denying them overtime pay. Moreover, in response to a Company motion arguing that plaintiffs' complaint was deficient in that it was ambiguous and failed to provide fair notice of the claims asserted and plaintiffs' opposition thereto, the Court, on April 8, 2013, held that the complaint adequately raises general allegations that the plaintiffs were not paid overtime for all hours worked in a week over 40, which may include claims for unpaid overtime under other theories of liability, such as alleged off-the-clock work, in addition to plaintiffs' more clearly stated allegations based on misclassification. On behalf of themselves and a class of current and former employees they allege are similarly situated, plaintiffs seek attorneys' fees, back wages and liquidated damages going back three years under the FLSA and three years under the Pennsylvania statute.  On October 8, 2013, the Court granted plaintiffs' motion for equitable tolling requesting that the statute of limitations for claims under the FLSA for plaintiffs who opt-in to the lawsuit be tolled from September 24, 2012, the date upon which plaintiffs filed their original motion for conditional certification, until 90 days after any notice of this lawsuit is issued following conditional certification. Following a motion for reconsideration filed by the Company, on December 3, 2013, the Court modified this order, holding that putative class members' FLSA claims are tolled from October 29, 2012 through the date of the Court's order on plaintiffs' motion for conditional certification. On January 13, 2014, the Court granted plaintiffs' July 10, 2013 motion for conditional certification of their FLSA claims and authorized issuance of notice to putative class members to provide them an opportunity to opt in to the action.  On April 17, 2014, that notice was mailed to putative class members. The period within which putative class members were permitted to opt into the action expired on July 16, 2014.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On September 10, 2014, the plaintiffs in the Connecticut case filed a motion for leave to amend their complaint to add a new claim under the Kentucky Wage and Hour Act (&#8220;KWHA&#8221;) alleging that the Company did not pay certain home health clinicians working in the Commonwealth of Kentucky all of the overtime wages they were owed, either because the Company misclassified them as exempt from overtime or, while treating them as overtime eligible, did not properly pay them overtime for all hours worked over 40 in a week. On behalf of themselves and a class of current and former employees they allege are similarly situated, plaintiffs seek attorneys' fees, back wages and liquidated damages going back five years before the filing of their original complaint under the KWHA. On October 1, 2014, the Company filed an opposition to the plaintiffs' motion to amend. On October 15, 2014, plaintiffs filed a reply brief in support of their motion.  On December 12, 2014, the Court granted the plaintiffs' motion to amend the complaint to add the claims under the KWHA. The Company and the plaintiffs agreed to explore the possibility of a mediated settlement of the Connecticut case, and on February 23, 2015 filed a joint motion to stay proceedings for six months to pursue that process, which was granted by the Court on February 24, 2015. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On June 10, 2015, the Company and plaintiffs participated in a mediation whereby they agreed to fully resolve all of plaintiffs' claims in the lawsuit for $8.0 million, subject to approval by the Court.&#160; The settlement agreement was submitted to the Court for preliminary approval and plaintiffs requested certification of Pennsylvania and Kentucky classes for the sole purpose of this proposed settlement.&#160; The Court granted preliminary approval, notice was issued to members of the settlement classes to provide them with an opportunity to object to the settlement and, in the case of members of the Pennsylvania and Kentucky classes, opt out of the settlement.&#160; Following this notice period, the Court held a final fairness hearing for the&#160;purpose of considering objections and deciding whether to grant final approval of the settlement. As of September 30, 2015, we had an accrual of $8.0 million for this matter. On January 29, 2016, the Court approved the final settlement of this case. The settlement became effective on February 26, 2016. As a result of the final amount calculated by the settlement administrator based on claims timely submitted, we reduced our accrual to $5.3 million as of December 31, 2015; this amount was paid during the three-month period ended March 31, 2016.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On September 13, 2012, a putative collective and class action complaint was filed in the United States District Court for the Northern District of Illinois against us in which a former employee alleges wage and hour law violations.&#160; The former employee claims she was paid on both a per-visit and an hourly basis, and that such a pay scheme resulted in her misclassification as an exempt employee, thereby denying her overtime. The plaintiff alleges violations of federal and state law and seeks damages under the FLSA and the Illinois Minimum Wage Law. &#160;Plaintiff seeks class certification of similar employees who were or are employed in Illinois and seeks </font><font style="font-family:Times New Roman;font-size:10pt;">attorneys' fees, back wages and liquidated damages going back three years under the FLSA and three years under the Illinois statute. On May 28, 2013, the Court granted the Company's motion to stay the case pending resolution of class certification issues and dispositive motions in the earlier-filed Connecticut case. On December 23, 2015, the parties agreed to explore the possibility of a mediated settlement of the Illinois case, and a mediation occurred on April 18, 2016. The parties agreed to settle the case for $0.8 million, subject to court approval, which the Company ha</font><font style="font-family:Times New Roman;font-size:10pt;">d</font><font style="font-family:Times New Roman;font-size:10pt;"> accrued as of September 30, 2016. On August 4, 2016, the Court approved the final settlement of this case</font><font style="font-family:Times New Roman;font-size:10pt;">. The final payment of $0.6 million was paid on November 21, 2016</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Frontier Litigation </font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On April 2, 2015, Frontier Home Health and Hospice, L.L.C. (&#8220;Frontier&#8221;) </font><font style="font-family:Times New Roman;font-size:10pt;">filed a complaint against the Company in the United States District Court for the District of Connecticut alleging breach of contract, negligent misrepresentation and unfair and deceptive trade practices under Conn. Gen. Stat. &#167;42-110b.&#160; Frontier acquired our interest in five home health and four hospice care centers in Wyoming and Idaho in April 2014.&#160; The complaint alleges that certain of the hospice patients on service at the time of the acquisition did not meet Medicare eligibility requirements and that we breached certain of the representations and warranties under the purchase agreement and therefore, the businesses were worth less than the purchase price. Under the complaint, Frontier seeks declaratory judgment from the District Court that, under the terms of the purchase agreement with Frontier, we are obligated to determine the amount of the alleged Medicare overpayments and reimburse the government for the same in a timely manner, as well as unspecified compensatory and punitive damages, attorneys' fees and pre- and post-judgment interest.</font><font style="font-family:Times New Roman;font-size:11pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">The Company resolved the Frontier litigation for $2.9 million</font><font style="font-family:Times New Roman;font-size:10pt;"> during the three-month period ended December 31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Other Investigative Matters</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"> - Ongoing</font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Corporate Integrity Agreement</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On April 23, 2014, with no admissions of liability on our part, we entered into a settlement agreement with the U.S. Department of</font><font style="font-family:Calibri;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">Justice relating to certain of our clinical and business operations.  Concurrently with our entry into this agreement, we entered into a corporate integrity agreement (&#8220;CIA&#8221;) with the Office of Inspector General-HHS (&#8220;OIG&#8221;). The CIA formalizes various aspects of our already existing ethics and compliance programs and contains other requirements designed to help ensure our ongoing compliance with federal health care program requirements. Among other things, the CIA requires us to maintain our existing compliance program, executive compliance committee and compliance committee of the Board of Directors; provide certain compliance training; continue screening new and current employees to ensure they are eligible to participate in federal health care programs; engage an independent review organization to perform certain auditing and reviews and prepare certain reports regarding our compliance with federal health care programs, our billing submissions to federal health care programs and our compliance and risk mitigation programs; and provide certain reports and management certifications to the OIG. Additionally, the CIA specifically requires that we report substantial overpayments that we discover we have received from federal health care programs, as well as probable violations of federal health care laws. Upon breach of the CIA, we could become liable for payment of certain stipulated penalties, or could be excluded from participation in federal health care programs.  The corporate integrity agreement has a term of five years.</font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Computer Inventory and Data Security Reporting</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On March 1 and March 2, 2015, we provided official notice under federal and state data privacy laws concerning the outcome of an </font><font style="font-family:Times New Roman;font-size:10pt;">extensive risk management process to locate and verify our large computer inventory. The process identified approximately 142 encrypted computers and laptops for which reports were required under federal and state data privacy laws. The devices at issue were originally assigned to Company clinicians and other team members</font><font style="font-family:Times New Roman;font-size:10pt;"> who left the Company between 2011 and 2014. We reported these devices to the U.S. Department of Health and Human Services, state agencies, and individuals whose information may be involved, as required under applicable law because we could not rule out unauthorized access to patient data on the devices. The Office of Civil Rights, U.S. Department of Health and Human Services (&#8220;OCR&#8221;) is reviewing our compliance with applicable laws, as is typical for any data breach involving more than 500 individuals. We are cooperating with OCR in its review and if any other regulatory reviews are formally commenced, will cooperate with applicable regulatory authorities. In accordance with our CIA, we have notified the OIG of this matter.</font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Frontier </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Litigation</font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Separate from the Frontier litigation described above under &#8220;Legal Proceedings - Settled&#8221;, the Company engaged an independent auditing firm to perform a </font><font style="font-family:Times New Roman;font-size:10pt;">clinical</font><font style="font-family:Times New Roman;font-size:10pt;"> audit </font><font style="font-family:Times New Roman;font-size:10pt;">of the hospice care centers acquired by Frontier. N</font><font style="font-family:Times New Roman;font-size:10pt;">o assurances can be given as to the timing or outcome of the audit on the Company, its consolidated financial condition, results of operations or cash flows, which could be material, individually or in the aggregate</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Other Investigative Matters - Settled</font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Corporate Integrity Agreement</font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">During the course of our compliance with the CIA, the Company identified several reportable events and notified the OIG as required. As of December 31, 2015, the Company had an accrual of $4.7 million for these matters. On May 5, 2016, the company entered into a settlement agreement with the OIG and the matters were fully resolved for $4.7 million; this amount was paid during the three-month period ended June 30, 2016.</font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Third Party Audits - Ongoing</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) conduct extensive review of claims data to identify potential improper payments under the Medicare program.  </font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a Zone Program Integrity Contractor (&#8220;ZPIC&#8221;) a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January 1, 2008 through March 31, 2010 (the &#8220;Review Period&#8221;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160; We acquired the hospice operations subject to this review on August 1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160; Based on the ZPIC's findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June 6, 2011, the MAC for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment.  We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An ALJ hearing was held in early January 2015. </font><font style="font-family:Times New Roman;font-size:10pt;">On January 18, 2016 we received a letter dated January 6, 2016 referencing the ALJ hearing decision for the overpayment issued on June 6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million with a balance owed of $5.6 million including interest based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid.&#160; No assurances can be given as to the timing or outcome of the </font><font style="font-family:Times New Roman;font-size:10pt;">Medicare Appeals Council decision. As of June 30, 2016, Medicare has withheld payments of $5.7 million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In </font><font style="font-family:Times New Roman;font-size:10pt;">the event we are not able to recoup this alleged overpayment, we are indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August 1, 2009.  As of </font><font style="font-family:Times New Roman;font-size:10pt;">December 31</font><font style="font-family:Times New Roman;font-size:10pt;">, 2016, we have an indemnity</font><font style="font-family:Times New Roman;font-size:10pt;"> receivable for the amount withheld related to the period prior to August 1, 2009</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In July 2016, </font><font style="font-family:Times New Roman;font-size:10pt;">the Company received a request for medical records from </font><font style="font-family:Times New Roman;font-size:10pt;">SafeGuard</font><font style="font-family:Times New Roman;font-size:10pt;"> Services, L.L.C. (&#8220;</font><font style="font-family:Times New Roman;font-size:10pt;">SafeGuard</font><font style="font-family:Times New Roman;font-size:10pt;">&#8221;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December 31, 2015. Subsequent to the initial ZPIC letter, on September 16, 2016, the Company received a letter from </font><font style="font-family:Times New Roman;font-size:10pt;">SafeGuard</font><font style="font-family:Times New Roman;font-size:10pt;"> notifying the Company&#160;that the </font><font style="font-family:Times New Roman;font-size:10pt;">Winterhaven</font><font style="font-family:Times New Roman;font-size:10pt;">, Bradenton, and Tampa care centers were on a prepayment review.&#160; On October 28, 2016, the company received a &#8220;Notice of Suspension of Medicare Payments&#8221; for up to 180 days for these three care centers.&#160; On January 10, 2017, the Company received a letter from </font><font style="font-family:Times New Roman;font-size:10pt;">SafeGuard</font><font style="font-family:Times New Roman;font-size:10pt;"> notifying the Company&#160;that the Clearwater care center was on a prepayment review.&#160; Subsequently, on February 2, 2017, the Company received a &#8220;Notice of </font><font style="font-family:Times New Roman;font-size:10pt;">Suspension of Medicare Payments&#8221; for up to 180 days for the Clearwater care center.&#160; Based on the information currently available to the Company, the Company cannot predict the timing or outcome of this audit or reasonably estimate the amount or range of potential losses, which may arise from this matter.</font></p><p style='margin-top:6pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Third Party Audits &#8211; Settled</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In January 2010, our subsidiary that provides home health services in Dayton, Ohio received from a Medicare Program Safeguard Contractor (&#8220;PSC&#8221;) a request for records regarding 137 claims submitted by the subsidiary paid from January 2, 2008 through November 10, 2009 (the &#8220;Claim Period&#8221;) to determine whether the underlying services met pertinent Medicare payment requirements.  Based on the PSC's findings for 114 of the claims, which were extrapolated to all claims for home health services provided by the Dayton subsidiary paid during the Claim Period, on March 9, 2011, the Medicare Administrative Contractor (&#8220;MAC&#8221;) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment of approximately $5.6 million. We disputed these findings, and our Dayton subsidiary filed appeals through the Original Medicare Standard Appeals Process, in which we were seeking to have those findings overturned. A consolidated administrative law judge (&#8220;ALJ&#8221;) hearing was held in late March 2013. In January 2014, the ALJ found fully in favor of our Dayton subsidiary on 74 appeals and partially in favor of our Dayton subsidiary on eight appeals. Taking into account the ALJ's decision, certain determinations that our Dayton subsidiary decided not to appeal as well as certain determinations made by the MAC, of the 114 claims that were originally extrapolated by the MAC, 76 claims were decided in favor of our Dayton subsidiary in full, 10 claims were decided in favor of our Dayton subsidiary in part, and 28 claims were decided against or not appealed by our Dayton subsidiary.  The ALJ ordered the MAC to recalculate the extrapolation amount based on the ALJ's decision.  The Medicare Appeals Council could decide on its own motion to review the ALJ's decisions.  As of July 13, 2016, we were notified that the PSC elected not to re-extrapolate the overpayment and instead issued a new calculated overpayment in the amount of $0.2 million. The overpayment has been paid in full and the matter is fully resolved</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Operating Leases</font></p><p style='margin-top:4.5pt; margin-bottom:9pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We have leased office space at various locations under non-cancelable agreements that </font><font style="font-family:Times New Roman;font-size:10pt;">expire between </font><font style="font-family:Times New Roman;font-size:10pt;">201</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;"> and 20</font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> and require various minimum annual rentals. Our typical operating leases are for lease terms </font><font style="font-family:Times New Roman;font-size:10pt;">of </font><font style="font-family:Times New Roman;font-size:10pt;">one</font><font style="font-family:Times New Roman;font-size:10pt;"> to seven years</font><font style="font-family:Times New Roman;font-size:10pt;"> and may include, in addition to base rental amounts, certain landlord pass-through costs for our pro-rata share of the lessor's real estate taxes, utilities and common area maintenance costs. Some of our operating leases contain escalation clauses, in which annual minimum base rentals increase over the term of the lease. </font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 14px"><td colspan="6"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Total minimum rental commitments as of December 31, 2016 are as follows (amounts in millions):</font></td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">2017</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">23.5</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">2018</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">17.5</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">2019</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">13.0</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">2020</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">9.1</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">2021</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.3</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Future years</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.6</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Total</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">72.0</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 10px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 34px"><td colspan="6"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Rent expense for non-cancelable operating leases was $27.5 million, $23.7 million and $26.5 million for 2016, 2015 and 2014.</font></td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Insurance </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We are obligated for certain costs associated with our insurance programs, including employee health, workers' compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">up to </font><font style="font-family:Times New Roman;font-size:10pt;">specified deductible limits</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not</font><font style="font-family:Times New Roman;font-size:10pt;"> reported</font><font style="font-family:Times New Roman;font-size:10pt;">. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis. </font></p><p style='margin-top:4.5pt; margin-bottom:9pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">The following table presents details of our insurance programs, including amounts accrued for the periods indicated (amounts in millions) in accrued expenses in our accompanying balance sheets. The amounts accrued below represent our total estimated liability for individual claims that are less than our noted insurance coverage amounts, which can include outstanding claims and claims incurred but not reported.</font><font style="font-family:Times New Roman;font-size:10pt;">  </font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="5"  style="width: 160px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:160px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">As of December 31,</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"><font style="FONT-WEIGHT: bold;TEXT-DECORATION: underline;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;">Type of Insurance</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:55px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 30px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:55px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Health insurance</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.6</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">11.7</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Workers' compensation</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">26.8</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">23.9</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Professional liability</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.7</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.1</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">42.1</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">39.7</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Less: long-term portion</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.8)</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.9)</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">41.3</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">38.8</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 34px"><td colspan="9"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The retention limit per claim for our health insurance, worker's compensation and professional liability is $0.9 million, $0.5 million and $0.3 million, respectively.</font></td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Employment Contracts </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We have commitments related to employment contracts with a number of our senior executives. These contracts generally commit us to pay severance benefits under certain circumstances. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Other </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We are subject to various other types of claims and disputes arising in the ordinary course of our business. While the resolution of such issues is not presently determinable, we believe that the ultimate resolution of such matters will not have a significant effect on our consolidated financial condition, results of operations and cash flows.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958410224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract', window );"><strong>Pension and Other Postretirement Benefits Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">EMPLOYEE BENEFIT PLANS</a></td>
<td class="text"><p style='margin-top:13pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;">11. EMPLOYEE BENEFIT PLANS</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">401(K) Benefit Plan</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We maintain a plan qualified under Section 401(k) of the Internal Revenue Code for all employees who have reached </font><font style="font-family:Times New Roman;font-size:10pt;">21</font><font style="font-family:Times New Roman;font-size:10pt;"> years of age, effective the first month after hire date. Under the plan, eligible employees may elect to defer a portion of their compensation, subject to Internal Revenue Service limits.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">During </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">2015</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">and  </font><font style="font-family:Times New Roman;font-size:10pt;">2014</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">our match of contributions to be made to each eligible employee contribution </font><font style="font-family:Times New Roman;font-size:10pt;">was </font><font style="font-family:Times New Roman;font-size:10pt;">$0.375 for every $1.00 of contribution made up to</font><font style="font-family:Times New Roman;font-size:10pt;"> the first 6%</font><font style="font-family:Times New Roman;font-size:10pt;"> of their salary. </font><font style="font-family:Times New Roman;font-size:10pt;">Effective January 1, 2017, our match of contributions to be made to each eligible employee contribution is $0.44 for every $1.00 of contribution made up to the first 6% of their salary. </font><font style="font-family:Times New Roman;font-size:10pt;">The match is discretionary and thus is subject to change at the discretion of management. These contributions are made in the form of our </font><font style="font-family:Times New Roman;font-size:10pt;">common stock, valued based upon the fair value of the stock as of the end of each calendar quarter end. We expensed approximately $</font><font style="font-family:Times New Roman;font-size:10pt;">6.</font><font style="font-family:Times New Roman;font-size:10pt;">9</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">m</font><font style="font-family:Times New Roman;font-size:10pt;">illion, $</font><font style="font-family:Times New Roman;font-size:10pt;">6.</font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million and $</font><font style="font-family:Times New Roman;font-size:10pt;">6.2</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million for </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">2015</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">2014</font><font style="font-family:Times New Roman;font-size:10pt;">, respectively.</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Deferred Compensation Plan</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We h</font><font style="font-family:Times New Roman;font-size:10pt;">ad</font><font style="font-family:Times New Roman;font-size:10pt;"> a Deferred Compensation Plan for additional tax-deferred savings to a select group of management or highly compensated employees.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">Amounts credited under the Deferred Compensation Plan </font><font style="font-family:Times New Roman;font-size:10pt;">were</font><font style="font-family:Times New Roman;font-size:10pt;"> funded into a rabbi trust, which is managed by a trustee. The trustee has the discretion to manage the assets of the Deferred Compensation Plan as deemed fit, thus the assets are not necessarily reflective of the same investment choices made by the participants.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Effective January 1, 2015, all prospective salary deferrals </font><font style="font-family:Times New Roman;font-size:10pt;">ceased</font><font style="font-family:Times New Roman;font-size:10pt;">. Participants will be allowed to make transactions with any remaining account balances as they wish per plan guidelines.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=49170332&amp;loc=SL14450702-114947<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e2410-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39675-114964<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6414199&amp;loc=d3e39622-114963<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6783780656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE REPURCHASE PROGRAM<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>EquityAbstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockTextBlock', window );">Treasury Stock</a></td>
<td class="text"><p style='margin-top:13pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;">12. S</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">TOCK</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"> REPURCHASE PROGRAM</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On </font><font style="font-family:Times New Roman;font-size:10pt;">September 9, 2015</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $</font><font style="font-family:Times New Roman;font-size:10pt;">75</font><font style="font-family:Times New Roman;font-size:10pt;"> million of our outstanding common stock</font><font style="font-family:Times New Roman;font-size:10pt;"> on or before September 6, 2016</font><font style="font-family:Times New Roman;font-size:10pt;">. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Under the terms of the program, we could repurchase shares from time to time in open market transactions, block purchases or in private transactions in accordance with </font><font style="font-family:Times New Roman;font-size:10pt;">applicable federal securities laws and other legal requirements. We </font><font style="font-family:Times New Roman;font-size:10pt;">could</font><font style="font-family:Times New Roman;font-size:10pt;"> enter into Rule 10b5-1 plans to effect some or all of the repurchases. </font><font style="font-family:Times New Roman;font-size:10pt;">The timing and the amount of the repurchases, if any, </font><font style="font-family:Times New Roman;font-size:10pt;">was</font><font style="font-family:Times New Roman;font-size:10pt;"> determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">P</font><font style="font-family:Times New Roman;font-size:10pt;">ursuant to this program, we repurchased </font><font style="font-family:Times New Roman;font-size:10pt;">324,141</font><font style="font-family:Times New Roman;font-size:10pt;"> shares of our common stock at a weighted average price of $</font><font style="font-family:Times New Roman;font-size:10pt;">37.96 </font><font style="font-family:Times New Roman;font-size:10pt;">per share and a total cost of approximately $12.3 million</font><font style="font-family:Times New Roman;font-size:10pt;"> during 2016 and </font><font style="font-family:Times New Roman;font-size:10pt;">116,859</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">shares of our common stock at a weighted average price of $</font><font style="font-family:Times New Roman;font-size:10pt;">39.20</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">per share and a total cost of approximately $</font><font style="font-family:Times New Roman;font-size:10pt;">4.6</font><font style="font-family:Times New Roman;font-size:10pt;"> million. The repurchased shares are classified as treasury shares</font><font style="font-family:Times New Roman;font-size:10pt;">. The stock repurchase program expired on September 6, 2016</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958423952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EXIT ACTIVITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">EXIT ACTIVITIES</a></td>
<td class="text"><p style='margin-top:13pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;">13</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">EXIT </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">AND RESTRUCTURING ACTIVITIES </font></p><p style='margin-top:4.5pt; margin-bottom:4.5pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">As of December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;">, we reported three home health care </font><font style="font-family:Times New Roman;font-size:10pt;">centers </font><font style="font-family:Times New Roman;font-size:10pt;">as held for sale. </font><font style="font-family:Times New Roman;font-size:10pt;">During 201</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;">, we sold assets associated with two of these care centers for cash consideration of approximately $0.8 million and recognized a gain of </font><font style="font-family:Times New Roman;font-size:10pt;">approximately </font><font style="font-family:Times New Roman;font-size:10pt;">$0.8 million which is included in discontinued operations. The remaining care center classified as held for sale was consolidated with a care center servicing the same market during 201</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:4.5pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">During 201</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;">, the Company sold its interest in five home health and four hospice care c</font><font style="font-family:Times New Roman;font-size:10pt;">enters in Wyoming and Idaho for </font><font style="font-family:Times New Roman;font-size:10pt;">approximately $5.0 million and recognized a gain of $2.1 million. We also exited our hospice inpatient unit in New Hampshire and recognized a loss of $0.5 million.</font></p><p style='margin-top:4.5pt; margin-bottom:4.5pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In addition to the exit activity related to the care centers mentioned above, we consolidated 21 operating home health care centers and four operating hospice care centers with care centers servicing the same markets and closed 22 home health care centers and four hospice care centers during 201</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;">. In connection with these care centers, we recorded non-cash charges of $2.2 million in other intangibles impairment expense related to the write-off of intangible assets, $2.1 million in other general and administrative expenses related to lease termination costs and $2.1 million in salaries and benefits related to severance costs. These care centers were not concentrated in certain selected geographical areas and did not meet the criteria to be classified as discontinued operations in accordance with applicable accounting guidance</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:0pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Restructuring Activity</font></p><p style='margin-top:0pt; margin-bottom:9pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">During </font><font style="font-family:Times New Roman;font-size:10pt;">201</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;">, we restructured our regional leadership and corporate support functions.  As such, we recorded charges of $3.4 million in salaries and benefits related to severance </font><font style="font-family:Times New Roman;font-size:10pt;">costs. </font><font style="font-family:Times New Roman;font-size:10pt;">In addition, </font><font style="font-family:Times New Roman;font-size:10pt;">during 2014</font><font style="font-family:Times New Roman;font-size:10pt;">, William F. Borne stepped down from his positions as Chief Executive Officer, Chairman and a member of our Board of Directors and we recorded charges of $2.3 million in salaries and benefits related to severance costs.</font></p><p style='margin-top:4.5pt; margin-bottom:4.5pt'>&#160;</p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 9px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 17px"><td colspan="15"  style="width: 646px; text-align:left;border-color:#000000;min-width:646px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Our reserve activity for our 2014 exit and restructuring activity is as follows (amounts in millions):</font></td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;">&#160;</td><td colspan="6"  style="width: 169px; text-align:center;border-color:#000000;min-width:169px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td colspan="5"  style="width: 159px; text-align:center;border-color:#000000;min-width:159px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="5"  style="width: 159px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:159px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2014 Exit Activity</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td colspan="5"  style="width: 159px; text-align:center;border-color:#000000;min-width:159px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 25px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 76px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:76px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Lease Termination</font></td><td   style="width: 7px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:7px;">&#160;</td><td colspan="2"  style="width: 76px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:76px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Severance</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td colspan="2"  style="width: 76px; text-align:center;border-color:#000000;min-width:76px;">&#160;</td><td   style="width: 7px; text-align:center;border-color:#000000;min-width:7px;">&#160;</td><td colspan="2"  style="width: 76px; text-align:center;border-color:#000000;min-width:76px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Balances at December 31, 2013</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 7px; text-align:center;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:center;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Charge in 2014</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.1</font></td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">7.8</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Cash expenditures in 2014</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(1.6)</font></td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(5.5)</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Balances at December 31, 2014</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.5</font></td><td   style="width: 7px; text-align:center;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.3</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:center;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Charge in 2015</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Cash expenditures in 2015</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.4)</font></td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(1.9)</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Balances at December 31, 2015</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.1</font></td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.4</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Charge in 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Cash expenditures in 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.1)</font></td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.4)</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Balances at December 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 66px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 66px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section P<br> -Subsection 3, 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6783860208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>VALUATION AND QUALIFYING ACCOUNTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsAbstract', window );"><strong>Valuation And Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">VALUATION AND QUALIFYING ACCOUNTS</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 13px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;">&#160;</td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 17px"><td colspan="18"  style="width: 709px; text-align:left;border-color:#000000;min-width:709px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">14. VALUATION AND QUALIFYING ACCOUNTS</font></td></tr><tr style="height: 9px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;">&#160;</td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 34px"><td colspan="18"  style="width: 709px; text-align:left;border-color:#000000;min-width:709px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following table summarizes the activity and ending balances in our allowance for doubtful accounts and estimated revenue adjustments (amounts in millions):</font></td></tr><tr style="height: 9px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;">&#160;</td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 18px"><td colspan="18"  style="width: 709px; text-align:left;border-color:#000000;min-width:709px;"><font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Allowance for Doubtful Accounts</font></td></tr><tr style="height: 9px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:center;border-color:#000000;min-width:69px;">&#160;</td><td   style="width: 81px; text-align:center;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 51px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:165px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Year End</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Balance at Beginning of Year</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Provision for Doubtful Accounts (1)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Write-Offs</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 79px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:79px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Balance at End of Year</font></td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:165px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">2016</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">16.5</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">19.5</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(18.3)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 69px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:69px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">17.7</font></td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">2015</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">14.3</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">14.1</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(11.9)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:right;border-color:#000000;min-width:69px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">16.5</font></td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">2014</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">14.2</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">16.4</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(16.3)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:right;border-color:#000000;min-width:69px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">14.3</font></td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 8px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;">&#160;</td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 34px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td colspan="16"  style="width: 547px; text-align:left;border-color:#000000;min-width:547px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;">(1) Includes $0.1 million from discontinued operations for the year ended December 31, 2014.</font></td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;">&#160;</td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 17px"><td colspan="18"  style="width: 709px; text-align:left;border-color:#000000;min-width:709px;"><font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Estimated Revenue Adjustments</font></td></tr><tr style="height: 9px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:center;border-color:#000000;min-width:69px;">&#160;</td><td   style="width: 81px; text-align:center;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 63px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:165px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Year End</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Balance at Beginning of Year</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Provision for Estimated Revenue Adjustments (1)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Write-Offs</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 79px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:79px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Balance at End of Year</font></td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:165px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">2016</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">7.9</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(7.8)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 69px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:69px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.1</font></td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">2015</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.1</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.1</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(5.2)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:right;border-color:#000000;min-width:69px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.0</font></td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">2014</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.9</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">5.1</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(5.9)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:right;border-color:#000000;min-width:69px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.1</font></td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 8px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;">&#160;</td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 36px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td colspan="16"  style="width: 547px; text-align:left;border-color:#000000;min-width:547px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;">(1) Includes $0.1 million from discontinued operations for the year ended December 31, 2014.</font></td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any allowance and reserve accounts (their beginning and ending balances, as well as a reconciliation by type of activity during the period). Alternatively, disclosure of the required information may be within the footnotes to the financial statements or a supplemental schedule to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 09<br> -Article 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6783686944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p style='margin-top:13pt; margin-bottom:0pt'><font style="font-family:Times New Roman Bold;font-size:10pt;font-weight:bold;margin-left:0px;">15</font><font style="font-family:Times New Roman Bold;font-size:10pt;font-weight:bold;">. Segment Information</font></p><p style='margin-top:9pt; margin-bottom:4.5pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Our operations involve servicing patients through our t</font><font style="font-family:Times New Roman;font-size:10pt;">hree</font><font style="font-family:Times New Roman;font-size:10pt;"> reportable </font><font style="font-family:Times New Roman;font-size:10pt;">business segments:</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">home health, </font><font style="font-family:Times New Roman;font-size:10pt;">hospice</font><font style="font-family:Times New Roman;font-size:10pt;"> and personal care</font><font style="font-family:Times New Roman;font-size:10pt;">.  Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with the essenti</font><font style="font-family:Times New Roman;font-size:10pt;">al activities of daily living. </font><font style="font-family:Times New Roman;font-size:10pt;">Our hospice segment provides palliative care and comfort to terminally il</font><font style="font-family:Times New Roman;font-size:10pt;">l patients and their families. </font><font style="font-family:Times New Roman;font-size:10pt;">Our personal care segment, which was established with the acquisition of Associated Home Care during the three-month period ended March 31, 2016, provides patients with assistance with the essential activities of daily living. </font><font style="font-family:Times New Roman;font-size:10pt;">The &#8220;other&#8221; column in the following tables consist</font><font style="font-family:Times New Roman;font-size:10pt;">s</font><font style="font-family:Times New Roman;font-size:10pt;"> of costs relating to </font><font style="font-family:Times New Roman;font-size:10pt;">executive management </font><font style="font-family:Times New Roman;font-size:10pt;">and administrative support functions</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration</font><font style="font-family:Times New Roman;font-size:10pt;">.  </font></p><p style='margin-top:4.5pt; margin-bottom:4.5pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">M</font><font style="font-family:Times New Roman;font-size:10pt;">anagement</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">evaluates performance and allocates resources based on the operating income of the reportable segments, </font><font style="font-family:Times New Roman;font-size:10pt;">which </font><font style="font-family:Times New Roman;font-size:10pt;">includes an allocation of </font><font style="font-family:Times New Roman;font-size:10pt;">corporate expenses</font><font style="font-family:Times New Roman;font-size:10pt;"> directly attribu</font><font style="font-family:Times New Roman;font-size:10pt;">table to the specific segment</font><font style="font-family:Times New Roman;font-size:10pt;"> and includes revenues and all other costs directly attributable to the specific segment</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">Segment assets are not reviewed by the company's chief operating decision maker and therefore are not disclosed below (amounts in millions).  </font></p><p style='margin-top:0pt; margin-bottom:9pt'>&#160;</p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 12px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td colspan="13"  style="width: 375px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:375px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Year Ended December 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Home Health</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Hospice</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Personal Care</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Other</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Total</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Net service revenue</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1,085.5</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">316.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">35.9</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1,437.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Cost of service, excluding depreciation and amortization</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">643.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">163.1</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">26.3</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">833.1</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">General and administrative expenses</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">283.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">70.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">7.9</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">141.9</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">503.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Provision for doubtful accounts</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">13.8</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">5.5</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">19.5</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Depreciation and amortization</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.3</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">12.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">19.7</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Asset impairment charge</font></td><td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Operating expenses</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">946.9</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">240.1</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">34.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">158.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1,380.1</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Operating income (loss)</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">138.6</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">75.9</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.5</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(158.7)</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">57.3</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td colspan="13"  style="width: 375px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:375px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Year Ended December 31, 2015</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Home Health</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Hospice</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Personal Care</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Other</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Total</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Net service revenue</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1,005.1</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">275.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1,280.5</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Cost of service, excluding depreciation and amortization</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">584.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">141.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">725.9</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">General and administrative expenses</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">263.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">62.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">126.5</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">452.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Provision for doubtful accounts</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">12.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.9</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">14.1</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Depreciation and amortization</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">5.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">13.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">20.0</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Asset impairment charge</font></td><td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">77.3</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">77.3</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Operating expenses</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">864.8</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">207.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">217.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1,289.7</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Operating income (loss)</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">140.3</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">67.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(217.2)</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(9.2)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td colspan="13"  style="width: 375px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:375px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Year Ended December 31, 2014</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Home Health</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Hospice</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Personal Care</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Other</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Total</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Net service revenue</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">956.9</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">247.6</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1,204.5</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Cost of service, excluding depreciation and amortization</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">559.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">131.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">691.1</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">General and administrative expenses</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">269.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">58.3</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">114.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">441.7</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Provision for doubtful accounts</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">14.8</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.5</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">16.3</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Depreciation and amortization</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">9.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.1</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">17.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">28.3</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Asset impairment charge</font></td><td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.6</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.5</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.1</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Operating expenses</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">853.8</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">195.1</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">131.6</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1,180.5</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Operating income (loss)</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">103.1</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">52.5</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(131.6)</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">24.0</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8981-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e9038-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 33<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8971-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8595-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8380-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 35<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8984-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e9031-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8538-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8864-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8924-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6783860208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 13px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;">&#160;</td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 17px"><td colspan="15"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">16. UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION</font></td></tr><tr style="height: 17px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;">&#160;</td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 20px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="5"  style="width: 154px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:154px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 7.5pt;COLOR: #000000;TEXT-ALIGN: center;">Net Income (Loss) Attributable to Amedisys, Inc. Common Stockholders (1)</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 77px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:77px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 7.5pt;COLOR: #000000;TEXT-ALIGN: center;">Revenue</font></td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 102px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:102px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 7.5pt;COLOR: #000000;TEXT-ALIGN: center;">Net Income (Loss) Attributable to Amedisys, Inc.</font></td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 72px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:72px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 7.5pt;COLOR: #000000;TEXT-ALIGN: center;">Basic</font></td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 72px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:72px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 7.5pt;COLOR: #000000;TEXT-ALIGN: center;">Diluted</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2016:</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:60px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:60px;">&#160;</td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1st Quarter (2) (3) (4)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">348.8</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.2</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.19</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.19</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2nd Quarter (2) (3) (4)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">360.7</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.7</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.32</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.32</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3rd Quarter (2) (3) (4)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">361.6</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">11.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.34</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.34</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4th Quarter (2) (3) (4) (5)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">366.3</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">8.9</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.27</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.26</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 1,437.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 90px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">37.3</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.12</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.10</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2015:</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;">&#160;</td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1st Quarter (6) (7)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">301.6</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(35.0)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(1.07)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(1.07)</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2nd Quarter (7)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">314.1</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.6</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.32</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.32</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3rd Quarter (6) (7) (9)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">326.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">8.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.25</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.25</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4th Quarter (7) (8) (9)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">338.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">12.9</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.39</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.38</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 1,280.5</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 90px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.0</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.09)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.09)</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:10pt'></p><ul><li style="margin-left:54px;list-style:decimal;"><font style="font-family:Times New Roman;font-size:10pt;">Because of the method used in calculating per share data, the quarterly per share data may not necessarily total to the per share data as computed for the entire year.</font></li><li style="margin-left:54px;list-style:decimal;"><font style="font-family:Times New Roman;font-size:10pt;">During each of the four quarters of 2016, we incurred certain costs associated with the implementation of Homecare </font><font style="font-family:Times New Roman;font-size:10pt;">Homebase</font><font style="font-family:Times New Roman;font-size:10pt;">. Net of income taxes, these costs amounted to </font><font style="font-family:Times New Roman;font-size:10pt;">$1.5 million, $1.6 million, $1.2 million and $</font><font style="font-family:Times New Roman;font-size:10pt;">0</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">8</font><font style="font-family:Times New Roman;font-size:10pt;"> million for the three-month periods ended March 31, 2016, June 30, 2016, September 30, 2016 and December 31, 2016, respectively.</font></li><li style="margin-left:54px;list-style:decimal;"><font style="font-family:Times New Roman;font-size:10pt;">During each of the four quarters of 2016, we incurred certain costs associated with various legal matters. Net of income taxes, these costs amounted to $0.9 million, $0.3 million, $0.2 million </font><font style="font-family:Times New Roman;font-size:10pt;">and $</font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">8</font><font style="font-family:Times New Roman;font-size:10pt;"> million</font><font style="font-family:Times New Roman;font-size:10pt;"> for the three-month periods ended March 31, 2016, June 30, 2016, September 30, 2016 and December 31, 2016, respectively.</font></li><li style="margin-left:54px;list-style:decimal;"><font style="font-family:Times New Roman;font-size:10pt;">During each of the four quarters of 2016, we incurred certain costs associated with various acquisition costs. Net of income taxes, these costs amounted to $1.0 million, $0.2 million, $0.3 million and </font><font style="font-family:Times New Roman;font-size:10pt;">$</font><font style="font-family:Times New Roman;font-size:10pt;">0</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;"> million for the three-month periods ended March 31, 2016, June 30, 2016, September 30, 2016 and December 31, 2016, respectively.</font></li><li style="margin-left:54px;list-style:decimal;"><font style="font-family:Times New Roman;font-size:10pt;">During the fourth quarter of 2016, we recorded a non-cash asset impairment charge to write-off assets as a result of our conversion from our proprietary operating system to Homecare </font><font style="font-family:Times New Roman;font-size:10pt;">Homebase</font><font style="font-family:Times New Roman;font-size:10pt;"> in the amount of $2.7 million, net of income taxes.</font></li><li style="margin-left:54px;list-style:decimal;"><font style="font-family:Times New Roman;font-size:10pt;">During the first quarter of 2015,</font><font style="font-family:Times New Roman;font-size:10pt;"> we rec</font><font style="font-family:Times New Roman;font-size:10pt;">orded</font><font style="font-family:Times New Roman;font-size:10pt;"> a n</font><font style="font-family:Times New Roman;font-size:10pt;">on-cash asset impairment charge to </font><font style="font-family:Times New Roman;font-size:10pt;">write-off the software costs incurred related to the development of AMS3 Home Health and Hospice</font><font style="font-family:Times New Roman;font-size:10pt;"> in the amount of $45.5 million, net of income taxes. During the third quarter of 2015, we recorded a non-cash asset impairment charge </font><font style="font-family:Times New Roman;font-size:10pt;">related to our corporate headquarters in the amount of $1.2 million, net of income taxes.</font></li><li style="margin-left:54px;list-style:decimal;"><font style="font-family:Times New Roman;font-size:10pt;">During each of the four quarters of 2015, we incurred certain costs associate</font><font style="font-family:Times New Roman;font-size:10pt;">d</font><font style="font-family:Times New Roman;font-size:10pt;"> with various legal matters. Net of income taxes, these costs amounted to $1.3 million, $4.8 million, $0.2 million and $</font><font style="font-family:Times New Roman;font-size:10pt;">(1</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">1)</font><font style="font-family:Times New Roman;font-size:10pt;"> million for the three-month periods ended March 31, 2015, June 30, 2015, September 30, 2015 and December 31, 2015, respectively.</font></li><li style="margin-left:54px;list-style:decimal;"><font style="font-family:Times New Roman;font-size:10pt;">During the fourth quarter of 2015, we recorded an accrual related to an OIG Self-Disclosure matter. Net of income taxes, this charge amounted to $</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;"> million.</font></li><li style="margin-left:54px;list-style:decimal;"><font style="font-family:Times New Roman;font-size:10pt;">During the third and fourth quarters of 2015, we incurred certain costs associated with the implementation of Homecare </font><font style="font-family:Times New Roman;font-size:10pt;">Homebase</font><font style="font-family:Times New Roman;font-size:10pt;">. Net of income taxes, these costs a</font><font style="font-family:Times New Roman;font-size:10pt;">mounted to $1.2 million and $1.4</font><font style="font-family:Times New Roman;font-size:10pt;"> million for the three-month periods ended September 30, 2015 and </font><font style="font-family:Times New Roman;font-size:10pt;">December 31, 2015, respectively</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></li></ul><p style='margin-top:0pt; margin-bottom:10pt'>&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the quarterly financial data in the annual financial statements.  The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=51655806&amp;loc=d3e765-108305<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=51825399&amp;loc=d3e1280-108306<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=51655806&amp;loc=d3e725-108305<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section G<br> -Subsection 1<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 302<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958288672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transaction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;">17</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">.&#160; </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">RELATED PARTY TRANSACTIONS</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On November </font><font style="font-family:Times New Roman;font-size:10pt;">20, 2015, we engaged KKR Consulting, LLC (&#8220;KKR Capstone&#8221;), a consulting company of operational professionals that works exclusively with portfolio companies of Kohlberg Kravis Roberts &amp; Co. Nathaniel M. </font><font style="font-family:Times New Roman;font-size:10pt;">Zilkha</font><font style="font-family:Times New Roman;font-size:10pt;">, a member of our Board of Directors, is a member of KKR Management, LLC, which is an affiliate of KKR Asset Management LLC (&#8220;KAM&#8221;), a substantial stockholder of our Company, and an affiliate of Kohlberg Kravis Roberts &amp; Co. KKR Capstone will receive a fee in connection with providing consulting services to the Company in the ordinary course of business. Mr. </font><font style="font-family:Times New Roman;font-size:10pt;">Zilkha</font><font style="font-family:Times New Roman;font-size:10pt;"> will not receive any direct compensation or direct financial benefit from the engagement of KKR Capstone. During 2016, we incurred costs of </font><font style="font-family:Times New Roman;font-size:10pt;">approximately $1.6 million</font><font style="font-family:Times New Roman;font-size:10pt;"> related to this related party engagement</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Effective October 22, 2015, we entered into a contract for </font><font style="font-family:Times New Roman;font-size:10pt;">telemonitoring</font><font style="font-family:Times New Roman;font-size:10pt;"> services with Care Innovations, LLC (&#8220;Care Innovations&#8221;). Paul Kusserow, our President and Chief Executive Officer, is a member of the Advisory Board to Care Innovations. Care Innovations will receive an annual fee of approximately $1.8 million in connection with our contract for </font><font style="font-family:Times New Roman;font-size:10pt;">telemonitoring</font><font style="font-family:Times New Roman;font-size:10pt;"> services for the Company. Care Innovations has confirmed to us that Mr. Kusserow will not receive any direct compensation or direct financial benefit from the engagement of Care Innovations as our </font><font style="font-family:Times New Roman;font-size:10pt;">telemonitoring</font><font style="font-family:Times New Roman;font-size:10pt;"> partner. During 2016 we incurred costs of </font><font style="font-family:Times New Roman;font-size:10pt;">approximately $</font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;"> million</font><font style="font-family:Times New Roman;font-size:10pt;"> related to this related party engagement.</font></p><p style='margin-top:0pt; margin-bottom:8pt'>&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph b<br> -Article 3A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6650387552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
<td class="text"><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;margin-left:0px;">18.&#160; SUBSEQUENT EVENT</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">On </font><font style="font-family:Times New Roman;font-size:10pt;">February </font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;">, 201</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;">, we acquired </font><font style="font-family:Times New Roman;font-size:10pt;">Home Staff, LLC</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">a</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">personal care provider</font><font style="font-family:Times New Roman;font-size:10pt;"> with </font><font style="font-family:Times New Roman;font-size:10pt;">three</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">care centers </font><font style="font-family:Times New Roman;font-size:10pt;">for a purchase price of $</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;">.0</font><font style="font-family:Times New Roman;font-size:10pt;"> million</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Unaudited - O</font><font style="font-family:Times New Roman;font-size:10pt;">n February 28, 2017, we signed a definitive agreement to acquire Tenet Healthcare's home health and hospice operations in Arizona, Illinois, Massachusetts and Texas</font><font style="font-family:Times New Roman;font-size:10pt;">. We do not believe that the closing of this acquisition will have a material impact on our 2017 results of operations</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:0pt; margin-bottom:8pt'>&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6779037504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Use of Estimates </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Our accounting and reporting policies conform with U.S.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">G</font><font style="font-family:Times New Roman;font-size:10pt;">enerally Accepted Accounting Principles (&#8220;U.S. G</font><font style="font-family:Times New Roman;font-size:10pt;">AAP</font><font style="font-family:Times New Roman;font-size:10pt;">&#8221;)</font><font style="font-family:Times New Roman;font-size:10pt;">. In preparing the consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. </font></p><p style='margin-top:9pt; margin-bottom:0pt'>&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComparabilityOfPriorYearFinancialData', window );">Reclassifications and Comparability</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Reclassifications and Comparability </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Certain </font><font style="font-family:Times New Roman;font-size:10pt;">reclassifications have been made to prior periods' financial statements in order to conform to the current period'</font><font style="font-family:Times New Roman;font-size:10pt;">s</font><font style="font-family:Times New Roman;font-size:10pt;"> presentation</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">In compliance with Accounting Standards Update (&#8220;ASU&#8221;) 2015-03, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Interest &#8211; Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of De</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">bt Issuance Costs, </font><font style="font-family:Times New Roman;font-size:10pt;">we have reclassified 2015 amounts related to unamortized debt issuance costs from other assets, net </font><font style="font-family:Times New Roman;font-size:10pt;">to </font><font style="font-family:Times New Roman;font-size:10pt;">long-term obligations, less current portion</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:9pt; margin-bottom:0pt'>&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Principles of Consolidation </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">These consolidated financial statements include the accounts of Amedisys, Inc.</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated financial statements, and business combinations accounted for as purchases have been included in our</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are </font><font style="font-family:Times New Roman;font-size:10pt;">accounted for as set forth below</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Investments</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Equity Investments </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We consolidate investments when the entity is a variable interest entity and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of </font><font style="font-family:Times New Roman;font-size:10pt;">50</font><font style="font-family:Times New Roman;font-size:10pt;">%. Third party equity interests in our consolidated joint ventures are reflected as </font><font style="font-family:Times New Roman;font-size:10pt;">noncontrolling</font><font style="font-family:Times New Roman;font-size:10pt;"> interests in our consolidated financial statements. </font><font style="font-family:Times New Roman;font-size:10pt;">During the three-month period ended September 30, 2016, we sold a 30% interest in one of our care centers while maintaining controlling interest in the newly formed joint venture.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold </font><font style="font-family:Times New Roman;font-size:10pt;">50</font><font style="font-family:Times New Roman;font-size:10pt;">% or less of the voting stock and the entity is not a variable interest entity in which we are the primary beneficiary. The book value of investments that we accounted for under the equity method of accounting w</font><font style="font-family:Times New Roman;font-size:10pt;">as $</font><font style="font-family:Times New Roman;font-size:10pt;">27</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">8</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million</font><font style="font-family:Times New Roman;font-size:10pt;"> as of </font><font style="font-family:Times New Roman;font-size:10pt;">December 31</font><font style="font-family:Times New Roman;font-size:10pt;">, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">$</font><font style="font-family:Times New Roman;font-size:10pt;">25.7</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">m</font><font style="font-family:Times New Roman;font-size:10pt;">illion</font><font style="font-family:Times New Roman;font-size:10pt;"> as</font><font style="font-family:Times New Roman;font-size:10pt;"> of December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">We account for investments in entities in which we have less than a </font><font style="font-family:Times New Roman;font-size:10pt;">20</font><font style="font-family:Times New Roman;font-size:10pt;">% ownership interest under the cost method of accounting if we do not have the ability to exercise signific</font><font style="font-family:Times New Roman;font-size:10pt;">ant influence over the investee</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Revenue Recognition</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;"> </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We earn net service </font><font style="font-family:Times New Roman;font-size:10pt;">revenue through our home health, </font><font style="font-family:Times New Roman;font-size:10pt;">hospice </font><font style="font-family:Times New Roman;font-size:10pt;">and personal-care </font><font style="font-family:Times New Roman;font-size:10pt;">care center</font><font style="font-family:Times New Roman;font-size:10pt;">s by providing a variety of services almost exclusively in the homes of our patients. This net service revenue is earned and billed either on an episode of care basis, on a per visit basis or on a daily basis depending upon the payment terms and conditions established with each </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;"> for services provided. We refer to home health revenue earned and billed on a </font><font style="font-family:Times New Roman;font-size:10pt;">60</font><font style="font-family:Times New Roman;font-size:10pt;">-day episode of care as episodic-based revenue. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">When we record our service revenue, we record it net of estimated revenue adjustments and contractual adjustments to reflect amounts we estimate to be realizable for services provided, as discussed below. We believe, based on information currently available to us and based on our judgment, that changes to one or more factors that impact the accounting estimates (such as our estimates related to revenue adjustments, contractual adjustments and episodes in progress) we make in determining net service revenue, which changes are likely to occur from period to period, will not materially impact our reported consolidated financial condition, results of operations, cash flows or our future financial results. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Home Health Revenue Recognition</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;">Medicare Revenue </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Net service revenue is recorded under the Medicare prospective payment system (&#8220;PPS&#8221;) based on a 60-day episode payment rate that is subject to adjustment based on certain variables including, but not limited to: (a)&#160;an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits was fewer than five; (c)&#160;a partial payment if our patient transferred to another provider or we received a patient from another provider before completing the episode; (d)&#160;a payment adjustment based upon the level of therapy services required (with various incremental adjustments made for additional visits, with larger payment increases associated with the sixth, fourteenth and twentieth visit thresholds); (e) adjustments to payments if we are unable to perform periodic therapy assessments; (f)&#160;the number of episodes of care provided to a patient, regardless of whether the same home health provider provided care for the entire series of episodes; (g)&#160;changes in the base episode payments established by the Medicare Program; (h)&#160;adjustments to the base episode payments for case mix and geographic wages; and (i</font><font style="font-family:Times New Roman;font-size:10pt;">)&#160;recoveries of overpayments. </font><font style="font-family:Times New Roman;font-size:10pt;">In addition, we make adjustments to Medicare revenue if we </font><font style="font-family:Times New Roman;font-size:10pt;">find that we </font><font style="font-family:Times New Roman;font-size:10pt;">are unable to produce </font><font style="font-family:Times New Roman;font-size:10pt;">appropriate </font><font style="font-family:Times New Roman;font-size:10pt;">documentation of a face to face encounter between the patient and physician.</font><font style="font-family:Times New Roman;font-size:10pt;">   </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We make adjustments to Medicare revenue </font><font style="font-family:Times New Roman;font-size:10pt;">to </font><font style="font-family:Times New Roman;font-size:10pt;">reflect</font><font style="font-family:Times New Roman;font-size:10pt;"> differences between estimated and actual payment amounts, </font><font style="font-family:Times New Roman;font-size:10pt;">our</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">discovered </font><font style="font-family:Times New Roman;font-size:10pt;">inability to obtain appropriate billing documentation or authorizations and other reasons unrelated to credit risk. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of </font><font style="font-family:Times New Roman;font-size:10pt;">over </font><font style="font-family:Times New Roman;font-size:10pt;">99</font><font style="font-family:Times New Roman;font-size:10pt;">%</font><font style="font-family:Times New Roman;font-size:10pt;"> on</font><font style="font-family:Times New Roman;font-size:10pt;"> Medicare claims, and record this estimate during the period in which services are rendered as an estimated revenue adjustment and a corresponding reduction</font><font style="font-family:Times New Roman;font-size:10pt;"> to patient accounts receivable. </font><font style="font-family:Times New Roman;font-size:10pt;">Therefore, we believe that our reported net service revenue and patient accounts receivable will be the net amounts to be realized from Medicare for services rendered. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In addition to revenue recognized on completed episodes, we also recognize a portion of revenue associated with episodes in progress. Episodes in progress are </font><font style="font-family:Times New Roman;font-size:10pt;">60</font><font style="font-family:Times New Roman;font-size:10pt;">-day episodes of care that begin during the reporting period, but were not completed as of the end of the period. We estimate this revenue on a monthly basis based upon historical trends. The primary factors underlying this estimate are the number of episodes in progress at the end of the reporting period, expected Medicare revenue per episode and our estimate of the average percentage complete based on </font><font style="font-family:Times New Roman;font-size:10pt;">the number of days elapsed during an episodes of care. </font><font style="font-family:Times New Roman;font-size:10pt;">As of </font><font style="font-family:Times New Roman;font-size:10pt;">December 31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">2015</font><font style="font-family:Times New Roman;font-size:10pt;">, the difference between the cash received from Medicare for a request for anticipated payment (&#8220;RAP&#8221;) on episodes in progress and the associated estimated revenue was immaterial and, therefore, the resulting credits were recorded as a reduction to our outstanding pa</font><font style="font-family:Times New Roman;font-size:10pt;">tient accounts receivable in our </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated balance sheets for such periods. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;">Non-Medicare Revenue </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Episodic-based Revenue. </font><font style="font-family:Times New Roman;font-size:10pt;">We recognize revenue in a similar manner as we recognize Medicare revenue for episodic-based rates that are paid by other insurance carriers, including Medicare Advantage programs; however, these rates can vary based upon the negotiated terms. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Non-episodic </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">b</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">ased Revenue. </font><font style="font-family:Times New Roman;font-size:10pt;">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates, as applicable. Contractual adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue and are also recorded as a reduction to our outstanding patient accounts receivable. In addition, we receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Hospice Revenue Recognition </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;">Hospice Medicare Revenue </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates.  The estimated payment rates are daily or hourly rates for each of the four levels of care </font><font style="font-family:Times New Roman;font-size:10pt;">we deliver.  The four levels of care</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">are routine care, general inpatient care, continuo</font><font style="font-family:Times New Roman;font-size:10pt;">us home care and respite care. </font><font style="font-family:Times New Roman;font-size:10pt;">Routine care accounts for </font><font style="font-family:Times New Roman;font-size:10pt;">99</font><font style="font-family:Times New Roman;font-size:10pt;">%, 9</font><font style="font-family:Times New Roman;font-size:10pt;">9</font><font style="font-family:Times New Roman;font-size:10pt;">%, and </font><font style="font-family:Times New Roman;font-size:10pt;">9</font><font style="font-family:Times New Roman;font-size:10pt;">8</font><font style="font-family:Times New Roman;font-size:10pt;">% </font><font style="font-family:Times New Roman;font-size:10pt;">of our total net Medic</font><font style="font-family:Times New Roman;font-size:10pt;">are hospice service revenue for </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> 2015</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">and 2014, </font><font style="font-family:Times New Roman;font-size:10pt;">respectively</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">Beginning January 1, 2016, CMS has provided for two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, beginning January 1, 2016, Medicare is also reimbursing for a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse (&#8220;RN&#8221;) or medical social worker (&#8220;MSW&#8221;) for patients in a routine level of care.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We make adjustments to Medicare revenue for an inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these adjustments based on our historical experience, which primarily includes our historical collection rate on Medicare claims, and record it during the period services are rendered as an estimated revenue adjustment and as a reduction to our outstanding patient accounts receivable</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Additionally, as Medicare hospice revenue is subject to an inpatient cap limit and an overall payment cap for each provider number, we monitor these caps and estimate amounts due back to Medicare if </font><font style="font-family:Times New Roman;font-size:10pt;">we estimate </font><font style="font-family:Times New Roman;font-size:10pt;">a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase </font><font style="font-family:Times New Roman;font-size:10pt;">in other accrued liabilities. Beginning for the cap year ending October 31, 2014, providers are </font><font style="font-family:Times New Roman;font-size:10pt;">required to self-report and pay their estimated cap liability by March 31</font><font style="font-family:Times New Roman;font-size:10pt;">st</font><font style="font-family:Times New Roman;font-size:10pt;"> of the following year.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">As of December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">, we</font><font style="font-family:Times New Roman;font-size:10pt;"> have settled our Medicare hospice reimbursements for all fiscal years through October 31, 20</font><font style="font-family:Times New Roman;font-size:10pt;">12 and </font><font style="font-family:Times New Roman;font-size:10pt;">we have recorded </font><font style="font-family:Times New Roman;font-size:10pt;">$</font><font style="font-family:Times New Roman;font-size:10pt;">0.8</font><font style="font-family:Times New Roman;font-size:10pt;"> million for estimated amounts due back to Medicare in other accrued liabilities for the Federal </font><font style="font-family:Times New Roman;font-size:10pt;">cap y</font><font style="font-family:Times New Roman;font-size:10pt;">ears ended October 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;"> through October 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">. As of December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;">, we </font><font style="font-family:Times New Roman;font-size:10pt;">had</font><font style="font-family:Times New Roman;font-size:10pt;"> recorded $</font><font style="font-family:Times New Roman;font-size:10pt;">1.4</font><font style="font-family:Times New Roman;font-size:10pt;"> million for estimated amounts due back to Medicare in other accrued liabilities for the Federa</font><font style="font-family:Times New Roman;font-size:10pt;">l </font><font style="font-family:Times New Roman;font-size:10pt;">cap years ended October 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;"> through October 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;">Hospice Non-Medicare Revenue </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We record gross revenue on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per </font><font style="font-family:Times New Roman;font-size:10pt;">day </font><font style="font-family:Times New Roman;font-size:10pt;">rates, as applicable. Contractual adjustments are recorded for the difference between our established rates and the amounts estimated to be realizable from patients, third parties and others for services provided and are deducted from gross revenue to determine our net service revenue and patient accounts receiv</font><font style="font-family:Times New Roman;font-size:10pt;">able</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Personal Care Revenue Recognition </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;margin-left:0px;">Personal Care Non-Medicare Revenue </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We generate net service revenues by providing our services directly to patients primarily on a per hour, visit or unit basis. We receive payment for providing such services from our </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;"> clients, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Net service revenues are principally provided based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> which are recognized as net service revenue at the time services are rendered</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Cash and Cash Equivalents </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Patient Accounts Receivable</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Patient Accounts Receivable </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other t</font><font style="font-family:Times New Roman;font-size:10pt;">hird-party </font><font style="font-family:Times New Roman;font-size:10pt;">payors</font><font style="font-family:Times New Roman;font-size:10pt;"> and patients. As of December 31, </font><font style="font-family:Times New Roman;font-size:10pt;">201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">, there is one s</font><font style="font-family:Times New Roman;font-size:10pt;">ingle </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;">, other than Medicare, that accounts for more than </font><font style="font-family:Times New Roman;font-size:10pt;">10</font><font style="font-family:Times New Roman;font-size:10pt;">% of our total outstanding patient receivables</font><font style="font-family:Times New Roman;font-size:10pt;"> (approximately </font><font style="font-family:Times New Roman;font-size:10pt;">10</font><font style="font-family:Times New Roman;font-size:10pt;">.1</font><font style="font-family:Times New Roman;font-size:10pt;">%). T</font><font style="font-family:Times New Roman;font-size:10pt;">hus</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We fully reserve for accounts which are aged at </font><font style="font-family:Times New Roman;font-size:10pt;">36</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;"> days or greater. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We believe the credit risk associated with our Medicare accounts</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">which </font><font style="font-family:Times New Roman;font-size:10pt;">represent </font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;">% and </font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;">% of our net patient accounts receivable at </font><font style="font-family:Times New Roman;font-size:10pt;">December 31, 2016</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">December 31, </font><font style="font-family:Times New Roman;font-size:10pt;">2015, respectively, is limited</font><font style="font-family:Times New Roman;font-size:10pt;"> due to our historical collection rate of over </font><font style="font-family:Times New Roman;font-size:10pt;">99</font><font style="font-family:Times New Roman;font-size:10pt;">% </font><font style="font-family:Times New Roman;font-size:10pt;">from Medicare and the fact that Medicare is a U.S. government </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;">. Accordingly, we do not record an allowance for doubtful accounts for our Medicare patient accounts receivable, which are recorded at their net realizable value after recording estimated revenue </font><font style="font-family:Times New Roman;font-size:10pt;">adjustments as discussed above. </font><font style="font-family:Times New Roman;font-size:10pt;">During </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">2015</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">2014</font><font style="font-family:Times New Roman;font-size:10pt;">, we </font><font style="font-family:Times New Roman;font-size:10pt;">recorded $</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">9</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million, $</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">.1</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million and $</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million, respectively, in estimated revenue adjustments to Medicare revenue.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We believe there is a certain level of credit risk associated with non-Medicare </font><font style="font-family:Times New Roman;font-size:10pt;">payors</font><font style="font-family:Times New Roman;font-size:10pt;">. To provide for our non-Medicare patient accounts receivable that could become uncollectible in the future, we establish an allowance for doubtful accounts to reduce the carrying amount to its estimated net realizable value.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Medicare Home Health </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients.  Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We submit a RAP for </font><font style="font-family:Times New Roman;font-size:10pt;">60</font><font style="font-family:Times New Roman;font-size:10pt;">% of our estimated payment for the initial episode at the start of care or </font><font style="font-family:Times New Roman;font-size:10pt;">50</font><font style="font-family:Times New Roman;font-size:10pt;">% of the estimated payment for any subsequent episodes of care contiguous with the first episode for a particular patient. The full amount of the episode is billed after the episode has been completed (&#8220;final billed&#8221;). The RAP received for that particular episode is then deducted from our final payment. If a final bill is not submitted within the greater of </font><font style="font-family:Times New Roman;font-size:10pt;">120</font><font style="font-family:Times New Roman;font-size:10pt;"> days from the start of the episode, or </font><font style="font-family:Times New Roman;font-size:10pt;">60</font><font style="font-family:Times New Roman;font-size:10pt;"> days from the date the RAP was paid, any RAPs received for that episode will be recouped by Medicare from any other claims in process for that particular provider number. The RAP and final claim must then be resubmitted. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Medicare Hospice </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services t</font><font style="font-family:Times New Roman;font-size:10pt;">hat we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. </font><font style="font-family:Times New Roman;font-size:10pt;">Once each patient has been confirmed for eligibility, we will bill Medicare on a monthly basis for the services provided to the patient. </font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:0px;">Non-Medicare Home Health,</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"> Hospice,</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"> and Personal Care</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient's eligibility for services with the applicable </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;">. Once the patient has been confirmed for eligibility, we will provide services to the patient </font><font style="font-family:Times New Roman;font-size:10pt;">and bill the applicable </font><font style="font-family:Times New Roman;font-size:10pt;">payor</font><font style="font-family:Times New Roman;font-size:10pt;">.  </font><font style="font-family:Times New Roman;font-size:10pt;">Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular </font><font style="font-family:Times New Roman;font-size:10pt;">payors</font><font style="font-family:Times New Roman;font-size:10pt;"> or groups of </font><font style="font-family:Times New Roman;font-size:10pt;">payors</font><font style="font-family:Times New Roman;font-size:10pt;"> with similar characteristics that would subject us to any significant credit risk.  </font><font style="font-family:Times New Roman;font-size:10pt;">We estimate an allowance for doubtful accounts</font><font style="font-family:Times New Roman;font-size:10pt;"> based upon our assessment of historical and expected net collections, business and economic conditions, trends in payment and an evaluation of </font><font style="font-family:Times New Roman;font-size:10pt;">collectability</font><font style="font-family:Times New Roman;font-size:10pt;"> based upon the date that the service was provided. Based upon our best judgment, we believe the allowance for doubtful accounts adequately provides for accounts that will not be collected due to credit risk</font><font style="font-family:Times New Roman;font-size:10pt;">. </font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property Plant And Equipment</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Property and Equipment </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Property and equipment is stated at cost and we depreciate it on a straight-line basis over the estimated useful lives of the assets. Additionally, we have internally developed c</font><font style="font-family:Times New Roman;font-size:10pt;">omputer software for our own use</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">Additions and improvements (including interest costs for construction of qualifying long-lived assets) are capitalized. Maintenance and repair expenses are charged to expense as incurred. The cost of property and equipment sold or disposed of and the related accumulated depreciation are eliminated from the property and related accumulated depreciation accounts, and any gain or loss is credited or charged to other </font><font style="font-family:Times New Roman;font-size:10pt;">general and administrative expenses</font><font style="font-family:Times New Roman;font-size:10pt;">.  </font></p><p style='margin-top:4.5pt; margin-bottom:4.5pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We consider our reporting units to represent asset groups for purposes of testing long-lived assets for impairment.  We assess the impairment of a long-lived asset group whenever events or changes in circumstances indicate that the asset's carrying value may not be recoverable. </font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">Factors we consider important that could trigger an impairment review include but are not limited to the following:</font></p><p style='margin-top:0pt; margin-bottom:0pt'></p><ul><li style="margin-left:72px;list-style:disc;"><font style="font-family:Times New Roman;font-size:10pt;">A significant change in the extent or manner in which the long-lived asset group is being used</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></li><li style="margin-left:72px;list-style:disc;"><font style="font-family:Times New Roman;font-size:10pt;">A significant change in the business climate that could affect the value of the long-lived asset group</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></li><li style="margin-left:72px;list-style:disc;"><font style="font-family:Times New Roman;font-size:10pt;">A significant change in the market value of the assets included in the asset group</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></li></ul><p style='margin-top:4.5pt; margin-bottom:4.5pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">If we determine that the carrying value of long-lived assets may not be recoverable, we compare the carrying value of the asset group to the undiscounted cash flows expected to be generated by the asset group. If the carrying value exceeds the undiscounted cash flows, an impairment charge is indicated. An impairment charge is recognized to the extent that the carrying value of the asset group exceeds its fair value. </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We generally provide for depreciation over the following estimated usef</font><font style="font-family:Times New Roman;font-size:10pt;">ul service lives</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 14px"><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 250px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:250px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Years</font></td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Building</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 250px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:250px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">39</font></td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Leasehold improvements</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Lesser of life or lease or expected useful life</font></td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Equipment and furniture</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">3 to 7</font></td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Vehicles</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">5</font></td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Computer software</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">3 to 5</font></td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">As of December 31, 2014, we had $</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">8</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million of internally developed software costs related to the development of AMS3 Home Health</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">Hospice</font><font style="font-family:Times New Roman;font-size:10pt;"> (&#8220;AMS3&#8221;)</font><font style="font-family:Times New Roman;font-size:10pt;">. Expanded beta testing to additional sites in February of 2015 demonstrated that AMS3 was disruptive to operations. Additional analysis of the system determined that the system was not ready to be fully implemented and would require significant time and investment to redesign. Therefore, during the three-month period ended March 31, 2015, we made the decision to discontinue AMS3 and recorded a non-cash </font><font style="font-family:Times New Roman;font-size:10pt;">asset impairment charge of $</font><font style="font-family:Times New Roman;font-size:10pt;">75.2</font><font style="font-family:Times New Roman;font-size:10pt;"> million</font><font style="font-family:Times New Roman;font-size:10pt;"> to write-off the software costs incurred related to the development of AMS3</font><font style="font-family:Times New Roman;font-size:10pt;">.  </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">During 201</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;">, we </font><font style="font-family:Times New Roman;font-size:10pt;">began </font><font style="font-family:Times New Roman;font-size:10pt;">the </font><font style="font-family:Times New Roman;font-size:10pt;">transition</font><font style="font-family:Times New Roman;font-size:10pt;"> of all our care centers from our proprietary operating system </font><font style="font-family:Times New Roman;font-size:10pt;">to </font><font style="font-family:Times New Roman;font-size:10pt;">Homecare </font><font style="font-family:Times New Roman;font-size:10pt;">Homebase</font><font style="font-family:Times New Roman;font-size:10pt;"> (&#8220;HCHB&#8221;), a leading home health and hospice platform, with all of our care centers operating on HCHB as of December 31,</font><font style="font-family:Times New Roman;font-size:10pt;"> 2016. As part of our conversion process, we determined that a number of assets (primarily laptops) were not compatible with HCHB</font><font style="font-family:Times New Roman;font-size:10pt;"> and had no other alternative or secondary use</font><font style="font-family:Times New Roman;font-size:10pt;">. As a result, we recorded a non-cash asset impairment charge of $</font><font style="font-family:Times New Roman;font-size:10pt;">4.4</font><font style="font-family:Times New Roman;font-size:10pt;"> million to write-off these assets during the three-month period ended December 31, 2016.</font></p><p style='margin-top:4.5pt; margin-bottom:4.5pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">During the three-month period ended September 30, 2015, we commenced an active program to sell our corporate headquarters located in Baton Rouge, Louisiana. In accordance with U.S. GAAP, we classified this asset as held for sale and reduced the carrying value of the asset to its estimated fair value less estimated costs to sell the asset; no further depreciation expense for the asset </font><font style="font-family:Times New Roman;font-size:10pt;">was</font><font style="font-family:Times New Roman;font-size:10pt;"> recorded. As a result, we recorded a non-cash asset </font><font style="font-family:Times New Roman;font-size:10pt;">impairment</font><font style="font-family:Times New Roman;font-size:10pt;"> charge of $</font><font style="font-family:Times New Roman;font-size:10pt;">2.1</font><font style="font-family:Times New Roman;font-size:10pt;"> million during the three-month period ended September 30, 2015</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">The asset was sold during the three-month period ended December 31, 2015</font><font style="font-family:Times New Roman;font-size:10pt;"> and the Company now leases </font><font style="font-family:Times New Roman;font-size:10pt;">equivalent</font><font style="font-family:Times New Roman;font-size:10pt;"> office space</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 14px"><td colspan="7"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following table summarizes the balances related to our property and equipment for 2016 and 2015 (amounts in millions):</font></td></tr><tr style="height: 9px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="4"  style="width: 160px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:160px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">As of December 31,</font></td></tr><tr style="height: 12px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 20px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015</font></td></tr><tr style="height: 14px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Building and leasehold improvements</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.9</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.3</font></td></tr><tr style="height: 14px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Equipment and furniture</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">71.9</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">89.6</font></td></tr><tr style="height: 14px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Computer software</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">96.8</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">92.6</font></td></tr><tr style="height: 14px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">175.6</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">184.5</font></td></tr><tr style="height: 14px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Less: accumulated depreciation</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(138.6)</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(141.8)</font></td></tr><tr style="height: 14px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">37.0</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">42.7</font></td></tr><tr style="height: 9px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;">&#160;</td></tr><tr style="height: 14px"><td colspan="7"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Depreciation expense for 2016, 2015 and 2014 was $17.2 million, $20.0 million and $28.0 million, respectively.</font></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill And Intangible Assets</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Goodwill and Other Intangible Assets</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Goodwill represents the amount of the purchase price in excess of the fair values assigned to the underlying identifiable net assets of acquired businesses. Goodwill is not amortized, but is subject to an annual impairment test. Tests are performed more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount.</font><font style="font-family:Times New Roman;font-size:10pt;"> These events or circumstances include but are not limited to, a significant adverse change in the business environment; regulatory environment or legal factors; or a substantial decline in market capitalization of our stock.</font><font style="font-family:Times New Roman;font-size:10pt;"> To determine whether goodwill is impaired, we perform a two-step impairment test. In the first step of the test, the fair values of the reporting units are compared to their aggregate carrying values, including goodwill. If the fair value of the reporting unit is greater than its carrying amount, goodwill is not considered impaired and no further testing is required. If the fair value of the reporting unit is less than its carrying amount, we would proceed to step two of the test. In step two of the test, the implied fair value of the goodwill of the reporting unit is determined by a hypothetical allocation of the fair value calculated in step one to all of the assets and liabilities of that reporting unit (including any recognized and unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value was reflective of the price paid to acquire the reporting unit. The implied fair value of goodwill is the excess, if any, of the calculated fair value after hypothetical allocation to the reporting unit's assets and liabilities. If the implied fair value of the goodwill is greater than the carrying amount of the goodwill at the analysis date, goodwill is not impaired and the analysis is complete. If the implied fair value of the goodwill is less than the carrying value of goodwill at the analysis date, goodwill is deemed impaired by the amount of that variance.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We calculate the estimated fair value of our reporting units using discounted cash flows </font><font style="font-family:Times New Roman;font-size:10pt;">as well as a market approach that compares our reporting units' earnings and revenue multiples to those of comparable public companies.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">To determine fair value we must make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> in particular expected organic growth rates, future Medicare reimbursement rates</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">capital requirements and income taxes), long-term growth rates for determining terminal value, and discount rates. Our estimates of discounted cash flows may differ from actual cash flows due to, among other things, economic conditions, changes to our business model or changes in operating performance. </font><font style="font-family:Times New Roman;font-size:10pt;">These factors increase the risk of differences between projected and actual performance that could impact future estimates of fair value of all reporting units. </font><font style="font-family:Times New Roman;font-size:10pt;">Significant differences between these estimates and actual cash flows could </font><font style="font-family:Times New Roman;font-size:10pt;">result in additional impairment in future periods.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Each of our operating segments described in </font><font style="font-family:Times New Roman;font-size:10pt;">Note 1</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;"> &#8211; Segment Information </font><font style="font-family:Times New Roman;font-size:10pt;">is considered to represent an individual reporting unit for goodwill impairment testing purposes. We consider each of our home health care centers to constitute an individual business for which discrete financial information is available. However, since these care centers have substantially similar operating and economic characteristics and resource allocation and significant investment decisions concerning these businesses are centralized and the benefits broadly distributed, we have aggregated these care centers and deemed them to constitute a single reporting unit. We have applied this same aggregation principle to our hospice care centers </font><font style="font-family:Times New Roman;font-size:10pt;">and personal-care care centers </font><font style="font-family:Times New Roman;font-size:10pt;">and have also deemed them to be a single reporting unit.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">During 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">, we did not record any goodwill impairment charges </font><font style="font-family:Times New Roman;font-size:10pt;">as a result of our annual impairment test </font><font style="font-family:Times New Roman;font-size:10pt;">and none of the goodwill associated with our various reporting units w</font><font style="font-family:Times New Roman;font-size:10pt;">as</font><font style="font-family:Times New Roman;font-size:10pt;"> considered at risk of impairment as of October 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">. Since</font><font style="font-family:Times New Roman;font-size:10pt;"> the date of our last annual goodwill impairment test, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than its carrying amount.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Intangible assets consist of Certificates of</font><font style="font-family:Times New Roman;font-size:10pt;"> Need, licenses, acquired names and</font><font style="font-family:Times New Roman;font-size:10pt;"> non-</font><font style="font-family:Times New Roman;font-size:10pt;">compete</font><font style="font-family:Times New Roman;font-size:10pt;"> agreements. We amortize non-compete agreements</font><font style="font-family:Times New Roman;font-size:10pt;"> and</font><font style="font-family:Times New Roman;font-size:10pt;"> acquired names that we do not intend to use in the future on a straight-line basis over their estimated useful lives, which is generally three years for non-compete agreements and up to five years for </font><font style="font-family:Times New Roman;font-size:10pt;">acquired names. </font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtIssuanceCostsPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Debt Issuance Costs</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We amortize deferred debt issuance costs related to our long-term obligations over its term through interest expense, unless the debt is extinguished, in which case unamortized balances are immediately expensed. We </font><font style="font-family:Times New Roman;font-size:10pt;">a</font><font style="font-family:Times New Roman;font-size:10pt;">mortized $</font><font style="font-family:Times New Roman;font-size:10pt;">0.</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;"> million</font><font style="font-family:Times New Roman;font-size:10pt;">, $0.</font><font style="font-family:Times New Roman;font-size:10pt;">8</font><font style="font-family:Times New Roman;font-size:10pt;"> million and $</font><font style="font-family:Times New Roman;font-size:10pt;">0.7</font><font style="font-family:Times New Roman;font-size:10pt;"> million in deferred debt issuance costs in </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">2015</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">2014</font><font style="font-family:Times New Roman;font-size:10pt;">, respectively. As of December 31, </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">2015</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">we had unamortized debt issuance costs of $</font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million and $</font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> respectively</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> recorded as </font><font style="font-family:Times New Roman;font-size:10pt;">long-term obligations, less current portion</font><font style="font-family:Times New Roman;font-size:10pt;"> in our accompanying consolidated balance sheets. The unamortized debt issuance costs of $</font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;"> million at December 31, 2016, will be amortize</font><font style="font-family:Times New Roman;font-size:10pt;">d over a weighted-average amortization period of </font><font style="font-family:Times New Roman;font-size:10pt;">3</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">years.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 9px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;">&#160;</td></tr><tr style="height: 18px"><td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Fair Value of Financial Instruments</font></td></tr><tr style="height: 8px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;">&#160;</td></tr><tr style="height: 17px"><td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</font></td></tr><tr style="height: 9px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="11"  style="width: 445px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:445px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Fair Value at Reporting Date Using</font></td></tr><tr style="height: 51px"><td   style="width: 255px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:255px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;">Financial Instrument</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 95px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:95px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">As of
December 31,
2016</font></td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 114px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:114px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Quoted Prices in Active Markets for Identical Items
(Level 1)</font></td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 102px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:102px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Significant Other Observable Inputs (Level 2)</font></td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 104px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:104px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Significant Unobservable Inputs (Level 3)</font></td></tr><tr style="height: 14px"><td   style="width: 255px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:255px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Long-term obligations</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">95.7</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 102px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:102px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">0</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">97.8</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 92px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:92px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">0</font></td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">The </font><font style="font-family:Times New Roman;font-size:10pt;">fair value hierarchy</font><font style="font-family:Times New Roman;font-size:10pt;"> is</font><font style="font-family:Times New Roman;font-size:10pt;"> based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'></p><ul><li style="margin-left:36px;list-style:disc;"><font style="font-family:Times New Roman;font-size:10pt;">Level 1 &#8211; Quoted prices in active markets for identical assets and liabilities.</font></li><li style="margin-left:36px;list-style:disc;"><font style="font-family:Times New Roman;font-size:10pt;">Level 2 &#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></li><li style="margin-left:36px;list-style:disc;"><font style="font-family:Times New Roman;font-size:10pt;">Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</font></li></ul><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. </font><font style="font-family:Times New Roman;font-size:10pt;">For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable</font><font style="font-family:Times New Roman;font-size:10pt;">, payroll and employee benefits </font><font style="font-family:Times New Roman;font-size:10pt;">and accrued expenses</font><font style="font-family:Times New Roman;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> we estimate the carrying amounts' approximate fair value. </font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Income Taxes</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We use the asset and liability approach for measuring deferred tax assets and liabilities based on temporary differences existing at each balance sheet date using currently enacted tax rates. Our deferred tax calculation requires us to make certain estimates about future operations. Deferred tax </font><font style="font-family:Times New Roman;font-size:10pt;">assets are reduced by a valuation allowance when we believe it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect of a change in tax rate is recognized as income or expense in the period that includes the enactment date. As of December 31, 201</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">and 201</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">our </font><font style="font-family:Times New Roman;font-size:10pt;">net </font><font style="font-family:Times New Roman;font-size:10pt;">deferred tax asset</font><font style="font-family:Times New Roman;font-size:10pt;">s</font><font style="font-family:Times New Roman;font-size:10pt;"> w</font><font style="font-family:Times New Roman;font-size:10pt;">ere</font><font style="font-family:Times New Roman;font-size:10pt;"> $</font><font style="font-family:Times New Roman;font-size:10pt;">107.9</font><font style="font-family:Times New Roman;font-size:10pt;"> million</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">$</font><font style="font-family:Times New Roman;font-size:10pt;">125</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">2</font><font style="font-family:Times New Roman;font-size:10pt;"> million, respectively</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Management regularly assesses the ability to realize deferred tax assets recorded in the Company's entities based upon the weight of available evidence, including such factors as the recent earnings history and expected future taxable income</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">In the event future taxable income is below management's estimates or is generated in tax jurisdictions different than projected, we could be required to increase the valuation allowance for deferred tax assets. This would result in an increase in our effective tax rate.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Share-Based Compensation</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We record all share-based compensation as expense in the financial statements measured at the fair value of the award. We recognize compensation cost on a straight-line basis over the requisite service period for each separately vesting portion of the award. We reflect the excess tax benefits related to stock option exercises as financing cash flows. Share-based compensation expense for </font><font style="font-family:Times New Roman;font-size:10pt;">2016</font><font style="font-family:Times New Roman;font-size:10pt;">, </font><font style="font-family:Times New Roman;font-size:10pt;">2015</font><font style="font-family:Times New Roman;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;">2014</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">was $</font><font style="font-family:Times New Roman;font-size:10pt;">1</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;"> million, $</font><font style="font-family:Times New Roman;font-size:10pt;">11</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">8</font><font style="font-family:Times New Roman;font-size:10pt;"> million and $</font><font style="font-family:Times New Roman;font-size:10pt;">5</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;"> million, respectively, and the total income tax benefit</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">recognized for these expenses was $</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million, $</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million and $</font><font style="font-family:Times New Roman;font-size:10pt;">2.</font><font style="font-family:Times New Roman;font-size:10pt;">0</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million, respectively.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Weighted-Average Shares Outstanding</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Weighted-Average Shares Outstanding</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Net</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">income</font><font style="font-family:Times New Roman;font-size:10pt;"> (loss)</font><font style="font-family:Times New Roman;font-size:10pt;"> per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calc</font><font style="font-family:Times New Roman;font-size:10pt;">ulate our basic and diluted net </font><font style="font-family:Times New Roman;font-size:10pt;">income (loss)</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">attributable to Amedisys, Inc. common stockholders (amounts in thousands):</font></p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 16px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="5"  style="width: 234px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:234px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Years Ended December 31, </font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:68px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 15px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:68px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015</font></td><td   style="width: 15px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:68px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2014</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Weighted average number of shares outstanding - basic</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">33,198</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">33,018</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">32,301</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Effect of dilutive securities:</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 68px; text-align:left;border-color:#000000;min-width:68px;">&#160;</td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; text-align:left;border-color:#000000;min-width:68px;">&#160;</td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; text-align:left;border-color:#000000;min-width:68px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Stock options</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 68px; text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">162</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Non-vested stock and stock units</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 68px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">381</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">521</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Weighted average number of shares outstanding - diluted</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">33,741</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">33,018</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">32,823</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Anti-dilutive securities</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 68px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">221</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">922</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">106</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Advertising Costs</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">We expense advertising costs as incurred. Advertising expense for 2016, 2015 and 2014 was $</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">8</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million, $</font><font style="font-family:Times New Roman;font-size:10pt;">6</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">9</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million </font><font style="font-family:Times New Roman;font-size:10pt;">and $</font><font style="font-family:Times New Roman;font-size:10pt;">4</font><font style="font-family:Times New Roman;font-size:10pt;">.</font><font style="font-family:Times New Roman;font-size:10pt;">7</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">million</font><font style="font-family:Times New Roman;font-size:10pt;">, respectively.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Recently Issued Accounting Pronouncements</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'>&#160;</p><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><p style='margin-top:12pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Times New Roman;font-size:10pt;">, which requires an entity to recognize the amount of revenue for which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP. In August 2015, the FASB issued ASU 2015-14,</font><font style="font-family:Georgia;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font><font style="font-family:Georgia;font-size:10pt;">,</font><font style="font-family:Times New Roman;font-size:10pt;"> to defer the effective date of the standard from January 1, 2017, to January 1, 2018, with an option that permits companies to adopt the standard as early as the original effective date. The new ASU reflects the decisions reached by the FASB at its meeting in July 2015. Early application prior to the original effective date is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Co</font><font style="font-family:Times New Roman;font-size:10pt;">mpany does not expect an impact on its consolidated financial statements upon </font><font style="font-family:Times New Roman;font-size:10pt;">implementation</font><font style="font-family:Times New Roman;font-size:10pt;"> of ASU 2014-09 and </font><font style="font-family:Times New Roman;font-size:10pt;">ASU 2015-14 on January 1, 2018, but is still evaluating the effect the standard will have on its related disclosures.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In April 2015, the FASB issued ASU 2015-03, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Interest - Imputation of Interest</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">(Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</font><font style="font-family:Times New Roman;font-size:10pt;">.&#160;The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. ASU 2015-03 is effective for annual and interim periods beginning on or after December 15, 2015. </font><font style="font-family:Times New Roman;font-size:10pt;">We adopted this ASU during the three-month period ended March 31, 2016, and applied the change retrospectively for prior period balances of unamortized debt issuance costs, resulting </font><font style="font-family:Times New Roman;font-size:10pt;">in a $3.4 million</font><font style="font-family:Times New Roman;font-size:10pt;"> reduction in other assets, net and long-term obligations, less current portion, on our consolidated balance sheet as of December 31, 2015</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In February 2016, the FASB issued ASU 2016-02, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Leases (Topic 842</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">), </font><font style="font-family:Times New Roman;font-size:10pt;">whic</font><font style="font-family:Times New Roman;font-size:10pt;">h will require lessees to recognize a lease liability and right-of-use asset for all leases (with the exception of short-term leases) at the commencement date</font><font style="font-family:Times New Roman;font-size:10pt;">. The ASU is effective for annual and interim periods beginning on or after December 15, 2018. Early adoption is permitted. The standard requires a modified retrospective transition method which requires application of the new guid</font><font style="font-family:Times New Roman;font-size:10pt;">ance for all periods presented. While the Company expects adoption of this standard to lead to a material increase in the assets and liabilities recorded on our balance sheet, we are still </font><font style="font-family:Times New Roman;font-size:10pt;">evaluating the </font><font style="font-family:Times New Roman;font-size:10pt;">overall impact on our</font><font style="font-family:Times New Roman;font-size:10pt;"> consolidated financial statements and related disclosures and the effect of the standard on </font><font style="font-family:Times New Roman;font-size:10pt;">our</font><font style="font-family:Times New Roman;font-size:10pt;"> ongoing financial reporting</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In March 2016, the FASB issued ASU 2016-09, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Compensation &#8211; Stock Compensation (Topic 718): Improvement to Employee Share-Based Payment Accounting</font><font style="font-family:Times New Roman;font-size:10pt;">, which will simplify the accounting for share-based payment award transactions, including income tax consequences, classification of awards as either equity or liability, and classification on the statement of cash flows. The ASU is effective for annual and interim periods beginning after December 15, 2016. Early adoption is permitted. </font><font style="font-family:Times New Roman;font-size:10pt;">The element of the new standard that will have the most impact on our consolidated financial statements will be income tax consequences. Excess tax benefits and tax deficiencies on share-based compensation awards will now be included in our tax provision within our consolidated statement of operations as discrete items in the reporting period in </font><font style="font-family:Times New Roman;font-size:10pt;">which they occur, rather than our current accounting of recording in additional paid-in capital on our consolidated balance sheets</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:4.5pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">In August 2016, the FASB issued ASU 2016-15, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:Times New Roman;font-size:10pt;">, which provides specific guidance on eight cash flow classification issues not specifically addressed by U.S. GAAP. The ASU is effective for annual and interim periods beginning after December 15, 2017. Early adoption is permitted. The standard should be applied using a retrospective transition method unless it is impractical to do so for some of the issues. In such case, the amendments for those issues would be applied prospectively as of the earliest date practicable. The Company is evaluating the effect that ASU 2016-15 will have on its consolidated financial statements and related disclosures and the effect of the standard on its ongoing financial reporting</font><font style="font-family:Times New Roman;font-size:10pt;">.</font></p><p style='margin-top:0pt; margin-bottom:0pt'>&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtIssuanceCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtIssuanceCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising costs. For those costs that cannot be capitalized, discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized, describes those assets and the accounting policy used, including a description of the qualifying activity, the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 20<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51677389&amp;loc=d3e8384-108330<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51662920&amp;loc=d3e8275-108329<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 203<br> -Paragraph 02-03<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComparabilityOfPriorYearFinancialData">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting any exceptions to the  comparability of prior year financial data with data shown for the most recent accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComparabilityOfPriorYearFinancialData</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph k<br> -Article 1<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02, 03<br> -Article 3A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the equity method of accounting for investments in common stock or other interests including unconsolidated subsidiaries, corporate joint ventures, noncontrolling interests in real estate ventures, limited partnerships, and limited liability companies. The accounting policy may include information such as: (1) initially recording an investment in the stock of an investee at cost; (2) adjusting the carrying amount of the investment to recognize the investor's share of the earnings or losses of the investee after the date of acquisition; and (3) adjustments to reflect the investor's share of changes in the investee's capital (dividends). This disclosure may also include a detailed description of the policy for determining the amount of equity method losses recognized after an investment has been reduced to zero as a result of previous losses, reasons for not using the equity method when the investor company owns 20 percent or more of the voting stock of the investee's company (including identification of the significant investee), reasons for using the equity method when the ownership percentage is less than 20 percent, and discussion of recognition of equity method losses when an investor's total investment in an investee includes, in addition to an investment in common stock, other investments such as preferred stock and loans to the investee. An entity also may describe how such investments are assessed for impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section B<br> -Paragraph Question 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6378556&amp;loc=d3e10133-111534<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5212-111524<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3, 4<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6783851200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock', window );">Estimated Useful Lives Of Property And Equipment</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 14px"><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 250px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:250px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Years</font></td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Building</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 250px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:250px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">39</font></td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Leasehold improvements</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Lesser of life or lease or expected useful life</font></td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Equipment and furniture</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">3 to 7</font></td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Vehicles</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">5</font></td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 280px; text-align:left;border-color:#000000;min-width:280px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Computer software</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 250px; text-align:center;border-color:#000000;min-width:250px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">3 to 5</font></td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property Plant and Equipment</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 14px"><td colspan="7"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following table summarizes the balances related to our property and equipment for 2016 and 2015 (amounts in millions):</font></td></tr><tr style="height: 9px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="4"  style="width: 160px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:160px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">As of December 31,</font></td></tr><tr style="height: 12px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 20px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015</font></td></tr><tr style="height: 14px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Building and leasehold improvements</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.9</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.3</font></td></tr><tr style="height: 14px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Equipment and furniture</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">71.9</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">89.6</font></td></tr><tr style="height: 14px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Computer software</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">96.8</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">92.6</font></td></tr><tr style="height: 14px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">175.6</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">184.5</font></td></tr><tr style="height: 14px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Less: accumulated depreciation</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(138.6)</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(141.8)</font></td></tr><tr style="height: 14px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">37.0</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">42.7</font></td></tr><tr style="height: 9px"><td   style="width: 530px; text-align:left;border-color:#000000;min-width:530px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;">&#160;</td></tr><tr style="height: 14px"><td colspan="7"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Depreciation expense for 2016, 2015 and 2014 was $17.2 million, $20.0 million and $28.0 million, respectively.</font></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FinancialInstrumentDetailsTextBlock', window );">Financial Instruments Where Carrying Value and Fair Value Differ</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 9px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;">&#160;</td></tr><tr style="height: 18px"><td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Fair Value of Financial Instruments</font></td></tr><tr style="height: 8px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;">&#160;</td></tr><tr style="height: 17px"><td colspan="13"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</font></td></tr><tr style="height: 9px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 102px; text-align:left;border-color:#000000;min-width:102px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 92px; text-align:left;border-color:#000000;min-width:92px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 255px; text-align:left;border-color:#000000;min-width:255px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="11"  style="width: 445px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:445px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Fair Value at Reporting Date Using</font></td></tr><tr style="height: 51px"><td   style="width: 255px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:255px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;">Financial Instrument</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 95px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:95px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">As of
December 31,
2016</font></td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 114px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:114px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Quoted Prices in Active Markets for Identical Items
(Level 1)</font></td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 102px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:102px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Significant Other Observable Inputs (Level 2)</font></td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 104px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:104px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Significant Unobservable Inputs (Level 3)</font></td></tr><tr style="height: 14px"><td   style="width: 255px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:255px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Long-term obligations</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">95.7</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 102px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:102px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">0</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">97.8</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 92px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:92px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">0</font></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Weighted-Average Shares Outstanding</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 16px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="5"  style="width: 234px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:234px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Years Ended December 31, </font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:68px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 15px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:68px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015</font></td><td   style="width: 15px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:68px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2014</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Weighted average number of shares outstanding - basic</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">33,198</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">33,018</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">32,301</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Effect of dilutive securities:</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 68px; text-align:left;border-color:#000000;min-width:68px;">&#160;</td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; text-align:left;border-color:#000000;min-width:68px;">&#160;</td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; text-align:left;border-color:#000000;min-width:68px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Stock options</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 68px; text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">162</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 359px; text-align:left;border-color:#000000;min-width:359px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Non-vested stock and stock units</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 68px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">381</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">521</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Weighted average number of shares outstanding - diluted</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">33,741</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">33,018</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">32,823</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td colspan="2"  style="width: 384px; text-align:left;border-color:#000000;min-width:384px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Anti-dilutive securities</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 68px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">221</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">922</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 68px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:68px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">106</font></td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>stimated Useful Lives Of Property And Equipment, table</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FinancialInstrumentDetailsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial instrument details, table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FinancialInstrumentDetailsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958480656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS - PRO FORMA CONDENSED CONSOLIDATED INCOME STATEMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract', window );"><strong>Business Acquisition Pro Forma Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Business Acquisition Pro Forma Information Text Block</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015</font></td><td   style="width: 45px; text-align:center;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Net service revenue</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">1,449.7</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">1,322.2</font></td><td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Operating income (loss)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">53.9</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(7.8)</font></td><td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Net income</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">35.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.4</font></td><td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Basic earnings (loss) per share</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">1.04</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(0.01)</font></td><td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Diluted earnings (loss) per share</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">1.03</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(0.01)</font></td><td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 416px; text-align:left;border-color:#000000;min-width:416px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td colspan="7" rowspan="5" style="width: 620px; text-align:left;border-color:#000000;min-width:620px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">The pro forma information presented above includes adjustments for (i) amortization of identifiable intangible assets and (ii) income tax provision using the Company&#8217;s statutory tax rate. This pro forma information is presented for illustrative purposes only and may not be indicative of the results of operations that would have actually occurred. In addition, future results may vary significantly from the results reflected in the pro forma information.</font></td><td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 19px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 30px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 45px; text-align:right;border-color:#000000;min-width:45px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6598138592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Summary of Activity Related to Goodwill and Other Intangible Assets Net</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 21px"><td colspan="14"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">The following table summarizes the activity related to our goodwill for 2016, 2015 and 2014 (amounts in millions):</font></td></tr><tr style="height: 9px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 78px; text-align:left;border-color:#000000;min-width:78px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:left;border-color:#000000;min-width:64px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:left;border-color:#000000;min-width:64px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:left;border-color:#000000;min-width:64px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="11"  style="width: 346px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:346px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Goodwill</font></td></tr><tr style="height: 33px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;">&#160;</td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 88px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:88px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Home Health</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 74px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:74px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Hospice</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 74px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:74px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Personal Care</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 74px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:74px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Total</font></td></tr><tr style="height: 14px"><td colspan="2"  style="width: 352px; text-align:left;border-color:#000000;min-width:352px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Balances at December 31, 2013</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 78px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:78px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">16.6</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">192.3</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">208.9</font></td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Write-off (1)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 78px; text-align:right;border-color:#000000;min-width:78px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.1)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(3.2)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(3.3)</font></td></tr><tr style="height: 14px"><td colspan="2"  style="width: 352px; text-align:left;border-color:#000000;min-width:352px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Balances at December 31, 2014</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 78px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:78px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">16.5</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">189.1</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">205.6</font></td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Additions</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 78px; text-align:right;border-color:#000000;min-width:78px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">50.6</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">5.5</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">56.1</font></td></tr><tr style="height: 14px"><td colspan="2"  style="width: 352px; text-align:left;border-color:#000000;min-width:352px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Balances at December 31, 2015</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 78px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:78px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">67.1</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">194.6</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">261.7</font></td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Additions</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 78px; text-align:right;border-color:#000000;min-width:78px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.4</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">22.7</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">27.1</font></td></tr><tr style="height: 14px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Adjustments related to acquisitions</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 78px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:78px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.1</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.1</font></td></tr><tr style="height: 14px"><td colspan="2"  style="width: 352px; text-align:left;border-color:#000000;min-width:352px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Balances at December 31, 2016</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 78px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:78px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">71.6</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">194.6</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">22.7</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">288.9</font></td></tr><tr style="height: 9px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 312px; text-align:left;border-color:#000000;min-width:312px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 78px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:78px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:64px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:64px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:64px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 30px"><td colspan="14"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following table summarizes the activity related to our other intangible assets, net for 2016, 2015 and 2014 (amounts in millions):</font></td></tr><tr style="height: 9px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;<font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;" /></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 95px; text-align:left;border-color:#000000;min-width:95px;">&#160;<font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;" /></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:left;border-color:#000000;min-width:64px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="11"  style="width: 380px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:380px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Other Intangible Assets, Net</font></td></tr><tr style="height: 10px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;">&#160;</td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Certificates of</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:80px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Acquired </font><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 105px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:105px;">&#160;<font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:64px;">&#160;</td></tr><tr style="height: 10px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;">&#160;</td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 85px; text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Need and</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 80px; text-align:center;border-color:#000000;min-width:80px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Names of</font><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Non-Compete</font><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:center;border-color:#000000;min-width:64px;">&#160;</td></tr><tr style="height: 10px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;">&#160;</td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Licenses</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:80px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Business</font><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 105px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:105px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Agreements (2)</font><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;" /></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 74px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:74px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Total</font></td></tr><tr style="height: 16px"><td colspan="2"  style="width: 318px; text-align:left;border-color:#000000;min-width:318px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Balances at December 31, 2013</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">25.4</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">$</font></td><td   style="width: 70px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">11.1</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">$</font></td><td   style="width: 95px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:95px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.2</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">$</font></td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">36.7</font></td></tr><tr style="height: 13px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Write-off (1)</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(0.2)</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 70px; text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.0</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 95px; text-align:right;border-color:#000000;min-width:95px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.0</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(0.2)</font></td></tr><tr style="height: 13px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Impairment</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(2.1)</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 70px; text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(1.0)</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 95px; text-align:right;border-color:#000000;min-width:95px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.0</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(3.1)</font></td></tr><tr style="height: 13px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Amortization</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.0</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 70px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.0</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 95px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:95px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(0.2)</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(0.2)</font></td></tr><tr style="height: 13px"><td colspan="2"  style="width: 318px; text-align:left;border-color:#000000;min-width:318px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Balances at December 31, 2014</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">23.1</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 70px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">10.1</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 95px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:95px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.0</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">33.2</font></td></tr><tr style="height: 13px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Additions</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">1.1</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 70px; text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">4.1</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 95px; text-align:right;border-color:#000000;min-width:95px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">5.9</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">11.1</font></td></tr><tr style="height: 13px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Write-off</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(0.3)</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 70px; text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.0</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 95px; text-align:right;border-color:#000000;min-width:95px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.0</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(0.3)</font></td></tr><tr style="height: 13px"><td colspan="2"  style="width: 318px; text-align:left;border-color:#000000;min-width:318px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Balances at December 31, 2015</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">23.9</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 70px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">14.2</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 95px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:95px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">5.9</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">44.0</font></td></tr><tr style="height: 13px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Additions</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.2</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 70px; text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">3.5</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 95px; text-align:right;border-color:#000000;min-width:95px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">1.5</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">5.2</font></td></tr><tr style="height: 13px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Amortization</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.0</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 70px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">0.0</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 95px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:95px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(2.5)</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(2.5)</font></td></tr><tr style="height: 13px"><td colspan="2"  style="width: 318px; text-align:left;border-color:#000000;min-width:318px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Balances at December 31, 2016</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 75px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">24.1</font></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">$</font></td><td   style="width: 70px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">17.7</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">$</font></td><td   style="width: 95px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:95px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">4.9</font><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">$</font></td><td   style="width: 64px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:64px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">46.7</font></td></tr><tr style="height: 13px"><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 278px; text-align:left;border-color:#000000;min-width:278px;">&#160;</td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 70px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:70px;">&#160;<font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 95px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:95px;">&#160;<font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;" /></td><td   style="width: 12px; text-align:right;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 64px; border-top-style:double;border-top-width:3px;text-align:right;border-color:#000000;min-width:64px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td colspan="6"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The estimated aggregate amortization expense related to intangible assets for each of the five succeeding years is as follows (amounts in millions):</font></td></tr><tr style="height: 11px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2017</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.7</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2018</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.2</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2019</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2020</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2021</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.9</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6783699888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DetailsOfCertainBalanceSheetAccountsAbstract', window );"><strong>Details Of Certain Balance Sheet Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Other Current Assets</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 20px"><td colspan="10"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">6. DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS</font></td></tr><tr style="height: 9px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 15px"><td colspan="9"  style="width: 690px; text-align:left;border-color:#000000;min-width:690px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Additional information regarding certain balance sheet accounts is presented below (amounts in millions):</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="5"  style="width: 180px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:180px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">As of December 31, </font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 75px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:75px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 30px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:30px;">&#160;</td><td colspan="2"  style="width: 75px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:75px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td colspan="2"  style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Other current assets:</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Payroll tax escrow</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.7</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.2</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Income tax receivable</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.3</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.5</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Due from joint ventures</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.7</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.8</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Other</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.6</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.1</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">11.3</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">14.6</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Other Assets</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 9px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td colspan="2"  style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Other assets:</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Workers' compensation deposits</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.4</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.3</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Health insurance deposits</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.5</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.2</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Other miscellaneous deposits</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.9</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.5</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Investments</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">27.8</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">25.7</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Other</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">8.9</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.1</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">38.5</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">32.8</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 9px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td colspan="2"  style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Accrued expenses:</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Health insurance</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.6</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">11.7</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Workers' compensation</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">26.8</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">23.9</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Legal and other settlements</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">5.7</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.5</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Lease liability</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.4</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.6</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Charity care</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.4</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.7</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Estimated Medicare cap liability</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.8</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.4</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Hospice cost of revenue</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">7.2</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.8</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">OIG self-disclosure accrual</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.7</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Patient liability</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.3</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">5.1</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Other</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.1</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.6</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">63.3</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">72.0</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock', window );">Other Liabilities</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 9px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td colspan="2"  style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Other long-term obligations:</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Reserve for uncertain tax positions</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.3</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.7</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Deferred compensation plan liability</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.8</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.8</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Other</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.6</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.9</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 440px; text-align:left;border-color:#000000;min-width:440px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.7</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.4</font></td><td   style="width: 20px; text-align:left;border-color:#000000;min-width:20px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DetailsOfCertainBalanceSheetAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DetailsOfCertainBalanceSheetAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other assets and other liabilities not separately disclosed on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958331600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Long-Term Debt</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">7. LONG-TERM OBLIGATIONS</font></td></tr><tr style="height: 9px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td></tr><tr style="height: 17px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Long-term debt consisted of the following for the periods indicated (amounts in millions):</font></td></tr><tr style="height: 9px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="5"  style="width: 205px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:205px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">As  of December 31, </font></td></tr><tr style="height: 12px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 90px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 15px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td colspan="2"  style="width: 100px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:100px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015</font></td></tr><tr style="height: 17px"><td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$100.0 million Term Loan;  principal payments plus accrued interest payable
quarterly; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the
applicable percentage (2.77% at December 31, 2016); due August 28, 2020</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">95.0</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">100.0</font></td></tr><tr style="height: 17px"><td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$200.0 million Revolving Credit Facility; interest only quarterly payments; interest rate at ABR Rate plus applicable percentage or Eurodollar Rate plus the applicable percentage; due August 28, 2020</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td></tr><tr style="height: 17px"><td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Promissory notes</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.7</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td></tr><tr style="height: 17px"><td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Deferred debt issuance costs</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(2.7)</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(3.4)</font></td></tr><tr style="height: 17px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">93.0</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">96.6</font></td></tr><tr style="height: 17px"><td colspan="2"  style="width: 495px; text-align:left;border-color:#000000;min-width:495px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Current portion of long-term obligations</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(5.2)</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(5.0)</font></td></tr><tr style="height: 17px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Total</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">87.8</font></td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 90px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">91.6</font></td></tr><tr style="height: 17px"><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 480px; text-align:left;border-color:#000000;min-width:480px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 15px; text-align:left;border-color:#000000;min-width:15px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 90px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:90px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Maturities of Long-Term Debt</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td colspan="6"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Maturities of debt as of December 31, 2016 are as follows (amounts in millions):</font></td></tr><tr style="height: 12px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 25px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 75px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:75px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Long-term obligations</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2017</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">5.2</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2018</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.5</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2019</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.0</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2020</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">70.0</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2021</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 485px; text-align:left;border-color:#000000;min-width:485px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">95.7</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Commitment Fee Under Credit Facilities</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 29px"><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td><td   style="width: 160px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:160px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Consolidated  Leverage Ratio</font></td><td   style="width: 19px; text-align:center;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:80px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Margin for ABR Loans</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 105px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:105px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Margin for Eurodollar Loans</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:80px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Commitment Fee</font></td><td   style="width: 19px; text-align:center;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:80px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Letter of Credit Fee</font></td><td   style="width: 19px; text-align:center;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td><td   style="width: 160px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:160px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">&#8805; 2.75 to 1.0</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.00%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 105px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.00%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.40%</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.00%</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td></tr><tr style="height: 23px"><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td><td   style="width: 160px; text-align:center;border-color:#000000;min-width:160px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">&lt; 2.75 to 1.0 but &#8805; 1.75 to 1.0</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.50%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 105px; text-align:right;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.50%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.35%</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.50%</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td></tr><tr style="height: 25px"><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td><td   style="width: 160px; text-align:center;border-color:#000000;min-width:160px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">&lt; 1.75 to 1.0 but &#8805; 0.75 to 1.0</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.00%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 105px; text-align:right;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.00%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.30%</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.00%</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td><td   style="width: 160px; text-align:center;border-color:#000000;min-width:160px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">&lt; 0.75 to 1.0</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.50%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 105px; text-align:right;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.50%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.25%</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.50%</font></td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td><td   style="width: 160px; text-align:center;border-color:#000000;min-width:160px;">&#160;</td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 105px; text-align:left;border-color:#000000;min-width:105px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 19px; text-align:left;border-color:#000000;min-width:19px;">&#160;</td><td   style="width: 124px; text-align:left;border-color:#000000;min-width:124px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958395408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProvisionForIncomeTaxesTextBlock', window );">Income Tax Provision</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td colspan="12"  style="width: 665px; text-align:left;border-color:#000000;min-width:665px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Income taxes attributable to continuing operations consist of the following (amounts in millions):</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="8"  style="width: 219px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:219px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Years Ended December 31, </font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2014</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Current income tax expense/(benefit):</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Federal</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.5)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.2</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(13.9)</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">State and local</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.1)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.5</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(1.1)</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.6)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.7</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(15.0)</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Deferred income tax expense/(benefit):</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Federal </font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">22.1</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.5)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">21.0</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">State and local</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.4</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.1)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.6</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Foreign</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.1)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.1</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">24.5</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.7)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">22.7</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td colspan="2"  style="width: 391px; text-align:center;border-color:#000000;min-width:391px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Income tax expense/(benefit) from continuing operations</font></td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">23.9</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">7.7</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:center;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:center;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td colspan="12" rowspan="2" style="width: 665px; text-align:left;border-color:#000000;min-width:665px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Total income tax expense for the years ended December 31, 2016, 2015 and 2014 was allocated as follows (amounts in millions):</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="8"  style="width: 219px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:219px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Years Ended December 31, </font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2014</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Income from continuing operations </font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">23.9</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">7.7</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Income from discontinued operations </font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.1)</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Interest expense</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.1)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.2</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.1)</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Goodwill</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.1)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td colspan="2"  style="width: 391px; text-align:left;border-color:#000000;min-width:391px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Stockholders' equity </font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(7.2)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(2.1)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.6</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 356px; text-align:left;border-color:#000000;min-width:356px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">16.6</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">8.1</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ReconciliationOfStatutoryTaxEffectsTextBlock', window );">Sources of Tax Effects</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 12px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="8"  style="width: 237px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:237px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Years Ended December 31,</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 71px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:71px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 71px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:71px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015 (1)</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 71px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:71px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2014</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 7px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 16px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 16px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 16px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Income tax expense at U.S. federal statutory rate</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">35.0</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">35.0</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">35.0</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">%</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">State and local income taxes, net of federal income tax benefit</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.8</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(7.1)</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">5.8</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Valuation allowance</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.1</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">79.1</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.5</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Tax credits</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.6)</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">136.0</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(8.4)</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Uncertain tax positions </font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(1.0)</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(230.3)</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.6</font></td><td   style="width: 16px; text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Other items, net (2)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.6</font></td><td   style="width: 16px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(663.3)</font></td><td   style="width: 16px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.1</font></td><td   style="width: 16px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:16px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 372px; text-align:left;border-color:#000000;min-width:372px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Income tax expense/(benefit)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">38.9</font></td><td   style="width: 16px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:16px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(650.6)</font></td><td   style="width: 16px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:16px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">%</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">36.6</font></td><td   style="width: 16px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:16px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">%</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Net Deferred Tax Assets</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td colspan="2"  style="width: 533px; text-align:left;border-color:#000000;min-width:533px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Deferred tax assets (liabilities) consist of the following components (amounts in millions):</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="5"  style="width: 142px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:142px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">As of December 31,</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:55px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:55px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Deferred tax assets:</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Allowance for doubtful accounts</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.9</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.4</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Accrued payroll &amp; employee benefits</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">11.4</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">5.1</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Workers' compensation</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.9</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">9.8</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Amortization of intangible assets</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">56.3</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">72.2</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Share-based compensation</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">7.8</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">5.0</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Net operating loss carryforwards (1)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">44.2</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">48.5</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Tax credit carryforwards (2)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.8</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.7</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Other</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.1</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.0</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Gross deferred tax assets</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">143.4</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">155.7</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Less: valuation allowance</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.4)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.3)</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Net deferred tax assets</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">143.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">155.4</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Deferred tax (liabilities):</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Property and equipment</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(7.8)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(9.5)</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Deferred revenue</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(23.2)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(18.5)</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Investment in partnerships</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(3.2)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.2)</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Other liabilities </font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.9)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(2.0)</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Gross deferred tax (liabilities)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(35.1)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(30.2)</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Net deferred tax assets (liabilities)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> $ </font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">107.9</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> $ </font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">125.2</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 508px; text-align:left;border-color:#000000;min-width:508px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">(1)</font></td><td colspan="7" rowspan="4" style="width: 660px; text-align:left;border-color:#000000;min-width:660px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The net operating loss ("NOL") carry forwards in the income tax returns include unrecognized tax benefits resulting from uncertain tax positions. Accordingly, the deferred tax assets recognized for the NOL carry forwards, as of December 31, 2016 and 2015, are presented net of unrecognized tax benefits of $3.1 million.</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">(2)</font></td><td colspan="7" rowspan="4" style="width: 660px; text-align:left;border-color:#000000;min-width:660px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The tax credit carry forwards in the income tax returns include unrecognized tax benefits resulting from uncertain tax positions. Accordingly, the deferred tax assets recognized for the tax credit carry forwards are presented net of unrecognized tax benefits of $0.7 million for each of the years ended December 31, 2016 and 2015.</font></td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:center;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 25px; text-align:left;border-color:#000000;min-width:25px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Uncertain Tax Positions</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 10px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 17px"><td colspan="10"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Uncertain Tax Positions</font></td></tr><tr style="height: 9px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 34px"><td colspan="10"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">We account for uncertain tax positions in accordance with the authoritative guidance for uncertain tax positions. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (amounts in millions):</font></td></tr><tr style="height: 9px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 23px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="5"  style="width: 142px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:142px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Years Ended December 31, </font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td colspan="2"  style="width: 468px; text-align:left;border-color:#000000;min-width:468px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Balance at beginning of period</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.7</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.0</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Additions for tax positions related to current year</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Additions for tax positions related to prior year</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.0</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Reductions for tax positions related to prior years</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Lapse of statute of limitations</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.6)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.3)</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 40px; text-align:left;border-color:#000000;min-width:40px;">&#160;</td><td   style="width: 428px; text-align:left;border-color:#000000;min-width:428px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Settlements</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td colspan="2"  style="width: 468px; text-align:left;border-color:#000000;min-width:468px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Balance at end of period</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.1</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.7</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProvisionForIncomeTaxesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision for Income Taxes Table</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProvisionForIncomeTaxesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ReconciliationOfStatutoryTaxEffectsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of Statutory Tax Effects Table</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ReconciliationOfStatutoryTaxEffectsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=51663037&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958292992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock', window );">Employee Stock Purchase Plan Activity</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"><font style="FONT-WEIGHT: bold;TEXT-DECORATION: underline;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;">Employee Stock Purchase Plan Period</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Shares Issued</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Price</font></td></tr><tr style="height: 16px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2014 and Prior</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2,899,528</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">13.78</font></td></tr><tr style="height: 14px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">January 1, 2015 to March 31, 2015</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">24,368</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">22.76</font></td></tr><tr style="height: 14px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">April 1, 2015 to June 30, 2015</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">15,750</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">33.77</font></td></tr><tr style="height: 14px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">July 1, 2015 to September 30, 2015</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">18,984</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">32.27</font></td></tr><tr style="height: 14px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">October 1, 2015 to December 31, 2015</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">19,082</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">33.42</font></td></tr><tr style="height: 14px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">January 1, 2016 to March 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">13,850</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">41.09</font></td></tr><tr style="height: 14px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">April 1, 2016 to June 30, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">14,236</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">42.91</font></td></tr><tr style="height: 14px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">July 1, 2016 to September 30, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">16,520</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">40.32</font></td></tr><tr style="height: 14px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">October 1, 2016 to December 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">16,882</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">36.24</font></td></tr><tr style="height: 14px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3,039,200</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 538px; text-align:left;border-color:#000000;min-width:538px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:left;border-color:#000000;min-width:55px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Options Activity</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 18px"><td colspan="5"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Stock Options</font></td></tr><tr style="height: 17px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:left;border-color:#000000;min-width:105px;">&#160;</td><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td></tr><tr style="height: 34px"><td colspan="5"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">We use the Black-Scholes option pricing model to estimate the fair value of our stock options. There were 268,538, 590,647 and 250,000 options granted during 2016, 2015 and 2014, respectively. Stock option compensation expense included in general and administrative expense in our accompanying consolidated statements of operations was $6.3 million, $3.8 million and $0.1 million for 2016, 2015 and 2014, respectively.</font></td></tr><tr style="height: 9px"><td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:center;border-color:#000000;min-width:395px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;">&#160;</td><td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;">&#160;</td></tr><tr style="height: 17px"><td colspan="5"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The fair value of the 2016 awards were estimated using the following assumptions:</font></td></tr><tr style="height: 15px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:left;border-color:#000000;min-width:105px;">&#160;</td><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Risk Free Rate</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">1.19% - 1.58%</font></td><td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Expected Volatility</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">53.44 % -  54.89%</font></td><td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Expected Term</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">5.86 - 6.25  years</font></td><td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Weighted Average Fair Value</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">$25.99</font></td><td   style="width: 100px; text-align:center;border-color:#000000;min-width:100px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;">&#160;</td><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td></tr><tr style="height: 14px"><td colspan="5"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">We used the simplified method to estimate the expected term for the stock options granted during 2016.</font></td></tr><tr style="height: 14px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:left;border-color:#000000;min-width:105px;">&#160;</td><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td colspan="9"  style="width: 692px; text-align:left;border-color:#000000;min-width:692px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following table presents our stock option activity for 2016:</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 40px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Number of Shares</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 97px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:97px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Weighted Average Exercise Price</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:70px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Weighted Average Contractual Life (Years)</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td colspan="2"  style="width: 406px; text-align:center;border-color:#000000;min-width:406px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Outstanding options at January 1, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 838,494</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 87px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:87px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">30.18</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">9.31</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Granted</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">268,538</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 87px; text-align:right;border-color:#000000;min-width:87px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">37.21</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Exercised</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 87px; text-align:right;border-color:#000000;min-width:87px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Canceled, forfeited or expired</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(98,875)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 87px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:87px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">35.45</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td colspan="2"  style="width: 406px; text-align:center;border-color:#000000;min-width:406px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Outstanding options at December 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 1,008,157</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 87px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:87px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">31.54</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">8.42</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td colspan="2"  style="width: 406px; text-align:center;border-color:#000000;min-width:406px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Exercisable options at December 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 281,458</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 87px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:87px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">28.86</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; border-top-style:double;border-top-width:3px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:70px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">8.21</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 87px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:87px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 31px"><td colspan="10"  style="width: 727px; text-align:left;border-color:#000000;min-width:727px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The aggregate intrinsic value of our outstanding options and exercisable options at December 31, 2016 was $11.9 million and $3.9 million, respectively.  There were no options exercised during 2016. Total intrinsic value of options exercised was $0.2 million and $0.1 million for 2015 and 2014, respectively.</font></td></tr><tr style="height: 18px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 87px; text-align:left;border-color:#000000;min-width:87px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 18px"><td colspan="9"  style="width: 692px; text-align:left;border-color:#000000;min-width:692px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following table presents our non-vested stock option award activity for 2016:</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 18px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td  rowspan="2" style="width: 85px; text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Number of Shares</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2" rowspan="2" style="width: 97px; text-align:center;border-color:#000000;min-width:97px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Weighted Average Grant Date Fair Value</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 26px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 87px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:87px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 17px"><td colspan="2"  style="width: 406px; text-align:left;border-color:#000000;min-width:406px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Non-vested stock options at January 1, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">775,994</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 87px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:87px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">30.47</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Granted</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">268,538</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 87px; text-align:right;border-color:#000000;min-width:87px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">37.21</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Vested</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(219,872)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 87px; text-align:right;border-color:#000000;min-width:87px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">29.55</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Forfeited</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(97,961)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 87px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:87px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">35.38</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 17px"><td colspan="2"  style="width: 406px; text-align:left;border-color:#000000;min-width:406px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Non-vested stock options at December 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 726,699</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 87px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:87px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 32.58</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 10px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 371px; text-align:left;border-color:#000000;min-width:371px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 87px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:87px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 39px"><td colspan="10"  style="width: 727px; text-align:left;border-color:#000000;min-width:727px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">At December 31, 2016, there was $7.2 million of unrecognized compensation cost related to stock options that we expect to be recognized over a weighted-average period of 2.1 years.</font></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Non-Vested Stock Activity</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 18px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Non-Vested Stock</font></td></tr><tr style="height: 9px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 68px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">We issue shares of non-vested stock with vesting terms ranging from one to six years. The compensation expense is determined based on the market price of our common stock at the date of grant applied to the total number of shares that are anticipated to fully vest. Non-vested stock compensation expense included in general and administrative expenses in our accompanying consolidated statements of operations was $2.3 million, $5.0 million and $4.6 million for 2016, 2015 and 2014, respectively.</font></td></tr><tr style="height: 9px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 17px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following table presents our non-vested stock award activity for 2016:</font></td></tr><tr style="height: 34px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Number of Shares</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Weighted Average Grant Date Fair Value</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Non-vested stock at January 1, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 500,888</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">18.24</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Granted</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 21,202</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">50.55</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Vested</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(222,783)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">18.00</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Canceled, forfeited or expired</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(89,929)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">17.26</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Non-vested stock at December 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 209,378</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">22.20</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 34px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The weighted average grant date fair value of non-vested stock granted was $50.55, $28.48 and $16.38 in 2016, 2015, and 2014, respectively.</font></td></tr><tr style="height: 11px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 34px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">At December 31, 2016, there was $1.4 million of unrecognized compensation cost related to non-vested stock award payments that we expect to be recognized over a  weighted average period of 0.9 years. </font></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Non-Vested Stock Unity Activity</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 18px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Non-Vested Stock Units - Service-Based </font></td></tr><tr style="height: 9px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 44px"><td colspan="8" rowspan="2" style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Service-based non-vested stock unit compensation expense included in general and administrative expenses in our accompanying consolidated statements of operations was $3.6 million and $1.0 million for 2016 and 2015, respectively.</font></td></tr><tr style="height: 17px"><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 19px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 17px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following table presents our service-based non-vested stock units activity for 2016:</font></td></tr><tr style="height: 34px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Number of Shares</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Weighted Average Grant Date Fair Value</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Non-vested stock units at January 1, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 183,332</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">37.89</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Granted</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 147,896</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">45.60</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Vested</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(32,607)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">38.81</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Canceled, forfeited or expired</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(49,192)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">39.38</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Non-vested stock units at December 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 249,429</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">42.05</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 34px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The weighted average grant date fair value of service-based non-vested stock units granted was $45.60 and $37.98 in 2016 and 2015, respectively.</font></td></tr><tr style="height: 11px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 34px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">At December 31, 2016, there was $6.7 million of unrecognized compensation cost related to our service-based non-vested stock units that we expect to be recognized over a  weighted average period of 2.2 years. </font></td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 17px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following table presents our performance-based non-vested stock units activity for 2016:</font></td></tr><tr style="height: 31px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Number of Shares</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Weighted Average Grant Date Fair Value</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Non-vested stock units at January 1, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 151,063</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">39.44</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Granted</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 182,796</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">46.29</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Vested</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> (44,729)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">34.83</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Canceled, forfeited or expired</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> (64,273)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">42.41</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Non-vested stock units at December 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 224,857</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">45.08</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 14px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Forward Interest Rate</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">0.327 % - 1.460%</font></td><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Expected Volatility</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">54.38%</font></td><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Requisite Service Period</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">3 years</font></td><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td><td   style="width: 395px; text-align:left;border-color:#000000;min-width:395px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Fair Value</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 105px; text-align:center;border-color:#000000;min-width:105px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">$ 10.51</font></td><td   style="width: 100px; text-align:left;border-color:#000000;min-width:100px;">&#160;</td></tr></table></div><p style='margin-top: 0pt; margin-bottom: 0pt;'></p><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 17px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 17px"><td colspan="8"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following table presents our market-based non-vested stock units activity for 2016:</font></td></tr><tr style="height: 31px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Number of Shares</font></td><td   style="width: 12px; text-align:center;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:90px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Weighted Average Grant Date Fair Value</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Non-vested stock units at January 1, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 164,534</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.51</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Granted (1)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 93,257</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.51</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Vested</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> (248,654)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.51</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Canceled, forfeited or expired</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> (9,137)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.51</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td colspan="2"  style="width: 478px; text-align:center;border-color:#000000;min-width:478px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: center;">Non-vested stock units at December 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:85px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> -</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 80px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:80px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0</font></td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:center;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:center;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:center;border-color:#000000;min-width:35px;">&#160;</td><td   style="width: 443px; text-align:center;border-color:#000000;min-width:443px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 35px; text-align:right;border-color:#000000;min-width:35px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: right;">(1) </font></td><td   style="width: 443px; text-align:left;border-color:#000000;min-width:443px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Represents shares awarded upon achievement of maximum payout. </font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 85px; text-align:left;border-color:#000000;min-width:85px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 80px; text-align:left;border-color:#000000;min-width:80px;">&#160;</td><td   style="width: 35px; text-align:left;border-color:#000000;min-width:35px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of employee stock purchase plan activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6934948480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Future Minimum Rental Commitments</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 14px"><td colspan="6"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Total minimum rental commitments as of December 31, 2016 are as follows (amounts in millions):</font></td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">2017</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">23.5</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">2018</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">17.5</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">2019</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">13.0</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">2020</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">9.1</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">2021</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.3</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Future years</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.6</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Total</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">72.0</font></td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 10px"><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td><td   style="width: 487px; text-align:left;border-color:#000000;min-width:487px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 70px; text-align:left;border-color:#000000;min-width:70px;">&#160;</td></tr><tr style="height: 34px"><td colspan="6"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Rent expense for non-cancelable operating leases was $27.5 million, $23.7 million and $26.5 million for 2016, 2015 and 2014.</font></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_InsuranceProgramsTableTextBlock', window );">Insurance Programs</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="5"  style="width: 160px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:160px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">As of December 31,</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"><font style="FONT-WEIGHT: bold;TEXT-DECORATION: underline;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;">Type of Insurance</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:55px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2016</font></td><td   style="width: 30px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:55px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2015</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Health insurance</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.6</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">11.7</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Workers' compensation</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">26.8</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">23.9</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Professional liability</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.7</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.1</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">42.1</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">39.7</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Less: long-term portion</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.8)</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.9)</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">41.3</font></td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 55px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:55px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">38.8</font></td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td><td   style="width: 450px; text-align:left;border-color:#000000;min-width:450px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 30px; text-align:left;border-color:#000000;min-width:30px;">&#160;</td><td   style="width: 10px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 55px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:55px;">&#160;</td><td   style="width: 45px; text-align:left;border-color:#000000;min-width:45px;">&#160;</td></tr><tr style="height: 34px"><td colspan="9"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The retention limit per claim for our health insurance, worker's compensation and professional liability is $0.9 million, $0.5 million and $0.3 million, respectively.</font></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_InsuranceProgramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Insurance Programs Details, Table</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_InsuranceProgramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6783846320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EXIT ACTIVITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Exit Activity Reserves</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 9px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 17px"><td colspan="15"  style="width: 646px; text-align:left;border-color:#000000;min-width:646px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Our reserve activity for our 2014 exit and restructuring activity is as follows (amounts in millions):</font></td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;">&#160;</td><td colspan="6"  style="width: 169px; text-align:center;border-color:#000000;min-width:169px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td colspan="5"  style="width: 159px; text-align:center;border-color:#000000;min-width:159px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 13px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="5"  style="width: 159px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:159px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">2014 Exit Activity</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td colspan="5"  style="width: 159px; text-align:center;border-color:#000000;min-width:159px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 25px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 76px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:76px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Lease Termination</font></td><td   style="width: 7px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:7px;">&#160;</td><td colspan="2"  style="width: 76px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:76px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Severance</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td colspan="2"  style="width: 76px; text-align:center;border-color:#000000;min-width:76px;">&#160;</td><td   style="width: 7px; text-align:center;border-color:#000000;min-width:7px;">&#160;</td><td colspan="2"  style="width: 76px; text-align:center;border-color:#000000;min-width:76px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Balances at December 31, 2013</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 7px; text-align:center;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:center;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Charge in 2014</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.1</font></td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">7.8</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Cash expenditures in 2014</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(1.6)</font></td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(5.5)</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Balances at December 31, 2014</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.5</font></td><td   style="width: 7px; text-align:center;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.3</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:center;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Charge in 2015</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Cash expenditures in 2015</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.4)</font></td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(1.9)</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Balances at December 31, 2015</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.1</font></td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.4</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Charge in 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Cash expenditures in 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.1)</font></td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.4)</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 218px; text-align:left;border-color:#000000;min-width:218px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Balances at December 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 66px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 66px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:66px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 8px; text-align:left;border-color:#000000;min-width:8px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 7px; text-align:left;border-color:#000000;min-width:7px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 66px; text-align:left;border-color:#000000;min-width:66px;">&#160;</td><td   style="width: 84px; text-align:left;border-color:#000000;min-width:84px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958270336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>VALUATION AND QUALIFYING ACCOUNTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsAbstract', window );"><strong>Valuation And Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ValuationAndQualifyingAccountsTableTextBlock', window );">Valuation and Qualifying Accounts</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 13px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;">&#160;</td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 17px"><td colspan="18"  style="width: 709px; text-align:left;border-color:#000000;min-width:709px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">14. VALUATION AND QUALIFYING ACCOUNTS</font></td></tr><tr style="height: 9px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;">&#160;</td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 34px"><td colspan="18"  style="width: 709px; text-align:left;border-color:#000000;min-width:709px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">The following table summarizes the activity and ending balances in our allowance for doubtful accounts and estimated revenue adjustments (amounts in millions):</font></td></tr><tr style="height: 9px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;">&#160;</td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 18px"><td colspan="18"  style="width: 709px; text-align:left;border-color:#000000;min-width:709px;"><font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Allowance for Doubtful Accounts</font></td></tr><tr style="height: 9px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:center;border-color:#000000;min-width:69px;">&#160;</td><td   style="width: 81px; text-align:center;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 51px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:165px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Year End</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Balance at Beginning of Year</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Provision for Doubtful Accounts (1)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Write-Offs</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 79px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:79px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Balance at End of Year</font></td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:165px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">2016</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">16.5</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">19.5</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(18.3)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 69px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:69px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">17.7</font></td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">2015</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">14.3</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">14.1</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(11.9)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:right;border-color:#000000;min-width:69px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">16.5</font></td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">2014</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">14.2</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">16.4</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(16.3)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:right;border-color:#000000;min-width:69px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">14.3</font></td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 8px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;">&#160;</td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 34px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td colspan="16"  style="width: 547px; text-align:left;border-color:#000000;min-width:547px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;">(1) Includes $0.1 million from discontinued operations for the year ended December 31, 2014.</font></td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;">&#160;</td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 17px"><td colspan="18"  style="width: 709px; text-align:left;border-color:#000000;min-width:709px;"><font style="FONT-WEIGHT: bold;FONT-STYLE: italic;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">Estimated Revenue Adjustments</font></td></tr><tr style="height: 9px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:center;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:center;border-color:#000000;min-width:69px;">&#160;</td><td   style="width: 81px; text-align:center;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 63px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:165px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Year End</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Balance at Beginning of Year</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Provision for Estimated Revenue Adjustments (1)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 85px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:85px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Write-Offs</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td colspan="2"  style="width: 79px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:79px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Balance at End of Year</font></td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:165px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">2016</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.0</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">7.9</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 75px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(7.8)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 69px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:69px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.1</font></td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">2015</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.1</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.1</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(5.2)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:right;border-color:#000000;min-width:69px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.0</font></td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">2014</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.9</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">5.1</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:right;border-color:#000000;min-width:75px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(5.9)</font></td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:right;border-color:#000000;min-width:69px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.1</font></td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 8px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td   style="width: 165px; text-align:left;border-color:#000000;min-width:165px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 75px; text-align:left;border-color:#000000;min-width:75px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 69px; text-align:left;border-color:#000000;min-width:69px;">&#160;</td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr><tr style="height: 36px"><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td><td colspan="16"  style="width: 547px; text-align:left;border-color:#000000;min-width:547px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: left;">(1) Includes $0.1 million from discontinued operations for the year ended December 31, 2014.</font></td><td   style="width: 81px; text-align:left;border-color:#000000;min-width:81px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ValuationAndQualifyingAccountsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A schedule of allowance and reserve accounts including their beginning and ending balances, as well as a reconciliation by type of activity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ValuationAndQualifyingAccountsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958299136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Operating Income of Reportable Segments</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 12px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td colspan="13"  style="width: 375px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:375px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Year Ended December 31, 2016</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Home Health</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Hospice</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Personal Care</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Other</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Total</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Net service revenue</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1,085.5</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">316.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">35.9</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1,437.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Cost of service, excluding depreciation and amortization</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">643.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">163.1</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">26.3</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">833.1</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">General and administrative expenses</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">283.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">70.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">7.9</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">141.9</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">503.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Provision for doubtful accounts</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">13.8</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">5.5</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">19.5</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Depreciation and amortization</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.3</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">12.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">19.7</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Asset impairment charge</font></td><td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Operating expenses</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">946.9</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">240.1</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">34.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">158.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1,380.1</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Operating income (loss)</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">138.6</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">75.9</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.5</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(158.7)</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">57.3</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td colspan="13"  style="width: 375px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:375px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Year Ended December 31, 2015</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Home Health</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Hospice</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Personal Care</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Other</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Total</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Net service revenue</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1,005.1</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">275.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1,280.5</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Cost of service, excluding depreciation and amortization</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">584.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">141.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">725.9</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">General and administrative expenses</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">263.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">62.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">126.5</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">452.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Provision for doubtful accounts</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">12.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.9</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">14.1</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Depreciation and amortization</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">5.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">13.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">20.0</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Asset impairment charge</font></td><td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">77.3</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">77.3</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Operating expenses</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">864.8</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">207.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">217.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1,289.7</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Operating income (loss)</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">140.3</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">67.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(217.2)</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(9.2)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 17px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td colspan="13"  style="width: 375px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:375px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">For the Year Ended December 31, 2014</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Home Health</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:61px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Hospice</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Personal Care</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:62px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Other</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:65px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 8pt;COLOR: #000000;TEXT-ALIGN: center;">Total</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Net service revenue</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">956.9</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">247.6</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1,204.5</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Cost of service, excluding depreciation and amortization</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">559.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">131.7</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">691.1</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">General and administrative expenses</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">269.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">58.3</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">114.4</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">441.7</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Provision for doubtful accounts</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">14.8</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.5</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">16.3</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Depreciation and amortization</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">9.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2.1</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">17.2</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">28.3</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Asset impairment charge</font></td><td   style="width: 6px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.6</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.5</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.1</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Operating expenses</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">853.8</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">195.1</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">131.6</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1,180.5</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">Operating income (loss)</font></td><td   style="width: 6px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">103.1</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 61px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:61px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">52.5</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.0</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 62px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:62px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(131.6)</font></td><td   style="width: 6px; text-align:left;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:10px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">24.0</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr><tr style="height: 9px"><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 300px; text-align:left;border-color:#000000;min-width:300px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 61px; text-align:center;border-color:#000000;min-width:61px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 62px; text-align:center;border-color:#000000;min-width:62px;">&#160;</td><td   style="width: 6px; text-align:center;border-color:#000000;min-width:6px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 65px; text-align:center;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8813-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958296016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Unaudited Summarized Quarterly Financial Information</a></td>
<td class="text"><div><table style="border-collapse:collapse;margin-top:20px;"><tr style="height: 13px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;">&#160;</td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 17px"><td colspan="15"  style="width: 710px; text-align:left;border-color:#000000;min-width:710px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;TEXT-ALIGN: left;">16. UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION</font></td></tr><tr style="height: 17px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;">&#160;</td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 20px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 65px; text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td colspan="5"  style="width: 154px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:154px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 7.5pt;COLOR: #000000;TEXT-ALIGN: center;">Net Income (Loss) Attributable to Amedisys, Inc. Common Stockholders (1)</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 12px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;">&#160;</td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 77px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:77px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 7.5pt;COLOR: #000000;TEXT-ALIGN: center;">Revenue</font></td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 102px; border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:102px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 7.5pt;COLOR: #000000;TEXT-ALIGN: center;">Net Income (Loss) Attributable to Amedisys, Inc.</font></td><td   style="width: 10px; text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 72px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:72px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 7.5pt;COLOR: #000000;TEXT-ALIGN: center;">Basic</font></td><td   style="width: 10px; border-top-style:solid;border-top-width:1px;text-align:center;border-color:#000000;min-width:10px;">&#160;</td><td colspan="2"  style="width: 72px; border-top-style:solid;border-top-width:1px;border-bottom-style:solid;border-bottom-width:1px;text-align:center;border-color:#000000;min-width:72px;"><font style="FONT-WEIGHT: bold;FONT-FAMILY: Times New Roman;FONT-SIZE: 7.5pt;COLOR: #000000;TEXT-ALIGN: center;">Diluted</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2016:</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:60px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; border-top-style:solid;border-top-width:1px;text-align:left;border-color:#000000;min-width:60px;">&#160;</td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1st Quarter (2) (3) (4)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">348.8</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">6.2</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.19</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.19</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2nd Quarter (2) (3) (4)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">360.7</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.7</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.32</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.32</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3rd Quarter (2) (3) (4)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">361.6</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">11.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.34</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.34</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4th Quarter (2) (3) (4) (5)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">366.3</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">8.9</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.27</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.26</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 1,437.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 90px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">37.3</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.12</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1.10</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2015:</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 65px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:65px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; border-top-style:double;border-top-width:3px;text-align:left;border-color:#000000;min-width:90px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:left;border-color:#000000;min-width:60px;">&#160;</td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">1st Quarter (6) (7)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">301.6</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(35.0)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(1.07)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(1.07)</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">2nd Quarter (7)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">314.1</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">10.6</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.32</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.32</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3rd Quarter (6) (7) (9)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 65px; text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">326.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">8.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.25</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.25</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">4th Quarter (7) (8) (9)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 65px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">338.4</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-bottom-style:solid;border-bottom-width:1px;text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 90px; border-bottom-style:solid;border-bottom-width:1px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">12.9</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.39</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;">&#160;</td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">0.38</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr><tr style="height: 14px"><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td><td   style="width: 247px; text-align:left;border-color:#000000;min-width:247px;">&#160;</td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 65px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:65px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;"> 1,280.5</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 90px; border-top-style:solid;border-top-width:1px;border-bottom-style:double;border-bottom-width:3px;text-align:right;border-color:#000000;min-width:90px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">3.0</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.09)</font></td><td   style="width: 10px; text-align:left;border-color:#000000;min-width:10px;">&#160;</td><td   style="width: 12px; text-align:left;border-color:#000000;min-width:12px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">$</font></td><td   style="width: 60px; text-align:right;border-color:#000000;min-width:60px;"><font style="FONT-FAMILY: Times New Roman;FONT-SIZE: 10pt;COLOR: #000000;">(0.09)</font></td><td   style="width: 50px; text-align:left;border-color:#000000;min-width:50px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=51825399&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6775672016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations Consolidation and Presentation of Financial Statements - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>Agencies </div>
<div>States</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent Of Net Services Revenue Provided By Medicare</a></td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number Of States With Facilities | States</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MinimumPercentOwnershipForControllingInterestPercent', window );">Minimum percent ownership for controlling interest percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity Method Investment Aggregate Cost | $</a></td>
<td class="nump">$ 27.8<span></span>
</td>
<td class="nump">$ 25.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MaximumPercentOwnershipForEquityMethodPercent', window );">Maximum Percent Ownership For Equity Method Percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MaximumPercentOwnershipForCostMethodPercent', window );">Maximum Percent Ownership For Cost Method Percent</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Operating Care Centers</a></td>
<td class="nump">327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Operating Care Centers</a></td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Operating Care Centers</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumPercentOwnershipForCostMethodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumPercentOwnershipForCostMethodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumPercentOwnershipForEquityMethodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumPercentOwnershipForEquityMethodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MinimumPercentOwnershipForControllingInterestPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MinimumPercentOwnershipForControllingInterestPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OperatingCareCenters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of care centers owned by the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OperatingCareCenters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OrganizationAndNatureOfOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OrganizationAndNatureOfOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6797097760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>D </div>
<div>Number_of_Visits</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EpisodeOfCareAsEpisodicBasedRevenue', window );">Episode of care as episodic-based revenue, days | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfTotalReimbursementOfOutlierPayment', window );">Percentage of total reimbursement of outlier payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits', window );">Low utilization payment adjustment, maximum number of visits | Number_of_Visits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FirstThresholdOfTherapyServicesRequired', window );">First threshold of therapy services required, visits | Number_of_Visits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SecondThresholdOfServicesRequired', window );">Second threshold of services required, visits | Number_of_Visits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ThirdThresholdOfTherapyServicesRequired', window );">Third threshold of therapy services required, visits | Number_of_Visits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EpisodesInProgressThatBeginDuringReportingPeriod', window );">Episodes in progress that begin during reporting period, days | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HospiceMedicareRevenueRateAccountedForRoutineCare', window );">Hospice Medicare revenue rate accounted for routine care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfPatientReceivablesOutstanding', window );">Percentage of patient receivables outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfPatientReceivablesOutstandingOverTenPercent', window );">Percentage of Patient Receivables Outstanding Over Ten Percent</a></td>
<td class="nump">10.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved', window );">Minimum days for accounts receivable outstanding to be fully reserved | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare', window );">Portion of accounts receivable derived from Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RevenueAdjustmentToMedicareRevenue', window );">Revenue adjustment to Medicare revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,900<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare', window );">Rate of request for anticipated payment submitted for the initial episode of care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare', window );">Rate of request for anticipated payment submitted for subsequent episodes of care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode', window );">Maximum days to submit final bill from the start of episode | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid', window );">Maximum days to submit final bill from the date the request for anticipated payment was paid | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,432<span></span>
</td>
<td class="nump">77,268<span></span>
</td>
<td class="nump">3,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets (liabilities)</a></td>
<td class="nump">$ 107,900<span></span>
</td>
<td class="nump">$ 125,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,900<span></span>
</td>
<td class="nump">125,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_InternallyDevelopedComputerSoftware', window );">Internally developed computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,200<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtIssuanceCostsLineItems', window );"><strong>Debt Issuance Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred debt issuance costs/debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">740<span></span>
</td>
<td class="nump">959<span></span>
</td>
<td class="nump">797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Write-off of deferred debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCosts', window );">Deferred debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_UnamortizedDebtIssuanceCostAmortizatinPeriod', window );">Unamortized debt issuance costs, weighted average amortization period, years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,401<span></span>
</td>
<td class="nump">11,824<span></span>
</td>
<td class="nump">5,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share-based compensation, tax benefit recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,800<span></span>
</td>
<td class="nump">6,900<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_AssetImpairmentAxis=amed_Ams3HomecareAndHospiceMember', window );">AMS3 Homecare and Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_AssetImpairmentAxis=amed_CorporateHeadquartersMember', window );">Corporate Headquarters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_AssetImpairmentAxis=amed_HomecareHomebaseMember', window );">Homecare Homebase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_DeferredDebtIssuanceCostsMember', window );">Deferred Debt Issuance Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtIssuanceCostsLineItems', window );"><strong>Debt Issuance Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred debt issuance costs/debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember', window );">Acquired Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedUsefulLifeOfIntangibleAssets', window );">Estimated Useful Life of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedUsefulLifeOfIntangibleAssets', window );">Estimated Useful Life of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CapYearAxis=amed_CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember', window );">Cap Year Two Thousand Thirteen Through Two Thousand Sixteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities', window );">Estimated amounts due back to Medicare</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtIssuanceCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Costs [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtIssuanceCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EpisodeOfCareAsEpisodicBasedRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days in a home health episode of care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EpisodeOfCareAsEpisodicBasedRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EpisodesInProgressThatBeginDuringReportingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days in an episode of care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EpisodesInProgressThatBeginDuringReportingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedUsefulLifeOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated useful life of the company's intangible assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedUsefulLifeOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FirstThresholdOfTherapyServicesRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of visits related to the first threshold of therapy services required.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FirstThresholdOfTherapyServicesRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_GoodwillAndIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and Intangible Assets [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_GoodwillAndIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HistoricalCollectionRateFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Historical collection rate from Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HistoricalCollectionRateFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HospiceMedicareRevenueRateAccountedForRoutineCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HospiceMedicareRevenueRateAccountedForRoutineCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes Line Items</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_InternallyDevelopedComputerSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Internally developed AMS3 computer software</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_InternallyDevelopedComputerSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the visit threshold for a low utilization payment adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LowUtilizationPaymentAdjustmentNumberOfVisits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the start of the episode in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumDaysToSubmitFinalBillFromStartOfEpisode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MinimumDaysAccountsReceivableOutstandingFullyReserved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of days required before a patient accounts receivable must be outstanding to be fully reserved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MinimumDaysAccountsReceivableOutstandingFullyReserved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfPatientReceivablesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of patient receivables outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfPatientReceivablesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfPatientReceivablesOutstandingOverTenPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of patient receivables outstanding over ten percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfPatientReceivablesOutstandingOverTenPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfTotalReimbursementOfOutlierPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage at which total reimbursement is capped if cost of care is unusually costly.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfTotalReimbursementOfOutlierPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of the entity's net patient accounts receivable that is derived from Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PortionOfPatientAccountsReceivableDerivedFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of estimated payment that is requested at the start of care for an initial episode of care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of estimated payment that is requested at the start of care for any subsequent episodes of care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RevenueAdjustmentToMedicareRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the provisions that reduce the amount of Medicare revenue recognized by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RevenueAdjustmentToMedicareRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SecondThresholdOfServicesRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of visits related to the second threshold of therapy services required.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SecondThresholdOfServicesRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ThirdThresholdOfTherapyServicesRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of visits related to the third threshold of therapy services required.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ThirdThresholdOfTherapyServicesRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_UnamortizedDebtIssuanceCostAmortizatinPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected amortization period of debt issuance cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_UnamortizedDebtIssuanceCostAmortizatinPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51824106&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt issuance costs (for example, but not limited to, legal, accounting, broker, and regulatory fees).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, before jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AssetImpairmentAxis=amed_Ams3HomecareAndHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AssetImpairmentAxis=amed_Ams3HomecareAndHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AssetImpairmentAxis=amed_CorporateHeadquartersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AssetImpairmentAxis=amed_CorporateHeadquartersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AssetImpairmentAxis=amed_HomecareHomebaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AssetImpairmentAxis=amed_HomecareHomebaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_DeferredDebtIssuanceCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_DeferredDebtIssuanceCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CapYearAxis=amed_CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CapYearAxis=amed_CapYearTwoThirteenTwelveThroughTwoThousandSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6779796544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Estimated Useful Lives of Property and Equipment (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">39 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated Useful Life</a></td>
<td class="text">Lesser of life or lease or expected useful life<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_EquipmentAndFurnitureMember', window );">Equipment And Furniture [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_EquipmentAndFurnitureMember', window );">Equipment And Furniture [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_ComputerSoftwareMember', window );">Computer Software [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_ComputerSoftwareMember', window );">Computer Software [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51661791&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_EquipmentAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_EquipmentAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958311664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Balances Related to Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BuildingAndLeaseholdImprovements', window );">Building and leasehold improvements</a></td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EquipmentAndFurniture', window );">Equipment and furniture</a></td>
<td class="nump">71,900<span></span>
</td>
<td class="nump">89,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Computer software</a></td>
<td class="nump">96,800<span></span>
</td>
<td class="nump">92,600<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">175,600<span></span>
</td>
<td class="nump">184,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(138,650)<span></span>
</td>
<td class="num">(141,793)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 36,999<span></span>
</td>
<td class="nump">$ 42,695<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BuildingAndLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Building And Leasehold Improvements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BuildingAndLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EquipmentAndFurniture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equipment And Furniture</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EquipmentAndFurniture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6939450160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Financial Instruments Where Carrying Value and Fair Value Differ (Detail)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Long-term obligations, excluding capital leases</a></td>
<td class="nump">$ 95.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value Inputs Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Long-term obligations, excluding capital leases</a></td>
<td class="nump">$ 97.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6649241392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Weighted Average Shares Outstanding (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding - basic</a></td>
<td class="nump">33,198<span></span>
</td>
<td class="nump">33,018<span></span>
</td>
<td class="nump">32,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonVestedStockAndStockUnits', window );">Non-vested stock and stock units</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding - diluted</a></td>
<td class="nump">33,741<span></span>
</td>
<td class="nump">33,018<span></span>
</td>
<td class="nump">32,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">922<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonVestedStockAndStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non vested stock and stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonVestedStockAndStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1500-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6799556128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 01, 2016 </div>
<div>USD ($) </div>
<div>Agencies</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 24, 2015 </div>
<div>USD ($) </div>
<div>Agencies</div>
</th>
<th class="th">
<div>Sep. 01, 2016 </div>
<div>USD ($) </div>
<div>Agencies</div>
</th>
<th class="th">
<div>Oct. 03, 2015 </div>
<div>USD ($) </div>
<div>Agencies</div>
</th>
<th class="th">
<div>Oct. 20, 2016 </div>
<div>USD ($) </div>
<div>Agencies</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>Y</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>Agencies </div>
<div>Y</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.1<span></span>
</td>
<td class="nump">$ 56.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Adjustments related to acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.0<span></span>
</td>
<td class="nump">96.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember', window );">Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">50.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Adjustments related to acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Adjustments related to acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Adjustments related to acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StateAxis=amed_FloridaMember', window );">Florida [Member] | Infinity HomeCare [Member] | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Acquisition, total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Acquisition, number of care centers acquired | Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Acquisition, recorded other assets and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill deductible for income tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears', window );">Period in which goodwill is expected to be deductible for income tax purposes, in years | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposit for indemnification purposes and working capital price adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Adjustments related to acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StateAxis=amed_TennesseeMember', window );">Tennessee [Member] | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Acquisition, total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Acquisition, number of care centers acquired | Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StateAxis=amed_GeorgiaMember', window );">Georgia [Member] | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Acquisition, total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Acquisition, number of care centers acquired | Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StateAxis=amed_MassachusettsMember', window );">Massachusetts [Member] | Associated Homecare [Member] | Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Acquisition, total purchase price</a></td>
<td class="nump">$ 27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Acquisition, number of care centers acquired | Agencies</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Acquisition, recorded other assets and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears', window );">Period in which goodwill is expected to be deductible for income tax purposes, in years | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposit for indemnification purposes and working capital price adjustments</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Adjustments related to acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StateAxis=amed_MassachusettsMember', window );">Massachusetts [Member] | Associated Homecare [Member] | Personal Care [Member] | Acquired Name Of Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StateAxis=amed_MassachusettsMember', window );">Massachusetts [Member] | Associated Homecare [Member] | Personal Care [Member] | Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StateAxis=amed_MassachusettsMember', window );">Massachusetts [Member] | Professional Profiles [Member] | Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Acquisition, total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Acquisition, number of care centers acquired | Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears', window );">Period in which goodwill is expected to be deductible for income tax purposes, in years | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StateAxis=amed_MassachusettsMember', window );">Massachusetts [Member] | Professional Profiles [Member] | Personal Care [Member] | Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StateAxis=amed_MassachusettsMember', window );">Massachusetts [Member] | Professional Profiles [Member] | Personal Care [Member] | Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StateAxis=amed_NewYorkMember', window );">New York [Member] | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Acquisition, total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Acquisition, number of care centers acquired | Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears', window );">Period in which goodwill is expected to be deductible for income tax purposes, in years | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StateAxis=amed_NewYorkMember', window );">New York [Member] | Home Health [Member] | Certificates Of Need And Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill Is Expected To Be Deductible For Income Tax Purposes Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Goodwillisexpectedtobedeductibleforincometaxpurposesyears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfBusinessAcquisitionsPurchasePriceAllocationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=35744172&amp;loc=d3e2207-128464<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956791&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=34752592&amp;loc=d3e961-128460<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 20, 22<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StateAxis=amed_FloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StateAxis=amed_FloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_InfinityHomeCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_InfinityHomeCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StateAxis=amed_TennesseeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StateAxis=amed_TennesseeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StateAxis=amed_GeorgiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StateAxis=amed_GeorgiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StateAxis=amed_MassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StateAxis=amed_MassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_AssociatedHomecareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_AssociatedHomecareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNameOfBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNameOfBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_ProfessionalProfilesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_ProfessionalProfilesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StateAxis=amed_NewYorkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StateAxis=amed_NewYorkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedAndLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedAndLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958345184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Pro Forma Condensed Consolidated Income Statement (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract', window );"><strong>Business Acquisition Pro Forma Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Net service revenue</a></td>
<td class="nump">$ 1,449.7<span></span>
</td>
<td class="nump">$ 1,322.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Businessacquisitionproformaoperatingincomeloss', window );">Operating income (loss)</a></td>
<td class="nump">53.9<span></span>
</td>
<td class="num">(7.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Basic earnings (loss) per share</a></td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Diluted earnings (loss) per share</a></td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Businessacquisitionproformaoperatingincomeloss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Businessacquisitionproformaoperatingincomeloss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=56956515&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6779793552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations and Assets Held For Sale - Additional Information (Detail) - Agencies<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfCareCentersConsolidated', window );">Number of care centers consolidated</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfCareCentersClosed', window );">Number of care centers closed</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | Assets Held-for-sale [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfCareCentersConsolidated', window );">Number of care centers consolidated</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfCareCentersAvailableForSale', window );">Number of care centers available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfCareCentersSold', window );">Number of care centers sold</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfCareCentersConsolidated', window );">Number of care centers consolidated</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfCareCentersClosed', window );">Number of care centers closed</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfCareCentersAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of care centers that were classified as available for sale during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfCareCentersAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfCareCentersClosed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating care centers that were closed during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfCareCentersClosed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfCareCentersConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating care centers that were consolidated with care centers servicing the same market during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfCareCentersConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfCareCentersSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of care centers sold during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfCareCentersSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958277296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Revenues and Operating Results (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract', window );"><strong>Discontinued Operation, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">(Loss) before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations, net of tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (216)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1361-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=d3e1012-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=SL51721523-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=d3e957-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=SL51721525-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=SL51721673-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 13<br> -Article 7<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 05<br> -Paragraph 15<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32672-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=SL51721525-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=SL51721523-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1361-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=18498875&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=SL51721675-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=SL51721675-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=d3e1012-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=SL51721525-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=SL51721523-107759<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=d3e957-107759<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1361-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 13<br> -Article 7<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 15<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6783683792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets, Net (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Other intangibles impairment charge</a></td>
<td class="num">$ (3.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillAndIntangibleAssetsImpairmentAxis=amed_CareCentersClosedOrConsolidatedMember', window );">Care Centers Closed Or Consolidated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Other intangibles impairment charge</a></td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillAndIntangibleAssetsImpairmentAxis=amed_AnnualImpairmentTestStepOneMember', window );">Annual Impairment Test Step One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Other intangibles impairment charge</a></td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_GoodwillAndIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and Intangible Assets [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_GoodwillAndIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_GoodwillAndIntangibleAssetsImpairmentAxis=amed_CareCentersClosedOrConsolidatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_GoodwillAndIntangibleAssetsImpairmentAxis=amed_CareCentersClosedOrConsolidatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_GoodwillAndIntangibleAssetsImpairmentAxis=amed_AnnualImpairmentTestStepOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_GoodwillAndIntangibleAssetsImpairmentAxis=amed_AnnualImpairmentTestStepOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6796166112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Activity Related to Goodwill (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 261,663<span></span>
</td>
<td class="nump">$ 205,600<span></span>
</td>
<td class="nump">$ 208,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">27,100<span></span>
</td>
<td class="nump">56,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill, Written off Related to Sale of Business Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Adjustments related to acquisitions</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">288,957<span></span>
</td>
<td class="nump">261,663<span></span>
</td>
<td class="nump">205,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">67,100<span></span>
</td>
<td class="nump">16,500<span></span>
</td>
<td class="nump">16,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">50,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill, Written off Related to Sale of Business Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Adjustments related to acquisitions</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">71,600<span></span>
</td>
<td class="nump">67,100<span></span>
</td>
<td class="nump">16,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">194,600<span></span>
</td>
<td class="nump">189,100<span></span>
</td>
<td class="nump">192,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill, Written off Related to Sale of Business Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Adjustments related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">194,600<span></span>
</td>
<td class="nump">194,600<span></span>
</td>
<td class="nump">189,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">22,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill, Written off Related to Sale of Business Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Adjustments related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 22,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_GoodwillAndIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and Intangible Assets [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_GoodwillAndIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=34752592&amp;loc=d3e961-128460<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6778605360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Activity Related to Other Intangible Assets, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning balance</a></td>
<td class="nump">$ 44,047<span></span>
</td>
<td class="nump">$ 33,200<span></span>
</td>
<td class="nump">$ 36,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OtherIntangibleAssetsAdditions', window );">Additions</a></td>
<td class="nump">5,200<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OtherIntangiblesWriteOffs', window );">Write-off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Other intangibles impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending balance</a></td>
<td class="nump">46,755<span></span>
</td>
<td class="nump">44,047<span></span>
</td>
<td class="nump">33,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning balance</a></td>
<td class="nump">5,900<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OtherIntangibleAssetsAdditions', window );">Additions</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OtherIntangiblesWriteOffs', window );">Write-off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Other intangibles impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending balance</a></td>
<td class="nump">4,900<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedAndLicensesMember', window );">Certificates Of Need And Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning balance</a></td>
<td class="nump">23,900<span></span>
</td>
<td class="nump">23,100<span></span>
</td>
<td class="nump">25,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OtherIntangibleAssetsAdditions', window );">Additions</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OtherIntangiblesWriteOffs', window );">Write-off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Other intangibles impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending balance</a></td>
<td class="nump">24,100<span></span>
</td>
<td class="nump">23,900<span></span>
</td>
<td class="nump">23,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesOfBusinessMember', window );">Acquired Names Of Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning balance</a></td>
<td class="nump">14,200<span></span>
</td>
<td class="nump">10,100<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OtherIntangibleAssetsAdditions', window );">Additions</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OtherIntangiblesWriteOffs', window );">Write-off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Other intangibles impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending balance</a></td>
<td class="nump">$ 17,700<span></span>
</td>
<td class="nump">$ 14,200<span></span>
</td>
<td class="nump">$ 10,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_GoodwillAndIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and Intangible Assets [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_GoodwillAndIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OtherIntangibleAssetsAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additions to Other Intangible Assets that occurred during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OtherIntangibleAssetsAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OtherIntangiblesWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off of intangible asets that occurred during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OtherIntangiblesWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedAndLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedAndLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesOfBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesOfBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6783708080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Activity Related to Other Intangible Assets, Net (Parenthetical) (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2017</a></td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2018</a></td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2019</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2020</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2021</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite Lived Intangible Assets Net</a></td>
<td class="nump">$ 4.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_GoodwillAndIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and Intangible Assets [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_GoodwillAndIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6647122736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Details of Certain Balance Sheet Accounts - Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DetailsOfCertainBalanceSheetAccountsAbstract', window );"><strong>Details Of Certain Balance Sheet Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayrollTaxEscrow', window );">Payroll tax escrow</a></td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromJointVenturesCurrent', window );">Due from joint ventures</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousCurrent', window );">Other</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">6,100<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">$ 11,260<span></span>
</td>
<td class="nump">$ 14,641<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DetailsOfCertainBalanceSheetAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DetailsOfCertainBalanceSheetAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayrollTaxEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payroll tax escrow</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayrollTaxEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromJointVenturesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from an entity in which the reporting entity shares joint control with another party or group, due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromJointVenturesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958429584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Details of Certain Balance Sheet Accounts - Other Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DetailsOfCertainBalanceSheetAccountsAbstract', window );"><strong>Details Of Certain Balance Sheet Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WorkersCompensationDeposits', window );">Workers compensation deposits</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HealthInsuranceDeposits', window );">Health insurance deposits</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OtherMiscellaneousDeposits', window );">Other miscellaneous deposit</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments</a></td>
<td class="nump">27,800<span></span>
</td>
<td class="nump">25,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousNoncurrent', window );">Other</a></td>
<td class="nump">8,900<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, net</a></td>
<td class="nump">$ 38,468<span></span>
</td>
<td class="nump">$ 32,802<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DetailsOfCertainBalanceSheetAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DetailsOfCertainBalanceSheetAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HealthInsuranceDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Health Insurance Deposits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HealthInsuranceDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OtherMiscellaneousDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Miscellaneous Deposits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OtherMiscellaneousDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WorkersCompensationDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Workers Compensation Deposits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WorkersCompensationDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total investments in (A) an entity in which the entity has significant influence, but does not have control, (B) subsidiaries that are not required to be consolidated and are accounted for using the equity and or cost method, and (C) an entity in which the reporting entity shares control of the entity with another party or group. Includes long-term advances receivable from a party that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6779871888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Details of Certain Balance Sheet Accounts - Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DetailsOfCertainBalanceSheetAccountsAbstract', window );"><strong>Details Of Certain Balance Sheet Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedInsuranceCurrent', window );">Health insurance</a></td>
<td class="nump">$ 10,600<span></span>
</td>
<td class="nump">$ 11,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Workers' compensation</a></td>
<td class="nump">26,800<span></span>
</td>
<td class="nump">23,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LegalAndOtherSettlements', window );">Legal and other settlements</a></td>
<td class="nump">5,700<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LeaseLiability', window );">Lease liability</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CharityCare', window );">Charity care</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedMedicareCapLiability', window );">Estimated Medicare CAP liability</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HospiceCostOfRevenue', window );">Hospice cost of revenue</a></td>
<td class="nump">7,200<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OigSelfDisclsoureAccrual', window );">OIG self-disclsoure accrual</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PatientLiability', window );">Patient liability</a></td>
<td class="nump">4,300<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">6,100<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 63,290<span></span>
</td>
<td class="nump">$ 71,965<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CharityCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses related to charity care</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CharityCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DetailsOfCertainBalanceSheetAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DetailsOfCertainBalanceSheetAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedMedicareCapLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses related to the estimated Medicare CAP liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedMedicareCapLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HospiceCostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses related to Hospice cost of revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HospiceCostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses related to lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LegalAndOtherSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses related to legal and other settlements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LegalAndOtherSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OigSelfDisclsoureAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses related to the OIG self-disclsoure accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OigSelfDisclsoureAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PatientLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses related to Patient liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PatientLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInsuranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInsuranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958585040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Details of Certain Balance Sheet Accounts - Other Long-Term Obligations (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DetailsOfCertainBalanceSheetAccountsAbstract', window );"><strong>Details Of Certain Balance Sheet Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_UncertainTaxBenefitsInLongTermObligations', window );">Reserve for uncertain tax positions</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DeferredCompensationPlanLiability', window );">Deferred compensation plan liability</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">$ 3,730<span></span>
</td>
<td class="nump">$ 4,456<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DeferredCompensationPlanLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Compensation Plan Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DeferredCompensationPlanLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DetailsOfCertainBalanceSheetAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DetailsOfCertainBalanceSheetAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_UncertainTaxBenefitsInLongTermObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Uncertain Tax Benefits In Long Term Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_UncertainTaxBenefitsInLongTermObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 24<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6780626160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long Term Debt (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt including current portion</a></td>
<td class="nump">$ 93,000<span></span>
</td>
<td class="nump">$ 96,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations</a></td>
<td class="num">(5,220)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total</a></td>
<td class="nump">87,800<span></span>
</td>
<td class="nump">91,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember', window );">Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt including current portion</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_OneHundredMillionTermLoanMember', window );">One Hundred Million Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt including current portion</a></td>
<td class="nump">95,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_TwoHundredMillionRevolvingCreditFacilityMember', window );">Two Hundred Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt including current portion</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 20, 22<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and capital leases due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_OneHundredMillionTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_OneHundredMillionTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_TwoHundredMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_TwoHundredMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6795834576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long Term Debt - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 28, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>Installment</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TotalLeverageRatio', window );">Total leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FixedChargeCoverageRatio', window );">Fixed charge coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCosts', window );">Deferred debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt including current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,000,000<span></span>
</td>
<td class="nump">96,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Write Off Of Deferred Debt Issuance Cost</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TimePeriodAxis=amed_FourRemainingQuarterlyPaymentsMember', window );">Four Remaining Quarterly Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentNumberOfPeriodicPayments', window );">Debt instrument, number of quarterly installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt Instrument Periodic Payment Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TimePeriodAxis=amed_SecondEightQuarterlyPaymentsMember', window );">Second Eight Quarterly Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentNumberOfPeriodicPayments', window );">Debt instrument, number of quarterly installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt Instrument Periodic Payment Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TimePeriodAxis=amed_FinalTwoQuarterlyPaymentsMember', window );">Final Two Quarterly Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentNumberOfPeriodicPayments', window );">Debt instrument, number of quarterly installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt Instrument Periodic Payment Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_TermLoanMember', window );">Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_SwingLineLoanMember', window );">Swing Line Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RevolvingCreditFacilityTotal', window );">Amount of Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LetterOfCreditMember', window );">Letter Of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RevolvingCreditFacilityTotal', window );">Amount of Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_SecondLienCreditAgreementTermLoanMember', window );">Second Lien Credit Agreement Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CallPremiumPayment', window );">Call Premium Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember', window );">Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt including current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Promissory notes, interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_CreditAgreementMember', window );">Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate', window );">Credit facility, additional interest rate over Federal Funds rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate', window );">Credit Facility, additional interest rate over Eurodollar Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ApplicableMarginRateOnBaseRate', window );">Credit Facility, applicable margin on Base Rate Advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ApplicableMarginRateOnEurodollarRate', window );">Credit Facility, applicable margin on Eurodollar Rate Advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries', window );">Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries', window );">Percentage of adjusted EBITDA that guarantor subsidiaries represent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_CreditAgreementMember', window );">Credit Agreement [Member] | One Month [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EurodollarDepositsInterestPeriod', window );">Eurodollar deposits interest period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_CreditAgreementMember', window );">Credit Agreement [Member] | Two Month [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EurodollarDepositsInterestPeriod', window );">Eurodollar deposits interest period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_CreditAgreementMember', window );">Credit Agreement [Member] | Three Month [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EurodollarDepositsInterestPeriod', window );">Eurodollar deposits interest period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_CreditAgreementMember', window );">Credit Agreement [Member] | Six Month [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EurodollarDepositsInterestPeriod', window );">Eurodollar deposits interest period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_OneHundredMillionTermLoanMember', window );">One Hundred Million Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WeightedAverageInterestRate', window );">Weighted-average interest rate for five year Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 28,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentNumberOfPeriodicPayments', window );">Debt instrument, number of quarterly installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt including current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_TwoHundredMillionRevolvingCreditFacilityMember', window );">Two Hundred Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WeightedAverageInterestRate', window );">Weighted-average interest rate for five year Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Availability under the revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Outstanding letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RevolvingCreditFacilityTotal', window );">Amount of Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LineOfCreditFacilityAdditionalBorrowingCapacity', window );">Credit facility, maximum additional borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 28,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt including current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ApplicableMarginRateOnBaseRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Applicable Margin Rate On Base Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ApplicableMarginRateOnBaseRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ApplicableMarginRateOnEurodollarRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Applicable Margin Rate On Eurodollar Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ApplicableMarginRateOnEurodollarRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CallPremiumPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Call premium paid during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CallPremiumPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Additional Interest Above Eurodollar Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Additional Interest Above Federal Fund Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentNumberOfPeriodicPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, number of quarterly installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentNumberOfPeriodicPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EurodollarDepositsInterestPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eurodollar Deposits Interest Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EurodollarDepositsInterestPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FixedChargeCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of adjusted earnings before interest, taxes , depreciation and amortization plus rent expense to certain fixed charges (interest expense, required principal payments and capital expenditures).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FixedChargeCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LineOfCreditFacilityAdditionalBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility Additional Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LineOfCreditFacilityAdditionalBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of adjusted EBITDA that guarantor subsidiaries represent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RevolvingCreditFacilityTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RevolvingCreditFacilityTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TotalLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of debt to earnings before interest, taxes, depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TotalLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt issuance costs (for example, but not limited to, legal, accounting, broker, and regulatory fees).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 20, 22<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TimePeriodAxis=amed_FourRemainingQuarterlyPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TimePeriodAxis=amed_FourRemainingQuarterlyPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TimePeriodAxis=amed_SecondEightQuarterlyPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TimePeriodAxis=amed_SecondEightQuarterlyPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TimePeriodAxis=amed_FinalTwoQuarterlyPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TimePeriodAxis=amed_FinalTwoQuarterlyPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_SwingLineLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_SwingLineLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_SecondLienCreditAgreementTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_SecondLienCreditAgreementTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TimePeriodAxis=amed_OneMonthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TimePeriodAxis=amed_OneMonthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TimePeriodAxis=amed_TwoMonthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TimePeriodAxis=amed_TwoMonthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TimePeriodAxis=amed_ThreeMonthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TimePeriodAxis=amed_ThreeMonthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TimePeriodAxis=amed_SixMonthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TimePeriodAxis=amed_SixMonthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_OneHundredMillionTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_OneHundredMillionTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_TwoHundredMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_TwoHundredMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6780686480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long Term Debt (Parenthetical) (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Aug. 28, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_TermLoanMember', window );">Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember', window );">Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior long-term notes, interest rate</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_SecondLienCreditAgreementTermLoanMember', window );">Second Lien Credit Agreement Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_OneHundredMillionTermLoanMember', window );">One Hundred Million Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_InterestRateOnNotesPayableToBank', window );">Eurodollar Rate plus the applicable percentage</a></td>
<td class="nump">2.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Aug. 28,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_TwoHundredMillionRevolvingCreditFacilityMember', window );">Two Hundred Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Aug. 28,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_InterestRateOnNotesPayableToBank">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate for the amounts borrowed under the Term Loan, including the terms and method for determining the interest rate at the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_InterestRateOnNotesPayableToBank</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_SecondLienCreditAgreementTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_SecondLienCreditAgreementTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_OneHundredMillionTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_OneHundredMillionTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_TwoHundredMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_TwoHundredMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958297984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Maturities of Debt (Detail)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaturitiesOfLongTermDebtAbstract', window );"><strong>Maturities of Long-term Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2017</a></td>
<td class="nump">$ 5.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2018</a></td>
<td class="nump">10.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2019</a></td>
<td class="nump">10.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2020</a></td>
<td class="nump">70.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2021</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Total longterm and shortterm debt</a></td>
<td class="nump">$ 95.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfLongTermDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaturitiesOfLongTermDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6780583744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment Fee Under Credit Facilities (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=amed_RangeOneMember', window );">Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment Fee</a></td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=amed_RangeOneMember', window );">Range One [Member] | Abr Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=amed_RangeOneMember', window );">Range One [Member] | Eurodollar Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=amed_RangeTwoMember', window );">Range Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment Fee</a></td>
<td class="nump">0.35%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=amed_RangeTwoMember', window );">Range Two [Member] | Abr Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=amed_RangeTwoMember', window );">Range Two [Member] | Eurodollar Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=amed_RangeThreeMember', window );">Range Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment Fee</a></td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=amed_RangeThreeMember', window );">Range Three [Member] | Abr Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=amed_RangeThreeMember', window );">Range Three [Member] | Eurodollar Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=amed_RangeFourMember', window );">Range Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment Fee</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=amed_RangeFourMember', window );">Range Four [Member] | Abr Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=amed_RangeFourMember', window );">Range Four [Member] | Eurodollar Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LetterOfCreditFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the letters of credit, for the letters of credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LetterOfCreditFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=amed_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=amed_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=amed_AbrLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=amed_AbrLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=amed_EurodollarLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=amed_EurodollarLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=amed_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=amed_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=amed_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=amed_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=amed_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=amed_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6797264944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>States</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Net change in total valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax benefits accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties recognized related to uncertain income tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest and penalties accrued related to uncertain income tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfIndividualStatesSubjectToIncomeTax', window );">Number of individual states subject to income taxes | States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Unrecognized Tax Benefits Period Increase Decrease</a></td>
<td class="num">$ (0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_UnrecognizedTaxBenefitsAxis=amed_NetOperatingLossMember', window );">Net Operating Loss [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax benefits accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_UnrecognizedTaxBenefitsAxis=amed_TaxCreditCarryforwardMember', window );">Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax benefits accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=amed_ResearchAndDevelopmentTaxCreditMember', window );">Research And Development Tax Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxCreditsAndAdjustments', window );">Tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=amed_EmploymentTaxCreditMember', window );">Employment Tax Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxCreditsAndAdjustments', window );">Tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=amed_AlternativeMinimumTaxCreditMember', window );">Alternative Minimum Tax Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxCreditsAndAdjustments', window );">Tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=amed_StateTaxCreditMember', window );">State Tax Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxCreditsAndAdjustments', window );">Tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=amed_OtherLongTermObligationsMember', window );">Other Long Term Obligations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax benefits accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=amed_DeferredIncomeTaxesMember', window );">Deferred Income Taxes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax benefits accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax years open to examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax years open to examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Net Operating Loss [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 268.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfIndividualStatesSubjectToIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of individual states subject to income tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfIndividualStatesSubjectToIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxCreditsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxCreditsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Unrecognized Tax Benefit<br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of all increases and decreases in unrecognized tax benefits for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_UnrecognizedTaxBenefitsAxis=amed_NetOperatingLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_UnrecognizedTaxBenefitsAxis=amed_NetOperatingLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_UnrecognizedTaxBenefitsAxis=amed_TaxCreditCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_UnrecognizedTaxBenefitsAxis=amed_TaxCreditCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=amed_ResearchAndDevelopmentTaxCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=amed_ResearchAndDevelopmentTaxCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=amed_EmploymentTaxCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=amed_EmploymentTaxCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=amed_AlternativeMinimumTaxCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=amed_AlternativeMinimumTaxCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=amed_StateTaxCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=amed_StateTaxCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=amed_OtherLongTermObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=amed_OtherLongTermObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=amed_DeferredIncomeTaxesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=amed_DeferredIncomeTaxesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958815184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Total Provision For Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal, current</a></td>
<td class="num">$ (500)<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="num">$ (13,900)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and local, current</a></td>
<td class="num">(100)<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax expense/(benefit)</a></td>
<td class="num">(600)<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal, deferred</a></td>
<td class="nump">22,100<span></span>
</td>
<td class="num">(500)<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and local, deferred</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign, deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DeferredIncomeTaxesForContinuingOperations', window );">Deferred income taxes</a></td>
<td class="nump">24,500<span></span>
</td>
<td class="num">(700)<span></span>
</td>
<td class="nump">22,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 23,935<span></span>
</td>
<td class="nump">$ 2,004<span></span>
</td>
<td class="nump">$ 7,671<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DeferredIncomeTaxesForContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Income Taxes For Continuing Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DeferredIncomeTaxesForContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section I<br> -Paragraph Question 1-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section I<br> -Subsection 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section I<br> -Subsection 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section I<br> -Subsection 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section I<br> -Subsection 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section I<br> -Subsection 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6780477216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax Expense Allocation (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 23,935<span></span>
</td>
<td class="nump">$ 2,004<span></span>
</td>
<td class="nump">$ 7,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncomeTaxEffectsAllocatedToInterestExpense', window );">Interest expense</a></td>
<td class="num">(100)<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncomeTaxEffectsAllocatedToGoodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityOther', window );">Stockholders' equity</a></td>
<td class="num">(7,200)<span></span>
</td>
<td class="num">(2,100)<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation', window );">Total income tax expense</a></td>
<td class="nump">$ 16,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncomeTaxEffectsAllocatedToGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tax effect of items occuring during the period that have been charged or credited directly to goodwill</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncomeTaxEffectsAllocatedToGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncomeTaxEffectsAllocatedToInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tax effect of items occuring during the period that have been charged or credited directly to interest expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncomeTaxEffectsAllocatedToInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32672-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=SL51721525-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=SL51721523-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1361-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=18498875&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=SL51721675-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51716988&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tax effect of items occurring during the period that have been charged or credited directly to components of shareholders' equity and are not otherwise defined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=18498875&amp;loc=d3e39076-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of income tax expense or benefit for the period that has been allocated among continuing operations, discontinued operations, extraordinary items, other comprehensive income, and items charged or credited directly to shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=18498875&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958895040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sources of Tax Effect (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory Tax Rate</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local income taxes and other, net of federal income tax benefit</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="num">(7.10%)<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">79.10%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="nump">136.00%<span></span>
</td>
<td class="num">(8.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Uncertain tax positions</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(230.30%)<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Other items, net</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="num">(663.30%)<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Continuing operations effective income tax rate</a></td>
<td class="nump">38.90%<span></span>
</td>
<td class="num">(650.60%)<span></span>
</td>
<td class="nump">36.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6781043296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Components of Net Deferred Tax Assets (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 6.9<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther', window );">Accrued payroll &amp; employee benefits</a></td>
<td class="nump">11.4<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation', window );">Workers' compensation</a></td>
<td class="nump">10.9<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1', window );">Amortization of intangible assets</a></td>
<td class="nump">56.3<span></span>
</td>
<td class="nump">72.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">44.2<span></span>
</td>
<td class="nump">48.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DeferredTaxAssetsOtherCurrent', window );">Other</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">143.4<span></span>
</td>
<td class="nump">155.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">143.0<span></span>
</td>
<td class="nump">155.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome', window );">Deferred revenue</a></td>
<td class="num">(23.2)<span></span>
</td>
<td class="num">(18.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates', window );">Investment in partnerships</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other liabilities</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Gross deferred tax (liabilities)</a></td>
<td class="nump">35.1<span></span>
</td>
<td class="nump">30.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets (liabilities)</a></td>
<td class="nump">$ 107.9<span></span>
</td>
<td class="nump">$ 125.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the estimated future tax effects attributable to the difference between the tax basis of intangible assets and the basis of intangible assets computed in accordance with generally accepted accounting principles. The difference in basis, whether due to amortization or other reasons, will increase future taxable income when such difference reverses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DeferredTaxAssetsOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of current deferred tax asset attributable to deductible temporary differences not separately disclosed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DeferredTaxAssetsOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax deferred expense compensation and benefits workers compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, before jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to other deductible loss carryforwards not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Carryforwards<br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from other compensation and benefits not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, before jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from tax deferred revenue or other income not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6783815152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Classification of Deferred Tax Assets and Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract', window );"><strong>Deferred Tax Assets Liabilities Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetNoncurrent', window );">Noncurrent deferred tax assets</a></td>
<td class="nump">$ 107,940<span></span>
</td>
<td class="nump">$ 125,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets (liabilities)</a></td>
<td class="nump">$ 107,900<span></span>
</td>
<td class="nump">$ 125,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, before jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of noncurrent deferred tax asset attributable to deductible temporary differences and carryforwards. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31928-109318<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6778339600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reconciliation of Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax benefits accrued, beginning balance</a></td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for tax positions related to current year</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions related to prior years</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions related to prior years</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statute of limitations</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax benefits accrued, ending balance</a></td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="nump">$ 4.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Unrecognized Tax Benefit<br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6798821040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock and Share-Based Compensation (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 03, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Jun. 07, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock Par Or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock Par Or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,253,577<span></span>
</td>
<td class="nump">34,786,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,597,215<span></span>
</td>
<td class="nump">33,607,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Percentageofownershipinsubsidiaries', window );">Percentage of Ownership in Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Equity-based Awards, Maximum Number of Shares Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Equity-based Awards, Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries', window );">Percentage of Total Combined Voting Power of the Ccompany and Our Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Percentage of Market Value at Which Eligible Employees May Purchase Shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan', window );">Common Stock Shares Authorized For Issuance To Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,460,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Employee Stock Purchase Plan expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic Value of Stock Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic Value of Stock Options Exerciseable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic Value of Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_ShareBasedAwardsMember', window );">Share-Based Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Fairvalueofshareofcommonstockpercentage', window );">Fair Value of Share of Common Stock, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember', window );">Share Based Awards To More Than Ten Percent Owner [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Fairvalueofshareofcommonstockpercentage', window );">Fair Value of Share of Common Stock, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockMember', window );">Non-Vested Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested Stock Granted, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.55<span></span>
</td>
<td class="nump">$ 28.48<span></span>
</td>
<td class="nump">$ 16.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense related to non-vested stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Non-vested stock award compensation expense weighted-average period, years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember', window );">Non-Vested Stock Units - Service-Based and Performance-Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested Stock Granted, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.29<span></span>
</td>
<td class="nump">$ 39.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense related to non-vested stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Non-vested stock award compensation expense weighted-average period, years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Performancebasedawardtargetshareamount', window );">Performance-based award, target number of shares to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember', window );">Non-Vested Stock Units - Service-Based and Market-Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested Stock Granted, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MarketBasedAwardTargetShareAmount', window );">Market-based award, target number of shares to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">417,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MarketBasedAwardMaximumShareAmount', window );">Market-based award, maximum number of shares authorized to be received</a></td>
<td class="nump">248,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">667,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceMember', window );">Non Vested Stock Units Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested Stock Granted, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.60<span></span>
</td>
<td class="nump">$ 37.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense related to non-vested stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Non-vested stock award compensation expense weighted-average period, years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense related to non-vested stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Non-vested stock award compensation expense weighted-average period, years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period of Equity-based Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period of Equity-based Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Contractual Term of Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">ten<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan', window );">Common Stock Shares Authorized For Issuance To Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance to the Company's employee stock purchase plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Fairvalueofshareofcommonstockpercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of a share of common stock, percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Fairvalueofshareofcommonstockpercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MarketBasedAwardMaximumShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock units authorized for exceeding targeted performance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MarketBasedAwardMaximumShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MarketBasedAwardTargetShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock units authorized for achievement of targeted performance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MarketBasedAwardTargetShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Percentageofownershipinsubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership in subsidiaries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Percentageofownershipinsubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of total combined voting power of the Company and our subsidiaries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Performancebasedawardtargetshareamount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock units authorized for achievement of targeted performance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Performancebasedawardtargetshareamount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of plan compensation cost recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of pertinent provisions of equity-based compensation awards that have actual or potential impact upon the company's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_ShareBasedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_ShareBasedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6778680560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Stock Purchase Plan (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">ESPP Shares Issued</a></td>
<td class="nump">3,039,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_PriorToTwoThousandFourteenMember', window );">Prior To Two Thousand Fourteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">ESPP Shares Issued</a></td>
<td class="nump">2,899,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare', window );">Price per ESPP Share Issued | $ / shares</a></td>
<td class="nump">$ 13.78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_January12015ToMarch312015Member', window );">January 1 2015 To March 31 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">ESPP Shares Issued</a></td>
<td class="nump">24,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare', window );">Price per ESPP Share Issued | $ / shares</a></td>
<td class="nump">$ 22.76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_April12015ToJune302015Member', window );">April 1 2015 To June 30 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">ESPP Shares Issued</a></td>
<td class="nump">15,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare', window );">Price per ESPP Share Issued | $ / shares</a></td>
<td class="nump">$ 33.77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_July12015ToSeptember302015Member', window );">July 1 2015 To September 30 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">ESPP Shares Issued</a></td>
<td class="nump">18,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare', window );">Price per ESPP Share Issued | $ / shares</a></td>
<td class="nump">$ 32.27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_October12015ToDecember312015Member', window );">October 1 2015 To December 31 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">ESPP Shares Issued</a></td>
<td class="nump">19,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare', window );">Price per ESPP Share Issued | $ / shares</a></td>
<td class="nump">$ 33.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_January12016ToMarch312016Member', window );">January 1 2016 To March 31 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">ESPP Shares Issued</a></td>
<td class="nump">13,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare', window );">Price per ESPP Share Issued | $ / shares</a></td>
<td class="nump">$ 41.09<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_April12016ToJune302016Member', window );">April 1 2016 To June 30 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">ESPP Shares Issued</a></td>
<td class="nump">14,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare', window );">Price per ESPP Share Issued | $ / shares</a></td>
<td class="nump">$ 42.91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_July12016ToSeptember302016Member', window );">July 1 2016 To September 30 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">ESPP Shares Issued</a></td>
<td class="nump">16,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare', window );">Price per ESPP Share Issued | $ / shares</a></td>
<td class="nump">$ 40.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_October12016ToDecember312016Member', window );">October 1 2016 To December 31 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">ESPP Shares Issued</a></td>
<td class="nump">16,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare', window );">Price per ESPP Share Issued | $ / shares</a></td>
<td class="nump">$ 36.24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued under employee stock purchase plan discounted value per share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StockIssuedUnderEmployeeStockPurchasePlanDiscountedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_PriorToTwoThousandFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_PriorToTwoThousandFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_January12015ToMarch312015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_January12015ToMarch312015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_April12015ToJune302015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_April12015ToJune302015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_July12015ToSeptember302015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_July12015ToSeptember302015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_October12015ToDecember312015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_October12015ToDecember312015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_January12016ToMarch312016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_January12016ToMarch312016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_April12016ToJune302016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_April12016ToJune302016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_July12016ToSeptember302016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_July12016ToSeptember302016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_October12016ToDecember312016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=amed_October12016ToDecember312016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6781086896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Activity (Detail) - Stock Option [Member] - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Beginning Balance</a></td>
<td class="nump">838,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock Options Granted, Number of Shares</a></td>
<td class="nump">268,538<span></span>
</td>
<td class="nump">590,647<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock Options Exercised, Number of Shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Stock Options Canceled, Forfeited or Expired, Number of Shares</a></td>
<td class="num">(98,875)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Ending Balance</a></td>
<td class="nump">1,008,157<span></span>
</td>
<td class="nump">838,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock Options Exerciseable, Number of Shares</a></td>
<td class="nump">281,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Beginning Balance, Weighted Average Exercise Price</a></td>
<td class="nump">$ 30.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock Options Granted, Weighted Average Exercise Price</a></td>
<td class="nump">37.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Stock Options Exercised, Weighted Average Exercise Price</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Stock Options Canceled, Forfeited or Expired, Weighted Average Exercise Price</a></td>
<td class="nump">35.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Ending Balance, Weighted Average Exercise Price</a></td>
<td class="nump">$ 31.54<span></span>
</td>
<td class="nump">$ 30.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Contractual Life</a></td>
<td class="text">8 years 5 months 1 day<span></span>
</td>
<td class="text">9 years 3 months 22 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Stock Options Exerciseable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 28.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Stock Options Exerciseable, Weighted Average Contractual Life</a></td>
<td class="text">8 years 2 months 16 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue', window );">Fair Value</a></td>
<td class="nump">$ 25.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Forward Interest Rate, Minimum</a></td>
<td class="nump">1.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Forward Interest Rate, Maximum</a></td>
<td class="nump">1.58%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected Volatility Rate, Maximum</a></td>
<td class="nump">54.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected Volatility Rate, Minimum</a></td>
<td class="nump">53.44%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense related to non-vested stock awards</a></td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Non-vested stock award compensation expense weighted-average period, years</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock Compensation Expense</a></td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term</a></td>
<td class="text">5 years 10 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The calculated fair value of a stock-based compensation award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section D<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6957785760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-Vested Stock Option Activity (Detail) - Stock Option [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested stock options beginning balance | shares</a></td>
<td class="nump">775,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted | shares</a></td>
<td class="nump">268,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested | shares</a></td>
<td class="num">(219,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited | shares</a></td>
<td class="num">(97,961)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested stock options ending balance | shares</a></td>
<td class="nump">726,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-Vested Stock Options Begining Balance, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="nump">$ 30.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Non-Vested Stock Options Granted, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="nump">37.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Non-Vested Stock Options Vested, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="nump">29.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Non-Vested Stock Options Forfeited, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="nump">35.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-Vested Stock Options Ending Balance, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="nump">$ 32.58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6780851072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-Vested Stock Activity (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockMember', window );">Non-Vested Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Stock Outstanding, Beginning Balance</a></td>
<td class="nump">500,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Non-vested Stock Granted, Number of Shares</a></td>
<td class="nump">21,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Non-vested Stock Vested, Number of Shares</a></td>
<td class="num">(222,783)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Non-vested Stock Canceled, Forfeited or Expired, Number of Shares</a></td>
<td class="num">(89,929)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Stock Outstanding, Ending Balance</a></td>
<td class="nump">209,378<span></span>
</td>
<td class="nump">500,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested Stock Outstanding, Beginning Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested Stock Granted, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">50.55<span></span>
</td>
<td class="nump">$ 28.48<span></span>
</td>
<td class="nump">$ 16.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested Stock Vested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Non-vested Stock Canceled, Forfeited or Expired, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">17.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested Stock Outstanding, Ending Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 22.20<span></span>
</td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember', window );">Non-Vested Stock Units - Service-Based and Performance-Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Stock Outstanding, Beginning Balance</a></td>
<td class="nump">151,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Non-vested Stock Granted, Number of Shares</a></td>
<td class="nump">182,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Non-vested Stock Vested, Number of Shares</a></td>
<td class="num">(44,729)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Non-vested Stock Canceled, Forfeited or Expired, Number of Shares</a></td>
<td class="num">(64,273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Stock Outstanding, Ending Balance</a></td>
<td class="nump">224,857<span></span>
</td>
<td class="nump">151,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested Stock Outstanding, Beginning Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 39.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested Stock Granted, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">46.29<span></span>
</td>
<td class="nump">$ 39.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested Stock Vested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">34.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Non-vested Stock Canceled, Forfeited or Expired, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">42.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested Stock Outstanding, Ending Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 45.08<span></span>
</td>
<td class="nump">$ 39.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember', window );">Non-Vested Stock Units - Service-Based and Market-Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Stock Outstanding, Beginning Balance</a></td>
<td class="nump">164,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Non-vested Stock Granted, Number of Shares</a></td>
<td class="nump">93,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Non-vested Stock Vested, Number of Shares</a></td>
<td class="num">(248,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Non-vested Stock Canceled, Forfeited or Expired, Number of Shares</a></td>
<td class="num">(9,137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Stock Outstanding, Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">164,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested Stock Outstanding, Beginning Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 10.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested Stock Granted, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">10.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested Stock Vested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">10.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Non-vested Stock Canceled, Forfeited or Expired, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">10.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested Stock Outstanding, Ending Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceMember', window );">Non Vested Stock Units Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Stock Outstanding, Beginning Balance</a></td>
<td class="nump">183,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Non-vested Stock Granted, Number of Shares</a></td>
<td class="nump">147,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Non-vested Stock Vested, Number of Shares</a></td>
<td class="num">(32,607)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Non-vested Stock Canceled, Forfeited or Expired, Number of Shares</a></td>
<td class="num">(49,192)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Stock Outstanding, Ending Balance</a></td>
<td class="nump">249,429<span></span>
</td>
<td class="nump">183,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested Stock Outstanding, Beginning Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 37.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested Stock Granted, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">45.60<span></span>
</td>
<td class="nump">$ 37.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested Stock Vested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">38.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Non-vested Stock Canceled, Forfeited or Expired, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">39.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested Stock Outstanding, Ending Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 42.05<span></span>
</td>
<td class="nump">$ 37.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6778437936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-Vested Stock Units (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockMember', window );">Non-Vested Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Stock Outstanding, Beginning Balance</a></td>
<td class="nump">500,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Non-vested Stock Granted, Number of Shares</a></td>
<td class="nump">21,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Non-vested Stock Vested, Number of Shares</a></td>
<td class="num">(222,783)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Non-vested Stock Canceled, Forfeited or Expired, Number of Shares</a></td>
<td class="num">(89,929)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Stock Outstanding, Ending Balance</a></td>
<td class="nump">209,378<span></span>
</td>
<td class="nump">500,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested Stock Outstanding, Beginning Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested Stock Granted, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">50.55<span></span>
</td>
<td class="nump">$ 28.48<span></span>
</td>
<td class="nump">$ 16.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested Stock Vested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Non-vested Stock Canceled, Forfeited or Expired, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">17.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested Stock Outstanding, Ending Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 22.20<span></span>
</td>
<td class="nump">$ 18.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember', window );">Non-Vested Stock Units - Service-Based and Performance-Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Stock Outstanding, Beginning Balance</a></td>
<td class="nump">151,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Non-vested Stock Granted, Number of Shares</a></td>
<td class="nump">182,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Non-vested Stock Vested, Number of Shares</a></td>
<td class="num">(44,729)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Non-vested Stock Canceled, Forfeited or Expired, Number of Shares</a></td>
<td class="num">(64,273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Stock Outstanding, Ending Balance</a></td>
<td class="nump">224,857<span></span>
</td>
<td class="nump">151,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested Stock Outstanding, Beginning Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 39.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested Stock Granted, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">46.29<span></span>
</td>
<td class="nump">$ 39.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested Stock Vested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">34.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Non-vested Stock Canceled, Forfeited or Expired, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">42.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested Stock Outstanding, Ending Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 45.08<span></span>
</td>
<td class="nump">$ 39.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember', window );">Non-Vested Stock Units - Service-Based and Market-Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Stock Outstanding, Beginning Balance</a></td>
<td class="nump">164,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Non-vested Stock Granted, Number of Shares</a></td>
<td class="nump">93,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Non-vested Stock Vested, Number of Shares</a></td>
<td class="num">(248,654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Non-vested Stock Canceled, Forfeited or Expired, Number of Shares</a></td>
<td class="num">(9,137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Stock Outstanding, Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">164,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested Stock Outstanding, Beginning Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 10.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested Stock Granted, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">10.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested Stock Vested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">10.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Non-vested Stock Canceled, Forfeited or Expired, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">10.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested Stock Outstanding, Ending Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Forward Interest Rate, Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.327%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Forward Interest Rate, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.46%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.38%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRequisiteServicePeriod', window );">Requisite Service Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceMember', window );">Non Vested Stock Units Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Stock Outstanding, Beginning Balance</a></td>
<td class="nump">183,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Non-vested Stock Granted, Number of Shares</a></td>
<td class="nump">147,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Non-vested Stock Vested, Number of Shares</a></td>
<td class="num">(32,607)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Non-vested Stock Canceled, Forfeited or Expired, Number of Shares</a></td>
<td class="num">(49,192)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Stock Outstanding, Ending Balance</a></td>
<td class="nump">249,429<span></span>
</td>
<td class="nump">183,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested Stock Outstanding, Beginning Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 37.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested Stock Granted, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">45.60<span></span>
</td>
<td class="nump">$ 37.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested Stock Vested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">38.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Non-vested Stock Canceled, Forfeited or Expired, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">39.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested Stock Outstanding, Ending Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 42.05<span></span>
</td>
<td class="nump">$ 37.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The calculated fair value of a stock-based compensation award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRequisiteServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The requisite service period that was used in the calculation of the fair value of a stock-based compensation award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRequisiteServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndMarketBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6804733392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contigencies (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">5 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">7 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">22 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 02, 2015 </div>
<div>Computers </div>
<div>Residents</div>
</th>
<th class="th">
<div>Jan. 18, 2016 </div>
<div>USD ($) </div>
<div>Claims</div>
</th>
<th class="th">
<div>Apr. 30, 2014 </div>
<div>Agencies</div>
</th>
<th class="th">
<div>Jan. 31, 2014 </div>
<div>Claims</div>
</th>
<th class="th">
<div>Mar. 09, 2011 </div>
<div>USD ($) </div>
<div>Claims</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 05, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 10, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>May 21, 2015</div></th>
<th class="th">
<div>Jun. 06, 2011 </div>
<div>Beneficiary</div>
</th>
<th class="th">
<div>Jul. 13, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 27, 2016</div></th>
<th class="th">
<div>Aug. 04, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 25, 2012 </div>
<div>Employee</div>
</th>
<th class="th">
<div>Sep. 13, 2012 </div>
<div>Employee</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Nov. 03, 2015</div></th>
<th class="th">
<div>Nov. 21, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>States</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 10, 2009 </div>
<div>Claims</div>
</th>
<th class="th">
<div>Mar. 31, 2010 </div>
<div>Beneficiary</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HealthInsuranceRetentionLimit', window );">Health insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WorkersCompensationInsuranceRetentionLimit', window );">Workers' compensation insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProfessionalLiabilityInsuranceRetentionLimit', window );">Professional liability insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CorporateIntegrityAgreementTerm', window );">Corporate Integrity Agreement Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number Of States With Facilities | States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for Legal Settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Wage and Hour Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Loss Contingency, Settlement Agreement, Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Wage and Hour Litigation [Member] | Illinois [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of former employees who filled a putative collective and class action complaint | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Loss Contingency, Settlement Agreement, Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for Legal Settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Wage and Hour Litigation [Member] | Connecticut [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of former employees who filled a putative collective and class action complaint | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for Legal Settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=amed_OigSelfDisclosureMember', window );">OIG Self-Disclosure [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for Legal Settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=amed_ComputerInventoryAndDataSecurityReportingMember', window );">Computer Inventory And Data Security Reporting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfMissingComputersAndLaptops', window );">Number of Missing Computers and Laptops | Computers</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ThresholdOfIndividualsInDataBreach', window );">Threshold of Individuals in Data Breach | Residents</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=amed_ComputerInventoryAndDataSecurityReportingMember', window );">Computer Inventory And Data Security Reporting [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_YearOfDeparture', window );">Year of Departure</a></td>
<td class="text">2011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=amed_ComputerInventoryAndDataSecurityReportingMember', window );">Computer Inventory And Data Security Reporting [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_YearOfDeparture', window );">Year of Departure</a></td>
<td class="text">2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=amed_FrontierLitigationMember', window );">Frontier Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for Legal Settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | Ohio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | Claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest', window );">Recovery amount of overpayment made to subsidiary including interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | Extrapolated [Member] | Ohio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | Claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of the overpayment made to the subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | Unfavorable [Member] | Ohio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | Claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | Favorable In Full [Member] | Ohio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | Claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsAppealed', window );">Number of claims appealed | Claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | Favorable In Part [Member] | Ohio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | Claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsAppealed', window );">Number of claims appealed | Claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | Frontier Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfCareCentersSold', window );">Number Of Care Centers Sold | Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member] | South Carolina [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfBeneficiaries', window );">Number of beneficiaries | Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member] | Extrapolated [Member] | South Carolina [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfBeneficiaries', window );">Number of beneficiaries | Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member] | Unfavorable [Member] | South Carolina [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | Claims</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of the overpayment made to the subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest', window );">Recovery amount of overpayment made to subsidiary including interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld', window );">Recovery amount of over payment made to subsidiary including interest withheld</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member] | Frontier Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfCareCentersSold', window );">Number Of Care Centers Sold | Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member] | US Department of Justice [Member] | Massachusetts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member] | US Department of Justice [Member] | Morgantown, West Virginia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member] | US Department of Justice [Member] | Parkersburg, West Virginia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CorporateIntegrityAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Corporate Integrity Agreement Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CorporateIntegrityAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HealthInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HealthInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfBeneficiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of beneficiaries who received services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfBeneficiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfCareCentersSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of care centers sold during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfCareCentersSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfClaimsAppealed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims appealed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfClaimsAppealed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfClaimsSubmittedBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims submitted by subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfClaimsSubmittedBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfMissingComputersAndLaptops">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of missing computers and laptops</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfMissingComputersAndLaptops</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Numberofpatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of patients</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Numberofpatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProfessionalLiabilityInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProfessionalLiabilityInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of the overpayment made to the subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RecoveryAmountOfOverpaymentMadeToSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of overpayment made to subsidiary including interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of over payment made to subsidiary including interest withheld</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ThresholdOfIndividualsInDataBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold of number of individuals involved in a data breach</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ThresholdOfIndividualsInDataBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WorkersCompensationInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WorkersCompensationInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_YearOfDeparture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Year of departure from the company</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_YearOfDeparture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of judgment or settlement awarded to (against) the entity in respect of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StateAxis=amed_IllinoisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StateAxis=amed_IllinoisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StateAxis=amed_ConnecticutMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StateAxis=amed_ConnecticutMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=amed_OigSelfDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=amed_OigSelfDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=amed_ComputerInventoryAndDataSecurityReportingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=amed_ComputerInventoryAndDataSecurityReportingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=amed_FrontierLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=amed_FrontierLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StateAxis=amed_OhioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StateAxis=amed_OhioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_ExtrapolatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_ExtrapolatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_UnfavorableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_UnfavorableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_FavorableInFullMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_FavorableInFullMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_FavorableInPartMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_FavorableInPartMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StateAxis=amed_SouthCarolinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StateAxis=amed_SouthCarolinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=amed_UsDepartmentOfJusticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=amed_UsDepartmentOfJusticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StateAxis=amed_MassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StateAxis=amed_MassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StateAxis=amed_MorgantownWestVirginiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StateAxis=amed_MorgantownWestVirginiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StateAxis=amed_ParkersburgWestVirginiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StateAxis=amed_ParkersburgWestVirginiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6781736768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Future Minimum Rental Commitments (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingLeaseObligationsLineItems', window );"><strong>Operating Lease Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2017</a></td>
<td class="nump">$ 23.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2018</a></td>
<td class="nump">17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2019</a></td>
<td class="nump">13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2020</a></td>
<td class="nump">9.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2021</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Future years</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">72.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingLeasesRentExpenseNetForContinuingOperations', window );">Rent expense for non-cancelable operating leases</a></td>
<td class="nump">$ 27.5<span></span>
</td>
<td class="nump">$ 23.7<span></span>
</td>
<td class="nump">$ 26.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingLeaseObligationsLineItems', window );"><strong>Operating Lease Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingLeaseTermYears', window );">Operating lease term, years</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingLeaseObligationsLineItems', window );"><strong>Operating Lease Obligations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingLeaseTermYears', window );">Operating lease term, years</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OperatingLeaseObligationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OperatingLeaseObligationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OperatingLeaseTermYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease term, years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OperatingLeaseTermYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OperatingLeasesRentExpenseNetForContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income for continuing operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OperatingLeasesRentExpenseNetForContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6937029680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insurance Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HealthInsurance', window );">Health insurance</a></td>
<td class="nump">$ 10.6<span></span>
</td>
<td class="nump">$ 11.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WokersCompensation', window );">Wokers compensation</a></td>
<td class="nump">26.8<span></span>
</td>
<td class="nump">23.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProfessionalLiability', window );">Professional liability</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedInsuranceTotal', window );">Estimated Insurance Total</a></td>
<td class="nump">42.1<span></span>
</td>
<td class="nump">39.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedInsuranceLongTermPortion', window );">Estimated Insurance Long Term Portion</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedInsuranceExcludingLongTermPortion', window );">Estimated Insurance Excluding Long Term Portion</a></td>
<td class="nump">$ 41.3<span></span>
</td>
<td class="nump">$ 38.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedInsuranceExcludingLongTermPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated insurance liability, excluding long-term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedInsuranceExcludingLongTermPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedInsuranceLongTermPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term portion of estimated insurance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedInsuranceLongTermPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedInsuranceTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated insurance, total</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedInsuranceTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HealthInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Health insurance, estimated liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HealthInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProfessionalLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Professional liability insurance, estimated liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProfessionalLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WokersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Workers' Compensation insurance, estimated liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WokersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6647080800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Detail)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>Y</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract', window );"><strong>Pension and Other Postretirement Benefits Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MinimumEligibleAgeForEmployeesToContributeToBenefitPlan', window );">Minimum Eligible Age For Employees To Contribute To Benefit Plan | Y</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DefinedContributionPlanEmployerMatchingContribution', window );">Employer Match Amount</a></td>
<td class="nump">$ 0.440<span></span>
</td>
<td class="nump">$ 0.375<span></span>
</td>
<td class="nump">$ 0.375<span></span>
</td>
<td class="nump">$ 0.375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram', window );">Employee Contribution Amount</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage', window );">Maximum Percentage of Employee Salary Eligible for Employer Match</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">401 (k) Expense Recognized by Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Percentage of Employee Salary Eligible for Employer Match</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan Employee Contribution For Employer Matching Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DefinedContributionPlanEmployerMatchingContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan employer matching contribution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DefinedContributionPlanEmployerMatchingContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MinimumEligibleAgeForEmployeesToContributeToBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum eligible age for employees to contribute to benefit plan, years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MinimumEligibleAgeForEmployeesToContributeToBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PensionAndOtherPostretirementBenefitsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the cost recognized during the period for defined contribution plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6936416512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Repurchase Program (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 09, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>EquityAbstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">StockRepurchaseProgramAuthorizedAmount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Shares repurchased</a></td>
<td class="num">$ (12,315)<span></span>
</td>
<td class="num">$ (4,581)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock Shares Repurchased</a></td>
<td class="nump">324,141<span></span>
</td>
<td class="nump">116,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury Stock Weighted Average Price</a></td>
<td class="nump">$ 37.96<span></span>
</td>
<td class="nump">$ 39.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6782185248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Exit Activities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>Agencies</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnSalesOfAssets', window );">Gains (Losses) on Sales of Assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 184<span></span>
</td>
<td class="nump">$ 2,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from Divestiture of Business</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 413<span></span>
</td>
<td class="nump">$ 4,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfCareCentersConsolidated', window );">Number of care centers consolidated | Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfCareCentersClosed', window );">Number of care centers closed | Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfCareCentersConsolidated', window );">Number of care centers consolidated | Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfCareCentersClosed', window );">Number of care centers closed | Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=amed_SeveranceForRegionalLeadershipAndCorporateSupportMember', window );">Severance For Regional Leadership And Corporate Support [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Other Restructuring Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=amed_SeveranceForFormerExecutiveMember', window );">Severance For Former Executive [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Other Restructuring Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TypeOfBusinessSoldAxis=amed_WyomingAndIdahoCareCentersMember', window );">Wyoming and Idaho Care Centers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnSalesOfAssets', window );">Gains (Losses) on Sales of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from Divestiture of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TypeOfBusinessSoldAxis=amed_WyomingAndIdahoCareCentersMember', window );">Wyoming and Idaho Care Centers [Member] | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfCareCentersSold', window );">Number of care centers sold | Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TypeOfBusinessSoldAxis=amed_WyomingAndIdahoCareCentersMember', window );">Wyoming and Idaho Care Centers [Member] | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfCareCentersSold', window );">Number of care centers sold | Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TypeOfBusinessSoldAxis=amed_AvailableForSaleMember', window );">Available For Sale [Member] | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnSalesOfAssets', window );">Gains (Losses) on Sales of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from Divestiture of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfCareCentersConsolidated', window );">Number of care centers consolidated | Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfCareCentersSold', window );">Number of care centers sold | Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TypeOfBusinessSoldAxis=amed_HospiceInpatientUnitMember', window );">Hospice Inpatient Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnSalesOfAssets', window );">Gains (Losses) on Sales of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfCareCentersClosed', window );">Number of care centers closed | Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OtherRestructuringCostsAxis=amed_TwoThousandAndFourteenExitActivityMember', window );">2014 Exit Activity [Member] | Lease Termination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Other Restructuring Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OtherRestructuringCostsAxis=amed_TwoThousandAndFourteenExitActivityMember', window );">2014 Exit Activity [Member] | Severance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Other Restructuring Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OtherRestructuringCostsAxis=amed_TwoThousandAndFourteenExitActivityMember', window );">2014 Exit Activity [Member] | Intangibles Write Off [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Other Restructuring Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfCareCentersClosed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating care centers that were closed during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfCareCentersClosed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfCareCentersConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating care centers that were consolidated with care centers servicing the same market during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfCareCentersConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfCareCentersSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of care centers sold during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfCareCentersSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnSalesOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnSalesOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section P<br> -Subsection 3, 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=amed_SeveranceForRegionalLeadershipAndCorporateSupportMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=amed_SeveranceForRegionalLeadershipAndCorporateSupportMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=amed_SeveranceForFormerExecutiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=amed_SeveranceForFormerExecutiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TypeOfBusinessSoldAxis=amed_WyomingAndIdahoCareCentersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TypeOfBusinessSoldAxis=amed_WyomingAndIdahoCareCentersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TypeOfBusinessSoldAxis=amed_AvailableForSaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TypeOfBusinessSoldAxis=amed_AvailableForSaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TypeOfBusinessSoldAxis=amed_HospiceInpatientUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TypeOfBusinessSoldAxis=amed_HospiceInpatientUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OtherRestructuringCostsAxis=amed_TwoThousandAndFourteenExitActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OtherRestructuringCostsAxis=amed_TwoThousandAndFourteenExitActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=amed_LeaseTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=amed_LeaseTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=amed_IntangiblesWriteOffMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=amed_IntangiblesWriteOffMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6781496624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Exit Activities - Reserve Activity (Detail) - 2014 Exit Activity [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OtherRestructuringCostsAxis=amed_TwoThousandAndFourteenExitActivityMember', window );">Lease Termination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring Reserve</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charge</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash Expenditure</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OtherRestructuringCostsAxis=amed_TwoThousandAndFourteenExitActivityMember', window );">Severance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring Reserve</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charge</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash Expenditure</a></td>
<td class="num">$ (0.4)<span></span>
</td>
<td class="num">$ (1.9)<span></span>
</td>
<td class="num">$ (5.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section P<br> -Subsection 3, 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section P<br> -Subsection 3, 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OtherRestructuringCostsAxis=amed_TwoThousandAndFourteenExitActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OtherRestructuringCostsAxis=amed_TwoThousandAndFourteenExitActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=amed_LeaseTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=amed_LeaseTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6796266752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Valuation and Qualifying Accounts (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision For Doubtful Accounts</a></td>
<td class="nump">$ 19,519<span></span>
</td>
<td class="nump">$ 14,053<span></span>
</td>
<td class="nump">$ 16,369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForDoubtfulAccountsMember', window );">Allowance for Doubtful Accounts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Valuation Allowances and Reserves, Balance, Beginning Balance</a></td>
<td class="nump">16,500<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
<td class="nump">14,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision For Doubtful Accounts</a></td>
<td class="nump">19,500<span></span>
</td>
<td class="nump">14,100<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Write-Offs</a></td>
<td class="num">(18,300)<span></span>
</td>
<td class="num">(11,900)<span></span>
</td>
<td class="num">(16,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Valuation Allowances and Reserves, Balance, Ending Balance</a></td>
<td class="nump">17,700<span></span>
</td>
<td class="nump">16,500<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForDoubtfulAccountsDiscontinuedOperationsMember', window );">Allowance for Doubtful Accounts - Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision For Doubtful Accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=amed_EstimatedRevenueAdjustmentsMember', window );">Estimated Revenue Adjustments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Valuation Allowances and Reserves, Balance, Beginning Balance</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Provision for Estimated Revenue Adjustments</a></td>
<td class="nump">7,900<span></span>
</td>
<td class="nump">6,100<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Write-Offs</a></td>
<td class="num">(7,800)<span></span>
</td>
<td class="num">(5,200)<span></span>
</td>
<td class="num">(5,900)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Valuation Allowances and Reserves, Balance, Ending Balance</a></td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=amed_EstimatedRevenueAdjustmentsDiscontinuedOperationsMember', window );">Estimated Revenue Adjustments, Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Provision for Estimated Revenue Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the adjustments in a given period to allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 09<br> -Article 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 09<br> -Article 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the deductions in a given period to allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, representing receivables written off as uncollectible and portions of the reserves utilized, respectively.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 09<br> -Article 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForDoubtfulAccountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForDoubtfulAccountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForDoubtfulAccountsDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForDoubtfulAccountsDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=amed_EstimatedRevenueAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=amed_EstimatedRevenueAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=amed_EstimatedRevenueAdjustmentsDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=amed_EstimatedRevenueAdjustmentsDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6783762384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>Segments</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable business segments</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6781728192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Income of Reportable Segments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationPatientServiceRevenue', window );">Net service revenue</a></td>
<td class="nump">$ 366,300<span></span>
</td>
<td class="nump">$ 361,600<span></span>
</td>
<td class="nump">$ 360,700<span></span>
</td>
<td class="nump">$ 348,800<span></span>
</td>
<td class="nump">$ 338,400<span></span>
</td>
<td class="nump">$ 326,400<span></span>
</td>
<td class="nump">$ 314,100<span></span>
</td>
<td class="nump">$ 301,600<span></span>
</td>
<td class="nump">$ 1,437,454<span></span>
</td>
<td class="nump">$ 1,280,541<span></span>
</td>
<td class="nump">$ 1,204,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServices', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,055<span></span>
</td>
<td class="nump">725,915<span></span>
</td>
<td class="nump">691,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GeneralAndAdministrativeExpenseSegment', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">503,400<span></span>
</td>
<td class="nump">452,400<span></span>
</td>
<td class="nump">441,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProvisionForDoubtfulAccountsForContinuingOperations', window );">Provision for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,519<span></span>
</td>
<td class="nump">14,053<span></span>
</td>
<td class="nump">16,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,678<span></span>
</td>
<td class="nump">20,036<span></span>
</td>
<td class="nump">28,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,432<span></span>
</td>
<td class="nump">77,268<span></span>
</td>
<td class="nump">3,107<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,380,114<span></span>
</td>
<td class="nump">1,289,707<span></span>
</td>
<td class="nump">1,180,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,340<span></span>
</td>
<td class="num">(9,166)<span></span>
</td>
<td class="nump">24,047<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationPatientServiceRevenue', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,085,500<span></span>
</td>
<td class="nump">1,005,100<span></span>
</td>
<td class="nump">956,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServices', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">643,700<span></span>
</td>
<td class="nump">584,200<span></span>
</td>
<td class="nump">559,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GeneralAndAdministrativeExpenseSegment', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,400<span></span>
</td>
<td class="nump">263,200<span></span>
</td>
<td class="nump">269,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProvisionForDoubtfulAccountsForContinuingOperations', window );">Provision for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800<span></span>
</td>
<td class="nump">12,200<span></span>
</td>
<td class="nump">14,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946,900<span></span>
</td>
<td class="nump">864,800<span></span>
</td>
<td class="nump">853,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,600<span></span>
</td>
<td class="nump">140,300<span></span>
</td>
<td class="nump">103,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationPatientServiceRevenue', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,000<span></span>
</td>
<td class="nump">275,400<span></span>
</td>
<td class="nump">247,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServices', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,100<span></span>
</td>
<td class="nump">141,700<span></span>
</td>
<td class="nump">131,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GeneralAndAdministrativeExpenseSegment', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,200<span></span>
</td>
<td class="nump">62,700<span></span>
</td>
<td class="nump">58,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProvisionForDoubtfulAccountsForContinuingOperations', window );">Provision for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,100<span></span>
</td>
<td class="nump">207,700<span></span>
</td>
<td class="nump">195,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,900<span></span>
</td>
<td class="nump">67,700<span></span>
</td>
<td class="nump">52,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationPatientServiceRevenue', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,900<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServices', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GeneralAndAdministrativeExpenseSegment', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,900<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProvisionForDoubtfulAccountsForContinuingOperations', window );">Provision for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">All Other Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationPatientServiceRevenue', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServices', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GeneralAndAdministrativeExpenseSegment', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,900<span></span>
</td>
<td class="nump">126,500<span></span>
</td>
<td class="nump">114,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProvisionForDoubtfulAccountsForContinuingOperations', window );">Provision for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,400<span></span>
</td>
<td class="nump">13,400<span></span>
</td>
<td class="nump">17,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">77,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,700<span></span>
</td>
<td class="nump">217,200<span></span>
</td>
<td class="nump">131,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (158,700)<span></span>
</td>
<td class="num">$ (217,200)<span></span>
</td>
<td class="num">$ (131,600)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DepreciationAndAmortizationForContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation And Amortization For Continuing Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DepreciationAndAmortizationForContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_GeneralAndAdministrativeExpenseSegment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of each segment of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_GeneralAndAdministrativeExpenseSegment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProvisionForDoubtfulAccountsForContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision For Doubtful Accounts For Continuing Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProvisionForDoubtfulAccountsForContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51824106&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to services rendered by an entity during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationPatientServiceRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized for providing services to patients, net of provisions for contractual allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51673510&amp;loc=d3e8184-115640<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51673510&amp;loc=d3e8195-115640<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51673510&amp;loc=SL9156442-115640<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51673531&amp;loc=SL9156464-115641<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51673510&amp;loc=SL9156442-115640<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationPatientServiceRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6795160592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Summarized Quarterly Financial Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>May 05, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_QuarterlyFinancialInformationLineItems', window );"><strong>Quarterly Financial Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationPatientServiceRevenue', window );">Net service revenue</a></td>
<td class="nump">$ 366,300<span></span>
</td>
<td class="nump">$ 361,600<span></span>
</td>
<td class="nump">$ 360,700<span></span>
</td>
<td class="nump">$ 348,800<span></span>
</td>
<td class="nump">$ 338,400<span></span>
</td>
<td class="nump">$ 326,400<span></span>
</td>
<td class="nump">$ 314,100<span></span>
</td>
<td class="nump">$ 301,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,437,454<span></span>
</td>
<td class="nump">$ 1,280,541<span></span>
</td>
<td class="nump">$ 1,204,554<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Amedisys, Inc.</a></td>
<td class="nump">$ 8,900<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="nump">$ 10,700<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="nump">$ 12,900<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="nump">$ 10,600<span></span>
</td>
<td class="num">$ (35,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,261<span></span>
</td>
<td class="num">$ (3,021)<span></span>
</td>
<td class="nump">$ 12,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings Per Share Basic</a></td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="nump">$ 0.34<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share Diluted</a></td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.34<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,432<span></span>
</td>
<td class="nump">$ 77,268<span></span>
</td>
<td class="nump">$ 3,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Write Off Of Deferred Debt Issuance Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnSalesOfAssets', window );">Gain on sale of care centers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="nump">2,967<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TypeOfBusinessSoldAxis=amed_HospiceInpatientUnitMember', window );">Hospice Inpatient Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_QuarterlyFinancialInformationLineItems', window );"><strong>Quarterly Financial Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnSalesOfAssets', window );">Gain on sale of care centers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (500)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=amed_OigSelfDisclosureMember', window );">OIG Self-Disclosure [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_QuarterlyFinancialInformationLineItems', window );"><strong>Quarterly Financial Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_QuarterlyFinancialInformationAxis=amed_NetOfTaxMember', window );">Net Of Tax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_QuarterlyFinancialInformationLineItems', window );"><strong>Quarterly Financial Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charge</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ReversalOfLegalAccrual', window );">Legal fee accrual reversal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SoftwareImplementationCosts', window );">Software Implementation Costs</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction-related expenses for aquisitions</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_QuarterlyFinancialInformationAxis=amed_NetOfTaxMember', window );">Net Of Tax [Member] | OIG Self-Disclosure [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_QuarterlyFinancialInformationLineItems', window );"><strong>Quarterly Financial Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_QuarterlyFinancialInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_QuarterlyFinancialInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ReversalOfLegalAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reversal of legal fee accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ReversalOfLegalAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SoftwareImplementationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs Incurred For Software Implementation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SoftwareImplementationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51824106&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnSalesOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets utilized in financial service operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnSalesOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationPatientServiceRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized for providing services to patients, net of provisions for contractual allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51673510&amp;loc=d3e8184-115640<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51673510&amp;loc=d3e8195-115640<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51673510&amp;loc=SL9156442-115640<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51673531&amp;loc=SL9156464-115641<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 605<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51673510&amp;loc=SL9156442-115640<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationPatientServiceRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TypeOfBusinessSoldAxis=amed_HospiceInpatientUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TypeOfBusinessSoldAxis=amed_HospiceInpatientUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=amed_OigSelfDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=amed_OigSelfDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_QuarterlyFinancialInformationAxis=amed_NetOfTaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_QuarterlyFinancialInformationAxis=amed_NetOfTaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6933943920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transaction (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 22, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=amed_KKRConsultingMember', window );">KKR Consulting [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party transaction expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=amed_CareInnovationsMember', window );">Care Innovations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction Amount</a></td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party transaction expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=amed_KKRConsultingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=amed_KKRConsultingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=amed_CareInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=amed_CareInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6958777056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Detail) - Personal Care [Member] - Home Staff LLC [Member]<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Feb. 01, 2017 </div>
<div>USD ($) </div>
<div>Agencies</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Acquisition, total purchase price | $</a></td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Acquisition, number of care centers acquired | Agencies</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_HomeStaffLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_HomeStaffLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>105
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M#[^KL O&[NT_-KX(=BW\NHON"U!+ P04    "  \0&%*F5R<(Q &  "<)P
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M9J?F['24G5J@HE.H-'4DZ%1A9PO%6T<R/S7GIZ/\U)R+!?WHV0JB/.DEL3'
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MTR2Z+89;Q-!1O!]O2,GUFK;Z!U!+ P04    "  \0&%*^DQ/5W4%  "1'
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ME_64O?&2$.&]-W7+UWXI1+<"@!<E:3!_IAUIY3\GRAHLY)2= >\8P4=-:FH
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M;,B3O4L[PP)H@0#RATL4&Q1M<_9T":?8XR5  %F@$E#L 1-9 &4D#B)I]K
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M.B><RUX8DXD!F6*&3(S)Q(!,>I]HP18GYG%9"5<F_%B1SY%4,)<$<"EJ+@F
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MH4LNBP_ID3QU[?WIQZI[&,:O,7W?'MYP._P8^N?CVWOSTRN$M_\#4$L#!!0
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M=[)HL9FE$@JT$T83"W5.;[>'8QKB8\!/ 8-;G$FHY&S,<S#NJYQN@B"04/K
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M'VPQ%-0^'#_CV4YC-AG>]/,/8LLW+OX"4$L#!!0    ( #Q 84H<E5 XM@$
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MDK919%MJ6E6=M$E1JVV?B7VV4<&X@./NW_? KN=MUKX =]Q[]^XXTL'85]<
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MRH?C+9[M.&:CX4TW_2 V?^/\ U!+ P04    "  \0&%*^RE=F;4!  #2 P
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M\&RG,9L,;_KY!['E&Q=_ 5!+ P04    "  \0&%*D43ET+0!  #2 P  &0
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M.H'"L:![^NIXDFWGHX.5>2]:^ K^6W^VP6(+2RTU&"?1$ M-0>_WQU,6XU/
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M,2YX;6Q]4V%OVR 0_2N('U 2XK159%MJ6E6=M$E1JVV?B7VV4<'G HZ[?U_
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M7S;VOT)TX*5LKOP(-?Z#S8:"RH7CC3^;<<Q&PV$W_2 V?^/\ U!+ P04
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M_VMC/*"4Y 9'J,4/MA@*:A^.'_!LIS&;#&_Z^0>QY1L7?P!02P,$%     @
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MUW-+R5S\%[B"\N%!B<]1HK)Q)>5@'>J9Q4O1XGG:91?W<;KA=S-L&\!G %\
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MH)GM)[!<=R0"%*X!(&C& 037-5E,*6+7 Q T8P*"RY^ VHY=&T#0G _P"4!
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M"SK_LK'_%:(#GTIRXT>H\1]L-A14+ASW_FS&,1L-A]WT@]C\C?,W4$L#!!0
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MV+F:+LP4&-G/;P%9'J3B+U!+ P04    "  \0&%*[F;YRN !   !!0  &0
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MVZA</,!Q]_8#['I>QA\#A^]R#G!<3-J\VA[ H3<IE"UQ[]QP),36/4AF[_0
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M@Y^;^2W/"Z>'I4W)^J^H_@!02P,$%     @ /$!A2G4<Q->X 0  T@,  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL;5/;;IPP$/T5RQ\0LX8DVQ4@
M91-%K=1*JU1-G[TP@!5?J&V6].]K&T))PHOM&9]SYN)Q/FKS8CL AUZE4+;
MG7/]@1!;=2"9O=(]*'_3:".9\Z9IB>T-L#J2I" T26Z(9%SA,H^^DRES/3C!
M%9P,LH.4S/P]@M!C@7?XS?'$V\X%!RGSGK7P$]RO_F2\11:5FDM0EFN%##0%
MOML=CEG 1\ SA]&NSBA4<M;Z)1C?Z@(G(2$04+F@P/QV@7L0(@CY-/[,FG@)
M&8CK\YOZ8ZS=UW)F%NZU^,UKUQ5XCU$-#1N$>]+C5YCKN<9H+OX[7$!X>,C$
MQZBTL'%%U6"=EK.*3T6RUVGG*N[C=)/>SK1M IT)="'L8QPR!8J9/S#'RMSH
M$9FI]ST+3[P[4-^;*CAC*^*=3]YZ[Z5,TWU.+D%HQAPG#%UA=@N">/4E!-T*
M<:2?Z'2;GFYFF$9ZNJ:GZ;9 MBF018'L78E?/I2X@<F2#T'(JJ<23!NGR:)*
M#RI.\LJ[#.P=C6_R'SY-^P]F6JXL.FOG7S;VO]':@4\EN?(CU/D/MA@"&A>.
MM_YLIC&;#*?[^0>1Y1N7_P!02P,$%     @ /$!A2A/:IH*W 0  T@,  !D
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M6SS;:<PFPYM^_D%L^<;%/U!+ P04    "  \0&%*15#@-[8!  #2 P  &0
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M("@=B#.P"R% 8J#H"-QE%@C_?^LBN/E1!+AP^\&"[AH"#UF%]P@$-&XZ&9"
M.Q<E'\@6;DP$==U#MNE#MMF04[@U$=";V<!21W!#H?$'DH7;!4&]\)#LY"%9
MY/9+<'.PUI0?S2U'>#MV:J0^>6YF^YO4 NN#V9E?HNFZNP_]D^FN9]\(/Y:-
M\+9,JF/?',X'QB15%L.1,E>H&V$_J.A!ZM=,O?/N6M0-)&OME2_H[YWY7U!+
M P04    "  \0&%*]7,5O*(%  #N'P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970T,"YX;6R5F>URHD@4AF_%\@)&^A-(&:NB,\I6[59-S=;N_B;:B=: N$#B
M[-TO(''DG+<3YD]4\IZOIL_3W3 _%^7W:N]</?F19\?J?KJOZ]/=;%9M]RY/
MJT_%R1V;_SP599[6S<_R>5:=2I?N.J,\F\D@L+,\/1RGBWEW[6NYF!<O=78X
MNJ_EI'K)\[3\;^FRXGP_%=.W"]\.S_NZO3!;S$_IL_O3U7^=OI;-K]G5R^Z0
MNV-U*(Z3TCW=3Q_$76)5:] I_CZX<W7S?=*6\E@4W]L?O^WNIT&;D<O<MFY=
MI,W'JUNY+&L]-7G\VSN=7F.VAK??W[RON^*;8A[3RJV*[)_#KM[?3Z/I9.>>
MTI>L_E:<$]<79*:3OOK?W:O+&GF;21-C6V15]W>R?:GJ(N^]-*GDZ8_+Y^'8
M?9Y[_V]FV$#V!O)J(,6[!JHW4&,-=&^@QQJ8WL",-;"]@;T:J.A=@[ W",=&
MB'J#B!C,+K>CN[^?TSI=S,OB/"DO4_24MIT@[J)F!FW;B]V$Z?[7W.*JN?JZ
M4*&8SUY;1[UF>='(@48.-6NN^>EEUF1P34.B-)82A%##$"N@,235S\B/'FJ^
M((TAY2"-'6HV(_))D)\0#XR"]T=U#M3 080=:.A =P[TP$%,JKUH3*<Y=AH;
MX!@&QC \1A20&$CCF2(6!K'  9V%EA5B<(@0A@A!"#(+UR$?*QPB@B$B$(),
MT'7$0@B-8\0P1@QBT D>LQC2<\M%@,$1@"B64@&)//-?>  E@(N(QA&C9["
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M)HER#)[4;)6Z)Z: DI/4VU3M^7!:#H%DW7@1@.DV*O\"4$L#!!0    ( #Q
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MV,ODC[R7TH!EC#>V[\&^Z35@T!LWW=JYFF_V'!@Y+H\6KW^.YC]02P,$%
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MI25@6E!,&S]21B4+J+T2,"T)IC/D \ JV0%?7@&(DFJM7K+<2@)$/&, HJ1
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MLP88:@)#=-?: ,#, ?>.# #,$"W,+P<73@1;ZC 2P-"$&*H$W/0Q #!SP"]
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M<$/W$7AIKK50 ;_,>WR%'R!^]D<F=_ZD<FY:Z'A#.X?!I7"?P]TA4W@-^-7
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MG)69YGHN7/=P"\7[J3.BN3U7?P%02P,$%     @ /$!A2ISYQVZ4 P  VQ
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M1MEN[RFI3Q&[=U7UM_5B4^SFG2I/I58O*P_LA76I'768=8N! 8;U"$MY[T,
M%6(-R!S& 388X4P@,8:$-DW"(?-T&GMG8.^"0SMP20=NX\ =%8I-"M5B_ 93
MM)GZS/>=2;H$S/9\>U+VF(*%D:U)VR-9>XBU&X03UBW&&\8)V)3-!J,\G^G(
M^"09GRCA=)]]%.:3X^C"!&28 .<<3G<J0&&TN81DD)#(9;+/ZQ 7-@PC+YA4
MEH 1IR8F8.-3,V(=D:PCQ-KQ ]H!LVF]L.<W$M-(#IO12AUHF*Y/G$H"QGP/
MM1()T]:.D3KVP&!&,W6@8237Q;0QRK/U?&A)8\Z,?NI HX;2'G5&2Q_#VH<[
MJ@/-:BE&BQ7#:H6;BF$A"A@2SPT!(\Y/3,#&YV?,F]8UAH7-\2.-"UJS6/ ?
M;44K$J,D">T25A$6N43Y"%P8$?6C_(%6L!DM2PSK$M%9$0J%6&.(I]U,H 4.
M[!E=U8'&_Z9 &XG60< ZB-L*L'+IHM"J!5BU<%,!UB/R6,S$Q11N?'S&U&F!
M RQP3J!S04L7N//["FA5 DJ5T#9A'4&U^R<DO@D9<Z65"+ 2X48"_(T%$."]
MQC =&5K3 '^($9V$O\1T46C9 RQ[1!=AF=)%H14*L$(1713A+W:JL!B&#L(M
M2,O7&DQX.2\/S?1<&5MQ+F0]* U6^PG] >H)<;*^5I-[.V=_N&G'_N])>4B+
MRG@14LV?S92X%T)RQ="^4[4\\F37/V1\+^O;0-V7[;C=/DAQZGY*L/K?,U9_
M 5!+ P04    "  \0&%*<_V 5><#  "<$P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6R5F&MOFT@4AO\*XGL*<\'8D6TI,:IVI:T4==7V,[''-BHP
M7L!Q^^]WN,2%.>^X[I<8)N^Y,N<QGN5%5]_KHU*-]Z/(RWKE'YOF]!@$]?:H
MBK3^H$^J-/_9ZZI(&W-;'8+Z5*ETUQD5><##<!84:5;ZZV6W]E*ME_K<Y%FI
M7BJO/A=%6OU\5KF^K'SFOR]\S@['IET(ULM3>E#_JN;+Z:4R=\'5RRXK5%EG
MNO0JM5_Y3^PQ$:(UZ!1?,W6I1]=>6\JKUM_;F[]W*S]L,U*YVC:MB]1\O*F-
MRO/6D\GCO\&I?XW9&HZOW[U_[(HWQ;RFM=KH_%NV:XXK?^Y[.[5/SWGS65_^
M4D-!D>\-U?^CWE1NY&TF)L96YW7WU]N>ZT87@Q>32I'^Z#^SLON\#/[?S; !
M'PSXU8#-;AJ(P4#\,I W#>1@("V#H"^EZTV2-NEZ6>F+5_6/]Y2VNX@]2M/]
M;;O8-;O[GVE/;5;?UA&7R^"M=31HGGL-'VG851$8[]<0'(5XYL2<3P-LJ$)8
MDH1*YB%.0L Z16<O1O:2"^Q 0@>R<R GC6)6HWK-K-.4?1 9RMBJEJJ$,(-J
M%0Q4LSATU!S!E".2LHSG5LJ])AJ%B4@N&RIBC+ERF<%<9J!]D15F1L(\"-(7
M(.*N5&*82DQ38=8S2F*0BK/B.0PS!Q7/K.[/03$1*1FI7+DL8"X+D(NP<EF0
M*'(61_8S BJZQ1.JFF[Q2<HLQ&0*Z?8=-7#JP@$W=O_4,PBO)\;OF/M!-)FB
M!9DBH+*?-)"XVX9!Q\0=4S^()A--]MT&J"9E3=/!V&2(F_:F&D0W.W-+,DT$
MPY!1&M*Q9Y1TKB@8<PQQSIYZAAA&QQ[*G.W'K&, =F3R&:6=!-N7JN@F3X#*
ME3'&)D/<C!TN,.W8XOZQYQ@^G,*'COT@FDRKH(V#,D8ZAV21=#UOCHG'V1W3
M/XA<E!FRIB+W=S['\.0(GO;P<\H\\+6/5,YAX!B-G**1(H!3Z#UP=^&8>AQ1
MS\8 _SWU;DJFB6#J<4 ],O^<4H]+LD$W2$:W>P)E[@9BCG+$T;G#!48?C_^
M IA%'+&(4("^GC$)Y@G(0D !(+LQ=QB G+[O 0J ES3Z#@!4TIF.P# 5"*8V
M!@3%G]V;FY)I(IB.@M*1 D!0\#V8BEV1,/D$(I\- /'[%\*;DFDBCM^]@'D$
M (-H_&.3Q3'9"TA&=WJ"9"'=,\'HB*)0U:$[_JF]K3Z73?M+?[1Z/6)ZXNT1
MA[7^S!Z3_J#HEYO^W.I36AVRLO9>==/HHCOFV&O=*)-E^,'T]*C2W?4F5_NF
MO8S-==6?%_4WC3X-9V'!]4!N_3]02P,$%     @ /$!A2K-WB6<@ @  . 8
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M[>',\3<&3]%S\28K !6\-ZR5F[!2JELC)(\5-%0^\0Y:_>;,14.57HH+DIT
M>K))#4-Q%&6HH74;EH6-[459\*MB=0M[$<AKTU#Q9PN,]YL0A_? :WVIE F@
MLNCH!;Z#^M'MA5ZAR>54-]#*FK>!@/,F_(37N]SHK>!G#;V<S0-3R8'S-[/X
M<MJ$D0$"!D=E'*@>;K #QHR1QO@]>H;3EB9Q/K^[O]C:=2T'*F''V:_ZI*I-
MN J#$YSIE:E7WG^&L9XT#,;BO\(-F)8;$KW'D3-IG\'Q*A5O1A>-TM#W8:Q;
M._:C_SW-GQ"/"?&4@)/_)I Q@2P2T$!F2WVFBI:%X'T@AH_54?-/X#71AWDT
M07MV]IVN5NKHK4P)+M#-&(V:[:")9YKXHV+G*L@_"=( $T7LI8AM/IGO@"._
M ?$:$&N0?"AC ;D=-)G5M%:3Y5&TJ,0CBJ,'*(D7)?&@D 7*H$EGNV#BH+BB
M]!%)ZB5)/23)@B1U2=Q#\8A6CU R+TKFH*RR!4GF;I(Y)*XHPX](<B])[I"0
M?$&2._\ QG&V1/&HDBS!"Q8TNXBF,7ZCXE*W,CAPI>^TO7EGSA5HQ^A)UU7I
M7CPM&)R5F>9Z+H:.-"P4[\9FBZ:.7_X%4$L#!!0    ( #Q 84H(UMT$'@(
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M*\)_$J0 9HI@DR(P]>%R!=_;-@@W#4)C$+V+X:]BC)K$:+H1TEM%+6S-SGL
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MI.ZFJL_[XMD/)&N'AP$87R?%7U!+ P04    "  \0&%*<T<(4'@%   ^(
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MY+\,Y]@@@0:)->#7!A1C@Q0:I+<9$'NW1DCCF&8&@V3 @+\+@C0)#C*#06;
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MQ96'R F3@@L&N:=B$% -8KL:;#Y0L0<UIH-+ @$U0?@RPDHFB_LGA6(!4B1
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M^OL]#(XJW=T>,K4WS6U2WY?=J5;W8/2Y/[&+;L>&Z_\!4$L#!!0    ( #Q
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M0DP$FXU!LS$@L+#,0DQLF868Q#(+,.&=9$Y L\FMP,(V"S"I]9_:0HR53@7
M+.^D00J:30$!.PT@QDX#B+'3 &+NI,$2-+L$!.R=A9C(,@LQ5JH4$)/ 9E51
M \]-#Y"X.3@AR/K*6P!*//M$ "$[<='LT&\(/YF"*IR2G5NIS\[9Z%2TGP-=
M-*SQC2[FIIA\R@PW@1^8G^I6.'LF54DRA>/(F"3*H_>D3H)*73ZF#B5'J9N)
M:O.A @\=R;KQ=H&F*T[^#U!+ P04    "  \0&%*#Z#!?PP#  #$#   &0
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M#N=Z./E#854W7FHV_5GROU!+ P04    "  \0&%*X[!V!5<"  "2!P  &0
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MG&<,YN$@#P=XJ,7#'1Z,$,?,*NW*Q=UKB!R,)P?B2:QX<G<+.4X8AWDP@J4
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M2]N_3;OW]>G$^W315H?Q-#\\_TMA^3]02P,$%     @ /$!A2I0]5>\S!0
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MISX4!CWD]QD, W#/-( OT^/&9 !?QF\Y8>#^H]+XSQL4:$L6,&A]!L, ^0"
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M2\,)7DOP.@)$'Q+\EN"_$X(/"4%+" 8$I[%B<K,CDJP6G-TMWOR]-=%5!/-
M9?^H)TVRS3>5'J%F;ZO4#1?.30=J,9L&X_4PT"$<%;V3\#")C3>B>X\"VS'"
M'T!V8TCBXHOP49^^X?L//B,\0( &"$R T 2H&A<NQ(-,-2!P^RA_%N(Z(:H3
M8CK)0*<! ?10$$_I1*A.A.FD YTQ"'Q<)$9%8D3$<P<B\=A,.INHL 2523 9
M&,@D8YE@-N$F1652$R%XJ*%A!:28RD2AZ3K!MJ0[TH%1!;2@ON?8FY"9V/F
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M[#_)5YG5XDTDM8^=RJKVU]E=*JWRWDH=2I[\ZIYIT3ZOW3]AT*MA!>H5Z*9
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M2'F/G3!FB'O)#S/;NO#FJ9GDZ,3$<,['1'40:L)PI;LCMVG1UO\!4$L#!!0
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MH<K@[5&9I9V*MI>'6+T6U=>@_)XU;^R;AR(]ZE\CK,M/(I/_ 5!+ P04
M"  \0&%*D*^&4PH"  #;!0  &0   'AL+W=O<FMS:&5E=',O<VAE970X-BYX
M;6R-5.MNFS 4?A7D!XBY) 0B0&I239NT25&G;;\=. FH-F:V$[JWGVTHH\2K
M^@?;Q]_E'!N?K.?B6=8 RGMAM)4YJI7J=AC+L@9&Y(IWT.J=,Q>,*+T4%RP[
M :2R)$9QZ/LQ9J1I49'9V%$4&;\JVK1P%)Z\,D;$GSU0WN<H0*^!I^92*Q/
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M6P%)+@$^::*4 )M[((#E(<*3-$?X<)8B3C*G;;@N*K[H]A!;%MDO>/]PIU,
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MHU3,\452DLJDNE@:J70,%_.$-?;$]78%VIK14(#,*D#*6A0=,6_6PD1Y?Y*
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M!EMJW<+3.48G,V;,TG0I+)M,2<S(&"7Q<=V% 7P EJJK)1 )W5*54!2I)"<
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MK/B3JB11F^\<HYO+;2K)>VC=OY?L!V*\ZG06-SOS^"EU%TJI5(8^H#X#*E]
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M'-8I)_LFA36P_%()A:'@#AJ5+$T[BC''C0@L=E 0@ SX"1X>^Y%-</ )MK4
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M&#N)# =3IWSB,*$MI>/"MK@L/_*W(>;T#"<!NZ@^!N0>6<_0A;IS:E$W^J'
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M3#E]^UVA<!_RXA[6F#\""?V$WI*_9=B3/DL0;Q-A9A=O]Z,=+R0)ESGI+ZN
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M)SDN\$><]KW7TIPU?Z36?.-BG>:+A7A_R(/Y6[I9+<TYDVJY4XR^$O?I-F@
M@"%"XB4UQ>_(Y03SR]X><&^+Y!'T\5RZQVDL;N5-0@EWTD^:EKSA_M%(4*B,
MS%S:*># &#@'Q$CBB(9=^1#+M.ILSKSL.$T&L ;]N4!8K&84E(0<1^70Z-W[
MF]/(B:(!$64KYFI5/BT^)TB*/TBU>SI*&*6#XDRJ24+8\9K;$CTI7/S.>%<K
M3NFB D5'Y/]3IQ1N98%]#,JLU$IK6/J(,HO0\4>M$Y:I8*,[Z8P\HMJ)>2IU
MZ2D[>[G>>'A+Y.L=FD=6VE1TZ>$,,_!N<DI*(A-QN<Y7; 5)G/E%3%Q)<;_E
M06"1:V-S#'$2>]-,,VD1IH5J*0)^>9?=;_-MU7.KH9X400+8(!E@9))D&H)V
MJ4(3G.S,^5KK,/-6-[EZILA6[(R]$W5;D1G1>2W]PI,9,'JNG%8DF2_5N^!3
M34S^,W$\;R1^"0Y3'\='))R"S9;::\%)0S>WJW!0J4^DAOZ\D-+:QNRF!3/5
M+YS/YT?PZ-%T0>G3L XZ:,L_+$"I@-ETD9*KFWSMLP "+HRWAH D1GK'+F):
MF2X^:[%,H6)8ZZT>@6'J#IJ+1"F4G%F'B\DV>$"81^F!3TPH$4D+EC\GK*?&
M($B>>.Y%]A];H?7"?R+V.-!S3.0X(LV[Y8E"\(UL^CJ@$%*-./#J34(_J74"
MA^#V+C/,JA1I9+&@JJ\L>[HK1Q;#YLK'5#^:\::R!V*_!EL?J C$4>8DAP5'
M_5 !4>0[(L<95_K0.IPIUHOBQ1ASS=C,C)@^ 6K>(Z>V.W3L%5FM*T-,[)83
M'$^Z,/Q3*2F,2'DL-0!11M>*LA?K([;/9<OH& +L8AQW>,5E_:8 )XECN?'3
M#.JGNLQG+)K3 JDM##;Q6,P\I71LG6[ DH9"3PT>CQ*X(H2^L^BS/Z(?F,4T
MPM@MXEN9&-?:@ET[H&.CC@;6Z=N.MAS$Q,+\8*]I9+V &<&VD3+X>FRN#ANE
MJ=/)(WEJA)]E',35@)_FU&P&9<TGTGS6S((8SUE^8F</!P$>^\W",<F$R*B6
MGC4USBUN)]9ZI,JJW(;FM;(T@!*J*K>\MF!I+M;3A8M)9 "MV=]'@;L<DKE_
MF5K\O51'+J"&@)"Z5S,K##?$+V;XRBI]%*'-DY6_ O'>3G]YJ@BW5L#ZZZ<?
M3WU@'E+S@(BI7*'.8)1T-$S/AD&QNIHE*V:@T@E91@#5XY$? VQQ:S)=N!S7
M9$[@Q;+\$;F()+/?I=-$*X@Y><?S-B9H2R-=<?Z]CHU5E>'HD6ICW5,G8V&T
MJ3ZCY19COV%JQ(H%^Y.GBDRV4_9U\L,_*[.=X]U@9FI<_("@TCNGPCP\1AKT
M ]P* VA"FL5'Z-RF5D+,*S?&!F#110C''>G -1Z'!IHU2NX@@)&W4?M<N2WP
MP!4O?[^=NCZSL(JT*O?32,A5^%COJ88,FFW\6F=]G<JP_@)+?I?>%<1,^N(H
M<##[F3*H_,XPNB"(^J"R"MD7+B[+%!Z-B6(;H"?+TF>5U4(L7+2M7\-0#<25
MF.91B"ZA7N'KP6]4:#?!"*)2\>5Q<-0^<!QS(&0H4)+XH(2 J22#6WXU\=4)
M8EN4W!7GM/N3#IBF.P:NP?64#TRH'B@D!A8IRHPK!(P;NK)SD3G369U]!S(O
MON:(+E$;TRFEQ)@R.+IU7GK9#6E>7@:XI&@:B!D-BXPM<_8U,I2[.F>Z XDN
MJ"HCD.&P05!P$*^, [MTA;JGT@BS,NNS4(F)UU,,<G6=5C)54YW4WJ92RO[X
M2&U-V/A%>C(9;H%-4CB+PMV 7"5;HJN<F^=;74TSDDY=R%@N>1P\O$.-AO5R
MDF"]KFKLBI!+RRU^W6*VK++B=A#!LQ_$W4C8FQ9C9A:!2VN(&9I2K>'*E4"F
MODQ-CZN )HS5"&TZ#>IF!01LKYTF"XSZ-A3&XH;/$8.-.;U8KCGR<N2C>AO%
MI<*IF9)#1E#"GCPCD^;>7#]X]#WO5A9&#531,F#BF3CPD^MRBVC*@49A@=JJ
M,#GX3[8_-GHK+U#AS7%_#5;(I"JXN.2!%UL@G9_I(?4P_*T-='BE&LUSR:IJ
MH:L;Z/!EE05%S5#B[+;M-XFP4_]:XCKE(B#H+PK95RFLT;:1>M '=L[W&-WG
MP@IE),:#&E_0XD=>KD0C TO:!:=N\C<$'7_4;H7_!?8;MPIKNZ'(HAV&&R,P
M?%M6Y1C'(K36-HD"6P52$^R(DPE-SDH64['_=QXX9,*DFZK850G:'ECAYK>*
MS#3@\I*>%8FTCI1)OYXT!6CZA? 4'F@D!G5]L>% #)H:=H#"@$]>4/'M(8EF
MKM5CTLRCQC;.<_AKV(VFV](SFIZ34XML7W;*DA<7.M,W:>D%!C*F5:<0@Z^O
MQ^B>^A'5XA]9WV65FSRZ<?2^\[YSUG&:M[[@M&\5OHVINR%1[C?Q(*F>?U=H
M36_MD8 ]=>]!"T9  6DL-!%52.,*6T*0]5_D$^P;@?:) C/!?$X5WU^<LQ/]
MD*XZM-!.]"__NS<^_G[8/^KUNG<&LLD4XR.%W[I$=VR.B8-;0P-KQ]91CF0+
MFUVE[&OZ])0OM>7LQ2QYP/8#>E9DH;D-O0DVN\TD("+X:A&   'MME3II<"V
M(<ZBIAA9,1\LL96D"X]@\P)?9!3?L\+DQVD1$CZ3=%9=37@4_,XC=>.H]-UQ
MS2&\NB$LI"!%GJ^2.HLU&OL1N7VE08P;B2I]8,MAG6/JH^G=(0H32X& DJ3U
M%&%N"\WO(HHKB,HM4?W2@Y99#?L@K4 G=)YRZ1 K>6"N3N+&N//EA,33X@X$
M^;<K2\D1D]GRCGS9^#RWZ>8=J,*4<(?V1.7&90+WJ@@<DS:#S14S0'B0!E=Q
ML,=5IBIY?ND1_Y*7FR,'1[T:H=5 5%FFA^XX3* QT>R^*46]CS#:U'3HBK20
M,$#Q@\0S'+DLYS/I4YA228)[ZA!UZL[0DTYGPJ9C7>4DJ)>N]Y4O62FQ ,B<
MZ-#IMI.00L[/9@U[C^B4(*ZIDGS\3/P-%MI8^0 5U\(6_J0T#8UU<0MJ6OC4
M 2IS@/([\+&8I_4L) E40HF<L TUFQ_8#WKTXX\W[N6KBQ]\@ATAS05YFI;4
M:[UTO?T23BO5[2<+H$*S)]]5'?3/;*J%2ETT,?!A$+E\ 5.$H'3I"0D<AWCQ
M#04-&=L#<\=.+!@@:&/&I6VJN*PF9KRP,F$P.&B'@+[WSMF*!BH1%RY.]<D2
M%16T1$B^JW0-R[0O7'5+L6DI9KZ=NH9$%4A,;>,WG+O>"N=[9^'PK0/=^\!
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M!FO6)"37H1O4G#&&@I3?]1H]DFS%-M_./:$Z1AS';BEU=-Q[*;FL0V"L]$U
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MAE$JN1]772*HEEC(5!40L'FQ^)A9GM6C.9ZZUBE%?R$CE5!/<D[X6\FM6I=
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M%.[R9*E\G/@(KSI\W0CH-+HE;$XC%5E(V+R3WM\#EL2F> -Z09 R>JOI[B0
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M5EUNTA\!CL%03G@+3RW2W$XRZ6+2H[M(P;JY@TQ&F)=">3BXE6WHN8Q,(%U
M=]#Q>(,CDA[PM=:H)PUW\,5&"\]?!9$T.WAZS:'H.2+!MP\I!SV\:3^=CS^]
MFP#2#F'-3?YVBA?NU<WIU=E?D_>3\[%1E\9GM>['3\O4[# :,05P >]@SEK3
M8%,VS[K>90G^S%<-%0B8+^N#,URG<74AE!/RY>B\ %9-B?KW;I#P> 1EAY3]
MECD;O"X8KWG0,?^ZB*#6'6(.6Q\37LSE,9+_VLM9])U.OTDYP .T?="/SKKL
M820EXFP=_M$UK"#V\ %XX_MP"(;(/-O00[NO9 8T<V+*^'&K3?\U\3XJ3!$$
M6[S0.DU"[H!@X29RKM9Q<Z!^\68)IE'DU:BME<R.VSX "U0;8M>'.+EVCWYX
MDX/GAOQL!YXS5P/,K(,_ANJ6@WS=)B4@-5%KXU\"ZW]*E?WNY%RN,,--+.7"
M-(K0^>XH7#M#^I&&(M!84P?O$#4.AF'D[(^LO805L@VUB>3XZ?I=<O#F<'Q/
MJ+782^4;/7XCD(^SIV,;+A8(Q.O[="F\<(RP);@<%]YR_/L9U!1#/+@ <>N2
M<DSA#3A9UU)?1([;)4&USI*W+S97O=C& -QI/Q0_-=L8^[0=^Y2-;V80M%#)
M9_ ENRS)Y#^3^ J*E8A399/5,X?6XQT#>4N0/D',6A*7Z=%B2[WH<$\I(>DC
MQ2&I0/ZQC4[!B_8_DS=APBM9Q^P*VZ&!G. W?!D?4W43V'%U ^WHI,Y72[TR
M8K]MJ/8O7;+R[4M2>($>*[;:B?:EQ9U__XBR4$"#[D9%^><$(LS#]D58*FO%
M%Z+*GE+06!KB4)<M,IP#@:9KLH,;J<P5+$CR$>HT<)QU'6Y1=?;+^,/'=+V3
MA\3Z>D=G[G^O[O[W;V"#KV1.W9*&A4M<J1H<'R$_X<E<Q>^RQ1SL-@B^M(90
M$.:S5?SH]&F>KV890:.3?3;#C^93-NFS&-Q(9ND+,(9W)2P-$^WO.-1CG<T?
M;[?KW&%Z;S>+N6$Y[*,NMM&*$O/9ZCG9@@M#BL8+M+R%V&I8H[@++OF"RVM&
MNFO%WU-I\ =S&!%=EH([U^G3BZO[)$4Y&_6;O89$@YG?[K>T=_,P7\^^_S!_
MP4JI"%TZ-8PFH^(AF#J)X4-EM\]H%&7<1$=H&'L"VS:"RS](-H-$ZA5AV\NI
M2MB/!6RQ!;4P@Y/X!R?2K UU 8E'AQN]+'V:E7K4#E+( P:M?EG@7J[4RSJ:
M\P(<J3?9LNS. /2O<(!RT>+R('IZ6"O;B\@D!RY%3K$>,8N>5@<T$6O2R/]S
M>+.2!/JMV)H:53_RJ; L=V8QXK^PJ\%;'$T&= U"!.''NR QX03Y]I8PX&U4
M\AS8(A3G\AE;,-@HPWE=MU!<'@LK;*37O*Q;D3!P6R$X#QM"9.1%<HO8C )K
M:79VC:Q39A+9S#V:FTDP]ZZY@?L+*A_$^B-%7X'BD;V\NBIZU?53*VUR!\"Y
M!^=>V1M*7DN$'IT!G+)I9L952A4X>'@Q.XM(^%U8$JQJ! [!#S%52N%BPGYJ
M/_JINHK4GH\WP@@0SR D;!R=KZ%$1C[98?)(DIE1FH%4@QNS) .Z45)&."#+
ML,QG\,C'ZP[: DG*,22S2[X]6:W-706GQHC3,\8BRDL?MVW#+S"5TB?M7D:)
MI^0EAYB)0)EECWE0LR'(;*4D&!9.N&,/<Z&90)6+[SYJ,03DJ6 [RT;>B3=R
MDCZ1???F>65%?\ S-KN1@3)@[O[[!__;Z_E7_+*L*S=3\9$"VM-M.OU=7TT!
MD4(1R>T"EZ2DR,3JSL]>=UQ)5)ABH[;.0=E8U5X$*S:*+YFK3#'1Y1)VKT9%
M7WN6M8BI];00P*S?VQ(-,B9SUXC 4SK,&DWP;5C6Q""^7K;&1CDGX!OB6LI'
M[#'NZI=WC%C3G/4N*V3I:FK+#XU.S9KD#MVY^DJMP(_?6::C?!^]:AVERU9V
M*\>GWB#<AACYEM;UJ&PY<RTO X1N;W^^M0)'3:NG>H^9.FR6PHDT# P+<LZ2
M"\#:@RQPC < :^4*XDCY [#35]\(4< V[=B2PE@4.%4Q4BYBP=4N:I%[$ [(
M88):M;(K=B3A<_Q?%:F_JGQ%,%*=612+D*\J4/&M(^(J%8&(4%*?(BI*6*RA
M6D37KC2M#2J_'59^.ZK\MM6L_!IM<<VX!Z#2KE]B7OOS=KGS&6W_*V]G<0PI
M^-I&6#FNFG.XF&[,LYU:[>*S[6:M=F/VRK_6<9Y(@\'#WL45*3)BV(B#0\#4
MLC%ALH%.4<63+(9%V2$ZJE!3 O(BE M#9:R?M+M1_:0&I'^,=R9E@)O_JA!$
MSQ%!M(PCOE^LUO-9JF6&R?)NCADWH&B<% 2*.N9_M0T--M<^R5Y@FE_E"XXW
M$8PR.0]H+=9H<BJC,J^98ND!5].U\C57^%6!;1?+PY8J15P9&S09K'2B"JMP
MG9.(J<\K+FE+:$#)/9L5CZ:WW8U#_5/6B/\S"8[,*:&=,ZPWMS'+'I>N%*.M
MQ@(3AI!8?0E3AJ8J/!/8D;/E$@LH^P13K05_R%;K^WFZ+XU]-#N33A^V -V=
MZY>-S+("N2N;.6U<?5W/J?1]6X?WM'8-;E'+L_[+AK"?MES:O1>[#7_,M6;S
M[2O\RO;IS7H\[P_H>[_%/<^>D[^:T[4OT==]SWSL%43!6 "0=%&0YY(G-;@W
MN$Q=L:Z3E>$62S"A>>C%;(IUE6:5T.QTPW]1DC.F8C:J!<(=1;<"V6%7S:WP
M!06"JD(K@/&QVO-+9C1-\,M?IX;E[G8>'Y5>3%JRZ928LMWZ"2[5-5;%@#U3
M/;]3!5+?OL"?AF&;SXU6NGW*83-8=2J;8*6Q/'[UZCS5NJ^8,88/E]"J6N\C
MLZY'.:QWZ1DH$0^^F#U(Y6Z$%FJ^:&863BK;2+P,480+:+CB6F!1(J_2"CFV
M[38SX]-0@:6^#669KC3"5M9%JJ=]702R4A!J&9I-76!'<H*[G5RL?<Y0RF&H
M3K/R\MR O^AZDSTE%\M:H1Z55=#VWINW%@^/*]*4+7@#*R1M,O!NWNF^D45H
M501X7"" D7Y=TL>.V=7;YKHSMFZB8&^44A/L^;?=*<ZY4$?^^:;EN$PA:_ A
MP\*IAW4-7Z#U9&AIC[DVPOIY__I.:L^ZBND%YBT.\*,D5GMI_WT+JQ=5< _G
M=0\&'J]C].WS>^V\.&,P7LLHN$;*RAG%^5JTJE&X;+:VT;>L0K' T?XK49Q<
MR4KYN96A.;JTP%'4F>/R&H,SKZH=E3MV;+3%R?BRO*V2VD?!KGDED/*5*H$4
M'H="):1OIV!7R.1"%T?9=QMK5$(*Q[J[&%*U%6C_89*'V%6JKF>M)S>^%36G
M?HF98#]-B[]LES.8VL=B@:)2_@\.U^);I85]2ELIK,].(;[X?K?2/#S>WA]S
M]9Z]0C5AP=/%(A:G2%E""ZD(@U)[>%%]!2JA%)CIJNI17J<[7B<7S7B[6J\9
M&3]],M^&I(4B@KFJ[^"ZK@@I"$8'^<17V:.A=VC>9:M<"GI0>=P"DI40HS8%
MNDI-<[=V.1HK2Y>R2-MD:C-:)0\$[,)4&BLTF6. Y2D8?/>9P'L,BP+*W>.E
MW4?!CI/#"8+AXC[BR:UL9VQ1ITL/4G@[8"VA"ZDE5+)29X8+2U/6_E'CD)^8
MK8-4CL<Y!,7'(W>+Q; :A1)=KJA6X%0Z[H<1>,$H2\=6/#JI+FNI1X!(-E+K
MYKWA63E^7FP0:QB5]/*^9B^%*F.!OR$6<QAVX2J2/5)9J15<BSD#QHYG7S .
MX'7M%.N@E;4631OQ U\]?"R)SJ5<1;!!@YCU=G+S;DQAP/?FR*7+C;EOGQ],
M_R]'D#HRP]C)^6QNI!AT 3 <2N E[.T>SHY>ZW4TB(:%EA*EX7!P?>(E5!ZY
MXI;<UNS4V3%1QQ0ZI/89!["UZG&TV<NU5ZL/ %1<W6[G%>U>S[_N:+5?TFK@
MY_./(0AT6 D8/7N6Q87D/0BWN1WC %P&[P4#:,LDC#_]K_\%L#3!RL0:'),I
MC 2C+5:IH[!<X?E3G[,%\IJ*!5@@_Z=HX^@%4"I@*#ZV6]8HBK%E^GM!K"W3
MY#VY++RRE@!Z[T!E8K=*Q1&K4=TQ0@R#LGWG\H>^^%XYNTCAQ8U=NO)0*I8L
MS>/X-(:,/!B)W4KTP=;6JG=8*CI?07Y0I3T/)195IM *\Q5*B#^H\(KM1I)\
M"C),[,5./%B_. ,P5M]*V<5R]Y+<A?A<K5:#FHYEC=/;P(O+GL!"C+M?JS65
M5HR_1-O:=P+(]BNF4-JM]V*M292\N.>(4:TI'W"[;,V]]_88;_&]VL/U4B/V
M3W0>[*''QE-X57E-YZVJ/-0.8\B65"L^ F9=H_$N"3N)@DHBA<**K_D5\&QM
M'2Y^'(Z<KP#$_<K,W;699UY5)16<XZPZ.A*CS+A3TK1487YUN\ZK!06DO\QG
M6RY4"+&*V]N_,_2F]C>5YEY_TB"@L'UO9;TX2L7L[!K-A888\)?8+CE?&7B\
MRM5>TS[SXQ-51*[\5!AQ&JNX@,/A'277D);I&JKJBZLD!A<[EM"IV]!X@?D]
M&/\H<=DU7J.BD#4>=";()#!![LSV\'.BRBZG'='D,$B*(%H9*L5"'5]3P6T+
M;[H=T>6V&.89%L/\LY%;\MF<$D%U]$1]LME5JC PR;!:7CI?Y"0.R0;\_7$.
M6M>DRCTVQ"Q:OBA8(;3TN3J5?4O[ELROG9V7/<A%>,L?4%R>G1TZPG+O5:M1
MH#:<2UAI-KZ]X1(&;<6JS9:*MM>V$"P\'#/$=*+VA*KBL,Y;4Z-,;&"F/AZ&
MO4$9V>8/P>![L6<CA69#&2>210R%:",]-\'R%O2,I6DC3P]!:H]@']7RFAR@
MS2MXFXK;1KYHQHR"Q?*W06M8!3?26CLV_9-H5>8,:0IN#ETG,D8[P^-19)6P
ML&YD"%!G-S8&6^]V14@PD:*[^RO6U15O@\?K%;T-7MM5VS8X5R7IG>5R0/6E
M45JM-G8;U7@LGO!3>I&7^$7+J\[&R;DJ8'E'[=F FA9F8BY,>'47I::TD"?T
M"F]DV*AN$):[W, !,9A\9];8DZN@6F>Y^+OO,:G6.AJJ_F9)+- K"G"^L@E5
M4#-<H;UK<@:FE^KRG*%IKC1,8=>29I6Q52<<PGYMLZ6(95 1D!/M;_\NT:N4
M-]2)8WQA$E!S@%^VHZPLB8Q+ >Y X*=^3OR98U*@=EC/!(M/\MW&5.PVDO7N
M/7V9KB' #T68&6?=74+6:2RZ]G(M![!F5\47]NHM-BNJ=UKGR8L*');X-.)M
MESQ<U;SG7G)878:PKI4S*5!94=+EZV[,9;!%%0NJ'G!1@EJ-R#9YL;380/70
M2<HVBWN+Y;U^6S'NUC.-!.SD)USWAD)6M^O*&?JM?Z0"89S9NDD^8Z+,J=&,
M4220(KBY>?#%)7U=V[IF>M.+/0VC<GKU,2$=44(@;E9)51G>N+VAI&1OB7(R
ML14'?Y,2,GZ9UPH:V_FNU)2,A0G6?CG4,Q5[)>HJ#YIP6;Q"M<5=:RCXND"I
M:$8]JIH_\@!NP'^Y!DMPNM1X273RRFW@<>BPH,!4N1$$OO5X^6E\GU5:+[W$
M9[=1LW1)I3TO6L5J9\FO&JG'>.E$6R\I=%B"Y;(S2;)F22]$!U75@.C3<I]U
M=#"703DAG"?@Q:SO#3,**PU*>:,,PH>_8>C$[7:,^J,NB?--(XNU%"+>2>T8
MQP-WSC>)S%>* NW8C*2]"\Y',:&=C7&H0]*/-O4;E[>\M%6G(C=C0*IED0[]
M$HP952(8[;KU&>DFV^\**3-9>>X;)]#2SZ"'Z\O+7<(.R/R&HWJX.."SJ@3&
MH4QL2,IR74AI^O]4<G8@,DOE)<+FOW$5W>F#4GL]U7:W;W%I]^J7J,B[?4?7
M>*]^T59[M^\JM/@=?>H)]HL3[->98+\PP?*7W 3[L0F6O^A-L!^98/FKWI&U
M"1U*V8J>Z6]2PIPH')&3&HE+^GE;DI#CG5![%Q<E[.K7[,'>]T57'.R]+@YV
M2L7!=K>V8_:<BU1KZEI$W-UQO<6.R#1^H?6:N_%-K:C-^:9V=NW5GHW7V+#O
MT^;.6O:!NL1W:L]>T'"I%I]BV+"D8P6ZW==XD<J^R[Z6-%5WEDX,B<L.Y9)W
MM))B0US&@3AQW!H%^D59$R2;A4WTAB%D;J108V4KO>[Q,!Q)13/Q^?0ZQ]UN
M>3,@ 94(3DE9J&=/A#FK))C?:BD)^UXY.Q4>J?8>&'&-!!.77J0N9-GW/-ZR
MKQU/*7NB=(R^5;3R_<BBY<2VJ]E.O(AFE3!7VMN>ZN[K.J$/_]@^[([]L=WL
MO!*^0U^Q<U/]NF?!V$_B*C> [)1VBF_*-N_]XC?+795+4"UV[;E\K[4+E2[6
M=VIN;W'H==WL)Q[5[B-BMZA%^U@G.;CUH&9RG1LU<A5WPAN]K+YRS(!MB^4N
M$;!E,V=PDMI1YN#":E,,O8!EYE=9/I_%_'-&@3U.6D,O//0$:JZ&WOVGM<7
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MX>O<#.>HH>K.+-$&8SC87XSP8-[/6O2(& [V+<Y(PRYMP>'_1/(34$L#!!0
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M'A26@P(]2)>#E!X4EX,B/2@M!R5ZT.-RT",]R&Z!C%M^$L*:K[4%7%N^UQ:
M;?EB6T"VY9MM =J6K[8%;%N^VQ; ;?ER6T"WY=MM =Z6K[< O86OMP"]985W
M;?2RS==;@-["UUN WL+76X#>PM=;@-["UUN WL+76X#>PM=;@-["U]L!O1U?
M;P?T=GR]'=#;K7!6@@Y+^'H[H+?CZ^V WHZOMP-Z.[[>#NCM^'H[H+?CZ^V
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( #Q 84KH(IE#[@   "L"   1
M          "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( #Q
M84J97)PC$ 8  )PG   3              "  ;8"  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ /$!A2J$YNP2P @  " H  !@
M ( !]P@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( #Q
M84H=&8)O3@0  ((4   8              "  =T+  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    "  \0&%*>NF- *4"  "R"0  &
M        @ %A$   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ /$!A2OI,3U=U!0  D1P  !@              ( !/!,  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( #Q 84J#'VO@9 (  -X'   8
M              "  ><8  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    "  \0&%*Z("U?%0(  "[.   &               @ &!&P  >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ /$!A2MI6*_DD!P
M3B@  !@              ( !"R0  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( #Q 84HV0-<0L0$  -(#   8              "  64K
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  \0&%*F(K*
M%K4!  #2 P  &               @ %,+0  >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ /$!A2O(RH5&U 0  T@,  !D
M ( !-R\  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  \
M0&%*')50.+8!  #2 P  &0              @ $C,0  >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( #Q 84J.28ISM0$  -(#   9
M          "  1 S  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#
M%     @ /$!A2OLI79FU 0  T@,  !D              ( !_#0  'AL+W=O
M<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  \0&%*D43ET+0!  #2
M P  &0              @ 'H-@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM
M;%!+ 0(4 Q0    ( #Q 84H>F9R,M0$  -(#   9              "  =,X
M  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ /$!A2ITF
MOMNW 0  T@,  !D              ( !OSH  'AL+W=O<FMS:&5E=',O<VAE
M970Q-BYX;6Q02P$"% ,4    "  \0&%*/=N)E;0!  #2 P  &0
M    @ &M/   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M #Q 84J_G_R3M0$  -(#   9              "  9@^  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ /$!A2GW8<6.V 0  T@,  !D
M             ( !A$   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    "  \0&%*]:]BQK0!  #2 P  &0              @ %Q0@  >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( #Q 84IMV0YTM0$
M -(#   9              "  5Q$  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ /$!A2I"#=S^V 0  T@,  !D              ( !
M2$8  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  \0&%*
MM,5+M+,!  #2 P  &0              @ $U2   >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( #Q 84J=R;KKMP$  -(#   9
M      "  1]*  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ /$!A2GG0DC6V 0  T@,  !D              ( !#4P  'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  \0&%*%#K-E7P"  #<"0
M&0              @ 'Z30  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( #Q 84H=^O$QXP$   $%   9              "  :U0  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ /$!A2@/K>JJW
M 0  T@,  !D              ( !QU(  'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    "  \0&%*8Y;)L;<!  #2 P  &0
M@ &U5   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( #Q
M84K$1J6QX $   $%   9              "  :-6  !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ /$!A2I9<&PO3 0  G 0  !D
M         ( !NE@  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M    "  \0&%*[F;YRN !   !!0  &0              @ '$6@  >&PO=V]R
M:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( #Q 84K_*3$FWP$   $%
M   9              "  =M<  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL
M4$L! A0#%     @ /$!A2D@?P4/$ 0  -P0  !D              ( !\5X
M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  \0&%*=1S$
MU[@!  #2 P  &0              @ 'L8   >&PO=V]R:W-H965T<R]S:&5E
M=#,U+GAM;%!+ 0(4 Q0    ( #Q 84H3VJ:"MP$  -(#   9
M  "  =MB  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
M/$!A2D50X#>V 0  T@,  !D              ( !R60  'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    "  \0&%*630ASK<!  #2 P  &0
M            @ &V9@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4
M Q0    ( #Q 84I6E.B?MP(  (,*   9              "  :1H  !X;"]W
M;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ /$!A2O5S%;RB!0
M[A\  !D              ( !DFL  'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6Q02P$"% ,4    "  \0&%*9Q!=WFL"  "?"0  &0              @ %K
M<0  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( #Q 84JV
M5X#\*@(  )D&   9              "  0UT  !X;"]W;W)K<VAE971S+W-H
M965T-#(N>&UL4$L! A0#%     @ /$!A2A$[-M^] 0  100  !D
M     ( !;G8  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #Q 84HG0Y^R%@(  .8%   9              "
M 3V&  !X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ /$!A
M2@5$*% $ @  J@4  !D              ( !BH@  'AL+W=O<FMS:&5E=',O
M<VAE970T.2YX;6Q02P$"% ,4    "  \0&%*G/G';I0#  #;$   &0
M        @ '%B@  >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0
M   ( #Q 84IS_8!5YP,  )P3   9              "  9".  !X;"]W;W)K
M<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ /$!A2K-WB6<@ @  . 8
M !D              ( !KI(  'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q0
M2P$"% ,4    "  \0&%*=J78@P@"  #]!0  &0              @ $%E0
M>&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( #Q 84H(UMT$
M'@(  (<&   9              "  427  !X;"]W;W)K<VAE971S+W-H965T
M-30N>&UL4$L! A0#%     @ /$!A2HD8RNF! @  3PD  !D
M ( !F9D  'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    "  \
M0&%*"Z]A(O(!  !N!0  &0              @ %1G   >&PO=V]R:W-H965T
M<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( #Q 84JZ!QZ/9@(  *D(   9
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M970V,2YX;6Q02P$"% ,4    "  \0&%*RZ'L[O8#  !"%   &0
M    @ 'FK@  >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    (
M #Q 84HO<K>^J@(  +L)   9              "  1.S  !X;"]W;W)K<VAE
M971S+W-H965T-C,N>&UL4$L! A0#%     @ /$!A2EV<^>EO @  /0@  !D
M             ( !]+4  'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"
M% ,4    "  \0&%*,T>R,70"  #N"   &0              @ &:N   >&PO
M=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( #Q 84H/H,%_# ,
M ,0,   9              "  46[  !X;"]W;W)K<VAE971S+W-H965T-C8N
M>&UL4$L! A0#%     @ /$!A2A -YY[, 0  900  !D              ( !
MB+X  'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    "  \0&%*
MX[!V!5<"  "2!P  &0              @ &+P   >&PO=V]R:W-H965T<R]S
M:&5E=#8X+GAM;%!+ 0(4 Q0    ( #Q 84KU#VYPMP4  /<?   9
M      "  1G#  !X;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%
M  @ /$!A2B?-H ]> P  ^0\  !D              ( !!\D  'AL+W=O<FMS
M:&5E=',O<VAE970W,"YX;6Q02P$"% ,4    "  \0&%*IP6FBZ<#   /$
M&0              @ &<S   >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+
M 0(4 Q0    ( #Q 84J?+ET77@(  (@'   9              "  7K0  !X
M;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ /$!A2E!SJ@K:
M!   7A@  !D              ( !#],  'AL+W=O<FMS:&5E=',O<VAE970W
M,RYX;6Q02P$"% ,4    "  \0&%*E#U5[S,%  "]&@  &0
M@ $@V   >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( #Q
M84KD6:J]408   HG   9              "  8K=  !X;"]W;W)K<VAE971S
M+W-H965T-S4N>&UL4$L! A0#%     @ /$!A2I8^>E.D @  D@D  !D
M         ( !$N0  'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"% ,4
M    "  \0&%*(TLZW58"   E!P  &0              @ 'MY@  >&PO=V]R
M:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( #Q 84K%+M^\: (  !4(
M   9              "  7KI  !X;"]W;W)K<VAE971S+W-H965T-S@N>&UL
M4$L! A0#%     @ /$!A2N:4GMDW @  /@8  !D              ( !&>P
M 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4    "  \0&%*!2=9
MG,0#  !X$P  &0              @ &'[@  >&PO=V]R:W-H965T<R]S:&5E
M=#@P+GAM;%!+ 0(4 Q0    ( #Q 84J[/1^@I0(  *X)   9
M  "  8+R  !X;"]W;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%     @
M/$!A2M>((]\C P  < T  !D              ( !7O4  'AL+W=O<FMS:&5E
M=',O<VAE970X,BYX;6Q02P$"% ,4    "  \0&%* N0"F[X!  #2 P  &0
M            @ &X^   >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4
M Q0    ( #Q 84JDD?ZJ808  +LF   9              "  :WZ  !X;"]W
M;W)K<VAE971S+W-H965T.#0N>&UL4$L! A0#%     @ /$!A2A\)+:[M!
M'AD  !D              ( !10$! 'AL+W=O<FMS:&5E=',O<VAE970X-2YX
M;6Q02P$"% ,4    "  \0&%*D*^&4PH"  #;!0  &0              @ %I
M!@$ >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    ( #Q 84I1
M=MQ)S0$  #<$   9              "  :H( 0!X;"]W;W)K<VAE971S+W-H
M965T.#<N>&UL4$L! A0#%     @ /$!A2N/UH"99XP  >'@# !0
M     ( !K@H! 'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ /$!A
M2EI>((A8 @  7 P   T              ( !.>X! 'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    "  \0&%*#5W!6Z\'  #6.   #P              @ &\\ $
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ /$!A2BE ZIBG @  VC,  !H
M             ( !F/@! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ /$!A2H;T"W(Y @  53(  !,              ( !=_L! %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     &  8 !2&@  X?T!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.6.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>337</ContextCount>
  <ElementCount>506</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>119</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>16</UnitCount>
  <MyReports>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000103 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/StatementCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000106 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000107 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000108 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>010109 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>010110 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010111 - Disclosure - ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONS</Role>
      <ShortName>ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010112 - Disclosure - DISCONTINUED OPERATIONS AND ASSETS HELD FOR SALE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DISCONTINUEDOPERATIONSANDASSETSHELDFORSALE</Role>
      <ShortName>DISCONTINUED OPERATIONS AND ASSETS HELD FOR SALE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>010113 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>010114 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS</Role>
      <ShortName>DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>010115 - Disclosure - LONG-TERM OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONS</Role>
      <ShortName>LONG-TERM OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>010116 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>010117 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION</Role>
      <ShortName>CAPITAL STOCK AND SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>010118 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>010119 - Disclosure - EMPLOYEE BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>010120 - Disclosure - SHARE REPURCHASE PROGRAM</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SHAREREPURCHASEPROGRAM</Role>
      <ShortName>SHARE REPURCHASE PROGRAM</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>010121 - Disclosure - EXIT ACTIVITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/EXITACTIVITIES</Role>
      <ShortName>EXIT ACTIVITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>010122 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/VALUATIONANDQUALIFYINGACCOUNTS</Role>
      <ShortName>VALUATION AND QUALIFYING ACCOUNTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>010123 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATION</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>010124 - Disclosure - UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION</Role>
      <ShortName>UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>010125 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>010126 - Disclosure - SUBSEQUENT EVENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUBSEQUENTEVENT</Role>
      <ShortName>SUBSEQUENT EVENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>020010 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureNATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSPolicies</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>030010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>030015 - Disclosure - ACQUISITIONS - PRO FORMA CONDENSED CONSOLIDATED INCOME STATEMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureACQUISITIONSPROFORMACONDENSEDCONSOLIDATEDINCOMESTATEMENTTables</Role>
      <ShortName>ACQUISITIONS - PRO FORMA CONDENSED CONSOLIDATED INCOME STATEMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>030030 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureGOODWILLANDOTHERINTANGIBLEASSETSNETTables</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030040 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables</Role>
      <ShortName>DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030050 - Disclosure - LONG-TERM OBLIGATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables</Role>
      <ShortName>LONG-TERM OBLIGATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/LONGTERMOBLIGATIONS</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>030060 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/INCOMETAXES</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>030070 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureCAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>CAPITAL STOCK AND SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>030080 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureCOMMITMENTSANDCONTINGENCIESTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>030090 - Disclosure - EXIT ACTIVITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/EXITACTIVITIESTables</Role>
      <ShortName>EXIT ACTIVITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/EXITACTIVITIES</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>030100 - Disclosure - VALUATION AND QUALIFYING ACCOUNTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureVALUATIONANDQUALIFYINGACCOUNTSTables</Role>
      <ShortName>VALUATION AND QUALIFYING ACCOUNTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/VALUATIONANDQUALIFYINGACCOUNTS</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>030110 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/SEGMENTINFORMATION</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>030120 - Disclosure - UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATIONTables</Role>
      <ShortName>UNAUDITED SUMMARIZED QUARTERLY FINANCIAL INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/UNAUDITEDSUMMARIZEDQUARTERLYFINANCIALINFORMATION</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>040010 - Disclosure - Nature of Operations Consolidation and Presentation of Financial Statements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureNatureOfOperationsConsolidationAndPresentationOfFinancialStatementsAdditionalInformationDetail</Role>
      <ShortName>Nature of Operations Consolidation and Presentation of Financial Statements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>040020 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040021 - Disclosure - Schedule of Estimated Useful Lives of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentDetail</Role>
      <ShortName>Schedule of Estimated Useful Lives of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>040022 - Disclosure - Schedule of Balances Related to Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ScheduleOfBalancesRelatedToPropertyAndEquipmentDetails</Role>
      <ShortName>Schedule of Balances Related to Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>040023 - Disclosure - Schedule of Financial Instruments Where Carrying Value and Fair Value Differ (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ScheduleOfFinancialInstrumentsWhereCarryingValueAndFairValueDifferDetail</Role>
      <ShortName>Schedule of Financial Instruments Where Carrying Value and Fair Value Differ (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>040024 - Disclosure - Schedule of Weighted Average Shares Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ScheduleOfWeightedAverageSharesOutstandingDetail</Role>
      <ShortName>Schedule of Weighted Average Shares Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>040030 - Disclosure - Acquisitions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureAcquisitionsDetail</Role>
      <ShortName>Acquisitions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>040035 - Disclosure - Acquisitions - Pro Forma Condensed Consolidated Income Statement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureAcquisitionsProFormaCondensedConsolidatedIncomeStatementDetail</Role>
      <ShortName>Acquisitions - Pro Forma Condensed Consolidated Income Statement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>040040 - Disclosure - Discontinued Operations and Assets Held For Sale - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureDiscontinuedOperationsAndAssetsHeldForSaleAdditionalInformationDetail</Role>
      <ShortName>Discontinued Operations and Assets Held For Sale - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>040041 - Disclosure - Net Revenues and Operating Results (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NetRevenuesAndOperatingResultsDetail</Role>
      <ShortName>Net Revenues and Operating Results (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>040050 - Disclosure - Goodwill and Other Intangible Assets, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureGoodwillAndOtherIntangibleAssetsNetDetail</Role>
      <ShortName>Goodwill and Other Intangible Assets, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>040051 - Disclosure - Summary of Activity Related to Goodwill (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureSummaryOfActivityRelatedToGoodwillDetail</Role>
      <ShortName>Summary of Activity Related to Goodwill (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>040052 - Disclosure - Summary of Activity Related to Other Intangible Assets, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureSummaryOfActivityRelatedToOtherIntangibleAssetsNetDetail</Role>
      <ShortName>Summary of Activity Related to Other Intangible Assets, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>040053 - Disclosure - Summary of Activity Related to Other Intangible Assets, Net (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SummaryOfActivityRelatedToOtherIntangibleAssetsNetParentheticalDetail</Role>
      <ShortName>Summary of Activity Related to Other Intangible Assets, Net (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>040060 - Disclosure - Details of Certain Balance Sheet Accounts - Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsOtherCurrentAssetsDetail</Role>
      <ShortName>Details of Certain Balance Sheet Accounts - Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>040061 - Disclosure - Details of Certain Balance Sheet Accounts - Other Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsOtherAssetsDetail</Role>
      <ShortName>Details of Certain Balance Sheet Accounts - Other Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>040062 - Disclosure - Details of Certain Balance Sheet Accounts - Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsAccruedExpensesDetail</Role>
      <ShortName>Details of Certain Balance Sheet Accounts - Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>040063 - Disclosure - Details of Certain Balance Sheet Accounts - Other Long-Term Obligations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureDetailsOfCertainBalanceSheetAccountsOtherLongTermObligationsDetail</Role>
      <ShortName>Details of Certain Balance Sheet Accounts - Other Long-Term Obligations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>040070 - Disclosure - Long Term Debt (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureLongTermDebtDetail</Role>
      <ShortName>Long Term Debt (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>040071 - Disclosure - Long Term Debt - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureLongTermDebtAdditionalInformationDetail</Role>
      <ShortName>Long Term Debt - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>040072 - Disclosure - Long Term Debt (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureLongTermDebtParentheticalDetail</Role>
      <ShortName>Long Term Debt (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>040073 - Disclosure - Maturities of Debt (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureMaturitiesOfDebtDetail</Role>
      <ShortName>Maturities of Debt (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>040074 - Disclosure - Commitment Fee Under Credit Facilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureCommitmentFeeUnderCreditFacilitiesDetail</Role>
      <ShortName>Commitment Fee Under Credit Facilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>040080 - Disclosure - Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureIncomeTaxesDetail</Role>
      <ShortName>Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>040081 - Disclosure - Total Provision For Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureTotalProvisionForIncomeTaxesDetail</Role>
      <ShortName>Total Provision For Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>040082 - Disclosure - Income Tax Expense Allocation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/IncomeTaxExpenseAllocationDetail</Role>
      <ShortName>Income Tax Expense Allocation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>040083 - Disclosure - Sources of Tax Effect (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SourcesOfTaxEffectDetail</Role>
      <ShortName>Sources of Tax Effect (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>040084 - Disclosure - Components of Net Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureComponentsOfNetDeferredTaxAssetsDetail</Role>
      <ShortName>Components of Net Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>040085 - Disclosure - Classification of Deferred Tax Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ClassificationOfDeferredTaxAssetsAndLiabilitiesDetail</Role>
      <ShortName>Classification of Deferred Tax Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>040086 - Disclosure - Reconciliation of Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureReconciliationOfUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Reconciliation of Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>040090 - Disclosure - Capital Stock and Share-Based Compensation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureCapitalStockAndShareBasedCompensationDetail</Role>
      <ShortName>Capital Stock and Share-Based Compensation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>040091 - Disclosure - Employee Stock Purchase Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureEmployeeStockPurchasePlanDetail</Role>
      <ShortName>Employee Stock Purchase Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>040092 - Disclosure - Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureStockOptionActivityDetail</Role>
      <ShortName>Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>040093 - Disclosure - Non-Vested Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureNonVestedStockOptionActivityDetail</Role>
      <ShortName>Non-Vested Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>040094 - Disclosure - Non-Vested Stock Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureNonVestedStockActivityDetail</Role>
      <ShortName>Non-Vested Stock Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>040095 - Disclosure - Non-Vested Stock Units (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureNonVestedStockUnitsDetail</Role>
      <ShortName>Non-Vested Stock Units (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>040100 - Disclosure - Commitments and Contigencies (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureCommitmentsAndContigenciesDetail</Role>
      <ShortName>Commitments and Contigencies (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>040101 - Disclosure - Future Minimum Rental Commitments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/FutureMinimumRentalCommitmentsDetail</Role>
      <ShortName>Future Minimum Rental Commitments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>040102 - Disclosure - Insurance Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureInsuranceProgramsDetails</Role>
      <ShortName>Insurance Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>040110 - Disclosure - Employee Benefit Plans (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/EmployeeBenefitPlansDetail</Role>
      <ShortName>Employee Benefit Plans (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>040115 - Disclosure - Share Repurchase Program (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ShareRepurchaseProgramDetail</Role>
      <ShortName>Share Repurchase Program (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>040120 - Disclosure - Exit Activities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureExitActivitiesDetail</Role>
      <ShortName>Exit Activities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>040121 - Disclosure - Exit Activities - Reserve Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureExitActivitiesReserveActivityDetail</Role>
      <ShortName>Exit Activities - Reserve Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>040130 - Disclosure - Valuation and Qualifying Accounts (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureValuationAndQualifyingAccountsDetail</Role>
      <ShortName>Valuation and Qualifying Accounts (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>040140 - Disclosure - Segment Information - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SegmentInformationAdditionalInformationDetail</Role>
      <ShortName>Segment Information - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>040141 - Disclosure - Operating Income of Reportable Segments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureOperatingIncomeOfReportableSegmentsDetail</Role>
      <ShortName>Operating Income of Reportable Segments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>040150 - Disclosure - Unaudited Summarized Quarterly Financial Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureUnauditedSummarizedQuarterlyFinancialInformationDetail</Role>
      <ShortName>Unaudited Summarized Quarterly Financial Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>040160 - Disclosure - Related Party Transaction (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/RelatedPartyTransactionDetail</Role>
      <ShortName>Related Party Transaction (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="amed-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>040170 - Disclosure - Subsequent Event (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DisclosureSubsequentEventDetail</Role>
      <ShortName>Subsequent Event (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>amed-20161231.xml</File>
    <File>amed-20161231.xsd</File>
    <File>amed-20161231_cal.xml</File>
    <File>amed-20161231_def.xml</File>
    <File>amed-20161231_lab.xml</File>
    <File>amed-20161231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>111
<FILENAME>0001193125-17-063925-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-17-063925-xbrl.zip
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M12+9D"\/S"7 Y5!K9<ABH&;25\5!RJ'8RA##9)(I+18'*8>R*T,"Y]C!4:J
MFI8F>;[/1S1W7%9^\:B_(B];C8/M#TX1*?C:<:0,,S4%>]S5X=%9W.J$G^HQ
M+15I_6/'IF!'6>U/QZTB3OQ")@EH9_M$+UO!7KBJ3;6LZY@+ 2>8@F]RU7X_
MZ[Z(@%+PS>YXM.'*EH:RB-;J),<HQ=UDJEB,(ZW(VA6U@?TB2?#]]+FJ*>K1
M(4GP];@"22,'1A(,F:?+("->)5M'JQ2WZ>%GHJU[+H9'Q$X$7\P?;B?%S8 J
MV.>J4F0$\.SGSG6PF$_%IXO; HD0P_&BNX$1? F_*>YX@!%]GXYMXXVNX+G
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MJT)%4!G/H+V#%EU4VUW+\FCJ;*65&3!E4D<W.S5H/-/I]N0ME>\SH?%,C3O
M;3C/3MH8C^6!OSLQ3IY=M2EN>*[U5:5B1Q:-9Y+:GH36N#]MOB.+QC,V;93:
M^&C+T/-)NX:>:SRSSS([/-;&(QK/!+1J.*G0>*1]E,-AR53#4@<;CV@\@] J
MTLZQ-![1- X#K!JNNMEX1.,9C%8-,0=J/%(J>7IW%S%-*S_#5[S2"C/"1]IH
M,A'41:Q^^;S&,RZMC*TR&DW:TF-#XQEHUK"5T@)L\(PLVY=]TB9JX1E(UKAE
MT@9\-&_/=K\CBS9HW)[M6D<6C6=.V/[LD!9T9-$&Y4O2FC- E,%P--J!D%(=
M681GY?.,[RICB[2_#H%G:%8+XBB'Q%1U._5TB] TGC%5K8BV'!!7/#.F6AR#
M.20&&[>@CZH(C6>J5+OB-0<<Z:NEYT<=R(92AV-U5+87?(M+]GCF196QN)31
MH*^<0BT3SVBH/1ENQXKIQJ/:%4KV3H;,&_=/9,E>A.OF/1Q9LE=\ HU[2[)D
M+X%NGHE@^[=_VX?T1_WU\WR.9GZ)/'^>:65E#+NQ.N!7>"4 ;A@+C7M8C5AI
MA\=;XY<:_#971RFP\;N0A@RHPV.N<0]KK^;0X?'9N!_5G'%S>.0U[@<U;:J4
M1N&.2A2>P7&E#(O!5*M;QL0SMFTO>3Z5=L$S4&V/-UQU=M2:C!H15,8SN^R@
M^3#5=M?*/)9J6VEQ_DEQL5R*G(F7>#G#Z[L@I^']_M(QXFU6-Y"V3%_6E&'*
MPBX#3IT--&Z1<'MG3>^X<3.B5A)#T[MO/,!9>NS.WDF]<0M%F#/3,"9XYG3M
MTPUI>MN-FT)U' C^S7\U;<?%0(3K8'#A'0B\BT\FW'<_!2"'L$.2#]A/CH75
M8*RT>::,E=%FFIJN]!0%<--H:-P,X]:)7<%<\R5T=71K5[#8>-2M0KRR*[AK
M/E-!E)+O"D8;MY>K&0M=05_C!C>WT;$?M9S3C()G1MV>%"M'*PV>(7('4&X\
M.VE-3+ B_.V/ E;959NB?]I8'55N.C-M7_!/&_?+-9TA$<';P/=\W3;PN^--
M%=6-73[\?GLM=G1TF.:L#8:CZ5 =)1*=LS#FI'DOJ4BFJV*"M0)X\,YQ0;Y<
M^E2FZT\6VB;3XWT76E0-;#QQ:,/-OBFU-]8LL@J-I8K(JM K>:*,1VKGD%=H
M*E5$7EE-=*Y,)Z-^YU!6:%%E4;9E2.^X>[0R*)Y65I71:FE]I6O2:E \L*PB
M$GDZVXT&XTGWL%9H?5;$&K=!,YQV#W&%!FX&<6+;C.[#DMAF.0[Z12."&]AV
M;#F.)Z/IZ%"6XZ!XT%?%C?,;0\/^@ 0\.L8L/&:WZ%ZPYRK03>=0QF-\[Z?]
M; =M AXCO(ENMZ/QI-\]TN.QPQOKK#L930ZHYM)SJ8K5G,@Z<&VH#K7A>'PH
M-5<\>*J!C7<X0#(HGBQ5$5D5; )M/!AWSNDMGAU5$7FE;8+!:#P>= YEA:'H
MJO1V8C9!\02HBDCDZX _''0/:SP6?&,7'U-MVCCB!%?Z#(0/@^J/M<Z5+0Z:
M'S]5H9=]-S'9^!",HRQ!'K1GT%;G,-?^H5[=PF?+QHAU"WFM'%S6* IYZ@(&
M-6:AY=^^#R?*'@M;!LU/0VM9#=>@^:EI+:[A&C0_<ZVL6MX[I3=O$G>CA&O0
M_%RW-I9P#7BFNNU?E97?/"E$QN1$\JS#?.L;^]+SD._=SBED] <W]C.B^C'&
M0GLFOU7:B! <M'#2FS9.3 ,^"%+:--CM<%AH_R"WP^&F98/;#H>(]@UJT_IU
MI4>HB/*73M7U(/R YUBFD?85-0[;<I!"2WYVJ3(<I.//W* )VQF'[9C965->
MTN%PP6$]5L-%A9SUJ=8.0N&9T58-.16BGH?#!H>M69%41+E<A\,1ARU:#4?5
MG+'#(83##JV&$&[EJO2'(Y'R)5LT2QL,9]5VC!$.F[2,7B69/P4UO/G@U-L"
MA^FX)P6ZCUUSV(G[4I7G8V7_IU_=,-Q?4XHF]MVXV=A80XDFL-&XX2BF&40#
M6^<93;8WG382+P=2&K!"QXL!SP2R4M=IVJAPDU4!;AH-C5]9'VD7J<&0PWH\
MP.U>5[!8_5;[U+M(#7@FBQWXGK$K&&W\QOZ8NT@->&: [>G><S]J^1/";#$S
MB0.._VTADJ%L&Y<K2%;^=SKL4&-Z5[Y]-85BM.0FRX!39P/5;_6WI.OV,Z?4
M\ 9XQDF5"7.H$VTPKKF!.]>9(61XE!#APH2,^[R=?PP\+# \+VY;/A ]LBG=
M<6@7&#7@KAZ!S&=N54M'X_FAU]_"G#Z: Q$_2.:N7NG>,LR.B+=1_?YZ2Y1L
MJ*:KO'C $K$AP6&_ ^ZDNDF4NY/15-'ZHHZ&AU.J&R+YG*+49137>38]++6N
M'?>3$SSY\\#"UJ$38%3$4%=OPKE%LPV5:1;NK6!4 ;AZIEX^P(/^< /10@&N
M'MG:,IY6&U7&,+@!COWY%;*;XPA4C>$T^2PX&:>+ZM+KEH-)<+!GU)],:\,D
M6!F.5&54&J8?L1,";05O[0?=PFR/3WV-7/_MSM*IY;U.I:'4&/F2?S4PG*05
M7CEXZNU!</[\^3A#E_O80_7+K2W5TL-I_8-(&K6W\VO3UNT9]I@@F]3#-B]V
MJS)2K,8XERTSF](ZNBQ =;<AN !T.IP>9!O5[X[R3V,Z%K"-_ 0R;*N8!K(-
M[]9->>OQ9JHW;]X2/U#3"IT/+B%[XAF$4H;.AJ/,Q>PA]E0]86=+#$$="MM3
M3EHCLX#NT0R9SU!S'N]$\#B2X3!K])8!I\X&JE]DY+NSHVR27-,;$.R^#K.-
MV$3 ?^>BM6X:G] <N=@U9%89EG\DL$[39N,="1[8=CY0-67'ELH *':3@GW<
M\]%@.-S#)LFCM]@JPAK-7F0W)3@S^5P930<[-I4'D-B3$FPAC-31+@DGXJ!"
M)KW3W]+R0K"-H$W'9>4% Z4JY#S#'<JPS'BDE54U=2$7K._/-2731DX$Z&Z
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M[O!)PR"-D)*N'??*V1A%Q)Z*:PA3TR R'0,R(Z&33>[O,##O_M:_&(;-^JM
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M)-'3RK%U/CU[F(O!>#%,;^V0>N5YE-D6=HF%F,,JH/^.R)Q<T=/HR\JT]2B
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M4IJG\WU<?FGI:RP@O3_C7[)T19*I0WL1$2P01 HW+<'#B?JBXX, 6YB80*3
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M/=F=13>@_AMMFQ>"[&?3=6Q /I1 +B 4Y[AOR<]I3]4%/J@Y'7]#)G+J<)8
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M:M2Z#S!?Y(64;G>_R#11Z*;:(PHS>.TL0A&@]\5NZ*192CM==J)Q30>A_[*
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M\F&0U=25#_H.Y- =<RO[&?1U=H4YENT7-MJ3OC-I+:7MZCK3JN6/5V#JWK!
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MATQJX\HL5$1Z3B3;,<3V;IG&?1U(RJ1!S?8=C0X[3_S=HJ(HS&+B51@RX7M
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MZE5J8A[]T/4BYB3^ P[/Q1'W_%\M*TZ!:(%4_E, '0)*#J(78()/%"B]F7L
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ME/ IJD@X1<RRNS]+OPA\1D)+Z]MJDH!ZCZP7'>6,^<:AHP9IVM,+Q'*F9>.
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MQH1'BEX?:E#-US%"'2-:)4@R:Z)M?9MX/@_57(3<4Y(QF0P0M#TRY<7Q@;8
M[\)LF=H(;H"]A[D%2&7"0N%RF8MD07?H'B-51JCUA.@M2%OPL1D9"=QMT J)
M.1]$Z[M#3"^$#><N)1Q-K^9[W#\EGBX[3?2YXG7-QS]T.[7:3P[Z/$2LY8>.
M&"GP8/RLM# W$Q]3P?5'GU%0L"#FLDO&O[O=-Q9OQ%'X6NCID^XI>&W@BT;
M*:0<0':\!Q\N?&#,HO2>(\HXLD3*D1*"KR5V33HS%EXD%U=YS!_%)=47'MW2
MGF9B3_8]23\4[;8CS$J0>G[J\I ;:#\0I?8/XE40]*@)X2>.#Z(0E$0N[>E%
ME-$B F:H%4 KP[J*-X9\._]L('F7,SV^S+'CB37RP_MX6_U8K1F/']&,6O&#
M!V!^=C:I%G/5@VYK'BK"[RFT7Q"\*\A*>L4M6X0T.#(8/. PX!>W+& C3PA8
M_,"%?SH>_!#U&2RITHJC4K_ ,RT6A/=B0<K+)?\%MHKO0ZZ@T"YYW5[%&0H(
M#P'XW*M!"D))#[8'O!E^$4OEFTE(Z1MZFJ4\9R-8"JC6 ;<*'$I;Q'YM<0#A
M:RF,1== J/Y%B-IV7;*1 #<SVW./X"/'GJ&L>=PQTQW0:;;LS^^@E@E_Y-B:
MA?^U2HD7*'H^H.B1@KY'X;F+DL2[8%%B WKI";P%]V:"H>@3(?7UXE3*>F(O
M%WZ.UCGN*H]3P>;H$C\7HO,2ET#,;P[DXV#HH3!T(W2U*(2EW!?6(8%/UO%-
MP#E+?1=%C0PAI90E:3_JH:0!Q4@\BMN#0,6+03PMW::%5AQRQ8CR4HAF#ARZ
M)(U3@#1 D;7F WK\,C>,Y<^M^_D-S@IA+1YP(8,5#NUA&)MNH^1^;GTF[XFX
MPX*@7G"_ ,I"88[R'4.=1C6^OZFF:T66Q[)LD3S=9]UTGF(RT%LD1: QP-PM
M0 2)[UT&TXH4H&,M*4#=_FYR@"IE=[]MG5_\WS\NKR]O+J\^7U>,L5B*J'K2
MEQ8E7Z/QXJ,M83M@D'+I$(MK! _-I)#_%TT4+.?##V9I!%Q-RCH&F9*P\0-R
M@X@&D-:'KV#%OU@B @\@>&\ISB :=]"S/)D#.U(S8BX63)!EQ->S4,@J-!&$
M+AFS<!S9,Y#Q&#*P8WX+@I$)LGNXU*?<D0G*K FS_62B6<. 7 .UIS?,I?^N
M%G1%3%:6@[$5K:^623A<) ,Q.!/$X"Q"9*)1QY6?2D^85L#&8>+QNZ])%*;C
M":!P^G,,V O&&'(L^%@4A:2[*5=8OA8WMH61:,/1'F(/]48+K[B09H0MBI5N
M+9Z<$='4)=R)W@L/>2PB6HJ=H1N0.66:(Z#G*B01F\*\%EE3P (2!WQ'^)-Y
MG^-QK2=O#KU(R?=5L4@J&9#^6QBZI%7'X"1%_(7X[#S"E<M-F=S%N(<E-.<<
MY6! #7RC8.P1TM!H<C$];.01%L&"RK[C8<9;YM@B"86_7"("H$BU3;03\6UA
M=R##$"@RA ?N"6AH-#BD.-.,09"SR<-,F)% [MC7"-L8P0'1(HIL+P9DC+QH
MRG.)8KR2E7[=R :4H+&#^4 8@1=JE$3N4@BU\9+<]_"!Z&$>W+"7,#-XP<S\
M,\7"JA:24\ 03?!,RTIG!*R 60]@F@EC=0Z>%FISE+\\@V@$DC^PQ\)CN$6Y
M'8/'3D0)A##E:T9L;'.GD%]#"&M.W#"KT6/X/IU6='C:I?'4K)3BRHD\]>V!
M:ZB"%&J(Z[PBO+Y(77B!HO&=QR,O#3E#Y8ZO-(=N>!PYRS:X%_P;820ACD.'
MZ^7?T68B&'$O.KP7.HZ'GV"5,TO:%4=D5_#_H7$SL;#GI$-&J@5EU"=@8-N9
M@*1.A&MH@TS!@,^\ AA9/_5.VB<RC8#?[\MP9[;AEW%Z^R?Y>F%F%W+Q18KL
M50L?X0?XJ=/6>VM?3S$65BM2SC*I:Q8[47A/@/("ETV#/#(!  .K6*CY^S#Z
MBTHE1?A,B/4<$I7V&:V%-AJWL!"R\.()89GK&S5C5C'*VM9;U0";K:)96F2[
MAT' > )'=K>L: ^BQNR&<"R-BY<_]?KMH22%5YP,E>2/>37!B>7E3X-V+W]H
M_4R<MO5NA6?^E8)"['<4=HHPOG4GDG=&E%G+W7YN&Y&U4:GPP;R+*5"#J3GB
M56Z*I# /Y0PTX$C]-&QWY#'U^PX9-N _: N&@;SMH-M>O?:M]ERD.9L)[UX$
MQ602!.1"3B4M05>Y^107KKBRQP)[RA.M;D5, UZT@$87O2L(@R.Z+D"'>PS4
MQ6WOES]UV_WL/?I3U$0"-%G)8"]&:I%&1E89UK6NSDU_+RX8C%I7X(4D(@42
MC5\N.;-+GDQHDH.!W!?^\#"% 6SQ[I#LVK@"Y$_8&KAFLT1$FZLL B63 ^CC
M2Q2.@-;YE0W^P_-1VEX&3GNAF3"HVTP8Y,F&K34-@LR\F%.[MB@WBD.0M4&8
M,%&A1,J22*<':Z(N@-,K*V(X.AR-.+@B4G$3L*/CI0I<MVI>16GE6)_77"75
M6U"B6T@U5<SJ51J/VQ6:77@CDG<MDALBD5?T,<EW^EUKO'F1)WX@#NR5WJ37
M)$31U>LLTEAZ4RBE^M,<Y4=&F,(Q0&+.4)4"NT=C._#^MN5-![[AW^#9"0U8
MJ?N.I5!=3?#/)[(OD_N#=>0^*%N]*.:*DHX9L)*A?N :Q C]PQ'ZE3(-3;91
MZ/OA/;$<Q=SQKH$"W&E@IZZ7\-0&8G,;OW2Q/8:[6F:7&AZGH#?G;#O1GJQ+
M4J!X):)U";P0X*&B8HWHL)5=!1&Z%PDHV<AK:+WD#$));D(.@/G-2Q-0RO%$
M/#2,[5?E&9;-B4OH]2]KZNXAFNKBGYRZQ6'S1KZ^/8O9:_G'&V6=7D?M1[Q!
M,_E-&CH/-FKH/.@>;[(6/;7V8C4V<5_2)/^LL_6@G]6FVY]UEK:AWL%T^W5[
M51N$U(R0\HW+(^PXS_FK'70%WM]NNL4A":0J5&\UH(\E67J6Z)S3'#8K+:7R
MUKJ#UU?:UG*>V@;0Y;:)R\]ZNLU95QHL<%K+855YP;=!2W1;@\%9N]Q1T="6
MH:WM::O?Z[77'2Q2$OLK'<PHHQJ5T15WD?-ZNY?@7L;E<%##A,;F@F"-I4[G
MEVH>'P[[[7)'9(.K1N+JY4G[=%W&,A*S<1(3S7<N*PWC'0;C]8?MM>=&&USM
M!U>==KD]O1&1!R8BW]JQYV"Y*4W&$B9E?J/P='FQ&5YFHQF\V^ZLR^&& )X2
M ;SLM#M=8P<?O)!_AS,2F6O$O.'R:C&_[AQV0P!/B0",F'_.Z1.'[.0:".X0
M@L^.X[,\EI,75A3>\[^'+^8V<-S;!-W'O?I4%-749-F7:CIEWDO?O@WOLO88
ML5HG1*F)+[U7ENBBOF*3!<I5?.G!<VJN:];>CW?B4IKM9@G4)V^HOVZ2)EAQ
MA$]%8AH,MOJJ/(:G]/'EZ;6^GU+/"NS5D2?8!CYO]SRUJ92)-R%TJ0CI+BL@
MXB6G\5P2*N^V2.VZJ&N6[20IM:V@EG\TB/4R[^+7LD9IDD;YRW#%.TSXC($@
M*)V;9I]E8PGD[\28FWRX0>6!*]*!#:<:8;_24D9;[@6 A@4-!1D6?(XL>&98
M\*E0D '@0;)@OV-8\*E0D '@ ;#@+U0FE_U+J9\[H$';],_-NA!J:ZZVPAYH
MS4/N0O@[[QM\*.T;^"SA@:S;5=LM8#M0T059;>V#H9P;%@0TCNRQ#C[#]FG>
MQ4!O,YS+S7O.#1]OYX4]"91>70W!XLHTF'4I.10ZO'(2O<.AJ8U(%5D#JK4N
MI#31TOI>6^_KE$[I\]PLQK<_QLL*0S2(EYO(IHN(O#1KM$B9E\'("W!:E%;$
MHS"XJ$J"V8KH7\H+CE[GC=QW]E'WS:O'B.FXOT'_5[W\M:!W7#_O17,H+5LS
MP@GO [S\RIOTN=AS90'K+^S1]P&,9L^UMV)+K:@:8G\@K6]<UA7TY4_=3EF2
M;+-:N3!J*]Y;NUNNUN6[6M]V$(!N6^=J'R.]B_PT.,E;?4GV_HE(/F,L$ T9
M;^%0)#D#04,S)JV'6=C9*9\SM-JDH.KI0JI;^"4*/^ %\E?>MR ?+73R @#B
MP"G]^)\OCH;+!@T-"X.&X*<I2%'ZW1_7[[#[3?3BUVZ_!SH._Z]\AB7[X0>P
MI\S-?JV(3>P*AS\.9<TKQQFFK>8'.=5[D*.34W&,#7:U.CX^L^22'OM8.,R9
MWL,,UL!(84<;$]9)I[/Z$>8G6%42UF!P=K('PCKI=/4>9-@_VQMAG71Z>@_3
M'W9J(RWYU'N1I_Z%130@EQ<I92?JJR?J;7R@F7@[4%J[,UAZGJ4;V_A8,BT_
M.]B@AH/U-SJ8V)HNC U7/MA2V98?[ A3EIN LN/FG&Q=G%WF"6:E 80GG9.U
M!Q":MGD'E?=MNK29MGD-1(AIF[=[@52%:M,VS[0VFS6^M9EIFV=HJR[:,FWS
MGH0R,FWS'N/91O.A:9MW.+@R;?.>A,0T;?,.C?%,V[S#P95IF_<$1*1IF[=7
M+[/1#&[:YCUS C#]E)Z&D#=M\PR7F[9YA@",F&^4F&]&^L0A.[D&@J9MGFF;
M9]KFF;9YSYM3GZFP-]U*&@M PX*&@@P+/D<6-&WSG@P%&0 >) N:MGE/AX(,
M  ^ !:O;YJU4^U=5NU<L_/N<8B.=JY%\">.OB=3BQ4(!?>?1XL5_I7YOP/^%
MA<S?K[$?ROD/+_Z>M3O[1.U[OHM-\%]@>$3NXIJ-*5I"3XE.</P9I1[R?,P"
MQV/QBU^50LC%YUG_W&?KG3LOVIP_MV@$,W?J"KS1KV47&MEP:$U@31GO6+8,
M7L/U 5;1;^(B#&+/%4&=&VRD,V(8O.EF(.RN4>N_4]I1JNYE-X=-#JH#1&MT
M$3@(,LM!>]SOU G;K\P)QX'W-W,OE=CI.<5+)0V?!^['O(\/?)<"R"ZSZ"K_
M\16V_KF9V,%O66\8B9RE71'.K[]??=@#R?8?AVI]L&D$6OJ/H^5PV*3;.7N:
M"*4$<8FRP9-"69T8 [ ]WIQ!]+S[@BWOSGVPZVA-B=/WHK'5C?WC7=;4ZGP:
MIH&"D>%3PLC@Y'@!2K1 K8@0^8!$X[LT\H+Q%Q9Y86X^=H^;;_L,YV"V[&";
M@&#S'F)-I[=A9[Z9V>.PH[9.\F=>++O/)>$MRUO/@</&KW@3^X>\:\7^<GFK
MINZ:_EC3@?IO1B)U*/I>;0R@(H&^IR:C[QA\[RE";VG_M$,3>OUY&BP<>FV'
MM]=9C["NG*33KP24Z(1<@^>Z(\>UMZY7MC-8K.4&K.A<K23,>VMTB&L*2%;7
M9ZNP1W]E]J#&5Y_L2/YK[OR?;&SK-TG!%$SB%:4)&(>AXV$K8H2$LZX\@3/'
M86#[N2"JY*^S7?'74G?@H(&94V/O9%%?RO59M%J=]5:PX0\1<O-VZ1*]MIKL
M6L,6E^36/S2@]?J;F_-UN?V]I1Y 1J '!^O!HE;&M08 =AMEZRUMG"R#GT&_
MLSO<?4"#FGWT[LKG>/OPR?XSC"Y\6)>_3$#A,VPLUV)U$$.)[YY(_&X-4EG!
MK6HPJ7P.T:&<,=C/.&)$#[402O>)1NY5B=]?>N6W%U+0HUUW*?!7\$;ZW?6\
MD6LVTV@&?HG"$7SL(>#P;\]G&CDF]T<&._)'^NNV/S\D<"IFRZ)^_S7%#/I+
M+^HX6%._"%:-DF%G8%T_%KQ??=U?X39NYZAHHL:N4^JOJ;#EI_(2Z]QQ\&8*
MZ.I<*2_+,+PT,D"<=SZ+%,X[1)U\5!HRL1*0BG#]& ;C&Q9-W[%;Q8I9&C#(
M&&2W*@!WFHB=WCS,F'QNZ@&THX?/85*/>)N/8JD06]]N.5G/;KERDEXU77YF
M]_\.H[\.]Y*AO\9DHMW"0E%MBZ[5=Y0>UW]\X!'>,U2-F]@=C/195?LQ!P8K
M^&SKPG4=;7[!HH3/@&3QU>@S$P=R6!"O*=%6PE<#E+JF5(#!FD[@8B0V3<GK
M30K0!>[>/L%=KS?33("O>>6Z,^%?3\[*.R^&KVS_MRA,9_$EM8\ TQ7G.H9H
MQ*;,O<J:*%1,>\SA-EA[+%/57.=NO[[IZ_>\G(Q&Q%3.>1ZTK7>7UQ=7GV\N
M/__Q_IUU]>7]U_.;RZO/UZ5^#;KV0>M:YY_?6>?7U^]OKJW?WW]\9WVX^FI=
MGW]\7VX3L70H]MGN1F*?QWJG^H:CTHCM/DTHGM@X]QT<;C[_6.NB<IBR@V8!
M*%P^KG7"?-Z$!-A"[^AM("^*RN@]!8!J0*"*@:"RYBV9HA3#G^]#T1\E9L5)
MTMA/!1B7IF'0[\. +?@IO<DNS*"?FT,-HLF::CV='?W%$IJZ#8O>X_\$87%7
M>DEB,2G@!Q5D6NZHNAV)K,GS@_9PIUQ_KYD'V0^PV5VMK\R&SH]9.([LV03,
M?-\"DK$YM<,WMH/CF>T A[<34<]F/OR*NA]E\1MKG'KTFQ81=Y$5:.(\T:-F
M^M/+/0N)6?,R)<[0+>+*'2VW(A&D@SB]C=E_4D:=G$AX F4@1VL&3L34/EVQ
MY2K&E=JB"E8/TXB$L5[=*B7["%S- +2"3_VY> B[0N!LL]9-D5&*FH5832]L
M-7/?(YJ-E)%FC>/I1;9":D!/@L[P% JAV23&N=^@_L2QXXDU\L/[.&ML%F>G
M;EL?0';(!FE 0VH#MS"8%Y%:#Z491&6B+,CV)9A'L5'2!2@ZM&ZPI?>X,1C/
M&*FWNEK?JUDB9_T#NV^L]V 46.?@R-Y1H$N_Z/_*XB0"3[D&<SS;MEX.J&@9
MV!R[\$KK6;.Q:+*I(AHMR'7)/?/OV-$4GIE@KW.\]V>!"TQ<,LK%,^&\"U.T
M[Q=I8GS"QG5]%(:O+>RN;MUB3(4IW3 963T_==J:.6&*81WL0:DTWKQE 1L!
M4_ %N_(W1,Q:5P]8PH]+&D#KJQ=!FY^I)\^DUY_2RC;%UBFS8E.4;4-II<!<
M^;%+(HB/@)X/@)W*G[PE*N4_O '"R>)SC]_.9]&Z02%:-ZB^")]/+-2TX16@
M +]Z/QJ![7(UJOP^/_,:.?@KG;F[RID?VYX2KI9WO1@>O^ 2ZOS.]GQT1,':
MND9'+3O,ZK?8_<)9^H7;?+H>XQ=%OX-#*%9Y^T ?95?\U42+#P"RT'_4?P7>
M%X'M%6"R'(+7Y,E)J*U>N3I' 8<!M=YBJ"$<ED/J0K6#,XBMWH/H("'670PQ
M%1X+4@^#TG7KLDN1X3KW1^M=BISMZE)DV+9^N[IZ]^WRXT>ZI[BZ^?W]5^OR
M\\WYY]\NWWY\+RXN6M;G]S=-ME%K"KUK?=^Q7C<2O7S7<ZE5>L0PX@GVXH,U
MSI(QIC/;BY!_+&<",-/N:8$E+8QXZL:>1K!^D-J%E1-PQ?0[>$%^BY&?=_Y2
M!#=T9X,;D6+C]AEVQP<*09D1\]"N(U)HT%L $'KQ7]0W/]\\#WQ>.7CW2LZ'
M9I_X^1!KV5#?"G+7'L;V$?LHS27U@?.72!*LX@*D10KV1XQ/";AE+, +IRF\
M),+ J<ONF!_.2.>T+/@'_1>X)P#NH0ANYKW"'Q0@PXV ,QKB:RW'BYQT&B?X
M:6$H@6.G%&L+[#'C>PEA==]C.-4AP0D)4_0^?>\OYC_@@P&Q-;T!CSF",P Q
M^RD=%ME<G+E$V+3<K=Y+',L'7<QWA6N RQT]X)(VM;)I]J56'8J!, *& 5 ,
M)EUH9^3A!K)]=7&\0PG:Z+"6H(QY9.H6I'IOD#5?O=TS(B^>F:C[\B;0'.TY
MHAL,+FF5@38E7J"0D]:5.^TSO<"1 3Z7TV"<L)G,S$"FHQCG(YI,<V)"83R.
M((O(U4T40!(<BQ4"#,ZN=2V])-!K]^HA@8CY)''!(JB(:',;@F0MN*$869V[
M=144Q"F&Q[S3..;W@P=X+52^OJGIHDB+:NHNBQTO>I/5*;^(/ONYO!/1FQO_
MI*;=\K1Y/W#?GL7LM?SCC;).<619N>]^KUOLNY_-3\/XZ%Q;\I.-NJV?U#C8
M$U,1^ T.*7$.G'0*YP<\QZ35;4XY#RJ+H73-)"K>(F%LABZ5AD1[Q$<ON6%+
M%K]@T_C5ZS+!K#C@X+$1(YN =K!1=_G^1OWY^QLVZ'^2LP!.3C=AA%,#P&P
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M)]-XM6<N\&J_P%LZ;]D0P7.XOQN8TO^&4MH3N[XSD:BF$MH3N[T;#):G,)L
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M@$$-"32#!!:8-SHWMMY(^E\2&U;._N5Z=_+OF=CZSU,[&L/;85>O+20)2WS
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M'N"& MY:HXLDJCVHF8O3,Z8>3W:8/ZQZ Z+2U!W2!R=PTQ'QY'<-C(@*4WM
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M[@.ZNOE*?OZ,WE]^O/Q\=8/N?[VY>4"75U=WOW]^N"_*\0MG$8JJ 9XE1Q>
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MS+:]AUKC.F,M=4+5S*TR]L#)@)L=:><+FN,P(_Y,AM>,MJ0E]7HN;Z'R/Z9
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MO\@8D+84#[4J((D^%\Q9/4J_ZJL(=#*APZZ(*'=)QPG*:<-:%<!P,QA>QJ?
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M:(.R',U'LE+2UG+=Z:SVE]7^LMI?MMYG_;**?[/&5@D%P'58X @R#>L"X+H
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MK&H]@[=ALGG/@1$+F3^U7>0':*C@L5+:1\**EK7JH'70\ W&-JHKX0+'X#T
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MW-AV&]SI0MM[OM [[[/GL[N)Y=XQ5YSU"A%SV4TWM[KKB):3U\N4?.Z#<O!
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M5T:#0P0H%@UZ8V4$>G^ ?WMM_BF8<PGG50I="7CMC7E/&2B<8CO4_$,9A"4
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M 5E?"T=_(BAPD"[FK\!=RI?UO]>7%^EZO:BZ(B[DQ886B;O9PER F4,8:;9
M.7&I*X%%%?/H'XCW$^\^:>J>'%AB4((I86>K5'/ OA:5YJ;ROUN9 2@W')VN
M:9W485*)$?(@$\(AAU*!XVU.68A[ 2T=.7."6\+MFHJ92(DU7UFBK\H:K:3<
M281*W#K"_V0Z!.^&^#,MD#I.W&",VDK01P'/HQ85=)3-257=% QZ<N'7$WLF
M--4@;S_R[E,-PA 9?L"\<S<IR-*[Z3N.ZZ]0. %)^];,<Z(L%*PMDKHL+&]/
M)SA,A-0R9F!D@J4D6 H@C7A61U>>W_CY_"))5DD6B^=9)>7N4AR <G=XMJ\8
M6,++.].TR1V;<=N'Y'%@-U\IA(#.00'M"':-.%J2=\9)G-UOB;%?<A7Z550
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MQ# <DA 3._LAB%UTC3@9/B)KN:5T_KNB&;XH9'DO,_2A2>G\2Y:<8A6X(#7
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MZ\<GI.%H4!Q(-P0T">*!*O=S^!&PJ*@J7]36>LX\JIP/L *7YJ@%R+C$P-R
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MYUMI1F0,A>XF4#"^X9!>A,(7[U%OX5^#12C@Y.$%"-"7B-+O!,W?L@>.X?C
MK]Z4\=J## SXU@$"9N]?_]ST4%N#H+<Q(N@(@L^6#Z>GO]:#('UQ0,SOGK]8
MV&L2-I?<)SW]09HEJAR0>GLK0-Z(N;WG5,U^-;Y*QE)^MD;LSLL%:%\&Z%DG
M#='SVV]7'X\*B+_?OL<Z=?_5VTZ7M'D!R@+ R<'-=Z3O@##Q<2I9 KQ!,6S\
M;>ZVNKF O/7FX>3"\D%ZN=9!(!K,["'+@#,Y^#,@9G<!+U-@V1QLG=:F8.-\
M#/#/)""VBH!-P8'-5L$#;\3#.OK&6-,FK+%<4_REE/P^XFAB5,TNW8]SQU'-
MQGJ+V+*-.#B/AATGT#->!O3R94 $CZUQSZP<]*XM?U$IW5V$+A*N(MS;7"$_
M9NCU]X-ZF^OP>P7>[^XX I]JP!GYD%N'=A>>/X,-A7"=(7OP[?#Y/)KH?(>9
M50D(NZN@UD6HO6=##K7NJ[?7G3_%?M:\0=K+G\R"?;]G.)4>NZPG[^[EO!LU
M0WI;)U*V#?[72KL*S&=T0OB7[B-LP .ES!V]MT+KE@WGN+<;:J($=[9P/S<6
M7".M\)F/^107\18U*G'2A?UO=+)^E4YF?5\X67OMR2)L^VP'Z-.)-H&^B4_6
M+/1FLNZU5F4MY>0R\43;!;;=-A8(:/F1I//?37P63#QG=#6^C'N!!9<NOO^=
MSRST4$7G[Z[5/<L^_PT#CH!<!DR6V%Q9?Z0\-FSY[((Z/@2W\*ATZ+4:Y_G,
MEU@O_&6V^%\K#_W11][*_$4/R>X<]5RP<8#)(DM-'[(0&-:JC@<"0[XIDL @
MHPNN@8$WGL$V*$R0''YSS4\@_K,A_EH0OY^M(  $G <L##?RH_T><*Z%1[X:
M_S8/POBX.X+H&A@AH(B9@D]R^LT L[E2UQ%>M9:9#QC/?[" ^)_<KRP(_[#1
M9V]GK/E#0*C;70FA)9[+<VS):#G7OO=H8Y12@EEGE=<H!VBQ6K*&C:YWN4H.
M'E,X>#;<_K9G[6Y^UJZ@G%:'_[7RK%?VPRUSQDG$8,59V[UMSEI<2>]N[E_M
M"B5=[_._]N/1VEY;SZ>'2%4?E.=B[6[@8CTZ.":H:?9V][,6>.HRZEJ+I@PH
M2:$$Z,%) WIKAW8&9%MRPEZK(->_93.N0"GD^OW63EP_>3UH+PY=!X>@=$R]
MX#%_F[OZ_H^Y=.?I$UYS' @^>OXG]F YR:\EG:=G%)9IP@6?(1OEH>45 G[%
MV90SDYZY 3.9.SS,G(&*R@!K A!C/PQ@,Y1I%T29!#@KS[+=W?*.W=[82PX]
MA4.'7A ?.FYO;HM#8T;4A,D&86^E&AO=L<MYV!$*C%S)O OHMA4<!53H0N;"
M_E7H8C326WO.V,,@:"1&KOV=<S/*6FX@]_H%;8*Y:_1R*>;:HO9B]W/_H7(6
M<E^MA=Q;J8OF0"W6E3)04YNRM*AB[%&1ZA?0%PD&Y_.'5ONP,%"I9?4+*)(+
MP9OM'([Y@G90E!\4.V115?*+]VCDJY+[NN3N?@&P4E'<X98+,?UMCW@[G+#1
MW &]A(]5%I$U'#$'M)^L<A7-E/M$(^7N4%V),UPE8+0+12@QN;;,^2/'/?>/
MYN-J4WY#FD]7E*H)L#)C,6B&'Z6)PW=\6%"0/\3GS8:5(R<^Y+BZ(T9+J5_K
M;E,G=D2#0$\*5_?.<(!Y%.W3=#1$<>BR^@RE'7JBM6$VB\Z'J$GX&$BX:#>#
MHR'A7>3:H:E-[]74=I+45K3U=TUM95";V6S5U'9ZU&84O=6:VDJ@MD'A?KXU
ML1T#L16]U9K82B"V=N'6>C6Q59[8N"]>>V:6'U2;Z"K:3[=;4C_=O1)VT;%\
M-6%7GK IA',4%%TW0EW)4ZK2"'6/#*AG'(G1W#HA#E3=^&/UFFTN(4B%^SJB
MR.;29IM'F>J ^2<:^X[],AGUUG0]]VR(?04=RA'QHG04> ;S4;0G*]!>&[VD
M468#_C2;O73?3*,K==+$93$]@I(D.O0#K/7<K85FDH*C)+,FG:RS\-/4NM&*
M[^?L8NYC<HB4E;-!GK.4EI.;169VZ+Z2\Q7;S%8'N73OGCRL>Y?3K5;F$F]T
M%KVWY5F2_6Q[G(G/V.*!5B8-;W8@7BBQU8'B'6UYI(_>W%\\T08%;VM.--"W
M/5"\GVW/8S]F;FB#NK(UYVDOEK(4W\]6Y[F;,)]9XY#YR7$&*]-R-SO.8DIE
MX>UL=1KI#"M3:S<Z0\_8DFBDI/F%)Y"W?^!"ZPL+@;?S=.HY_. JZ3::'*)H
MZNPZ'AWSM:TWI^YL!;)B%TH^ELB?7G7.5J 4JITZ6SO_;-W]W1NV]UE@9X.M
M4I27-M^YUO_,W7C\YD)[*]+A:'W[G.O>YGN[C%JV7_O>@V]-E^8X#_(Z(54G
MQ[D>!+*SH1G;3IV,[00/[.Q9'E+KEK5;[:ZVM[Y^N/SEU[LW&C4UW]0"ZZ\V
MP,3.Z*7GF63R@LZ@>KC;/D9VIJZ=[N[]AXNKF_.[RRNX0.K'[]@NVP4CN*?Z
M>49MX&.V6/#V#S^GIZ!C5C7YEC36MX2CK!FVM6]&A&*T(/*9NPQMW@PHAYPU
M5Z-J=5&U:%9O+26K-MCZUX413J<D^(XW^GK4 ^_U5N%DCL,/TZO1J')HI#>+
MUN/5XJ5JXN4KS0,,?DC- ZRZC"GE59VM<FOW2&]&M_ HX-+9]@N]&;-9M-"J
MYH15XX37N?-/J\X**YKQG%)L]ICQO$>B;A?6;@ZE)->7OX?++UI>5#/TTXBV
M'=(<W:N_LTK4910FKQ-U0+R4&S<'M:_@Z#7D3Z >O]$<SWTXPTG:&LT0JKZW
MH-:2]H40/[::_9^.A)'7U[^/ZQ\4O?Z:J]=J\@NLUE23GJ"X6G.?&KY>N!%$
MI37\&EE/&%G-?N' RD'$V*"68H>18@>O+5Y"D0KWU=D*#P[/L^NKJ1*'6EKV
M/3C&LN^["=-\%C(7O1R:8T_M4)LQ7QOB=$8JV/;FOC992-!K:$^44_%#D,JI
MH(KN66Z,4;,#[3784E*Q>$NJ#*=:\5;33+[V63##*6>/S'G>M4!\DVHCJ2Z)
MIR/&OY?JD%:6V18O']1;J0&#"^^5=O35PP26"QG4R::*SKU95]/8[<N;RKY:
MVI<<3_Z47+78FMDJ.HYF71%LJB(Q]^72YCX$(;PY9*,8HGR<0[*][:?%Y&_/
MT.7]+7G_RAU^\MP'+)6[YFY'::^**U?/^JNWNK"1E9O^\%T,+UN^^^TGMN1#
M6C=7;W_9EC:@<K-5H-ATDT):7>_M3.5F:_OYSTNJ>P?*J'S[67-++E<ME:\?
M$5=H>^:@MS\J+R!@-MGKV:!4*B\@B3:"='\-DRI.Y3>1JO.)-)UXZ[IB2358
M0?'I/:3HWU^DPO4;5RS#.FFNL.F&UG&+]>=0+-_,M3QD_4E$V?T'T-QM4!7/
M']A'S_\PG3G>,V/!G8=M 7S[?AX"R;]C+AO;X;5C202AF\7F..:>":OF@5_K
MXBQ;;BK=_>,]?.RR4?Q;.#S^Z,(+0AQ:^N#:_\=&TCF*3J)=<SG=Q0%Y&^UG
M85(<8"3\[-P=7843YE_#3\&.L7T^CI(?/$@FN66["IAZH7-05X&9,,1^D+H%
MZ";86IKX@+L WX#Y]4.>_8;_/AM;8.0\OUDTW^B[  [ZAJPW^O.)VYQ4/"?>
M@*;;F]A U/6F]N'S]:>K/S]\T-Y]^/+AX^6==OWI_,MMUF2:1?_*.\6@G$/P
M[\E[8(.4M(?YQVJW]!__YR=-7*.&N%#P/.UF9R\GRMWN5P8OLMT0_D^SM!GR
M@+_G<+JQ#51$!>+:+=JR("SQ9'_]A&7>@+4:38=&._F&/3)WSK0+;\2[KUF.
MH[&(JK6GB:=-K$<TU2UL<J9EH+'E<7AJ=S91:9?E>!-E/*+UP!H:&X^Y'4\G
M'MM^$&I3>&RB\2Y)$Z!9;01RO:G]3J#"GR$,X5'!Y"1(3*UG^!@6U$(/>-(8
M?F]%21H"JK:?<DHTM&!^_Q_Q1 ;@M\Q_M$'[)\]'D.-HJ Z6O9_[V'Y/[=7G
M57KOLF"V9<5.J*3ZL-E:X>IL#WU@R@_<5GN[:O>'KD70Z(<3I-RA)/P#I-5[
MY*K #N&?R/6RW"#UB-J=87-+I0NB<[/7(=;.<":\]EIOMEJ+Y^8'GL_@S&H1
M-6&]W7^H73GFN8$%NMUS4RW8/L3" Q2S.:RO\0FKO8:F%'FX=[K=+G!!*9CN
M&0SHI>=GA8V.0*E%51>L&=@F<HUP,@_P&TG0#2?8H4NS0MIF\@AN%-X"DAGU
MY*8&*P=L 7PXO);.">H,'=+SI_@<0ESIL7"2+FPI"$$O;VB/EC,'U>;>"E!K
MFGGBY18 E;Z*E";ZN9B\BW\S@ #\DZYY:#GPI^6C_N6C=@%_-370ST1GVY%F
MS6:^]YT<"0Y<LM+S=+/ZPR[+9>OMJB.LIDI7BV-"5;X.Q5JRVNN0XVB*@6@<
MP;F1;5=<,:ZZ+HNH4W7M<TU0^(@\'._1=/5!'J7"/4?@Z)BHM7E&BI%86PY8
M[E<9C>R0YR:$UO>S4?3KP'H$XYI41TL+N(?AP?= TTLI3)J'#HN'":@.L8\!
MGH[]$VHECEIZ/)]Z<S<,-- $ 0:Q9PI5J!5 4VM6,3_;W&DG"(WQ$"/05.GB
M?.O^WM9"?QZ$#>UI8G.%F5\?:):@+?,O&2/--_I#FX VN: GPWK\.?K""@(6
MQAKG"G#!0B,&J#("TP#V0)JYM "JUJX7:BX;LB"P?#@G,+6Q(XR<2,.UIJA\
M/[(@)*0;3CQ[2,XO4,KA%.0A _W6'MHSRZVXVVJ9"==ID),3M/&(IPO;B;OU
M?,M1;((/L0^Q6G[3U*ZE:]">0!M!RQ/.Y3T!"A ._85H9@&2#+EU]62CZ]/%
M>T>G,;KTK.$021-,'P<#4H'&T?$9?AM,*!V+?,H/<WO$L-7HT@M/(BK;AD=V
MBQ,IS@3H+LXDV").5/0(!;(%-NDTWC6V/P+%^Y;\7D3\_,_H%0 <DK^73I/*
M)S!WC=N1#TO$(;?8U\:G8O+G4G@S6E1D\$GG3&4>&#OGY37CT+&2C2X>/+.<
M:*)^[@*#=.CA:Q8O=DM<$3[ OI<HD.)C&RT%Q[X&\L>K;77E(^^VQ;T=6-_X
MP,OY2QD'5H?:AJ'@R.6A]K:<RC WYE2;'+,L3K7N5.V-3[6),*DL_S4Z&R/I
M)N<\&O[;57#L@[*C=?C;VQA_>ZD#]I;@;[N]V<66C;_]C2]RDW,>#?YNKC8M
M/_;^\#=2F>]\L-SF_O,M!GYR$KG,0IEU%4WD,II:-F=+U2MY$/'JXG_V^P;M
MYL/U[S<7OY[??M"N;ZY^N3G_7 DG;2[$KQ3[MF[9+.2#6P;<OU'E\,$3TRS7
M]>;N$-T4$RNDX.X[S_(IEOK>]MDP]/Q L^;AQ//)1K9$Y-5GL[D_G%@!0^<-
M\J>&<"5RC]L3HRPMZ6<\7JXV+M53'/Z((DDBSNW-PR"T7$PNU^0PM>+D"1<=
MRO=L[/F8BA8A$!^0JC;^E).14!E23/+^L.=2[&:-L>L),Q3FSDC&J6!B^?"B
ML>]-M1#>21D9-OE-<58M9FKX?[$PY7MK:/<D.:)% H0^_'[FVX]6N."GPUS.
MX=#S1U0=1%X[M:&/V<RQAS2;;,S@_):C!6PX]^W0AF<=ZRF@D)R'[CO-80_P
MO<_^G@L77D!9#8JS,0#$:O&;!G5PY_S-' ZJM^X[9SIY,RG4PG-#M<"#>Q-)
MK^+NDYL.]I!+ XA"?E?*G0%62)&1G%<W-'N,OEK5W-<*U,)YQ)!P4-'$\( 4
MKN+)-)@8H+ESXBUPR+%%O!T.YXKZ&0WT-(I+4!HL]UP3@2%I8+DO4 ;][M%S
MYE-&@'M@+B&MH#-0P'AD#=:U B!9N$O,T7&I5)C8J#7#B&@*BQOQ,O?S #W;
M@;20A/]BRX696*F1CFNEESKW@[GEACS3S Y2W#!!4<4Q>]-H-_2VXDP7P:J%
M9)6E*>:G61K7(U'#> 14>!!(A[]7JS*8O>:@JQ9>&)OAA(*X:L%E(88/O8"X
MR4*N&>CX<8&[8OKGJ>&H-*C/X]#U;J/?J7(R6F40;- T6A6&4R%L5?KF=LXT
M'A7J.@_CR^Q0X (><NA80<"+<#"@*KP(XA>*E>N[.#$U:QYA\JGM<SF\9R5_
M;5PXWY>2]K?0=S?Q,803ZCRV!'DBB2XY8-)%J L3A?EL<#AX:[#<82\&:4N!
MT@UWL<)5=$L7?3XD=4.*\9K&QF69RV,-?'&L[N\"<UP"X/0.5FPU^LDY9U 8
M#;YF/CTN[=M4$PJ:B96QEAT8UI*]K]C2-C!O*RB%C6 .6@HH*>7 ?//(QLK(
ML@1SU$)VA?D-"T)_/@Q)[I^[HQOF8"+:.>;1D &YLO+5+#+SNZH.TVSO157O
M6^8O4;K^A_]W>;?G5YQ_>:_=?+B]N_G]XN[WF\LOOVCG%W>7?US>77ZX56)(
MT8=[,:6RH[!16*I5UA3[9[E9YOED/D]\S"I$MX9HG35$KJ(XG0V=*XISY$!/
MFC!G1*FR@>4PQ;Z7][&=HE:[5'^5 5!1G+09!-[0ID1?<@.&3Y[P%6'I%&F:
MXBX0;$,KF"!W#6QTZD4U5PO*=:O93_4^\Y-4-$M[P#IR>$:UNU':@-*E4Z>)
MLVZY<XER<RFO%AZT72SP\F8"+D&DO4=YD!(L%Y3W%%)J6)V)$,9FK<FU6*GG
M RKLQE7CC%KAJ1H= Q(J2>G='W\^$D+&J\<<;4RW)8JV0T1,P _0GQ QQYAV
M+/-I),8QM3ST@ADZ"3A.*=V78!;P^J_/7NR(OAQ9$T]](=,"X^DT6^L9SVNC
MJ2<6]E=,: X\L&+)-2P#QW9G0,GH:$9=%T^$F_G5FLX":NN0>0.HI"39Y>:/
M%4?U2S<N&HFJ?A$2FL5U;0QTDNX=?9D2"%/>60C/?N\],A'*DCB7H4?\$- @
MHS!$R\18*?]6QD_Q.^*#J4^6LD&^*-H(N MC@W?GOO$XF*D&EPA@=T43%B[%
M,^);Z' 8\P.8N)Y[QF4YF%\/W+T(A&'$Y(.T0L$)[/SB4G4Y$#4P&]NGV(LH
M.5[$CR<?R.C,&X]QP>11H6PT4L27O",*DY#C;@1,PP8#T**J"?&>0'Z1@[4.
M&@\*<1T$O7S\,A=?0%47&'/$+^]%:8"\6( %\10%I47BHO$4YC%1V0)@QL]\
M>AA6'S*?^N+PFBJ&<2-TY,Q 3<#CH/5++Q[9(WI^RABO61\BG'S;$M7\:7U@
MB4*1%[25XJRBS@(1%FLI<D?-ERFT6Y4J24SY%#3A2L@9#EKT2(/CZH=383XF
M&%1T34(8^^Q!-%MF%I@<('EGG+=[/IBCF-<0S&=HF&*QW% HWMHYMHL83M(\
M3V9U9K.])9=0G)5 +$?IFI)(5QS93\2AZIO_BE=A3;6/3>V=Y[L8;6"S&8!^
MY#VY/ V&HL1>$ 7/ ^UB8K.Q]N$[&\Y)4ER-QR# _09\@4+*<D4<:,JBU(!E
M66#PLV5X(@4UMY(FBK6_=$_WE4MI.<R*/OLANQ712QS_24W&HXM,>KD[UBQ@
M;Z)__"R]QTCU<R\\\Z+?WJ*)/#U4N*%^?YLW;?,B0]_F5?RIPB_;J@O_=I,2
M2GQ5M[O%J^BAPJ_J;3/%H 9?Z51UFN"KL6\W[-N3^%@]C;"W9$@*QJ(78='>
M"ACM!!H+RI7Z*2E7I&:C+X4E?I]H. HJ>\(E1.XNV8J*?VR30C;VL#- H/UH
MB5X<H# )W2GXZ4U6$ZK>Q=:ZBEI=)2:,;H8N].Y@X;W<V;*6(]%SU8%G?,0L
MZ>N=+8_8^?_;^[;>MI$DW/<%YC\TC 7& 6Q%)$5*<BZ 8B<SGHVMC.WLG#DO
M D.U+)Y0I)87)YY??[JI^\426VQ21;* W8'M2&37I:N^JNZJ.HS$HYA"#;=,
M4>']?M5--=Q87-FW>;J_/E[_]OO#!8ES?4E]7VNWZYNN;-['C7SD_NWEG"!:
MEB-8%E5'RU)XRZ)N3@TT9(RFE6R$FKO1=M8VZ'-\GO6P.,\2-$%-49:*,PBE
M+EWJ][-4,3B'\Y+\TG X14HD3Q7-B<3C8/4&>E1QCRHQ_1(_\,.\#6*X<05X
M\]8NF)R>LGUZ<S(G([@LV2S?K/9*DK\\D%:?;S:!9*<TU_,B^?7:9MG>T2PP
MZE6%]0K/BJ2>%66^+<O&0(1=E85=E_&E'GXDM?7Z$IC=<,R-)\/%I)&16MN\
MGXBGYT<72[/60C^/=T(*PS[T\M7U\KRD)2X9Z=O\#GE0%(>?*MV=]:Y-M;AC
M>Z]3I6:\@@TK4/B9"5^OZ:+"1_""X 7!"X(74"=#10$P&6?P#_5>94BV;[8$
M!Y8M1A7(5@74FNCY,$(9/&]!,(-@YMCG+:*N"\];<HF.TU\,*65P5SRQH)_'
ME 5Z>?3R8,Y;P#M\3+EGEG*OUQIXWE)5X2NU-IZW('@I#OL0O%06O.PZ;RD*
M@,%D>V;G+<#OHJ("9*T HF>N"&00R""002!SW+.6S9E[8'8#)O4!XPD4"WIY
M]/+0V8=>OKI>_H6S%O .']/M&9ZU*'C64EWA"Q^T(7A!\(+@!<$+J+.6H@"8
M@_M6]KWHFT.W^A0ME</+/@N>?8NK= P[MA,&G]8IE.ZBID+25 2+"!9+#19?
MQ\/NYK]-I^"]?1T%YX^F.;Y8F1G:<?MWDSE_TT$!-@VN[(#/&(Y\^L#6^<'Q
MK._O?_D7(6_-$>U?W$8<Y70'EZ9/+R>39._C,=W]=R?75SU%TYHGI$\M>V0Z
MP;N3^@D?+\L)OJ,#MN'ONC>]/TRWKO1X_6_OH=MCP$F;_L9?T'MX'M/NX$,4
MV"X-XF=W?MI!K_-DV@ZG[)/GWYL.O8G15F]*5>\^9$3P&;[S+])'_FL0?_EW
M;T1_CP<E3[YV$@^_CE?4>:2NQ:@^>:^^?;V+P@D/9ES\XGL6I?W@D^^-KNPG
MQM,X?;58.,]DS5G26F;)N0Z=)U_OK_A,1/_D?2O6Q87R)"![E4^_F;8;?/;X
M/W1=OL:@.^C$8Y.7V-,N"WM>IE9D!S7JF>R@Z>1ZMN7CN?5+KY>_E_0D>RDA
M-Q38W(@GK.]@12,SL])0L]DW^UBS=2OH]3Q,14,#1+*J2-K^E\S=TF65;V2B
M\E-=O7;')O/S;OB5D;1#<967%7>RX /$IV<COD24+01WKF<E..-@P<D$,CN0
MS++D$E-U.*++P8@FHLASXQ X'FB]H*L%0EJ[]MG2N@^BL U:<AO4S?9C-QQ2
M?R50N>2#QQ>$Z?64AN2%-\1$/?SP'H9>%)ANGSF$3U[DAY2Z?)S:;)K:&D38
M>$X<5L6S1^,'7KNAZ3[:#(D&?_EVR"S88)=;4=>LTPMK%6694B26Q=.CEH9'
MB;AA2?Q*@:Z24CF?EL0B%/:_$?4__J16Q#BVN:66"-:R(3@%MCJ$X#OZR 1K
M.DS4?68-AO:8??C2\\>>SRS"?31F/^SRXBQ.$F"#F.'4LT%@V2<QA)Q)<M5(
MB]MRM1T?1V/'>Z9TKFS2C<>]-:3]R&$B?B&;%G]GGCY;8J2QBW7&"NN,D_<\
M@S=-X,4)1:XZLXSB(FGHF.. 7LQ^>#,R_4?;Y6G^"W7E9 )'0TLY18:9Q"YG
MOAR/&](=-^!A%VI?F0^[MMR,:J[Z-&LV'%/9G#AM- YB1B.3\^SEB:KQ,N(W
M=".?^!-L0\PI'"(#SR<,)L4M= GE8[X9=N(?6T"1Q8?M@)@!^XKC>#\"<FJ.
MO,@-XVO6(]MQ& (/7EV(GJ$?0["(5>1BE?G&,#8GL1L'3F(W#IO$GA4_K6H/
MFU<TW#)%A??[53?5-7]Q99=V*U-@F'CLWW@B@,PR 5 N>U7<LJ@Z6I;"6Y:7
MIL6GO3TJV0@U=Z/MK&U0?!!!EDXB#KD9?6#_&(FMV5'J0E*?IX[!.9R7Y)>&
MPS"F!T A$0NZ"N-1):9?]A9TB8XI 5W05:4*%^ -V=*66I5D A+JU9'U"L^*
MI)X5X5@EA%T(NPYH]0=^*&0U>\JIT%L'5U,LS5H+_3S>"2D,^]#+5]?+O]#J
M#[S#3Y7NQFYONR?K&-CJKZK"UVLZMOI#\%(<]B%XJ2QXV74R5!0 @U-U,DNV
MBT[6*NDA3G550*V)G@\CE,'S%@0S"&:.?=X"?BAD-1/[X'OPHEC0SV/* CK[
MT,M7U\N_<-X"WN%CRCVSE/L!TW7PO*4LPE=J;3QO0?!2'/8A>*DL>-EUWE(4
M (/)]LS.6X#?144%R%H!1,]<$<@@D$$@@T#FN&<MX(="8E(?))Y L:"71R\/
MG7WHY:OKY5\X:P'O\#'=GN%9BX)G+=45OO!!&X(7!"\(7A"\@#IK*0J R6'6
MO82&5G*SX-FWN$K'L&,[8?!IG4+I+FHJ)$U%L(A@L=1@\74\[&[^VW0*WF).
MG^ (OM7Y?2M?F8X.7!K2U]PU[;!SW^M^*LQPU/5)U]LH%^)-2X W&FS>R&1+
M&SA;1&9B2N2+L7-.\QI?=-CJLCXI-#5O=@YD!L ;$9U9G\6;FCD[IR^O,<>
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M ?O8=!R;F1O&+"[_6",L;\3L:$A";\XHMC;;D;HJ9V'E^#L9HVV?Q-]G',F
M RMJ/N/#&5,EVQJ2'V; Q,R-EQT,F1K,96]:_XN8@^>&FDNI$P2>9<>-?7[G
M6GW)G]6/8O7C'P^Y63T?L24,^0MMKS^]BG!C^NPUTWL(QMDR_Z=,B%^Y0_WR
MU)@']MK)Y866JM;?>&P9_OQWY0V_8!*-W-D6'7@<8L4LX-8_X-"%DR%U29NM
M>5(9/L8_RPL8VWWJF&&\=D\N#^E/:D7QOF*?,!]IO.WDVA"V;<P^VYZ,U_YD
M"P?1F#MA,HC<230C]862/=K89_C?YTIL+W#;W &<,76/@303SAD9,"/$=L49
M^<;O C%Q3>R4X] )G6?$H8^F<\9MUY@9M/BSOAU\7^)^O.LLAK@GO[!W?Z>3
MIUOLD;;%=]@2.SWWC+ ?;#?^R##BH-2G 8-BW#VM,W\+XDSI.@41; Q7\\.P
M-Y)5>2HCP-"./L4!)[?9U(_U-6Y.Q?6 V3\K_I>%?GPS WX_;6(AIV"?J:WM
M6MQO,//#_[X$F6?@5O(>F[@WJ8^T9W?SV'Z84C[UCE)?8WD^8P[C*J$_Q]0-
MJ&0/T+<9= R9\3'#T+>_15*?/I$IQT],RL&86O: 8="IC.5#^+E(_$D>*)BI
M)8E=]]35K5.<WR(EPY-9N,_0$N7PD6$PUPLY\3;]P7;=M^>8).X*3/?Y5P9(
MAC8=+.U"GGJ*>S6.S.^,/5/\Z5.VJ^G\<?U)AH8_CS)\0T[-T32+Y<YNI :O
MQ.UT?=-*MV<V>O6^Z,['D"W/B?_VZ^8RII=*XTNN$V,SX?OB(JMCC@-Z,?OA
MS=)[U)7N+%M*<M7=UYQSO%&NU0]YU^1;XM?7ESK%9-F#T4C=LR?+U243U.(^
MNK9Q'UU;Z=V4Y5JU/>6)6;>S_#2]H#[KL[SE@KIP:\.,-M?N(GS<\<EZ0Q7"
M.D"AY, B(@4@*89R5#L3)Z9^C].M@N9$6,-17U%?)>CK]H,-U-4CZZH*D!1#
M/:JN?ID=(EQN.RM#C46-A::QW?CL!C45F*8*-RS.0U./&Q\_>*&Y><0,,0#>
MTX6N4 'P-DFGZ09T2\/9$=XL&YVC]4G40R(?VP.B"_;V#@O";;&%HQ;A]E2[
M0Y T"JF<U5MZ3;2)LG%(<Q)4K"HIEJ88PEU34:UR42OA.$!8K7:#^E1JI0LW
M!T6M0JW:HU5U-%4PE2KSR379=)R>0JN&UJP)]YC&F U8S';I!>'2W?LS0G_R
M^T23FS)CG_(;S_RV3'RI:,3KE_YYH<8&DD7)IXOA>H>X8Z-2HZ'5FB@8>()1
M#/%&R:44S'HWTV-#(]6H:2@7>'(!#UGS$<M!G?@S!'TM[8#)5PCY@$&^WZA+
M?5[PLEE#].)U^PIN/F@@0FUIPO$6"B8'P33K-17E @]$B(]H1K'D(!:EH:!@
M(*([O2[N8!#=04-W\[9$\52$_K0QT:R@&I$=0 "A:+46R@6>7,!?':DF@$"X
M#50LF+,#B.J4MK 50U '#=1=X5%LL: #^.N!U12+@L=]"!U0+$EWBXH'#D A
MG>@U'X1TT"!=AS>P(O9H;-I^W-'*&IK^8YJ"J</J _.YVYO=VB0T8SAL<<?&
M,N"=)HH>10],]&I.HJ\P5$;19R7Z!G0T#E7TZ;L,'AOQBXL> 3\TP-^=MZ!-
M<\M2I%PLE<IC,Q> 3=V.#3S;#0/ZW2U4J^*IE=JH0Z^/*H=:Y=LD[=B 62L*
M8D:M*I!6*7H+>I5M.=0JWSYYQP[QE#.M)>X%,<R#&^9-Y_V<.EX0O#I&K,<O
M?SMTJ_)KQS@$ D*(DHGPC]45+1V_CHW\%:U5$YU\43!GBLI;5N5MEJI=6\5U
M5TH0(UMW,XQBH->VH.JBZFY7W=,X C\(4:/Z E1?*7&^;/7-L,RZ*7P)_3A1
M?K-$4;[HK+<\#T)S/5,2)TQ!)B(3LRUT$)ZF@TQ$)DIAXGIIA_"T'  E*SBQ
M-9/"")S1' L-9S0O9C07HY >=SR8D^_*G^'CS%N<T8SZ6G!]Q1G-('45)][B
MC&;4V()K+,YH!JFI.*,99S2#"(!EGS[BC.;#5@7Z!+W(HW25LWI=+U/U%RH6
M#,52FWJ9RK_*I%8X31>5"I4*E0J^4A5[1+/:JF/S[\*';#BB.>5Y#B!0JK<:
M.+T"HF#X5#+@5?TY]LE#:(1B0;$DQ8> ,%]3%:])1<0'#?'AA.9"8@C5T!#<
M012,H2*V0Q"!8DD\]\6 WAV@FNBNH8M/Y$%T!PW=X83FP@$(145@!U(NT!LP
M51- (*Y#L< 5"S14IS2P[6OA01U.:"X8=- 1T4$4BP+]SB9"!Q0+&+$H&FX7
MB)!.%=\O".F@03J<T"QG;1):,11SK!5XIXFB1]$#$WWQQ_2BZ"LK^J9X:V>4
M_0+ YR#[#&]>%J6M-T+^),.[<$8S0$HDP$DH@P2S@YXMHU%K%<(+H5H52*W4
M>A/Z)=IRJ%6UIND6)5I"I2J04JE*$_KI;CG4JFHCFM566]@)8I0'-\K#$<VR
M[%&%YM55;,JMTJ@7)*N)RHO*NU[Y6?J@M4*Z6[$YMZ4/C5%URZJZIW$$CB.:
MRZ*^%1O1?-H65][CA/DXHSF?@]!<SY3$"</QPLC$C$L=<+PP,O$X3,09S67V
MXCD<;N&,9EEK+<",YF+T1\(=#^;HN_*'^#CS%F<TH[X67%]Q1C-(7<6)MSBC
M&36VX!J+,YI!:BK.:,89S2 "8-G'CSBC^;!5@3Y"+_(HW;9N0&^TBVI5/+52
M&\V:@6H%4:UPF"XJ%2H5*A5\I2KXA.9Z R<T%SY@PPG-*4]S (%276]C3UV(
M@E$TG-"\@%$(C5 L*):D^! 0YC/:"HY[*3SBPPG-A<00JM%&JPA1,'H+>H\)
M!!$H%C!B490&!JD0T5VC(1ZD(KJ#ANYP0G/A (0"ONEQ1>4B?+Q12K%  Q"(
MZU L<,4"#=4I!L[V*#RHPPG-!8,.F*H#*195^/BBE&)!Z(!B20(=P$\BJ":D
M4\4/'!#208-T.*%9SMHD-&(HYE KI2#U)RCZZB4FH8J^^&-ZP4-E%#V*'ICH
MBS^@6<-KEX4'_#B?N8R-7*HU2+>E:]"O*J!:%4^ME+8./3%?#K6JUBC=H@!F
M5*H"*14OY2Q&XJW@:E6U^<Q*JX[M%$H4Y>%\9EGVJ$+#ZBHVXE:IBV>V"N9,
M47G+JKRZ6I!C.-3=G(*8X@RY+7UHC*I;5M4]C2-PG,]<%O6MV'QFM2%L>H\2
MY;=+%.3C)%(<+(Q,A,)$'"R,3(3!Q))-9WX=F@P$S7_KVT_\Y[>OH^#\T33'
M%_?TD5<:W-$Q+QYU'Z_LP'*\(/+I UO6!\>SOK__Y5^$O)U]X3;BTVF[@\DW
M^,.GCPB(W7]W<GW54QIU]83TJ66/3"=X=U(_(1;#->QQ=W3 T-)=]Z;WA^G6
ME9Y:5XS>0[=W12UM\ML)B5Q[\KG98T_>:XOEOOSVU55.9EWRB6Q=_]%TIU6Q
M7]A_V6?O)VV-[R:C:):6K2TO^UP76'=O^N+>?6B&E"_H0Q38+@V"V?HZ/^V@
MQ^=P3I9V$P_Y72+WZ_V5YSBF?_)>J;=T/9;Z@FX!>F0PHI$](^(!CSNXH#&]
M/BX3]*R9T'&<>!3;[(\[N'$\+AC)N:"O<$&7NR?JNG)<=6AFSXA]>T)MZHWC
M,J&5-1,*L2?:R;G06.%"0^:>:.M&^ZC:H-2SY\/>+=%H&L=E@I(U$W+>$O?6
MD/8CAW8'Z]CPVAUX_BA^SH?GZ3_.4>(21U01P/>>X](I+(UA,@=U,YR\@,*.
M.0[HQ>R'-R/3?V2(./3&%^I*(G/+U12UPEFK'*YR':LX2&84R+X=C$WWW8G"
M0H!UH373UPHE6^OD32^GF+.>MOK)\PDS-.1O:OKDH]NG?<(V:FQMB*:<$;Y?
MBY"FQAT/YZ)GY:^LYENU(9Q\/H:=X>B63/!)UG<@45]17R7H:QR%H*Y"T]5\
MJTR$CU..H:M?J!]XKND0'OFAQJ+&@M?8.+>!F@I-4_,MM1(^93V&ICYXH>D4
M(@#&:JR7+]O=TG VV);XDP1HCM8'T!W3,ET8%8Y: -6,*&?UEEZFLA%4+!B*
MI2E&F4HZRJ16PG$ H&(+3:^U4:M0J[#ZK!)*)1P( BJL4<X:6E-XLB3&;-!B
MMDLO"(DWF,5M9X3^M)RHSUMJ]'$,CEA]RK%1J='0A$>*HF#RB$,-\(TW<FP+
M#0@:J>+CVE N"%FK.@JGI6%K[.)#OM^H2WW3F4"Z/GNG'82\B]H33=4KNVR;
M#QJ(4%N:<+R%@LE!,,TZ#FZ#""*:T).IU12+TE!0,!#1G5X7=S"([J"ANR^^
M]V0'/&4W\'S".S6%@XB!/<OR(C=$9 <00"C@QWQ44R[@KXY4$T @W 8J%LS9
M 41U2AOG'!0>U%WA46RQH /XZX'5%(N"QWT('5 L27>+B@<.0"&=Z#4?A'30
M(%TG"&A([-'8M'W>[HE80]-_3%,PE=TD\!).*5=2+^[86 :\TT31H^B!B5[-
M2?05ALHH^JQ$WX".QJ&*/GV7P6,C?G'1(^"'!O@7LVK3W+(4*1=+I?+8S 5@
M4[=C \]VPX!^=PO5JGAJI3;JT.NCRJ%6^39).S9@UHJ"F%&K"J15BMZ"7F5;
M#K7*MT_>L4,\Y4QKB7M!#//@AGFV:_%VW*>.%P0'#5!.J_MRQQKC?&:07='2
M\>O8R%_16C71R1<%<Z:HO&55WF:IVK557'>E!#&R=3?#* 9Z;0NJ+JKN=M4]
MC2/P@Q UJB] ]942Y\M6WPS+K)O"E]"/$^4W2Q3EB\YZR_,@--<S)7'"%&0B
M,C';0@?A:3K(1&2B%":NEW8(3\L!4+*"$ULS*8S &<VQT'!&\V)&<S$*Z7''
M@SGYKOP9/LZ\Q1G-J*\%UU><T0Q25W'B+<YH1HTMN,;BC&:0FHHSFG%&,X@
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MKREM%#>*&S%9<3"9ZO:KA<G27#4X.GPRZK4FB@8BTE%0,F#=E%9B$%HQR2"
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ME*"U!+P_7Y>15+43A\2=!G_AO\M30(HE!='!4!IG[1$4E;FN?EJ62>X<8ET
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M[\L"16Q7B,X2\'7".T9X_>G]_6C)35(8'<GT^'$P49I1=;#:POQS69@"5CY
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M486P%2"ZHOU!/H@!9!9BLQ!=)\97$&,A $%#IBIX;0%+3E1E 1?#(3J!OX+
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M2&C*"KNW(V?#/2OS\J+3:?O:%W)P4L\;$;\+LL]83F=[[;[2QG=)O2<QF_J
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M1P+R<P"MGZ4['H6XGAOL*]OW[3!,DCX#V'0E/9(FA."KTA4>6;^@^F;D,'R
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MM V3! SCX1QF@'B0)HS$;);HDL3S@QV!F+^N(JX;DMR11Q*F)&Z'T\$27I)
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M6K4S/-8.+;VIW\*48-P?PX\K+E*92DSMJN#+DI1NUROSQ<AX,.L0"G\++[R
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M*)AAZJF M;/QOM.<6')^8M._NNLSO*?[4C@B,<5'@EG$:TI!6?>LUAH'A0C
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M>T%A<>DLUS&LU!/@Z(8AVN?XE.NHI-G5?YTFOE87=Y#01P,/A9=Q&&(/9'E
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M-G)UZ9+Z*FEX16*GF:_37-Y,%[FG0Y([Z3P<O( $R2A+DQ1%/C7F9--PN)V
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M617R$!!1MAM :SVY7FY$V#Q5!-N2I>_XR.*W^SL)X ST9#0I_4.[H@H(*.X
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MTE+0]QQ-ALA./3['T:8\(E?3@2I_>/(DI]GW@3>C\LOG8,HU_Y")$,IQK(5
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MK]&>JMXO*IRRT^*F>8&3&3#T7>"%-GLQU;E:O0$T-SQF4?+@6-&C6 $(G(V
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MSBJQM)9QB! ;"C-A"J(W(3ZP:?:$J$(GK:PV+6E3V?GG+3#Y(B/CY"!R%&;
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MT[,C1D"+A9Q6D!M6[QXY5P8 465.-.UE4:M-;\%@66FV*\[F]CQV;X+H2YB
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M"&/9MC7.!&MU_TZ4@3-=,A!IPOY$PFX>P7CZ$0<(X]IB^G<;!Z5[<Y8EGV@
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M-$X6HHIA5CI(%M$?]W1N"'$T7B)H4^/$(/881ML ,8?V)AWWB&ZXI\D-(RV
M R![]J4MQ*% @$'=VX  HLSMZ92YM3#P;,@_(F9A9*W,/U'0]G3N3EPK_WL[
M%1L' 3&W,,16@D TN+U&!O>%AX]!=5>0%NDR#(C'A6&V;B3Y\,Q#[JSBTI4(
M/:+*[9E5N;OV-;Q&V54T3A8B=&%6.D@6T>GV+'"Z$*^D9#+?9)P<1._"J%M'
M3@DO?:+9[6LWNY6M:MC_F&:GC[A<F('.L$/4N/UV-&XM@-2^&\;Q0)0L#+)U
M>%SY'T62J\Q9G^AD^Z:=;-[ QE(VKVD<+L3*PKQT$2ZBENU;H64!8?W3_JEQ
M9A O"\-M(S/N"Z]DAJAM^[JU;>T&-N^0LIK&X4*4+\Q+%^$B&N%^*T:X,6&B
M0S*]?4PA- 5F;-#$8+% &1M$6]S7MYRWI"%UULT8QP*1QC#2-F-!=,=]S:M_
M#[!Q:/V+<3X0CPQ#;N&IYD%\:O6YAFB2^V9-<K&%S=>[Y%6-\X789)B93O)%
M],E]"WPR!ID(W,PX-8A)AO%ND9KPR?'=?ZAUBN?%6Y3G_O).9%E\9_7G[>JC
MZSO^PG4\M5-8$F<W6HB.7R3@P%,JQ@.B<A[H4L[OW/R\/RL<E^T=F(DCL^*A
MY>XX^<'9[NAL=WCV17X 4Y]@_*[? >*S87J_/X*)XGN@57QKPOAF_O#KYTMV
M^Y'=WEU^GC]<W=[<G[!S\;^WUU<7ZF\VO[E@=Y\O[R]O'I(71.F/5S?SF_.K
M^36[%R]>?A+OW1OG%A'M,*D=X;9ZY^+Q@.C>![K<^WNT&>MC3]YTLL[;3C8H
MZ62MV36[$/,"GR9=O=PW>N_)<;LE1.+:[W;UX'PKPX]HYP>:-MVHTZ3];;/W
MGYQ7?!JHO/P59VY1PS@XB+"'&>@&.$1%/]"Y[7)S>A9[]%BURFZ B'@8_9:A
MF4<1CR.Y&47E/:P#HFL?:-IW&6W#/A')NVSWMG$.$+D.XVLI!T2O/FBV"ON(
MWJ(:!D>]:\,37@JA*&!@4J8WP8#HT0?-/'K#Q?C=P@!QYC"\1C#X)*Y2N2>B
MS8-M5+W'P8#HQP>Z_'AU:_:H*"]FG!'$>\.(6\\(T7$/M#KN!J 8QP$1VC"X
MYG$X>!H9$A7U4)>B/MB@0QV'/:/-(>*.8=R[  O1!@^UVN!FQ!B' A&S,+XM
M0W&_]9?AZ[7K/*9/PCF,!-&Y#G4YUP/-V1^,)@59H>2)15>K0\21PKC;CPK1
MCPZUKEYNPHMQ(!#W":-KE_N\XZ$;++/-5;-=P@_,Z R)9G2H:_$RN<&'E:EQ
MR!!7"O-A9-12?9$S)(K2H7Y1BEW29);4D@O>(:)(861M3#_1CPY;\J,H ^G9
M)K5CQAE _"@,KXT,$.7HL"4YV@4&$#D*P]LR XV&G40O.M3I16M<FQ2*V'1-
M@OA0&&F;L2"JT*%V%5J##2_PGSZ(JFL6/'KNDUKT8[['0-PHC+;%:(R(3G34
MR(D><_;H*AHCQ(3":+>,QB_<YZ'CS?WE?+EV?5=>H,7B.NSRVT8^.KP,$J(+
M'35RH0U/*P>:M$]*6E@MT=XOSM+RQK%!7"F,?S>P(?K242-?>LQIIPD[QL%
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MN ,*IL4D4 TW$9STB JYUX)"/M"RZI[)XBTI"\$KX&2)3CX2)Z)6[FG=>X'
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M)_GCKCK[W"1%CL(C6%G[**(1(H]A[,UP4N-IKB.B-!YID\9X,_"^0Y:PJ.M
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M?*0_KWO='F([M_0YRVN7#S6K^QS3 I:LQD>(L@TA.DFB$47M44>9WH]F6W"
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MD*UIE?9'W](76[^J@#Y/A _OYDV@^3M5?6M'[*:O YK^6M:V?ZD,'98(M"=
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MZ \;F#HJ=X0),FHFK@)9A/V>/#%]2W#)C"4&GK +K/1R[\U6,2"ZO :6NKQ
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M(Z@*]DS;V?[V:6&>#9BZ#2%HG0T'.$"5N&=='/#?U[.#LX4]XP$F@$, NF8
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MZ=FF'MH*/:G::%_;_4Y:!C+SM,#448@"Y1Q4%+MKF7C]EC]S?\OGRW]M(W4
M.-H?.=2GRJ-]'5&D![N3GW_*"K*T)"L5M2<>J(^)I=#T1@A 54C[7829OCE"
M8,(HA,(((:AJ:+^1&MID=FB'!>;!QW1.:'8]X,M @N3Z5+XLKF,]0 FJY-EO
M)'G2)XE]G:S%D0^LW$3YPFQ[AA!,(85(6<0BJG+:;Z2<MC_3O M68=HK1,XB
M5E$UV7XC3;:EZ8I,)?:QBDOF*83)MA F H6^NKZ[WJ[//??1%3O"^:,\.W"^
MWGC!"^?1?2 O' _=AVW,[X,T@NY& %5)(:J<V]=QSO_(3F;L2:NSK#X3#:B3
M$GD3\EK1HA'YK[09)MLQ3R-,#X90V4.C 54:'G1Q8+\E6O&,5HZ@E0Q*XSFM
MY$7'!:W$OQY26FU$.Q_8"W?,)R0JV;K$+H@@*6A^Y?I\F=M3(" -F9HZ_.K$
MBR?7?RP_KV0654\>Z AF/:*#Q:$+5965GZE1)QN=0I95WRECGC:8P OAL80V
M5)UWT$4,; LT6I1I)$>9;#0*90*TA$;E,N8=!0-,$89X6<(CJD8\T!9"2R#/
M[DC#YFOI*S!/#$PIA@!H(P8O?UY:&6263,,%*JE"59,'.N)M6^ER[;F+[SXJ
MK[F+62UMU#S?,"$:HF@MWZAB]:"+T%U;^!=:R#],"X>H6LL_JC(^T!8,W"KI
M<&K9,F=B2CA$ALHA8,JOSD^Y%Y[[_M;QE.%N>&[(.\=SPA?QP4*.!8^5:?X&
M5%5\H"<) [G#.^,5-EREK;&DN709)NH7XUC2)"O:-$\U3!Z'$%I*-:I4/N@B
M?+E%ZF4,*Y[( ++7],H5TA68*<WS#=/2(8Z6\HVJJP\TYGGXDV0[.$&2M:FT
M"W/S,)2+D?6&^U$2X1>& B#U$U(3%A:\7B5F4_5DB2J*#:F:^U!'.#:YNZ6Y
M4S7$RBVQ4E,,8=_U*B-=WIYQB@TQN1V"9R7%J.+[L(M@[M8HEQ%JLS.<.<D:
M+4IX%3\Y,9,WS+@+=^,D-\JH6'#!U#A@2]FF;(")$7>MCA;*(&WYTQS_Y2\1
MPVEMA==QB G\D )6$I4J]P^UA76WQDY19.W&,B9BF3T"]/Q0XJYY/F%"/T2J
M4SXEZYO/@;^-#I.*JOT/=<2'M]-GZBR;;EQ5HS;-M9@+ >)H+^6H/H1A(Q^"
MWG%L'^_V#V8/LHY=8QGF*X!HV4LLJK-@V)&SH$6.[5W.*8J]Z=4<YEV -" P
M]I];83@>>B_R,D=_X3K>I2^V^&MEA"O7YY<Q7U?>US"DN@^&.@+KZ_4I8UA>
MFN7%6:D\^UW68*J*^?#F(>8J@"B8(P35&S!LY UH,O>]959@JCZ$@L *V=OK
MU9D8)=WXPI'GFN.7J\#QSX*H>KJBRO5#'>F6]_4D U]A*W-QJU(L*\9D.28+
MFD<<T]6AP;M&G"J8#QL)YD<N4-X( S#1&P+0,0-&5#U[U$C/;C+^UX%=_LV<
M* K$>"_W-3_<^(EM0EZZG]H35<R'?X\P/1H:GW(#<7(@QW^\XD[$KQ\\]S$Y
MGW-P#3"B"LXC'='>A_N3WT.<E62J*"N5M6O:'V%:+[2^&1)0Q=R1-C'W+3(!
M4VDA! 0F_(,[7OR4I]VJA)TJMXYTR*VO?GP&;_(QRS\W#R.F?$*3=@ C5<(<
M=9%48S^L;O;Y!\;SDZB>ZSRHF=\\UI@8">W> =9457&D+5]&38#-8XG)=-"N
M!"Q_"_X09BD+E)5P4B6YD0Y)#O[^#,SDR8[V:AY/3&6#ANT&3ZJB-NHBZ\0^
M?$/YZ"^[ZKKM@S,FJ$$DNB$ 548;:4L0<?"M7ECU5F.:&;0N[8Z/%8_D]1:.
M=Y61N1)7JE@VTI&U >U"Z1J7_"&[LN=MQ:0P:-ZN@!U3-;!Q%WD4Z@.=#\NV
MC]IC3!2#:'3& ZH.-FZD@S6\N:<I^.;1Q=0N:.,V,COE.X[[(':\2GRI$M>X
MD<15<P"OZ 1,RE2D4%<%S..+:5C0QAWB2]6RQHVT+&J^MT-XEP;OV [ ,;4+
M&KU#P*FJU[A9X)[\+7L'; 7DB;_5F,P%#=TJR%>!_WC/P_5-$.[;6(VIPM>X
MD?!U]/C]JCO[,)=%F2S+TL+F\<>D,6AY(_A3E;)Q(Z6LM?&]@@\*>QGBR#;)
M ^FMYG#X-T\)3%V#8!BA!%5L&VL+7WMKXP*FL$'SMTJ"\Y_I?1YUV4!5WL8Z
M MCJ]VL?(_(Z-G(#$^H@&&:Y057OQEV$NE&XDD\8A0;P@?&<-IZH_U%.-^;I
M@LE_$!^C=)E0-<&)MKBXMS^>3#!=$")"T07STRG!*OCA"^,^N1OY CU$[M)U
M0I=7!DI-J"KA1$>T7(T.E4Z!'2IJG@&8=@@M;X@!5!UQHBU4[B@:R'W'=598
M3"/LSBHJ8#(CA, 0%:B2XZ0+R?%H5@1E5M@U0&!:)$2#P(H+QPV?'6\K;!8]
M.:'XSR)8KP,_BH/%'YN#N8@F5&URHB,Q:<U.96RH6=P\&S#1$B)@D U4Z7+2
MQ4G@(]C!5'EUQ)>I.O+/I!93U:PZ4#[!Q$V(C4&>4"7.B;;TGL>0X]>,''<9
M-<X2:MPEU+ HT>($$SDA'"TM,Y2G2-CO069,?0[DD85-\(.'XLD37R0GW1U_
M*8"NM0JAJJ 3'2D]Z?W%=BS'M62>7IA\"G&SDUY4677211I/'713N2=D6RQK
MC"6M,=7<J]04ZCI@T:9E*V5,G(60VLD\JF@[T9;04Q?=5!2 9%1"MU\3NMWL
MT&U1XMNUX)M=^W5,W85 4M3=?V_=^.6S$_'E_(<3+I-KNJLX-*4JN5,=&3OQ
M/N2"K7K*U&.6/&>_JQ+FCRY.,7$6&KD[?*EZ[+2+=)DGC#<FQ4*C$_!6FX.2
M:?;?OSFEJJ]3'5&<>!\R?-73C[OPVG(!ZQ335Z&1N\.7*JE.NY!4F^)M'F9,
M,(6V;A'F^^!K$/+[)\>_YWZZR%%NA@/X4X73J0[AM&'G=HBP.Z[?!TQ69;(N
M$Y4S$21QP5@T+F":*@3' L)0M=5I%]HJA4 ?'Q2!G(1 <<#DXE_Y9N26H/?I
M_V%!R-9!HK#)#>B!/>LVLG.K.L7D60@O@7*)_*C41V79:+Z-GX+0_0]?7@3A
M911MDU#M_ X&6?)&4.=)(+#O+MXI5;B=ZCC%3>YND6>ID&T3,3=B15OJRJ^L
M-3G %9=1J I9BW;DZ)QB2B_$STJ6487>:1=GRUMCW;>M' KEB!4EE',*RLEK
M3=R,<F)(W$T1FUT.G?B@V"8CX,8* F):,(26,K/*7L^?'=>3>TAA](MMO UY
M9OKO_K*X9J86[Z@*\%1'8.VQO<SG5L6-O $UBB5-%(.9:J08SRP;R3!I%V)E
M$Y&H@NZTBRC</XF%:;@0.P*QO@7^KSR*^5+9:O\"?T95<&<Z%%RL!_G$%?@?
MDX?I"LB:7=T,4V^A@;M"EJK=SKK0;O<A?<?#9W>1:3VO<3</-R;>0JNW!O=W
MWXVCU";)9M=?BLVM2L/MIQ\=H 15WIWID'>/[67E@*":8!_9+G_DKKS44/JI
M/8,')A5#P&QB$U5,GC42DYLXD$U2RCR3,#4:@J6525^=\ \>UR$159&>Z5"D
MC^C@$=1)VK!N(,*T:0B3)?2AZM.S+O3I[NEDGD68W S1(K"H9#*E^M\[X2./
ME2B67&5?R1FJG#S3(2<?[$YQ"90L6/9[L:1L&@B<E#9/ $P)AJ8W0@"JTCO3
MEMB@(0O*SJL/+$YHX+]6=N. /7 6\@5WGVT8&C")%F)BA!E4+7;6131N;9*4
M-'XU=VS5W/%*Z'<63RY_3J[&E$&0JC'Q;%,L;,U3!A-C(5@M4B:]:J\.9ZBR
MZTQ'ZM+#_=DSGV3W#-HUH6"Z*32^"0Z,/A%55-5 -S/*(2+L3BGKE E@3BD-
M(G9-+R53%CQ! #+#$Z(FJQKH?'ZIIDRM"8;_7'"NLF'8.+>43%KF2ZLQN-(V
MTCG%ESON+>";_^)&"VE>OE2'^VYXJ&Q>R2:BG*L::'WFH?9VU]&7-/3:HX>$
MOK"BN?1HI&@PF<',4PS1=A'T;*084>-5#6@?L-JEG)M0;JLHMR_8A2T+RB5'
MM>7%RI$=E$-$8 1-&RE'5(15 WK64FWQ["9T%PE9SN]N;M)E=M*N>>(@\B^"
M22NAR16WHG]^*8K<))=-JG6(//:N[%E)':(:K!IH?T(D]Q>+>-^Y0:;4&/O\
MPLKET@;3G5V1.< \T1"%&$'03J(1)635@*8QJC6VV<051$Q&0+"3*T2U636@
M?PG5&FWNGSA;.-YBZZFLB*O7B6SD7)F*#.4;D1+%P3S3$'$:@= HT^9BI;#>
MJ)M7;_F_MV[DQCQU!XJ5AALL*ZE(E+=5 Q;.CP<-HF,"9:5O9?G79GY9EGRQ
M>3XCRCG"@Q/E,U%Z5PV<P-!:F]]R[ US*D8I%3>J#(N?G)C]<"*VC51&8W6L
M(QNITQ3Y\J-3&[$1OP#"C--D>(_J6.AI<RQT2&MK1]<>YFN F!&X=^F+5X[?
M.S^EI. %T3;D5P>NFQ_UJ%Z&GHXLROMZD@&=E&&B$"M*676[?,DV9<C;=!<<
M!3G5%=!KY HX<B9\*Q3 Y'R( "5"4OG5KE>7_M)]=I=;Q[L3=N31W?;A7WP1
MWP>Y)2L)017N>XV$^YIC0/U^00]C48<EE5A:2QZ*+EACGAV8\@[A,,L.JL;>
M:Z2Q'QLV2V"+6[ E2M@2I6R) _%0L26V@2V8W [A,<L6JJS>:R2K-SKHH9\B
MYG-WE.Q7)DF;4OD7ON)AR)?"4&)5SN,H^^#\IUS:\^_B@XT3QO+W7*_^>QO%
M8A5^Q^,X^8GSQ2+<5MXE.>I1Y?*>CHCK=OJ<\2JKK%8N27LL_RQMD7V_8T6;
M['K%TE99T2Q+VS5/.DQSATC:2SJJ[M[K0G=OEX1)=!9[X"N9L,CQ%!JIM",5
MG52W$9__D+%7D?Q\F9%4C'7,D;^!.7$<N@_;6!VP%X/ADB^WB]A5_^+K31 Z
MX0M;NBM1D:MF)'78][_?_;U,[Z"@=U30V[&%WIC0#SEC+[VI6GZOD9;?9%)N
ME]-W%G('$]4A(&UR1VZ:=ZVXH[KYR\_<YRLWCGX+PC\$%.6GE12BRN<]'9'K
MK79]W^RL)(;7,_2N5\A?LJQQEK:^4\(\$S'Q&^)J.Q/[5)F[WTCF;FNN;I69
M^?0;J3_S:9FGS-QUO0AF/F3,_)$R<V$3,_N8- YQMIZ95"V]WTA+)TVS;= Q
M??07R\B$B>X0FC;)=!T_\?!L*SZK/L[1IZKN?1T!^'N[LF]"5.586M \YIC*
M#BW>.>948;W?141\+0X<LUM<)$VTLFOT@UCL#,5.P(FY]Z*BZ;W @N0%)8C*
MU&M3PC^.>E35OJ\M,KX6W]1GYL'%%'=H6LJ=/<Z+^#6>L,5Y)'[7CTH\J;IZ
M7T>X^NM?GQ]:2#Y7+SQ73\Q#B>GBT*I=0$E5N/N-%.YCK_$Z(6@Q]1E:F7**
MER_=A1/RW]SXZ2GPEI6Q%7VJD-S7<0,@^/GY,>[T <N?F <3TUJA60E@(CN:
M+WP31&*S4PDK54#MZPB&WM.15UNT7:DJ*V0>:TP;A;;N&&NJTMGO(E#X]+''
MU$AH^VZQ'U"UQ8&V$-H&@.^H?TM; !]@(A\T. 'P?W#'BY\N_6@;RCWH0;"I
M<MU 1^AK12<RC)/'+']NSPL]P'0W:.,.\:4J;H,NXEQ/%V],<X,V[Q!OJMHV
MT)9CN![(;@ZR/8,VIFY!0Q- 5D+/5S=:<$]8D ?;Z"#.5&EKH",-<'4_=B0M
MME/$HK<94[J@I;L%FJIY#;I(V'OJP&.Z&+1\M\!3%;*!MI0)==%>[Z"=CN?F
MP<:4,FAM MA7_-'QYOY26:$(QZJ&FBJ8#70(9E6]R#!6SU7(3X)VJ8AYC#$!
M#9JY2XRIZMF@BTRYAS!//:#RF+,,+2RB;2(6\B1_11PP3S%#W>JIF!'9Q Q,
M;H/@=,D,JM8V:*2U-1GHZPT!E@*-:6O0UB2@'6%)UWEP/3=^J8)W2)73ACHN
M#-O][06>,E5?_K%Q#(>87 8-JA]#JDHV["(-+8YIW2%;(N^EE2VX?[EDLC+V
M;4II-;&G*FC#1@I:L^&Y^B7V['F),8T,6I5RQ?&3$XJ>GNU)DCFDZF)#'<>[
M2S\\O]PZ^8B=V9 4=8@I7]"4FJ&C2EW#+LY>(U#6&WD7*> +*P#'%# (@&;
MJ9+74-OQZ3TOK!WX84(6M"<!O_,H=M>2NUG8S)FS.3R'4K6LH8[SS'N[DL&;
M%V)YG) H9M,:&9.SH,$[AYRJ:0V[.$U<BP+UQG&9"8XC9)G?V+06PW0Q"%7G
M9*&*8T-M9W./'B3LPAU3O:#56PC0+\?FR,SNA[&GRE]#G8=J*[L#S@7M1)BI
M"S8LFB,P+0P:W@3\(ZH\-NKR).O;H,,(D]4@$$;H0%7:1MJ/C];GP$X,HKH
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M$NI6>(][5(3:TX%0FUJ3FR0OEV[WE)=DU:+=:X^A5!CV+K2G\M2>"9YZ5E[
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M@LFD$U]^B &1W"*D<9;XA KN)CJ6J!_:JF*'E&H.%KDT.3^%R7-8?I)%QL!
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M@><YH8I!K1NHQ&VH8VES8W/V_OYEV84J:XO^&&"#D>]$?RIR&YI8OGQN?L!
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MQ./K]<9Q0_F5>U:)S'I4<M;3L6,=TH""KLA#K#QFR2*02ARJJK8ZF>P(5:D
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M.^P!*$!$T0%= 8EM1L0!C;/(DZWLB0)5E" Y-B@3(-@=@ *L>6R@H1@;*.9
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MN&)QFSP]_$9"%[*:T^IR$RKGCN\';XGJ/*S\J41!-:D1@&Y$/I@4DQD[#R7
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MSIG\:QQDHN[X_9ANPZF8PQ65G+  4;E! =VQ1 +..4?W)?ECK5+D49N5X>#
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M4H)IJS=*Q:IJL4.<@/V]P)^8T-;-.( 7B_?%D8>VPNXAM=6:I&*=M9AH(Y!
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M& -)[37#9-Q>NM?/;@><:T0!J"(.,75B'P:&L/SA]UF7%F.A3.*ZDBVVQ0,
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MP.'7TQ6^#-36PN.XY-28E 29:>E1G!N5: MIL[IDX,_C]6G>F'Y,HE-YT2N
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MQO0[/$)W'@5*:NM\%#<QY,#,M.AH3H",]D[YN/A(Q=4B<  <C0)/[F;H]BM
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M!+].K&V*0P&2.FSHBKOWE$!<KFLM2HTTNE<+(9! 0DFW@?L.T%:'_1FGP8X
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M3_Y,7H7V'@9J$+FU8KZQXM ,8"C2 :I2(Y/^Z(<5=OR'E><IS$;Y%X J!$Z
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M$UGWJ(Y4]<2B<[01PW2Q2^/EKUF0S?UP*=F^1FDND+@#SM.NG-B*K<.]1LO
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M @M<=Q&MVX+)1,3+)/574#3Z@;P1"G$EQ"U^4"X<#-2BC'@* 6:D/\ERC*$
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MC16W+-8+*OA\A=AL<Q+%+9E#(8O7.9^IO@VR KNE#F,IY=^A#AOM3UR)LA0
MYY^#Q8)++&<84.B<W\1I,BQFM=3%4U<]=YLM?;]F":4D22:S_V1^XI?84L<4
M_D!M^C),Z1;V1(]<B3<3*6?#60$+Y[PK?K??9DB4JNW$Q9BA9R6=/6#B/"V5
M&PS4.G%VK6++6&9EF>W^M9(),>GEFNA0RWTY*CL<*'9B#Z_ JZ-76]QVKUG&
M9&4R=GE'Z.;PY/T2/_/=_B70X<3>N04;0VMJ67/VH:1%I]=@.04GG-PJYNQ#
M&8?%9K61["F9WGLQ!KU02G"Z*(^NCU$P%VW"]2. +B?VL2J*C"6)RV$K;VQ,
M2L'D#E6=7[R%[O\:Z,&R4W$18V@"DZ-6-B@3:)N\P_H]2E[]&;D.7XMWN]]"
M/Q6?5=BC@#XL]U-,]!B:(.2J3B.ZJP%UE:50(L4/H<?D \P<G$>KE;\N866U
MSM,#M,"4.(U\_.['Z,NAQ5S9G ZI0I657P+-"'2;A27[@+3/ X;:.MHRL)B7
MNK8^*:JW?@MT(P@NL1%E:T\='T[KCT4';MTA6$Y_JK^E=!\A<-G8B'+TIX8/
M##5K*YOG))QO7@+X1+Y+N-9<]#1Q:K*F7'$PV#L1"#U1WCA*XQB1ONG@RSCE
M27#=RLF_'2E].309*5C7/@V7-\1+R/0Y6,=5DAN9&U+Q:* 72P1! E>&!DGS
MV4KTJ7T9G=A\Q;9-8++E]-Q[[X6ODY'S+([9N;]ZDP'G",[W:G)B[[M:S",K
MT=6%LEMT)R1%=!T^_8S^(EXL<J^5YP/^$;@E:M)JK/)[_#<H >:JUEMT@N2E
M1+]*S.K]QXP4 S2/XZ0E9D+S=Q&PU<39GN[;?%HG+:>K*(N-JO['A(  ED.X
MM+P,:/XN +8:,%M4?(N9J?)B\M_,KOD?$P("6&XJI>5E0O%W $!64:T+Q<?O
MT#Z]D)AXBU08%E:>#_AWRJVM?R[8E'_]XFS.:CU^S]:,K@.O3GFQ]2\.];A&
M5NBM"[TVVI!GZXN50/!5%->W!9.G7V8VN*QPR@^M?VS8C'MD!>,ZT&&CSPYW
M%@RXT[C\]4K"A-R1E&)?W)=E] <Z6BPW'_#DE%?)>:38@']DY>*ZT&23R:C;
M7WPB\8KG"O*& &5..7OU#P\E6,16P*T+G3.9 KMC[9-E3/*7R=3D_<*X 6V%
M]9(Q ]#ME!]VRDZ55>)XJQ8; @5M*Q/#8G1-*_\6R_(H@2O;6=KER&Z.]B89
MJ5K8:!E[JW6"=F(K0]MBMMN7(Y.'W:+MV >\W&<*VS\%2A <49N@R%B.ZQFU
ME<O1 X4U>:;],_J;P@F%>*D'D2L:3V?W?PWT(%BJFV#)4%LFK[;R,7J@N29/
MQG3K6I $BJ%[P8WO/>?ESWC*6SL J$)P[FV"*$-_>>S:2JOH@0J;+!ESF:3^
MRDO)_&-S?(*FC3PE9@P!RA!<,C1!E:'&?(8;I$DT:H_9 T4V>4^Q+Z2;*%Q"
M+.@^BD6'"N%@2NT(P2U$$Z2EE;N>=5M)$>ZK^<BD=[<OKLM?LR";0ZBIB;ZS
M9@'Z'?8)1VR?4!D#LPD2-F(NEZO7('HGY#&-9G_?9_'LQ4O(?>"%=A_'ESU\
MBVXLI:LSB6,(78&LO[YO?K*^X)_\].*Y*&!N[@.@ A8SPG.!01</,K_(^RK>
MD]B/YCG1"5.J0ECT9J588*B.9%RX[!AJ,Z#<#C.Y89Q&ZT%5Q/V-KK4Q>]F$
MG(TLI'O(=R_(2-D6FK?S-IT;>$6T'QL3'F.3-@27V_&RQ]D+F6<!F2ZVV)_^
M#"EQ+_XK\'_Y.+W?;/3<N[JFTU),;99P=F-!PI!;84C0G'W1%%(8RET@M#*+
M6?G2Q'Y]AS]*7*UKS @8((J,-Q0EVX[TH<%09PB-JEA,Y^=3G!]0>,4,5:<!
M;A'%VO7EI6L3>U#@-X16E,!D!/V>^K3Q4_3T,WIZB;+$"^?P(C0E)!07O!2-
MI;1B*I>D"#'S>E.*Z<^IFF.3'OD?7IAY\?LA</<4W5*!OXSR_R'63,%0H!21
M/ZT(,$,QY7C&<.BVH)<F4Y<FK[$?K&'^(PO)Z$!.*7GC@$9$SJ,BM R-E&"X
M65%Q9]719#[2'UE0&OTC>4US=&554C06:$7DBRE"S%HHY9BNIGA\(M4TF6<T
MG:41!70-]@69%5A+;N+BT4"O,Q[1'LP,]91FNYJ<\8D4U*3W4SDS?:F>F;XH
M'3'KAE)*S]ST?<9LWT>.YVK*Q.?1RS.3KL_'R>E+Y>0DH92\<4"CFT[/&=OI
MD6"X6@KB$ZFC28^G/#%]V3TQR:R3@K% JYN>SQG;\Y%DNEKAX1.IIM%WRIO3
MTI>=TY*$<HI' [UN>D!GG(?*LFQ7"S?8S&$LV'W- 9^E_IN?OCO7VF=LLT6+
M9EN0,;KV+!4LV==(^SQ@",?KRD#OH;#UUCYC3,^*]Q%E:T\='QC"YMHV[&9K
MGS':UCYCI=8^XZ/&UX&L9R'_R>A&F.=9Y0E6XF(=]2. (]MMYU3W4@1G,C&B
M@AVJPDLK35%,ZH?%/<B)W,\QFA8^7!FR-=(8"!BN])Q0F2]G-A\7Z3)0>&')
M;_2':7(=%H]BVD*K]F,_1J<'B(X&QE2A!=ODX>?X\P@7+/STP.:VR7N_5@FH
M))>_2#SS$R*T8N4) 0$$VZ)QD7(L51<CMRNC.&*-+CY@6NO+510OB \E >$-
M_*:B9%=;L/#[@"^B>QQC"M/>KBP+J4:MF;-B:0C)$FH=#(N#S G,8G2^J29-
MLS1)O1"J6-QE$I$VX]\#_!#=%!A3B/:,GP6A?MV U^*DD7IQ.AB\S.)N,>39
M X,_/4 0@C6N$)T:? ZA?HFMPN OPV%_EY*NP_O[VEF$.&XGYK[W/<"O9_M[
MKA#MF3L+0EL-USZ3J:.^K$J48K5_$G_Y0EVXR1N)O24IHT;WL<\L\FZ!$L"\
M;W&^AK=EQL&UU0WL4RT<F .$(HTJE0;%VJ%$#"#?M] AOS^+%7QM=6'[5"N(
MPT$%83RZS06E3=I +GT+5O#3RS# ;:T#WV=:;PX<3B&J1,0LKBR25(!2]RSI
M*%>>3@*>$L#J-^P>[CT4=PZ' Z'.+1E]"YKRWUUU"VR##JK#U8F2T&T?,I[%
M##PKJ]0#@8>R]._04 0ZAV1> /T_CF0@[98B*@-,CZ&,*95@);$"<KFJ#'G1
M+:XH-I^T&KS9LW@&D:0"L.[;S0S_]6ZWP):KQ9"WW>9J8?M:IL%&Q%8GUD9T
MV/+Y0X,BD$'?+FCJ.S#;![E<471:BPXKBJSP7;RFN?+\..]S-$F2;%7HV8.?
M_'T5$W(=4N&3)'WPTM9.'K+?!WS[=MU2W^^Z:TC+M<'1?JR.K T6XZ-U^G#Y
MZY7,H,59%%!VH)FZA)'+3P0<]RU*6=_66QN;TNR&I,TVS<[%("-/E5H]RPL_
M3!'%U+O<F(JT<&27Q;)<!C3N*(=E0%;&(Q=O)^5WE'5ML"Z/Z%Q" /&^[?ZC
M=NXH=;$MZZP,K:#;7#9LGQY:UJBB)"6"9:,@A"+>MV[PIX)N\%UC6RX;PSUD
MB\N&7@=YPX772?SFST@]/W=1^$:2]*.47Y1Z0?7?SZ,DO8O2OTCZ0&;1,O3_
M$99Q:NV[@&??[AKKN]1W!66Y!@RWBVVN 19O%UM3H")+_RJ*UW^"WXF"$=T2
M \CW[4[QF'NG: 7?<@D9KA/;7$(L7B=.@GQR,J_G!(Z:82*Z+I";!#CMV\7>
M,?=B3PF7TM2&V[DV'7W;N4!M7O-:</,Y9 #:?=NA1^U4=-1#MKQ0&%YDM[E@
M]#G5Q\)U H<,0+MOYX.1W<2?;63+$\;PI+K-!<-D(]?F"L)@V=#LP&_?8G8C
M=KM88X"56W?GY9@Z:/5C\82=4_)$OR+1#FKKMT W@K.J&%F.KUG##X:VA4UD
M8OWE!L_6F366-ER$<VBI>D?%*M4$MXU/ HH(-)LGX0;G(WU ,)A&CU3,II>T
M:8LBU2=R[_= OTM^A[Z(.);&  6QF3PG^?LG/85?#X;0JU;J3^OGJ-,3_ DR
MVR RSLQ<!NO4RT:#\+LH_)Y?F^5VT+1'>/N'[#'F@Q$&-WP\1G#H$<NPA=#0
M+@@86D^[H3+6GY#H,%"HUW5(E^(L/QQ,TQ<2/[UX8:>=-A7)H&CW[7G)6.)Y
M27?(#MTYVU\O]"*]V->+XAQD?;W8)@/0[EF<>5P?9[:$K$;_T*%)H+K(73RV
M"Q5J7>T9P:*Q1PE@CL 1,*Y$-M8-%KA#?]%.G!,7'[8*=>HC7;G=OF2J= #>
M/7O6.N87M>@:VJ%/:6=G#A<3V!Q>./J6PC9N*85-$]JAWVE'R\8G"(;NE%;,
M__&"GDA%R7/HZ*3RZMM[^G%+[^E;@EZ__\@0;Y75")NO[;L*Q^%=DA3I!'GU
M+6++?\V/#?JAXVL'2U*? [K0O@_O>J1")$BJ;V%@?K$ 5+@/G6,[\-?Z'1_&
MNP[)DPA2ZEM4N:5BB>917Z]!&C68AX"SXL;4[X!S3U:BOE5B&?,KL2!"O4%C
MZ^8A[ Y2TVT6,VKPUG",P"#$R+(UO(X?#*]W&LD$\Z'6F<=Y8T2'SCH)-UBU
M]0'!8!H]4C&3C^@VWR_6/^ZK3LX(2M>92[=B^M#O6Y 8EL$ 3$KAK)VJ+^L#
M0'0;Q03.G$\$+@%FE*3ISY#$ZI8AF HX<>G61E]8DB8CAY<3;^S<L26M2Q6&
M+6V_[!4;3-WO@2:7K@_T86=8!0>4ZL.10?4;RT#+>992_6^AGR;KVM'% A="
MY>=%%*^\</TG5?.0GQ-X0^!@=R ^*1-2!J[ZR&(PL\9RTHHK:)O9K1?_35)C
M%K8W'7"$R,=O46C:QL7"K)I./-A58Q&9# .PA=K$B$KIGQWT/S1PQ@X-2 )4
MO35%9AYFRC^-D99_&KM4_FFL4?YIC+?\4VX-:&L_G9UBOA3!D(%P=HK@,"26
M80N7U;L@.!&70J$R![U,Y$5:^^GLP*5HFJSZV$@^J45VJ/W4P7K1RR0WI+6?
MS@Y<"AW*JH^-]:(6V:'V4R<KAHO'=K=K/YT=(' $C"N1C76#!>Y0^ZF3I:.7
M#Y_1EG Y.W I!496@6PL&_70#K6?.ELX>EG$!>_"<8@_:*^N0#@6CL.#H?93
M5\N&S19N7<7*\#[C4RY =(:A=9UQ!;0?3I6%?JC]U,&2] GBK7B7).4"1&>'
M?8O8'J*(V,I"/]1^ZF!)ZG- MT^UG\X.^Q8&/K0;!E;!?:C]U,%*U._X,-YU
M2*7VQ]EAWZ+*A[:CRK*H#[6?.EN)^AUP[LE*=-2W,/6A[3"U+.I6:S]]IH7H
MR,4CT8>V3)(D6Q4J]N G?U_%A%R']#Q,=>V!:M6M'_JK;-46CHID -I].]H<
MM7.TT4.V7#0T+LP''TI:XB[>>4GKD_<+Q8)1D %H]^W&ZJB=&RL]9,L%8W@!
MT.:"X>*-5)T^7?YZ)3-Z=OT>!72:@)YX0:.Z7"OJ*0",^W:+=-3.+9(RJ.4*
MH9+S/ZP0JL(V667$[!9"J&>;^"E9O_GGINYW]7E K&\7-?5-5SM&M#1VE2S]
MP=A5)=U.!51=W6C7EBF_H[[%$(]DZJ@V!*RT1(T,UF:6V$%5"HN1_TT1'.42
MXV=C!'HL1I9]9JSC!T-IWT8RP1R\=:48U]D845"V3L(-_"!]0#"81H]4S&2E
MWLWWB_5/O^S[V=BE\*(^],+C2@TL@P$8E8+)>KV[<NNR[/L9AO8W'0A+TF3D
M\'*BO)8[MM1>45[=LN]GF%KGM @[PRHXH QEWXW*H)NZN<4"UVW9][/^M^ Y
MX[3@:0C<4/;=I)R,-NG!4/;]K/_->LXXS7KT,1O*OAL547L->XR7?>]_(Y\S
MZ48^3(!Z7_;];&1290U>HXSPJ^<VB Q%XS*(I>S[4Y1ZP7T<O?D)G?LJBJ]#
M^BORY/TBVO7?S2C_!R$;8B4UGS,2C-MBTMIY%H/F71$J?"^@%$*&4IB0KR0D
M"U_$EV T\(8H@B66 OOV0XY3_2)J&'(Z6M-OBV_RUW)[I H'VS(0KJOE_#F
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M"^1G@2JN@GN!"D=]]:?T*@RVQX^$LK&& 3?(]^ JZFIGT J#&(+0YD6G5W^
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M(@ 1              "  0    !A;65D+3(P,38Q,C,Q+GAM;%!+ 0(4 Q0
M   ( #Q 84J4NF0U?RP  /H# @ 1              "  6H) @!A;65D+3(P
M,38Q,C,Q+GAS9%!+ 0(4 Q0    ( #Q 84JM$<T,,"   -0& @ 5
M      "  1@V @!A;65D+3(P,38Q,C,Q7V-A;"YX;6Q02P$"% ,4    "  \
M0&%*[S1"8VV/   6)0H %0              @ %[5@( 86UE9"TR,#$V,3(S
M,5]D968N>&UL4$L! A0#%     @ /$!A2@!?V\Z$' $ 11@1 !4
M     ( !&^8" &%M960M,C Q-C$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( #Q
M84K*+8Z6C\(  $LG#@ 5              "  =("! !A;65D+3(P,38Q,C,Q
>7W!R92YX;6Q02P4&      8 !@"* 0  E,4$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
